PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chang, S; Hemmings, HC; Aderem, A				Chang, S; Hemmings, HC; Aderem, A			Stimulus-dependent phosphorylation of MacMARCKS, a protein kinase C substrate, in nerve termini and PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR SPECIFIC SUBSTRATE; SYNAPTIC VESICLE; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; 87-KDA PROTEIN; BRAIN SYNAPTOSOMES; CALCIUM CALMODULIN; MARCKS FAMILY; PHORBOL ESTER; B-50 GAP-43	MacMARCKS (also known as myristoylated alanine-rich C kinase substrate (MARCKS)-related protein) is a member of the MARCKS family of protein kinase C substrates, which binds Ca2+/calmodulin in a phosphorylation-dependent manner. Immunoprecipitation demonstrated that MacMARCKS is present in both PC12 cells and in neurons. Upon depolarization of PC12 cells with 60 mM KCl, MacMARCKS phosphorylation increased 4-fold over basal levels in a Ca2+-dependent manner. By immunofluorescence microscopy, MacMARCKS was colocalized in PC12 cells to neurite tips with the synaptic vesicle membrane protein synaptophysin and to vesicles in the perinuclear region. Subcellular fractionation demonstrated that MacMARCKS associates tightly with membranes in PC12 cells. In Percoll-purified rat cerebrocortical synaptosomes, depolarization with 60 mM KCl in the presence of exogenous Ca2+ transiently increased MacMARCKS phosphorylation, whereas phorbol ester promoted a sustained increase in MacMARCKS phosphorylation. Subcellular fractionation of rat brain indicated that MacMARCKS was present in both soluble and particulate fractions; particulate MacMARCKS was associated with both small vesicles and highly purified synaptic vesicles. These results are consistent with a role for MacMARCKS in integrating Ca2+-calmodulin and protein kinase C-dependent signals in the regulation of neurosecretion.	ROCKEFELLER UNIV, SIGNAL TRANSDUCT LAB, NEW YORK, NY 10021 USA; CORNELL UNIV MED COLL, DEPT ANESTHESIOL, NEW YORK, NY 10021 USA; CORNELL UNIV MED COLL, DEPT PHARMACOL, NEW YORK, NY 10021 USA	Rockefeller University; Cornell University; Cornell University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032972, R01AI025032, R37AI025032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007739] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 32972, AI 25032] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM07739] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; DEKKER LV, 1990, J NEUROCHEM, V54, P1645, DOI 10.1111/j.1471-4159.1990.tb01217.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DEKKER LV, 1991, PROG BRAIN RES, V89, P209; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; LOBACH DF, 1993, GENOMICS, V17, P194, DOI 10.1006/geno.1993.1301; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MALENKA RC, 1987, BRAIN RES, V403, P198, DOI 10.1016/0006-8993(87)90145-4; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V269, P30132; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; NICHOLS RA, 1987, J NEUROCHEM, V48, P615, DOI 10.1111/j.1471-4159.1987.tb04137.x; OUIMET CC, 1990, J NEUROSCI, V10, P1683; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; ROBINSON PJ, 1991, MOL NEUROBIOL, V5, P87, DOI 10.1007/BF02935541; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; WANG JKT, 1988, J NEUROSCI, V8, P281; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; ZURGIL N, 1985, FEBS LETT, V185, P257, DOI 10.1016/0014-5793(85)80918-2	43	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1174	1178		10.1074/jbc.271.2.1174	http://dx.doi.org/10.1074/jbc.271.2.1174			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557647	hybrid			2022-12-25	WOS:A1996TP88900084
J	Haugen, BR; McDermott, MT; Gordon, DF; Rupp, CL; Wood, WM; Ridgway, EC				Haugen, BR; McDermott, MT; Gordon, DF; Rupp, CL; Wood, WM; Ridgway, EC			Determinants of thyrotrope-specific thyrotropin beta promoter activation - Cooperation of Pit-1 with another factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PIT-1/GHF-1; SUBUNIT GENE; ANTERIOR-PITUITARY; FACTOR GHF-1; EXPRESSION; PROTEIN; ELEMENTS; HOMEODOMAIN; HOMEOBOX; MUTATION	Thyrotropin (TSH) beta is a subunit of TSH, the expression of which is limited to the thyrotrope cells of the anterior pituitary gland, We have utilized the thyrotrope-derived TtT-97 thyrotropic tumors to investigate tissue specific expression of the TSH beta promoter, TSH beta promoter activity in thyrotropes is conferred by sequences between -270 and -80 of the 5'-flanking region, We have recently reported that the proximal region from -133 to -100 (P1) is required for promoter expression in thyrotropes. This region interacts with the pituitary-specific transcription factor Pit-1. While Pit-1 appears necessary for TSH beta promoter activity in thyrotropes, this transcription factor is not alone sufficient for promoter activity in pituitary-derived cells, In this report, we have generated a series of promoter mutations in the P1 region to identify additional protein-DNA interactions and determine their functional significance. We have found that Pit-1 interacts with the distal portion of the P1 region, and a second protein interacts with the proximal segment of this region, Each protein is able to independently interact with the TSH beta promoter, but neither alone can maintain promoter activity. Both proteins appear to be necessary for full promoter activity in thyrotropes, Southwestern analysis with the proximal segment of the P1 region (-117 to -88) reveals interaction with a 50-kDa protein, Interestingly, this protein is not found in the pituitary-derived GH3 cells and may represent a thyrotrope-specific transcription factor. Further characterization of this newly identified DNA binding protein will further our understanding of the tissue-specific expression of the TSH beta gene.	FITZSIMONS ARMY MED CTR,AURORA,CO 80045		Haugen, BR (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL DIABET & METAB,B151,4200 E 9TH AVE,DENVER,CO 80262, USA.				NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036843, K08DK002331] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline; NIDDK NIH HHS [DK02331, DK36843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BCH I, 1995, P NATL ACAD SCI USA, V92, P2720; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; Cochran W.G, 1957, STAT METHODS, V6th ed; DROLET DW, 1991, GENE DEV, V5, P1739, DOI 10.1101/gad.5.10.1739; GORDON DF, 1993, MOL CELL ENDOCRINOL, V96, P75, DOI 10.1016/0303-7207(93)90097-4; HAUGEN BR, 1994, MOL ENDOCRINOL, V8, P1574, DOI 10.1210/me.8.11.1574; HAUGEN BR, 1995, ENDOCRINOLOGIST, V5, P132, DOI 10.1097/00019616-199503000-00009; HAUGEN BR, 1993, J BIOL CHEM, V268, P20818; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; KIM MK, 1993, J BIOL CHEM, V268, P23366; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; LIN SC, 1994, DEVELOPMENT, V120, P515; MASON ME, 1993, BIOCHEMISTRY-US, V32, P8932, DOI 10.1021/bi00085a026; MCCORMICK A, 1991, GENE DEV, V5, P1490, DOI 10.1101/gad.5.8.1490; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OCRAN KW, 1990, MOL ENDOCRINOL, V4, P766, DOI 10.1210/mend-4-5-766; ORKIN SH, 1992, BLOOD, V80, P575; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; SHUPNIK MA, 1992, MOL ENDOCRINOL, V6, P43, DOI 10.1210/me.6.1.43; STEGER DJ, 1994, MOL CELL BIOL, V14, P5592, DOI 10.1128/MCB.14.8.5592; STEINFELDER HJ, 1992, J CLIN INVEST, V89, P409, DOI 10.1172/JCI115600; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; STEINFELDER HJ, 1992, P NATL ACAD SCI USA, V89, P5942, DOI 10.1073/pnas.89.13.5942; THEILL LE, 1989, NATURE, V342, P945, DOI 10.1038/342945a0; THEILL LE, 1993, ENDOCR REV, V14, P670, DOI 10.1210/er.14.6.670; WOOD WM, 1990, MOL ENDOCRINOL, V4, P1897, DOI 10.1210/mend-4-12-1897; WOOD WM, 1989, J BIOL CHEM, V264, P14840	35	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					385	389		10.1074/jbc.271.1.385	http://dx.doi.org/10.1074/jbc.271.1.385			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550592	hybrid			2022-12-25	WOS:A1996TP36100061
J	Hertz, R; Seckbach, M; Zakin, MM; BarTana, J				Hertz, R; Seckbach, M; Zakin, MM; BarTana, J			Transcriptional suppression of the transferrin gene by hypolipidemic peroxisome proliferators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTOR SUPERFAMILY; ACYL-COA OXIDASE; RESPONSE ELEMENT; BINDING-PROTEIN; TRANSGENIC MICE; RETINOIC ACID; MESSENGER-RNA; RAT-LIVER; EXPRESSION; PROMOTER	Activation of gene expression by hypolipidemic peroxisome proliferators (e.g. native and substituted long chain fatty acids, aryloxyalkanoic fibrate drugs) is accompanied by transcriptional suppression of liver transferrin gene in treated animals or human hepatoma cell line, Transcriptional suppression of Liver transferrin by hypolipidemic peroxisome proliferators results from (a) displacement of hepatic nuclear factor (HNF)-4 from the transferrin promoter by nonproductive binding of the peroxisome proliferator-activated receptor-retinoic acid X receptor heterodimer to the (-76/-52) PRI promoter element of the human transferrin gene and (b) suppression of liver HNF-4 gene expression by hypolipidemic peroxisome proliferators with a concomitant decrease in its availability for binding to the transferrin PRI promoter element. HNF-4 gene suppression and its displacement from the transferrin promoter result in eliminating HNF-4-enhanced transcription of transferrin, Liver transferrin suppression by hypolipidemic peroxisome proliferators may result in reduced iron availability as well as modulation of transferrin-induced differentiation processes. Transcriptional suppression of HNF-4-enhanced liver genes (e.g. apolipoprotein C-III, transferrin) may complement the pleiotropic biological effect exerted by hypolipidemic peroxisome proliferators.	HEBREW UNIV JERUSALEM, FAC MED, DEPT HUMAN NUTR & METAB, IL-91120 JERUSALEM, ISRAEL; INST PASTEUR, UNITE EXPRESS GENES EUCARYOTES, F-75724 PARIS 15, FRANCE	Hebrew University of Jerusalem; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ADRIAN GS, 1990, J BIOL CHEM, V265, P13344; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BRUNEL F, 1988, J BIOL CHEM, V263, P10180; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEJONG G, 1990, CLIN CHIM ACTA, V190, P1, DOI 10.1016/0009-8981(90)90278-Z; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GIBSON G, 1993, PEROXISOMES BIOL IMP; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HERTZ R, 1991, BIOCHEM J, V274, P745, DOI 10.1042/bj2740745; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; IDZERDA RL, 1989, MOL CELL BIOL, V9, P5154, DOI 10.1128/MCB.9.11.5154; IDZERDA RL, 1986, P NATL ACAD SCI USA, V83, P3723, DOI 10.1073/pnas.83.11.3723; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEVIN MJ, 1984, BIOCHEM BIOPH RES CO, V122, P212, DOI 10.1016/0006-291X(84)90461-3; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T, 1989, MOL CLONING; MCKNIGHT GS, 1980, J BIOL CHEM, V255, P148; MENDELZON D, 1990, NUCLEIC ACIDS RES, V18, P5717, DOI 10.1093/nar/18.19.5717; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PETROPOULOS I, 1991, J BIOL CHEM, V266, P24220; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SCHAEFFER E, 1993, J BIOL CHEM, V268, P23399; SCHAEFFER E, 1987, GENE, V56, P109, DOI 10.1016/0378-1119(87)90163-6; SCHAEFFER E, 1989, J BIOL CHEM, V264, P7153; SHARMA R, 1988, BIOCHEM PHARMACOL, V37, P1203, DOI 10.1016/0006-2952(88)90771-X; SIRTORI CR, 1988, PHARMACOL THERAPEUT, V37, P167, DOI 10.1016/0163-7258(88)90024-1; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, IN PRESS TRANSCRIPTI; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; ZAKIN MM, 1992, FASEB J, V6, P3253, DOI 10.1096/fasebj.6.14.1426763; ZHANG BW, 1993, J BIOL CHEM, V268, P12939	43	67	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					218	224		10.1074/jbc.271.1.218	http://dx.doi.org/10.1074/jbc.271.1.218			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550563	hybrid			2022-12-25	WOS:A1996TP36100034
J	Laminet, AA; Apell, G; Conroy, L; Kavanaugh, WM				Laminet, AA; Apell, G; Conroy, L; Kavanaugh, WM			Affinity, specificity, and kinetics of the interaction of the SHC phosphotyrosine binding domain with asparagine-X-X-phosphotyrosine motifs of growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SEQUENCES; KINASE	The phosphotyrosine binding (PTB) domain specifically binds to tyrosine-phosphorylated proteins, but differs in structure and mechanism of action from the SH2 domain family, We quantitated the affinity, specificity, and kinetics of the interaction of the SHC PTB domain with a sequence motif, asparagine-X-X-phosphotyrosine (NXX(pY)), found in several receptor tyrosine kinases and oncogenic proteins. PTB domain-mediated interaction with the NXX(pY) motif of c-ErbB2 was characterized by similar overall affinity but slower kinetics than that reported for SH2 domains, This suggested that unlike SH2 domains, PTB domains may not rapidly exchange among associated proteins. Furthermore, when directly and quantitatively compared, PTB domain binding specificity did not significantly overlap with a panel of seven SH2 domains, Thus, signaling pathways involving PTB and SH2 domain-mediated interactions can be regulated separately. Finally, our data define the minimal SHC PTB domain binding motif as NXX(pY), not NPX(pY) as suggested by other authors, and suggest a high affinity motif, hydrophobic residue-(D/E)-N-X-X-pY-(W/F), found in the Trk and ErbB receptor tyrosine kinase families. We conclude that PTB domains mediate specific protein-protein interactions independent from those mediated by SH2 domains.	CHIRON CORP,EMERYVILLE,CA 94608	Novartis								BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAVANAUGH WM, 1995, IN PRESS MODULAR TEX; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SEGATTO O, 1993, ONCOGENE, V8, P2105; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Summers MD, 1987, MANUAL METHODS BACUL; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; 1995, BIAEVALUATION 2 1 SO	32	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					264	269		10.1074/jbc.271.1.264	http://dx.doi.org/10.1074/jbc.271.1.264			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550571	hybrid			2022-12-25	WOS:A1996TP36100041
J	Simonson, MS; Wang, Y; Herman, WH				Simonson, MS; Wang, Y; Herman, WH			Nuclear signaling by endothelin-1 requires Src protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENT; NIH 3T3 CELLS; GLOMERULAR MESANGIAL CELLS; C-FOS PROMOTER; RAT-1 FIBROBLASTS; CYCLIC-AMP; FAMILY; TRANSFORMATION; TRANSDUCTION; EXPRESSION	In response to changes in vascular homeostasis, endothelial cells secrete endothelin-1 (ET-1), which in turn regulates gene expression and phenotype in underlying vascular cells. We characterized a nuclear signaling cascade in which Src protein-tyrosine kinases link the ET-1 receptor to induction of c-fos transcription. A dominant negative SrcK-kinase mutant blocked ET-1-stimulated c-fos transcription. Expression of the COOH-terminal Src kinase (Csk), which represses Src kinases, also blocked induction of c-fos transcription by ET-1. Activation of the c-fos promoter by ET-1 required both the CArG DNA sequence of the c-fos serum response element and the Ca2+/cAMP response element. In contrast, Src-induced c-fos transcription required only the CArG cis-element, demonstrating a divergence in signals regulating c-fos transcription. Thus, Src kinases contribute to a nuclear signaling cascade linking an ET-1 receptor to the CArG element of the c-fos serum response element. A Src-based pathway might play a more general role to propagate ET-1 nuclear signals that regulate cell growth and development. In addition, these results point to a widening role for nonreceptor protein-tyrosine kinases in propagating signals from G protein-coupled receptors.			Simonson, MS (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED,DEPT MED,DIV NEPHROL,BIOMED RES BLDG, RM 427, 2065 ADELBERT RD, CLEVELAND, OH 44106 USA.				NIDDK NIH HHS [DK-46939] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046939] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; BENIGNI A, 1993, KIDNEY INT, V44, P440, DOI 10.1038/ki.1993.263; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DOUGLAS SA, 1994, CIRC RES, V75, P190, DOI 10.1161/01.RES.75.1.190; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORCE T, 1991, J BIOL CHEM, V266, P6650; FORCE T, 1992, Journal of the American Society of Nephrology, V3, P491; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GUTMAN A, 1991, MOL CELL BIOL, V11, P5381, DOI 10.1128/MCB.11.10.5381; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; HERMAN WH, 1995, J BIOL CHEM, V270, P11654, DOI 10.1074/jbc.270.19.11654; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; MASAKI T, 1993, ENDOCR REV, V14, P256, DOI 10.1210/er.14.3.256; MATTINGLY RR, 1992, J BIOL CHEM, V267, P7470; MULDOON LL, 1990, CELL REGUL, V1, P379, DOI 10.1091/mbc.1.4.379; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PRIBNOW D, 1992, MOL ENDOCRINOL, V6, P1003, DOI 10.1210/me.6.7.1003; RIVERA V M, 1990, New Biologist, V2, P751; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; RUBANYI GM, 1993, J CARDIOVASC PHARM, V22, pS1, DOI 10.1097/00005344-199304000-00002; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; SIMONSON MS, 1992, J BIOL CHEM, V267, P8643; SIMONSON MS, 1990, J CLIN INVEST, V85, P790, DOI 10.1172/JCI114505; SIMONSON MS, 1990, FASEB J, V4, P2989, DOI 10.1096/fasebj.4.12.2168326; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SIMONSON MS, 1993, PHYSIOL REV, V73, P375, DOI 10.1152/physrev.1993.73.2.375; SIMONSON MS, 1994, MOL PHARMACOL, V46, P41; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREISMAN R, 1992, TRANSCRIPTIONAL REGU, P881; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; YAN MH, 1994, J BIOL CHEM, V269, P19067; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	60	68	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					77	82		10.1074/jbc.271.1.77	http://dx.doi.org/10.1074/jbc.271.1.77			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550628	hybrid			2022-12-25	WOS:A1996TP36100013
J	Kallmeier, RC; Somasundaram, C; Babij, P				Kallmeier, RC; Somasundaram, C; Babij, P			A novel smooth muscle-specific enhancer regulates transcription of the smooth muscle myosin heavy chain gene in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN GENE; EXPRESSION; ELEMENTS; ISOFORMS; CIS; PROMOTER; MOTIF	Transient DNA transfection analysis of 5' end deletion mutants of the rabbit smooth muscle myosin heavy chain (SMHC) gene promoter was performed in primary cultures of rabbit vascular smooth muscle cells (VSMC), A positive element located at position -1,332 upstream of the transcription start site consistently gave the high est relative chloramphenicol acetyltransferase (CAT) activity (6.3 +/- 1.5-fold over the minimal SMHC promoter), suggesting that inclusion of the extra 107-base pair (bp) DNA fragment between -1,332 and -1,225 could significantly enhance CAT activity in VSMC. Transfection of mutants into several muscle and nonmuscle cell lines did not show any significant CAT activity above control, showing that factors unique to smooth muscle cells were required for SMHC expression, Gel shift analysis indicated that multiple factors interacted with the 107-bp element, two of which appeared to show smooth muscle specificity. Tests of enhancer function in transfected VSMC indicated that the 107-bp fragment behaved as a classical enhancer, i.e. independently of position and orientation. These results indicate that a novel DNA element may regulate the tissue-restricted expression of the SMHC gene and provides the first example of a role for a smooth muscle-specific enhancer in VSMC.	CITY UNIV LONDON,DEPT PHYSIOL,LONDON WC1E 6BT,ENGLAND	City University London				Somasundaram, Chandra/0000-0001-5669-8469				BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BABIJ P, 1992, AM J PHYSIOL, V262, pC607, DOI 10.1152/ajpcell.1992.262.3.C607; BABIJ P, 1993, AM J PHYSIOL, V265, pL127, DOI 10.1152/ajplung.1993.265.2.L127; BABIJ P, 1991, P NATL ACAD SCI USA, V88, P10676, DOI 10.1073/pnas.88.23.10676; BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; BLANK RS, 1992, J BIOL CHEM, V267, P984; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; KATOH Y, 1994, J BIOL CHEM, V269, P30538; KUROO M, 1989, J BIOL CHEM, V264, P18272; LATCHMAN DS, 1993, TRANSCRIPTION FACTOR, P1; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; NACHTIGAL M, 1989, IN VITRO CELL DEV B, V25, P892; NAGAI R, 1989, J BIOL CHEM, V264, P9734; REILLY CF, 1990, J CELL PHYSIOL, V142, P342, DOI 10.1002/jcp.1041420217; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	25	31	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30949	30957		10.1074/jbc.270.52.30949	http://dx.doi.org/10.1074/jbc.270.52.30949			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537351	hybrid			2022-12-25	WOS:A1995TN44400019
J	Lowe, M; Kreis, TE				Lowe, M; Kreis, TE			In vitro assembly and disassembly of coatomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; CLATHRIN-COATED VESICLES; GOLGI MEMBRANES; BETA-COP; BREFELDIN-A; GUANINE-NUCLEOTIDE; TRANSPORT VESICLES; SUBUNIT; COMPLEX	Coatomer, a complex of seven proteins, is the major component of the non-clathrin (COP I) membrane coat. We report here the first system to reversibly disassemble and reassemble this complex in vitro. Coatomer disassembles at high salt concentrations and reassembles when returned to a more physiological buffer. Using this system, we show that alpha-, beta'-, and epsilon-COP interact directly and that gamma-COP interacts with zeta-COP. A partial complex comprising alpha-, beta'-, and epsilon-COP, obtained after coatomer disassembly, can bind to membranes in vitro. This binding is, at least in part, mediated by interactions with cytoplasmic KKXX motifs of proteins normally retained in or retrieved to the endoplasmic reticulum. Using coatomer disassembly and epitope-specific antibodies, we also demonstrate that the N- and C-terminal domains of beta-COP are buried within the native coatomer complex. These results provide the first insights into how the coatomer is structured.	UNIV GENEVA,DEPT BIOL CELLULAIRE,CH-1211 GENEVA,SWITZERLAND	University of Geneva								AHLE S, 1989, J BIOL CHEM, V264, P20089; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; HARAKUGE S, 1994, J CELL BIOL, V124, P883, DOI 10.1083/jcb.124.6.883; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KREIS TE, 1994, CURR OPIN CELL BIOL, V6, P533, DOI 10.1016/0955-0674(94)90073-6; KUGE O, 1993, J CELL BIOL, V123, P1727, DOI 10.1083/jcb.123.6.1727; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SCARMATO P, 1990, J BIOL CHEM, V265, P3661; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STENBECK G, 1993, EMBO J, V12, P2841, DOI 10.1002/j.1460-2075.1993.tb05945.x; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WOODWARD MP, 1978, P NATL ACAD SCI USA, V75, P4394, DOI 10.1073/pnas.75.9.4394	35	84	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31364	31371		10.1074/jbc.270.52.31364	http://dx.doi.org/10.1074/jbc.270.52.31364			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537409	hybrid			2022-12-25	WOS:A1995TN44400076
J	Sabe, H; Shoelson, SE; Hanafusa, H				Sabe, H; Shoelson, SE; Hanafusa, H			Possible v-Crk-induced transformation through activation of Src kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; PHOSPHOTYROSINE-CONTAINING PROTEINS; MONOCLONAL-ANTIBODIES; CELL-TRANSFORMATION; C-SRC; ONCOGENE PRODUCT; FOCAL ADHESIONS; AVIAN-SARCOMA; ASSOCIATION; PAXILLIN	p47(gag-crk) (v-Crk) encoded by avian sarcoma virus CT10, causes an elevation of tyrosine phosphorylation of several cellular proteins, The lack of a protein tyrosine kinase domain in v-Crk suggests its co-operation with cellular protein-tyrosine kinase activity, We have shown that suppression of a certain fraction of c-Src activity by Csk may require the binding of Csk to tyrosine phosphorylated paxillin. In this study, we detected co-immunoprecipitation of tyrosine phosphorylated paxillin with v-Crk in CT10-transformed chicken embryo fibroblasts (CEF), and demonstrated that v-Crk binding to paxillin can inhibit Csk binding to paxillin. A phosphotyrosine peptide, which can inhibit v-Crk binding to paxillin, did not inhibit Csk, binding to paxillin, suggesting that v-Crk and Csk bind to different tyrosine-phosphorylated sites in paxillin. We also found that the kinase activity of the endogenous c-Src in CEF is elevated severalfold after CT10-transformation, We therefore suggest that the competitive binding of overexpressed v-Crk affects an efficient interaction of Csk with tyrosine-phosphorylated paxillin in CT10 transformed CEF. This would result in a failure in the suppression of the kinase activities of a population of c-Src and other Src family protein-tyrosine kinases as well, and these kinases may then contribute to the phosphorylation of cellular proteins in CT10-transformed CEF.	ROCKEFELLER UNIV, MOLEC ONCOL LAB, NEW YORK, NY 10021 USA; BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Rockefeller University; Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Sabe, Hisataka/A-4066-2012; Sabe, Hisataka/GPF-4385-2022		NCI NIH HHS [CA44356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DOMCHEK SM, 1992, BIOCHEMISTRY-US, V31, P9865, DOI 10.1021/bi00156a002; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FUKUI Y, 1991, MOL CELL BIOL, V11, P1972, DOI 10.1128/MCB.11.4.1972; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KITAS EA, 1991, HELV CHIM ACTA, V74, P1314, DOI 10.1002/hlca.19910740621; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MATSUDA M, 1990, J BIOL CHEM, V265, P12000; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARTANEN J, 1991, ONCOGENE, V6, P2013; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31219	31224		10.1074/jbc.270.52.31219	http://dx.doi.org/10.1074/jbc.270.52.31219			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537387	hybrid			2022-12-25	WOS:A1995TN44400055
J	Feres, EJ; Choi, YJ; Han, XY; Takala, TES; Trackman, PC				Feres, EJ; Choi, YJ; Han, XY; Takala, TES; Trackman, PC			Pre- and post-translational regulation of lysyl oxidase by transforming growth factor-beta 1 in osteoblastic MC3T3-E1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; MINERALIZING CULTURES; COLLAGEN-SYNTHESIS; MESSENGER-RNA; RAT; PROTEINS; BONE; PURIFICATION; EXPRESSION; DNA	The final enzymatic step required for collagen crosslinking is the extracellular oxidative deamination of peptidyl-lysine and -hydroxylysine residues by lysyl oxidase. A cross-linked collagenous extracellular matrix is required for bone formation. The goals of this study were to compare the transforming growth factor (TGF)-beta 1 regulation of lysyl oxidase enzyme activity and steady state mRNA levels to changes in COL1A1 mRNA levels in MC3T3-E1 osteoblastic cells. TGF-beta 1 increased steady state lysyl oxidase and COL1A1 mRNA levels in a dose- and time-dependent manner. The increase in lysyl oxidase mRNA levels was transient, peaking at 12 h and 8.8 times controls in cells treated with 400 pM TGF-beta 1. COL1A1 steady state mRNA levels increased maximally to 3.5-fold of controls. Development of increased lysyl oxidase enzyme activity was delayed and was of slightly lower magnitude than the increase in its mRNA levels. This suggested limiting post translational processing of lysyl oxidase proenzyme. Pulse-labeling/immunoprecipitation studies demonstrated slow proenzyme secretion and proteolytic processing. Development and application of an independent assay for lysyl oxidase proenzyme proteolytic processing activity verified its proportionately lower stimulation by 400 pM TGF-beta 1. Thus, lysyl oxidase regulation by TGF-beta 1 in osteoblastic cell cultures occurs at both pre- and post-translational levels. This regulation is consistent with increased production of a collagenous extracellular matrix.	BOSTON UNIV,MED CTR,GOLDMAN SCH GRAD DENT,DEPT PERIODONT & ORAL BIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; UNIV JYVASKYLA,DEPT BIOL PHYS ACTIV,SF-40100 JYVASKYLA,FINLAND	Boston University; Boston University; University of Jyvaskyla			Trackman, Philip C/AAX-9280-2021	Trackman, Philip C/0000-0001-5064-614X; Feres-Filho, Eduardo Jorge/0000-0001-5795-8058	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011004, R29DE011004] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 11004] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALMASSIAN B, 1991, CONNECT TISSUE RES, V25, P197, DOI 10.3109/03008209109029156; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BAILEY AJ, 1992, BIOCHEM BIOPH RES CO, V185, P801, DOI 10.1016/0006-291X(92)91697-O; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; BOAK AM, 1994, AM J RESP CELL MOL, V11, P751, DOI 10.1165/ajrcmb.11.6.7946403; CENTRELLA M, 1986, ENDOCRINOLOGY, V119, P2306, DOI 10.1210/endo-119-5-2306; CENTRELLA M, 1992, ENDOCRINOLOGY, V131, P2863, DOI 10.1210/en.131.6.2863; CHEN TL, 1993, J BONE MINER RES, V8, P423; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIFE RS, 1994, BBA-GEN SUBJECTS, V1201, P19, DOI 10.1016/0304-4165(94)90145-7; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; GERSTENFELD LC, 1993, J BONE MINER RES, V8, P1031; GUAN C, 1987, GENE, V67, P21; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; HUERRE C, 1982, P NATL ACAD SCI-BIOL, V79, P6627, DOI 10.1073/pnas.79.21.6627; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; LAIHO M, 1986, J CELL BIOL, V103, P2403, DOI 10.1083/jcb.103.6.2403; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PIEZ KA, 1961, BIOCHIM BIOPHYS ACTA, V53, P596, DOI 10.1016/0006-3002(61)90226-8; QUARLES LD, 1992, J BONE MINER RES, V7, P683; ROMEROCHAPMAN N, 1991, BIOCHEM J, V275, P657, DOI 10.1042/bj2750657; SELYE H., 1957, REV CANADIENNE BIOL, V16, P1; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; SHIBANUMA M, 1993, EUR J BIOCHEM, V217, P13, DOI 10.1111/j.1432-1033.1993.tb18212.x; SHIBANUMA M, 1991, CELL GROWTH DIFFER, V2, P583; SHIBATA Y, 1993, INT J BIOCHEM, V25, P239, DOI 10.1016/0020-711X(93)90012-4; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; TAKEUCHI Y, 1995, J CELL PHYSIOL, V162, P315, DOI 10.1002/jcp.1041620303; TRACKMAN PC, 1991, BIOCHEMISTRY-US, V30, P8282, DOI 10.1021/bi00247a025; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; WILLIAMSON PR, 1986, BIOCHEM J, V235, P597, DOI 10.1042/bj2350597; YAMADA T, 1993, J BIOL CHEM, V268, P8965	41	83	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30797	30803		10.1074/jbc.270.51.30797	http://dx.doi.org/10.1074/jbc.270.51.30797			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530522	hybrid			2022-12-25	WOS:A1995TL67500087
J	Gu, WG; Reines, D				Gu, WG; Reines, D			Variation in the size of nascent RNA cleavage products as a function of transcript length and elongation competence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-ALPHA; DNA-BINDING PROTEIN; POLYMERASE-II; ESCHERICHIA-COLI; DEPENDENT TRANSCRIPTION; TERNARY COMPLEXES; TERMINATION; INVITRO; IDENTIFICATION; MECHANISM	RNA polymerase II arrested at specific template locations can be rescued by elongation factor SII via RNA cleavage, The size of the products removed from the S'-end of the RNA varies, The release of single nucleotides, dinucleotides, and larger oligonucleotides has been detected by different workers, Dinucleotides tend to originate from SII-independent complexes and 7-14 base products from SII-dependent complexes (Izban, M, G., and Luse, D. S. (1993) J. Biol. Chem. 268, 12874-12885), Different modes of cleavage have also been recognized for bacterial transcription complexes and are thought to represent important structural differences between functionally distinct transcription intermediates. Using an elongation complex ''walking'' technique, we have observed factor-independent complexes as they approach and become arrested at an arrest site. Dinucleotides or 7-9-base (large) oligonucleotides were released from SII-independent or dependent complexes, respectively. The abrupt shift between the release of dinucleotide versus large products accompanied the change from factor-dependent to factor-independent elongation, as described by others. However, not all factor-independent complexes showed cleavage in dinucleotide intervals since oligonucleotides 2-6 bases long were also liberated from elongation-competent complexes, These were all 5'-coterminal oligonucleotides indicating that a preferred phosphodiester bond is targeted for cleavage in a series of related complexes, This is consistent with recent models postulating a large product binding site that can hold RNA chains whose size increases as a function of chain polymerization, A specific transitional complex was identified that acquired the ability to cleave in a large increment one base insertion event prior to attaining the arrested configuration.	EMORY UNIV,SCH MED,GRAD PROGRAM BIOCHEM & MOLEC BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University; Emory University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046331, GM-46331] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CATHALA G, 1990, NUCLEIC ACIDS RES, V18, P201, DOI 10.1093/nar/18.1.201; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CONAWAY RC, 1996, IN PRESS METHODS ENZ; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; FENG GH, 1994, J BIOL CHEM, V269, P22282; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1995, J BIOL CHEM, V270, P2290, DOI 10.1074/jbc.270.5.2290; IZBAN MG, 1993, J BIOL CHEM, V268, P12684; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; LEE DN, 1994, J BIOL CHEM, V269, P22295; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1991, J BIOL CHEM, V266, P10510; REINES D, 1994, TRANSCRIPTION MECHAN, P263; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SATO K, 1986, MOL CELL BIOL, V47, P259; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843	34	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30441	30447		10.1074/jbc.270.51.30441	http://dx.doi.org/10.1074/jbc.270.51.30441			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530472	Green Accepted, hybrid			2022-12-25	WOS:A1995TL67500037
J	Kinane, TB; Finder, JD; Kawashima, A; Brown, D; Abbate, M; Fredericks, WJ; Sukhatme, VP; Rauscher, FJ; Ercolani, L				Kinane, TB; Finder, JD; Kawashima, A; Brown, D; Abbate, M; Fredericks, WJ; Sukhatme, VP; Rauscher, FJ; Ercolani, L			LLC-PK1 cell growth is repressed by WT1 inhibition of g-protein alpha(i-2) protooncogene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR GENE-PRODUCT; WILMS-TUMOR; MULTICELLULAR DEVELOPMENT; SIGNAL TRANSDUCTION; RENAL-CELLS; SUBUNIT; DICTYOSTELIUM; KIDNEY; G-ALPHA-I-3; INDUCTION	The temporal expression of the early growth response gene (EGR-1) is one molecular mechanism for both maximal activation of the G alpha(i-2) gene and accelerated growth in mitotically active predifferentiated LLC-PK1 renal cells. These events are dependent on an enhancer area in the 5'-flanking region of the G alpha(i-2) gene that contains an EGR-1 motif (5'-CGCCCCCGC-3'). However, acquisition of the polarized phenotype in LLC-PK1 cells is accompanied by loss of EGR-1 expression and occupancy of the EGR-1 site by nuclear binding proteins other than EGR-1. We now demonstrate that one of these binding proteins is the Wilms' tumor suppressor (WT1). Furthermore, the temporal expression of WT1 in LLC-PK1 cells acquiring the polarized phenotype represses both G alpha(i-2) gene activation and growth in these cells. These findings suggest the existence of differentiation-induced pathways in LLC-PK1 cells that alternatively abrogrates EGR-1 and promotes WT1 gene expression, thereby modulating a target protooncogene G alpha(i-2) that is participatory for growth and differentiation in renal cells. These studies emphasize the usefulness of the LLC-PK1 renal cell as a model to elucidate normal programs of genetic differentiation in which WT1 participates.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; MASSACHUSETTS GEN HOSP,DEPT MED,RENAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,PEDIAT PULM UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114; BETH ISRAEL HOSP,RENAL UNIT,BOSTON,MA 02214; HARVARD UNIV,SCH MED,BOSTON,MA 02129	The Wistar Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Mauro, Abbate/ABH-3533-2020; Finder, Jonathan/AAB-2651-2021; Sukhatme, Vikas/W-2776-2019	Mauro, Abbate/0000-0002-2092-7474; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007540, F32DK008838, R01DK042543] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32 DK-07540, F32 DK-08838, DK-42543] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBAUMER L, 1990, CRIT REV BIOCHEM MOL, V25, P225, DOI 10.3109/10409239009090610; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CUTLER SJ, 1975, NATL CANCER I MONOGR, V41, P420; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1996, MOL BASIS MED; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HADWIGER JA, 1991, P NATL ACAD SCI USA, V88, P8213, DOI 10.1073/pnas.88.18.8213; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; HOLTZMAN EJ, 1993, J BIOL CHEM, V268, P3964; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; KINANE TB, 1993, J BIOL CHEM, V268, P24669; KINANE TB, 1994, J BIOL CHEM, V269, P27503; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; SHARMA PM, 1994, P NATL ACAD SCI USA, V91, P9931, DOI 10.1073/pnas.91.21.9931; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234	33	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30760	30764		10.1074/jbc.270.51.30760	http://dx.doi.org/10.1074/jbc.270.51.30760			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530517	hybrid			2022-12-25	WOS:A1995TL67500082
J	Look, DC; Pelletier, MR; Tidwell, RM; Roswit, WT; Holtzman, MJ				Look, DC; Pelletier, MR; Tidwell, RM; Roswit, WT; Holtzman, MJ			Stat1 depends on transcriptional synergy with Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTERCELLULAR-ADHESION MOLECULE-1; INTERFERON REGULATORY FACTOR; DNA-BINDING PROTEINS; GAMMA-INTERFERON; EPITHELIAL-CELLS; GENE PROMOTER; IFN-GAMMA; ACTIVATION; INDUCTION; ELEMENTS	STAT (Signal transducer and activator of transcription) proteins combine with cytokine receptors and receptor-associated kinases in distinct protein/protein interactions that are critical for STAT-dependent signal transduction events, but the nature of any subsequent STAT interactions with DNA-binding proteins in the nucleus is less certain. Based on assays of DNA/protein binding and activity of transfected reporter plasmids, we determined that occupation of contiguous DNA binding sites for Stat1 (the first member of the STAT family) and the transcriptional activator Sp1 are both required for full activation of the intercellular adhesion molecule-1 gene by interferon-gamma, Thus, Stat1 binding to DNA cannot by itself be equated with biologic actions of Stat1. In co-immunoprecipitation experiments, are also obtained evidence of direct and selective Stat1/Sp1 interaction (in primary culture cells without overexpression), further indicating that Stat1/Sp1 synergy confers an element of specificity in the pathway leading to cytokine-activated transcription and cytokine-dependent immunity and inflammation.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007317, R01HL051071] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL/AI-51071, HL-07317, HL-40078] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LOOK DC, 1992, AM J PHYSIOL, V263, pL79, DOI 10.1152/ajplung.1992.263.1.L79; LOOK DC, 1994, J BIOL CHEM, V269, P8952; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; REIN T, 1994, NUCLEIC ACIDS RES, V22, P3033, DOI 10.1093/nar/22.15.3033; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHORNICK LP, 1993, J BIOL CHEM, V268, P371; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	37	236	238	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30264	30267		10.1074/jbc.270.51.30264	http://dx.doi.org/10.1074/jbc.270.51.30264			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530443	hybrid			2022-12-25	WOS:A1995TL67500008
J	BOGOYEVITCH, MA; KETTERMAN, AJ; SUGDEN, PH				BOGOYEVITCH, MA; KETTERMAN, AJ; SUGDEN, PH			CELLULAR STRESSES DIFFERENTIALLY ACTIVATE C-JUN N-TERMINAL PROTEIN-KINASES AND EXTRACELLULAR SIGNAL-REGULATED PROTEIN-KINASES IN CULTURED VENTRICULAR MYOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; MYOCARDIAL-INFARCTION; MAP KINASE; GENE-EXPRESSION; PHORBOL ESTERS; HYPERTROPHY; GROWTH; PHOSPHORYLATION; FOS; TRANSCRIPTION	Anisomycin or osmotic stress induced by sorbitol activated c-Jun N-terminal protein kinases (JNKs) in ventricular myocytes cultured from neonatal rat hearts. After 15-30 min, JNK was activated by 10-20-fold. Activation by anisomycin was transient, but that by sorbitol was sustained for at least 4 h. In-gel JNK assays confirmed activation of two renaturable JNKs of 46 and 55 kDa (JNK-46 and JNK-55, respectively). An antibody against human JNK1 immunoprecipitated JNK-46 activity. Endothelin-1, an activator of extracellular signal-regulated protein kinases (ERKs), also transiently activated JNKs by 25-fold after 30 min. Phorbol 12-myristate 13-acetate did not activate the JNKs although it activated ERK1 and ERK2, which phosphorylated the c-Jun transactivation domain in vitro. ATP depletion and repletion achieved by incubation in cyanide + deoxyglucose and its subsequent removal from the medium activated the ERKs but failed to activate the JNKs. Sorbitol (but not anisomycin) also stimulated the ERKs. Sorbitol-stimulated JNK activity could be resolved into three peaks by fast protein liquid chromatography on a Mono Q column. The two major peaks contained JNK-46 or JNK-55. These results demonstrate that cellular stresses differentially activate the JNKs and ERKs and that there may be ''cross-talk'' between these MAPK pathways.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, NATL HEART & LUNG INST, LONDON SW3 6LY, ENGLAND	Imperial College London				Bogoyevitch, Marie/0000-0001-9745-3716	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANVERSA P, 1986, CIRC RES, V58, P26, DOI 10.1161/01.RES.58.1.26; ANVERSA P, 1985, AM J PATHOL, V118, P484; ANVERSA P, 1985, AM J PHYSIOL, V248, pH876, DOI 10.1152/ajpheart.1985.248.6.H876; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLERK A, 1994, J BIOL CHEM, V269, P32848; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FERRARI R, 1993, EUR HEART J, V14, P25; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GERDES AM, 1992, CIRCULATION, V86, P426, DOI 10.1161/01.CIR.86.2.426; GRANGER DN, 1995, ANNU REV PHYSIOL, V57, P311, DOI 10.1146/annurev.ph.57.030195.001523; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HUANG Y, 1994, J BIOL CHEM, V269, P31183; JENNINGS RB, 1991, ANNU REV MED, V42, P225, DOI 10.1146/annurev.med.42.1.225; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; OLIVETTI G, 1991, CIRC RES, V68, P856, DOI 10.1161/01.RES.68.3.856; PFEFFER JM, 1995, ANNU REV PHYSIOL, V57, P805, DOI 10.1146/annurev.ph.57.030195.004105; PIERCE GN, 1995, J MOL CELL CARDIOL, V27, P53; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUGDEN PH, 1994, CIRCULATION, V90, P303; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TOBE K, 1991, J BIOL CHEM, V266, P24793; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WEBER KT, 1994, HYPERTENSION, V23, P869, DOI 10.1161/01.HYP.23.6.869; WEBSTER KA, 1994, CIRC RES, V74, P679, DOI 10.1161/01.RES.74.4.679; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; YAN MH, 1994, NATURE, V372, P798; YAO A, 1995, J CLIN INVEST, V96, P69, DOI 10.1172/JCI118081	70	202	207	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29710	29717						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530360				2022-12-25	WOS:A1995TK38000020
J	SALERNO, A; LAWRENCE, DS				SALERNO, A; LAWRENCE, DS			COVALENT MODIFICATION WITH CONCOMITANT INACTIVATION OF THE CAMP-DEPENDENT PROTEIN-KINASE BY AFFINITY LABELS CONTAINING ONLY L-AMINO-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINYL-L-CYSTEINE; CATALYTIC SUBUNIT; ACTIVE-SITE; SULFHYDRYL-GROUP; BOVINE HEART; CATHEPSIN-B; PEPTIDES; INHIBITORS; RESIDUES; PAPAIN	Affinity labels for proteins that process other proteins (e.g. proteinases and protein kinases) are an amalgam of two components, an active site-directed peptide carrier and a nonpeptidic electrophilic appendage. We have synthesized several affinity labels for the cAMP-dependent protein kinase that are composed solely Of L-amino acids and therefore contain only functionality present in naturally occurring proteins. We have found that 2 adjacent cysteine residues, when covalently linked via a peptide bond and an intramolecular disulfide loop (abbreviated as Cys double line arrow pointing left and right Cys), serves as a potent electrophile. The peptides Leu-Arg-Arg-Cys double line arrow pointing left and right Cys-Leu-Gly (1), Leu-Arg-Arg-Ala-Cys double line arrow pointing left and right Cys-Gly (2), and Leu-Arg-Arg-Ala-Ala-Cys double line arrow pointing left and right Cys-Gly (3) inactivate the cAMP-dependent protein kinase in a time-dependent fashion. Since dialysis does not restore activity, but dithiothreitol does, this strongly suggests that covalent modification of the target enzyme has occurred at a cysteine residue. Although there are 2 cysteine moieties contained within the protein kinase, the C-14-acetylated affinity labels modify the enzyme only once. In addition, since ATP blocks inactivation of the protein kinase, this implies that it is the active site cysteine residue (Cys-199) that has undergone covalent modification. Based on the K(I(inact)) values obtained from inactivation kinetics, we conclude that the optimal site on the affinity label for the electrophilic Cys double line arrow pointing left and right Cys is 1 amino acid removed from the 2 arginine residues (i.e. 2). In addition, the efficacy of these inhibitors is also dependent upon the size of the disulfide ring. The eight-membered disulfide ring-containing peptides 1-3 are relatively poor affinity labels compared to the 12-membered ring-containing inhibitor, [GRAPHICS]	SUNY Buffalo, DEPT CHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045989] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45989] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG RN, 1978, BIOCHEMISTRY-US, V17, P2840, DOI 10.1021/bi00607a022; BLAKESLEY RW, 1977, ANAL BIOCHEM, V82, P580, DOI 10.1016/0003-2697(77)90197-X; BODANSZK.M, 1974, P NATL ACAD SCI USA, V71, P2791, DOI 10.1073/pnas.71.7.2791; BRAMSON HN, 1982, J BIOL CHEM, V257, P575; BRAMSON HN, 1983, CRC CRIT REV BIOCH, V15, P93; CAPASSO S, 1977, ACTA CRYSTALLOGR B, V33, P2080, DOI 10.1107/S0567740877007778; CHANDRAS.R, 1969, BIOCHIM BIOPHYS ACTA, V188, P1, DOI 10.1016/0005-2795(69)90039-7; CHANDRASEKHARAN R, 1968, Proceedings of the Indian Academy of Sciences Section A, V68, P13; EVANS B, 1983, J BIOL CHEM, V258, P227; FERAMISCO JR, 1978, J BIOL CHEM, V253, P8968; FUJII N, 1987, J CHEM SOC CHEM COMM, P163, DOI 10.1039/c39870000163; HATA Y, 1977, ACTA CRYSTALLOGR B, V33, P3561, DOI 10.1107/S0567740877011480; JAKOBY WB, 1977, METHOD ENZYMOL, V46, P1; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; KAO PN, 1986, J BIOL CHEM, V261, P8085; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEARY R, 1977, BIOCHEMISTRY-US, V16, P5857, DOI 10.1021/bi00645a033; MILLER SM, 1989, BIOCHEMISTRY-US, V28, P1194, DOI 10.1021/bi00429a037; MISE T, 1980, J BIOL CHEM, V255, P8516; MOBASHERY S, 1988, BIOCHEMISTRY-US, V27, P3691, DOI 10.1021/bi00410a025; MOORE S, 1954, J BIOL CHEM, V211, P907; ONG EB, 1965, J BIOL CHEM, V240, P694; OVICHINNIKOV YA, 1985, FEBS LETT, V179, P107; PLAPP BV, 1982, METHOD ENZYMOL, V87, P469; PROROK M, 1989, J BIOCHEM BIOPH METH, V18, P167, DOI 10.1016/0165-022X(89)90001-8; PROROK M, 1990, J AM CHEM SOC, V112, P8628; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; RIORDAN JF, 1967, METHOD ENZYMOL, V11, P565; SHAW E, 1988, J BIOL CHEM, V263, P2768; SHAW ELLIOTT, 1965, BIOCHEMISTRY, V4, P2219, DOI 10.1021/bi00886a039; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; SLUYTERMAN LA, 1973, BIOCHIM BIOPHYS ACTA, V302, P95, DOI 10.1016/0005-2744(73)90012-0; SUKUMARAN DK, 1991, J AM CHEM SOC, V113, P706, DOI 10.1021/ja00002a067; THOMPSON SA, 1986, J MED CHEM, V29, P104, DOI 10.1021/jm00151a018; VEBER DF, 1972, J AM CHEM SOC, V94, P5456, DOI 10.1021/ja00770a600; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WIBERG KB, 1992, J AM CHEM SOC, V114, P831, DOI 10.1021/ja00029a005; YABE Y, 1988, J AM CHEM SOC, V110, P4043, DOI 10.1021/ja00220a056; ZHANG RM, 1989, J BIOL CHEM, V264, P18472; ZHANG RM, 1988, BIOCHEMISTRY-US, V27, P3785, DOI 10.1021/bi00410a040	41	10	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13043	13049						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514745				2022-12-25	WOS:A1993LH55300008
J	Long, SD; Pekala, PH				Long, SD; Pekala, PH			Regulation of GLUT4 gene expression by arachidonic acid - Evidence for multiple pathways, one of which requires oxidation to prostaglandin E(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE-TRANSPORTER; NECROSIS-FACTOR-ALPHA; ENHANCER BINDING-PROTEIN; 3T3-L1 ADIPOCYTES; FATTY-ACIDS; TRANSCRIPTIONAL REPRESSION; RAT ADIPOCYTES; ACTIVATED RECEPTOR; MESSENGER-RNA; C-FOS	We have previously described the ability of arachidonic acid (AA) to regulate GLUT4 gene expression (Tebbey, P. W., McGowan, K. M., Stephens, J. M., Buttke, T. M., and Pekala, P. H. (1994) J. Biol. Chem. 269, 639-644). Chronic exposure (48 h) of fully differentiated 3T3 L1 cells to AA resulted in an similar to 90% suppression of GLUT4 mRNA accumulation. This decrease was demonstrated to be due to a 50% decrease in GLUT4 gene transcription as well as a destabilization of the GLUT4 message (t(1/2) decreased from 8.0 to 4.6 h). In the current study we have identified, at least in part, the mechanism by which AA exerts its effects on GLUT4 expression. Compatible with a cyclooxygenase mediated event, the AA-induced suppression of GLUT4 mRNA was abolished by pretreating the cells with the inhibitor, indomethacin. Consistent with this observation, exposure of the cells to 10 mu M PGE(2) mimicked the effect of AA, in contrast to products of the lipoxygenase pathway which were unable to suppress GLUT4 mRNA content. Quantification of the conversion of AA to PGE(2) demonstrated a 50-fold increase in PGE(2) released into the media within 7 h of AA addition. Cyclic AMP levels were also increased 50-fold with AA treatment consistent with PGE(2) activation of adenylate cyclase. Various long chain fatty acids, including the nonmetabolizable analog of AA, eicosatetraenoic acid (ETYA), also decreased GLUT4 mRNA levels. The effect of ETYA, a potent inhibitor of both lipo- and cyclooxygenases and a potent activator of peroxisome proliferator activated receptors (PPARs), suggested the presence of a second pathway where nonmetabolized fatty acid functioned to suppress GLUT4 mRNA levels. Further support for a PPAR-mediated mechanism was obtained by exposure of the cells to the classic PPAR activator, clofibrate, which resulted in a similar to 75% decrease in GLUT4 mRNA content. Nuclear extracts prepared from the adipocytes contained a protein complex that bound to the PPAR responsive element (PPRE) found in the promoter of the fatty acyl-CoA oxidase gene. When the adipocytes were treated with either AA or ETYA, binding to the PPRE was disrupted, consistent with an ability of these fatty acids to control gene expression by altering the occupation of a PPRE. However, a perfect PPRE has yet to be identified in the GLUT4 promoter, but this does not rule the possibility of a PPAR playing an indirect role in the AA-induced GLUT4 mRNA suppression.	E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27858	University of North Carolina; East Carolina University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032892] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32892] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AXELROD L, 1981, DIABETES, V30, P163, DOI 10.2337/diabetes.30.2.163; BELL RM, 1991, J BIOL CHEM, V266, P4661; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTKE TM, 1989, P NATL ACAD SCI USA, V86, P6133, DOI 10.1073/pnas.86.16.6133; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CLARKE SD, 1992, FASEB J, V6, P3146, DOI 10.1096/fasebj.6.13.1397836; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DANESCH U, 1994, J BIOL CHEM, V269, P27258; DAVIES P, 1992, INFLAMMATION BASIC P, P123; DISTEL RJ, 1992, J BIOL CHEM, V267, P5937; DOOLAN CM, 1994, BRIT J PHARMACOL, V111, P509, DOI 10.1111/j.1476-5381.1994.tb14766.x; EZAKI O, 1992, AM J PHYSIOL, V263, pE94, DOI 10.1152/ajpendo.1992.263.1.E94; EZAKI O, 1993, P NATL ACAD SCI USA, V90, P3348, DOI 10.1073/pnas.90.8.3348; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; FLORESRIVEROS JR, 1993, BIOCHEM BIOPH RES CO, V194, P1148, DOI 10.1006/bbrc.1993.1942; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GRUNFELD C, 1981, BIOCHEM BIOPH RES CO, V103, P46; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HARDY RW, 1991, BIOCHEM BIOPH RES CO, V177, P343, DOI 10.1016/0006-291X(91)91989-P; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HUNNICUTT JW, 1994, DIABETES, V43, P540, DOI 10.2337/diabetes.43.4.540; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN BB, 1992, J CLIN INVEST, V89, P1367, DOI 10.1172/JCI115724; KATHER H, 1982, PROSTA LEUKOTR MED, V9, P531, DOI 10.1016/0262-1746(82)90034-8; KATHER H, 1979, RES EXP MED, V176, P25, DOI 10.1007/BF01852108; KATHER H, 1977, J CYCLIC NUCL PROT, V3, P199; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; MURER E, 1992, DIABETES, V41, P1063, DOI 10.2337/diabetes.41.9.1063; NEUFELD EJ, 1983, J CLIN INVEST, V72, P214, DOI 10.1172/JCI110959; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; RICHELSEN B, 1987, BIOCHEM J, V247, P389, DOI 10.1042/bj2470389; STANKOVA J, 1992, BIOCHEM J, V282, P625; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; SVEDBERG J, 1990, DIABETES, V39, P570, DOI 10.2337/diabetes.39.5.570; TAYLOR AS, 1985, BIOCHIM BIOPHYS ACTA, V883, P229; TEBBEY PW, 1994, J BIOL CHEM, V269, P639; TEBBEY PW, 1992, BIOCHIM BIOPHYS ACTA, V1171, P27, DOI 10.1016/0167-4781(92)90136-N; TOBIAS LD, 1978, LIPIDS, V14, P181; TOMASKA L, 1993, J BIOL CHEM, V268, P5317; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X	51	100	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1138	1144		10.1074/jbc.271.2.1138	http://dx.doi.org/10.1074/jbc.271.2.1138			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557642	hybrid			2022-12-25	WOS:A1996TP88900079
J	Kikuchi, A; Williams, LT				Kikuchi, A; Williams, LT			Regulation of interaction of ras p21 with RalGDS and raf-1 by cyclic AMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; RECEPTOR TYROSINE KINASES; GTP-BINDING PROTEIN; MAP KINASE; EXCHANGE PROTEIN; SMG P21; GROWTH; ACTIVATION; CELLS; PHOSPHORYLATION	RalGDS is a GDP/GTP exchange protein for ral p24, a member of small GTP-binding protein superfamily. We have recently shown that RalGDS interacts directly with the GTP-bound active form of ras p21 through the effector loop of ras p21 in vitro, in insect cells and in the yeast two-hybrid system. These results suggest that RalGDS functions as an effector protein of ras p21. Here, we report that RalGDS interacts with ras p21 in mammalian cells in response to an extracellular signal. Epidermal growth factor (EGF) induced the interaction of c-ras p21 and RalGDS in COS cells expressing both proteins, but not in the cells expressing RalGDS and c-ras p21(T35A) which is an effector loop mutant of ras p21. We also found that cyclic AMP-dependent protein kinase (protein kinase A) regulated the selectivity of ras p21-binding to either RalGDS or Raf-1. Protein kinase A phosphorylated RalGDS as well as (1-149)Raf (amino acid residues 1-149). Although the phosphorylated (1-149)Raf had a lower affinity for ras p21 than the unphosphorylated (1-149)Raf, both the phosphorylated and unphosphorylated RalGDS had the similar affinities for ras p21. The phosphorylation of RalGDS did not affect its activity to stimulate the GDP/GTP exchange of ral p24. Pretreatment of COS cells with forskolin further stimulated the interaction of ras p21 and RalGDS induced by EGF under the conditions that EGF-dependent Raf-1 activity was inhibited. These results indicate that ras p21 distinguishes between RalGDS and Raf-1 by their phosphorylation by protein kinase A.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143; CHIRON CORP,EMERYVILLE,CA 94608	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Novartis								ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; GORMAN C, 1985, DNA CLONING PRACTICA, V2; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HATA Y, 1991, J BIOL CHEM, V266, P6571; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAIKUMAR P, 1988, ONCOGENE RES, V3, P213; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					588	594		10.1074/jbc.271.1.588	http://dx.doi.org/10.1074/jbc.271.1.588			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550624	hybrid			2022-12-25	WOS:A1996TP36100089
J	Reddy, ST; Herschman, HR				Reddy, ST; Herschman, HR			Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; ENDOPEROXIDE SYNTHASE; II PHOSPHOLIPASE-A2; ENDOTHELIAL-CELLS; ARACHIDONIC-ACID; MESANGIAL CELLS; BIOSYNTHESIS; EXPRESSION; DRUGS; LEUKOTRIENE-B4	Prostaglandins mediate many biological processes. Arachidonic acid, the common precursor for all prostaglandins, is released from membrane phospholipids by both secretory and cytoplasmic forms of phospholipase A(2). Free arachidonate is converted to prostaglandin H-2, the common precursor to all prostanoids, by prostaglandin synthase, Both mitogen-induced prostaglandin synthesis in fibroblasts and endotoxin-induced prostaglandin synthesis in macrophages require expression of the inducible prostaglandin synthase-2; arachidonate released in these contexts is unavailable to prostaglandin synthase-1 constitutively present in fibroblasts or macrophages. In contrast to the results for fibroblasts and macrophages, prostaglandin synthesis by activated mast cells is mediated by prostaglandin synthase-1. Mast cell activation also provokes release of secretory phospholipase A(2) (sPLA(2)). We now demonstrate that sPLA(2) released from activated mast cells can mobilize arachidonate from distal Swiss 3T3 cells. This arachidonate is then used by prostaglandin synthase-1 present in 3T3 cells for prostaglandin synthesis. We thus distinguish two pathways for prostaglandin synthesis: (i) an intracellular pathway by which arachidonate released following ligand stimulation is made available only to prostaglandin synthase-1, and (ii) a transcellular pathway by which sPLA(2) of proximal cells mobilizes, in distal cells, arachidonate available to prostaglandin synthase-1. Molecular and pharmacologic approaches to modulating prostaglandin-mediated events will differ for these two pathways.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,INST MOLEC BIOL 341A,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT PHARMACOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,CTR HLTH SCI,LAB STRUCT BIOL & MOLEC MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034567, U01AI034567] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34567] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; BARSUMIAN EL, 1985, CELL IMMUNOL, V90, P131, DOI 10.1016/0008-8749(85)90175-3; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; DEWITT DL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P121, DOI 10.1016/0005-2760(91)90032-D; EDENIUS C, 1988, BIOCHEM BIOPH RES CO, V157, P801, DOI 10.1016/S0006-291X(88)80320-6; FEINMARK SJ, 1987, BIOCHIM BIOPHYS ACTA, V922, P125, DOI 10.1016/0005-2760(87)90146-9; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; IVERSEN L, 1994, ARCH DERMATOL RES, V286, P261, DOI 10.1007/BF00387598; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUJUBU DA, 1993, J BIOL CHEM, V268, P5425; LANNI C, 1983, AM J PATHOL, V113, P90; LINDGREN JA, 1993, TRENDS PHARMACOL SCI, V14, P351, DOI 10.1016/0165-6147(93)90092-X; MARCHESELLI VL, 1988, NEUROMETHODS, V7, P83; MARSHALL LA, 1991, J RHEUMATOL, V18, P59; MARSHALL LA, 1995, IN PRESS J PHARM EXP; MASFERRER JL, 1994, J PHARMACOL EXP THER, V270, P1340; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; OKA S, 1991, J BIOL CHEM, V266, P9956; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; REDDY ST, 1994, J BIOL CHEM, V269, P15473; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SOLA J, 1992, J INVEST DERMATOL, V98, P333, DOI 10.1111/1523-1747.ep12499800; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479	37	106	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					186	191		10.1074/jbc.271.1.186	http://dx.doi.org/10.1074/jbc.271.1.186			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550557	hybrid			2022-12-25	WOS:A1996TP36100029
J	DelSal, G; Murphy, M; Ruaro, EM; Lazarevic, D; Levine, AJ; Schneider, C				DelSal, G; Murphy, M; Ruaro, EM; Lazarevic, D; Levine, AJ; Schneider, C			Cyclin D1 and p21/waf1 are both involved in p53 growth suppression	ONCOGENE			English	Article						cyclin; D1; p53; p21/waf1; cell cycle G1 arrest	WILD-TYPE P53; CELL-CYCLE; DEPENDENT KINASES; PROTEIN; APOPTOSIS; GENE; DNA; TRANSFORMATION; FIBROBLASTS; INHIBITION	Overexpression of the wild type p53 gene in normal and transformed cells induces G1 arrest of cellular proliferation. In cell lines carrying the valine 135 temperature-sensitive p53 mutant gene, restoration of wild type p53 protein conformation at the permissive temperature causes an increase in the levels of cyclin D1, as well as the cyclin/cdk inhibitor p21/waf1, Accumulation of cyclin D1 is the result both of (post)transcriptional and post-translational regulatory mechanisms. Ablation of cyclin D1 induction by antisense cDNA microinjection significantly delays the onset of growth arrest, indicating that increased cyclin D1 levels Likely contribute to wild type p53 G1 arrest. Whereas antisense ablation of either cyclin D1 or p21/waf1 can delay the onset of p53-induced growth arrest, ablation of neither is able to overcome a pre-existing p53-induced G1 block. In summary, the accumulated evidence indicate that induction of both cyclin D1 and p21/waf1 are involved in establishing the p53-mediated growth arrest in murine cell lines expressing temperature sensitive p53 protein.	LAB NAZL CONSORZIO INTERUNIV BIOTECHNOL, I-34012 TRIESTE, ITALY; INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY; DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOLEC VL, I-34012 TRIESTE, ITALY; PRINCETON UNIV, LEWIS THOMAS LAB, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	International Center for Genetic Engineering & Biotechnology (ICGEB); Princeton University			Lazarevic, Dejan/AAN-1861-2020	DEL SAL, GIANNINO/0000-0003-2185-6003; Murphy, Maureen/0000-0001-7644-7296; lazarevic, dejan/0000-0003-4527-290X				ATADJA P, 1995, EXP CELL RES, V217, P205, DOI 10.1006/excr.1995.1080; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAM SW, 1994, ONCOGENE, V9, P2663; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	47	71	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					177	185						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552389				2022-12-25	WOS:A1996TQ01400022
J	Vider, BZ; Zimber, A; Chastre, E; Prevot, S; Gespach, C; Estlein, D; Wolloch, Y; Tronick, SR; Gazit, A; Yaniv, A				Vider, BZ; Zimber, A; Chastre, E; Prevot, S; Gespach, C; Estlein, D; Wolloch, Y; Tronick, SR; Gazit, A; Yaniv, A			Evidence for the involvement of the Wnt 2 gene in human colorectal cancer	ONCOGENE			English	Article						Wnt genes; colorectal cancer	MAMMARY ONCOGENE INT-1; WINGLESS PROTEIN; DEVELOPMENTAL REGULATORS; PROVIRAL ACTIVATION; CELL-LINE; EXPRESSION; XENOPUS; EMBRYOS; TRANSFORMATION; FAMILY	Colorectal cancer (CRC) is onte of the most frequent cancers in humans. It develops via a multistage process involving alterations of both protooncogenes and tumor suppressor genes. In the present report we determined the level of expression of several Wnt genes in CRC by RT-PCR and direct sequencing. While Wnt-1 was not detectably expressed in any colonic tissues, Wnt-5a gene was efficiently expressed both in nontumorous as well as in colonic tumor tissues. In contrast, the Wnt-2 gene, which was expressed at low levels in normal colon, exhibited overexpression in all tumor tissue samples at the different Dukes' stages of CRC progression, including premalignant polyps and liver metastases. Overexpression of the Wnt-2 gene occurred also in other digestive neoplasms such as gastric and esophageal carcinomas, as well as in diverticulitis associated with stenosis or pseudo-tumor.	TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL; HEBREW UNIV JERUSALEM,DEPT ANIM SCI,IL-76100 REHOVOT,ISRAEL; HOSP ST ANTOINE,INSERM,U55,EQUIPE CANCEROGENESE & DIFFERENCIAT EPITHELIUM GA,F-75571 PARIS 12,FRANCE; HASHARON HOSP,DEPT SURG B,PETAH TIQWA,ISRAEL; SANTA CRUZ BIOTECHNOL,SANTA CRUZ,CA 95060	Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Rabin Medical Center			CHASTRE, Eric/L-8446-2018	CHASTRE, Eric/0000-0002-8993-1228				BLASBAND A, 1992, ONCOGENE, V7, P153; BOS JL, 1989, CANCER RES, V49, P4682; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; BURKITT DP, 1978, AM J CLIN NUTR, V31, P118; CABALLERO OL, 1995, NUCLEIC ACIDS RES, V23, P192, DOI 10.1093/nar/23.1.192; CHAKRABARTI A, 1992, DEVELOPMENT, V115, P355; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; DUKAS K, 1993, ANAL BIOCHEM, V215, P66, DOI 10.1006/abio.1993.1555; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY GJ, 1993, MUTAT RES, V290, P3, DOI 10.1016/0027-5107(93)90027-D; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HUGUET EL, 1994, CANCER RES, V54, P2615; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; LYNCH HT, 1992, CANCER, V70, P1300, DOI 10.1002/1097-0142(19920901)70:3+<1300::AID-CNCR2820701517>3.0.CO;2-O; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; PAINTER NS, 1971, BMJ-BRIT MED J, V2, P450, DOI 10.1136/bmj.2.5759.450; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PARKIN NT, 1993, GENE DEV, V7, P2181, DOI 10.1101/gad.7.11.2181; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; PORTE H, 1995, INT J CANCER, V64, P1; RAMAKRISHNA NR, 1993, DEVELOPMENT, P95; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1992, ONCOGENE, V7, P487; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WANG LM, 1993, CANCER RES, V53, P717; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; ZAKANY J, 1993, NATURE, V362, P546, DOI 10.1038/362546a0	62	105	112	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					153	158						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552386				2022-12-25	WOS:A1996TQ01400019
J	Baksh, S; Burns, K; Andrin, C; Michalak, M				Baksh, S; Burns, K; Andrin, C; Michalak, M			Interaction of calreticulin with protein disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; MUSCLE SARCOPLASMIC-RETICULUM; ION AFFINITY-CHROMATOGRAPHY; ENDOPLASMIC-RETICULUM; CA2+-BINDING PROTEIN; MOLECULAR-CLONING; SEQUENCE; EXPRESSION; IDENTIFICATION; CALSEQUESTRIN	We report here that calreticulin interacts with protein disulfide isomerase (PDI), The PDI-calreticulin complex can be dissociated by Zn2+-iminodiacetate substituted Sepharose-agarose chromatography, suggesting that these interactions may be Zn2+ dependent. Direct interaction between calreticulin and PDI is also documented by calreticulin affinity chromatography. PDI was the only pancreatic microsomal protein retained on the calreticulin affinity column. Calreticulin and PDI were identified by their NH2-terminal amino acid sequence analysis, mobilities in SDS-polyacrylamide gel electrophoresis, binding of Ca-45(2+), and their reactivity with specific antibodies. Using glutathione S-transferase-calreticulin fusion proteins, we show that PDI interacts strongly with the P-domain and only weakly with the N-domain of calreticulin. Expression of calreticulin domains and PDI as fusion proteins with GAL4 in the yeast two-hybrid system revealed that calreticulin interacted with PDI also under normal cellular conditions. Interaction with PDI required only the NH2-terminal region of the N-domain (amino acid residues 1-83) and the P-domain (amino acid residues 150-240) of calreticulin. Importantly, interaction between calreticulin and PDI led to the modulation of their activities. In the presence of PDI, calreticulin does not bind Ca2+ with high affinity. Calreticulin or the N-domain of calreticulin inhibited PDI ability to refold scrambled RNase A.	UNIV ALBERTA,MRC,GRP MOLEC BIOL MEMBRANE,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta			Baksh, Shairaz/GRX-2106-2022					Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BAKSH S, 1992, PROTEIN EXPRES PURIF, V3, P322, DOI 10.1016/1046-5928(92)90008-K; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BAKSH S, 1995, IN PRESS FEBS LETT; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Burns Kimberly, 1994, Trends in Cell Biology, V4, P152, DOI 10.1016/0962-8924(94)90190-2; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GHOSAL D, 1994, BBA-GEN SUBJECTS, V1200, P175, DOI 10.1016/0304-4165(94)90133-3; HEILMANN C, 1993, BIOCHEM BIOPH RES CO, V193, P611, DOI 10.1006/bbrc.1993.1668; HEMDAN ES, 1989, P NATL ACAD SCI USA, V86, P1811, DOI 10.1073/pnas.86.6.1811; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; JOHNSON E, 1992, J BIOL CHEM, V267, P14412; KHANNA NC, 1986, J BIOL CHEM, V261, P8883; KOCH GLE, 1987, J CELL SCI, V87, P491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERT N, 1983, BIOCHEM J, V213, P225, DOI 10.1042/bj2130225; LEBECHE D, 1994, BIOCHEM BIOPH RES CO, V202, P556, DOI 10.1006/bbrc.1994.1964; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; LIU NG, 1994, J BIOL CHEM, V269, P28635; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCERO HA, 1994, J BIOL CHEM, V269, P23112; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MICHALAK M, 1995, CALRETICULIN; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MILNER RE, 1991, J BIOL CHEM, V266, P7155; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OSTWALD TJ, 1974, J BIOL CHEM, V249, P5867; OZAWA M, 1993, J BIOL CHEM, V268, P699; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PICELLO E, 1992, BIOCHEM BIOPH RES CO, V186, P659, DOI 10.1016/0006-291X(92)90797-O; PORATH J, 1983, BIOCHEMISTRY-US, V22, P1621, DOI 10.1021/bi00276a015; RACCHETTI G, 1994, BIOCHEM BIOPH RES CO, V203, P828, DOI 10.1006/bbrc.1994.2257; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; TJOELKER LW, 1994, BIOCHEMISTRY-US, V33, P3229, DOI 10.1021/bi00177a013; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WATANABE D, 1994, J BIOL CHEM, V269, P7744; YOKOI T, 1993, BIOCHIM BIOPHYS ACTA, V1158, P339, DOI 10.1016/0304-4165(93)90033-5	58	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31338	31344		10.1074/jbc.270.52.31338	http://dx.doi.org/10.1074/jbc.270.52.31338			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537405	hybrid			2022-12-25	WOS:A1995TN44400072
J	Burbelo, PD; Miyamoto, S; Utani, A; Brill, S; Yamada, KM; Hall, A; Yamada, Y				Burbelo, PD; Miyamoto, S; Utani, A; Brill, S; Yamada, KM; Hall, A; Yamada, Y			p190-B, a new member of the Rho GAP family, and Rho are induced to cluster after integrin cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; RECEPTOR TYROSINE KINASES; CELL-ADHESION; FIBRONECTIN RECEPTOR; FOCAL ADHESIONS; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAIN; ACTIVATING PROTEIN; MOLECULAR-CLONING	p120(GAP) forms distinct complexes with two phosphoproteins, p62 and p190, Here we have cloned a cDNA encoding a protein with 51% amino acid identity to p190 (hereafter designated p190-A) and have designated it p190-B. The N-terminal portion of p190-B contained several motifs characteristic of a GTPase domain, while its C terminus contained a Rho GAP domain, A recombinant Rho GAP domain polypeptide showed GAP activity for RhoA, Rac1, and G25K/CDC42Hs. Immunoprecipitation and immunofluorescence studies demonstrated that p190-B protein was expressed in a variety of cells and was localized diffusely in the cytoplasm and in fibrillar patterns that co-localized with the alpha(5) beta(1) integrin receptor for fibronectin, Adhesion of fibronectin-coated latex beads to cells resulted in recruitment of significant amounts of p190-B and Rho to the plasma membrane beneath the site of bead binding, In contrast, beads coated with polylysine or concanavalin A were unable to recruit p190-B or Rho, Additionally, anti-beta(1) or anti-alpha(5) integrin antibody-coated beads were also able to recruit large amounts of p190-B and Rho, These results identify a novel second member of the p190 family and establish the existence of a novel transmembrane link between integrins and a new protein p190-B and Rho.	NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Burbelo, PD (corresponding author), UCL, MRC, MOLEC CELL BIOL LAB, CRC ONCOGENE & SIGNAL TRANSDUCT GRP, GOWER ST, LONDON WC1E 6BT, ENGLAND.		Burbelo, Peter D./B-1027-2009	Yamada, Kenneth/0000-0003-1512-6805				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURBELO PD, 1994, GENE, V139, P241, DOI 10.1016/0378-1119(94)90763-3; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHANG JH, 1993, ONCOGENE, V8, P959; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; GEIGER B, 1992, J CELL SCI, V103, P943; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRINNELL F, 1986, EXP CELL RES, V162, P449, DOI 10.1016/0014-4827(86)90349-6; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HALL A, 1992, CELL, V69, P389, DOI 10.1016/0092-8674(92)90441-E; HART MJ, 1991, J BIOL CHEM, V266, P20840; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LECLERC S, 1991, J BIOL CHEM, V266, P17333; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MARCANTONIO EE, 1990, CELL REGUL, V1, P597, DOI 10.1091/mbc.1.8.597; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30919	30926		10.1074/jbc.270.52.30919	http://dx.doi.org/10.1074/jbc.270.52.30919			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537347	hybrid			2022-12-25	WOS:A1995TN44400015
J	Fiore, F; Zambrano, N; Minopoli, G; Donini, V; Duilio, A; Russo, T				Fiore, F; Zambrano, N; Minopoli, G; Donini, V; Duilio, A; Russo, T			The regions of the Fe65 protein homologous to the phosphotyrosine interaction phosphotyrosine binding domain of Shc bind the intracellular domain of the Alzheimer's amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; TYROSINE KINASES; DISEASE; RECEPTOR; PHOSPHORYLATION; ASSOCIATION; PATHWAY; SYSTEM; GENE	Fe65 is a protein mainly expressed in several districts of the mammalian nervous system, The search of protein sequence data banks revealed that Fe65 contains two phosphotyrosine interaction (PID) or phosphotyrosine binding (PTB) domains, previously identified in the Shc adaptor molecule. The two putative PID/PTB domains of Fe65 were used to construct glutathione S-transferase-Fe65 fusion proteins, Co-precipitation experiments demonstrated that the Fe65 PID/PTB domains interacted with several proteins of apparent molecular mass 135, 115, 105, and 51 kDa, The region of Fe65 containing the PID/PTB domains was used as a bait to screen a human brain cDNA library in yeast by the two-hybrid system, Three different cDNA clones were isolated, two of which contain overlapping segments of the cDNA encoding the COOH terminus of the Alzheimer's beta-amyloid-precursor protein (APP), that represents the short intracellular domain of this membrane protein, The third clone contains a cDNA fragment coding for the COOH terminus of the human counterpart of a mouse beta-amyloid-like precursor protein. The alignment of the three APP encoding cDNA fragments found in the screening suggests that the region of APP involved in the binding is centered on the NPTY sequence, which is analogous to that present in the intracellular domains of the growth factor receptors interacting with the PID/PTB domain of Shc.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY	University of Naples Federico II			Zambrano, Nicola/B-9352-2014; Russo, Tommaso/K-1331-2016	Zambrano, Nicola/0000-0001-9395-3481; Russo, Tommaso/0000-0003-4426-0106				BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESPOSITO F, 1990, DEV NEUROSCI-BASEL, V12, P373, DOI 10.1159/000111865; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FARAONIO R, 1994, NUCLEIC ACIDS RES, V22, P4876, DOI 10.1093/nar/22.23.4876; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIORE F, 1995, CELL CYCLE MATERIALS, P211; GANDY S, 1988, P NATL ACAD SCI USA, V85, P6218, DOI 10.1073/pnas.85.16.6218; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WU RY, 1994, J BIOL CHEM, V269, P25085	37	274	281	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30853	30856		10.1074/jbc.270.52.30853	http://dx.doi.org/10.1074/jbc.270.52.30853			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537337	hybrid			2022-12-25	WOS:A1995TN44400005
J	Uchida, K; Mori, H; Mizushima, S				Uchida, K; Mori, H; Mizushima, S			Stepwise movement of preproteins in the process of translocation across the cytoplasmic membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON MOTIVE FORCE; PROTEIN-TRANSLOCATION; SECRETORY PROTEINS; INVITRO TRANSLOCATION; PRESECRETORY PROTEINS; SECA; VESICLES; EXPORT; COMPONENTS; MACHINERY	Derivatives of proOmpA possessing the second cysteine residue at position +302 and the first one at different positions were constructed at the DNA level. They were oxidized to form disulfide-bridged loops of different sizes at different positions. In the presence of a protonmotive force, proOmpAs possessing a smaller loop could be translocated across the membrane in vitro, whereas ones possessing loops comprising more than 16 amino acid residues were hard to translocate. The sizes of polypeptide chains that had been translocated and had become protease-resistant were determined in both the presence and absence of the protonmotive force. The size was the same for all proOmpAs possessing the first cysteine residue between +244 (proOmpA L59) and +274 (proOmpA L29). When the first cysteine residue was moved further away from the N terminus, a sudden in crease in size, of approximately 30 amino acid residues, was observed, the size being the same for proOmpAs possessing the first cysteine residue between +278 (proOmpA L25) and +293 (proOmpA L10). The shift in size between proOmpA L29 and proOmpA L25 was observed with different proteases exhibiting different substrate specificities. Treatment with these proteases resulted in complete digestion of SecA on everted membrane vesicles, whereas Sec proteins integrated into membranes were considerably resistant to the treatment. These results can be best interpreted as that the translocation of preproteins through the secretory machinery takes place in every 30 amino acid residues and that SecA is responsible for the stepwise movement.	TOKYO UNIV PHARM & LIFE SCI, SCH LIFE SCI, HACHIOJI, TOKYO 19203, JAPAN; UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, BUNKYO KU, TOKYO 113, JAPAN	Tokyo University of Pharmacy & Life Sciences; University of Tokyo				Mori, Hiroyuki/0000-0002-0429-1269				AHN T, 1994, BIOCHEM BIOPH RES CO, V203, P326, DOI 10.1006/bbrc.1994.2185; AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; DRIESSEN AJM, 1990, P NATL ACAD SCI USA, V87, P3107, DOI 10.1073/pnas.87.8.3107; DRIESSEN AJM, 1992, EMBO J, V11, P847, DOI 10.1002/j.1460-2075.1992.tb05122.x; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FREUDL R, 1989, J MOL BIOL, V205, P771, DOI 10.1016/0022-2836(89)90321-5; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; HANADA M, 1994, J BIOL CHEM, V269, P23625; KATO M, 1992, J BIOL CHEM, V267, P413; KATO M, 1993, J BIOL CHEM, V268, P3586; Keil B., 1992, SPECIFICITY PROTEOLY, V331, P201, DOI DOI 10.1007/978-3-642-48380-6; KIM YJ, 1994, CELL, V78, P845; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MATSUYAMA S, 1995, ADV CELL MOL BIOL M, V4, P61; MIZUSHIMA S, 1986, BACTERIAL OUTER MEMB, P163; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; SAGARA K, 1994, J BACTERIOL, V176, P4111, DOI 10.1128/JB.176.13.4111-4116.1994; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SCHEKMAN R, 1994, CELL, V78, P911, DOI 10.1016/0092-8674(94)90265-8; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHINKAI A, 1990, BIOCHEM BIOPH RES CO, V172, P1217, DOI 10.1016/0006-291X(90)91578-G; TANI K, 1991, FEBS LETT, V285, P127, DOI 10.1016/0014-5793(91)80741-K; TANI K, 1989, J BIOL CHEM, V264, P18582; TANI K, 1990, J BIOL CHEM, V265, P17341; VESTWEBER D, 1988, J CELL BIOL, V107, P2045, DOI 10.1083/jcb.107.6.2045; WICKNER WT, 1994, SCIENCE, V266, P1197, DOI 10.1126/science.7973701; YAMADA H, 1989, J BIOL CHEM, V264, P1723; YAMANE K, 1987, J BIOL CHEM, V262, P2358	42	75	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30862	30868		10.1074/jbc.270.52.30862	http://dx.doi.org/10.1074/jbc.270.52.30862			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537339	hybrid			2022-12-25	WOS:A1995TN44400007
J	Schievella, AR; Regier, MK; Smith, WL; Lin, LL				Schievella, AR; Regier, MK; Smith, WL; Lin, LL			Calcium-mediated translocation of cytosolic phospholipase A(2) to the nuclear envelope and endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SWISS 3T3 CELLS; ARACHIDONIC-ACID; ACTIVATION; RELEASE; PROTEIN; PHOSPHORYLATION; 5-LIPOXYGENASE; DEXAMETHASONE; ACCUMULATION	Cytosolic phospholipase A(2) (cPLA(2)) is activated by a wide variety of stimuli to release arachidonic acid, the precursor of the potent inflammatory mediators prostaglandin and leukotriene. Specifically, cPLA(2) releases arachidonic acid in response to agents that increase intracellular Ca2+. In vitro data have suggested that these agents induce a translocation of cPLA(2) from the cytosol to the cell membrane, where its substrate is localized. Here, we use immunofluorescence to visualize the translocation of cPLA(2) to distinct cellular membranes. In Chinese hamster ovary cells that stably overexpress cPLA(2), this enzyme translocates to the nuclear envelope upon stimulation with the calcium ionophore A23187. The pattern of staining observed in the cytoplasm suggests that cPLA(2) also translocates to the endoplasmic reticulum. We find no evidence for cPLA(2) localization to the plasma membrane. Translocation or cPLA(2) is dependent on the calcium-dependent phospholipid binding domain, as a calcium-dependent phospholipid binding deletion mutant of cPLA(2) (Delta CII) fails to translocate in response to Ca2+. In contrast, cPLA(2) mutated at Ser-505, the site of mitogen-activated protein kinase phosphorylation, translocates normally. This observation, combined with the observed phosphorylation of Delta CII, establishes that translocation and phosphorylation function independently to regulate cPLA(2). The effect of these mutations on cPLA(2) translocation was confirmed by subcellular fractionation. Each of these mutations abolished the ability of cPLA(2) to release arachidonic acid, establishing that cPLA(2)-mediated arachidonic acid release is strongly dependent on both phosphorylation and translocation. These data help to clarify the mechanisms by which cPLA(2) is regulated in intact cells and establish the nuclear envelope and endoplasmic reticulum as primary sites for the liberation of arachidonic acid in the cell.	GENET INST INC,SMALL MUSCLE DRUG DISCOVERY GRP,CAMBRIDGE,MA 02140; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NIDDK NIH HHS [DK22042, DK20945] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022042, R01DK022042] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNETT RL, 1994, AM J PHYSIOL, V266, pF46, DOI 10.1152/ajprenal.1994.266.1.F46; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CAPRIOTTI AM, 1988, J BIOL CHEM, V263, P10029; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHEPENIK KP, 1994, J BIOL CHEM, V269, P21786; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DOMIN J, 1993, J BIOL CHEM, V268, P8927; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; GIL J, 1991, J CELL BIOL, V113, P943, DOI 10.1083/jcb.113.4.943; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; KAST R, 1993, J BIOL CHEM, V268, P16795; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; LARKIN M, 1992, J BIOL CHEM, V267, P13661; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; NEUFELD EJ, 1985, J CELL BIOL, V101, P573, DOI 10.1083/jcb.101.2.573; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; RAMESHA CS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P37, DOI 10.1016/0005-2760(93)90263-9; REDDY ST, 1994, J BIOL CHEM, V269, P15473; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SCHALKWIJK CG, 1993, FEBS LETT, V333, P339, DOI 10.1016/0014-5793(93)80683-L; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SHARP JD, 1993, J LIPID MEDIATOR, V8, P183; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; WADE MH, 1993, BIOANALYTICAL INSTRU, V37, P117; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	41	415	417	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30749	30754		10.1074/jbc.270.51.30749	http://dx.doi.org/10.1074/jbc.270.51.30749			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530515	hybrid			2022-12-25	WOS:A1995TL67500080
J	Seale, JW; Horowitz, PM				Seale, JW; Horowitz, PM			The C-terminal sequence of the chaperonin GroES is required for oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; GEL-ELECTROPHORESIS; GENE-PRODUCTS; PROTEINS; COOPERATIVITY; PURIFICATION; HYDROLYSIS	The Escherichia coli protein GroES is a co-chaperonin that is able to assist GroEL in the refolding of proteins. GroES is a heptamer of seven identical subunits, Recent work has focused on the structural aspects of GroES. We have investigated the role of the C-terminal portion of GroES on its oligomerization. Limited proteolysis of GroES by carboxypeptidase Y gives a product in which the C-terminal 7 amino acid residues have been re moved, Sedimentation velocity analysis reveals that the truncated form of GroES is unable to reassemble. The results presented here implicate the C-terminal sequence in intermonomer actions within the GroES oligomer, In addition, this work provides experimental verification of predictions implied in the recent x-ray determination of the GroES structure (Hunt, J. F., Weaver, A. J., Landry, S. J., Gierasch, L. M., and Deisenhofer, J. Nature, in press).	UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78240 USA	University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ES 05729] Funding Source: Medline; NIGMS NIH HHS [GM 25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HAYASHI R, 1973, J BIOL CHEM, V248, P2296; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; NEUHOFF V, 1986, ELECTROPHORESIS, V7, P56, DOI 10.1002/elps.1150070110; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SRINIVASAN R, 1995, PROTEINS, V22, P81, DOI 10.1002/prot.340220202; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VALENCIA A, 1995, PROTEINS, V22, P199, DOI 10.1002/prot.340220302; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; ZONDLO J, 1995, BIOCHEMISTRY-US, V34, P10334, DOI 10.1021/bi00033a003	24	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30268	30270		10.1074/jbc.270.51.30268	http://dx.doi.org/10.1074/jbc.270.51.30268			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530444	hybrid			2022-12-25	WOS:A1995TL67500009
J	Takasawa, S; Ishida, A; Nata, K; Nakagawa, K; Noguchi, N; Tohgo, A; Kato, I; Yonekura, H; Fujisawa, H; Okamoto, H				Takasawa, S; Ishida, A; Nata, K; Nakagawa, K; Noguchi, N; Tohgo, A; Kato, I; Yonekura, H; Fujisawa, H; Okamoto, H			Requirement of calmodulin-dependent protein kinase II in cyclic ADP-ribose-mediated intracellular Ca2+ mobilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CARDIAC RYANODINE RECEPTOR; PROINSULIN SYNTHESIS; INSULIN-SECRETION; BETA-CELLS; RELEASE; PHOSPHORYLATION; MECHANISM; GLUCOSE; CHANNEL	Cyclic ADP-ribose (cADPR) is generated in pancreatic islets by glucose stimulation, serving as a second messenger for Ca2+ mobilization from the endoplasmic reticulum for insulin secretion (Takasawa, S., Nata, K., Yonekura, H., and Okamoto, H. (1993) Science 259, 370-373), In the present study, we observed that the addition of calmodulin (CaM) to rat islet microsomes sensitized and activated the cADPR-mediated Ca2+ release, Inhibitors for CaM-dependent protein kinase II (CaM kinase II) completely abolished the glucose-induced insulin secretion as well as the cADPR-mediated and CaM-activated Ca2+ mobilization. Western blot analysis revealed that the microsomes contain the alpha isoform of CaM kinase II but do not contain CaM. When the active 30-kDa chymotryptic fragment of CaM kinase II was added to the microsomes, fully activated cADPR-mediated Ca2+ release was observed in the absence of CaM. These results along with available evidence strongly suggest that CaM kinase II is required to phosphorylate and activate the ryanodine-like receptor, a Ca2+ channel for cADPR as an endogenous activator, for the cADPR-mediated Ca2+ release.	TOHOKU UNIV, SCH MED, DEPT BIOCHEM, AOBA KU, SENDAI, MIYAGI 98077, JAPAN; ASAHIKAWA MED COLL, DEPT BIOCHEM, ASAHIKAWA 078, HOKKAIDO, JAPAN	Tohoku University; Asahikawa Medical College			Nakagawa, Kei/K-2294-2019	Nakagawa, Kei/0000-0002-3058-5674; Takasawa, Shin/0000-0002-4066-0199				CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HAIN J, 1995, J BIOL CHEM, V270, P2074, DOI 10.1074/jbc.270.5.2074; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HOHENEGGER M, 1993, BIOCHEM J, V296, P303, DOI 10.1042/bj2960303; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; ISHIDA A, 1995, J BIOL CHEM, V270, P2163, DOI 10.1074/jbc.270.5.2163; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; NORLING LL, 1994, CELL CALCIUM, V16, P137, DOI 10.1016/0143-4160(94)90008-6; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; OKAMOTO H, 1995, BIOCHIMIE, V77, P356, DOI 10.1016/0300-9084(96)88146-6; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TAKASAWA S, 1993, SCIENCE, V262, P585, DOI 10.1126/science.262.5133.585-a; TAKASAWA S, 1994, INSULIN SECRETION PA, P123; TANAKA Y, 1995, P NATL ACAD SCI USA, V92, P3244, DOI 10.1073/pnas.92.8.3244; Thomas A.P., 1991, CELLULAR CALCIUM PRA, P1; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOHGO A, 1994, J BIOL CHEM, V269, P28555; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; WITCHER DR, 1991, J BIOL CHEM, V266, P11144	29	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30257	30259		10.1074/jbc.270.51.30257	http://dx.doi.org/10.1074/jbc.270.51.30257			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530441	hybrid			2022-12-25	WOS:A1995TL67500006
J	Frank, R; Zhang, J; Uchida, H; Meyers, S; Hiebert, SW; Nimer, SD				Frank, R; Zhang, J; Uchida, H; Meyers, S; Hiebert, SW; Nimer, SD			The AML1/ETO fusion protein blocks transactivation of the GM-CSF promoter by AML1B	ONCOGENE			English	Article						AML1/ETO; AML1B; GM-CSF promoter; transcriptional activation	COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; CELL RECEPTOR-DELTA; TRANSCRIPTIONAL ENHANCER; DNA-BINDING; TRANSLOCATION PROTEIN; REGULATORY ELEMENTS; ENDOTHELIAL-CELLS; GENE; RUNT	The t(8;21) translocation, commonly found myelogenous leukemia (AML), generates protein containing N-terminal AML1 and C-terminal ETO amino acids. The human AML1 gene encodes several related proteins that specifically bind to the sequence TGT/cGGT, located in the promoter regions of a variety of hematopoietic growth factor genes. To examine the abilities of the AML1B protein (which contains 479 amino acids), a shorter AML1A isoform (which contains amino acids 1-250), and the AML1/ETO fusion protein (which contains AML1A amino acids 1-177) to stimulate transcription from the GMCSF promoter, we performed co-transfection experiments in T cells using a human GM-CSF promoter-CAT reporter gene plasmid and expression vectors that contain the cDNAs for one of the above proteins, Our data demonstrate that AML1B, but not AML1A or AML1/ETO transactivates the GM-CSF promoter, requiring the TGTGGT sequence contained between base pairs -68 and -53. Furthermore, we show that AML1/ETO, but not AML1A, inhibits the ability of AML1B to stimulate CAT expression. Electrophoretic mobility shift assays demonstrated the specific binding of AML1 proteins to the GM-CSF promoter TGTGGT sequence, which does not require GM-CSF sequences immediately upstream of this binding site. Our data support a role for AML1B as a transcriptional activator and establish that the AML1/ETO fusion protein can act as a dominant negative protein on the human GMCSF promoter. Although AML1/ETO does not stimulate the transcription of GM-CSF, it may function by inhibiting the normal activity of AML1B in AML cells with the t(8;21) translocation.	MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST, LAB MOLEC ASPECTS HEMATOPOIESIS, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [R01CA064140, T32CA009512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA64140, CA09512] Funding Source: Medline; NIDDK NIH HHS [R01 DK43025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BEGLEY CG, 1987, LEUKEMIA, V1, P1; BRADBURY D, 1990, LEUKEMIA, V4, P44; BROUDY VC, 1986, P NATL ACAD SCI USA, V83, P7467, DOI 10.1073/pnas.83.19.7467; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON P, 1992, BLOOD, V80, P1825; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GILL LL, 1991, EUR J IMMUNOL, V21, P807, DOI 10.1002/eji.1830210339; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HAJRA A, 1995, P NATL ACAD SCI USA, V92, P1926, DOI 10.1073/pnas.92.6.1926; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAUSHANSKY K, 1989, J IMMUNOL, V143, P2525; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NICHOLS J, 1992, BLOOD, V80, P2953; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; NIMER SD, 1989, J IMMUNOL, V143, P2374; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; SASSONECORSI P, 1986, TRENDS GENET, V2, P215, DOI 10.1016/0168-9525(86)90233-7; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; YOUNG DR, 1986, BLOOD, V68, P1168; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	48	199	208	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2667	2674						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545124				2022-12-25	WOS:A1995TP18800023
J	King, AG; Ozanne, BW; Smythe, C; Ashworth, A				King, AG; Ozanne, BW; Smythe, C; Ashworth, A			Isolation and characterisation of a uniquely regulated threonine, tyrosine phosphatase (TYP 1) which inactivates ERK2 and p54(jnk)	ONCOGENE			English	Article						dual-specificity phosphatase; MAP kinase inhibitor	ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; MAP KINASE; CELL-PROLIFERATION; MESSENGER-RNAS; GROWTH; DEPHOSPHORYLATION; TRANSFORMATION; PURIFICATION; SEQUENCE	The recent discovery of the vaccinia virus protein phosphatase VH1, and its mammalian counterparts has highlighted a novel subfamily of protein tyrosine phosphatases that exhibit dual specificity toward phosphotyrosine- and phosphoserine/threonine-residues. We have identified further members of this subfamily. The characterisation of one clone in particular, which we have named threonine-tyrosine phosphatase 1 (TYP 1), encodes a protein homologous to CL100, but differs dramatically in its regulation, TYP 1 is not expressed in human fibroblasts unlike other CL100-like genes, Furthermore, northern analysis has demonstrated that following mitogenic stimulation of squamous cells, induction of TYP 1 mRNA reaches its maximal levels after four hours, in contrast to the immediate early CL100-like genes, Both TYP 1 and CL100 mRNAs are induced upon TGF-beta treatment of squamous cell lines sensitive to the growth factors antiproliferative effects, When TYP 1 is transfected into COS-1 cells, the gene product inhibits both ERK2 and p54 MAP kinase subfamilies, In addition, we show that purified TYP 1 protein efficiently inactivates recombinant ERK2 in vitro by the concomitant dephosphorylation of both its phosphothreonine and -tyrosine residues, TYP 1 encodes a nuclear protein, which when expressed in COS cells is stabilised by EGF treatment.	BEATSON INST CANC RES,CANC RES CAMPAIGN LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Beatson Institute; University of Dundee; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ASHWORTH A, 1993, TRANSCRIPTION FACTOR, P125; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUFF JL, 1995, J BIOL CHEM, V270, P1; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAU KHW, 1993, CRIT REV ONCOGENESIS, V4, P451; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1981, CANCER RES, V41, P1657; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SETH A, 1992, J BIOL CHEM, V267, P24796; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P25317; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	65	57	58	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2553	2563						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545112				2022-12-25	WOS:A1995TP18800011
J	LEVYTOLEDANO, R; BLAETTLER, DH; LAROCHELLE, WJ; TAYLOR, SI				LEVYTOLEDANO, R; BLAETTLER, DH; LAROCHELLE, WJ; TAYLOR, SI			INSULIN-INDUCED ACTIVATION OF PHOSPHATIDYLINOSITOL (PI)3-KINASE - INSULIN-INDUCED PHOSPHORYLATION OF INSULIN-RECEPTORS AND INSULIN-RECEPTOR SUBSTRATE-1 DISPLACES PHOSPHORYLATED PLATELET-DERIVED GROWTH-FACTOR RECEPTORS FROM BINDING-SITES ON PI-3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ASSOCIATION; PROTEIN; INVITRO; IRS-1; PHOSPHOTYROSINE; STIMULATION; ENDOCYTOSIS; MUTATION; PATHWAY	Phosphatidylinositol (PI) 3-kinase is an enzyme that functions in the signaling pathways downstream from multiple cell surface receptors, The p85 regulatory subunit of PI 3-kinase binds to phosphotyrosine residues of various phosphoproteins including the platelet-derived growth factor (PDGF) receptor, the insulin receptor, and insulin receptor substrate-1 (IRS-1). Using NIH-3T3 cells overexpressing the human insulin receptor, we demonstrate that the p85 regulatory subunit of PI 3-kinase binds to phosphorylated PDGF receptor in cells incubated in the absence of insulin. When insulin is added, p85 is released from phosphorylated PDGF receptors and binds to phosphorylated insulin receptors and insulin receptor substrate-1. Moreover, insulin-induced dissociation of PDGF receptors from binding sites on PI 3-kinase requires a functional insulin receptor and is not prevented by vanadate treatment. In contrast, insulin activation does not displace PDGF receptors from binding sites on Ras GTPase-activating protein. This competition for binding to PI 3-kinase provides a mechanism for cross-talk among signaling pathways initiated by distinct peptide hormones and growth factors such as insulin and PDGF.	NIDDK,DIABET BRANCH,BETHESDA,MD 20892; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CAMA A, 1992, J BIOL CHEM, V267, P8383; CAMA A, 1991, J CLIN ENDOCR METAB, V73, P894, DOI 10.1210/jcem-73-4-894; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FLEMING TP, 1992, ONCOGENE, V7, P1355; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2538; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; ULLRICH A, 1985, NATURE, V813, P756; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; YONEZAWA K, 1992, J BIOL CHEM, V267, P440	26	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30018	30022						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530404				2022-12-25	WOS:A1995TK38000064
J	KASPRZAK, AA				KASPRZAK, AA			MYOSIN SUBFRAGMENT-1 INHIBITS DISSOCIATION OF NUCLEOTIDE AND CALCIUM FROM G-ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN; MONOMERIC ACTIN; CONFORMATIONAL CHANGE; ROTATIONAL-DYNAMICS; SLIDING MOVEMENT; BINDING REGION; METAL-ION; MUSCLE; POLYMERIZATION; COMPLEX	The dissociation rates of 1,N6-ethenoadenosine 5'-triphosphate (epsilonATP) and of Ca2+ from G-actin and its complex with myosin subfragment 1 (S1) were measured by recording a large decrease in the fluorescence intensity of the dissociating nucleotide. Under the experimental conditions employed, the binary G-acto-S1A2 complex does not polymerize (Chaussepied, P., and Kasprzak, A. A. (1989) Nature 342, 950-953). The released nucleotide was hydrolyzed either by alkaline phosphatase or by apyrase; to trap Ca2+, EDTA was used. From the anisotropy of N-iodoacetyl-N'-(5-sulfo-1-naphthyl)ethylenediamine (1,5-IAEDANS)-actin, it was established that during the dissociation of epsilonATP, the G-acto-S1 complex remained stable and the equilibrium of the system was unaltered. The reactions followed first order kinetics. The dissociation rate constant, k(d) for epsilonATP decreased from 5.5 x 10(-2) s-1 for free G-actin to 1 x 10(-4) s-1 for G-acto-S1A2; for Ca2+, k(d) was also similarly reduced from 2.8 x 10(-2) s-1 to 4 x 10(-3) s-1. Two proteolytically derived actin variants were also examined. For free subtilisin-cleaved actin, k(d) for epsilonATP was elevated 2-fold but was almost unchanged for Ca2+. In the complex of the cleaved G-actin with S1A2, k(d) for both epsilonATP and for Ca2+ were reduced. The removal of the last 3 amino acids from actin produced a derivative whose behavior in binding to S1, as well as in the kinetics of epsilonATP and Ca2+ dissociation, was undistinguishable from the unmodified protein.	UNIV MONTPELLIER 1, CNRS, CTR RECH BIOCHIM MACROMOLEC, INSERM, U249, F-34033 MONTPELLIER, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	KASPRZAK, AA (corresponding author), CNRS, CRBM, BP 5051, ROUTE MENDE, F-34033 MONTPELLIER 1, FRANCE.		Kasprzak, Andrzej A. A/R-4476-2016	Kasprzak, Andrzej A. A/0000-0002-3602-5379				ADAMS SB, 1993, BIOPHYS J, V64, pA147; ANDO T, 1989, J BIOCHEM-TOKYO, V105, P818, DOI 10.1093/oxfordjournals.jbchem.a122751; BARDEN JA, 1990, BIOCHEMISTRY-US, V29, P1348, DOI 10.1021/bi00457a034; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BETTACHE N, 1989, P NATL ACAD SCI USA, V86, P6028, DOI 10.1073/pnas.86.16.6028; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; CHAUSSEPIED P, 1989, J BIOL CHEM, V264; CHEN T, 1991, BIOCHEMISTRY-US, V30, P4546, DOI 10.1021/bi00232a026; CHEN T, 1992, BIOCHEMISTRY-US, V31, P2941, DOI 10.1021/bi00126a014; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; DASGUPTA G, 1992, BIOCHEMISTRY-US, V31, P1836, DOI 10.1021/bi00121a036; DETMERS P, 1981, J BIOL CHEM, V256, P99; ESTES JE, 1987, J BIOL CHEM, V262, P4952; ESTES JE, 1978, BIOCHEMISTRY-US, V17, P2495, DOI 10.1021/bi00606a006; FORNE T, 1992, J MUSCLE RES CELL M, V13, P233; FRIEDEN C, 1988, BIOCHEMISTRY-US, V27, P3812, DOI 10.1021/bi00410a044; HARVEY SC, 1977, ARCH BIOCHEM BIOPHYS, V179, P391, DOI 10.1016/0003-9861(77)90126-6; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1991, CURR OPIN STRUC BIOL, V1, P270, DOI 10.1016/0959-440X(91)90073-3; HOZUMI T, 1992, BIOCHEMISTRY-US, V31, P10070, DOI 10.1021/bi00156a029; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KASPRZAK AA, 1988, BIOCHEMISTRY-US, V27, P4512, DOI 10.1021/bi00412a044; KASPRZAK AA, 1993, BIOPHYS J, V64, pA231; KNIGHT P, 1980, BIOCHEMISTRY-US, V19, P4682, DOI 10.1021/bi00561a022; KORN ED, 1982, PHYSIOL REV, V62, P672, DOI 10.1152/physrev.1982.62.2.672; KUEHL WM, 1969, J BIOL CHEM, V244, P4720; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; MEJEAN C, 1987, BIOCHEM J, V244, P571, DOI 10.1042/bj2440571; MIKI M, 1984, BIOCHIM BIOPHYS ACTA, V786, P188, DOI 10.1016/0167-4838(84)90088-8; MIKI M, 1987, EUR J BIOCHEM, V168, P339, DOI 10.1111/j.1432-1033.1987.tb13425.x; MILLER L, 1987, BIOCHEMISTRY-US, V26, P6064, DOI 10.1021/bi00393a018; MOCKRIN SC, 1981, J BIOL CHEM, V256, P8228; MOSSAKOWSKA M, 1993, BIOCHEM J, V289, P897, DOI 10.1042/bj2890897; MOSSAKOWSKA M, 1988, EUR J BIOCHEM, V175, P557, DOI 10.1111/j.1432-1033.1988.tb14228.x; MULHERN S, 1975, BIOCHEMISTRY-US, V14, P3863, DOI 10.1021/bi00688a020; NISHIDA E, 1985, BIOCHEMISTRY-US, V24, P1160, DOI 10.1021/bi00326a015; NOWAK E, 1988, BIOCHEMISTRY-US, V27, P1785, DOI 10.1021/bi00405a060; ODONOGHUE SI, 1992, ARCH BIOCHEM BIOPHYS, V293, P110, DOI 10.1016/0003-9861(92)90372-4; OFFER G, 1972, J MOL BIOL, V66, P435, DOI 10.1016/0022-2836(72)90425-1; OSTAP EM, 1992, BIOPHYS J, V63, P966, DOI 10.1016/S0006-3495(92)81684-3; PARDEE JD, 1982, J CELL BIOL, V93, P648, DOI 10.1083/jcb.93.3.648; PROCHNIEWICZ E, 1990, J MOL BIOL, V216, P761, DOI 10.1016/0022-2836(90)90397-5; PURICH DL, 1978, FEBS LETT, V96, P83, DOI 10.1016/0014-5793(78)81067-9; RICH SA, 1976, J MOL BIOL, V104, P777, DOI 10.1016/0022-2836(76)90181-9; ROUAYRENC JF, 1985, EUR J BIOCHEM, V146, P391, DOI 10.1111/j.1432-1033.1985.tb08665.x; ROUAYRENC JF, 1981, EUR J BIOCHEM, V116, P73, DOI 10.1111/j.1432-1033.1981.tb05302.x; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SCHWYTER DH, 1990, J CELL BIOL, V111, P465, DOI 10.1083/jcb.111.2.465; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; THOMAS DD, 1979, J MOL BIOL, V132, P257, DOI 10.1016/0022-2836(79)90259-6; TIRION MM, 1993, BIOPHYS J, V64, pA146; VALENTINRANC C, 1991, J BIOL CHEM, V266, P7668; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; ZIMMERLE CT, 1988, BIOCHEMISTRY-US, V27, P7759, DOI 10.1021/bi00420a026	57	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13261	13266						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514764				2022-12-25	WOS:A1993LH55300038
J	Adams, JW; Migita, DS; Yu, MK; Young, R; Hellickson, MS; CastroVargas, FE; Domingo, JD; Lee, PH; Bui, JS; Henderson, SA				Adams, JW; Migita, DS; Yu, MK; Young, R; Hellickson, MS; CastroVargas, FE; Domingo, JD; Lee, PH; Bui, JS; Henderson, SA			Prostaglandin F-2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; MYOSIN LIGHT CHAIN-2; ANGIOTENSIN-II; CARDIAC MYOCYTES; MYOCARDIAL-CELLS; MOLECULAR CHARACTERIZATION; ENDOTHELIAL-CELLS; SKELETAL-MUSCLE; HEART-CELLS; RECEPTOR	Prostaglandin F-2 alpha (PGF(2 alpha)) stimulates protein synthesis of skeletal and smooth muscle cells in culture and is elevated in the heart during compensatory growth. We hypothesized that PGF(2 alpha) stimulates hypertrophic growth of neonatal rat cardiac myocytes. Prostaglandin F-2 alpha increased [H-3]phenylalanine incorporation by cultured ventricular myocytes in a dose-dependent manner (EC(50) = 11 nM), suggesting action through a PGF-specific receptor. Semiquantitative reverse transcriptase polymerase chain reaction revealed that PGF receptor mRNA is expressed in ventricular myocytes > A7R5 vascular smooth muscle cells >> cardiac fibroblast-like cells. The protein content of cardiomyocyte cultures was increased by 10 nM PGF(2 alpha) and 11 beta-PGF(2 alpha) but was unchanged by 10 nM PGD(2), PGE(2), PGF(1 alpha) carbaprostacyclin, U-46619, or 12- or 15-hydroxyeicosatrienoic acid. Stimulation of myofibrillar gene expression by PGF(2 alpha) was demonstrated by Northern and Western blot analysis for myosin light chain-2 (MLC 2) and by transient transfection experiments with MLC-2 luciferase expression plasmids. In addition, myofibrillogenesis was increased by PGF(2 alpha) as assessed by immunocytochemical staining with MLC-2 antisera. Prostaglandin F-2 alpha did not affect myocyte proliferation or [H-3]thymidine incorporation, thus myocyte growth occurred by hypertrophy. Proliferative and hypertrophic growth of cardiac fibroblast-like cells were unaffected by PGF(2 alpha). We conclude that PGF(2 alpha) stimulates hypertrophic growth of neonatal rat ventricular myocytes in culture and speculate that PGF(2 alpha) plays a role in myocardial adaptation to chronic hypertrophic stimuli, recovery from injury, and cardiac ontogeny.	UNIV CALIF LOS ANGELES,DEPT PHYSIOL SCI,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050706] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50706] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUMADA GG, 1980, J MOL CELL CARDIOL, V12, P685, DOI 10.1016/0022-2828(80)90099-1; ALI S, 1993, J BIOL CHEM, V268, P17397; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; CHAZOV EI, 1979, CIRC RES, V45, P205, DOI 10.1161/01.RES.45.2.205; CHEN LY, 1992, ARCH BIOCHEM BIOPHYS, V296, P17, DOI 10.1016/0003-9861(92)90539-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIAZFLORES L, 1994, ANAT REC, V238, P68, DOI 10.1002/ar.1092380109; DORN GW, 1992, J BIOL CHEM, V267, P24897; DOSTAL DE, 1992, AM J HYPERTENS, V5, P276; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; ESCOBAR E, 1983, AM J CARDIOL, V52, P424, DOI 10.1016/0002-9149(83)90158-3; GADSBY JE, 1993, BIOL REPROD, V49, P604, DOI 10.1095/biolreprod49.3.604; GARDNER DG, 1990, J CLIN INVEST, V86, P52, DOI 10.1172/JCI114714; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HENDERSON SA, 1988, NUCLEIC ACIDS RES, V16, P4722, DOI 10.1093/nar/16.10.4722; ITO S, 1994, BIOCHEM BIOPH RES CO, V200, P756, DOI 10.1006/bbrc.1994.1515; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KATZ AM, 1990, J MOL CELL CARDIOL, V22, P739, DOI 10.1016/0022-2828(90)90086-H; KENTERA D, 1979, RESPIRATION, V37, P192, DOI 10.1159/000194026; LAKS MM, 1973, CHEST, V64, P75, DOI 10.1378/chest.64.1.75; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LINSSEN MCJG, 1993, AM J PHYSIOL, V264, pH973, DOI 10.1152/ajpheart.1993.264.3.H973; LONG CS, 1992, BASIC RES CARDIOL, V87, P19; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MCLENNAN IS, 1991, PROSTAG LEUKOTR ESS, V43, P77, DOI 10.1016/0952-3278(91)90175-5; MICHELS C, 1993, AM J PHYSIOL, V264, pC866, DOI 10.1152/ajpcell.1993.264.4.C866; MORGAN HE, 1991, CIRCULATION, V83, P13, DOI 10.1161/01.CIR.83.1.13; NATARAJAN R, 1994, HYPERTENSION, V23, pI142, DOI 10.1161/01.HYP.23.1_Suppl.I142; OUDOT F, 1995, AM J PHYSIOL-HEART C, V268, pH308, DOI 10.1152/ajpheart.1995.268.1.H308; PALMER RM, 1990, BRIT J PHARMACOL, V101, P835, DOI 10.1111/j.1476-5381.1990.tb14166.x; RAO GN, 1994, J BIOL CHEM, V269, P32586; REFSNES M, 1994, J CELL PHYSIOL, V159, P35, DOI 10.1002/jcp.1041590106; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1995, CIRC RES, V76, P1; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIDER MD, 1992, BASIC RES CARDIOL, V87, P33; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SEN A, 1988, J BIOL CHEM, V263, P19132; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SOKOLOVSKY M, 1993, RECEPTOR CHANNEL, V1, P295; SPIRITO P, 1991, CIRCULATION, V84, P322, DOI 10.1161/01.CIR.84.1.322; SPISNI E, 1992, PROSTAG LEUKOTR ESS, V47, P111, DOI 10.1016/0952-3278(92)90146-A; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; VANBILSEN M, 1989, MOL CELL BIOCHEM, V88, P113, DOI 10.1007/BF00223432; VANDENBURGH HH, 1990, AM J PHYSIOL, V259, pC232, DOI 10.1152/ajpcell.1990.259.2.C232; WATANABE T, 1995, J BIOL CHEM, V270, P8984, DOI 10.1074/jbc.270.15.8984; WEBER DR, 1989, CIRC RES, V65, P671, DOI 10.1161/01.RES.65.3.671; YAMAZAKI T, 1995, HERZ, V20, P109	54	82	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1179	1186		10.1074/jbc.271.2.1179	http://dx.doi.org/10.1074/jbc.271.2.1179			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557648	hybrid			2022-12-25	WOS:A1996TP88900085
J	Connolly, CN; Krishek, BJ; McDonald, BJ; Smart, TG; Moss, SJ				Connolly, CN; Krishek, BJ; McDonald, BJ; Smart, TG; Moss, SJ			Assembly and cell surface expression of heteromeric and homomeric gamma-aminobutyric acid type A receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTORS; ENDOPLASMIC-RETICULUM; SUBUNIT COMPOSITION; MOLECULAR-BIOLOGY; RAT-BRAIN; 2 FORMS; PROTEIN; SUBTYPES; PHOSPHORYLATION; PHARMACOLOGY	The ability of differing subunit combinations of gamma-aminobutyric acid type A (GABA(A)) receptors produced from murine alpha 1, beta 2, and gamma 2L subunits to form functional cell surface receptors was analyzed in both A293 cells and Xenopus oocytes using a combination of molecular, electrophysiological, biochemical, and morphological approaches. The results revealed that GABA(A) receptor assembly occurred within the endoplasmic reticulum and involved the interaction with the chaperone molecules immunoglobulin heavy chain binding protein and calnexin. Despite all three subunits possessing the ability to oligomerize with each other, only alpha 1 beta 2 and alpha 1 beta 2 gamma 2L subunit combinations could produce functional surface expression in a process that was not dependent on N-linked glycosylation. Single subunits and the alpha 1 gamma 2L and beta 2 gamma 2L combinations were retained within the endoplasmic reticulum. These results suggest that receptor assembly occurs by defined pathways, which may serve to limit the diversity of GABA(A) receptors that exist on the surface of neurons.	UCL, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; UCL, DEPT PHARMACOL, LONDON WC1E 6BT, ENGLAND; UNIV LONDON SCH PHARM, DEPT PHARMACOL, LONDON WC1N 1AX, ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; University of London School of Pharmacy				Connolly, Christopher/0000-0002-0445-8874				AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; ANGELOTTI TP, 1993, J NEUROSCI, V13, P1418; BENKE D, 1994, J BIOL CHEM, V269, P2710; BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; BULLER AL, 1994, MOL PHARMACOL, V46, P858; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; CONNOLLY CN, 1994, J CELL BIOL, V127, P641, DOI 10.1083/jcb.127.3.641; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; DRAGUHN A, 1990, NEURON, V5, P781, DOI 10.1016/0896-6273(90)90337-F; DUGGAN MJ, 1990, J BIOL CHEM, V265, P3831; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6729; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; HADDINGHAM KL, 1992, P NATL ACAD SCI USA, V89, P6378; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KAMATCHI GL, 1995, BBA-GENE STRUCT EXPR, V1261, P134, DOI 10.1016/0167-4781(95)00009-6; KHAN ZU, 1994, J NEUROCHEM, V63, P371; KOFUJI P, 1991, J NEUROCHEM, V56, P713, DOI 10.1111/j.1471-4159.1991.tb08209.x; KRISHEK BJ, 1994, NEURON, V12, P1081, DOI 10.1016/0896-6273(94)90316-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; MERTENS S, 1993, J BIOL CHEM, V268, P5965; MOSS SJ, 1995, NATURE, V377, P344, DOI 10.1038/377344a0; MOSS SJ, 1992, SCIENCE, V257, P661, DOI 10.1126/science.1323140; MOSS SJ, 1990, EUR J PHARM-MOLEC PH, V189, P77, DOI 10.1016/0922-4106(90)90232-M; MOSSIER B, 1994, J BIOL CHEM, V269, P25777; NAYEEM N, 1994, J NEUROCHEM, V62, P815; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; POLLARD S, 1993, J BIOL CHEM, V268, P3753; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; QUIRK K, 1994, J BIOL CHEM, V269, P16020; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SIGEL E, 1989, FEBS LETT, V257, P377, DOI 10.1016/0014-5793(89)81576-5; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMART TG, 1991, BRIT J PHARMACOL, V103, P1837, DOI 10.1111/j.1476-5381.1991.tb12337.x; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WANG JB, 1992, J MOL NEUROSCI, V3, P177, DOI 10.1007/BF03380136; WHITING P, 1990, P NATL ACAD SCI USA, V87, P9966, DOI 10.1073/pnas.87.24.9966; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y	44	279	281	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					89	96		10.1074/jbc.271.1.89	http://dx.doi.org/10.1074/jbc.271.1.89			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550630	hybrid			2022-12-25	WOS:A1996TP36100015
J	Drugan, JK; KhosraviFar, R; White, MA; Der, CJ; Sung, YJ; Hwang, YW; Campbell, SL				Drugan, JK; KhosraviFar, R; White, MA; Der, CJ; Sung, YJ; Hwang, YW; Campbell, SL			Ras interaction with two distinct binding domains in Raf-1 may be required for Ras transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; ACTIVATION; PHOSPHATIDYLSERINE; MUTAGENESIS; DEFINITION; ONCOGENE; SEQUENCE; PRODUCT; MUTANTS	Although Raf-1 is a critical has effector target, how Ras mediates Raf-1 activation remains unresolved, Raf-1 residues 55-131 define a Ras-binding domain essential for Raf-1 activation. Therefore, our identification of a second Ras-binding site in the Raf-1 cysteine-rich domain (residues 139-184) was unexpected and suggested a more complex role for Ras in Raf-1 activation, Both Ras recognition domains preferentially associate with Ras-GTP, Therefore, mutations that impair Ras activity by perturbing regions that distinguish Ras-GDP from Ras-GTP (switch I and II) may disrupt interactions with either Raf-1 binding domain. We observed that mutations of Ras that impaired Ras transformation by perturbing its switch I (T35A and E37G) or switch II (G60A and Y64W) domain preferentially diminished binding to Raf-1-(55-131) or the Raf-1 cysteine-rich domain, respectively. Thus, these Ras binding domains recognize distinct Ras-GTP determinants, and both may be essential for Ras transforming activity. Finally, since Ha-Ras T35A and E37G mutations prevent Ras interaction with full-length Raf-1, we suggest that Raf-Cys is a cryptic binding site that is unmasked upon Ras interaction with Raf-1-(55-131).	UNIV N CAROLINA, PROT ENGN & MOLEC GENET TRAINING PROGRAM, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOCHEM & BIOPHYS, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOLEC BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; NEW YORK STATE INST BASIC RES, DEPT MOLEC BIOL, STATEN ISL, NY 10314 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Cold Spring Harbor Laboratory			Khosravi-Far, Roya/C-3789-2008	campbell, sharon/0000-0003-0311-409X; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA42978, CA63071, CA55008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063071, R01CA042978, R01CA055008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOW YH, 1995, J BIOL CHEM, V270, P14100, DOI 10.1074/jbc.270.23.14100; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CLARK GJ, 1996, IN PRESS P NATL ACAD; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1995, MOL CELL BIOL, V15, P4125; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HWANG YW, 1989, NATO ADV SCI I A-LIF, V165, P77; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ISHIKAWA F, 1988, ONCOGENE, V3, P653; JOHN J, 1993, J BIOL CHEM, V268, P923; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LEE E, 1992, J BIOL CHEM, V267, P1212; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER AF, 1993, BIOCHEMISTRY-US, V32, P7367, DOI 10.1021/bi00080a006; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MOODIE SA, 1995, ONCOGENE, V11, P447; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; SUNG YJ, 1995, BIOCHEMISTRY-US, V34, P3470, DOI 10.1021/bi00010a040; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; ZHANG XF, 1995, METHOD ENZYMOL, V255, P323; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	59	134	135	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					233	237		10.1074/jbc.271.1.233	http://dx.doi.org/10.1074/jbc.271.1.233			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550565	hybrid, Green Published			2022-12-25	WOS:A1996TP36100036
J	Soltoff, SP; Cantley, LC				Soltoff, SP; Cantley, LC			p120(cbl) is a cytosolic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-CBL; PHOSPHORYLATION; TRUNCATION; BINDING; DOMAIN	Although epidermal growth factor (EGF) activates phosphoinositide (PI) 3-kinase activity in a number of types of cells or cell lines, in most cases that we have investigated the p85 regulatory subunit of PI 3-kinase does not appear to bind directly to the EGF receptor. Previously we demonstrated that EGF dependent activation of PI 3-kinase activity in A431 cells is accompanied by the binding of p85 to ErbB3, an EGF receptor homologue. However, this mechanism did not explain the large activation of PI 3-kinase activity that was found in PC12 and A549 cells, which possess little or no ErbB3. Here we provide evidence that the p120(cbl) protooncoprotein is an intracellular adapter protein that associates with PI 3-kinase and thus is involved in the EGF-dependent activation of this enzyme in these two cell lines. Using an anti-p120(cbl) antibody, we immunoprecipitated the EGF receptor from PC12 cells and PI 3-kinase activity from PC12 and A549 cells in an EGF-dependent fashion. Treatment of PC12 cells with nerve growth factor or insulin stimulated large increases in PI 3-kinase activity that was immunoprecipitated using anti-Tyr(P) antibody but not using anti p120(cbl) antibody. In EGF-treated PC12 cells, the tyrosine phosphorylation of p120(cbl) displayed similar kinetics to the activation of PI 3-kinase as measured by both in vivo lipid production and lipid kinase assays conducted using anti-p120(cbl) and anti-Tyr(P) immunoprecipitates. The use of glutathione S-transferase fusion proteins of various domains of p85 demonstrated that p120(cbl) associated with both the SH2 and SH3 domains of p85, p120(cbl) was also present in A431 cells and offers an additional pathway by which EGF can activate PI 3-kinase in these cells.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	Soltoff, SP (corresponding author), BETH ISRAEL HOSP, DEPT MED, DIV SIGNAL TRANSDUCT, ALPERT BLDG, 200 LONGWOOD AVE, BOSTON, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NIGMS NIH HHS [R01 GM041890, GM-36624] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R01GM036624] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KIM HH, 1994, J BIOL CHEM, V269, P24747; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; WHITE MF, 1994, J BIOL CHEM, V269, P1; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	25	133	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					563	567		10.1074/jbc.271.1.563	http://dx.doi.org/10.1074/jbc.271.1.563			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550620	hybrid			2022-12-25	WOS:A1996TP36100085
J	Yee, A; Wu, LT; Liu, L; Kobayashi, R; Xiong, Y; Hall, FL				Yee, A; Wu, LT; Liu, L; Kobayashi, R; Xiong, Y; Hall, FL			Biochemical characterization of the human cyclin-dependent protein kinase activating kinase - Identification of p35 as a novel regulatory subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OSTEOSARCOMA CELLS; PHOSPHORYLATION SITES; P34(CDC2); EXPRESSION; P40(MO15); CDC2; G1	The activation of cyclin-dependent protein kinases (Cdks) is dependent upon site specific phosphorylation and dephosphorylation reactions, as well as positive and negative regulatory subunits. The human Cdk-activating protein kinase (Cak1) is itself a Cdc2-related cyclin-dependent protein kinase that associates with cyclin Il. The present study utilized specific anti-Cak1 antibodies and immunoaffinity chromatography to identify additional Cak1-associated proteins and potential target substrates. Immunoprecipitation of metabolically labeled human osteosarcoma cells revealed a number of Cak1-associated proteins, including p95, p37 (cyclin H), and a 35-kDa protein that was further characterized herein. Microsequence analysis obtained after limited proteolysis revealed peptide fragments that are similar, but not identical to, human and yeast cyclins, thus identifying p35 as a cyclin-like regulatory subunit. The greatest sequence similarity of human p35 is with Mcs2, a yeast cyclin that is essential for cell cycle progression. Immunoaffinity chromatography performed under nondenaturing conditions afforded the isolation of enzymatically active Cak1 from cell lysates, enabling studies of kinase autophosphorylation and comparative substrate utilization. Immunoaffinity-purified Cak1 phosphorylated monomeric Cdc2 and Cdk2, but not Cdk4; the phosphorylation of both Cdc2 and Cdk2 were increased in the presence of recombinant cyclin A. These studies indicate that the Cak1 catalytic subunit, like Cdc2 and Cdk2, associates with multiple regulatory partners and suggests that subunit composition may be an important determinant of this multifunctional enzyme.	CHILDRENS HOSP LOS ANGELES,RES INST,DIV ORTHOPED SURG,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90033; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27590; UNIV N CAROLINA,PROGRAM MOLEC BIOL & BIOTECHNOL,CHAPEL HILL,NC 27590; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27590	Children's Hospital Los Angeles; University of Southern California; Cold Spring Harbor Laboratory; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [1R01-GM49715-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049715] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Hunt T, 1991, Semin Cell Biol, V2, P213; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MARCOTE MJ, 1993, MOL CELL BIOL, V13, P5122, DOI 10.1128/MCB.13.8.5122; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PEEPER DS, 1993, EMBO J, V12, P1957; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Williams R. T., 1993, Molecular Biology of the Cell, V4, p239A; WILLIAMS RT, 1993, J BIOL CHEM, V268, P8871; WILLIAMS RT, 1994, ARCH BIOCHEM BIOPHYS, V314, P99, DOI 10.1006/abbi.1994.1416; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WU LT, 1994, ONCOGENE, V9, P2089; WU LT, 1993, INT J ONCOL, V3, P859; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	44	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					471	477		10.1074/jbc.271.1.471	http://dx.doi.org/10.1074/jbc.271.1.471			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550604	hybrid			2022-12-25	WOS:A1996TP36100072
J	Kitada, S; Krajewski, S; Miyashita, T; Krajewska, M; Reed, JC				Kitada, S; Krajewski, S; Miyashita, T; Krajewska, M; Reed, JC			gamma-Radiation induces upregulation of Bax protein and apoptosis in radiosensitive cells in vivo	ONCOGENE			English	Article						Bax; Bcl-2; apoptosis; radiation	INDUCTION; P53; AGENTS; DEATH	Lymphoid cells and small intestinal epithelial (SIE) cells are among the most radiosensitive in the body. The factors that account for the differential sensitivity to gamma-radiation among different tissue-types remain poorly understood, but can only partly be explained by differences in rates of cell proliferation. Here we demonstrate that exposure of mice to 800 cGy of gamma-radiation results in rapid elevations in the levels of the Bax protein, a pro-apoptotic member of the Bcl-2 protein family, in lymphoid cells and SIEs. gamma-Radiation-induced increases in Bax protein were evident within 2 h and persisted for at least 24 h, as determined by immunoblotting and immunohistochemical assays. Increases in Bax were followed by massive apoptosis in lymphoid organs and in the small intestinal crypts, as determined by morphological criteria and in situ end-labeling of fragmented nuclear DNA by terminal deoxynucleotidyl transferase (TUNEL method). Radiation did not induce elevations in Bax or apoptosis in radioresistant tissues such as heart, skeletal muscle, brain, kidney, liver, lung, vascular smooth muscle and connective tissue. The findings suggest that Bax may be one of the mediators of radiation-induced apoptosis in vivo.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA-60381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRISTOW RG, 1994, ONCOGENE, V9, P1527; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; GORCZYCA W, 1992, INT J ONCOL, V1, P639; Hill R. P., 1992, BASIC SCI ONCOLOGY, P259; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HORNING SJ, 1993, SEMIN ONCOL, V20, P75; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MERRITT AJ, 1994, CANCER RES, V54, P614; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEZZELLA F, 1990, AM J PATHOL, V137, P225; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; POTTEN CS, 1983, CYTOTOXIC INSULT TIS; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, ONCOGENE, V9, P3743	26	159	167	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					187	192						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552390				2022-12-25	WOS:A1996TQ01400023
J	Winston, JT; Coats, SR; Wang, YZ; Pledger, WJ				Winston, JT; Coats, SR; Wang, YZ; Pledger, WJ			Regulation of the cell cycle machinery by oncogenic ras	ONCOGENE			English	Article						ras; cell cycle; cyclins; cdk4; Kip1	EPIDERMAL GROWTH-FACTOR; FIBROBLASTS; INHIBITION; G(1); TRANSFORMATION; EXPRESSION; INDUCTION; KINASE; RAF-1; DNA	The ras proto-oncogene has been implicated during the formation of tumors in vivo as well as the transformation of cell lines in culture. Conditional expression of an activated ras mutant in Balb/c-3T3 fibroblasts failed to stimulate S phase entry in the absence of plasma-derived progression factors, but did shorten the G(1) interval from 12 to 6 h and abrogate the normal proliferative requirement for platelet-derived growth factor. Ras-dependent alteration of the 3T3 cell cycle was accompanied by a dramatic increase in the expression of the G(1) regulatory protein, cyclin D1, while expression of cyclin E and cyclin A proteins were only weakly induced. Cyclin/cdk complexes assembled in response to ectopic ras expression in the absence of growth factor stimulation bound the cdk inhibitory factor, Kip1, and were inactive. However, plasma-stimulated regulatory pathways functioned co-operatively with the oncogenic ras molecule to decrease Kip1 levels, induce the kinase activities associated with cyclins D, E and A, and trigger the initiation of DNA replication. Our results suggest that a ras-activated signal transduction pathway may link environmental mitogenic stimuli to the cell cycle machinery via modulation of G(1) cyclin expression.	UNIV S FLORIDA,H LEE MOFFITT CANC CTR & RES INST,TAMPA,FL 33612; UNIV S FLORIDA,DEPT INTERNAL MED,TAMPA,FL 33612; UNIV S FLORIDA,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV S FLORIDA,DEPT MED MICROBIOL,TAMPA,FL 33612; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Vanderbilt University					NATIONAL CANCER INSTITUTE [P01CA043720, R01CA067360] Funding Source: NIH RePORTER; NCI NIH HHS [CA43720, CA67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIADES HN, 1975, P NATL ACAD SCI USA, V74, P1973; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COATS SR, 1992, J CELL BIOCHEM, V48, P242, DOI 10.1002/jcb.240480304; COFFEY RJ, 1987, J CELL PHYSIOL, V132, P143, DOI 10.1002/jcp.1041320120; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; LEOF EB, 1989, CANCER RES, V49, P2356; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJITEK AB, 1993, CELL, V74, P206; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	39	197	200	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					127	134						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552383				2022-12-25	WOS:A1996TQ01400016
J	Ciapponi, L; Graziani, R; Paonessa, G; Lahm, A; Ciliberto, G; Savino, R				Ciapponi, L; Graziani, R; Paonessa, G; Lahm, A; Ciliberto, G; Savino, R			Definition of a composite binding site for gp130 in human interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RECEPTOR-BINDING; RNA-POLYMERASE; EXPRESSION; CYTOKINES; PROTEINS	The helical cytokine interleukin-6 (IL-6) assembles a multiprotein receptor complex, The starting event in the activation of intracellular signaling is the binding of the IL-6/IL-6R alpha subcomplex to two gp130 chains, The homodimerization of gp130 is triggered by two distinct and independent regions of IL-6 called sites 2 and 3. Several IL-6 antagonists have been obtained that affect signaling, but not IL-6 . IL-6R alpha subcomplex formation. In this paper, we analyze in detail the impact of these antagonists on gp130 binding and dimerization and show that each signaling variant affects gp130 dimerization in vitro and that biological activity on cells decreases in precise parallel to the decrease in gp130 dimerization in vitro. All IL-6 antagonists can be classified into two groups, mapping at either site 2 or 3 in correspondence to their mode of interaction with gp130. We found that site 3 is a large region, which includes residues at the beginning of helix D spatially flanked by residues in the putative AB loop and located at one extremity of the cytokine 4-helix bundle. Interestingly, in leukemia inhibitory factor, another cytokine that signals through gp130, site 3, is topologically conserved but has evolved to bind leukemia inhibitory factor receptor.	IST RIC BIOL MOLEC P ANGELETTI,I-00040 POMEZIA,ITALY				Ciapponi, Laura/H-6867-2013; Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605; Savino, Rocco/0000-0002-4046-1472; CIAPPONI, LAURA/0000-0002-0817-1862				ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOULAY JL, 1993, CURR BIOL, V3, P573, DOI 10.1016/0960-9822(93)90002-6; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; BRAKENHOFF JPJ, 1992, SERONO S PUBLICATION, V88, P33; DEHON FD, 1994, J EXP MED, V180, P2395, DOI 10.1084/jem.180.6.2395; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EHLERS M, 1994, J IMMUNOL, V153, P1744; FIORILLO MT, 1992, EUR J IMMUNOL, V22, P2609, DOI 10.1002/eji.1830221021; GREGORY B, 1994, J IMMUNOL METHODS, V170, P47, DOI 10.1016/0022-1759(94)90244-5; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LAYTON MJ, 1994, J BIOL CHEM, V269, P29891; LOVEJOY B, 1993, J MOL BIOL, V234, P640, DOI 10.1006/jmbi.1993.1617; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; SALVATI AL, 1995, J BIOL CHEM, V270, P12242, DOI 10.1074/jbc.270.20.12242; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1994, EMBO J, V13, P1357, DOI 10.1002/j.1460-2075.1994.tb06389.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; WARD LD, 1994, J BIOL CHEM, V269, P23286; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5	34	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31249	31254		10.1074/jbc.270.52.31249	http://dx.doi.org/10.1074/jbc.270.52.31249			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537391	hybrid			2022-12-25	WOS:A1995TN44400058
J	Katz, BA; Cass, RT; Liu, BS; Arze, R; Collins, N				Katz, BA; Cass, RT; Liu, BS; Arze, R; Collins, N			Topochemical catalysis achieved by structure-based ligand design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PEPTIDES; BIOSPECIFIC INTERACTION ANALYSIS; SURFACE-PLASMON RESONANCE; CORE STREPTAVIDIN; CRYSTAL-STRUCTURE; BINDING; BIOTIN; IMMOBILIZATION; DIFFRACTION; PROTEINS	Recently, a cyclic peptide ligand, cyclo-Ac-[CHPQG-PPC]-NH2, that binds to streptavidin with high affinity was discovered by screening phage libraries, From the streptavidin-bound crystal structures of cyclo-Ac[CHPQGPPC]-NH2 and of a related but more weakly binding linear ligand, FSHPQNT, we designed linear thiol-containing streptavidin binding ligands, FCH-PQNT-NH2, and Ac-CHPQNT-NH2, which are dimerized catalytically by the streptavidin crystal lattice of space group I222, as demonstrated by high performance liquid chromatography and mass spectrometry, The catalytic dimerization relies on presentation of the ligand thiols toward one another in the lattice, The streptavidin crystal lattice mediated catalysis achieved by structure-based design is the first example of catalysis of a chemical reaction by a protein crystal lattice, The spontaneous and crystal catalyzed rates of disulfide formation were determined by high performance liquid chromatography at pH 3.1, 4.0, 5.0, and 6.0. The ratio of the catalyzed to uncatalyzed rate was maximal at pH 3.1 (k(cat)/k(uncat) = 3.8), diminishing to 1.2 at pH 6.0. The crystal structures of the streptavidin bound dimerized peptide ligands, FCHPQNT-NH2 dimer at 1.95 Angstrom and Ac-CHPQNT-NH22 dimer at 1.80 Angstrom, are described and compared with the structures of streptavidin-bound FSHPQNT monomer and cyclo-Ac-[CHPQGPPC]-NH2 dimer.			Katz, BA (corresponding author), ARRIS PHARMACEUT CORP,S SAN FRANCISCO,CA 94080, USA.							Austin D J, 1994, Chem Biol, V1, P131, DOI 10.1016/1074-5521(94)90002-7; BREAKER RR, 1994, TRENDS BIOTECHNOL, V12, P268, DOI 10.1016/0167-7799(94)90138-4; BRUNGER AT, 1992, XPLOR VERSION 3 1 SY, P187; BUCKLAND RM, 1986, NATURE, V320, P557, DOI 10.1038/320557a0; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CHAMBERS JL, 1979, ACTA CRYSTALLOGR B, V35, P1861, DOI 10.1107/S0567740879007925; DHANARAJ V, 1994, PROGR BIOTECHNOL, V9, P3; FAGERSTAM L, 1991, TECHNIQUES PROTEIN C, V2, P65; Fagerstam L G, 1990, J Mol Recognit, V3, P208, DOI 10.1002/jmr.300030507; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FINERMOORE JS, 1992, PROTEINS, V12, P203, DOI 10.1002/prot.340120302; FUCCILLO D A, 1985, Biotechniques, V3, P494; GIEBEL LB, 1995, IN PRESS BIOCHEMISTR; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; IMBIHL R, 1993, PROG SURF SCI, V44, P185, DOI 10.1016/0079-6816(93)90086-B; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Jonsson U., 1992, ADV BIOSENSOR, P291; KATZ BA, 1986, J BIOL CHEM, V261, P5480; KATZ BA, 1995, CHEM BIOL, V2, P591, DOI 10.1016/1074-5521(95)90123-X; KATZ BA, 1995, J AM CHEM SOC, V117, P8541, DOI 10.1021/ja00138a008; KATZ BA, 1995, IN PRESS BIOCHEMISTR; KLIBANOV AM, 1979, ANAL BIOCHEM, V93, P1; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; PAHLER A, 1987, J BIOL CHEM, V262, P13933; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; PERSICHETTI RA, 1995, J AM CHEM SOC, V117, P2732, DOI 10.1021/ja00115a008; Seed B, 1994, Chem Biol, V1, P125, DOI 10.1016/1074-5521(94)90001-9; SOMORJAI GA, 1994, SURF SCI, V299, P849, DOI 10.1016/0039-6028(94)90702-1; TIJAN R, 1994, CELL, V77, P5; UHLEN M, 1989, NATURE, V340, P733, DOI 10.1038/340733a0; WEBER PC, 1992, BIOCHEMISTRY-US, V31, P9350, DOI 10.1021/bi00154a004; WEBER PC, 1992, J AM CHEM SOC, V114, P3197, DOI 10.1021/ja00035a004; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WEBER PC, 1994, J AM CHEM SOC, V116, P2717, DOI 10.1021/ja00086a004; WILCHEK M, 1988, ANAL BIOCHEM, V171, P1, DOI 10.1016/0003-2697(88)90120-0	37	8	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31210	31218		10.1074/jbc.270.52.31210	http://dx.doi.org/10.1074/jbc.270.52.31210			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537386	hybrid			2022-12-25	WOS:A1995TN44400054
J	Suzuki, T; Lett, MC; Sasakawa, C				Suzuki, T; Lett, MC; Sasakawa, C			Extracellular transport of VirG protein in Shigella	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; ENTEROPATHOGENIC ESCHERICHIA-COLI; TOXIN-B-SUBUNIT; OUTER-MEMBRANE; ALKALINE-PHOSPHATASE; DIFFUSE ADHERENCE; AIDA-I; RICKETTSIA-RICKETTSII; SEQUENCE-ANALYSIS; SIGNAL PEPTIDE	The ability of Shigella to spread within and between epithelial cells is a prerequisite for causing bacillary dysentery and requires the function encoded by the virG gene on the large plasmid, The outer membrane VirG (IcsA) protein is essential for bacterial spreading by eliciting polar deposition of filamentous actin (F-actin) in the cytoplasm of epithelial cells, Recent studies have indicated that an N-terminal 80-kDa VirG portion is exposed on the bacterial cell surface and released into the external medium, while the following 37-kDa C-terminal portion is embedded in the outer membrane, although little is known about the extracellular transport of the VirG protein, In this study, we attempted to elucidate the export pathway of VirG protein across the outer membrane and found that the C-terminal 37-kDa portion, termed VirG beta-core, serves as the self transporter for the secretion of the preceding 80-kDa portion from the periplasmic side of the outer membrane to the external side, Indeed, foreign polypeptides such as MalE or PhoA covalently linked to the N terminus of VirG beta-core were transported to the external side of the outer membrane, and it was further shown that the folding structure of the passenger polypeptide at the periplasmic side of the outer membrane interferes with its translocation, Analysis of the secondary structure of VirG beta-core predicted that the critical structural property was a beta-barrel channel consisting of amphipathic antiparallel transmembrane beta-strands, interspersed by hairpin turns and loops. These results thus strongly suggest that the secretion of VirG protein from Shigella is similar to the export system utilized by the IgA protease of Neisseria.	UNIV TOKYO, INST MED SCI, DEPT BACTERIOL, MINATO KU, TOKYO 108, JAPAN; UNIV STRASBOURG 1, CNRS, URA D 1481, INST BOT, LAB MICROBIOL & GENET, F-67083 STRASBOURG, FRANCE	University of Tokyo; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ANDREWS GP, 1991, INFECT IMMUN, V59, P1997, DOI 10.1128/IAI.59.6.1997-2005.1991; BANKAITIS VA, 1984, CELL, V37, P243, DOI 10.1016/0092-8674(84)90320-9; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BASSFORD P, 1979, NATURE, V277, P538, DOI 10.1038/277538a0; BENZ I, 1989, INFECT IMMUN, V57, P1506, DOI 10.1128/IAI.57.5.1506-1511.1989; BENZ I, 1992, MOL MICROBIOL, V6, P1539, DOI 10.1111/j.1365-2958.1992.tb00875.x; BENZ I, 1993, ZBL BAKT-INT J MED M, V278, P197; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; CHANG CN, 1986, GENE, V44, P121; COVER TL, 1994, J BIOL CHEM, V269, P10566; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEMAAGD RA, 1986, J BACTERIOL, V167, P1083, DOI 10.1128/jb.167.3.1083-1085.1986; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EARHART CF, 1979, FEMS MICROBIOL LETT, V6, P277; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FIKES JD, 1987, J BACTERIOL, V169, P2345, DOI 10.1128/jb.169.6.2345-2351.1987; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FUKUDA I, 1995, J BACTERIOL, V177, P1719, DOI 10.1128/jb.177.7.1719-1726.1995; GILMORE RD, 1989, MOL MICROBIOL, V3, P1579, DOI 10.1111/j.1365-2958.1989.tb00143.x; GILMORE RD, 1991, MOL MICROBIOL, V5, P2361, DOI 10.1111/j.1365-2958.1991.tb02082.x; GOLDBERG MB, 1993, J BACTERIOL, V175, P2189, DOI 10.1128/JB.175.8.2189-2196.1993; INOUYE H, 1981, J BACTERIOL, V146, P668, DOI 10.1128/JB.146.2.668-675.1981; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KASHIWAGI K, 1993, J BIOL CHEM, V268, P19358; KLAUSER T, 1990, EMBO J, V9, P1991, DOI 10.1002/j.1460-2075.1990.tb08327.x; KLAUSER T, 1993, BIOESSAYS, V15, P799, DOI 10.1002/bies.950151205; KLAUSER T, 1993, J MOL BIOL, V234, P579, DOI 10.1006/jmbi.1993.1613; KLAUSER T, 1992, EMBO J, V11, P2327, DOI 10.1002/j.1460-2075.1992.tb05292.x; KLEFFEL B, 1985, EMBO J, V4, P1589, DOI 10.1002/j.1460-2075.1985.tb03821.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LETT MC, 1989, J BACTERIOL, V171, P353, DOI 10.1128/jb.171.1.353-359.1989; MAKINO S, 1986, CELL, V46, P551, DOI 10.1016/0092-8674(86)90880-9; MENARD R, 1994, CELL, V79, P515, DOI 10.1016/0092-8674(94)90260-7; MICHAELIS S, 1983, J BACTERIOL, V154, P356, DOI 10.1128/JB.154.1.356-365.1983; NAKATA N, 1993, MOL MICROBIOL, V9, P459, DOI 10.1111/j.1365-2958.1993.tb01707.x; NEU HC, 1967, J BACTERIOL, V94, P1934, DOI 10.1128/JB.94.6.1934-1945.1967; NIKAIDO H, 1979, BACTERIAL OUTER MEMB, P319; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; PALZKILL T, 1994, J BACTERIOL, V176, P563, DOI 10.1128/jb.176.3.563-568.1994; PHADNIS SH, 1994, INFECT IMMUN, V62, P1557, DOI 10.1128/IAI.62.5.1557-1565.1994; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; POULSEN K, 1989, INFECT IMMUN, V57, P3097, DOI 10.1128/IAI.57.10.3097-3105.1989; POULSEN K, 1992, J BACTERIOL, V174, P2913, DOI 10.1128/JB.174.9.2913-2921.1992; PREVOST MC, 1992, INFECT IMMUN, V60, P4088; PROVENCE DL, 1994, INFECT IMMUN, V62, P1369, DOI 10.1128/IAI.62.4.1369-1380.1994; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; SASAKAWA C, 1986, INFECT IMMUN, V51, P470, DOI 10.1128/IAI.51.2.470-475.1986; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; SHEN LM, 1991, BIOCHEMISTRY-US, V30, P11775, DOI 10.1021/bi00115a006; STGEME JW, 1994, MOL MICROBIOL, V14, P217, DOI 10.1111/j.1365-2958.1994.tb01283.x; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WATARAI M, 1995, EMBO J, V14, P2461, DOI 10.1002/j.1460-2075.1995.tb07243.x; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; YANAGIDA N, 1986, J BACTERIOL, V166, P937, DOI 10.1128/jb.166.3.937-944.1986	56	102	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30874	30880		10.1074/jbc.270.52.30874	http://dx.doi.org/10.1074/jbc.270.52.30874			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537341	hybrid			2022-12-25	WOS:A1995TN44400009
J	Puymirat, J; EtongueMayer, P; Dussault, JH				Puymirat, J; EtongueMayer, P; Dussault, JH			Thyroid hormones stabilize acetylcholinesterase mRNA in neuro-2A cells that overexpress the beta 1 thyroid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; SUBUNIT MESSENGER-RNA; PROTEIN KINASE-C; PHORBOL ESTER; MAMMALIAN ACETYLCHOLINESTERASE; POSTTRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; GROWTH-FACTORS; UP-REGULATION; MALIC ENZYME	We investigated the intracellular events involved in the 3,3',5-triiodo-L-thyronine (T-3)-induced accumulation in acetylcholinesterase (AChE) activity in neuroblastoma cells (neuro-2a) that overexpress the human thyroid receptor beta 1 (hTR beta 1). Treatment of these cells with T-3 increased AChE activity and its mRNAs after a lag period of 24-48 h, and these levels increased through stabilization of the transcripts by T-3. T-3 had no effect on the transcriptional rate or processing of AChE transcripts. The protein kinase inhibitor H7 inhibited T-3-induced accumulation in AChE activity and its mRNAs, whereas okadaic acid (a potent inhibitor of phosphatases 1 and 2A) potentiated the effect of T-3. Okadaic acid and H7 have no effect on the binding of hTR beta 1 to T-3 or the transcriptional rate of the AChE gene. Finally, treatment of cells with T-3 stimulated cytosolic serine/threonine, but not tyrosine kinase, activities. The time course analysis reveals that the increase in serine/threonine activity precedes the effect of T-3 on AChE mRNAs. These results suggest that activation of a serine/threonine protein kinase pathway might be a link between nuclear thyroid hormone receptor activation and stabilization of AChE mRNA.			Puymirat, J (corresponding author), CHU LAVAL, RES CTR, DEPT MED & MOLEC BIOL, 2705 BLVD LAURIER, ST FOY, PQ G1V 4G2, CANADA.							BACK DW, 1986, J BIOL CHEM, V261, P2555; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLEMENTS JA, 1988, J BIOL CHEM, V263, P16132; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; EGYHAZI E, 1975, P NATL ACAD SCI USA, V72, P947, DOI 10.1073/pnas.72.3.947; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; GARZA R, 1988, DEV BRAIN RES, V43, P287, DOI 10.1016/0165-3806(88)90106-X; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HAMBURGH M, 1957, J NEUROCHEM, V1, P279, DOI 10.1111/j.1471-4159.1957.tb12083.x; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; HARTMANN KKP, 1990, ENDOCRINOLOGY, V127, P2038, DOI 10.1210/endo-127-4-2038; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOD Y, 1988, J BIOL CHEM, V263, P7747; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JONES KE, 1994, ENDOCRINOLOGY, V134, P543, DOI 10.1210/en.134.2.543; JULIANI MH, 1990, J BIOL CHEM, V265, P9077; JUNGMANN RA, 1983, J BIOL CHEM, V258, P5312; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KRANE IM, 1991, MOL ENDOCRINOL, V5, P469, DOI 10.1210/mend-5-4-469; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LI Y, 1993, J BIOL CHEM, V268, P5790; LI Y, 1991, J BIOL CHEM, V266, P23083; LIM RW, 1987, ONCOGENE, V1, P263; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MAULET Y, 1990, NEURON, V4, P289, DOI 10.1016/0896-6273(90)90103-M; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MINANA MD, 1990, P NATL ACAD SCI USA, V87, P4335, DOI 10.1073/pnas.87.11.4335; MURPHY D, 1992, MOL CELL BIOL, V12, P2624, DOI 10.1128/MCB.12.6.2624; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; PUYMIRAT J, 1986, NEUROSCI LETT, V68, P299, DOI 10.1016/0304-3940(86)90506-9; PUYMIRAT J, 1992, PROG NEUROBIOL, V39, P281, DOI 10.1016/0301-0082(92)90019-B; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; RACKER E, 1991, METHOD ENZYMOL, V200, P107; RASTOGI RB, 1977, BRAIN RES, V123, P188, DOI 10.1016/0006-8993(77)90655-2; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SIKORAV JL, 1988, EMBO J, V7, P2983, DOI 10.1002/j.1460-2075.1988.tb03161.x; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SIMONET WS, 1988, J BIOL CHEM, V263, P12448; STOTT D, 1991, GENE TRANSFER EXPRES, P327; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SWIERCZYNSKI J, 1991, J BIOL CHEM, V266, P17459; TAMM I, 1976, J CELL BIOL, V69, P229, DOI 10.1083/jcb.69.2.229; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; Valcana T., 1971, INFLUENCE HORMONES N, P174; WODNARFILIPOWIC.A, 1980, P NATL ACAD SCI USA, V87, P777; WONG NCW, 1986, J BIOL CHEM, V261, P387	56	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30651	30656		10.1074/jbc.270.51.30651	http://dx.doi.org/10.1074/jbc.270.51.30651			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530502	hybrid			2022-12-25	WOS:A1995TL67500067
J	Ino, T; Yasui, H; Hirano, M; Kurosawa, Y				Ino, T; Yasui, H; Hirano, M; Kurosawa, Y			Identification of a member of the TIS11 early response gene family at the insertion point of a DNA fragment containing a gene for the T-cell receptor beta chain in an acute T-cell leukemia	ONCOGENE			English	Article						TIS11d gene; gene rearrangement; T-cell receptor gene; T-cell leukemia; leukemogenesis	SWISS 3T3 CELLS; CIRCULAR DNA; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; CONSTANT REGION; CYCLIC-AMP; PROTEIN; TRANSCRIPTION; RECOMBINATION; DELETION	In a previous paper (Proc. Natl. Acad. Sci. USA 84, 4264, 1987) we reported that a DNA fragment containing a gene for the T-cell receptor beta chain, which had been excised from chromosome 7q35 during D beta-J beta joining, was inserted into chromosome 6p21.3 in a patient with acute T-cell leukemia. We have since screened for genes in the vicinity of the insertion point and have identified a gene that is equivalent to the murine TIS11d gene, a member of TIS11 early response gene family, that contains unique Cysteine-Histidine motifs. The human TIS11d gene consists of two exons and encodes a polypeptide of 492 amino acids. The insertion of the DNA fragment observed in this patient is located at the carboxy-terminal portion of the TIS11d protein.	FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,TOYOAKE,AICHI 47011,JAPAN	Fujita Health University	Ino, T (corresponding author), FUJITA HLTH UNIV,SCH MED,DEPT INTERNAL MED,TOYOAKE,AICHI 47011,JAPAN.							BARNARD RC, 1993, NUCLEIC ACIDS RES, V21, P3580, DOI 10.1093/nar/21.15.3580; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FOLGER KR, 1982, MOL CELL BIOL, V2, P1372, DOI 10.1128/MCB.2.11.1372; FUJIMOTO S, 1987, NATURE, V327, P242, DOI 10.1038/327242a0; GOMPERTS M, 1990, ONCOGENE, V5, P1081; INO T, 1987, P NATL ACAD SCI USA, V84, P4264, DOI 10.1073/pnas.84.12.4264; INO T, 1988, BIOCHEM BIOPH RES CO, V152, P257, DOI 10.1016/S0006-291X(88)80708-3; INO T, 1988, ACTA HEMATOL JPN, V51, P185; IWASATO T, 1990, CELL, V62, P143, DOI 10.1016/0092-8674(90)90248-D; KANEDA N, 1987, BIOCHEM BIOPH RES CO, V146, P971, DOI 10.1016/0006-291X(87)90742-X; LAI WS, 1990, J BIOL CHEM, V265, P16556; LIM RW, 1987, ONCOGENE, V1, P263; MATSUOKA M, 1990, CELL, V62, P135, DOI 10.1016/0092-8674(90)90247-C; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OKAZAKI K, 1987, CELL, V49, P477, DOI 10.1016/0092-8674(87)90450-8; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; VONSCHWEDLER U, 1990, NATURE, V345, P452, DOI 10.1038/345452a0	24	14	16	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2705	2710						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545129				2022-12-25	WOS:A1995TP18800028
J	Makela, TP; Hellsten, E; Vesa, J; Hirvonen, H; Palotie, A; Peltonen, L; Alitalo, K				Makela, TP; Hellsten, E; Vesa, J; Hirvonen, H; Palotie, A; Peltonen, L; Alitalo, K			The rearranged L-myc fusion gene (RLF) encodes a Zn-15 related zinc finger protein	ONCOGENE			English	Article						RLF-L-myc rearrangement; small-cell lung carcinoma; zinc finger; transcription factor	CELL LUNG-CANCER; EXPRESSION; AMPLIFICATION; DROSOPHILA; BINDING; COMMON; MAX	We have previously characterized intrachromosomal rearrangements at 1p32 fusing the first exon of the RLF gene with L-myc, Here we present the full-length cDNA sequence of the 6251 bp RLH mRNA, The predicted 1914 amino acid Rlf protein contains sixteen widely spaced zinc finger motifs, and is related to the Zn-15 transcription factor, RLF is widely expressed in fetal and adult tissues, suggesting that it has a general role in transcriptional regulation. The zinc fingers are not contained in the 79 amino acid N-terminal region of RLP involved in the RLF-L-myc fusions, and the transforming ability of the RLF-L-myc and the normal L-myc proteins is indistinguishable. These findings suggest that the role of the rearrangements fusing RLF and L-myc is to the tightly controlled deregulate expression of the L-myc gene.	HELSINKI UNIV, HAARTMAN INST, MOLEC CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; NATL PUBL HLTH INST, DEPT HUMAN MOLEC GENET, SF-00300 HELSINKI, FINLAND; UNIV TURKU, DEPT BIOCHEM MED, SF-20520 TURKU, FINLAND; HELSINKI UNIV, CENT HOSP, DEPT CLIN CHEM, SF-00290 HELSINKI, FINLAND	University of Helsinki; Massachusetts Institute of Technology (MIT); Whitehead Institute; Finland National Institute for Health & Welfare; University of Turku; University of Helsinki; Helsinki University Central Hospital			Alitalo, Kari K/J-5013-2014; makela, tomi/B-3734-2009	Alitalo, Kari K/0000-0002-7331-0902; makela, tomi/0000-0002-4869-8044; Palotie, Aarno/0000-0002-2527-5874				ALITALO K, 1992, GENE AMPLIFICATION M, P371; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; FASANO L, 1991, CELL, V64, P63, DOI 10.1016/0092-8674(91)90209-H; HELLSTEN E, 1995, GENOMICS, V25, P404, DOI 10.1016/0888-7543(95)80040-S; HIRVONEN H, 1991, BLOOD, V78, P3012; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIPKIN SM, 1993, GENE DEV, V7, P1674, DOI 10.1101/gad.7.9.1674; MACLEANHUNTER S, 1994, ONCOGENE, V9, P3509; MAKELA TP, 1992, ONCOGENE, V7, P405; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; RHODES D, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0293-56; SEKIDO Y, 1992, MOL CELL BIOL, V12, P1747, DOI 10.1128/MCB.12.4.1747	18	16	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2699	2704						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545128				2022-12-25	WOS:A1995TP18800027
J	BAO, SC; SMITH, RM; JARETT, L; GARVEY, WT				BAO, SC; SMITH, RM; JARETT, L; GARVEY, WT			THE EFFECTS OF BREFELDIN-A ON THE GLUCOSE-TRANSPORT SYSTEM IN RAT ADIPOCYTES - IMPLICATIONS REGARDING THE INTRACELLULAR LOCUS OF INSULIN-SENSITIVE GLUT4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; PROTEINS; TRANSLOCATION; CELLS; LOCALIZATION; RESISTANCE; FRACTION	Insulin activates glucose transport by recruiting Glut4 glucose transporters from an intracellular pool to plasma membrane (PM). To localize intracellular translocating Glut4, we studied the effects of brefeldin A (BFA), which disassembles Golgi and prevents trans-Golgi vesicular budding, on the glucose transport system. Isolated rat adipocytes were treated with and without both BFA (10 mu g/ml) and insulin. BFA did not affect maximal rates of either 2-deoxyglucose or 3-O-methylglucose transport or the insulin:glucose transport dose-response curve but did increase basal transport by similar to 2-fold (p < 0.05). We also measured Glut4 in PM, low (LDM) and high density microsome subfractions. In basal cells, BFA increased PM Glut4 by 58% concomitant with a 18% decrease in LDM (p < 0.05). Insulin alone increased PM Glut4 by 3-fold concomitant with a 56% decrease in LDM. BFA did not affect insulin-induced changes in Glut4 levels in PM or LDM, Most intracellular Glut4 was localized to sub-PM vesicles by immunoelectron microscopy in basal cells, and BFA did not affect insulin-mediated recruitment of immunogold-labeled Glut4 to PM. In summary, 1) in basal cells, BFA led to a small increase in glucose transport activity and redistribution of a limited number of transporters from LDM to PM; 2) BFA did not affect insulin's ability to stimulate glucose transport or recruit normal numbers of LDM Glut4 to PM; and 3) insulin action is predominantly mediated by a BFA-insensitive pool of intracellular Glut4, which localizes to sub-PM vesicles. Thus, the major translocating pool of Glut4 in rat adipocytes does not involve trans-Golgi.	MED UNIV S CAROLINA,DEPT MED,DIV ENDOCRINOL,CHARLESTON,SC 29425; RALPH H JOHNSON VET AFFAIRS MED CTR,CHARLESTON,SC 29425; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; University of Pennsylvania					NIDDK NIH HHS [DK-19525, DK-28143, DK-38765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028143, P30DK019525, R01DK038765, R29DK038765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOCK J, 1988, J CELL BIOL, V106, P69; CHAKRABARTI R, 1994, J BIOL CHEM, V261, P7926; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; FOLEY JE, 1980, BIOCHIM BIOPHYS ACTA, V599, P689, DOI 10.1016/0005-2736(80)90210-2; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1985, J CLIN INVEST, V76, P22, DOI 10.1172/JCI111950; GARVEY WT, 1993, DIABETES, V42, P1773, DOI 10.2337/diabetes.42.12.1773; GARVEY WT, 1995, DIABETES, V44, P164; GARVEY WT, 1994, MOL BIOL DIABETES, V2, P437; JARETT L, 1975, P NATL ACAD SCI USA, V68, P3526; LACHAAL M, 1994, J BIOL CHEM, V269, P23689; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE K, 1990, FEBS LETT, V261, P459, DOI 10.1016/0014-5793(90)80615-P; LIPPINCOTTSCHWA.J, 1990, CELL, V60, P821; MCKEEL DW, 1970, J CELL BIOL, V44, P417, DOI 10.1083/jcb.44.2.417; ORCI L, 1991, CELL, V64, P1183; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SLOT JW, 1990, NATURE, V346, P369, DOI 10.1038/346369a0; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; WHITESELL RR, 1979, J BIOL CHEM, V254, P5276	24	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30199	30204						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530430				2022-12-25	WOS:A1995TK38000090
J	MORELLO, D; LAVENU, A; POURNIN, S; BABINET, C				MORELLO, D; LAVENU, A; POURNIN, S; BABINET, C			THE 5' AND 3' NONCODING SEQUENCES OF THE C-MYC GENE, REQUIRED INVITRO FOR ITS POSTTRANSCRIPTIONAL REGULATION, ARE DISPENSABLE INVIVO	ONCOGENE			English	Article							MESSENGER-RNA DEGRADATION; MOUSE-LIVER REGENERATION; CELL-FREE SYSTEM; PROTEIN-SYNTHESIS; TRANSGENIC MICE; PREMATURE TERMINATION; STABILITY INVITRO; LYMPHOMA-CELLS; RAT-LIVER; EXPRESSION	We have previously shown that in vivo the steady-state level of c-myc mRNA in different quiescent organs and its induction in the early stages of hepatic regeneration and after inhibition of protein synthesis are mainly controlled by post-transcriptional mechanisms. In order to localize the target sequences for these mechanisms, transgenic lines expressing various versions of the human c-myc proto-oncogene have been constructed. To avoid all possible transcriptional controls due to the c-mye 5' regulatory region, the c-mye genomic sequences were fused to MHC H-2K(b) class I regulatory sequences, which have previously been shown to be able to drive reporter gene expression in most adult tissues. The transgenes contained either all human c-mye genomic sequences or were deleted for one of the sequences which have been shown in in vitro experiments to play a role in c-mye mRNA stabilization, in particular exon 1, intron 1 and the 3' non-coding region. Several independent transgenic lines were derived for each construct. Using S1 nuclease protection analysis, we have monitored H-2K, mouse c-myc and transgene mRNA expression in several quiescent adult organs, at the start of liver regeneration and after inhibition of protein synthesis in each transgenic line. Our results indicate that the 5' non-coding sequences, including exon 1 and intron 1, and the 3' untranslated region are all dispensable in the different aspects of c-myc post-transcriptional regulation.			MORELLO, D (corresponding author), INST PASTEUR, DEPT IMMUNOL, UNITE GENET MAMMIFERES, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.							AGHIB DF, 1991, ONCOGENE, V6, P2371; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAUER SR, 1989, ONCOGENE, V4, P615; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BONNIEU A, 1990, ONCOGENE, V5, P1585; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; GOYETTE M, 1984, MOL CELL BIOL, V4, P1493, DOI 10.1128/MCB.4.8.1493; GRAVES RA, 1987, CELL, V48, P615, DOI 10.1016/0092-8674(87)90240-6; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LAIRDOFFRINGA IA, 1991, NUCLEIC ACIDS RES, V19, P2387, DOI 10.1093/nar/19.9.2387; LATHE R, 1987, GENE, V57, P193, DOI 10.1016/0378-1119(87)90122-3; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; MAKINO R, 1984, NATURE, V310, P697, DOI 10.1038/310697a0; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MORELLO D, 1989, ONCOGENE, V4, P955; MORELLO D, 1989, ONCOGENE RES, V4, P111; MORELLO D, 1986, EMBO J, V5, P1877, DOI 10.1002/j.1460-2075.1986.tb04439.x; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; MORELLO D, 1990, ONCOGENE, V5, P1511; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SOBCZAK J, 1989, ONCOGENE, V4, P1503; SWARTWOUT SG, 1989, MOL CELL BIOL, V9, P288, DOI 10.1128/MCB.9.1.288; THEODORAKIS NG, 1992, MOL CELL BIOL, V12, P791, DOI 10.1128/MCB.12.2.791; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505	58	27	27	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1921	1929						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510935				2022-12-25	WOS:A1993LG68200025
J	NISHIMURA, JS; YBARRA, J; MANN, CJ; MITCHELL, T				NISHIMURA, JS; YBARRA, J; MANN, CJ; MITCHELL, T			SENSITIVITY OF ESCHERICHIA-COLI SUCCINYL-COA MUTANTS AT TRP(BETA-76) TO CLOSTRIPAIN AND TO TRYPSIN - ADP AND ATP PROTECT AGAINST CLEAVAGE BY CLOSTRIPAIN AT ARG(BETA-80)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETASE; COENZYME; ENZYME; MUTAGENESIS; REACTIVITY; SUBUNIT; BINDING	Mutant forms of Escherichia coli succinyl-CoA synthetase, W76F (Trp(beta76) replaced by Phe) (Nishimura, J. S., Mann, C. J., Ybarra, J., Mitchell, T., and Horowitz, P. M. (1990) Biochemistry 29, 862-865), and W43,76,248F (all three Trp replaced by Phe) were found to be more sensitive to proteolysis by clostripain than the wild-type enzyme or other Trp mutant proteins. Like wild-type enzyme, sensitivity to trypsin was apparent when the enzyme forms were in the dephosphorylated state. Sensitivity to clostripain was the same, whether mutant or wild-type forms were in the phosphorylated or dephosphorylated state. The substrates ADP and ATP both protected the enzymes against inactivation by clostripain, with dissociation constants for protection of W76F of 33 and 125 muM, respectively. Polyacrylamide gel electrophoresis of clostripain digests revealed preferential digestion of the beta-subunit and the appearance of 40- and 31-kDa species, with amino termini corresponding to residues 15 and 81, respectively, of the beta-subunit. Mutagenic replacement of Arg(beta80), but not Arg(beta14), with Lys resulted in an enzyme that was as resistant to clostripain as wild-type enzyme. These results suggest that Arg(beta80) is the principal site of inactivation by clostripain and may be involved in the binding of ADP and ATP to succinyl-CoA synthetase.			NISHIMURA, JS (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA.				NIGMS NIH HHS [GM-17534] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017534] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKIER AT, 1983, TECHNIQUES NUCLEIC B, V5, P1; BOWMAN CM, 1975, J BIOL CHEM, V250, P5609; Bridger W. A., 1974, ENZYMES, P581; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; COLLIER GE, 1978, J BIOL CHEM, V253, P4938; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GRINNELL FL, 1969, BIOCHEMISTRY-US, V8, P562, DOI 10.1021/bi00830a015; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; KAUFMAN S, 1955, J BIOL CHEM, V216, P153; KHAN IA, 1988, J BIOL CHEM, V263, P2152; KRATZIN HD, 1989, ANAL BIOCHEM, V183, P1, DOI 10.1016/0003-2697(89)90161-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN CJ, 1989, J BIOL CHEM, V264, P1457; MANN CJ, 1991, BIOCHEMISTRY-US, V30, P1497, DOI 10.1021/bi00220a008; MITCHELL WM, 1968, J BIOL CHEM, V243, P4683; MOFFET FJ, 1972, J BIOL CHEM, V247, P8139; NISHIMURA JS, 1990, BIOCHEMISTRY-US, V29, P862, DOI 10.1021/bi00456a002; NISHIMURA JS, 1986, ADV ENZYMOL RELAT AR, V36, P141; PEARSON PH, 1975, J BIOL CHEM, V250, P8524; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; YBARRA J, 1986, BIOCHEMISTRY-US, V25, P7174, DOI 10.1021/bi00370a061	22	1	1	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13717	13722						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514803				2022-12-25	WOS:A1993LH55300098
J	MURTHARIEL, P; DAVIES, MV; SCHERER, BJ; CHOI, SY; HERSHEY, JWB; KAUFMAN, RJ				MURTHARIEL, P; DAVIES, MV; SCHERER, BJ; CHOI, SY; HERSHEY, JWB; KAUFMAN, RJ			EXPRESSION OF A PHOSPHORYLATION-RESISTANT EUKARYOTIC INITIATION FACTOR-II ALPHA-SUBUNIT MITIGATES HEAT-SHOCK INHIBITION OF PROTEIN-SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN INITIATION; HAMSTER OVARY CELLS; FACTOR-II; FACTOR EIF-2; TRANSLATIONAL CONTROL; MOLECULAR-CLONING; PHORBOL ESTERS; HELA-CELLS; RNA; COMPLEX	Protein synthesis is dramatically reduced upon exposure of cells to elevated temperature. Concordant with this inhibition, multiple phosphorylation and dephosphorylation reactions occur on specific eukaryotic initiation factors that are required for protein synthesis. Most notably, phosphorylation of the alpha-subunit of eukaryotic initiation factor-2 (eIF-2alpha) on serine residue 51 occurs. To identify the importance of phosphorylation in control of protein synthesis, we have evaluated the effects of expression of a mutant eIF-2alpha which is resistant to phosphorylation. Expression of a serine to alanine mutant at residue 51 of eIF-2alpha partially protected cells from the inhibition of protein synthesis in response to heat treatment. The overexpressed serine to alanine 51 mutant subunit was incorporated into the eIF-2 heterotrimer and was resistant to phosphorylation. These results are consistent with the hypothesis that heat shock inhibition of translation is mediated in part through phosphorylation of eIF-2alpha. Expression of the wild type or mutant eIF-2alpha did not affect cell survival or induction of hsp70 mRNA upon heat shock, indicating that although eIF-2alpha is a heat shock-induced protein, its increased synthesis during heat shock does not alter the heat-shock response.	GENET INST INC,CAMBRIDGE,MA 02140; UNIV CALIF DAVIS,DEPT BIOL CHEM,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07577, GM22135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI SY, 1992, J BIOL CHEM, V267, P286; CLEMENS MJ, 1987, J BIOL CHEM, V262, P767; COLBERT RA, 1987, J BIOL CHEM, V262, P16763; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; DAVIES MV, 1989, P NATL ACAD SCI USA, V86, P9163, DOI 10.1073/pnas.86.23.9163; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1987, MOL CELL BIOL, V7, P1293, DOI 10.1128/MCB.7.3.1293; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1985, MOL CELL BIOL, V5, P1750, DOI 10.1128/MCB.5.7.1750; KAUFMAN RJ, 1987, P NATL ACAD SCI USA, V83, P1568; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; MAURIDES PA, 1989, ANAL BIOCHEM, V183, P144, DOI 10.1016/0003-2697(89)90182-6; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1989, J BIOL CHEM, V264, P2401; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WETTENHALL REH, 1986, J BIOL CHEM, V261, P2444; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330	42	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12946	12951						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509427				2022-12-25	WOS:A1993LG65800103
J	Becker, TC; Noel, RJ; Johnson, JH; Lynch, RM; Hirose, H; Tokuyama, Y; Bell, GI; Newgard, CB				Becker, TC; Noel, RJ; Johnson, JH; Lynch, RM; Hirose, H; Tokuyama, Y; Bell, GI; Newgard, CB			Differential effects of overexpressed glucokinase and hexokinase I in isolated islets - Evidence for functional segregation of the high and low K-m enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; PANCREATIC-ISLETS; DIABETES-MELLITUS; GLUCOSE; RAT; CELLS; PROTEIN; LIVER; EXPRESSION; METABOLISM	Glucose-stimulated insulin secretion is believed to require metabolism of the sugar via a high K-m pathway in which glucokinase (hexokinase IV) is rate-limiting, In this study, we have used recombinant adenoviruses to overexpress the liver and islet isoforms of glucokinase as well as low K-m hexokinase I in isolated rat islets of Langerhans. Glucose phosphorylating activity increased by up to 20-fold in extracts from islets treated with adenoviruses containing the cDNAs encoding either tissue isoform of glucokinase, but such cells exhibited no increase in 2- or 5-[H-3]glucose usage, lactate production, glycogen content, or glucose oxidation, Furthermore, glucokinase overexpression enhanced insulin secretion in response to stimulatory glucose or glucose plus arginine by only 36-53% relative to control. islets, In contrast to the minimal effects of overexpresed glucokinases, overexpression of hexokinase I caused a 2.5-4-fold enhancement in all metabolic parameters except glycogen content when measured at a basal glucose concentration (3 mM). Eased on measurement of glucose phosphorylation in intact cells, overexpressed glucokinase is clearly active in a non-islet cell line (CV-1) but not within islet cells, That this result cannot be ascribed to the levels of glucokinase regulatory protein in islets is shown by direct measurement of its activity and mRNA. These data provide evidence for functional partitioning of glucokinase and hexokinase and suggest that overexpressed glucokinase must interact with factors found in limiting concentration in the islet cell in order to become activated and engage in productive metabolic signaling.	UNIV TEXAS, GIFFORD LABS DIABET RES, SW MED CTR, DALLAS, TX 75235 USA; UNIV TEXAS, DEPT BIOCHEM & INTERNAL MED, SW MED CTR, DALLAS, TX 75235 USA; VET ADM MED CTR, DALLAS, TX 75216 USA; UNIV ARIZONA, ARIZONA HLTH SCI CTR, DEPT PHYSIOL & PHARMACOL, TUCSON, AZ 85724 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Arizona; University of Arizona Health Sciences; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042582, R01DK046492, P01DK044840, R37DK046492] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46492, DK42582, DK44840] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BECKER TC, 1994, J BIOL CHEM, V269, P21234; CHEN C, 1994, DIABETES, V43, P684, DOI 10.2337/diabetes.43.5.684; CHEN C, 1994, J CLIN INVEST, V94, P1616, DOI 10.1172/JCI117503; COLLINS H, 1992, J BIOL CHEM, V267, P1357; DETHEUX M, 1994, FEBS LETT, V339, P312; DETHEUX M, 1993, FEBS LETT, V321, P111, DOI 10.1016/0014-5793(93)80089-D; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GHOSH A, 1991, J BIOL CHEM, V266, P22887; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; HUGHES SD, 1992, P NATL ACAD SCI USA, V89, P688, DOI 10.1073/pnas.89.2.688; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; ISHIHARA H, 1994, J BIOL CHEM, V269, P3081; IWASHIMA Y, 1993, DIABETES, V42, P948, DOI 10.2337/diabetes.42.7.948; JOHNSON JH, 1990, NEW ENGL J MED, V322, P653, DOI 10.1056/NEJM199003083221003; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; MALAISSE WJ, 1990, EUR J BIOCHEM, V190, P539, DOI 10.1111/j.1432-1033.1990.tb15607.x; MALAISSE WJ, 1991, INT J BIOCHEM, V23, P1471, DOI 10.1016/0020-711X(91)90290-4; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; NOMA Y, 1995, DIABETES, V44, pA21; QUAADE C, 1991, FEBS LETT, V280, P47, DOI 10.1016/0014-5793(91)80201-D; SCHWAB DA, 1988, J BIOL CHEM, V263, P3220; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; VOSSMCCOWAN ME, 1994, J BIOL CHEM, V269, P15814; WILSON JE, 1984, REGULATION CARBOHYDR, P45; YIN L, 1992, DIABETES, V41, P792	35	103	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					390	394		10.1074/jbc.271.1.390	http://dx.doi.org/10.1074/jbc.271.1.390			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550593	hybrid			2022-12-25	WOS:A1996TP36100062
J	Bush, EW; Taft, CS; Meixell, GE; Perryman, MB				Bush, EW; Taft, CS; Meixell, GE; Perryman, MB			Overexpression of myotonic dystrophy kinase in BC(3)H1 cells induces the skeletal muscle phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; 3' UNTRANSLATED REGION; MESSENGER-RNA; CREATINE-PHOSPHOKINASE; TRIPLET REPEAT; DIFFERENTIATION; GENE; ANTICIPATION; EXPRESSION; MYOGENESIS	Myotonic muscular dystrophy is an autosomal dominant defect that produces muscle wasting, myotonia, and cardiac conduction abnormalities. The myotonic dystrophy locus codes for a putative serine-threonine protein kinase of unknown function. We report that overexpression of human myotonic dystrophy protein kinase induces the expression of skeletal muscle-specific genes in undifferentiated BC(3)H1 muscle cells. BC(3)H1 clones expressing myotonic dystrophy kinase appear equivalent to differentiated cells with respect to expression of myogenin, retinoblastoma tumor supressor gene, M creatine kinase, beta-tropomyosin, and vimentin. In addition, differential display analysis demonstrates that the pattern of gene expression exhibited by myotonic dystrophy kinase-expressing cells is essentially identical to that of differentiated BC(3)H1 muscle cells, These observations suggest that myotonic dystrophy kinase may function in the myogenic pathway.	UNIV COLORADO,HLTH SCI CTR,DIV CARDIOL,DEPT MED,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [1RO1HL50715] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050715] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHIZAWA T, 1992, NEUROLOGY, V42, P1871; ASHIZAWA T, 1992, NEUROLOGY, V42, P1877; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BENNETT GS, 1979, J CELL BIOL, V82, P577, DOI 10.1083/jcb.82.2.577; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUNNE PW, 1994, BIOCHEMISTRY-US, V33, P10809, DOI 10.1021/bi00201a031; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GALLANTI A, 1992, ACTA NEUROPATHOL, V85, P88, DOI 10.1007/BF00304637; GROSSMANN ME, 1994, MOL ENDOCRINOL, V8, P448, DOI 10.1210/me.8.4.448; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HARPER PS, 1989, METABOLIC BASIS INHE, V2, P2869; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI L, 1992, MOL CELL BIOL, V12, P4478, DOI 10.1128/MCB.12.10.4478; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; MAEDA M, 1995, J BIOL CHEM, V270, P20246, DOI 10.1074/jbc.270.35.20246; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MORRIS GE, 1972, EXP CELL RES, V74, P582, DOI 10.1016/0014-4827(72)90422-3; MOUNTFORD PS, 1992, J NEUROENDOCRINOL, V4, P656; OLSON EN, 1983, J BIOL CHEM, V258, P2644; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PERRIARD JC, 1978, J BIOL CHEM, V253, P6529; PERRYMAN MB, 1993, TRENDS CARDIOVAS MED, V3, P82, DOI 10.1016/1050-1738(93)90028-5; PULEO PR, 1989, CLIN CHEM, V35, P1452; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; SARNAT HB, 1992, NEUROLOGY, V42, P1616, DOI 10.1212/WNL.42.8.1616; SHAW DJ, 1993, GENOMICS, V18, P673, DOI 10.1016/S0888-7543(05)80372-6; Steinert H., 1909, DTSCH Z NERVENHEILK, V37, P38; TURNER DC, 1974, DEV BIOL, V37, P63, DOI 10.1016/0012-1606(74)90170-5; VATER R, 1994, HISTOCHEM J, V26, P916; WANG YC, 1992, J BIOL CHEM, V267, P2728; WHITING EJ, 1995, HUM MOL GENET, V4, P1063, DOI 10.1093/hmg/4.6.1063	41	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					548	552		10.1074/jbc.271.1.548	http://dx.doi.org/10.1074/jbc.271.1.548			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550617	hybrid			2022-12-25	WOS:A1996TP36100083
J	Guo, W; Jorgensen, AO; Jones, LR; Campbell, KP				Guo, W; Jorgensen, AO; Jones, LR; Campbell, KP			Biochemical characterization and molecular cloning of cardiac triadin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM GLYCOPROTEIN TRIADIN; SARCOPLASMIC-RETICULUM; VENTRICULAR MUSCLE; ULTRASTRUCTURAL-LOCALIZATION; CALCIUM RELEASE; CALSEQUESTRIN; RYANODINE; PROTEIN; RECEPTOR; CHANNEL	Triadin is an intrinsic membrane protein first identified in the skeletal muscle junctional sarcoplasmic reticulum and is considered to play an important role in excitation-contraction coupling, Using polyclonal antibodies to skeletal muscle triadin, me have identified and characterized three isoforms in rabbit cardiac muscle. The cDNAs encoding these three isoforms of triadin have been isolated by reverse transcription-polymerase chain reaction and cDNA library screening. The deduced amino acid sequences show that these proteins are identical in their N-terminal sequences, whereas the C-terminal sequences are distinct from each other and from that of skeletal muscle triadin. Based upon both the amino acid sequences and biochemical analysis, all three triadin isoforms share similar membrane topology with skeletal muscle triadin. Immunofluorescence staining of rabbit cardiac muscle with antibodies purified from the homologous region of triadin shows that cardiac triadin is primarily confined to the I-band region of cardiac myocytes, where the junctional and corbular sarcoplasmic reticulum is located, Furthermore, we demonstrate that the conserved region of the luminal domain of triadin is able to bind both the ryanodine receptor and calsequestrin in cardiac muscle. These results suggest that triadin colocalizes with and binds to the ryanodine receptor and calsequestrin and carries out a function in the lumen of the junctional sarcoplasmic reticulum that is important for both skeletal and cardiac muscle excitation-contraction coupling.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA; UNIV TORONTO, DEPT ANAT & CELL BIOL, TORONTO, ON M5S 1A8, CANADA; INDIANA UNIV, SCH MED, KRANNERT INST CARDIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT MED, INDIANAPOLIS, IN 46202 USA	Howard Hughes Medical Institute; University of Iowa; University of Toronto; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				Campbell, Kevin/0000-0003-2066-5889	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28556] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS BA, 1990, FASEB J, V4, P2809, DOI 10.1096/fasebj.4.10.2165014; BRANDT NR, 1993, J MEMBRANE BIOL, V131, P219, DOI 10.1007/BF02260110; CARL SL, 1995, J CELL BIOL, V129, P673, DOI 10.1083/jcb.129.3.673; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; GILCHRIST JSC, 1992, J BIOL CHEM, V267, P20850; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; IKEMOTO N, 1989, BIOCHEMISTRY-US, V28, P6764, DOI 10.1021/bi00442a033; IKEMOTO N, 1991, BIOCHEMISTRY-US, V30, P5230, DOI 10.1021/bi00235a017; JORGENSEN AO, 1987, J CELL BIOL, V104, P1343, DOI 10.1083/jcb.104.5.1343; JORGENSEN AO, 1984, J CELL BIOL, V98, P1597, DOI 10.1083/jcb.98.4.1597; JORGENSEN AO, 1985, J CELL BIOL, V101, P257, DOI 10.1083/jcb.101.1.257; JORGENSEN AO, 1993, J CELL BIOL, V120, P969, DOI 10.1083/jcb.120.4.969; JORGENSEN AO, 1984, CIRC RES, V55, P267, DOI 10.1161/01.RES.55.2.267; KAWASAKI T, 1994, BIOCHEM BIOPH RES CO, V199, P1120, DOI 10.1006/bbrc.1994.1347; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTY I, 1995, BIOCHEM J, V307, P769, DOI 10.1042/bj3070769; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PENG M, 1994, FEBS LETT, V348, P17, DOI 10.1016/0014-5793(94)00556-7; STEM MD, 1992, FASEB LETT, V6, P3092; SUN XH, 1995, J CELL BIOL, V129, P659, DOI 10.1083/jcb.129.3.659; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41	28	91	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					458	465		10.1074/jbc.271.1.458	http://dx.doi.org/10.1074/jbc.271.1.458			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550602	hybrid			2022-12-25	WOS:A1996TP36100070
J	Fujimura, Y; Ohno, T; Siddique, H; Lee, L; Rao, VN; Reddy, ESP				Fujimura, Y; Ohno, T; Siddique, H; Lee, L; Rao, VN; Reddy, ESP			The EWS-ATF-1 gene involved in malignant melanoma of soft parts with t(12;22) chromosome translocation, encodes a constitutive transcriptional activator	ONCOGENE			English	Article						malignant melanoma; EWS; transactivation; ATF-1; chromosome translocation	ETS-RELATED GENE; TISSUE-SPECIFIC EXTINGUISHER; PROTEIN-KINASE-A; EWINGS-SARCOMA; DNA-BINDING; REGULATORY SUBUNIT; TSE1 ENCODES; FACTOR CREB; CYCLIC-AMP; FLI-1 GENE	Molecular characterization of malignant melanoma of soft parts or soft tissue clear cell sarcoma which shares t(12;22) chromosome translocation revealed fusion of EWS with a transcriptional factor gene ATF-1. The EWS gene, which encodes an RNA binding protein, was also shown to be involved in Ewing sarcoma, related primitive neuroectodermal tumors and desmoplastic small round cell tumors. In order to understand the functional role of EWS-ATF-1 chimeric protein in human solid tumors, we have cloned the aberrant human ATF-1 (EWS-ATF-1) cDNA and studied its DNA binding, transcriptional activation properties and compared with normal ATF-1 protein. Our results demonstrate that EWS-ATF-1 binds weakly to DNA in vitro but functions as an efficient constitutive transcriptional activator unlike the normal ATF-1 which needs to be induced with cAMP. Deletion analysis revealed that EWS-fusion domain functions as a regulatory domain for the transcriptional activation properties of EWS-ATF-1 chimeric protein. Deletion of leucine zipper domain results in a loss of transcriptional activation of EWS-ATF-1 chimeric protein suggesting that protein-protein interaction play a role in the transcriptional activation properties of EWS-ATF-1. We demonstrate that EWS-fusion domain negatively regulates the DNA binding activity of EWS-ATF-1 chimeric protein. Therefore replacement of part of the amino-terminal kinase regulatory domain of ATF-1 protein with EWS regulatory domain results in an altered DNA binding, protein-protein interactions and transcriptional activation properties of EWS-ATF-1 causing deregulated gene expression which may be responsible for the genesis of t(12;22) chromosome translocation-bearing human solid tumors. Targeting the transcriptional cofactors (CBP, etc) by EWS-fusion proteins could be one of the mechanisms of activation of EWS-fusion proteins in human neoplasia.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; SAIC,FREDERICK,MD 21702	Jefferson University; Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [CA 51083, CA 58642, CA 57157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051083, R01CA057157, R01CA058642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AURIAS A, 1983, NEW ENGL J MED, V309, P496; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BROWN AD, 1995, ONCOGENE, V10, P1749; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; HELM S, 1994, GENES CHROM CANC, V11, P256; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LADANYI M, 1994, CANCER RES, V54, P2837; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LIU F, 1993, J BIOL CHEM, V268, P6714; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHNO T, 1994, ONCOGENE, V9, P3087; OHNO T, 1993, CANCER RES, V53, P5859; OUCHIDA M, 1995, ONCOGENE, V11, P1049; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PRASAD DDK, 1994, ONCOGENE, V9, P669; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1993, ONCOGENE, V8, P2167; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VAIRO G, 1990, J BIOL CHEM, V265, P2692; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	55	103	104	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					159	167						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552387				2022-12-25	WOS:A1996TQ01400020
J	Schmidt, G; Lenzen, C; Simon, I; Deuter, R; Cool, RH; Goody, RS; Wittinghofer, A				Schmidt, G; Lenzen, C; Simon, I; Deuter, R; Cool, RH; Goody, RS; Wittinghofer, A			Biochemical and biological consequences of changing the specificity of p21(ras) from guanosine to xanthosine nucleotides	ONCOGENE			English	Article						Ras D119N mutant; interactions; change of specificity; xanthosine nucleotide	ELONGATION-FACTOR-TU; H-RAS P21; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; BINDING-PROTEINS; PC12 CELLS; GTP; IDENTIFICATION; HYDROLYSIS	The D119N mutation of p21(ras) was prepared by site-directed mutagenesis. Its nucleotide binding properties were investigated using fluorescently labelled guanosine and xanthosine nucleotides. Its affinity for guanosine nucleotides is severely reduced, with a concomitant increase in the affinity for xanthosine nucleotides, which leads to an almost complete reversal of base specificity. The protein is a GTPase as well as a XTPase and the hydrolysis reaction can be efficiently stimulated by GAP. Dissociation of XDP from the mutant is stimulated by the guanine nucleotide exchange factor Cdc25(Mm) in a similar manner to that of GDP from wildtype. The interaction of the mutant with the effector domain of c-Raf kinase or Ral-GEF is normal. In microinjection experiments in PC12 and NIH3T3 cells the protein behaves as an oncogenic mutant due to its high dissociation rate for GDP. However, when the protein is loaded with XDP before microinjection the onset of the oncogenic signal can be efficiently retarded. Thus, the protein behaves initially as wildtype and later as an oncogenic protein.	MAX PLANCK INST MOLEK PHYSIOL,ABT STRUKT BIOL,D-44139 DORTMUND,GERMANY; MAX PLANCK INST MOLEK PHYSIOL,PHYS BIOCHEM ABT,D-44139 DORTMUND,GERMANY	Max Planck Society; Max Planck Society			Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444; Cool, Robbert/0000-0002-9845-2202				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEVALLIERMULTON MC, 1993, J BIOL CHEM, V268, P11113; DER CJ, 1988, ONCOGENE, V3, P105; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GLAZEBROOK MA, 1990, J GEN MICROBIOL, V136, P581, DOI 10.1099/00221287-136-3-581; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; GOODY RS, 1986, TETRAHEDRON LETT, V27, P3599, DOI 10.1016/S0040-4039(00)84859-5; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HERRMANN C, 1995, IN PRESS J BIOL CHEM; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HWANG YW, 1987, J BIOL CHEM, V262, P13081; JACQUET E, 1994, BIOCHEM BIOPH RES CO, V199, P497, DOI 10.1006/bbrc.1994.1256; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; KANG C, 1994, J BIOL CHEM, V269, P24046; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OKAMOTO K, 1995, J BIOL CHEM, V270, P7816, DOI 10.1074/jbc.270.14.7816; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; RENSLAND H, 1995, BIOCHEMISTRY-US, V34, P593, DOI 10.1021/bi00002a026; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SCHWEINS T, 1994, CURR BIOL, V4, P547, DOI 10.1016/S0960-9822(00)00122-6; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3442; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEIJLAND A, 1994, BIOCHEMISTRY-US, V33, P10711, DOI 10.1021/bi00201a019; WEIJLAND A, 1994, TRENDS BIOCHEM SCI, V19, P188, DOI 10.1016/0968-0004(94)90018-3; WEIJLAND A, 1993, SCIENCE, V259, P1311, DOI 10.1126/science.8446899; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P383; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHONG JM, 1995, J BIOL CHEM, V270, P10002, DOI 10.1074/jbc.270.17.10002	67	61	62	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					87	96						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552403				2022-12-25	WOS:A1996TQ01400011
J	Osawa, S; Weiss, ER				Osawa, S; Weiss, ER			The effect of carboxyl-terminal mutagenesis of G(t)alpha on rhodopsin and guanine nucleotide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCING G-PROTEINS; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; ADENYLYL CYCLASE; REGULATORY COMPONENT; LIMITED PROTEOLYSIS; ADP-RIBOSYLATION; BETA-GAMMA; RECEPTOR; ANTIBODIES	The carboxyl terminus of G protein alpha subunits plays an important role in receptor recognition. To identify the amino acids that participate in this interaction, COOH-terminal mutants of alpha(t) (the transducin alpha subunit) were expressed in vitro and analyzed for their ability to interact with rhodopsin and to bind guanine nucleotide. Gly-348, the reported site of a beta turn, was replaced with other neutral amino acids without severely affecting rhodopsin binding. However, proline substitution abolished rhodopsin interaction, suggesting that flexibility is important at this site. A comparison between C347Y, which lost both rhodopsin and guanine nucleotide binding, and a mutant substituted with alpha(q) sequence (D346E/C347/G348N/F350V), in which guanine nucleotide binding was restored, implies that distinct motifs maintain the structure of the alpha subunit and are necessary for selective interaction with receptors. Surprisingly, mutants L344A, L349A, F350stop, and stop351A demonstrated a parallel loss of rhodopsin and guanine nucleotide binding. Altered profiles of L344A and F350stop on sucrose density gradients indicate that these mutants may undergo denaturation. The equivalent of alpha(t)L344A generated in alpha(s) and alpha(i) did not show such a severe loss of guanine nucleotide binding, revealing that the alpha(t) carboxyl terminus is unique in its susceptibility to changes in amino acid sequence.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Osawa, S (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CB 7090,108 TAYLOR HALL,CHAPEL HILL,NC 27599, USA.		Weiss, Ellen/AAK-9868-2020		NIGMS NIH HHS [GM47438, GM43582] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM047438, R29GM047438, R29GM043582, R01GM043582] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BOLLUM FJ, 1968, METHODS ENZYMOLOGY B, V12, P169; CODINA J, 1994, J BIOL CHEM, V269, P29339; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HINGORANI VN, 1988, J BIOL CHEM, V263, P19804; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; HONG K, 1973, BIOCHEMISTRY-US, V12, P4517, DOI 10.1021/bi00746a033; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; JONES DT, 1987, J BIOL CHEM, V262, P14241; JOURNOT L, 1989, FEBS LETT, V251, P230, DOI 10.1016/0014-5793(89)81460-7; KATADA T, 1984, J BIOL CHEM, V259, P3568; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; OSAWA S, 1990, MOL CELL BIOL, V10, P2931, DOI 10.1128/MCB.10.6.2931; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WEISS ER, 1987, J BIOL CHEM, V262, P4319; WEISS ER, 1990, J MOL ENDOCRINOL, V4, P71, DOI 10.1677/jme.0.0040071; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; WESSLINGRESNICK M, 1987, TRENDS BIOCHEM SCI, V12, P473, DOI 10.1016/0968-0004(87)90233-7; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; WESSLINGRESNICK M, 1987, BIOCHEMISTRY-US, V26, P4316, DOI 10.1021/bi00388a020; WEST RE, 1985, J BIOL CHEM, V260, P4428; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371	51	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31052	31058		10.1074/jbc.270.52.31052	http://dx.doi.org/10.1074/jbc.270.52.31052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537363	hybrid			2022-12-25	WOS:A1995TN44400031
J	Charron, G; Guy, LG; Bazinet, M; Julien, JP				Charron, G; Guy, LG; Bazinet, M; Julien, JP			Multiple neuron-specific enhancers in the gene coding for the human neurofilament light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE FILAMENT PROTEIN; DOPA DECARBOXYLASE GENE; CENTRAL-NERVOUS-SYSTEM; CIS-ACTING ELEMENT; TRANSGENIC MICE; NF-L; REGULATORY ELEMENTS; FUNCTIONAL-ANALYSIS; MOUSE EMBRYO; EXPRESSION	To define DNA regions involved in the neuron-specific expression of the neurofilament light (NF-L) gene, we generated transgenic mice bearing different NF-L constructs. A 4.9-kilobase human NF-L fragment including -292 base pairs of 5'-flanking sequences contained sufficient elements for nervous system expression in transgenic mice. Deletion of introns 1 and 2 from this 4.9-kilobase DNA fragment resulted in reduced levels of transgene expression in the cortex, while deletion of intron 3 had little effect. Both introns 1 and 2 could act independently as enhancers to confer neuronal expression of the basal heat shock promoter (hsp68) fused to lacZ in transgenic mice. The hNF-L basal promoter (-292 base pairs) was found to contain elements for directing neuronal expression of either the lacZ re porter gene or an intronless hNF-L construct. Sequence comparison revealed that intron 1, intron 2, and the basal human NF-L promoter all contain an ETS-like mo tif, CAGGA, present in a variety of genes expressed in the nervous system.	MCGILL UNIV,MONTREAL GEN HOSP,RES INST,CTR RES NEUROSCI,MONTREAL,PQ H3G 1A4,CANADA	McGill University								BEAUDET L, 1992, GENE, V116, P205, DOI 10.1016/0378-1119(92)90517-S; BERGERON C, 1994, J NEUROPATH EXP NEUR, V53, P221, DOI 10.1097/00005072-199405000-00002; BONNEROT C, 1990, P NATL ACAD SCI USA, V87, P6331, DOI 10.1073/pnas.87.16.6331; BRAY SJ, 1988, EMBO J, V7, P177, DOI 10.1002/j.1460-2075.1988.tb02798.x; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; CHARRON G, 1995, J BIOL CHEM, V270, P25739, DOI 10.1074/jbc.270.43.25739; CHING GY, 1991, J BIOL CHEM, V266, P19459; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHARD P, 1984, J NEUROSCI, V4, P2080; COHENTANNOUDJI M, 1992, MOL REPROD DEV, V33, P149, DOI 10.1002/mrd.1080330206; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DANCIGER E, 1989, P NATL ACAD SCI USA, V86, P8565, DOI 10.1073/pnas.86.21.8565; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOHNSON WA, 1989, GENE DEV, V3, P676, DOI 10.1101/gad.3.5.676; JULIEN JP, 1995, NEUROBIOL AGING, V16, P487, DOI 10.1016/0197-4580(94)00169-2; JULIEN JP, 1990, J PHYSIOLOGY PARIS, V84, P50; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; JULIEN JP, 1987, BIOCHIM BIOPHYS ACTA, V909, P10, DOI 10.1016/0167-4781(87)90041-8; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; KOTHARY R, 1988, NATURE, V335, P435, DOI 10.1038/335435a0; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; LEWIS SA, 1986, MOL CELL BIOL, V6, P1529, DOI 10.1128/MCB.6.5.1529; LIEBERBURG I, 1989, P NATL ACAD SCI USA, V86, P2463, DOI 10.1073/pnas.86.7.2463; LIEM RKH, 1978, J CELL BIOL, V79, P637, DOI 10.1083/jcb.79.3.637; LIESI P, 1986, J HISTOCHEM CYTOCHEM, V34, P923, DOI 10.1177/34.7.3458811; LOGAN C, 1993, DEVELOPMENT, V117, P905; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; MONTEIRO MJ, 1990, J CELL BIOL, V111, P1543, DOI 10.1083/jcb.111.4.1543; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MUMA NA, 1993, LAB INVEST, V69, P436; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; OSBORN M, 1982, CELL, V31, P303, DOI 10.1016/0092-8674(82)90122-2; POSPELOV VA, 1994, CELL GROWTH DIFFER, V5, P187; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SAKIMURA K, 1987, GENE AMST, V60, P107; TUGGLE CK, 1990, GENE DEV, V4, P180, DOI 10.1101/gad.4.2.180; VANDAELE S, 1991, GENE DEV, V5, P1136, DOI 10.1101/gad.5.7.1136; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; YAZDANBAKHSH K, 1993, NUCLEIC ACIDS RES, V21, P455, DOI 10.1093/nar/21.3.455; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	56	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30604	30610		10.1074/jbc.270.51.30604	http://dx.doi.org/10.1074/jbc.270.51.30604			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530496	hybrid			2022-12-25	WOS:A1995TL67500061
J	Weaver, AM; Owens, GK; Gonias, SL				Weaver, AM; Owens, GK; Gonias, SL			Native and activated forms of alpha(2)-macroglobulin increase expression of platelet-derived growth factor alpha-receptor in vascular smooth muscle cells - Evidence for autocrine transforming growth factor-beta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-AA HOMODIMER; ALPHA-2-MACROGLOBULIN RECEPTOR; PERITONEAL-MACROPHAGES; ARTERIAL INJURY; BINDING DOMAIN; PROTEIN; METHYLAMINE; FACTOR-BETA-1; ATHEROSCLEROSIS; PROLIFERATION	Cellular response to platelet-derived growth factor AA (PDGF-AA) is mediated exclusively by the PDGF alpha-receptor. Vascular smooth muscle cells (VSMCs) in culture typically express very low levels of alpha-receptor. In this study, we demonstrate that the proteinase inhibitor and cytokine carrier alpha(2)-macroglobulin (alpha(2)M) increases rat VSMC PDGF alpha-receptor expression, PDGF alpha-receptor mRNA levels increased 3-fold by 6 h and were sustained at that level through 24 h in VSMCs treated with 280 nM methylamine modified alpha(2)M (alpha(2)M-MA), a form of activated alpha(2)M. PDGF beta-receptor mRNA levels were unchanged in the same time period. In I-125-PDGF-AA binding experiments, treatment of VSMCs with alpha(2)M-MA increased the maximum binding capacity (B-max) from 1.9 to 9.2 fmol/mg of cell protein without affecting binding affinity (K-D similar to 80 pm). alpha(2)M-MA also increased the VSMC response to PDGF-AA as determined by tyrosine phosphorylation of a 170-kDa band, corresponding in mass to the PDGF alpha-receptor. The native form of alpha(2)M was comparable to alpha(2)M-MA in its ability to increase PDGF-AA binding to VSMCs and tyrosine phosphorylation of the 170-kDa band. Recombinant and proteolytic alpha(2)M derivatives were used to demonstrate that alpha(2)M increases PDGF alpha-receptor expression by binding VSMC-secreted cytokine(s) and interrupting an autocrine loop that ordinarily suppresses alpha-receptor expression in these cells. Transforming growth factor-beta-neutralizing antibody mimicked the activity of alpha(2)M, increasing the binding capacity of VSMCs for PDGF-AA. This study demonstrates that VSMC PDGF alpha-receptor expression and responsiveness to PDGF-AA are regulated by autocrine transforming growth factor-beta activity, potentially other autocrine growth factors, and alpha(2)M.	UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT MOLEC PHYSIOL & CELLULAR BIOPHYS,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53462] Funding Source: Medline; NHLBI NIH HHS [HL-19242] Funding Source: Medline; NIGMS NIH HHS [GM 07267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGROTIS A, 1994, CLIN EXP PHARMACOL P, V21, P145, DOI 10.1111/j.1440-1681.1994.tb02484.x; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BONNER JC, 1995, J BIOL CHEM, V270, P6389, DOI 10.1074/jbc.270.11.6389; BONNER JC, 1995, J BIOL CHEM, V270, P16236, DOI 10.1074/jbc.270.27.16236; BORTH W, 1989, J BIOL CHEM, V264, P5818; BORTH W, 1990, J IMMUNOL, V145, P3747; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; FLAUMENHAFT R, 1992, MOL BIOL CELL, V3, P1057, DOI 10.1091/mbc.3.10.1057; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; GRAINGER DJ, 1994, CARDIOVASC RES, V28, P1238, DOI 10.1093/cvr/28.8.1238; HALL SW, 1992, BIOCHEM J, V281, P569, DOI 10.1042/bj2810569; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HOFFMAN M, 1988, AGENTS ACTIONS, V25, P360, DOI 10.1007/BF01965043; HOFFMAN M, 1983, BIOCHIM BIOPHYS ACTA, V760, P421, DOI 10.1016/0304-4165(83)90384-7; HOVI T, 1977, J EXP MED, V145, P1580, DOI 10.1084/jem.145.6.1580; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; INUI H, 1994, J BIOL CHEM, V269, P30546; INUI H, 1992, BIOCHEM BIOPH RES CO, V188, P524, DOI 10.1016/0006-291X(92)91087-7; INUI H, 1993, J BIOL CHEM, V268, P10745; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; KANTHOU C, 1992, FEBS LETT, V314, P143, DOI 10.1016/0014-5793(92)80961-F; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LINDROOS PM, 1996, IN PRESS AM J RESPIR; LYSIAK JJ, 1995, J BIOL CHEM, V270, P21919, DOI 10.1074/jbc.270.37.21919; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MATSUI T, 1991, JPN CIRC J, V55, P1027, DOI 10.1253/jcj.55.1027; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; RAINES EW, 1993, BRIT HEART J, V69, pS30; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALVESEN G, 1992, FEBS LETT, V313, P198, DOI 10.1016/0014-5793(92)81443-P; SCHOLLMANN C, 1992, J BIOL CHEM, V267, P18032; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; Sottrup-Jensen L, 1987, PLASMA PROTEINS STRU, V5, P192; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STOUFFER GA, 1993, J BIOL CHEM, V268, P18340; STOUFFER GA, 1993, AM J PHYSIOL, V264, pC390, DOI 10.1152/ajpcell.1993.264.2.C390; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; WEBB DJ, 1995, BIOCHEM J, V312, P579, DOI 10.1042/bj3120579; WEBB DJ, 1996, IN PRESS EUR J BIOCH; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; WESTERMARK B, 1993, ACTA ONCOL, V32, P101, DOI 10.3109/02841869309083897; WU S, 1995, J CELL BIOL, V116, P187	57	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30741	30748		10.1074/jbc.270.51.30741	http://dx.doi.org/10.1074/jbc.270.51.30741			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530514	hybrid			2022-12-25	WOS:A1995TL67500079
J	Chung, GTY; Sundaresan, V; Hasleton, P; Rudd, R; Taylor, R; Rabbitts, PH				Chung, GTY; Sundaresan, V; Hasleton, P; Rudd, R; Taylor, R; Rabbitts, PH			Sequential molecular genetic changes in lung cancer development	ONCOGENE			English	Article						chromosome 3; p53; LOH; pre-neoplasia; dysplasia; tumour progression	SMALL-CELL; SHORT ARM; P53 PROTEIN; DELETION; ABNORMALITIES; CHROMOSOME-3; EXPRESSION; CARCINOMA; HETEROZYGOSITY; ACCUMULATION	Epithelial tumours develop through a sequence of preinvasive lesions of increasing disarray driven by underlying somatic genetic changes, We have studied the occurrence of the two most common somatic genetic changes associated with lung cancer in a series of premalignant bronchial lesions representing different stages in lung tumorigenesis, We present evidence that allele loss on chromosome 3 precedes damage to the p53 gene, Damage to chromosome 3 itself appears to be sequential in that the pattern of allele loss seen in dysplasia is often much more discrete than in invasive tumours, This implies that preneoplastic lesions may be a useful source of material for deletion mapping studies aimed at localising the position of tumour suppressor genes, We illustrate this by the comparison of an interstitial deletion described in this study with a homozygous deletion we have described previously, which has resulted in a better definition of the localisation of a tumour suppressor gene believed to be involved in lung cancer development.	MRC, CLIN ONCOL & RADIOTHERAPEUT UNIT, MRC CTR, CAMBRIDGE CB2 2QH, ENGLAND; WYTHENSHAWE HOSP, REG CARDIOTHORAC CTR, DEPT PATHOL, MANCHESTER M23 9LT, LANCS, ENGLAND; LONDON CHEST HOSP, LONDON E2 9JX, ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of London; Queen Mary University London								BENNETT WP, 1993, CANCER RES, V53, P4817; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; DALY MC, 1991, GENOMICS, V9, P113, DOI 10.1016/0888-7543(91)90227-6; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DODSON MK, 1993, CANCER RES, V53, P4456; ELDER PA, 1994, ONCOGENE, V9, P3433; GANLY PS, 1992, GENOMICS, V12, P221, DOI 10.1016/0888-7543(92)90369-4; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KLEIN N, 1993, LAB INVEST, V68, P26; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LUBINSKI J, 1994, CANCER RES, V54, P3710; MARCHETTI A, 1993, CANCER RES, V53, P2846; MATHEW S, 1994, CANCER RES, V54, P6265; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NUORVA K, 1993, AM J PATHOL, V142, P725; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RABBITTS PH, 1994, BRIT MED BULL, V50, P688, DOI 10.1093/oxfordjournals.bmb.a072917; RODENHUIS S, 1992, CANCER RES, V52, pS2665; RUBIO MP, 1993, CANCER RES, V53, P3465; SATO S, 1994, CANCER RES, V54, P5652; SATO T, 1991, CANCER RES, V51, P5794; SOZZI G, 1991, CANCER RES, V51, P400; SUGIO K, 1994, CANCER RES, V54, P5811; SUNDARESAN V, 1992, ONCOGENE, V7, P1989; SUNDARESAN V, 1995, IN PRESS ANNALS ONCO; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VIEL A, 1992, BRIT J CANCER, V66, P1030, DOI 10.1038/bjc.1992.405; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WALKER C, 1994, BRIT J CANCER, V70, P297, DOI 10.1038/bjc.1994.296; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; WU CL, 1994, CANCER RES, V54, P6484; YOKOYAMA S, 1992, CANCER RES, V52, P873	36	86	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2591	2598						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545116				2022-12-25	WOS:A1995TP18800015
J	KAESTNER, KH; MONAGHAN, AP; KERN, H; ANG, SL; WEITZ, S; LICHTER, P; SCHUTZ, G				KAESTNER, KH; MONAGHAN, AP; KERN, H; ANG, SL; WEITZ, S; LICHTER, P; SCHUTZ, G			THE MOUSE FKH-2 GENE - IMPLICATIONS FOR NOTOCHORD, FOREGUT, AND MIDBRAIN REGIONALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING-DOMAIN; FORK-HEAD; TRANSCRIPTION FACTORS; FAMILY; EXPRESSION; GASTRULATION; MOTIF	The ''winged helix'' or ''forkhead'' transcription factors comprise a large gene family whose members are defined by a common 100-amino acid DNA binding domain, Here we describe the structure and expression of the mouse fkh-2 gene, which encodes a protein of 48 kDa with high similarity to other winged helix transcription factors within the DNA binding region, but unique potential transactivation domains, The gene is encoded by a single exon and is expressed in headfold stage embryos in the notochord, the anterior neuroectoderm, and a few cells of the definite endoderm. This expression becomes restricted to the anteriormost portions of the invaginating foregut and the developing midbrain. From day 11.5 of gestation onward, fkh-2 transcripts are restricted to the midbrain and become progressively localized to the red nuclei as the sole site of expression. The fkh-2 gene maps to chromosome 19B and is a candidate gene for the mouse mutation mdf(muscle-deficient) which is characterized by nervous tremors and degeneration of the hindlimb muscles. Although the expression patterns of the fkh-2 gene and another winged helix protein, HNF-3 beta, are overlapping in early stages of gestation and although the promoter of the fkh-2 gene contains a HNF-3 binding site, we demonstrate that the activation of the fkh-2 gene is independent of HNF-3 beta.	GERMAN CANC RES CTR,DIV ORG COMPLEX GENOMES,D-69120 HEIDELBERG,GERMANY; INST GENET & BIOL MOLEC CELLULAIRE,CNRS,LGME,INSERM,U184,F-67404 ILLKIRCH GRAFFENS,FRANCE	Helmholtz Association; German Cancer Research Center (DKFZ); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	KAESTNER, KH (corresponding author), GERMAN CANC RES CTR,DIV MOLEC BIOL CELL 1,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.							ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; AVRAHAM KB, 1995, GENOMICS, V25, P388, DOI 10.1016/0888-7543(95)80038-N; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; CONLON RA, 1993, METHOD ENZYMOL, V225, P373; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; KAESTNER KH, 1993, P NATL ACAD SCI USA, V90, P7628, DOI 10.1073/pnas.90.16.7628; KAESTNER KH, 1989, J BIOL CHEM, V264, P14755; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Lyon M., 1989, GENETIC VARIANTS STR; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; TAM PPL, 1989, DEVELOPMENT, V107, P55; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; WOMACK JE, 1980, J HERED, V71, P68, DOI 10.1093/oxfordjournals.jhered.a109316; 1994, HUM MOL GENET, V3, P621	35	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30029	30035						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530406	hybrid			2022-12-25	WOS:A1995TK38000066
J	YUN, HY; MILGRAM, SL; KEUTMANN, HT; EIPPER, BA				YUN, HY; MILGRAM, SL; KEUTMANN, HT; EIPPER, BA			PHOSPHORYLATION OF THE CYTOSOLIC DOMAIN OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; PEPTIDE PROCESSING ENZYME; INDEPENDENT MECHANISMS; SECRETORY GRANULES; RECEPTOR; CELLS; FORMS; EXPRESSION; BINDING; INTERMEDIATE	Peptidylglycine alpha-amidating monooxygenase (PAM) is a bifunctional enzyme that catalyzes the COOH-terminal alpha-amidation of neural and endocrine peptides through a two-step reaction carried out sequentially by its monooxygenase and lyase domains. PAM occurs in soluble and integral membrane forms. Metabolic labeling of stably transfected hEK-293 and AtT-20 cells showed that [P-32]PO43- was efficiently incorporated into Ser and Thr residues of membrane PAM but not into soluble PAM. Truncation of integral membrane PAM proteins (which terminate with Ser(976)) at Tyr(936) eliminated their phosphorylation, suggesting that the COOH-terminal region of the protein was the site of phosphorylation. Recombinant PAM COOH-terminal domain was phosphorylated on Ser(932) and Ser(937) by protein kinase C (PKC). PAM-1 protein recovered from different subcellular fractions of stably transfected AtT-20 cells was differentially susceptible to calcium-dependent, staurosporine-inhibitable phosphorylation catalyzed by endogenous cytosolic protein kinase(s). Although phorbol ester treatment of hEK-293 cells expressing PAM-1 stimulated the cleavage/release of a bifunctional 105-kDa PAM protein, the effect was an indirect one since it was also observed in hEK-293 cells expressing a truncated PAM-1 protein that was not phosphorylated. AtT-20 cells expressing PAM-1 lacking one of the PKC sites (PAM-1/Ser(937) --> Ala) exhibited an altered pattern of PARI PARI antibody internalization, with the mutant protein targeted to lysosomes upon internalization. Thus, phosphorylation of Ser(937) in the COOH-terminal cytosolic domain of membrane PAM plays a role in a specific step in the targeting of this protein.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, BOSTON, MA 02114 USA	Johns Hopkins University; Harvard University; Massachusetts General Hospital					NIDDK NIH HHS [DK-32949] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032949, R37DK032949, R56DK032949] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BANNYKH S, 1993, MOL CELL BIOL, V4; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EHLERS MRW, 1995, BIOCHEM BIOPH RES CO, V206, P541, DOI 10.1006/bbrc.1995.1077; EIPPER BA, 1992, J BIOL CHEM, V267, P4008; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EMESON RB, 1986, J NEUROSCI, V6, P837; FABBRI M, 1994, J BIOL CHEM, V269, P26848; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4491; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUGHES EN, 1981, J BIOL CHEM, V256, P664; HUNG AY, 1994, EMBO J, V13, P534, DOI 10.1002/j.1460-2075.1994.tb06291.x; HUSTEN EJ, 1993, J BIOL CHEM, V268, P9709; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MILES K, 1989, NEURON, V2, P1517, DOI 10.1016/0896-6273(89)90198-0; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; MILGRAM SL, 1994, MOL BIOL CELL, V5; MILLER DA, 1992, ARCH BIOCHEM BIOPHYS, V298, P380, DOI 10.1016/0003-9861(92)90425-V; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; OUAFIK L, 1989, J BIOL CHEM, V264, P5839; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; ROSORIUS O, 1993, J BIOL CHEM, V268, P21470; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; TAUSK FA, 1992, MOL ENDOCRINOL, V6, P2185, DOI 10.1210/me.6.12.2185; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088; YUN HY, 1993, ARCH BIOCHEM BIOPHYS, V301, P77, DOI 10.1006/abbi.1993.1117; YUN HY, 1994, J BIOL CHEM, V269, P10946	45	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30075	30083						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530412				2022-12-25	WOS:A1995TK38000072
J	AHMED, NN; FRANKE, TF; BELLACOSA, A; DATTA, K; GONZALEZPORTAL, ME; TAGUCHI, T; TESTA, JR; TSICHLIS, PN				AHMED, NN; FRANKE, TF; BELLACOSA, A; DATTA, K; GONZALEZPORTAL, ME; TAGUCHI, T; TESTA, JR; TSICHLIS, PN			THE PROTEINS ENCODED BY C-AKT AND V-AKT DIFFER IN POSTTRANSLATIONAL MODIFICATION, SUBCELLULAR-LOCALIZATION AND ONCOGENIC POTENTIAL	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; MURINE LEUKEMIA-VIRUS; MYRISTIC ACID; CELLS; GENE; TRANSFORMATION; MYRISTYLATION; EXPRESSION; BINDING; VECTORS	The acute retrovirus AKT8, isolated from an AKR mouse T-cell lymphoma, transforms mink lung cells in culture and is oncogenic when inoculated into newborn mice. The oncogene carried by this virus, v-akt, arose by recombination between Gag and the 5' untranslated region of the cellular gene c-akt. v-akt encodes a 105 kilodalton (kd) Gag-Akt fusion protein which is phosphorylated on serine and threonine residues. c-akt encodes a 55 kd serine-threonine protein-kinase, which is related to members of the protein kinase C (PKC) family and contains an SH2-like domain. The SH2-like and catalytic domains of Akt were expressed in E. coli as fusions to the carboxy-terminus of the Maltose binding protein (MBP). Antibodies against these proteins were raised in rabbits and they were used to determine the potential myristylation and subcellular localization of the v-akt and c-akt protein products. Immunoprecipitation of v-akt and c-akt from lysates of [S-35]methionine and [H-3]myristic acid labeled AKT8 transformed mink lung cells revealed that only v-akt was myristylated. Fractionation of Dounce-homogenized cellular extracts from uninfected and v-akt-transformed mink lung and PA317 cells and from uninfected PC12 cells by differential centrifugation showed that while the c-akt protein was localized primarily in the cytosol (90%), the v-akt protein was dispersed among the cellular compartments with approximately 40% on the plasma membranes, approximately 30% in the nucleus and approximately 30% in the cytosol. To determine whether the differences in post-translational modification and subcellular distribution between c-akt and v-akt translated into oncogenicity differences between the two proteins, we used retrovirus based constructs to express them both in the nontumorigenic rat T cell lymphoma line 5675. Intraperitoneal (IP) inoculation of the parental and c-akt expressing 5675 cells in nude Balb/c mice revealed that neither was oncogenic. In sharp contrast to these results, v-akt expressing 5675 cells inoculated in nude Balb/c mice were found to be highly oncogenic.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center			Gonzalez, Maria Eugenia/B-5146-2008	Gonzalez, Maria Eugenia/0000-0003-0355-5469	NCI NIH HHS [CA-06927, CA-38047] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA038047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BELLACOSA A, 1992, IN PRESS ONCOGENE; BIGBEE WL, 1983, MOL IMMUNOL, V20, P1353, DOI 10.1016/0161-5890(83)90166-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; BUSTOS JG, 1990, BIOCHIM BIOPHYS ACTA, V1071, P83; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HAY AJ, 1974, VIROLOGY, V60, P398, DOI 10.1016/0042-6822(74)90335-3; HENDERSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P339, DOI 10.1073/pnas.80.2.339; HOMSEY VS, 1986, IMMUNOL METH, V93, P83; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KELJO DJ, 1978, BIOCHIM BIOPHYS ACTA, V508, P500, DOI 10.1016/0005-2736(78)90095-0; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RHEE SS, 1987, J VIROL, V61, P1045, DOI 10.1128/JVI.61.4.1045-1053.1987; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SCHULTZ AM, 1989, J VIROL, V63, P2370, DOI 10.1128/JVI.63.5.2370-2373.1989; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; WILLINGHAM MC, 1990, FOCUS, V12, P62; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; XIA YP, 1992, J VIROL, V66, P914, DOI 10.1128/JVI.66.2.914-921.1992	33	151	151	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1957	1963						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510938				2022-12-25	WOS:A1993LG68200028
J	OSTMAN, A; ANDERSSON, M; BACKSTROM, G; HELDIN, CH				OSTMAN, A; ANDERSSON, M; BACKSTROM, G; HELDIN, CH			ASSIGNMENT OF INTRACHAIN DISULFIDE BONDS IN PLATELET-DERIVED GROWTH-FACTOR B-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR-PERMEABILITY FACTOR; FACTOR PDGF; A-CHAIN; CYSTEINE RESIDUES; RECEPTORS; PROTEIN; CDNA; IDENTIFICATION; LOCALIZATION; RETENTION	Platelet-derived growth factor (PDGF)-BB is a dimeric protein held together by two disulfide bonds involving the 2nd and 4th cysteine residues from the NH2 terminus. To localize the three intrachain disulfide bonds in PDGF, a method was devised that made it possible to cleave PDGF at specific sites. A set of PDGF derivatives in which specific amino acids were mutated to methionine residues was generated. The recombinant proteins, immunoprecipitated from metabolically labeled transfected COS cells, were then subjected to CNBr cleavage and analyzed by SDS-gel electrophoresis under nonreducing conditions. Based on whether the mutated proteins remained in one piece or fell apart after CNBr cleavage, it was possible to deduce the disulfide bond arrangement in the PDGF B-chain; one bond involves the 1st and 6th cysteine residues, another the 3rd and 7th, and the last the 5th and 8th. The latter disulfide bond was found to be dispensable for receptor binding, whereas the former two were found to be essential for the correct folding or stability of the PDGF B-chain.	LUDWIG INST CANC RES, CTR BIOMED, BOX 595, S-75124 UPPSALA, SWEDEN	Ludwig Institute for Cancer Research								ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HOPPE J, 1989, BIOCHEMISTRY-US, V28, P2956, DOI 10.1021/bi00433a032; JAUMANN M, 1991, BIOCHEMISTRY-US, V30, P3303, DOI 10.1021/bi00227a019; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; ROBSON MC, 1992, LANCET, V339, P23, DOI 10.1016/0140-6736(92)90143-Q; SAUER MK, 1988, MOL CELL BIOL, V8, P1011, DOI 10.1128/MCB.8.3.1011; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; THYBERG J, 1990, J CELL SCI, V97, P219; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	22	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13372	13377						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514775				2022-12-25	WOS:A1993LH55300053
J	SEISER, C; TEIXEIRA, S; KUHN, LC				SEISER, C; TEIXEIRA, S; KUHN, LC			INTERLEUKIN-2-DEPENDENT TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF TRANSFERRIN RECEPTOR MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-RESPONSIVE ELEMENT; 3' UNTRANSLATED REGION; HUMAN LYMPHOCYTES-T; 4F2 HEAVY-CHAIN; CELL-PROLIFERATION; C-FOS; SEQUENTIAL EXPRESSION; GENE-EXPRESSION; BINDING-PROTEIN; DNA-SYNTHESIS	Interleukin-2 (IL-2) controls the proliferation of the murine T cell line B6.1 and induces transferrin receptor (TfR) mRNA steady-state levels 50-fold when added to arrested, IL-2-deprived cells. In addition, TfR mRNA is post-transcriptionally regulated by intracellular iron. Low iron levels activate a cytoplasmic RNA-binding protein, called iron regulatory factor (IRF) or iron-responsive element-binding protein, which coordinately stabilizes TfR mRNA and inhibits ferritin mRNA translation. Since ferritin expression is known to be modulated by cytokines, we decided to investigate the mechanism by which IL-2 activates TfR gene expression in B6.1 cells. Induction by IL-2 of both nuclear and cytoplasmic TfR RNA was compared with run-on transcription rates in isolated nuclei. The results revealed a 3-fold increase in TfR gene transcription and a 6-fold rise in nuclear TfR RNA reaching its steady-state level within 2 h. The main accumulation of mature mRNA in the cytoplasm occurred after 6 h in parallel with the activation of IRF. However, stimulation of IRF binding activity by the iron chelator desferrioxamine, in the absence of IL-2, failed to induce TfR mRNA. Moreover, deprivation of growing B6.1 cells of IL-2 resulted in cell arrest and a rapid decay of TfR mRNA, which was not prevented by the activation of IRF with desferrioxamine. TfR mRNA stabilization appears, therefore, to depend on IL-2. We conclude that TfR mRNA expression is controlled by at least three steps at the onset of cell proliferation: (i) the growth factor-dependent activation of transcription; (ii) mRNA stabilization by IRF in the cytoplasm; and (iii) an additional IL-2-dependent activity which prevents TfR mRNA degradation. Our results indicate that expression of TfR, like ferritin, is controlled by both iron and cytokines.	SWISS INST EXPTL CANC RES, 155 CHEMIN BOVERESSES, CH-1066 EPALINGES, SWITZERLAND	Swiss Institute Experimental Cancer Research			TEIXEIRA, SANTUZA MR/I-8137-2013	Seiser, Christian/0000-0002-7046-9352				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; BEARD P, 1992, NUCLEIC ACIDS RES, V19, P7117; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; DEPPER JM, 1985, P NATL ACAD SCI USA, V82, P4230, DOI 10.1073/pnas.82.12.4230; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; HOFBAUER R, 1991, EUKARYOTIC GENE EXPR, V1, P247; KEHRL JH, 1984, J IMMUNOL, V132, P2857; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; KRONKE M, 1985, J EXP MED, V161, P1593, DOI 10.1084/jem.161.6.1593; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; KUMAGAI N, 1988, J IMMUNOL, V140, P37; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LINDSTEN T, 1988, MOL CELL BIOL, V8, P3820, DOI 10.1128/MCB.8.9.3820; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERCER WE, 1989, EXP CELL RES, V181, P531, DOI 10.1016/0014-4827(89)90109-2; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; MISKIMINS WK, 1986, J CELL BIOL, V103, P1781, DOI 10.1083/jcb.103.5.1781; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; Naeve GS, 1991, CURR OPIN CELL BIOL, V3, P261, DOI 10.1016/0955-0674(91)90150-W; NECKERS LM, 1986, MOL CELL BIOL, V6, P4244, DOI 10.1128/MCB.6.12.4244; NECKERS LM, 1984, J IMMUNOL, V133, P2437; NECKERS LM, 1983, P NATL ACAD SCI-BIOL, V80, P3494, DOI 10.1073/pnas.80.11.3494; NIKAIDO T, 1991, EXP CELL RES, V192, P102, DOI 10.1016/0014-4827(91)90163-O; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARMACEK MS, 1989, NUCLEIC ACIDS RES, V17, P1915, DOI 10.1093/nar/17.5.1915; PELOSI E, 1986, J BIOL CHEM, V261, P3036; PELOSITESTA E, 1988, IMMUNOLOGY, V64, P273; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; ROGERS JT, 1990, J BIOL CHEM, V265, P14572; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SEKALY RP, 1982, J IMMUNOL, V129, P1407; SHIMUZU A, 1985, NUCLEIC ACIDS RES, V13, P1505, DOI 10.1093/nar/13.5.1505; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STEARNE PA, 1985, J IMMUNOL, V134, P3474; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; TESTA U, 1991, J BIOL CHEM, V266, P13925; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; TROWBRIDGE IS, 1982, P NATL ACAD SCI-BIOL, V79, P1175, DOI 10.1073/pnas.79.4.1175; VONBOEHMER H, 1979, EUR J IMMUNOL, V9, P592, DOI 10.1002/eji.1830090804; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	60	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13074	13080						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514748				2022-12-25	WOS:A1993LH55300013
J	ZOLFAGHARI, R; GLICK, JM; FISHER, EA				ZOLFAGHARI, R; GLICK, JM; FISHER, EA			THE EFFECTS OF VARYING THE EXPRESSION OF A NEUTRAL CHOLESTERYL ESTER HYDROLASE ON THE TURNOVER OF CHOLESTERYL ESTER IN RAT HEPATOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY LIPOPROTEIN; CARBOXYLESTER LIPASE; CDNA CLONING; LIVER; LYSOPHOSPHOLIPASE; PURIFICATION; MACROPHAGES; CLEARANCE; PANCREAS; PLASMA	A neutral bile salt-dependent cholesteryl ester hydrolase (CEH) in rat liver has been shown to be indistinguishable from the pancreatic CEH by a number of criteria (Harrison, E. H. (1988) Biochim. Biophys. Acta 963,28-34; Zolfaghari, R., Harrison, E. H., Ross, A. C., and Fisher, E. A. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 6913-6919; Camulli, E. D., Linke, M. J., Brockman, H. L., and Hui, D. Y. (1989) Biochim. Biophys. Acta 1005, 177-182). The rat hepatoma cell line Fu5AH, which lacks this particular CEH activity, was stably transfected with the cDNA of rat pancreatic CEH, and the effects on cholesterol and cholesteryl ester metabolism in clones with varying levels of CEH expression determined. In spite of significant amounts of intracellular enzyme protein demonstrated by Western blotting, in cell lysates there was a consistently low level of catalytic activity, and in cultured cells there was no evidence that CEH served as an effective intracellular cholesteryl ester hydrolase or synthase. In contrast, the catalytic activity of the secreted enzyme was relatively higher and there was a small, but significant, increase in the ability of high density lipoprotein (added to the medium) to promote the clearance of cholesteryl ester from cells secreting high levels of CEH. Overall, these results suggest that in the liver, intracellular CEH does not significantly affect the turnover of cholesteryl esters and warrant future studies focusing on the function of the secreted enzyme. For example, secreted CEH may modify lipoproteins and affect their interactions with cells.	MED COLL PENN, DEPT BIOCHEM, PHILADELPHIA, PA 19129 USA	Drexel University				Fisher, Edward/0000-0001-9802-143X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL007433, P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22633, HL07433] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABA T, 1991, BIOCHEMISTRY-US, V30, P500, DOI 10.1021/bi00216a028; BERNARD DW, 1991, J BIOL CHEM, V266, P710; BERNARD DW, 1990, ARTERIOSCLEROSIS, V10, P135, DOI 10.1161/01.ATV.10.1.135; BLANER WS, 1984, BIOCHIM BIOPHYS ACTA, V794, P419, DOI 10.1016/0005-2760(84)90008-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028; BROWN WJ, 1980, BIOCHIM BIOPHYS ACTA, V617, P305, DOI 10.1016/0005-2760(80)90173-3; CALAME KB, 1975, ARCH BIOCHEM BIOPHYS, V168, P57, DOI 10.1016/0003-9861(75)90227-1; CAMULLI ED, 1989, BIOCHIM BIOPHYS ACTA, V1005, P177, DOI 10.1016/0005-2760(89)90184-7; DREVON CA, 1977, BIOCHIM BIOPHYS ACTA, V487, P122, DOI 10.1016/0005-2760(77)90049-2; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fourney R.M., 1988, FOCUS, V10, P5; Fowler S.D., 1984, P329; GAD MZ, 1991, J LIPID RES, V32, P685; GLICK JM, 1987, ATHEROSCLEROSIS, V64, P223, DOI 10.1016/0021-9150(87)90250-4; GLICK JM, 1983, J BIOL CHEM, V258, P3425; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HARRISON EH, 1990, J LIPID RES, V31, P2187; HARRISON EH, 1979, J LIPID RES, V20, P760; HARRISON EH, 1988, BIOCHIM BIOPHYS ACTA, V963, P28, DOI 10.1016/0005-2760(88)90334-7; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; HUANG Y, 1991, J BIOL CHEM, V266, P6720; HUI DY, 1989, CIRCULATION, V80, P334; IMANAKA T, 1982, FEBS LETT, V137, P115, DOI 10.1016/0014-5793(82)80327-X; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KYGER EM, 1989, BIOCHEM BIOPH RES CO, V164, P1302, DOI 10.1016/0006-291X(89)91811-1; KYGER EM, 1990, BIOCHEMISTRY-US, V29, P3853, DOI 10.1021/bi00468a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MUDERHWA JM, 1990, J BIOL CHEM, V265, P19644; MUDERHWA JM, 1992, BIOCHEMISTRY-US, V31, P149, DOI 10.1021/bi00116a022; MUDERHWA JM, 1992, BIOCHEMISTRY-US, V31, P141, DOI 10.1021/bi00116a021; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PITOT H. C., 1964, NAT CANCER INST MONOGR, V13, P229; PRYSTOWSKY JH, 1981, J BIOL CHEM, V256, P4498; Reid L C, 1979, Methods Enzymol, V58, P152; REUE K, 1991, J LIPID RES, V32, P267; ROSS AC, 1984, J BIOL CHEM, V259, P815; Rudd E.A., 1984, P185; Sambrook J, 1989, MOL CLONING LABORATO; TSUJITA T, 1989, J BIOL CHEM, V264, P8612; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, P617; WAHL GM, 1981, TRANSFER IMMOBILIZAT; WARNER TG, 1981, J BIOL CHEM, V256, P2952; WINKLER KE, 1992, BIOCHIM BIOPHYS ACTA, V1126, P151; ZOLFAGHARI R, 1992, ARTERIOSCLER THROMB, V12, P295, DOI 10.1161/01.ATV.12.3.295; ZOLFAGHARI R, 1989, P NATL ACAD SCI USA, V86, P6913, DOI 10.1073/pnas.86.18.6913; ZOLFAGHARI R, 1993, IN PRESS CLIN CHEM	50	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13532	13538						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514786				2022-12-25	WOS:A1993LH55300074
J	Li, ZW; Zhan, LJ; Deutscher, MP				Li, ZW; Zhan, LJ; Deutscher, MP			The role of individual cysteine residues in the activity of Escherichia coli RNase T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; END-TURNOVER; PROTEIN; BINDING; EXORIBONUCLEASES; PURIFICATION; INVIVO; DNA	Escherichia coli RNase T, which is responsible for the 3' processing and end-turnover of tRNA and the maturation of 5 S RNA, is extremely sensitive to sulfhydryl reagents and to oxidation, suggesting a role for cysteine residues in its activity. Titration of homogeneous RNase T with 5,5'-dithiobis-(2-nitrobenzoic acid) revealed that the 4 cysteine residues present in each of the two protein subunits are in a reduced form and that 1 or 2 of them are important for activity. To identify these residue(s), each of the cysteines in RNase T was changed individually to either serine or alanine. The serine mutant at position 168 is greatly reduced in RNase T activity both in vivo and in vitro; likewise, the serine mutant at position 112 and the alanine mutants at positions 112 and 168 also display decreased RNase T activity. Mutations at the other cysteine positions show little or no change. Kinetic analyses of the mutant enzymes showed that the K-m values of C168S and C168A are increased considerably, whereas their V-max values are reduced only slightly compared to the wild type enzyme. The other mutant enzymes are little changed. Additional amino acid replacements at position 168 showed that the in vivo and in vitro activities of RNase T are in the order Cys approximate to Val > Ala >> Ser >> Asn approximate to Asp, which closely follows the relative hydrophobicity of these amino acid residues. However, the affinity for tRNA, determined by fluorescence quenching, is not altered in C168S, suggesting that Cys-168 is not directly involved in substrate binding. Interestingly, proteins altered at position 168 showed increased temperature sensitivity as the residue at that position became less hydrophobic. These data indicate that Cys-168 contributes a hydrophobic group that influences the structure and ultimately the catalytic activity of RNase T.	UNIV CONNECTICUT, CTR HLTH, DEPT BIOCHEM, FARMINGTON, CT 06030 USA	University of Connecticut					NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLACK SD, 1991, ANAL BIOCHEM, V193, P72, DOI 10.1016/0003-2697(91)90045-U; BRENNER S, 1965, J MOL BIOL, V13, P629, DOI 10.1016/S0022-2836(65)80131-0; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; CUDNY H, 1986, J BIOL CHEM, V261, P6450; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1984, P NATL ACAD SCI-BIOL, V81, P4290, DOI 10.1073/pnas.81.14.4290; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P663; FILONENKO VV, 1994, J BIOL CHEM, V269, P17375; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HUANG S, 1993, J BIOL CHEM, V267, P25609; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LARSEN JEL, 1984, GENE, V28, P45, DOI 10.1016/0378-1119(84)90086-6; LI Z, 1995, J BIOL CHEM, V271, P1133; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; LI ZW, 1994, J BIOL CHEM, V269, P6064; MANZELLA JM, 1992, J BIOL CHEM, V267, P7077; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NUREKI O, 1993, J BIOL CHEM, V268, P15368; PADMANABHA KP, 1991, J BACTERIOL, V173, P1376, DOI 10.1128/jb.173.4.1376-1381.1991; REUVEN NB, 1993, FASEB J, V7, P143, DOI 10.1096/fasebj.7.1.8422961; REUVEN NB, 1993, P NATL ACAD SCI USA, V90, P4350, DOI 10.1073/pnas.90.10.4350; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Sambrook J, 1989, MOL CLONING LABORATO; STARZYK RM, 1982, NATURE, V298, P136, DOI 10.1038/298136a0; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50	29	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1127	1132		10.1074/jbc.271.2.1127	http://dx.doi.org/10.1074/jbc.271.2.1127			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557640	hybrid			2022-12-25	WOS:A1996TP88900077
J	Moffat, GJ; McLaren, AW; Wolf, CR				Moffat, GJ; McLaren, AW; Wolf, CR			Sp1-mediated transcriptional activation of the human Pi class glutathione S-transferase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST CANCER-CELLS; RNA POLYMERASE-II; DNA-BINDING PROTEINS; SV40 EARLY PROMOTER; FUNCTIONAL-ANALYSIS; CONFERS RESISTANCE; MOLECULAR-FORMS; MAMMALIAN-CELLS; MESSENGER-RNA; FACTOR SP1	Previous studies in this laboratory have identified an essential AP-1 recognition sequence (C1 region; -69 to -63) in the human Pi class glutathione S-transferase (GSTP1) promoter and a negatively acting regulatory element (-105 to -86) that acts to suppress GSTP1 transcription in the human mammary carcinoma cell line, MCF7 (1). The data presented here further delineate the functional characteristics of the GSTP1 promoter by examining the significance of two potential binding sites for the transcription factor, Sp1 (-57 to -49 and -47 to -39). The introduction of mutations within these Sp1-like elements and the use of Sp1 antisera in electrophoretic mobility shift assays demonstrated that Sp1 was bound to this region of the GSTP1 promoter in three different cell lines, MCF7, VCREMS, and EJ. Moreover, these in vitro studies indicated that only one of the two putative Sp1 response elements was utilized. Transient transfection assays using GSTP1 promoter constructs that incorporated mutations of the Sp1 elements clearly demonstrated that binding of Sp1 to the GSTP1 promoter was absolutely required for optimal levels of GSTP1 transcription. In particular, disruption of the distal Sp1 recognition motif (-57 to -49) markedly reduced GSTP1 promoter activity in each cell line, thus indicating preferential binding of Sp1 to the distal site. However, insertion of the repressor binding site (-105 to -86) into these constructs suggested that Sp1 was not involved in mediating the suppressive effects of the GSTP1 transcriptional repressor in MCF7 cells, because inhibition of Sp1 binding did not alleviate repressor activity. Therefore, these studies provide strong evidence that Sp1 plays a central role in regulating basal levels of GSTP1 transcription.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH,BIOMED RES CTR, IMPERIAL CANC RES FUND,MOLEC PHARMACOL UNIT, DUNDEE DD1 9SY, SCOTLAND	University of Dundee								ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BATIST G, 1986, J BIOL CHEM, V261, P5544; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; BORELLINI F, 1990, MOL CELL BIOL, V10, P5541, DOI 10.1128/MCB.10.10.5541; BUCHMANN A, 1985, CARCINOGENESIS, V6, P513, DOI 10.1093/carcin/6.4.513; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DICCIANNI MB, 1992, NUCLEIC ACIDS RES, V20, P5153, DOI 10.1093/nar/20.19.5153; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIXON KH, 1989, BIOCHEM BIOPH RES CO, V163, P815, DOI 10.1016/0006-291X(89)92295-X; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EVERETT RD, 1983, NUCLEIC ACIDS RES, V11, P2447, DOI 10.1093/nar/11.8.2447; FARBER E, 1976, CANCER RES, V36, P2703; FARBER E, 1984, CAN J BIOCHEM CELL B, V62, P486, DOI 10.1139/o84-066; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GORMAN C, 1986, DNA CLONING PRACTICA, V3; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KANO T, 1987, CANCER RES, V47, P5626; KITAHARA A, 1984, CANCER RES, V44, P2698; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOFFAT GJ, 1994, J BIOL CHEM, V269, P16397; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MORROW CS, 1989, GENE, V75, P3, DOI 10.1016/0378-1119(89)90377-6; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; PARKER BA, 1979, J VIROL, V31, P360, DOI 10.1128/JVI.31.2.360-369.1979; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1989, ADV CANCER RES, V52, P205; SATO K, 1984, CARCINOGENESIS, V5, P473, DOI 10.1093/carcin/5.4.473; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; THIESEN HJ, 1990, NUCLEIC ACIDS RES, V18, P3203, DOI 10.1093/nar/18.11.3203; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Whelan R D, 1989, Cancer Commun, V1, P359; WHELAN RDH, 1992, INT J CANCER, V52, P241, DOI 10.1002/ijc.2910520215; XIA CL, 1991, BIOCHEM BIOPH RES CO, V176, P233, DOI 10.1016/0006-291X(91)90914-S	64	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1054	1060		10.1074/jbc.271.2.1054	http://dx.doi.org/10.1074/jbc.271.2.1054			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557630	hybrid			2022-12-25	WOS:A1996TP88900067
J	Dorseuil, O; Reibel, L; Bokoch, GM; Camonis, J; Gacon, G				Dorseuil, O; Reibel, L; Bokoch, GM; Camonis, J; Gacon, G			The Rac target NADPH oxidase p67(phox) interacts preferentially with Rac2 rather than Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; 2 CYTOSOLIC COMPONENTS; GTP-BINDING PROTEINS; CELL-FREE SYSTEM; SUPEROXIDE PRODUCTION; ACTIVATION; MEMBRANE; COMPLEX; CYTOCHROME-B558; TRANSLOCATION	NADPH oxidase is a plasma membrane enzyme of phagocytes generating superoxide anions which serve as bactericidal agents. Activation of this multimolecular enzyme minimally requires assembly at the membrane with flavocytochrome b(558) of cytosolic components p47(phox), p67(phox) and Rac proteins. Rac1 and Rac2 are 92% homologous cytosolic small GTPase proteins. Both Rac1 and Rac2 have been implicated with NADPH oxidase activation in vitro; however, Rac2 is largely predominant in human phagocytes. Here, using the yeast two hybrid system, we provide data demonstrating in vivo interactions between human p47(phox), p67(phox), and Rac proteins. Rac proteins interact with p67(phox) in a GTP-dependent manner, but do not interact with p47(phox). Moreover, Rac effector site mutants, which are known to be inactive in NADPH oxidase, lose their interaction with p67(phox); Rac2L61 mutant, which has an increased NADPH oxidase affinity, shows an increased affinity for p67(phox). Finally, we observe that p67(phox) interacts 6-fold better with Rac2 than with Rac1. We also show a strong intracellular interaction between p47(phox) and p67(phox). These results indicate that activated Rac can regulate NADPH oxidase by interacting with p67(phox) and that Rac2 is the main p67(phox)-interacting GTPase in human cells.	INST COCHIN GENET MOLEC, INSERM, U257, F-75014 PARIS, FRANCE; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; INSERM, U248, F-75010 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Scripps Research Institute; Scripps Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm)								ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; ANDO S, 1992, J BIOL CHEM, V267, P25709; BARTEL PL, 1996, IN PRESS METHODS ENZ; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CLARK RA, 1989, NEW ENGL J MED, V321, P647, DOI 10.1056/NEJM198909073211005; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; CURNUTTE JT, 1993, CLIN IMMUNOL IMMUNOP, V67, pS2; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINAN P, 1994, J BIOL CHEM, V269, P11372; FREEMAN JL, 1994, BICOHEMISTRY, V33, P1343; FUCHS A, 1995, J BIOL CHEM, V270, P5695, DOI 10.1074/jbc.270.11.5695; FUCHS A, 1994, EUR J BIOCHEM, V226, P587, DOI 10.1111/j.1432-1033.1994.tb20084.x; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KRECK ML, 1994, J BIOL CHEM, V269, P4161; KURAS L, 1995, MOL CELL BIOL, V15, P208, DOI 10.1128/MCB.15.1.208; LECABEC V, 1994, BIOCHEM BIOPH RES CO, V198, P1216, DOI 10.1006/bbrc.1994.1172; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LEUSEN JHW, 1994, J EXP MED, V180, P2329, DOI 10.1084/jem.180.6.2329; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; MALY FE, 1994, J BIOL CHEM, V269, P18743; MOREAU PL, 1987, J MOL BIOL, V194, P621, DOI 10.1016/0022-2836(87)90239-7; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; PARK JW, 1992, J BIOL CHEM, V267, P17327; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUINN MT, 1993, J BIOL CHEM, V268, P20983; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Sherman F., 1986, METHODS YEAST GENETI; SOMEYA A, 1993, FEBS LETT, V330, P215, DOI 10.1016/0014-5793(93)80276-Z; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WIENTJES FB, 1993, BIOCHEM J, V296, P557, DOI 10.1042/bj2960557; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	58	94	98	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					83	88		10.1074/jbc.271.1.83	http://dx.doi.org/10.1074/jbc.271.1.83			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550629	hybrid			2022-12-25	WOS:A1996TP36100014
J	Francisco, WA; AbuSoud, HM; Topgi, R; Baldwin, TO; Raushel, FM				Francisco, WA; AbuSoud, HM; Topgi, R; Baldwin, TO; Raushel, FM			Interaction of bacterial luciferase with 8-substituted flavin mononucleotide derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BAEYER-VILLIGER REACTION; BIOLUMINESCENCE REACTION; CYCLOHEXANONE OXYGENASE; INTERMEDIATE; MECHANISM; LUMINESCENCE; RIBOFLAVIN; KINETICS; ELECTRON; THIOL	Bacterial luciferase catalyzes the emission of visible light from the reaction of reduced flavin, molecular oxygen, and an n-alkyl aldehyde. The mechanism of the reaction was probed by measuring the electronic effects of various substituents at the 8-position of the flavin ring system. Substituent effects were obtained for CH3-, Cl-, CH3O-, CH3S-, F-, and H- on the rate of formation and decay of the hydroperoxyflavin intermediate and the time courses for the emission of visible light. The rate constant for the decay of light emission increases for the series Cl < F < H < CH3S < CH3 < CH3O. These results are not compatible with a standard Baeyer-Villiger type mechanism for the chemical transformation, but they are consistent with a decrease in the electron density at the reaction center of the flavin moiety during the rate-limiting step of the reaction.	TEXAS A&M UNIV,DEPT CHEM,COLLEGE STN,TX 77843; TEXAS A&M UNIV,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station			Raushel, Frank/B-7125-2015	Raushel, Frank/0000-0002-5918-3089	NIGMS NIH HHS [GM33894] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033894] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD H, 1992, BIOCHEMISTRY-US, V31, P3807, DOI 10.1021/bi00130a011; ABUSOUD HM, 1993, J BIOL CHEM, V268, P7699; ADAM W, 1989, ACCOUNTS CHEM RES, V22, P205, DOI 10.1021/ar00162a002; BALDWIN TO, 1989, J BIOLUM CHEMILUM, V4, P40, DOI 10.1002/bio.1170040111; BALDWIN TO, 1992, CHEM BIOCH FLAVOENZY, P467; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BRANCHAUD BP, 1985, J AM CHEM SOC, V107, P2153, DOI 10.1021/ja00293a054; BRUICE TC, 1984, FLAVINS FLAVOPROTEIN, P45; CHEN L, 1984, FLAVINS FLAVOPROTEIN, P785; EBERHARD A, 1992, BIOCHEM BIOPH RES CO, V47, P348; ECKSTEIN JW, 1993, BIOCHEMISTRY-US, V32, P404, DOI 10.1021/bi00053a004; FRITZ BJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P113, DOI 10.1111/j.1751-1097.1987.tb08411.x; HASTINGS JW, 1973, P NATL ACAD SCI USA, V70, P3468, DOI 10.1073/pnas.70.12.3468; KASAI S, 1979, J NUTR SCI VITAMINOL, V25, P289; KURFURST M, 1984, P NATL ACAD SCI-BIOL, V81, P2990, DOI 10.1073/pnas.81.10.2990; Lambooy J. P., 1971, METHODS ENZYMOL B, V18, P437; MACHEROUX P, 1990, BIOCHEMISTRY-US, V29, P2670, DOI 10.1021/bi00463a008; MOORE EG, 1979, J BIOL CHEM, V254, P8173; NELSEN SF, 1993, J ORG CHEM, V58, P1657, DOI 10.1021/jo00059a008; OGATA Y, 1972, J AM CHEM SOC, V94, P4189, DOI 10.1021/ja00767a025; RAUSHEL FM, 1989, BIOCHEM BIOPH RES CO, V164, P1137, DOI 10.1016/0006-291X(89)91787-7; SCHOPFER LM, 1981, J BIOL CHEM, V256, P7329; SCHUSTER GB, 1979, ACCOUNTS CHEM RES, V12, P366, DOI 10.1021/ar50142a003; SCHWAB JM, 1983, J AM CHEM SOC, V105, P4800, DOI 10.1021/ja00352a044; SCOLANAGELSCHNEIDER G, 1976, EUR J BIOCHEM, V66, P567, DOI 10.1111/j.1432-1033.1976.tb10583.x; SHORTER J, 1978, CORRELATION ANAL CHE, P119; SINCLAIR JF, 1993, BIOCHEMISTRY-US, V32, P5036, DOI 10.1021/bi00070a010; SUZUKI K, 1983, BIOCHIM BIOPHYS ACTA, V722, P297, DOI 10.1016/0005-2728(83)90076-2; VERVOORT J, 1986, BIOCHEMISTRY-US, V25, P8062, DOI 10.1021/bi00372a040; WATANABE T, 1978, J BIOCHEM-TOKYO, V84, P1441, DOI 10.1093/oxfordjournals.jbchem.a132266; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; Williams C H Jr, 1979, Methods Enzymol, V62, P185; ZIMMERLE CT, 1989, BIOCHEM J, V258, P381, DOI 10.1042/bj2580381	33	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					104	110		10.1074/jbc.271.1.104	http://dx.doi.org/10.1074/jbc.271.1.104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550543	hybrid			2022-12-25	WOS:A1996TP36100017
J	Gachter, T; Werenskiold, AK; Klemenz, R				Gachter, T; Werenskiold, AK; Klemenz, R			Transcription of the interleukin-1 receptor-related T1 gene is initiated at different promoters in mast cells and fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ST2 GENE; NIH 3T3 FIBROBLASTS; ALPHA-B-CRYSTALLIN; HA-RAS; EXPRESSION; TRANSFORMATION; INVITRO; TUMORS; INDUCTION; ONCOGENE	The delayed early serum response gene T1 encodes glycoproteins of the immunoglobulin superfamily with significant sequence similarity to the type 1 interleukin-1 receptor. The T1 gene is transcribed in fibroblasts into an abundant 2.7-kilobase (kb) and a rare 5-kb mRNA in response to proliferation-inducing stimuli. It gives predominantly rise to the longer transcript in the bone marrow of adult mice and in cultured mast cells. Alternative 3' processing is responsible for the two mRNA forms. The short transcript encodes a secreted protein with marked similarity to the extracellular domain of the interleukin-1 receptor, whereas the long mRNA is translated into a protein with an additional putative transmembrane and an intracellular domain. Here we demonstrate that T1 transcription in mast cells and fibroblasts initiates at two different start sites which are 10.5 kb apart. The alternative first exons are both spliced to exon 2 which contains the translation start site. Northern blot analysis and primer extension experiments revealed that promoter usage is strictly cell type-specific. T1 transcription in mast cells is initiated exclusively at the distal promoter, whereas in fibroblasts both the short and the long T1 mRNA start at the proximal promoter. Two GATA-1 elements were identified in the 5'-flanking region of the mast cell-specific distal exon 1.	UNIV ZURICH HOSP,DEPT PATHOL,DIV CANC RES,CH-8091 ZURICH,SWITZERLAND; GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT,D-85764 OBERSCHLEISSHEIM,GERMANY	University of Zurich; University Zurich Hospital; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; BARNHART KM, 1989, MOL CELL BIOL, V9, P2606, DOI 10.1128/MCB.9.6.2606; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; HIRSCH HH, 1993, J EXP MED, V178, P403, DOI 10.1084/jem.178.2.403; HOLTKE HJ, 1990, NUCLEIC ACIDS RES, V18, P5843, DOI 10.1093/nar/18.19.5843; ISHIZAKA T, 1976, J IMMUNOL, V116, P747; KALOUSEK MB, 1994, J BIOL CHEM, V269, P6866; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KLEMENZ R, 1989, P NATL ACAD SCI USA, V86, P5708, DOI 10.1073/pnas.86.15.5708; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LECOINTE N, 1994, ONCOGENE, V9, P2623; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; NAIR APK, 1992, ONCOGENE, V7, P1963; ROSSLER U, 1993, ONCOGENE, V8, P609; ROSSLER U, 1995, DEV BIOL, V168, P86, DOI 10.1006/dbio.1995.1063; SANGER F, 1978, FEBS LETT, V87, P107, DOI 10.1016/0014-5793(78)80145-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P194, DOI 10.1016/0167-4889(93)90009-E; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; TRUB T, 1994, P NATL ACAD SCI USA, V91, P3896, DOI 10.1073/pnas.91.9.3896; WERENSKIOLD AK, 1992, EUR J BIOCHEM, V204, P1041, DOI 10.1111/j.1432-1033.1992.tb16726.x; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; YANAGISAWA K, 1992, FEBS LETT, V302, P51, DOI 10.1016/0014-5793(92)80282-L; ZON LI, 1991, J BIOL CHEM, V266, P22948	39	76	80	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					124	129						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550546				2022-12-25	WOS:A1996TP36100020
J	GarciaHiguera, I; Thomas, TC; Yi, F; Neer, EJ				GarciaHiguera, I; Thomas, TC; Yi, F; Neer, EJ			Intersubunit surfaces in g protein alpha beta gamma heterotrimers - Analysis of cross-linking and mutagenesis of beta gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; COILED-COIL; SUBUNIT; TRANSDUCIN; CLONING	Heterotrimeric guanine nucleotide binding proteins (G proteins) are made up of alpha, beta, and gamma subunits, the last two forming a very tight complex, Stimulation of cell surface receptors promotes dissociation of alpha from the beta gamma dimer, which, in turn, allows both components to interact with intracellular enzymes or ion channels and modulate their activity, At present, little is known about the conformation of the beta gamma dimer or about the areas of beta gamma that interact with alpha, Direct information on the orientation of protein surfaces can be obtained from analysis of chemically cross-linked products, Previous work in this laboratory showed that 1,6-bismaleimidohexane, which reacts with cysteine residues, specifically cross-links alpha to beta and beta to gamma (Yi, F., Denker, B. M., and Neer, E. J. (1991) J. Biol. Chem. 266, 3900-3906), To identify the residues in beta and gamma involved in cross-linking to each other or to alpha, we have mutated the cysteines in beta(1), gamma(2), and gamma(3) and analyzed the mutated proteins by in vitro translation in a rabbit reticulocyte lysate, All the mutants were able to form beta gamma dimers that could interact with the alpha subunit, We found that 1,6-bismaleimidohexane can cross-link beta(1) to gamma(3) but not to gamma(2). The cross-link goes from Cys(25) in beta(1) to Cys(30) in gamma(3). This cysteine is absent from any of the other known gamma isoforms and therefore confers a distinctive property to gamma(3). The beta subunit in the beta(1) gamma(2) dimer can be cross-linked to an unidentified protein in the rabbit reticulocyte lysate, generating a product slightly larger than cross-linked beta(1) gamma(3). The beta subunit can also be cross-linked to alpha, giving rise to two products on SDS-polyacrylamide gel electrophoresis, both of which were previously shown to be formed by cross-linking beta to Cys(215) in alpha(o) (Thomas, T. C., Schmidt, C. J., and Neer, E. J. (1993) Proc, Natl, Acad, Sci, U. S. A. 90, 10295-10299). Mutation of Cys(204) in beta(1) abolished one of these two products, whereas mutation of Cys(271) abolished the other, Because both alpha-beta cross-linked products are formed in approximately equal amounts, Cys(204) and Cys(271) in beta are equally accessible from Cys(215) in alpha(o). Our findings begin to define intersubunit surfaces, and they pose structural constraints upon any model of the beta gamma dimer.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	GarciaHiguera, I (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.		Garcia-Higuera, Irene/L-5004-2014	Garcia-Higuera, Irene/0000-0001-6331-075X	NIGMS NIH HHS [GM36259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036259, R37GM036259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUBIS J, 1990, J BIOL CHEM, V265, P12995; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DENKER BM, 1992, J BIOL CHEM, V267, P6272; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEE CH, 1995, J BIOL CHEM, V270, P8779, DOI 10.1074/jbc.270.15.8779; LUPAS AN, 1992, FEBS LETT, V314, P105, DOI 10.1016/0014-5793(92)80952-D; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; RYBA NJP, 1995, J BIOL CHEM, V270, P6757, DOI 10.1074/jbc.270.12.6757; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; WILCOX MD, 1994, J BIOL CHEM, V269, P12508; YI F, 1991, J BIOL CHEM, V266, P3900	34	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					528	535		10.1074/jbc.271.1.528	http://dx.doi.org/10.1074/jbc.271.1.528			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550614	hybrid			2022-12-25	WOS:A1996TP36100080
J	Martin, EL; RensDomiano, S; Schatz, PJ; Hamm, HE				Martin, EL; RensDomiano, S; Schatz, PJ; Hamm, HE			Potent peptide analogues of a G protein receptor-binding region obtained with a combinatorial library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; AMINO-ACIDS; TRANSDUCIN; LIGANDS; SITE; IDENTIFICATION; EPITOPE	The C terminus of the G protein alpha subunit represents an important site of interaction between heterotrimeric Cf proteins and their cognate receptors, We have screened a combinatorial peptide library based on the C terminus of the alpha subunit of G(t) (340-350) and have identified unique sequences that bind rhodopsin with high affinity. Six of these sequences, as both fusion proteins and synthetic peptides, were significantly more potent than the parent sequence in binding to and stabilization of metarhodopsin II, These sequences provide information about which residues are required for appropriate receptor interaction. We observed that in all the high affinity sequences, a positively charged residue at position 341 was changed to a neutral one, Thus, it appears that the receptor-G protein interaction was designed to be low affinity to ensure efficient catalysis of G protein activation, We also observed Cys-347 and Gly-348 to be invariant, and hydrophobic residues were always located at positions 340, 344, 349, and 350, demonstrating the critical nature of these residues, A composite of the structures of the high affinity sequences was modeled based upon the structure of rhodopsin-bound trNOESY MMR of this region of G(t alpha) ( Dratz, E. D., Fursteneau, J. E., Lambert, C. G., Thireault, D. L., Rarick, H., Schepers, T., Pakhlevaniants, S., and Hamm, H. E. (1993) Nature 363, 276-280) and provides insight into the complementary G protein-binding surface of the receptor.	UNIV ILLINOIS,DEPT PHYSIOL BIOPHYS,CHICAGO,IL 60612; AFFYMAX RES INST,PALO ALTO,CA 94304	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014		PHS HHS [06062] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLUML K, 1994, P NATL ACAD SCI USA, V91, P7980, DOI 10.1073/pnas.91.17.7980; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; GATES CM, 1996, IN PRESS J MOL BIOL, V255; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEE CH, 1995, MOL PHARMACOL, V47, P218; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MORO O, 1993, J BIOL CHEM, V268, P22273; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; SCHATZ PJ, 1996, IN PRESS METHODS ENZ; SCHWINDINGER WF, 1994, J BIOL CHEM, V269, P25387; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; WEST RE, 1985, J BIOL CHEM, V260, P4428	25	141	146	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					361	366		10.1074/jbc.271.1.361	http://dx.doi.org/10.1074/jbc.271.1.361			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550587	hybrid			2022-12-25	WOS:A1996TP36100056
J	Chen, LQ; Xin, XH; Eckhart, AD; Yang, NY; Faber, JE				Chen, LQ; Xin, XH; Eckhart, AD; Yang, NY; Faber, JE			Regulation of vascular smooth muscle growth by alpha(1)-adrenoreceptor subtypes in vitro and in situ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTE HYPERTROPHY; ANGIOTENSIN-II; ALPHA-1-ADRENERGIC RECEPTOR; GENE-EXPRESSION; DNA-SYNTHESIS; RAT-HEART; SYMPATHETIC DENERVATION; ENDOTHELIAL DENUDATION; INTIMAL HYPERPLASIA; PROTEIN-SYNTHESIS	Rat aorta smooth muscle cells which express all three alpha(1)-adrenoreceptors (alpha(1A), alpha(1B) and alpha(1D)) were used to determine the effect of stimulation of alpha(1)-adrenergic receptor subtypes on cell growth. ''Combined'' alpha(1)-adrenoreceptor subtype stimulation with norepinephrine alone caused a concentration-dependent, prazosin sensitive increase in protein content and synthesis: 48 h of stimulation at 1 mu M increased cell protein to 216 +/- 40% of time-matched controls (p = 0.008) and RNA to 140 +/- 13% (p = 0.03); protein synthesis increased to 167 +/- 13% (p < 0.01) after 24 h, Stimulation with norepinephrine plus the selective alpha(1A)/alpha(1D) antagonist 5-methylurapidil produced greater increases in alpha-actin mRNA (270 +/- 40% at 8 h; p = 0.007), total cell protein (220 +/- 45% at 24 h; p = 0.004), and RNA (135 +/- 8% at 24 h; p = 0.01). These effects were prevented by pretreatment with the selective alpha(1B) antagonist chloroethylclonidine. Comparable results were obtained for intact aortae. Stimulation with norepinephrine plus 5-methylurapidil increased (p < 0.05) tissue protein, RNA, dry weight, and alpha-actin mRNA; and as in cultured cells, combined stimulation with norepinephrine alone attenuated these responses. By comparison, adventitia (fibroblasts) was unaffected, Removal of endothelial cells had no effect. alpha(1B) mRNA decreased by 42 +/- 12% (p = 0.01) in cultured cells during combined alpha(1)-adrenoreceptor stimulation and by 23 +/- 8% (p = 0.03) for intact aorta. alpha(1D) and beta-actin mRNA were unchanged in cultured cells, aorta media, and adventitia. These findings suggest that prolonged stimulation of chloroethylclonidine-sensitive, possibly alpha(1B)-adrenoreceptors induces hypertrophy of arterial smooth muscle cells and that stimulation of 5-methylurapidil-sensitive, non-alpha(1B)-adrenoreceptors attenuates this growth response.	UNIV N CAROLINA,DEPT PHYSIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL52610] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKINS RE, 1992, BIOTECHNIQUES, V12, P496; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; BAUCH HJ, 1984, CIRCULATION, V69, P441; BEVAN RD, 1979, BLOOD VESSELS, V16, P109; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BLAES N, 1983, J CELL PHYSIOL, V116, P167, DOI 10.1002/jcp.1041160207; BYLUND DB, 1994, PHARMACOL REV, V46, P121; CHEN Y, 1994, AM J PHYSIOL, V266, pE224, DOI 10.1152/ajpendo.1994.266.2.E224; CHICHESTER CO, 1987, J CARDIOVASC PHARM, V10, pS21; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CRUISE JL, 1985, SCIENCE, V227, P749, DOI 10.1126/science.2982212; DECKER RS, 1993, AM J PHYSIOL, V265, pH329, DOI 10.1152/ajpheart.1993.265.1.H329; DELBALZO U, 1990, CIRC RES, V67, P1535, DOI 10.1161/01.RES.67.6.1535; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FINGERLE J, 1990, ARTERIOSCLEROSIS, V10, P1082, DOI 10.1161/01.ATV.10.6.1082; FISHER DB, 1971, BIOCHIM BIOPHYS ACTA, V248, P434, DOI 10.1016/0005-2760(71)90232-3; FORD PDW, 1994, TRENDS PHARMACOL SCI, V15, P167; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GOLDSCHMIDT RC, 1989, ANAL BIOCHEM, V177, P41, DOI 10.1016/0003-2697(89)90010-9; GURDAL H, 1993, FASEB J, V7, pA46; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; HAN C, 1992, EUR J PHARM-MOLEC PH, V226, P141, DOI 10.1016/0922-4106(92)90175-U; HART MN, 1980, HYPERTENSION, V2, P419, DOI 10.1161/01.HYP.2.4.419; HEAD RJ, 1991, BLOOD VESSELS, V28, P173; HELIN P, 1970, ATHEROSCLEROSIS, V12, P125, DOI 10.1016/0021-9150(70)90089-4; HOLYCROSS BJ, 1993, J VASC RES, V30, P80, DOI 10.1159/000158979; HOUSTON MC, 1992, VASC MED, P621; HU ZW, 1993, J BIOL CHEM, V268, P3610; IKEDA U, 1991, AM J PHYSIOL, V260, pH953, DOI 10.1152/ajpheart.1991.260.3.H953; IKEOKA K, 1993, AM J PHYSIOL, V265, pH1988, DOI 10.1152/ajpheart.1993.265.6.H1988; IVES HE, 1978, J EXP MED, V148, P1400, DOI 10.1084/jem.148.5.1400; IZZO NJ, 1994, J BIOL CHEM, V269, P1705; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; KNOWLTON KU, 1993, J BIOL CHEM, V268, P15374; KONES RJ, 1979, ANGIOLOGY, V30, P327, DOI 10.1177/000331977903000506; KOWALA MC, 1989, J CARDIOVASC PHARM, V13, pS45, DOI 10.1097/00005344-198900132-00009; KUKREGA RS, 1981, ATHEROSCLEROSIS, V40, P292; LEE RMKW, 1985, CAN J PHYSIOL PHARM, V63, P392, DOI 10.1139/y85-070; LEECH CJ, 1995, IN PRESS AM J PHYSL; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; LONG CS, 1991, J CARDIOVASC PHARM, V17, pS20, DOI 10.1097/00005344-199117002-00005; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MOALIC JM, 1989, J HYPERTENS, V7, P195; MULVANY MJ, 1980, BLOOD VESSELS, V17, P202; NYBORG NCB, 1985, CARDIOVASC RES, V19, P528, DOI 10.1093/cvr/19.9.528; OKAZAKI M, 1994, J CLIN INVEST, V94, P210, DOI 10.1172/JCI117309; OMALLEY MK, 1989, BRIT J SURG, V76, P936, DOI 10.1002/bjs.1800760921; OMALLEY MK, 1989, BRIT J SURG, V76, P629; PEREZ DM, 1994, MOL PHARMACOL, V46, P823; PING PP, 1993, AM J PHYSIOL, V265, pH1501, DOI 10.1152/ajpheart.1993.265.5.H1501; PRICE DT, 1994, MOL PHARMACOL, V46, P221; REIDY MA, 1992, VASC MED REV, V3, P156; ROKOSH DG, 1994, BIOCHEM BIOPH RES CO, V200, P1177, DOI 10.1006/bbrc.1994.1575; RORIVE GL, 1980, CLIN SCI, V59, P335; SADOSHIMA S, 1986, BRAIN RES, V379, P205, DOI 10.1016/0006-8993(86)90772-9; SANDLER M, 1963, ATHEROSCLEROSIS O ED, P167; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIWIK DA, 1994, FASEB J, V8, pA173; STARKSEN NF, 1986, P NATL ACAD SCI USA, V83, P8348, DOI 10.1073/pnas.83.21.8348; STEWART JM, 1992, AM J PHYSIOL, V262, pH331, DOI 10.1152/ajpheart.1992.262.2.H331; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VANKLEEF EM, 1992, CIRC RES, V70, P1122, DOI 10.1161/01.RES.70.6.1122; VASHISHT R, 1992, BRIT J SURG, V79, P1285, DOI 10.1002/bjs.1800791212	65	97	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30980	30988		10.1074/jbc.270.52.30980	http://dx.doi.org/10.1074/jbc.270.52.30980			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537355	hybrid			2022-12-25	WOS:A1995TN44400023
J	Fritzler, MJ; Lung, CC; Hamel, JC; Griffith, KJ; Chan, EKL				Fritzler, MJ; Lung, CC; Hamel, JC; Griffith, KJ; Chan, EKL			Molecular characterization of golgin-245, a novel Golgi complex protein containing a granin signature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR TRANSPORT; MEMBRANE-PROTEIN; MESSENGER-RNAS; LEUCINE ZIPPER; GENE; AUTOANTIBODIES; SEQUENCE; APPARATUS; PATIENT; FAMILY	The serum from a Sjogren's syndrome patient with anti-Golgi antibodies was used as a probe to isolate a 4.6-kilobase pair cDNA insert from a HeLa cDNA library. Expression of the cDNA in Escherichia coli and the in vitro translation products of the cDNA yielded a recombinant protein that migrated in SDS-polyacrylamide gel electrophoresis at 180 kDa. This protein was immuno-precipitated by the human anti-Golgi serum and by immune rabbit serum but not by normal human serum or preimmune rabbit serum. Western blot analysis showed that the prototype human and immune rabbit sera recognized a 245-kDa protein, suggesting that the isolated clone contained a partial cDNA. The 5'-upstream sequence obtained by the rapid amplification of cDNA ends methodology using human placental cDNA and the combined HeLa cDNA contained 6965 base pairs and encoded a protein of 245 kDa and, like other Golgi autoantigens described earlier, is highly rich in colied-colis. The deduced amino acid sequence included the decapeptide ESLALEELEL, which was identified as one of two signature sequences previously reported in a family of peptide hormones and neuropeptides known as ''granins.'' This is the first report of a Golgi complex autoantigen that bears structural similarities to the granin family of proteins.	SCRIPPS RES INST, WM KECK AUTOIMMUNE DIS CTR, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DNA CORE LAB STRUCT ANAL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Fritzler, MJ (corresponding author), UNIV CALGARY, FAC MED, DEPT MED BIOCHEM, 3330 HOSP DR NW, CALGARY, AB T2N 4N1, CANADA.		Chan, Edward K. L./B-5671-2009	Chan, Edward K. L./0000-0003-3938-9503	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041803] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR00833] Funding Source: Medline; NIAMS NIH HHS [AR41803] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APTE AN, 1993, BIOTECHNIQUES, V15, P890; BLASCHEK MA, 1988, SCAND J RHEUMATOL, V17, P291, DOI 10.3109/03009748809098799; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BRITTON P, 1991, NATURE, V353, P394, DOI 10.1038/353394a0; BUCKLAND R, 1992, J GEN VIROL, V73, P1703, DOI 10.1099/0022-1317-73-7-1703; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM MW, 1993, CLIN IMMUNOL IMMUNOP, V68, P118, DOI 10.1006/clin.1993.1106; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; FRITZLER MJ, 1984, J IMMUNOL, V132, P2904; GASPAR ML, 1988, J NEUROIMMUNOL, V17, P287, DOI 10.1016/0165-5728(88)90120-8; GENTRIC A, 1991, CLIN IMMUNOL IMMUNOP, V59, P487, DOI 10.1016/0090-1229(91)90043-A; HIDA C, 1994, ARCH NEUROL-CHICAGO, V51, P555, DOI 10.1001/archneur.1994.00540180033010; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HONG HS, 1993, SCAND J IMMUNOL, V36, P785; HUIDBUCHEL E, 1991, ANN MED INTERNE, V142, P343; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; KOOY J, 1992, J BIOL CHEM, V267, P20255; KOOY J, 1994, IMMUNOL CELL BIOL, V72, P123, DOI 10.1038/icb.1994.19; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LINDSTEDT AD, 1993, MOL BIOL CELL, V4, P679; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARKS DL, 1994, J CELL SCI, V107, P2417; NAIR J, 1990, J CELL BIOL, V110, P1897, DOI 10.1083/jcb.110.6.1897; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; ORCI L, 1991, CELL, V64, P1183; PFEFFER U, 1995, BIOTECHNIQUES, V18, P204; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; RENIER G, 1994, J AUTOIMMUN, V7, P133, DOI 10.1006/jaut.1994.1010; REYNIER MO, 1992, GASTROENTEROLOGY, V102, P2024, DOI 10.1016/0016-5085(92)90328-V; RODRIGUEZ JL, 1982, CLIN EXP IMMUNOL, V49, P579; ROSSIE KM, 1992, SCAND J RHEUMATOL, V21, P109, DOI 10.3109/03009749209095080; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; SEELIG HP, 1994, MOL CELL BIOL, V14, P2564, DOI 10.1128/MCB.14.4.2564; SEOG DH, 1994, J BIOCHEM-TOKYO, V116, P1341, DOI 10.1093/oxfordjournals.jbchem.a124685; SIMON JP, 1989, BIOCHEM J, V262, P1; SOHDA M, 1994, BIOCHEM BIOPH RES CO, V205, P1399, DOI 10.1006/bbrc.1994.2821; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUCKER S, 1991, VIROLOGY, V16, P2431; VONMUHLEN CA, 1995, SEMIN ARTHRITIS RHEU, V24, P323, DOI 10.1016/S0049-0172(95)80004-2; YANEVA M, 1989, J BIOL CHEM, V264, P13407; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303	51	98	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31262	31268		10.1074/jbc.270.52.31262	http://dx.doi.org/10.1074/jbc.270.52.31262			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537393	hybrid			2022-12-25	WOS:A1995TN44400060
J	Maraboeuf, F; Voloshin, O; CameriniOtero, RD; Takahashi, M				Maraboeuf, F; Voloshin, O; CameriniOtero, RD; Takahashi, M			The central aromatic residue in loop L2 of RecA interacts with DNA - Quenching of the fluorescence of a tryptophan reporter inserted in L2 upon binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED DNA; ESCHERICHIA-COLI; ENERGY-TRANSFER; PROTEIN; RECOMBINATION; BACTERIOPHAGE-T4; STOICHIOMETRY; MUTAGENESIS; ORIENTATION; COMPLEXES	To determine the role of the central aromatic residue in one of the DNA binding domains in Escherichia coli RecA protein, we have constructed a protein in which a tryptophan fluorescence reporter is inserted in the place of phenylalanine residue 203 in loop L2, a putative DNA binding site, and measured its fluorescence, The modified protein is active both in vivo and in vitro, The binding of nucleotide cofactor (ATP or its analog adenosine 5'-O-3-thiotriphosphate) does not modify the fluorescence, By contrast, the binding of DNA, both in the absence and presence of cofactor, strongly decreases the fluorescence in intensity (40-65%) and shifts the emission peak from 344 to 337 nm. The change occurs both with single- and double-stranded DNA and also upon the binding of a second single-stranded DNA. The results indicate that the residue 203 is in fact close to the first and second DNA binding sites. However, the quenching is not total and depends only slightly can the nature of DNA bases, thus suggesting an indirect interaction with DNA bases.	INST CURIE, F-91405 ORSAY, FRANCE; NIDDK, GENET & BIOCHEM BRANCH, BETHESDA, MD 20892 USA	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Maraboeuf, F (corresponding author), CNRS, URA 1342, ETUD MUTAGENESE & CANCEROGENESE GRP, F-91405 ORSAY, FRANCE.							BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CAZAUX C, 1994, J BIOL CHEM, V269, P8246; CHABBERT M, 1991, J BIOL CHEM, V266, P5395; DEJONG EAM, 1989, J MOL BIOL, V206, P133, DOI 10.1016/0022-2836(89)90529-9; DICAPUA E, 1992, J MOL BIOL, V226, P707, DOI 10.1016/0022-2836(92)90627-V; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; ERIKSSON S, 1993, J BIOL CHEM, V268, P1805; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; HSIEH P, 1992, P NATL ACAD SCI USA, V89, P6492, DOI 10.1073/pnas.89.14.6492; KIM SK, 1993, J BIOL CHEM, V268, P14799; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P5872, DOI 10.1021/bi00368a006; KUBISTA M, 1990, J BIOL CHEM, V265, P18891; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MORIMATSU K, 1995, ADV BIOPHYS, V31, P23, DOI 10.1016/0065-227X(95)99381-X; NASTRI HG, 1994, J BIOL CHEM, V269, P26311; PRASAD BVV, 1987, J MOL BIOL, V193, P579; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH KC, 1989, BIOESSAYS, V10, P12, DOI 10.1002/bies.950100104; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; TAKAHASHI M, 1994, ADV BIOPHYS, V30, P1, DOI 10.1016/0065-227X(94)90009-4; TAKAHASHI M, 1991, FEBS LETT, V279, P270, DOI 10.1016/0014-5793(91)80165-Y; TAKAHASHI M, 1989, EUR J BIOCHEM, V183, P617, DOI 10.1111/j.1432-1033.1989.tb21091.x; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TOULME JJ, 1980, BIOCHIM BIOPHYS ACTA, V606, P95, DOI 10.1016/0005-2787(80)90101-X; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WITTUNG P, 1995, EUR J BIOCHEM, V228, P149, DOI 10.1111/j.1432-1033.1995.0149o.x; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428	34	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30927	30932		10.1074/jbc.270.52.30927	http://dx.doi.org/10.1074/jbc.270.52.30927			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537348	hybrid			2022-12-25	WOS:A1995TN44400016
J	Okano, I; Hiraoka, J; Otera, H; Nunoue, K; Ohashi, K; Iwashita, S; Hirai, M; Mizuno, K				Okano, I; Hiraoka, J; Otera, H; Nunoue, K; Ohashi, K; Iwashita, S; Hirai, M; Mizuno, K			Identification and characterization of a novel family of serine threonine kinases containing two N-terminal LIM motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSERVED FEATURES; PROTEIN-KINASES; GENE; LOCALIZATION; HOMEODOMAIN; ACTIVATION; DOMAINS	We previously isolated human cDNA coding for LIMK1 (LIM motif containing protein kinase-1), a putative protein kinase containing two LIM motifs at the N terminus and an unusual protein kinase domain at the C terminus, In the present study, we isolated human cDNA encoding LIMK2, a second member of a LIMK family, with a domain structure similar to LIMK1 and 50% overall amino acid identity with LIMK1. The protein kinase domains of LIMK1 and LIMK2 are unique in that they contain an unusual sequence motif Asp Leu-Asn-Ser-His-Asn in subdomain VIB and a highly basic insert between subdomains VII and VIII, Expression patterns of LIMK1 and LIMK2 mRNAs in human tissues differ significantly. Chromosomal localization of human LIMK1 and LIMK2 genes was assigned to 7q11.23 and 22q12, respectively, by fluorescence in situ hybridization, The Myc epitope-tagged LIMK1 and LIMK2 proteins transiently expressed in COS cells exhibited serine/threonine-specific kinase activity toward myelin basic protein and histone in in vitro kinase assay. Immunofluorescence and subcellular fractionation analysis revealed that Myc-tagged LIMK1 and LIMK2 were localized mainly in the cytoplasm, The ''native'' LIMK1 protein endogenously expressed in A431 epidermoid carcinoma cells also exhibited serine/threonine kinase activity. The specific activity of native LIMK1 from A431 cells was apparently much higher than that of ''recombinant'' LIMK1 ectopically expressed in COS cells, hence, it is likely that there is a mechanism, by which native LIMK1 is activated, A 140-kDa tyrosine phosphorylated protein (pp140) was co-immunoprecipitated with native LIMK1 from A431 cell lysates; therefore, pp140 may be a LIMK1-associated protein involved in the regulation of LIMK1 function.	KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 812, JAPAN; MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN; UNIV TOKYO, GRAD SCH SCI, DEPT SCI BIOL, TOKYO 113, JAPAN; JRDC, PRESTO, INHERITANCE & VARIAT GRP, KYOTO 61902, JAPAN	Kyushu University; University of Tokyo; Japan Science & Technology Agency (JST)			Ohashi, Kazumasa/U-7028-2019; Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X; Iwashita, Shintaro/0000-0001-8086-9192				BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, EMBO J, V12, P4243, DOI 10.1002/j.1460-2075.1993.tb06108.x; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P546; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WANG XK, 1992, J BIOL CHEM, V267, P9176; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	37	171	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31321	31330		10.1074/jbc.270.52.31321	http://dx.doi.org/10.1074/jbc.270.52.31321			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537403	hybrid			2022-12-25	WOS:A1995TN44400070
J	Pavao, MSG; Mourao, PAS; Mulloy, B; Tollefsen, DM				Pavao, MSG; Mourao, PAS; Mulloy, B; Tollefsen, DM			A unique dermatan sulfate-like glycosaminoglycan from ascidian - Its structure and the effect of its unusual sulfation pattern on anticoagulant activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN COFACTOR-II; BRANCHED CHONDROITIN SULFATE; PLICATA CHORDATA-TUNICATA; RELATIVE EFFICACY; ANTITHROMBIN-III; SEA-CUCUMBER; L-GALACTANS; MUCOPOLYSACCHARIDES; POLYSACCHARIDE; IDENTIFICATION	A dermatan sulfate, similar to the mammalian glycosaminoglycans but not identical with any of them, has been isolated from the body of the ascidian Ascidia nigra. Degradation with chondroitin ABC lyase, analysis of the disaccharide products by digestion with chondro-4- and -6-sulfatases, and H-1 and C-13 NMR data confirm that the predominant structure is [4-alpha-L-IdoA-(2SO(4))-1-->3-beta-D-GalNAc(6SO(4))-1](n). Mammalian dermatan sulfate is an anticoagulant due to its ability to potentiate inhibition of thrombin by heparin cofactor II. The structure in dermatan sulfate which binds to heparin cofactor II is [4-alpha-L-IdoA-(2SO(4))-1-->3-beta-D-GalNAc(4SO(4))-1](n), where n greater than or equal to 3. We have compared the ascidian derma tan sulfate with mammalian dermatan sulfate and with chemically oversulfated mammalian dermatan sulfate for anticoagulant activity as measured by the activated partial thromboplastin time assay and for its ability to potentiate heparin cofactor II. In spite of its high content of 2-O-sulfated alpha-L-iduronic acid residues, the ascidian compound had no discernible anticoagulant activity and had low ability to potentiate heparin cofactor II. These results suggest that 4-O sulfation of the N-acetyl-beta-D-galactosamine residues is essential for the anticoagulant activity of dermatan sulfate.	UNIV FED RIO DE JANEIRO, INST CIENCIAS BIOMED, DEPT BIOQUIM, BR-21941590 RIO DE JANEIRO, BRAZIL; NATL INST BIOL STAND & CONTROLS, POTTERS BAR EN6 3QG, HERTS, ENGLAND; WASHINGTON UNIV, DEPT INTERNAL MED, DIV HEMATOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	Universidade Federal do Rio de Janeiro; National Institute for Biological Standards & Control; Washington University (WUSTL); Washington University (WUSTL)			Mourao, Paulo/AAA-5386-2020	Pavao, Mauro Sergio Goncalves/0000-0002-1336-4271	NHLBI NIH HHS [HL 14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBANO RM, 1990, CARBOHYD RES, V208, P163, DOI 10.1016/0008-6215(90)80096-L; ALBANO RM, 1986, J BIOL CHEM, V261, P758; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BOSSENNEC V, 1990, BIOCHEM J, V267, P625, DOI 10.1042/bj2670625; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CARDOSO LEM, 1994, ARTERIOSCLER THROMB, V14, P115, DOI 10.1161/01.ATV.14.1.115; CASSARO CMF, 1977, J BIOL CHEM, V252, P2254; DIETRICH CP, 1977, J CHROMATOGR, V130, P299, DOI 10.1016/S0021-9673(00)89809-X; DIETRICH CP, 1976, ANAL BIOCHEM, V70, P645, DOI 10.1016/0003-2697(76)90496-6; DOL F, 1988, THROMB RES, V52, P153, DOI 10.1016/0049-3848(88)90094-1; EGGLETON CA, 1981, THROMB RES, V34, P319; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; HAMER GK, 1976, CARBOHYD RES, V49, P37, DOI 10.1016/S0008-6215(00)83123-7; HEINEGARD D, 1984, EXTRACELLULAR MATRIX, P277; KAKKAR VV, 1989, HEPARIN CHEM BIOL PR, P455; KJELLEN L, 1991, ANNU REV BIOCHEM, V47, P385; LUDWIGBAXTER KG, 1991, CARBOHYD RES, V214, P245, DOI 10.1016/0008-6215(91)80032-I; MAAROUFI RM, 1990, THROMB RES, V59, P749, DOI 10.1016/0049-3848(90)90056-I; MAGGI A, 1987, HAEMOSTASIS, V17, P329; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; MERTON RE, 1987, THROMB HAEMOSTASIS, V58, P839; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P431, DOI 10.1111/j.1432-1033.1987.tb13534.x; MULLOY B, 1994, J BIOL CHEM, V269, P22113; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; OFOSU FA, 1987, BIOCHEM J, V248, P889, DOI 10.1042/bj2480889; PAVAO MSG, 1989, J BIOL CHEM, V264, P9972; PAVAO MSG, 1994, BBA-GEN SUBJECTS, V1199, P229, DOI 10.1016/0304-4165(94)90001-9; PAVAO MSG, 1990, CARBOHYD RES, V208, P153, DOI 10.1016/0008-6215(90)80095-K; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; RONDLE CJM, 1955, BIOCHEM J, V61, P586, DOI 10.1042/bj0610586; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAITO H, 1968, J BIOL CHEM, V243, P1536; SANDERSON PN, 1989, BIOCHEM J, V257, P347, DOI 10.1042/bj2570347; SANTOS JA, 1992, EUR J BIOCHEM, V204, P669, DOI 10.1111/j.1432-1033.1992.tb16680.x; SCULLY MF, 1988, BIOCHEM J, V254, P547, DOI 10.1042/bj2540547; SCULLY MF, 1986, THROMB RES, V41, P489, DOI 10.1016/0049-3848(86)91694-4; SHAKA AJ, 1983, J MAGN RESON, V53, P313, DOI 10.1016/0022-2364(83)90035-5; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SIE P, 1988, BIOCHIM BIOPHYS ACTA, V966, P188, DOI 10.1016/0304-4165(88)90111-0; THOMAS DP, 1982, THROMB RES, V28, P343, DOI 10.1016/0049-3848(82)90116-5; THOMAS DP, 1989, ANN NY ACAD SCI, V556, P313; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; WELTI D, 1979, EUR J BIOCHEM, V94, P505, DOI 10.1111/j.1432-1033.1979.tb12919.x	46	110	113	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31027	31036		10.1074/jbc.270.52.31027	http://dx.doi.org/10.1074/jbc.270.52.31027			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537360	hybrid			2022-12-25	WOS:A1995TN44400028
J	Pedersen, SE; Papineni, RVL				Pedersen, SE; Papineni, RVL			Interaction of d-tubocurarine analogs with the Torpedo nicotinic acetylcholine receptor - Methylation and stereoisomerization affect site-selective competitive binding and binding to the noncompetitive site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BUNGAROTOXIN BINDING; LIGAND-BINDING; SUBUNIT INTERFACES; AFFINITY; IDENTIFICATION; RESIDUES; DESENSITIZATION; STOICHIOMETRY; CALIFORNICA; MEMBRANES	Analogs of d-tubocurarine were used to determine the individual effects of methylation, stereoisomerization, and halogenation of d-tubocurarine on the affinity for each of the two acetylcholine (ACh) binding sites of the Torpedo nicotinic acetylcholine receptor (AChR) and for the noncompetitive antagonist site. Eight analogs were synthesized, including three new compounds: 7'-O-methylchondoeurarine, 12'-O-methylchondocurarine, and 13'-bromo-d-tubocurarine. The two ACh sites differ in their affinities for d-tubocurarine by 400-fold, as shown by inhibition of [H-3]ACh binding, whereas the affinity ratio for metocurine, the trimethylated derivative of d-tubocurarine, is reduced to 30 due to a de creased affinity for the high affinity site, Binding anal ysis of five d-tubocurarine analogs demonstrates that methylation of the phenols alone is responsible for the observed changes in affinity. Substitution with bromine or iodine at the 13'-position affected affinity at both sites with a net increase in site selectivity. Stereoisomers of d-tubocurare had decreased affinity for only the high affinity ACh site. Thus, the ring systems, including the 12'- and 13'-positions and the 1-position stereocenter, appear to be important in discriminating between the two ACh binding sites. Desensitization of the AChR was measured by increased affinity for [H-3]phencyclidine, Binding to only the single, high affinity acetylcholine binding site, comprised by the alpha gamma-subunits, was required for partial desensitization of the AChR by d-tubocurarine and its analogs. Stronger desensitization, to the same extent observed in the presence of the agonist carbamylcholine, occurred upon binding by iodonated or brominated d-tubocurarine. Interaction of the analogs at the noncompetitive antagonist site of the AChR was also measured by [H-3]phencyclidine binding. The bis-tertiary ammonium analogs of either the d- or l-stereoisomers bound to the noncompetitive antagonist binding site of the AChR with 100-fold higher affinity than the corresponding quaternary ammonium analogs.			Pedersen, SE (corresponding author), BAYLOR COLL MED, DEPT MOLEC PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA.			Pedersen, Steen E./0000-0001-8755-8899	NINDS NIH HHS [NS28879] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028879] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; BICK IRC, 1974, J PHARM PHARMACOL, V26, P985, DOI 10.1111/j.2042-7158.1974.tb09223.x; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; Breitmaier E., 1987, CARBON 13 NMR SPECTR; CHATURVEDI V, 1993, BIOCHEMISTRY-US, V32, P9570, DOI 10.1021/bi00088a008; CHIARA D C, 1992, Biophysical Journal, V61, pA106; COHEN JB, 1991, J BIOL CHEM, V266, P23354; COHEN JB, 1985, EFFECTS ANESTHESIA, P53; COHEN JB, 1987, MOL MECHANISMS DESEN; COHEN JB, 1986, MOL CELLULAR MECHANI; COLQUHOUN D, 1979, J PHYSIOL-LONDON, V293, P247, DOI 10.1113/jphysiol.1979.sp012888; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P1046, DOI 10.1021/bi00456a029; DAMLE VN, 1978, BIOCHEMISTRY-US, V17, P2039, DOI 10.1021/bi00604a002; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; DUTCHER JD, 1946, J AM CHEM SOC, V68, P419, DOI 10.1021/ja01207a022; DUTCHER JD, 1952, J AM CHEM SOC, V74, P2221, DOI 10.1021/ja01129a021; EVERETT AJ, 1970, J CHEM SOC CHEM COMM, P1020, DOI 10.1039/c29700001020; FU DX, 1994, J BIOL CHEM, V269, P26152; GUND TM, 1991, METHOD ENZYMOL, V203, P677; KALOW W, 1954, J PHARMACOL EXP THER, V110, P433; KAO PN, 1984, J BIOL CHEM, V259, P1662; KING HJ, 1935, CHEM SOC, P1381; KOIKE L, 1981, J ORG CHEM, V46, P2385, DOI 10.1021/jo00324a036; KRODEL EK, 1979, MOL PHARMACOL, V15, P294; MARSHALL IG, 1967, J PHARM PHARMACOL, VS 19, pS53; MENEZ A, 1973, BIOCHIMIE, V55, P919, DOI 10.1016/S0300-9084(73)80169-5; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; NAGHAWAY J, 1979, J PHARM SCI, V68, P655, DOI 10.1002/jps.2600680540; NAGHAWAY JA, 1978, J PHARM SCI, V67, P1204, DOI 10.1002/jps.2600670904; NAGHAWAY JA, 1978, J PHARM SCI, V67, P473, DOI 10.1002/jps.2600670408; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; NEUBIG RR, 1982, BIOCHEMISTRY-US, V21, P3460, DOI 10.1021/bi00257a032; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; PEDERSEN SE, 1995, MOL PHARMACOL, V47, P1; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; SCHMIDT J, 1973, ANAL BIOCHEM, V52, P349, DOI 10.1016/0003-2697(73)90036-5; SHAMMA M, 1966, TETRAHEDRON LETT, P1375; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SOBELL HM, 1972, P NATL ACAD SCI USA, V69, P2212, DOI 10.1073/pnas.69.8.2212; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; WILSON PT, 1984, P NATL ACAD SCI-BIOL, V81, P2553, DOI 10.1073/pnas.81.8.2553; WOLOSIN JM, 1980, EUR J BIOCHEM, V109, P495, DOI 10.1111/j.1432-1033.1980.tb04821.x	48	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31141	31150		10.1074/jbc.270.52.31141	http://dx.doi.org/10.1074/jbc.270.52.31141			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537377	hybrid			2022-12-25	WOS:A1995TN44400045
J	VanHellemond, JJ; Klockiewicz, M; Gaasenbeek, CPH; Roos, MH; Tielens, AGM				VanHellemond, JJ; Klockiewicz, M; Gaasenbeek, CPH; Roos, MH; Tielens, AGM			Rhodoquinone and complex II of the electron transport chain in anaerobically functioning eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIMETHYLAMINE N-OXIDE; ESCHERICHIA-COLI; RESPIRATORY-CHAIN; ASCARIS-SUUM; RAT-TISSUES; FUMARATE; UBIQUINONE; MITOCHONDRIA; MENAQUINONE; NITRATE	Many anaerobically functioning eukaryotes have an anaerobic energy metabolism in which fumarate is reduced to succinate. This reduction of fumarate is the opposite reaction to succinate oxidation catalyzed by succinate-ubiquinone oxidoreductase, complex II of the aerobic respiratory chain. Prokaryotes are known to contain two distinct enzyme complexes and distinct quinones, menaquinone and ubiquinone (Q), for the reduction of fumarate and the oxidation of succinate, respectively. Parasitic helminths are also known to contain two different quinones, Q and rhodoquinone (RQ). This report demonstrates that RQ was present in all examined eukaryotes that reduce fumarate during anoxia, not only in parasitic helminths, but also in freshwater snails, mussels, lugworms, and oysters. It was shown that the measured RQ/Q ratio correlated with the importance of fumarate reduction in vivo. This is the first demonstration of the role of RQ in eukaryotes, other than parasitic helminths. Furthermore, throughout the development of the liver fluke Fasciola hepatica, a strong correlation was found between the quinone composition and the type of metabolism: the amount of Q was correlated with the use of the aerobic respiratory chain, and the amount of RQ with the use of fumarate reduction. It can be concluded that RQ is an essential component for fumarate reduction in eukaryotes, in contrast to prokaryotes, which use menaquinone in this process, Analyses of enzyme kinetics, as well as the known differences in primary structures of prokaryotic and eukaryotic complexes that reduce fumarate, support the idea that fumarate-reducing eukaryotes possess an enzyme complex for the reduction of fumarate, structurally related to the succinate dehydrogenase-type complex II, but with the functional characteristics of the prokaryotic fumarate reductases.	UNIV UTRECHT,FAC VET MED,INST INFECT DIS & IMMUNOL,VET BIOCHEM LAB,3508 TD UTRECHT,NETHERLANDS; UNIV UTRECHT,FAC VET MED,INST INFECT DIS & IMMUNOL,DEPT PARASITOL & VET TROP MED,3508 TD UTRECHT,NETHERLANDS; DLO,INST ANIM SCI & HLTH,8200 AB LELYSTAD,NETHERLANDS	Utrecht University; Utrecht University			van Hellemond, Jaap/T-7555-2019	van Hellemond, Jaap/0000-0003-4862-7796; Klockiewicz, Maciej/0000-0002-9655-9153				Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1993, FEBS LETT, V326, P92, DOI 10.1016/0014-5793(93)81768-U; ALLEN PC, 1973, EXP PARASITOL, V34, P211, DOI 10.1016/0014-4894(73)90080-5; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; COLLICUTT JM, 1977, J COMP PHYSIOL, V115, P147, DOI 10.1007/BF00692526; COLLINS MD, 1981, MICROBIOL REV, V45, P316, DOI 10.1128/MMBR.45.2.316-354.1981; CRANE FL, 1970, METHODS ENZYMOL C, V18, P137; de Zwaan A., 1991, P186; DEZWAAN A, 1976, NETH J ZOOL, V26, P549; Ernster L., 1967, METHOD ENZYMOL, V10, P86; FRY M, 1984, EXP PARASITOL, V57, P86, DOI 10.1016/0014-4894(84)90067-5; FURUSHIMA R, 1990, FEBS LETT, V263, P325, DOI 10.1016/0014-5793(90)81405-D; HAGERHALL C, 1992, BIOCHEMISTRY-US, V31, P7411, DOI 10.1021/bi00147a028; HIRAISHI A, 1988, ARCH MICROBIOL, V150, P56, DOI 10.1007/BF00409718; KITA K, 1992, PARASITOL TODAY, V8, P155, DOI 10.1016/0169-4758(92)90009-Q; LENAZ G, 1990, FREE RADICAL RES COM, V8, P317, DOI 10.3109/10715769009053365; Ochman H, 1987, ESCHERICHIA COLI SAL, P1649; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; PARSON WW, 1965, J BIOL CHEM, V240, P1855; PORTNER HO, 1984, J COMP PHYSIOL B, V155, P1, DOI 10.1007/BF00688785; POWLS R, 1966, PHYTOCHEMISTRY, V5, P1235, DOI 10.1016/S0031-9422(00)86119-1; ROOS MH, 1994, MOL BIOCHEM PARASIT, V66, P2732; SARUTA F, 1995, J BIOL CHEM, V270, P928, DOI 10.1074/jbc.270.2.928; SAZ HJ, 1981, ANNU REV PHYSIOL, V43, P323, DOI 10.1146/annurev.ph.43.030181.001543; SCHNEIDER T, 1985, PLANTA, V166, P67, DOI 10.1007/BF00397387; SCHOTTLER U, 1988, MAR BIOL, V99, P215, DOI 10.1007/BF00391983; SUCHETA A, 1992, NATURE, V356, P361, DOI 10.1038/356361a0; SUCHETA A, 1993, BIOCHEMISTRY-US, V32, P5455, DOI 10.1021/bi00071a023; TAKAHASHI T, 1993, LIPIDS, V28, P803, DOI 10.1007/BF02536234; TAKAMIYA S, 1994, ARCH BIOCHEM BIOPHYS, V312, P142, DOI 10.1006/abbi.1994.1292; TAKAMIYA S, 1993, BIOCHIM BIOPHYS ACTA, V1141, P65, DOI 10.1016/0005-2728(93)90190-Q; THELIN A, 1992, FEBS LETT, V313, P118, DOI 10.1016/0014-5793(92)81425-L; TIELENS AGM, 1994, PARASITOL TODAY, V10, P346, DOI 10.1016/0169-4758(94)90245-3; TIELENS AGM, 1982, MOL BIOCHEM PARASIT, V6, P277, DOI 10.1016/0166-6851(82)90060-3; TIELENS AGM, 1984, MOL BIOCHEM PARASIT, V13, P301, DOI 10.1016/0166-6851(84)90121-X; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WANG H, 1992, Japanese Journal of Parasitology, V41, P122; Williams A.G., 1991, P61; WISSENBACH U, 1990, ARCH MICROBIOL, V154, P60; WISSENBACH U, 1992, ARCH MICROBIOL, V158, P68, DOI 10.1007/BF00249068; WU GH, 1993, J GEN MICROBIOL, V139, P1795, DOI 10.1099/00221287-139-8-1795; ZHU QS, 1982, BIOCHIM BIOPHYS ACTA, V680, P69, DOI 10.1016/0005-2728(82)90317-6	43	87	88	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31065	31070		10.1074/jbc.270.52.31065	http://dx.doi.org/10.1074/jbc.270.52.31065			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537365	hybrid			2022-12-25	WOS:A1995TN44400033
J	Wood, IC; Roopra, A; Harrington, C; Buckley, NJ				Wood, IC; Roopra, A; Harrington, C; Buckley, NJ			Structure of the m4 cholinergic muscarinic receptor gene and its promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-SPECIFIC EXPRESSION; TISSUE-SPECIFIC EXPRESSION; MESSENGER-RNA; ACETYLCHOLINE-RECEPTORS; REGULATORY ELEMENTS; BINDING-PROPERTIES; SILENCER ELEMENT; RABBIT LUNG; RAT-BRAIN; CELLS	Cholinergic muscarinic receptor genes are members of the G-protein receptor gene superfamily, In this study we describe the structure of the gene and promoter of the rat m4 muscarinic receptor gene, A rat cosmid clone containing the coding region for the m4 gene and 25 kilobases of upstream sequence was isolated, This clone directed expression of the rat m4 gene when introduced in IMR32 cells, a human neuroblastoma that expresses m4, but did not drive expression when introduced into Chinese hamster ovary cells, a line that does not express the m4 gene, S1 nuclease, modified 5'-rapid amplification of cDNA ends and polymerase chain reaction analysis of rat cosmid DNA and cDNA showed that the gene consists of a 2.6-kilobase coding exon, extending 34 base pairs (bp) upstream from the initiating ATG, separated from a 460-493 bp noncoding exon by a 4.8-kilobase intron, DNA sequence analysis shows that the noncoding exon is CC-rich and that the promoter does not contain a TATA or CAAT box and has several consensus sequences for enhancer elements including five Sp-1 binding sites, one AP-2 site, one AP-3 binding site and two E-boxes within the proximal 600 bp, A reporter construct consisting of 1440 bp of flanking DNA and 80 bp of the first exon cloned into a luciferase reporter plasmid, drove cell specific expression in transient transfection assays, Removal of 1088 bp of the 5' end of this construct resulted in expression in non-m4 expressing cell lines suggesting there is a repressor element in this region.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research	Wood, IC (corresponding author), UCL, WELLCOME LAB MOLEC PHARMACOL, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.		Buckley, Noel J/B-9675-2012; Wood, Ian/AAK-9423-2021	Buckley, Noel J/0000-0003-1152-0653; Wood, Ian/0000-0003-1886-2533				AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; BLOEM LJ, 1993, MOL BRAIN RES, V17, P194, DOI 10.1016/0169-328X(93)90002-7; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRADLEY PB, 1957, BRAIN, V80, P77, DOI 10.1093/brain/80.1.77; Brown D. A., 1995, MOL B INT U, P165; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS S, 1993, BIOCHIM BIOPHYS ACTA, V1172, P171, DOI 10.1016/0167-4781(93)90287-N; COOLS AR, 1984, CLIN NEUROL NEUROSUR, V86, P178, DOI 10.1016/0303-8467(84)90195-1; DAVIDSON EH, 1979, SCIENCE, V204, P1052, DOI 10.1126/science.451548; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAO B, 1994, J BIOL CHEM, V269, P15762; GERARD NP, 1993, BIOCHEMISTRY-US, V32, P1243, DOI 10.1021/bi00056a007; GROSVELD FG, 1982, NUCLEIC ACIDS RES, V10, P6715, DOI 10.1093/nar/10.21.6715; HABECKER BA, 1992, P NATL ACAD SCI USA, V89, P5035, DOI 10.1073/pnas.89.11.5035; HAGAN JJ, 1988, HDB PSYCHOPHARMACOLO, V20; HASSALL CJS, 1993, NEUROSCIENCE, V56, P1041, DOI 10.1016/0306-4522(93)90149-A; HAUSER F, 1994, FEBS LETT, V345, P225, DOI 10.1016/0014-5793(94)00444-7; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LAZARENO S, 1990, MOL PHARMACOL, V38, P805; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LILES WC, 1986, J BIOL CHEM, V261, P5307; MAK JCW, 1993, LIFE SCI, V53, P1501, DOI 10.1016/0024-3205(93)90624-C; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MOREAU A, 1994, BIOTECNIQUES, V17, P233; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RAMARAO CS, 1992, J BIOL CHEM, V267, P21936; SAKIMURA K, 1995, MOL BRAIN RES, V28, P19, DOI 10.1016/0169-328X(94)00177-G; Sambrook J, 1989, MOL CLONING LABORATO; STEEL MC, 1993, MOL PHARMACOL, V43, P694; TOL HHM, 1991, NATURE, V350, P610; VANSELOW J, 1994, J NEUROSCI, V14, P499; VIDAL M, 1990, EMBO J, V9, P833, DOI 10.1002/j.1460-2075.1990.tb08180.x; WANG HY, 1992, MOL ENDOCRINOL, V6, P320, DOI 10.1210/me.6.3.320; WOOD IC, 1995, FORME, V5, P29; ZHOU QY, 1992, J NEUROCHEM, V59, P1875, DOI 10.1111/j.1471-4159.1992.tb11023.x; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	48	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30933	30940		10.1074/jbc.270.52.30933	http://dx.doi.org/10.1074/jbc.270.52.30933			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537349	hybrid			2022-12-25	WOS:A1995TN44400017
J	Li, CH; Liu, JN; Gurewich, V				Li, CH; Liu, JN; Gurewich, V			Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELL-SURFACE; PRO-UROKINASE; RECEPTOR; TYROSINE; PROTEIN; DOMAIN; EXPRESSION; THROMBIN; CLONING; SHAPE	Urokinase-type plasminogen activator (u-PA) or its amino-terminal fragment (ATF) containing the u-PA receptor (u-PAR) binding domain, is known to promote monocyte adhesion. In the present study, U937 monocyte adhesion to a plastic surface was used to investigate the mechanism of its promotion by u-PA and ATF. Adhesion was found to be inhibited by cycloheximide or actinomycin D, implicating protein synthesis and gene expression in u-PA-induced monocyte adhesion. Adhesion was prevented by 2'-deoxyadenosine 3'-monophosphate, indicating that a cAMP-dependent pathway of signal transduction was involved, This concept was supported by the complementary finding that u-PA-induced adhesion was greatly promoted by forskolin, cholera toxin, or 8-bromo-cAMP, which by themselves induced little adhesion. Furthermore, similar to many other cAMP-dependent activities, cGMP diminished u-PA-induced adhesion. When u-PA or ATF was treated with immobilized carboxypeptidase B, its proadhesive effect was abolished, implicating the involvement of carboxyl-terminal lysine residues (Lys(158) on u-PA and Lys(135) on ATF). Moreover, when a carboxyl-terminal lysine analog was added, the proadhesive effect of carboxypeptidase B-treated u-PA or ATF was restored. In conclusion, the present study indicates that u-PA or ATF-induced monocyte adhesion involves cAMP-dependent signal transduction, which is triggered by u-PAR binding. It is also critically dependent on the presence of a carboxyl-terminal lysine.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,INST PREVENT CARDIOVASC DIS,VASC RES LAB,BOSTON,MA 02215; NANJING UNIV,DEPT BIOCHEM,NANJING 210008,PEOPLES R CHINA	Harvard University; Harvard Medical School; Nanjing University								APPELLA E, 1987, J BIOL CHEM, V262, P4437; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; DEPETRO G, 1994, EXP CELL RES, V213, P286, DOI 10.1006/excr.1994.1200; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; GLASS WF, 1988, J CLIN INVEST, V82, P1992, DOI 10.1172/JCI113819; GLASS WF, 1991, AM J PHYSIOL, V261, pF336, DOI 10.1152/ajprenal.1991.261.2.F336; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; LANGER DJ, 1993, CIRC RES, V72, P330, DOI 10.1161/01.RES.72.2.330; LIU JN, 1993, BLOOD, V81, P980; LIU JN, 1995, J BIOL CHEM, V270, P8408, DOI 10.1074/jbc.270.15.8408; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MOSER TL, 1995, BIOCHEM J, V307, P867, DOI 10.1042/bj3070867; MYOHANEN HT, 1993, J HISTOCHEM CYTOCHEM, V41, P1291; PANNELL R, 1987, BLOOD, V69, P22; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WEI Y, 1994, J BIOL CHEM, V269, P32380; ZIEGLER A, 1991, J BIOL CHEM, V266, P21067	22	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30282	30285		10.1074/jbc.270.51.30282	http://dx.doi.org/10.1074/jbc.270.51.30282			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530448	hybrid			2022-12-25	WOS:A1995TL67500013
J	Morris, DP; Stevens, RD; Wright, DJ; Stafford, DW				Morris, DP; Stevens, RD; Wright, DJ; Stafford, DW			Processive post-translational modification - Vitamin K-dependent carboxylation of a peptide substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; RNA POLYMERASE-II; GLUTAMYL CARBOXYLASE; PROPEPTIDE; PROTEIN; MECHANISM; BINDING; SITE; IDENTIFICATION; PURIFICATION	Mass spectrometry has been used to demonstrate that vitamin K-dependent carboxylation is a processive posttranslational modification (i.e. multiple carboxylations occur during a single association between enzyme and substrate), Purified vitamin K-dependent carboxylase can carboxylate as many as 12 glutamate residues in FIXQ/S, a peptide substrate based on amino acids -18 to 41 of the human blood clotting enzyme factor M. Mass spectrometry was used to determine the number of gamma-carboxyl groups added to FIXQ/S by the carboxylase during an in vitro reaction. Despite the fact that most substrate molecules in a reaction were uncarboxylated, almost all carboxylated FIXQ/S molecules were carboxylated many times. This observation can only be explained by two types of mechanisms. in a processive mechanism, multiple carboxylations could occur during a single substrate binding event. Alternatively, a distributive mechanism could result in the observed behavior if the initial carboxylation event results in a substrate that is additionally carboxylated far more efficiently than the uncarboxylated FIXQ/S. Kinetic experiments and arguments were used to show that the vitamin K-dependent carboxylase is not distributive but rather is one of the first well documented examples of an enzyme that catalyzes a processive post-translational modification.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; DUKE UNIV,MED CTR,DEPT PEDIAT,DIV BIOCHEM GENET,DURHAM,NC 27710	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University					NHLBI NIH HHS [HL48318, HL06350-30] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DEJONG L, 1991, BIOCHIM BIOPHYS ACTA, V1079, P103, DOI 10.1016/0167-4838(91)90030-4; DVIR A, 1993, J BIOL CHEM, V268, P10440; ENGELKE JA, 1991, BIOCHIM BIOPHYS ACTA, V1078, P31, DOI 10.1016/0167-4838(91)90088-H; FERSHT A, 1985, ENZYME STRUCTURE MEC, P111; FURIE B, 1990, BLOOD, V75, P1753; GOODLETT DR, 1990, ANAL BIOCHEM, V186, P116, DOI 10.1016/0003-2697(90)90583-U; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KELLARIS KV, 1989, BIOCHEMISTRY-US, V28, P3469, DOI 10.1021/bi00434a048; KNOBLOCH JE, 1987, J BIOL CHEM, V262, P15334; Kornberg A., 1992, DNA REPLICATION; MORRIS DP, 1993, J BIOL CHEM, V268, P8735; PAN LC, 1985, P NATL ACAD SCI USA, V82, P6109, DOI 10.1073/pnas.82.18.6109; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; SUTTIE J W, 1988, Biofactors, V1, P55; SUTTIE JW, 1993, FASEB J, V7, P445, DOI 10.1096/fasebj.7.5.8462786; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; SUTTIE JW, 1980, CRC CR REV BIOCH MOL, V8, P191, DOI 10.3109/10409238009105469; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; WU SM, 1990, J BIOL CHEM, V265, P13124; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236	23	85	89	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30491	30498		10.1074/jbc.270.51.30491	http://dx.doi.org/10.1074/jbc.270.51.30491			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530480	hybrid			2022-12-25	WOS:A1995TL67500045
J	Murante, RS; Rust, L; Bambara, RA				Murante, RS; Rust, L; Bambara, RA			Calf 5' to 3' exo/endonuclease must slide from a 5' end of the substrate to perform structure-specific cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; REPLICATION; PROTEINS	Calf 5' to 3' exo/endonuclease, the counterpart of the human FEN-1 and yeast RTH-1 nucleases, performs structure-specific cleavage of both RNA and DNA and is implicated in Okazaki fragment processing and DNA repair, The substrate for endonuclease activity is a primer annealed to a template but with a 5' unannealed tail, The results presented here demonstrate that the nuclease must enter the 5' end of the unannealed tail and then slide to the region of hybridization where the cleavage occurs. The presence of bound protein or a primer at any point on the single-stranded tail prevents cleavage, However, biotinylation of a nucleotide at the 5' end or internal to the tail does not prevent cleavage. The sliding process is bidirectional, If the nuclease slides onto the tail, later binding of a primer to the tail traps the nuclease between the primer binding site and the cleavage site, preventing the nuclease from departing from the 5' end, A model for 5' entry, sliding, and cleavage is presented, The possible role of this unusual mechanism in Okazaki fragment processing, DNA repair, and protection of the replication fork from inappropriate endonudeolytic cleavage is presented.	UNIV ROCHESTER,MED CTR,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NIGMS NIH HHS [GM24441, T32-GM07102] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441, T32GM007102] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMBARA RA, 1995, PROG NUCLEIC ACID RE, V51, P93, DOI 10.1016/S0079-6603(08)60877-6; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; GREEN NM, 1970, BIOCHEM J, V118, P71, DOI 10.1042/bj1180071; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HUANG L, 1994, J BIOL CHEM, V269, P25922; HWANG PI, 1995, FASEB J, V9, pA1398; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KORNBERG A, 1992, DNA REPLICATION, P332; LYAMICHEV V, 1993, SCIENCE, V193, P963; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P975; ROBINS P, 1994, J BIOL CHEM, V269, P28535; RUYECHAN WT, 1976, BIOCHEMISTRY-US, V15, P5057, DOI 10.1021/bi00668a017; Sambrook J, 1989, MOL CLONING LABORATO; SIEGAL G, 1992, J BIOL CHEM, V267, P13629; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923	22	184	194	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30377	30383		10.1074/jbc.270.51.30377	http://dx.doi.org/10.1074/jbc.270.51.30377			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530463	hybrid			2022-12-25	WOS:A1995TL67500028
J	Muthuchamy, M; Grupp, IL; Grupp, G; OToole, BA; Kier, AB; Boivin, GP; Neumann, J; Wieczorek, DF				Muthuchamy, M; Grupp, IL; Grupp, G; OToole, BA; Kier, AB; Boivin, GP; Neumann, J; Wieczorek, DF			Molecular and physiological effects of overexpressing striated muscle beta-tropomyosin in the adult murine heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGIONS; HEAVY-CHAIN GENES; SKELETAL-MUSCLE; ACTIN GENES; CONTRACTILE PROTEINS; ALPHA-TROPOMYOSIN; CARDIAC MYOSIN; MESSENGER-RNAS; TROPONIN-T; HYPERTROPHIC CARDIOMYOPATHY	Tropomyosins comprise a family of actin-binding proteins that are central to the control of calcium-regulated striated muscle contraction. To understand the functional role of tropomyosin isoform differences in cardiac muscle, we generated transgenic mice that overexpress striated muscle-specific beta-tropomyosin in the adult heart. Nine transgenic lines show a 150-fold increase in beta-tropomyosin mRNA expression in the heart, along with a 34-fold increase in the associated protein. This increase in beta-tropomyosin message and protein causes a concomitant decrease in the level of alpha-tropomyosin transcripts and their associated protein. There is a preferential formation of the alpha beta-heterodimer in the transgenic mouse myofibrils, and there are no detectable alterations in the expression of other contractile protein genes, including the endogenous beta-tropomyosin isoform. When expression from the beta-tropomyosin transgene is terminated, alpha-tropomyosin expression returns to normal levels. No structural changes were observed in these transgenic hearts nor in the associated sarcomeres. Interestingly, physiological analyses of these hearts using a work-performing model reveal a significant effect on diastolic function. As such, this study demonstrates that a coordinate regulatory mechanism exists between alpha and beta-tropomyosin gene expression in the murine heart, which results in a functional correla tion between alpha and beta-tropomyosin isoform content and cardiac performance.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT PHYSIOL & BIOPHYS & MED, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT PATHOL & LAB MED, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046826] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46826] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAN R, 1994, J CLIN INVEST, V93, P280, DOI 10.1172/JCI116957; BEALL CJ, 1989, GENE DEV, V3, P131, DOI 10.1101/gad.3.2.131; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BRIGGS MM, 1987, J MUSCLE RES CELL M, V8, P1, DOI 10.1007/BF01767259; Briggs MM, 1989, CELLULAR MOL BIOL MU, P597; BRONSON DD, 1982, J BIOL CHEM, V257, P3937; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; CAPLAN AI, 1983, SCIENCE, V221, P921, DOI 10.1126/science.6348946; CHIZZONITE RA, 1984, J BIOL CHEM, V259, P5564; CLAYTON L, 1988, J MOL BIOL, V201, P507, DOI 10.1016/0022-2836(88)90633-X; CUMMINS P, 1974, BIOCHEM J, V141, P43, DOI 10.1042/bj1410043; DECHESNE CA, 1987, J CELL BIOL, V105, P3031, DOI 10.1083/jcb.105.6.3031; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; FERRARO R, 1984, THESIS U PADOVA PADO; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GORZA L, 1984, CIRC RES, V54, P694, DOI 10.1161/01.RES.54.6.694; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; GUNNING P, 1990, DEV BIOL, V138, P443, DOI 10.1016/0012-1606(90)90210-A; GUNNING P, 1984, J MOL EVOL, V20, P202, DOI 10.1007/BF02104727; GWATHMEY JK, 1991, J CLIN INVEST, V87, P1023, DOI 10.1172/JCI115061; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P5901, DOI 10.1073/pnas.79.19.5901; HASENFUSS G, 1992, CIRC RES, V70, P1225, DOI 10.1161/01.RES.70.6.1225; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; HOGAN B, 1986, MANIPULATING MOUSE E, P79; HOH JFY, 1978, J MOL CELL CARDIOL, V10, P1053, DOI 10.1016/0022-2828(78)90401-7; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KARLIK CC, 1985, CELL, V41, P57, DOI 10.1016/0092-8674(85)90061-3; LEAVITT J, 1987, MOL CELL BIOL, V7, P2467, DOI 10.1128/MCB.7.7.2467; LEAVITT J, 1987, MOL CELL BIOL, V7, P2457, DOI 10.1128/MCB.7.7.2457; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEESMILLER JP, 1990, J MOL BIOL, V213, P399, DOI 10.1016/S0022-2836(05)80202-5; LEGER J, 1976, PFLUG ARCH EUR J PHY, V362, P271, DOI 10.1007/BF00581181; LEMANSKI LF, 1973, DEV BIOL, V33, P312, DOI 10.1016/0012-1606(73)90140-1; LIN JJC, 1985, HYBRIDOMA, V4, P223, DOI 10.1089/hyb.1985.4.223; LLOYD C, 1992, J CELL BIOL, V117, P787, DOI 10.1083/jcb.117.4.787; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MATSUDA R, 1981, DEV BIOL, V82, P11, DOI 10.1016/0012-1606(81)90424-3; MEINNEL T, 1989, DEV BIOL, V131, P430, DOI 10.1016/S0012-1606(89)80015-6; MERCADIER JJ, 1983, CIRC RES, V53, P52, DOI 10.1161/01.RES.53.1.52; METZGER JM, 1993, P NATL ACAD SCI USA, V90, P9036, DOI 10.1073/pnas.90.19.9036; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MOORE GE, 1985, J MUSCLE RES CELL M, V6, P513, DOI 10.1007/BF00712587; MOORE GE, 1987, J MUSCLE RES CELL M, V8, P13, DOI 10.1007/BF01767260; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; NG SY, 1988, MOL CELL BIOL, V8, P1790, DOI 10.1128/MCB.8.4.1790; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RUBENSTEIN PA, 1990, BIOESSAYS, V12, P309, DOI 10.1002/bies.950120702; RUEGG JC, 1988, CALCIUM MUSCLE ACTIV, P165; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SAMUEL JL, 1986, AM J PHYSIOL, V250, pH333, DOI 10.1152/ajpheart.1986.250.3.H333; SARTORE S, 1981, J CELL BIOL, V88, P226, DOI 10.1083/jcb.88.1.226; SCHACHAT FH, 1985, J BIOL CHEM, V260, P1108; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; SCHWARTZ K, 1993, J AM COLL CARDIOL, V22, pA30, DOI 10.1016/0735-1097(93)90459-E; SHARP SB, 1989, GENE, V80, P293, DOI 10.1016/0378-1119(89)90293-X; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; TANSEY T, 1987, EMBO J, V6, P1375, DOI 10.1002/j.1460-2075.1987.tb02378.x; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; THOMAS L, 1994, BIOPHYS J, V66, pA310; VANDEKERCKHOVE J, 1986, J BIOL CHEM, V261, P1838; Walter C A, 1989, Biotechniques, V7, P1065; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618; WIECZOREK DF, 1988, MOL CELL BIOL, V8, P679, DOI 10.1128/MCB.8.2.679; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	71	112	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30593	30603		10.1074/jbc.270.51.30593	http://dx.doi.org/10.1074/jbc.270.51.30593			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530495	hybrid			2022-12-25	WOS:A1995TL67500060
J	Jiang, HP; Lin, JJ; Su, ZZ; Goldstein, NI; Fisher, PB				Jiang, HP; Lin, JJ; Su, ZZ; Goldstein, NI; Fisher, PB			Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression	ONCOGENE			English	Article						terminal cell differentiation; cDNA cloning; peptide antibodies; in vitro translation	GLIOBLASTOMA-MULTIFORME CELLS; POLYMERASE CHAIN-REACTION; ANTIGENIC PHENOTYPE; TRANSFORMED PHENOTYPE; MAMMALIAN-CELLS; RESPONSE GENE; EXPRESSION; SUPPRESSION; PROTEIN; INTERFERON	Cultured human melanoma cells lose proliferative capacity and terminally differentiate after treatment with the combination of recombinant human fibroblast interferon (IFN-beta) and mezerein (MEZ). Subtraction hybridization of cDNA libraries prepared from actively proliferating human H0-1 melanoma cells from cDNA libraries produced from H0-1 cells treated with IFN-beta+MEZ identifies a novel melanoma differentiation-associated (mda) cDNA, mda-7, that displays elevated expression in differentiation inducer-treated H0-1 cells. mda-7 encodes a novel protein of 206 amino acids with a predicted size of 23.8 kDa. The level of mda-7 mRNA is elevated in actively proliferating normal human melanocytes versus primary and metastatic human melanomas. In the Matrigel-assisted melanoma progression model, mda-7 expression decreases in early vertical growth phase primary human melanoma cells selected for autonomous or enhanced tumor formation in nude mice. Treatment of human melanomas with IFN-beta+MEZ, and to a lesser extent with MEZ, results in growth suppression and induced or enhanced mda-7 expression, Immunoprecipitation analyses using peptide-derived rabbit polyclonal antibodies detect increases in mda-7 protein, and a higher molecular weight protein of similar to 90 to 100 kDa, in MEZ and IFN-beta+MEZ treated H0-1 cells. mda-7 is a highly conserved gene with an homologous sequence in the genome of yeast. Transfection of mda-7 expression constructs into H0-1 and C8161 human melanoma cells reduces growth and inhibits colony formation. These results confirm that mda-7 has antiproliferative properties in human melanoma cells and in this context may contribute to terminal cell differentiation, The mda-7 gene may also function as a negative regulator of melanoma progression.	COLUMBIA UNIV COLL PHYS & SURG, COLUMBIA PRESBYTERIAN MED CTR, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, COLUMBIA PRESBYTERIAN MED CTR, DEPT UROL, NEW YORK, NY 10032 USA; IMCLONE SYST INC, DEPT IMMUNOL MONOCLONAL ANTIBODIES, NEW YORK, NY 10014 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Eli Lilly					NCI NIH HHS [CA35675] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Chellappan Srikumar P., 1994, Molecular and Cellular Differentiation, V2, P201; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; CLAUDIO PP, 1994, CANCER RES, V54, P5556; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DUIGOU GJ, 1991, ONCOGENE, V6, P1813; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIOVANELLA BC, 1976, J NATL CANCER I, V56, P1131, DOI 10.1093/jnci/56.6.1131; GRAHAM GM, 1991, CANCER IMMUNOL IMMUN, V32, P382, DOI 10.1007/BF01741333; GUARINI L, 1992, PIGM CELL RES, P123; GUARINI L, 1989, CANCER IMMUNOL IMMUN, V30, P262, DOI 10.1007/BF01744892; GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Herlyn M, 1990, Adv Cancer Res, V54, P213, DOI 10.1016/S0065-230X(08)60812-X; HERLYN M, 1990, CANCER METAST REV, V9, P101, DOI 10.1007/BF00046337; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1995, ONCOGENE, V11, P1179; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; JIANG HP, 1992, INT J ONCOL, V1, P227; JIMENEZ JJ, 1987, SCIENCE, V238, P1278, DOI 10.1126/science.3685979; Kerbel R S, 1990, Adv Cancer Res, V55, P87, DOI 10.1016/S0065-230X(08)60469-8; KOBAYASHI H, 1994, AM J PATHOL, V144, P776; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIN J, 1994, INT J ONCOL, V5, P5; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; MANCIANTI ML, 1988, J INVEST DERMATOL, V90, P134, DOI 10.1111/1523-1747.ep12462099; MELBER K, 1989, CANCER RES, V49, P3650; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOOSLEHNER K, 1991, MOL CELL BIOL, V11, P886, DOI 10.1128/MCB.11.2.886; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; OHARA O, 1989, P NATL ACAD SCI USA, V86, P5673, DOI 10.1073/pnas.86.15.5673; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REDDY PG, 1991, J NATL CANCER I, V83, P1307, DOI 10.1093/jnci/83.18.1307; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEN RQ, 1995, P NATL ACAD SCI USA, V92, P6778, DOI 10.1073/pnas.92.15.6778; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SU ZZ, 1991, MOL CARCINOGEN, V4, P231, DOI 10.1002/mc.2940040310; SU ZZ, 1993, CANCER RES, V53, P1929; TOKUNAGA K, 1987, CANCER RES, V47, P5616; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; WAXMAN S, 1988, STATUS DIFFERENTIATI, V1; WAXMAN S, 1991, STATUS DIFFERENTIATI, V2; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	71	450	557	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2477	2486						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545104				2022-12-25	WOS:A1995TP18800003
J	Lengye, E; Singh, B; Gum, R; Nerlov, C; Sabichi, A; Birrer, M; Boyd, D				Lengye, E; Singh, B; Gum, R; Nerlov, C; Sabichi, A; Birrer, M; Boyd, D			Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene	ONCOGENE			English	Article						urokinase; mos; MAPK; AP-1	PROTEIN-KINASE ACTIVITY; GENE-EXPRESSION; MAP KINASE; PHORBOL-ESTER; SARCOMA-VIRUS; C-JUN; TRANSFORMATION; PRODUCT; RAS; FOS	We undertook a study to determine if the serine-threonine kinase-encoding v-mos oncogene regulated the expression of the urokinase-type plasminogen activator. An expression vector encoding v-mos, but not a kinase-inactive mutant, stimulated urokinase promoter activity in CAT assays employing a squamous cell carcinoma cell line, The induction of urokinase promoter activity by v-mos was mediated, in part, via an increased AP-1 activity since (a) mutation of 2 AP-1 binding sites (at -1967 and -1885), or the co-expression of a transactivation domain-lacking c-jun mutant reduced the induction of the urokinase promoter by v-mos and (b) expression of v-mos increased the activity of a CAT reporter driven by three AP-1 tandem repeats, The stimulation of the urokinase promoter by v-mos was partially countered by co-expression of an ERK1/ERK2-inactivating phosphatase. Western blotting and zymographic analysis indicated that v-mos-transformed NM3T3 cells (MSV NIH-3T3) secreted more urokinase compared with NIH3T3 cells and this was associated with a higher level of activated ERK1 and ERK2, Expression of a catalytically-inactive MAPKK mutant reduced the activity of a urokinase promoter-driven CAT reporter in the MSV NIH-3T3 cells, In conclusion, the data herein indicate that urokinase expression is regulated by v-mos through a MAPKK-dependent signaling pathway.	MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG,HOUSTON,TX 77030; MD ANDERSON CANC CTR,DEPT MOLEC BIOL,HOUSTON,TX 77030; UNIV COPENHAGEN,INST MICROBIOL,COPENHAGEN,DENMARK; NIH,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Copenhagen; National Institutes of Health (NIH) - USA			Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ANDREASEN PA, 1990, ENDOCRINOLOGY, V126, P2567, DOI 10.1210/endo-126-5-2567; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BELL SM, 1990, J BIOL CHEM, V265, P1333; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; BROWN PH, 1993, ONCOGENE, V8, P877; CHAN JC, 1992, J BIOL CHEM, V267, P1099; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; KAMADA S, 1994, J BIOL CHEM, V269, P4565; KASAI S, 1985, J BIOL CHEM, V260, P2382; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LIOTTA LA, 1981, CANCER RES, V41, P4629; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; NAKAGAWA J, 1988, J BIOL CHEM, V263, P2460; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; NOVAK U, 1991, NUCLEIC ACIDS RES, V19, P3389, DOI 10.1093/nar/19.12.3389; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SALO T, 1982, INT J CANCER, V30, P669, DOI 10.1002/ijc.2910300520; SCHONTHAL A, 1990, New Biologist, V2, P143; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1992, MOL CARCINOGEN, V6, P182, DOI 10.1002/mc.2940060303; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; STACEY DW, 1991, ONCOGENE, V6, P2297; STRICKLAND S, 1976, CELL, V9, P231, DOI 10.1016/0092-8674(76)90114-8; TESTA JE, 1989, INT J CANCER, V43, P816, DOI 10.1002/ijc.2910430513; TOURAY M, 1991, ONCOGENE, V6, P211; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; VANBEVEREN C, 1981, NATURE, V289, P258, DOI 10.1038/289258a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x	53	18	18	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2639	2648						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545121				2022-12-25	WOS:A1995TP18800020
J	Taylor, ICA; Roy, S; Varmus, HE				Taylor, ICA; Roy, S; Varmus, HE			Overexpression of the Sky receptor tyrosine kinase at the cell surface or in the cytoplasm results in ligand-independent activation	ONCOGENE			English	Article						Sky receptor tyrosine kinase; dimerization; isoforms	PROTEIN; ONCOGENE	Most receptor tyrosine kinases are activated by dimerization induced by their cognate ligands, Protein S, an abundant serum protein previously shown to be a potent anticoagulation factor, has been proposed to be a ligand for the Sky tyrosine kinase (Stitt et al., 1995), Here we show that Sky, when expressed to high levels, is tyrosine phosphorylated even in the absence of a ligand, Furthermore, a version of Sky (termed Sky Delta SS) engineered to be overexpressed in the cytoplasm and thus in a ligand-free environment, can function as a dimeric tyrosine kinase, Sky Delta SS can transform RatB1a fibroblasts and thus retains all the properties of the full-length Sky kinase, These data suggest that Sky, when overexpressed either at the cell surface or in the cytoplasm, is competent to form dimers even in the absence of its ligand. We also demonstrate that an isoform of Sky, originally reported as Brt and here termed Sky Isoform I, resides in the cytoplasm, Therefore, the activities of Sky Delta SS we describe may reflect those of the naturally occurring Isoform I.	NCI,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BIESECKER LG, 1993, P NATL ACAD SCI USA, V90, P7044, DOI 10.1073/pnas.90.15.7044; BIESECKER LG, 1995, ONCOGENE, V10, P2239; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; CROSIER PS, 1994, GROWTH FACTORS, V11, P125, DOI 10.3109/08977199409001054; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599; DAI W, 1994, ONCOGENE, V9, P975; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GRECO A, 1992, ONCOGENE, V7, P237; LAI C, 1994, ONCOGENE, V9, P2567; MARK MR, 1994, J BIOL CHEM, V269, P10720; MARU Y, 1990, ONCOGENE, V5, P445; OHASHI K, 1994, ONCOGENE, V9, P699; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x	21	40	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2619	2626						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545119				2022-12-25	WOS:A1995TP18800018
J	Welter, JF; Eckert, RL				Welter, JF; Eckert, RL			Differential expression of the fos and jun family members c-fos, fosB, Fra-1, Fra-2, c-jun, junB and junD during human epidermal keratinocyte differentiation	ONCOGENE			English	Article						activator protein 1; AP-1; Fra-1; Fra-2; jun; fos; keratinocyte differentiation; transcription factor; epidermis	HUMAN PAPILLOMAVIRUS TYPE-18; HUMAN INVOLUCRIN GENE; PROTEIN-KINASE-C; TRANSGENIC MICE; TRANSCRIPTION FACTOR; NONSPECIFIC-BINDING; EPITHELIAL-CELLS; AP-1; PROTOONCOGENE; INDUCTION	Activator protein 1 (AP1) family proteins have been implicated in the regulation of genes expressed in the epidermis. However, no comprehensive analysis of the expression patterns of the known AP1 family proteins in the human epidermis or any other terminally differentiating tissue has been performed. In the present study we describe the localization of c-fos, fosB, Fra-1, Fra-2, c-jun, junB and junD in the normal human epidermis. Each is expressed in specific epidermal layers, c-fos is localized in the nuclei of the upper spinous and granular layer cells. FosB is present in the nuclei in all layers. Fra-1 is absent from the basal layer, but is present in all other layers. Fra-2 is detected in all layers, but staining intensity is increased in the upper spinous layer. c-jun staining is limited to the granular layer, while junB and junD are present in all layers. The differentiation-dependent pattern of expression of the AP1 family members suggest an important role for these proteins in specifying the temporal and spatial pattern of gene expression during keratinoctye differentiation.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL BIOPHYS, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT DERMATOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT REPROD BIOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT ONCOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University					NIAMS NIH HHS [AR41456, AR39750] Funding Source: Medline; NIDDK NIH HHS [DK07678] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041456, P30AR039750, R55AR041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM WC, 1991, MOL NEUROBIOL, V5, P297, DOI 10.1007/BF02935553; AMSTAD P, 1990, B CANCER, V77, P501; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, ANN NY ACAD SCI, V511, P117, DOI 10.1111/j.1749-6632.1987.tb36242.x; BASSETSEGUIN N, 1990, J INVEST DERMATOL, V94, P418, DOI 10.1111/1523-1747.ep12874493; BERNERD F, 1992, J INVEST DERMATOL, V98, P902, DOI 10.1111/1523-1747.ep12460344; Bernerd Francoise, 1993, Gene Expression, V3, P187; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; CARRASCO D, 1995, ONCOGENE, V10, P1069; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; COHEN D R, 1989, Critical Reviews in Oncogenesis, V1, P65; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; Curran T, 1988, ONCOGENE HDB, P307; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; FISHER C, 1991, DEVELOPMENT, V111, P253; GANDARILLAS A, 1995, IN PRESS ONCOGENE; GILLARDON F, 1994, ONCOGENE, V9, P3219; GILOH H, 1982, SCIENCE, V217, P1252, DOI 10.1126/science.7112126; GRUBE D, 1980, HISTOCHEMISTRY, V66, P149, DOI 10.1007/BF00494642; GRUBE D, 1981, ACTA HISTOCHEM, P277; HUFF CA, 1993, J BIOL CHEM, V268, P377; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KHARBANDA S, 1993, BIOCHEM PHARMACOL, V45, P675, DOI 10.1016/0006-2952(93)90142-J; LU B, 1994, J BIOL CHEM, V269, P7443; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MURTHY S, 1993, J STRUCT BIOL, V111, P68, DOI 10.1006/jsbi.1993.1037; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RODDEY PK, 1994, J INVEST DERMATOL, V102, P296, DOI 10.1111/1523-1747.ep12371785; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; RUCK P, 1990, J HISTOCHEM CYTOCHEM, V38, P859, DOI 10.1177/38.6.2335741; RYSECK RP, 1991, ONCOGENE, V6, P533; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; SHAH G, 1993, CANCER RES, V53, P38; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; STREEFKERK JG, 1972, J HISTOCHEM CYTOCHEM, V20, P829, DOI 10.1177/20.10.829; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; YAFFE MB, 1993, J INVEST DERMATOL, V100, P3, DOI 10.1111/1523-1747.ep12349857; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858	54	117	120	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2681	2687						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545126				2022-12-25	WOS:A1995TP18800025
J	WILLIGER, BT; REICH, R; NEEMAN, M; BERCOVICI, T; LISCOVITCH, M				WILLIGER, BT; REICH, R; NEEMAN, M; BERCOVICI, T; LISCOVITCH, M			RELEASE OF GELATINASE-A (MATRIX METALLOPROTEINASE-2) INDUCED BY PHOTOLYSIS OF CAGED PHOSPHATIDIC-ACID IN HT-1080 METASTATIC FIBROSARCOMA CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHOLIPASE-D; BASEMENT-MEMBRANE; HUMAN NEUTROPHILS; IV COLLAGENASE; ACTIVATION; TUMOR; LAMININ; SIGNAL	Phosphatidic acid (PA) is a putative novel messenger in signal transduction and membrane traffic. We have synthesized a photolyzable derivative of PA, termed caged PA (cPA), which may be utilized as a new tool in studies of PA-mediated cellular events, 1-(2-Nitrophenyl)diazoethane, synthesized from 2-nitroacetophenone, was reacted with dipalmitoyl-PA to yield a 1-(2-nitrophenyl)ethyl ester of Pk Photolysis of the compound by ultraviolet Light resulted in the formation of phosphatidic acid, The structure of the compound and of its photolytic products was verified by NMR spectroscopy, The utility of cPA was examined in HT 1080 metastatic fibrosarcoma cells, in which the formation of PA by phospholipase D was implicated in laminin-induced release of gelatinase A (matrix metalloproteinase 2 (MMP-2)), The uptake of cPA by BT 1080 cells reached a plateau after 120 min of incubation, Ultraviolet illumination of cPA-loaded cells for 5 s resulted in photolysis of 1.8% of the cell-incorporated cPA. The photolysis of cPA caused a 2-fold elevation in the release of MMP-2 to the medium, whereas nonphotolyzed cPA caused no change in MMP-2 release, Moreover, the effect of cPA photolysis was significantly higher than that obtained with extracellularly introduced Pk Thus, the effect of laminin on MMP-2 secretion can be mimicked by photolysis of cPA, suggesting a pivotal role for phospholipase D in laminin-induced cancer cell invasiveness and metastasis, These results indicate that cPA could serve as a unique tool for studying the cellular roles of PA.	WEIZMANN INST SCI,DEPT BIOL REGULAT,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV JERUSALEM,DEPT PHARMACOL,IL-91120 JERUSALEM,ISRAEL; WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Hebrew University of Jerusalem; Weizmann Institute of Science			Neeman, Michal/A-8264-2008; Neeman, Michal/AAH-9602-2019	Neeman, Michal/0000-0002-6296-816X; Neeman, Michal/0000-0002-6296-816X				BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BAULDRY SA, 1991, J BIOL CHEM, V266, P4173; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; KASZKIN M, 1992, BIOCHEM J, V287, P51, DOI 10.1042/bj2870051; LIOTTA LA, 1979, P NATL ACAD SCI USA, V76, P2268, DOI 10.1073/pnas.76.5.2268; LIOTTA LA, 1981, BIOCHEMISTRY-US, V20, P100, DOI 10.1021/bi00504a017; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; PATTON WF, 1991, ANAL BIOCHEM, V196, P31, DOI 10.1016/0003-2697(91)90113-8; PREISS J, 1986, J BIOL CHEM, V261, P8597; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; SANG QX, 1991, BIOL REPROD, V45, P387, DOI 10.1095/biolreprod45.3.387; SVANBORG A, 1961, ACTA MED SCAND, V169, P43; TERRANOVA VP, 1986, JNCI-J NATL CANCER I, V77, P311; TOU JS, 1991, BIOCHEM J, V280, P625, DOI 10.1042/bj2800625; TURPEENNIEMIHUJ.T, 1986, J BIOL CHEM, V261, P1883; WALKER JW, 1987, NATURE, V327, P249, DOI 10.1038/327249a0; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036	24	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29656	29659						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530350				2022-12-25	WOS:A1995TK38000010
J	KATZAV, S				KATZAV, S			SINGLE-POINT MUTATIONS IN THE SH2 DOMAIN IMPAIR THE TRANSFORMING POTENTIAL OF VAV AND FAIL TO ACTIVATE PROTO-VAV	ONCOGENE			English	Article							CYTOPLASMIC SIGNALING PROTEINS; TYROSINE KINASE; V-FPS; GENE-PRODUCT; SRC GENE; PROTOONCOGENE; MUTAGENESIS; DELETIONS; P60C-SRC; CELLS	The importance of an intact Src Homology 2 (SH2) domain for transformation by members of the tyrosine kinase family, including v-src, c-src, c-abl, fps and fyn is well documented. To determine the role of the SH2 domain in transformation by a protein which is not a member of this family, we employed site directed mutagenesis to change four highly conserved residues in the SH2 domain of the vav oncogene and the vav proto-oncogene (proto-vav). Proto-vav encodes a protein that contains one SH2 domain and two Src Homology 3 (SH3) domains, in addition to a number of other motifs usually found in transcriptional factors and guanine nucleotide exchange factors. Substitution of arginine 629 to glycine (R629G) and arginine 647 to leucine (R647L) in vav did not impair its transforming potential in NIH3T3 fibroblasts. By contrast, substitutions of tryptophan 622 to arginine (W622R) and glycine 642 to valine (G642V) in the vav SH2, greatly reduced its transforming potential. Similar point mutations introduced in the SH2 domain of proto-vav did not activate the transforming potential of the normal gene. Interestingly, although all the vav SH2 mutant proteins were constitutively phosphorylated on tyrosine when expressed in NIH3T3 cells, they fail to bind to a phosphorylated epidermal growth factor receptor (EGFR), regardless of their transforming potential.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BOGUSKI MS, 1992, NATURE, V358, P113, DOI 10.1038/358113a0; BOOKER GW, 1992, NATURE, V358, P685; BUESTLO XR, 1992, SCIENCE, V256, P1196; BUESTLO XR, 1992, NATURE, V356, P69; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GALLAND F, 1992, ONCOGENE, V7, P585; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8952; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1988, ONCOGENE, V2, P305; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KATZAV S, 1992, BRIT J HAEMATOL, V81, P141, DOI 10.1111/j.1365-2141.1992.tb08198.x; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PARSONS JT, 1989, CURR TOP MICROBIOL I, V147, P97; ROSENBERG NE, 1988, ADV VIRUS RES, V54, P39; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SEMBA K, 1990, MOL CELL BIOL, V10, P3095, DOI 10.1128/MCB.10.6.3095; ULRICH A, 1990, CELL, V61, P203; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989	40	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1757	1763						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510922				2022-12-25	WOS:A1993LG68200006
J	DRAKE, SK; BOURRET, RB; LUCK, LA; SIMON, MI; FALKE, JJ				DRAKE, SK; BOURRET, RB; LUCK, LA; SIMON, MI; FALKE, JJ			ACTIVATION OF THE PHOSPHOSIGNALING PROTEIN CHEY .1. ANALYSIS OF THE PHOSPHORYLATED CONFORMATION BY F-19 NMR AND PROTEIN ENGINEERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; GALACTOSE CHEMOSENSORY RECEPTOR; D-LACTATE DEHYDROGENASE; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; SIGNAL TRANSDUCTION; CRYSTAL-STRUCTURE; RESPONSE REGULATOR; SALMONELLA-TYPHIMURIUM; CONSERVED ASPARTATE	CheY, the 14-kDa response regulator protein of the Escherichia coli chemotaxis pathway, is activated by phosphorylation of Asp57. In order to probe the structural changes associated with activation, an approach which combines F-19 NMR, protein engineering, and the known crystal structure of one conformer has been utilized. This first of two papers examines the effects of Mg(II) binding and phosphorylation on the conformation of CheY. The molecule was selectively labeled at its six phenylalanine positions by incorporation of 4-fluorophenylalanine, which yielded no significant effect on activity. One of these F-19 probe positions monitored the vicinity of Lys109, which forms a salt bridge to Asp57 in the apoprotein and has been proposed to act as a structural ''switch'' in activation. F-19 NMR chemical shift studies of the labeled protein revealed that the binding of the cofactor Mg(II) triggered local structural changes in the activation site, but did not perturb the probe of the Lys109 region. The structural changes associated with phosphorylation were then examined, utilizing acetyl phosphate to chemically generate phospho-CheY during NMR acquisition. Phosphorylation triggered a long-range conformational change extending from the activation site to a cluster of 4 phenylalanine residues at the other end of the molecule. However, phosphorylation did not perturb the probe of Lys109. The observed phosphorylated conformer is proposed to be the first step in the activation of CheY; later steps appear to perturb Lys109, as evidenced in the following paper. Together these results may give insight into the activation of other prokaryotic response regulators.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of Colorado System; University of Colorado Boulder; California Institute of Technology			Bourret, Robert/X-3606-2019	Bourret, Robert/0000-0002-6666-9220	NIAID NIH HHS [AI07798, R01 AI019296, AI19296] Funding Source: Medline; NIGMS NIH HHS [R01 GM040731-12, R01 GM040731, GM40731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; AUSPURGER J, 1993, J MAGN RESON, V100, P342; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1993, J BIOL CHEM, V268, P13089; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; GAMMON KL, 1972, J AM CHEM SOC, V94, P4573, DOI 10.1021/ja00768a027; GREGORY DH, 1991, BIOPOLYMERS, V31, P845, DOI 10.1002/bip.360310705; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1991, METHOD ENZYMOL, V200, P188; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; KAR L, 1992, BIOCHEM J, V287, P521, DOI 10.1042/bj2870521; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KIM HW, 1990, FEBS LETT, V272, P34, DOI 10.1016/0014-5793(90)80442-L; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; LEBIODA L, 1991, BIOCHEMISTRY-US, V30, P2817, DOI 10.1021/bi00225a012; LI E, 1991, J BIOL CHEM, V266, P3622; LI E, 1990, J BIOL CHEM, V265, P11549; LU P, 1976, P NATL ACAD SCI USA, V73, P3471, DOI 10.1073/pnas.73.10.3471; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4257, DOI 10.1021/bi00231a022; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P6484, DOI 10.1021/bi00240a019; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; LUNDQVIST T, 1991, BIOCHEMISTRY-US, V30, P904, DOI 10.1021/bi00218a004; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NEEDHAM JV, 1993, BIOCHEMISTRY-US, V32, P3363, DOI 10.1021/bi00064a020; Ninfa A J, 1991, Genet Eng (N Y), V13, P39; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Pauling L., 1960, NATURE CHEM BOND, V3rd; PEERSEN OB, 1990, BIOCHEMISTRY-US, V29, P3256, DOI 10.1021/bi00465a017; POST JFM, 1984, J MOL BIOL, V179, P729, DOI 10.1016/0022-2836(84)90164-5; PRATT EA, 1975, BIOCHEMISTRY-US, V14, P3035, DOI 10.1021/bi00684a037; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; ROBERTSON DE, 1977, BIOCHEMISTRY-US, V16, P1443, DOI 10.1021/bi00626a032; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; RULE GS, 1987, BIOCHEMISTRY-US, V26, P549, DOI 10.1021/bi00376a029; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SIXL F, 1990, BIOCHEM J, V266, P545, DOI 10.1042/bj2660545; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; STOCK JB, 1992, J BIOL CHEM, V267, P19753; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; SYKES BD, 1974, P NATL ACAD SCI USA, V71, P469, DOI 10.1073/pnas.71.2.469; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WACKS DB, 1985, J BIOL CHEM, V260, P1651; WESTHEAD EW, 1961, BIOCHIM BIOPHYS ACTA, V54, P145, DOI 10.1016/0006-3002(61)90947-7; WILSON ML, 1985, BIOCHEMISTRY-US, V24, P1920, DOI 10.1021/bi00329a018; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6	62	66	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13081	13088						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514749				2022-12-25	WOS:A1993LH55300014
J	JAKUS, J; WOLFF, EC; PARK, MH; FOLK, JE				JAKUS, J; WOLFF, EC; PARK, MH; FOLK, JE			FEATURES OF THE SPERMIDINE-BINDING SITE OF DEOXYHYPUSINE SYNTHASE AS DERIVED FROM INHIBITION STUDIES - EFFECTIVE INHIBITION BY BIS-GUANYLATED AND MONO-GUANYLATED DIAMINES AND POLYAMINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-4D; PROTEIN-SYNTHESIS; HYPUSINE FORMATION; AMINO-ACID; FACTOR 4D; IDENTIFICATION; PRECURSOR; SUBSTRATE; CHEMISTRY; SECONDARY	Several types of basic compounds structurally related to spermidine, one of the substrates for deoxyhypusine synthase, were tested as inhibitors of this enzyme. The results indicate that inhibitory compounds associate with the enzyme at the site of spermidine binding and must possess two charged primary amino or guanidino groups, or one of each. The efficiency of inhibition is related to the maximum possible distance between the primary amino groups and is adversely affected by substitutions on the secondary amino group or in the carbon chains of polyamines. The mono-guanyl derivatives are much more effective inhibitors than the parent amines or their bis-guanylated counterparts, N1-guanyl-1,7-diaminoheptane being the most effective compound with a K(i) value of about 10 nM. Based on these observations we have proposed a model for the spermidine-binding site of deoxyhypusine synthase. Studies with Chinese hamster ovary cells reveal a direct correlation between prevention of hypusine formation by several guanyldiamines and their in vitro inhibition of deoxyhypusine synthase. This evidence for disruption of the initial step in the post-translational maturation of eukaryotic initiation factor 5A provides a basis for the potential control of protein biosynthesis and cell proliferation.			JAKUS, J (corresponding author), NIDR, CELLULAR DEV & ONCOL LAB, BLDG 30, RM 211, BETHESDA, MD 20892 USA.							ABBRUZZESE A, 1989, BIOCHIM BIOPHYS ACTA, V997, P248, DOI 10.1016/0167-4838(89)90195-7; BAILLON JG, 1988, EUR J BIOCHEM, V176, P237, DOI 10.1111/j.1432-1033.1988.tb14274.x; BERGERON RJ, 1982, SYNTHESIS-STUTTGART, P689; BROWN HC, 1973, J ORG CHEM, V38, P912, DOI 10.1021/jo00945a015; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; CHEN KY, 1983, BIOCHIM BIOPHYS ACTA, V756, P395, DOI 10.1016/0304-4165(83)90350-1; CLARKE DD, 1959, ARCH BIOCHEM BIOPHYS, V79, P338, DOI 10.1016/0003-9861(59)90413-8; COOPER HL, 1983, P NATL ACAD SCI-BIOL, V80, P1854, DOI 10.1073/pnas.80.7.1854; COOPER HL, 1982, CELL, V29, P791, DOI 10.1016/0092-8674(82)90441-X; DIETRICH B, 1979, HELV CHIM ACTA, V62, P2763, DOI 10.1002/hlca.19790620827; ELORANTA TO, 1990, J BIOCHEM-TOKYO, V108, P593, DOI 10.1093/oxfordjournals.jbchem.a123248; GERNER EW, 1986, BIOCHEM J, V239, P379, DOI 10.1042/bj2390379; GORDON ED, 1987, J BIOL CHEM, V262, P16590; KHOMUTOV AR, 1989, BIOORG KHIM+, V15, P698; KHOMUTOV RM, 1963, CHEM BIOL ASPECTS PY, P313; MAKHATADZE GI, 1992, J MOL BIOL, V226, P491, DOI 10.1016/0022-2836(92)90963-K; MURPHEY RJ, 1987, J BIOL CHEM, V262, P15033; NAGARAJAN S, 1985, J ORG CHEM, V50, P5735, DOI 10.1021/jo00350a059; PARK MH, 1983, METHOD ENZYMOL, V94, P458; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; PARK MH, 1988, J BIOL CHEM, V263, P15264; PARK MH, 1991, J BIOL CHEM, V266, P7988; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; ROBIN Y, 1967, COMP BIOCHEM PHYSIOL, V22, P787, DOI 10.1016/0010-406X(67)90771-2; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SMITH TA, 1983, METHOD ENZYMOL, V94, P311; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; TAYLOR GR, 1972, Patent No. 1294443; TORRELIO BM, 1984, EXP CELL RES, V154, P454, DOI 10.1016/0014-4827(84)90169-1; WALSH C, 1983, ADV ENZYMOL RAMB, V55, P197; WOLFF EC, 1990, J BIOL CHEM, V265, P4793	33	158	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13151	13159						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514754				2022-12-25	WOS:A1993LH55300023
J	KARARA, A; MAKITA, K; JACOBSON, HR; FALCK, JR; GUENGERICH, FP; DUBOIS, RN; CAPDEVILA, JH				KARARA, A; MAKITA, K; JACOBSON, HR; FALCK, JR; GUENGERICH, FP; DUBOIS, RN; CAPDEVILA, JH			MOLECULAR-CLONING, EXPRESSION, AND ENZYMATIC CHARACTERIZATION OF THE RAT-KIDNEY CYTOCHROME-P-450 ARACHIDONIC-ACID EPOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; RABBIT KIDNEY; METABOLISM; BIOSYNTHESIS; INHIBITORS; OXYGENASE; EPOXIDES; SEQUENCE	A cDNA containing an open reading frame coding for the rat kidney cytochrome P-450 arachidonic acid epoxygenase was isolated from a male rat kidney cDNA library. Sequence analysis showed that with the exception of 11 nucleotides, this cDNA is identical with the published sequence for rat liver cytochrome 2C23 and encodes a polypeptide of 494 amino acids. Nucleic acid blot hybridization indicated that the levels of expression of the corresponding mRNA are high in rat kidney and liver and are undetectable in brain and heart. The cDNA coding region was cloned into a pCMV2 vector and expressed in COS-1 cells. The recombinant microsomal protein catalyzed the NADPH-dependent metabolism of arachidonic acid to a mixture of 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acids as the only oxygenation products. The enantiofacial selectivity of the recombinant protein was nearly identical with that reported for the kidney microsomal enzyme and generated 8(R),9(S)-, 11(R),12(S)-, and 14(S),15(R) with optical purities of 95, 85, and 75%, respectively. On the basis of mRNA abundance and the close similarities between the regio- and stereochemical selectivity of the recombinant and kidney microsomal proteins, we concluded that cytochrome P-450 2C23 is the predominant enzyme isoform responsible for arachidonic acid epoxidation in the rat kidney.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, MED CTR N S-3223, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, CELL BIOL, NASHVILLE, TN 37232 USA; SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Southwestern Medical Center Dallas			DuBois, Raymond N./AAX-8869-2020	Falck, John/0000-0002-9219-7845	NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44353] Funding Source: Medline; NIDDK NIH HHS [DK 38226] Funding Source: Medline; NIEHS NIH HHS [ES 00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; CHACOS N, 1983, ARCH BIOCHEM BIOPHYS, V223, P639, DOI 10.1016/0003-9861(83)90628-8; COOK EA, 1990, NUCLEIC ACIDS RES, V18, P7156, DOI 10.1093/nar/18.23.7156; DEES JH, 1982, CANCER RES, V42, P1423; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; ENDOU H, 1983, JPN J PHARMACOL, V33, P423, DOI 10.1254/jjp.33.423; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; IWAI N, 1991, HYPERTENSION, V17, P161, DOI 10.1161/01.HYP.17.2.161; JACOBSON HR, 1984, PROSTAGLANDINS MEMBR, P311; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KHANI SC, 1988, BIOCHEM BIOPH RES CO, V150, P10, DOI 10.1016/0006-291X(88)90479-2; LAETHEM RM, 1992, J BIOL CHEM, V267, P5552; MORRISON AR, 1981, P NATL ACAD SCI-BIOL, V78, P7375, DOI 10.1073/pnas.78.12.7375; MORRISON AR, 1986, AM J MED, V80, P3, DOI 10.1016/0002-9343(86)90927-7; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OLIW EH, 1981, BIOCHIM BIOPHYS ACTA, V666, P327, DOI 10.1016/0005-2760(81)90291-5; OMATA K, 1992, AM J PHYSIOL, V262, pF591, DOI 10.1152/ajprenal.1992.262.4.F591; PRESTWICH GD, 1985, ARCH BIOCHEM BIOPHYS, V242, P11, DOI 10.1016/0003-9861(85)90473-4; ROMERO MF, 1991, ADV PROSTAG THROMB L, V21, P205; ROMKES M, 1991, BIOCHEMISTRY-US, V30, P3247, DOI 10.1021/bi00227a012; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pF464, DOI 10.1152/ajprenal.1987.253.3.F464; SHIMADA T, 1986, J BIOL CHEM, V261, P909; Waterman M.R, 1991, METHOD ENZYMOL, V206, P100, DOI 10.1016/0076-6879(91)06081-d; WAXMAN DJ, 1991, METHODS ENZYMOL, V206, P249	32	96	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13565	13570						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514789				2022-12-25	WOS:A1993LH55300078
J	SAUTER, A; RUDIN, M				SAUTER, A; RUDIN, M			DETERMINATION OF CREATINE-KINASE KINETIC-PARAMETERS IN RAT-BRAIN BY NMR MAGNETIZATION-TRANSFER - CORRELATION WITH BRAIN-FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE SPECTROSCOPY; SATURATION TRANSFER; ATP SYNTHESIS; LIVING RAT; P-31; INVIVO; ENERGY; MUSCLE; HEART; CONSUMPTION	The pseudo first-order rate constant k(f) of the creatine kinase (CK) forward reaction as well as the CK forward flux F(CK, f) have been shown to correlate better with cardiac performance than the steady-state levels of ATP and PCr (Bittl, J. A., and Ingwall, J. S. (1985) J. Biol. Chem. 260, 3512-3517). In order to elucidate the relationship between the CK kinetic parameters and brain activity, we have determined, using the noninvasive NMR technique of magnetization transfer, k(f) and F(CK, f) in rats, in which brain activity was experimentally varied by administration of either thiopental sodium or bicuculline to decrease or increase electroencephalogram EEG) intensity, respectively. The steady-state levels of ATP and PCr, as well as the accumulation of deoxyglucose 6-phosphate (DG-6P) in brain following intraperitoneal administration of deoxyglucose, were determined simultaneously by the NMR technique, whereas the cortical EEG was recorded in a separate experiment. The EEG intensity (range, 1-20 Hz), taken as a measure for brain performance, as well as the amount of DG-6P formed in brain, reflecting the synthesis rate of high energy phosphates (ATP and PCr), linearly correlated with k(f). Despite large changes in both EEG intensity (50-250%) and k(f) (0.12-0.69 s-1) between thiopental sodium- and bicuculline-treated rats, the ATP levels remained constant. whereas the PCr levels decreased with high EEG activity. In contrast to the expectation based on model calculations of CK kinetics, the PCr levels did not increase above control values at reduced EEG intensity (50% of controls). At EEG intensities exceeding control values (bicuculline-treated rats) F(CK, f) increased as predicted by CK equilibrium. In conclusion, we have shown that in the rat brain, like in the heart, the CK forward rate constant k(f), in contrast to ATP and PCr levels, is a sensitive reliable indicator of both increased and reduced function.			SAUTER, A (corresponding author), SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND.		Rudin, Markus/F-2417-2010					ALGER JR, 1984, Q REV BIOPHYS, V17, P83, DOI 10.1017/S0033583500005266; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BITTL JA, 1985, J BIOL CHEM, V260, P3512; BITTL JA, 1987, BIOCHEMISTRY-US, V26, P6083, DOI 10.1021/bi00393a021; BITTL JA, 1987, J CLIN INVEST, V79, P1852, DOI 10.1172/JCI113027; BITTL JA, 1986, CIRC RES, V58, P378, DOI 10.1161/01.RES.58.3.378; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; DEGANI H, 1987, MAGNET RESON MED, V5, P1, DOI 10.1002/mrm.1910050102; DEUEL RK, 1985, SCIENCE, V228, P1329, DOI 10.1126/science.4001946; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; EVELHOCH JL, 1985, MAGNET RESON MED, V2, P410, DOI 10.1002/mrm.1910020409; FORSEN S, 1963, J CHEM PHYS, V39, P2892, DOI 10.1063/1.1734121; HOULT DI, 1974, NATURE, V252, P285, DOI 10.1038/252285a0; KINGSLEYHICKMAN PB, 1987, BIOCHEMISTRY-US, V26, P7501, DOI 10.1021/bi00397a045; KOGA K, 1988, BIOCHEM BIOPH RES CO, V157, P1258, DOI 10.1016/S0006-291X(88)81010-6; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MORRIS GA, 1978, J MAGN RESON, V29, P433, DOI 10.1016/0022-2364(78)90003-3; MORRISON JF, 1966, J BIOL CHEM, V241, P673; PETROFF OAC, 1984, ANN NEUROL, V16, P169, DOI 10.1002/ana.410160203; PRICHARD JW, 1983, P NATL ACAD SCI-BIOL, V80, P2748, DOI 10.1073/pnas.80.9.2748; RUDIN M, 1989, J PHARMACOL EXP THER, V251, P700; RUDIN M, 1992, NMR BASIC PRINCIPLES, V27, P257; SAUTER A, 1987, MAGNET RESON MED, V4, P1, DOI 10.1002/mrm.1910040102; SHOUBRIDGE EA, 1982, FEBS LETT, V140, P288, DOI 10.1016/0014-5793(82)80916-2; Siesjo B.K., 1978, BRAIN ENERGY METABOL; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Taylor D J, 1983, Mol Biol Med, V1, P77	27	92	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13166	13171						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514755				2022-12-25	WOS:A1993LH55300025
J	UHLER, MD				UHLER, MD			CLONING AND EXPRESSION OF A NOVEL CYCLIC GMP-DEPENDENT PROTEIN-KINASE FROM MOUSE-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; 2 ISOFORMS; PHOSPHORYLATION; INHIBITOR; ISOZYME; CDNA; RNA; RAT	Synthetic oligonucleotides were used to amplify mouse brain cDNA sequences homologous to conserved regions of known cGMP-dependent protein kinases, and two classes of products were identified. The first class (CGKI) of amplification products contained approximately 1.0 kilobase (kb) of DNA sequence between the oligonucleotide primers, and this sequence showed a high degree of homology (90% identity) with the known bovine and human type I cDNA sequences for cGMP-dependent protein kinase. The second class (CGKII) of amplification products contained approximately 1.1 kb of DNA sequence between the oligonucleotide primers, and this sequence showed a much lower homology (65% identity) with the bovine and human type I cDNA sequences. Northern blot analysis showed that CGKI transcripts of 8.5 kb were abundant in brain and lung, whereas a 7-kb transcript could be detected in testis. CGKII transcripts of 6 kb were also abundant in brain and lung but could be detected at lower levels in kidney. The CGKII amplification product was used to screen a mouse brain cDNA library, and four overlapping cDNA clones were isolated which comprised the entire CGKII coding region. The predicted CGKII protein consists of 761 amino acids and has a molecular mass of 87 kDa. The CGKII protein shows highest homology to the catalytic (66% amino acid identity) and regulatory domains (45% identity) of bovine and human CGKI. Little homology is observed at the amino terminus or in the region linking the regulatory and catalytic domains. An expression vector for mouse CGKII was constructed and transfected into COS-1 cells where it directed the expression of a protein kinase which was activated by cGMP with an apparent K(a) of 300 nM cGMP.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	UHLER, MD (corresponding author), UNIV MICHIGAN, MENTAL HLTH RES INST, 205 ZINA PITCHER PL, ANN ARBOR, MI 48109 USA.				NIGMS NIH HHS [GM 38788] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038788, R29GM038788] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEEBE SJ, 1986, ENZYMES, V17, P43; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTIS BM, 1985, P NATL ACAD SCI USA, V82, P2528, DOI 10.1073/pnas.82.8.2528; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; GLASS DB, 1982, J BIOL CHEM, V257, P1196; HOFMANN F, 1992, BIOCHIM BIOPHYS ACTA, V1135, P51, DOI 10.1016/0167-4889(92)90165-8; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; KALDERON D, 1989, J BIOL CHEM, V264, P10738; Krebs EG, 1986, ENZYMES, V17, P3, DOI 10.1016/S1874-6047(08)60426-6; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; OLSEN SR, 1991, MOL ENDOCRINOL, V5, P1246, DOI 10.1210/mend-5-9-1246; OLSEN SR, 1991, J BIOL CHEM, V266, P11158; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WOLFE L, 1989, J BIOL CHEM, V264, P7734	20	125	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13586	13591						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514791				2022-12-25	WOS:A1993LH55300081
J	ULLU, E; TSCHUDI, C				ULLU, E; TSCHUDI, C			2'-O-METHYL RNA OLIGONUCLEOTIDES IDENTIFY 2 FUNCTIONAL ELEMENTS IN THE TRYPANOSOME SPLICED LEADER RIBONUCLEOPROTEIN PARTICLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; 5' END; PROTEIN-COMPONENTS; C-ELEGANS; BRUCEI; U2; TRANSCRIPTION; SEQUENCES; SYSTEM; SITE	Using permeable trypanosomes as an in vivo model system for trans-splicing, we have searched for functional elements in the Trypanosoma brucei spliced leader (SL) RNA by masking various regions of the molecule with short antisense 2'-O-methyl RNA oligomers. Initial probing of the structure of newly synthesized SL RNA by deoxyoligonucleotide-directed ribonuclease (RNase) H cleavage revealed three accessible regions: the 5' end, sequences downstream of the 5' splice site, and a putative single-stranded sequence between stem-loops II and III, which is thought to be analogous to the mammalian Sm-binding site of U small nuclear RNAs. Using antisense 2'-O-methyl RNA oligomers, two functional elements of the SL RNA became apparent. Masking of positions 1-18 inhibited modification of the cap 4 structure of newly synthesized SL RNA and, thereby, blocked utilization of the SL RNA in trans-splicing. In addition, nucleotides +1 to +4 relative to the 5' splice site, which include the invariant GU dinucleotide were accessible to oligomer binding in the SL ribonucleoprotein particle, and their blockade resulted in complete inhibition of trans-splicing. In contrast, RNA oligomer binding to the single-stranded region between stem-loop II and III of the SL RNA had no detectable effect on trans-splicing activity of the SL RNA.	YALE UNIV, SCH MED, YALE MACARTHUR CTR MOLEC PARASITOL, DEPT INTERNAL MED, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University; Yale University					NIAID NIH HHS [AI 28798] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028798] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANGS JD, 1992, J BIOL CHEM, V267, P9805; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOOTHROYD JC, 1982, GENE, V20, P281, DOI 10.1016/0378-1119(82)90046-4; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; DELANGE T, 1983, CELL, V34, P891, DOI 10.1016/0092-8674(83)90546-9; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LECUYER KA, 1993, IN PRESS BIOCHEMISTR; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MARONEY PA, 1990, EMBO J, V9, P3667, DOI 10.1002/j.1460-2075.1990.tb07578.x; MARONEY PA, 1990, P NATL ACAD SCI USA, V87, P709, DOI 10.1073/pnas.87.2.709; MAYEDA A, 1990, J BIOCHEM-TOKYO, V108, P399, DOI 10.1093/oxfordjournals.jbchem.a123213; MCNALLY KP, 1992, MOL CELL BIOL, V12, P4844, DOI 10.1128/MCB.12.11.4844; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; TSCHUDI C, 1986, NUCLEIC ACIDS RES, V14, P8893, DOI 10.1093/nar/14.22.8893; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; ULLU E, 1990, NUCLEIC ACIDS RES, V18, P3319, DOI 10.1093/nar/18.11.3319; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	31	14	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13068	13073						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514747				2022-12-25	WOS:A1993LH55300012
J	Bock, PE; Day, DE; Verhamme, IMA; Bernardo, MM; Olson, ST; Shore, JD				Bock, PE; Day, DE; Verhamme, IMA; Bernardo, MM; Olson, ST; Shore, JD			Analogs of human plasminogen that are labeled with fluorescence probes at the catalytic site of the zymogen - Preparation, characterization, and interaction with streptokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE CHLOROMETHYL KETONES; BLOOD-COAGULATION PROTEINASES; ACTIVATOR SCU-PA; GLU-PLASMINOGEN; SERINE PROTEASES; LYS-PLASMINOGEN; GLUTAMIC-ACID; AFFINITY CHROMATOGRAPHY; CONFORMATIONAL CHANGE; CLEAVAGE PRODUCTS	Fluorescent analogs of the proteinase zymogen, plas minogen (Pg), which are specifically inactivated and labeled at the catalytic site have been prepared and characterized as probes of the mechanisms of Pg activation. The active site induced non-proteolytically in Pg by streptokinase (SK) was inactivated stoichiometrically with the thioester peptide chloromethyl ketone, N-alpha-[(acetylthio)acetyl]-(D-Phe)-Phe-Arg-CH2Cl; the thiol group generated subsequently on the incorporated inhibitor with NH2OH was quantitatively labeled with the fluorescence probe, 2-((4'-iodoacetamido) anilino)naphthalene-6-sulfonic acid; and the labeled Pg was separated from SK. Cleavage of labeled [Glu]Pg(1) by urokinase-type plasminogen activator (uPA) was accompanied by a fluorescence enhancement (Delta F-max/F-o) of 2.0, and formation of 1% plasmin (Pm) activity. Comparison of labeled and native [Glu]Pg(1) as uPA substrates showed that activation of labeled [Glu]Pg(1) generated [Glu]Pm-1 as the major product, while native [Glu]Pg(1) was activated at a faster rate and produced [Lys]Pm-1 because of concurrent proteolysis by plasmin, When a mixture of labeled and native Pg was activated, to include plasmin-feedback reactions, the zymogens were activated at equivalent rates. The lack of potential proteolytic activity of the Pg derivatives allowed their interactions with SK to be studied under equilibrium binding conditions. SK bound to labeled [Glu]Pg(1) and [Lys]Pg(1) with dissociation constants of 590 +/- 110 and 11 +/- 7 nM, and fluorescence enhancements of 3.1 +/- 0.1 and 1.6 +/- 0.1, respectively. Characterization of the interaction of SK with native [Glu]Pg(1) by the use of labeled [Glu]Pg(1) as a probe indicated a similar to 6-fold higher affinity of SK for the native Pg zymogen compared to the labeled Pg analog. Saturating levels of epsilon-aminocaproic acid reduced the affinity of SH for labeled [Glu]Pg(1) by similar to 2-fold and lowered the flu orescence enhancement to 1.8 +/- 0.1, whereas the affinity of SK for labeled [Lys]Pg(1) was reduced by similar to 98-fold with little effect on the enhancement. These results demonstrate that occupation of lysine binding sites modulates the affinity of SK for Pg and the changes in the environment of the catalytic site associated with SK-induced conformational activation. Together, these studies show that the labeled Pg derivatives behave as analogs of native Pg which report functionally significant changes in the environment of the catalytic site of the zymogen.	HENRY FORD HOSP,DIV BIOCHEM RES,DETROIT,MI 48202; UNIV ILLINOIS,CTR MOLEC BIOL ORAL DIS,CHICAGO,IL 60612	Henry Ford Health System; Henry Ford Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Bock, PE (corresponding author), VANDERBILT UNIV,SCH MED,DEPT PATHOL,C-3321 MED CTR N,NASHVILLE,TN 37232, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045930] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45930, HL02832] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJAJ SP, 1977, J BIOL CHEM, V252, P492; BOCK PE, 1993, METHOD ENZYMOL, V222, P478; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BOCK PE, 1989, ARCH BIOCHEM BIOPHYS, V273, P375, DOI 10.1016/0003-9861(89)90496-7; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; CASSELS R, 1987, BIOCHEM J, V247, P395, DOI 10.1042/bj2470395; CASTELLINO FJ, 1981, METHOD ENZYMOL, V80, P365; CHIBBER BAK, 1986, J BIOL CHEM, V261, P5289; CHIBBER BAK, 1985, BIOCHEMISTRY-US, V24, P3429, DOI 10.1021/bi00335a006; CHRISTENSEN U, 1992, BIOCHEM J, V285, P419, DOI 10.1042/bj2850419; CHRISTENSEN U, 1984, BIOCHEM J, V223, P413, DOI 10.1042/bj2230413; CHRISTENSEN U, 1977, BIOCHIM BIOPHYS ACTA, V481, P638, DOI 10.1016/0005-2744(77)90297-2; COLLEN D, 1986, J BIOL CHEM, V261, P1259; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FLEURY V, 1993, J BIOL CHEM, V268, P18554; FREDENBURGH JC, 1992, J BIOL CHEM, V267, P26150; GONZALEZGRONOW M, 1978, J BIOL CHEM, V253, P1090; HENKIN J, 1991, PROG CARDIOVASC DIS, V34, P135, DOI 10.1016/0033-0620(91)90010-J; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LINDAHL P, 1991, BIOCHEM J, V276, P387, DOI 10.1042/bj2760387; LIU JN, 1992, BIOCHEMISTRY-US, V31, P6311, DOI 10.1021/bi00142a021; LONGSTAFF C, 1992, J BIOL CHEM, V267, P173; LUCAS MA, 1983, J BIOL CHEM, V258, P2171; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; MARKUS G, 1978, J BIOL CHEM, V253, P733; MARSHALL JM, 1994, BIOCHEMISTRY-US, V33, P3599, DOI 10.1021/bi00178a017; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; MELHADO LL, 1982, J AM CHEM SOC, V104, P7299, DOI 10.1021/ja00389a065; NESHEIM M, 1990, J BIOL CHEM, V265, P21541; NIEUWENHUIZEN W, 1989, THROMB HAEMOSTASIS, V61, P208; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; PIRIESHEPHERD SR, 1995, J BIOL CHEM, V270, P5877, DOI 10.1074/jbc.270.11.5877; PONTING CP, 1992, BIOCHIM BIOPHYS ACTA, V1159, P155, DOI 10.1016/0167-4838(92)90020-E; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Powell J.L., 1986, PROTEINASE INHIBITOR, P55; RAMAKRISHNAN V, 1991, BIOCHEMISTRY-US, V30, P3963, DOI 10.1021/bi00230a023; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SJOHOLM I, 1973, EUR J BIOCHEM, V39, P471, DOI 10.1111/j.1432-1033.1973.tb03146.x; STRICKLAND DK, 1982, BIOCHEMISTRY-US, V21, P721, DOI 10.1021/bi00533a021; TAYLOR FB, 1968, BIOCHEMISTRY-US, V7, P232, DOI 10.1021/bi00841a028; URANO T, 1987, J BIOL CHEM, V262, P15959; URANO T, 1988, BIOCHEMISTRY-US, V27, P6522, DOI 10.1021/bi00417a049; VIOLAND BN, 1978, J BIOL CHEM, V253, P5395; VIOLAND BN, 1976, J BIOL CHEM, V2511, P3906; WALLEN P, 1970, BIOCHIM BIOPHYS ACTA, V221, P220; WIMAN B, 1975, EUR J BIOCHEM, V50, P489, DOI 10.1111/j.1432-1033.1975.tb09887.x; WOHL RC, 1983, BIOCHIM BIOPHYS ACTA, V745, P20, DOI 10.1016/0167-4838(83)90165-6; WOHL RC, 1980, J BIOL CHEM, V255, P2005	61	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1072	1080		10.1074/jbc.271.2.1072	http://dx.doi.org/10.1074/jbc.271.2.1072			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557633	hybrid			2022-12-25	WOS:A1996TP88900070
J	Nagamatsu, S; Fujiwara, T; Nakamichi, Y; Watanabe, T; Katahira, H; Sawa, H; Akagawa, K				Nagamatsu, S; Fujiwara, T; Nakamichi, Y; Watanabe, T; Katahira, H; Sawa, H; Akagawa, K			Expression and functional role of syntaxin 1/HPC-1 in pancreatic beta cells - Syntaxin 1A, but not 1B, plays a negative role in regulatory insulin release pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROINSULIN-PROCESSING ENDOPEPTIDASE; ISLET AMYLOID POLYPEPTIDE; EPITHELIAL MORPHOGENESIS; SECRETION; SYNAPTOTAGMIN; INHIBITION; FORSKOLIN; PEPTIDES; FAMILY; CA-2+	Syntaxin 1/HPC-1 is an integral membrane protein, which is thought to be implicated in the regulation of synaptic neurotransmitter release. We investigated syntaxin 1 expression in pancreatic beta cells and the functional role of syntaxin 1 in the insulin release mechanism. Expression of syntaxin 1A, but not 1B, was detected in mouse isolated islets by the reverse transcriptase-polymerase chain reaction procedure. An immunoprecipitation study of metabolically labeled islets with an anti-rat syntaxin 1/HPC-1 antibody demonstrated syntaxin 1A protein with an apparent molecular mass of similar to 35 kDa. Immunohistochemistry of the mouse pancreas demonstrated that syntaxin 1/HPC-1 was present in the plasma membranes of the islets of Langerhans. In order to determine the functional role of syntaxin 1 in pancreatic beta-cells, rat syntaxin 1A or 1B was overexpressed in mouse beta TC3 cells using the transient transfection procedure. Transfection of beta TC3 cells with either syntaxin 1 resulted in approximately 7-fold increases in their immunodetectable protein levels. Glucose-stimulated insulin release by syntaxin 1A-overexpressing cells was suppressed to about 50% of the level in control cells, whereas insulin release by syntaxin 1B-overexpressing and control cells did not differ. Next, we established stable beta TC3 cell lines that overexpressed syntaxin 1A and used them to evaluate the effect of syntaxin 1A on the regulatory insulin release pathway. Two insulin secretogogues, 4-beta-phorbol 12-myristate 13-acetate or forskolin, increased insulin release by untransfected beta TC3 cells markedly, but their effects were diminished in syntaxin 1A overexpressing beta TC3 cells. Glucose-unstimulated insulin release and the proinsulin biosynthetic rate were not affected by syntaxin 1A overexpression, indicating a specific role of syntaxin 1A in the regulatory insulin release pathway. Finally, in vitro binding assays showed that syntaxin 1A binds to insulin secretory granules, indicating an inhibitory role of syntaxin 1A in insulin exocytosis via its interaction with vesicular proteins. These results demonstrate that syntaxin 1A is expressed in the islets of Langerhans and functions as a negative regulator in the regulatory insulin release pathway.	KYORIN UNIV, SCH MED, DEPT PHYSIOL, MITAKA, TOKYO 181, JAPAN; KYORIN UNIV, SCH MED, DEPT CLIN PATHOL, MITAKA, TOKYO 181, JAPAN; KYORIN UNIV, SCH MED, DEPT INTERNAL MED 3, MITAKA, TOKYO 181, JAPAN; KYORIN UNIV, SCH MED, DEPT NEUROSURG, MITAKA, TOKYO 181, JAPAN	Kyorin University; Kyorin University; Kyorin University; Kyorin University	Nagamatsu, S (corresponding author), KYORIN UNIV, SCH MED, DEPT BIOCHEM, SHINKAWA 6-20-2, MITAKA, TOKYO 181, JAPAN.			Fujiwara, Tomonori/0000-0003-1369-7305				BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BECKER TC, 1994, J BIOL CHEM, V269, P21234; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIE MR, 1984, BIOCHEM J, V218, P87, DOI 10.1042/bj2180087; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DUKES ID, 1993, AM J PHYSIOL, V264, pE348, DOI 10.1152/ajpendo.1993.264.3.E348; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GRILL V, 1979, DIABETOLOGIA, V16, P47, DOI 10.1007/BF00423150; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; INOUE A, 1992, J BIOL CHEM, V267, P10613; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; KEAHEY HH, 1989, DIABETES, V38, P188, DOI 10.2337/diabetes.38.2.188; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; KOMAZAKI S, 1995, EXP CELL RES, V221, P11, DOI 10.1006/excr.1995.1347; KUSHIMA Y, 1995, BIOCHEM BIOPH RES CO, V212, P97, DOI 10.1006/bbrc.1995.1941; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; NAGAMATSU S, 1992, ENDOCRINOLOGY, V130, P748, DOI 10.1210/en.130.2.748; NAGAMATSU S, 1991, J BIOL CHEM, V266, P13737; NAGAMATSU S, 1993, J NEUROCHEM, V61, P2048, DOI 10.1111/j.1471-4159.1993.tb07441.x; NISHI M, 1989, P NATL ACAD SCI USA, V86, P5738, DOI 10.1073/pnas.86.15.5738; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; POPOV SV, 1993, CELL, V73, P1247, DOI 10.1016/0092-8674(93)90352-Q; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; RHODES CJ, 1989, BIOCHEM J, V258, P305, DOI 10.1042/bj2580305; ROE MW, 1994, AM J PHYSIOL, V266, pE852, DOI 10.1152/ajpendo.1994.266.6.E852; ROJAS E, 1994, ENDOCRINOLOGY, V134, P1771, DOI 10.1210/en.134.4.1771; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SEGER R, 1994, J BIOL CHEM, V269, P25699; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAMAGAWA T, 1985, FEBS LETT, V183, P433, DOI 10.1016/0014-5793(85)80825-5; THOMASREETZ AC, 1994, FASEB J, V8, P209, DOI 10.1096/fasebj.8.2.7907072; ULLRICH S, 1984, J BIOL CHEM, V259, P4111; WATANABE T, 1994, BRAIN RES, V655, P128, DOI 10.1016/0006-8993(94)91606-3; YAMAGUCHI K, 1994, NEUROSCI RES, V20, P289, DOI 10.1016/0168-0102(94)90049-3; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	49	99	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1160	1165		10.1074/jbc.271.2.1160	http://dx.doi.org/10.1074/jbc.271.2.1160			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557645	hybrid			2022-12-25	WOS:A1996TP88900082
J	Goossens, V; Grooten, J; Fiers, W				Goossens, V; Grooten, J; Fiers, W			The oxidative metabolism of glutamine - A modulator of reactive oxygen intermediate-mediated cytotoxicity of tumor necrosis factor in L929 fibrosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)+-DEPENDENT MALIC ENZYME; MAJOR ENERGY-SOURCE; MITOCHONDRIA; INHIBITORS; LIVER; TNF	Treatment of the mouse fibrosarcoma cell line L929 with tumor necrosis factor (TNF) induces necrotic cell death, A crucial step in the cytotoxic action mechanism of TNF involves perturbation of mitochondrial. functions leading to the formation of reactive oxygen intermediates (ROI), L929 cells have energy requirements adapted to a high proliferation rate. Glutamine (Gln) is utilized as a major energy source and drives mitochondrial ATP formation, while glucose is mainly converted to lactate through glycolysis. We investigated the role of the bioenergetic pathways involved in substrate utilization on the cytotoxic action of TNF and established a link between Gln oxidation and TNF-induced mitochondrial distress. Omission of Gan from the medium desensitizes the cells to TNF cytotoxicity, while the lack of glucose in the medium does not alter the TNF response, Sudden depletion of Gln from the culture medium results in a sharp decline in mitochondrial respiration in the cells, which might explain the decreased TNF responsiveness. However, when L929 cells are adapted to long term growth under conditions without Gln, these so-called L929/Gln(-) cells have restored respiration, but they still display a decreased sensitivity to TNF cytotoxicity, Thus the TNF responsiveness of L929 cells depends on bioenergetic reactions that are specifically involved in the oxidation of Gln. This is further confirmed by the desensitizing effect of specific inhibitors of these Gln-linked enzyme reactions on TNF cytotoxicity in the parental cells, but not in the L929/Gln(-) cells. Analysis of the induction of mitochondrial ROI formation by TNF in parental and L929/Gln(-) cells suggests that the effect of Gln on the sensitivity to TNF cytotoxicity involves a mechanism that renders the mitochondria more susceptible to TNF-induced mediators, resulting in enhanced ROI production and accelerated cytotoxicity.	STATE UNIV GHENT,MOLEC BIOL LAB,B-9000 GHENT,BELGIUM; FLEMISH INST BIOTECHNOL,B-9000 GHENT,BELGIUM	Ghent University								BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; FIERS W, 1995, BIOL THERAPY CANCER; FRANSEN L, 1985, NUCLEIC ACIDS RES, V13, P4417, DOI 10.1093/nar/13.12.4417; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1; LOW SY, 1993, BIOCHEM J, V295, P617, DOI 10.1042/bj2950617; MATSUNO T, 1992, CANCER RES, V52, P1192; MATSUNO T, 1987, INT J BIOCHEM, V19, P303, DOI 10.1016/0020-711X(87)90002-4; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MOREADITH RW, 1984, J BIOL CHEM, V259, P6215; NAGEL WO, 1980, J BIOL CHEM, V255, P3849; NALDINI A, 1994, LYMPHOKINE CYTOK RES, V13, P233; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; OSTROVE JM, 1979, P SOC EXP BIOL MED, V160, P354; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; ROTHE G, 1991, J IMMUNOL METHODS, V138, P133, DOI 10.1016/0022-1759(91)90074-P; SAUER LA, 1980, J BIOL CHEM, V255, P3844; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TUROWSKI GA, 1994, CANCER RES, V54, P5974; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; ZIELKE HR, 1984, FED PROC, V43, P121	26	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					192	196		10.1074/jbc.271.1.192	http://dx.doi.org/10.1074/jbc.271.1.192			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550558	hybrid			2022-12-25	WOS:A1996TP36100030
J	Shpetner, HS; Herskovits, JS; Vallee, RB				Shpetner, HS; Herskovits, JS; Vallee, RB			A binding site for SH3 domains targets dynamin to coated pits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANT; DROSOPHILA-MELANOGASTER; MECHANOCHEMICAL ENZYME; PLASMA-MEMBRANES; ENDOCYTOSIS; MICROTUBULES; SHIBIRE; GTPASE; HOMOLOGY; PROTEINS	.Dynamin is a GTPase that plays a critical role in the very early stages of endocytosis, regulating the scission of clathrin-coated and non-clathrin-coated pits from the plasma membrane. While the ligands through which dynamin exerts its in vivo effects are unknown, dynamin exhibits in vitro binding to several proteins containing Src homology 3 (SH3) domains, as well as to microtubules and anionic phospholipids, via a basic, proline-rich C-terminal domain. To begin to identify the in vivo binding partners of dynamin, we have examined by immunofluorescence the association of mutant and wild-type forms of dynamin with plasma membranes pre pared by sonication of transiently transfected cells. Wild-type dynamin was found almost exclusively in association with clathrin-containing domains. Binding to these regions was abolished by removal of a nine-amino acid sequence within the C-terminal domain encoding a candidate SH3 domain binding site, Binding did not require clathrin and resisted extraction at both high and low ionic strength, consistent with an interaction with an SH3 domain. Surprisingly, we also find that dynamin contains multiple regions involved in binding to non-clathrin-containing domains, including a 13-amino acid sequence directly upstream of the C-terminal domain. These observations suggest that a protein containing an SH3 domain is involved in recruiting dynamin to coated pits and provide the first evidence for a biological role for SH3 domains in dynamin function.	WORCESTER FDN EXPTL BIOL INC,CELL BIOL GRP,SHREWSBURY,MA 01545; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM,WORCESTER,MA 01655	Worcester Foundation for Biomedical Research; University of Massachusetts System; University of Massachusetts Worcester								BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HERSKOVIS JS, 1994, MOL BIOL CELL, V5, P76; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KOENIG JH, 1989, J NEUROSCI, V9, P1937; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; KRIEGLER M, 1991, GENE TRANSFER EXPRES, P99; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553	30	107	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					13	16		10.1074/jbc.271.1.13	http://dx.doi.org/10.1074/jbc.271.1.13			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550547	hybrid			2022-12-25	WOS:A1996TP36100003
J	Wood, JS; Yan, XW; Mendelow, M; Corbin, JD; Francis, SH; Lawrence, DS				Wood, JS; Yan, XW; Mendelow, M; Corbin, JD; Francis, SH; Lawrence, DS			Precision substrate targeting of protein kinases - THE cGMP-and cAMP-dependent protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMER-BOUND OXIME; APOLIPOPROTEIN-A-I; CATALYTIC SUBUNIT; PEPTIDE INHIBITOR; CRYSTAL-STRUCTURE; SPECIFICITY; PHOSPHORYLATION; SEQUENCE; SEGMENTS; SITES	The cAMP-dependent (PKA) and cGMP-dependent protein kinases (PKG) share a strong primary sequence homology within their respective active site regions. Not surprisingly, these enzymes also exhibit overlapping substrate specificities, a feature that often interferes with efforts to elucidate their distinct biological roles. In this report, we demonstrate that PKA and PKG exhibit dramatically different behavior with respect to the phosphorylation of alpha-substituted alcohols. Although PKA will phosphorylate only residues that contain an alpha-center configuration analogous to that found in L-serine, PKG utilizes residues that correspond to both L- and D-serine as substrates. The PKG/PKA selectivity of these substrates is the highest ever reported.	SUNY BUFFALO, DEPT CHEM, BUFFALO, NY 14260 USA; SUNY BUFFALO, DEPT MED CHEM, BUFFALO, NY 14260 USA; VANDERBILT UNIV, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045989] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40029] Funding Source: Medline; NIGMS NIH HHS [GM45989] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BUTT E, 1994, J BIOL CHEM, V269, P14509; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; DEGRADO WF, 1982, J ORG CHEM, V47, P3258, DOI 10.1021/jo00138a011; DEGRADO WF, 1980, J ORG CHEM, V45, P1295, DOI 10.1021/jo01295a026; ELLER M, 1991, BIOCHEM INT, V25, P453; ELLER M, 1993, J BIOCHEM-TOKYO, V114, P177, DOI 10.1093/oxfordjournals.jbchem.a124151; FERRARI S, 1985, FEBS LETT, V184, P72, DOI 10.1016/0014-5793(85)80656-6; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; GLASS DB, 1982, J BIOL CHEM, V257, P1196; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GLASS DB, 1979, J BIOL CHEM, V254, P9728; GLASS DB, 1992, BIOCHEMISTRY-US, V31, P1728, DOI 10.1021/bi00121a021; HASHIMOTO E, 1976, J BIOL CHEM, V251, P6287; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KAISER ET, 1989, ACCOUNTS CHEM RES, V22, P47, DOI 10.1021/ar00158a001; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KWON YG, 1993, J AM CHEM SOC, V115, P7527, DOI 10.1021/ja00069a072; KWON YG, 1993, J BIOL CHEM, V268, P16725; KWON YG, 1993, J BIOL CHEM, V268, P10713; KWON YG, 1994, J BIOL CHEM, V269, P4839; LEE TR, 1994, BIOCHEMISTRY-US, V33, P4245, DOI 10.1021/bi00180a019; LEE TR, 1995, J BIOL CHEM, V270, P5375, DOI 10.1074/jbc.270.10.5375; LEE TR, 1993, J AM CHEM SOC, V115, P9888, DOI 10.1021/ja00075a003; LINCOLN TM, 1977, P NATL ACAD SCI USA, V74, P3239, DOI 10.1073/pnas.74.8.3239; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NAKAGAWA SH, 1983, J ORG CHEM, V48, P678, DOI 10.1021/jo00153a012; NAKAGAWA SH, 1985, J AM CHEM SOC, V107, P7087, DOI 10.1021/ja00310a055; ORR JW, 1994, J BIOL CHEM, V269, P8383; PROROK M, 1989, J BIOCHEM BIOPH METH, V18, P167, DOI 10.1016/0165-022X(89)90001-8; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; SHOJI S, 1983, BIOCHEMISTRY-US, V22, P3702, DOI 10.1021/bi00284a025; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS NE, 1987, BIOCHEMISTRY-US, V26, P4471, DOI 10.1021/bi00388a043; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	43	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					174	179		10.1074/jbc.271.1.174	http://dx.doi.org/10.1074/jbc.271.1.174			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550555	hybrid			2022-12-25	WOS:A1996TP36100027
J	Decker, SJ				Decker, SJ			Nerve growth factor-induced growth arrest and induction of p21(Cip/WAF1) in NIH-3T3 cells expressing TrkA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; PC12 CELLS; PHOSPHOLIPASE-C; PHOSPHORYLATION; DIFFERENTIATION; CDK4; SUPPRESSION; FIBROBLASTS; INHIBITION; RECEPTOR	Treatment of NIH-3T3 cells expressing human TrkA with nerve growth factor (NGF) resulted in a rapid cessation of growth. Cells stopped dividing within 24 h of NGF treatment and failed to divide as long as NGF was present, accumulating in the G(1) stage of the cell cycle. NGF caused a prolonged activation of mitogen-activated protein kinase relative to EGF. NGF treatment of cells greatly increased levels of the p21(Cip1/WAF1) protein, an inhibitor of cyclin-dependent kinases, without affecting levels of p27(KIP1) or p16(INK4). Levels of p21(Cip1/WAF1) remained elevated for at least 48 h following NGF addition. EGF had little effect on p21(Cip1/WAF1) expression in the same parental cells expressing the human EGF receptor. NGF treatment of cells completely inhibited the activity of the cyclin-dependent protein kinases CDK2 and CDK4. Inhibition correlated with a 10-20-fold increase in the amount of p21(Cip1/WAF1) complexed with CDK2 and CDK4. Levels of CDK2 and CDK4 were decreased following NGF treatment of cells; however, levels of cyclin E and cyclin D were increased. These data indicate that NGF can induce cell cycle arrest of NIH-3T3, perhaps through modulation of p21(Cip1/WAF1) levels. The data also show that distinct signals are generated by TrkA versus the EGF receptor in NIH-3T3 cells.	UNIV MICHIGAN,SCH MED,DEPT MICROBIOL,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan	Decker, SJ (corresponding author), PARKE DAVIS PHARMACEUT RES DIV,2800 PLYMOUTH RD,ANN ARBOR,MI 48106, USA.							BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURGER C, 1994, J CELL SCI, V107, P2047; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHAO MV, 1992, NEURON, V9, P55; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; KAPLAN DR, 1991, SCIENCE, V252, P552; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIESS M, 1995, ONCOGENE, V10, P159; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KIM UH, 1991, J BIOL CHEM, V266, P1359; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; OHMICHI M, 1994, J BIOL CHEM, V269, P1173; OMICHI M, 1992, J BIOL CHEM, V267, P14604; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; POLYAK K, 1994, GENE DEV, V8, P1750; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	50	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30841	30844		10.1074/jbc.270.52.30841	http://dx.doi.org/10.1074/jbc.270.52.30841			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537334	hybrid			2022-12-25	WOS:A1995TN44400002
J	Shih, W; Gallusser, A; Kirchhausen, T				Shih, W; Gallusser, A; Kirchhausen, T			A clathrin-binding site in the hinge of the beta 2 chain of mammalian AP-2 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE ASSEMBLY POLYPEPTIDES; FACTOR-II RECEPTOR; COATED VESICLES; PLASMA-MEMBRANE; PROTEIN COMPLEX; INVITRO BINDING; GOLGI MEMBRANES; ADAPTERS; ADAPTINS; DOMAINS	The assembly of cytosolic clathrin into the cytoplasmic face of coated pits and coated vesicles appears to be driven by the clathrin-associated protein (AP) complexes. We have previously shown that one of the large chains of the AP complexes, the beta chain, is sufficient to drive coat assembly in vitro. This chain consists of two domains, the amino-terminal trunk and the carboxyl-terminal ear, linked by a ''hinge.'' We report here that presence of the hinge in recombinant beta trunk or in recombinant beta ear fragments is essential for driving in vitro assembly of clathrin into coats. We have also used a binding assay to map the clathrin-binding site by nested deletion of hinge sequences to a 50-residue region in the center of the hinge. This sequence is conserved in all known beta sequences from multicellular organisms. The interaction of a single beta hinge with a clathrin triskelion is weak, and we propose that recruitment of cytosolic clathrin to a forming coated pit involves simultaneous contacts between the legs of single clathrin trimers and the beta hinges of two or three membrane-bound AP complexes. Uncoating is likely to require interruption of these contacts.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)								AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANDREWS P, 1965, BIOCHEM J, V96, P595, DOI 10.1042/bj0960595; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; CAMIDGE DR, 1994, J CELL SCI, V107, P709; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HARRISON SC, 1983, CELL, V33, P650, DOI 10.1016/0092-8674(83)90007-7; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KEEN JH, 1991, J BIOL CHEM, V266, P7950; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LINDNER R, 1992, J BIOL CHEM, V267, P16567; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MURPHY JE, 1992, J BIOL CHEM, V267, P10850; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TUCKER KL, 1990, NUCLEIC ACIDS RES, V18, P5306, DOI 10.1093/nar/18.17.5306; UNANUE ER, 1981, CELL, V26, P439, DOI 10.1016/0092-8674(81)90213-0; UNGEWICKELL E, 1994, EUR J BIOCHEM, V222, P33, DOI 10.1111/j.1432-1033.1994.tb18838.x; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; VIRSHUP DM, 1988, J CELL BIOL, V106, P39, DOI 10.1083/jcb.106.1.39; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108; ZAREMBA S, 1993, J CELL BIOL, V121, P61	48	171	172	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31083	31090		10.1074/jbc.270.52.31083	http://dx.doi.org/10.1074/jbc.270.52.31083			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537368	hybrid			2022-12-25	WOS:A1995TN44400036
J	Sonnenburg, WK; Seger, D; Kwak, KS; Huang, J; Charbonneau, H; Beavo, JA				Sonnenburg, WK; Seger, D; Kwak, KS; Huang, J; Charbonneau, H; Beavo, JA			Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulin-stimulated cyclic nucleotide phosphodiesterases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; BOVINE BRAIN; MOLECULAR-CLONING; MASS-SPECTROMETRY; CHROMATOGRAPHY; PURIFICATION; PEPTIDES; 61-KDA; ACTIVATION; EXPRESSION	Using a bovine 61-kDa (PDE1A2) calmodulin-stimulated phosphodiesterase (CaM-PDE) cDNA and a bovine lung 59-kDa (PDE1A1) CaM-PDE cDNA reported here, we have identified two new regions within the primary structure of these two related isozymes that are important for regulation by Ca2+/CaM, PDE1A1 is identical to the PDE1A2 isozyme except for the amino terminal 18 residues, In agreement with earlier studies, the CaM concentration required for half maximal activation (K-CaM) of recombinant PDE1A1 (0.3 nM) was approximate to 10-fold less than the K-CaM for recombinant PDE1A2 (4 nM), A series of deletion mutations of the PDE1A2 cDNA removing nucleotide sequence encoding the first 46-106 aminoterminal residues were constructed and expressed using the baculovirus system, Deletion of the amino acids encompassing a previously identified, putative CaM-binding domain (residues 4-46) produced a polypeptide that was still activated 3-fold by CaM (K-CaM approximate to 3 nM), However, complete CaM-independent activation occurred when residues 4-98 were deleted, To determine the location of the additional CaM-binding domain(s), the inhibitory potency of seven overlapping, synthetic peptides spanning amino acids 76-149 of PDE1A2 was tested using the CaM-activated enzyme, One peptide spanning amino acids 114-137 of PDE1A2 appeared to be the most potent inhibitor of CaM-stimulated activity, These results reveal the existence of a CaM-binding domain located approximately 90 residues carboxyl-terminal to the putative CaM-binding domains previously identified within the PDE1A1 and PDE1A2 isozymes, Moreover, a discrete segment important for holding these CaM-PDEs in a less active state at low Ca2+ concentrations is located between the two CaM-binding domains.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	University of Washington; University of Washington Seattle; Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44948] Funding Source: Medline; NIDDK NIH HHS [DK21723] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BELTMAN J, 1993, MOL CELL BIOCHEM, V128, P239, DOI 10.1007/BF01076775; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CHARBONNEAU H, 1990, CYCLIC NUCLEOTIDE PH, V2, P267; CLORE GM, 1993, CURR OPIN STRUC BIOL, V3, P838, DOI 10.1016/0959-440X(93)90146-C; COVEY TR, 1991, ANAL CHEM, V63, P1193, DOI 10.1021/ac00013a003; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; FLORIO VA, 1994, BIOCHEMISTRY-US, V33, P8948, DOI 10.1021/bi00196a012; GUARDABASSO V, 1988, FASEB J, V2, P209, DOI 10.1096/fasebj.2.3.3350235; HANSEN RS, 1988, METHOD ENZYMOL, V159, P543; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; HARLOW E, 1988, ANTIBODIES LABORATOR; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P10884; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JARRETT HW, 1991, J BIOL CHEM, V266, P362; KANAREK L, 1964, J BIOL CHEM, V239, P4202; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; KLEE CB, 1980, PROTEIN PHOSPHORYLAT, P61; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAPORTE DC, 1979, BIOCHEMISTRY-US, V18, P2820, DOI 10.1021/bi00580a021; LAUE TM, 1990, METHOD ENZYMOL, V182, P566; LOUGHNEY K, 1994, FASEB J, V8, pA81; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; MALITSCHEK B, 1991, BIOTECHNIQUES, V11, P177; Maniatis T., 1982, MOL CLONING; MANN SG, 1989, J GEN VIROL, V70, P3501, DOI 10.1099/0022-1317-70-12-3501; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASTERS DB, 1992, BIOTECHNIQUES, V12, P902; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PESCE A, 1964, J BIOL CHEM, V239, P1753; POTSCHKA M, 1987, ANAL BIOCHEM, V162, P47, DOI 10.1016/0003-2697(87)90009-1; Segel I.H., 1975, ENZYME KINETICS; SHARMA RK, 1986, J BIOL CHEM, V261, P14160; SHARMA RK, 1991, BIOCHEMISTRY-US, V30, P5963, DOI 10.1021/bi00238a021; SHARMA RK, 1985, P NATL ACAD SCI USA, V82, P2603, DOI 10.1073/pnas.82.9.2603; SHARMA RK, 1986, BIOCHEM CELL BIOL, V64, P1072, DOI 10.1139/o86-142; SHARMA RK, 1984, J BIOL CHEM, V259, P9248; SHARMA RK, 1980, J BIOL CHEM, V255, P5916; SHEARWIN KE, 1990, EUR J BIOCHEM, V190, P523, DOI 10.1111/j.1432-1033.1990.tb15605.x; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Sober HA, 1970, HDB BIOCH; SODERLING TR, 1993, BIOTECHNOL APPL BIOC, V18, P185; Sonnenburg W K, 1994, Adv Pharmacol, V26, P87, DOI 10.1016/S1054-3589(08)60052-6; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; SUND H, 1963, BIOCHEM Z, V337, P24; THORNE CJR, 1963, J BIOL CHEM, V238, P1861; TUCKER MM, 1981, J BIOL CHEM, V256, P9051; WANG JH, 1990, MOL PHARM CELL REGUL, V2, P19; WORTHINGTON CS, 1972, WORTHINGTON ENZYME M; YAN C, 1994, FASEB J, V8, P470; ZHANG GY, 1993, MOL CELL BIOCHEM, V122, P159, DOI 10.1007/BF01076100; [No title captured]; 1991, PROGRAM MANUAL GCG P	63	90	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30989	31000		10.1074/jbc.270.52.30989	http://dx.doi.org/10.1074/jbc.270.52.30989			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537356	hybrid			2022-12-25	WOS:A1995TN44400024
J	Marsolais, F; Varin, L				Marsolais, F; Varin, L			Identification of amino acid residues critical for catalysis and cosubstrate binding in the flavonol 3-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; MOLECULAR CHARACTERIZATION; PARTIAL-PURIFICATION; KINETIC-PROPERTIES; ADENYLATE KINASE; ESCHERICHIA-COLI; HUMAN LIVER; SULFOTRANSFERASE; CLONING; EXPRESSION	The comparison of the deduced amino acid sequences of plant and animal sulfotransferases (ST) has allowed the identification of four well conserved regions, and previous experimental evidence suggested that regions I and IV might be involved in the binding of the cosubstrate, 3'-phosphoadenosine 5'-phosphosulfate (PAPS), Moreover, region IV is homologous to the glycine-rich phosphate binding loop (P-loop) motif known to be involved in nucleotide phosphate binding in several protein families. In this study, the function of amino acid residues within these two regions was investigated by site directed mutagenesis of the plant flavonol 3-ST. In region I, our results identify Lys(59) as critical for catalysis, since replacement of this residue with alanine re suited in a 300-fold decrease in specific activity, while a 15-fold reduction was observed after the conservative replacement with arginine. Photoaffinity labeling of K59R and K59A with [S-35]PAPS revealed that Lys(59) is not required for cosubstrate binding, However, the K59A mutant had a reduced affinity for 3'-phosphoadenosine 5'-phosphate (PAP)-agarose, suggesting that Lys(59) may participate in the stabilization of an intermediate during the reaction, In region TV, all substitutions of Arg(276) resulted in a marked decrease in specific activity. Conservative and unconservative replacements of Arg(276) resulted in weak photoaffinity labeling with [S-35]PAPS and the R276A/T73A and R276E enzymes displayed reduced affinities for PAP-agarose, suggesting that the Arg(276) side chain is required to bind the cosubstrate, The analysis of the kinetic constants of mutant enzymes at residues Lys(277), Gly(281), and Lys(284) allowed to confirm that region TV is involved in cosubstrate binding.	UNIV LAVAL,DEPT BIOL,ST FOY,PQ G1K 7P4,CANADA	Laval University				Marsolais, Frederic/0000-0003-3914-141X				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANANVORANICH S, 1995, PLANT PHYSIOL, V107, P1019, DOI 10.1104/pp.107.3.1019; BARNES S, 1989, J LIPID RES, V30, P529; BERNIER F, 1994, MOL CELL ENDOCRINOL, V99, pR11, DOI 10.1016/0303-7207(94)90159-7; BORCHARDT RT, 1982, BIOCHIM BIOPHYS ACTA, V708, P280, DOI 10.1016/0167-4838(82)90438-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYEON IJL, 1995, BIOCHEMISTRY-US, V34, P3172, DOI 10.1021/bi00010a006; COMER KA, 1993, BIOCHEM J, V289, P233, DOI 10.1042/bj2890233; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRISCOLL WJ, 1993, J BIOL CHEM, V268, P23496; FALANY CN, 1994, CHEM-BIOL INTERACT, V92, P57, DOI 10.1016/0009-2797(94)90053-1; FALANY CN, 1990, ARCH BIOCHEM BIOPHYS, V278, P34; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; HIRSHEY SJ, 1992, MOL PHARMACOL, V42, P257; HOBKIRK R, 1985, CAN J BIOCHEM CELL B, V63, P1127, DOI 10.1139/o85-141; KOBAYASHI DY, 1990, MOL PLANT MICROBE IN, V3, P94, DOI 10.1094/MPMI-3-094; KOMATSU K, 1994, BIOCHEM BIOPH RES CO, V204, P1178, DOI 10.1006/bbrc.1994.2587; KONG ANT, 1992, BIOCHEM BIOPH RES CO, V187, P448, DOI 10.1016/S0006-291X(05)81514-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; OGURA K, 1989, BIOCHEM BIOPH RES CO, V165, P168, DOI 10.1016/0006-291X(89)91050-4; OTTERNESS DM, 1991, MOL PHARMACOL, V39, P34; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SATISHCHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P11684, DOI 10.1021/bi00162a003; VARIN L, 1995, J BIOL CHEM, V270, P12498, DOI 10.1074/jbc.270.21.12498; VARIN L, 1991, PLANT PHYSIOL, V95, P1254, DOI 10.1104/pp.95.4.1254; VARIN L, 1989, PLANT PHYSIOL, V90, P977, DOI 10.1104/pp.90.3.977; VARIN L, 1992, J BIOL CHEM, V267, P1858; VARIN L, 1987, ANAL BIOCHEM, V161, P176, DOI 10.1016/0003-2697(87)90669-5; VARIN L, 1992, P NATL ACAD SCI USA, V89, P1286, DOI 10.1073/pnas.89.4.1286; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEINSHILBOUM R, 1994, HDB EXPT PHARM CONJU, V112, P45; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313; ZHU XY, 1993, BIOCHEM BIOPH RES CO, V195, P120, DOI 10.1006/bbrc.1993.2018	40	64	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30458	30463		10.1074/jbc.270.51.30458	http://dx.doi.org/10.1074/jbc.270.51.30458			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530475	hybrid			2022-12-25	WOS:A1995TL67500040
J	Sakata, N; Patel, HR; Terada, N; Aruffo, A; Johnson, GL; Gelfand, EW				Sakata, N; Patel, HR; Terada, N; Aruffo, A; Johnson, GL; Gelfand, EW			Selective activation of c-Jun kinase mitogen-activated protein kinase by CD40 on human B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; TYROSINE KINASE; LYMPHOCYTES-B; FACTOR RECEPTOR; CROSS-LINKING; EXPRESSION; PHOSPHORYLATION; APOPTOSIS; IMMUNOGLOBULIN	The B cell surface antigen receptor, surface IgM (sIgM), is involved in B cell activation and proliferation, CD40 is involved in regulating IgE production and B cell survival. Cross linking of B cell sIgM activates the Ras/ Raf/p42(erk2) pathway. In contrast, ligation of CD40 by antibody or soluble gp39 (CD40 ligand) leads to activation of the c-Jun kinase (JNK)/stress-activated protein kinase pathway. JNK/stress activated protein kinase activation correlated with the stimulation of MEK kinase activity. CD40 does not activate the p42(erk2) pathway, and sIgM fails to regulate the JNK/stress-activated protein kinase pathway in B cells. Thus, two important cell surface receptors involved in controlling specific B cell response differentially regulate sequential protein kinase pathways involving different members of the mitogen-activated protein kinase family. Anti-CD40 also rescued B cell apoptosis induced by anti-IgM. CD40 ligation did not affect the sIgM stimulation of p42(erk2) activity. Conversely, sIgM ligation did not influence CD40 stimulation of JNK/stress-activated protein kinase. These results suggest that independent, parallel protein kinase response pathways are involved in the integration of sIgM and CD40 control of B cell phenotype and function.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	National Jewish Health; Bristol-Myers Squibb								ARMITAGE RJ, 1993, J IMMUNOL, V150, P3671; BAJORATH J, 1995, BIOCHEMISTRY-US, V34, P1833, DOI 10.1021/bi00006a003; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BRODIE C, 1994, J NEUROIMMUNOL, V52, P87, DOI 10.1016/0165-5728(94)90166-X; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CHEUNG RK, 1991, J BIOL CHEM, V266, P8667; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FANSLOW WC, 1992, J IMMUNOL, V149, P655; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; FRANKLIN RA, 1994, J IMMUNOL, V153, P4890; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GORCZYCA W, 1993, CANCER RES, V53, P3186; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HASBOLD J, 1990, EUR J IMMUNOL, V20, P1685, DOI 10.1002/eji.1830200810; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KLEMSZ MJ, 1989, J IMMUNOL, V143, P1032; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1995, METHOD ENZYMOL, V255, P290; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LEDBETTER JA, 1995, CIRC SHOCK, V44, P67; LEDERMAN S, 1994, J IMMUNOL, V152, P2163; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; REN CL, 1994, J EXP MED, V179, P673, DOI 10.1084/jem.179.2.673; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROIFMAN CM, 1992, BIOCHEM BIOPH RES CO, V183, P411, DOI 10.1016/0006-291X(92)90496-8; ROIFMAN CM, 1991, J IMMUNOL, V146, P2965; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUMIMOTO SI, 1994, J IMMUNOL, V153, P2488; TAKASE K, 1995, J CELL PHYSIOL, V162, P246, DOI 10.1002/jcp.1041620210; TORDAI A, 1994, J BIOL CHEM, V269, P7538; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; YAN M, 1994, NATURE, V372, P795	59	171	173	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30823	30828		10.1074/jbc.270.51.30823	http://dx.doi.org/10.1074/jbc.270.51.30823			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530526	hybrid			2022-12-25	WOS:A1995TL67500091
J	Thannickal, VJ; Fanburg, BL				Thannickal, VJ; Fanburg, BL			Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL GLOMERULONEPHRITIS; EXTRACELLULAR-MATRIX; FACTOR-BETA-1; NEUTROPHILS; EXPRESSION; ANTIBODY; RELEASE; REPAIR; SYSTEM	The cellular source(s) and mechanisms of generation of reactive oxygen species (ROS) in nonphagocytic cells stimulated by cytokines are unclear, In this study, we demonstrate that transforming growth factor beta 1 (TGF-beta 1, 1 ng/ml) induces the release of H2O2 from human lung fibroblasts within 8 h following exposure to this cytokine, Elevation in H2O2 release peaked at 16 h (similar to 22 pmol/min/10(6) cells) and gradually declined to undetectable levels at 48 h after TGF-beta 1 treatment. NADH consumption by these cells was stimulated by TGF-beta 1 while that of NADPH remained unchanged. NADH oxidase activity as measured by diphenyliodonium (DPI)-inhibitable NADH consumption in TGF-beta 1-treated cells followed a time course similar to that of H2O2 release. DPI, an inhibitor of the NADPH oxidase complex of neutrophils and other flavoproteins, also inhibited the TGF-beta 1-induced H2O2 production, Inhibitors of other enzymatic systems involving flavoproteins that may be responsible for the production of H2O2 in these cells, including xanthine oxidase, nitric oxide synthase, and both mitochondrial and microsomal electron transport systems, failed to inhibit TGF-beta 1-induced NADH oxidation and H2O2 production. The delay (>4 h) following TGF-beta 1 exposure along with the inhibition of this process by cycloheximide and actinomycin D suggest the requirement of new protein synthesis for induction of NADH oxidase activity in TGF-beta 1-stimulated fibroblasts.			Thannickal, VJ (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DEPT MED,DIV PULM & CRIT CARE,750 WASHINGTON ST,NEMC 369,BOSTON,MA 02111, USA.				NHLBI NIH HHS [1 HL07053] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELLAVITE P, 1988, FREE RADICAL BIO MED, V4, P225, DOI 10.1016/0891-5849(88)90044-5; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1105, P109, DOI 10.1016/0005-2736(92)90168-L; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Mohazzab HKM, 1994, AM J PHYSIOL, V266, P2568; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; THANNICKAL VJ, 1993, AM J PHYSIOL, V265, pL622, DOI 10.1152/ajplung.1993.265.6.L622; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; YOKOTA K, 1965, BIOCHIM BIOPHYS ACTA, V105, P301, DOI 10.1016/S0926-6593(65)80154-0	26	365	374	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30334	30338		10.1074/jbc.270.51.30334	http://dx.doi.org/10.1074/jbc.270.51.30334			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530457	hybrid			2022-12-25	WOS:A1995TL67500022
J	BUCHOU, T; KRANENBURG, O; VANDAM, H; ROELEN, D; ZANTEMA, A; HALL, FL; VANDEREB, A				BUCHOU, T; KRANENBURG, O; VANDAM, H; ROELEN, D; ZANTEMA, A; HALL, FL; VANDEREB, A			INCREASED CYCLIN-A AND DECREASED CYCLIN-D LEVELS IN ADENOVIRUS-5 E1A-TRANSFORMED RODENT CELL-LINES	ONCOGENE			English	Article							LARGE T-ANTIGEN; E1A PROTEINS; TRANSFORMED-CELLS; MONOCLONAL-ANTIBODIES; GROWTH-FACTOR; FACTOR-I; FUNCTIONAL DOMAINS; CONSERVED REGION-1; NUCLEAR ANTIGEN; MESSENGER-RNAS	Adenovirus-(Ad)- E1A proteins carry two conserved domains (CR1 and CR2) required for transformation of primary rodent cells and essential for association with cellular proteins, including p105RB, p58cyclin A and p33cdk 2. We show that in normal rat kidney 49F (NRK) cell lines expressing various mutant Ad5-E1A genes, CR2-, but not CR-1-, deletion mutants induce a typical transformed phenotype as characterized by morphology, absence of density arrest and loss of serum requirement. This indicates that induction of these transformed properties is a function of CR1. The fact that E1A proteins with deletions in CR2 show a greatly reduced association with RB, cyclin A and p33cdk 2 suggests that these associations are dispensable for E1A-mediated transformation of NRK cells. Induction of the transformed properties is accompanied by a CR1-dependent increase in Proliferating Cell Nuclear Antigen and cyclin A gene expression. Elevated mRNA and protein levels of cyclin A were also found in Ad12-E1-transformed NRK cells but not in ras-transformed NRK cells. On the other hand, cyclin D expression is decreased in a CR1-dependent manner. Although Ad5-E1A proteins are sufficient to transform NRK cells, further deregulation of growth is obtained when Ad5-E1B proteins are co-expressed. One of the Ad5-E1B effects is the sequestration of the p53 protein into a cytoplasmic body containing the p53/Ad5-E1B-55 kD complex. Interestingly, in NRK cell lines expressing Ad5-E1B-55 kD, cyclin A could be detected not only in the nucleus but also in the cytoplasmic bodies. These results indicate that the deregulation of cell cycle control by the Adenovirus-E1 region may be due to a CR1-dependent alteration of the expression of cyclins A and D.	LEIDEN UNIV, SYLVIUS LAB, MOLEC CARCINOGENESIS LAB, POB 9503, 2300 RA LEIDEN, NETHERLANDS; CTR RECH PARIS ST ANTOINE, INSERM, U55, F-75571 PARIS 12, FRANCE; CHILDRENS HOSP LOS ANGELES, DIV ORTHOPAED SURG, LOS ANGELES, CA 90054 USA	Leiden University; Leiden University - Excl LUMC; Institut National de la Sante et de la Recherche Medicale (Inserm); Children's Hospital Los Angeles			BUCHOU, THIERRY/N-2553-2013; Kranenburg, Onno/K-4115-2015; BUCHOU, Thierry/F-3136-2019	Kranenburg, Onno/0000-0002-2112-4390; BUCHOU, Thierry/0000-0002-9206-2377; van Dam, Hans/0000-0002-8307-4325				ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLINT SJ, 1990, MOL BIOL TUMOR VIRUS, V2, P547; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL FL, 1991, J BIOL CHEM, V266, P17430; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KIMELMAN D, 1986, MOL CELL BIOL, V6, P1487, DOI 10.1128/MCB.6.5.1487; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NIELSCH U, 1991, ONCOGENE, V6, P1031; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; RILEY TEW, 1990, MOL CELL BIOL, V10, P6664, DOI 10.1128/MCB.10.12.6664; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TIMMERS HTM, 1988, J BIOL CHEM, V263, P1329; TIMMERS HTM, 1988, ONCOGENE RES, V3, P67; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1989, ONCOGENE, V4, P1207; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	70	64	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1765	1773						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510923				2022-12-25	WOS:A1993LG68200007
J	MITSUI, K; BRADY, M; PALFREY, HC; NAIRN, AC				MITSUI, K; BRADY, M; PALFREY, HC; NAIRN, AC			PURIFICATION AND CHARACTERIZATION OF CALMODULIN-DEPENDENT PROTEIN KINASE-III FROM RABBIT RETICULOCYTES AND RAT PANCREAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-II; HEAT-SHOCK PROTEIN; TRANSFER RNA-SYNTHETASE; MR 100,000 SUBSTRATE; PHOSPHORYLATION SITES; BOVINE BRAIN; OKADAIC ACID; PC12 CELLS; CA-2+; IDENTIFICATION	Calmodulin-dependent protein kinase III (CaM kinase III) phosphorylates and thereby inactivates eukaryotic elongation factor-2 (EF-2). This enzyme, purified to homogeneity from either rabbit reticulocytes or rat pancreas, had similar properties: it migrated with an apparent M(r) of 140,000 by gel filtration, was comprised of a major polypeptide of M(r) 95,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and had a high affinity for CaM (half-maximal activation < 1 nM). The M(r) 95,000 polypeptide was autophosphorylated by an intramolecular mechanism on seryl residues in the presence of Ca2+, CaM, and ATP, and phosphopeptide mapping indicated that several sites were phosphorylated. Autophosphorylation of CaM kinase III resulted in the generation of a partially Ca2+/calmodulin-independent activity. The enzyme could also be phosphorylated by the catalytic subunit of cAMP-dependent protein kinase. Amino acid sequencing of CaM kinase III indicated that it is distinct from other known proteins including the heat-shock protein hsp90, which was recently suggested to be identical to CaM kinase III (Nygard, O., Nilsson, A., Carlberg, U., Nilsson, L., and Amons, R. (1991) J. Biol. Chem. 266, 16425-16430). Furthermore, hsp90 did not copurify with CaM kinase III, and the M(r) 95,000 protein did not cross-react with antibodies to hsp90. CaM kinase III exhibited Michaelis-Menten kinetics toward its substrates ATP and EF-2, with K(m) values of 15 and 2 muM, respectively. CaM kinase III was able to phosphorylate yeast EF-2 with an K(m) of 2 muM, but the enzyme did not significantly phosphorylate a variety of other substrates, confirming its identification as a novel protein kinase.	ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	Rockefeller University; University of Chicago				Nairn, Angus/0000-0002-7075-0195	NIGMS NIH HHS [GM-24725] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BINART N, 1989, BIOCHEM BIOPH RES CO, V159, P140, DOI 10.1016/0006-291X(89)92415-7; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; BRADY MJ, 1990, J NEUROCHEM, V54, P1034, DOI 10.1111/j.1471-4159.1990.tb02354.x; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; CELIS JE, 1990, P NATL ACAD SCI USA, V87, P4231, DOI 10.1073/pnas.87.11.4231; CLEVELAND D W, 1989, New Biologist, V1, P121; DONOVAN MG, 1991, FEBS LETT, V291, P303, DOI 10.1016/0014-5793(91)81307-T; FLANAGAN SD, 1984, ANAL BIOCHEM, V140, P510, DOI 10.1016/0003-2697(84)90202-1; GAY DA, 1989, P NATL ACAD SCI USA, V86, P5763, DOI 10.1073/pnas.86.15.5763; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAF E, 1980, ARCH BIOCHEM BIOPHYS, V203, P719, DOI 10.1016/0003-9861(80)90231-3; GRAND RJA, 1979, BIOCHEM J, V177, P521, DOI 10.1042/bj1770521; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINCKE MT, 1992, BIOCHEM J, V282, P877, DOI 10.1042/bj2820877; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; ITOH H, 1990, ARCH BIOCHEM BIOPHYS, V282, P290, DOI 10.1016/0003-9861(90)90119-J; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KINCAID RL, 1986, J CYCLIC NUCL PROT, V11, P473; KOYASU S, 1989, J BIOL CHEM, V264, P15083; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEVENSON RM, 1989, J BIOL CHEM, V264, P11904; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MACKIE KP, 1989, J BIOL CHEM, V264, P1748; MARZOUKI A, 1989, FEBS LETT, V255, P72, DOI 10.1016/0014-5793(89)81063-4; MATTS RL, 1992, J BIOL CHEM, V267, P18160; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MITSUI K, 1992, 1992 M TRANSL CONTR, P182; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MOORE SK, 1989, J BIOL CHEM, V264, P5343; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NAIRN AC, 1987, J BIOL CHEM, V262, P14265; NAIRN AC, 1988, FASEB J, V2, P777; NAIRN AC, 1991, J CELL BIOCHEM     S, V15, P201; NAIRN AC, 1990, ADV SEC MESS PHOSPH, V24, P202; NILSSON A, 1991, EUR J BIOCHEM, V195, P377, DOI 10.1111/j.1432-1033.1991.tb15716.x; NYGARD O, 1991, J BIOL CHEM, V266, P16425; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; ORTI E, 1989, J BIOL CHEM, V264, P231; OVCHINNIKOV LP, 1990, FEBS LETT, V275, P209, DOI 10.1016/0014-5793(90)81473-2; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; PRICE NT, 1991, FEBS LETT, V282, P253, DOI 10.1016/0014-5793(91)80489-P; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; REDPATH NT, 1991, BIOCHIM BIOPHYS ACTA, V1093, P36, DOI 10.1016/0167-4889(91)90135-K; REDPATH NT, 1989, BIOCHEM J, V262, P69, DOI 10.1042/bj2620069; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; RYAZANOV AG, 1987, FEBS LETT, V214, P331, DOI 10.1016/0014-5793(87)80081-9; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; VENEMA RC, 1991, J BIOL CHEM, V266, P11993; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WONG WL, 1991, INT J BIOCHEM, V23, P605; WOODGETT JR, 1987, J BIOL CHEM, V262, P4836	64	75	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13422	13433						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514778				2022-12-25	WOS:A1993LH55300059
J	NOGUCHI, M; ADELSTEIN, S; CAO, XQ; LEONARD, WJ				NOGUCHI, M; ADELSTEIN, S; CAO, XQ; LEONARD, WJ			CHARACTERIZATION OF THE HUMAN INTERLEUKIN-2 RECEPTOR GAMMA-CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CHAIN; MOLECULAR-CLONING; EXPRESSION; PROMOTER; IDENTIFICATION; LOCALIZATION; ORGANIZATION; ACTIVATION; SEQUENCES; PROTEINS	The interleukin-2 (IL-2) receptor gamma chain is an essential component of high and intermediate affinity IL-2 receptors (IL-2Rs), playing critical roles for ligand binding and internalization. We report here the isolation and characterization of the genomic locus for human IL-2Rgamma, which, like IL-2Rbeta, is a member of the cytokine receptor superfamily. The IL-2Rgamma gene is composed of eight exons and seven introns and spans approximately 4.2 kilobases. Analogous to the IL-2Rbeta gene, the two pairs of conserved cysteines typical of cytokine receptor superfamily proteins are located in adjacent exons, and the conserved WSXWS motif is located in the exon preceding the one that encodes the transmembrane domain and a Small part of the cytoplasmic domain. In each gene, the remainder of the cytoplasmic domain is encoded by the final two exons. Southern blot analysis suggests that IL-2Rgamma is encoded by a single copy gene. Cross-hybridizing sequences were detected in DNA derived from a number of other mammalian species but not from yeast. Primer extension analysis and ribonuclease protection assays revealed that there are three principal transcription initiation sites located 32-38 nucleotides 5' to the translation initiation AUG codon. These sites are upstream of the 5' end of the published IL-2Rgamma cDNA sequence. The region 5' to the transcription initiation sites exhibited promoter activity when cloned upstream of the luciferase reporter gene. With this study, the organization of the genes encoding all three chains (alpha, beta, and gamma) of the IL-2 receptor has been determined and promoters for each identified.	NHLBI, PULM & MOLEC IMMUNOL SECT, INTRAMURAL RES PROGRAM, OFF DIRECTOR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Adelstein, Stephen/I-7936-2016; Leonard, Warren/AAA-1397-2022	Adelstein, Stephen/0000-0001-7221-6298; 				ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; BALLARD D W, 1989, New Biologist, V1, P83; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; GORMAN DM, 1992, J BIOL CHEM, V267, P15842; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; ISHIDA N, 1985, NUCLEIC ACIDS RES, V13, P7579, DOI 10.1093/nar/13.21.7579; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEONARD WJ, 1985, SCIENCE, V228, P1547, DOI 10.1126/science.3925551; LEONARD WJ, 1985, SCIENCE, V230, P633, DOI 10.1126/science.2996141; LEONARD WJ, 1984, NATURE, V311, P625; LEONARD WJ, 1992, INTERLEUKIN 2, P29; LIU JM, 1991, VIROLOGY, V182, P361, DOI 10.1016/0042-6822(91)90682-2; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NOGOCHI M, 1993, CELL, V73, P147; SHARON M, 1988, J EXP MED, V167, P1265, DOI 10.1084/jem.167.3.1265; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P551; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303	31	71	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13601	13608						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514792				2022-12-25	WOS:A1993LH55300083
J	McKnight, AJ; Macfarlane, AJ; Dri, P; Turley, L; Willis, AC; Gordon, S				McKnight, AJ; Macfarlane, AJ; Dri, P; Turley, L; Willis, AC; Gordon, S			Molecular cloning of F4/80, a murine macrophage-restricted cell surface glycoprotein with homology to the G-protein linked transmembrane 7 hormone receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONONUCLEAR PHAGOCYTE SYSTEM; ACTIVATED MOUSE MACROPHAGES; IMMUNOHISTOCHEMICAL LOCALIZATION; DENDRITIC CELLS; CALCIUM-BINDING; ANTIGEN F4/80; ENDOCYTOSIS; EXPRESSION; SEQUENCE; REPEATS	F4/80 is a monoclonal antibody that recognizes a murine macrophage-restricted cell surface glycoprotein and has been extensively used to characterize macrophage populations in a wide range of immunological studies. Apart from the tightly regulated pattern of expression of the F4/80 antigen, little is known about its possible role in macrophage differentiation and function, We have sought to characterize the molecule at the molecular level, through the isolation of cDNA clones, and now describe the sequence of the F4/80 protein, The primary amino acid sequence demonstrates homology to two protein superfamilies. The NH2-terminal region consists of seven epidermal growth factor-like domains, separated by approximately 300 amino acids from a COOH-terminal region that shows homology to members of the seven transmembrane-spanning family of hormone receptors, The potential role of these distinct domains is discussed with respect to the possible function of the F4/80 molecule.	UNIV OXFORD,MRC,IMMUNOCHEM UNIT,OXFORD OX1 3RE,ENGLAND	University of Oxford	McKnight, AJ (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.							AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; EZEKOWITZ RAB, 1981, J EXP MED, V154, P60, DOI 10.1084/jem.154.1.60; EZEKOWITZ RAB, 1982, J EXP MED, V155, P1623; GORDON S, 1992, CURR TOP MICROBIOL I, V181, P11; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HUME DA, 1984, J CELL SCI, V66, P189; HUME DA, 1983, J EXP MED, V158, P1522, DOI 10.1084/jem.158.5.1522; HUME DA, 1985, MONONUCLEAR PHAGOCYT, P9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; NUSSENZWEIG MC, 1981, J EXP MED, V154, P168, DOI 10.1084/jem.154.1.168; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REICHERT LE, 1991, TRENDS PHARMACOL SCI, V12, P199, DOI 10.1016/0165-6147(91)90547-6; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; STARKEY PM, 1987, IMMUNOLOGY, V60, P117; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Watson S., 1994, G PROTEIN LINKED REC	23	186	194	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					486	489		10.1074/jbc.271.1.486	http://dx.doi.org/10.1074/jbc.271.1.486			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550607	hybrid			2022-12-25	WOS:A1996TP36100074
J	Sugimoto, T; Haneda, M; Togawa, M; Isono, M; Shikano, T; Araki, S; Nakagawa, T; Kashiwagi, A; Guan, KL; Kikkawa, R				Sugimoto, T; Haneda, M; Togawa, M; Isono, M; Shikano, T; Araki, S; Nakagawa, T; Kashiwagi, A; Guan, KL; Kikkawa, R			Atrial natriuretic peptide induces the expression of MKP-1, a mitogen-activated protein kinase phosphatase, in glomerular mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; MAP KINASE; GENE-PRODUCT; GROWTH; RELAXATION; 3CH134	Atrial natriuretic peptide (ANP) has been shown to inhibit the proliferation of various types of cells including glomerular mesangial cells, The activation of mitogen-activated protein kinase (MAPK) is one of the main signal transduction systems leading to cell proliferation, MAPK is tightly regulated by the activating kinase, MEK, and specific phosphatase MKP-1. Constitutive expression of MKP-1 has been shown to inhibit cell proliferation by suppressing MAPK activity. In order to understand the mechanism of the anti-proliferative effect of ANP, we examined whether ANP could inhibit MAPK by inducing MKP-1 in cultured rat glomerular mesangial cells, ANP increased the expression of MKP-1 mRNA in a dose-dependent (10 nM maximum) and time-dependent, with a peak stimulation at 30 min, manner, Receptor for ANP is a transmembrane guanylyl cyclase, Activation of guanylyl cyclase of ANP receptor by ligand plays an essential role in ANP signal transduction. 8-Bromo-cGMP, a cell permeable analogue of cyclic GMP, and sodium nitroprusside, an activator of soluble guanylyl cyclase, could mimic the effects of ANP and were able to induce the expression of MKP-1 in a similar time course as ANP, The protein expression of MKP-1 was maximally stimulated by ANP at 120 min, Treatment of the cells with ANP for 120 min resulted in an inhibition of phorbol ester-induced activation of MAPK, while the activation of MEK was not affected by ANP. These results indicate that ANP might inhibit the proliferation of mesangial cells by inactivating MAPK through the induction of MKP-1.	SHIGA UNIV MED SCI,DEPT MED 3,OTSU,SHIGA 52021,JAPAN; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Shiga University of Medical Science; University of Michigan System; University of Michigan			Kashiwagi, Atsunori/H-8712-2019					ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DUUFF JL, 1995, J BIOL CHEM, V270, P7161; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; HANEDA M, 1991, KIDNEY INT, V40, P188, DOI 10.1038/ki.1991.199; HANEDA M, 1993, BIOCHEM BIOPH RES CO, V192, P642, DOI 10.1006/bbrc.1993.1463; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KIKKAWA R, 1987, DIABETES, V36, P240, DOI 10.2337/diabetes.36.2.240; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OHLSTEIN EH, 1985, HYPERTENSION, V7, P306, DOI 10.1161/01.HYP.7.2.306; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SINGHAL PC, 1989, AM J PHYSIOL, V257, pC86, DOI 10.1152/ajpcell.1989.257.1.C86; STUDER RK, 1994, KIDNEY INT, V46, P1074, DOI 10.1038/ki.1994.369; SUGIMOTO T, 1993, BIOCHEM BIOPH RES CO, V195, P72, DOI 10.1006/bbrc.1993.2011; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	34	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					544	547		10.1074/jbc.271.1.544	http://dx.doi.org/10.1074/jbc.271.1.544			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550616	hybrid			2022-12-25	WOS:A1996TP36100082
J	Zhou, Z; Misler, S				Zhou, Z; Misler, S			Amperometric detection of quantal secretion from patch-clamped rat pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; ISLET B-CELLS; INSULIN RELEASE; K+ CHANNEL; MOUSE; EXOCYTOSIS; ASSAY; ATP	Serotonin (5-HT) is taken up in insulin granules and co-released with insulin on stimulation of pancreatic islet beta-cells. Based on these observations, we have used microcarbon fiber amperometry to examine secretogogue-induced 5-HT release from rat beta-cells preloaded for 4-16 h with 5-HT and then exposed to a bath solution containing 10 mu M forskolin, In response to local application of KCl (60 mM) or tolbutamide (50-200 mu M), We recorded barrages of amperometric events, Each amperometric event consisted of a short pulse of current measurable at electrode voltages that catalyze 5-HT oxidation. With either secretogogue, release was calcium-dependent. On combining amperometry with perforated patch whole-cell recording, we found that barrages of such events were well coupled in time and graded in intensity with depolarization-induced Ca2+ currents and well correlated with increases in membrane capacitance. In cell-attached patch recording, amperometric events evoked by application of tolbutamide followed the closure of ATP-sensitive K+ channels and coincided with the onset of electrical activity. These experiments suggest that amperometry is a useful technique for studying, in real time, the dynamic aspects of stimulus-secretion coupling in beta-cells. Their performance was facilitated by the design of a new carbon fiber electrode (ProCFE) described within.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,MED CTR,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)			zhou, zhuan/A-8285-2011		NIDDK NIH HHS [DK37380] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037380] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ARMSTRONGJAMES M, 1979, J NEUROSCI METH, V1, P279, DOI 10.1016/0165-0270(79)90039-6; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; BARNETT DW, 1995, PFLUG ARCH EUR J PHY, V430, P593, DOI 10.1007/BF00373898; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; EKHOLM R, 1971, DIABETOLOGIA, V7, P339, DOI 10.1007/BF01219468; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; GILLIS KD, 1993, PFLUG ARCH EUR J PHY, V424, P195, DOI 10.1007/BF00374612; GILLIS KD, 1989, AM J PHYSIOL, V257, pC1119, DOI 10.1152/ajpcell.1989.257.6.C1119; GILLIS KD, 1992, PFLUG ARCH EUR J PHY, V420, P121, DOI 10.1007/BF00378654; GYLFE E, 1980, ACTA PHYSIOL SCAND, V109, P155, DOI 10.1111/j.1748-1716.1980.tb06581.x; GYLFE E, 1978, J ENDOCRINOL, V78, P239, DOI 10.1677/joe.0.0780239; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HELLMAN B, 1972, BIOCHEM PHARMACOL, V21, P695, DOI 10.1016/0006-2952(72)90062-7; HERRINGTON J, 1993, PULSE CONTROL MANUAL; HIRIART M, 1988, J GEN PHYSIOL, V91, P617, DOI 10.1085/jgp.91.5.617; KAWAGOE KT, 1993, J NEUROSCI METH, V48, P225, DOI 10.1016/0165-0270(93)90094-8; KENNEDY RT, 1993, ANAL CHEM, V65, P1882, DOI 10.1021/ac00062a012; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; PEREZARMENDARIZ M, 1991, BIOPHYS J, V59, P76, DOI 10.1016/S0006-3495(91)82200-7; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PRESSEL DM, 1991, J MEMBRANE BIOL, V124, P239, DOI 10.1007/BF01994357; PROKS P, 1995, IN PRESS J PHYSL LON; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; RORSMAN P, 1985, PFLUG ARCH EUR J PHY, V405, P305, DOI 10.1007/BF00595682; SCOTT AM, 1981, DIABETOLOGIA, V21, P470; SMITH PA, 1995, PFLUG ARCH EUR J PHY, V430, P808, DOI 10.1007/BF00386180; Stamford JA, 1992, MONITORING NEURONAL, P113; TOLEDO GA, 1993, NATURE, V363, P554; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; ZHOU Z, 1995, J BIOL CHEM, V270, P3498, DOI 10.1074/jbc.270.8.3498; ZHOU Z, 1995, P NATL ACAD SCI USA, V92, P6938, DOI 10.1073/pnas.92.15.6938; Zhou Z., 1995, Society for Neuroscience Abstracts, V21, P334; Zhou Z., 1995, Biophysical Journal, V68, pA117; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245, DOI 10.1113/jphysiol.1993.sp019813	42	104	116	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					270	277		10.1074/jbc.271.1.270	http://dx.doi.org/10.1074/jbc.271.1.270			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550572	hybrid			2022-12-25	WOS:A1996TP36100042
J	Hodge, DR; Robinson, L; Watson, D; Lautenberger, J; Zhang, XK; Venanzoni, M; Seth, A				Hodge, DR; Robinson, L; Watson, D; Lautenberger, J; Zhang, XK; Venanzoni, M; Seth, A			Interaction of ETS-1 and ERGB/FLI-1 proteins with DNA is modulated by spacing between multiple binding sites as well as phosphorylation	ONCOGENE			English	Article						ETS-1,ERGB FL1-1; transcription factors; HIV-1 enhancer; transactivation; EBS palindrome; Cam-KII phosphorylation site	TRANSCRIPTION; COMPLEX; FAMILY; GENE; IDENTIFICATION; PROTOONCOGENE; ACTIVATION; MECHANISM; SEQUENCES; ONCOGENE	ETS is a family of transcription factors that contain a highly conserved ETS DNA binding domain. Various members of the ETS family are expressed in cells of hematopoietic lineage. ETS-1, ETS-2 and ERGB/FLI-1 are expressed at high levels in T-lymphocytes. HIV-1 infects T-cells and it has been shown that its LTR contains binding sites for various transcription factors. In this study we show that the HIV-1 core enhancer is directly regulated by ERGB/FLI-1 protein positively, as well as, negatively, depending upon the presence or absence of accessory factors in different cell types. In addition, we show that the ETS-1 transactivation activity is enhanced upon dephosphorylation of the Calmodulin-dependant Protein Kinase II phosphorylation site located in exon VII. Finally, we demonstrate that the spacing two EBS cores in palindromic or direct play a crucial role in binding of ETS proteins to DNA.	UNIV TORONTO, DEPT PATHOL, TORONTO, ON M5S 1B2, CANADA; UNIV TORONTO, MRC, PERIODONTAL PHYSIOL GRP, TORONTO, ON M5S 1B2, CANADA; WOMENS COLL HOSP, MOLEC PATHOL LAB, TORONTO, ON M5S 1B2, CANADA; NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA; PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21702 USA; MED UNIV S CAROLINA, CTR MOLEC & STRUCT BIOL, CHARLESTON, SC 29425 USA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Medical University of South Carolina								ASCIONE R, 1992, INT J ONCOL, V1, P631; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CULLEN BR, 1992, AIDS RES HUM RETROV, V8, P387, DOI 10.1089/aid.1992.8.387; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DALTON S, 1993, PHILOS T ROY SOC B, V340, P325, DOI 10.1098/rstb.1993.0074; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HODGE DR, 1993, MIAMI SHORT REP, V3, P32; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; KOIZUMI S, 1990, ONCOGENE, V5, P675; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; PAPAS TS, 1991, SER SYMP AD, V4, P211; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; RABAULT B, 1994, J BIOL CHEM, V269, P28143; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1989, ONCOGENE RES, V5, P61; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SETH A, 1994, ONCOGENE, V9, P469; SETH A, 1990, ONCOGENE, V5, P1761; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; VENANZONI MC, 1996, IN PRESS ONCOGENE; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792	31	31	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					11	18						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552380				2022-12-25	WOS:A1996TQ01400002
J	Srinivasan, R; Maxwell, SA				Srinivasan, R; Maxwell, SA			A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region	ONCOGENE			English	Article						p53; DNA-binding; regulation; non-small cell lung carcinoma; tumor suppressors	WILD-TYPE P53; LARGE T-ANTIGEN; TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; SIMIAN VIRUS-40; MOUSE P53; TRANSCRIPTIONAL ACTIVATION; CONFORMATIONAL DOMAIN; GENE-PRODUCT; RAT-CELLS	Mutational inactivation of the p53 gene product is one of the most common genetic aberrations so far identified in human cancers. The p53 protein suppresses the transformed phenotype by transactivation or repression of genes involved in cell growth control. Missense mutations in the p53 protein coding sequence observed in human cancers are clustered within a central conserved (conformational) domain spanning amino acid residues 100-300 of a total of 393. Using the conformational domain of p53 fused with protein A, we have shown that the p53 conformational domain possesses Zn+2-dependent, sequence-specific DNA-binding activity. In addition to binding DNA, this domain interacts with at least five cellular proteins ranging in sizes from 30K to 90K M(r) and with the SV40 large T antigen viral oncoprotein. We investigated these cellular proteins for their modulatory effects on the sequence-specific DNA binding activity of full-length wild-type p53. A mixture of p53 conformational domain-binding proteins in bulk enhanced the DNA-binding activity of p53 greater than two-fold. Selective elution of the p53-binding proteins from the p53 hybrid protein by using a sequential step-wise NaCl gradient implicated one protein of 35K M(r) as contributing to a greater than four-fold activation of p53 DNA-binding activity. A p53 conformational domain protein containing a tumor-derived mutation at amino acid 175 failed to associate with the 35K M(r) protein. We propose that proteins interacting with the conformational domain of wild type p53 regulate the DNA-binding activity of p53, thus providing a biochemical basis for the alterations in its function induced by point mutations.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC & CARDIOVASC SURG,SECT THORAC MOLEC ONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA045187, P30CA016672, R37CA045187] Funding Source: NIH RePORTER; NCI NIH HHS [CA45187, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARTEK J, 1993, EUR J CANCER, V29A, P101, DOI 10.1016/0959-8049(93)90584-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EFRAT S, 1987, EMBO J, V6, P2699, DOI 10.1002/j.1460-2075.1987.tb02562.x; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAINAUT P, 1993, CANCER RES, V53, P1739; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MAXWELL SA, 1995, ONCOL REP, V2, P81; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIDGWAY PJ, 1993, ONCOGENE, V8, P1069; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TISHLER RB, 1993, CANCER RES, V53, P2212; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG WW, 1994, CANCER GENE THER, V1, P1; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	81	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					193	200						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552392				2022-12-25	WOS:A1996TQ01400024
J	Gu, ZX; Quan, YD; Li, Z; Arts, EJ; Wainberg, MA				Gu, ZX; Quan, YD; Li, Z; Arts, EJ; Wainberg, MA			Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIDOVUDINE AZT; BINDING-SITE; HIV-1; RESISTANCE; SENSITIVITY; INVITRO; BI-RG-587; MUTATION; THERAPY; ANALOGS	We have employed a cell-free human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) assay to study the effects of non-nucleoside inhibitors of RT (NNRTI) by directly monitoring specific HIV DNA products using a HIV-1 genome-derived template and an oligodeoxynucleotide primer. As previously shown by ourselves and others, nucleoside analog triphosphates, e.g. 3'-azido-3'-deoxythymidine triphosphate and 2',3'-dideoxyadenosine triphosphate, could directly inhibit HIV RT RNA-dependent DNA polymerase activity by causing chain termination, as visualized in a RT reaction that yields specific DNA products. In contrast, each of two NNRTIs, nevirapine and delavirdine, directly inhibited RT activity without causing chain termination effects. We also analyzed interactions between nucleoside analogs and NNRTIs or among NNRTIs by chain elongation/dNTP incorporation and/or steady-state kinetic assays. Combinations of nevirapine with the triphosphates of either the (-)-strand of 2',3'-dideoxy-3'-thiacytidine or 2',3'-dideoxyadenosine yielded additive/ synergistic effects on RT activity. However, only an additive effect was observed when combinations of nevirapine and 3'-azido-3'-deoxythymidine triphosphate were employed. Combinations of nevirapine and delavirdine had an antagonistic effect on the inhibition of HIV-1 RT activity.	MCGILL UNIV,JEWISH GEN HOSP,LADY DAVIS INST,CTR AIDS,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University				Arts, Eric/0000-0002-4880-7968				BALZARINI J, 1993, P NATL ACAD SCI USA, V90, P6952, DOI 10.1073/pnas.90.15.6952; CHOU TC, 1984, ADV ENZYME REGUL, V22, P17; COHEN KA, 1991, J BIOL CHEM, V266, P14670; DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9; DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407; ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303; FARAJ A, 1994, ANTIMICROB AGENTS CH, V38, P2300, DOI 10.1128/AAC.38.10.2300; GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863; GU ZX, 1995, P NATL ACAD SCI USA, V92, P2760, DOI 10.1073/pnas.92.7.2760; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; GU ZX, 1994, J BIOL CHEM, V269, P28118; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KOUP RA, 1993, AIDS, V7, P1181, DOI 10.1097/00002030-199309000-00005; LACEY SF, 1992, J BIOL CHEM, V267, P15789; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; MAZUMDER A, 1994, P NATL ACAD SCI USA, V91, P5771, DOI 10.1073/pnas.91.13.5771; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; NUNBERG JH, 1991, J VIROL, V65, P4887, DOI 10.1128/JVI.65.9.4887-4892.1991; RICHMAN D, 1991, ANTIMICROB AGENTS CH, V35, P305, DOI 10.1128/AAC.35.2.305; RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241; ROOKE R, 1989, AIDS, V3, P411, DOI 10.1097/00002030-198907000-00001; Segel I.H., 1975, ENZYME KINETICS; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; VANDAMME AM, 1994, AIDS RES HUM RETROV, V10, P39, DOI 10.1089/aid.1994.10.39; Weiss R, 1985, RNA TUMOR VIRUSES; WHITE EL, 1993, ANTIVIR RES, V22, P295, DOI 10.1016/0166-3542(93)90039-L; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003; ZHANG D, 1994, ANTIMICROB AGENTS CH, V38, P282, DOI 10.1128/AAC.38.2.282	35	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31046	31051		10.1074/jbc.270.52.31046	http://dx.doi.org/10.1074/jbc.270.52.31046			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537362	hybrid			2022-12-25	WOS:A1995TN44400030
J	Winston, LA; Hunter, T				Winston, LA; Hunter, T			JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase mitogenactivated protein kinase by growth hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; RECEPTOR; DOMAIN; CELLS	Protein-tyrosine kinases (PTKs) of the JAK family have been characterized on the basis of their ability to mediate the rapid induction of transcription of interferon-responsive genes through the stimulation of a class of latent cytoplasmic transcription factors known as signal transducers and activators of transcription (STATs). STAT activation, which has been described as being Ras-independent, requires tyrosine phosphorylation, but STAT transactivating activity is enhanced by phosphorylation on serine as well, probably by extracellular signal-regulated kinase/mitogen-activated protein kinase(s) (ERK/MAPK), STATs can be activated upon binding of ligands to receptor PTKs, to G-protein-linked receptors, and to cytokine receptors, Whether JAKs are required for the activation of signaling pathways other than that leading to STAT activation is not known. The binding of growth hormone (GH) to its receptor (GHR) activates JAK2 and STATs as well as ERK/MAP kinases. We have used a transient transfection system in 293 cells to evaluate the requirement for JAK2 in the activation of ERK2/MAPK by GH, We found that JAK2 is required for GH-stimulated activation of ERK2/MAPK. Employing the transient expression of dominant negative forms of H-Ras and Raf-1, we determined that the GHR/JAK2-mediated activation of ERK2/MAPK is dependent on both Ras and Raf. Thus, JAK protein-tyrosine kinases may represent a common component in the activation of the ERK2/MAPK and STAT signaling pathways, which appear to bifurcate upstream of Ras activation but converge with ERK/MAPK phosphorylation of STATs.			Winston, LA (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007698] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780] Funding Source: Medline; NICHD NIH HHS [HD07698] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON N G, 1992, Biochemical Society Transactions, V20, p270S; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BARINAGA M, 1995, SCIENCE, V269, P1673, DOI 10.1126/science.7569891; BRISCOE J, 1994, CURR BIOL, V4, P1033, DOI 10.1016/S0960-9822(00)00236-0; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; COFFER P, 1995, ONCOGENE, V10, P985; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LOBIE PE, 1995, J BIOL CHEM, V270, P21745, DOI 10.1074/jbc.270.37.21745; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; SUZUKI K, 1990, J BIOL CHEM, V265, P11320; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WEI L, 1994, MOL CELL BIOL, V14, P509; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411	47	159	160	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30837	30840		10.1074/jbc.270.52.30837	http://dx.doi.org/10.1074/jbc.270.52.30837			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537333	hybrid			2022-12-25	WOS:A1995TN44400001
J	Gaudino, G; Avantaggiato, V; Follenzi, A; Acampora, D; Simeone, A; Comoglio, PM				Gaudino, G; Avantaggiato, V; Follenzi, A; Acampora, D; Simeone, A; Comoglio, PM			The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues	ONCOGENE			English	Article						bone; development; MSP; neuroendocrine tissues; RON	HEPATOCYTE GROWTH-FACTOR; MACROPHAGE STIMULATING PROTEIN; TYROSINE KINASE; SCATTER FACTOR; C-MET; FACTOR-RECEPTOR; PROTOONCOGENE; CELLS; IDENTIFICATION; EXPRESSION	We previously showed that the proto-oncogene RON encodes the tyrosine kinase receptor for Macrophage Stimulating Protein (MSP), originally isolated as a chemotactic factor for peritoneal macrophages. To elucidate the biological role of MSP we studied the expression of the Ron receptor in vivo, and the response to the factor in vitro, RON specific transcripts were detectable in mouse liver from early embryonal life (day 12.5 p.c.) through adult life, Adrenal gland, spinal ganglia, skin, lung and - unexpectedly - ossification centers of developing mandible, clavicle and ribs were also positive at later stages (day 13.5-16.5 p.c.). From day 17.5 RON was expressed in the gut epithelium and in a specific area of the central nervous system, corresponding to the nucleus of the hypoglossus, In adult mouse tissues RON transcripts were observed in brain, adrenal glands, gastro-intestinal tract, testis and kidney, Epithelial, osteoclast-like and neuroendocrine cells express the Ron receptor and respond to MSP in vitro. In the neuroendocrine PC12 cell line, while NGF induced growth arrest and morphological differentiation, MSP behaved as a strong mitogen. These findings show that the Ron receptor and its ligand are involved in the development of epithelial tissues, bones, and neuroendocrine derivatives driving cells towards the proliferation program.	UNIV TURIN,CANC RES INST,SCH MED,I-10126 TURIN,ITALY; INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	University of Turin; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			Simeone, Antonio/ABG-5269-2020; Acampora, Dario/C-2156-2013	Simeone, Antonio/0000-0003-2693-9836; Comoglio, Paolo/0000-0002-7056-5328; Follenzi, Antonia/0000-0001-9780-300X				BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAN AML, 1988, ONCOGENE, V2, P593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FRIEZNERDEGEN SJ, 1991, BIOCHEMISTRY-US, V30, P9781; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GRANO M, 1994, J BONE MINER RES, V9, P1013; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; Kuhlenbeck H., 1973, CENTRAL NERVOUS SYST; Larsen WJ, 1993, HUMAN EMBRYOLOGY; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PFEILSCHIFTER J, 1990, J BONE MINER RES, V5, P825; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SACCONE S, 1992, GENOMICS, V13, P912, DOI 10.1016/0888-7543(92)90191-T; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; THEILER K, 1989, HOUSE MOUSE; THOROGOOD P, 1988, DEVELOPMENT, V103, P141; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	43	102	107	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2627	2637						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545120				2022-12-25	WOS:A1995TP18800019
J	Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM				Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM			High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident	ONCOGENE			English	Article						RET oncogene; RT-PTC1; ret/PTC1; ret/PTC3; papillary thyroid carcinoma; RET/ELE transcript	TYROSINE KINASE ONCOGENES; PROTO-ONCOGENE; CARCINOMAS; ACTIVATION; CANCER; PTC; PROTOONCOGENE; EXPRESSION; GLAND; RAS	RET rearrangement was studied in papillary thyroid carcinomas (PTC) of children exposed to radioactive fallout in Belarus after the Chernobyl accident, To detect RET rearrangement in small tissue samples from thyroidectomy specimen (12 PTC of children; 2 PTC and 1 follicular carcinoma of adults; non-tumorous thyroid tissue of 4 children and 4 adults as controls), a RT-multiplex PCR was developed using primers suited to amplify fragments in different quantities depending on the presence or absence of RET rearrangements in the tissues, The type of rearrangement was determined by RT-PCR and direct sequencing using primers for ret/PTC1, 2 and 3, Two-thirds of the papillary thyroid carcinomas of the children revealed a RET rearrangement, with ret/PTC3 being more frequent by a factor of 3 than ret/PTC1. ret/PTC2 was not detected, All RET rearrangement-positive tumors had lymph node metastasis while half of the tumors with wild-type cRET had not, More than half of the cases with ret/PTC3 expressed not only the ELE/RET transcript as expected, but also the RET/ELE transcript, Intrachromosomal rearrangement involving RET and the adjacent H4 or ELE gene on chromosome no, 10 is a very frequent event in thyroid cancer of children of the Chernobyl-contaminated zone of Belarus.	UNIV MUNICH, INST PATHOL, D-80337 MUNICH, GERMANY; UNIV MUNICH, INST RADIAT BIOL, MUNICH, GERMANY; MED HIGH SCH MINSK, CHAIR ONCOL, MINSK, BELARUS	University of Munich; University of Munich								AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BOS JL, 1989, CANCER RES, V49, P4682; CHOU Q, 1992, NUCLEIC ACIDS RES, V20, P1717, DOI 10.1093/nar/20.7.1717; DIRENZO MF, 1992, ONCOGENE, V7, P2549; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; FABIEN N, 1992, BRIT J CANCER, V66, P1094, DOI 10.1038/bjc.1992.416; FURMANCHUK AW, 1992, HISTOPATHOLOGY, V21, P401, DOI 10.1111/j.1365-2559.1992.tb00423.x; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1992, CANCER RES, V52, P1369; ITO T, 1994, LANCET, V344, P259; JHIANG SM, 1992, ONCOGENE, V7, P1331; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KUMA K, 1993, MOL BIOL EVOL, V10, P539; KWOK JBJ, 1993, ONCOGENE, V8, P2575; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; SHORE RE, 1993, AM J EPIDEMIOL, V137, P1068, DOI 10.1093/oxfordjournals.aje.a116610; SOZZI G, 1992, GENE CHROMOSOME CANC, V5, P212, DOI 10.1002/gcc.2870050307; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; ZOU MJ, 1994, CANCER, V73, P176, DOI 10.1002/1097-0142(19940101)73:1<176::AID-CNCR2820730130>3.0.CO;2-T	40	267	271	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2459	2467						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545102				2022-12-25	WOS:A1995TP18800001
J	JORDAN, C; PUSCHEL, B; KOOB, R; DRENCKHAHN, D				JORDAN, C; PUSCHEL, B; KOOB, R; DRENCKHAHN, D			IDENTIFICATION OF A BINDING MOTIF FOR ANKYRIN ON THE ALPHA-SUBUNIT OF NA+,K+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANE; PLASMA-MEMBRANE; CDNA SEQUENCE; ANION-EXCHANGER; PROTEIN; NA,K-ATPASE; KIDNEY; BAND-3; CELLS; CYTOSKELETON	Cytoskeleton membrane associations are important for a variety of cellular functions. The anion exchanger of erythrocytes (AE1) and Na+,K+-ATPase of polarized epithelial cells provide well studied examples of how integral membrane proteins are anchored via the linker molecule ankyrin to the spectrin-based membrane cytoskeleton. In the present study we have generated several recombinant fragments of the large (third) cytoplasmic domain (CD3) of Na+,K+-ATPase to define binding sites of ankyrin on CD3 at a molecular level. We provide evidence that a cluster of four amino acids, ALLK, is essential for binding of ankyrin to both recombinant CD3 and to native Na+,K+-ATPase. Once bound, conformational changes might uncover further binding sites for ankyrin on Na+,K+-ATPase. A motif related to the ALLK cluster is also present in the cytoplasmic domain of AEl where this sequence (ALLK) turned out to be also important for ankyrin binding. These motifs are highly conserved during evolution of both Na+,K+-ATPase and AE1, further underlining their potential role in cytoskeleton to membrane linkage.	UNIV WURZBURG,INST ANAT,D-97070 WURZBURG,GERMANY	University of Wurzburg								ALPER SL, 1994, J CLIN INVEST, V93, P1430, DOI 10.1172/JCI117120; ATHERTON E, 1981, J CHEM SOC PERK T 1, P538, DOI 10.1039/p19810000538; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; COX JV, 1988, MOL CELL BIOL, V8, P1327, DOI 10.1128/MCB.8.3.1327; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; DRENCKHAHN D, 1995, TREATISE CYTOSKELETO, V2; DRENCKHAHN D, 1985, SCIENCE, V230, P1281; Glover D.M, 1985, DNA CLONING PRACTICA; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERRERA VLM, 1987, J CELL BIOL, V105, P1855, DOI 10.1083/jcb.105.4.1855; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; JAUNIN P, 1992, J BIOL CHEM, V267, P577; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KOOB R, 1987, European Journal of Cell Biology, V45, P230; KOOB R, 1990, EUR J CELL BIOL, V53, P93; KRAEMER D, 1990, J CELL BIOL, V111, P2377; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOVITZ RM, 1989, EMBO J, V8, P193, DOI 10.1002/j.1460-2075.1989.tb03364.x; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SULKOWSKI E, 1985, TRENDS BIOTECHNOL, V3, P1, DOI 10.1016/0167-7799(85)90068-X; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; WALLACE RB, 1979, NUCLEIC ACIDS RES, V6, P3543, DOI 10.1093/nar/6.11.3543; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; WOOD PG, 1992, PROGR CELL RES, V2, P325	42	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29971	29975						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530398				2022-12-25	WOS:A1995TK38000058
J	LANGLEY, E; ZHOU, ZX; WILSON, EM				LANGLEY, E; ZHOU, ZX; WILSON, EM			EVIDENCE FOR AN ANTI-PARALLEL ORIENTATION OF THE LIGAND-ACTIVATED HUMAN ANDROGEN RECEPTOR DIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; BULBAR MUSCULAR-ATROPHY; DNA-BINDING DOMAIN; GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; ESTROGEN-RECEPTOR; STEROID-BINDING; HIGH-AFFINITY; TRANSCRIPTIONAL ACTIVATION; PROGESTERONE-RECEPTOR	Domain interactions of the human androgen receptor (AR) dimer were investigated using a protein-protein interaction assay in which the NH2- and carboxyl-terminal regions of human AR mere fused to the Saccharomyces cerevisiae GAL4 DNA-binding domain and herpes simplex virus VP16 transactivation domain to produce chimeric proteins. Transcriptional activation of a GAIA luciferase reporter vector up to 100-fold was greater than Fos/Jun leucine zipper binding, indicating stable AR interaction between AR NH2-terminal residues 1-503 and steroid-binding domain residues 624-919 that was specific for and dependent on androgen binding to the steroid-binding domain and was inhibited by anti-androgen binding, Deletion mutagenesis within the NH2-terminal region indicated transactivation domain residues 142-337 were not required for dimerization, whereas deletions near the NH2 terminus (Delta 14-150) or NH2-terminal to the DNA-binding domain (Delta 339-499) reduced or eliminated the AR interaction, respectively, An NH2-/NH2-terminal interaction was also observed, but no interaction was detected between ligand-free or bound steroid-binding domains. The results indicate that high affinity androgen binding promotes interactions between the NH2-terminal and steroid-binding domains of human AR, raising the possibility of an androgen-induced anti-parallel AR dimer.	UNIV N CAROLINA,REPROD BIOL LABS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Langley, Elizabeth/0000-0001-6180-8036	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD018968, R37HD016910, R01HD016910] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD18968, HD16910] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; COHENSOLAL K, 1993, EUR J BIOCHEM, V214, P189, DOI 10.1111/j.1432-1033.1993.tb17912.x; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DAHLMANWRIGHT K, 1993, J STEROID BIOCHEM, V45, P239, DOI 10.1016/0960-0760(93)90338-W; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; ERIKSSON P, 1991, J STRUCT BIOL, V107, P48, DOI 10.1016/1047-8477(91)90030-Z; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINKEL T, 1993, J BIOL CHEM, V268, P5; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; French F S, 1990, Recent Prog Horm Res, V46, P1; FURLOW JD, 1993, J BIOL CHEM, V268, P12519; HARRIS SE, 1991, MOLECULAR AND CELLULAR BIOLOGY OF PROSTATE CANCER, P315; HO KC, 1993, J BIOL CHEM, V268, P27226; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEE JW, 1992, MOL ENDOCRINOL, V6, P1867, DOI 10.1210/me.6.11.1867; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LORENI F, 1988, MOL CELL BIOL, V8, P2350, DOI 10.1128/MCB.8.6.2350; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MCPHAUL MJ, 1991, FASEB J, V5, P2910, DOI 10.1096/fasebj.5.14.1752359; MOHAMED MK, 1994, J STEROID BIOCHEM, V51, P241, DOI 10.1016/0960-0760(94)90036-1; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; PATTERSON MN, 1994, BAILLIERE CLIN ENDOC, V8, P379, DOI 10.1016/S0950-351X(05)80258-7; PRINS GS, 1991, ENDOCRINOLOGY, V129, P3187, DOI 10.1210/endo-129-6-3187; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RODRIGUEZ R, 1990, MOL ENDOCRINOL, V4, P1782, DOI 10.1210/mend-4-12-1782; SABBAH M, 1989, J BIOL CHEM, V264, P2397; SALOMONSSON M, 1994, J STEROID BIOCHEM, V48, P447, DOI 10.1016/0960-0760(94)90192-9; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; TAN JA, 1992, J BIOL CHEM, V267, P4456; THOLE HH, 1994, J STEROID BIOCHEM, V48, P463, DOI 10.1016/0960-0760(94)90194-5; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VELDSCHOLTE J, 1990, BIOCHIM BIOPHYS ACTA, V1052, P187, DOI 10.1016/0167-4889(90)90075-O; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WONG CI, 1993, J BIOL CHEM, V268, P19004; WONG CI, 1995, J BIOL CHEM, V270, P19998, DOI 10.1074/jbc.270.34.19998; WRANGE O, 1989, J BIOL CHEM, V264, P5253; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115; ZHUANG Y, 1995, MOL ENDOCRINOL, V9, P457, DOI 10.1210/me.9.4.457	60	226	240	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29983	29990						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530400				2022-12-25	WOS:A1995TK38000060
J	CUI, JS; NI, LY; SOMERVILLE, RL				CUI, JS; NI, LY; SOMERVILLE, RL			ATPASE ACTIVITY OF TYRR, A TRANSCRIPTIONAL REGULATORY PROTEIN FOR SIGMA(70) RNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI K-12; GENE; ACTIVATOR; REPRESSOR; PROMOTER; MTR	The TyrR protein of Escherichia coli is the chief transcriptional regulator of several genes essential for aromatic amino acid biosynthesis and transport. It was established in previous studies that this protein binds ATP, that the TyrR . ATP complex has enhanced affinity for tyrosine, and that the susceptibility of the TyrR protein to hydrolysis by trypsin is altered by ATP. Here we show that the TyrR protein has ATPase activity, which is stimulated by tyrosine. In this respect the TyrR protein resembles the transcriptional activator NtrC. The NtrC protein contains an internal polypeptide segment, 220 amino acid residues in length, with a high degree of identity to the TyrR protein, that contains the presumptive ATPase catalytic center.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022131] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22131] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; ANDREWS AE, 1991, J BACTERIOL, V173, P5079, DOI 10.1128/jb.173.16.5079-5085.1991; ARGYROPOULOS VS, 1989, THESIS U MELBOURNE A; AUSTIN S, 1991, NUCLEIC ACIDS RES, V19, P2281, DOI 10.1093/nar/19.9.2281; AUSTIN S, 1992, EMBO J, V11, P2219, DOI 10.1002/j.1460-2075.1992.tb05281.x; CONWAY TW, 1964, P NATL ACAD SCI USA, V52, P1462, DOI 10.1073/pnas.52.6.1462; CORNISH EC, 1986, J BIOL CHEM, V261, P403; CUI JS, 1993, J BACTERIOL, V175, P1777, DOI 10.1128/JB.175.6.1777-1784.1993; CUI JS, 1993, J BIOL CHEM, V268, P5040; CUI JS, 1993, J BACTERIOL, V175, P303, DOI 10.1128/JB.175.1.303-306.1993; HEATWOLE VM, 1991, J BACTERIOL, V173, P3601, DOI 10.1128/jb.173.11.3601-3604.1991; KASIAN PA, 1986, J BACTERIOL, V167, P556, DOI 10.1128/jb.167.2.556-561.1986; KRISHNAN PS, 1955, METHOD ENZYMOL, V2, P591, DOI 10.1016/S0076-6879(55)02260-X; PITTARD AJ, 1991, MOL MICROBIOL, V5, P1585, DOI 10.1111/j.1365-2958.1991.tb01904.x; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; SARSERO JP, 1991, J BACTERIOL, V173, P4133, DOI 10.1128/jb.173.13.4133-4143.1991; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WHIPP MJ, 1977, J BACTERIOL, V132, P453, DOI 10.1128/JB.132.2.453-461.1977; YANG J, 1993, J BACTERIOL, V175, P1767, DOI 10.1128/JB.175.6.1767-1776.1993	20	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13023	13025						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514743				2022-12-25	WOS:A1993LH55300004
J	KUNO, K; OKAMOTO, S; HIROSE, K; MURAKAMI, S; MATSUSHIMA, K				KUNO, K; OKAMOTO, S; HIROSE, K; MURAKAMI, S; MATSUSHIMA, K			STRUCTURE AND FUNCTION OF THE INTRACELLULAR PORTION OF THE MOUSE INTERLEUKIN-1 RECEPTOR (TYPE-I) - DETERMINING THE ESSENTIAL REGION FOR TRANSDUCING SIGNALS TO ACTIVATE THE INTERLEUKIN-8 GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; IL-1 RECEPTOR; CYTOPLASMIC REGION; ENDOTHELIAL-CELLS; DOWN-REGULATION; LIGAND-BINDING; BETA-CHAIN; CYCLIC-AMP; PROTEIN; EXPRESSION	The structural and functional relationships of the intracellular portion of mouse interleukin 1 receptor (muIL-1R) type I were examined with regard to activation of the human IL-8 gene in the Jurkat T cell line. C-terminal deletion mutations of muIL-1R revealed that the C-terminal boundary for receptor function is localized between 28 and 42 amino acids from the C-terminal end. The internal deletion mutants between amino acids 364 and 474 had a loss of activity, demonstrating the requirement for a large region of the mIL-1R cytoplasmic portion for receptor function. Amino acid substitution revealed that the putative nuclear localization elements (amino acids at 429-433, 523-527, and 507-519) and putative protein kinase C or A acceptor sites (Ser-431, Ser-509, Ser-528) do not participate in IL-1 signaling to induce IL-8 gene expression. A truncated mutation within the segment, which possesses homology with gp130, beta chain of IL-6R, or a point mutation of box 1- and box 2-like elements within the gp130 homologous segment, abolished the capacity to induce IL-8 gene expression, suggesting similar structural requirements in the cytoplasmic portion of several cytokine receptors.	KANAZAWA UNIV, CANC RES INST, DEPT PHARMACOL, 13-1 TAKARA MACHI, KANAZAWA, ISHIKAWA 920, JAPAN; NCI, FREDERICK CANC RES & DEV CTR, DIV CANC TREATMENT, BIOL RESPONSE MODIFIERS PROGRAM, FREDERICK, MD 21702 USA; KANAZAWA UNIV, CANC RES INST, DEPT BIOPHYS, KANAZAWA, ISHIKAWA 920, JAPAN	Kanazawa University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Kanazawa University			KUNO, Kouji/D-8439-2015					AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALDARI CT, 1991, J BIOL CHEM, V266, P19103; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BIRD TA, 1989, J IMMUNOL, V142, P126; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTIS BM, 1990, J IMMUNOL, V144, P1295; CURTIS BM, 1989, P NATL ACAD SCI USA, V86, P3045, DOI 10.1073/pnas.86.9.3045; DINARELLO CA, 1991, BLOOD, V77, P1627; DORN PL, 1988, J VIROL, V62, P3522, DOI 10.1128/JVI.62.9.3522-3526.1988; DOWER SK, 1989, J IMMUNOL, V142, P4314; DOWER SK, 1987, IMMUNOL TODAY, V8, P46, DOI 10.1016/0167-5699(87)90238-6; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; DOWER SK, 1986, P NATL ACAD SCI USA, V83, P1060, DOI 10.1073/pnas.83.4.1060; FURUTANI Y, 1985, NUCLEIC ACIDS RES, V13, P5869, DOI 10.1093/nar/13.16.5869; GALLIS B, 1989, J IMMUNOL, V143, P3235; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HORUK R, 1987, J BIOL CHEM, V262, P16275; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; LARSEN CG, 1989, BIOCHEM BIOPH RES CO, V160, P1403, DOI 10.1016/S0006-291X(89)80160-3; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P95; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVIN EG, 1991, J IMMUNOL, V146, P3772; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1987, J IMMUNOL, V139, P3367; MATSUSHIMA K, 1986, J IMMUNOL, V136, P4496; MATSUSHIMA K, 1986, J IMMUNOL, V137, P3183; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; MORI H, 1991, INT IMMUNOL, V3, P149, DOI 10.1093/intimm/3.2.149; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SICA A, 1990, J IMMUNOL, V144, P3034; SIMS JE, 1989, P NATL ACAD SCI USA, V86, P8946, DOI 10.1073/pnas.86.22.8946; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAGISAWA H, 1990, IMMUNOLOGY, V71, P242; YAMAYOSHI M, 1990, LYMPHOKINE RES, V9, P405; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	55	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13510	13518						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514784				2022-12-25	WOS:A1993LH55300071
J	PETERSEN, JGL; MEYN, G; RASMUSSEN, JS; PETERSEN, J; BJORN, SE; JONASSEN, I; CHRISTIANSEN, L; NORDFANG, O				PETERSEN, JGL; MEYN, G; RASMUSSEN, JS; PETERSEN, J; BJORN, SE; JONASSEN, I; CHRISTIANSEN, L; NORDFANG, O			CHARACTERIZATION OF HUMAN TISSUE FACTOR PATHWAY INHIBITOR VARIANTS EXPRESSED IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION INHIBITOR; EXTRINSIC PATHWAY; FACTOR-XA; NUCLEOTIDE-SEQUENCE; MONOCLONAL-ANTIBODY; BLOOD-COAGULATION; ESCHERICHIA-COLI; HEPATOMA CELLS; HEPARIN; GENE	Human tissue factor pathway inhibitor (TFPI) and three derivatives with deletions of 1) the complete COOH-terminal third of the polypeptide including the third Kunitz domain, 2) the third Kunitz domain alone, or 3) the penultimate basic COOH-terminal region alone were expressed in yeast as secreted products. High expression yield was obtained only with the derivative that lacked both the third Kunitz domain and the penultimate COOH tail (TFPI1-161). The purified short form was heterogenously glycosylated with a high mannose glycan. The specific activities of the different mutant polypeptides toward FXa.tissue factor.FVIIa in a chromogenic assay were similar to that of TFPI expressed in baby hamster kidney cells, suggesting that correct folding takes place in yeast and that neither the third Kunitz domain nor the COOH-terminal region is required for this activity. However, in a clotting assay the anticoagulant activities of yeast-produced TFPI and the shortened derivative TFPI1-161 were about 5- and 50-fold lower, respectively, than for full-length TFPI from mammalian cells. Clotting assays with purified short form TFPI showed that it acted mainly via inhibition of FVIIa.tissue factor rather than FXa. The anticoagulant activity of short form TFPI was comparable with that of high affinity antibodies toward tissue factor.			PETERSEN, JGL (corresponding author), NOVO NORD AS, NOVO ALLE, DK-2880 BAGSVAERD, DENMARK.							ALBER T, 1982, Journal of Molecular and Applied Genetics, V1, P419; BARR PJ, 1987, F BIOTECH IND FERMEN, V5, P139; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BROZE GJ, 1987, THROMB RES, V48, P253, DOI 10.1016/0049-3848(87)90422-1; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BROZE GJ, 1987, BLOOD, V69, P150; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; DAY KC, 1990, BLOOD, V76, P1538; DUGAICZYK A, 1982, P NATL ACAD SCI-BIOL, V79, P71, DOI 10.1073/pnas.79.1.71; EGELMITANI M, 1987, NUCLEIC ACIDS RES, V15, P6303, DOI 10.1093/nar/15.15.6303; GIRARD TJ, 1989, THROMB RES, V55, P37, DOI 10.1016/0049-3848(89)90454-4; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; HAGENBUCHLE O, 1981, NATURE, V289, P643, DOI 10.1038/289643a0; HAMAMOTO T, 1993, J BIOL CHEM, V268, P8704; HOPWOOD DA, 1985, GENETIC MANIPULATION, P13; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KAWASAKI G, 1990, Patent No. 4931373; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDAHL AK, 1991, THROMB RES, V62, P607, DOI 10.1016/0049-3848(91)90365-4; LITSKE JG, 1986, NUCLEIC ACIDS RES, V14, P9631, DOI 10.1093/nar/14.24.9631; Maniatis T., 1982, MOL CLONING; MIKKELSEN J, 1987, BIOCHEM J, V248, P709, DOI 10.1042/bj2480709; NEMERSON Y, 1988, BLOOD, V71, P1; NORDFANG O, 1991, BIOCHEMISTRY-US, V30, P10371, DOI 10.1021/bi00107a002; NORDFANG O, 1991, THROMB HAEMOSTASIS, V66, P464; NOVOTNY WF, 1991, BLOOD, V78, P394; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1987, BLOOD, V69, P645; RAPAPORT SI, 1989, BLOOD, V73, P359; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUSSELL PR, 1985, GENE, V40, P125, DOI 10.1016/0378-1119(85)90031-9; SANDSET PM, 1987, THROMB RES, V47, P389, DOI 10.1016/0049-3848(87)90454-3; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI, P163; SLEEP D, 1990, BIO-TECHNOL, V8, P42, DOI 10.1038/nbt0190-42; TAYLOR FB, 1991, CIRC SHOCK, V33, P127; VALENTIN S, 1991, BLOOD COAGUL FIBRIN, V2, P629, DOI 10.1097/00001721-199110000-00007; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISS HJ, 1989, BLOOD, V73, P968; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WUN TC, 1988, J BIOL CHEM, V263, P6001; WUN TC, 1992, BLOOD, V79, P430; WUN TC, 1990, J BIOL CHEM, V265, P16096	49	49	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13344	13351						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514773				2022-12-25	WOS:A1993LH55300049
J	PAUL, P; LUTZ, TM; OSBORN, C; KYOSSEVA, S; ELBEIN, AD; TOWBIN, H; RADOMINSKA, A; DRAKE, RR				PAUL, P; LUTZ, TM; OSBORN, C; KYOSSEVA, S; ELBEIN, AD; TOWBIN, H; RADOMINSKA, A; DRAKE, RR			SYNTHESIS AND CHARACTERIZATION OF A NEW CLASS OF INHIBITORS OF MEMBRANE-ASSOCIATED UDP-GLYCOSYLTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCEREBROSIDE SYNTHETASE; PROTEIN; BRAIN; ANALOGS; OLIGOSACCHARIDES; GLYCOSYLATION; TUNICAMYCIN; AMPHOMYCIN; GLUCOSE; ASSAY	A new class of compounds designed to inhibit membrane-associated glycosyltransferases were synthesized and their biological activities were characterized in liver microsomes and human lymphoma cell lines. These inhibitors are composed of N-acyl phenylaminoalcohol derivatives linked to uridine via different spacers. One inhibitor, termed PP36 (5'-[[N-(2-decanoylamino-3-hydroxy-3-phenylpropyloxycarbonyl)-glycyl] amino]-5'-deoxyuridine) competitively inhibited the enzyme glucosyl phosphoryldolichol synthase (Glc-P-Dol synthase) in rat liver microsomes. In rat and human liver microsomes-incubated with PP36 and photolabeled with [beta-P-32]5-azido-UDP-Glc, Glc-P-Dol synthase was the only protein observed to have decreased photoincorporation. Two other inhibitors, PP37 (5'-O-[[(2-decanoylamino-3-hydroxy-3-phenyl-propyloxycarbonyl) amino]sulfonyl]uridine and PP55 (5'-O-[[(2-decanoylamino-3-phenylpropyloxycarbonyl)amino]sulfonyl]uridine), were also shown to be competitive inhibitors of Glc-P-Dol synthase activity and photolabeling. Activities of glycosyltransferases involved in glycosphingolipid biosynthesis were little affected by these compounds. Analysis of the effects of PP36, PP37, and PP55 on the incorporation of [H-3] leucine and [C-14]galactose into glycoprotein and glycolipid fractions from two human cell lines indicated the following: PP36 reduced incorporation into both fractions, PP37 was ineffective, and PP55 only decreased incorporation into glycolipids.	UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOLEC BIOL,LITTLE ROCK,AR 72205; CIBA GEIGY AG,PHARMACEUT RES LABS,CH-4002 BASEL,SWITZERLAND; UNIV ARKANSAS MED SCI HOSP,DEPT MED,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences; Novartis; University of Arkansas System; University of Arkansas Medical Sciences					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021800, R01DK038678] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38678, DK-21800] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BASU M, 1987, METHOD ENZYMOL, V138, P575; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BIELAWSKA A, 1992, J BIOL CHEM, V267, P18493; BOYSE E A, 1964, Methods Med Res, V10, P39; CAMARASA MJ, 1985, J MED CHEM, V28, P40, DOI 10.1021/jm00379a010; CASTRO B, 1975, TETRAHEDRON LETT, V14, P1219; CESTELLI A, 1979, BIOCHIM BIOPHYS ACTA, V572, P283, DOI 10.1016/0005-2760(79)90043-2; DRAKE R, 1990, BIOSCIENCE REP, V10, P61, DOI 10.1007/BF01116852; DRAKE RR, 1992, J BIOL CHEM, V267, P11360; DRAKE RR, 1991, PLANT PHYSIOL, V97, P396, DOI 10.1104/pp.97.1.396; DRAKE RR, 1991, J BIOL CHEM, V266, P23257; DRAKE RR, 1992, GLYCOBIOLOGY, V2, P279, DOI 10.1093/glycob/2.4.279; DUSKIN D, 1982, J BIOL CHEM, V257, P3105; ELBEIN AD, 1991, BIOL CARBOHYDRATES, V3, P119; ERICSON MC, 1978, ARCH BIOCHEM BIOPHYS, V191, P698, DOI 10.1016/0003-9861(78)90409-5; HARRINGTON CR, 1990, ANAL BIOCHEM, V186, P285, DOI 10.1016/0003-2697(90)90081-J; HEIFETZ A, 1979, BIOCHEMISTRY-US, V18, P2186, DOI 10.1021/bi00578a008; HORWITZ JP, 1962, J ORG CHEM, V27, P3045, DOI 10.1021/jo01056a013; INOKUCHI JI, 1987, J LIPID RES, V28, P565; KANG MS, 1979, J BIOL CHEM, V254, P37; KEENAN RW, 1981, BIOCHEMISTRY-US, V20, P2968, DOI 10.1021/bi00513a039; KIJIMASUDA I, 1985, CHEM PHARM BULL, V33, P730; KISHIMOTO Y, 1983, ENZYMES, V16, P357; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUAN SF, 1989, J BIOL CHEM, V264, P19721; LONG LM, 1949, J AM CHEM SOC, V71, P2473, DOI 10.1021/ja01175a068; MULLER T, 1981, FEBS LETT, V128, P208, DOI 10.1016/0014-5793(81)80082-8; PACIC MM, 1989, J BIOL CHEM, V264, P17174; PAUL P, 1992, ANAL BIOCHEM, V204, P265, DOI 10.1016/0003-2697(92)90237-2; PULVERTAFT RJV, 1964, LANCET, V1, P238; Radin N S, 1981, Methods Enzymol, V72, P673; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; TIPSON RS, 1968, SYNTHETIC P NUCL ACI, V1, P431; TRINCHERA M, 1991, BIOCHEMISTRY-US, V30, P2719, DOI 10.1021/bi00224a021; VAGHEFI MM, 1987, J MED CHEM, V30, P1383, DOI 10.1021/jm00391a020; VUNNAM RR, 1980, CHEM PHYS LIPIDS, V26, P265; WINCHESTER B, 1992, GLYCOBIOLOGY, V2, P199, DOI 10.1093/glycob/2.3.199; 1965, Patent No. 660366	41	28	31	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12933	12938						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509426				2022-12-25	WOS:A1993LG65800101
J	Akesson, P; Sjoholm, AG; Bjorck, L				Akesson, P; Sjoholm, AG; Bjorck, L			Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH GLYCOPROTEIN; GROUP-A STREPTOCOCCI; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE; CLONING VECTORS; CLUSTERIN; BINDING; PLASMA; GENE; IGG	The human pathogen Streptococcus pyogenes possesses a chromosomal region, the mga regulon, that contains co-regulated genes important to the virulence of these bacteria. A novel gene located in the mga regulon of a S. pyogenes strain of serotype M1 was cloned and sequenced. It translates into a protein of 305 amino acid residues, including a signal sequence of 32 amino acids and a central region consisting of three tandem repeats, The sequence represents a navel structure with no significant homology to any previously published sequence. The protein was purified from the streptococcal culture media where it is present in substantial amounts. Affinity chromatography of human plasma on Sepharose coupled with the protein specifically adsorbed two plasma proteins which were identified as clusterin and histidine-rich glycoprotein (HRG). The interactions between the streptococcal protein and the plasma proteins were further characterized using purified clusterin and HRG. Inhibition experiments indicated that they have affinity for overlapping or closely located sites in the streptococcal protein. Both clusterin and HRG are regulators of the membrane attack complex (C5b-C9) of complement. When the streptococcal protein was added to serum, complement-mediated lysis of sensitized sheep erythrocytes and guinea pig erythrocytes was inhibited. In addition, the streptococcal protein was incorporated into C5b-C9 in serum, indicating the location of its action. The name, protein SIC, streptococcal inhibitor of complement mediated lysis, is therefore suggested for this novel protein, The occurrence of protein SIC and its gene was investigated in a collection of S. pyogenes strains comprising 55 different M serotypes. Only M1 and M57 strains were positive in this screening, indicating that protein SIC could be a virulence determinant. Thus, during recent years, the M1 serotype has been connected with a world-wide in crease of severe and toxic S. pyogenes infections.	LUND UNIV,DEPT MED MICROBIOL,S-22100 LUND,SWEDEN	Lund University	Akesson, P (corresponding author), LUND UNIV,DEPT CELL & MOLEC BIOL,SECT MOLEC PATHOGENESIS,POB 94,S-22100 LUND,SWEDEN.							AKESSON P, 1990, MOL IMMUNOL, V27, P523, DOI 10.1016/0161-5890(90)90071-7; AKKESSON P, 1994, BIOCHEM J, V300, P877; BENNASR A, 1995, BIOCHEM J, V305, P173, DOI 10.1042/bj3050173; BERGE A, 1995, J BIOL CHEM, V270, P6862; CAPARON MG, 1987, P NATL ACAD SCI USA, V84, P8677, DOI 10.1073/pnas.84.23.8677; CHANG NS, 1992, BLOOD, V79, P2973; CHEN CC, 1990, J BIOL CHEM, V265, P3161; COUSER WG, 1985, KIDNEY INT, V28, P879, DOI 10.1038/ki.1985.214; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; DDECHATEAU M, 1994, J BIOL CHEM, V269, P12147; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FRENCH LE, 1992, CLIN EXP IMMUNOL, V88, P389; GOMI H, 1990, J IMMUNOL, V144, P4046; HOLM SE, 1992, J INFECT DIS, V166, P31, DOI 10.1093/infdis/166.1.31; HOLM SE, 1988, APMIS, V96, P189, DOI 10.1111/j.1699-0463.1988.tb05289.x; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; KEHOE MA, 1994, NEW COMPR BIOCH, V27, P217; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; KOIDE T, 1986, BIOCHEMISTRY-US, V25, P2220, DOI 10.1021/bi00356a055; MARTIN DR, 1993, J INFECT DIS, V167, P1112, DOI 10.1093/infdis/167.5.1112; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P197, DOI 10.1111/j.1365-3083.1985.tb01871.x; MOLLNES TE, 1985, SCAND J IMMUNOL, V22, P183, DOI 10.1111/j.1365-3083.1985.tb01870.x; MORGAN BP, 1989, BIOCHEM J, V264, P1; MUSSER JM, 1993, J INFECT DIS, V167, P337, DOI 10.1093/infdis/167.2.337; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; NILSSON UR, 1984, J IMMUNOL METHODS, V72, P49, DOI 10.1016/0022-1759(84)90432-0; NOWAK R, 1994, SCIENCE, V264, P1665, DOI 10.1126/science.8209244; OKADA N, 1995, P NATL ACAD SCI USA, V92, P2489, DOI 10.1073/pnas.92.7.2489; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; SAIGO K, 1989, J BIOL CHEM, V264, P8249; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS JR, 1994, KIDNEY INT, V45, P817, DOI 10.1038/ki.1994.108; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SIMPSON WJ, 1990, J BACTERIOL, V172, P696, DOI 10.1128/jb.172.2.696-700.1990; THERN A, 1995, J IMMUNOL, V154, P375; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUEDSSON L, 1981, ACTA PATH MICRO IM C, V89, P161; Tschopp J, 1994, Clin Exp Immunol, V97 Suppl 2, P11; TSCHOPP J, 1993, J IMMUNOL, V151, P2159; WEXLER DE, 1985, P NATL ACAD SCI USA, V82, P8144, DOI 10.1073/pnas.82.23.8144; WEXLER DE, 1983, INFECT IMMUN, V39, P239, DOI 10.1128/IAI.39.1.239-246.1983; WILSON MR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P319, DOI 10.1016/0167-4838(92)90062-I; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZWIRNER J, 1989, J IMMUNOL METHODS, V124, P121, DOI 10.1016/0022-1759(89)90193-2	48	194	199	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1081	1088		10.1074/jbc.271.2.1081	http://dx.doi.org/10.1074/jbc.271.2.1081			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557634	hybrid			2022-12-25	WOS:A1996TP88900071
J	Gibson, MA; Hatzinikolas, G; Kumaratilake, JS; Sandberg, LB; Nicholl, JK; Sutherland, GR; Cleary, EG				Gibson, MA; Hatzinikolas, G; Kumaratilake, JS; Sandberg, LB; Nicholl, JK; Sutherland, GR; Cleary, EG			Further characterization of proteins associated with elastic fiber microfibrils including the molecular cloning of MAGP-2 (MP25)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARFAN-SYNDROME; GLYCOPROTEIN MAGP; LAMININ RECEPTOR; FIBRILLIN; SEQUENCE; GENE; TISSUES; COMPONENTS; LOCALIZATION; ANTIGEN	Together with the 31-kDa microfibril-associated glycoprotein (MAGP), four polypeptides designated MP340 (340 kDa), MP78 (78 kDa), MP70 (70 kDa), and MP25 (25 kDa) have previously been identified in tissue extracts designed specifically to solubilize the microfibrillar component of elastic fibers, In the present study, both MP78 and MP70 were shown to be forms of a protein which is closely related to the human protein beta ig-h3, and MP340 was confirmed to be the bovine form of fibrillin-1. Peptide sequences from MP25 proved to be unique, and affinity-purified anti-MP25 antibodies were shown, by immunofluorescence and immunoelectron microscopy, to localize specifically to the elastin-associated microfibrils. This confirmed that MP25 was a distinct component of these structures. Expression screening of nuchal ligament cDNA libraries yielded a cDNA, cM10A (770 base pairs) which encodes amino acid sequences matching those of the MP25 peptides. Further library screening with cM10A identified cDNAs which encode the complete primary structures of bovine and human MP25. Bovine and human MP25 were found to be around 80% homologous and contain 170 and 173 amino acids, respectively. Data base searches revealed that MP25 had significant similarity of structure only with MAGP, indicating that the two proteins form a new family of microfibrillar proteins. In acknowledgment, MP25 has been formally renamed MAGP-2, and MAGP is referred to as MAGP-1. The close similarity between the two proteins (57%) is confined to a central region of 60 amino acids where there is precise alignment of 7 cysteine residues. Elsewhere the MAGP-2 molecule is rich in serine and threonine residues and contains an RGD motif. MAGP-2 lacks the proline-, glutamine-, and tyrosine-rich sequences and a hydrophobic carboxyl terminus, characteristic of MAGP-1. These structural differences sug gest that MAGP-2 has some functions which are distinct from those of MAGP-1. The locus of the human MAGP-2 gene was identified on chromosome 12 in the region of 12p12.3-12p13.1.	WOMENS & CHILDRENS HOSP,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; JERRY L PETTIS MEM VET ADM MED CTR,LOMA LINDA,CA 92367	Womens & Childrens Hospital Australia	Gibson, MA (corresponding author), UNIV ADELAIDE,DEPT PATHOL,ADELAIDE,SA 5005,AUSTRALIA.		Sutherland, Grant Robert/D-2606-2012					ABRAMS WR, 1995, GENOMICS, V26, P47, DOI 10.1016/0888-7543(95)80081-V; BASHIR MM, 1994, BIOCHEMISTRY-US, V33, P593, DOI 10.1021/bi00168a026; BROWNAUGSBURGER P, 1994, J BIOL CHEM, V269, P28443; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Chu Mon-Li, 1993, P149; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; CLEARY EG, 1995, STRUCTURE FUNCTION E, P95; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; ESCRIBANO J, 1994, J CELL PHYSIOL, V160, P511, DOI 10.1002/jcp.1041600314; FARACO J, 1995, GENOMICS, V25, P630, DOI 10.1016/0888-7543(95)80004-6; GIBSON MA, 1986, J BIOL CHEM, V261, P1429; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1991, J BIOL CHEM, V266, P7596; GIBSON MA, 1987, IMMUNOL CELL BIOL, V65, P345, DOI 10.1038/icb.1987.39; GIBSON MA, 1983, COLLAGEN REL RES, V3, P469; HINEK A, 1994, J CELL BIOL, V126, P563, DOI 10.1083/jcb.126.2.563; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; KUMARATILAKE JS, 1989, EUR J CELL BIOL, V50, P117; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MAGENIS RE, 1991, GENOMICS, V11, P346, DOI 10.1016/0888-7543(91)90142-2; MARIENCHECK MC, 1994, CONNECT TISSUE RES, V31, P1; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MASLEN CL, 1993, DNA CELL BIOL, V12, P561, DOI 10.1089/dna.1993.12.561; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; MECHAM RP, 1988, BIOCHEM BIOPH RES CO, V151, P822, DOI 10.1016/S0006-291X(88)80355-3; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; RAMIREZ F, 1993, BIOESSAYS, V15, P589, DOI 10.1002/bies.950150904; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sambrook J, 1989, MOL CLONING LABORATO; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITE JF, 1988, J HISTOCHEM CYTOCHEM, V36, P1543, DOI 10.1177/36.12.3142951; YEH H, 1994, GENOMICS, V23, P443, DOI 10.1006/geno.1994.1521; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHAO ZY, 1995, HUM MOL GENET, V4, P589, DOI 10.1093/hmg/4.4.589	44	127	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1096	1103		10.1074/jbc.271.2.1096	http://dx.doi.org/10.1074/jbc.271.2.1096			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557636	hybrid			2022-12-25	WOS:A1996TP88900073
J	GuyCaffey, JK; Bodepudi, V; Bishop, JS; Jayaraman, K; Chaudhary, N				GuyCaffey, JK; Bodepudi, V; Bishop, JS; Jayaraman, K; Chaudhary, N			Novel polyaminolipids enhance the cellular uptake of oligonucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX FORMATION; ANTISENSE OLIGONUCLEOTIDES; FORMING OLIGONUCLEOTIDES; MAMMALIAN-CELLS; DNA COMPLEXES; TRANSCRIPTION; INHIBITION; GENE; RNA; OLIGODEOXYNUCLEOTIDES	Two new polyaminolipids have been synthesized for the purpose of improving cellular uptake of oligonucleotides. The amphipathic compounds are conjugates of spermidine or spermine linked through a carbamate bond to cholesterol, The polyaminolipids are relatively nontoxic to mammalian cells, In tissue culture assays, using fluorescent-tagged or radiolabeled triple helix-forming oligonucleotides, spermine-cholesterol and spermidine-cholesterol significantly enhance cellular uptake of the oligomers in the presence of serum, Spermine-cholesterol is comparable with DOTMA/DOPE (a 1:1 (w/w) formulation of the cationic lipid N-[1-(2,3-dioleyloxy)-propyl]-N,N,N-trimethylammonium chloride (DOTMA) and the neutral lipid dioleylphosphatidylethanolamine (DOPE)) in increasing cellular uptake of oligonucleotides, while spermidine-cholesterol is more efficient, The internalized oligonucleotides are routed to the nucleus as early as 20 min after treatment, suggesting that the polyaminolipids increase the permeability of cellular membranes to oligonucleotides. At later times, much of the incoming oligonucleotides are sequestered within punctate cytoplasmic granules, presumably compartments of endosomal origin, Coadministration with polyaminolipids markedly improves the cellular stability of the oligonucleotides; more than 80% of the material can be recovered intact up to 24 h after addition to cells. In the absence of the polyaminolipids, nearly all of the material is degraded within 6 h, These data suggest that the new polyaminolipids may be useful for the delivery of nucleic acid-based therapeutics into cells.	ARONEX PHARMACEUT INC, THE WOODLANDS, TX 77381 USA									Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; AKHTAR S, 1991, NUCLEIC ACIDS RES, V19, P5551, DOI 10.1093/nar/19.20.5551; Alberts B., 1994, MOL BIOL CELL; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BEHR JP, 1994, BIOCONJUGATE CHEM, V5, P382, DOI 10.1021/bc00029a002; BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BOUTORIN AS, 1989, FEBS LETT, V254, P129, DOI 10.1016/0014-5793(89)81023-3; CHIN D J, 1990, New Biologist, V2, P1091; COHEN JS, 1994, SCI AM, V271, P76, DOI 10.1038/scientificamerican1294-76; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FENNEWALD SM, 1995, ANTIVIR RES, V26, P37, DOI 10.1016/0166-3542(94)00064-F; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; FRESHNEY RI, 1983, CULTURE ANIMAL CELLS; GEE JE, 1995, BIOCHEMISTRY-US, V34, P2042, DOI 10.1021/bi00006a026; GRIGORIEV M, 1993, CR ACAD SCI III-VIE, V316, P492; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; ING NH, 1993, NUCLEIC ACIDS RES, V21, P2789, DOI 10.1093/nar/21.12.2789; Jager C, 1999, J NON-CRYST SOLIDS, V258, P161, DOI 10.1016/S0022-3093(99)00436-6; JAROSZEWSKI JW, 1991, ADV DRUG DELIVER REV, V6, P235, DOI 10.1016/0169-409X(91)90019-9; KABANOV AV, 1995, BIOCONJUGATE CHEM, V6, P7, DOI 10.1021/bc00031a002; KABANOV AV, 1990, FEBS LETT, V259, P327, DOI 10.1016/0014-5793(90)80039-L; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; LEONETTI JP, 1990, P NATL ACAD SCI USA, V87, P2448, DOI 10.1073/pnas.87.7.2448; LEONETTI JP, 1991, P NATL ACAD SCI USA, V88, P2702, DOI 10.1073/pnas.88.7.2702; LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P7587, DOI 10.1021/bi00148a021; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MATTHEWS HR, 1993, BIOESSAYS, V15, P561, DOI 10.1002/bies.950150811; MILLIGAN JF, 1993, NUCLEIC ACIDS RES, V21, P327, DOI 10.1093/nar/21.2.327; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; MORGAN AR, 1968, J MOL BIOL, V37, P63, DOI 10.1016/0022-2836(68)90073-9; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NELSON PS, 1989, NUCLEIC ACIDS RES, V17, P7187, DOI 10.1093/nar/17.18.7187; NELSON PS, 1989, NUCLEIC ACIDS RES, V17, P7179, DOI 10.1093/nar/17.18.7179; OBERHAUSER B, 1992, NUCLEIC ACIDS RES, V20, P533, DOI 10.1093/nar/20.3.533; OJWANG J, 1994, J ACQ IMMUN DEF SYND, V7, P560; POSTEL EH, 1992, ANN NY ACAD SCI, V660, P57, DOI 10.1111/j.1749-6632.1992.tb21057.x; RANDO RF, 1994, NUCLEIC ACIDS RES, V22, P678, DOI 10.1093/nar/22.4.678; RAO TS, 1995, BIOCHEMISTRY-US, V34, P765, DOI 10.1021/bi00003a009; RAO TS, 1994, NUCLEOS NUCLEOT, V13, P95, DOI 10.1080/15257779408013229; ROSS C, 1992, BIOCHEM BIOPH RES CO, V189, P1674, DOI 10.1016/0006-291X(92)90270-U; ROY C, 1993, NUCLEIC ACIDS RES, V21, P2845, DOI 10.1093/nar/21.12.2845; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; SARHAN S, 1989, BIOL CHEM H-S, V370, P1279, DOI 10.1515/bchm3.1989.370.2.1279; SHEA RG, 1990, NUCLEIC ACIDS RES, V18, P3777, DOI 10.1093/nar/18.13.3777; SHOJI Y, 1991, NUCLEIC ACIDS RES, V19, P5543, DOI 10.1093/nar/19.20.5543; SKOOG JU, 1993, NUCLEIC ACIDS RES, V21, P2131, DOI 10.1093/nar/21.9.2131; UHLMANN E, 1990, CHEM REV, V90, P543, DOI 10.1021/cr00102a001; VU H, 1993, NUCLEOS NUCLEOT, V12, P853, DOI 10.1080/07328319308018556; VU H, 1994, BIOCONJUGATE CHEM, V5, P666, DOI 10.1021/bc00030a024; VU H, 1993, NUCLEIC ACIDS S SER, V29, P19; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WALKER C, 1992, P NATL ACAD SCI USA, V89, P7915, DOI 10.1073/pnas.89.17.7915; YOUNG SL, 1991, P NATL ACAD SCI USA, V88, P10023, DOI 10.1073/pnas.88.22.10023; ZENDEGUI JG, 1992, NUCLEIC ACIDS RES, V20, P307, DOI 10.1093/nar/20.2.307	63	55	95	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31391	31396		10.1074/jbc.270.52.31391	http://dx.doi.org/10.1074/jbc.270.52.31391			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537413	hybrid			2022-12-25	WOS:A1995TN44400080
J	Lee, H; Lee, YH; Huh, YS; Moon, H; Yun, Y				Lee, H; Lee, YH; Huh, YS; Moon, H; Yun, Y			X-gene product antagonizes the p53-mediated inhibition of hepatitis B virus replication through regulation of the pregenomic/core promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; TATA-BINDING PROTEIN; WILD-TYPE P53; ESCHERICHIA-COLI; TRANSCRIPTION FACTOR; E6 ONCOPROTEIN; TUMOR-ANTIGEN; T-ANTIGEN; DNA; EXPRESSION	Employing the glutathione S-transferase column retention method and far Western analysis, we found a physical association between tumor suppressor p53 and the hepatitis B virus X-gene product, which led us to study the function of observed interaction in relation to viral propagation, In the cell culture-based in vitro replication system, expression of p53 resulted in dramatic inhibition of viral replication, and this inhibition was relieved by the coexpression of the X gene product in a dose-dependent manner, Furthermore, the activity of pregenomic/core promoter, responsible for the synthesis of pregenomic RNA, was almost completely inhibited upon expression of p53, and as in the replication assay, the inhibition was rescued by the coexpression of the X-gene product in a dose-dependent manner, Based on these results, we propose that the ratio of X-gene product to p53 is an important factor determining the fate of viral replication through modulation of the pregenomic/core promoter.	MOGAM BIOTECHNOL RES INST, SIGNAL TRANSDUCT LAB, YONGINGOON 449910, KYUNGGIDO, SOUTH KOREA					Lee, Hyunsook/0000-0002-2251-5019				AVANTAGGIATI ML, 1992, ARCH VIROL, P57; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DEB SP, 1994, ONCOGENE, V9, P1341; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; ELFASSI E, 1986, P NATL ACAD SCI USA, V83, P2219, DOI 10.1073/pnas.83.7.2219; EVANS AS, 1991, VIRAL INFECTIONS HUM, P3; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FUJIYAMA A, 1983, NUCLEIC ACIDS RES, V11, P4601, DOI 10.1093/nar/11.13.4601; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hoofnagle J. H., 1984, VIRAL HEPATITIS LIVE, P97; JACKSON P, 1993, ONCOGENE, V8, P589; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MEYERS ML, 1986, J VIROL, V57, P101, DOI 10.1128/JVI.57.1.101-109.1986; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PUISIEUX A, 1995, P NATL ACAD SCI USA, V92, P1342, DOI 10.1073/pnas.92.5.1342; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RANEY AK, 1990, J VIROL, V64, P2360, DOI 10.1128/JVI.64.5.2360-2368.1990; Sambrook J, 1989, MOL CLONING LABORATO; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEEGER C, 1986, SCIENCE, V232, P477, DOI 10.1126/science.3961490; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SU H, 1992, P NATL ACAD SCI USA, V89, P2708, DOI 10.1073/pnas.89.7.2708; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG GH, 1993, J VIROL, V67, P6507, DOI 10.1128/JVI.67.11.6507-6512.1993; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	65	36	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31405	31412		10.1074/jbc.270.52.31405	http://dx.doi.org/10.1074/jbc.270.52.31405			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537415	hybrid			2022-12-25	WOS:A1995TN44400082
J	Long, FX; Linsenmayer, TF				Long, FX; Linsenmayer, TF			Tissue-specific regulation of the type X collagen gene - Analyses by in vivo footprinting and transfection with a proximal promoter region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR WEIGHT COLLAGEN; TRANSCRIPTION FACTOR; CHICK-EMBRYO; FIBRIL ASSOCIATION; CARTILAGE MATRIX; CHONDROCYTES; TIBIOTARSUS; ENHANCERS; SEQUENCES; PROTEINS	During endochondral bone formation, hypertrophic chondrocytes initiate synthesis of type X collagen. Previous studies have shown that regulation of this molecule is at the level of transcription, To further explore this regulation, we have studied a segment of the type X collagen gene extending from 562 base pairs (bp) upstream to 86 bp downstream of the transcriptional start site. We have studied this ''proximal promoter region'' by both structural analysis by DNase I in vivo footprint and functional analysis by transient transfections. In type X collagen expressing, hypertrophic chondrocytes, in vivo footprinting detected a fully protected TATA region flanked by hypersensitive sites but no other major protection, Type X collagen-negative cells (nonhypertrophic chondrocytes and tendon fibroblasts) showed major protection at a number of other sites, most notably an 8-bp region overlapping an AP2 site and a 9-bp region including the sequence CACACA. The importance of the proximal promoter region in restricting expression of type X collagen to hypertrophic chondro cytes was supported by transfection studies. A chloramphenicol acetyltransferase construct containing this region directed 5-10-fold higher chloramphenicol acetyltransferase expression in hypertrophic chondrocytes than in the other cell types. A 2.6-kilobase upstream fragment produced no additional effect. Thus, the proximal promoter region contains at least some regulatory elements for the cell-specific expression of type X collagen.	TUFTS UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, BOSTON, MA 02111 USA	Tufts University					NICHD NIH HHS [HD 23681] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; CAPASSO O, 1984, EMBO J, V3, P823, DOI 10.1002/j.1460-2075.1984.tb01891.x; CHEN Q, 1992, BONE MINER, V17, P223, DOI 10.1016/0169-6009(92)90741-U; CHEN Q, 1990, P NATL ACAD SCI USA, V87, P8046, DOI 10.1073/pnas.87.20.8046; CHEN Q, 1992, J CELL BIOL, V117, P687, DOI 10.1083/jcb.117.3.687; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GIBSON GJ, 1984, J CELL BIOL, V99, P208, DOI 10.1083/jcb.99.1.208; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KIM JJ, 1977, J BIOL CHEM, V252, P8292; LINSENMAYER TF, 1991, DEVELOPMENT, V111, P191; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; LUVALLE P, 1989, DEV BIOL, V133, P613, DOI 10.1016/0012-1606(89)90065-1; MUELLER PR, 1994, CURRENT PROTOCOLS MO; PFEIFER GP, 1991, GENE DEV, V5, P1102, DOI 10.1101/gad.5.6.1102; PIRROTTA V, 1994, BIOESSAYS, V16, P549, DOI 10.1002/bies.950160808; POOLE AR, 1989, J CELL BIOL, V109, P2547, DOI 10.1083/jcb.109.5.2547; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID TM, 1990, DEV BIOL, V138, P53, DOI 10.1016/0012-1606(90)90176-J; SCHMID TM, 1982, J BIOL CHEM, V257, P2444; SCHMID TM, 1986, J BIOL CHEM, V261, P4184; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; STOCUM DL, 1979, J EMBRYOL EXP MORPH, V54, P155; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VALLE PL, 1993, J CELL BIOL, V121, P1173, DOI 10.1083/jcb.121.5.1173; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; WOODCOCK CL, 1995, TRENDS CELL BIOL, V5, P272, DOI 10.1016/S0962-8924(00)89038-8	30	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31310	31314		10.1074/jbc.270.52.31310	http://dx.doi.org/10.1074/jbc.270.52.31310			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537401	hybrid			2022-12-25	WOS:A1995TN44400068
J	Schricker, R; Magdolen, V; Strobel, G; Bogengruber, E; Breitenbach, M; Bandlow, W				Schricker, R; Magdolen, V; Strobel, G; Bogengruber, E; Breitenbach, M; Bandlow, W			Strain-dependent occurrence of functional GTP:AMP phosphotransferase (AK3) in Saccharomyces cervisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INORGANIC PYROPHOSPHATASE; ADENYLATE KINASE FAMILY; ESCHERICHIA-COLI; YEAST MITOCHONDRIA; HO-GENE; CEREVISIAE; PROTEIN; EXPRESSION; SEQUENCE; BINDING	The gene for yeast GTP:AMP phosphotransferase (PAK3) was found to encode a nonfunctional protein in 10 laboratory strains and one brewers' strain. The protein product showed high similarity to vertebrate AK3 and was located exclusively in the mitochondrial matrix. The deduced amino acid sequence revealed a protein that was shorter at the carboxyl terminus than all other known adenylate kinases. Introduction of a +1 frameshift into the 3'-terminal region of the gene extended homology of the deduced amino acid sequence to other members of the adenylate kinase family including vertebrate AK3. Frameshift mutations obtained after in vitro and in vivo mutagenesis were capable of complementing the adk1 temperature-conditional deficiency in Escherichia coli, indicating that the frameshift led to the expression of a protein that could phosphorylate AMP. Some yeasts, however, including strain D273-10B, two wine yeasts, and two more distantly related yeast genera, harbored an active allele, named AKY3, which contained a +1 frameshift close to the carboxyl terminus as compared with the laboratory strains. The encoded protein exhibited GTP:AMP and ITP:AMP phosphotransferase activities but did not accept ATP as phosphate donor. Although single copy in the haploid genome, disruption of the ARY3 allele displayed no phenotype, excluding the possibility that labo ratory and brewers' strains had collected second site suppressors. It must be concluded that yeast mitochondria can completely dispense with GTP:AMP phosphotransferase activity.	UNIV MUNICH, INST GENET & MIKROBIOL, D-80638 MUNICH, GERMANY; SALZBURG UNIV, INST GENET & ALLGEMEINE BIOL, A-5020 SALZBURG, AUSTRIA	University of Munich; Salzburg University								ADOLPHUS, 1983, EMBO J, V2, P1765, DOI 10.1002/j.1460-2075.1983.tb01655.x; ALGERI AA, 1981, GENETICS, V97, P27; ATKINSON DE, 1977, CELLULAR ENERGY META, P85; BANDLOW W, 1988, EUR J BIOCHEM, V178, P451, DOI 10.1111/j.1432-1033.1988.tb14469.x; Boyer P.D, 1973, ENZYMES, P279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRUNE M, 1985, NUCLEIC ACIDS RES, V13, P7139, DOI 10.1093/nar/13.19.7139; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; DIEDERICHS K, 1991, J MOL BIOL, V217, P541, DOI 10.1016/0022-2836(91)90756-V; FOX TD, 1979, J MOL BIOL, V130, P63, DOI 10.1016/0022-2836(79)90552-7; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; HADFIELD C, 1987, GENE, V52, P59, DOI 10.1016/0378-1119(87)90395-7; HELDT HW, 1967, EUR J BIOCHEM, V1, P199, DOI 10.1111/j.1432-1033.1967.tb00064.x; HENSON JM, 1982, MOL GEN GENET, V186, P488, DOI 10.1007/BF00337953; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; JENSENIUS JC, 1981, J IMMUNOL METHODS, V46, P63, DOI 10.1016/0022-1759(81)90333-1; KONRAD M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P12, DOI 10.1016/0167-4781(93)90262-C; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LILJELUND P, 1989, BIOCHEM BIOPH RES CO, V165, P464, DOI 10.1016/0006-291X(89)91093-0; LINDROS KO, 1986, ALCOHOL, V3, P63, DOI 10.1016/0741-8329(86)90072-8; LUNDIN M, 1991, J BIOL CHEM, V266, P12168; LUNDIN M, 1992, BIOCHIM BIOPHYS ACTA, V1098, P217, DOI 10.1016/S0005-2728(05)80339-1; MAGDOLEN V, 1992, FEBS LETT, V299, P267, DOI 10.1016/0014-5793(92)80129-5; MULLER G, 1989, BIOCHEMISTRY-US, V28, P9957; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; PFAFF E, 1965, BIOCHIM BIOPHYS ACTA, V104, P312, DOI 10.1016/0304-4165(65)90258-8; REYNOLDS P, 1985, NUCLEIC ACIDS RES, V13, P2357, DOI 10.1093/nar/13.7.2357; RODEL G, 1985, J BACTERIOL, V161, P7; RUSSELL DW, 1986, MOL CELL BIOL, V6, P4281, DOI 10.1128/MCB.6.12.4281; Sambrook J, 1989, MOL CLONING LABORATO; SCHRICKER R, 1992, MOL GEN GENET, V233, P363, DOI 10.1007/BF00265432; SCHRICKER R, 1992, GENE, V122, P111, DOI 10.1016/0378-1119(92)90038-Q; SCHULZ GE, 1987, COLD SPRING HARB SYM, V52, P429, DOI 10.1101/SQB.1987.052.01.050; TANABE T, 1993, J BIOCHEM-TOKYO, V113, P200, DOI 10.1093/oxfordjournals.jbchem.a124026; TOMASSELLI AG, 1986, FEBS LETT, V202, P303, DOI 10.1016/0014-5793(86)80706-2; TOMASSELLI AG, 1979, EUR J BIOCHEM, V93, P257, DOI 10.1111/j.1432-1033.1979.tb12818.x; TOMASSELLI AG, 1979, EUR J BIOCHEM, V93, P263, DOI 10.1111/j.1432-1033.1979.tb12819.x; WIESMULLER L, 1990, J BIOL CHEM, V265, P6339; WOLF K, 1973, MOL GEN GENET, V125, P53, DOI 10.1007/BF00292983; YONEYA T, 1990, J BIOL CHEM, V265, P21488	41	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31103	31110		10.1074/jbc.270.52.31103	http://dx.doi.org/10.1074/jbc.270.52.31103			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537371	hybrid			2022-12-25	WOS:A1995TN44400039
J	Sorimachi, H; Kinbara, K; Kimura, S; Takahashi, M; Ishiura, S; Sasagawa, N; Sorimachi, N; Shimada, H; Tagawa, K; Maruyama, K; Suzuki, K				Sorimachi, H; Kinbara, K; Kimura, S; Takahashi, M; Ishiura, S; Sasagawa, N; Sorimachi, N; Shimada, H; Tagawa, K; Maruyama, K; Suzuki, K			Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT PROTEASE; CA-2+-ACTIVATED NEUTRAL PROTEASE; SKELETAL-MUSCLE; MOLECULAR-CLONING; THIOL PROTEASE; LARGE SUBUNIT; CDNA; DOMAIN; PROTEINS; GENES	p94, a muscle-specific member of calpain family, is unique in that it undergoes rapid and exhaustive autolysis with a half-life of less than 1 h resulting in its disappearance from muscle. Recently, p94 was shown to be responsible for limb girdle muscular dystrophy type 2A. To elucidate the muscular proteolytic system mediated by p94 and to solve the mystery of its unusually rapid autolysis, we searched for p94-binding proteins by the two hybrid system. Although calpain small subunit plays a crucial role for regulation of ubiquitous calpains, it did not associate with p94. After a screening of skeletal muscle library, connectin (or titin), a gigantic filamentous protein spanning the M- to Z-lines of muscle sarcomere, was found to bind to p94 through a p94-specific region, IS2. The connectin-insoluble fraction of washed myofibrils contained full-length intact p94, suggesting that connectin regulates p94 activity.	CHIBA UNIV, FAC SCI, DEPT BIOL, INAGE KU, CHIBA 263, JAPAN; TOKYO METROPOLITAN INST MED SCI, DEPT IMMUNOL, BUNKYO KU, TOKYO 113, JAPAN	Chiba University; Tokyo Metropolitan Institute of Medical Science	Sorimachi, H (corresponding author), UNIV TOKYO, INST MOLEC & CELLULAR BIOSCI, DEPT MOLEC BIOL, LAB MOLEC STRUCT & FUNCT, BUNKYO KU, TOKYO 113, JAPAN.		Sorimachi, Hiroyuki/C-6448-2009	Sorimachi, Hiroyuki/0000-0001-9509-6727				AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; EMORI Y, 1986, J BIOL CHEM, V261, P9472; GAUTEL M, 1993, EMBO J, V12, P3827, DOI 10.1002/j.1460-2075.1993.tb06061.x; GROVE BK, 1984, J CELL BIOL, V98, P518, DOI 10.1083/jcb.98.2.518; IMAJOH S, 1988, BIOCHEMISTRY-US, V27, P8122, DOI 10.1021/bi00421a022; KIMURA S, 1993, BIOMED RES-TOKYO, V14, P89; MARUYAMA K, 1993, BIOCHEM BIOPH RES CO, V194, P1288, DOI 10.1006/bbrc.1993.1963; MARUYAMA K, 1994, BIOPHYS CHEM, V50, P73, DOI 10.1016/0301-4622(94)85021-6; MATSUURA T, 1991, J BIOCHEM, V110, P474, DOI 10.1093/oxfordjournals.jbchem.a123606; MELLGREN RL, 1990, INTRACELLULAR CALCIU; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SASAGAWA N, 1994, FEBS LETT, V351, P22, DOI 10.1016/0014-5793(94)00808-6; SORIMACHI H, 1995, BBA-GENE STRUCT EXPR, V1261, P381, DOI 10.1016/0167-4781(95)00027-E; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SORIMACHI H, 1992, BIOCHIM BIOPHYS ACTA, V1160, P55, DOI 10.1016/0167-4838(92)90037-E; TAKAHASHI K, 1992, J BIOCHEM-TOKYO, V111, P778, DOI 10.1093/oxfordjournals.jbchem.a123835; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; TRINICK J, 1994, TRENDS BIOCHEM SCI, V19, P405, DOI 10.1016/0968-0004(94)90088-4; VANOMMEN GJ, 1995, NAT MED, V1, P412; VINKEMEIER U, 1993, J CELL SCI, V106, P319; WOLFE FH, 1989, BIOCHIM BIOPHYS ACTA, V998, P236, DOI 10.1016/0167-4838(89)90280-X; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348; YOSHIZAWA T, 1995, FEBS LETT, V358, P101, DOI 10.1016/0014-5793(94)01401-L	32	280	281	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31158	31162		10.1074/jbc.270.52.31158	http://dx.doi.org/10.1074/jbc.270.52.31158			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537379	hybrid			2022-12-25	WOS:A1995TN44400047
J	Huby, RDJ; Carlile, GW; Ley, SC				Huby, RDJ; Carlile, GW; Ley, SC			Interactions between the protein-tyrosine kinase ZAP-70, the proto-oncoprotein Vav, and tubulin in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MICROTUBULE-ASSOCIATED PROTEINS; ANTIGEN RECEPTOR-ZETA; PHOSPHORYLATION; IDENTIFICATION; STIMULATION; ACTIVATION; PRODUCT; CHAIN	Two molecules involved in signal transduction via the T cell antigen receptor, namely the protein-tyrosine kinase ZAP-70 and the proto-oncoprotein Vav, were found to be constitutively associated with tubulin in jurkat T cells, Both were able to bind to tubulin independently of one another, as determined by transient transfection into COS-7 cells. The ZAP-70 associated with tubulin was preferentially tyrosine-phosphorylated after T cell antigen receptor stimulation of Jurkat T cells, suggesting that this interaction was functionally significant, Vav was also found to co-immunoprecipitate with ZAP-70 from cell extracts depleted of tubulin. This raised the possibility that Vav might be a substrate for ZAP-70 protein-tyrosine kinase activity. However, tyrosine phosphorylation of Vav preceded that of ZAP-70, indicating that Vav was unlikely to be a downstream target of ZAP-70. The association of ZAP-70 and Vav with tubulin implies that the microtubules may be involved in the signaling function of these two molecules, perhaps by targeting them to their appropriate intracellular location.	NATL INST MED RES, DIV CELLULAR IMMUNOL, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research								ADAMS JM, 1992, ONCOGENE, V7, P611; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DAVIES AA, 1992, P NATL ACAD SCI USA, V89, P6368, DOI 10.1073/pnas.89.14.6368; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; HEGISHI I, 1995, NATURE, V376, P435; HIVROZ C, 1994, CURR BIOL, V4, P731, DOI 10.1016/S0960-9822(00)00162-7; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LEY SC, 1994, EUR J IMMUNOL, V24, P99, DOI 10.1002/eji.1830240116; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; OLMSTED JB, 1986, ANNU REV CELL BIOL, V2, P421, DOI 10.1146/annurev.cb.02.110186.002225; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; SOLOMON F, 1986, METHOD ENZYMOL, V134, P139; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; VALLEE RB, 1986, METHOD ENZYMOL, V134, P116; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	33	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30241	30244		10.1074/jbc.270.51.30241	http://dx.doi.org/10.1074/jbc.270.51.30241			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530437	hybrid			2022-12-25	WOS:A1995TL67500002
J	Mars, WM; Patmasiriwat, P; Maity, T; Huff, V; Weil, MM; Saunders, GF				Mars, WM; Patmasiriwat, P; Maity, T; Huff, V; Weil, MM; Saunders, GF			Inheritance of unequal numbers of the genes encoding the human neutrophil defensins HP-1 and HP-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-ACTH; ANTIMICROBIAL PEPTIDES; BIOLOGICAL-ACTIVITY; SMALL-INTESTINE; MESSENGER-RNA; HOST DEFENSE; PANETH CELLS; PURIFICATION; EXPRESSION; CHROMOSOME-8	It is unclear whether the six known human defensin peptides are all encoded by separate genes or whether some of them are allelic. Three of the peptides, HP-1, HP-2, and HP-3, differ by only one amino acid, and it is thought that HP-2 may represent a proteolytic product of HP-1 and/or HP-3. To help determine the relationship of these three proteins, we isolated a nearly full-length cDNA encoding HP-1 with a sequence very similar to, but different from, the previously isolated HP-1 and -3 cDNAs. Gene copy number experiments established that there were at least two but fewer than five defensin genes with a high level of similarity to the HP-1 cDNA (HP-1/3-like). Three genomic clones were isolated that contained two different configurations of the HP-1/3-like sequences. Sequencing established that one encoded the HP-1 peptide, whereas the other encoded HP-3. Analysis of DNAs obtained from 18 unrelated individuals by Southern blot analysis revealed the expected fragments as well as additional fragments that were not present in the genomic clones. This suggested the possibility of alleles; however, when DNAs from families were examined, these fragments did not segregate in an obvious Mendelian fashion. The HP-1/3-like defensin genes are on human chromosome 8. Surprisingly, somatic cell hybrid mapping showed that the number of HP-1/3-like genes on isolated copies of chromosome 8 was variable. We conclude that individuals can inherit versions of chromosome 8 harboring either two or three copies of the genes that encode the HP-1, HP-2, and/or HP-3 peptides.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELCOURT D, 1992, REGUL PEPTIDES, V40, P87, DOI 10.1016/0167-0115(92)90086-A; CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500; CHARP PA, 1988, BIOCHEM PHARMACOL, V37, P951, DOI 10.1016/0006-2952(88)90187-6; COMPTON DA, 1988, CELL, V55, P827, DOI 10.1016/0092-8674(88)90138-9; DAHER KA, 1986, J VIROL, V60, P1068, DOI 10.1128/JVI.60.3.1068-1074.1986; DAHER KA, 1988, P NATL ACAD SCI USA, V85, P7327, DOI 10.1073/pnas.85.19.7327; EISENHAUER P, 1990, INFECT IMMUN, V58, P3899, DOI 10.1128/IAI.58.12.3899-3902.1990; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3556, DOI 10.1128/IAI.60.9.3556-3565.1992; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GANZ T, 1989, J IMMUNOL, V143, P1358; GANZ T, 1990, EUR J HAEMATOL, V44, P1; GRAHAM MY, 1987, NUCLEIC ACIDS RES, V15, P4437, DOI 10.1093/nar/15.11.4437; HARPER ME, 1982, AM J HUM GENET, V34, P227; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HU J, 1991, BIOCHEM BIOPH RES CO, V180, P558; HUFF V, 1990, HUM GENET, V84, P253; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KUN SC, 1986, BLOOD, V68, P1411; LEHRER RI, 1988, J CLIN INVEST, V81, P1829, DOI 10.1172/JCI113527; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; LICHTENSTEIN AK, 1988, CELL IMMUNOL, V114, P104, DOI 10.1016/0008-8749(88)90258-4; LINZMEIER R, 1993, FEBS LETT, V321, P267, DOI 10.1016/0014-5793(93)80122-B; MARS WM, 1988, BLOOD, V71, P1713; OKRENT DG, 1990, AM REV RESPIR DIS, V141, P179, DOI 10.1164/ajrccm/141.1.179; OUELLETTE AJ, 1992, FEBS LETT, V304, P146, DOI 10.1016/0014-5793(92)80606-H; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; PALFREE RGE, 1993, MOL ENDOCRINOL, V7, P199, DOI 10.1210/me.7.2.199; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; SELSTED ME, 1987, INFECT IMMUN, V55, P2281, DOI 10.1128/IAI.55.9.2281-2286.1987; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; SINGH A, 1988, BIOCHEM BIOPH RES CO, V155, P524, DOI 10.1016/S0006-291X(88)81118-5; SPARKES RS, 1989, GENOMICS, V5, P240, DOI 10.1016/0888-7543(89)90052-9; STALLINGS RL, 1988, AM J HUM GENET, V43, P144; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; TOMINAGA T, 1990, J ENDOCRINOL, V125, P287, DOI 10.1677/joe.0.1250287; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WIEDEMANN LM, 1989, LEUKEMIA, V3, P227; WILDE CG, 1989, J BIOL CHEM, V264, P11200; ZHU Q, 1989, ENDOCR RES, V15, P129, DOI 10.1080/07435808909039093; ZHU QH, 1988, P NATL ACAD SCI USA, V85, P592, DOI 10.1073/pnas.85.2.592; ZHU QZ, 1987, J STEROID BIOCHEM, V27, P1017	47	53	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30371	30376		10.1074/jbc.270.51.30371	http://dx.doi.org/10.1074/jbc.270.51.30371			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530462	hybrid			2022-12-25	WOS:A1995TL67500027
J	Wong, SKF; Ma, CP; Foster, DC; Chen, AY; Garbers, DL				Wong, SKF; Ma, CP; Foster, DC; Chen, AY; Garbers, DL			The guanylyl cyclase-A receptor transduces an atrial natriuretic peptide ATP activation signal in the absence of other proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; KINASE FAMILY; RAT LUNG; PURIFICATION; MEMBRANES; DOMAIN	Attempts to activate partially purified preparations of the guanylyl cyclase-A (GC-A) receptor with atrial natriuretic peptide (ANP) have previously failed, leading to speculation that essential cofactors are lost during purification procedures. The receptor was modified to contain the FLAG epitope (DYKDDDDK), expressed in Sf9 cells, and purified to apparent homogeneity (4.3 mu mol cyclic GMP formed/min/mg protein; 5.8 nmol I-125-ANP binding site/mg protein) by a combination of immunoaffinity, Q-Sepharose FF, and wheat germ agglutinin batch chromatography. High initial protein/detergent ratios, the presence of glycerol (40%), and the inclusion of protein phosphatase inhibitors in all buffers resulted in the purification of a receptor that continued to transduce the ANP/ATP activation signal. Both native and purified GC-A contained a single class of high affinity ANP binding sites (K-d = 60 pM) and an equivalent EC(50) for ATP (0.3 mM). Positive cooperativity as a function of MnGTP was retained during purification. Thus, GC-A is capable of transducing a ligand binding signal in the absence of other proteins.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yale University	Wong, SKF (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049588] Funding Source: NIH RePORTER; NHLBI NIH HHS [7R01-HL49588] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; GARBERS DL, 1976, J BIOL CHEM, V251, P4071; GARBERS DL, 1992, CELL, V71, P1; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSBROUGH JR, 1981, J BIOL CHEM, V256, P1447; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P3; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; KUNO T, 1986, J BIOL CHEM, V261, P5817; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; MELOCHE S, 1988, BIOCHEMISTRY-US, V27, P8151, DOI 10.1021/bi00421a025; MERRIL CR, 1986, ANAL BIOCHEM, V156, P96, DOI 10.1016/0003-2697(86)90160-0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; POTTER LR, 1992, J BIOL CHEM, V267, P14531; POTTER LR, 1994, J BIOL CHEM, V269, P14636; RAMARAO CS, 1988, J BIOL CHEM, V263, P1524; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SUMMERS MD, 1987, TEX AGR EXP STN B, V55, P1; TAKAYANAGI R, 1987, J BIOL CHEM, V262, P12104; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; XIE XS, 1988, METHOD ENZYMOL, V157, P634; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602	33	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30818	30822		10.1074/jbc.270.51.30818	http://dx.doi.org/10.1074/jbc.270.51.30818			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530525	hybrid			2022-12-25	WOS:A1995TL67500090
J	Hansen, R; Reddel, R; Braithwaite, A				Hansen, R; Reddel, R; Braithwaite, A			The transforming oncoproteins determine the mechanism by which p53 suppresses cell transformation: pRb-mediated growth arrest or apoptosis	ONCOGENE			English	Article						p53; retinoblastoma protein; SV40 large T antigen; transformation; cell cycle; apoptosis	WILD-TYPE P53; LARGE T-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; SV40 LARGE-T; ADENOVIRUS E1A PROTEINS; LARGE TUMOR-ANTIGEN; HUMAN-DIPLOID FIBROBLASTS; TRANSCRIPTION FACTOR E2F; SIMIAN VIRUS-40; SUSCEPTIBILITY GENE	To investigate the mechanisms by which p53 suppresses cell transformation, we used the simian virus 40 (SV40) large T antigen (LTag), the adenovirus Ela proteins, and an activated ras protein (EJ-ras), to examine different pathways of transformation for their susceptibility to suppression by p53, While p53 can suppress transformation by various oncoproteins, we have shown that it is unable to suppress the transformation of rat embryo fibroblasts (REFs) by LTag, Interestingly, the function of LTag which enables it to overcome the proliferative effects of p53 is not the binding inactivation of p53, but the binding and inactivation of the pRb family of proteins, This observation indicates that pRb mediates a suppressive effect of p53 on cell transformation, We have also observed that in contrast to LTag, both Ela and EJ-ras cause transformation-related events which are susceptible to suppression by p53, Further studies have revealed that cells expressing Ela are susceptible to p53-mediated apoptosis, while cells expressing EJ-ras are susceptible to p53-induced growth inhibition, We therefore propose that p53 suppresses transformation either by arresting cell growth (mediated by pRb in late G1) or by inducing apoptosis, with the mechanism being determined by the transforming oncoprotein(s).	CHILDRENS MED RES INST,SYDNEY,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia; University of Sydney	Hansen, R (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CANBERRA,ACT 0200,AUSTRALIA.		Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107				BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EGAN C, 1989, ONCOGENE, V4, P383; ELDIERY WS, 1993, CELL, V75, P817; ELDIERY WS, 1994, CANCER RES, V54, P1169; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GERSHEY EL, 1979, J VIROL, V30, P76, DOI 10.1128/JVI.30.1.76-83.1979; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hiscott J B, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P343; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKSON P, 1993, ONCOGENE, V8, P589; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LIN JY, 1991, J VIROL, V65, P2066, DOI 10.1128/JVI.65.4.2066-2072.1991; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MACLEAN K, 1994, ONCOGENE, V9, P719; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHAELMICHALOVITZ D, 1991, J VIROL, V65, P4160, DOI 10.1128/JVI.65.8.4160-4168.1991; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MORGANBESSER AD, 1994, NATURE, V371, P72; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NEVINS JR, 1992, SCIENCE, V258, P424; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Reed Michael, 1993, Gene Expression, V3, P95; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SEGAWA K, 1993, ONCOGENE, V8, P543; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SOMPAYRAC L, 1992, VIROLOGY, V191, P439, DOI 10.1016/0042-6822(92)90206-5; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	97	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2535	2545						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545110				2022-12-25	WOS:A1995TP18800009
J	Zhan, SL; Shapiro, DN; Helman, LJ				Zhan, SL; Shapiro, DN; Helman, LJ			Loss of imprinting of IGF2 in Ewing's sarcoma	ONCOGENE			English	Article						IGF2; Ewing's sarcoma; genomic imprinting; pediatric sarcoma	FACTOR-II GENE; GROWTH-FACTOR; WILMS-TUMOR; METHYLATION; EXPRESSION; RELAXATION; TRANSLOCATION; FUSION	yInsulin-like Growth Factor 2 (IGF2) has recently been demonstrated to be maternally imprinted in both mice and humans, We previously reported loss of imprinting (LOI) of IGF2 in rhabdomyosarcoma (RMS) where IGF2 has been shown to act as an autocrine growth factor and play an important role in pathogenesis, Since IGF2 does not appear to play a role in the pathogenesis of Ewing's sarcoma, we sought to determine whether normal IGF2 imprinting was maintained in these tumors, Of 32 Ewing's tumors examined for imprinting of IGF2, 10 were informative heterozygotes and three of these expressed IGF2 biallelically. Furthermore, all three tumors with LOI and five of seven tumors with normal imprinting transcribed IGF2 mRNA at lower levels while relatively higher levels of IGFS expression was observed in the remaining two tumors with normal imprinting, These data demonstrate altered imprinting of IGF2 occurs some Ewing's sarcomas, However, LOI of IGF2 Ewing's sarcoma was not associated with increased expression of IGF2 mRNA, suggesting that LOI may not be involved in the regulation of IGF2 expression and may be related to genetic or epigenetic abnormalities in tumors independent of IGF2 expression.	NCI, PEDIAT BRANCH, MOLEC ONCOL SECT, BETHESDA, MD 20892 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-23099, CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EKSBERG R, 1993, NAT GENET, V5, P143; EVERSOLECIRE P, 1993, MOL CELL BIOL, V13, P4928, DOI 10.1128/MCB.13.8.4928; GLOUDEMANS T, 1992, CANCER RES, V52, P6516; HALL JG, 1990, AM J HUM GENET, V46, P857; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; KONDO M, 1995, ONCOGENE, V10, P1193; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OGAWA O, 1993, NAT GENET, V5, P408, DOI 10.1038/ng1293-408; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RAINIER S, 1995, CANCER RES, V55, P1836; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; SAKAI T, 1991, AM J HUM GENET, V48, P880; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; STEENMAN MJC, 1994, NAT GENET, V7, P432; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; YUNIS EJ, 1986, AM J SURG PATHOL, V10, P54; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	31	62	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2503	2507						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545106				2022-12-25	WOS:A1995TP18800005
J	EISENBERGDOMOVICH, Y; OELMULLER, R; HERRMANN, RG; OHAD, I				EISENBERGDOMOVICH, Y; OELMULLER, R; HERRMANN, RG; OHAD, I			ROLE OF THE RCII-D1 PROTEIN IN THE REVERSIBLE ASSOCIATION OF THE OXYGEN-EVOLVING COMPLEX PROTEINS WITH THE LUMENAL SIDE OF PHOTOSYSTEM-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; D1 PROTEIN; SCENEDESMUS-OBLIQUUS; EXTRINSIC PROTEINS; PHOTOINHIBITION; LIGHT; DEGRADATION; MEMBRANES; MUTANT; PLASTOCYANIN	The nuclear-encoded proteins of the oxygen-evolving complex (OEC) of photosystem II are bound on the lumenal side of the thylakoid membrane and stabilize the manganese ion cluster forming the photosystem II electron donor side. The OEC proteins are released from their binding site(s) following light-induced degradation of reaction center II (RCII)-D1 protein in Chlamydomonas reinhardtii. The kinetics of OEC proteins release correlates with that of RCII-D1 protein degradation. Only a limited amount of RCII-D2 protein is degraded during the process, and no loss of the core proteins CP43 and CP47 is detected. The release of the OEC proteins is prevented when the photoinactivated RCII-D1 protein degradation is retarded by addition of 3-(3,5-dichlorophenyl)-1,1-dimethylurea or by a high PQH(2)/PQ ratio prevailing in membranes of the plastocyanin-deficient mutant Ac-208. The released proteins are not degraded but persist in the thylakoid lumen for up to 8 h and reassociate with photosystem II when new D1 protein is synthesized in cells exposed to low light, thus allowing recovery of photosystem II function. Reassociation also occurs following D1 protein synthesis in darkness when RCII activity is only partially recovered. These results indicate that (i) the D1 protein participates in the formation of the lumenal OEC proteins binding site(s) and (ii) the photoinactivation of RCII-D1 protein does not alter the conformation of the donor side of photosystem II required for the binding of the OEC proteins.	HEBREW UNIV JERUSALEM, SILBERMAN INST LIFE SCI, DEPT BIOL CHEM, IL-91904 JERUSALEM, ISRAEL; UNIV MUNICH, INST BOT, D-80638 MUNICH, GERMANY	Hebrew University of Jerusalem; University of Munich								ADIR N, 1990, J BIOL CHEM, V265, P12563; BROCK IW, 1995, J BIOL CHEM, V270, P1657, DOI 10.1074/jbc.270.4.1657; DINER BA, 1988, J BIOL CHEM, V263, P8972; ETTINGER WF, 1991, J CELL BIOL, V115, P321, DOI 10.1083/jcb.115.2.321; GHANOTAKIS DF, 1990, ANNU REV PLANT PHYS, V41, P255, DOI 10.1146/annurev.pp.41.060190.001351; GONG H, 1991, J BIOL CHEM, V266, P21293; GONG HS, 1995, BBA-BIOENERGETICS, V1228, P181, DOI 10.1016/0005-2728(94)00170-A; GUENTHER JE, 1990, PHOTOSYNTH RES, V24, P35, DOI 10.1007/BF00032642; HAEHNEL W, 1989, J CELL BIOL, V108, P1397, DOI 10.1083/jcb.108.4.1397; HASHIMOTO A, 1993, BIOCHIM BIOPHYS ACTA, V1183, P397, DOI 10.1016/0005-2728(93)90245-B; HUNDAL T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P235, DOI 10.1016/0005-2728(90)90190-F; HUSE H, 1989, PHOTOSYNTH RES, V21, P171, DOI 10.1007/BF00037181; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITSCH J, 1994, PLANTA, V194, P15, DOI 10.1007/BF00201029; MALNOE P, 1988, J CELL BIOL, V106, P609, DOI 10.1083/jcb.106.3.609; METZ JG, 1986, FEBS LETT, V205, P269, DOI 10.1016/0014-5793(86)80911-5; OHAD I, 1967, J CELL BIOL, V35, P521, DOI 10.1083/jcb.35.3.521; Ohad I., 1994, MOL MECH F, P161; PALOMARES R, 1993, EUR J BIOCHEM, V217, P345, DOI 10.1111/j.1432-1033.1993.tb18252.x; PRASIL O, 1992, PHOTOSYSTEMS STRUCTU, P295, DOI DOI 10.1016/B978-0-444-89440-3.50017-5; QUINN J, 1993, J BIOL CHEM, V268, P7832; REGITZ G, 1976, J BIOL CHEM, V251, P247; REISMAN S, 1986, BIOCHIM BIOPHYS ACTA, V849, P41, DOI 10.1016/0005-2728(86)90094-0; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; ROCHAIX JD, 1988, TRENDS BIOCHEM SCI, V13, P56, DOI 10.1016/0968-0004(88)90029-1; ROVA M, 1994, PHOTOSYNTH RES, V39, P75, DOI 10.1007/BF00027145; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P403, DOI 10.1111/j.1432-1033.1988.tb14389.x; SCHUSTER G, 1984, BIOCHIM BIOPHYS ACTA, V767, P596, DOI 10.1016/0005-2728(84)90061-6; TAMURA N, 1989, BIOCHIM BIOPHYS ACTA, V976, P173, DOI 10.1016/S0005-2728(89)80227-0; TAYLOR MA, 1988, FEBS LETT, V235, P109, DOI 10.1016/0014-5793(88)81243-2; VERMAAS WFJ, 1993, PHOTOSYNTH RES, V38, P249, DOI 10.1007/BF00046750; VIRGIN I, 1988, FEBS LETT, V233, P408, DOI 10.1016/0014-5793(88)80472-1; WANG WQ, 1992, PLANT PHYSIOL, V99, P16, DOI 10.1104/pp.99.1.16; ZER H, 1994, J BIOL CHEM, V269, P17670; ZER H, 1995, EUR J BIOCHEM, V231, P448, DOI 10.1111/j.1432-1033.1995.tb20718.x	36	29	30	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30181	30186						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530427				2022-12-25	WOS:A1995TK38000087
J	LIN, TM; YOUNG, WJ; CHANG, CS				LIN, TM; YOUNG, WJ; CHANG, CS			MULTIPLE FUNCTIONS OF THE TR2-11 ORPHAN RECEPTOR IN MODULATING ACTIVATION OF 2 KEY CIS-ACTING ELEMENTS INVOLVED IN THE RETINOIC ACID SIGNAL-TRANSDUCTION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; RESPONSE ELEMENTS; NUCLEAR RECEPTORS; DNA-BINDING; X-RECEPTOR; VITAMIN-D; ESTROGEN-RECEPTOR; GENE-EXPRESSION; COUP-TF; TRANSCRIPTION	The testicular receptor 2 (TR2) orphan receptor binds to hormone response elements (HREs) consisting of two AGGTCA half-site direct repeat consensus sequences (DR) with various spacing in the following order: DR1 > DR2 > DR5 DR4 DR6 > DR3. When binding to natural HREs, TR2 orphan receptor remains flexible with higher binding affinities to (a) cellular retinol-binding protein II promoter region (CRBPIIp) (DR1), SV40 +55 region (DR2), and retinoic acid response element beta (RARE beta) (DR5) than to (b) NGFI-B response element (NBRE) and also to (c) the palindromic thyroid hormone response element (TREpal). This wide spectrum of HRE recognition sequences suggests possible versatility of the TR2 orphan receptor in cross-talking with other signal transduction systems. Chloramphenicol acetyltransferase (CAT) assay demonstrates that the TR2 orphan receptor competes with CRBPIIp- and RARE beta-CAT gene expression activated by retinoid X receptor alpha (RXR alpha) and retinoic acid receptor alpha (RAR alpha)/RXR alpha heterodimers, respectively. In addition, this suppression may not be mediated by the formation of heterodimers between TR2 orphan receptor and either RXR alpha or RAR alpha. Instead, a minimum of 100-fold higher affinity of the TR2 orphan receptor for CRBPIIp than RXR alpha may explain why the TR2 orphan receptor dominates RXR alpha in CRBPIIp-CAT activation. Together, our data suggest that the TR2 orphan receptor may be a master regulator in modulating the activation of two key HREs, RARE beta and CRBPIIp, involved in the retinoic acid signal transduction pathway.	UNIV WISCONSIN,CTR COMPREHENS CANC,CTR CLIN SCI K4632,DEPT MED,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA55639, CA09471] Funding Source: Medline; NIDDK NIH HHS [DK47258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055639, T32CA009471, R29CA055639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROWN M, 1990, J BIOL CHEM, V265, P11238; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DAMASSA DA, 1991, ENDOCRINOLOGY, V129, P75, DOI 10.1210/endo-129-1-75; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUCKABY CS, 1987, P NATL ACAD SCI USA, V84, P8380, DOI 10.1073/pnas.84.23.8380; IDETA R, 1995, ENDOCRINE, V3, P277, DOI 10.1007/BF03021406; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MERTZ J, 1994, J CELL BIOCH S18B, V55, P369; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NORMAN AW, 1992, NUTR REV, V50, P230, DOI 10.1111/j.1753-4887.1992.tb01333.x; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; RUBERTE E, 1991, DEVELOPMENT, V111, P45; SMITH SM, 1991, DEVELOPMENT, V111, P245; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZUO F, 1995, THESIS U WISCONSIN M; ZUO FR, 1995, P NATL ACAD SCI USA, V92, P8586, DOI 10.1073/pnas.92.19.8586	41	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30121	30128						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530418				2022-12-25	WOS:A1995TK38000078
J	SIDDIQUE, HR; RAO, VN; LEE, L; REDDY, ESP				SIDDIQUE, HR; RAO, VN; LEE, L; REDDY, ESP			CHARACTERIZATION OF THE DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION DOMAINS OF THE ERG PROTEIN	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS ONCOGENE; C-ETS-1 PROTOONCOGENE; C-ETS; V-ETS; GENE; SEQUENCE; CHROMOSOME-21	erg, an ets related gene encodes a sequence specific DNA binding transcriptional activator protein. We have identified four functional domains of erg protein that are responsible for DNA binding, transcriptional activation and negative regulation of transcriptional activation. Deletion analysis revealed that the 3'-ets domain of the erg protein is sufficient for DNA binding activity. Analysis of these deletion mutants also revealed the presence of two autonomous transcriptional activation domains, one at the amino and the other at the carboxy-terminal region. This aminoterminal transcriptional activator domain (5'-ets domain) is conserved in six of the ets genes suggesting that it (ETA, ets Transcriptional Activation domain) may contribute to a common function among these genes. The transcriptional activation function of the carboxy terminal transcriptional activation domain (CTA) was inhibited by the presence of a Negative Regulatory Transcriptional activation domain (NRT), which is located at the amino terminal region of erg DNA binding domain. These results may help in understanding the structure/function relationship of other erg/ets related proteins.	JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; PROGRAM RESOURCES INC,FREDERICK,MD 21702	Jefferson University					NATIONAL CANCER INSTITUTE [P01CA051083, R01CA057157] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57157, CA 51083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; COQUILLAND M, 1988, ONCOGENE RES, V2, P335; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GARDINER K, 1990, EMBO J, V9, P25, DOI 10.1002/j.1460-2075.1990.tb08076.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PRASAD DDK, 1992, CANCER RES, V52, P5833; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; RAO VN, 1992, ONCOGENE, V11, P2335; RAO VN, 1993, IN PRESS ONCOGENE; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; REDDY ESP, 1993, IN PRESS ERG ELK 1 E; REDDY ESP, 1990, CANCER RES, V50, P5013; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SETH A, 1990, ONCOGENE, V5, P1761; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; [No title captured]	48	60	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1751	1755						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510921				2022-12-25	WOS:A1993LG68200005
J	WOLIN, M; KORNUC, M; HONG, C; SHIN, SK; LEE, F; LAU, R; NIMER, S				WOLIN, M; KORNUC, M; HONG, C; SHIN, SK; LEE, F; LAU, R; NIMER, S			DIFFERENTIAL EFFECT OF HTLV INFECTION AND HTLV TAX ON INTERLEUKIN-3 EXPRESSION	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; T-CELL LEUKEMIA; TRANS-ACTIVATOR PROTEIN; GENE-EXPRESSION; HUMAN-LYMPHOCYTES; MULTI-CSF; RECEPTOR; POLYMERASE; ELEMENT; DNA	To characterize the interactions between human T-cell leukemia virus (HTLV) infection and cellular gene expression, we examined the expression of the lymphokine interleukin 3 (IL-3) in the presence and absence of HTLV infection. IL-3, like granulocyte-macrophage colony-stimulating factor (GM-CSF), is produced by activated but not resting T cells, but although GM-CSF is constitutively expressed in HTLV-infected T cells IL-3 mRNA cannot be detected in either unstimulated or mitogen-stimulated HTLV-infected cells by polymerase chain reaction (PCR) analysis. In contrast, transient co-transfection studies with an IL-3 promoter-CAT reporter gene and an HTLV-II Tax expression construct demonstrate that Tax can transactivate the IL-3 promoter in HTLV-uninfected T cells. To determine whether differences in IL-3 promoter-binding proteins present in HTLV-infected and uninfected T cells account for this discrepancy, DNAase I footprinting of the IL-3 promoter was performed. Although crude nuclear extracts from both cell types protected the IL-3 sequences located between base pairs -168 and -125, the sequences between -125 and -103, which contain the lymphokine consensus sequences CK-1 and CK-2, were protected by extracts from HTLV-infected but not HTLV-uninfected T cells. Deletion of the region containing the CK-1 and CK-2 sequences from an IL-3 promoter CAT construct resulted in a sixfold rise in promoter activity in HTLV-infected but not uninfected T-cell lines, indicating that this region participates in the repression of IL-3 gene expression in HTLV-infected T cells.	UNIV CALIF LOS ANGELES,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	WOLIN, M (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43025] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; CANN AJ, 1988, ONCOGENE, V3, P123; CHAN JY, 1986, P NATL ACAD SCI USA, V83, P8669, DOI 10.1073/pnas.83.22.8669; CHIRGWIN J, 1979, BIOCHEMISTRY-US, V118, P5294; CROSS SL, 1987, CELL, V49, P4756; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EMERSON SG, 1988, J CLIN INVEST, V82, P1282, DOI 10.1172/JCI113727; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; KAUSHANSKY K, 1989, J IMMUNOL, V143, P2525; LEARY AG, 1987, BLOOD, V70, P1343; MALEFYT RD, 1990, J IMMUNOL, V145, P2297; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NIEMEYER CM, 1989, BLOOD, V73, P945; NIMER SD, 1989, J IMMUNOL, V143, P2374; NIMER SD, 1989, ONCOGENE, V4, P671; NIMER SD, 1988, MOL CELL BIOL, V8, P1979, DOI 10.1128/MCB.8.5.1979; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SALAHUDDIN SZ, 1984, SCIENCE, V223, P703, DOI 10.1126/science.6320367; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; SUGAMURA K, 1986, Cancer Reviews, V1, P96; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YANG YC, 1986, CELL, V47, P3, DOI 10.1016/0092-8674(86)90360-0; YOSHIDA MI, 1982, P NATL ACAD SCI USA, V78, P2031	39	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1905	1911						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510934				2022-12-25	WOS:A1993LG68200023
J	CHEN, L; FINCHER, GB; HOJ, PB				CHEN, L; FINCHER, GB; HOJ, PB			EVOLUTION OF POLYSACCHARIDE HYDROLASE SUBSTRATE-SPECIFICITY - CATALYTIC AMINO-ACIDS ARE CONSERVED IN BARLEY 1,3-1,4-GLUCANASE AND 1,3-BETA-GLUCANASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCAN HYDROLASES; SITE-DIRECTED INHIBITION; (1->3)-BETA-GLUCAN ENDOHYDROLASE; NICOTIANA-PLUMBAGINIFOLIA; GERMINATING BARLEY; MOLECULAR-CLONING; LYSOZYME; IDENTIFICATION; PURIFICATION; TOBACCO	Catalytic amino acid residues in a 1,3-beta-D-glucan 3-glucanohydrolase (EC 3.2.1.39) and a homologous 1,3-4-beta-D-glucan 4-glucanohydrolase (EC 3.2.1.73) from barley have been investigated. To identify amino acids responsible for protonation of the glycosidic oxygen during hydrolysis, carbodiimide-mediated labeling of the enzymes with [C-14]glycine ethyl ester was performed. This resulted in loss of activity and specific modification of the Glu288 residues in both enzymes. The stoichiometry of labeling was approximately 1:1, and modification was reduced in the presence of substrate analogues. Based on these data, the Glu288 residues are likely to be present at the active sites of the respective enzymes and may represent the catalytic acids in the hydrolytic reaction. The catalytic nucleophiles of the two enzymes were investigated by labeling with specific, mechanism-based epoxyalkyl-beta-oligoglucosides. Amino acid residues Glu232 and Glu231 were identified as the likely catalytic nucleophiles in the 1,3-1,4- and 1,3-beta-glucanases, respectively. Thus the position of the catalytic nucleophile and the putative proton donating amino acids in the two classes of beta-glucan endohydrolases are conserved. The acquisition of distinct substrate specificities in the evolution of these related enzymes may therefore not require the recruitment of novel catalytic amino acids but rather differences in their positioning at the active site and/or changes in substrate binding residues.	LA TROBE UNIV, DEPT BIOCHEM, BUNDOORA, VIC 3083, AUSTRALIA	La Trobe University			Hoj, Peter B/E-8526-2011					ANDERSON MA, 1975, FEBS LETT, V52, P202, DOI 10.1016/0014-5793(75)80806-4; Bacic A., 1988, BIOCHEM PLANT, V14, P297, DOI [DOI 10.1016/B978-0-08-092615-5.50014-X, 10.1016/B978-0-08-092615-5.50014-X]; BANERJEE SK, 1973, J BIOL CHEM, V248, P4786; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P365, DOI 10.1098/rspb.1967.0034; BOLLER T, 1987, PLANT MICROBE INTERA, V2, P385; BUECHLER JA, 1988, BIOCHEMISTRY-US, V27, P7356, DOI 10.1021/bi00419a027; CAMPBELL ID, 1975, PROC R SOC SER B-BIO, V189, P485, DOI 10.1098/rspb.1975.0069; CASTRESANA C, 1990, PLANT CELL, V2, P1131, DOI 10.1105/tpc.2.12.1131; DELOOSE M, 1988, GENE, V70, P13, DOI 10.1016/0378-1119(88)90100-X; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; DOAN DNP, 1993, DNA CELL BIOL, V12, P97, DOI 10.1089/dna.1993.12.97; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; ESHDAT Y, 1973, J BIOL CHEM, V248, P5892; FINCHER GB, 1989, ANNU REV PLANT PHYS, V40, P305, DOI 10.1146/annurev.pp.40.060189.001513; FINCHER GB, 1986, P NATL ACAD SCI USA, V83, P2081, DOI 10.1073/pnas.83.7.2081; FORD LO, 1974, J MOL BIOL, V88, P349, DOI 10.1016/0022-2836(74)90487-2; HOARE DG, 1967, J BIOL CHEM, V242, P2447; HOJ PB, 1992, J BIOL CHEM, V267, P25059; HOJ PB, 1991, J BIOL CHEM, V266, P11628; HOJ PB, 1988, FEBS LETT, V230, P67, DOI 10.1016/0014-5793(88)80643-4; HOJ PB, 1989, PLANT MOL BIOL, V13, P31, DOI 10.1007/BF00027333; HOJ PB, 1989, J BIOL CHEM, V264, P4939; HOUEN G, 1991, ANAL BIOCHEM, V193, P186, DOI 10.1016/0003-2697(91)90006-F; HRMOVA M, 1993, BIOCHEM J, V289, P453, DOI 10.1042/bj2890453; KLEBL F, 1989, J BACTERIOL, V171, P6259, DOI 10.1128/jb.171.11.6259-6264.1989; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KURAMITSU S, 1977, J BIOCHEM-TOKYO, V82, P585; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; LEGLER G, 1981, FEBS LETT, V135, P139, DOI 10.1016/0014-5793(81)80962-3; LINTHORST HJM, 1990, P NATL ACAD SCI USA, V87, P8756, DOI 10.1073/pnas.87.22.8756; LUMB KJ, 1992, FEBS LETT, V296, P153, DOI 10.1016/0014-5793(92)80368-Q; MAUCH F, 1988, PLANT PHYSIOL, V87, P325, DOI 10.1104/pp.87.2.325; MOORE AE, 1972, BIOCHIM BIOPHYS ACTA, V258, P248, DOI 10.1016/0005-2744(72)90983-7; MOULT J, 1973, J MOL BIOL, V75, P1, DOI 10.1016/0022-2836(73)90524-X; Nelson N, 1944, J BIOL CHEM, V153, P375; NITTA Y, 1989, J BIOCHEM-TOKYO, V105, P573, DOI 10.1093/oxfordjournals.jbchem.a122706; ORI N, 1990, EMBO J, V9, P3429, DOI 10.1002/j.1460-2075.1990.tb07550.x; PARRISH FW, 1960, CAN J CHEM, V38, P2094, DOI 10.1139/v60-284; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; PLANAS A, 1992, FEBS LETT, V308, P141, DOI 10.1016/0014-5793(92)81262-K; RODRIGUEZ EB, 1990, AUST J CHEM, V43, P665, DOI 10.1071/CH9900665; RODRIGUEZ EB, 1990, AUST J CHEM, V43, P1391, DOI 10.1071/CH9901391; RODRIGUEZ EB, 1989, THESIS U W AUSTR NED; SHINSHI H, 1988, P NATL ACAD SCI USA, V85, P5541, DOI 10.1073/pnas.85.15.5541; SLAKESKI N, 1992, FEBS LETT, V306, P98, DOI 10.1016/0014-5793(92)80977-O; SLAKESKI N, 1992, PLANT PHYSIOL, V99, P1226, DOI 10.1104/pp.99.3.1226; SLAKESKI N, 1990, MOL GEN GENET, V224, P437, DOI 10.1007/BF00262439; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; SPERISEN C, 1991, P NATL ACAD SCI USA, V88, P1820, DOI 10.1073/pnas.88.5.1820; SVENSSON B, 1990, EUR J BIOCHEM, V188, P29, DOI 10.1111/j.1432-1033.1990.tb15367.x; SVENSSON B, 1993, IN PRESS J BIOTECHNO, V29; TAKEUCHI Y, 1990, PLANT PHYSIOL, V93, P673, DOI 10.1104/pp.93.2.673; VERNON CA, 1967, PROC R SOC SER B-BIO, V167, P389, DOI 10.1098/rspb.1967.0036; WOODWARD JR, 1982, EUR J BIOCHEM, V121, P663, DOI 10.1111/j.1432-1033.1982.tb05837.x; WOODWARD JR, 1983, THESIS LA TROBE U BU; XU PL, 1992, GENE, V120, P157, DOI 10.1016/0378-1119(92)90089-8; YAMADA H, 1981, BIOCHEMISTRY-US, V20, P4836, DOI 10.1021/bi00520a005; ZIMMERMAN CL, 1977, ANAL BIOCHEM, V77, P569, DOI 10.1016/0003-2697(77)90276-7	58	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13318	13326						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514770				2022-12-25	WOS:A1993LH55300046
J	MINGARRO, I; SENDRA, R; SALVADOR, ML; FRANCO, L				MINGARRO, I; SENDRA, R; SALVADOR, ML; FRANCO, L			SITE-SPECIFICITY OF PEA HISTONE ACETYLTRANSFERASE-B INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; LINKING NUMBER CHANGE; ACETYLATION SITES; SACCHAROMYCES-CEREVISIAE; PHYSARUM-POLYCEPHALUM; PARTIAL-PURIFICATION; ZEA-MAYS; TRANSCRIPTION; TETRAHYMENA; YEAST	Histone acetyltransferase B from pea embryonic axes has been purified almost-equal-to 300-fold by a combination of chromatographic procedures, including affinity chromatography on histone-agarose. The enzyme preparation has been used for the in vitro transfer of acetyl groups from [1-C-14]acetyl-CoA to non-acetylated pea histone H4. Up to three acetyl groups can be introduced into the histone. The resulting mono-, di-, and triacetylated H4 isoforms were separated and sequenced to determine the acetylated sites. Only sites 5, 12, and 16 were used by histone acetyltransferase B, but no clear preference among them was observed. The absence of modification of other potentially acetylatable sites is another indication that acetylation of the different lysine residues in the N-terminal H4 tail serves as a specific signal in different nuclear processes.	UNIV VALENCIA, DEPT BIOCHEM & MOLEC BIOL, DR MOLINER 50, E-46100 BURJASSOT, SPAIN	University of Valencia			Sendra, Ramón/K-3549-2014; Mingarro, Ismael/B-4745-2014	Sendra, Ramón/0000-0002-5519-4362; Mingarro, Ismael/0000-0002-1910-1229; Franco, Luis/0000-0001-9610-6448				ALFAGEME CR, 1974, J BIOL CHEM, V249, P3729; BROSCH G, 1992, J BIOL CHEM, V267, P20561; CHAMBERS SAM, 1984, J BIOL CHEM, V259, P3458; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; CHICOINE LG, 1987, J CELL BIOL, V105, P127, DOI 10.1083/jcb.105.1.127; COUPPEZ M, 1987, J BIOL CHEM, V262, P2854; COUSENS LS, 1982, J BIOL CHEM, V257, P3945; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DELANGE RJ, 1969, J BIOL CHEM, V244, P5669; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; GEORGIEVA EI, 1991, J BIOL CHEM, V266, P18751; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; JACKSON V, 1981, NUCLEIC ACIDS RES, V9, P4563, DOI 10.1093/nar/9.18.4563; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KELNER DN, 1984, J BIOL CHEM, V259, P3413; LAGENBUCH J, 1983, PLANT MOL BIOL, V2, P207; LAZURE C, 1990, HPLC BIOL MACROMOLEC, P263; LIBBY PR, 1980, ARCH BIOCHEM BIOPHYS, V203, P384, DOI 10.1016/0003-9861(80)90190-3; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; LOIDL P, 1988, FEBS LETT, V227, P91, DOI 10.1016/0014-5793(88)80874-3; LOPEZRODAS G, 1989, J BIOL CHEM, V264, P19028; LOPEZRODAS G, 1993, FEBS LETT, V317, P175, DOI 10.1016/0014-5793(93)81271-Z; LOPEZRODAS G, 1991, J BIOL CHEM, V266, P18745; LOPEZRODAS G, 1991, BIOCHEMISTRY-US, V30, P3728, DOI 10.1021/bi00229a020; LOPEZRODAS G, 1985, ARCH BIOCHEM BIOPHYS, V239, P184, DOI 10.1016/0003-9861(85)90825-2; LUTTER LC, 1992, MOL CELL BIOL, V12, P5004, DOI 10.1128/MCB.12.11.5004; MANN RK, 1992, EMBO J, V11, P3297, DOI 10.1002/j.1460-2075.1992.tb05408.x; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; NORTON VG, 1990, J BIOL CHEM, V265, P19848; OLIVA R, 1990, NUCLEIC ACIDS RES, V18, P2739, DOI 10.1093/nar/18.9.2739; PESIS KH, 1986, ARCH BIOCHEM BIOPHYS, V251, P665, DOI 10.1016/0003-9861(86)90376-0; PETERSON JD, 1972, J BIOL CHEM, V247, P4866; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; SALVADOR ML, 1985, FEBS LETT, V191, P55, DOI 10.1016/0014-5793(85)80992-3; SENDRA R, 1986, PLANT SCI, V46, P189, DOI 10.1016/0168-9452(86)90191-3; SENDRA R, 1988, PLANT MOL BIOL, V11, P857, DOI 10.1007/BF00019525; SENDRA R, 1991, PLANT SCI, V78, P43, DOI 10.1016/0168-9452(91)90160-A; SHIMAMURA A, 1989, J BIOL CHEM, V264, P14524; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; THWAITS BH, 1976, FEBS LETT, V71, P197, DOI 10.1016/0014-5793(76)80930-1; THWAITS BH, 1976, FEBS LETT, V71, P193, DOI 10.1016/0014-5793(76)80929-5; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; TURNER BM, 1989, EXP CELL RES, V182, P206, DOI 10.1016/0014-4827(89)90292-9; TURNER BM, 1991, J CELL SCI, V99, P13; ULL M A, 1986, Plant Molecular Biology, V7, P25; VIDALI G, 1988, ADV POST TRANSLATION, P583; WATERBORG JH, 1983, EUR J BIOCHEM, V136, P245, DOI 10.1111/j.1432-1033.1983.tb07734.x; WATERBORG JH, 1992, BIOCHEMISTRY-US, V31, P6211, DOI 10.1021/bi00142a006	51	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13248	13252						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514763				2022-12-25	WOS:A1993LH55300036
J	MULICHAK, AM; HUI, JO; TOMASSELLI, AG; HEINRIKSON, RL; CURRY, KA; TOMICH, CS; THAISRIVONGS, S; SAWYER, TK; WATENPAUGH, KD				MULICHAK, AM; HUI, JO; TOMASSELLI, AG; HEINRIKSON, RL; CURRY, KA; TOMICH, CS; THAISRIVONGS, S; SAWYER, TK; WATENPAUGH, KD			THE CRYSTALLOGRAPHIC STRUCTURE OF THE PROTEASE FROM HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2 WITH 2 SYNTHETIC PEPTIDIC TRANSITION-STATE ANALOG INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HIV-1 PROTEASE; COMPLEX; RESOLUTION; DESIGN	The crystal structure of human immunodeficiency virus (HIV) type 2 protease has been determined in complexes with peptidic inhibitors Noa-His-ChaPSI[CH(OH)CH(OH)]Val-Ile-Amp (U75875) and Qnc-Asn-ChaPSI[CH(OH)CH2]Val-Npt(U92163)(where Noa is naphthyloxyacetyl, Cha is cyclohexylalanine, Amp is 2-aminomethylpyridine, Qnc is quinoline-2-carbonyl, and Npt is neopentylamine), which have dihydroxyethylene and hydroxyethylene moieties, respectively, in place of the normal scissile bond of the natural ligand. The complexes crystallize in space group P2(1)2(1)2(1), with one dimer-inhibitor complex per asymmetric unit and average cell dimensions of a = 33.28 angstrom, b = 45.35 angstrom, c = 135.84 angstrom. Data were collected to approximately 2.5-angstrom resolution. The model structures were refined with resulting R-factors of around 0.19. As expected, the HIV-2 protease structure is approximately C2-symmetric with a gross structure very similar to that of the HIV-1 enzyme. The inhibitors bind in an extended conformation positioned lengthwise in the binding cleft in a manner similar to that found in the HIV-1 protease-inhibitor complexes previously reported. The substitution of the bulkier Ile82 side chain in the HIV-2 protease may help explain the better ability of HIV-2 protease to bind and hydrolyze ligands with small Pl and P1' side groups. It appears that differences in specificity between the proteases of HIV-1 and HIV-2 are not merely a result of simple side chain substitutions, but may be complicated by differences in main chain flexibility as well.	UPJOHN CO, DISCOVERY RES, KALAMAZOO, MI 49007 USA	Pfizer								ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BONE R, 1991, J AM CHEM SOC, V113, P9382, DOI 10.1021/ja00024a061; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; HALL SR, 1990, XTAL 3 0 REFERENCE M; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, P43; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JONES TA, 1985, METHOD ENZYMOL, V115, P157; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MURTHY KHM, 1992, J BIOL CHEM, V267, P22770; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; THAISRIVONGS S, 1991, J MED CHEM, V34, P1276, DOI 10.1021/jm00108a006; THAISRIVONGS S, 1991, J MED CHEM, V34, P2344, DOI 10.1021/jm00112a005; THANKI N, 1992, PROTEIN SCI, V1, P1061, DOI 10.1002/pro.5560010811; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7	20	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13103	13109						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514751				2022-12-25	WOS:A1993LH55300017
J	WILLIAMS, M; HANAKAHI, LA; MAIZELS, N				WILLIAMS, M; HANAKAHI, LA; MAIZELS, N			PURIFICATION AND PROPERTIES OF LR1, AN INDUCIBLE DNA-BINDING PROTEIN FROM MAMMALIAN B-LYMPHOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; RNA POLYMERASE-II; PHOSPHORYLATION; IMMUNOGLOBULIN; DIFFERENTIATION; NUCLEAR; SITES	LR1 is a lipopolysaccharide-inducible B cell-specific DNA binding activity, with sites in the immunoglobulin heavy chain enhancer and switch regions. We describe the purification of this 106-kDa protein from nuclear extracts of PD31 murine pre-B cells, using three chromatographic steps. The DNA binding activity of LR1 is dependent upon phosphorylation, and we show that LR1 is post-translationally modified by N-acetylglucosamine addition. The importance of regulatory modification to LR1 DNA binding activity is apparent from the chromatographic pattern on the anion exchange resin Mono Q: while the LR1 polypeptide elutes over a broad salt range from the column, DNA binding activity is confined to a narrow peak eluting at the highest salt.	YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06510 USA	Yale University					NIGMS NIH HHS [R01 GM039799, R01GM39799] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039799] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; AHN NG, 1990, J BIOL CHEM, V265, P11487; ANSORGE WJ, 1985, BIOCH BIOPHYS METHOD, V2, P13; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BAUERLE PA, 1988, CELL, V53, P211; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GUY GR, 1985, BIOCHEM BIOPH RES CO, V131, P484, DOI 10.1016/0006-291X(85)91828-5; HARLOW E, 1988, ANTIBODIES LABORTORY; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADANOGA JT, 1986, P NATL ACAD SCI USA, V83, P5889; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LIAO F, 1992, J IMMUNOL, V148, P2909; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; WATERS SH, 1989, MOL CELL BIOL, V9, P5594, DOI 10.1128/MCB.9.12.5594; WILLIAMS M, 1991, GENE DEV, V5, P2353, DOI 10.1101/gad.5.12a.2353; WILLIAMS M, 1992, NUCLEIC ACIDS RES, V20, P4935, DOI 10.1093/nar/20.18.4935	28	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13731	13737						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514805				2022-12-25	WOS:A1993LH55300100
J	LAETHEM, RM; BALAZY, M; FALCK, JR; LAETHEM, CL; KOOP, DR				LAETHEM, RM; BALAZY, M; FALCK, JR; LAETHEM, CL; KOOP, DR			FORMATION OF 19(S)-HYDROXYEICOSATETRAENOIC, 19(R)-HYDROXYEICOSATETRAENOIC, AND 18(R)-HYDROXYEICOSATETRAENOIC ACIDS BY ALCOHOL-INDUCIBLE CYTOCHROME-P450 2E1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; SPONTANEOUSLY HYPERTENSIVE RATS; ARACHIDONIC-ACID; 20-HYDROXYEICOSATETRAENOIC ACID; ETHANOL OXIDATION; TREATED RABBITS; METABOLISM; HYDROXYLATION; IDENTIFICATION; CYCLOOXYGENASE	When reconstituted with cytochrome b5 and NADPH cytochrome P450 oxidoreductase, cytochrome P450 2E1 metabolized lauric, stearic, oleic, linoleic, linolenic, and arachidonic acid to multiple metabolites. Two major metabolites, accounting for 78% of the total metabolism, were produced with arachidonic acid. The V(max) for total metabolite formation from arachidonic acid was 5 nmol/min/nmol P450 with an apparent K(m) of 62 muM. Gas chromatography-mass spectrometry analysis identified the two major metabolites as mono-hydroxylated eicosatetraenoic acids (HETEs). The major HETE was 19-hydroxyeicosatetraenoic acid (19-HETE) and comprised 46% of the total metabolite produced. The second metabolite was the omega-2 hydroxylated metabolite (18-HETE) and comprised 32% of the total product formed. Chiral analysis demonstrated that 19-HETE was 70% 19(S)-HETE and 30% 19(R)-HETE. In contrast, 18-HETE was essentially 100% R isomer. Approximately 18% of the total metabolite produced from arachidonic acid coeluted with epoxyeicosatrienoic acid (EET) standards. The EET metabolites were 56.4% 14,15-EET and 43.6% as a mixture of 11,12-EET and 8,9-EET. 5,6-EET was not detected. Anti-P450 2E1 IgG inhibited arachidonic acid metabolism by renal and hepatic microsomes prepared from acetone-treated rabbits. With renal cortex microsomes, the formation of 18-HETE and 19-HETE was inhibited 67 and 25%, respectively, by the antibody. Liver microsomal formation of 18-HETE was inhibited by 87% and 19-HETE by 70%. Thus, under conditions where cytochrome P450 2E1 is induced, the enzyme could contribute significantly to the formation of the omega-1 and omega-2 hydroxylated metabolites of arachidonic acid.	OREGON HLTH SCI UNIV, SCH MED,DEPT PHARMACOL,L221, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA; NEW YORK MED COLL, DEPT PHARMACOL, VALHALLA, NY 10595 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA	Oregon Health & Science University; New York Medical College; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Falck, John/0000-0002-9219-7845; Balazy, Ph.D., Michael/0000-0003-0218-8820	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041618, P01HL034300] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-34300, HL41618] Funding Source: Medline; NIADDK NIH HHS [T32 AM07139] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM NG, 1991, BLOOD, V78, P1461; BALAZY M, 1991, J BIOL CHEM, V266, P23561; BAUMERT T, 1989, EUR J BIOCHEM, V182, P223, DOI 10.1111/j.1432-1033.1989.tb14821.x; BONVENTRE JV, 1991, KIDNEY INT, V39, P438, DOI 10.1038/ki.1991.55; BRASH AR, 1990, METHOD ENZYMOL, V187, P187; BRODOWSKY ID, 1992, BIOCHIM BIOPHYS ACTA, V1124, P59, DOI 10.1016/0005-2760(92)90126-G; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CARROLL MA, 1991, J BIOL CHEM, V266, P12306; CHUNG SK, 1974, TETRAHEDRON LETT, P3023; CLARE RA, 1991, J CHROMATOGR-BIOMED, V562, P237, DOI 10.1016/0378-4347(91)80581-V; Coon M J, 1978, Methods Enzymol, V52, P109; DIEZ E, 1987, BIOCHIM BIOPHYS ACTA, V921, P82, DOI 10.1016/0005-2760(87)90173-1; DUTTON DR, 1987, ARCH BIOCHEM BIOPHYS, V255, P316, DOI 10.1016/0003-9861(87)90399-7; ESCALANTE B, 1988, BIOCHEM BIOPH RES CO, V152, P1269, DOI 10.1016/S0006-291X(88)80422-4; ESCALANTE B, 1989, J PHARMACOL EXP THER, V248, P229; ESCALANTE B, 1990, J CARDIOVASC PHARM, V16, P438, DOI 10.1097/00005344-199009000-00013; FALCK JR, 1990, J BIOL CHEM, V265, P10244; FALCK JR, 1992, TETRAHEDRON LETT, V33, P4893, DOI 10.1016/S0040-4039(00)61226-1; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; GARRO AJ, 1990, ANNU REV PHARMACOL, V30, P219, DOI 10.1146/annurev.pa.30.040190.001251; GIBSON GG, 1989, XENOBIOTICA, V19, P1123; HILL E, 1992, BRIT J PHARMACOL, V106, P267, DOI 10.1111/j.1476-5381.1992.tb14327.x; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; HURST JS, 1991, J BIOL CHEM, V266, P6726; ISHAK KG, 1991, ALCOHOL CLIN EXP RES, V15, P45, DOI 10.1111/j.1530-0277.1991.tb00518.x; KOOP DR, 1984, MOL PHARMACOL, V25, P494; KOOP DR, 1984, ARCH BIOCHEM BIOPHYS, V235, P228, DOI 10.1016/0003-9861(84)90272-8; KOOP DR, 1986, MOL PHARMACOL, V29, P399; KOOP DR, 1986, ALCOHOL CLIN EXP RES, V10, pS44, DOI 10.1111/j.1530-0277.1986.tb05179.x; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; KOOP DR, 1982, J BIOL CHEM, V257, P8472; LAETHEM RM, 1992, J BIOL CHEM, V267, P5552; LAETHEM RM, 1992, MOL PHARMACOL, V42, P958; LIEBER CS, 1990, PHARMACOL THERAPEUT, V46, P1, DOI 10.1016/0163-7258(90)90032-W; LIN TN, 1988, ALCOHOL CLIN EXP RES, V12, P795, DOI 10.1111/j.1530-0277.1988.tb01348.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; OLIW EH, 1981, J BIOL CHEM, V256, P9924; OLIW EH, 1989, J BIOL CHEM, V264, P17845; OMATA K, 1992, AM J PHYSIOL, V262, pF8, DOI 10.1152/ajprenal.1992.262.1.F8; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; SACERDOTI D, 1989, SCIENCE, V243, P388, DOI 10.1126/science.2492116; SACERDOTI D, 1988, BIOCHEM PHARMACOL, V37, P521, DOI 10.1016/0006-2952(88)90223-7; SCHWARTZMAN ML, 1989, J BIOL CHEM, V264, P11658; SCHWARTZMAN ML, 1990, METHOD ENZYMOL, V187, P372; SCHWARTZMAN ML, 1990, ADV PROSTAG THROMB L, V20, P241; SHI CJ, 1969, J AM CHEM SOC, V91, P3685; Strittmatter P, 1978, Methods Enzymol, V52, P97; STUBBS CD, 1992, LIPIDS, V27, P255, DOI 10.1007/BF02536471; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; TANAKA S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P177, DOI 10.1016/0005-2760(90)90293-7; TOIVANEN J, 1984, THROMB RES, V33, P1, DOI 10.1016/0049-3848(84)90149-X; ZIMMERMAN HJ, 1986, ALCOHOL CLIN EXP RES, V10, P3, DOI 10.1111/j.1530-0277.1986.tb05605.x	55	178	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12912	12918						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509425				2022-12-25	WOS:A1993LG65800098
J	Ma, ZM; Ramanadham, S; Corbett, JA; Bohrer, A; Gross, RW; McDaniel, ML; Turk, J				Ma, ZM; Ramanadham, S; Corbett, JA; Bohrer, A; Gross, RW; McDaniel, ML; Turk, J			Interleukin-1 enhances pancreatic islet arachidonic acid 12-lipoxygenase product generation by increasing substrate availability through a nitric oxide-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; GROUP-II PHOSPHOLIPASE-A(2); PROMOTES INSULIN RELEASE; RAT MESANGIAL CELLS; BETA-CELLS; MESSENGER-RNA; CYTOSOLIC PHOSPHOLIPASE-A2; SUICIDE INHIBITION; SECRETION; METABOLISM	Interleukin-1 (IL-1) impairs insulin secretion from pancreatic islets and may contribute to the pathogenesis of insulin-dependent diabetes mellitus. IL-1 increases islet expression of nitric oxide (NO) synthase, and the resultant overproduction of NO participates in inhibition of insulin secretion because NO synthase inhibitors, e.g. N-G-monomethyl-arginine (NMMA), prevent this inhibition, While exploring effects of IL-1 on islet arachidonic acid metabolism, we found that IL-1 increases islet production of the 12-lipoxygenase product 12-hydroxyeicosatetraenoic acid 12-(HETE). This effect requires NO production and is prevented by NMMA. Exploration of the mechanism of this effect indicates that it involves increased availabilty of the substrate arachidonic acid rather than enhanced expression of 12-lipoxygenase. Evidence supporting this conclusion includes the facts that IL-1 does not increase islet 12-lipoxygenase protein or mRNA levels and does not enhance islet conversion of exogenous arachidonate to 12-HETE. Mass spectrometric stereochemical analyses nonetheless indicate that 12-HETE produced by IL-1-treated islets consists only of the S-enantiomer and thus arises from enzyme action. IL-1 does enhance release of nonesterified arachidonate from islets, as measured by isotope dilution mass spectrometry, and this effect is suppressed by NMMA and mimicked by the NO-releasing compound 3-morpholinosydnonimine. Although IL-1 increases neither islet phospholipase A(2) (PLA(2)) activities nor mRNA levels for cytosolic or secretory PLA(2), a suicide substrate which inhibits an islet Ca2+-independent PLA(2) prevents enhancement of islet arachidonate release by IL-1. IL-1 also impairs esterification of [H-3(8)]arachidonate into islet phospholipids, and this effect is prevented by NMMA and mimicked by the mitochondrial ATP-synthase inhibitor oligomycin. Experiments with exogenous substrates indicate that NMMA does not inhibit and that the NO-releasing compound does not activate islet 12-lipoxygenase or PLA(2) activities. These results indicate that a novel action of NO is to increase levels of nonesterified arachidonic acid in islets.	WASHINGTON UNIV,SCH MED,DIV ENDOCRINOL DIABET & METAB,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV BIOORGAN CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034388] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR-00954] Funding Source: Medline; NIDDK NIH HHS [R37-DK-34388] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAYAMA K, 1986, J LAB CLIN MED, V107, P459; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CASELLI A, 1994, J BIOL CHEM, V269, P24878; CHANG WC, 1993, J BIOL CHEM, V268, P18734; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; CORBETT JA, 1992, BIOCHEM J, V287, P229, DOI 10.1042/bj2870229; CORBETT JA, 1991, J BIOL CHEM, V266, P21351; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; CORBETT JA, 1992, J CLIN INVEST, V90, P2384, DOI 10.1172/JCI116129; CORBETT JA, 1993, BIOCHEMISTRY-US, V32, P13767, DOI 10.1021/bi00213a002; CORBETT JA, 1994, BIOCHEM J, V299, P719, DOI 10.1042/bj2990719; Davis LG, 1994, BASIC METHODS MOL BI; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DUNLOP ME, 1984, BIOCHEM BIOPH RES CO, V120, P820, DOI 10.1016/S0006-291X(84)80180-1; GENG YJ, 1994, BBA-GENE STRUCT EXPR, V1218, P421, DOI 10.1016/0167-4781(94)90196-1; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; GROSS RW, 1982, J BIOL CHEM, V258, P15046; HADA T, 1994, BBA-LIPID LIPID MET, V1211, P221, DOI 10.1016/0005-2760(94)90272-0; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HUGHES JH, 1990, J CLIN INVEST, V86, P856, DOI 10.1172/JCI114785; HUGHES JH, 1989, DIABETES, V38, P1251, DOI 10.2337/diabetes.38.10.1251; ISHIZAKI J, 1989, BIOCHEM BIOPH RES CO, V162, P1030, DOI 10.1016/0006-291X(89)90777-8; JOLLY YC, 1993, BIOCHEMISTRY-US, V32, P12209, DOI 10.1021/bi00096a034; KONRAD RJ, 1992, BIOCHIM BIOPHYS ACTA, V1135, P215, DOI 10.1016/0167-4889(92)90139-3; KONRAD RJ, 1992, BIOCHEM J, V287, P283, DOI 10.1042/bj2870283; KONRAD RJ, 1993, MOL CELL ENDOCRINOL, V92, P1135; KRAMER RM, 1986, BIOCHIM BIOPHYS ACTA, V878, P394, DOI 10.1016/0005-2760(86)90248-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYCHOCK SG, 1982, CELL CALCIUM, V3, P43, DOI 10.1016/0143-4160(82)90036-7; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P237; LOWETH AC, 1994, BIOCHEM SOC T, V22, pS430, DOI 10.1042/bst022430s; MALAISSE WJ, 1982, P NATL ACAD SCI-BIOL, V79, P927, DOI 10.1073/pnas.79.3.927; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MCDANIEL ML, 1988, DIABETES, V37, P1311, DOI 10.2337/diabetes.37.10.1311; MERY PF, 1993, J BIOL CHEM, V268, P26286; METZ S, 1983, J CLIN INVEST, V71, P1191, DOI 10.1172/JCI110868; METZ S, 1991, FEBS LETT, V295, P110, DOI 10.1016/0014-5793(91)81397-Q; METZ SA, 1990, BIOCHEM BIOPH RES CO, V167, P61, DOI 10.1016/0006-291X(90)91730-G; METZ SA, 1988, DIABETES, V37, P1453, DOI 10.2337/diabetes.37.11.1453; METZ SA, 1985, P NATL ACAD SCI USA, V82, P198, DOI 10.1073/pnas.82.1.198; METZ SA, 1991, DIABETES, V40, P1565, DOI 10.2337/diabetes.40.12.1565; METZ SA, 1987, BIOCHEM J, V242, P863; MONCADA S, 1991, PHARMACOL REV, V43, P109; NAKATSUKA M, 1994, BIOCHEM BIOPH RES CO, V200, P1630, DOI 10.1006/bbrc.1994.1638; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; RABINOVITCH A, 1993, DIABETES REV, V1, P215; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P5339, DOI 10.1021/bi00071a009; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; RAMANADHAM S, 1992, BIOCHEM BIOPH RES CO, V184, P647, DOI 10.1016/0006-291X(92)90638-2; RAMANADHAM S, 1994, BIOCHEMISTRY-US, V33, P7442, DOI 10.1021/bi00189a052; ROBERTSON RP, 1988, DIABETES, V37, P367, DOI 10.2337/diabetes.37.4.367; ROY P, 1994, BBA-LIPID LIPID MET, V1214, P171, DOI 10.1016/0005-2760(94)90041-8; SALERNO JC, 1979, BIOCHIM BIOPHYS ACTA, V579, P246, DOI 10.1016/0005-2795(79)90104-1; SANDSTROM PA, 1994, J BIOL CHEM, V269, P798; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCHALKWIJK CG, 1993, FEBS LETT, V333, P339, DOI 10.1016/0014-5793(93)80683-L; SHANNON VR, 1992, AM J PHYSIOL, V263, pE908; SHINOHARA H, 1992, FEBS LETT, V304, P69, DOI 10.1016/0014-5793(92)80591-4; SPRINGER TA, 1991, CURRENT PROTOCOLS MO, V2; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TSURA Y, 1994, J GEN PHYSIOL, V104, P1079; TURK J, 1988, ANAL BIOCHEM, V174, P580, DOI 10.1016/0003-2697(88)90059-0; TURK J, 1989, BIOCHIM BIOPHYS ACTA, V1001, P16, DOI 10.1016/0005-2760(89)90301-9; TURK J, 1984, BIOCHIM BIOPHYS ACTA, V794, P110, DOI 10.1016/0005-2760(84)90304-7; TURK J, 1985, BIOCHIM BIOPHYS ACTA, V835, P1, DOI 10.1016/0005-2760(85)90023-2; TURK J, 1988, DIABETES, V37, P992, DOI 10.2337/diabetes.37.7.992; TURK J, 1986, BIOCHIM BIOPHYS ACTA, V879, P399, DOI 10.1016/0005-2760(86)90232-8; TURK J, 1984, BIOCHIM BIOPHYS ACTA, V794, P125, DOI 10.1016/0005-2760(84)90305-9; TURK J, 1985, BIOCHIM BIOPHYS ACTA, V834, P23, DOI 10.1016/0005-2760(85)90172-9; TURK J, 1992, BIOCHIM BIOPHYS ACTA, V1125, P280, DOI 10.1016/0005-2760(92)90057-3; TURK J, 1986, J BIOL CHEM, V261, P3510; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	87	49	50	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1029	1042		10.1074/jbc.271.2.1029	http://dx.doi.org/10.1074/jbc.271.2.1029			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557627	hybrid			2022-12-25	WOS:A1996TP88900064
J	Rich, SA; Bose, M; Tempst, P; Rudofsky, UH				Rich, SA; Bose, M; Tempst, P; Rudofsky, UH			Purification, microsequencing, and immunolocalization of p36, a new interferon-alpha-induced protein that is associated with human lupus inclusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULATING LYMPHOCYTES; LEUKOCYTE INTERFERON; AUTOIMMUNE-DISEASE; HIV-INFECTION; DAUDI CELLS; ERYTHEMATOSUS; INDUCTION; MEMBRANE; THERAPY; AIDS	The trace interferon-alpha induced protein, p36, was induced in Raji cells in association with lupus inclusions. It was solubilized in a nonionic detergent buffer, enriched by differential centrifugation and by preparative isoelectric focusing, and purified to homogeneity on two-dimensional protein gels. Failure to obtain N-terminal amino acid sequence, however, suggested a blocked alpha-amino group. Sequences of six tryptic peptides, 13-19 amino acids in length, were obtained after digestion, microbore-high performance liquid chromotography purification, and chemical sequence analysis. None of the six sequences, which represented approximately 25% of the entire protein, shared any meaningful homologies with entries in protein sequence repositories. Raji-cell p36 was shown in Western blots with antipeptide antibodies to be induced at least 400-fold and by immunofluorescence microscopy to co-localize with the endoplasmic reticulum resident protein, protein disulfide isomerase. These results show that p36 is a new interferon-alpha-induced protein that localizes in the endoplasmic reticulum, the cell region in which the lupus inclusions form, and that p36 is probably physically associated with the lupus inclusions.	SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12201; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	State University of New York (SUNY) System; State University of New York (SUNY) Albany; Cornell University; Memorial Sloan Kettering Cancer Center	Rich, SA (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,LAB CELL REGULAT,EMPIRE STATE PLAZA,POB 509,ALBANY,NY 12201, USA.				PHS HHS [AK 41619] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Baron S, 1992, INTERFERON PRINCIPLE, P1; BERESINI MH, 1988, J IMMUNOL, V140, P485; BOOS H, 1990, J GEN VIROL, V71, P1811, DOI 10.1099/0022-1317-71-8-1811; DESTEFANO E, 1982, J INFECT DIS, V146, P451, DOI 10.1093/infdis/146.4.451; DIANZANI F, 1992, INTERFERON PRINCIPLE, P409; Dron M., 1992, INTERFERON PRINCIPLE, P33; DURUM SK, 1991, CYTOKINE HDB, P413; DZANDU JK, 1984, P NATL ACAD SCI-BIOL, V81, P1733, DOI 10.1073/pnas.81.6.1733; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; FELLER W, 1952, INTRO PROBABILITY TH, P75; FEREMANS WW, 1988, J CLIN PATHOL, V41, P62, DOI 10.1136/jcp.41.1.62; GRAUSZ H, 1970, NEW ENGL J MED, V283, P506, DOI 10.1056/NEJM197009032831003; GUSTAFSSON A, 1982, J IMMUNOL, V129, P1952; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; GYORKEY F, 1969, NEW ENGL J MED, V280, P333; HARLOW E, 1988, ANTIBODIES LABORATOR, P145; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HENCO K, 1985, J MOL BIOL, V185, P227, DOI 10.1016/0022-2836(85)90401-2; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOLAN V, 1992, IMMUNOLOGY, V75, P176; Hooper W. Craig, 1994, P101; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Isaacs A., 1957, P R SOC LOND B, V147, P258; KUMAR R, 1994, J BIOL CHEM, V269, P25437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEANDERSON T, 1982, EMBO J, V1, P1505, DOI 10.1002/j.1460-2075.1982.tb01347.x; MULLER S, 1986, MOL IMMUNOL, V23, P593, DOI 10.1016/0161-5890(86)90095-7; NOIVA R, 1992, J BIOL CHEM, V267, P3553; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ORENSTEIN JM, 1985, AM J CLIN PATHOL, V84, P603, DOI 10.1093/ajcp/84.5.603; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PENMAN S, 1969, FUNDAMENTAL TECHNIQU, P35; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PLAUE S, 1988, LABORATORY TECHNIQUE, V19, P41; PREBLE OT, 1982, SCIENCE, V216, P429, DOI 10.1126/science.6176024; QUEMENEUR E, 1994, J BIOL CHEM, V269, P5485; RICH SA, 1990, ARTHRITIS RHEUM, V33, P1420, DOI 10.1002/art.1780330915; RICH SA, 1989, J BIOL CHEM, V264, P3529; RICH SA, 1981, SCIENCE, V213, P772, DOI 10.1126/science.6166984; RICH SA, 1984, J INTERFERON RES, V4, P335, DOI 10.1089/jir.1984.4.335; RICH SA, 1986, ARTHRITIS RHEUM, V29, P501, DOI 10.1002/art.1780290407; RICH SA, 1995, J CLIN INVEST, V95, P219, DOI 10.1172/JCI117643; RICH SA, 1983, LANCET, V1, P127; RICH SA, 1992, J STRUCT BIOL, V108, P25, DOI 10.1016/1047-8477(92)90004-T; RICH SA, 1989, TECHNIQUE PHILA, V1, P196; RUBINSTEIN S, 1981, J VIROL, V37, P755, DOI 10.1128/JVI.37.2.755-758.1981; SCHATTNER A, 1994, CLIN IMMUNOL IMMUNOP, V70, P177, DOI 10.1006/clin.1994.1027; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SIDHU GS, 1985, HUM PATHOL, V16, P377, DOI 10.1016/S0046-8177(85)80231-8; SKURKOVICH S, 1993, MED HYPOTHESES, V41, P177, DOI 10.1016/0306-9877(93)90066-Y; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TOLAYMAT A, 1992, J PEDIATR-US, V120, P429, DOI 10.1016/S0022-3476(05)80913-8; VANREGENMORTEL MH, 1988, LABORATORY TECHNIQUE, V19, P145; WANDL UB, 1992, CLIN IMMUNOL IMMUNOP, V65, P70, DOI 10.1016/0090-1229(92)90250-R; WICKRAMASINGHE SN, 1992, CLIN LAB HAEMATOL, V14, P213	60	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1118	1126		10.1074/jbc.271.2.1118	http://dx.doi.org/10.1074/jbc.271.2.1118			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557639	hybrid			2022-12-25	WOS:A1996TP88900076
J	Sekine, Y; Eisaki, N; Ohtsubo, E				Sekine, Y; Eisaki, N; Ohtsubo, E			Identification and characterization of the linear IS3 molecules generated by staggered breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RETROVIRAL INTEGRATION; INSERTION SEQUENCES; VIRAL-DNA; PROTEIN; TRANSPOSITION; INTERMEDIATE; INVITRO; TN10; ELEMENTS	Insertion sequence IS3 encodes two, out-of-phase, overlapping open reading frames, orfA and orfB. The OrfAB transframe protein that is IS3 transposase is produced by -1 translational frameshifting between orfA and orfB. Efficient production of the IS3 transposase in the cells harboring the IS3-carrying plasmid has been shown to generate miniplasmids as well as characteristic minicircles, called IS3 circles, consisting of the entire IS3 sequence and one of the 3-base pair sequences flanking IS3 in the parental plasmid. Here, we show that the IS3 transposase also generates the linear molecules of IS3 with 3-nucleotide overhangs at the 5'-ends. The nucleotide sequences of the overhangs are the same as those flanking IS3 in the parental plasmid, suggesting that the linear IS3 molecules are generated from the parental plasmid DNA by staggered double strand breaks at the end regions of IS3. The linear IS3 molecules are likely to be the early intermediates in the transposition reaction, which proceeds in a non-replicative manner.	UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CLEWELL DB, 1970, BIOCHEMISTRY-US, V9, P4428; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DEONIER RC, 1979, J BACTERIOL, V137, P1421, DOI 10.1128/JB.137.3.1421-1424.1979; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; HANIFORD DB, 1991, CELL, V64, P171; HE M, 1990, NUCLEIC ACIDS RES, V18, P1660, DOI 10.1093/nar/18.6.1660; HU S, 1975, J BACTERIOL, V123, P687, DOI 10.1128/JB.123.2.687-692.1975; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; MALAMY MH, 1972, MOL GEN GENET, V119, P207, DOI 10.1007/BF00333859; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORISATO D, 1984, CELL, V39, P181, DOI 10.1016/0092-8674(84)90204-6; POLARD P, 1992, EMBO J, V11, P5079, DOI 10.1002/j.1460-2075.1992.tb05615.x; PRERE MF, 1990, J BACTERIOL, V172, P4090, DOI 10.1128/jb.172.7.4090-4099.1990; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ E, 1988, NUCLEIC ACIDS RES, V16, P6789, DOI 10.1093/nar/16.14.6789; SEKINE Y, 1994, J MOL BIOL, V235, P1406, DOI 10.1006/jmbi.1994.1097; SEKINE Y, 1991, NEW ASPECTS GENETICS, P243; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SOMMER H, 1979, MOL GEN GENET, V177, P85, DOI 10.1007/BF00267256; SPIELMANNRYSER J, 1991, MOL GEN GENET, V226, P441, DOI 10.1007/BF00260657; TIMMERMAN KP, 1985, NUCLEIC ACIDS RES, V13, P2127, DOI 10.1093/nar/13.6.2127; UMEDA M, 1989, J MOL BIOL, V208, P601, DOI 10.1016/0022-2836(89)90151-4; VARMUS H, 1989, MOBILE DNA, P53; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOGELE K, 1991, NUCLEIC ACIDS RES, V19, P4377, DOI 10.1093/nar/19.16.4377; WADA M, 1988, J MOL BIOL, V204, P581, DOI 10.1016/0022-2836(88)90357-9; YOSHIOKA Y, 1987, J BACTERIOL, V169, P619, DOI 10.1128/jb.169.2.619-623.1987	34	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					197	202		10.1074/jbc.271.1.197	http://dx.doi.org/10.1074/jbc.271.1.197			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550559	hybrid			2022-12-25	WOS:A1996TP36100031
J	Shen, ZY; Cloud, KG; Chen, DJ; Park, MS				Shen, ZY; Cloud, KG; Chen, DJ; Park, MS			Specific interactions between the human RAD51 and RAD52 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; RECOMBINATION; GENES; SEQUENCE; REPAIR; COMPLEX; HOMOLOG; CLONING; MOUSE	Processing of DNA damage by the DNA double-strand break repair pathway in mammalian cells is accomplished by multiprotein complexes. However, the nature of these complexes and details of the molecular interactions are not fully understood. Interaction of the yeast RAD51 and RAD52 proteins plays a crucial role in yeast DNA homologous recombination and DNA double-strand break repair. Here, specific interactions between human RAD51 and RAD52 proteins are demonstrated both in vivo, using the yeast two-hybrid system and immunoprecipitation of insect cells co-infected with RAD51 and RAD52 recombinant viruses, and in vitro, using affinity chromatography with purified recombinant proteins. These results suggest that RAD52 may modulate the catalytic activities of RAD51 protein such as homologous pairing and strand exchange through a direct physical interaction. In addition, the domain in RAD52 that mediates this interaction was determined in vitro and in vivo. The RAD51-interacting region (amino acids 291-330) of the human RAD52 protein shows no homology with the yeast RAD52 protein, indicating that the interaction between RAD51 and RAD52 is species-specific.			Shen, ZY (corresponding author), LOS ALAMOS NATL LAB,DIV LIFE SCI,LS-6,MS M888,LOS ALAMOS,NM 87545, USA.		Park, Min Sung/HCH-2207-2022	Shen, Zhiyuan/0000-0003-2834-0309	NATIONAL CANCER INSTITUTE [R01CA050519, R37CA050519] Funding Source: NIH RePORTER; NCI NIH HHS [CA50519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AJIMURA M, 1993, GENETICS, V133, P51; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; Game J., 1983, YEAST GENETICS FUNDA, P109; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Haynes R.H., 1981, MOL BIOL YEAST SACCH, P371; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; JANG YK, 1994, GENE, V142, P207, DOI 10.1016/0378-1119(94)90262-3; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RESNICK M A, 1987, P157; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SANCAR A, 1994, SCIENCE, V266, P1953; SHEN ZY, 1995, GENOMICS, V25, P199, DOI 10.1016/0888-7543(95)80126-7; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Summers MD, 1987, TEXAS AGR EXP STATIO, V1555; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1655	40	174	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					148	152		10.1074/jbc.271.1.148	http://dx.doi.org/10.1074/jbc.271.1.148			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550550	hybrid			2022-12-25	WOS:A1996TP36100023
J	Kataoka, K; Noda, M; Nishizawa, M				Kataoka, K; Noda, M; Nishizawa, M			Transactivation activity of Maf nuclear oncoprotein is modulated by Jun, Fos and small Maf proteins	ONCOGENE			English	Article						Maf; Jun; Fos; AP-1; NF-E2; transformation	AVIAN TRANSFORMING RETROVIRUS; DNA-BINDING SPECIFICITY; YA SUBUNIT GENE; LEUCINE ZIPPER; C-JUN; TRANSCRIPTIONAL ACTIVATION; V-MAF; EMBRYO FIBROBLASTS; RESPONSIVE ELEMENT; YEAST GCN4	The v-maf oncogene encodes a nuclear bZip protein which specifically recognizes relatively long palindromic sequences related to an AP-1 site. In this study, we investigated the relationship of transactivation and transformation activity of Maf. The amino-terminal two thirds of the molecule were dispensable for its DNA-binding activity but conferred its transactivation potential. Transactivation activities of a set of deletion mutants correlated well with their cell transforming abilities. However, a point mutant associated with enhanced oncogenic activity was not more effective in transactivation than the wild type, suggesting that some other function(s) of Maf is also important for its transforming ability. We also examined the effect of other bZip proteins on the transactivation activity of Maf. Three small Maf family proteins (MafK, MafF and MafG), which are missing the transactivation domain of v-Maf, competitively inhibited transactivation by Maf. Co-expression of Jun or Fos also affected the transactivation potential of Maf by forming Maf/Jun or Maf/Fos heterodimers of distinct DNA-binding specificities. In addition to these factors, we noticed the presence of a strong endogenous transactivating activity associated with a sequence related to an NF-E2 site rather than the typical AP-1 site in fibroblast cells. These results indicate that AP-1 site-like cis-regulatory elements of eukaryotic genes are regulated by multiple sets of bZip dimers with different DNA-binding and transactivation properties.	JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research								ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHATTON B, 1994, ONCOGENE, V9, P375; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATAOKA K, 1994, MOL CELL BIOL, V14, P700; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGAN IM, 1993, ONCOGENE, V8, P1135; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; NISHIZAWA M, 1987, J VIROL, V61, P3733, DOI 10.1128/JVI.61.12.3733-3740.1987; OKUDA A, 1987, J BIOL CHEM, V262, P3858; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; SUCKOW M, 1994, NUCLEIC ACIDS RES, V22, P2198, DOI 10.1093/nar/22.12.2198; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG B, 1994, BBA-GENE STRUCT EXPR, V1219, P645, DOI 10.1016/0167-4781(94)90223-2; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; WONG WY, 1992, ONCOGENE, V7, P2077; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894	45	51	56	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					53	62						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552399				2022-12-25	WOS:A1996TQ01400007
J	vandenBorn, J; Gunnarsson, K; Bakker, MAH; Kjellen, L; KuscheGullberg, M; Maccarana, M; Berden, JHM; Lindahl, U				vandenBorn, J; Gunnarsson, K; Bakker, MAH; Kjellen, L; KuscheGullberg, M; Maccarana, M; Berden, JHM; Lindahl, U			Presence of N-unsubstituted glucosamine units in native heparan sulfate revealed by a monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; BASEMENT-MEMBRANE; MOLECULAR-ORGANIZATION; ENDOTHELIAL-CELLS; BINDING SEQUENCE; PROTEOGLYCANS; BIOSYNTHESIS; GLYCOSAMINOGLYCANS; ANTITHROMBIN; PROTEIN	Immunohistochemical application of antibodies against heparan sulfate proteoglycan core protein and heparitinase-digested heparan sulfate stubs showed the presence of heparan sulfate proteoglycan in all basement membranes of the rat kidney. However, a monoclonal antibody (JM-403) against native heparan sulfate (van den Born, J., van den Heuvel, L. P. W. J., Bakker, M. A. H., Veerkamp, J. H., Assmann, K. J. M., and Berden, J. H. M. (1992) Kidney Int. 41, 115-123) largely failed to stain tubular basement membranes, suggesting the presence of heparan sulfate chains lacking the specific JM-403 epitope, Heparan sulfate preparations from various sources differed markedly with regard to JM-403 binding, as demonstrated by liquid phase inhibition in enzyme-linked immunosorbent assay, the interaction decreasing with increasing sulfate contents of the polysaccharide. Mapping of the JM-403 epitope indicated that it was dominated by one or more N-unsubstituted glucosamine unit(s), since treatments that destroyed or altered the structure of such units in heparan sulfate preparations (cleavage at N-unsubstituted glucosamine units with HNO2 at pH 3.9 and N-acetylation with acetic anhydride, respectively), abolished antibody binding, Conversely, immunoreactivity could be induced in a (D-glucuronyl-1,4-N-acetyl-D-glucosaminyl-1,4) polysaccharide by the generation of N-unsubstituted glucosamine units by chemical N-deacetylation, The presence of N-unsubstituted glucosamine in a JM-403-binding heparan sulfate (preparation HS-II from human aorta) was demonstrated by an similar to 3 fold reduction in molecular size following HNO2 (pH 3.9) treatment. Further characterization of the epitope recognized by JM-403, based on enzyme-linked immunosorbent assay inhibition tests with chemically/enzymatically modified polysaccharides, indicated that one or more N-sulfated glucosamine units are invariable present, whereas L-iduronic acid and O-sulfate residues appear to inhibit JM-403 reactivity. It is concluded that the epitope contains one or more N-unsubstituted glucosamine and D-glucuronic acid units and is located in a region of the heparan sulfate chain composed of mixed N-sulfated and N-acetylated disaccharide units.	UNIV UPPSALA, DEPT MED & PHYSIOL CHEM, S-75123 UPPSALA, SWEDEN; UNIV UPPSALA, SWEDISH UNIV AGR SCI, DEPT VET MED CHEM, S-75123 UPPSALA, SWEDEN	Uppsala University; Swedish University of Agricultural Sciences; Uppsala University	vandenBorn, J (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP, DIV NEPHROL, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		Kusche-Gullberg, Marion/P-4466-2016; maccarana, marco/AAB-4764-2021; Berden, J.H.M./H-8009-2014; Kjellen, Lena/F-1362-2011	Kusche-Gullberg, Marion/0000-0002-5636-1695; Maccarana, Marco/0000-0003-3549-8921				ABBOUD HE, 1993, KIDNEY INT, V43, P252, DOI 10.1038/ki.1993.39; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; DANIEL T, 1992, KIDNEY PHYSL PATHOPH, P3135; DANISHEFSKY I., 1965, BIOCHIM BIOPHYS ACTA, V101, P37, DOI 10.1016/0926-6534(65)90028-X; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DAWES J, 1992, THROMB HAEMOSTASIS, V67, P468; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FREEMAN C, 1992, ADV EXP MED BIOL, V313, P121; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GROGGEL GC, 1990, AM J PHYSIOL, V258, pF259, DOI 10.1152/ajprenal.1990.258.2.F259; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HAHNENBERGER R, 1993, GLYCOBIOLOGY, V3, P567, DOI 10.1093/glycob/3.6.567; IOZZO RV, 1989, J BIOL CHEM, V264, P2690; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; KATO M, 1994, J BIOL CHEM, V269, P18881; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KURE S, 1986, J IMMUNOL, V137, P3900; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LINDAHL U, 1965, J BIOL CHEM, V240, P2817; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LINDBLOM A, 1991, BIOCHEM J, V279, P821, DOI 10.1042/bj2790821; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P12208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; OLDBERG A, 1979, J BIOL CHEM, V254, P8505; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PEJLER G, 1994, J BIOL CHEM, V269, P14451; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SCHMIDT A, 1990, EUR J CELL BIOL, V52, P229; SCHMIDT A, 1992, EUR J CELL BIOL, V59, P322; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; TAYLOR RL, 1973, BIOCHEMISTRY-US, V12, P3633, DOI 10.1021/bi00743a010; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; VANDENBORN J, 1992, KIDNEY INT, V41, P115, DOI 10.1038/ki.1992.15; VANDENBORN J, 1993, KIDNEY INT, V43, P454, DOI 10.1038/ki.1993.67; VANDENBORN J, 1991, LAB INVEST, V65, P287; VANDENBORN J, 1994, J HISTOCHEM CYTOCHEM, V42, P89, DOI 10.1177/42.1.8263327; VANDENBORN J, 1995, DIABETOLOGIA, V38, P161, DOI 10.1007/s001250050266; VANDENHEUVEL LPWJ, 1989, BIOCHEM J, V264, P457, DOI 10.1042/bj2640457; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; WALKER A, 1994, J BIOL CHEM, V269, P931; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885	63	133	137	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31303	31309		10.1074/jbc.270.52.31303	http://dx.doi.org/10.1074/jbc.270.52.31303			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537400	Green Submitted, Green Published, hybrid			2022-12-25	WOS:A1995TN44400067
J	Kamano, H; Burk, B; NobenTrauth, K; Klempnauer, KH				Kamano, H; Burk, B; NobenTrauth, K; Klempnauer, KH			Differential splicing of the mouse B-myb gene	ONCOGENE			English	Article						B-myb; differential splicing; transactivation; heat shock promotor	C-MYB; V-MYB; A-MYB; MOLECULAR-CLONING; TRANS-ACTIVATION; MAMMALIAN-CELLS; HUMAN HSP70; EXPRESSION; ONCOGENE; PROLIFERATION	The myb gene family consists of three members, the c-myb proto-oncogene and two myb-related genes (A-myb and B-myb), all of which encode nuclear DNA-binding proteins. Unlike c-myb, which plays a critical role in hematopoietic cells, B-myb is expressed in a large spectrum of hematopoietic as well as non-homatopoietic cells and has been implicated in the control of cell proliferation. The isolation of B-myb cDNA clones from several species has shown that B-myb shares limited homology to the so-called exon 9A of the c-myb gene. This exon is involved in differential splicing as only a subfraction of c-myb mRNA contains exon 9A sequences. The presence in the B-myb cDNA of a sequence related to the exon 9A of c-myb has prompted us to investigate whether B-myb mRNA is also spliced differentially. We here show that B-myb mRNAs containing or lacking exon 9A related sequences are present in many cell types. In contrast to c-myb, where RNA containing the exon 9A constitutes only a minor mRNA fraction, B-myb RNA containing the exon 9A related sequences is the major mRNA form, The proteins encoded by the two B-myb mRNA species are unable to activate promoters to which they bind. Curiously, both B-myb proteins differ in their ability to activate the HSP70 promoter by a myb binding-site independent mechanism; B-myb protein containing exon 9A related aminoacid sequences activates the HSP70 promoter much more potently than the B-myb protein which lacks these sequences. Our results suggest that differential splicing may be a general feature of the members of the myb family and provide first evidence for functional differences of the splice variants.	MAX PLANCK INST IMMUNOBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY	Max Planck Society								ALESSANDRO A, 1987, P NATL ACAD SCI USA, V84, P1794; ARSURA M, 1992, BLOOD, V79, P2708; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1991, EMBO J, V10, P3731; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUDEK H, 1989, ONCOGENE, V4, P1061; FARRAR JJ, 1980, J IMMUNOL, V125, P2555; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; IGLESIAS A, 1991, EMBO J, V10, P2147, DOI 10.1002/j.1460-2075.1991.tb07749.x; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KIM KJ, 1979, J IMMUNOL, V122, P549; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1992, ONCOGENE, V7, P1185; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON J, 1988, ONCOGENE, V3, P717; METTUS RV, 1994, ONCOGENE, V9, P3077; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MIZGUCHI G, 1990, J BIOL CHEM, V265, P9280; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; MUSCENSKI ML, 1991, CELL, V65, P677; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; PATULEIA MC, 1967, CANCER RES, V67, P726; RETH MG, 1985, NATURE, V317, P353, DOI 10.1038/317353a0; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Tavassoli M, 1983, BONE MARROW STRUCTUR; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WILLIAMS RL, 1988, CELL, V52, P121; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	58	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2575	2582						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545114				2022-12-25	WOS:A1995TP18800013
J	ACHLEITNER, G; ZWEYTICK, D; TROTTER, PJ; VOELKER, DR; DAUM, G				ACHLEITNER, G; ZWEYTICK, D; TROTTER, PJ; VOELKER, DR; DAUM, G			SYNTHESIS AND INTRACELLULAR-TRANSPORT OF AMINOGLYCEROPHOSPHOLIPIDS IN PERMEABILIZED CELLS OF THE YEAST, SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; MITOCHONDRIAL CONTACT SITES; RAT-LIVER MITOCHONDRIA; PHOSPHATIDYLSERINE DECARBOXYLASE; ANIMAL-CELLS; SUBCELLULAR MEMBRANES; LIPID-COMPOSITION; IMPORT; TRANSLOCATION; GENE	The sequence of biosynthetic steps from phosphatidylserine to phosphatidylethanolamine (via decarboxylation) and then phosphatidylcholine (via methylation) is linked to the intracellular transport of these amino-glycerophospholipids. Using a [H-3]serine precursor and permeabilized yeast cells, it is possible to follow the synthesis of each of the aminoglycerophospholipids and examine the requirements for their interorganelle transport. This experimental approach reveals that in permeabilized cells newly synthesized phosphatidylserine is readily translocated to the locus of phosphatidylserine decarboxylase 1 in the mitochondria but not to the locus of phosphatidylserine decarboxylase 2 in the Gels and vacuoles. Phosphatidylserine transport to the mitochondria is ATP independent and exhibits no requirements for cytosolic factors. The phosphatidylethanolamine formed in the mitochondria is exported to the locus of the methyltransferases (principally the endoplasmic reticulum) and converted to phosphatidylcholine , The export of phosphatidylethanolamine requires ATP but not any other cytosolic factors and is not obligately coupled to methyltransferase activity. The above described lipid transport reactions also occur in permeabilized cells that have been disrupted by homogenization, indicating that the processes are extremely efficient and may be dependent upon stable structural elements between organelles.	GRAZ TECH UNIV,INST BIOCHEM & LEBENSMITTELCHEM,A-8010 GRAZ,AUSTRIA; NATL JEWISH CTR IMMUNOL & RESP MED,LORD & TAYLOR LAB LUNG BIOCHEM,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,ANNA PERAHIA ADATTO CLIN RES CTR,DENVER,CO 80206	Graz University of Technology; National Jewish Health; National Jewish Health				Zweytick, Dagmar/0000-0002-4766-7713	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032453, F32GM016701, R01GM032453] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 16701, GM 32453] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARDAIL D, 1990, J BIOL CHEM, V265, P18797; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; ARDAIL D, 1991, J BIOL CHEM, V266, P7978; BAELEE MS, 1984, J BIOL CHEM, V259, P857; BAKER D, 1988, CELL, V54, P336; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BYERS LD, 1982, METHOD ENZYMOL, V89, P326; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DAUM G, 1986, BIOCHIM BIOPHYS ACTA, V878, P93, DOI 10.1016/0005-2760(86)90347-4; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEUTSCH J, 1983, METHOD ENZYMAT AN, P190; EILERS M, 1989, J BIOL CHEM, V264, P2945; GAIGG G, 1995, BIOCHIM BIOPHYS ACTA, V1234, P214; GNAMUSCH E, 1992, BIOCHIM BIOPHYS ACTA, V1111, P120, DOI 10.1016/0005-2736(92)90281-P; GOORMAGHTIGH E, 1984, BIOCHIM BIOPHYS ACTA, V779, P271, DOI 10.1016/0304-4157(84)90013-3; HAID A, 1983, METHOD ENZYMOL, V96, P192; KODAKI T, 1989, EUR J BIOCHEM, V185, P243, DOI 10.1111/j.1432-1033.1989.tb15109.x; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFER G, 1991, BIOCHIM BIOPHYS ACTA, V1069, P139, DOI 10.1016/0005-2736(91)90115-O; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lundin A., 1982, LUMINESCENT ASSAYS P, P29; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; SIMBENI R, 1993, BIOCHIM BIOPHYS ACTA, V1145, P1, DOI 10.1016/0005-2736(93)90374-9; SPERKAGOTTLIEB C, 1990, YEAST, V6, P331, DOI 10.1002/yea.320060406; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VOELKER DR, 1991, J BIOL CHEM, V266, P12185; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	45	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29836	29842						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530379				2022-12-25	WOS:A1995TK38000039
J	NAKAMURA, M; SAKANAKA, C; AOKI, Y; OGASAWARA, H; TSUJI, T; KODAMA, H; MATSUMOTO, T; SHIMIZU, T; NOMA, M				NAKAMURA, M; SAKANAKA, C; AOKI, Y; OGASAWARA, H; TSUJI, T; KODAMA, H; MATSUMOTO, T; SHIMIZU, T; NOMA, M			IDENTIFICATION OF 2 ISOFORMS OF MOUSE NEUROPEPTIDE Y-Y1 RECEPTOR GENERATED BY ALTERNATIVE SPLICING - ISOLATION, GENOMIC STRUCTURE, AND FUNCTIONAL EXPRESSION OF THE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR RECEPTOR; PROTEIN-COUPLED RECEPTOR; DNA-FORMING SEQUENCES; ADENYLATE-CYCLASE; 2 ISOFORMS; Y NPY; MOLECULAR-CLONING; BRAIN PEPTIDE; MESSENGER-RNA; MAP KINASE	Two cDNA clones homologous with human neuropeptide (NP) Y-Y1 receptor have been isolated from a mouse bone marrow cDNA library, One was thought to be the cognate of the human NPY-Y1 receptor, termed Y1 alpha receptor, and the other form, termed Y1 beta receptor, differed from the Y1 alpha receptor in the seventh transmembrane domain and C-terminal tail, Analysis of the mouse genomic DNA showed that both receptors originated from a single gene, The different peptide sequences of the Y1 beta receptor mere encoded by separate exons, hence, these receptors were generated by differential RNA splicing, High affinity binding of [I-125]NPY to each receptor expressed in Chinese hamster ovary (CHO) cells and sequestration of [I-125]NPY after binding to each receptor were observed. In the CHO cells expressing the Y1 alpha receptor, intracellular Ca2+ increase, inhibition of forskolin-induced cAMP accumulation, and mitogen-activated protein kinase (MAPK) activation were observed by stimulation of NPY, and these responses were abolished by pretreatment with pertussis toxin, Since wortmannin completely inhibited NPY-elicited MAPK activation, we speculate that a wortmannin-sensitive signaling molecule(s) such as phosphoinositide 3-kinase may Lie between pertussis toxin-sensitive G-protein and MAPK. in contrast, these intracellular signals were not detected in CHO cells expressing the Y1 beta receptor. Northern blots and reverse transcriptase-polymerase chain reaction analyses indicated that the Y1 alpha receptor was highly expressed in the brain, heart, kidney, spleen, skeletal muscle, and lung, whereas the Y1 beta receptor mRNA was not detected in these tissues. However, the Y1 beta receptor was expressed in mouse embryonic developmental stage (7 and 11 days), bone marrow cells and several hematopoietic cell Lines, These results suggest that the Y1 beta receptor is an embryonic and a bone marrow form of the NPY-Y1 receptor, which decreases in the expression during development and differentiation.	UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	NAKAMURA, M (corresponding author), JAPAN TOBACCO INC,LIFE SCI RES LAB,AOBA KU,6-2 UMEGAOKA,YOKOHAMA,KANAGAWA 227,JAPAN.		Tsuji, Takashi/N-6086-2015					AAKERLUND L, 1990, FEBS LETT, V260, P73, DOI 10.1016/0014-5793(90)80069-U; ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BITO H, 1994, J BIOL CHEM, V269, P12722; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHABRY J, 1993, J BIOL CHEM, V268, P17138; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DUMANT Y, 1992, PROG NEUROBIOL, V38, P125; ERICSSON A, 1991, EXP CELL RES, V192, P604, DOI 10.1016/0014-4827(91)90082-6; ERICSSON A, 1987, P NATL ACAD SCI USA, V84, P5585, DOI 10.1073/pnas.84.16.5585; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; EVA C, 1990, FEBS LETT, V271, P81, DOI 10.1016/0014-5793(90)80377-U; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FETH F, 1992, BRIT J PHARMACOL, V105, P71, DOI 10.1111/j.1476-5381.1992.tb14212.x; FONG TM, 1992, MOL PHARMACOL, V41, P24; FUHLENDORFF J, 1990, P NATL ACAD SCI USA, V87, P182, DOI 10.1073/pnas.87.1.182; GIROS B, 1989, NATURE, V342, P923, DOI 10.1038/342923a0; GLOVER ID, 1985, EUR J BIOCHEM, V142, P379; HAMADA H, 1982, NATURE, V298, P396, DOI 10.1038/298396a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HERZOG H, 1993, J BIOL CHEM, V268, P6703; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUNYADY L, 1994, J BIOL CHEM, V269, P24798; IRIE A, 1994, EUR J BIOCHEM, V224, P161, DOI 10.1111/j.1432-1033.1994.tb20007.x; IRIE A, 1994, BIOCHEM BIOPH RES CO, V204, P303, DOI 10.1006/bbrc.1994.2460; JANS DA, 1990, EMBO J, V9, P2693, DOI 10.1002/j.1460-2075.1990.tb07455.x; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOGNER P, 1992, BLOOD, V80, P1324; KRAUSE J, 1992, MOL PHARMACOL, V41, P817; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; MICHEL MC, 1991, TRENDS PHARMACOL SCI, V12, P389, DOI 10.1016/0165-6147(91)90610-5; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; NAKAMURA M, 1992, FEBS LETT, V314, P125, DOI 10.1016/0014-5793(92)80957-I; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; PETITTO JM, 1994, J NEUROIMMUNOL, V54, P81, DOI 10.1016/0165-5728(94)90234-8; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SAKANAKA C, 1994, BIOCHEM BIOPH RES CO, V205, P18, DOI 10.1006/bbrc.1994.2623; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; SCHWARZ H, 1994, J NEUROIMMUNOL, V51, P53, DOI 10.1016/0165-5728(94)90128-7; SEGALOFF DL, 1981, J BIOL CHEM, V256, P1420; STALLINGS RL, 1991, GENOMICS, V10, P807, DOI 10.1016/0888-7543(91)90467-S; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SUNDLER F, 1986, ANN REV CYTOL, V102, P234; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; TATEMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P5485, DOI 10.1073/pnas.79.18.5485; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; TOSO RD, 1989, EMBO J, V8, P4025; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANETTI M, 1993, FEBS LETT, V331, P260, DOI 10.1016/0014-5793(93)80349-Y; WAHLESTEDT C, 1986, REGUL PEPTIDES, V13, P307, DOI 10.1016/0167-0115(86)90048-0; WAHLESTEDT C, 1989, PROG NEURO-PSYCHOPH, V13, P31, DOI 10.1016/0278-5846(89)90003-1; WAHLESTEDT C, 1992, LIFE SCI, V50, P7; WALKER P, 1994, J BIOL CHEM, V269, P2863; WHARTON J, 1993, P NATL ACAD SCI USA, V90, P687, DOI 10.1073/pnas.90.2.687; WINITZ S, 1993, J BIOL CHEM, V268, P19196; YAMADA M, 1994, MOL PHARMACOL, V46, P470; ZHANG X, 1994, P NATL ACAD SCI USA, V91, P11738, DOI 10.1073/pnas.91.24.11738	68	87	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30102	30110						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530415	hybrid			2022-12-25	WOS:A1995TK38000075
J	SCHUUR, ER; DASGUPTA, P; REDDY, EP; RABINOVICH, JM; BALUDA, MA				SCHUUR, ER; DASGUPTA, P; REDDY, EP; RABINOVICH, JM; BALUDA, MA			ALTERNATIVE SPLICING OF THE CHICKEN C-MYB EXON-9A	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; GENE V-MYB; TRANSFORMING GENE; PROTO-ONCOGENE; MESSENGER-RNA; DIFFERENTIAL EXPRESSION; HEMATOPOIETIC-CELLS; NUCLEOTIDE-SEQUENCE; MYELOID-LEUKEMIA; DOWN-REGULATION	The c-myb gene products are thought to be regulators of cellular replication and of differentiation and heterogeneity may underlie their multiple functions. To investigate the possible existence of heterogeneity we have examined the chicken c-myb mRNAs by Northern blot analysis and polymerase chain reaction amplification of cDNAs (RT-PCR). Northern blot analysis with the c-myb cDNA clone pSG3, which contains the entire open reading frame (ORF) plus 500 base pairs of 3' untranslated sequences (Gerondakis & Bishop, 1986), and genomic probes revealed c-myb RNA species of 4.3 kb in addition to the major 4.0 kb species. The 4.3 kb c-myb RNA contained the alternatively spliced exon 9A which is highly conserved and has also been detected in a minor 4.3 kb alternatively spliced c-myb mRNA in murine and human cells. Sequencing of the avian exon 9A revealed 360 bp exon homologous to that found in murine and human mRNAs, which contains three highly conserved sequence regions shared by all three species. RT-PCR demonstrated usage of exon 9A in five hematopoietic tissues and revealed an additional splicing variant which used the 3' portion of exon 9A. Northern blot analysis using splice site-specific oligonucleotide probes spanning the two splice junctions between exon 9 and 9A revealed four additional c-myb RNAs of 4.4 kb, 2.2 kb, 2.0 kb and 1.4 kb.	UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90024	University of Southern California; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA010197] Funding Source: NIH RePORTER; NCI NIH HHS [CA 10197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BALUDA MA, 1990, ONCOGENESIS ONCOGENE, P131; BENDER TP, 1987, J IMMUNOL, V139, P3822; BERGER SL, 1987, METHOD ENZYMOL, V152, P227; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CHEN JH, 1980, J VIROL, V36, P162, DOI 10.1128/JVI.36.1.162-170.1980; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DUDEK H, 1989, ONCOGENE, V4, P1061; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIM WK, 1989, MOL CELL BIOL, V9, P3771, DOI 10.1128/MCB.9.9.3771; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; Lipsick J S, 1986, Gene Amplif Anal, V4, P73; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MANIATIS T, 1982, MOL CLONING LABORATO, P280; Moscovici C., 1973, Methods Cell Biol, V7, P313; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; PERBAL B, 1983, J VIROL, V45, P925, DOI 10.1128/JVI.45.3.925-940.1983; PERBAL B, 1982, J VIROL, V44, P586, DOI 10.1128/JVI.44.2.586-594.1982; PERBAL B, 1982, J VIROL, V41, P250, DOI 10.1128/JVI.41.1.250-257.1982; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHUUR ER, 1991, ONCOGENE, V6, P1923; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VELLARD M, 1991, ONCOGENE, V6, P505; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1990, ONCOGENE, V5, P1117; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	57	16	17	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1839	1847						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510928				2022-12-25	WOS:A1993LG68200016
J	RICHARDSON, RM; KIM, C; BENOVIC, JL; HOSEY, MM				RICHARDSON, RM; KIM, C; BENOVIC, JL; HOSEY, MM			PHOSPHORYLATION AND DESENSITIZATION OF HUMAN M2 MUSCARINIC CHOLINERGIC RECEPTORS BY 2 ISOFORMS OF THE BETA-ADRENERGIC-RECEPTOR KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED PHOSPHORYLATION; GTP-BINDING PROTEINS; CHICK HEART; ACETYLCHOLINE-RECEPTOR; RHODOPSIN KINASE; HIGH-AFFINITY; GUANINE-NUCLEOTIDES; FAMILY; RECONSTITUTION; EXPRESSION	Studies of the human m2 (hm2) muscarinic cholinergic receptors (mAChR) have been performed to provide further insights into the potential regulation of these receptors by isoforms of the beta-adrenergic receptor kinase (betaARK). The hm2 mAChR and the isoforms betaARK1 and betaARK2 were individually expressed in, and purified from, insect Sf9 cells infected with recombinant baculoviruses. The expressed hm2 receptors were tested as substrates for betaARK1 and betaARK2 in vitro using concentrations of receptors and kinases similar to those found in intact cells. The hm2 mAChR were phosphorylated in an agonist-dependent manner to 4-5 mol of phosphate/mol of receptor by betaARK1 or betaARK2. The reactions were highly dependent on agonist; the antagonist atropine, and heparin, a betaARK inhibitor, both prevented the betaARK-mediated phosphorylation. The rates of phosphorylation catalyzed by both isoforms were similar, with half-maximal phosphorylation occurring in less than 5 min. Under the conditions employed the stoichiometries, but not the rates, of phosphorylation catalyzed by both kinases were increased 2-3-fold by either the heterotrimeric G-protein G(o) or the betagamma subunits of transducin. Phosphopeptide mapping experiments indicated that similar sites were phosphorylated by the two betaARK isoforms. In order to test for functional effects of the phosphorylation mediated by the betaARK isoforms, the receptors were reconstituted with purified G(o) and were tested for their ability to stimulate guanosine 5'-3-O-(thio)triphosphate (GTPgammaS) binding. The conditions leading to maximal receptor phosphorylation resulted in a 30-50% reduction in the ability of the receptors to stimulate GTPgammaS binding to G(o). The results demonstrate that the hm2 mAChR are excellent substrates in vitro for both betaARK1 and betaARK2 and that extensive phosphorylation by these enzymes occurs in the presence of the betagamma subunits of G proteins. The betaARK-mediated phosphorylation of the m2 mAChR causes a perturbation of receptor/G-protein coupling.	NORTHWESTERN UNIV, SCH MED, DEPT PHARMACOL, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Northwestern University; Jefferson University					NHLBI NIH HHS [HL 31601] Funding Source: Medline; NIGMS NIH HHS [GM44944] Funding Source: Medline; NINDS NIH HHS [5T32-NS07140-80] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007140] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HAGA K, 1989, MOL PHARMACOL, V35, P286; HAGA K, 1989, BIOMED RES-TOKYO, V10, P293, DOI 10.2220/biomedres.10.293; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1983, J BIOL CHEM, V258, P3575; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; KATADA T, 1987, FEBS LETT, V213, P353, DOI 10.1016/0014-5793(87)81521-1; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KWATRA MM, 1986, J BIOL CHEM, V261, P2429; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, MOL PHARMACOL, V35, P553; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MAYOR F, 1987, J BIOL CHEM, V262, P6468; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PARKER EM, 1991, J BIOL CHEM, V266, P519; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RICHARDSON RM, 1992, J BIOL CHEM, V267, P10127; RICHARDSON RM, 1990, BIOCHEMISTRY-US, V29, P8555, DOI 10.1021/bi00489a008; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TIETJE KM, 1991, J BIOL CHEM, V266, P17382	37	106	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13650	13656						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514797				2022-12-25	WOS:A1993LH55300089
J	Denlinger, LC; Fisette, PL; Garis, KA; Kwon, G; VazquezTorres, A; Simon, AD; Nguyen, B; Proctor, RA; Bertics, PJ; Corbett, JA				Denlinger, LC; Fisette, PL; Garis, KA; Kwon, G; VazquezTorres, A; Simon, AD; Nguyen, B; Proctor, RA; Bertics, PJ; Corbett, JA			Regulation of inducible nitric oxide synthase expression by macrophage purinoreceptors and calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERITONEAL-MACROPHAGES; ENDOTOXIN; LIPOPOLYSACCHARIDE; ATP; NUCLEOTIDES; ACTIVATION; MEMBRANES; RECEPTORS; INHIBIT; AGONIST	Macrophage activation is central to the progression of multiple diseases via the release of inflammatory mediators such as cytokines and nitric oxide. Despite the recognized overlap in the regulatory mechanisms involved in mediator production, little information exists regarding receptor-initiated signaling pathways that coordinately control multiple end points, such as tumor necrosis factor-alpha (TNF-alpha) and nitric oxide production. In this study, the expression of inducible nitric oxide synthase (iNOS) in macrophages is shown to be regulated by calcium and by a purinoreceptor signaling system. The P-2Y purinoreceptor partial agonist, 2-methylthio-ATP (2-MeS-ATP), inhibits the expression of iNOS induced by lipopolysaccharide (LPS) plus interferon-gamma (IFN-gamma) in primary macrophages. Additionally, 2-MeS-ATP attenuates the expression of iNOS in macrophages isolated from CD-1 mice challenged with LPS, and it inhibits LPS-induced TNF-alpha and interleukin-1 alpha (IL-1 alpha) release, thereby preventing endotoxic death. Thus, purinoreceptors and calcium are likely to be critical for macrophage activation and the production of inflammatory mediators stimulated by LPS.	UNIV WISCONSIN, SCH MED, MD PHD PROGRAM, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, DEPT MED MICROBIOL & IMMUNOL, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, DEPT CELLULAR & MOLEC BIOL, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, DEPT SURG, MADISON, WI 53706 USA; UNIV WISCONSIN, SCH MED, DEPT MED, MADISON, WI 53706 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; ST LOUIS UNIV, DEPT BIOCHEM & MOLEC BIOL, ST LOUIS, MO 63104 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Saint Louis University					NCI NIH HHS [CA47881] Funding Source: Medline; NIDDK NIH HHS [DK08748] Funding Source: Medline; NIGMS NIH HHS [GM53271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; BERTICS PJ, 1993, INT CONGR SER, V1020, P233; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; CORBETT JA, 1994, AM J PHYSIOL, V267, pC48, DOI 10.1152/ajpcell.1994.267.1.C48; COUGHLIN RT, 1983, BIOCHEMISTRY-US, V22, P2002, DOI 10.1021/bi00277a041; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; DENLINGER LC, 1995, NOVEL THERAPEUTIC ST, P227; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; GRIFFITHS RJ, 1995, J IMMUNOL, V154, P2821; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; KWIATKOWSKI D, 1990, LANCET, V336, P1201, DOI 10.1016/0140-6736(90)92827-5; LEE HC, 1986, CIRC SHOCK, V18, P193; LETARI O, 1991, J IMMUNOL, V147, P980; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MISKO TP, 1993, EUR J PHARMACOL, V233, P119, DOI 10.1016/0014-2999(93)90357-N; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PARMELY MJ, 1993, J IMMUNOL, V151, P389; PROCTOR RA, 1994, P NATL ACAD SCI USA, V91, P6017, DOI 10.1073/pnas.91.13.6017; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROUBENOFF R, 1994, J CLIN INVEST, V93, P2379, DOI 10.1172/JCI117244; RUPPRECHT AP, 1991, J IMMUNOL METHODS, V144, P157, DOI 10.1016/0022-1759(91)90082-Q; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHMIDT HHHW, 1992, MOL PHARMACOL, V41, P615; STEINBERG TH, 1987, J CELL BIOL, V105, P2695, DOI 10.1083/jcb.105.6.2695; SZABO C, 1993, BIOCHEM BIOPH RES CO, V196, P825, DOI 10.1006/bbrc.1993.2323; TANKE T, 1991, BIOCHEM J, V277, P379, DOI 10.1042/bj2770379; TONETTI M, 1994, BIOCHEM BIOPH RES CO, V203, P430, DOI 10.1006/bbrc.1994.2200; XIE QW, 1994, J BIOL CHEM, V269, P4705; XU YP, 1991, J NEUROCHEM, V56, P1889, DOI 10.1111/j.1471-4159.1991.tb03445.x	34	149	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					337	342		10.1074/jbc.271.1.337	http://dx.doi.org/10.1074/jbc.271.1.337			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550583				2022-12-25	WOS:A1996TP36100052
J	Gao, AG; Lindberg, FP; Finn, MB; Blystone, SD; Brown, EJ; Frazier, WA				Gao, AG; Lindberg, FP; Finn, MB; Blystone, SD; Brown, EJ; Frazier, WA			Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL BINDING DOMAIN; PLATELET THROMBOSPONDIN; CARCINOMA-CELLS; ATTACHMENT; IDENTIFICATION; PEPTIDES	The C-terminal ''cell-binding domain'' (CBD) of thrombospondin-1 (TS1) is a binding site for many cell types. Cell-binding peptides based on the sequence RFYVVM from the CBD of TS1 affinity label a 52-kDa cell surface glycoprotein, which we show is integrin-associated protein (IAP or CD47). IAP associates with alpha(v) beta(3) and thereby modulates the activity of several integrins. Cells that express IAP bind strongly to TS1, the CBD, and its active cell-binding peptides while IAP negative cells do not. The 52-kDa protein is affinity labeled on IAP-positive but not IAP negative cells, and monoclonal antibodies against IAP specifically immunoprecipitate the affinity-labeled 52-kDa protein from lysates of IAP-positive cells. Consistent with the association of IAP with alpha(v) beta(3) integrin, the labeled 52-kDa protein is immunoprecipitated by an anti-alpha(v) beta(3) antibody. Endothelial cells exhibit chemotaxis toward TS1 (at concentrations above 10 nM) and RFYVVM peptides. Chemotaxis to both agents is specifically inhibited by a function blocking anti-IAP monoclonal antibody. These data establish IAP (CD47) as a receptor for the CBD of TS1 and suggest a mechanism for the well established effects of the CBD on cell motility.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED & INFECT DIS, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008990] Funding Source: NIH RePORTER; NIAID NIH HHS [F32-AI-08990] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; GAO AG, 1994, J BIOL CHEM, V269, P29650; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; KOSFELD MD, 1992, J BIOL CHEM, V267, P16230; KOSFELD MD, 1991, J BIOL CHEM, V266, P24257; LAWLER J, 1993, THROMBOSPONDIN, P7; LAWLER J, 1993, THROMBOSPONDIN, P275; LINDBERG FP, 1994, J BIOL CHEM, V269, P1567; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; ROSALES C, 1992, J IMMUNOL, V149, P2759; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; SUCHARD SJ, 1993, THROMBOSPONDIN, P177; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TSAO PW, 1995, J BIOL CHEM, V270, P23747, DOI 10.1074/jbc.270.40.23747; TUSZYNSKI GP, 1989, EXP CELL RES, V182, P473, DOI 10.1016/0014-4827(89)90251-6; VARANI J, 1986, EXP CELL RES, V167, P376, DOI 10.1016/0014-4827(86)90178-3; YABKOWITZ R, 1993, J CELL PHYSIOL, V157, P24, DOI 10.1002/jcp.1041570104; YABKOWITZ R, 1993, CANCER RES, V53, P378; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	34	328	342	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					21	24		10.1074/jbc.271.1.21	http://dx.doi.org/10.1074/jbc.271.1.21			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550562				2022-12-25	WOS:A1996TP36100005
J	Melchers, K; Weitzenegger, T; Buhmann, A; Steinhilber, W; Sachs, G; Schafer, KP				Melchers, K; Weitzenegger, T; Buhmann, A; Steinhilber, W; Sachs, G; Schafer, KP			Cloning and membrane topology of a P type ATPase from Helicobacter pylori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STREPTOCOCCUS-FAECALIS; CANDIDATE GENE; MENKES DISEASE; SARCOPLASMIC-RETICULUM; GASTRIC EPITHELIUM; ENTEROCOCCUS-HIRAE; CADMIUM-RESISTANCE; PROTEIN SEQUENCES; K+-ATPASE	Southern blot screening of a genomic Helicobacter pylori library was employed to find a P type ATPase using a mixture of 16 DNA oligonucleotides coding for the DKTGT(I/L)T consensus sequence specific for the phosphorylation site of this family of ATPases, A positive clone, pRH439, was isolated and sequenced, The inserted 3.4-kb H. pylori DNA contained an intact open reading frame encoding a protein of 686 amino acids carrying the consensus sites for phosphorylation and ATP binding, The amino acid sequence exhibits a 25-30% identity with bacterial Cd2+ and Cu2+ ATPases, Genomic Southern blot analysis showed that this ATPase was present in all H. pylori strains examined, whereas it was not detectable in Campylobacter jejuni and other bacteria, The membrane topology of this ATPase was investigated using in vitro transcription/translation of fusion vectors to find signal anchor and/or stop transfer sequences. Eight regions of the II, pylori ATPase acted as signal anchor and/or stop transfer sequences and were ordered pairwise along the polypeptide chain placing the N and C-terminal amino acids in the cytoplasm, These transmembrane segments are contained between positions 73 and 92 (H1), 98 and 125 (H2), 128 and 148 (H3), 149 and 176 (H4), 309 and 327 (H5), 337 and 371 (H6), 637 and 658 (H7), and 659 and 685 (HS), The membrane domain of the ATPase, therefore, consists of at least four pairs of transmembrane segments with the phosphorylation site and ATP binding domain located in the large cytoplasmic loop between H6 and H7. The cytoplasmic domain contains several histidines and cysteines, perhaps indicative of divalent cation binding sites. There are several charged amino acids (3 Lys, 2 Glu, 2 Asp) predicted to be in the membrane domain mainly in H2, H3, and H4 and a Cys-Pro-Cys putative metal ion site in H6. The extracytoplasmic domain also has several charged amino acids (5 Glu, 1 Asp, 1 Lye, 1 Arg), It is likely that this novel protein is a heavy metal cation transporting ATPase and belongs to a family of P type ATPases containing eight transmembrane segments.	UNIV CALIF LOS ANGELES,WADSWORTH VET AFFAIRS HOSP,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles	Melchers, K (corresponding author), BYK GULDEN LOMBERG GMBH,DEPT MOLEC BIOL,POB 100310,D-78462 CONSTANCE,GERMANY.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R01DK046917, R01DK040615] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40615, DK41301, DK46917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APELL HJ, 1990, BIOCHIM BIOPHYS ACTA, V1017, P221, DOI 10.1016/0005-2728(90)90188-A; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BULL PC, 1994, TRENDS GENET, V10, P246, DOI 10.1016/0168-9525(94)90172-4; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; COVER TL, 1995, ASM NEWS, V61, P21; CUSSAC V, 1992, J BACTERIOL, V174, P2466, DOI 10.1128/jb.174.8.2466-2473.1992; DICK JD, 1990, ANNU REV MICROBIOL, V44, P249; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; EPSTEIN W, 1990, BACTERIA, V12, P87; EPSTEIN W, 1985, CURR TOP MEMBR TRANS, V25, P153; FURST P, 1986, J BIOL CHEM, V261, P4302; GE ZM, 1995, MOL MICROBIOL, V15, P97, DOI 10.1111/j.1365-2958.1995.tb02224.x; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GRAHAM DY, 1993, GASTROENTEROLOGY, V105, P279, DOI 10.1016/0016-5085(93)90038-E; HAZELL SL, 1986, J INFECT DIS, V153, P658, DOI 10.1093/infdis/153.4.658; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; HUGENTOBLER G, 1983, J BIOL CHEM, V258, P7611; KAHN D, 1989, J BACTERIOL, V171, P929, DOI 10.1128/jb.171.2.929-939.1989; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIMINS LA, 1981, P NATL ACAD SCI-BIOL, V78, P464, DOI 10.1073/pnas.78.1.464; LEE A, 1993, INFECT IMMUN, V61, P1601, DOI 10.1128/IAI.61.5.1601-1610.1993; LEYING H, 1992, MOL MICROBIOL, V6, P2863, DOI 10.1111/j.1365-2958.1992.tb01466.x; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MALFERTHEINER P, 1993, EUR J GASTROEN HEPAT, V5, pS1; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PHUNG LT, 1994, P NATL ACAD SCI USA, V91, P9651, DOI 10.1073/pnas.91.20.9651; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; SERRANO R, 1988, BIOCHIM BIOPHYS ACTA, V947, P1, DOI 10.1016/0304-4157(88)90017-2; SHIN JM, 1994, J BIOL CHEM, V269, P22533; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SILVER S, 1993, MOL MICROBIOL, V10, P7, DOI 10.1111/j.1365-2958.1993.tb00898.x; SILVER S, 1989, TRENDS BIOCHEM SCI, V14, P76, DOI 10.1016/0968-0004(89)90048-0; SMITH DL, 1993, J BIOL CHEM, V268, P22469; SOLIOZ M, 1987, J BIOL CHEM, V262, P7358; SPIEGELHALDER C, 1993, INFECT IMMUN, V61, P5315, DOI 10.1128/IAI.61.12.5315-5325.1993; SUERBAUM S, 1994, MOL MICROBIOL, V14, P959, DOI 10.1111/j.1365-2958.1994.tb01331.x; TRENOR C, 1994, BIOCHEM BIOPH RES CO, V205, P1644, DOI 10.1006/bbrc.1994.2856; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WARREN JR, 1983, LANCET, V1, P1273; WU LF, 1992, RES MICROBIOL, V143, P347, DOI 10.1016/0923-2508(92)90027-L	51	98	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					446	457		10.1074/jbc.271.1.446	http://dx.doi.org/10.1074/jbc.271.1.446			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550601	hybrid			2022-12-25	WOS:A1996TP36100069
J	Hadman, M; Gabos, L; Loo, M; Sehgal, A; Bos, TJ				Hadman, M; Gabos, L; Loo, M; Sehgal, A; Bos, TJ			Isolation and cloning of JTAP-1: A cathepsin like gene upregulated in response to V-Jun induced cell transformation	ONCOGENE			English	Article						Jun; targets; cysteine protease; transformation; cathepsin O	CHICKEN-EMBRYO FIBROBLASTS; C-JUN; GLUCOCORTICOID RECEPTOR; DNA-BINDING; FUNCTIONAL ANTAGONISM; COLLAGENASE GENE; FOS; EXPRESSION; AP-1; INHIBITION	The oncogenic potential of Jun in chicken embryo fibroblasts (CEF) varies depending on its structure. V-Jun, which has a number of structural differences from c-Jun is highly transforming and tumorigenic. C-Jun however, is only weakly transforming and is not tumorigenic. We have used this difference in oncogenic potential between v-Jun and c-Jun to screen for downstream target genes associated with the v-Jun induced transformed phenotype. We describe here the identification, cloning and characterization of one of these genes, JTAP-1. JTAP-1 is consistently overexpressed 7 to 10-fold in CEF transformed by v-Jun compared with c-Jun overexpressing or normal CEF. This pattern of expression suggests that JTAP-1 is associated with the transformed phenotype. DNA and amino acid homology search analysis revealed that JTAP-1 shares a high degree of similarity with over 100 cysteine proteases from a variety of species and is likely the chicken homolog of cathepsin O. Analysis of expression of JTAP-1 in CEF overexpressing other oncogenes including v-Ha-ras, v-Src, c-Fos, and Myc revealed that it's overexpression is unique to v-Jun transformed cells. Thus, JTAP-1 is likely a specific target of v-Jun overexpression and not simply a consequence of cell transformation.	EASTERN VIRGINIA MED SCH,DEPT MICROBIOL & IMMUNOL,NORFOLK,VA 23501	Eastern Virginia Medical School					NCI NIH HHS [R29 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ATKINS KB, 1995, CELL GROWTH DIFFER, V6, P713; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRODT P, 1992, BIOCHIM BIOPHYS ACTA, V1139, P77, DOI 10.1016/0925-4439(92)90085-2; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GINSBERG D, 1991, ONCOGENE, V6, P669; GIZANGGINSBERG E, 1990, GENE DEV, V4, P447; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HADMAN M, 1993, ONCOGENE, V8, P1895; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HARTL M, 1992, CELL GROWTH DIFFER, V3, P899; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; KASAI M, 1993, CELL IMMUNOL, V150, P124, DOI 10.1006/cimm.1993.1184; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kozyreva E. A., 1994, Voprosy Meditsinskoi Khimii, V40, P25; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LETO G, 1994, IN VIVO, V2, P231; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; OBERHUBER H, 1995, MOL CARCINOGEN, V12, P198, DOI 10.1002/mc.2940120404; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; SLOANE BF, 1994, J CELL SCI, V107, P373; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOLOVYEVA NI, 1995, INT J CANCER, V8; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TOURAY M, 1991, ONCOGENE, V6, P1227; VALASCO G, 1994, J BIOL CHEM, V269, P27136; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1990, CANCER BIOL, V1, P27; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	48	29	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					135	142						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552384				2022-12-25	WOS:A1996TQ01400017
J	Bruyns, E; HendricksTaylor, LR; Meuer, S; Koretzky, GA; Schraven, B				Bruyns, E; HendricksTaylor, LR; Meuer, S; Koretzky, GA; Schraven, B			Identification of the sites of interaction between lymphocyte phosphatase-associated phosphoprotein (LPAP) and CD45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE-PHOSPHATASE; SIGNAL-TRANSDUCTION; TRANSMEMBRANE DOMAIN; CHAIN TRANSMEMBRANE; CYTOPLASMIC DOMAIN; C ACTIVATION; COMPLEX; KINASE; EXPRESSION	Human lymphocyte phosphatase-associated phosphoprotein (LPAP) is a phosphoprotein of unknown function that noncovalently associates with CD45 in lymphocytes. In CD45-deficient human T cells, LPAP protein is synthesized at normal levels but is more rapidly degraded than in wild-type cells, Expression of CD45 cDNA rescues LPAP protein expression. This strongly suggests that LPAP is protected from degradation through its interaction with CD45. We have mapped the sites of interaction between LPAP and CD45 employing chimeric CD45 molecules and LPAP deletion mutants. Our data demonstrate that the interaction between LPAP and CD45 is mediated via the transmembrane regions of both molecules, In addition, the intracytoplasmic amino acids adjacent to the transmembrane region of LPAP may influence its binding to CD45.	GERMAN CANC RES CTR,DEPT APPL IMMUNOL,D-69120 HEIDELBERG,GERMANY; UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Helmholtz Association; German Cancer Research Center (DKFZ); University of Iowa; University of Iowa			Koretzky, Gary/AAU-5381-2021		NCI NIH HHS [CA56050, CA56843] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA056843, R01CA056050] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCOVER A, 1990, J BIOL CHEM, V265, P4131; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BLUM JH, 1993, J BIOL CHEM, V268, P27236; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; JOHN S, 1989, EUR J IMMUNOL, V19, P335, DOI 10.1002/eji.1830190218; JUNE CH, 1990, J IMMUNOL, V144, P1591; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MANOLIOS N, 1990, SCIENCE, V249, P274, DOI 10.1126/science.2142801; MANOLIOS N, 1994, EUR J IMMUNOL, V24, P84, DOI 10.1002/eji.1830240114; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MICHNOFF CH, 1994, J BIOL CHEM, V269, P24237; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; PATEL MD, 1987, J BIOL CHEM, V262, P5831; PEYRON JF, 1991, INT IMMUNOL, V3, P1357, DOI 10.1093/intimm/3.12.1357; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; ROSS SE, 1994, BIOCHEM BIOPH RES CO, V198, P88, DOI 10.1006/bbrc.1994.1013; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHRAVEN B, 1992, EUR J IMMUNOL, V22, P1857, DOI 10.1002/eji.1830220727; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STEVENS TL, 1994, J IMMUNOL, V152, P4397; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEDA A, 1994, J BIOL CHEM, V269, P2357; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x	40	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31372	31376						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537410				2022-12-25	WOS:A1995TN44400077
J	McGuire, J; Coumailleau, P; Whitelaw, ML; Gustafsson, JA; Poellinger, L				McGuire, J; Coumailleau, P; Whitelaw, ML; Gustafsson, JA; Poellinger, L			The basic helix-loop-helix PAS factor Sim is associated with hsp90 - Implications for regulation by interaction with partner factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; NUCLEAR TRANSLOCATOR PROTEIN; DNA-BINDING ACTIVITY; DIOXIN RECEPTOR; AH-RECEPTOR; GLUCOCORTICOID RECEPTOR; LIGAND; ARNT; RECOGNITION; CLONING	Sim is a Drosophila developmental basic helix-loop-helix (bHLH) transcription factor containing a Per-Arnt-Sim (PAS) region of homology. Here we demonstrate that Sim, in analogy to the structurally related bHLH/PAS dioxin receptor, was stably associated with the molecular chaperone hsp90. In the case of the dioxin receptor, release of hsp90 and derepression of receptor function appear to be regulated by ligand binding and dimerization with Arnt, a non-hsp90-associate bHLH/PAS factor. Dimerization with Amt very efficiently disrupted Sim . hsp90 interaction, a process that required both the bHLH and PAS dimerization motifs of Arnt. Moreover, hsp90 was also released upon dimerization of Sim with the Drosophila PAS factor Per, whereas the hsp90-associated dioxin receptor failed to interact with Sim. These results indicate that hsp90 may play a role in conditional regulation of Sim function, and that Per and possibly bHLH/PAS partner factors may activate Sim by inducing release of hsp90 during the dimerization process.	KAROLINSKA INST, NOVUM, DEPT MED NUTR, S-14186 HUDDINGE, SWEDEN; KAROLINSKA INST, NOVUM, DEPT BIOSCI, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet; Karolinska Institutet			coumailleau, pascal/K-1697-2015					ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; AUTONSSON C, 1995, MOL CELL BIOL, V15, P756; BACSI SG, 1995, MOL PHARMACOL, V47, P432; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CARVER LA, 1994, J BIOL CHEM, V269, P30109; CHEN HS, 1994, J BIOL CHEM, V269, P27554; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DORSHKIND K, 1994, CELL, V79, P751, DOI 10.1016/0092-8674(94)90065-5; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HORD NG, 1994, MOL PHARMACOL, V46, P618; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; LITTLEWOOD TD, 1995, PROTEIN PROFILE, V2, P621; MA Q, 1995, J BIOL CHEM, V270, P12697, DOI 10.1074/jbc.270.21.12697; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NAMBU JR, 1993, COMP BIOCHEM PHYS A, V104, P399, DOI 10.1016/0300-9629(93)90439-B; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PROBST MR, 1993, MOL PHARMACOL, V44, P511; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; SHUE G, 1994, J BIOL CHEM, V269, P2702; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WHARTON KA, 1994, DEVELOPMENT, V120, P3563; WHITELAW M, 1993, MOL CELL BIOL, V13, P2504, DOI 10.1128/MCB.13.4.2504; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x; [No title captured]	50	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31353	31357		10.1074/jbc.270.52.31353	http://dx.doi.org/10.1074/jbc.270.52.31353			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537407	hybrid			2022-12-25	WOS:A1995TN44400074
J	Potvin, B; Raju, TS; Stanley, P				Potvin, B; Raju, TS; Stanley, P			lec32 is a new mutation in Chinese hamster ovary cells that essentially abrogates CMP-N-acetylneuraminic acid synthetase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; SIALIC-ACID; EMBRYONIC ANTIGEN; MUTANTS; DEFICIENT; BINDING; OLIGOSACCHARIDES; PURIFICATION; ACTIVATION; SELECTION	LEC29.Lec32 is a glycosylation mutant that was isolated from a selection of mutagenized Chinese hamster ovary (CHO) cells for lectin resistance. Compared with LEC29 CHO cells, the double mutant exhibited an unusually high sensitivity to the toxic lectin, ricin, indicating increased exposure of galactose residues on cell surface carbohydrates. Structural analysis of LEC29.Lec32 cellular glycoproteins showed a nearly complete lack of sialic acid residues. Genetic analysis demonstrated that the lec32 mutation is recessive and novel. Biochemical analysis showed that the mutant cells contained less than 5% of the cytidine 5'-monophosphate N-acetylneuraminic acid (CMP-NeuAc) present in parental CHO cells (1.6 nmol/mg of cell protein). A sensitive radiochemical assay used to measure CMP-NeuAc synthetase activity showed that the properties of this enzyme in parental CHO cells were essentially identical to those of CMP-NeuAc synthetase in various mammalian tissues. However, no CMP-NeuAc synthetase activity was detected in LEC29.Lec32 extracts. Mixing experiments provided no evidence for an inhibitor in the mutant CHO cells, and two revertants, which expressed only the LEC29 phenotype, had normal CMP-NeuAc synthetase levels. The combined evidence indicates that the lec32 mutation resides in either the structural gene encoding CMP-NeuAc synthetase or in a gene that regulates the production of active enzyme.	ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, NEW YORK, NY 10461 USA; YESHIVA UNIV, DEPT BIOL, NEW YORK, NY 10033 USA	Yeshiva University; Yeshiva University				Stanley, Pamela/0000-0001-5704-3747	PHS HHS [R01 36434, R37 30645, P01 13330] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRILES EB, 1977, J BIOL CHEM, V252, P1107; CAMPBELL C, 1983, CELL, V35, P303, DOI 10.1016/0092-8674(83)90233-7; COATES SW, 1980, J BIOL CHEM, V255, P9225; DENNIS JW, 1986, CANCER RES, V46, P4594; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; EDWARDS U, 1992, FEMS MICROBIOL LETT, V96, P161; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; ENGEL P, 1995, J EXP MED, V181, P1581, DOI 10.1084/jem.181.4.1581; FINNE J, 1982, J CELL BIOL, V92, P277, DOI 10.1083/jcb.92.2.277; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HIGA HH, 1985, J BIOL CHEM, V260, P8838; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; HUBBARD SC, 1994, J BIOL CHEM, V269, P3717; KEAN E L, 1991, Glycobiology, V1, P441, DOI 10.1093/glycob/1.5.441; KEAN EL, 1969, EXP EYE RES, V8, P44, DOI 10.1016/S0014-4835(69)80079-5; KEAN EL, 1970, J BIOL CHEM, V245, P2301; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KIMBER SJ, 1990, INT REV CYTOL, V120, P53; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; KRONIS KA, 1982, BIOCHEMISTRY-US, V21, P3050, DOI 10.1021/bi00256a003; LIU D, 1995, THESIS A EINSTEIN CO; OGATA S, 1995, CANCER RES, V55, P1869; POTVIN B, 1991, CELL REGUL, V2, P989, DOI 10.1091/mbc.2.12.989; POTVIN B, 1990, J BIOL CHEM, V265, P1615; POWELL LD, 1995, J BIOL CHEM, V270, P7523, DOI 10.1074/jbc.270.13.7523; POWELL LD, 1994, J BIOL CHEM, V269, P10628; RICHARD M, 1975, BIOCHEM BIOPH RES CO, V64, P108, DOI 10.1016/0006-291X(75)90225-9; RIPKA J, 1992, BIOCHEM BIOPH RES CO, V186, P102, DOI 10.1016/S0006-291X(05)80781-8; RODRIGUEZAPARICIO LB, 1992, J BIOL CHEM, V267, P9257; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SALLUSTIO S, 1989, SOMAT CELL MOLEC GEN, V15, P387, DOI 10.1007/BF01534890; SHAMES S L, 1991, Glycobiology, V1, P187, DOI 10.1093/glycob/1.2.187; SHAW L, 1991, GLYCOCONJUGATE J, V8, P434, DOI 10.1007/BF00731295; SINGHAL A, 1990, BIOESSAYS, V12, P223, DOI 10.1002/bies.950120506; STANLEY P, 1981, MOL CELL BIOL, V1, P687, DOI 10.1128/MCB.1.8.687; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; STANLEY P, 1993, BIOL EXTRACELLULAR M, P181; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; TOYAMA S, 1983, J BIOL CHEM, V258, P9147; VANDENEIJNDEN DH, 1973, J NEUROCHEM, V21, P949, DOI 10.1111/j.1471-4159.1973.tb07539.x; VANN WF, 1987, J BIOL CHEM, V262, P17556; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; Varki Ajit, 1995, Seminars in Developmental Biology, V6, P127, DOI 10.1016/S1044-5781(06)80022-8; WANG WC, 1988, J BIOL CHEM, V263, P4576; WRIGHT CS, 1992, J BIOL CHEM, V267, P14345; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; ZAPATA G, 1993, BIOCHEM J, V295, P485, DOI 10.1042/bj2950485; ZAPATA G, 1989, J BIOL CHEM, V264, P14769	52	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30415	30421		10.1074/jbc.270.51.30415	http://dx.doi.org/10.1074/jbc.270.51.30415			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530468	hybrid			2022-12-25	WOS:A1995TL67500033
J	GalchevaGargova, Z; Theroux, SJ; Davis, RJ				GalchevaGargova, Z; Theroux, SJ; Davis, RJ			The epidermal growth factor receptor is covalently linked to ubiquitin	ONCOGENE			English	Article						EGF; signal transduction; ubiquitin	TYROSINE KINASE-ACTIVITY; COATED PIT FORMATION; FACTOR BETA-RECEPTOR; MEDIATED ENDOCYTOSIS; PROTEIN-DEGRADATION; HUMAN-FIBROBLASTS; AFFINITY; PHOSPHORYLATION; BINDING; INTERNALIZATION	Incubation of cultured human fibroblasts with epidermal growth factor (EGF) causes a proliferative response that is mediated by the binding of the growth factor to specific cell surface receptors, One event that occurs rapidly following EGF binding is the covalent modification of the EGF receptor (EGF-R) by phosphorylation on Ser, Thr, and Tyr residues, Here we report the identification of ubiquitination as a second form of EGF-stimulated covalent modification of the receptor, The EGF receptor was not ubiquitinated in serum-starved cells, However, treatment with EGF caused a rapid increase in EGF-R ubiquitination, In contrast, no EGF-stimulated ubiquitination was found in experiments using cells that express a mutant tyrosine kinase-negative EGF-R. Similarly, ubiquitination of the EGF-R was not observed at 4 degrees C or if the cells are depleted of intracellular K+. Together, these data establish ubiquitination as a form of EGF-stimulated covalent modification of the EGF-R.	UNIV MASSACHUSETTS, SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA; ASSUMPTION COLL, WORCESTER, MA 01609 USA; HOWARD HUGHES MED INST, COCONUT GROVE, FL 33133 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Assumption College; Howard Hughes Medical Institute					NCI NIH HHS [R01-CA58396] Funding Source: Medline; NIGMS NIH HHS [R15-GM49465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM049465] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BENVENISTE M, 1989, J CELL BIOL, V109, P2105, DOI 10.1083/jcb.109.5.2105; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1993, ADV LIPID RES, V25, P131; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FAN Z, 1994, J BIOL CHEM, V269, P27595; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GLENNEY JJ, 1993, J CELL BIOL, V121, P61; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOU D, 1994, J BIOL CHEM, V269, P14244; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1993, J BIOL CHEM, V268, P577; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; SELVA E, 1993, J BIOL CHEM, V268, P2250; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	44	106	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2649	2655						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545122				2022-12-25	WOS:A1995TP18800021
J	BUSHMEYER, S; PARK, K; ATCHISON, ML				BUSHMEYER, S; PARK, K; ATCHISON, ML			CHARACTERIZATION OF FUNCTIONAL DOMAINS WITHIN THE MULTIFUNCTIONAL TRANSCRIPTION FACTOR, YY1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC PROMOTER; ZINC-FINGER; BINDING-PROTEINS; MAMMALIAN-CELLS; GLOBIN GENE; NF-E1 YY-1; REPRESSION; ELEMENTS; KRUPPEL; DELTA	YY1 is a multifunctional transcription factor capable of either activation or repression of transcription. Using a series of mutant proteins, we have characterized domains responsible for activation or repression. We found that the YY1 transcriptional activation domain lies near the amino terminus and requires amino acids 16-29 and 80-100 for maximal activity. The region between residues 16 and 29 has the potential to form an acidic amphipathic helix, whereas residues between 80 and 100 are rich in proline and glutamine. The YY1 repression domain lies near the carboxyl terminus and is embedded within the YY1 zinc finger region necessary for binding to DNA. Deletion of YY1 amino acids, which include zinc fingers 3 and 4, abolishes repression. However, site-directed mutagenesis, progressive deletion, and internal deletion mutant analyses indicate that the normal structures of zinc fingers 3 and 4 are not required for repression.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania					NIGMS NIH HHS [GM42415, 5-T32-GM07170] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042415, T32GM007170] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; BASU A, 1993, J BIOL CHEM, V268, P4188; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; BAUKNECHT T, 1995, J VIROL, V69, P1; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHUNG S, 1993, NUCLEIC ACIDS RES, V21, P3301, DOI 10.1093/nar/21.14.3301; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; DONG XP, 1994, INT J CANCER, V58, P803, DOI 10.1002/ijc.2910580609; FALB D, 1992, MOL CELL BIOL, V12, P4093, DOI 10.1128/MCB.12.9.4093; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HA L, 1993, GENE DEV, V7, P1021; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HARIHARAN N, 1989, NUCLEIC ACIDS RES, V17, P5323, DOI 10.1093/nar/17.13.5323; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; HOLMGREN RA, 1992, GENE DEV, V6, P161, DOI 10.1101/gad.6.2.161; INOUYE CJ, 1994, J BIOL CHEM, V296, P6506; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEE TC, 1994, ONCOGENE, V9, P1047; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MAY M, 1994, EMBO J, V13, P1460, DOI 10.1002/j.1460-2075.1994.tb06400.x; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PETERS B, 1993, J BIOL CHEM, V268, P3430; PISANESCHI G, 1994, BIOCHEM BIOPH RES CO, V205, P1236, DOI 10.1006/bbrc.1994.2797; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SATYAMOORTHY K, 1993, MOL CELL BIOL, V13, P6621, DOI 10.1128/MCB.13.11.6621; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; YOST SE, 1993, MOL CELL BIOL, V13, P5439, DOI 10.1128/MCB.13.9.5439; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	65	119	124	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30213	30220						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530432				2022-12-25	WOS:A1995TK38000092
J	CHU, RY; LIN, Y; RAO, MS; REDDY, JK				CHU, RY; LIN, Y; RAO, MS; REDDY, JK			COOPERATIVE FORMATION OF HIGHER-ORDER PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AND RETINOID-X RECEPTOR COMPLEXES ON THE PEROXISOME PROLIFERATOR RESPONSIVE ELEMENT OF THE RAT HYDRATASE-DEHYDROGENASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							COA OXIDASE GENE	Peroxisome proliferator-activated receptor (PPAR) forms a heterodimer with retinoid X receptor (RXR) that binds to the peroxisome proliferator responsive element (PPRE) to regulate the expression of target genes, PPRE of the rat enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD) gene has previously been shown to consist of three imperfect TGACCT half-sites and form two distinct complexes (C1 and C2) with the nuclear extracts from H4IIEC3 cells. The present study identifies another imperfect TGACCT motif involved in the PPAR/RXR-mediated trans-activation process and demonstrates that these four imperfect TGACCT motifs constitute an unique binding site consisting of two DR1 elements overlapping a DR2 element. PPAR and RXR cooperatively bind the two DR1 elements to form C1 complex or bind DR2 element to form C2 complex with a 1:1 ratio. Saturation of the HD PPRE probes with receptor proteins cannot convert the heterodimeric C2 complex to the higher order C1 complex, suggesting that they are formed independently. Transfection analyses indicate that mutation of any one of these TGACCT motifs or truncation of the entire HD PPRE into a separate DR1 and DR2 element significantly reduced the transcriptional response of HD PPRE to peroxisome proliferators. The rat HD PPRE differentially binds with one or two PPAR/RXR heterodimers providing the peroxisome proliferator signaling pathway with two levels of response.	NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611	Northwestern University					NIGMS NIH HHS [R37 GM 23570] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, P911; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; CHU R, 1995, IN PRESS P NATL ACAD; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; GERING KL, 1993, P NATL ACAD SCI USA, V90, P1440; GREEN S, 1993, MOL CELL ENDOCRINOL, V100, P149; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	20	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29636	29639						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530345				2022-12-25	WOS:A1995TK38000005
J	SIVARAM, P; OBUNIKE, JC; GOLDBERG, IJ				SIVARAM, P; OBUNIKE, JC; GOLDBERG, IJ			LYSOLECITHIN-INDUCED ALTERATION OF SUBENDOTHELIAL HEPARAN-SULFATE PROTEOGLYCANS INCREASES MONOCYTE BINDING TO MATRIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; PROTEIN-KINASE-C; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; FIBRONECTIN RECEPTOR; LIPOPROTEIN-LIPASE; POTENTIAL ROLE; GROWTH-FACTORS; ARTERIAL-WALL	The cause and consequence of altered proteoglycans in atherosclerosis are poorly understood. To determine whether proteoglycans affect monocyte binding, we studied the effects of heparin and proteoglycan degrading enzymes on THP-1 monocyte adhesion to subendothelial matrix (SEM). Monocyte binding increased about 2-fold after SEM was treated with heparinase. In addition, heparin decreased monocyte binding to fibronectin, a known SEM protein, by 60%. These data suggest that SEM heparan sulfate inhibits monocyte binding to SEM proteins. We next examined whether lysolecithin, a constituent of modified lipoproteins, affects endothelial heparan sulfate proteoglycan (HSPG) production and monocyte binding, Lysolecithin (10-200 mu M) decreased total (SO4)-S-35 in SEM (20-75%). 2-fold more monocytes bound to SEM from lysolecithin treated cells than to control SEM. Heparinase treatment did not further increase monocyte binding 60 lysolecithin-treated SEM. HSPG degrading activity was found in medium from lysolecithin-treated but not control cells, (SO4)-S-35-labeled products obtained from labeled matrix treated with lysolecithin-conditioned medium were similar in size to those generated by heparinase. These data suggest that lysolecithin-treated endothelial cells secrete a heparanase-like activity. We hypothesize that decreased vessel wall HSPG, as occurs in atherogenic conditions, allows increased monocyte retention within the vessel and is due to the actions of an endothelial heparanase.	COLUMBIA UNIV,COLL PHYS & SURG,SPECIALIZED CTR RES ARTERIOSCLEROSIS,NEW YORK,NY 10032	Columbia University	SIVARAM, P (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DEPT MED,BB 906,630 W 168TH ST,NEW YORK,NY 10032, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, R01HL045095, P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 21006, HL 45095] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CHARO IF, 1992, CURR OPIN LIPIDOL, V3, P335; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; CULP LA, 1986, CIBA F SYMP, V124, P158; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; EHRLICH K, 1978, EXPERIENTIA, V34, P179, DOI 10.1007/BF01944662; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; GLUKHOVA MA, 1989, J CELL BIOL, V109, P357, DOI 10.1083/jcb.109.1.357; HAUTANEN A, 1989, J BIOL CHEM, V264, P1437; HAYASHI K, 1992, J CELL BIOL, V119, P945, DOI 10.1083/jcb.119.4.945; HOFF HF, 1986, ATHEROSCLEROSIS, V61, P231, DOI 10.1016/0021-9150(86)90143-7; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HOOK M, 1986, CIBA F SYMP, V124, P143; INOUE N, 1992, CIRC RES, V71, P1410, DOI 10.1161/01.RES.71.6.1410; JORIS I, 1983, AM J PATHOL, V113, P341; KINSELLA MG, 1988, BIOCHEMISTRY-US, V27, P2136, DOI 10.1021/bi00406a048; KUGIYAMA K, 1992, CIRC RES, V71, P1422, DOI 10.1161/01.RES.71.6.1422; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LEBARON RG, 1988, J CELL BIOL, V106, P945, DOI 10.1083/jcb.106.3.945; LEDBETTER SR, 1987, BIOCHEMISTRY-US, V26, P988, DOI 10.1021/bi00378a003; MARTEN M, 1994, AM HEART ASS, V56; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519, DOI 10.1002/jlb.51.6.519; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; OISHI K, 1988, J BIOL CHEM, V263, P6865; OLGEMOLLER B, 1990, FEBS LETT, V264, P37, DOI 10.1016/0014-5793(90)80758-B; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; PAULSSON M, 1987, J MOL BIOL, V197, P297, DOI 10.1016/0022-2836(87)90125-2; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; RICHARDSON M, 1980, LAB INVEST, V43, P509; ROSENFELD ME, 1987, ARTERIOSCLEROSIS, V7, P9, DOI 10.1161/01.ATV.7.1.9; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAGE H, 1981, ARTERIOSCLEROSIS, V1, P427, DOI 10.1161/01.ATV.1.6.427; SAKU T, 1989, J BIOL CHEM, V264, P3514; SALISBURY BGJ, 1985, EXP MOL PATHOL, V42, P306, DOI 10.1016/0014-4800(85)90081-4; SANDERS S, 1988, J CELL BIOL, V106, P423; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SMITH EB, 1986, BIOCHIM BIOPHYS ACTA, V880, P10, DOI 10.1016/0304-4165(86)90113-3; SRINIVASAN SR, 1989, BIOCHIM BIOPHYS ACTA, V1006, P159, DOI 10.1016/0005-2760(89)90190-2; STINS MF, 1992, ARTERIOSCLER THROMB, V12, P1437, DOI 10.1161/01.ATV.12.12.1437; TAKASAKI I, 1991, J BIOL CHEM, V266, P17686; Timpl R., 1994, V70, P123; VIJAYAGOPAL P, 1988, BIOCHEM J, V255, P639; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WAGNER WD, 1978, LAB INVEST, V39, P322; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WRIGHT SD, 1985, J EXP MED, V162, P762, DOI 10.1084/jem.162.2.762	57	36	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29760	29765						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530367				2022-12-25	WOS:A1995TK38000027
J	BOURRET, RB; DRAKE, SK; CHERVITZ, SA; SIMON, MI; FALKE, JJ				BOURRET, RB; DRAKE, SK; CHERVITZ, SA; SIMON, MI; FALKE, JJ			ACTIVATION OF THE PHOSPHOSIGNALING PROTEIN CHEY .2. ANALYSIS OF ACTIVATED MUTANTS BY F-19 NMR AND PROTEIN ENGINEERING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; RESPONSE REGULATOR; CRYSTAL-STRUCTURE; SALMONELLA-TYPHIMURIUM; CONSERVED ASPARTATE; PHOSPHORYLATION; RESOLUTION; GENE	The Escherichia coli CheY protein is activated by phosphorylation, and in turn alters flagellar rotation. To investigate the molecular mechanism of activation, an extensive collection of mutant CheY proteins was analyzed by behavioral assays, in vitro phosphorylation, and F-19 NMR chemical shift measurements. Substitution of a positively charged residue (Arg or Lys) in place of Asp13 in the CheY activation site results in activation, even for mutants which cannot be phosphorylated. Thus phosphorylation plays an indirect role in the activation mechanism. Lys109, a residue proposed to act as a conformational ''switch'' in the activation site, is required for activation of CheY by either phosphorylation or mutation. The F-19 NMR chemical shift assay described in the preceding article (Drake, S. K., Bourret, R. B., Luck, L. A., Simon, M. I., and Falke, J. J. (1993) J. Biol Chem. 268, 13081-13088) was again used to monitor six phenylalanine positions in CheY, including one position which probed the vicinity of Lys109. Mutations which activate CheY were observed to perturb the Lys109 probe, providing further evidence that Lys109 is directly involved in the activating conformational change. Two striking contrasts were observed between activation by mutation and phosphorylation. (i) Each activating mutation generates a relatively localized perturbation in the activation site region, whereas phosphorylation triggers a global structural change. (ii) The perturbation of the Lys109 region observed for activating mutations is not detected in the phosphorylated protein. These results are consistent with a two-step model of activated CheY docking to the flagellar switch.	UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of Colorado System; University of Colorado Boulder; California Institute of Technology			Bourret, Robert/X-3606-2019	Bourret, Robert/0000-0002-6666-9220	NIAID NIH HHS [R01 AI019296, AI07798, AI19296] Funding Source: Medline; NIGMS NIH HHS [GM40731, R01 GM040731-12, R01 GM040731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRAY D, 1993, IN PRESS MOL BIOL CE; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; DEFRANCO AL, 1979, J BACTERIOL, V139, P107, DOI 10.1128/JB.139.1.107-114.1979; DRAKE SK, 1993, J BIOL CHEM, V268, P13081; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1991, METHOD ENZYMOL, V200, P188; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; LEBIODA L, 1991, BIOCHEMISTRY-US, V30, P2817, DOI 10.1021/bi00225a012; LUKAT GS, 1991, J BIOL CHEM, V266, P8348; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; LUNDQVIST T, 1991, BIOCHEMISTRY-US, V30, P904, DOI 10.1021/bi00218a004; Macnab R. M., 1987, ESCHERICHIA COLI SAL, V1, P732; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; MCCLEARY WR, 1990, J BACTERIOL, V172, P4877, DOI 10.1128/jb.172.9.4877-4887.1990; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; RAMAKRISHNAN G, 1990, P NATL ACAD SCI USA, V87, P2369, DOI 10.1073/pnas.87.6.2369; ROMAN SJ, 1992, J BACTERIOL, V174, P6247, DOI 10.1128/JB.174.19.6247-6255.1992; RUSSELL CB, 1989, J BACTERIOL, V171, P2614, DOI 10.1128/jb.171.5.2614-2618.1989; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; STEWART RC, 1987, CHEM REV, V87, P997, DOI 10.1021/cr00081a007; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STOCK JB, 1992, J BIOL CHEM, V267, P19753; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; VOLZ K, 1991, J BIOL CHEM, V266, P15511	36	89	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13089	13096						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514750				2022-12-25	WOS:A1993LH55300015
J	OWNBY, DW; ZHU, H; SCHNEIDER, K; BEAVIS, RC; CHAIT, BT; RIGGS, AF				OWNBY, DW; ZHU, H; SCHNEIDER, K; BEAVIS, RC; CHAIT, BT; RIGGS, AF			THE EXTRACELLULAR HEMOGLOBIN OF THE EARTHWORM, LUMBRICUS-TERRESTRIS - DETERMINATION OF SUBUNIT STOICHIOMETRY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRILLIANT BLUE-R; OXYGENATION PROPERTIES; QUATERNARY STRUCTURE; ELECTRON-MICROSCOPY; MASS-SPECTROMETRY; PROTEINS; CHAINS; TRIMER; MODEL; CHLOROCRUORINS	The giant extracellular hemoglobin of the earthworm, Lumbricus terrestris, has four major O2-binding chains, a, b, and c (forming a disulfide-linked trimer) and d (''monomer''). Participation of additional ''linker'' chains L1, L2, and L3 is necessary for the assembly of the almost-equal-to 3,900+ kDa two-tiered hexagonal structure. We have determined the proportions of linker chains, trimer, and chain d in the hemoglobin by reverse phase high performance liquid chromatography which resolves all of the components and also permits simultaneous determination of the heme content. The proportions of components were determined by two independent procedures: integration of the absorbance peaks at 220 nm and amino acid analysis of the peak fractions. The results indicate that the weight proportion of linker chains is 0.163 +/- 0.023. This value, together with molecular masses determined both by amino acid sequence analysis and by matrix-assisted laser desorption mass spectrometry, gives a molar ratio of abcd chains to linkers of 8:1, corresponding to the minimal unit (abcd)2.L. This ratio suggests that 24 (abcd)2 units and 24 linker chains form the complete structure with a total calculated mass of polypeptide of 3,975 kDa with hemes on chains a, b, c and d and on one linker. The calculated heme content is 3.1% not including carbohydrate. This accounts for a measured heme content of 3.0% on a polypeptide basis. Additional mass (almost-equal-to 133 kDa, 3.4%), attributed to carbohydrate, brings the total mass to 4,108 kDa with a minimum molecular mass/heme of 20,500 Da. The presence of equimolar quantities of three unique linker chains means that the apparent one-twelfth structural units seen by electron microscopy cannot all be identical.	UNIV TEXAS, DEPT ZOOL, AUSTIN, TX 78712 USA; ROCKEFELLER UNIV, MASS SPECTROMETRY & GASEOUS ION CHEM LAB, NEW YORK, NY 10021 USA	University of Texas System; University of Texas Austin; Rockefeller University			Schneider, Klaus/N-6604-2014	Schneider, Klaus/0000-0002-3068-8681	NCRR NIH HHS [RR 00867] Funding Source: Medline; NIGMS NIH HHS [GM 35847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BEAVIS RC, 1990, ANAL CHEM, V62, P1836, DOI 10.1021/ac00216a020; BUNN HF, 1968, J BIOL CHEM, V243, P465; CHEW MY, 1965, BIOCHEM J, V94, P378, DOI 10.1042/bj0940378; CHIANCONE E, 1981, BIOCHIM BIOPHYS ACTA, V670, P84, DOI 10.1016/0005-2795(81)90052-0; CHIANCONE E, 1980, BIOCHIM BIOPHYS ACTA, V623, P146, DOI 10.1016/0005-2795(80)90017-3; DAVID MM, 1974, J MOL BIOL, V87, P89, DOI 10.1016/0022-2836(74)90561-0; FUSHITANI K, 1986, J BIOL CHEM, V261, P8414; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; FUSHITANI K, 1988, P NATL ACAD SCI USA, V85, P9461, DOI 10.1073/pnas.85.24.9461; FUSHITANI K, 1991, J BIOL CHEM, V266, P10275; GIBSON QH, 1991, J BIOL CHEM, V266, P13097; GIBSON QH, 1963, J BIOL CHEM, V238, P1384; GROS G, 1978, BIOPHYS J, V22, P453, DOI 10.1016/S0006-3495(78)85499-X; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; IGARASHI Y, 1991, J BIOCHEM, V109, P256; JONES RT, 1963, BIOCHEMISTRY-US, V2, P1357, DOI 10.1021/bi00906a031; KAPP OH, 1990, ANAL BIOCHEM, V184, P74, DOI 10.1016/0003-2697(90)90014-Z; KAPP OH, 1987, P NATL ACAD SCI USA, V84, P7532, DOI 10.1073/pnas.84.21.7532; KAPP OH, 1982, BIOCHIM BIOPHYS ACTA, V704, P546, DOI 10.1016/0167-4838(82)90079-6; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; LEVIN O, 1963, J MOL BIOL, V6, P95, DOI 10.1016/S0022-2836(63)80084-4; MAINWARING MG, 1986, J BIOL CHEM, V261, P899; NOZAKI Y, 1986, ARCH BIOCHEM BIOPHYS, V249, P437, DOI 10.1016/0003-9861(86)90020-2; PILZ I, 1980, INT J BIOL MACROMOL, V2, P279, DOI 10.1016/0141-8130(80)90045-8; QABAR AN, 1991, J MOL BIOL, V222, P1109, DOI 10.1016/0022-2836(91)90596-X; ROCHE J, 1960, BIOCHIM BIOPHYS ACTA, V41, P182, DOI 10.1016/0006-3002(60)90397-8; ROYER WE, 1988, J BIOL CHEM, V263, P13762; SHISHIKURA F, 1986, BIOCHIM BIOPHYS ACTA, V869, P314, DOI 10.1016/0167-4838(86)90071-3; SHISHIKURA F, 1987, J BIOL CHEM, V262, P3123; SHLOM JM, 1973, J BIOL CHEM, V248, P7904; STANDLEY PR, 1988, BIOCHEM J, V249, P915, DOI 10.1042/bj2490915; SUZUKI T, 1993, J BIOL CHEM, V268, P13548; SUZUKI T, 1990, J BIOL CHEM, V265, P12168; SVEDBERG T, 1940, ULTRACENTRIFUGE, P360; SWANEY JB, 1971, ARCH BIOCHEM BIOPHYS, V147, P475, DOI 10.1016/0003-9861(71)90404-8; TAL M, 1985, J BIOL CHEM, V260, P9976; TOMITA S, 1971, J BIOL CHEM, V246, P547; TOMPKINSON AE, 1990, J BIOL CHEM, V265, P12611; TSFADIA Y, 1990, INVERTEBRATE DIOXYGEN CARRIERS, P263; van Heel M., 1989, BIOCHIM BIOPHYS ACTA, V957, P370; Vinogradov S. N., 1982, ELECTRON MICROS, P135; VINOGRADOV SN, 1977, BIOCHIM BIOPHYS ACTA, V492, P136, DOI 10.1016/0005-2795(77)90221-5; VINOGRADOV SN, 1988, COMP BIOCHEM PHYS B, V91, P577, DOI 10.1016/0305-0491(88)90024-7; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; VINOGRADOV SN, 1980, COMP BIOCHEM PHYS B, V67, P1, DOI 10.1016/0305-0491(80)90262-X; VINOGRADOV SN, 1985, COMP BIOCHEM PHYS B, V82, P1, DOI 10.1016/0305-0491(85)90120-8; VINOGRADOV SN, 1991, COMP BIOCHEM PHYS B, V98, P187, DOI 10.1016/0305-0491(91)90165-A; VOBURKA Z, 1992, BIOCHEM INT, V27, P679; WAXMAN L, 1971, J BIOL CHEM, V246, P7318; WOOD EJ, 1976, BIOCHEM J, V153, P589, DOI 10.1042/bj1530589; YAMAGISHI M, 1966, J MOL BIOL, V21, P467, DOI 10.1016/0022-2836(66)90019-2	54	70	71	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13539	13547						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514787				2022-12-25	WOS:A1993LH55300075
J	RUSH, JS; SHELLING, JG; ZINGG, NS; RAY, PH; WAECHTER, CJ				RUSH, JS; SHELLING, JG; ZINGG, NS; RAY, PH; WAECHTER, CJ			MANNOSYLPHOSPHORYLDOLICHOL-MEDIATED REACTIONS IN OLIGOSACCHARIDE-P-P-DOLICHOL BIOSYNTHESIS - RECOGNITION OF THE SATURATED ALPHA-ISOPRENE UNIT OF THE MANNOSYL DONOR BY PIG BRAIN MANNOSYLTRANSFERASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SACCHAROMYCES-CEREVISIAE; LINKED OLIGOSACCHARIDES; CALF BRAIN; GLYCOSYLATION; PHOSPHATE; PROTEIN; MUTANT; YEAST; SYNTHASE	The specificity of Man-P-Dol:Man5-8GlcNAC2-P-P-Dol (Oligo-P-P-Dol) mannosyltransferase activity in pig brain was investigated by comparing a variety of mannosylphosphorylisoprenols as mannosyl donors. For this comparison the beta-Man-P-isoprenols were synthesized using a partially purified preparation of mannosylphosphorylundecaprenol (Man-P-Undec) synthase from Micrococcus luteus. The bacterial mannosyltransferase efficiently catalyzed the transfer of mannose from GDP-[H-3]Man to a series of defined isoprenyl monophosphate substrates. Two alpha-Man-P-dolichols were synthesized chemically and also examined as substrates. When exogenous beta-[H-3]Man-P-Dol95, was tested as a substrate for Man-P-Dol:Oligo-P-P-Dol mannosyltransferase activity in pig brain microsomes, [H-3]mannose was actively transferred to endogenous Oligo-P-P-Dol acceptors. The major enzymatically labeled product was Man9GlcNAC2-P-P-Dol. Under identical conditions beta-[H-3]mannosylphosphorylpolyprenol (Man-P-Poly95) was an extremely poor substrate, indicating that the saturated alpha-isoprene unit of the dolichyl moiety is critical for recognition of the lipophilic mannosyl donor by the endoplasmic reticulum-associated mannosyltransferase(s). When Man-P-dolichols containing 2, 11, or 19 isoprene units were compared, the initial rates for the mannosyl transfer reactions and the affinity of the enzyme(s) for the mannophospholipid substrate increased with the length and hydrophobicity of the polyisoprenol chain. The anomeric configuration of the mannosyl moiety is apparently essential because the brain mannosyltransferases exhibited a strong preference for beta-Man-P-dolichols over the corresponding chemically synthesized alpha-stereoisomers. These results: 1) describe a simple two-step procedure for obtaining a partially purified preparation of Man-P-Undec synthase that efficiently synthesizes a variety of beta-Man-P-isoprenols; 2) indicate that pig brain Man-P-Dol:Oligo-P-P-Dol mannosyltransferase activity is relatively specific for lipophilic mannosyl donors containing 19 isoprene units with a beta-Man 1-P group attached to the saturated alpha-isoprene unit of dolichol; and 3) emphasize the importance of the reduction of the alpha-isoprene unit in the biosynthesis and function of Dol-P in mammalian cells.	UNIV KENTUCKY, COLL MED, DEPT BIOCHEM, LEXINGTON, KY 40536 USA; BURROUGHS WELLCOME CO, DIV MOLEC GENET & MICROBIOL, RES TRIANGLE PK, NC 27709 USA	University of Kentucky; Burroughs Wellcome Fund					NIGMS NIH HHS [GM 36065] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036065] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERENDES R, 1992, BIOL CHEM H-S, V373, P35, DOI 10.1515/bchm3.1992.373.1.35; BRAELL WA, 1976, ANAL BIOCHEM, V74, P484, DOI 10.1016/0003-2697(76)90229-3; CRANE FL, 1977, ANNU REV BIOCHEM, V46, P439, DOI 10.1146/annurev.bi.46.070177.002255; CRICK DC, 1991, J NEUROCHEM, V57, P1354, DOI 10.1111/j.1471-4159.1991.tb08301.x; D'Souza-Schorey Crislyn, 1992, Glycobiology, V2, P476; DANILOV LL, 1981, FEBS LETT, V131, P310, DOI 10.1016/0014-5793(81)80392-4; DITTMER JC, 1964, J LIPID RES, V5, P126; DUNPHY PJ, 1967, BIOCHIM BIOPHYS ACTA, V136, P136, DOI 10.1016/0304-4165(67)90329-7; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLASER L, 1966, METHOD ENZYMOL, V8, P183; HARFORD JB, 1979, J NEUROCHEM, V32, P1707; HASELBECK A, 1982, P NATL ACAD SCI-BIOL, V79, P1520, DOI 10.1073/pnas.79.5.1520; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; JANKOWSKI WJ, 1989, CHEM PHYS LIPIDS, V51, P249, DOI 10.1016/0009-3084(89)90012-1; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LENNARZ WJ, 1966, J BIOL CHEM, V241, P2707; MANKOWSKI T, 1977, ARCH BIOCHEM BIOPHYS, V181, P393; MCLACHLAN KR, 1992, GLYCOBIOLOGY, V2, P313, DOI 10.1093/glycob/2.4.313; OCONNOR JV, 1979, BIOCHEMISTRY-US, V18, P500, DOI 10.1021/bi00570a020; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PARODI AJ, 1979, BIOCHIM BIOPHYS ACTA, V559, P1, DOI 10.1016/0304-4157(79)90006-6; PREISS J, 1966, METHOD ENZYMOL, V3, P271; PRESPER KA, 1983, ENZYMES, V16, P449; REARICK JI, 1981, J BIOL CHEM, V256, P3762; RODRIGUEZVICO F, 1989, ANAL BIOCHEM, V183, P275, DOI 10.1016/0003-2697(89)90479-X; RUSH J S, 1991, Glycobiology, V1, P229, DOI 10.1093/glycob/1.2.229; Rush Jeffrey S., 1992, Glycobiology, V2, P483; RUSH JS, 1992, ANAL BIOCHEM, V206, P328, DOI 10.1016/0003-2697(92)90374-G; SCHER M, 1969, J BIOL CHEM, V244, P2777; SHARMA CB, 1990, BIOCHEMISTRY-US, V29, P8901, DOI 10.1021/bi00490a004; SNIDER MD, 1984, CELL, V36, P753, DOI 10.1016/0092-8674(84)90355-6; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; STOLL J, 1988, J BIOL CHEM, V263, P10766; STOLL J, 1982, P NATL ACAD SCI-BIOL, V79, P2296, DOI 10.1073/pnas.79.7.2296; STOLL J, 1988, J BIOL CHEM, V263, P10774; SUMBILLA C, 1985, METHOD ENZYMOL, V111, P471; SZKOPINSKA A, 1992, INT J BIOCHEM, V7, P1151; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; WAECHTER CJ, 1976, ARCH BIOCHEM BIOPHYS, V174, P726, DOI 10.1016/0003-9861(76)90403-3; WAECHTER CJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P401, DOI 10.1016/0003-9861(73)90637-1; WAECHTER CJ, 1989, NEUROBIOLOGY GLYCOCO, P127; WAECHTER CJ, 1981, RES METHODS NEUROCHE, V5, P201; Warren C D, 1978, Methods Enzymol, V50, P122; WARREN CD, 1973, BIOCHEMISTRY-US, V12, P5038, DOI 10.1021/bi00749a002; WEDGWOOD JF, 1974, J BIOL CHEM, V249, P6316	47	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13110	13117						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514752				2022-12-25	WOS:A1993LH55300018
J	Li, SH; Kumar, NV; Varshney, U; RajBhandary, UL				Li, SH; Kumar, NV; Varshney, U; RajBhandary, UL			Important role of the amino acid attached to tRNA in formylation and in initiation of protein synthesis in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RNA-SYNTHETASE; FORMYLMETHIONINE TRANSFER-RNA; TYROSINE TRANSFER-RNA; DISCRIMINATOR BASE; IDENTITY INVIVO; ANTICODON STEM; ACCEPTOR STEM; AMINOACYLATION; SEQUENCE; RECOGNITION	In attempts to convert an elongator tRNA to an initiator tRNA, we previously generated a mutant elongator methionine tRNA carrying an anticodon sequence change from CAU to CUA along with the two features important for activity of Escherichia coli initiator tRNA in initiation. This mutant tRNA (Mi:2 tRNA) was active in initiation in vivo but only when aminoacylated with methionine by overproduction of methionyl-tRNA synthetase. Here we show that the Mi:2 tRNA is normally aminoacylated in vivo with lysine and that the tRNA aminoacylated with lysine is a very poor substrate for formylation compared with the same tRNA aminoacylated with methionine. By introducing further changes at base pairs 4:69 and 5:68 in the acceptor stem of the Mi:2 tRNA to those found in the E. coli initiator tRNA, we show that change of the U4:A69 base pair to G4:C69 and overproduction of lysyl-tRNA synthetase and methionyl-tRNA transformylase results in partial formylation of the mutant tRNA and activity of the formyllysyl-tRNAs in initiation of protein synthesis. Thus, the G4:C69 base pair contributes toward formylation of the tRNA and protein synthesis in E. coli can be initiated with formyllysine. We also discuss the implications of these and other results on recognition of tRNAs by E. coli lysyl-tRNA synthetase and on competition in cells among aminoacyl-tRNA synthetases.	INDIAN INST SCI,CTR GENET ENGN,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore	Li, SH (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		Varshney, Umesh/Q-6914-2019; Varshney, Umesh/A-8062-2009	Nandicoori, Vinay/0000-0002-5682-4178	NIGMS NIH HHS [GM17151] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017151, R01GM017151, R56GM017151, R37GM017151] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; CHOW CM, 1993, J BIOL CHEM, V268, P12855; DICKERMA.HW, 1967, J BIOL CHEM, V242, P1522; DYSON MR, 1993, BIOCHIMIE, V75, P1051, DOI 10.1016/0300-9084(93)90004-C; GIEGE R, 1973, FEBS LETT, V30, P291, DOI 10.1016/0014-5793(73)80672-6; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUILLON JM, 1993, J BACTERIOL, V175, P4507, DOI 10.1128/JB.175.14.4507-4514.1993; GUILLON JM, 1992, J BACTERIOL, V174, P4294, DOI 10.1128/JB.174.13.4294-4301.1992; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; HOU YM, 1989, BIOCHEMISTRY-US, V28, P4942, DOI 10.1021/bi00438a005; KOZAK M, 1983, MICROBIOL REV, V47, P1; KUMAR NV, 1994, CURR SCI INDIA, V67, P728; LEE CP, 1991, J BIOL CHEM, V266, P18012; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; LI SH, 1993, J BIOL CHEM, V268, P18335; MANGROO D, 1995, J BIOL CHEM, V270, P12203, DOI 10.1074/jbc.270.20.12203; MARCKER K, 1964, J MOL BIOL, V8, P835, DOI 10.1016/S0022-2836(64)80164-9; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MCCLAIN WH, 1988, SCIENCE, V241, P1804, DOI 10.1126/science.2459773; MEINNEL T, 1993, J BACTERIOL, V175, P993, DOI 10.1128/JB.175.4.993-1000.1993; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; PALLANCK L, 1992, J BIOL CHEM, V267, P7221; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SEONG BL, 1989, J BIOL CHEM, V246, P6504; SHIMURA Y, 1972, FEBS LETT, V22, P144, DOI 10.1016/0014-5793(72)80240-0; SMITH JD, 1973, NATURE-NEW BIOL, V243, P66; SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1; SUNDARI RM, 1976, J BIOL CHEM, V251, P3338; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VARSHNEY U, 1992, J BACTERIOL, V174, P7819, DOI 10.1128/JB.174.23.7819-7826.1992; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586; VARSHNEY U, 1993, P NATL ACAD SCI USA, V90, P2305, DOI 10.1073/pnas.90.6.2305; WAGNER T, 1984, J BIOL CHEM, V259, P4706; WAKAO H, 1989, J BIOL CHEM, V264, P20363; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WEYGANDDURASEVIC I, 1993, P NATL ACAD SCI USA, V90, P2010, DOI 10.1073/pnas.90.5.2010; YARUS M, 1972, NATURE-NEW BIOL, V239, P106, DOI 10.1038/newbio239106a0	46	28	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1022	1028		10.1074/jbc.271.2.1022	http://dx.doi.org/10.1074/jbc.271.2.1022			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557626	hybrid			2022-12-25	WOS:A1996TP88900063
J	Li, ZW; Zhan, LJ; Deutscher, MP				Li, ZW; Zhan, LJ; Deutscher, MP			Escherichia coli RNase T functions in vivo as a dimer dependent on cysteine 168	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								It was shown that Cys-168 is required for RNase T function and thermostability and that its hydrophobic properties are important for this role (Li, Z., Zhan, L., and Deutscher, M. P. (1996) J. Biol Chem. 271, 1127-1132). To understand the molecular basis for these findings, further studies of Cys-168 and RNase T structure were carried out. Treatment of RNase T with the sulfhydryl-modifying agent 5,5'-dithiobis-(2-nitrobenzoic acid) leads not only to inactivation, but also to monomerization of the protein. Similarly, specifically converting Cys-168 to either serine or asparagine leads to loss of activity and to monomer formation at 37 degrees C. However, at 10 degrees C the serine mutant remains as a dimer and retains full RNase T activity, whereas the asparagine derivative shows only a low level of activity and of dimer formation. These data show a strong correlation between activity and the dimer form of RNase T. The importance of dimer formation was also shown in vivo using genetic studies. An inactive mutant of RNase T, termed HA2, which exists as a dimer at 37 degrees C in vitro, completely suppresses endogenous RNase T activity in vivo and in vitro when introduced into a RNase T+ cell on a multicopy phagemid, most likely as a consequence of inactive heterodimer formation. Introduction of the HA2 gene on a single copy plasmid, as expected, leads to a propertionally smaller effect on endogenous activity. The dominant negative effect displayed by the HA2 protein can be relieved by an additional mutation in HA2 RNase T that abolishes its ability to dimerize. An inactive mutant asparagine derivative of Cys-168, which also does not dimerize, also shows little of the dominant negative phenotype. Thus, these data demonstrate that RNase T dimerizes in vine, that the dimer form is required for RNase T activity, and that Cys-168 is needed for dimerization of the enzyme.	UNIV CONNECTICUT,CTR HLTH,DEPT BIOCHEM,FARMINGTON,CT 06030	University of Connecticut					NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Davis R., 1980, ADV BACTERIAL GENETI; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; DEUTSCHER MP, 1978, NUCLEIC ACIDS RES, V5, P1949; Deutscher Murray P., 1995, P51; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; LI Z, 1995, J BIOL CHEM, V271, P1127; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883	9	17	17	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1133	1137		10.1074/jbc.271.2.1133	http://dx.doi.org/10.1074/jbc.271.2.1133			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557641	hybrid			2022-12-25	WOS:A1996TP88900078
J	Liu, Q; Ji, X; Breitman, ML; Hitchcock, PF; Swaroop, A				Liu, Q; Ji, X; Breitman, ML; Hitchcock, PF; Swaroop, A			Expression of the bZIP transcription factor gene Nrl in the developing nervous system	ONCOGENE			English	Article						neuronal development; gene expression; transcription factor	LEUCINE-ZIPPER; MAF ONCOGENE; V-MAF; RETINA; DOMAIN; FOS; MECHANISMS; DIVERSITY; PROTEINS; ENCODES	Proteins of the Maf/Nrl subfamily of bZIP transcription factors are involved in the regulation of tissue-specific gene expression. The Nrl gene, initially identified from a subtracted retinal library, is expressed in all cell layers of the adult retina, including photoreceptors. The Nrl protein has high sequence homology with Maf proteins, binds to an AP-1 like sequence element, and in photoreceptors appears to be involved in regulating the expression of rhodopsin. In the present study, we investigated the expression of Nrl in the developing and adult mouse using in situ hybridization and RT-PCR. We demonstrate that beginning at embryonic day 12.5 Nrl is expressed throughout the developing central and peripheral nervous system, with the exception of the nasal epithelium. The spatial pattern of hybridization suggests that Nrl is transcribed in post-mitotic, differentiating neurons, the developing cephalic mesenchyme and lens. Nrl expression is downregulated postnatally in the brain, and becomes restricted to neocortex and brainstem in the adult. High levels of Nrl transcripts, however, persist in the mature photoreceptors and other retinal neurons. Our studies suggest a role for the Nrl protein in neuronal differentiation and in mature neurons of the adult retina.	UNIV MICHIGAN, WK KELLOGG EYE CTR, DEPT OPHTHALMOL, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, WK KELLOGG EYE CTR, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, WK KELLOGG EYE CTR, DEPT HUMAN GENET, ANN ARBOR, MI 48105 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5S 1X5, CANADA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Hitchcock, Peter/AAY-9559-2020	Hitchcock, Peter/0000-0001-9454-2684; Swaroop, Anand/0000-0002-1975-1141	NEI NIH HHS [EY07003, EY07060] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BLAY HM, 1992, ANNU REV BIOCHEM, V6, P1213; BOK D, 1989, RETINA, P69; CAUBET JF, 1989, MOL CELL BIOL, V9, P2269, DOI 10.1128/MCB.9.5.2269; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; FARJO Q, 1993, GENOMICS, V18, P216, DOI 10.1006/geno.1993.1458; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAVAIL MM, 1991, J COMP NEUROL, V309, P86, DOI 10.1002/cne.903090107; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; REHEMTULLA A, IN PRESS P NATL ACAD; Sidman RL, 1961, STRUCTURE EYE, P487; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	28	58	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					207	211						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552394				2022-12-25	WOS:A1996TQ01400026
J	Marhin, WW; Hei, YJ; Chen, SJ; Jiang, Z; Gallie, BL; Phillips, RA; Penn, LZ				Marhin, WW; Hei, YJ; Chen, SJ; Jiang, Z; Gallie, BL; Phillips, RA; Penn, LZ			Loss of Rb and Myc activation co-operate to suppress cyclin D1 and contribute to transformation	ONCOGENE			English	Article						Myc; Rb; cyclin D1; MEF; transformation	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; CELL-CYCLE; SUSCEPTIBILITY GENE; NEGATIVE AUTOREGULATION; BINDING PROTEIN; G1 PHASE; LARGE-T; EXPRESSION; PHOSPHORYLATION	Cyclin D1 can bind and phosphorylate the product (pRb) of the retinoblastoma gene (RB-1) and recent evidence suggests pRb, in turn, may regulate cyclin D1 protein expression. In transformed cell lines, loss of pRb activity strongly correlates with a decrease in cyclin D1 protein expression, and conversely, introduction of pRb can induce cyclin D1 promoter activity. We show here that pRb does not regulate cyclin D1 directly as basal and serum-stimulated levels of cyclin D1 protein and kinase activity are similar in wildtype and pRb-deficient primary mouse embryonic fibroblasts (MEFs). These observations suggest that the suppression of cyclin D1 in pRb-minus tumour cell lines requires both loss of pRb and at least one additional genetic event. We have determined that constitutive, ectopic Myc expression in pRb-deficient, but not wildtype, MEFs suppresses cyclin D1 protein expression and kinase activity. Regulation is evident at either the level of RNA or protein expression. Phenotypically, pRb-deficient MEFs consistently exhibited a delayed growth response in comparison to wildtype MEFs. This growth delay is abrogated in pRb-deficient MEFs which are expressing ectopic Myc protein, coincident with the loss of cyclin D1 protein expression. Moreover, these cells exhibit an increased proliferative capacity, and they no longer show contact inhibition. Our results support a cross-regulatory mechanism between Myc, pRb and cyclin D1 and suggest a novel role for cyclin D1 in tumorigenesis.	HOSP SICK CHILDREN, RES INST, DEPT MICROBIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT IMMUNOL & CANC, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT MED & MOLEC GENET, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, TORONTO, ON M5G 1X8, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto				Penn, Linda/0000-0001-8133-5459; Gallie, Brenda/0000-0002-9697-9211				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCHOU T, 1993, ONCOGENE, V8, P1765; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cleveland J L, 1988, Oncogene Res, V3, P357; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FUNG YKT, 1993, ONCOGENE, V8, P2659; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HAUPT Y, 1995, ONCOGENE, V10, P1563; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NEVINS JR, 1992, SCIENCE, V258, P424; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Penn L J, 1990, Semin Cancer Biol, V1, P69; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SQUIRE J, 1986, NATURE, V322, P555, DOI 10.1038/322555a0; TAM SW, 1994, ONCOGENE, V9, P2663; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	82	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					43	52						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552398				2022-12-25	WOS:A1996TQ01400006
J	Bertolino, E; Reimund, B; WildtPerinic, D; Clerc, RG				Bertolino, E; Reimund, B; WildtPerinic, D; Clerc, RG			A novel homeobox protein which recognizes a TGT core and functionally interferes with a retinoid-responsive motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; STEROID-RECEPTOR SUPERFAMILY; SINGLE AMINO-ACID; THYROID-HORMONE; TRANSCRIPTION FACTOR; GENE PROMOTER; HOMEODOMAIN PROTEINS; X-RECEPTOR; VITAMIN-A; II GENE	We describe here a novel homeobox gene, denoted TGIF (5'<(TG)under bar>3' interacting factor), which belongs to an expanding TALE (three amino acid loop extension) superclass of atypical homeodomains. The TGIF homeodomain binds to a previously characterized retinoid X receptor (RXR) responsive element from the cellular retinol-binding protein II promoter (CRBPII-RXRE), which contains an unusual DNA target for a homeobox. The interactions of both the homeoprotein TGIF and receptor RXR alpha with the CRBPII-RXRE DNA motif occur on overlapping areas and generate a mutually exclusive binding in vitro. Transient cellular transfections demonstrate that TGIF inhibits the 9-cis-retinoic acid-dependent RXR alpha transcription activation of the retinoic acid responsive element. TGIF transcripts were detected in a restricted number of tissues. The canonical binding site of TGIF is conserved and is an integral part of several responsive elements which are organized like the CRBPII-RXRE. Hence, a novel auxiliary factor to the steroid receptor superfamily may participate in the transmission of nuclear signals during development and in the adult, as illustrated by the down-modulation of the RXR alpha activities.	ROCHE LTD,RES LABS,CH-4070 BASEL,SWITZERLAND	Roche Holding								BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BAXTER SM, 1994, BIOCHEMISTRY-US, V33, P15309, DOI 10.1021/bi00255a012; BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; Burglin T.R, 1994, EVOLUTION HOMEOBOX G, P27; BURGLIN TR, 1995, BIODIVERSITY EVOLUTI; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHAMBON P, 1991, RETINOIDS : 10 YEARS ON, P10; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHYTIL F, 1941, RETINOIDS 10 YEARS, P38; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CONLON RA, 1995, TRENDS GENET, V11, P314, DOI 10.1016/S0168-9525(00)89089-7; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HEERY DM, 1994, NUCLEIC ACIDS RES, V22, P726, DOI 10.1093/nar/22.5.726; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KOMURO I, 1993, EMBO J, V12, P1387, DOI 10.1002/j.1460-2075.1993.tb05783.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRUMLAUF R, 1992, TRENDS GENET, V8, P297, DOI 10.1016/0168-9525(92)90259-7; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIU YH, 1991, J BIOL CHEM, V266, P21880; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Maxam A.M., 1980, METHODS ENZYMOL, V65, P449; MUNOZCANOVES P, 1990, J BIOL CHEM, V265, P20065; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; POMERANTZ JL, 1994, BIOCHEMISTRY-US, V33, P10851, DOI 10.1021/bi00202a001; SAGAMI I, 1986, MOL CELL BIOL, V6, P4259, DOI 10.1128/MCB.6.12.4259; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SINGH H, 1989, BIOTECHNIQUES, V7, P252; STARK MR, 1994, NATURE, V371, P429, DOI 10.1038/371429a0; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREISMAN J, 1989, CELL, V59, P553; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	69	243	255	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31178	31188		10.1074/jbc.270.52.31178	http://dx.doi.org/10.1074/jbc.270.52.31178			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537382	hybrid			2022-12-25	WOS:A1995TN44400050
J	Calzi, ML; Raviolo, C; Ghibaudi, E; DeGioia, L; Salmona, M; Cazzaniga, G; Kurosaki, M; Terao, M; Garattini, E				Calzi, ML; Raviolo, C; Ghibaudi, E; DeGioia, L; Salmona, M; Cazzaniga, G; Kurosaki, M; Terao, M; Garattini, E			Purification, cDNA cloning, and tissue distribution of bovine liver aldehyde oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XANTHINE DEHYDROGENASE; RABBIT LIVER; MOLYBDENUM HYDROXYLASES; DROSOPHILA-MELANOGASTER; BINDING SITE; PROTEIN; SPECIFICITIES; DINUCLEOTIDE; METABOLITE; FERREDOXIN	Aldehyde oxidase was purified to homogeneity from bovine liver and primary structural information obtained by sequencing a series of cleavage peptides permitted the cloning of the corresponding cDNA. The cDNA is 4,630 base pairs long, and it consists of a 102-base pair 5'-untranslated region followed by a 4017-base pair coding region and a 511-base pair 3'-untranslated region. The open reading frame predicts a 1339-amino acid polypeptide with a calculated molecular weight of 147,441, which is consistent with the size of the aldehyde oxidase monomeric subunit. The aldehyde oxidase polypeptide contains consensus sequences for iron-sulfur centers and a molybdopterin binding site. The amino acid sequence deduced from the cDNA shows significant similarity with that of xanthine dehydrogenases from various sources. The primary structure of bovine aldehyde oxidase is remarkably similar (approximately 86%) to that of the translation product of a cDNA recently isolated by Wright et al. (Wright, R. M., Vaitaitis, G. M., Wilson, C. M., Repine, T. B., Terada, L. S., and Repine, J. E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10690-10694) and reported to represent human xanthine dehydrogenase, With the help of a monospecific antibody raised against the purified protein and the isolated cDNA, the tissue distribution of the bovine aldehyde oxidase protein and corresponding mRNA was determined, Aldehyde oxidase is expressed at high levels in liver, lung, and spleen, and, at a much lower level, in many other organs.	MARIO NEGRI INST PHARMACOL RES,CTR CATULLO & DANIELA BORGOMAINERIO,MOLEC BIOL UNIT,I-20157 MILAN,ITALY; MARIO NEGRI INST PHARMACOL RES,ENZYME RES LAB,I-20157 MILAN,ITALY	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS			KUROSAKI, Mami/ABG-2224-2020; Garattini, Enrico/AAI-1998-2019; salmona, mario/ABI-4066-2020; De Gioia, Luca/K-6439-2016; Terao, Mineko/AAA-6415-2020; terao, mineko/AAU-8089-2020; salmona, mario/AAA-7116-2020; Cazzaniga, Giovanni/K-6338-2016	KUROSAKI, Mami/0000-0001-8231-713X; Terao, Mineko/0000-0002-9976-9869; salmona, mario/0000-0002-9098-9873; Garattini, Enrico/0000-0001-8983-886X; Cazzaniga, Giovanni/0000-0003-2955-4528				AMAYA Y, 1990, J BIOL CHEM, V265, P14170; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; BARBER MJ, 1982, BIOCHEMISTRY-US, V21, P3561, DOI 10.1021/bi00258a006; BEEDHAM C, 1990, BIOCHEM PHARMACOL, V39, P1213, DOI 10.1016/0006-2952(90)90265-M; CARPANI G, 1990, ARCH BIOCHEM BIOPHYS, V279, P237, DOI 10.1016/0003-9861(90)90487-J; CAZZANIGA G, 1994, GENOMICS, V23, P390, DOI 10.1006/geno.1994.1515; CORRELL CC, 1993, PROTEIN SCI, V2, P2112, DOI 10.1002/pro.5560021212; CRITCHLEY DJP, 1992, BIOCHEM BIOPH RES CO, V185, P54, DOI 10.1016/S0006-291X(05)80954-4; ENDRES W, 1988, EUR J PEDIATR, V148, P246, DOI 10.1007/BF00441412; GLATIGNY A, 1995, J BIOL CHEM, V270, P3534, DOI 10.1074/jbc.270.8.3534; Hille R., 1985, Metal Ions in Biology, V7, P443; HOUDE M, 1989, GENE, V85, P391, DOI 10.1016/0378-1119(89)90432-0; HUANG DY, 1994, BIOCHEM BIOPH RES CO, V205, P1278, DOI 10.1006/bbrc.1994.2803; ICHIDA K, 1993, GENE, V133, P279; JACOBS SA, 1976, J CLIN INVEST, V57, P534, DOI 10.1172/JCI108308; JOHNSON C, 1984, BIOCHEM PHARMACOL, V33, P3699, DOI 10.1016/0006-2952(84)90159-X; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JOHNSON JL, 1989, METABOLIC BASIS INHE, V1, P1463; KITAMURA S, 1983, CHEM PHARM BULL, V31, P776; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRENITSKY TA, 1972, ARCH BIOCHEM BIOPHYS, V150, P585, DOI 10.1016/0003-9861(72)90078-1; KRENITSKY TA, 1974, COMP BIOCHEM PHYSIOL, V49, P687, DOI 10.1016/0305-0491(74)90256-9; KUROSAKI M, 1995, BIOCHEM J, V306, P225, DOI 10.1042/bj3060225; LEE CS, 1987, GENETICS, V116, P55; Maniatis T, 1989, DECONTAMINATION DILU; NISHINO T, 1989, J BIOL CHEM, V264, P5468; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO A, 1995, J BIOL CHEM, V270, P2818, DOI 10.1074/jbc.270.6.2818; Sporn M.B., 1994, RETINOIDS BIOL CHEM; STELL JGP, 1989, J CHROMATOGR, V475, P363, DOI 10.1016/S0021-9673(01)89690-4; STIRPE F, 1969, J BIOL CHEM, V244, P3855; TAYLOR SM, 1984, BIOCHEM J, V220, P67, DOI 10.1042/bj2200067; TERAO M, 1992, BIOCHEM J, V283, P863, DOI 10.1042/bj2830863; TURNER N, 1987, BIOCHEM J, V243, P755, DOI 10.1042/bj2430755; WRIGHT RM, 1993, P NATL ACAD SCI USA, V90, P10690, DOI 10.1073/pnas.90.22.10690; XU P, 1994, BIOCHEM BIOPH RES CO, V199, P998, DOI 10.1006/bbrc.1994.1328; YOSHIHARA S, 1985, ARCH BIOCHEM BIOPHYS, V242, P213, DOI 10.1016/0003-9861(85)90495-3	39	64	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31037	31045						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537361	hybrid			2022-12-25	WOS:A1995TN44400029
J	Penta, K; Sawyer, ST				Penta, K; Sawyer, ST			Erythropoietin induces the tyrosine phosphorylation, nuclear translocation, and DNA binding of STAT1 and STAT5 in erythroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; CYTOPLASMIC ACTIVATION; GROWTH-FACTOR; RECEPTOR; PROTEIN; GENE; TRANSCRIPTION; KINASE; PROMOTER; IDENTIFICATION	We have investigated whether Signal Transducing and Activators of Transcription (STAT) proteins become activated following the binding of erythropoietin (EPO) to immature erythroid cells from the spleens of mice infected with the anemia strain of Friend virus. STAT1 and STATE proteins are phosphorylated and translocated to the nucleus in EPO-treated cells. STAT1 and STATE DNA binding activities were also activated in an EPO-dependent manner. The presence of these STAT proteins in the DNA binding complex was confirmed by Western blot analysis of the proteins bound to the DNA element in the gel mobility shift assays. This EPO-dependent activation of STAT proteins was maximum within 10 min of exposure of the cells to 10 units of EPO/ml, the concentration of EPO required for maximum STAT activation. The magnitude of the EPO-dependent STATE activation appeared to be greater than the EPO-dependent activation of STAT1. The significance of STAT protein activation in EPO signal transduction is discussed.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, RICHMOND, VA 23298 USA; VANDERBILT UNIV, SCH MED, DEPT MED, DIV HEMATOL, NASHVILLE, TN 37232 USA	Virginia Commonwealth University; Vanderbilt University					NIDDK NIH HHS [R01DK39781] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039781] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRUSBY MJ, 1990, P NATL ACAD SCI USA, V87, P6897, DOI 10.1073/pnas.87.17.6897; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KRANTZ SB, 1991, BLOOD, V77, P419; KRANTZ SB, 1995, MOL BIOL HEMATOPOIES, V3, P135; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MIURA O, 1994, BLOOD, V84, P1501; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PARK DJ, 1993, BLOOD, V82, P77, DOI 10.1182/blood.V82.1.77.bloodjournal82177; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P1; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAWYER ST, 1994, HEMATOL ONCOL CLIN N, V8, P895, DOI 10.1016/S0889-8588(18)30136-9; SAWYER ST, 1987, J BIOL CHEM, V262, P5554; SAWYER ST, 1987, P NATL ACAD SCI USA, V84, P3690, DOI 10.1073/pnas.84.11.3690; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SPANGLER R, 1992, BLOOD, V79, P52; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31282	31287		10.1074/jbc.270.52.31282	http://dx.doi.org/10.1074/jbc.270.52.31282			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537396	hybrid			2022-12-25	WOS:A1995TN44400063
J	Chattopadhyay, P; Banerjee, M; Sarkar, C; Mathur, M; Mohapatra, AK; Sinha, S				Chattopadhyay, P; Banerjee, M; Sarkar, C; Mathur, M; Mohapatra, AK; Sinha, S			Infrequent alteration of the c-myc gene in human glial tumours associated with increased numbers of c-myc positive cells	ONCOGENE			English	Article						gliomas; c-myc rearrangement; c-myc immunohistochemistry	HUMAN GLIOBLASTOMA; AMPLIFICATION; EXPRESSION; LEUKEMIA; LINE; OVEREXPRESSION; REARRANGEMENT; CARCINOMA; ONCOGENES; PROTEIN	Twenty five human glial rumours of different grades of malignancy were examined by Southern blotting and polymerase chain reaction (PCR) for alterations (rearrangements, amplification and deletions) in the c-myc gene, Number of c-myc positive cells per thousand cells were also counted in all the rumours after immunohistochemical staining for c-myc protein was done on fixed sections of the tumours, No rumours exhibited any amplification of the gene, as found by Southern blotting, One astrocytoma and one mixed glioma showed some rearrangements in the 3' end of the gene, as detected by Southern blotting and hydridization, These two tumours had higher number of c-myc positive cells than in other rumours of the same histopathological groups, Deletion in the first promoter region, as determined by PCR, was seen in only one astrocytoma. However, the number of c-myc positive cells in that tumour did not show any deviation from that found in other astrocytomas. In light of present literature, it is speculated that the 3' rearrangements may be the cause of increased number of c-myc immunopositive cells in those tumours by disrupting the 3' end of the gene leading to increased c-myc mRNA stability, Such a mechanism may play a part in small subset of glial and possibly other tumours.	ALL INDIA INST MED SCI,DEPT BIOCHEM,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT PATHOL,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT NEUROSURG,NEW DELHI 110029,INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi			Banerjee, Moinak/X-4471-2018	Banerjee, Moinak/0000-0002-0842-0398				AGHIB DF, 1991, ONCOGENE, V6, P2371; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dixon WJ, 1983, INTRO STAT ANAL, P92; ENGELHARD HH, 1989, J NEUROSURG, V71, P224, DOI 10.3171/jns.1989.71.2.0224; FLEMING WH, 1986, CANCER RES, V46, P1535; HOLM R, 1993, J PATHOL, V169, P21, DOI 10.1002/path.1711690105; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; ORIAN JM, 1992, BRIT J CANCER, V66, P106, DOI 10.1038/bjc.1992.225; PETRONI D, 1992, CARCINOGENESIS, V13, P883, DOI 10.1093/carcin/13.5.883; RAMAEL M, 1993, J PATHOL, V169, P421, DOI 10.1002/path.1711690406; SAGLIO G, 1986, CANCER RES, V46, P1413; Sambrook J, 1987, MOL CLONING LAB MANU; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	18	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2711	2714						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545130				2022-12-25	WOS:A1995TP18800029
J	MORTON, HC; VANDENHERIKOUDIJK, IE; VOSSEBELD, P; SNIJDERS, A; VERHOEVEN, AJ; CAPEL, PJA; VANDEWINKEL, JGJ				MORTON, HC; VANDENHERIKOUDIJK, IE; VOSSEBELD, P; SNIJDERS, A; VERHOEVEN, AJ; CAPEL, PJA; VANDEWINKEL, JGJ			FUNCTIONAL ASSOCIATION BETWEEN THE HUMAN MYELOID IMMUNOGLOBULIN-A FC RECEPTOR (CD89) AND FCR GAMMA-CHAIN - MOLECULAR-BASIS FOR CD89/FCR GAMMA-CHAIN ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; HUMAN POLYMORPHONUCLEAR CELLS; SURFACE EXPRESSION; IGE RECEPTOR; EPSILON-RI; ANTIBODIES; MONOCYTES; RESIDUES; SUBUNIT; DOMAIN	FcR gamma chain has previously been shown to interact with the TCR-CD3 complex, the IgE Fc receptor I (Fc epsilon RI), and the class I and IIIA IgG receptors (Fc gamma RI and Fc gamma RIIIa). Here, we demonstrate that the Fc receptor gamma chain associates with Fc alpha R in transfected IIA1.6 B lymphocytes. Fc alpha R could be expressed at the surface of IIA1.6 B cells by itself, but was devoid of signaling capacity. Upon co-expression of FcR gamma chain, a physical interaction with Fc alpha R could be demonstrated. This association proved crucial for the triggering of both proximal (intracellular calcium increase and tyrosine phosphorylation), as well as distal (IL-2 release), signal transduction responses. We next tested the hypothesis that a positively charged arginine residue (Arg(209)) within the transmembrane domain of Fc alpha R promotes association with FcR gamma chain. We therefore constructed Fc alpha R molecules where Arg(209) was mutated to either a positively charged histidine, a negatively charged aspartic acid, or an uncharged leucine. A functional association between Fc alpha R and FcR gamma chain was observed only with a positively charged residue (Arg(209) or His(209)) present within the Fc alpha R transmembrane domain. These data show that transmembrane signal transduction by the Fc alpha R is mediated via FcR gamma chain, and that Fc alpha R requires a positively charged residue within the transmembrane domain to promote functional association.	UNIV UTRECHT HOSP,DEPT IMMUNOL,3584 CX UTRECHT,NETHERLANDS; NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,1066 CX AMSTERDAM,NETHERLANDS	Utrecht University; Utrecht University Medical Center			Morton, H. Craig/H-8600-2012	Morton, H. Craig/0000-0002-9440-5759				ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; BONNEROT C, 1992, EMBO J, V11, P2747, DOI 10.1002/j.1460-2075.1992.tb05340.x; COSSON P, 1992, SCIENCE, V258, P659, DOI 10.1126/science.1329208; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; DEWIT TPM, 1995, J IMMUNOL, V155, P1203; DUITS AJ, 1993, CLIN EXP IMMUNOL, V92, P225; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; FANGER MW, 1983, MOL IMMUNOL, V20, P1019, DOI 10.1016/0161-5890(83)90043-3; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P367; HO SN, 1988, GENE AMST, V77, P51; HOSTOFFER RW, 1993, J IMMUNOL, V150, P4532; INDIK ZK, 1994, EXP HEMATOL, V22, P599; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JOHN S, 1989, EUR J IMMUNOL, V19, P335, DOI 10.1002/eji.1830190218; JONES B, 1986, J IMMUNOL, V136, P348; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; KINET JP, 1992, CURR OPIN IMMUNOL, V4, P43, DOI 10.1016/0952-7915(92)90122-U; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MASUDA M, 1993, J IMMUNOL, V151, P7188; MONTEIRO RC, 1993, J CLIN INVEST, V92, P1681, DOI 10.1172/JCI116754; MONTEIRO RC, 1992, J IMMUNOL, V148, P1764; MONTEIRO RC, 1990, J EXP MED, V171, P597, DOI 10.1084/jem.171.3.597; MORLEY BJ, 1988, J EXP MED, V168, P1971, DOI 10.1084/jem.168.6.1971; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PARK JG, 1993, J CLIN INVEST, V92, P2073, DOI 10.1172/JCI116804; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SAVELKOUL HFJ, 1994, J IMMUNOL METHODS, V170, P185, DOI 10.1016/0022-1759(94)90394-8; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; SHEN L, 1981, CELL IMMUNOL, V59, P75, DOI 10.1016/0008-8749(81)90435-4; SHEN L, 1992, IMMUNOL RES, V11, P273, DOI 10.1007/BF02919133; SHEN L, 1989, J IMMUNOL, V143, P4117; STEWART WW, 1991, IMMUNOLOGY, V73, P491; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; VANDENHERIKOUDI.IE, 1995, BLOOD, V85, P2202; VANDENHERIKOUDI.IE, 1994, J IMMUNOL, V152, P574; VERHOEVEN AJ, 1988, BLOOD, V71, P505; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	46	164	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29781	29787						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530370				2022-12-25	WOS:A1995TK38000030
J	SANCHEZ, JA; WONSEY, DR; HARRIS, L; MORALES, J; WANGH, LJ				SANCHEZ, JA; WONSEY, DR; HARRIS, L; MORALES, J; WANGH, LJ			EFFICIENT PLASMID DNA-REPLICATION IN XENOPUS EGG EXTRACTS DOES NOT DEPEND ON PRIOR CHROMATIN ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; TOPOISOMERASE-II; LICENSING FACTOR; INVITRO; LAEVIS; CYCLE	Small plasmids replicate efficiently in unfertilized Xenopus eggs provided they are injected before rather than after activation of the cell cycle, Here we use Xenopus egg extracts to test the hypothesis that efficient replication results from chromatin assembly prior to activation giving preloaded plasmids a head start toward the formation of a replicating pseudonucleus (Sanchez, J. A., Marek, D., and Wangh, L. J. (1992) J. Cell Sci. 103, 907-918). As in ovum, plasmid DNA preincubated in unactivated egg cytoplasmcytostatic factor extracts) replicate more efficiently after extract activation than does the same DNA added to the same extract after activation, Unlike in ovum, however, plasmids that replicate efficiently in vitro do not assemble into chromatin during preincubation and become topologically knotted instead, But even DNA knotting does not explain subsequent efficient replication. Also, plasmids preassembled into chromatin in vitro do not replicate efficiently in activated egg cytoplasm unless first preincubated in a CSF extract, We conclude that unactivated eggs contain replication-enhancing activities that can act independently of plasmid chromatin assembly and DNA topology, These postulated ''preloading'' factor(s) may be related to Licensing factor, an activity that controls initiation of DNA replication in eukaryotic cells, The experimental conditions described here will permit characterization of preloading/licensing factor(s) in the context of a small plasmid substrate.			SANCHEZ, JA (corresponding author), BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA.							ALMOUZNI G, 1993, EXP CELL RES, V205, P1, DOI 10.1006/excr.1993.1051; BLOW JJ, 1990, J CELL SCI, V95, P383; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BOWATER R, 1992, METHOD ENZYMOL, V212, P105; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; HSIEH T, 1983, J BIOL CHEM, V258, P8413; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1983, J BIOL CHEM, V258, P5365; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; LUKE M, 1989, DEV BIOL, V136, P459, DOI 10.1016/0012-1606(89)90271-6; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MARINI NJ, 1991, MOL CELL BIOL, V11, P299, DOI 10.1128/MCB.11.1.299; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; ROCA J, 1993, J BIOL CHEM, V268, P14250; SANCHEZ JA, 1992, J CELL SCI, V103, P907; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WANGH LJ, 1995, J CELL SCI, V108, P2187; WANGH LJ, 1989, J CELL SCI, V93, P1	25	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29676	29681						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530355				2022-12-25	WOS:A1995TK38000015
J	SHYNG, SL; LEHMANN, S; MOULDER, KL; HARRIS, DA				SHYNG, SL; LEHMANN, S; MOULDER, KL; HARRIS, DA			SULFATED GLYCANS STIMULATE ENDOCYTOSIS OF THE CELLULAR ISOFORM OF THE PRION PROTEIN, PRPC IN CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SCRAPIE-ASSOCIATED FORM; AGENT REPLICATION; INCUBATION PERIOD; ENDOTHELIAL-CELLS; DEXTRAN SULFATE; CONGO RED; INHIBITION; MICE; INTERNALIZATION	There is currently no effective therapy for human prion diseases. However, several polyanionic glycans, including pentosan sulfate and dextran sulfate, prolong the incubation time of scrapie in rodents, and inhibit the production of the scrapie isoform of the prion protein (PrPSc), the major component of infectious prions, in cultured neuroblastoma cells. We report here that pentosan sulfate and related compounds rapidly and dramatically reduce the amount of PrPC, the non-infectious precursor of PrPSc, present on the cell surface. This effect results primarily from the ability of these agents to stimulate endocytosis of PrPC, thereby causing a redistribution of the protein from the plasma membrane to the cell interior. Pentosan sulfate also causes a change in the ultrastructural localization of PrPC, such that a portion of the protein molecules are shifted into late endosomes and/or lysosomes. In addition, we demonstrate, using PrP-containing bacterial fusion proteins, that cultured cells express saturable and specific surface binding sites for PrP, many of which are glycosaminoglycan molecules. Our results raise the possibility that sulfated glycans inhibit prion production by altering the cellular localization of PrPC precursor, and they indicate that endogenous proteoglycans are Likely to play an important role in the cellular metabolism of both PrPC and PrPSc.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL)			Lehmann, Sylvain/P-1301-2017	Lehmann, Sylvain/0000-0001-6117-562X; Harris, David/0000-0002-6985-5790	NIA NIH HHS [AG12925] Funding Source: Medline; NINDS NIH HHS [T32 NS07071, NS30137] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS030137, T32NS007071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012925] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1993, J VIROL, V67, P6270, DOI 10.1128/JVI.67.10.6270-6272.1993; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; DIRINGER H, 1991, J GEN VIROL, V72, P457, DOI 10.1099/0022-1317-72-2-457; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FARQUHAR CF, 1986, J GEN VIROL, V67, P463, DOI 10.1099/0022-1317-67-3-463; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; GAJDUSEK DC, 1990, VIROLOGY, P2289; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GULROY DC, 1991, ACTA NEUROPATHOL, V82, P87; HARRIS DA, 1993, P NATL ACAD SCI USA, V90, P4309, DOI 10.1073/pnas.90.9.4309; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HARRIS DA, 1986, CURR TOP MICROBIOL I, V207, P79; HART PD, 1975, NATURE, V256, P47, DOI 10.1038/256047a0; INGROSSO L, 1995, J VIROL, V69, P506, DOI 10.1128/JVI.69.1.506-508.1995; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KIMBERLIN RH, 1986, ANTIMICROB AGENTS CH, V30, P409, DOI 10.1128/AAC.30.3.409; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; LADOGANA A, 1992, J GEN VIROL, V73, P661, DOI 10.1099/0022-1317-73-3-661; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; POCCHIARI M, 1991, EUR J EPIDEMIOL, V7, P556, DOI 10.1007/BF00143139; PRIOLA SA, 1994, MOL NEUROBIOL, V8, P113, DOI 10.1007/BF02780661; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; REILAND J, 1993, J CELL SCI, V105, P1085; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; SHYNG SL, 1995, J BIOL CHEM, V270, P14793, DOI 10.1074/jbc.270.24.14793; SNOW AD, 1990, LAB INVEST, V63, P601; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TARABOULOS A, 1993, MOL BIOL CELL, V3, P851	50	168	177	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30221	30229						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530433				2022-12-25	WOS:A1995TK38000093
J	VALDENAIRE, O; ROHRBACHER, E; MATTEI, MG				VALDENAIRE, O; ROHRBACHER, E; MATTEI, MG			ORGANIZATION OF THE GENE ENCODING THE HUMAN ENDOTHELIN-CONVERTING ENZYME (ECE-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL ENDOPEPTIDASE; MOLECULAR-CLONING; CELLS; MAPS; ENKEPHALINASE; EXPRESSION; SEQUENCE; BINDING; PROTEIN	The two human endothelin-converting enzyme (ECE-1) isoforms, which differ by their N-terminal region, are encoded by a single gene. The gene is composed of 19 exons that span more than 68 kilobases and has been mapped 60 the 1p36 band of the human genome, The two isoform mRNAs display different tissue distributions, Their precursors are transcribed from two distinct start sites, upstream from exon 1 and exon 3, respectively. Sequence analysis of the two putative promoters revealed the presence of motifs characteristic for several transcription factors. Comparison of the ECE-1 gene structure with those of other zinc metalloproteases, as well as a phylogenetic study, confirm the existence of a metalloprotease subfamily composed of ECE-I, ECE-2, neutral endopeptidase, Kell blood group protein, and two bacterial enzymes.	HOP ENFANTS LA TIMONE, INSERM, U406, F-13385 MARSEILLE 05, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	VALDENAIRE, O (corresponding author), F HOFFMANN LA ROCHE & CO LTD, DIV PHARMA, PRECLIN RES, PRPV 69-348, GRENZACHERSTR 124, CH-4002 BASEL, SWITZERLAND.							BARKER PE, 1989, J IMMUNOL, V142, P283; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; CORDER R, 1995, BIOCHEM BIOPH RES CO, V207, P355, DOI 10.1006/bbrc.1995.1195; DADAMIO L, 1989, P NATL ACAD SCI USA, V86, P7103, DOI 10.1073/pnas.86.18.7103; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; IKURA T, 1994, BIOCHEM BIOPH RES CO, V203, P1417, DOI 10.1006/bbrc.1994.2343; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE S, 1995, BLOOD, V85, P1364, DOI 10.1182/blood.V85.5.1364.bloodjournal8551364; LEE S, 1993, BLOOD, V81, P2804; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; MAGNUSON MA, 1992, J CELL BIOCHEM, V48, P115, DOI 10.1002/jcb.240480202; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MIERAU I, 1993, J BACTERIOL, V175, P2087, DOI 10.1128/JB.175.7.2087-2096.1993; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; OMLAND T, 1994, CIRCULATION, V89, P1573, DOI 10.1161/01.CIR.89.4.1573; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER BW, 1993, GENOMICS, V17, P767; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; SEIFERT V, 1995, J NEUROSURG, V82, P55, DOI 10.3171/jns.1995.82.1.0055; SHIMADA K, 1995, BIOCHEM BIOPH RES CO, V207, P807, DOI 10.1006/bbrc.1995.1258; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; STEIN PD, 1994, J MED CHEM, V37, P329, DOI 10.1021/jm00029a001; STEWART EA, 1990, AM J HUM GENET, V46, P795; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; TAMURA T, 1994, CYTOGENET CELL GENET, V66, P132, DOI 10.1159/000133684; TEERLINK JR, 1994, CIRCULATION, V90, P2510, DOI 10.1161/01.CIR.90.5.2510; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WERNERT N, 1992, AM J PATHOL, V140, P119; WILLETTE RN, 1994, STROKE, V25, P2450, DOI 10.1161/01.STR.25.12.2450; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YORIMITSU K, 1995, BIOCHEM BIOPH RES CO, V208, P721, DOI 10.1006/bbrc.1995.1397	40	196	200	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29794	29798						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530372				2022-12-25	WOS:A1995TK38000032
J	Pitsillides, AA; Rawlinson, SCF; Suswillo, RFL; Bourrin, S; Zaman, G; Lanyon, LE				Pitsillides, AA; Rawlinson, SCF; Suswillo, RFL; Bourrin, S; Zaman, G; Lanyon, LE			Mechanical strain-induced NO production by bone cells: A possible role in adaptive bone (re)modeling?	FASEB JOURNAL			English	Article						bone; osteocytes; osteoblasts; nitric oxide; mechanical loading	NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; CANCELLOUS BONE; GAP-JUNCTIONS; CYCLIC-GMP; L-ARGININE; PROSTACYCLIN; RELEASE; STIMULATION; INVIVO	The structural competence of the skeleton is maintained by an adaptive mechanism in which resident bone cells respond to load-induced strains. To investigate the possible role of the messenger molecule nitric oxide (NO) in this response, we studied NO production in well-characterized organ culture systems, rat long bone-derived osteoblast-like (LOBs) cells, and embryonic chick osteocytes (LOCYs) in monolayer culture. In superfused cancellous bone cores, loading (for 15 min) produces increases in NO2- (stable NO metabolite) release during the loading period, which paralleled those in PGI(2) and PGE(2). Loading of rat vertebrae and ulnae produces increases in NO2- release, and in ulnae NO synthase inhibitors diminish these responses. Transient rapid increases in NO release are stimulated by strain hi both LOBs and LOCYs. Polymerase chain reaction amplification of extracted mRNA shows that rat ulnae, LOBs, and LOCYs express both the inducible anti neuronal (constitutive) isoforms of NO synthase. Adaptability to mechanical strain relies oil assessment of the strain environment followed by modification of bone architecture. Immediate increases in NO production induced by loading suggest the involvement of NO in strain measurement and cellular communication to establish strain distribution, as well as potentially in adaptive changes in bone cell behavior.			Pitsillides, AA (corresponding author), UNIV LONDON ROYAL VET COLL,DEPT VET BASIC SCI,32 BELGRAVE SQ,LONDON NW1 0TU,ENGLAND.			Rawlinson, Simon/0000-0003-2367-7391	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALBINA JE, 1993, J IMMUNOL, V150, P5080; BARON R, 1993, PHYSL PHARM BONE, P111; BINDERMAN I, 1988, CALCIFIED TISSUE INT, V42, P261, DOI 10.1007/BF02553753; BINDERMAN I, 1984, CALCIFIED TISSUE INT, V36, pS82, DOI 10.1007/BF02406139; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOURRIN S, 1994, J BONE MINER RES  S1, V9, pS255; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRIGHTON CT, 1991, J BONE JOINT SURG AM, V73A, P320, DOI 10.2106/00004623-199173030-00002; CHENG MZ, 1994, J BONE MINER RES, V9, P805; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW JWM, 1994, AM J PHYSIOL, V267, pE287, DOI 10.1152/ajpendo.1994.267.2.E287; DALLAS SL, 1993, J BONE MINER RES, V8, P251; DAMOULIS PD, 1994, BIOCHEM BIOPH RES CO, V201, P924, DOI 10.1006/bbrc.1994.1790; DAVIDOVITCH Z, 1977, CALC TISS RES, V24, P73, DOI 10.1007/BF02223299; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DODDS RA, 1994, J HISTOCHEM CYTOCHEM, V42, P599, DOI 10.1177/42.5.8157931; DONALDSON C L, 1970, Metabolism Clinical and Experimental, V19, P1071, DOI 10.1016/0026-0495(70)90032-6; DOTY SB, 1981, CALCIFIED TISSUE INT, V33, P509, DOI 10.1007/BF02409482; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FUKISHIMA O, 1991, J HISTOCHEM CYTOCHEM, V39, P529; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Howard G A, 1985, Prog Clin Biol Res, V187, P67; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; JEE WSS, 1987, BONE, V8, P171, DOI 10.1016/8756-3282(87)90017-2; JONES HH, 1977, J BONE JOINT SURG AM, V59, P204, DOI 10.2106/00004623-197759020-00012; JONES SJ, 1993, ANAT EMBRYOL, V187, P343; JONES SJ, 1977, CELL TISSUE RES, V184, P179; KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569; KAWASE T, 1993, J BONE MINER RES, V8, pS372; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LANYON LE, 1982, J BIOMECH, V15, P141, DOI 10.1016/0021-9290(82)90246-9; LANYON LE, 1993, CALCIFIED TISSUE INT, V53, pS102, DOI 10.1007/BF01673415; LINCOLN TM, 1989, PHARMACOL THERAPEUT, V41, P479, DOI 10.1016/0163-7258(89)90127-7; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWIK CWGM, 1994, J CLIN INVEST, V93, P1465, DOI 10.1172/JCI117124; MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MAYER B, 1986, BIOCHIM BIOPHYS ACTA, V875, P641, DOI 10.1016/0005-2760(86)90088-3; MESSMER UK, 1994, FEBS LETT, V355, P23; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURRAY DW, 1990, CALCIFIED TISSUE INT, V47, P35, DOI 10.1007/BF02555863; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEAD MJ, 1988, CALCIFIED TISSUE INT, V43, P92, DOI 10.1007/BF02555153; PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658; POHL U, 1991, AM J PHYSIOL, V261, pH2016, DOI 10.1152/ajpheart.1991.261.6.H2016; RALSTON SH, 1994, ENDOCRINOLOGY, V135, P330, DOI 10.1210/en.135.1.330; RAWLINSON SCF, 1993, CALCIFIED TISSUE INT, V53, P324, DOI 10.1007/BF01351837; RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345; RIANCHO JA, 1995, J BONE MINER RES, V10, P439; RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SHROR K, 1991, BASIC RES CARDIOL, V86, P117; SMITH EL, 1970, J BONE MINER RES, V6, P139; VANDERPLAS A, 1992, J BONE MINER RES, V7, P389; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; WALTER CL, 1987, FOOD ADDIT CONTAMIN, V6, P235; YEH CK, 1984, CALCIFIED TISSUE INT, V36, pS67, DOI 10.1007/BF02406136; ZAMAN G, 1994, J BONE MINER RES, V9, pS303	62	268	276	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	DEC	1995	9	15					1614	1622		10.1096/fasebj.9.15.8529841	http://dx.doi.org/10.1096/fasebj.9.15.8529841			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529841				2022-12-25	WOS:A1995TM76100015
J	GUNZL, A; CROSS, M; PALFI, Z; BINDEREIF, A				GUNZL, A; CROSS, M; PALFI, Z; BINDEREIF, A			ASSEMBLY OF THE U2 SMALL NUCLEAR RIBONUCLEOPROTEIN FROM TRYPANOSOMA-BRUCEI - A MUTATIONAL ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SPLICED LEADER; STRUCTURAL ORGANIZATION; PROTEIN-COMPONENTS; SNRNP; U1; PARTICLES; U4; IDENTIFICATION; PURIFICATION	trans-Splicing in trypanosomes requires the functions of U2 and U4/U6 small nuclear (sn) RNPs. We have analyzed protein binding and assembly of the Trypanosoma brucei U2 snRNP, using specific antibodies against U2 snRNP proteins and in vitro reconstitution assays of U2 deletion derivatives and human-trypanosome hybrid RNAs. Stable binding of both the U2-specific 40-kDa and the common proteins requires only the 3'-terminal domain (stem-loop IIb, single-stranded region, and stem-loop IV), with loop IV providing the critical sequence determinant; stem-loop IV suffices for binding of the 40 kDa-protein, but not of the common proteins; surprisingly, the sequence of the ''Sm-analogous'' single-stranded region between stem-loops IIb and IV is not essential for protein binding. Our mutational analysis further indicates that interactions between common and specific proteins play an important role in the assembly of a stable core complex. Finally, a partially assembled U2 RNP complex could be identified as a kinetic intermediate of U2 snRNP assembly. We propose a model of the domain structure and assembly of the trans-spliceosomal U2 snRNP, which deviates in several aspects from that of the cis-spliceosomal U2 snRNP; these differences may be related to the trans-splicing-specific functions of the trypanosomal U2 snRNP.	MAX PLANCK INST MOLEC GENET, OTTO WARBURG LAB, IHNESTR 73, W-1000 BERLIN 33, GERMANY	Max Planck Society				Gunzl, Arthur/0000-0002-7487-2261				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BINDEREIF A, 1987, EMBO J, V6, P2415, DOI 10.1002/j.1460-2075.1987.tb02520.x; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P455, DOI 10.1093/nar/19.3.455; BRANLANT C, 1982, EMBO J, V1, P1259, DOI 10.1002/j.1460-2075.1982.tb00022.x; BRUN R, 1979, ACTA TROP, V36, P289; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CROSS M, 1991, MOL CELL BIOL, V11, P5516, DOI 10.1128/MCB.11.11.5516; CROSS M, 1993, EMBO J, V12, P1239, DOI 10.1002/j.1460-2075.1993.tb05765.x; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; GUNZL A, 1992, MOL CELL BIOL, V12, P468; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HARTSHORNE T, 1990, GENE DEV, V4, P2121, DOI 10.1101/gad.4.12a.2121; JARMOLOWSKI A, 1993, EMBO J, V12, P223, DOI 10.1002/j.1460-2075.1993.tb05648.x; LAMOND AI, 1989, CELL, V58, P383, DOI 10.1016/0092-8674(89)90852-0; LIAUTARD JP, 1982, J MOL BIOL, V162, P623, DOI 10.1016/0022-2836(82)90392-8; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1986, EMBO J, V5, P997, DOI 10.1002/j.1460-2075.1986.tb04314.x; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MIRAGLIA L, 1991, P NATL ACAD SCI USA, V88, P7061, DOI 10.1073/pnas.88.16.7061; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; NILSEN TW, 1992, INFECT AGENT DIS, V1, P212; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; PALFI Z, 1992, J BIOL CHEM, V267, P20159; PALFI Z, 1991, P NATL ACAD SCI USA, V88, P9097, DOI 10.1073/pnas.88.20.9097; REVEILLAUD I, 1984, MOL CELL BIOL, V4, P1890, DOI 10.1128/MCB.4.9.1890; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; TSCHUDI C, 1990, GENE, V91, P71, DOI 10.1016/0378-1119(90)90164-M; TSCHUDI C, 1986, NUCLEIC ACIDS RES, V14, P8893, DOI 10.1093/nar/14.22.8893; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; TSCHUDI C, 1988, NUCLEIC ACIDS RES, V16, P11375, DOI 10.1093/nar/16.23.11375; VANDOREN K, 1988, NATURE, V335, P556; WATKINS KP, 1991, GENE DEV, V5, P1859, DOI 10.1101/gad.5.10.1859; WERSIG C, 1992, MOL CELL BIOL, V12, P1460, DOI 10.1128/MCB.12.4.1460; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WU JA, 1992, MOL CELL BIOL, V12, P5464, DOI 10.1128/MCB.12.12.5464	42	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13336	13343						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514772				2022-12-25	WOS:A1993LH55300048
J	SAWADA, R; JARDINE, KA; FUKUDA, M				SAWADA, R; JARDINE, KA; FUKUDA, M			THE GENES OF MAJOR LYSOSOMAL MEMBRANE-GLYCOPROTEINS LAMP-1 AND LAMP-2 - THE 5'-FLANKING SEQUENCE OF LAMP-2 GENE AND COMPARISON OF EXON ORGANIZATION IN 2 GENES (VOL 268, PG 9014, 1993)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction, Addition																		SAWADA R, 1993, J BIOL CHEM, V268, P9014	1	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					13010	13010						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509432				2022-12-25	WOS:A1993LG65800114
J	Lacerda, HM; Lax, AJ; Rozengurt, E				Lacerda, HM; Lax, AJ; Rozengurt, E			Pasteurella multocida toxin, a potent intracellularly acting mitogen, induces p125(FAK) and paxillin tyrosine phosphorylation, actin stress fiber formation, and focal contact assembly in Swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADHESION KINASE; MONOCLONAL-ANTIBODIES; BOMBESIN STIMULATION; PARTIAL-PURIFICATION; DERMONECROTIC TOXIN; BACTERIAL TOXINS; ESCHERICHIA-COLI; MAJOR SUBSTRATE; GROWTH-FACTORS	Treatment of Swiss 3T3 cells with recombinant Pasteurella multocida toxin (rPMT), a potent intracellularly acting mitogen, stimulated tyrosine phosphorylation of multiple substrates including bands of M(r) 110,000-130,000 and M(r) 70,000-80,000. Tyrosine phosphorylation induced by rPMT occurred after a pronounced lag period (1 h) and was blocked by either lysosomotrophic agents or incubation at 22 degrees C. Focal adhesion kinase (p125(FAK)) and paxillin are prominent substrates for rPMT-stimulated tyrosine phosphorylation, Tyrosine phosphorylation by rPMT could be dissociated from both protein kinase C activation and the mobilization of calcium from intracellular stores. rPMT stimulated striking actin stress fiber formation and focal adhesion assembly in Swiss 3T3 cells, Cytochalasin D, which disrupts the actin cytoskeleton, completely inhibited rPMT-induced tyrosine phosphorylation, In addition, tyrosine phosphorylation of p125(FAK) and paxillin in response to rPMT was completely abolished when cells were subsequently treated with platelet-derived growth factor at a concentration (30 ng/ml) that disrupted the actin cytoskeleton, Our results demonstrate for the first time that rPMT, a bacterial toxin, induces tyrosine phosphorylation of p125(FAK) and paxillin and promotes actin stress fiber formation and focal adhesion assembly in Swiss 3T3 cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; AFRC,INST ANIM HLTH,NEWBURY RG20 7NN,BERKS,ENGLAND	Cancer Research UK; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute								AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANN REV CELL BIOL, V7, P337; BUYS WECM, 1990, NUCLEIC ACIDS RES, V18, P2815, DOI 10.1093/nar/18.9.2815; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; CHANTER N, 1986, J GEN MICROBIOL, V132, P1089; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FALKOW S, 1992, ANNU REV CELL BIOL, V8, P333, DOI 10.1146/annurev.cb.08.110192.002001; FOGED NT, 1988, INFECT IMMUN, V56, P1901, DOI 10.1128/IAI.56.8.1901-1906.1988; FOGED NT, 1987, FEMS MICROBIOL LETT, V43, P45, DOI 10.1111/j.1574-6968.1987.tb02095.x; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LAX AJ, 1990, J GEN MICROBIOL, V136, P81, DOI 10.1099/00221287-136-1-81; LAX AJ, 1990, FEBS LETT, V277, P59, DOI 10.1016/0014-5793(90)80809-W; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOPEZRIVAS A, 1982, P NATL ACAD SCI-BIOL, V79, P6275, DOI 10.1073/pnas.79.20.6275; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; MURPHY AC, 1992, J BIOL CHEM, V267, P25296; NAKAI T, 1984, INFECT IMMUN, V46, P429, DOI 10.1128/IAI.46.2.429-434.1984; NEVILLE DM, 1986, ANNU REV BIOCHEM, V55, P195, DOI 10.1146/annurev.biochem.55.1.195; Olsnes S., 1988, IMMUNOTOXINS, P39; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; PETERSEN SK, 1989, INFECT IMMUN, V57, P3907, DOI 10.1128/IAI.57.12.3907-3913.1989; PETTIT RK, 1995, LAB INVEST, V69, P94; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1995, CANCER SURV, V24, P81; ROZENGURT E, 1983, P NATL ACAD SCI USA, V80, P7224; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SMYTH MG, 1995, FEBS LETT, V360, P62, DOI 10.1016/0014-5793(95)00077-M; SMYTHE E, 1989, J CELL BIOL, V108, P843, DOI 10.1083/jcb.108.3.843; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STADDON JM, 1990, J BIOL CHEM, V265, P11841; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; TURNER CE, 1994, J CELL SCI, V107, P1583; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VUORI K, 1993, J BIOL CHEM, V268, P21459; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	64	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					439	445		10.1074/jbc.271.1.439	http://dx.doi.org/10.1074/jbc.271.1.439			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550600	hybrid			2022-12-25	WOS:A1996TP36100068
J	Lee, TC; Ou, MC; Shinozaki, K; Malone, B; Snyder, F				Lee, TC; Ou, MC; Shinozaki, K; Malone, B; Snyder, F			Biosynthesis of N-acetylsphingosine by platelet-activating factor: Sphingosine CoA-independent transacetylase in HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-LABILE FACTOR; PROTEIN KINASE-C; CHOLESTEROL ACYLTRANSFERASE; HUMAN-PLASMA; FACTOR PAF; SIGNAL TRANSDUCTION; RAT SPLEEN; 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; CERAMIDE; ACETYLHYDROLASE	We have previously identified a novel CoA-independent transacetylase in the membrane fraction of HL-60 cells that transfers the acetate group from platelet activating factor (PAF) to a variety of lysophospholipid accepters (Lee, T.-c., Uemura, Y., and Snyder, F. (1992) J. Biol. Chem. 267, 19992-20001). In the present study, we demonstrate that a similar transacetylase can transfer the acetate group from PAF to sphingosine forming N-acetylsphingosine (C-2-ceramide). The chemical structure of the reaction product, C-2-ceramide, was established by its identical R(f) value with authentic C-2-ceramide standard on thin-layer plate, sensitivity to acid treatment, resistance to alkaline hydrolysis, and ability to form the C-2-ceramide dibenzoate derivative. Nonspecific transfer of the acetate from PAF to sphingosine in the absence of enzyme and nonlinearity of the reaction rates were rectified by complexing sphingosine to bovine serum albumin in a 1:1 molar ratio. Under these conditions, the apparent K-m for PAF is 5.4 mu M, which is in the same range as the K-m (12.0 mu M) when lysoplasmalogen is the acetate acceptor. PAF:sphingosine transacetylase has a narrow substrate specificity and strict stereochemical configuration requirements. Ceramide, sphingosylphosphocholine, stearylamine, sphingosine 1-phosphate, or sphingomyelin are not substrates, whereas sphinganine has a limited capacity to accept the acetate from PAF. Also, only the naturally synthesized D-erythroisomer but not the synthetic L-erythro, D-threo-, or L-threoisomers of sphingosine can serve as a substrate. PAF transacetylase activity is widely distributed among several tissues and may involve histidine and cysteine for its catalytic activity due to inhibitory effects to the enzyme by diethyl pyrocarbonate and N-ethylmaleimide, respectively. C-2-ceramide is produced via PAF:sphingosine transacetylase, and physiological levels of C-2-ceramide are detected in both undifferentiated and differentiated intact HL-60 cells. Collectively, because C-2-ceramide has many biological activities that differ from that of PAF and sphingosine, the CoA-independent, PAF-dependent transacetylase serves as a modifier of PAF, and sphingosine functions by generating a variant lipid mediator, C-2-ceramide.			Lee, TC (corresponding author), OAK RIDGE ASSOCIATED UNIV,OAK RIDGE INST SCI & EDUC,DIV MED RES,POB 117,OAK RIDGE,TN 37831, USA.				NHLBI NIH HHS [HL27109-14] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL027109] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berdyshev E V, 1991, Biomed Sci, V2, P485; BLANK ML, 1983, ANAL BIOCHEM, V133, P430, DOI 10.1016/0003-2697(83)90105-7; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLANK ML, 1983, BIOCHEM BIOPH RES CO, V113, P666, DOI 10.1016/0006-291X(83)91778-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHUNG J, 1979, J BIOL CHEM, V254, P7456; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DIXON M, 1964, ENZYMES, P81; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; FARR RS, 1983, FED PROC, V42, P3120; FUJINO Y, 1962, J BIOL CHEM, V237, P2069; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GLOMSET JA, 1972, BLOOD LIPIDS LIPOPRO, P745; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HANAHAN DJ, 1992, CURR TOP CELL REGUL, V33, P65; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1993, ADV LIPID RES, V25, P27; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; KATES M, 1986, TECHNIQUES LIPIDOL 2, V3, P132; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LADINSKY JL, 1967, CANCER RES, V27, P1689; LEE TC, 1985, J BIOL CHEM, V260, P952; LEE TC, 1988, J BIOL CHEM, V263, P1755; LEE TC, 1986, J BIOL CHEM, V261, P5373; LEE TC, 1992, J BIOL CHEM, V267, P19992; LIU M, 1994, P NATL ACAD SCI USA, V91, P6035, DOI 10.1073/pnas.91.13.6035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; MARCEL YL, 1980, P NATL ACAD SCI-BIOL, V77, P2969, DOI 10.1073/pnas.77.5.2969; MARCEL YL, 1982, ADV LIPID RES, V19, P85; MAVIS RD, 1972, J BIOL CHEM, V247, P2835; MERRILL AH, 1991, J BIOENERG BIOMEMBR, V23, P83; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; NIETO ML, 1991, J BIOL CHEM, V266, P18699; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RAINES MA, 1993, J BIOL CHEM, V268, P14572; RENOOIJ W, 1981, BIOCHIM BIOPHYS ACTA, V663, P545, DOI 10.1016/0005-2760(81)90182-X; SHUKLA SD, 1992, FASEB J, V6, P2296, DOI 10.1096/fasebj.6.6.1312046; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; SNYDER F, 1992, PROG LIPID RES, V31, P65, DOI 10.1016/0163-7827(92)90016-C; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VENABLE ME, 1993, J LIPID RES, V34, P691; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; WOLF RA, 1985, J LIPID RES, V26, P629; WONG K, 1995, J BIOL CHEM, V270, P3056, DOI 10.1074/jbc.270.7.3056; WOODARD DS, 1987, J BIOL CHEM, V262, P2520; WYKLE RL, 1980, J BIOL CHEM, V255, P256; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	59	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					209	217		10.1074/jbc.271.1.209	http://dx.doi.org/10.1074/jbc.271.1.209			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550561				2022-12-25	WOS:A1996TP36100033
J	Lin, X; Dotson, DG; Putkey, JA				Lin, X; Dotson, DG; Putkey, JA			Covalent binding of peptides to the N-terminal hydrophobic region of cardiac troponin C has limited effects on function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE TROPONIN; NUCLEAR-MAGNETIC-RESONANCE; CONFORMATIONAL TRANSITION; CROSS-LINKING; CALCIUM; CALMODULIN; COMPLEX; SITES; FLUORESCENCE; AFFINITY	Exposure of an N-terminal hydrophobic region in troponin C is thought to be important for the regulation of contraction in striated muscle, To test this hypothesis, single Cys residues were engineered at positions 45, 81, 84, or 85 in the N-terminal hydrophobic region of cardiac troponin C (cTnC) to provide specific sites for attachment of blocking groups, A synthetic peptide, Ac-Val-Arg-Ala-Ile-Gly-Lys-Leu-Ser-Ser, or biotin was coupled to these Cys residues, and the covalent adducts were tested for activity in TnC-extracted myofibrils. Covalent modification of cTnC(C45) had no effect on maximal myofibril ATPase activity. Greatly decreased myofibril ATPase activity (70-80% inhibited) resulted when the peptide was conjugated to Cys-81 in cTnC(C81), while a lesser degree of inhibition (10-25% inhibited) resulted from covalent modification of cTnC(C84) and cTnC(C85), Inhibition was not due to an altered affinity of the cTnC(C81)/peptide conjugate for the myofibrils, and the Ca2+ dependence of ATPase activity was essentially identical to tire unmodified protein. Thus, a subregion of the N-terminal hydrophobic region in cTnC is sensitive to disruption, while other regions are less important or can adapt to rather bulky blocking groups. The data suggest that Ca2+-sensitizing drugs may bind to the N-terminal hydrophobic region on cTnC but not interfere with transmission of the Ca2+ signal.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045724] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45724] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRITO RMM, 1991, BIOCHEMISTRY-US, V30, P10236, DOI 10.1021/bi00106a023; DASILVA ACR, 1993, EUR J BIOCHEM, V213, P599; DOTSON DG, 1993, J BIOL CHEM, V268, P24067; ELSALEH SC, 1987, J BIOL CHEM, V262, P17240; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HOWARTH JW, 1995, PROTEIN SCI, V4, P671; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; KOBAYASHI T, 1995, BIOCHEMISTRY-US, V34, P10946, DOI 10.1021/bi00034a029; KUREBAYASHI N, 1988, J PHYSIOL-LONDON, V403, P407, DOI 10.1113/jphysiol.1988.sp017256; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P6983, DOI 10.1021/bi00418a047; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; LIN X, 1994, BIOCHEMISTRY-US, V33, P14434, DOI 10.1021/bi00252a009; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; NEGELE JC, 1992, J BIOL CHEM, V267, P825; NGAI SM, 1994, J BIOL CHEM, V269, P2165; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P12800, DOI 10.1021/bi00209a011; PEARLSTONE JR, 1992, BIOCHEMISTRY-US, V31, P6545, DOI 10.1021/bi00143a026; POLLESELLO P, 1994, J BIOL CHEM, V269, P28584; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; PUTKEY JA, 1993, J BIOL CHEM, V268, P6827; REID DG, 1990, J BIOL CHEM, V265, P9744; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SHENG ZL, 1990, J BIOL CHEM, V265, P21554; SLUPSKY CM, 1992, PROTEIN SCI, V1, P1595, DOI 10.1002/pro.5560011207; SOLARO RJ, 1986, J PHARMACOL EXP THER, V238, P502; SWENSON CA, 1992, BIOCHEMISTRY-US, V31, P3420, DOI 10.1021/bi00128a017; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; WANG ZY, 1990, J BIOL CHEM, V265, P4953; WANG ZY, 1992, P NATL ACAD SCI USA, V89, P11814, DOI 10.1073/pnas.89.24.11814; ZOT HG, 1982, J BIOL CHEM, V257, P7678	38	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					244	249		10.1074/jbc.271.1.244	http://dx.doi.org/10.1074/jbc.271.1.244			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550567	hybrid			2022-12-25	WOS:A1996TP36100038
J	Skiba, NP; Bae, H; Hamm, HE				Skiba, NP; Bae, H; Hamm, HE			Mapping of effector binding sites of transducin alpha-subunit using G alpha(t)/G alpha(i1) chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; G-PROTEIN-ALPHA; NUCLEOTIDE REGULATORY PROTEINS; AMINO-ACID SEQUENCE; CGMP-PHOSPHODIESTERASE; GAMMA-SUBUNIT; RETINAL RODS; MOLECULAR MECHANISM; INHIBITORY SUBUNIT	The G protein transducin has been an often-used model for biochemical, structural, and mechanistic studies of G protein function, Experimental studies have been limited, however, by the inability to express quantities of mutants in heterologous systems with ease. In this study we have made a series of G alpha(t)/G alpha(i1) chimeras differing at as few as 11 positions from native G alpha(t). Ten chimeras are properly folded, contain GDP, can assume an AlF4--induced activated conformation, and interact with beta gamma(t) and light-activated rhodopsin. They differ dramatically in their affinity for GDP, from G(i)-like (initial rates 225 mu mol/mol s) to G(t)-like (initial rates 4.9 mu mol/mol s). We have used these chimeras to define contact sites on G alpha(t) with the effector enzyme cGMP phosphodiesterase. G alpha(t)GTP but not G alpha(t)GDP activates it by removing the phosphodiesterase (PDE) gamma inhibitory subunit, In solution, G alpha(t)GTP interacts with PDE gamma (K-d 12 nM), while G alpha(t)GDP binds PDE gamma more weakly (K-d 0.88 mu M). The interaction of G alpha(i)GDP with PDE gamma is undetectable, but G alpha(i)GDP-AlF4- interacts weakly with PDE gamma (K-d 2.4 mu M) Using defined G alpha(t)/G alpha(i) chimeras, we have individuated the regions on G alpha(t) most important for interaction with PDE gamma in the basal and activated states, The G alpha(t), sequence encompassing alpha helix 3 and the alpha 3/beta 5 loop contributes most binding energy to interaction with PDE gamma. Another composite P gamma interaction site is the conserved switch, through which the GTP-bound G alpha(t) as well as G alpha(i1) interact with P gamma. Competition studies between PDE gamma and truncated regions of PDE gamma provide evidence for the point-to point interactions between the two proteins, The amino-terminal 1-45 segment containing the central polycationic region binds to G alpha(t)'s alpha 3 helix and alpha 3/beta 5 loop, while the COOH-terminal region of P gamma, 63-87, binds in concert to the conserved switch regions. The first interaction provides specific interaction with both the GDP- and GTP-liganded G alpha(t), while the second one is conserved between G alpha(t) and G alpha(i1) and dependent on the activated conformation.	UNIV ILLINOIS,COLL MED,DEPT PHYSIOL & BIOPHYS,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Hamm, Heidi E/G-2374-2014; Bae, Hyunsu/ABH-6248-2020	Bae, Hyunsu/0000-0002-0299-3582	PHS HHS [12092] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BRUCKERT F, 1994, BIOCHEMISTRY-US, V33, P12625, DOI 10.1021/bi00208a013; CATTY P, 1992, J BIOL CHEM, V267, P19489; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CLERC A, 1992, J BIOL CHEM, V267, P6620; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CUNNICK J, 1994, BIOCHEM J, V297, P87, DOI 10.1042/bj2970087; DENKER BM, 1992, J BIOL CHEM, V267, P9998; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; ERICKSON JW, 1995, BIOCHEMISTRY-US, V34, P8693, DOI 10.1021/bi00027a019; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; ILRL T, 1994, NATURE, V371, P164; ITOH H, 1991, J BIOL CHEM, V266, P16226; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KUTUZOV M, 1994, EUR J BIOCHEM, V220, P963, DOI 10.1111/j.1432-1033.1994.tb18700.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEE E, 1994, METHOD ENZYMOL, V237, P146; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; LINDER ME, 1990, J BIOL CHEM, V265, P8243; Lipkin V M, 1990, Biomed Sci, V1, P305; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NUKADA T, 1986, FEBS LETT, V197, P305, DOI 10.1016/0014-5793(86)80347-7; OSAWA S, 1990, MOL CELL BIOL, V10, P2931, DOI 10.1128/MCB.10.6.2931; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; OTTOBRUC A, 1994, FEBS LETT, V343, P183, DOI 10.1016/0014-5793(94)80552-0; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; PHILLIPS WJ, 1988, J BIOL CHEM, V263, P15498; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; TANG WJ, 1992, COLD SPRING HARB SYM, V57, P135, DOI 10.1101/SQB.1992.057.01.017; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	65	144	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					413	424		10.1074/jbc.271.1.413	http://dx.doi.org/10.1074/jbc.271.1.413			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550597	hybrid			2022-12-25	WOS:A1996TP36100065
J	Fromm, L; Overbeek, PA				Fromm, L; Overbeek, PA			Regulation of cyclin and cyclin-dependent kinase gene expression during lens differentiation requires the retinoblastoma protein	ONCOGENE			English	Article						retinoblastoma; cell cycle; cyclins; cyclin-dependent kinases; lens; crystallins	CELL-CYCLE; PRODUCT; PHOSPHORYLATION; MOUSE; IDENTIFICATION; ACTIVATION	The retinoblastoma protein (pRb) functions as a negative regulator of the cell cycle and is essential to maintain certain cell types in a post-mitotic state during terminal differentiation. In the ocular lens, inactivation of this protein is sufficient to cause lens fiber cells, which are normally post-mitotic, to enter the cell cycle. The current studies address whether regulation of the cell cycle during lens fiber differentiation in normal lenses or in lenses in which pRB has been inactivated is accompanied by changes in expression of cyclin and cyclin-dependent kinase genes. In the normal lens, our experiments using in-situ hybridization reveal that the expression of cyclin A, cyclin B1, cdc2 and cdk2 is restricted to the proliferative epithelial cells, with no expression in the differentiating fiber cells. Cyclins D1 and D2 and cdk4 show a less restrictive pattern and are expressed in some of the post-mitotic cells. Lenses from RB-deficient embryos, in contrast, show inappropriate expression in the fiber cells of cyclins A, B1 and E, as well as cdc2 and cdk2. The lens fiber cells in these embryos express protein markers for differentiation, such as beta- and gamma-crystallins, even though the cells do not withdraw from the cell cycle. These results indicate that the regulated expression of multiple cell cycle regulatory genes during lens fiber cell differentiation requires the presence of pRb.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT OPHTHALMOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine				Overbeek, Paul/0000-0001-9784-2084				CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; CHAPMAN DL, 1992, MOL REPROD DEV, V33, P259, DOI 10.1002/mrd.1080330305; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DAMJANOV I, 1994, BIOCHEM BIOPH RES CO, V201, P994, DOI 10.1006/bbrc.1994.1800; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; ISHII T, 1993, EXP CELL RES, V208, P407, DOI 10.1006/excr.1993.1262; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; KATO J, 1993, GENE DEV, V7, P331; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; SPURR NK, 1990, J DNA SEQUENCING MAP, V1, P49; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	40	44	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					69	75						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552401				2022-12-25	WOS:A1996TQ01400009
J	Arruda, LK; Vailes, LD; Hayden, ML; Benjamin, DC; Chapman, MD				Arruda, LK; Vailes, LD; Hayden, ML; Benjamin, DC; Chapman, MD			Cloning of cockroach allergen, Bla g 4, identifies ligand binding proteins (or calycins) as a cause of IgE antibody responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO HORNWORM; MAJOR ALLERGEN; MANDUCA-SEXTA; RISK-FACTORS; DUST MITE; ASTHMA; PURIFICATION; PHEROMONE; HYPERSENSITIVITY; SENSITIZATION	An allergen cloned from a Blattella germanica (German cockroach) cDNA library, encoded a 182-amino acid protein of 20,904 Da. This protein, designated B. germanica allergen 4 (Bla g 4), was expressed as a glutathione S-transferase fusion protein in Escherichia coli and purified by affinity chromatography and high-performance liquid chromatography. The prevalence of serum IgE antibody to recombinant Bla g 4 in 73 cockroach allergic patients with asthma ranged from 40% (antigen binding radioimmunoassay) to 60% (plaque immunoassay). Cockroach allergic patients gave positive intradermal skin tests to recombinant Bla g 4 at concentrations of 10(-3)-10(-5) mu g/ml, whereas non-allergic controls, or cockroach allergic patients with no detectable serum IgE antibody to Bla g 4, gave negative skin tests to 1 mu g/ml. Polymerase chain reaction and Southern analysis identified a 523-base pair DNA encoding Bla g 4 in both B. germanica and Periplaneta americana (American cockroach). However, Northern analysis showed that mRNA encoding Bla g 4 was transcribed in B. germanica but not in P. americana, suggesting that allergen expression was species specific. Sequence similarity searches showed that Bla g 4 was a ligand binding protein or calycin and unexpectedly revealed that this family contained several important allergens: beta-lactoglobulin, from cow milk, and rat and mouse urinary proteins. Although the overall sequence homology between these proteins was low (similar to 20%), macromolecular modeling techniques were used to generate two models of the tertiary structure of Bla g 4, based on comparisons with the x-ray crystal coordinates of bilin binding protein and rodent urinary proteins. The results show that members of the calycin protein family can cause IgE antibody responses by inhalation or ingestion and are associated with asthma and food hypersensitivity.	UNIV VIRGINIA, HLTH SCI CTR, DEPT INTERNAL MED, ASTHMA & ALLERG DIS CTR, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia			Arruda, L. Karla/D-5845-2013	Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632	NIAID NIH HHS [AI 34607, AI 32557] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034607, R01AI032557, U19AI034607] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARRUDA LK, 1992, J IMMUNOL, V149, P3354; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; BALL G, 1994, CLIN EXP ALLERGY, V24, P758, DOI 10.1111/j.1365-2222.1994.tb00987.x; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; BRUCCOLERI RE, 1987, BIOPOLYMERS, V26, P137, DOI 10.1002/bip.360260114; BRUCCOLERI RE, 1988, NATURE, V335, P564, DOI 10.1038/335564a0; Burge H, 1993, INDOOR ALLERGENS ASS; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; DANDEU JP, 1995, J ALLERGY CLIN IMMUN, V95, P348; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GURKA G, 1989, J ALLERGY CLIN IMMUN, V83, P945, DOI 10.1016/0091-6749(89)90110-3; HELM RM, 1988, INT ARCH ALLER A IMM, V87, P230, DOI 10.1159/000234678; HELM RM, 1995, J ALLERGY CLIN IMMUN, V95, P158; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUBER R, 1987, J MOL BIOL, V195, P423, DOI 10.1016/0022-2836(87)90661-9; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; KOZNIECZNY A, 1995, J ALLERGY CLIN IMMUN, V95, P161; KRIEGER J, 1993, INSECT BIOCHEM MOLEC, V23, P449, DOI 10.1016/0965-1748(93)90052-T; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; LI WC, 1992, EUR J BIOCHEM, V205, P491, DOI 10.1111/j.1432-1033.1992.tb16805.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERVAIZ S, 1985, SCIENCE, V228, P335, DOI 10.1126/science.2580349; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; PRESTWICH GD, 1987, SCIENCE, V237, P999, DOI 10.1126/science.3616631; PRESTWICH GD, 1993, ARCH INSECT BIOCHEM, V22, P75, DOI 10.1002/arch.940220108; Sakaguchi Masahiro, 1994, Japanese Journal of Allergology, V43, P1309; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER L, 1987, NATURE, V327, P659, DOI 10.1038/327659a0; SCHAL C, 1983, J INSECT PHYSIOL, V29, P575, DOI 10.1016/0022-1910(83)90023-9; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANKUS RP, 1990, J ALLERGY CLIN IMMUN, V86, P781, DOI 10.1016/S0091-6749(05)80183-6; STEINBERG DR, 1987, J ALLERGY CLIN IMMUN, V80, P586, DOI 10.1016/0091-6749(87)90012-1; STEWART GA, 1992, IMMUNOLOGY, V75, P29; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; VAILES L, 1990, Journal of Allergy and Clinical Immunology, V85, P171; VAILES LD, 1995, J ALLERGY CLIN IMMUN, V95, P347; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1; WU CH, 1995, J ALLERGY CLIN IMMUN, V96, P352, DOI 10.1016/S0091-6749(95)70054-4	51	127	137	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31196	31201		10.1074/jbc.270.52.31196	http://dx.doi.org/10.1074/jbc.270.52.31196			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537384	hybrid			2022-12-25	WOS:A1995TN44400052
J	Saturno, J; Blanco, L; Salas, M; Esteban, JA				Saturno, J; Blanco, L; Salas, M; Esteban, JA			A novel kinetic analysis to calculate nucleotide affinity of proofreading DNA polymerases - Application to phi 29 DNA polymerase fidelity mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; REVERSE-TRANSCRIPTASE; REPLICATION FIDELITY; CONSERVED REGION; KLENOW FRAGMENT; I KLENOW; MECHANISM; BINDING; ALPHA; EXONUCLEASE	Amino acids Tyr(254) and Tyr(390) of phi 29 DNA polymerase belong to one of the most conserved regions in eukaryotic-type DNA polymerases, In this paper we report a mutational study of these two residues to address their role in nucleotide selection, This study was carried out by means of a new kinetic analysis that takes advantage of the competition between DNA polymerization and 3' --> 5' exonuclease activity to measure the K-m values for correct and incorrect nucleotides in steady-state conditions, This method is valid for any 3' --> 5' exonucleasecontaining DNA polymerase, without any restriction concerning catalytic rates of nucleotide incorporation. The results showed that the discrimination factor achieved by phi 29 DNA polymerase in the nucleotide binding step of DNA polymerization is 2.4 x 10(3), that is, a wrong nucleotide is bound with a 2.4 x 10(3)-fold lower affinity than the correct one, Mutants Y254F, Y390F, and Y390S showed discrimination values of 7.0 x 10(2), > 1.9 x 10(3), and 2.9 x 10(2), respectively. The reduced accuracy of nucleotide binding produced by mutations Y254F and Y390S lead us to propose that phi 29 DNA polymerase residues Tyr(254) and Tyr(390), highly conserved in eukaryotic-type DNA polymerases, are involved in nucleotide binding selection, thus playing a crucial role in the fidelity of DNA replication. Comparison of the discrimination factors of mutants Y390S and Y390F strongly suggests that the phenyl ring of Tyr(390) is directly involved in checking base-pairing correctness of the incoming nucleotide.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Blanco, Luis/I-1848-2015; Esteban, Jose/L-4944-2014; Salas, Margarita/J-9873-2014	Esteban, Jose/0000-0002-3759-3300; Salas, Margarita/0000-0001-5939-3441	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 R01 GM27242-16] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BAKHANASHVILI M, 1992, FEBS LETT, V306, P151, DOI 10.1016/0014-5793(92)80988-S; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; Blanco L, 1995, METHOD ENZYMOL, V262, P283; BLASCO MA, 1992, J BIOL CHEM, V267, P19427; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; CREIGHTON S, 1995, J BIOL CHEM, V270, P4759, DOI 10.1074/jbc.270.9.4759; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONG Q, 1993, J BIOL CHEM, V268, P24163; DONG Q, 1993, J BIOL CHEM, V268, P24175; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; DONLIN MJ, 1994, BIOCHEMISTRY-US, V33, P14908, DOI 10.1021/bi00253a030; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; ELDEIRY WS, 1988, BIOCHEMISTRY-US, V27, P546, DOI 10.1021/bi00402a007; ESTEBAN JA, 1993, J BIOL CHEM, V268, P2719; HALL ZW, 1968, J MOL BIOL, V36, P321, DOI 10.1016/0022-2836(68)90158-7; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; KATI WM, 1992, J BIOL CHEM, V267, P25988; KHAN NN, 1994, NUCLEIC ACIDS RES, V22, P232, DOI 10.1093/nar/22.2.232; Kornberg A., 1992, DNA REPLICATION; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUNKEL TA, 1992, J BIOL CHEM, V267, P18251; LAZARO JM, 1995, METHOD ENZYMOL, V262, P283; LOEB LA, 1982, ANNU REV BIOCHEM, V52, P429; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; TRAUTNER TA, 1962, P NATL ACAD SCI USA, V48, P449, DOI 10.1073/pnas.48.3.449; VARELAECHAVARRIA A, 1992, J BIOL CHEM, V267, P24681; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	39	25	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31235	31243		10.1074/jbc.270.52.31235	http://dx.doi.org/10.1074/jbc.270.52.31235			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537389	hybrid			2022-12-25	WOS:A1995TN44400057
J	Venable, ME; Lee, JY; Smyth, MJ; Bielawska, A; Obeid, LM				Venable, ME; Lee, JY; Smyth, MJ; Bielawska, A; Obeid, LM			Role of ceramide in cellular senescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; SPHINGOMYELIN TURNOVER; DIFFERENTIATION; CELLS; GROWTH; TRANSCRIPTION; ALPHA	Recently the sphingomyelin cycle, involving the hydrolysis of membrane sphingomyelin by an activated sphingomyelinase to generate ceramide, has emerged as a key pathway in cell differentiation and apoptosis in leukemic and other cell types. Here we investigate a role for this pathway in the senescence of WI-38 human diploid fibroblasts (HDF), We found that endogenous levels of ceramide increased considerably (4-fold) and specifically (compared with other lipids) as cells entered the senescent phase. Investigation of the mechanism of increased ceramide led to the discovery that neutral sphingomyelinase activity is elevated 8-10 fold in senescent cells. There were no changes in sphingomyelinase activity or ceramide levels as HDF entered quiescence following serum withdrawal or contact inhibition. Thus, the activation of the sphingomyelinase/ceramide pathway in HDF is due to senescence and supports the hypotheses that senescence represents a distinct program of cell development that can be differentiated from quiescence, Additional studies disclosed the ability of ceramide to induce a senescent phenotype. Thus, when exogenous ceramide (15 mu M) was administered to young WI-38 HDF, it produced endogenous levels comparable to those observed in senescent cells (as determined by metabolic labeling studies). Ceramide concentrations of 10-15 mu M inhibited the growth of young HDF and induced a senescent phenotype by its ability to inhibit DNA synthesis and mitogenesis. These concentrations of ceramide also induced retinoblastoma dephosphorylation and inhibited serum-induced AP-1 activation in young HDF, thus recapitulating basic biochemical and molecular changes of senescence. Sphingomyelinase and ceramide may thus be implicated as mediators of cellular senescence.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV GERIATR,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV HEMATOL ONCOL,DURHAM,NC 27710; VET AFFAIRS MED CTR,GRECC,DURHAM,NC 27710	Duke University; Duke University; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Venable, Mark/0000-0003-1708-9163; obeid, lina/0000-0002-0734-0847	NIA NIH HHS [AG00520] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG000520] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AFSHARI CA, 1994, CANCER RES, V54, P2317; BARBOUR S, 1992, J CELL PHYSIOL, V150, P610, DOI 10.1002/jcp.1041500322; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brady R. O., 1983, METABOLIC BASIS INHE, P831; CHAO R, 1992, J BIOL CHEM, V267, P23459; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; FOLCH J, 1957, J BIOL CHEM, V226, P497; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KIM MY, 1991, J BIOL CHEM, V266, P484; KIRKLAND JL, 1992, CLIN BIOCHEM, V25, P61, DOI 10.1016/0009-9120(92)80047-K; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LUMPKIN CK, 1986, SCIENCE, V232, P393, DOI 10.1126/science.2421407; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORWOOD TH, 1974, P NATL ACAD SCI USA, V71, P2231, DOI 10.1073/pnas.71.6.2231; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; PREISS J, 1986, J BIOL CHEM, V261, P8597; RADIN NS, 1993, ADV LIPID RES, V26, P183; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; RUBELJ I, 1994, EXP CELL RES, V211, P82, DOI 10.1006/excr.1994.1062; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SPENCE MW, 1993, ADV LIPID RES, V26, P3; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; STOFFEL W, 1971, H-S Z PHYSIOL CHEM, V352, P1058, DOI 10.1515/bchm2.1971.352.2.1058; SUZUKI K, 1987, METHOD ENZYMOL, V138, P727; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; WALKER PR, 1993, EXP CELL RES, V207, P142, DOI 10.1006/excr.1993.1173	43	363	375	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30701	30708		10.1074/jbc.270.51.30701	http://dx.doi.org/10.1074/jbc.270.51.30701			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530509	hybrid			2022-12-25	WOS:A1995TL67500074
J	SHIRATORI, Y; HOUWELING, M; ZHA, XH; TABAS, I				SHIRATORI, Y; HOUWELING, M; ZHA, XH; TABAS, I			STIMULATION OF CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE BY FREE-CHOLESTEROL LOADING OF MACROPHAGES INVOLVES SIGNALING THROUGH PROTEIN DEPHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; LOW-DENSITY LIPOPROTEIN; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; ISOLATED RAT HEPATOCYTES; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; OKADAIC ACID; ATHEROSCLEROTIC LESIONS; INTRACELLULAR-TRANSPORT; INDUCED INHIBITION; REDUCTASE-ACTIVITY	Free cholesterol-loaded macrophages in atheromata synthesize excess phosphatidylcholine (PC), which may be an important adaptive response to the excess free cholesterol (FC) load, We have recently shown that FC loading of macrophages leads to 2-4-fold increases in PC mass and biosynthesis and to the post-translational activation of the membrane-bound form of CTP:phosphocholine cytidylyltransferase (CT), a key enzyme in PC biosynthesis, Herein, we explore further the mechanism of CT activation in FC-loaded macrophages, First, enrichment of membranes from control macrophages with FC in vitro did not increase CT activity, and PC biosynthesis in vivo is up-regulated by FC loading even when CT and FC appear to be mostly in different intracellular sites, These data imply that FC activates membrane-bound CT by a signaling mechanism, That the proposed signaling mechanism involves structural changes in the CT protein was suggested by data showing that two different antibodies against synthetic CT peptides showed increased recognition of membrane-bound CT from FC-loaded cells despite no increase in CT protein. Since CT is phosphorylated, two-dimensional maps of peptides from P-32-labeled control and FC-loaded macrophages were compared: six peptide spots from membrane-bound CT, but none from soluble CT, were dephosphorylated in the FC-loaded cells, Furthermore, incubation of FC-loaded macrophages with the phosphatase inhibitor, calyculin A, blocked increases in both PC biosynthesis and antipeptide-antibody recognition of CT, Last, treatment of membranes from control macrophages with lambda phage protein phosphatase in vitro increased both CT activity (Q-fold) and antipeptide-antibody recognition of CT; soluble CT activity and antibody recognition were not substantially affected by phosphatase treatment, In summary, FC loading of macrophages leads to the partial dephosphorylation of membrane-bound CT, and possibly other cellular proteins, which appears to be important in CT activation, This novel regulatory action of FC may allow macrophages to adapt to FC loading in atheromata.	COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV, COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; UNIV ALBERTA, LIPID & LIPOPROT RES GRP, EDMONTON, AB T6G 2S2, CANADA; UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2S2, CANADA	Columbia University; Columbia University; Columbia University; University of Alberta; University of Alberta			Shiratori, Yoshimune/I-6206-2014		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054591, P50HL021006, R01HL039703] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54591, HL-39703, HL-21006] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS CWM, 1963, J PATHOL BACTERIOL, V86, P421, DOI 10.1002/path.1700860216; ARIASDIAZ J, 1994, J CLIN INVEST, V94, P244, DOI 10.1172/JCI117313; ASHKENAS J, 1993, J LIPID RES, V34, P983; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BEG ZH, 1986, ARCH BIOCHEM BIOPHYS, V244, P310, DOI 10.1016/0003-9861(86)90120-7; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BOTTCHER CJF, 1963, EVOLUTION ATHEROSCLE, P109; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BUCK RC, 1951, AMA ARCH PATHOL, V51, P224; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; COHEN PTW, 1989, BIOCHEM J, V260, P931, DOI 10.1042/bj2600931; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; DAY AJ, 1969, EXP MOL PATHOL, V11, P263, DOI 10.1016/0014-4800(69)90014-8; FOWLER S, 1980, ACTA MED SCAND, P151; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARA A, 1990, JPN J EXP MED, V60, P311; HATCH GM, 1992, J BIOL CHEM, V267, P15751; HATCH GM, 1991, BIOCHIM BIOPHYS ACTA, V1081, P25, DOI 10.1016/0005-2760(91)90245-D; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; HOUWELING M, 1991, BIOCHEM J, V278, P347, DOI 10.1042/bj2780347; HOUWELING M, 1995, IN PRESS EUR J CELL; INOUE S, 1991, J BIOL CHEM, V266, P13311; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JACKSON RL, 1976, ATHEROSCLER REV, V1, P1; JAMIL H, 1992, J BIOL CHEM, V267, P1752; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KATZ S S, 1976, Journal of Clinical Investigation, V58, P200; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; LUNDBERG B, 1985, ATHEROSCLEROSIS, V56, P93, DOI 10.1016/0021-9150(85)90087-5; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; OKWU AK, 1994, J LIPID RES, V35, P644; PELECH SL, 1983, J BIOL CHEM, V258, P6782; RAPP JH, 1983, J LIPID RES, V24, P1329; ROBISHAW JD, 1993, ANAL BIOCHEM, V208, P283, DOI 10.1006/abio.1993.1047; ROONEY SA, 1990, BIOCHIM BIOPHYS ACTA, V1044, P385, DOI 10.1016/0005-2760(90)90085-C; ROSS AC, 1984, J BIOL CHEM, V259, P815; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SHIRATORI Y, 1994, J BIOL CHEM, V269, P11337; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SMALL DM, 1988, ARTERIOSCLEROSIS, V8, P103, DOI 10.1161/01.ATV.8.2.103; SUCKLING KE, 1985, J LIPID RES, V26, P647; TABAS I, 1994, J BIOL CHEM, V269, P22547; TABAS I, 1990, J BIOL CHEM, V265, P8042; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TIPPING PG, 1993, AM J PATHOL, V142, P1721; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VONGUNTEN CF, 1989, BIOCHIM BIOPHYS ACTA, V1001, P218, DOI 10.1016/0005-2760(89)90151-3; WAHLQVIST ML, 1969, EXP MOL PATHOL, V11, P275, DOI 10.1016/0014-4800(69)90015-X; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WANG Y, 1995, ANAL BIOCHEM, V208, P283; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WRIGHT PS, 1985, J BIOL CHEM, V260, P7919; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; ZILVERSMIT DB, 1954, CIRCULATION, V9, P581, DOI 10.1161/01.CIR.9.4.581	72	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29894	29903						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530387				2022-12-25	WOS:A1995TK38000047
J	MenginLecreulx, D; vanHeijenoort, J				MenginLecreulx, D; vanHeijenoort, J			Characterization of the essential gene glmM encoding phosphoglucosamine mutase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; DIHYDROPTEROATE SYNTHASE GENE; PEPTIDOGLYCAN SYNTHESIS; NUCLEOTIDE-SEQUENCES; CYTOPLASMIC STEPS; CLONING; BIOSYNTHESIS; K-12; IDENTIFICATION; TRANSFERASE	Two different approaches to identify the gene encoding the phosphoglucosamine mutase in Escherichia coli were used: (i) the purification to near homogeneity of this enzyme from a wild type strain and the determination of its N-terminal amino acid sequence; (ii) the search in data bases of an E. coli protein of unknown function showing sequence similarities with other hexosephosphate mutase activities. Both investigations revealed the same open reading frame named yhbF located within the leuU-dacB region at 69.5 min on the chromosome (Dallas, W. S., Dev, I. K., and Ray, P. H. (1993) J. Bacteriol, 175, 7743-7744). The predicted 445-residue protein with a calculated mass of 47.5 kDa contained in particular a short region GIVISASHNP with high similarity to the putative active site of hexosephosphate mutases. In vitro assays showed that the overexpression of this gene in E. coli cells led to a significant overproduction (from 15- to 50-fold) of phosphoglucosamine mutase activity. A hexose 1,6-diphosphate-dependent phosphorylation of the enzyme, which probably involves the serine residue at position 102, is apparently required for its catalytic action. As expected, the inactivation of this gene, which is essential for bacterial growth, led to the progressive depletion of the pools of precursors located downstream from glucosamine 1-phosphate in the pathway for peptidoglycan synthesis. This was followed by various alterations of cell shape and finally cells were lysed when their peptidoglycan content decreased to a critical value corresponding to about 60% of its normal level. The gene for this enzyme, which is essential for peptidoglycan and lipopolysaccharide biosyntheses, has been designated glmM.			MenginLecreulx, D (corresponding author), UNIV PARIS 11, CNRS, URA 1131, ENVELOPPES BACTERIENNES & PEPTIDES LAB, BATIMENT 432, F-91405 ORSAY, FRANCE.			MENGIN-LECREULX, Dominique/0000-0003-3205-0275				BOLES E, 1994, EUR J BIOCHEM, V220, P83, DOI 10.1111/j.1432-1033.1994.tb18601.x; Cabib E.., 1981, ENCY PLANT PHYSL N B, V13, P395; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; DALLAS WS, 1992, J BACTERIOL, V174, P5961, DOI 10.1128/jb.174.18.5961-5970.1992; DALLAS WS, 1993, J BACTERIOL, V175, P7743, DOI 10.1128/JB.175.23.7743-7744.1993; DAVIS RW, 1972, ADV BACTERIAL GENETI; DOBROGOS.WJ, 1968, J BACTERIOL, V95, P578, DOI 10.1128/JB.95.2.578-584.1968; DOUBLET P, 1993, J BACTERIOL, V175, P2970, DOI 10.1128/JB.175.10.2970-2979.1993; DUTKAMALEN S, 1988, BIOCHIMIE, V70, P287, DOI 10.1016/0300-9084(88)90073-9; GOODELL EW, 1985, J BACTERIOL, V163, P305, DOI 10.1128/JB.163.1.305-310.1985; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Heijenoort J.V, 1994, NEW COMPR BIOCH, V27, P39, DOI 10.1016/S0167-7306(08)60406-8; HOFMANN M, 1994, EUR J BIOCHEM, V221, P741, DOI 10.1111/j.1432-1033.1994.tb18787.x; HOLTJE JV, 1985, MOL CYTOLOGY ESCHERI, P77; JOSHI JG, 1964, J BIOL CHEM, V239, P2741; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUHN HM, 1988, FEMS MICROBIOL LETT, V54, P195, DOI 10.1111/j.1574-6968.1988.tb02743.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEPLATOIS P, 1983, BIOCHIMIE, V65, P317, DOI 10.1016/S0300-9084(83)80153-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU M, 1994, J BACTERIOL, V176, P5847, DOI 10.1128/JB.176.18.5847-5851.1994; MARQUARDT JL, 1992, J BACTERIOL, V174, P5748, DOI 10.1128/JB.174.17.5748-5752.1992; MCCOY EE, 1959, J BIOL CHEM, V234, P3017; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; MENGINLECREULX D, 1993, J BACTERIOL, V175, P6150, DOI 10.1128/JB.175.19.6150-6157.1993; MENGINLECREULX D, 1989, J BACTERIOL, V171, P6126, DOI 10.1128/jb.171.11.6126-6134.1989; MENGINLECREULX D, 1983, J BACTERIOL, V154, P1284, DOI 10.1128/JB.154.3.1284-1290.1983; MENGINLECREULX D, 1991, J BACTERIOL, V173, P4625, DOI 10.1128/jb.173.15.4625-4636.1991; MENGINLECREULX D, 1985, J BACTERIOL, V163, P208, DOI 10.1128/JB.163.1.208-212.1985; MIYAKAWA T, 1972, J BACTERIOL, V112, P950, DOI 10.1128/JB.112.2.950-958.1972; MOTTL H, 1991, FEMS MICROBIOL LETT, V78, P213, DOI 10.1016/0378-1097(91)90160-C; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; PLUMBRIDGE J, 1995, EMBO J, V14, P3958, DOI 10.1002/j.1460-2075.1995.tb00067.x; PLUMBRIDGE JA, 1993, J BACTERIOL, V175, P4951, DOI 10.1128/JB.175.16.4951-4956.1993; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; Ray WJ., 1972, ENZYMES, P407; ROTHFIELD L, 1969, J MOL BIOL, V44, P477, DOI 10.1016/0022-2836(69)90374-X; Sambrook J, 1989, MOL CLONING LABORATO; SARVAS M, 1971, J BACTERIOL, V105, P467, DOI 10.1128/JB.105.2.467-471.1971; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; WHITE RJ, 1968, BIOCHEM J, V106, P847, DOI 10.1042/bj1060847; WU HC, 1971, J BACTERIOL, V105, P455, DOI 10.1128/JB.105.2.455-466.1971; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	47	119	121	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					32	39		10.1074/jbc.271.1.32	http://dx.doi.org/10.1074/jbc.271.1.32			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550580	hybrid			2022-12-25	WOS:A1996TP36100007
J	Otteken, A; Moss, B				Otteken, A; Moss, B			Calreticulin interacts with newly synthesized human immunodeficiency virus type 1 envelope glycoprotein, suggesting a chaperone function similar to that of calnexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT VACCINIA VIRUSES; CALCIUM-BINDING PROTEINS; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEIN; APLYSIA LEADS; CELL; RECOGNIZES; INCREASE; COMPLEX; REGION	The ubiquitous eukaryotic protein calreticulin has been detected in a wide variety of different cell types. Recently, calreticulin was found to bind in vitro to a number of proteins isolated from the endoplasmic reticulum. In addition, calreticulin has sequence similarities with the molecular chaperone calnexin. These data suggest that calreticulin might also act as a chaperone. We found that calreticulin associated transiently with a large number of newly synthesized cellular proteins. In cells expressing recombinant human immunodeficiency virus (HIV) envelope glycoprotein, gp160 bound transiently to calreticulin with a peak at 10 min after its synthesis. Binding of gp120 to calreticulin was not detected because proteolytic cleavage of gp160 occurs in the trans-Golgi. Nonglycosylated HIV envelope protein was not associated with calreticulin, suggesting a requirement for N-linked oligosaccharides on newly synthesized proteins as has been reported for calnexin. The in vivo binding kinetics of calnexin and calreticulin to gp160 were very similar. Sequential immunoprecipitations provided evidence for the existence of ternary complexes of gp160, calreticulin, and calnexin. The data suggested that most of the gp160 associated with calreticulin was also bound to calnexin but that only a portion of the gp160 associated with calnexin was also bound to calreticulin.	NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Moss, Bernard/0000-0002-2154-8564				BURNS K, 1993, FEBS LETT, V318, P181, DOI 10.1016/0014-5793(93)80017-O; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CONWAY EM, 1995, J BIOL CHEM, V270, P17011, DOI 10.1074/jbc.270.28.17011; DAVID V, 1993, J BIOL CHEM, V268, P9585; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GROSS V, 1983, J BIOL CHEM, V258, P2203; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Herbert Daniel N., 1995, Cell, V81, P425; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; KELLY RB, 1990, NATURE, V345, P480, DOI 10.1038/345480a0; KENNEDY TE, 1992, NEURON, V9, P1013, DOI 10.1016/0896-6273(92)90062-I; KUHL D, 1992, J CELL BIOL, V119, P1069, DOI 10.1083/jcb.119.5.1069; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MOSS B, 1968, J VIROL, V2, P1028, DOI 10.1128/JVI.2.10.1028-1037.1968; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OTTEKEN A, 1993, VIROLOGY, V194, P37, DOI 10.1006/viro.1993.1232; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PLAKIDOUDYMOCK S, 1994, CELL CALCIUM, V16, P1, DOI 10.1016/S0143-4160(05)80002-8; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; STEIN BS, 1990, J BIOL CHEM, V265, P2640; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WADA I, 1991, J BIOL CHEM, V266, P19599; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	32	116	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					97	103		10.1074/jbc.271.1.97	http://dx.doi.org/10.1074/jbc.271.1.97			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550632	hybrid			2022-12-25	WOS:A1996TP36100016
J	Persechini, A; White, HD; Gansz, KJ				Persechini, A; White, HD; Gansz, KJ			Different mechanisms for Ca2+ dissociation from complexes of calmodulin with nitric oxide synthase or myosin light chain kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOPPED-FLOW FLUORESCENCE; DEPENDENT PROTEIN-KINASE; CALCIUM-BINDING; ACTIVATION; KINETICS; QUIN-2; DOMAIN	We have determined the stoichiometry and rate constants for the dissociation of Ca2+ ion from calmodulin (CaM) complexed with rabbit skeletal muscle myosin light chain kinase (skMLCK), rat brain nitric oxide synthase (nNOS) or with the respective peptides (skPEP and nPEP) representing the CaM-binding domains in these enzymes. Ca2+ dissociation kinetics determined by stopped-flow fluorescence using the Ca2+ chelator quin-2 MF are as follows. 1) Two sites in the CaM-nNOS and CaM-nPEP complexes have a rate constant of 1 s(-1). 2) The remaining two sites have a rate constant of 18 s(-1) for CaM-nPEP and > 1000 s(-1) for CaM-nNOS. 3) Three sites have a rate constant of 1.6 s(-1) for CaM-skMLCK and 0.15 s(-1) for CaM-skPEP. 4) The remaining site has a rate constant of 2 s(-1) for CaM-skPEP and > 1000 s(-1) for CaM-skMLCK. Comparison of these rate constants with those determined for complexes between the peptides and tryptic fragments representing the C- or N-terminal lobes of CaM indicate a mechanism for Ca2+ dissociation from CaM-nNOS of 2C slow + 2N fast and from CaM-skMLCK of (2C + 1N) slow + 1N fast, Ca2+ removal inactivates CaM-nNOS and CaM-skMLCK activities with respective rate constants of > 10 s(-1) and 1 s(-1). CaM-nNOS inactivation is fit by a model in which rapid Ca2+ dissociation from the N-terminal lobe of CaM is coupled to enzyme inactivation and slower Ca2+ dissociation from the C-terminal lobe is coupled to dissociation of the CaM-nNOS complex. CaM-skMLCK inactivation is fit by a model in which the three slowly dissociating Ca2+-binding sites are coupled to both dissociation of the complex and enzyme inactivation.	EASTERN VIRGINIA MED SCH,DEPT BIOCHEM,NORFOLK,VA 23501	Eastern Virginia Medical School	Persechini, A (corresponding author), UNIV ROCHESTER,MED CTR,DEPT PHYSIOL,601 ELMWOOD AVE,BOX 642,ROCHESTER,NY 14642, USA.				NHLBI NIH HHS [HL41776] Funding Source: Medline; NIDDK NIH HHS [DK44322] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; DYSON RD, 1971, BIOCHEMISTRY-US, V10, P3233, DOI 10.1021/bi00793a012; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; HAUGHLAND RP, 1992, HDB FLUORESCENT PROB, P122; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ITAKURA M, 1992, J BIOCHEM, V112, P183, DOI 10.1093/oxfordjournals.jbchem.a123875; JOHNSON JD, 1981, J BIOL CHEM, V256, P2194; KASTURI R, 1993, J BIOL CHEM, V268, P7958; MCCARTHY JJ, 1994, ANAL BIOCHEM, V221, P250, DOI 10.1006/abio.1994.1409; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; OLWIN BB, 1984, J BIOL CHEM, V259, P949; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; STULL JT, 1985, ADV ENZYME REGUL, P123; SUKO J, 1986, EUR J BIOCHEM, V159, P425, DOI 10.1111/j.1432-1033.1986.tb09904.x; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; ZHANG MJ, 1994, J BIOL CHEM, V269, P981	22	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					62	67		10.1074/jbc.271.1.62	http://dx.doi.org/10.1074/jbc.271.1.62			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550626	hybrid			2022-12-25	WOS:A1996TP36100011
J	Voisin, T; Lorinet, AM; Maoret, JJ; Couvineau, A; Laburthe, M				Voisin, T; Lorinet, AM; Maoret, JJ; Couvineau, A; Laburthe, M			G alpha(i) RNA antisense expression demonstrates the exclusive coupling of peptide YY receptors to G(i2) proteins in renal proximal tubule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN HYBRID GENE; NEUROPEPTIDE-Y; TRANSGENIC MICE; ADENYLYL-CYCLASE; BINDING; DIFFERENTIATION; ACTIVATION; INHIBITION; MEMBRANES; TRANSPORT	A clone PKSV-PCT Cl.10 referred to as Cl.10 was selected from the PKSV-PCT renal proximal tubule cell line which expressed peptide YY (PYY) receptors (Voisin, T., Bens, M., Cluzeaud, F., Vandewalle, A., and Laburthe, M. (1993) J. Biot. Chem. 268, 20547-20554). In order to identify G(i) protein(s) coupled to PYY receptors, antisense G alpha(i) protein RNAs were expressed in Cl.10 cells by transfecting the pcDNA3 vector into which were inserted 39 bases of the 5'-noncoding region of G alpha(i2), or G alpha(i3) used as specific antisense, templates. A Cl.10/alpha(i2)(-) clone was selected which displayed a drastic decrease (>90%) of the expression of G alpha(i2) without changes of G alpha(i3), G alpha(s), and G beta subunits (G alpha(i1) is not present in Cl.10 cells) as evidenced by Western blots. When compared to untransfected cells, this clone exhibited: (i) an increase in the dissociation constant of PYY receptors (5.3 versus 0.6 nM) identical to that observed in pertussis toxin-treated untransfected cells; (ii) an absence of inhibition of I-125-PYY binding by guanosine 5'-O-(thiotriphosphate) (GTP gamma S); and (iii) the failure of PYY to inhibit cAMP levels and to stimulate [methyl-H-3]thymidine incorporation into DNA. A clone was also selected which exhibited a specific decrease (>80%) of G alpha(i3), as compared to untransfected cells. The sensitivity to GTP gamma S and the dissociation constant of PYY receptors as well as PYY-mediated inhibition of cAMP were identical to those observed in untransfected cells. These findings support an exclusive coupling of PYY receptors to G alpha(i2).			Voisin, T (corresponding author), UNIV PARIS 07,FAC MED XAVIER BICHAT,INSERM,U410,F-75870 PARIS 18,FRANCE.		voisin, thierry/R-1241-2017; couvineau, alain/T-3466-2019; LABURTHE, Marc/C-1875-2012; couvineau, alain/G-3641-2013	voisin, thierry/0000-0002-4320-5183; couvineau, alain/0000-0003-2912-5168; couvineau, alain/0000-0003-2912-5168				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BALASUBRAMANIAM A, 1993, PEPTIDES, V14, P1011, DOI 10.1016/0196-9781(93)90079-V; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTIER N, 1993, J CELL SCI, V104, P695; CASTAN I, 1992, ENDOCRINOLOGY, V131, P1970, DOI 10.1210/en.131.4.1970; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COUVINEAU A, 1992, AM J PHYSIOL, V262, pC1478, DOI 10.1152/ajpcell.1992.262.6.C1478; COX HM, 1988, J PHYSIOL-LONDON, V398, P65, DOI 10.1113/jphysiol.1988.sp017029; DEMAZANCOURT P, 1994, BIOCHEM J, V303, P369, DOI 10.1042/bj3030369; FREITAG C, 1995, J NEUROCHEM, V64, P643; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; HELENE C, 1994, EUR J CANCER, V30A, P1721, DOI 10.1016/0959-8049(93)E0352-Q; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; ITOH H, 1988, J BIOL CHEM, V263, P6656; JONES DT, 1987, J BIOL CHEM, V262, P14241; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KRAUSE J, 1992, MOL PHARMACOL, V41, P817; LABURTHE M, 1986, ENDOCRINOLOGY, V118, P1910, DOI 10.1210/endo-118-5-1910; LABURTHE M, 1994, BAILLIERE CLIN ENDOC, V8, P77, DOI 10.1016/S0950-351X(05)80227-7; LABURTHE M, 1990, TRENDS ENDOCRIN MET, V1, P168, DOI 10.1016/1043-2760(90)90031-W; LACAVE R, 1993, J CELL SCI, V104, P705; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MARTIN MC, 1991, TRENDS PHARMACOL SCI, V10, P389; MOXHAM CM, 1993, SCIENCE, V260, P991, DOI 10.1126/science.8493537; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUNTZ KH, 1992, CIRCULATION, V86, P764; NAGATSU T, 1976, ANAL BIOCHEM, V74, P466, DOI 10.1016/0003-2697(76)90227-X; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; PADRELL E, 1987, ENDOCRINOLOGY, V120, P2316, DOI 10.1210/endo-120-6-2316; POBINER BF, 1991, MOL PHARMACOL, V40, P156; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SERVIN AL, 1989, ENDOCRINOLOGY, V124, P692, DOI 10.1210/endo-124-2-692; SHEIKH SP, 1989, FEBS LETT, V245, P209, DOI 10.1016/0014-5793(89)80223-6; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; VOISIN T, 1993, J BIOL CHEM, V268, P20547; VOISIN T, 1991, J BIOL CHEM, V266, P10762; VOISIN T, 1990, AM J PHYSIOL, V255, pG113; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681; WINITZ S, 1993, J BIOL CHEM, V268, P19196; Zweibaum A., 1991, HDB PHYSL GASTROINTE, P223	46	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					574	580		10.1074/jbc.271.1.574	http://dx.doi.org/10.1074/jbc.271.1.574			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550622	hybrid			2022-12-25	WOS:A1996TP36100087
J	Werner, DS; Lee, TR; Lawrence, DS				Werner, DS; Lee, TR; Lawrence, DS			Is protein kinase substrate efficacy a reliable barometer for successful inhibitor design?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; SPECIFICITY; PHOSPHORYLATION	We have addressed the question of whether protein kinase substrate efficacy is a reliable barometer for successful inhibitor design by assessing the dependence of k(cat) and k(cat)/K-m for eight separate alcohol-bearing residues on solvent viscosity. We have found that the K-m for three structurally distinct primary alcohol-containing peptides overestimates the affinity that these species exhibit for the cAMP-dependent protein kinase. In all three cases, the rate-determining step is product release, and substrate binding is best described as rapid equilibrium. In contrast, peptides containing the following phosphorylatable residues all provide K-m values that are accurate assessments of substrate affinity for the protein kinase: a secondary alcohol, a simple phenol, and a primary alcohol with a relatively long side chain, In the latter three instances, the rate-determining step is phosphoryl transfer. Finally, two aromatic alcohol-containing residues that possess lipophilic side chains exhibit Michaelis constants that underestimate enzyme affinity. These results demonstrate that while it may be tempting to employ structural elements from the most efficient substrates (e.g. primary alcohols) for inhibitor design, less effective substrates may serve as a more accurate assessment of inhibitory success.	SUNY BUFFALO,DEPT CHEM,BUFFALO,NY 14260; SUNY BUFFALO,DEPT MED CHEM,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo				Lee, Tae Ryong/0000-0002-6914-1237	NIGMS NIH HHS [GM45989] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045989] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; CHESSA G, 1983, EUR J BIOCHEM, V135, P609, DOI 10.1111/j.1432-1033.1983.tb07695.x; FERAMISCO JR, 1978, J BIOL CHEM, V253, P8968; GLASS DB, 1983, BIOCHEM J, V213, P159, DOI 10.1042/bj2130159; GLASS DB, 1989, J BIOL CHEM, V264, P8802; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KEMP BE, 1979, PEPTIDES STRUCTURE B, P169; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KWON YG, 1993, J AM CHEM SOC, V115, P7527, DOI 10.1021/ja00069a072; KWON YG, 1993, J BIOL CHEM, V268, P16725; KWON YG, 1993, J BIOL CHEM, V268, P10713; KWON YG, 1994, J BIOL CHEM, V269, P4839; LEE TR, 1994, BIOCHEMISTRY-US, V33, P4245, DOI 10.1021/bi00180a019; LEE TR, 1995, J BIOL CHEM, V270, P27022, DOI 10.1074/jbc.270.45.27022; LEE TR, 1995, J BIOL CHEM, V270, P5375, DOI 10.1074/jbc.270.10.5375; LEE TR, 1993, J AM CHEM SOC, V115, P9888, DOI 10.1021/ja00075a003; LINBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114; MARTIN BL, 1990, J BIOL CHEM, V265, P7108; MENDELOW M, 1993, J BIOL CHEM, V268, P12289; MITCHELL RD, 1995, BIOCHEMISTRY-US, V34, P528, DOI 10.1021/bi00002a018; PROROK M, 1989, J BIOCHEM BIOPH METH, V18, P167, DOI 10.1016/0165-022X(89)90001-8; PROROK M, 1989, BIOCHEM BIOPH RES CO, V158, P136, DOI 10.1016/S0006-291X(89)80188-3; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; Wood JS, 1996, J BIOL CHEM, V271, P174, DOI 10.1074/jbc.271.1.174	25	8	8	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					180	185		10.1074/jbc.271.1.180	http://dx.doi.org/10.1074/jbc.271.1.180			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550556				2022-12-25	WOS:A1996TP36100028
J	Clark, GJ; Kinch, MS; Gilmer, TM; Burridge, K; Der, CJ				Clark, GJ; Kinch, MS; Gilmer, TM; Burridge, K; Der, CJ			Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers	ONCOGENE			English	Article						transformation; adherens junctions; motility	MAMMARY EPITHELIAL-CELLS; HA-RAS; AMINO-ACIDS; ONCOGENE; TRANSFORMATION; EXPRESSION; ACTIVATION; CARCINOMAS; LINE; INVIVO	Although experimental studies suggest that aberrant Ras function can promote the malignant progression of human breast epithelial cells, the occurrence of mutated pas genes in breast tumors is infrequent. One possible explanation for this apparent paradox is that aberrant function of the Ras-related protein TC21/R-Ras2, which causes malignant transformation of NIH 3T3 cells via upregulation of the Ras signal transduction pathway, may contribute to breast tumor development in the absence of Ras mutations. To address this possibility, we utilized two complementary approaches. First, we determined that aberrant TC21 function caused transformation of the MCF-10A human breast epithelial cell line. TC21-transformed MCF-10A cells exhibited altered cellular morphology associated with a disruption of cell-cell adherens junctions, formed colonies in soft agar, and showed enhanced motility in vitro. These alterations were similar to, but more dramatic than, those observed with oncogenic Ras-transformed MCF-10A cells. Furthermore, overexpression of normal TC21, but not Ras, also caused transformation of these cells. Second, we observed that TC21 protein expression was greatly elevated in 7 of 9 breast tumor lines when compared to untransformed MCF-10A cells. Taken together, these results support the possibility that overexpression of TC21 may contribute to aberrant growth properties of breast carcinoma cells.	UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELLULAR BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; GLAXO INC,RES INST,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline				Kinch, Michael/0000-0003-3939-3756; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA055008, R01CA052072, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA55008, CA52072, CA42978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1988, MOL CELL BIOL, V8, P3960, DOI 10.1128/MCB.8.9.3960; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CLAIR T, 1987, CANCER RES, V47, P5290; CLARDIELLO F, 1992, MOL CARCINOGEN, V6, P43; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CLARK GJ, 1993, GTPASES BIOL, V108, P259; CLARK R, 1988, CANCER RES, V48, P4689; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; COX AD, 1994, ONCOGENE, V9, P3281; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; DEBORTOLI ME, 1985, BIOCHEM BIOPH RES CO, V127, P699, DOI 10.1016/S0006-291X(85)80218-7; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; GUNZBURG WH, 1988, CARCINOGENESIS, V9, P1849, DOI 10.1093/carcin/9.10.1849; HAND PH, 1987, J NATL CANCER I, V79, P59; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; HYNES NE, 1994, CANCER BIOL, V4, P19; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; OCHIENG J, 1991, INVAS METAST, V11, P38; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRESS MF, 1994, CANCER RES, V54, P2771; QUI RG, 1995, NATURE, V374, P457; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; REDMOND SMS, 1988, ONCOGENE, V2, P259; SAEZ R, 1994, ONCOGENE, V9, P2977; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOULE HD, 1990, CANCER RES, V50, P6075; SPANDIDOS DA, 1987, ANTICANCER RES, V7, P991; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; THOR A, 1986, LAB INVEST, V6, P603; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001	47	81	85	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					169	176						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552388				2022-12-25	WOS:A1996TQ01400021
J	Fueyo, J; GomezManzano, C; Yung, WKA; Clayman, GL; Liu, TJ; Bruner, J; Levin, VA; Kyritsis, AP				Fueyo, J; GomezManzano, C; Yung, WKA; Clayman, GL; Liu, TJ; Bruner, J; Levin, VA; Kyritsis, AP			Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells	ONCOGENE			English	Article						brain tumors; tumor suppressor genes; p16/CDKN2; adenovirus		The p16 (MTS1/CDKN2) gene localized at the 9p21 chromosomal region encodes for a cell cycle inhibitor protein and is altered in many human cancers. The frequency of p16 alterations in gliomas exceeds 50%. To restore the missing wild-type p16 gene efficiently in glioma cells an adenovirus vector carrying the full length coding sequence of the wild-type p16 cDNA, Ad5RSV-p16, was constructed. Three human glioma cell lines, U-251 MG, U-87 MG and D54 MG, that did not express endogenous p16/CDKN2 gene and were easily infected with adenovirus vectors were selected for these experiments. Introduction of the Ad5RSV-p16 in these malignant glioma cell lines directed the biosynthesis of functional p16 protein in the majority of the exposed cells, significantly inhibited cell growth, influenced cell morphology and modified the transformed phenotype of cells including the ability to form colonies in soft agar. Flow cytometric studies revealed that the majority of the Ad5RSV-p16 infected glioma cells were arrested in the G0-G1 phases of the cell cycle. These results suggest that p16/CDKN2 inactivation is a significant factor in the genesis and progression of gliomas and that the restoration of the wild-type p16 protein could have clinical and therapeutic utility.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEAD & NECK SURG,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030, USA.			Gomez-Manzano, Candelaria/0000-0002-1259-2133; Fueyo, Juan/0000-0001-6941-2335	NATIONAL CANCER INSTITUTE [P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; ARAP W, 1995, CANCER RES, V55, P1351; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; CLAYMAN GL, 1995, CANCER RES, V55, P1; GIANI C, 1994, CANCER RES, V54, P6338; Graham FL, 1991, METHOD MOL BIOL, P109; GRUNHAUS A, 1992, SEMIN VIROL, V3, P237; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JEN J, 1994, CANCER RES, V54, P6353; JIN XM, 1995, CANCER RES, V55, P3250; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LI Y, 1994, CANCER RES, V54, P6078; LIU TJ, 1994, CANCER RES, V54, P3662; LIU TJ, 1995, CANCER RES, V55, P3117; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090; WANG JX, 1995, CANCER GENE THER, V2, P9; WASHIMI O, 1995, CANCER RES, V55, P514; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868; ZHANG WW, 1994, CANCER GENE THER, V1, P5	27	92	99	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					103	110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552379				2022-12-25	WOS:A1996TQ01400013
J	Hawes, JW; Schnepf, RJ; Jenkins, AE; Shimomura, Y; Popov, KM; Harris, RA				Hawes, JW; Schnepf, RJ; Jenkins, AE; Shimomura, Y; Popov, KM; Harris, RA			Roles of amino acid residues surrounding phosphorylation site 1 of branched-chain alpha-ketoacid dehydrogenase (BCKDH) in catalysis and phosphorylation site recognition by BCKDH kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PYRUVATE-DEHYDROGENASE; ACTIVE-SITE; RABBIT LIVER; RAT-HEART; COMPLEX; DECARBOXYLASE; TRANSKETOLASE; DIPHOSPHATE; MUSCLE; ENZYME	Branched-chain alpha-ketoacid dehydrogenase is regulated by reversible phosphorylation of serine 293 (site 1) on the E1 alpha subunit. Alanine-scanning mutagenesis was used to examine the roles of residues surrounding serine 293 in catalysis by the dehydrogenase and in sub strate recognition by branched-chain alpha-ketoacid dehydrogenase kinase. Alanine substitution of serine 293 resulted in a 10-fold increased K-m for alpha-ketoisovalerate, a less increased (2.8-fold) K-m for alpha-ketoisocaproate, but no change in V-max or the K-m for thiamine pyrophosphate. Alanine substitutions of arginine 288, histidine 292, and aspartate 296, residues highly conserved among alpha-ketoacid dehydrogenases, resulted in inactive enzymes. Each of the inactive E1 mutants bound to the E2 core subunit with equal affinity as wild-type E1, and each produced circular dichroism spectra identical to that of wild-type E1. Two mutations, H292A and S293E, abolished the ability of E1 apoenzyme to reconstitute with thiamine pyrophosphate. Each alanine-substituted E1 was phosphorylated at site 1 by branched-chain alpha-ketoacid dehydrogenase kinase with similar rates, with the exception of the R288A mutant, which displayed no detectable phosphorylation. Thiamine pyrophosphate inhibited the phosphorylation of all mutant enzymes with the exception of H292A, the mutant E1 that did not bind thiamine pyrophosphate.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019259] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19259] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI MS, 1993, J BIOL CHEM, V268, P22353; ALI MS, 1995, J BIOL CHEM, V270, P4570, DOI 10.1074/jbc.270.9.4570; BUTLER JR, 1977, BIOCHEM BIOPH RES CO, V74, P1667, DOI 10.1016/0006-291X(77)90636-2; CHUN K, 1993, HUM MOL GENET, V2, P449, DOI 10.1093/hmg/2.4.449; Cleland W W, 1979, Methods Enzymol, V63, P103; COOK KG, 1983, FEBS LETT, V157, P59, DOI 10.1016/0014-5793(83)81116-8; COOK KG, 1985, BIOCHEM J, V225, P731, DOI 10.1042/bj2250731; DIEFENBACH RJ, 1991, BIOCHEM J, V276, P439, DOI 10.1042/bj2760439; GOODWIN GW, 1987, ANAL BIOCHEM, V162, P536, DOI 10.1016/0003-2697(87)90430-1; HARPER AE, 1984, ANNU REV NUTR, V4, P409, DOI 10.1146/annurev.nu.04.070184.002205; HARRIS RA, 1990, ADV ENZYME REGUL, V30, P245; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; KHAILOVA LS, 1989, ANN NY ACAD SCI, V573, P36, DOI 10.1111/j.1749-6632.1989.tb14985.x; Korochkina L G, 1993, Biokhimiia, V58, P1503; KOROTCHKINA LG, 1995, FEBS LETT, V364, P185, DOI 10.1016/0014-5793(95)00382-J; LAU KS, 1982, FEBS LETT, V144, P57, DOI 10.1016/0014-5793(82)80568-1; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; PAXTON R, 1986, ARCH BIOCHEM BIOPHYS, V244, P187, DOI 10.1016/0003-9861(86)90108-6; PAXTON R, 1988, METHOD ENZYMOL, V166, P313; PAXTON R, 1984, ARCH BIOCHEM BIOPHYS, V231, P48, DOI 10.1016/0003-9861(84)90361-8; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; ROBINSON BH, 1993, FEBS LETT, V328, P99, DOI 10.1016/0014-5793(93)80973-X; SHIMOMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P210, DOI 10.1016/0003-9861(88)90252-4; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; STEPP LR, 1985, BIOCHEMISTRY-US, V24, P7187, DOI 10.1021/bi00346a026; WALSH DA, 1976, BIOCHEM J, V157, P41, DOI 10.1042/bj1570041; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YEAMAN SJ, 1986, TRENDS BIOCHEM SCI, V11, P293, DOI 10.1016/0968-0004(86)90033-2; ZHAO Y, 1994, J BIOL CHEM, V269, P18583	30	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31071	31076		10.1074/jbc.270.52.31071	http://dx.doi.org/10.1074/jbc.270.52.31071			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537366	hybrid			2022-12-25	WOS:A1995TN44400034
J	Nakamura, F; Amieva, MR; Furthmayr, H				Nakamura, F; Amieva, MR; Furthmayr, H			Phosphorylation of threonine 558 in the carboxyl-terminal actin-binding domain of moesin by thrombin activation of human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; HUMAN BLOOD-PLATELETS; MICROVILLAR CORE PROTEIN; INTACT HUMAN PLATELETS; GLYCOPROTEIN-IIIA; SIGNAL-TRANSDUCTION; GENE-PRODUCT; P-SELECTIN; T-CELLS; EZRIN	The phosphorylation and localization of the membrane-linking protein moesin was analyzed during early activation of platelets with thrombin, Activated platelets elaborate filopodia and spread to assume flat pancake-like shapes, and moesin is localized in filopodia and cell body, In resting platelets, approximately 25% of moesin molecules are phosphorylated as shown by metabolic labeling with P-32(i) and by isoelectric focusing, Within seconds after exposure to thrombin, phosphorylation increases, reaching a maximum of 35% labeled molecules by 1 min, followed by a decrease to a new basal level within 5 min. This modification affects a single residue, Thr(558), which is located within or close to a binding site for F-actin, Rapid shifts (0-100%) in the number of phosphorylated molecules are observed in the presence of inhibitors of serine/threonine kinases and phosphatases. Inhibitors affecting tyrosine phosphorylation also modulate phosphorylation at this site suggesting that the enzymes involved in the modification of Thr(558) are regulated by tyrosine phosphorylation. Platelets respond to both extremes of modification by forming extremely long filopodia and the absence of spreading on glass. Completely phosphorylated moesin is concentrated together with F-actin in the center of the cell, The rapid modification of moesin at or near its actin-binding domain suggests a model for regulated membrane-cytoskeleton interaction during cell activation.	STANFORD UNIV,SCH MED,EXPTL ONCOL LAB,DEPT PATHOL,STANFORD,CA 94305	Stanford University			Furthmayr, Heinz -/A-6295-2010; Nakamura, Fumihiko/N-5476-2016; Amieva, Manuel/U-2581-2017	Amieva, Manuel/0000-0002-5601-4490; Nakamura, Fumihiko/0000-0002-6872-4246	NCI NIH HHS [CA09302] Funding Source: Medline; NIAMS NIH HHS [AR41045] Funding Source: Medline; NIGMS NIH HHS [2T32GM07365] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041045] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; AMIEVA MR, 1994, EXP CELL RES, V210, P140, DOI 10.1006/excr.1994.1021; AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; ANDREOLI C, 1994, J CELL SCI, V107, P2509; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BERTAGNOLLI ME, 1993, J CELL SCI, V106, P1189; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRUIN T, 1991, THROMB HAEMOSTASIS, V65, P206; CARROLL RC, 1982, BLOOD, V59, P466; CELIS JE, 1993, ELECTROPHORESIS, V14, P1195; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOI ES, 1995, BLOOD, V85, P402; CORREAS I, 1986, J BIOL CHEM, V261, P3310; CROVELLO CS, 1993, J BIOL CHEM, V268, P14590; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; EGERTON M, 1992, J IMMUNOL, V149, P1847; FALLON RJ, 1990, BIOCHEM BIOPH RES CO, V170, P1191, DOI 10.1016/0006-291X(90)90519-S; FAZIOLI F, 1993, ONCOGENE, V8, P1335; FEDER D, 1990, J BIOL CHEM, V265, P8205; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FINDIK D, 1990, FEBS LETT, V262, P1, DOI 10.1016/0014-5793(90)80138-9; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; FROSCH PM, 1991, MOL BIOCHEM PARASIT, V48, P121, DOI 10.1016/0166-6851(91)90108-I; FUJIMOTO T, 1993, BLOOD, V82, P1758; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; FURTHMAYR H, 1992, KIDNEY INT, V41, P665, DOI 10.1038/ki.1992.102; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; KEANE AM, 1990, NATURE, V344, P265, DOI 10.1038/344265a0; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KRIEG J, 1992, J BIOL CHEM, V267, P19258; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKES W, 1988, BIOCHEM J, V251, P831, DOI 10.1042/bj2510831; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LANKES WT, 1993, BIOCHIM BIOPHYS ACTA, V1216, P479, DOI 10.1016/0167-4781(93)90018-9; LEREA KM, 1991, BIOCHEMISTRY-US, V30, P6819, DOI 10.1021/bi00242a003; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; MITCHISON T, 1988, NEURON, V1, P769; MODDERMAN PW, 1994, BIOCHEM J, V299, P613, DOI 10.1042/bj2990613; MORII N, 1992, J BIOL CHEM, V267, P20921; MURPHY CT, 1994, BIOCHEM J, V301, P531, DOI 10.1042/bj3010531; MURPHY CT, 1993, EUR J BIOCHEM, V216, P639, DOI 10.1111/j.1432-1033.1993.tb18184.x; NACHMIAS VT, 1991, CELL MOTIL CYTOSKEL, V20, P190, DOI 10.1002/cm.970200303; NAKANO H, 1987, J ANTIBIOT, V40, P706, DOI 10.7164/antibiotics.40.706; NOBES C, 1995, CELL, V81, P1137; ODA A, 1992, J BIOL CHEM, V267, P20075; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PACKHAM MA, 1994, CAN J PHYSIOL PHARM, V72, P278, DOI 10.1139/y94-043; PARISE LV, 1990, BLOOD, V75, P2363; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; RAYMONDDENISE A, 1993, MOL BIOCHEM PARASIT, V59, P123, DOI 10.1016/0166-6851(93)90013-N; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SCHUSTER CB, 1995, J CELL BIOL, V128, P837; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TANGEN O, 1971, THROMB DIATH HAEMOST, V25, P268; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; URUSHIDANI T, 1989, AM J PHYSIOL, V256, pG1070, DOI 10.1152/ajpgi.1989.256.6.G1070; VANDEKERCKHOVE J, 1992, Current Opinion in Cell Biology, V4, P36, DOI 10.1016/0955-0674(92)90056-I; VOSTAL JG, 1993, BIOCHEM J, V294, P675, DOI 10.1042/bj2940675; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; WEISS HJ, 1975, NEW ENGL J MED, V293, P531, DOI 10.1056/NEJM197509112931105; WEISS HJ, 1975, NEW ENGL J MED, V293, P580, DOI 10.1056/NEJM197509182931204; WILGENBUS KK, 1993, GENOMICS, V16, P199, DOI 10.1006/geno.1993.1159; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	85	181	188	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31377	31385		10.1074/jbc.270.52.31377	http://dx.doi.org/10.1074/jbc.270.52.31377			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537411	hybrid			2022-12-25	WOS:A1995TN44400078
J	Navarro, P; Caveda, L; Breviario, F; Mandoteanu, I; Lampugnani, MG; Dejana, E				Navarro, P; Caveda, L; Breviario, F; Mandoteanu, I; Lampugnani, MG; Dejana, E			Catenin-dependent and -independent functions of vascular endothelial cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; CYTOPLASMIC DOMAIN; N-CADHERIN; TYROSINE PHOSPHORYLATION; MOLECULE UVOMORULIN; INTERCELLULAR COMMUNICATION; GENE FAMILY; EXPRESSION; PROTEIN; COMPLEX	Vascular endothelial cadherin (VE-cadherin, cadherin-5, or 7B4) is an endothelial specific cadherin that regulates cell to cell junction organization in this cell type, Cadherin linkage to intracellular catenins was found to be required for their adhesive properties and for localization at cell to cell junctions. We constructed a mutant form of VE-cadherin lacking the last 82 amino acids of the cytoplasmic domain, Surprisingly, despite any detectable association of this truncated VE-cadherin to catenin-cytoskeletal complex, the molecule was able to cluster at cell-cell contacts in a manner similar to wild type VE-cadherin. Truncated VE-cadherin was also able to promote calcium-dependent cell to cell aggregation and to partially inhibit cell detachment and migration from a confluent monolayer. In contrast, intercellular junction permeability to high molecular weight molecules was severely impaired by truncation of VE-cadherin cytoplasmic domain. These results suggest that the VE-cadherin extracellular domain is enough for early steps of cell adhesion and recognition. However, interaction of VE-cadherin with the cytoskeleton is necessary to provide strength and cohesion to the junction. The data also suggest that cadherin functional regulation might not be identical among the members of the family.	INST CELLULAR BIOL & PATHOL,R-79691 BUCHAREST,ROMANIA; CEN GRENOBLE,CEA,HEMATOL LAB,INSERM,U217,DBMS,GRENOBLE,FRANCE	Romanian Academy of Sciences; Nicolae Simionescu Institute of Cellular Biology & Pathology; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Navarro, P (corresponding author), IST RIC FARMACOL MARIO NEGRI,VIA ERITREA 62,I-20157 MILAN,ITALY.		Manduteanu, ileana/AAX-8661-2020; Navarro, Pilar/A-2122-2010; Navarro, Pilar/ABF-2728-2020	Navarro, Pilar/0000-0003-4314-4584; Navarro, Pilar/0000-0003-4314-4584; DEJANA, ELISABETTA/0000-0002-0007-0426; Lampugnani, Maria Grazia/0000-0002-4802-7064; Manduteanu, Ileana/0000-0002-8079-4191				ALEXANDER JS, 1993, J CELL PHYSIOL, V156, P610, DOI 10.1002/jcp.1041560321; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; BALZAC F, 1993, J CELL BIOL, V121, P171, DOI 10.1083/jcb.121.1.171; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BLOCH RJ, 1992, J CELL BIOL, V116, P449, DOI 10.1083/jcb.116.2.449; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; DUFOUR S, 1994, J CELL BIOL, V127, P521, DOI 10.1083/jcb.127.2.521; EDELMAN GM, 1991, DEV DYNAM, V193, P2; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENGVALL E, 1972, J IMMUNOL, V109, P129; FRACHET P, 1990, MOL BIOL REP, V14, P27, DOI 10.1007/BF00422712; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; GEIGER B, 1990, J CELL SCI, V97, P607; GINGELL D, 1992, J CELL SCI, V101, P255; GULINO D, 1992, J BIOL CHEM, V267, P1001; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; Kemler R, 1992, Semin Cell Biol, V3, P149; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOCH PJ, 1992, P NATL ACAD SCI USA, V89, P353, DOI 10.1073/pnas.89.1.353; KOLLER E, 1994, MOL BIOL CELL, V5, P1073; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; LEACH L, 1993, J CELL SCI, V104, P1073; LEVINE E, 1994, DEVELOPMENT, V120, P901; MAARS JA, 1993, J CELL BIOL, V123, P149; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MARTINPADURA I, 1994, J BIOL CHEM, V269, P3124; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; MCNEILL H, 1993, J CELL BIOL, V120, P1217, DOI 10.1083/jcb.120.5.1217; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARADIES NE, 1993, J NEUROSCI RES, V117, P415; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; Sambrook J, 1989, MOL CLONING LABORATO; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKEICHI M, 1987, TRENDS GENET, V3, P213, DOI 10.1016/0168-9525(87)90238-1; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANIHARA H, 1994, J CELL SCI, V107, P1697; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; VANWEEME.BK, 1971, FEBS LETT, V15, P232, DOI 10.1016/0014-5793(71)80319-8; VESTAL DJ, 1992, J CELL BIOL, V119, P451, DOI 10.1083/jcb.119.2.451; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305	63	193	195	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30965	30972		10.1074/jbc.270.52.30965	http://dx.doi.org/10.1074/jbc.270.52.30965			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537353	hybrid			2022-12-25	WOS:A1995TN44400021
J	Zhang, R; Zhao, JJ; Potter, JD				Zhang, R; Zhao, JJ; Potter, JD			Phosphorylation of both serine residues in cardiac troponin is required to decrease the Ca2+ affinity of cardiac troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 ADJACENT PHOSPHOSERINES; SKELETAL-MUSCLE; CYCLIC-AMP; I PHOSPHORYLATION; PROTEIN-KINASES; RAT-HEART; BOVINE; RABBIT; CELLS; SPECTROSCOPY	The phosphorylation of cardiac muscle troponin I (CTnI) at two adjacent N-terminal serine residues by cAMP-dependent protein kinase (PKA) has been implicated in the inotropic response of the heart to beta-agonists. Phosphorylation of these residues has been shown to reduce the Ca2+ affinity of the single Ca2+-specific regulatory site of cardiac troponin C (CTnC) and to in crease the rate of Ca2+ dissociation from this site (Robertson, S. P., Johnson, J. D., Holroyde, M. J., Kranias, E. G., Potter, J. D., and Solaro, R. J. (1982) J. Biol. Chem. 257, 260-263). Recent studies (Zhang, R., Zhao, J., and Potter, J. D. (1995) Circ. Res. 76, 1028-1035) have correlated this increase in Ca2+ dissociation with a reduced Ca2+ sensitivity of force development and a faster rate of cardiac muscle relaxation in a PKA phosphorylated skinned cardiac muscle preparation. To further determine the role of the two PKA phosphorylation sites in mouse CTnI (serine 22 and 23), serine 22 or 23, or both were mutated to alanine. The wild type and the mutated CTnIs were expressed in Escherichia coli and purified. Using these mutants, it was found that serine 23 was phosphorylated more rapidly than serine 22 and that both serines are required to be phosphorylated in order to observe the characteristic reduction in the Ca2+ sensitivity of force development seen in a skinned cardiac muscle preparation. The latter result confirms that PKA phosphorylation of CTnI, and not other proteins, is responsible for this change in Ca2+ sensitivity. The results also suggest that one of the serines (23) may be constitutively phosphorylated and that serine 22 may be functionally more important.	UNIV MIAMI,SCH MED,DEPT MOLEC & CELLULAR PHARMACOL,MIAMI,FL 33101	University of Miami					NHLBI NIH HHS [R37 HL42325] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILIN G, 1979, AM J PHYSIOL, V236, pC41, DOI 10.1152/ajpcell.1979.236.1.C41; ENGLAND PJ, 1976, BIOCHEM J, V160, P295, DOI 10.1042/bj1600295; FABIATO A, 1975, NATURE, V253, P556, DOI 10.1038/253556b0; FARAH CS, 1994, J BIOL CHEM, V269, P5230; GARVEY JL, 1988, BIOCHEM J, V249, P709, DOI 10.1042/bj2490709; GUO XD, 1994, J BIOL CHEM, V269, P15210; GUTH K, 1987, J BIOL CHEM, V262, P13627; HARTZELL HC, 1984, J GEN PHYSIOL, V83, P563, DOI 10.1085/jgp.83.4.563; HOFMANN PA, 1994, CIRC RES, V74, P718, DOI 10.1161/01.RES.74.4.718; JAQUET K, 1993, BIOCHEMISTRY-US, V32, P13873, DOI 10.1021/bi00213a016; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KRUDY GA, 1994, J BIOL CHEM, V269, P23731; LESZYK J, 1988, BIOCHEMISTRY-US, V27, P2821, DOI 10.1021/bi00408a024; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MITTMANN K, 1990, FEBS LETT, V273, P41, DOI 10.1016/0014-5793(90)81046-Q; MITTMANN K, 1992, FEBS LETT, V302, P133, DOI 10.1016/0014-5793(92)80423-E; MOPE L, 1980, J GEN PHYSIOL, V75, P271, DOI 10.1085/jgp.75.3.271; MURPHY AM, 1991, BIOCHEMISTRY-US, V30, P707, DOI 10.1021/bi00217a018; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; RAPUNDALO ST, 1989, CIRC RES, V64, P104, DOI 10.1161/01.RES.64.1.104; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; SOLARO RJ, 1986, PROTEIN PHOSPHORYLAT, P129; STRAUSS JD, 1992, FEBS LETT, V310, P229, DOI 10.1016/0014-5793(92)81338-M; STULL JT, 1980, FED PROC, V39, P1552; SWIDEREK K, 1988, EUR J BIOCHEM, V176, P335, DOI 10.1111/j.1432-1033.1988.tb14286.x; SWIDEREK K, 1990, EUR J BIOCHEM, V190, P575, DOI 10.1111/j.1432-1033.1990.tb15612.x; TALOSI L, 1993, AM J PHYSIOL, V264, pH791; Tsien R W, 1977, Adv Cyclic Nucleotide Res, V8, P363; VENEMA RC, 1993, J BIOL CHEM, V268, P2705; ZHANG R, 1995, CIRC RES, V76, P1028, DOI 10.1161/01.RES.76.6.1028; ZHANG R, 1992, Biophysical Journal, V61, pA280; ZHANG R, 1994, BIOPHYS J, V66, pA316; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	36	137	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30773	30780		10.1074/jbc.270.51.30773	http://dx.doi.org/10.1074/jbc.270.51.30773			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530519	hybrid			2022-12-25	WOS:A1995TL67500084
J	CARTAUD, A; STETZKOWSKIMARDEN, F; CARTAUD, J				CARTAUD, A; STETZKOWSKIMARDEN, F; CARTAUD, J			IDENTIFICATION OF DYSTROPHIN-BINDING PROTEIN(S) IN MEMBRANES FROM TORPEDO ELECTROCYTE AND RAT MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; ACETYLCHOLINE-RECEPTOR; ELECTRIC ORGAN; POSTSYNAPTIC MEMBRANE; MARMORATA ELECTROCYTE; GLYCOPROTEIN COMPLEX; PURIFICATION; MICE; LOCALIZATION	Using solubilized dystrophin isolated from torpedo electric tissue and in vitro blot overlay assay, we have identified dystrophin-binding proteins in membranes from Torpedo electrocyte and rat muscle. In acetylcholine receptor-rich membranes from Torpedo marmorata electric tissue, an extrinsic protein of M(r) 52,000, known as the 58-kDa protein (Froehner, S. C. (1984) J. Cell Biol. 99, 88-96), represents the major binding site for dystrophin. When membranes were solubilized by non-ionic detergents, the 52-kDa protein as well as a few proteins of M(r) 200,000, 87,000, and 45,000 coextract and copurify with dystrophin. In rat sarcolemma, a protein doublet of approximately 58-60 kDa also binds dystrophin in vitro, this protein likely being the DAP 59 characterized by Ervasti and Campbell (Ervasti, J. M., and Campbell, K. P. (1991) Cell 66, 1121-1131). We postulate that the 52- and 59-kDa proteins are functional homologs that play the role of ''receptors'' for dystrophin in various specialized membrane domains.	UNIV PARIS 07, CNRS,INST JACQUES MONOD, DEPT BIOL SUPRAMOLEC & CELLULAIRE,2 PL JUSSIEU, F-75251 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite								Bollag D.M., 1991, PROTEIN METHODS; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; BYERS TJ, 1991, J CELL BIOL, V115, P411, DOI 10.1083/jcb.115.2.411; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CARR DW, 1992, TRENDS BIOCHEM SCI, V17, P246, DOI 10.1016/0968-0004(92)90402-U; CARTAUD A, 1992, NEUROSCIENCE, V48, P995, DOI 10.1016/0306-4522(92)90288-D; CARTAUD A, 1990, J CELL BIOL, V111, P581, DOI 10.1083/jcb.111.2.581; CARTAUD A, 1992, MOL BIOL CELL, V3, pA366; CARTAUD J, 1978, J CELL SCI, V29, P313; CARTAUD J, 1993, EUR J NEUROSCI, V5, P191, DOI 10.1111/j.1460-9568.1993.tb00485.x; CHANG HW, 1989, J BIOL CHEM, V264, P20831; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FARDEAU M, 1990, CR ACAD SCI III-VIE, V311, P197; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; FROEHNER SC, 1984, J CELL BIOL, V99, P88, DOI 10.1083/jcb.99.1.88; HAMMONDS RG, 1987, CELL, V51, P1, DOI 10.1016/0092-8674(87)90002-X; HEUSER JE, 1979, J CELL BIOL, V82, P150, DOI 10.1083/jcb.82.1.150; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; JASMIN BJ, 1990, P NATL ACAD SCI USA, V87, P3938, DOI 10.1073/pnas.87.10.3938; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KORDELI E, 1986, J CELL BIOL, V102, P748, DOI 10.1083/jcb.102.3.748; KORDELI E, 1989, J CELL BIOL, V108, P127, DOI 10.1083/jcb.108.1.127; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROCHELLE WJ, 1990, J NEUROSCI, V10, P3460; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; MUELLER H, 1983, J MOL BIOL, V163, P647, DOI 10.1016/0022-2836(83)90116-X; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PONS F, 1991, FEBS LETT, V282, P161, DOI 10.1016/0014-5793(91)80468-I; RICHARDSON GP, 1987, CELL TISSUE RES, V247, P651, DOI 10.1007/BF00215760; SATO O, 1992, J BIOCHEM-TOKYO, V112, P631, DOI 10.1093/oxfordjournals.jbchem.a123951; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SHIMIZU T, 1989, BIOMED RES-TOKYO, V10, P405, DOI 10.2220/biomedres.10.405; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; YEADON JE, 1991, J CELL BIOL, V115, P1069, DOI 10.1083/jcb.115.4.1069; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	47	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13019	13022						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514742				2022-12-25	WOS:A1993LH55300003
J	HEI, YJ; MCNEILL, JH; SANGHERA, JS; DIAMOND, J; BRYERASH, M; PELECH, SL				HEI, YJ; MCNEILL, JH; SANGHERA, JS; DIAMOND, J; BRYERASH, M; PELECH, SL			CHARACTERIZATION OF INSULIN-STIMULATED SERYL THREONYL PROTEIN-KINASES IN RAT SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-REGULATED KINASES; ACTIVATED S6 KINASE; RIBOSOMAL PROTEIN-S6; 3T3 CELLS; XENOPUS EGGS; II ACTIVITY; PHOSPHORYLATION; PURIFICATION; RAF-1	Postinsulin receptor signal transduction is mediated by a cascade of seryl/threonyl protein kinases which includes a family of mitogen-activated protein (MAP) kinases, ribosomal protein S6 kinases, and casein kinase-2. Previous studies have characterized these kinases primarily in cultured or isolated cells. We have demonstrated that intravenous injection of insulin into fasted rats significantly stimulated the activities of MAP kinases and S6 kinases in skeletal muscle, independently of the blood glucose levels in these animals. Anion exchange chromatography on Mono Q afforded the resolution of at least five peaks of insulin-stimulated myelin basic protein kinase activity. By immunological criteria, these myelin basic protein kinases included the p42mapk and p44erk1 as well as other potentially novel 44-kDa MAP kinases. Insulin-activated ribosomal S6 kinases were resolved into two major peaks by Mono Q chromatography, the latter of which contained a 100-kDa isoform of p90rsk as revealed by immunoblotting with an anti-rsk-peptide antibody. A 32-kDa S6 kinase in the earlier peak may represent a novel protein kinase in this tissue. Skeletal muscle casein kinase-2 was not significantly stimulated following insulin injection into rats under our experimental conditions. These results indicate that the intact rat can serve as a useful model system to investigate the mechanisms of insulin signal transduction.	UNIV BRITISH COLUMBIA, FAC PHARMACEUT SCI, DIV PHARMACOL & TOXICOL, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, FAC MED, DEPT MED, VANCOUVER V6T 1Z3, BC, CANADA; KINETEK BIOTECHNOL CORP, RICHMOND V7C 1T6, BC, CANADA	University of British Columbia; University of British Columbia								ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; AVRUCH J, 1991, RECENT ADV INSULIN A, P63; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BLENIS J, 1991, CANCER CELL, V3, P1; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; CRWW C, 1992, P NATL ACAD SCI USA, V89, P8205; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; ETTEHADIEH E, 1992, SCIENCE, V255, P853, DOI 10.1126/science.1311128; GERICH JE, 1988, DIABETES, V37, P1608, DOI 10.2337/diabetes.37.12.1608; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HECHT LB, 1988, BIOCHEM BIOPH RES CO, V152, P1200, DOI 10.1016/S0006-291X(88)80412-1; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KAWAKAMI M, 1991, EXP CELL RES, V193, P120, DOI 10.1016/0014-4827(91)90545-6; KLARLUND JK, 1988, J BIOL CHEM, V263, P15872; KLARLUND JK, 1990, J BIOL CHEM, V265, P227; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KRIEG J, 1988, METHOD ENZYMOL, V164, P575; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE RM, 1991, J BIOL CHEM, V266, P10351; LEE RM, 1992, J BIOL CHEM, V267, P1088; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELECH SL, 1987, J BIOL CHEM, V262, P11598; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; ROTH RA, 1990, INSULIN, P169; SANGHERA JS, 1992, BIOCHIM BIOPHYS ACTA, V1135, P335, DOI 10.1016/0167-4889(92)90240-C; SEGER R, 1992, J BIOL CHEM, V267, P14373; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P8834, DOI 10.1073/pnas.84.24.8834; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TABARINI D, 1987, BIOCHEM BIOPH RES CO, V144, P891, DOI 10.1016/S0006-291X(87)80048-7; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOBE K, 1992, J BIOL CHEM, V267, P21089; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701	69	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13203	13213						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514759				2022-12-25	WOS:A1993LH55300030
J	Singh, K; Balligand, JL; Fischer, TA; Smith, TW; Kelly, RA				Singh, K; Balligand, JL; Fischer, TA; Smith, TW; Kelly, RA			Regulation of cytokine-inducible nitric oxide synthase in cardiac myocytes and microvascular endothelial cells - Role of extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2) and STAT1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASES; EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE; MAP KINASE; CELLULAR PROLIFERATION; TRANSDUCTION PATHWAYS; INVERSE CORRELATION; INTERFERON-GAMMA; PC12 CELLS; ACTIVATION	Adult rat ventricular myocytes and cardiac microvascular endothelial cells (CMEC) both express an inducible nitric oxide synthase (iNOS or NOS2) following exposure to soluble inflammatory mediators, However, NOS2 gene expression is regulated differently in response to specific cytokines in each cell type, Interleukin-1 beta (IL-1 beta) induces NOS2 in both, whereas interferon gamma (IFN gamma) induces NOS2 expression in myocytes but not in CMEC, Therefore, we examined the specific signal transduction pathways that could regulate NOS2 mRNA levels, including activation of 44- and 42-kDa mitogen activated protein kinases (MAPKs; ERK1/ERK2) and STAT1 alpha, a transcriptional regulatory protein linked to cell membrane receptors, Although IL-1 beta treatment increased ERK1/ERK2 activities in both cell types, IFN gamma activated these MAPKs only in myocytes, STAT1 alpha phosphorylation, consistent with IFN gamma-induced signaling, was readily apparent in both cell types, and binding of activated STAT1 alpha from cytoplasmic or nuclear fractions from IFN gamma-treated adult myocytes to a sis-inducible element could be demonstrated by gel-shift assay, The farnesyl transferase inhibitor BZA-5B blocked activation of ERK1/ERK2 and induction of NOS2 by IFN gamma and IL-1 beta in myocytes, IL-1 beta and IFN gamma-induced NOS2 gene expression in myocytes was also down-regulated by both protein kinase C (PKC) desensitization and by the PKC inhibitor bisindolylmaleimide, implicating PKC-linked activation of Ras or Raf in the induction of NOS2 by IL-1 beta and IFN gamma in cardiac muscle cells, In CMEC, the MAPK kinase inhibitor PD 98059 blocked activation of ERK1/ERK2 and down-regulated IL-1 beta-mediated NOS2 induction, whereas activation of ERK2 in the absence of cytokines by okadaic acid, an inhibitor of phosphoserine protein phosphatases, also induced NOS2 mRNA, These data demonstrate that ERK1/ERK2 activation appears to be necessary for the induction of NOS2 by IL-1 beta and IFN gamma in cardiac myocytes and CMEC. In the absence of ERK1/ERK2 activation by IFN gamma in CMEC, phosphorylation of STAT1 alpha is not sufficient for NOS2 gene expression, These overlapping yet distinct cellular responses to specific cytokines may serve to target NOS2 gene expression to specific cells or regions within the heart and also provide for rapid escalation of NO production if required for host defense.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Balligand, Jean-Luc J/D-7543-2012	BALLIGAND, Jean-Luc/0000-0002-0522-4156	NHLBI NIH HHS [IP50-HL52320, R37-HL36141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036141, P50HL052320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BALLIGAND JL, 1995, AM J PHYSIOL-HEART C, V268, pH1293, DOI 10.1152/ajpheart.1995.268.3.H1293; BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BERGER HJ, 1994, AM J PHYSIOL, V266, pH341, DOI 10.1152/ajpheart.1994.266.1.H341; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHANDLER LJ, 1995, AM J PHYSIOL-CELL PH, V268, pC700, DOI 10.1152/ajpcell.1995.268.3.C700; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; GOUREAU O, 1993, P NATL ACAD SCI USA, V90, P4276, DOI 10.1073/pnas.90.9.4276; GUAN KL, 1994, CELL SIGNAL, V6, P581, DOI 10.1016/0898-6568(94)90041-8; HECK DE, 1992, J BIOL CHEM, V267, P21277; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KANNO K, 1993, HYPERTENSION, V22, P34, DOI 10.1161/01.HYP.22.1.34; LAZAU A, 1994, CIRC  RES, V75, P932; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIYASAKA T, 1990, BIOCHEM BIOPH RES CO, V168, P1237, DOI 10.1016/0006-291X(90)91161-K; MUHL H, 1994, BIOCHEM J, V303, P607; MUROYA K, 1992, ONCOGENE, V7, P277; NAKAYAMA I, 1994, J BIOL CHEM, V269, P11628; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIDA M, 1993, AM J PHYSIOL, V264, pH639, DOI 10.1152/ajpheart.1993.264.2.H639; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PANSE RL, 1994, MOL PHARMACOL, V46, P445; PERRELLA MA, 1994, J BIOL CHEM, V269, P27045; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; PUNJABI CJ, 1992, J IMMUNOL, V149, P2179; RICHARDSON CA, 1995, AM J PHYSIOL-RENAL, V268, pF273, DOI 10.1152/ajprenal.1995.268.2.F273; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P486, DOI 10.1161/01.RES.77.3.486; UNGUREANULONGROIS D, 1995, J MOL CELL CARDIOL, V27, P155, DOI 10.1016/S0022-2828(08)80015-6; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P494, DOI 10.1161/01.RES.77.3.494; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; YANG XC, 1994, J CLIN INVEST, V94, P714, DOI 10.1172/JCI117390	65	137	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1111	1117		10.1074/jbc.271.2.1111	http://dx.doi.org/10.1074/jbc.271.2.1111			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557638	hybrid			2022-12-25	WOS:A1996TP88900075
J	Cheng, KR; Koland, JG				Cheng, KR; Koland, JG			Nucleotide binding by the epidermal growth factor receptor protein-tyrosine kinase - Trinitrophenyl-ATP as a spectroscopic probe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; PHOSPHORYLATION; MECHANISM; ACTIVATION; SITES; EGF	The nucleotide binding properties of the epidermal growth factor (EGF) receptor protein tyrosine kinase were investigated with the fluorescent nucleotide analog 2'(3')-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate (TNP-ATP). TNP-ATP was found to be an active substrate for the autophosphorylation reaction of the recombinant EGF receptor protein tyrosine kinase domain (TKD). Whereas the V-max for the TNP-ATP-dependent autophosphorylation reaction was approximately 200-fold lower than that of ATP, the K-m for this reaction was similar to that observed with ATP. The nucleotide analog was also shown to be an inhibitor of the ATP-dependent autophosphorylation and substrate phosphorylation reactions of the TKD. Spectroscopic studies demonstrated both a high affinity binding of TNP-ATP to the recombinant TKD and a markedly enhanced fluorescence of the bound nucleotide analog. The fluorescence of enzyme-bound TNP-ATP was attenuated in the presence of ATP, which enabled determination of the dissociation constants for both ATP and the Mn2+ complex of ATP. A truncated form of the EGF receptor TKD lacking the C-terminal autophosphorylation domain exhibited an enhanced affinity for TNP-ATP, which indicated that the autophosphorylation domain occupied the peptide substrate binding site of the TKD and modulated the binding of the nucleotide substrates.	UNIV IOWA, COLL MED, DEPT PHARMACOL, IOWA CITY, IA 52242 USA	University of Iowa				Koland, John/0000-0002-5028-4297	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044684, R01DK044684] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44684] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROGLIE KE, 1983, J BIOL CHEM, V258, P2940; CARPENTER G, 1979, J BIOL CHEM, V254, P4884; ERNEUX C, 1983, J BIOL CHEM, V258, P4137; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; GUYER CA, 1994, ARCH BIOCHEM BIOPHYS, V312, P573, DOI 10.1006/abbi.1994.1347; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HISABORI T, 1992, J BIOL CHEM, V267, P4551; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HUBLER L, 1992, BIOCHEM J, V281, P107, DOI 10.1042/bj2810107; HUNTER T, 1986, ENZYMES, V17, P191; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOLAND JG, 1990, BIOCHIM BIOPHYS ACTA, V1052, P489, DOI 10.1016/0167-4889(90)90160-F; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; Morrison J F, 1979, Methods Enzymol, V63, P257; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; POSNER I, 1992, J BIOL CHEM, V267, P20638; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIERKE SL, 1993, BIOCHEMISTRY-US, V32, P10102, DOI 10.1021/bi00089a028; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					311	318		10.1074/jbc.271.1.311	http://dx.doi.org/10.1074/jbc.271.1.311			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550578	hybrid			2022-12-25	WOS:A1996TP36100048
J	Colomer, V; Kicska, GA; Rindler, MJ				Colomer, V; Kicska, GA; Rindler, MJ			Secretory granule content proteins and the luminal domains of granule membrane proteins aggregate in vitro at mildly acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; B SECRETOGRANIN-I; CHROMOGRANIN-A; ATT-20 CELLS; CONDENSING VACUOLE; VESICLE MEMBRANE; EXOCRINE CELLS; CALCIUM; INVITRO; BINDING	A major unresolved issue in the field of secretory granule biogenesis is the extent to which the aggregation of granule content proteins is responsible for the sorting of regulated from constitutively secreted proteins, The aggregation process is postulated to take place in the trans-Golgi network and immature secretory granules as the proteins encounter mildly acidic pH and high calcium concentrations, We have developed in vitro assays that reconstitute the precipitation out of solution of secretory granule content proteins of anterior pituitary gland and adrenal medulla. In the assays, all of the major granule content polypeptides form a precipitate as the pH is titrated below 6.5, and this precipitate can be recovered in the pellet fraction after centrifugation. Addition of calcium is required for the aggregation of chromaffin granule content. In contrast to the proteins secreted by the regulated pathway, the constitutively secreted proteins IgG, albumin, and angiotensinogen, when added to the assays, remain predominantly in the supernatant, Among the individual proteins tested, prolactin is found to aggregate homophilically under these conditions and can drive the co-aggregation of other proteins, such as the chromogranins, Soluble forms of granule membrane proteins, including dopamine beta-hydroxylase and peptidyl glycine alpha-amidating enzyme also co-aggregated with granule content proteins, The results are consistent with the idea that spontaneous aggregation of proteins occurring under ionic conditions similar to those at the sites of granule formation is a property restricted to those proteins packaged in secretory granules, In addition, the association of luminal domains of membrane proteins with content proteins in vibro raises the possibility that analogous interactions between membrane-bound and content proteins also occur during granule formation in intact cells.	NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University					NIDDK NIH HHS [DK44238] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044238] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASSETTI M, 1990, J HISTOCHEM CYTOCHEM, V38, P1353, DOI 10.1177/38.9.2387987; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; CARNELL L, 1994, J CELL BIOL, V127, P693, DOI 10.1083/jcb.127.3.693; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; COLOMER V, 1994, EMBO J, V13, P3711, DOI 10.1002/j.1460-2075.1994.tb06680.x; DESCHEPPER CF, 1990, HYPERTENSION, V16, P147, DOI 10.1161/01.HYP.16.2.147; DHAWAN S, 1987, J BIOL CHEM, V262, P1869; EIPPER BA, 1988, J BIOL CHEM, V263, P8371; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GIANNATTASIO G, 1975, J CELL BIOL, V64, P246, DOI 10.1083/jcb.64.1.246; GORR SU, 1988, BONE MINER, V4, P17; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; GRIMES M, 1992, J CELL BIOL, V117, P539, DOI 10.1083/jcb.117.3.539; JAMIESON JD, 1971, J CELL BIOL, V48, P503, DOI 10.1083/jcb.48.3.503; KAARSHOLM NC, 1990, ARCH BIOCHEM BIOPHYS, V283, P496, DOI 10.1016/0003-9861(90)90673-M; KADNER SS, 1984, ENDOCRINOLOGY, V155, P2406; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; LEBLOND FA, 1993, BIOCHEM J, V291, P289, DOI 10.1042/bj2910289; MATA M, 1987, HISTOCHEMISTRY, V87, P339, DOI 10.1007/BF00492588; MAY V, 1988, J BIOL CHEM, V263, P7550; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MITRA A, 1994, J BIOL CHEM, V269, P19876; MOORE HP, 1983, NATURE, V302, P434, DOI 10.1038/302434a0; NOLAN J, 1985, ARCH BIOCHEM BIOPHYS, V240, P257, DOI 10.1016/0003-9861(85)90031-1; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1994, J CELL BIOL, V126, P1149, DOI 10.1083/jcb.126.5.1149; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1987, NATURE, V326, P77, DOI 10.1038/326077a0; OZAWA H, 1994, J HISTOCHEM CYTOCHEM, V42, P1097, DOI 10.1177/42.8.8027529; RAMBOURG A, 1992, ANAT RECORD, V232, P169, DOI 10.1002/ar.1092320202; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; SACHS E, 1992, AM J PHYSIOL, V262, pG257, DOI 10.1152/ajpgi.1992.262.2.G257; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SCAMMELL JG, 1990, J HISTOCHEM CYTOCHEM, V38, P949, DOI 10.1177/38.7.2192000; SCHMIDT WK, 1994, J BIOL CHEM, V269, P27115; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; VONZASTROW M, 1989, J BIOL CHEM, V264, P6566; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; YOO SH, 1994, J BIOL CHEM, V269, P12001; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; YOO SH, 1993, BIOCHIM BIOPHYS ACTA, V1179, P239, DOI 10.1016/0167-4889(93)90078-4	47	131	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					48	55		10.1074/jbc.271.1.48	http://dx.doi.org/10.1074/jbc.271.1.48			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550606	hybrid			2022-12-25	WOS:A1996TP36100009
J	Le, XF; Yang, P; Chang, KS				Le, XF; Yang, P; Chang, KS			Analysis of the growth and transformation suppressor domains of promyelocytic leukemia gene, PML	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER; RAR-ALPHA; T(15-17) TRANSLOCATION; SEQUENCE MOTIF; BREAKPOINT; EXPRESSION; PROTEINS; BINDING; FAMILY; FUSES	The promyelocytic leukemia gene (PML) involved in the t(15;17) (q22;q12) translocation in acute promyelocytic leukemia is a growth suppressor. To elucidate the functional domains of PML, several mutants lacking the nuclear localization signal (PMLnls-), the dimerization domain (PMLdim-), the proline-rich domain at the N-terminal (PMLpro-), the proline-rich RING finger motif (PMLpr-), the proline-rich RING finger B-box-1 (PML-prb-), the serine-proline-rich domain at the C-terminal (PMLsp-), and the double mutant (PMLprb-nls-) have been constructed. Immunofluorescence staining of transiently transfected NIH3T3 cells demonstrated that the RING finger motif, dimerization domain, and nuclear localization signal are all required for the formation of PML oncogenic domains (PODs). Immunofluorescence staining of transiently transfected GM637D human fibroblasts indicated that expression of PMLprb-, PM-Lnls-, and PMLprb-nls- led to a significant reduction or, in some cases, complete elimination of PODs, PMLdim-, PMLnls-, PMLpr-, PMLprb-, and PMLprb-nls- mutants were found to lose their ability to suppress transformation of NIH3T3 cells by activated neu, while PMLpro- and PMLsp- mutants did not. These results suggest that the ability of PML to form a POD is essential for suppression of growth and transformation. Furthermore, since PMLprb-, PMLnls-, and PMLprb-nls- mutants could block the suppression effect of wild-type PML on transformation of NIH3T3 cells by the neu oncogene, these PML mutants are potential dominant negative inhibitors of PML. Our study also suggests that the RING finger motif may interact with other nuclear proteins.	UNIV TEXAS, MD ANDERSON CANC CTR, DIV LAB MED, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA055577] Funding Source: NIH RePORTER; NCI NIH HHS [CA55577] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROWLEY JD, 1977, LANCET, V1, P549; TERRIS B, 1995, CANCER RES, V55, P1590; TESTA U, 1994, CANCER RES, V54, P4508; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; ZHU ZM, 1994, J VIROL, V68, P3027, DOI 10.1128/JVI.68.5.3027-3040.1994	34	116	120	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					130	135		10.1074/jbc.271.1.130	http://dx.doi.org/10.1074/jbc.271.1.130			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550548	hybrid			2022-12-25	WOS:A1996TP36100021
J	Liauw, S; Steinberg, RA				Liauw, S; Steinberg, RA			Dephosphorylation of catalytic subunit of cAMP-dependent protein kinase at Thr-197 by a cellular protein phosphatase and by purified protein phosphatase-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION; SITES	Thr-197 phosphate is essential for optimal activity of the catalytic (C) subunit of cAMP-dependent protein kinase enzyme, and, in the C subunit crystal structure, it is buried in a cationic pocket formed by the side chains of His-87, Arg-165, Lys-189, and Thr-195. Because of its apparent role in stabilizing the active conformation of C subunit and its resistance to several phosphatases, the phosphate on Thr-197 has been assumed to be metabolically stable. We now show that this phosphate can be removed from C subunit by a protein phosphatase activity extracted from S49 mouse lymphoma cells or by purified protein phosphatase-2A (PP-2A) with concomitant loss of enzymatic activity. By anion-exchange chromatography, inhibitor sensitivity, and relative activity against glycogen phosphorylase a and C subunit as substrates, the cellular phosphatase resembled a multimeric form of PP-2A. PP-1 was ineffective against native C subunit, but it was able to dephosphorylate Thr-197 in urea-treated C subunit. Accessibility of Thr-197 phosphate to the cellular phosphatase was enhanced by storage of C subunit in a phosphate-free buffer or by inclusion of modest concentrations of urea in the reactions and was reduced by salt concentrations in the physiological range and/or by amino-terminal myristoylation. It is concluded that a multimeric form of PP-2A or a closely related enzyme from cell extracts is capable of removing the Thr-197 phosphate from native C subunit in vitro and could account for significant turnover of this phosphate in intact cells.	UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,BMSB 853,OKLAHOMA CITY,OK 73190	University of Oklahoma System; University of Oklahoma Health Sciences Center								BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Fiske CH, 1925, J BIOL CHEM, V66, P375; GRUPPUSO PA, 1985, J BIOL CHEM, V260, P4288; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARUSYK R, 1980, ANAL BIOCHEM, V105, P403, DOI 10.1016/0003-2697(80)90477-7; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; SHOJI S, 1979, J BIOL CHEM, V254, P6211; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STEINBERG RA, 1978, CELL, V15, P1351, DOI 10.1016/0092-8674(78)90060-0; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TONERWEBB J, 1992, J BIOL CHEM, V267, P25174; YAN MH, 1994, J BIOL CHEM, V269, P19067; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	25	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					258	263		10.1074/jbc.271.1.258	http://dx.doi.org/10.1074/jbc.271.1.258			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550570				2022-12-25	WOS:A1996TP36100040
J	Takusagawa, F; Kamitori, S; Misaki, S; Markham, GD				Takusagawa, F; Kamitori, S; Misaki, S; Markham, GD			Crystal structure of S-adenosylmethionine synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; ARABIDOPSIS-THALIANA; DATA-COLLECTION; EXPRESSION; GENE; CDNA	The structure of S-adenosylmethionine synthetase (MAT, ATP:L-methionine S-adenosyltransferase, EC 2.5.1.6.) from Escherichia coli has been determined at 3.0 Angstrom resolution by multiple isomorphous replacement using a uranium derivative and the selenomethionine form of the enzyme (SeMAT). The SeMAT data (9 selenomethionine residues out of 383 amino acid residues) have been found to have a sufficient phasing power to determine the structure of the 42,000 molecular weight protein by combining them with the other heavy atom derivative data (multiple isomorphous replacement). The enzyme consists of four identical subunits; two subunits form a spherical tight dimer, and pairs of these dimers form a peanut-shaped tetrameric enzyme. Each pair dimer has two active sites which are located between the subunits. Each subunit consists of three domains that are related to each other by pseudo-3-fold symmetry. The essential divalent (Mg2+/Co2+) and monovalent (K+) metal ions and one of the product, P-i ions, were found in the active site from three separate structures.	UNIV KANSAS,DEPT BIOCHEM,LAWRENCE,KS 66045; FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111	University of Kansas; Fox Chase Cancer Center	Takusagawa, F (corresponding author), UNIV KANSAS,DEPT CHEM,MALOTT HALL,LAWRENCE,KS 66045, USA.			Kamitori, Shigehiro/0000-0002-3950-3372	NCI NIH HHS [CA06927] Funding Source: Medline; NIGMS NIH HHS [GM37233, GM31186] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABADZAPATERO C, 1987, J MOL BIOL, V198, P445, DOI 10.1016/0022-2836(87)90293-2; BILLINGSLEY ML, 1982, J PHARMACOL EXP THER, V223, P681; BOUCHARD P, 1981, P NATL ACAD SCI-BIOL, V78, P1033, DOI 10.1073/pnas.78.2.1033; Brunger A.T., 1993, X PLOR 3 1 SYSTEM XR; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CANTONI GL, 1953, J BIOL CHEM, V204, P403; CHAWLA RK, 1990, DRUGS, V40, P98, DOI 10.2165/00003495-199000403-00010; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; DILIBERTO EJ, 1982, CELLULAR REGULATION, P147; GILLILAND GL, 1983, J BIOL CHEM, V258, P6963; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HORIKAWA S, 1989, EUR J BIOCHEM, V184, P497, DOI 10.1111/j.1432-1033.1989.tb15042.x; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; HORIKAWA S, 1991, BIOCHEM INT, V25, P81; HORIKAWA S, 1992, FEBS LETT, V312, P37, DOI 10.1016/0014-5793(92)81405-B; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOSHLAND DE, 1988, BIOCHEMISTRY-US, V27, P5829, DOI 10.1021/bi00416a001; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LARSEN PB, 1991, PLANT PHYSIOL, V96, P997, DOI 10.1104/pp.96.3.997; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MARKHAM GD, 1981, J BIOL CHEM, V256, P1903; MARKHAM GD, 1988, J BIOL CHEM, V263, P8666; MARKHAM GD, 1984, J BIOL CHEM, V259, P4505; MCQUENEY MS, 1995, J BIOL CHEM, V270, P18277, DOI 10.1074/jbc.270.31.18277; MUDD SH, 1958, J BIOL CHEM, V231, P481; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; PASCALE RM, 1992, CANCER RES, V52, P4979; PEGG AE, 1988, CANCER RES, V48, P759; PELEMAN J, 1989, PLANT CELL, V1, P81, DOI 10.1105/tpc.1.1.81; PELEMAN J, 1989, GENE, V84, P359, DOI 10.1016/0378-1119(89)90510-6; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; RECZKOWSKI RS, 1991, FASEB J, V5, pA1150; REESE LS, 1991, EMBO J, V10, P25; REGLAND B, 1992, MED HYPOTHESES, V38, P11, DOI 10.1016/0306-9877(92)90153-4; SATISHCHANDRAN C, 1993, MOL MICROBIOL, V9, P835, DOI 10.1111/j.1365-2958.1993.tb01742.x; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; TAKUSAGAWA F, 1992, J APPL CRYSTALLOGR, V25, P26, DOI 10.1107/S0021889891009019; TANAKA I, 1990, J APPL CRYSTALLOGR, V23, P334, DOI 10.1107/S0021889890004009; THOMAS CS, 1987, INT CLIN PSYCHOPHARM, V2, P97, DOI 10.1097/00004850-198704000-00001; THOMAS D, 1988, MOL CELL BIOL, V8, P5132, DOI 10.1128/MCB.8.12.5132; THOMAS D, 1987, J BIOL CHEM, V262, P16704; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433	54	101	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					136	147		10.1074/jbc.271.1.136	http://dx.doi.org/10.1074/jbc.271.1.136			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550549				2022-12-25	WOS:A1996TP36100022
J	Zwerschke, W; Joswig, S; JansenDurr, P				Zwerschke, W; Joswig, S; JansenDurr, P			Identification of domains required for transcriptional activation and protein dimerization in the human papillomavirus type-16 E7 protein	ONCOGENE			English	Article						papillomavirus; transformation; E7; transcriptional activation; dimerization	ADENOVIRUS E1A; RETINOBLASTOMA PROTEIN; HUMAN KERATINOCYTES; DNA-SYNTHESIS; TRANSFORMATION; SEQUENCES; GENE; ONCOPROTEIN; BINDING; TRANSACTIVATION	To analyse the potential of the E7 oncogene of HPV-16 to activate transcription, we constructed hybrid proteins containing various portions of the HPV-16 E7 protein fused to the DNA binding region of the bacterial LexA repressor. We found that full length HPV-16 E7 is capable to mediate activation of two different reporter genes, which carry LexA binding sites in their promoters. In contrast, E7 from HPV-11, a low-risk type papillomavirus, was unable to activate transcription, when analysed in the same assay. Mutations in the transforming domains of HPV-16 E7 did not affect the ability of the protein to activate transcription, indicating that it represents a novel function of the oncoprotein, which is not sensitive to any known inactivating mutations. Analysis of E7 subdomains revealed that the N-terminal part of HPV-16 E7 retains the capacity to activate transcription. A second trans-activation domain is located in the C-terminal part of E7; however, in the context of the full length E7 protein this activity is blocked by an adjacent domain. These results reveal a second pathway for transcriptional activation by HPV-16 E7, independent of its interaction with pRB-E2F complexes. Using the E7-LexA hybrid proteins, it is shown that E7 can form homodimers and this property involves a zinc finger structure in the C-terminal part of the protein, partially overlapping with the domain that negatively regulates transcriptional activation by E7.	DEUTSCH KREBSFORSCHUNGSZENTRUM, FORSCH SCHWERPUNKT ANGEW TUMORVIROL, ABT 620, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953				ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BANKS L, 1990, ONCOGENE, V5, P1383; BRENT R, 1984, NATURE, V312, P612, DOI 10.1038/312612a0; CICCOLINI F, 1994, ONCOGENE, V9, P2633; DEFEOJONES D, 1993, J VIROL, V67, P716, DOI 10.1128/JVI.67.2.716-725.1993; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIORE F, 1995, CELL CYCLE MATERIALS, P211; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HECK DV, 1992, P NATL ACAD SCI USA, V89, P4442, DOI 10.1073/pnas.89.10.4442; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; KAMENS J, 1991, NEW BIOL, V3, P1005; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, J VIROL, V63, P4417; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RAWLS JA, 1990, J VIROL, V64, P6121, DOI 10.1128/JVI.64.12.6121-6129.1990; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; TOMMASINO M, 1993, ONCOGENE, V8, P195; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245; ZURHAUSEN H, 1985, VIRUSES CANCER, P82	37	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					213	220						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552395				2022-12-25	WOS:A1996TQ01400027
J	Ames, JB; Tanaka, T; Ikura, M; Stryer, L				Ames, JB; Tanaka, T; Ikura, M; Stryer, L			Nuclear magnetic resonance evidence for Ca2+-induced extrusion of the myristoyl group of recoverin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; S-MODULIN; PROTEIN; TERMINUS; RODS	Recoverin, a recently discovered member of the EF-hand protein superfamily, serves as a Ca2+ sensor in vision, A myristoyl or related N-acyl group covalently attached to the amino terminus of recoverin enables it to translocate to retinal disc membranes when the Ca2+ level is elevated. Two-dimensional H-1-C-13 shift correlation NMR spectra of recoverin containing a C-13-labeled myristoyl group were obtained to selectively probe the effect of Ca2+ on the environment of the attached myristoyl group, In the Ca2+-free state, each pair of methylene protons bonded to carbon atoms 2, 3, 11, and 12 of the myristoyl group gives rise to two peaks. The splittings, caused by nonequivalent methylene proton chemical shifts, indicate that the myristoyl group interacts intimately with the protein in the Ca2+-free state. By contrast, only one peak is seen for each pair of methylene protons in the Ca2+-bound state, indicating that the myristoyl group is located in an isotropic environment in this form. Furthermore, the H-1-C-13 shift correlation NMR spectrum of Ca2+-bound recoverin is very similar to that of myristic acid in solution, H-1-C-13 Shift correlation NMR experiments were also performed with C-13-labeled recoverin to selectively probe the resonances of methyl groups in the hydrophobic core of the protein. The spectrum of Ca2+-bound myristoylated recoverin is different from that of Ca2+-free myristoylated recoverin but similar to that of Ca2+-bound unmyristoylated recoverin. Hence, the myristoyl group interacts little with the hydrophobic core of myristoylated recoverin in the Ca2+-bound state. Three-dimensional (C-13/F-1)-edited (C-13/F-3)-filtered heteronuclear multiple quantum correlation-nuclear Overhauser effect spectroscopy spectra of recoverin containing a C-13-labeled myristoyl group were obtained to selectively probe protein residues located within 5 Angstrom of the myristoyl group. The myristoyl group makes close contact with a number of aromatic residues in Ca2+-free recoverin, whereas the myristoyl group makes no observable contacts with the protein in the Ca2+-bound state. These NMR data demonstrate that the binding of Ca2+ to recoverin induces the extrusion of its myristoyl group into the solvent, which would enable it to interact with a lipid bilayer or a hydrophobic site of a target protein.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M4X 1K9,CANADA	Stanford University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto				Ikura, Mitsuhiko/0000-0002-9524-1303	NEI NIH HHS [EY02005] Funding Source: Medline; NIGMS NIH HHS [GM24032] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002005, R01EY002005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024032, R37GM024032] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; BAX A, 1981, J MAGN RESON, V43, P478, DOI 10.1016/0022-2364(81)90060-3; BENDALL MR, 1983, J MAGN RESON, V52, P81, DOI 10.1016/0022-2364(83)90264-0; DELAGLIO F, 1993, NMRPIPE SYSTEM SOFTW; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRAYKELLER MP, 1993, NEURON, V10, P523, DOI 10.1016/0896-6273(93)90339-S; HUGHES RE, 1995, BIOCHEMISTRY-US, V34, P11410, DOI 10.1021/bi00036a013; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; KATAOKA M, 1993, J BIOCHEM-TOKYO, V114, P535, DOI 10.1093/oxfordjournals.jbchem.a124212; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; Koch K W, 1994, Rev Physiol Biochem Pharmacol, V125, P149, DOI 10.1007/BFb0030910; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; KUNO T, 1992, BIOCHEM BIOPH RES CO, V184, P1219, DOI 10.1016/S0006-291X(05)80012-9; LADANT D, 1995, J BIOL CHEM, V270, P3179; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P257; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; STRYER L, 1991, J BIOL CHEM, V266, P10711; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	32	80	80	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30909	30913		10.1074/jbc.270.52.30909	http://dx.doi.org/10.1074/jbc.270.52.30909			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537345	hybrid			2022-12-25	WOS:A1995TN44400013
J	Hattori, M; Adachi, H; Aoki, J; Tsujimoto, M; Arai, H; Inoue, K				Hattori, M; Adachi, H; Aoki, J; Tsujimoto, M; Arai, H; Inoue, K			Cloning and expression of a cDNA encoding the beta-subunit (30-kDa subunit) of bovine brain platelet-activating factor acetylhydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA; SIGNALING PROTEINS; PH DOMAIN; IDENTIFICATION; CELLS; PURIFICATION; RECEPTOR; CLONES; GENE; PCR	Bovine brain platelet-activating factor (PAF) acetyl hydrolase isoform Ib is a heterotrimeric enzyme, Its gamma-subunit (which, formerly, we called the 29-kDa subunit) acts as a catalytic subunit, whereas the alpha-subunit (45 kDa) is the bovine homolog of the product of human LIS-1, the causative gene of Miller-Dieker lissencephaly, indicating that this intracellular PAF acetylhydrolase plays a key role in brain development. In the current study, we cloned the cDNA for the beta-subunit (30 kDa) of bovine brain PAF acetylhydrolase Ib. The predicted 229-amino acid sequence was homologous (63.2% identity) to that of the gamma-subunit, especially (86% identity) in the catalytic and PAF receptor homologous domains, The recombinant beta-protein produced in Escherichia coli showed significant PAF acetylhydrolase activity, A mutant protein, in which Ser(48), which corresponds to the active serine residue of the gamma-subunit, was replaced with cysteine showed no enzymatic activity, suggesting Ser(48) is the active serine residue, Although the beta- and gamma-subunits form a heterocomplex in the native enzyme, both recombinant beta- and gamma-proteins exist as a homodimer, The purified recombinant beta-protein was labeled readily with [1,3-H-3]diisopropyl fluorophosphate, whereas the beta-subunit in the native complex was only labeled with higher concentrations of [1,3(3)H]diisopropyl fluorophosphate to a lesser extent than the gamma-subunit, Combined with our previous data, the present study demonstrated that bovine brain PAF acetylhydrolase Ib is a unique enzyme possessing two catalytic subunits and another, possibly regulatory, subunit.	UNIV TOKYO, FAC PHARMACEUT SCI, DEPT HLTH CHEM, BUNKYO KU, TOKYO 113, JAPAN; SUNTORY INST BIOMED RES, MISHIMA, OSAKA 618, JAPAN	University of Tokyo; Suntory Holdings Ltd			Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969; Aoki, Junken/0000-0001-9435-1896				ADACHI H, 1995, BIOCHEM BIOPH RES CO, V214, P180, DOI 10.1006/bbrc.1995.2272; BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; BLANK ML, 1981, J BIOL CHEM, V256, P175; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; DOBYNS WB, 1991, AM J HUM GENET, V48, P584; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; ISOLA NR, 1991, BIOTECHNIQUES, V11, P580; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KWIATKOWSKI TJ, 1990, NUCLEIC ACIDS RES, V18, P7191, DOI 10.1093/nar/18.23.7191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCHESELLI VL, 1994, J NEUROSCI RES, V37, P54, DOI 10.1002/jnr.490370108; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; SOGOS V, 1990, J NEUROSCI RES, V27, P706, DOI 10.1002/jnr.490270431; STAFFORINI DM, 1991, LIPIDS, V26, P979, DOI 10.1007/BF02536488; STAFFORINI DM, 1991, METHOD ENZYMOL, V197, P411; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TAMATANI T, 1990, INT IMMUNOL, V2, P165, DOI 10.1093/intimm/2.2.165; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; VENABLE ME, 1993, J LIPID RES, V34, P691; WANG DS, 1995, BIOCHEM BIOPH RES CO, V209, P622, DOI 10.1006/bbrc.1995.1545; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; YANOSHITA R, 1988, J BIOCHEM-TOKYO, V103, P815, DOI 10.1093/oxfordjournals.jbchem.a122352	40	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31345	31352		10.1074/jbc.270.52.31345	http://dx.doi.org/10.1074/jbc.270.52.31345			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537406	hybrid			2022-12-25	WOS:A1995TN44400073
J	Laine, A; Frappier, L				Laine, A; Frappier, L			Identification of Epstein-Barr virus nuclear antigen 1 protein domains that direct interactions at a distance between DNA-bound proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID REPLICATION; INITIATOR PROTEIN; BINDING-PROTEIN; ORIGIN; ACTIVATION; ENHANCER; SITES; CELLS; EBNA1; SEQUENCES	The EBNA1 protein of Epstein-Barr virus (EBV) binds to and activates DNA replication from the EBV latent origin of replication, oriP, via a direct interaction with the two noncontiguous subelements of oriP. The EBNA1 molecules bound to the oriP subelements interact efficiently with each other by a DNA looping mechanism. We have previously mapped a region of EBNA1 (termed the looping region) that is required to mediate the interaction of the EBNA1 molecules bound to the oriP subelements. We now demonstrate that two fragments of this region of EBNA1, which consist largely of an eight amino acid repeat, can mediate homotypic interactions when transferred to another DNA-binding protein. Protein interactions mediated by the EBNA1 looping region appear to be dependent on DNA binding since these interactions were detected between DNA-bound forms of the proteins only.	MCMASTER UNIV,DEPT PATHOL,CANC RES GRP,INST MOLEC BIOL & BIOTECHNOL,HAMILTON,ON L8N 3Z5,CANADA	McMaster University								ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHATTORAJ DK, 1988, CELL, V52, P551, DOI 10.1016/0092-8674(88)90468-0; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FRAPPIER L, 1994, J BIOL CHEM, V269, P1057; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GAHN TA, 1995, J VIROL, V69, P2633, DOI 10.1128/JVI.69.4.2633-2636.1995; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; HARPER JW, 1993, CELL, V75, P805; HOCHSCHILD A, 1988, NATURE, V336, P353, DOI 10.1038/336353a0; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KNIGHT JD, 1991, P NATL ACAD SCI USA, V88, P3204, DOI 10.1073/pnas.88.8.3204; KRAMER H, 1987, EMBO J, V6, P1481, DOI 10.1002/j.1460-2075.1987.tb02390.x; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; MIDDLETON T, 1992, J VIROL, V66, P489, DOI 10.1128/JVI.66.1.489-495.1992; MIRON A, 1992, EMBO J, V11, P1205, DOI 10.1002/j.1460-2075.1992.tb05161.x; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; WYMAN C, 1995, EMBO J, V14, P117, DOI 10.1002/j.1460-2075.1995.tb06981.x; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	34	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30914	30918		10.1074/jbc.270.52.30914	http://dx.doi.org/10.1074/jbc.270.52.30914			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537346	hybrid			2022-12-25	WOS:A1995TN44400014
J	Webb, BL; Cox, MM; Inman, RB				Webb, BL; Cox, MM; Inman, RB			An interaction between the Escherichia coli RecF and RecR proteins dependent on ATP and double-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; NUCLEOSIDE TRIPHOSPHATE; BACILLUS-SUBTILIS; PHAGE-LAMBDA; M13 VECTORS; RECOMBINATION; BINDING; GENES; PURIFICATION; K-12	The DNA binding and ATPase activities of RecF protein are modulated by RecR protein, Stoichiometric amounts of RecF protein bind to double stranded (ds) DNA (about 1 RecF monomer/4-6 base pairs) in the presence of adenosine 5'-O-(3-thio)triphosphate (ATP gamma S), forming a homogeneous protein coating on the DNA, Little or no cooperativity is evident in the binding process, In the presence of ATP, RecF binding to dsDNA is much weaker, and no RecF protein coating forms, Instead, small numbers of RecF protomers are interspersed randomly along the DNA. RecR protein does not bind appreciably to the dsDNA under these same conditions, However, a protein coating, similar to that which was observed with RecF protein alone in the presence of ATP gamma S, was produced when both RecF and RecR proteins were incubated with dsDNA in the presence of ATP, An interaction between RecF and RecR enables both proteins to bind tightly to the dsDNA in an approximately 1:1 molar ratio, We also report a weak ATP hydrolytic activity of RecF which is stimulated by RecR.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014711] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM14711, GM07215] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; ALONSO JC, 1993, J BIOL CHEM, V268, P1424; BLANAR MA, 1984, P NATL ACAD SCI-BIOL, V81, P4622, DOI 10.1073/pnas.81.15.4622; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; COHEN A, 1983, MOL GEN GENET, V189, P471, DOI 10.1007/BF00325911; COX MM, 1981, J BIOL CHEM, V256, P4676; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Davis R., 1980, ADV BACTERIAL GENETI; DUNN K, 1982, CELL, V28, P757, DOI 10.1016/0092-8674(82)90055-1; GRIFFIN TJ, 1990, J BACTERIOL, V172, P6291, DOI 10.1128/jb.172.11.6291-6299.1990; GUYER MS, 1980, COLD SPRING HARB SYM, V45, P135, DOI 10.1101/SQB.1981.045.01.022; HEGDE S, 1995, MOL GEN GENET, V246, P254, DOI 10.1007/BF00294689; KOLODNER R, 1985, J BACTERIOL, V163, P1060, DOI 10.1128/JB.163.3.1060-1066.1985; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LUISI DC, 1994, J MOL BIOL, V236, P124; MADIRAJU MVVS, 1992, J BACTERIOL, V174, P7705, DOI 10.1128/JB.174.23.7705-7710.1992; MADIRAJU MVVS, 1991, NUCLEIC ACIDS RES, V19, P6295, DOI 10.1093/nar/19.22.6295; MAHDI AA, 1989, NUCLEIC ACIDS RES, V17, P6781, DOI 10.1093/nar/17.17.6781; MAHDI AA, 1989, MOL GEN GENET, V216, P503, DOI 10.1007/BF00334397; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; REZNIKOFF R, 1986, MAXIMIZING GENE EXPR, P227; Sambrook J., 1989, MOL CLONING LAB MANU, pA9; SANDLER SJ, 1992, NUCLEIC ACIDS RES, V20, P839, DOI 10.1093/nar/20.4.839; SAWITZKE JA, 1992, GENETICS, V130, P7; SMITH GR, 1989, GENOME, V31, P520, DOI 10.1139/g89-100; STASIAK A, 1982, NATURE, V299, P185, DOI 10.1038/299185a0; STASIAK A, 1994, EXPERIENTIA, V50, P192, DOI 10.1007/BF01924002; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TSENG YC, 1994, MUTAT RES, V315, P1; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; WANG TCV, 1993, MUTAT RES, V294, P157, DOI 10.1016/0921-8777(93)90024-B; WHITBY MC, 1995, MOL GEN GENET, V246, P174, DOI 10.1007/BF00294680	39	65	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31397	31404		10.1074/jbc.270.52.31397	http://dx.doi.org/10.1074/jbc.270.52.31397			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537414	hybrid			2022-12-25	WOS:A1995TN44400081
J	West, MJ; Sullivan, NF; Willis, AE				West, MJ; Sullivan, NF; Willis, AE			Translational upregulation of the c-myc oncogene in Bloom's syndrome cell lines	ONCOGENE			English	Article						c-myc; Bloom's syndrome; translation; eIF-4E; eIF-2 alpha	DNA LIGASE-I; 5' UNTRANSLATED REGION; HEAVY-CHAIN LOCUS; MESSENGER-RNA; MALIGNANT TRANSFORMATION; ERYTHROLEUKEMIA-CELLS; SYNDROME LYMPHOCYTES; SYNDROME FIBROBLASTS; INCREASED EXPRESSION; BURKITTS-LYMPHOMA	Previous studies have shown a constitutive increase in the levels of c-myc protein in cell lines derived from patients with the cancer-prone disorder Bloom's Syndrome (BS), We report here that this overexpression results from a specific increase in the translation of the c-myc mRNA and is not the result of either a chromosomal translocation involving the c-myc locus or an amplification of this gene, We also did not detect any increase in the stability of the c-myc protein or any significant increases in the levels of c-myc mRNA expressed in BS cells compared to control cell Lines, Overall, there is a 39-80% increase in the association of the c-myc mRNA with polysomes in BS cell lines, Since, in some cases, overexpression of the c-myc protein has been shown to increase levels of the translation initiation factors eIF-4E and eIF-2 alpha, which may themselves play a role in malignant conversion, we have also examined the levels of these proteins in BS cells and found them to be either comparable or lower than those in control cell lines, These data suggest that if c-myc does contribute to the cancer predisposition phenotype in BS then it does not appear to act via an eIF-4E and eIF-2 alpha mediated pathway.	UNIV LEICESTER, DEPT BIOCHEM, LEICESTER LE1 7RH, LEICS, ENGLAND; NUVENTURES LTD, NEWCASTLE UPON TYNE NE2 4HE, TYNE & WEAR, ENGLAND	University of Leicester				Willis, Anne/0000-0002-1470-8531; West, Michelle/0000-0002-9497-9365				BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNHEIM A, 1981, CANCER GENET CYTOGEN, V3, P307, DOI 10.1016/0165-4608(81)90039-X; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; CHAN JYH, 1988, J BIOL CHEM, V263, P18231; CHAN JYH, 1987, NATURE, V325, P357, DOI 10.1038/325357a0; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DALLAFAVERA R, 1982, NATURE, V299, P61; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; GERMAN J, 1989, CLIN GENET, V35, P57; GERMAN J, 1994, P NATL ACAD SCI USA, V91, P6669, DOI 10.1073/pnas.91.14.6669; GERMAN J, 1977, AM J HUM GENET, V29, P553; GERMAN J, 1983, CHROMOSOME MUTATION; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HERRICK DJ, 1994, MOL CELL BIOL, V14, P2119, DOI 10.1128/MCB.14.3.2119; ISHIZAKI K, 1981, MUTAT RES, V80, P213, DOI 10.1016/0027-5107(81)90189-5; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KREPINSKY AB, 1979, HUM GENET, V50, P151, DOI 10.1007/BF00390236; KURIHARA T, 1987, MUTAT RES, V184, P147, DOI 10.1016/0167-8817(87)90071-X; LANDERS JE, 1994, ONCOGENE, V9, P2745; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LAZARUS P, 1992, ONCOGENE, V7, P1037; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCDANIEL LD, 1992, P NATL ACAD SCI USA, V89, P7968, DOI 10.1073/pnas.89.17.7968; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MOORE JP, 1987, ONCOGENE RES, V2, P65; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROWE M, 1989, J VIROL, V63, P1031, DOI 10.1128/JVI.63.3.1031-1039.1989; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SEABRIGH.M, 1971, LANCET, V2, P971; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; SHIRAMIZU B, 1991, BLOOD, V77, P1516; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; SULLIVAN NF, 1988, CURR TOP MICROBIOL, V141, P208; SULLIVAN NF, 1989, ONCOGENE, V4, P1509; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; WARREN ST, 1981, P NATL ACAD SCI-BIOL, V78, P3133, DOI 10.1073/pnas.78.5.3133; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WEI YF, 1995, MOL CELL BIOL, V15, P3206; WILLIS AE, 1987, NATURE, V325, P355, DOI 10.1038/325355a0; WILLIS AE, 1987, P NATL ACAD SCI USA, V84, P8016, DOI 10.1073/pnas.84.22.8016; YANG SW, 1992, P NATL ACAD SCI USA, V89, P2227, DOI 10.1073/pnas.89.6.2227; ZECH L, 1976, INT J CANCER, V17, P47, DOI 10.1002/ijc.2910170108	61	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2515	2524						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545108				2022-12-25	WOS:A1995TP18800007
J	MADDEN, SL; COOK, DM; RAUSCHER, FJ				MADDEN, SL; COOK, DM; RAUSCHER, FJ			A STRUCTURE-FUNCTION ANALYSIS OF TRANSCRIPTIONAL REPRESSION MEDIATED BY THE WT1, WILMS-TUMOR SUPPRESSOR PROTEIN	ONCOGENE			English	Article							RETINOBLASTOMA-SUSCEPTIBILITY GENE; ADENOVIRUS E1A PROTEIN; ZINC FINGER PROTEIN; MAMMALIAN-CELLS; EXPRESSION; ACTIVATION; PRODUCT; BINDING; DOMAINS; GROWTH	The chromosome 11p13 Wilms' tumor locus (wt1) encodes a zinc finger-containing transcription factor (WT1). WT1 binds to the consensus sequence (5'-GCGGGGGCG3') and represses transcription when bound to this site in vivo. The mechanism of repression is not yet defined. To investigate the mechanisms of transcriptional repression and map the domains of WT1 responsible, we constructed hybrid proteins between the yeast GAL4 1-147 DNA binding domain and WT1. Fusion of a 298 amino acid glutamine-proline-rich N-terminal segment of WT1 to the GAL4 DNA binding domain created a potent transcriptional repressor. The use of N- and C-terminal truncations of this segment demonstrated that as few as 96 amino acids were required for active repression by GAL4-WT1 hybrid proteins in NIH3T3 fibroblasts. However, the truncated GAL4-WT1 fusion proteins functioned poorly as repressors in embryonic kidney-derived 293 cells, suggesting cell type-specific requirements for transcriptional repression. Site-directed mutagenesis of the WT1 repression domain revealed that deletion of homopolymeric proline and glycine regions, as well as single amino acid changes, partially inactivated the repression function. Single repressor binding sites placed upstream of the transcription start site conferred WT1-mediated repression to a heterologous promoter, whereas multiple sites resulted in additive (non-synergistic) increases in transcriptional repression. Significant repression of transcription was observed when binding sites were placed 760 base pairs upstream or 1000 base pairs downstream relative to the site of transcription initiation. We conclude that the transcriptional repression function of WT1 is contained in the N-terminal, non-DNA binding domain of the protein and that repression can be functionally transferred to a heterologous DNA binding domain.	WISTAR INST ANAT & BIOL,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NATIONAL CANCER INSTITUTE [P01CA047983, P01CA052009, P30CA010815] Funding Source: NIH RePORTER; NCI NIH HHS [CA10815, CA47983, CA52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, IN PRESS P NATL ACAD; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTENARH M, 1992, ONCOGENE, V7, P1673; MORRIS JF, 1991, ONCOGENE, V6, P2339; NEVINS JR, 1992, SCIENCE, V258, P424; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHARMA PM, 1992, CANCER RES, V52, P6407; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SPAETE RR, 1985, J VIROL, V56, P136; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	46	118	122	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1713	1720						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510918				2022-12-25	WOS:A1993LG68200001
J	MICHELIN, S; DAYAGROSJEAN, L; SUREAU, F; SAID, S; SARASIN, A; SUAREZ, HG				MICHELIN, S; DAYAGROSJEAN, L; SUREAU, F; SAID, S; SARASIN, A; SUAREZ, HG			CHARACTERIZATION OF A C-MET PROTOONCOGENE ACTIVATED IN HUMAN XERODERMA-PIGMENTOSUM CELLS AFTER TREATMENT WITH N-METHYL-N'-NITRO-N-NITROSOGUANIDINE (MNNG)	ONCOGENE			English	Article							TYROSINE KINASE FAMILY; DNA; GENE; LINE; TRANSFORMATION; REARRANGEMENTS; ABNORMALITIES; RECEPTOR; PRODUCT; REPEATS	Human xeroderma pigmentosum (XP) fibroblasts were transformed with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). The transformed cells, called ASKMN, were immortalized, grew in agar and were tumorigenic in nude mice. A trp-met oncogene was identified in ASKMN cells, after transfection of high molecular weight DNA on 3T3 mouse cells. The ASKMN cells and the 3T3 transformants expressed the 5-kb mRNA transcribed by the tpr-met oncogene and its p65tpr-met phosphorylated protein. Using the polymerase chain reaction (PCR) technique followed by hybridization with synthetic probes or direct sequencing, we showed that the sequence encompassing the 'rearranged breakpoint' was the same as that previously described in the tpr-met oncogene present in the MNNG-HOS cells. However, G to A transitions found in the tpr or met sequences of the ASKMN oncogene, probably the result of the specific mutagenic activity of MNNG, were absent in the MNNG-HOS gene. Apparently normal chromosomes 1 and 7 were identified in the ASKMN cell metaphases using several cytogenetic techniques.	INST RECH SCI CANC,GENET MOLEC LAB,CNRS,UPR 42,BOITE POSTALE 8,F-94801 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS)								ALLARD MW, 1991, BIOTECHNIQUES, V10, P24; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BERNHEIM A, 1981, HUM GENET, V57, P432, DOI 10.1007/BF00281699; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROOKES P, 1964, NATURE, V202, P781, DOI 10.1038/202781a0; CARIELLO NF, 1990, MUTAT RES, V231, P165, DOI 10.1016/0027-5107(90)90023-W; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; Deininger PL, 1989, MOBILE DNA, P619; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRECO A, 1992, ONCOGENE, V7, P237; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HYRIEN O, 1987, EMBO J, V6, P2401, DOI 10.1002/j.1460-2075.1987.tb02518.x; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MICHELIN S, 1991, EXP CELL RES, V196, P314, DOI 10.1016/0014-4827(91)90266-W; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; NALDINI L, 1991, ONCOGENE, V6, P501; NARDEUX PC, 1987, BIOCHEM BIOPH RES CO, V146, P395, DOI 10.1016/0006-291X(87)90542-0; PARK M, 1986, COLD SPRING HARB SYM, V51, P967, DOI 10.1101/SQB.1986.051.01.110; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; STARY A, 1992, NUCLEIC ACIDS RES, V20, P4269, DOI 10.1093/nar/20.16.4269; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; SUAREZ H, 1988, BIOCHIMIE, V70, P969, DOI 10.1016/0300-9084(88)90239-8; SUAREZ HG, 1989, ANTICANCER RES, V9, P1331; SUAREZ HG, 1991, ONCOGENE, V6, P677; TESTA JR, 1990, ONCOGENE, V5, P1565; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1973; YOSIDA TH, 1983, CANCER GENET CYTOGEN, V8, P153, DOI 10.1016/0165-4608(83)90047-X; YUNIS JJ, 1978, CYTOGENET CELL GENET, V22, P679, DOI 10.1159/000131052	36	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1983	1991						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510940				2022-12-25	WOS:A1993LG68200031
J	SHACKLEFORD, GM; SHIVAKUMAR, S; SHIUE, L; MASON, J; KENYON, C; VARMUS, HE				SHACKLEFORD, GM; SHIVAKUMAR, S; SHIUE, L; MASON, J; KENYON, C; VARMUS, HE			2 WNT GENES IN CAENORHABDITIS-ELEGANS	ONCOGENE			English	Article							PROTO-ONCOGENE INT-1; SEGMENT-POLARITY GENE; XENOPUS EMBRYOS; C-ELEGANS; DROSOPHILA HOMOLOG; MESSENGER-RNA; SEQUENCE; EXPRESSION; PROTOONCOGENE; WINGLESS	wnt genes encode secretory glycoproteins that have been implicated in growth control and development in mice, frogs and insects. In this report we examine properties of two wnt genes recently identified in the nematode Caenorhabditis elegans. The first gene, Ce-wnt-1, was previously identified by a polymerase chain reaction-based screen of genomic DNA, and the second, Ce-wnt-2, was fortuitously encountered in a survey of clones in a cDNA library by the Caenorhabditis Genome Project. Full-length or nearly full-length cDNAs representing both mRNAs encode proteins that are similar in length, sequence and functional domains to other Wnt proteins. Primary products of 372 and 362 amino acids begin with a hydrophobic signal peptide, include two potential N-linked glycosylation sites and contain the 22 cysteine residues conserved throughout the wnt family. In contrast to mammalian and insect wnt genes with four or five exons and conserved intron-exon boundaries, Ce-wnt-1 has nine coding exons; only one of the eight identified introns interrupts the coding sequence at a position homologous to an intron position in other wnt genes. The major transcript derived from Ce-wnt-1 is 1.4 kb in length, and the 22 nucleotides at its 5' end are added by a trans-splicing mechanism. Ce-wnt-2 is also expressed via a single major transcript, 1.5 kb in length. Both RNAs are detectable in all larval forms and adults, but they are most abundant at the embryonic stage. Ce-wnt-1 is localized to the left arm of chromosome II and Ce-wnt-2 maps to a cluster of genes on chromosome IV.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Mason, John O/A-1926-2010	Mason, John O/0000-0002-0489-2400				BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BRENNER S, 1974, GENETICS, V77, P71; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; EISENBERG LM, 1992, IN PRESS DEV BIOL; EMMONS SW, 1979, P NATL ACAD SCI USA, V76, P1333, DOI 10.1073/pnas.76.3.1333; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; FROHMAN M, 1992, IN PRESS METHODS ENZ; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; KRAUSE M, 1984, MOL BIOL CYTOSKELETO; Maniatis T., 1982, MOL CLONING; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROSENQUIST TA, 1988, GENE DEV, V2, P606, DOI 10.1101/gad.2.5.606; RUSSELL J, 1992, UNPUB DEVELOPMENT; SCHALLER D, 1990, NUCLEIC ACIDS RES, V18, P2033, DOI 10.1093/nar/18.8.2033; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; UZVOLGYI E, 1988, P NATL ACAD SCI USA, V85, P3034, DOI 10.1073/pnas.85.9.3034; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WTERSTON R, 1992, NAT GENET, V1, P114	35	26	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1857	1864						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510930				2022-12-25	WOS:A1993LG68200018
J	NUTTALL, FQ; GANNON, MC				NUTTALL, FQ; GANNON, MC			ALLOSTERIC REGULATION OF GLYCOGEN-SYNTHASE IN LIVER - A PHYSIOLOGICAL DILEMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY FRUCTOSE INTOLERANCE; FASTED RATS; GLUCOSE; DEGRADATION; ADULT	Glycogen synthase catalyzes the transfer of the glucosyl moiety from UDP-glucose to the terminal branch of the glycogen molecule and is considered to be the rate-limiting enzyme for glycogen synthesis. However, under ideal assay conditions, i.e. 37-degrees-C with saturating concentrations of UDP-glucose and the activator, glucose-6-P, the maximal catalytic activity of glycogen synthase was only 78% of the in vivo glycogen synthetic rate. Using concentrations of UDP-glucose and glucose-6-P likely to be present in vivo, the rate was only approximately 30%. This prompted us to reassess a possible role of allosteric effectors on synthase activity. Glycogen synthase was assayed at 37-degrees-C using dilute, pH 7.0, buffered extracts, initial rate conditions, and UDPglucose and glucose-6-P concentrations, which approximate those calculated to be present in total liver cell water. Several allosteric effectors were tested. Magnesium and AMP had little effect on activity. P(i), ADP, ATP, and UTP inhibited activity. When a combination of effectors were added at concentrations approximating those present in cell water, synthase activity could account for only 2% of the glycogen synthetic rate. Thus, although allosteric effectors are likely to be playing a major role in regulating synthase enzymic activity in liver cells, to date, a metabolite that can stimulate activity and/or overcome nucleotide inhibition has yet to be identified. If such a metabolite cannot be identified, an additional or alternative pathway for glycogen synthesis must be considered.	UNIV MINNESOTA, DEPT MED, MINNEAPOLIS, MN 55417 USA	University of Minnesota System; University of Minnesota Twin Cities	NUTTALL, FQ (corresponding author), VET ADM MED CTR, ENDOCRINOL METAB & NUTR SECT, 1 VET DR, MINNEAPOLIS, MN 55417 USA.		Gannon, Mary Carol/L-7092-2016	Gannon, Mary Carol/0000-0001-5460-2478	NIDDK NIH HHS [DK 43018-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043018] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEMIYA T, 1978, CELL MOL BIOL, V23, P155; BURCH HB, 1969, BIOCHEM BIOPH RES CO, V34, P619, DOI 10.1016/0006-291X(69)90783-9; BURMEISTER LA, 1991, ARCH INTERN MED, V151, P773, DOI 10.1001/archinte.151.4.773; DAVID M, 1990, J CLIN INVEST, V86, P612, DOI 10.1172/JCI114752; DEWULF H, 1968, EUR J BIOCHEM, V6, P545; FULTON AB, 1982, CELL, V30, P345, DOI 10.1016/0092-8674(82)90231-8; GANNON MC, 1987, DIABETES, V36, P52, DOI 10.2337/diabetes.36.1.52; GILBOE DP, 1973, BIOCHEM BIOPH RES CO, V53, P164, DOI 10.1016/0006-291X(73)91415-0; GOLD AH, 1970, BIOCHEMISTRY-US, V9, P946, DOI 10.1021/bi00806a034; GOLD AH, 1968, BIOCHEM BIOPH RES CO, V31, P361, DOI 10.1016/0006-291X(68)90484-1; GOLD AH, 1967, ARCH BIOCHEM BIOPHYS, V120, P359, DOI 10.1016/0003-9861(67)90251-2; HAVERSTICK DM, 1980, J BIOL CHEM, V255, P1351; HETENYI G, 1969, CAN J PHYSIOL PHARM, V47, P361, DOI 10.1139/y69-064; HIZUKURI S, 1964, BIOCHEMISTRY-US, V3, P1783, DOI 10.1021/bi00899a034; LANE RD, 1989, BIOCHEM INT, V18, P961; MERSMANN HJ, 1967, P NATL ACAD SCI USA, V58, P1688, DOI 10.1073/pnas.58.4.1688; NIEWOEHNER CB, 1984, AM J PHYSIOL, V247, pE505, DOI 10.1152/ajpendo.1984.247.4.E505; NIEWOEHNER CB, 1988, DIABETES, V37, P1559, DOI 10.2337/diabetes.37.11.1559; NIEWOEHNER CB, 1986, DIABETES, V35, P705, DOI 10.2337/diabetes.35.6.705; NIEWOEHNER CB, 1984, AM J PHYSIOL, V246, pE89, DOI 10.1152/ajpendo.1984.246.1.E89; NUTTALL FQ, 1989, ANAL BIOCHEM, V178, P311, DOI 10.1016/0003-2697(89)90644-1; NUTTALL FQ, 1988, AM J MED, V85, P77, DOI 10.1016/0002-9343(88)90400-7; PIRAS R, 1968, BIOCHEMISTRY-US, V7, P56, DOI 10.1021/bi00841a009; PIRAS R, 1969, BIOCHEMISTRY-US, V8, P2153, DOI 10.1021/bi00833a056; ROACH PJ, 1976, J BIOL CHEM, V251, P1920; TAN AWH, 1976, BIOCHIM BIOPHYS ACTA, V445, P118, DOI 10.1016/0005-2744(76)90165-0; TAN AWH, 1979, BIOCHIM BIOPHYS ACTA, V582, P543, DOI 10.1016/0304-4165(79)90146-6; VANDENBERGHE G, 1973, BIOCHEM J, V134, P637; WILLIAMSON DH, 1981, CONCENTRATIONS METAB, V4, P2266; YOUN JH, 1987, J BIOL CHEM, V262, P11470	30	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13286	13290						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514767				2022-12-25	WOS:A1993LH55300042
J	RUMBLEY, CA; DENZIN, LK; YANTZ, L; TETIN, SY; VOSS, EW				RUMBLEY, CA; DENZIN, LK; YANTZ, L; TETIN, SY; VOSS, EW			CONSTRUCTION, CHARACTERIZATION, AND SELECTED SITE-SPECIFIC MUTAGENESIS OF AN ANTI-SINGLE-STRANDED DNA SINGLE-CHAIN AUTOANTIBODY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MONOCLONAL-ANTIBODY; SECONDARY STRUCTURE; BINDING SITES; PROTEIN; CLONING; FRAGMENTS; SLE	Single-chain antibodies are comprised of immunoglobulin light and heavy chain variable domains joined through a polypeptide linker. A single-chain autoantibody, containing the 14-amino acid 212-polypeptide linker (GSTSGSGKSSEGKG), was constructed based on the light and heavy chain variable region gene sequences of anti-single-stranded DNA autoantibody BV04-01 (IgG2b,kappa). Following protein expression in Escherichia coli, denaturation, refolding, and affinity purification, single-chain autoantibody 04-01 binding with single-stranded DNA and poly(dT) was characterized in solid-phase and solution-phase assays. Homopolymer ligand binding results demonstrated that single-chain autoantibody 04-01 possessed anti-DNA binding properties similar to BV04-01 IgG and Fab fragments. Based on x-ray crystallographic analyses of BV04-01, site-specific mutagenesis studies were conducted on 2 residues (L32Tyr and H100aTrp) involved in aromatic stacking interactions with the middle thymidine of a (dT)3 ligand.	UNIV ILLINOIS, DEPT MICROBIOL, 131 BURRILL HALL, 407 S GOODWIN AVE, URBANA, IL 61801 USA; UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign								BALLARD DW, 1985, J IMMUNOL, V135, P3372; BALLARD DW, 1984, J BIOL CHEM, V259, P3492; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BOSS MA, 1984, NUCLEIC ACIDS RES, V12, P3791, DOI 10.1093/nar/12.9.3791; CABILLY S, 1984, P NATL ACAD SCI-BIOL, V81, P3273, DOI 10.1073/pnas.81.11.3273; CASPERSON GF, 1983, MOL IMMUNOL, V20, P581, DOI 10.1016/0161-5890(83)90002-0; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P1066, DOI 10.1073/pnas.87.3.1066; COLCHER D, 1990, JNCI-J NATL CANCER I, V82, P1191, DOI 10.1093/jnci/82.14.1191; CONDRA JH, 1990, J BIOL CHEM, V265, P2292; DAVIS GT, 1991, BIO-TECHNOL, V9, P165, DOI 10.1038/nbt0291-165; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; DURING K, 1990, PLANT MOL BIOL, V15, P281, DOI 10.1007/BF00036914; EISEN H N, 1964, Methods Med Res, V10, P115; GIVOL D, 1979, INT REV BIOCHEM, V23, P71; GLOCKSHUBER R, 1990, BIOCHEMISTRY-US, V29, P1362, DOI 10.1021/bi00458a002; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HUGHES GRV, 1980, CONNECTIVE TISSUE DI, P3; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; LACY MJ, 1989, J IMMUNOL METHODS, V116, P87, DOI 10.1016/0022-1759(89)90316-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Pisetsky D S, 1984, Clin Immunol Rev, V3, P169; PLUCKTHUN A, 1987, COLD SPRING HARB SYM, V52, P105, DOI 10.1101/SQB.1987.052.01.015; REICHLIN M, 1981, CLIN EXP IMMUNOL, V44, P1; SCANDELLA D, 1985, J CELL BIOCH B, V9, P203; SEN J, 1986, Proteins Structure Function and Genetics, V1, P256, DOI 10.1002/prot.340010308; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SMITH R G, 1989, Journal of the Indian Institute of Science, V69, P25; SMITH RA, 1983, APPL ENVIRON MICROB, V45, P586, DOI 10.1128/AEM.45.2.586-590.1983; SMITH RG, 1990, MOL IMMUNOL, V27, P463, DOI 10.1016/0161-5890(90)90171-U; Stollar B D, 1980, Methods Enzymol, V70, P70; STOLLAR BD, 1980, J CLIN INVEST, V66, P210, DOI 10.1172/JCI109846; STOLLAR BD, 1979, TRENDS BIOCHEM SCI, V4, P5, DOI 10.1016/0968-0004(79)90236-6; TAN EM, 1982, ADV IMMUNOL, V33, P167, DOI 10.1016/S0065-2776(08)60836-6; VOSS EW, 1982, ANTIDNA ANTIBODIES S, P4; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0	42	46	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13667	13674						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514799				2022-12-25	WOS:A1993LH55300091
J	IZBAN, MG; LUSE, DS				IZBAN, MG; LUSE, DS			THE INCREMENT OF SII-FACILITATED TRANSCRIPT CLEAVAGE VARIES DRAMATICALLY BETWEEN ELONGATION COMPETENT AND INCOMPETENT RNA POLYMERASE-II TERNARY COMPLEXES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TERMINATION SITES; INVITRO; GENE; PURIFICATION; SEQUENCES; MECHANISM; SUBUNIT; TFIIS	Elongation factor SII is required to increase the efficiency of transcription by RNA polymerase II through intrinsic arrest sites. RNA polymerase II ternary complexes exhibit a ribonuclease activity in the presence of SII, truncating nascent transcripts in a 3' --> 5' direction. We show here that transcript cleavage is an obligatory step in re-establishing the elongation competency of complexes that have become blocked in elongation at an intrinsic arrest site. SII-facilitated transcript cleavage by these arrested complexes released 7-14 nucleotide RNA fragments. In contrast, SII-facilitated transcript cleavage by elongation competent complexes, which are stalled because of the absence of a nucleoside triphosphate from the reaction mixture, occurred primarily in dinucleotide increments. We can partially recreate the arrested phenotype and the preference for the large cleavage increment by stalling ternary complexes such that the 3'-end of the transcript contains consecutive U residues, which mimics the sequence of the 3'-ends of transcripts in arrested complexes.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NIGMS NIH HHS [GM 29487, GM 14111] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487, F32GM014111] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; FLORES O, 1990, J BIOL CHEM, V265, P5629; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LEE DN, 1990, J BIOL CHEM, V265, P15145; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; MI H, 1983, EUR J BIOCHEM, V131, P113; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; RESNEKOV O, 1989, J BIOL CHEM, V264, P9953; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SPENCER CA, 1990, ONCOGENE, V5, P777; STEVENS A, 1969, J BIOL CHEM, V244, P425; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	34	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12874	12885						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509421				2022-12-25	WOS:A1993LG65800094
J	Huynh, H; Yang, XF; Pollak, M				Huynh, H; Yang, XF; Pollak, M			Estradiol and antiestrogens regulate a growth inhibitory insulinlike growth factor binding protein 3 autocrine loop in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I GENE-EXPRESSION; PURE ANTIESTROGEN; HUMAN FIBROBLASTS; IGF-I; TAMOXIFEN	MCF-7 human breast cancer cells are commonly used to model tissues responsive to estrogens and antiestrogens. We examined the effects of estradiol and the antiestrogen ICI 182780 on MCF-7 cell proliferation and insulin-like growth factor binding protein 3 (IGFBP-3) gene expression. ICI 182780-induced growth inhibition was associated with increased transcription of the IGFBP-3 gene, increased IGFBP-3 mRNA abundance, and increased IGFBP-3 protein accumulation in the conditioned medium. The growth stimulatory effect of estradiol was associated with opposite effects, and the correlation between cellular proliferation and IGFBP-3 mRNA abundance was strong (r = -0.91). Recombinant IGFBP-3 inhibited basal and estradiol-stimulated MCF-7 cell proliferation, and an IGFBP-3 antisense oligode-oxynucleotide abolished antiestrogen-induced growth inhibition. These results provide evidence for an estradiol and antiestrogen-regulated IGFBP-3 growth inhibitory autocrine pathway in MCF-7 cells.	MCGILL UNIV,JEWISH GEN HOSP,LADY DAVIS RES INST,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA	McGill University; McGill University; McGill University			Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604				BASERGA R, 1995, CANCER RES, V55, P249; BUTTA A, 1992, CANCER RES, V52, P4261; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; CONOVER CA, 1994, J BIOL CHEM, V269, P7076; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FONTANA JA, 1991, ENDOCRINOLOGY, V128, P1115, DOI 10.1210/endo-128-2-1115; GOLDSTEIN S, 1991, P NATL ACAD SCI USA, V88, P9680, DOI 10.1073/pnas.88.21.9680; HEMBREE JR, 1994, CANCER RES, V54, P3160; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; HUYNH H, 1994, CANCER RES, V54, P3115; HUYNH HT, 1993, CANCER RES, V53, P5585; HUYNH HT, 1993, CANCER RES, V53, P1727; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; KNAUER DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7252, DOI 10.1073/pnas.77.12.7252; LERNER LJ, 1990, CANCER RES, V50, P4177; LIU L, 1992, J CELL PHYSIOL, V153, P15, DOI 10.1002/jcp.1041530104; MARTIN JL, 1991, ENDOCRINOLOGY, V128, P1425, DOI 10.1210/endo-128-3-1425; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MCGUIRE WL, 1992, J NATL CANCER I, V84, P1336, DOI 10.1093/jnci/84.17.1336; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; OSBORNE CK, 1995, J NATL CANCER I, V87, P746, DOI 10.1093/jnci/87.10.746; POLLAK M, 1990, J NATL CANCER I, V82, P1693, DOI 10.1093/jnci/82.21.1693; POLLAK M, 1993, ADJUVANT THERAPY CAN, V7; PRATT SE, 1994, BIOCHEM BIOPH RES CO, V198, P292, DOI 10.1006/bbrc.1994.1041; RESNICOFF M, 1995, CANCER RES, V55, P2463; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; Spratt SK, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037503; TRESSEL TJ, 1991, BIOCHEM BIOPH RES CO, V178, P625, DOI 10.1016/0006-291X(91)90154-Y; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; WAKELING AE, 1991, CANCER RES, V51, P3867	34	204	210	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1016	1021		10.1074/jbc.271.2.1016	http://dx.doi.org/10.1074/jbc.271.2.1016			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557625	hybrid, Green Published			2022-12-25	WOS:A1996TP88900062
J	Gibbons, DL; Horowitz, PM				Gibbons, DL; Horowitz, PM			Ligand-induced conformational changes in the apical domain of the chaperonin GroEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER RHODANESE; RIBULOSE BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; MITOCHONDRIAL RHODANESE; PROTEINS; ATP; HYDROLYSIS; PURIFICATION; CYCLE	Although the role of nucleotides in the catalytic cycle of the GroESL chaperonin system has been extensively studied, the molecular effects of nucleotides in modulating exposure of sites on GroEL has not been thoroughly investigated. We report here that nucleotides (ATP, ADP, or adenosine 5'-(beta,gamma-imino)triphosphate) in the presence of Mg2+ make the oligomer selectively sensitive to trypsin proteolysis in a fashion suggesting conformational changes in the monomers of one heptameric ring. The site of proteolysis in the monomer that is exposed upon nucleotide binding by the oligomer is in the apical domain (Arg-268). Further, complexes of GroEL with GroES or rhodanese display the same sensitivity to proteolysis, unlike the GroEL-GroES-rhodanese complex, which is protected from proteolysis. The influence of various cations on trypsin proteolysis is investigated to elucidate the differential effects that monovalent and divalent cations have on the oligomeric structure of the chaperonin. These results are discussed in relation to the molecular basis for the chaperonin activity.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BANEYX F, 1992, J BIOL CHEM, V267, P11637; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P23869; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; DEMEDICIS E, 1986, APPL ENVIRON MICROB, V52, P567; DIAMANT S, 1995, BIOCHEMISTRY-US, V34, P273, DOI 10.1021/bi00001a033; ELLIS RJ, 1990, BIOCH SOC S, V55, P145; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GOROVITS BM, 1995, J BIOL CHEM, V270, P28551, DOI 10.1074/jbc.270.48.28551; GOROVITS BM, 1995, J BIOL CHEM, V270, P13057, DOI 10.1074/jbc.270.22.13057; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KRATZIN HD, 1989, ANAL BIOCHEM, V183, P1, DOI 10.1016/0003-2697(89)90161-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P25963; MERRILL GA, 1993, J BIOL CHEM, V268, P15611; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; NEUHOFF V, 1986, ELECTROPHORESIS, V7, P56, DOI 10.1002/elps.1150070110; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; RINDERKNECHT H, 1968, CLIN CHIM ACTA, V21, P197, DOI 10.1016/0009-8981(68)90127-7; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHMIDT M, 1994, J BIOL CHEM, V269, P27964; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; YBARRA J, 1995, J BIOL CHEM, V270, P22962, DOI 10.1074/jbc.270.39.22962; YIFRACH O, 1994, J MOL BIOL, V243, P397, DOI 10.1006/jmbi.1994.1667; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001; ZAHN R, 1994, J MOL BIOL, V242, P165, DOI 10.1006/jmbi.1994.1567; ZAHN R, 1994, J MOL BIOL, V242, P150, DOI 10.1006/jmbi.1994.1566	51	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					238	243		10.1074/jbc.271.1.238	http://dx.doi.org/10.1074/jbc.271.1.238			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550566	hybrid			2022-12-25	WOS:A1996TP36100037
J	Hepler, JR; Biddlecome, GH; Kleuss, C; Camp, LA; Hofmann, SL; Ross, EM; Gilman, AG				Hepler, JR; Biddlecome, GH; Kleuss, C; Camp, LA; Hofmann, SL; Ross, EM; Gilman, AG			Functional importance of the amino terminus of G(q alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; ALPHA-SUBUNITS; G-PROTEINS; BETA-GAMMA; PHOSPHOLIPASE C-BETA-1; LIPID MODIFICATIONS; ADENYLATE-CYCLASE; MEMBRANE-PROTEINS; SF9 CELLS; PALMITOYLATION	G(q alpha) is palmitoylated at residues Cys(9) and Cys(10), Removal of palmitate from purified G(q alpha) with palmitoylthioesterase in vitro failed to alter interactions of G(q alpha) with phospholipase C-beta 1, the G protein beta gamma subunit complex, or m1 muscarinic cholinergic receptors, Mutants C9A, C10A, C9A/C10A, C9S/C10S, and truncated G(q alpha) (removal of residues 1-6) were synthesized in Sf9 cells and purified, Loss of both Cys residues or truncation prevented palmitoylation of G(q alpha), However, truncated G(q alpha) and the single Cys mutants activated phospholipase C-beta 1 normally, while the double Cys mutants were poor activators. Loss of both Cys residues impaired but did not abolish interaction of G(q alpha) with m1 receptors, These Cys residues are thus important regardless of their state of palmitoylation, When expressed in HEK-293 or Sf9 cells, all of the proteins studied associated entirely or predominantly with membranes, although a minor fraction of nonpalmitoylated G(q alpha) proteins accumulated in the cytosol of HEK-293 cells, When subjected to TX-114 phase partitioning, a significant fraction of all of the proteins, including those with no palmitate, was found in the detergent-rich phase. Removal of residues 1-34 of G(q alpha) caused a loss of surface hydrophobicity as evidenced by complete partitioning into the aqueous phase, The Cys residues at the amino terminus of G(q alpha) are thus important for its interactions with effector and receptor, and the amino terminus conveys a hydrophobic character to the protein distinct from that contributed by palmitate.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NCI NIH HHS [CA61823] Funding Source: Medline; NIGMS NIH HHS [GM30355, GM34497] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R37GM030355, R01GM030355, R01GM034497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JOURNOT L, 1991, J BIOL CHEM, V266, P9009; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MCCALLUM JF, 1995, BIOCHEM SOC T, V23, pS9, DOI 10.1042/bst023009s; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NAVON SE, 1987, J BIOL CHEM, V262, P15746; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VEIT M, 1994, FEBS LETT, V339, P160, DOI 10.1016/0014-5793(94)80406-0; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YING YS, 1992, COLD SPRING HARB SYM, V57, P593, DOI 10.1101/SQB.1992.057.01.065	40	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					496	504		10.1074/jbc.271.1.496	http://dx.doi.org/10.1074/jbc.271.1.496			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550609	hybrid			2022-12-25	WOS:A1996TP36100076
J	Zvaritch, E; Lambeau, G; Lazdunski, P				Zvaritch, E; Lambeau, G; Lazdunski, P			Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-TYPE PHOSPHOLIPASE-A2; LIGAND-INDUCED INTERNALIZATION; DENSITY-LIPOPROTEIN RECEPTOR; LYSOSOMAL ACID-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; MANNOSE RECEPTOR; CYTOPLASMIC DOMAIN; BINDING-SITES; LDL RECEPTOR; TOXIC PHOSPHOLIPASES-A2	Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A(2)(sPLA(2)) were first investigated in rabbit myocytes that express it at high levels. Internalization of the receptor was shown to be clathrin-coated pit-mediated, rapid (k(e) = 0.1 min(-1)), and ligand-independent. The signal sequence for internalization was then identified upon transient and stable expression of various receptor constructs with mutated cytoplasmic sequences. Analysis of the internalization efficiency of the mutants suggested that the NSYY motif encodes the major endocytic signal, with the distal tyrosine residue playing the key role. Amino acid substitutions at the putative casein kinase II phosphorylation site of the receptor did not affect internalization. A chimeric protein composed of the extracellular and transmembrane domains of the rabbit sPLA(2) receptor and of the cytoplasmic domain of the structurally homologous human macrophage mannose receptor retained the high affinity for sPLA(2) and was internalization competent, exhibiting 50% endocytic activity of the M-type sPLA(2) receptor, The results indicate the compatibility of the structural domains of the two parent proteins and provide evidence for the interchangeable character of their internalization signals.	INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE				Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X				AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ALMOND BD, 1994, J BIOL CHEM, V269, P26635; ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; ARITA H, 1991, J BIOL CHEM, V266, P19139; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; CARPENTIER JL, 1994, ANN NY ACAD SCI, V733, P266, DOI 10.1111/j.1749-6632.1994.tb17276.x; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CLACKSON T, 1989, NUCLEIC ACIDS RES, V17, P10163, DOI 10.1093/nar/17.24.10163; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CORVERA S, 1994, J CELL BIOL, V126, P979, DOI 10.1083/jcb.126.4.979; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FRY MR, 1992, BIOL REPROD, V47, P751, DOI 10.1095/biolreprod47.5.751; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAFT CR, 1994, J BIOL CHEM, V269, P26286; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; ITIN C, 1995, EMBO J, V14, P2250, DOI 10.1002/j.1460-2075.1995.tb07219.x; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; KRUSKAL BA, 1992, J EXP MED, V176, P1673, DOI 10.1084/jem.176.6.1673; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; LAMBEAU G, 1991, FEBS LETT, V293, P29, DOI 10.1016/0014-5793(91)81145-X; LAMBEAU G, 1995, J BIOL CHEM, V270, P5534, DOI 10.1074/jbc.270.10.5534; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LAMBEAU G, 1991, NEUROCHEM RES, V16, P651, DOI 10.1007/BF00965551; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEW DB, 1994, J CLIN INVEST, V94, P1855, DOI 10.1172/JCI117535; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUND KA, 1990, J BIOL CHEM, V265, P15713; MAGNUSSON S, 1989, BIOCHEM J, V257, P651, DOI 10.1042/bj2570651; MALLABIABARRENA A, 1995, EMBO J, V14, P2257, DOI 10.1002/j.1460-2075.1995.tb07220.x; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; OGATA S, 1994, J BIOL CHEM, V269, P5210; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SHARMA RJ, 1986, BIOCHIM BIOPHYS ACTA, V862, P199, DOI 10.1016/0005-2736(86)90483-9; SOMMERS CD, 1992, EUR J PHARMACOL, V216, P87, DOI 10.1016/0014-2999(92)90213-N; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STEIN BS, 1984, J BIOL CHEM, V259, P4762; STEIN BS, 1986, J BIOL CHEM, V261, P319; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; ZVARITCH E, 1995, J BIOL CHEM, V270, P2679, DOI 10.1074/jbc.270.6.2679	69	107	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					250	257		10.1074/jbc.271.1.250	http://dx.doi.org/10.1074/jbc.271.1.250			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550569	hybrid			2022-12-25	WOS:A1996TP36100039
J	Kushner, DB; Pereira, DS; Liu, XH; Graham, FL; Ricciardi, RP				Kushner, DB; Pereira, DS; Liu, XH; Graham, FL; Ricciardi, RP			The first exon of Ad12 E1A excluding the transactivation domain mediates differential binding of COUP-TF and NF-kappa B to the MHC class I enhancer in transformed cells	ONCOGENE			English	Article						adenovirus; E1A; COUP-TF; NF-kappa B	DNA-BINDING; RAT-CELLS; GENE-EXPRESSION; P65 SUBUNIT; TRANSCRIPTION FACTORS; REL ONCOGENE; ADENOVIRUS-TYPE-12; PROTEINS; P50; REPRESSION	The major histocompatibility complex class I enhancer is the target for adenovirus-12 E1A-mediated down-regulation of class I transcription. In Ad12 transformed rodent cells, the class I enhancer is down-regulated through increased binding of the repressor COUP-TF to the R2 element and decreased binding of the activator NF-kappa B (p50/p65) to the R1 element. The reduced surface levels of class I antigens contribute to the tumorigenic potential of Ad12 transformed cells by favoring their immunoescape from cytotoxic T-lymphocytes. Previous studies using transformed containing hybrid Ad5/Ad12 E1A (plus Ad12 E1B) genes have indicated that sequences within the first exon of the 266R Ad12 E1A gene are required for class I down-regulation and tumorigenesis. In this study we demonstrate that these same sequences, which exclude the Ad12 CR3 transactivation domain, are also required for increased COUP-TF binding to the R2 element and decreased NF-kappa B binding to the R1 element of the class I enhancer. We further show that diminished NF-kappa B binding is not due to a lack of NF-kappa B1-p50 in the nuclei of Ad12 transformed rat cells.	UNIV PENN,SCH DENT MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104; UNIV PENN,GRAD GRP MOLEC BIOL,PHILADELPHIA,PA 19104; MCMASTER UNIV,DEPT BIOL,HAMILTON,ON L8S 4K1,CANADA; MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8S 4K1,CANADA	University of Pennsylvania; University of Pennsylvania; McMaster University; McMaster University				Kushner, David B/0000-0002-6260-5094	NCI NIH HHS [CA-29797] Funding Source: Medline; NIAID NIH HHS [5-T32-AI0735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKRILL AM, 1988, ONCOGENE, V3, P483; ACKRILL AM, 1989, VIROLOGY, V172, P643, DOI 10.1016/0042-6822(89)90207-9; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRAHAM FL, 1974, NATURE, V251, P687, DOI 10.1038/251687a0; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JELINEK T, 1994, J VIROL, V68, P888, DOI 10.1128/JVI.68.2.888-896.1994; JELINEK T, 1992, J VIROL, V66, P4117, DOI 10.1128/JVI.66.7.4117-4125.1992; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; LIU X, 1996, IN PRESS MOL CELL BI, V16; LIU XH, 1994, ONCOGENE, V9, P2183; MEIJER I, 1992, CELL IMMUNOL, V145, P56, DOI 10.1016/0008-8749(92)90312-D; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; NIELSCH U, 1991, EMBO J, V10, P4169, DOI 10.1002/j.1460-2075.1991.tb04995.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEREIRA DS, 1995, VIROLOGY, V211, P268, DOI 10.1006/viro.1995.1400; PEREIRA DS, 1994, INT J ONCOL, V5, P1197; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PERRICAUDET M, 1980, NATURE, V288, P174, DOI 10.1038/288174a0; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; QIU YH, 1994, TRENDS ENDOCRIN MET, V5, P234, DOI 10.1016/1043-2760(94)P3081-H; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RAZIUDDIN J A M, 1991, Proceedings of the National Academy of Sciences of the United States of America, V88, P9426; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; TELLING GC, 1994, J VIROL, V68, P877, DOI 10.1128/JVI.68.2.877-887.1994; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; YEWDELL JW, 1988, VIROLOGY, V162, P236, DOI 10.1016/0042-6822(88)90413-8	53	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					143	151						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552385				2022-12-25	WOS:A1996TQ01400018
J	Zhou, MM; Harlan, JE; Wade, WS; Crosby, S; Ravichandran, KS; Burakoff, SJ; Fesik, SW				Zhou, MM; Harlan, JE; Wade, WS; Crosby, S; Ravichandran, KS; Burakoff, SJ; Fesik, SW			Binding affinities of tyrosine-phosphorylated peptides to the COOH-terminal SH2 and NH2-terminal phosphotyrosine binding domains of Shc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDDLE-T-ANTIGEN	The adaptor protein Shc has been implicated in Ras signaling via association with many tyrosine-phosphorylated receptors, including growth factor receptors, antigen receptors on T and B cells, and cytokine receptors. Shc could interact with the activated receptors through the carboxyl-terminal Src homology 2 (SH2) domain or the structurally unrelated amino-terminal phosphotyrosine binding (PTB) domain. Using NMR and surface plasmon resonance techniques, we have measured the binding affinities of the SH2 and the PTB domains of Shc to a series of phosphotyrosine-containing peptides derived from known She binding sites. Tyrosine-phosphorylated peptides derived from Trk (pY490), polyoma virus middle T-antigen (pY250), ErbB3 (pY1309), and epidermal growth factor receptor (pY1086, pY1148, and pY1114) that contain NPXpY sequences bind preferentially to the PTB domain of Shc with K-d values of 0.02-5.3 mu M. The binding affinities of these peptides to the Shc SH2 domain were in the range of 220-1290 mu M. In contrast, tyrosine-phosphorylated peptides from epidermal growth factor receptor (pY992, pY1173) and the zeta chain of the T-cell receptor bind preferentially to the SH2 domain (K-d = 50-130 mu M) versus the PTB domain (K-d > 680 mu M). From these studies, the relative contribution of the individual domains of Shc for binding to the phosphotyrosine-containing portions of these proteins was determined. In addition, our data indicate that the high affinity binding of the PTB domain to the NPXpY-containing peptides results from a very high association rate and a rapid dissociation rate, which is similar to previous results observed for the SH2-phosphopeptide complexes.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,DEPT 47G,ABBOTT PK,IL 60064; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115	Abbott Laboratories; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute			Ravichandran, Kattur Soundarapandian/AAG-7319-2019	Ravichandran, Kattur Soundarapandian/0000-0003-2397-461X				BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DRUKER BJ, 1992, J VIROL, V66, P5770, DOI 10.1128/JVI.66.10.5770-5776.1992; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GRANZOW R, 1992, BIO-TECHNOL, V10, P390, DOI 10.1038/nbt0492-390; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRINGENT SA, 1994, EMBO J, V13, P2831; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; SMIT L, 1994, J BIOL CHEM, V269, P20209; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TRUB T, 1995, J BIOL CHEM, V270, P18205; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784	27	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31119	31123		10.1074/jbc.270.52.31119	http://dx.doi.org/10.1074/jbc.270.52.31119			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537373	hybrid			2022-12-25	WOS:A1995TN44400041
J	Judware, R; Culp, LA				Judware, R; Culp, LA			Over-expression of transfected N-myc oncogene in human SKNSH neuroblastoma cells down-regulates expression of beta 1 integrin subunit	ONCOGENE			English	Article						neuroblastoma; N-myc; integrin; NCAM; transfection	NEURO-BLASTOMA; SIGNAL TRANSDUCTION; GENE-EXPRESSION; ADHESION; MODULATION; ANTIGENS; CULTURE; MAX; HLA	Amplification of the N-myc oncogene is associated with progression of neuroblastoma in humans, Previous studies indicated that neuroblastoma cell lines which are amplified for the N-myc gene and over-express N-myc exhibit enhanced tumorigenic properties when injected into athymic nude mice, In addition, neuroblastoma cells which over-express N-myc (IMR32 cells) expressed little or no beta 1, alpha 2, or alpha 3 integrin subunits, as compared with cells which do not express N-myc (SKNSH cells), In order to probe the possible relationship between N-myc and beta 1 integrin gene expressions more directly, transfection experiments were performed in which an N-myc cDNA (on the episomal expression vector pREP4; high-level constitutive expression is driven by an RSV-LTR promoter) was introduced into SKNSH cells, Expression of N-myc produced significant morphological alterations in transfected cells; one subpopulation of cells remained spread on tissue culture substrata, while a second subpopulation became rounded and grew as multi-cellular aggregates, Spread (attached) cells expressed low levels of N-myc and high levels of beta 1 integrin, while rounded (loose) cells expressed relatively high levels of N-myc and low levels of beta 1 integrin, Maintenance of transfected cells in higher concentrations of selective agent produced a higher proportion of loose cells, which expressed even greater amounts of N-myc and even less beta 1 integrin; a similar effect was observed in attached cells, Interestingly, loose cell populations expressed elevated levels of the neural cell adhesion molecule [NCAM]. The results presented here infer that N-myc regulates the expression of the beta 1 integrin and NCAM cell-surface receptors responsible for cell:extracellular matrix interaction and possibly cell:cell adhesion.			Judware, R (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.				NATIONAL CANCER INSTITUTE [F32CA065068, T32CA059366] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017139] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA65068, CA59366] Funding Source: Medline; NINDS NIH HHS [NS17139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKESON R, 1990, MOL CELL BIOL, V10, P2012, DOI 10.1128/MCB.10.5.2012; ALBELDA SM, 1993, LAB INVEST, V68, P4; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1991, EMBO J, V10, P1119, DOI 10.1002/j.1460-2075.1991.tb08052.x; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRADYKALNAY SM, 1993, CLIN EXP METASTAS, V11, P313, DOI 10.1007/BF00058051; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1991, BIOCH MOL ASPECTS SE, P251; CERVELLA P, 1993, J BIOL CHEM, V268, P5148; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; COOPER MJ, 1990, CANCER RES, V50, P3694; FELTNER DE, 1989, J IMMUNOL, V143, P4292; FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185; Goridis C, 1992, Semin Cell Biol, V3, P189; GROSS N, 1994, INT J CANCER, V59, P141, DOI 10.1002/ijc.2910590124; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JUDWARE R, 1995, CLIN EXP METASTAS, V13, P123, DOI 10.1007/BF00133617; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KLEINMAN NR, 1994, BRIT J CANCER, V69, P670, DOI 10.1038/bjc.1994.129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MOENS CB, 1993, DEVELOPMENT, V119, P485; RASCHELLA G, 1994, CANCER RES, V54, P2251; RETTIG WJ, 1987, CANCER RES, V47, P1383; Sambrook J, 1989, MOL CLONING LABORATO; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	33	40	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2599	2607						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545117				2022-12-25	WOS:A1995TP18800016
J	NISHIMURA, RN; DWYER, BE				NISHIMURA, RN; DWYER, BE			PHARMACOLOGICAL INDUCTION OF HEAT-SHOCK-PROTEIN-68 SYNTHESIS IN CULTURED RAT ASTROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSCRIPTIONAL REGULATION; ISCHEMIC TOLERANCE; STRESS PROTEIN; ACTIVATION; NEURONS; INVITRO; CELLS	The induction of the highly inducible 70-kDa heat shock protein (HSP 70) is associated with thermotolerance and survival from many other types of stress. This investigation studied the pharmacological induction of HSP 68 (HSP 68 is the rat homolog of human HSP 70) by 1,10-phenanthroline in cultured rat astrocytes under conditions that activated heat shock transcription factor-1 without inducing HSP 68 synthesis. Two conditions that activate heat shock transcription factor-1 and promote its binding to the heat shock element without subsequent transcription of HSP 68 mRNA, intracellular acidosis and exposure to salicylate, showed synthesis of HSP 68 when 1,10-phenanthroline was added to culture medium after the activation of heat shock transcription factor-1. 1,10-phenanthroline mimicked heat shock by inducing HSP 68 mRNA and protein under both conditions. 1,10-phenanthroline added alone to culture medium did not induce the synthesis of HSP 68 or activate heat shock transcription factor-1. These findings strongly suggest a multistep activation for HSP 68 synthesis and also demonstrate that the synthesis of HSP 68 can be pharmacologically regulated.	UNIV CALIF LOS ANGELES,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,BRAIN RES INST,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	NISHIMURA, RN (corresponding author), VET AFFAIRS HOSP,DEPT NEUROL,111N-1,16111 PLUMMER ST,SEPULVEDA,CA 91343, USA.							CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; Cole R., 1989, DISSECTION TISSUE CU, P121; DWYER BE, 1995, MOL BRAIN RES, V30, P37, DOI 10.1016/0169-328X(94)00273-H; GREEN M, 1995, J CELL BIOCH S, V19, P189; JAATTELA M, 1989, EUR J IMMUNOL, V19, P1413, DOI 10.1002/eji.1830190810; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MORIMOTO RI, 1995, J CELL BIOCH B S, V19, P192; Morimoto RI, 1990, STRESS PROTEINS BIOL; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; NAKATA N, 1993, NEUROREPORT, V4, P695, DOI 10.1097/00001756-199306000-00023; NISHI S, 1993, BRAIN RES, V615, P281, DOI 10.1016/0006-8993(93)90039-P; NISHIMURA RN, 1991, MOL BRAIN RES, V9, P39, DOI 10.1016/0169-328X(91)90128-K; NISHIMURA RN, 1988, J NEUROSCI RES, V20, P12, DOI 10.1002/jnr.490200103; NISHIMURA RN, 1989, EXP CELL RES, V180, P276, DOI 10.1016/0014-4827(89)90231-0; NISHIMURA RN, 1988, NATO ASI SER, V1122, P229; PRIVALLE CT, 1993, P NATL ACAD SCI USA, V90, P2310, DOI 10.1073/pnas.90.6.2310; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SHOHAMI E, 1994, RESTOR NEUROL NEUROS, V6, P107, DOI 10.3233/RNN-1994-6204; VEAL JM, 1991, BIOCHEMISTRY-US, V30, P1132, DOI 10.1021/bi00218a035; VOELLMY B, 1995, J CELL BIOCH B S, V19, P189; WU C, 1995, J CELL BIOCHEM, V19, P190	25	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29967	29970						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530397				2022-12-25	WOS:A1995TK38000057
J	CROUCH, DH; FISHER, F; CLARK, W; JAYARAMAN, PS; GODING, CR; GILLESPIE, DAF				CROUCH, DH; FISHER, F; CLARK, W; JAYARAMAN, PS; GODING, CR; GILLESPIE, DAF			GENE-REGULATORY PROPERTIES OF MYC HELIX-LOOP-HELIX LEUCINE-ZIPPER MUTANTS - MAX-DEPENDENT DNA-BINDING AND TRANSCRIPTIONAL ACTIVATION IN YEAST CORRELATES WITH TRANSFORMING CAPACITY	ONCOGENE			English	Article							HUMAN C-MYC; SACCHAROMYCES-CEREVISIAE; PROTEIN EXPRESSION; ESCHERICHIA-COLI; CELL-CYCLE; MOTIF; DIFFERENTIATION; OLIGOMERIZATION; SPECIFICITY; RECOGNITION	Max is a basic helix-loop-helix/leucine zipper (bHLH/LZ) protein that forms sequence-specific DNA-binding complexes with the c-Myc oncoprotein (Myc). Using Saccharomyces cerevisiae, we have shown that the Max bHLH/LZ domain enables Myc to activate transcription through CACGTG and CACATG sequences in vivo, and that the number and context of such sites determines the level of activation. In addition, we have used yeast to investigate the role of the Myc helix-loop-helix (HLH) and leucine zipper (LZ) motifs in mediating Max-dependent DNA-binding and transcriptional activation in vivo using HLH/LZ mutants generated by site-directed mutagenesis. The results show that, while both motifs are essential for Myc to activate transcription, helix 2 of the HLH together with the contiguous LZ suffice to mediate complex formation with Max, whilst helix 1 is essential for sequence-specific DNA binding of Myc-Max complexes. Furthermore, the ability of Myc HLH/LZ mutants to hind DNA and activate transcription in collaboration with Max correlates closely with their neoplastic transforming activity in higher eukaryotic cells.	BEATSON INST CANC RES, CANC RES CAMPAIGN,BEATSON LABS,GARSCUBE ESTATE, SWITCHBACK RD, GLASGOW G61 1BD, SCOTLAND; MARIE CURIE RES INST, EUKARYOT TRANSCRIPT LAB, OXTED RH8 0TL, SURREY, ENGLAND	Beatson Institute			Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544; /0000-0002-6500-9095; Goding, Colin/0000-0002-1614-3909				Abate C, 1990, Semin Cancer Biol, V1, P19; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISHER F, 1991, ONCOGENE, V6, P1099; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; GIBOSN TJ, 1993, IN PRESS PROTEIN ENG; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MIN SY, 1992, ONCOGENE, V7, P1531; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Penn L J, 1990, Semin Cancer Biol, V1, P69; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; REDDY CD, 1992, ONCOGENE, V7, P2085; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STAROVASNIK MA, 1992, BIOCHEMISTRY-US, V31, P9891, DOI 10.1021/bi00156a006; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VINSON CR, 1992, NEW BIOL, V4, P396; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WATERS CM, 1991, ONCOGENE, V6, P797; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448	51	37	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1849	1855						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510929				2022-12-25	WOS:A1993LG68200017
J	LECHLEIDER, RJ; FREEMAN, RM; NEEL, BG				LECHLEIDER, RJ; FREEMAN, RM; NEEL, BG			TYROSYL PHOSPHORYLATION AND GROWTH-FACTOR RECEPTOR ASSOCIATION OF THE HUMAN CORKSCREW HOMOLOG, SH-PTP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF RECEPTOR; DROSOPHILA; PROTEIN; KINASE; TORSO; PP60C-SRC; FAMILY; SH2	The pivotal role of tyrosine kinases in signal transduction is well established, but the role of tyrosine phosphatases remains obscure. The discovery of src homology 2 domain-containing protein tyrosine phosphatases suggested roles for these molecules in growth factor signaling pathways, since src homology 2 domains direct association of downstream signaling molecules with activated growth factor receptors and other phosphotyrosyl proteins. We have found that SH-PTP2, a putative homologue of Drosophila corkscrew, associates in vivo with the ligand-activated epidermal growth factor and platelet-derived growth factor receptors. The N-terminal src homology 2 domain of SH-PTP2 directly associates with activated receptors. SH-PTP2 itself is a phosphoprotein, and it becomes tyrosyl phosphorylated upon growth factor activation. These findings suggest several possible models for SH-PTP2 signaling.	BRIGHAM & WOMENS HOSP, DIV PULM MED, BOSTON, MA 02115 USA; HARVARD UNIV, COMM VIROL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University	LECHLEIDER, RJ (corresponding author), BETH ISRAEL HOSP, MOLEC MED UNIT, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.			Freeman, Robert/0000-0003-1463-9748				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1987, CELL, V49, P65; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; Mendelsohn J, 1989, Trans Am Clin Climatol Assoc, V100, P31; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PIWINICAWORMS H, 1987, CELL, V49, P75; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	30	200	203	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13434	13438						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514779				2022-12-25	WOS:A1993LH55300060
J	RITZENTHALER, JD; GOLDSTEIN, RH; FINE, A; SMITH, BD				RITZENTHALER, JD; GOLDSTEIN, RH; FINE, A; SMITH, BD			REGULATION OF THE ALPHA-1(I) COLLAGEN PROMOTER VIA A TRANSFORMING GROWTH-FACTOR-BETA ACTIVATION ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR-I; LUNG FIBROBLASTS; DNA-BINDING; TRANSCRIPTION; GENE; ACCUMULATION; INHIBITION; SEQUENCES	A transforming growth factor-beta (TGF-beta) activating element (TAE), with a nuclear factor-1 (NF-1)-like sequence, was previously located 1.6 kilobases upstream from the transcription start site in the alpha1(I) collagen promoter (Ritzenthaler, J. D., Goldstein, R. H., Fine, A., Lichtler, A., Rowe, D. W., and Smith, B. D. (1991) Biochem. J. 280, 157-162). Double-stranded TAE, but not NF-1 consensus sequences, abrogated TGF-beta stimulation of co-transfected collagen promoter-chloramphenicol acetyltransferase constructs. Mutations in non-NF-1 binding sites, located by methylation interference, eliminated activity of the TAE oligonucleotide. However, TAE sequences failed to bind in vitro expressed NF-1 protein, to compete for NF-1-binding proteins, and to bind with protein which reacts with antibodies to NF-1 family of proteins. Within the TAE there was an activator protein 2 (AP-2) binding site. Although AP-2 protein bound to TAE, antibodies to AP-2 did not react with nuclear protein-TAE complexes. TAE bound to a 34,000-Da protein on Southwestern analysis. However, the UV-cross-linked TAE-nuclear protein complex was 82,000 Da. Finally, a dose-response study demonstrated that TGF-beta increased TAE nuclear binding proteins at lower doses with a different response curve than NF-1 nuclear binding proteins. Taken together these data demonstrated that TGF-beta functions in human lung fibroblasts to activate collagen transcription through TAE sites by protein complexes independent of NF-1 or AP-2 protein.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, K-124, 80 E CONCORD ST, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, CTR PULM, BOSTON, MA 02118 USA; VET ADM MED CTR JAMAICA PLAIN, BOSTON, MA 02130 USA	Boston University; Boston University				Smith, Barbara/0000-0002-5375-7627; Fine, Alan/0000-0001-9351-3048	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041373, P01HL046902] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL-41373, P01HL-46902] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1967, J MOL BIOL, V26, P365; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FINE A, 1990, CONNECT TISSUE RES, V24, P237, DOI 10.3109/03008209009152152; FINE A, 1987, J BIOL CHEM, V262, P3897; FINE A, 1989, J BIOL CHEM, V264, P16988; GIL G, 1988, J BIOL CHEM, V263, P19009; GOLDSTEIN RH, 1990, J BIOL CHEM, V265, P13623; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; LEASK A, 1991, P NATL ACAD SCI USA, V66, P1301; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCQUILLAN JJ, 1991, NUCLEIC ACIDS RES, V23, P6627; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; PLUMB M, 1991, J VIROL, V65, P1991, DOI 10.1128/JVI.65.4.1991-1999.1991; RITZENTHALER JD, 1991, BIOCHEM J, V280, P157, DOI 10.1042/bj2800157; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; STUIVER MH, 1990, J VIROL, V65, P376; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670	24	104	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13625	13631						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514794				2022-12-25	WOS:A1993LH55300086
J	SUZUKI, T; RIGGS, AF				SUZUKI, T; RIGGS, AF			LINKER CHAIN L1 OF EARTHWORM HEMOGLOBIN - STRUCTURE OF GENE AND PROTEIN - HOMOLOGY WITH LOW-DENSITY-LIPOPROTEIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GIANT EXTRACELLULAR HEMOGLOBIN; AQUATICUS DNA-POLYMERASE; LUMBRICUS-TERRESTRIS; LDL RECEPTOR; QUATERNARY STRUCTURE; APOLIPOPROTEIN-E; SUBUNIT; GLOBIN; TRIMER	The extracellular hemoglobins (Hbs) of annelids and tube worms are giant multisubunit proteins of up to almost-equal-to 200 polypeptides and molecular masses to at least 3,900 kDa. They differ from all other Hbs in having both O2-binding chains and ''linker'' chains. The latter are required for assembly and structural integrity of the protein and are deficient in or lack heme. We have determined the nucleotide sequences of the cDNA and gene for linker chain L1 of the hemoglobin of Lumbricus terrestris. The cDNA-derived amino acid sequence has 225 residues and a calculated molecular mass of 25,847 Da. The chain is 21-28% identical to linker chains of the related annelid Tylorrhynchus heterochaetus and the deep-sea tube worm Lamellibrachia sp. A remarkable feature of the linker chains is a conserved 38-39-residue segment that contains a repeating pattern of cysteinyl residues: (CYS-X6)3-Cys-X5-Cys-X10-Cys. This pattern, not present in any globin sequence, corresponds exactly to the cysteine-rich repeats of the ligand binding domains of the low density lipoprotein (LDL) receptors of man and Xenopus laevis. Furthermore, the cysteine-rich segment of linker chain L1 has the sequence Asp-Gly-Ser-Asp-Glu which is characteristic of LDL receptor repeats. Similar cysteine-rich sequences also occur in two other mammalian proteins, complement C9 and renal glycoprotein GP330. The results support the conclusion that the cysteine-rich motif of the LDL receptor and annelid Hbs is a multipurpose protein-binding unit of ancient origin which has been incorporated into diverse unrelated proteins, presumably by the process of exon shuffling.	UNIV TEXAS, DEPT ZOOL, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin					NIGMS NIH HHS [GM28410, GM35847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847, R01GM028410] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER RL, 1969, BIOCH MICROCALORIMET, P221; CALVETE JJ, 1992, FEBS LETT, V309, P316, DOI 10.1016/0014-5793(92)80797-K; DISCIPIO RG, 1984, P NATL ACAD SCI-BIOL, V81, P7298, DOI 10.1073/pnas.81.23.7298; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FUSHITANI K, 1988, J BIOL CHEM, V263, P6502; FUSHITANI K, 1988, P NATL ACAD SCI USA, V85, P9461, DOI 10.1073/pnas.85.24.9461; FUSHITANI K, 1991, J BIOL CHEM, V266, P10275; GARLICK RL, 1982, J BIOL CHEM, V257, P9005; GIBSON QH, 1991, J BIOL CHEM, V266, P13097; GILLET D, 1992, PROTEIN ENG, V5, P273, DOI 10.1093/protein/5.3.273; HUELSENBECK JP, 1993, IN PRESS SYSTEMATIC; JHIANG SM, 1989, J BIOL CHEM, V264, P19003; JHIANG SM, 1988, SCIENCE, V240, P334, DOI 10.1126/science.2832953; KAPP OH, 1987, P NATL ACAD SCI USA, V84, P7532, DOI 10.1073/pnas.84.21.7532; KIMBALL MR, 1979, BIOCHEM BIOPH RES CO, V88, P950, DOI 10.1016/0006-291X(79)91500-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAINWARING MG, 1986, J BIOL CHEM, V261, P899; MASSEFSKI W, 1990, SCIENCE, V249, P521, DOI 10.1126/science.1696395; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MORRIS SC, 1985, ORIGINS RELATIONSHIP, P350; NAITO Y, 1991, P NATL ACAD SCI USA, V88, P6672, DOI 10.1073/pnas.88.15.6672; NICHOLS DAVID, 1967, SYMP ZOOL SOC LONDON, V20, P209; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; OWNBY DW, 1993, J BIOL CHEM, V268, P13539; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERUTZ MF, 1990, J MOL BIOL, V213, P203, DOI 10.1016/S0022-2836(05)80178-0; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; SHISHIKURA F, 1986, BIOCHIM BIOPHYS ACTA, V869, P314, DOI 10.1016/0167-4838(86)90071-3; SHISHIKURA F, 1987, J BIOL CHEM, V262, P3123; SHLOM JM, 1973, J BIOL CHEM, V248, P7904; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; SUZUKI T, 1988, BIOCHEM J, V255, P541; SUZUKI T, 1990, J BIOL CHEM, V265, P12168; SUZUKI T, 1990, J BIOL CHEM, V265, P1551; SUZUKI T, 1991, FASEB J, V5, pA1545; Swofford David L., 1990, P411; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TU AT, 1973, ANNU REV BIOCHEM, V42, P235, DOI 10.1146/annurev.bi.42.070173.001315; VINOGRADOV SN, 1986, P NATL ACAD SCI USA, V83, P8034, DOI 10.1073/pnas.83.21.8034; VINOGRADOV SN, 1991, J BIOL CHEM, V266, P13091; VINOGRADOV SN, 1985, COMP BIOCHEM PHYS B, V82, P1, DOI 10.1016/0305-0491(85)90120-8; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WRIGHT CS, 1984, BIOCHEMISTRY-US, V23, P280, DOI 10.1021/bi00297a017	46	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13548	13555						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514788				2022-12-25	WOS:A1993LH55300076
J	Perkins, AS; Kim, JH				Perkins, AS; Kim, JH			Zinc fingers 1-7 of EVI1 fail to bind the GATA motif by itself but require the core site GACAAGATA for binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; PORPHOBILINOGEN DEAMINASE GENE; MYELOID-TRANSFORMING GENE; TRANSCRIPTION FACTOR; GLOBIN GENE; T-CELL; ERYTHROID-DIFFERENTIATION; PROTEIN INTERACTIONS; ENDOTHELIAL-CELLS; HORMONE RECEPTOR	EVI1 is a zinc finger oncoprotein that binds via fingers 1-7 to the sequence GACAAGATAA. The target genes on which EVI1 acts are unknown. This binding motif over laps with that for the GATA transcription factors, (T/A)GATA(A/G), and GATA-1 can bind to and activate transcription via a GACAAGATAA motif. The possibility has been raised that, when overexpressed in leukemogenesis, EVI1 may function by interfering with the differentiation-promoting action of GATA factors. To explore this, we have assessed the affinity of EVI1 for the GATA binding sites derived from erythroid-specific GATA-1 target genes, and found only low affinity interactions. We examined the contacts between EVI1 and DNA by methylation interference studies, which revealed extensive contacts between EVI1 and its binding site. The importance of the contacts for high affinity binding was shown by in vitro quantitative gel shift studies and in vivo cotransfection studies. To examine what types of sequences from mouse genomic DNA bind to EVI1, we isolated and sequenced five EVI1-binding fragments, and each showed the GACAAGATA site. The data presented contribute to our knowledge of the binding specificity of EVI1, and yield a clearer picture of what sequences can, and cannot, act as targets for EVI1 action.			Perkins, AS (corresponding author), YALE UNIV, SCH MED, DEPT PATHOL, POB 208023, NEW HAVEN, CT 06520 USA.							ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BERGERON D, 1992, VIROLOGY, V191, P661, DOI 10.1016/0042-6822(92)90241-G; BORDEREAUX D, 1990, ONCOGENE, V5, P925; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DESJARLAIS JR, 1992, PROTEINS, V12, P101, DOI 10.1002/prot.340120202; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FEARON ER, 1992, P NATL ACAD SCI USA, V89, P7958, DOI 10.1073/pnas.89.17.7958; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GONG QH, 1991, MOL CELL BIOL, V11, P2558, DOI 10.1128/MCB.11.5.2558; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; JOHNSTON J, 1992, GENOMICS, V12, P459, DOI 10.1016/0888-7543(92)90435-U; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KELLEY C, 1993, DEVELOPMENT, V118, P817; KEMPER B, 1987, MOL CELL BIOL, V7, P2059, DOI 10.1128/MCB.7.6.2059; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEVY ER, 1994, BLOOD, V83, P1348; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARTIN DIK, 1989, NATURE, V338, P435, DOI 10.1038/338435a0; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NAGAI T, 1994, BLOOD, V84, P1074, DOI 10.1182/blood.V84.4.1074.bloodjournal8441074; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OVAL J, 1992, LEUKEMIA, V6, P446; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; Sambrook J, 1989, MOL CLONING LABORATO; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089; WATT P, 1990, NUCLEIC ACIDS RES, V18, P1339, DOI 10.1093/nar/18.6.1339; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	65	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1104	1110		10.1074/jbc.271.2.1104	http://dx.doi.org/10.1074/jbc.271.2.1104			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557637	hybrid			2022-12-25	WOS:A1996TP88900074
J	Dunn, D; Chen, L; Lawrence, DS; Zhang, ZY				Dunn, D; Chen, L; Lawrence, DS; Zhang, ZY			The active site specificity of the Yersinia protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PEPTIDES; SUBSTRATE-SPECIFICITY; VIRULENCE DETERMINANT; BOVINE HEART; ASSAY; PURIFICATION; INTERMEDIATE; EXPRESSION; CD45; LAR	Yersinia protein-tyrosine phosphatase substrates have been synthesized employing an expedient methodology that incorporates phosphorylated non amino acid residues into an active site-directed peptide. While the peptidic portion of these compounds serves an enzyme targeting role, the nonpeptidic component provides a critical assessment of the range of functionality that can be accommodated within the active site region. We have found that the Yersinia phosphatase hydrolyzes both L- and D-stereoisomers of phosphotyrosine in active site-directed peptides, with the former serving as a 10-fold more efficient substrate than the latter. In addition, this enzyme catalyzes the hydrolysis of a variety of aromatic and aliphatic phosphates. Indeed, a peptide bearing the achiral phosphotyrosine analog, phosphotyramine, is not only the most efficient substrate described in this study, it is also one of the most efficient substrates ever reported for the Yersinia phosphatase. Straight chain peptide-bound aliphatic phosphates of the general structure, (Glu)(4)-NH-(CH2)(n)-OPO32- (n = 2-8), are also hydrolyzed, where the most efficient substrate contains seven methylene groups. Finally, a comparison of the substrate efficacy of the peptide-bound species with that of the corresponding non-peptidic analogs, reveals that the peptide component enhances k(cat)/K-m by up to nearly 3 orders of magnitude.	ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; SUNY BUFFALO,DEPT CHEM,BUFFALO,NY 14260	Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIDDK NIH HHS [5P60 DK20541-17] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHATTERJEE S, 1992, PEPTIDES CHEM BIOL, P553; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; KWON YG, 1993, J BIOL CHEM, V268, P10713; KWON YG, 1994, J BIOL CHEM, V269, P4839; LEE TR, 1994, BIOCHEMISTRY-US, V33, P4245, DOI 10.1021/bi00180a019; LEE TR, 1995, J BIOL CHEM, V270, P5375, DOI 10.1074/jbc.270.10.5375; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; PERCH JW, 1988, SYNTHESIS-STUTTGART, P142; RUZZENE M, 1993, EUR J BIOCHEM, V211, P289, DOI 10.1111/j.1432-1033.1993.tb19897.x; SPARKS JW, 1985, J BIOL CHEM, V260, P2042; TONKS NK, 1988, J BIOL CHEM, V263, P6731; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C; ZHANG ZY, 1994, J BIOL CHEM, V269, P8140; ZHANG ZY, 1995, J BIOL CHEM, V270, P16052; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHAO ZZ, 1992, ANAL BIOCHEM, V202, P361, DOI 10.1016/0003-2697(92)90119-R	34	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					168	173		10.1074/jbc.271.1.168	http://dx.doi.org/10.1074/jbc.271.1.168			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550553	hybrid			2022-12-25	WOS:A1996TP36100026
J	Kaplan, DH; Greenlund, AC; Tanner, JW; Shaw, AS; Schreiber, RD				Kaplan, DH; Greenlund, AC; Tanner, JW; Shaw, AS; Schreiber, RD			Identification of an interferon-gamma receptor alpha chain sequence required for JAK-1 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR; ERYTHROPOIETIN RECEPTOR; SIGNAL-TRANSDUCTION; EXPRESSION; CLONING; CDNA; PHOSPHORYLATION; PURIFICATION; DOMAIN	We have shown previously that a four-amino acid block residing at positions 266-269 (LPKS) in the intracellular domain of the human interferon-gamma (IFN-gamma) receptor alpha chain is critical for IFN-gamma-dependent tyrosine kinase activation and biologic response induction, Herein we show that this sequence is required for the constitutive attachment of the tyrosine kinase JAK-1. Using a vaccinia expression system, a receptor alpha chain-specific monoclonal antibody coprecipitated JAK-1 from cells coexpressing JAK-1 and either (a) wild type IFN-gamma receptor alpha chain, (b) a receptor alpha chain truncation mutant containing only the first 59 intracellular domain amino acids, or (c) a receptor mutant containing alanine substitutions for the functionally irrelevant residues 272-275, In contrast, JAK-1 was not coprecipitated when coexpressed with a receptor alpha chain mutant containing alanine substitutions for the functionally critical residues 266-269 (LPKS), Mutagenesis of the LPKS sequence revealed that Pro-267 is the only residue obligatorily required for receptor function. In addition, Pro-267 is required for JAK-1 binding, These results thus identify a site in the IFN-gamma receptor alpha chain required for constitutive JAK-1 association and establish that this association is critical for IFN-gamma signal transduction.			Kaplan, DH (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PATHOL,CTR IMMUNOL,ST LOUIS,MO 63110, USA.		Kaplan, Daniel H/N-2779-2013; Schreiber, Robert/Q-7550-2019; Schreiber, Robert D/A-1276-2013	Kaplan, Daniel H/0000-0002-7851-7320; Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341				AGUET M, 1987, J EXP MED, V165, P988, DOI 10.1084/jem.165.4.988; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; BASU MT, 1988, P NATL ACAD SCI USA, V85, P6282, DOI 10.1073/pnas.85.17.6282; CALDERON J, 1988, P NATL ACAD SCI USA, V85, P4837, DOI 10.1073/pnas.85.13.4837; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HERSHEY GK, 1990, J BIOL CHEM, V265, P1768; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; JANSSEN JWG, 1986, CYTOMETRY, V7, P411, DOI 10.1002/cyto.990070504; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; MARSTERS SA, 1995, P NATL ACAD SCI USA, V92, P5401, DOI 10.1073/pnas.92.12.5401; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; NOVICK D, 1987, J BIOL CHEM, V262, P8463; PENNICA D, 1992, J BIOL CHEM, V267, P21172; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	46	78	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					9	12		10.1074/jbc.271.1.9	http://dx.doi.org/10.1074/jbc.271.1.9			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550631				2022-12-25	WOS:A1996TP36100002
J	Kyritsis, AP; Zhang, BH; Zhang, W; Xiao, M; Takeshima, H; Bondy, ML; Cunningham, JE; Levin, VA; Bruner, J				Kyritsis, AP; Zhang, BH; Zhang, W; Xiao, M; Takeshima, H; Bondy, ML; Cunningham, JE; Levin, VA; Bruner, J			Mutations of the p16 gene in gliomas	ONCOGENE			English	Article						astrocytoma; brain tumor; MTS1; glioblastoma	SSCP ANALYSIS; CELLS	In the present study we investigated the frequency of p16 gene exon 2 mutations in 35 malignant gliomas, using either direct sequencing of the PCR products or cloning into the pCRII vector and sequencing of the cloned PCR products. No mutations were detected during direct sequencing of the PCR products. However, after sequencing ofindividual clones, we found multiple mutations in 5 tumors involving codons 73(GCC to ACC, Ala to Thr), 76 (GCC to GTC, Ala to Va), 85(GCT to ACT, Ala to Thr), 98(CAC to TAC, His to Tyr), 102 (GCG to GTG, Ala to Val), 106 (GTG to ATG, Val to Met), 107 (CGC to TGC, Arg to Cys), 127 (GCA to GTA, Ala to Val), 128 (CGG to TGG, Arg to Trp) and 136 (GGC to GAG, Gly to Asp). Mutations were found only in glioblastomas and were either C to T or G to A transitions. Each mutation was detected in a small percentage of tumor cells (1.3-22%) using individual colony sequencing and southern hybridization with mutant oligonucleotides, consistent with the heterogenous cell population of glioblastomas. The presence of p16 gene mutations only in glioblastomas suggests that they are late events in glioma development.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EPIDEMIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kyritsis, AP (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT NEUROONCOL,1515 HOLCOMBE BLVD,BOX 100,HOUSTON,TX 77030, USA.		Cunningham, John/GWB-9698-2022	Cunningham, John/0000-0002-1805-9743	NCI NIH HHS [CCSG-CA16672, P01-CA55261] Funding Source: Medline; NINDS NIH HHS [R29 NS32269-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055261, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; FAN E, 1993, MUTAT RES, V288, P85, DOI 10.1016/0027-5107(93)90210-7; GIANI C, 1994, CANCER RES, V54, P6338; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HE J, 1994, CANCER RES, V54, P5804; IGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090, DOI 10.1006/bbrc.1994.2294; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KYRITSIS AP, 1992, INT J ONCOL, V1, P149; KYRITSIS AP, 1994, JNCI-J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; LI Y, 1994, CANCER RES, V54, P6078; MOULTON T, 1995, AM J PATHOL, V146, P613; NELSON JS, 1983, CANCER, V52, P550, DOI 10.1002/1097-0142(19830801)52:3<550::AID-CNCR2820520327>3.0.CO;2-C; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WU JK, 1993, AM J HUM GENET, V52, P1273; ZHOU XL, 1994, ONCOGENE, V9, P3737	22	58	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					63	67						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552400				2022-12-25	WOS:A1996TQ01400008
J	Communi, D; Pirotton, S; Parmentier, M; Boeynaems, JM				Communi, D; Pirotton, S; Parmentier, M; Boeynaems, JM			Cloning and functional expression of a human uridine nucleotide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP RECEPTOR; CELLS	In order to isolate new subtypes of P-2 purinoceptors, sets of degenerate oligonucleotide primers were synthesized on the basis of the best conserved segments in the published sequences of the chick brain P-2Y/P2Y(1) and murine neuroblastoma P-2U/P2Y(2) receptors. Their use in polymerase chain reaction (PCR) experiments on human genomic DNA amplified, among other things, a 712-base pair sequence, that was used as a probe to screen a human genomic DNA library. Several clones corresponding to a single locus were isolated, and the sequence analysis revealed an intronless 1095-base pair open reading frame. The deduced amino acid sequence is consistent with a G protein-coupled receptor and exhibits 51% identity with the human P2Y(2) receptor and 35% with the chick P2Y(1) receptor. A close comparison with the human P2Y(2) sequence reveals the conservation of histidine 262, arginine 265, lysine 289, and arginine 292, which were reported to be involved in nucleotide binding (Erb, L., Garrad, R., Wang, Y., Quinn, T., Turner, J. T., and Weisman, G. A. (1995) J. Biol. Chem. 270, 4185-4188). Northern blot analysis detected a 1.8-kilobase messenger RNA in human placenta, The coding sequence was inserted in the pcDNA3 vector in order to transfect 1321N1 human astrocytoma cells. In cells stably expressing the receptor, UTP and UDP stimulated the formation of inositol phosphates with equivalent potency and maximal effect, ATP behaved as a partial agonist, and ADP was almost inactive. We have thus cloned a new member of the G protein coupled P-2 purinergic receptor family, which functionally behaves as a pyrimidinergic receptor.	FREE UNIV BRUSSELS,ERASME HOSP,DEPT MED CHEM,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel	Communi, D (corresponding author), FREE UNIV BRUSSELS,SCH MED,INST INTERDISCIPLINARY RES,BLDG C,808 ROUTE LENNIK,B-1070 BRUSSELS,BELGIUM.			Parmentier, Marc/0000-0001-8081-4685				BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BROWN HA, 1991, MOL PHARMACOL, V40, P648; COMMUNI D, 1995, CIRC RES, V76, P191, DOI 10.1161/01.RES.76.2.191; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERB L, 1993, P NATL ACAD SCI USA, V90, P10449, DOI 10.1073/pnas.90.22.10449; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; HARRISON JK, 1994, NEUROSCI LETT, V169, P85, DOI 10.1016/0304-3940(94)90362-X; HENDERSON DJ, 1995, BIOCHEM BIOPH RES CO, V212, P648, DOI 10.1006/bbrc.1995.2018; KAPLAN MH, 1993, J IMMUNOL, V151, P628; LAZAROWSKI ER, 1994, J BIOL CHEM, V269, P11830; LIBERT F, 1989, SCIENCE, V244, P569, DOI 10.1126/science.2541503; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; OCONNOR SE, 1991, TRENDS PHARMACOL SCI, V12, P137, DOI 10.1016/0165-6147(91)90530-6; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; RICE WR, 1995, AM J RESP CELL MOL, V12, P27, DOI 10.1165/ajrcmb.12.1.7811468; Sambrook J, 1989, MOL CLONING LABORATO; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; TOKOYAMA Y, 1995, BIOCHEM BIOPH RES CO, V211, P211; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	26	227	241	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30849	30852		10.1074/jbc.270.52.30849	http://dx.doi.org/10.1074/jbc.270.52.30849			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537336	hybrid			2022-12-25	WOS:A1995TN44400004
J	Kohler, SA; Henderson, BR; Kuhn, LC				Kohler, SA; Henderson, BR; Kuhn, LC			Succinate dehydrogenase b mRNA of Drosophila melanogaster has a functional iron-responsive element in its 5'-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRITIN MESSENGER-RNA; 5-AMINOLEVULINATE SYNTHASE; TRANSLATIONAL REGULATION; BINDING PROTEIN; UNTRANSLATED REGION; IDENTIFICATION; REPRESSOR; CELLS; GENE; BIOSYNTHESIS	Iron-responsive elements (IREs) are cis-acting mRNA stem-loop structures that specifically bind cytoplasmic iron regulatory proteins (IRPs), IRP-IRE interactions mediate the coordinate post transcriptional regulation of key proteins in iron metabolism, such as ferritin, transferrin receptor, and erythroid 5-aminolevulinic acid synthase. Depending on whether the IRE is located in the 5'- or 3'-untranslated region (UTR), binding of IRP will inhibit mRNA translation or degradation, respectively, Here we describe a new IRE in the 5'-UTR of succinate dehydrogenase subunit b (SDHb) mRNA of Drosophila melanogaster. The SDHb IRE binds in vitro to vertebrate and insect IRPs with a high affinity equal to that of human ferritin H chain IRE. Under conditions of iron deprivation, SDHb mRNA of Drosophila SL-2 cells shifts to a non-polysome-bound pool. Moreover, translation of a human growth hormone mRNA with the SDHb IRE in its 5'-UTR is iron-dependent in stably transfected L cells, We conclude that the SDHb IRE mediates translational inhibition both in insect and vertebrate cells, This constitutes the first identification of a functional IRE in insects. Furthermore, Drosophila SDHb represents the second example, after porcine mitochondrial aconitase, of an enzyme of the citric acid cycle whose mRNA possesses all necessary features for translational regulation by cellular iron levels.	SWISS INST EXPTL CANC RES,GENET UNIT,CH-1066 EPALINGES,SWITZERLAND	Swiss Institute Experimental Cancer Research								ACKRELL BAC, 1984, J BIOL CHEM, V259, P53; AU HC, 1995, GENE, V159, P249, DOI 10.1016/0378-1119(95)00162-Y; AU HC, 1994, GENE, V149, P261, DOI 10.1016/0378-1119(94)90158-9; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1995, TRENDS GENET, V11, P45, DOI 10.1016/S0168-9525(00)88996-9; DANDEKAR T, 1991, EMBO J, V10, P1908; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; GRAY NK, 1993, EUR J BIOCHEM, V218, P657, DOI 10.1111/j.1432-1033.1993.tb18420.x; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; KUHN LC, 1994, BAILLIERE CLIN HAEM, V7, P763, DOI 10.1016/S0950-3536(05)80123-4; LEIBOLD EA, 1987, J BIOL CHEM, V262, P7335; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MAY BK, 1990, MOL BIOL MED, V7, P405; MELEFORS O, 1993, BLOOD REV, V7, P251, DOI 10.1016/0268-960X(93)90012-S; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; QIAN S, 1987, NUCLEIC ACIDS RES, V15, P987, DOI 10.1093/nar/15.3.987; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SIERZPUTOWSKAGRACZ H, 1995, NUCLEIC ACIDS RES, V23, P146, DOI 10.1093/nar/23.1.146; SINGER TP, 1985, FEBS LETT, V190, P189, DOI 10.1016/0014-5793(85)81282-5; SUCHETA A, 1993, BIOCHEMISTRY-US, V32, P5455, DOI 10.1021/bi00071a023; TANNE Z, 1994, BIOCHEM PHARMACOL, V47, P1759, DOI 10.1016/0006-2952(94)90303-4; THEIL EC, 1994, BIOCHEM J, V304, P1; VONDARL M, 1994, EUR J BIOCHEM, V222, P353; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; ZHENG LM, 1992, ARCH BIOCHEM BIOPHYS, V299, P356, DOI 10.1016/0003-9861(92)90287-7	43	104	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30781	30786		10.1074/jbc.270.51.30781	http://dx.doi.org/10.1074/jbc.270.51.30781			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530520	hybrid			2022-12-25	WOS:A1995TL67500085
J	Raju, TS; Ray, MK; Stanley, P				Raju, TS; Ray, MK; Stanley, P			LEC18, a dominant Chinese hamster ovary glycosylation mutant synthesizes N-linked carbohydrates with a novel core structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; RESISTANT CHO CELLS; GDP-FUCOSE; LECTIN; OLIGOSACCHARIDES; SPECIFICITY; MICROHETEROGENEITY; GLYCOPROTEINS; GLYCOPEPTIDES; SELECTION	The dominant Chinese hamster ovary cell glycosylation mutant, LEC18, was selected for resistance to pealectin (Pisum sativum agglutinin (PSA)). Lectin binding studies show that LEC18 cells express altered cell surface carbohydrates with markedly reduced binding to I-125-PSA and increased binding to I-125-labeled Datura stramonium agglutinin (DSA) compared with parental cells, Desialylated [H-3]Glc-labeled LEC18 cellular glycopeptides that did not bind to concanavalin A-Sepharose exhibited an increased proportion of species that were bound to DSA-agarose. Most of these glycopeptides bound to ricin-agarose and were unique to LEC18 cells. This fraction was purified from similar to 10(10) cells and shown by H-1 NMR spectroscopy and methylation linkage analysis to contain novel N-linked structures, Digestion of these glycopeptides with mixtures of beta-D-galactosidases and N-acetyl-beta-D-glucosaminidases gave core glycopeptides that, in contrast to cores from parental cells, were mainly not bound to concanavalin A-Sepharose or to PSA-agarose, H-1 NMR spectroscopy, matrix-assisted laser desorption ionization/time of flight mass spectrometry, electrospray mass spectrometry, and collision-activated dissociation mass spectrometry showed that the LEC18 core glycopeptides contained a new GlcNAc residue that substitutes the core GlcNAc residue. Methylation linkage analysis of the parent compound provided evidence that the GlcNAc is linked at O-6 to give the following novel, N-linked core structure.	ALBERT EINSTEIN COLL MED,DEPT BIOL,NEW YORK,NY 10461	Yeshiva University				Stanley, Pamela/0000-0001-5704-3747	NATIONAL CANCER INSTITUTE [R01CA036434] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005351] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36434] Funding Source: Medline; NCRR NIH HHS [2-P41-RR05351-06] Funding Source: Medline; PHS HHS [P0 13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALONSO JM, 1988, EUR J BIOCHEM, V177, P187, DOI 10.1111/j.1432-1033.1988.tb14361.x; ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; ASPINALL GO, 1993, EUR J BIOCHEM, V213, P1017, DOI 10.1111/j.1432-1033.1993.tb17849.x; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BAKKER H, 1994, J BIOL CHEM, V269, P30326; CAMPBELL C, 1984, J BIOL CHEM, V259, P3370; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FOURNET B, 1987, EUR J BIOCHEM, V166, P321, DOI 10.1111/j.1432-1033.1987.tb13517.x; GREY AA, 1982, CAN J BIOCHEM CELL B, V60, P1123, DOI 10.1139/o82-144; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HARDY MR, 1994, METHOD ENZYMOL, V230, P208; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; HUANG CC, 1970, CARBOHYD RES, V13, P127, DOI 10.1016/S0008-6215(00)84902-2; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; POTVIN B, 1991, CELL REGUL, V2, P989, DOI 10.1091/mbc.2.12.989; REINHOLD VN, 1995, ANAL CHEM, V67, P1772, DOI 10.1021/ac00107a005; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; RIPKA J, 1986, SOMAT CELL MOLEC GEN, V12, P51, DOI 10.1007/BF01560727; ROBERTSON MA, 1978, CELL, V13, P515, DOI 10.1016/0092-8674(78)90325-2; RUPLEY JA, 1964, BIOCHIM BIOPHYS ACTA, V83, P245, DOI 10.1016/0926-6526(64)90001-1; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; STANLEY P, 1987, METHOD ENZYMOL, V138, P443; STANLEY P, 1981, CELL, V23, P763, DOI 10.1016/0092-8674(81)90440-2; STAUDACHER E, 1991, EUR J BIOCHEM, V199, P745, DOI 10.1111/j.1432-1033.1991.tb16179.x; STRECKER G, 1989, GLYCOCONJUGATE J, V6, P67, DOI 10.1007/BF01047891; TAGUCHI T, 1993, J BIOL CHEM, V268, P2353; VANKUIK JA, 1993, TRENDS FOOD SCI TECH, V4, P73; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YORK WS, 1984, METHOD ENZYMOL, V118, P3	37	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30294	30302		10.1074/jbc.270.51.30294	http://dx.doi.org/10.1074/jbc.270.51.30294			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530451	hybrid			2022-12-25	WOS:A1995TL67500016
J	Wong, A; Sakamoto, KM				Wong, A; Sakamoto, KM			Granulocyte-macrophage colony-stimulating factor induces the transcriptional activation of egr-1 through a protein kinase A-independent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTERLEUKIN-3; INHIBITION; CELLS; PHOSPHORYLATION; CAMP	Granulocyte-macrophage colony-stimulating factor (GM-CSF) rapidly and transiently induces the transcriptional activation of the early growth response gene-1 (egr-1) in the human factor-dependent myeloid leukemic cell line, TF-1. We previously demonstrated that the cAMP response element (CRE) is required for GM-CSF-induced egr-1 expression and that phosphorylation of CREB on serine 133 plays a critical role during GM-CSF signal transduction. To determine whether GM-CSF activates signaling pathways through a protein kinase A-dependent or -independent pathway, we measured cAMP levels following GM-CSF or forskolin treatment of TF-1 cells. Forskolin but not GM-CSF stimulation resulted in an increase in cAMP levels. Transient transfection assays with TF-1 cells were also performed with a -116-nucleotide egr-1 promoter construct and the protein kinase inhibitor, PKI. Although PKI inhibited forskolin induction of the -116-nucleotide construct, it did not affect GM-CSF stimulation of this construct. In the present study, we demonstrated that GM-CSF induces egr-1 expression through a protein kinase A-independent pathway.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,GWYNNE HAZEN CHERRY MEM LABS,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,DEPT EXPTL PATHOL & LAB MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA59463-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA059463] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUDE EJ, 1994, J BIOL CHEM, V269, P18128; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; COLEMAN DL, 1989, J IMMUNOL, V143, P4134; DURONIO V, 1992, J BIOL CHEM, V267, P21856; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; LEE JHJ, 1995, J BIOL CHEM, V270, P15979; Lee KAW, 1991, CURR OPIN CELL BIOL, V3, P953, DOI 10.1016/0955-0674(91)90113-D; MCKNIGHT GS, 1991, CURR OPIN CELL BIOL, V3, P2213; MIYAJIMA A, 1993, BLOOD, V82, P1960; MUI A, 1994, ADV EXP MED BIOL, V365, P217; OLSEN SR, 1991, MOL ENDOCRINOL, V5, P1246, DOI 10.1210/mend-5-9-1246; ORELLANA SA, 1993, J BIOL CHEM, V268, P6843; PIQUETPELLORCE C, 1991, LIFE SCI, V48, P2377, DOI 10.1016/0024-3205(91)90370-Q; SAKAMOTO KM, 1994, RECEPTOR CHANNEL, V2, P175; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SAKAMOTO KM, 1991, INT J CELL CLONING, V9, P531, DOI 10.1002/stem.5530090603; SATOH T, 1992, J BIOL CHEM, V267, P2537; SCHWARTZ EL, 1991, BLOOD, V77, P2716; YOUNG MR, 1993, INT J CANCER, V53, P667, DOI 10.1002/ijc.2910530424	23	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30271	30273		10.1074/jbc.270.51.30271	http://dx.doi.org/10.1074/jbc.270.51.30271			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530445	hybrid			2022-12-25	WOS:A1995TL67500010
J	Miyaki, M; Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Takeichi, M				Miyaki, M; Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Takeichi, M			Increased cell-substratum adhesion, and decreased gelatinase secretion and cell growth, induced by E-cadherin transfection of human colon carcinoma cells	ONCOGENE			English	Article						E-cadherin; colon carcinoma; cell adhesion; gelatinase; cell growth	FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-CELLS; EXPRESSION; CANCER; PROGRESSION; MOLECULES; TUMORIGENICITY; SUPPRESSION; INVASION	Metastasis of colon carcinomas is assumed to be caused by multiple steps, which include a loss of cell adhesion that results in the release of carcinoma cells from the original tumor tissue, A human colon carcinoma cell line COKFu was established from a poorly differentiated metastatic adenocarcinoma without cell-cell adhesion and without expression of E-cadherin mRNA and protein, This cell line was co-transfected with mouse E-cadherin cDNA in an expression vector and a neomycin-resistant gene, The parental carcinoma cells had a spindle shape and were scattered, whereas the transfected cells, which expressed exogenous E-cadherin gene, showed a more compact shape with strong cell-cell adhesion and with increased adhesiveness to collagen gel, These cells showed a significantly low anchorage independency (2-7%) and decreased invasiveness (30%) compared to the parental cells, Growth rate of transfectants was decreased both in vitro and in the subcutis of nude mice, with decreased lymphnode metastasis in the case of intravenous injection, It was additionally found that activity of 62 kd gelatinase, secreted from parental cells, was lost or decreased in E-cadherin-transfected cells. These results suggest that E-cadherin is not only involved in the cell-cell adhesion of colon carcinomas, it also has a wider effect, including cell-substratum adhesion and the regulation of proteinase secretion from the cells resulting in partial suppression of invasiveness and tumorigenic growth.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	Miyaki, M (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				ALBINI A, 1987, CANCER RES, V47, P3239; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; DIMANCHEBOITREL MT, 1994, INT J CANCER, V56, P512, DOI 10.1002/ijc.2910560410; DOKI M, 1992, CANCER RES, V53, P3421; DORUDI S, 1993, AM J PATHOL, V142, P981; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; HASHIMOTO M, 1989, JPN J CANCER RES, V80, P459, DOI 10.1111/j.1349-7006.1989.tb02336.x; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MIYAKI M, 1994, CANCER RES, V54, P3011; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCIPPER JH, 1991, CANCER RES, V51, P6328; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TANAKA K, 1993, ONCOGENE, V8, P2253; UMBAS R, 1992, CANCER RES, V52, P5104; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	32	57	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2547	2552						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545111				2022-12-25	WOS:A1995TP18800010
J	CATLING, AD; WYKE, JA; FRAME, MC				CATLING, AD; WYKE, JA; FRAME, MC			MITOGENESIS OF QUIESCENT CHICK FIBROBLASTS BY V-SRC - DEPENDENCE ON EVENTS AT THE MEMBRANE LEADING TO EARLY CHANGES IN AP-1	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; DNA-BINDING ACTIVITY; C-JUN; TRANSFORMING PROTEIN; PHOSPHORYLATION; FOS; PP60V-SRC; SEQUENCE; PROMOTER; INVITRO	Activation of rapidly reversible temperature-sensitive (ts) v-Src in quiescent chicken embryo fibroblasts (CEFs) results in both morphological transformation and exit from G0 to G1, resulting in mitosis. This phenomenon permits examination of cellular responses very soon after activating the oncoprotein, and we have used this to study changes in endogenous AP-1, and the regulation of its major components, in the first few hours after activating v-Src. This approach contrasts with a number of studies that have demonstrated enhanced activity of exogenously added AP-1 components in cells transformed by v-Src. Reactivation of a membrane-associated tyrosine kinase (tsRCAN-29) results in a several-fold increase in AP-1 DNA binding and a similar increase in the activity of an AP-1-responsive reporter soon after temperature shift. c-Jun and c-Fos are regulated at a number of levels in response to both stimuli. In quiescent RCAN-29-infected CEFs stimulated into cycle by shift to permissive temperature, c-fos transcripts are elevated by 15 min and remain above basal level for at least 4 h. Serum induces much greater elevation of c-fos transcripts, although this response is transient. Despite the difference in magnitude of the transcript responses, the stimulation of nuclear c-Fos protein is similar in both serum and v-Src-stimulated cultures. No elevation in c-jun transcripts or nuclear c-Jun protein level is evident in v-Src-stimulated quiescent CEFs. However, there is an early change in the tryptic phosphopeptide map of p39 c-Jun in response to both v-Src and serum. Upon stimulation we observed a novel redistribution of phosphate in the carboxy-terminal tryptic phosphopeptide that may be responsible in part for the increase in AP-1 DNA binding. Phosphorylation of amino-terminal serines 63 and 73 on peptides Y and X, believed to be responsible for regulation of the transactivation function of c-Jun, is constitutively high in resting CEF cultures; stimulation with serum or v-Src results in only a modest increase in phosphorylation at these sites. Significantly, reactivation of a non-myristylated, transformation-defective version of the tsRCAN-29 v-Src protein (RCAN-29A2) is unable to induce resting CEFs to reenter cycle. In addition, this mutant fails to induce early increases in AP-1 activity, implying that these nuclear changes require crucial signalling events at the cell periphery, and that these events correlate with the biological consequences of expression of v-Src.	BEATSON INST CANC RES,CANC RES CAMPAIGN,BEATSON LABS,WOLFSON LAB MOLEC PATHOL,GLASGOW G61 1BD,SCOTLAND	Beatson Institute								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BELL JG, 1975, J GEN VIROL, V27, P127, DOI 10.1099/0022-1317-27-2-127; BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CALOTHY G, 1987, J VIROL, V61, P1678, DOI 10.1128/JVI.61.5.1678-1681.1987; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COOPER JA, 1988, PEPTIDES PROTEIN PHO, P85; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CROUCH DH, 1990, ONCOGENE, V5, P683; CURRAN T, 1984, CELL, V36, P259; DURKIN JP, 1984, J CELL PHYSIOL, V120, P135, DOI 10.1002/jcp.1041200205; Fourney R.M., 1988, FOCUS, V10, P5; FRAME MC, 1991, ONCOGENE, V6, P205; GILLESPIE DAF, 1991, SEMINARS VIROLOGY, V2, P329; GILMER TM, 1983, J VIROL, V45, P462, DOI 10.1128/JVI.45.1.462-465.1983; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HARLOW E, 1988, ANTIBODIES LABORATOR, P641; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JACKSON JA, 1992, J BIOL CHEM, V267, P17444; JAHNER D, 1991, ONCOGENE, V6, P1259; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; LUO K, 1990, ONCOGENE, V5, P921; Maniatis T., 1982, MOL CLONING; MULLER R, 1987, ONCOGENE RES, V2, P19; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; WELHAM MJ, 1990, ONCOGENE, V5, P161; WHITE MK, 1988, MOL CELL BIOL, V8, P135; WYKE JA, 1973, VIROLOGY, V53, P152, DOI 10.1016/0042-6822(73)90474-1	52	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1875	1886						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510932				2022-12-25	WOS:A1993LG68200020
J	HUPP, TR; KAGUNI, JM				HUPP, TR; KAGUNI, JM			ACTIVATION OF MUTANT FORMS OF DNAA PROTEIN OF ESCHERICHIA-COLI BY DNAK AND GRPE PROTEINS OCCURS PRIOR TO DNA-REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIALIZED NUCLEOPROTEIN STRUCTURES; HEAT-SHOCK PROTEINS; BACTERIOPHAGE-LAMBDA; CHROMOSOMAL ORIGIN; INITIATION PROTEIN; GENE-PRODUCT; ENZYMATIC REPLICATION; GROWTH; PURIFICATION; TEMPERATURES	Mutant forms of DnaA protein, inert in a replication system composed of other purified proteins, are ''activated'' by DnaK and GrpE heat shock proteins (Hupp, T. R., and Kaguni, J. M. (1993) J. Biol. Chem. 268, 13137-13142). The effect of these heat shock proteins on DnaA5 and DnaA46 protein was separated from the event of DNA synthesis by incubation in two stages. Components necessary during the first stage for ''activation'' included GrpE and DnaK proteins, ATP at 0.2 mm or greater, and polyvinyl alcohol (8%) or glycerol, optimal at concentrations between 20 and 30%. An ATP regenerating system provided by creatine kinase and creatine phosphate was stimulatory. Addition of the activated form of DnaA5 or DnaA46 protein to a reconstituted system containing other purified replication proteins during the second stage of incubation resulted in DNA replication. Activation of DnaA5 or DnaA46 protein by heat shock proteins was thermolabile, suggesting that the temperature sensitivity of dnaA5 and dnaA46 mutants is related to this thermolabile interaction. A third heat shock protein, DnaJ protein, interfered with the activation of DnaA5 protein if present during the first stage of incubation. This inhibitory effect was less striking if included during the second stage of incubation. These results suggest a mechanism for regulation of the activity of DnaA protein.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University				Kaguni, Jon/0000-0002-3096-4447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM033992, GM33992] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1988, NUCLEIC ACIDS RES, V16, P9611, DOI 10.1093/nar/16.20.9611; ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ANG D, 1991, J BIOL CHEM, V266, P24233; ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; ATLUNG T, 1987, MOL GEN GENET, V206, P51, DOI 10.1007/BF00326535; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BOCHNER BR, 1986, J BACTERIOL, V168, P931, DOI 10.1128/jb.168.2.931-935.1986; BOYE E, 1988, BIOCHIM BIOPHYS ACTA, V951, P359, DOI 10.1016/0167-4781(88)90107-8; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BUKAU B, 1989, J BACTERIOL, V171, P6030, DOI 10.1128/jb.171.11.6030-6038.1989; CHAKRABORTY T, 1982, EMBO J, V1, P1545, DOI 10.1002/j.1460-2075.1982.tb01353.x; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DODSON M, 1986, P NATL ACAD SCI USA, V83, P7638, DOI 10.1073/pnas.83.20.7638; DODSON M, 1989, J BIOL CHEM, V264, P10719; DONACHIE WD, 1968, NATURE, V219, P1077, DOI 10.1038/2191077a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FULLER RS, 1986, CELL, V38, P5616; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS CP, 1977, MOL GEN GENET, V151, P35, DOI 10.1007/BF00446910; GOMES SL, 1990, J BACTERIOL, V172, P3051, DOI 10.1128/jb.172.6.3051-3059.1990; HANSEN EB, 1984, MOL GEN GENET, V196, P387, DOI 10.1007/BF00436184; HANSEN FG, 1991, J BACTERIOL, V173, P5194, DOI 10.1128/jb.173.16.5194-5199.1991; HANSEN FG, 1992, MOL GEN GENET, V234, P14, DOI 10.1007/BF00272340; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HUPP TR, 1993, J BIOL CHEM, V268, P13137; HWANG DS, 1988, J BIOL CHEM, V263, P10633; HWANG DS, 1991, J BIOL CHEM, V266, P7537; HWANG DS, 1990, J BIOL CHEM, V265, P19244; HWANG DS, 1988, J BIOL CHEM, V263, P10625; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LIBEREK K, 1988, P NATL ACAD SCI USA, V85, P6632, DOI 10.1073/pnas.85.18.6632; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MCMACKEN R, 1983, MECHANISMS DNA REPLI, P819; OHKI M, 1989, NUCLEIC ACIDS RES, V17, P3479, DOI 10.1093/nar/17.9.3479; PIERUCCI O, 1989, J BACTERIOL, V171, P3760, DOI 10.1128/jb.171.7.3760-3766.1989; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; SAITO H, 1978, MOL GEN GENET, V164, P1, DOI 10.1007/BF00267592; SAKAKIBARA Y, 1988, J BACTERIOL, V170, P972, DOI 10.1128/jb.170.2.972-979.1988; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SKARSTAD K, 1989, MOL GEN GENET, V218, P50, DOI 10.1007/BF00330564; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; WANG QP, 1989, J BIOL CHEM, V264, P7338; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0; WICKNER SH, 1979, COLD SPRING HARB SYM, V43, P303, DOI 10.1101/SQB.1979.043.01.037; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; ZIMMERMAN SB, 1988, NUCLEIC ACIDS RES, V16, P6309, DOI 10.1093/nar/16.14.6309; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	63	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13143	13150						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514753				2022-12-25	WOS:A1993LH55300022
J	OGISO, M; IRIE, A; KUBO, H; KOMOTO, M; MATSUNO, T; KOIDE, Y; HOSHI, M				OGISO, M; IRIE, A; KUBO, H; KOMOTO, M; MATSUNO, T; KOIDE, Y; HOSHI, M			CHARACTERIZATION OF NEUTRAL GLYCOSPHINGOLIPIDS IN HUMAN CATARACTOUS LENS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SENILE CATARACTS; N-FUCOPENTAOSE-III; SIALIC ACIDS; GANGLIOSIDES; CELLS; ACETYLGLUCOSAMINE; LACTOSYLCERAMIDE; PURIFICATION; RECOGNITION; CERAMIDE	Neutral glycosphingolipids were purified from human senile cataractous lenses by a combination of solvent extraction, Folch's partition, acetylation, and column chromatography using DEAE-Sephadex and Iatrobeads. Six major glycosphingolipids (A-F) from monohexosylceramide to pentahexosylceramide were identified by sugar composition analysis, methylation analysis, secondary ion-mass spectrometry, glycosidase digestion, and chromium trioxide oxidation. Their structures suggested that they were closely related in their metabolism: their sugar chains were in sequence and their ceramide moieties were similarly composed, namely C16:0 and C24:1 constituted most of the fatty acids, and long-chain base components were mostly C18-dihydrosphingosine with a small portion of C18-sphingosine. The sugar chains implied two pathways branching from lactosylceramide: one to globotriaosylceramide and the other to lactotriaosylceramide, which leads to the production of Le(x) glycolipid via neolacto type 2 core chain.	TOHO UNIV, SCH MED, DEPT OPHTHALMOL, TOKYO 143, JAPAN; TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL, DEPT LIFE SCI, YOKOHAMA, KANAGAWA 227, JAPAN; ZENYAKU KOGYO CO LTD, RES LAB, TOKYO 178, JAPAN	Toho University; Tokyo Institute of Technology	OGISO, M (corresponding author), TOHO UNIV, SCH MED, DEPT PHYSIOL, 5-21-16 OHMORI NISHI, OHTA KU, TOKYO 143, JAPAN.							[Anonymous], 1977, Lipids, V12, P455; [Anonymous], 1981, MOL CELLULAR BIOL EY; BASU S, 1970, Federation Proceedings, V29, P410; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; Dickson D.H., 1975, CATARACT ABNORMALITI, P49; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FELDMAN GERALD L., 1965, INVEST OPHTHAL MOL, V4, P162; FELDMAN GL, 1966, LIPIDS, V1, P21, DOI 10.1007/BF02668120; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FOLCH J, 1957, J BIOL CHEM, V226, P497; GAVER RC, 1965, J AM OIL CHEM SOC, V42, P294, DOI 10.1007/BF02540132; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; IRIE A, 1990, J BIOCHEM-TOKYO, V108, P531, DOI 10.1093/oxfordjournals.jbchem.a123237; KANNAGI R, 1987, METHOD ENZYMOL, V138, P3, DOI 10.1016/0076-6879(87)38003-6; KOJIMA N, 1991, Glycobiology, V1, P623, DOI 10.1093/glycob/1.6.623; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; LAINE RA, 1975, J LIPID RES, V16, P102; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; OGISO M, 1990, EXP EYE RES, V50, P51, DOI 10.1016/0014-4835(90)90010-R; OGISO M, 1990, INVEST OPHTH VIS SCI, V31, P2171; OGISO M, 1992, J BIOL CHEM, V267, P6467; SARKAR CP, 1982, BIOCHIM BIOPHYS ACTA, V711, P503, DOI 10.1016/0005-2760(82)90065-0; STEIGERWALD JC, 1975, J BIOL CHEM, V250, P6727; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; SWANSON AA, 1978, INTERDISCPL TOPICS G, V12, P241; SWINDELL RT, 1987, CURR EYE RES, V6, P451, DOI 10.3109/02713688709025201; SWINDELL RT, 1988, OPHTHALMIC RES, V20, P232, DOI 10.1159/000266650; TAKI T, 1979, BIOCHIM BIOPHYS ACTA, V572, P113; TANIGUCHI N, 1985, J BIOL CHEM, V260, P4908; TAO RVP, 1986, CURR EYE RES, V5, P167, DOI 10.3109/02713688609015105; TAO RVP, 1982, CURR EYE RES, V2, P427, DOI 10.3109/02713688208996345; TAO RVP, 1983, BIOCHIM BIOPHYS ACTA, V753, P89, DOI 10.1016/0005-2760(83)90102-9; WINDELER AS, 1970, BIOCHIM BIOPHYS ACTA, V202, P361, DOI 10.1016/0005-2760(70)90199-2; YANG HJ, 1971, J BIOL CHEM, V246, P1192; ZIELENSKI J, 1982, EUR J BIOCHEM, V125, P323, DOI 10.1111/j.1432-1033.1982.tb06686.x	38	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13242	13247						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514762				2022-12-25	WOS:A1993LH55300035
J	STRAUS, AH; LEVERY, SB; JASIULIONIS, MG; SALYAN, MEK; STEELE, SJ; TRAVASSOS, LR; HAKOMORI, SI; TAKAHASHI, HK				STRAUS, AH; LEVERY, SB; JASIULIONIS, MG; SALYAN, MEK; STEELE, SJ; TRAVASSOS, LR; HAKOMORI, SI; TAKAHASHI, HK			STAGE-SPECIFIC GLYCOSPHINGOLIPIDS FROM AMASTIGOTE FORMS OF LEISHMANIA (L) AMAZONENSIS - IMMUNOGENICITY AND ROLE IN PARASITE BINDING AND INVASION OF MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTALLY REGULATED ANTIGEN; BOMBARDMENT MASS-SPECTROMETRY; MONOCLONAL-ANTIBODIES; LIQUID-CHROMATOGRAPHY; METHYLATION ANALYSIS; LIPOPHOSPHOGLYCAN; MEXICANA; SURFACE; PROMASTIGOTES; GLYCOLIPIDS	Neutral glycosphingolipids (GSLs) from amastigote forms of Leishmania (L.) amazonensis were isolated, and their structures and biological properties were characterized. Based on various immunochemical methods, these GSLs were shown to be expressed at certain stages of amastigote development. GSLs were extracted and purified from amastigotes of hamster foot lesions by established procedures. Three mouse monoclonal antibodies (MoAbs) specific for carbohydrate epitopes of these GSLs were established, and their inhibition of parasite binding and macrophage invasion was analyzed. MoAb ST-3 inhibited 80% of macrophage invasion by amastigotes and 60% of that by promastigotes. Since GSLs reacting with MoAb ST-3 were found in amastigotes but not in promastigotes, ST-3 reactivity with promastigotes presumably depends on an epitope present on an unidentified promastigote glycoconjugate. MoAbs ST-4 and ST-5 inhibited 60-80% of macrophage invasion by amastigotes but were not effective in preventing macrophage invasion by promastigotes. Fab fragments of ST-3 inhibited invasion of cultured mouse macrophages by amastigotes (80%) or promastigotes (60%). The GSL with the simplest structure recognized by these MoAbs was isolated and characterized (by negative ion fast atom bombardment-mass spectrometry, gas chromatography-mass spectrometry of the permethylated compound, degradation with exoglycosidases, and H-1 NMR) as the novel globoseries structure Galbeta1 --> 3Galalpha1-->4Galbeta1-->4Glcbeta1-->Cer, which has beta1-->3Gal in place of the beta1-->3GalNAc of globoside. The ceramide contains a 16:0 fatty acid and d18:1 sphingosine as the long chain base. The MoAbs also reacted with a series of GSLs from amastigote forms of L. amazonensis, with longer carbohydrate chains, probably containing identical end groups Galbeta1-->3Galalpha1-->R. Expression of surface GSLs may render amastigote forms more effective than promastigotes in binding and invading host macrophages, thus enhancing the infectious process.	ESCOLA PAULISTA MED, DEPT BIOCHEM, CP 20372, BR-04023 SAO PAULO, BRAZIL; ESCOLA PAULISTA MED, DEPT MICROBIOL IMMUNOL & PARASITOL, DIV CELL BIOL, BR-04023 SAO PAULO, BRAZIL; BIOMEMBRANE INST, SEATTLE, WA 98119 USA; UNIV WASHINGTON, DEPT PATHOBIOL, SEATTLE, WA 98195 USA	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); University of Washington; University of Washington Seattle			Travassos, Luiz R/J-3631-2012; Straus, Anita H/K-7629-2013; Takahashi, Helio/J-1725-2012; Travassos, Luiz/V-2467-2019; Jasiulionis, Miriam/G-2207-2012	Jasiulionis, Miriam/0000-0002-4135-0440	NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETOBERGTER E, 1992, MOL BIOCHEM PARASIT, V51, P263, DOI 10.1016/0166-6851(92)90076-V; BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUEHLER J, 1986, ANAL BIOCHEM, V158, P283, DOI 10.1016/0003-2697(86)90551-8; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; CHANG CS, 1986, P NATL ACAD SCI USA, V83, P100, DOI 10.1073/pnas.83.1.100; Chang K.-P., 1990, P79; CHANG KP, 1983, INT REV CYTOL, P267; CHAUDHURI G, 1989, J BIOL CHEM, V264, P7483; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DABROWSKI J, 1980, BIOCHEMISTRY-US, V19, P5652, DOI 10.1021/bi00565a030; DITTMER JC, 1964, J LIPID RES, V5, P126; EPERON S, 1989, J PROTOZOOL, V36, P502, DOI 10.1111/j.1550-7408.1989.tb01086.x; FOLCH J, 1951, J BIOL CHEM, V191, P819; FUJII I, 1985, J CHEM SOC CHEM COMM, P405, DOI 10.1039/c39850000405; GIORGIO S, 1992, EXP PARASITOL, V75, P119, DOI 10.1016/0014-4894(92)90127-V; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HANDMAN E, 1986, J IMMUNOL, V137, P3608; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; ILG T, 1992, J BIOL CHEM, V267, P6834; ISOBE R, 1987, TRAC-TREND ANAL CHEM, V6, P78, DOI 10.1016/0165-9936(87)87037-1; JAFFE CL, 1989, INFECT IMMUN, V57, P3770, DOI 10.1128/IAI.57.12.3770-3777.1989; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KAHL LP, 1987, J IMMUNOL, V138, P1587; KANNAGI R, 1983, J BIOL CHEM, V258, P8934; KANNAGI R, 1982, J BIOL CHEM, V257, P4865; KANNAGI R, 1987, METHOD ENZYMOL, V138, P3, DOI 10.1016/0076-6879(87)38003-6; LAINE RA, 1981, ANAL BIOCHEM, V116, P383, DOI 10.1016/0003-2697(81)90376-6; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; MAGNANI JL, 1980, ANAL BIOCHEM, V109, P399, DOI 10.1016/0003-2697(80)90667-3; MCCONVILLE MJ, 1992, J BIOL CHEM, V267, P5855; MCCONVILLE MJ, 1991, J BIOL CHEM, V266, P15170; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MCNEIL M, 1977, CARBOHYD RES, V56, P239, DOI 10.1016/S0008-6215(00)83346-7; PALATNIK CB, 1989, INFECT IMMUN, V57, P754, DOI 10.1128/IAI.57.3.754-763.1989; PAN AA, 1984, EXP PARASITOL, V58, P72, DOI 10.1016/0014-4894(84)90022-5; PAN AA, 1988, J IMMUNOL, V140, P2406; PETRY K, 1988, MOL BIOCHEM PARASIT, V30, P113, DOI 10.1016/0166-6851(88)90104-1; RAINEY PM, 1991, MOL BIOCHEM PARASIT, V49, P111, DOI 10.1016/0166-6851(91)90134-R; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; RUSSELL DG, 1988, J EXP MED, V57, P630; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; SAITO T, 1971, J LIPID RES, V12, P257; SCHNEIDER P, 1990, J BIOL CHEM, V265, P16955; STRAUS AH, 1992, ANAL BIOCHEM, V201, P1, DOI 10.1016/0003-2697(92)90167-6; TAKAHASHI HK, 1988, CANCER RES, V48, P4361; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; VERMELHO AB, 1986, J PROTOZOOL, V38, P97; YARWOOD A, 1989, PROTEIN SEQUENCING P, P119; YU RK, 1972, J LIPID RES, V13, P680; ZINDZADZE C, 1935, IND ENG CHEM, V7, P227	56	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13723	13730						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514804				2022-12-25	WOS:A1993LH55300099
J	Cali, JJ; Parekh, RS; Krupinski, J				Cali, JJ; Parekh, RS; Krupinski, J			Splice variants of type VIII adenylyl cyclase - Differences in glycosylation and regulation by Ca2+/calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; AREA CA1; CLONING; EXPRESSION; RECEPTOR; SEQUENCE; CALCIUM; FAMILY; BRAIN; CELLS	Three alternatively spliced type VIII adenylyl cyclase messages have been identified by cDNA cloning and am plification from rat brain cDNA. Type VIII-A was previously referred to simply as type VIII (Cali, J. J., Zwaagstra, J. C., Mons, N., Cooper, D. M. F., and Krupinski, J. (1994) J. Biol. Chem. 269, 12190-12195). The types VIII-B and -C cDNAs differ from that of type VIII-A by deletion of 90 and 198 base pair exons, respectively, which encode a 30-amino acid extracellular domain with two consensus sites for N-linked glycosylation and a 66-amino acid cytoplasmic domain. Stable expression of types VIII-A, -B, and -C cDNAs in human embryonal kidney 293 (HEK-293) cells leads to the appearance of novel proteins, which are recognized by type VIII-specific antibodies and which co-migrate with immunoreactive species detected on immunoblots of rat brain membranes. Types VIII-A and -C are modified by N-linked glycosylation, while type VIII-B is insensitive to treatment with N-glycosidase F. An influx of extracellular Ca2+ stimulates cAMP accumulation in HEK-293 cells stably expressing type VIII-A, -B, or -C, but not in control cells. Adenylyl cyclase activity of each of the variants is stimulated by Ca2+/calmodulin and the EC(50) for activation of type VIII-C is one fourth of that for either type VIII-A or -B. Type VIII-C also has a distinct K-m for substrate, which is approximately 4-12-fold higher than that for types VIII-A or -B depending on whether Mn2+ or Mg2+ is the counterion for ATP. The differences in the structural and enzymatic properties of these three variants are discussed.	WEIS CTR RES,GEISINGER CLIN,DANVILLE,PA 17822				Parekh, Rulan/AAQ-4411-2020		NIGMS NIH HHS [GM46395] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046395] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; DEFER N, 1994, FEBS LETT, V351, P109, DOI 10.1016/0014-5793(94)00836-1; ERICKSONWIITANE.S, 1986, METHOD ENZYMOL, V139, P455; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELLEVUO K, 1993, BIOCHEM BIOPH RES CO, V192, P311, DOI 10.1006/bbrc.1993.1415; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KATSUSHIKA S, 1993, J BIOL CHEM, V268, P2273; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; KRUPINSKI J, 1991, MOL CELL BIOCHEM, V104, P73; LEHRMAN MA, 1985, SCIENCE, V227, P140, DOI 10.1126/science.3155573; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; MUMBY S, 1988, J BIOL CHEM, V263, P2020; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PREMONT RT, 1994, METHOD ENZYMOL, V238, P116; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SWERDLOW PS, 1986, ANAL BIOCHEM, V156, P147, DOI 10.1016/0003-2697(86)90166-1; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WU ZL, 1993, J BIOL CHEM, V268, P23766; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	39	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1089	1095		10.1074/jbc.271.2.1089	http://dx.doi.org/10.1074/jbc.271.2.1089			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557635	hybrid			2022-12-25	WOS:A1996TP88900072
J	Frandsen, G; MullerUri, F; Nielsen, M; Mundy, J; Skriver, K				Frandsen, G; MullerUri, F; Nielsen, M; Mundy, J; Skriver, K			Novel plant Ca2+-binding protein expressed in response to abscisic acid and osmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; BARLEY EMBRYO; LEA PROTEINS; GENE; DESICCATION; REDUCTASE; CHANNELS; CLEAVAGE; CLONING; ENCODES	A cDNA corresponding to an mRNA which accumulates in germinating rice seeds in response to the phytohormone abscisic acid was isolated by differential hybridization. Northern blotting indicated that the mRNA also accumulates in vegetative tissues in response to treatment with abscisic acid and to osmotic stress. Sequencing identified a major open reading frame encoding a novel protein of 27.4 kDa. The identity of the open reading frame was confirmed by comparing the translation products of cellular, hybrid selected, and in vitro transcribed RNAs and by immunoprecipitation. Western blotting of cellular extracts indicated that the protein is associated with microsomal or membrane fractions. Data base searches indicated that it contains a conserved Ca2+-binding, EF-hand motif and that related proteins are similarly expressed in Arabidopsis thaliana. A fusion protein purified from Escherichia coli containing the putative EF-hand region was shown to bind Ca2+ in blot binding assays. These data identify a novel gene family encoding proteins involved in the response of plants to abscisic acid and osmotic stress.					mundy, john/A-2361-2013; Skriver, Karen/K-9860-2014	mundy, john/0000-0001-7490-4588; Skriver, Karen/0000-0003-2225-4012				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARTELS D, 1991, EMBO J, V10, P1037, DOI 10.1002/j.1460-2075.1991.tb08042.x; BARTELS D, 1990, PLANTA, V181, P27, DOI 10.1007/BF00202321; BARTELS D, 1988, PLANTA, V175, P485, DOI 10.1007/BF00393069; BLATT MR, 1993, ANNU REV PLANT PHYS, V44, P543, DOI 10.1146/annurev.pp.44.060193.002551; BRAY EA, 1993, PLANT PHYSIOL, V103, P1035, DOI 10.1104/pp.103.4.1035; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DELAUNEY AJ, 1990, MOL GEN GENET, V221, P299, DOI 10.1007/BF00259392; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURE L, 1989, PLANT MOL BIOL, V12, P475, DOI 10.1007/BF00036962; GILROY S, 1994, BIOESSAYS, V16, P677, DOI 10.1002/bies.950160914; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; GODAY A, 1994, PLANT CELL, V6, P351, DOI 10.1105/tpc.6.3.351; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HALKIER BA, 1989, PLANT PHYSIOL, V90, P1552, DOI 10.1104/pp.90.4.1552; HANSON AD, 1994, P NATL ACAD SCI USA, V91, P306, DOI 10.1073/pnas.91.1.306; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HENRY RJ, 1991, PLANT MOL BIOL REP, V9, P139; HETHERINGTON AM, 1991, NEW PHYTOL, V119, P9, DOI 10.1111/j.1469-8137.1991.tb01004.x; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LU GH, 1994, PLANT CELL, V6, P501, DOI 10.1105/tpc.6.4.501; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MAINA CV, 1988, GENE, V74, P265; MANTYLA E, 1995, PLANT PHYSIOL, V107, P141, DOI 10.1104/pp.107.1.141; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MONTCRIEF ND, 1990, J MOL EVOL, V30, P522; MUNDY J, 1986, PLANT PHYSIOL, V81, P630, DOI 10.1104/pp.81.2.630; MUNDY J, 1988, EMBO J, V7, P2279, DOI 10.1002/j.1460-2075.1988.tb03070.x; NAGY F, 1988, PLANT MOL BIOL MANUA, P1; PERERA IY, 1992, PLANT MOL BIOL, V19, P649, DOI 10.1007/BF00026791; RIED JL, 1993, PLANT PHYSIOL, V102, P125, DOI 10.1104/pp.102.1.125; ROBERTS JK, 1993, PLANT CELL, V5, P769, DOI 10.1105/tpc.5.7.769; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SCHROEDER JI, 1989, TRENDS BIOCHEM SCI, V14, P187, DOI 10.1016/0968-0004(89)90272-7; SKRIVER K, 1990, PLANT CELL, V2, P503, DOI 10.1105/tpc.2.6.503; TINGEY SV, 1987, EMBO J, V6, P1; VONHEIJNE G, 1981, EUR J BIOCHEM, V120, P275; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WILLIAMS ME, 1992, PLANT CELL, V4, P485, DOI 10.1105/tpc.4.4.485; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251	48	83	109	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					343	348		10.1074/jbc.271.1.343	http://dx.doi.org/10.1074/jbc.271.1.343			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550584	hybrid			2022-12-25	WOS:A1996TP36100053
J	Kuznetsov, AV; Clark, JF; Winkler, K; Kunz, WS				Kuznetsov, AV; Clark, JF; Winkler, K; Kunz, WS			Increase of flux control of cytochrome c oxidase in copper-deficient mottled brindled mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OXIDATIVE-PHOSPHORYLATION; RAT-LIVER MITOCHONDRIA; HUMAN MUSCLE-FIBERS; KINKY HAIR DISEASE; MOUSE; CARDIOMYOPATHY; METABOLISM; MYOPATHIES; DELETIONS; BRAIN	The brindled mottled mouse (Mo-br), an animal model of the Menkes' copper deficiency syndrome, was used for the investigation of changes in respiratory flux control associated with cytochrome c oxidase deficiency in muscle. Enzymatic analysis of cardiac and skeletal muscles showed an approximately 2-fold decrease in cytochrome c oxidase activity of brindled mutants in both types of muscles as compared with controls, The activities of NADH-cytochrome c oxidoreductase (respiratory chain segment I-III) and succinate-cytochrome c oxidoreductase (segment II-III) were normal. Assessment of mitochondrial respiratory function was performed using chemically skinned musculus quadriceps or heart muscle fibers isolated from control and brindled mottled mice. In skeletal muscle, there was no difference found in maximal rates of respiration, In the Mo-br hearts, this parameter was slightly lower than control, Alternately, the determination of flux control coefficients of cytochrome c oxidase performed by a step by step inhibition of respiration with increasing concentrations of azide or cyanide revealed significantly sharper inhibition curves for brindled mice than for control, indicating more than 2-fold elevated flux control coefficients of cytochrome c oxidase, This investigation proved essential in characterizing the metabolic effect of a cytochrome c oxidase deficiency. We conclude, therefore, that application of metabolic control analysis can be a valuable approach to study defects of mitochondrial oxidative phosphorylation.	UNIV KLINIKUM MAGDEBURG,NEUROL KLIN,LAB NEUROBIOCHEM,D-39120 MAGDEBURG,GERMANY; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	University Hospital Magdeburg; University of Oxford			Kunz, Wolfram/K-1232-2019	Kunz, Wolfram/0000-0003-1113-3493				BOELENS R, 1984, BIOCHIM BIOPHYS ACTA, V765, P196, DOI 10.1016/0005-2728(84)90014-8; BYRNE E, 1985, J NEUROL SCI, V71, P257, DOI 10.1016/0022-510X(85)90064-4; CAMAKARIS J, 1979, BIOCHEM J, V180, P597, DOI 10.1042/bj1800597; CHAO JCJ, 1993, COMP BIOCHEM PHYS A, V104, P163, DOI 10.1016/0300-9629(93)90024-X; DANKS DM, 1977, INORG PERSPECT BIOL, V1, P73; DAVIES NT, 1985, BIOCHIM BIOPHYS ACTA, V809, P362, DOI 10.1016/0005-2728(85)90186-0; DAVIES NT, 1986, BIOCHIM BIOPHYS ACTA, V848, P294, DOI 10.1016/0005-2728(86)90203-3; DIMAURO S, 1994, MITOCHONDRIAL DISORD, P91; FUJII T, 1990, J NEUROCHEM, V55, P885, DOI 10.1111/j.1471-4159.1990.tb04574.x; GELLERICH FN, 1990, FEBS LETT, V274, P167, DOI 10.1016/0014-5793(90)81355-R; GOHIL K, 1981, CLIN PHYSIOL, V1, P195, DOI 10.1111/j.1475-097X.1981.tb00888.x; HAGINOYA K, 1992, PEDIATR NEUROL, V8, P13, DOI 10.1016/0887-8994(92)90046-2; HEINRICH R, 1974, EUR J BIOCHEM, V42, P97, DOI 10.1111/j.1432-1033.1974.tb03319.x; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603; HUNT DM, 1977, COMP BIOCHEM PHYS C, V57, P79, DOI 10.1016/0306-4492(77)90082-X; HUNT DM, 1974, NATURE, V249, P852, DOI 10.1038/249852a0; KACSER H, 1973, RATE CONTROL BIOL PR, P65; KODAMA H, 1993, J HISTOCHEM CYTOCHEM, V41, P1529, DOI 10.1177/41.10.8245411; KOPP SJ, 1983, AM J PHYSIOL, V245, pH855, DOI 10.1152/ajpheart.1983.245.5.H855; KUNZ WS, 1993, BIOCHIM BIOPHYS ACTA, V1144, P46, DOI 10.1016/0005-2728(93)90029-F; KUNZ WS, 1993, FEBS LETT, V323, P188, DOI 10.1016/0014-5793(93)81477-H; LARSSON L, 1993, J PHYSIOL-LONDON, V472, P595, DOI 10.1113/jphysiol.1993.sp019964; LETELLIER T, 1994, BIOCHEM J, V302, P171, DOI 10.1042/bj3020171; LETELLIER T, 1992, PEDIATR RES, V32, P17, DOI 10.1203/00006450-199207000-00004; LETELLIER T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P58, DOI 10.1016/0005-2728(93)90189-M; LI WB, 1993, BIOCHEMISTRY-US, V32, P1833, DOI 10.1021/bi00058a018; MAEHARA M, 1983, BRAIN DEV-JPN, V5, P533, DOI 10.1016/S0387-7604(83)80056-4; MARTENS ME, 1988, ANN NEUROL, V24, P630, DOI 10.1002/ana.410240507; MATSUDA C, 1994, BIOCHEM BIOPH RES CO, V200, P671, DOI 10.1006/bbrc.1994.1503; MEDEIROS DM, 1993, P SOC EXP BIOL MED, V203, P262, DOI 10.3181/00379727-203-43599; MEDEIROS DM, 1991, J NUTR, V121, P815, DOI 10.1093/jn/121.6.815; MULLERHOCKER J, 1993, ARCH PATHOL LAB MED, V117, P202; OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G; PRINS HW, 1979, J INORG BIOCHEM, V10, P19, DOI 10.1016/S0162-0134(00)81002-8; REZEK DL, 1986, EXP NEUROL, V91, P640, DOI 10.1016/0014-4886(86)90060-9; SPARACO M, 1993, BRAIN PATHOL, V3, P349, DOI 10.1111/j.1750-3639.1993.tb00762.x; TAYLOR RW, 1994, J BIOL CHEM, V269, P3523; Tsurui S, 1990, No To Hattatsu, V22, P566; VANGELDER BF, 1966, BIOCHIM BIOPHYS ACTA, V118, P36, DOI 10.1016/S0926-6593(66)80142-X; VEKSLER VI, 1987, BIOCHIM BIOPHYS ACTA, V892, P191, DOI 10.1016/0005-2728(87)90174-5; Wharton DC., 1967, METHOD ENZYMOL, P245; YOSHIMURA N, 1990, ACTA PATHOL JAPON, V40, P383; YOSHIMURA N, 1993, J INTELL DISABIL RES, V37, P561	44	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					283	288		10.1074/jbc.271.1.283	http://dx.doi.org/10.1074/jbc.271.1.283			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550574	hybrid			2022-12-25	WOS:A1996TP36100044
J	Lee, SB; Rhee, SG				Lee, SB; Rhee, SG			Molecular cloning, splice variants, expression, and purification of phospholipase C-delta 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; DROSOPHILA; SEQUENCE; SYSTEM	Complementary DNAs encoding a previously unidentified phosphoinositide-specific phospholipase C (PLC) isozyme were cloned from a rat brain cDNA library by the polymerase chain reaction with degenerate oligonucleotide primers based on sequences common to three known delta-type PLC isozymes. The encoded polypeptide contains 772 amino acids (calculated molecular mass, 88,966 daltons) and is similar in primary structure to delta-type PLC isozymes, with overall sequence identities of 45% to PLC-delta 1, 72% to PLC-delta 2, and 47% to PLC-delta 3. Thus, the new PLC isozyme was named PLC-delta 4. Recombinant PLC-delta 4 was purified from extracts of HeLa cells that had been infected with vaccinia virus containing the corresponding cDNA, The purified protein exhibited an apparent molecular mass of 90 kDa on SDS-polyacrylamide gels. The specific activity of PLC-delta 4 and its dependence on Ca2+ were similar to those of PLC-delta 1. The distribution of PLC-delta 4 in 16 different rat tissues was studied by immunoblot analysis with PLC-delta 4-specific antibodies of fractions obtained after an enzyme-enrichment procedure. The 90-kDa immunoreactive protein was detected unambiguously in only eight tissues and was present at concentrations that were low compared to those of other major PLC isozymes. A 93-kDa immunoreactive protein was also prominent in testis but was not detected in the other seven positive tissues. The 93-kDa enzyme appears to be derived from a splice variant of the mRNA that encodes the 90-kDa PLC-delta 4 and contains an additional 32 amino acids between the X and Y catalytic domains. Splice variants have not previously been detected for delta-type PLC isozymes.	NHLBI,CELL SIGNALLING LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ASANO M, 1994, J BIOL CHEM, V269, P12360; BAHK YY, 1994, J BIOL CHEM, V269, P8240; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRISTOL JA, 1994, TRENDS ENDOCRIN MET, V5, P402, DOI 10.1016/1043-2760(95)92522-K; CHOI KD, 1992, ADV SEC MESS PHOSPH, P35; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FERREIRA PA, 1993, P NATL ACAD SCI USA, V90, P6042, DOI 10.1073/pnas.90.13.6042; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; KIM S, 1995, J BIOL CHEM, V270, P14376, DOI 10.1074/jbc.270.24.14376; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEE CW, 1993, J BIOL CHEM, V268, P21318; LEE SB, 1993, J BIOL CHEM, V268, P25952; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; MELDRUM E, 1991, EUR J BIOCHEM, V196, P159, DOI 10.1111/j.1432-1033.1991.tb15799.x; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RHEE SG, 1994, SIGNAL ACTIVATED PHO, P1; Sambrook J, 1989, MOL CLONING LABORATO; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; WU DQ, 1993, J BIOL CHEM, V268, P3704; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179	23	82	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					25	31		10.1074/jbc.271.1.25	http://dx.doi.org/10.1074/jbc.271.1.25			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550568	hybrid			2022-12-25	WOS:A1996TP36100006
J	Tauer, TJ; Volle, DJ; Rhode, SL; Lewis, RE				Tauer, TJ; Volle, DJ; Rhode, SL; Lewis, RE			Expression of the insulin receptor with a recombinant vaccinia virus - Biochemical evidence that the insulin receptor has intrinsic serine kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE RESIDUES; HEPATOMA-CELLS; BETA-SUBUNIT; IM-9 CELLS; PHOSPHORYLATION; AUTOPHOSPHORYLATION; IDENTIFICATION; ACQUISITION; PRORECEPTOR; ANTIBODY	We have previously reported the tight association of a serine kinase activity with the human insulin receptor (Lewis, R. E., Wu, G. P., MacDonald, R. G., and Czech, M. P. (1990) J. Biol. Chem. 265, 947-954). We tested the possibility that the associated serine kinase activity was intrinsic to the receptor catalytic domain, The ratio of phosphoserine to phosphotyrosine on insulin receptors phosphorylated in vitro was used as an index of the associated serine kinase activity. Phosphorylation and phosphoamino acid analysis of insulin proreceptors revealed associated serine kinase activity early in receptor synthesis, Insulin receptors were expressed in HeLa cells using a recombinant vaccinia virus. The ratio of phosphoserine to phosphotyrosine on insulin receptors expressed by the recombinant vaccinia virus was determined relative to endogenous insulin receptors in cells treated with alpha-amanitin to block host cell mRNA synthesis, alpha-Amanitin treatment had no effect on the ratio of phosphoserine to phosphotyrosine on insulin receptors expressed from the recombinant virus even though they were present in a 4000-fold excess above endogenous receptors, We conclude that the serine kinase activity associated with the insulin receptor is intrinsic to the receptor catalytic domain. Receptor-catalyzed autophosphorylation of serine may play an important role in modulating insulin receptor signaling.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM & MOLEC BIOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center			Lewis, Robert E./H-3404-2019		NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041896] Funding Source: NIH RePORTER; NCI NIH HHS [CA36727] Funding Source: Medline; NIDDK NIH HHS [DK41896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAMOAH KA, 1995, BIOCHEM J, V308, P915, DOI 10.1042/bj3080915; BALLOTTI R, 1986, BIOCHEM BIOPH RES CO, V139, P179, DOI 10.1016/S0006-291X(86)80096-1; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; BOLDOGH I, 1991, J MED VIROL, V34, P241, DOI 10.1002/jmv.1890340409; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; HEIDENREICH K, 1994, BIOL CHEM H-S, V375, P99, DOI 10.1515/bchm3.1994.375.2.99; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P6211, DOI 10.1073/pnas.80.20.6211; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; LECONTE I, 1992, J BIOL CHEM, V267, P17415; LEWIS RE, 1990, J BIOL CHEM, V265, P947; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LIU F, 1994, BIOCHEM J, V298, P471, DOI 10.1042/bj2980471; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OLSON TS, 1987, J BIOL CHEM, V262, P6816; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PANG DT, 1985, J BIOL CHEM, V260, P7131; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; SMITH DM, 1988, BIOCHEM J, V256, P903, DOI 10.1042/bj2560903; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; STADTMAUER L, 1986, J BIOL CHEM, V261, P3402; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TORNQVIST HE, 1987, J BIOL CHEM, V262, P10212; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; YONEZAWA K, 1991, MOL ENDOCRINOL, V5, P194, DOI 10.1210/mend-5-2-194; ZICK Y, 1983, BIOCHEM BIOPH RES CO, V116, P1129, DOI 10.1016/S0006-291X(83)80260-5	32	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					331	336		10.1074/jbc.271.1.331	http://dx.doi.org/10.1074/jbc.271.1.331			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550582	hybrid			2022-12-25	WOS:A1996TP36100051
J	Jones, J; Sugiyama, M; Speight, PM; Watt, FM				Jones, J; Sugiyama, M; Speight, PM; Watt, FM			Restoration of alpha(v)beta(5) integrin expression in neoplastic keratinocytes results in increased capacity for terminal differentiation and suppression of anchorage-independent growth	ONCOGENE			English	Article						squamous cell carcinoma; adhesion; extracellular matrix; vitronectin	SQUAMOUS-CELL CARCINOMAS; MONOCLONAL-ANTIBODIES; HUMAN-SKIN; FIBRONECTIN; ADHESION; VITRONECTIN; INVOLUCRIN; RECEPTOR; LOCALIZATION; ALPHA-5-BETA-1-INTEGRIN	Loss of expression of specific integrins is a feature of poorly differentiated oral squamous cell carcinomas (SCCs) and cell lines derived from them. In order to test whether there is a direct link between loss of integrins and abnormal keratinocyte growth and differentiation, we 'repaired' an SCC line, H357, by transfection of its missing integrin subunit, alpha(v). We analysed seven independent alpha(v)-expressing clones and compared them with four empty vector controls and with the parental cell line. alpha(v) was expressed on the cell surface as a functional alpha(v) beta(5) heterodimer. The parental cells expressed beta(5) mRNA and introduction of alpha(v) had no effect on beta(5) mRNA levels nor on cell surface levels of any other integrins examined. Introduction of alpha(v) had no consistent effect on the growth rate of cells on tissue culture plastic. However, anchorage-independent growth was strongly suppressed and the alpha(v)-transfectants showed an increased capacity for terminal differentiation, as assayed by expression of involucrin. These results are consistent with the known role of integrins in regulating keratinocyte terminal differentiation and suggest that integrin loss may be directly responsible for the abnormal behaviour of keratinocytes in a subset of oral SCCs.	IMPERIAL CANC RES FUND, KERATINOCYTE LAB, LONDON WC2A 3PX, ENGLAND; UCL EASTMAN DENT HOSP, INST DENT SURG, DEPT ORAL PATHOL, LONDON WC1X 8LD, ENGLAND	Cancer Research UK; University College London Hospitals NHS Foundation Trust; University of London; University College London			Watt, Fiona/AHB-0226-2022	Watt, Fiona/0000-0001-9151-5154				ADAMS JC, 1991, J CELL BIOL, V115, P829, DOI 10.1083/jcb.115.3.829; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBELDA SM, 1993, LAB INVEST, V68, P4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DITTEL BN, 1993, BLOOD, V81, P2272; DOWNER CS, 1993, J PATHOL, V171, P183, DOI 10.1002/path.1711710306; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; EISENBERG E, 1987, ORAL SURG ORAL MED O, V64, P313, DOI 10.1016/0030-4220(87)90011-9; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GLADSON CL, 1994, INTEGRINS BIOL PROBL, P83; GRINNELL F, 1992, J INVEST DERMATOL, V98, P410, DOI 10.1111/1523-1747.ep12499839; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; HOTCHIN NA, 1993, J CELL SCI, V106, P1131; HUDSON DL, 1992, HYBRIDOMA, V11, P367, DOI 10.1089/hyb.1992.11.367; HUGHES DE, 1994, J PATHOL, V173, P97, DOI 10.1002/path.1711730205; JONES J, 1993, J PATHOL, V169, P235, DOI 10.1002/path.1711690210; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NICHOLSON LJ, 1991, J CELL SCI, V98, P225; PELTONEN J, 1989, J CLIN INVEST, V84, P1916, DOI 10.1172/JCI114379; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; REILLY JT, 1988, J CLIN PATHOL, V41, P1269, DOI 10.1136/jcp.41.12.1269; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RYYNANEN J, 1991, J INVEST DERMATOL, V97, P562, DOI 10.1111/1523-1747.ep12481896; SCHREINER C, 1991, CANCER RES, V51, P1738; SONNENBERG A, 1986, J HISTOCHEM CYTOCHEM, V34, P1037, DOI 10.1177/34.8.2426332; SUGIYAMA M, 1993, CARCINOGENESIS, V14, P2171, DOI 10.1093/carcin/14.10.2171; SUMITOMO S, 1986, ORAL SURG ORAL MED O, V62, P155, DOI 10.1016/0030-4220(86)90038-1; TENCHINI ML, 1993, CELL ADHES COMMUN, V1, P55, DOI 10.3109/15419069309095681; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONDEMBORNE AEG, 1989, LEUCOCYTE TYPING, V4, P951; WATT FM, 1993, J CELL SCI, V106, P175; WATT FM, 1993, DEVELOPMENT, P185; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; Wolf G T, 1992, J Natl Cancer Inst Monogr, P67; WOLF GT, 1990, JNCI-J NATL CANCER I, V82, P1566, DOI 10.1093/jnci/82.19.1566; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853	47	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					119	126						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552382				2022-12-25	WOS:A1996TQ01400015
J	Kamps, MP; Wright, DD; Lu, Q				Kamps, MP; Wright, DD; Lu, Q			DNA-binding by oncoprotein E2A-Pbx1 is important for blocking differentiation but dispensable for fibroblast transformation	ONCOGENE			English	Article						E2A-Pbx1; oncoprotein; differentiation; leukemia	PRE-B; MAMMALIAN-CELLS; TRANSLOCATION PROTEIN; CRYSTAL-STRUCTURE; HOMEOBOX GENES; LEUKEMIA; MICE; COMPLEX; DOMAIN; PBX1	The t(1;19) chromosomal translocation of pediatric pre-B cell lymphoblastic leukemia produces the E2A-PBX1 oncogene, which can transform fibroblasts, induce acute myeloid leukemia and T cell lymphomas in mice, and immortalize factor-dependent myeloid progenitors in cultured marrow. The homeodomain of Pbx1 binds ATCAATCAA, and while Pbx1 does not activate transcription through this motif, E2A-Pbx1 induces constitutive transactivation. Here, we investigate whether DNA-binding by Pbx1 or transcriptional activation by E2A are essential for the transforming abilities off E2A-Pbx1. Elimination of DNA-binding in E2A-Pbx1 by point mutations in the Pbx1 homeodomain or by large deletions that removed the Pbx1 homeodomain and carboxyl terminus did not alter ability of E2A-Pbx1 to induce focus-formation in fibroblast, even though these mutations completely eliminated its ability to activate transcription through the PRS. These same DNA-binding mutations, however, severely impaired or eliminated the ability of E2A-Pbx1 to immortalize factor-dependent myeloid progenitors in marrow cultures. Elimination of the first transcriptional activation domain of E2A abolished both fibroblast and myeloid transforming activities while elimination of the second altered neither of these activities. We conclude that DNA-binding is important for the ability of E2A-Pbx1 to disrupt differentiation, as evidenced in myeloblast immortalization, but dispensable for its ability to induce focus-formation, and that the aminoterminal domain of E2A, which strongly activates transcription, is essential for both transforming activities.	UNIV CALIF SAN DIEGO,SCH MED,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego	Kamps, MP (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,DEPT PATHOL,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [5 RO1 CA56876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER S, 1988, CELL, V52, P685, DOI 10.1016/0092-8674(88)90406-0; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; CARROLL A, 1984, BLOOD, V63, P716; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; FITZPATRICK VD, 1992, NATURE, V356, P610, DOI 10.1038/356610a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBRUN DP, 1994, ONCOGENE, V9, P1641; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; LU Q, 1996, IN PRESS P NATL ACAD; LU QA, 1995, MOL CELL BIOL, V15, P3786; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PEERS B, 1995, UNPUB; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VERSHON AK, 1995, GENE DEV, V9, P182, DOI 10.1101/gad.9.2.182; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	32	39	39	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					19	30						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552391				2022-12-25	WOS:A1996TQ01400003
J	Ashton, AC; Li, Y; Doussau, F; Weller, U; Dougan, G; Poulain, B; Dolly, JO				Ashton, AC; Li, Y; Doussau, F; Weller, U; Dougan, G; Poulain, B; Dolly, JO			Tetanus toxin inhibits neuroexocytosis even when its Zn2+-dependent protease activity is removed	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTRANSMITTER RELEASE; BOTULINUM NEUROTOXIN; TRANSGLUTAMINASE; SYNAPTOBREVIN; MECHANISM; CHAIN; ZINC	Tetanus toxin (TeTX) is a dichain protein that blocks neuroexocytosis, an action attributed previously to Zn2+-dependent proteolysis of synaptobrevin (Sbr) by its light chain (LC), Herein, its cleavage of Sbr in rat cerebrocortical synaptosomes was shown to be minimized by captopril, an inhibitor of certain metalloendoproteases, whereas this agent only marginally antagonized the inhibition of noradrenaline release, implicating a second action of the toxin, This hypothesis was proven by preparing three mutants (H233A, E234A, H237A) of the LC lacking the ability to cleave Sbr and reconstituting them with native heavy chain, The resultant dichains were found to block synaptosomal transmitter release, albeit with lower potency than that made from wild type LC; as expected, captopril attenuated only the inhibition caused by the protease-active wild type toxin, Moreover, these protease-inactive toxins or their LCs blocked evoked quantal release of transmitter when micro-injected inside Aplysia neurons, TeTX was known to stimulate in vitro a Ca2+-dependent transglutaminase (TGase) (Facchiano, F,, and Luini, A, (1992) J, Biol, Chem, 267, 13267-13271), an affect found here to be reduced by an inhibitor of this enzyme, monodansylcadaverine. Accordingly, treatment of synaptosomes with the latter antagonized the inhibition of noradrenaline release by TeTX while not affecting Sbr cleavage, This drug also attenuated the inhibitory action of all the mutants, Hence, it is concluded that TeTX inhibits neurotransmitter release by proteolysis of Sbr and a protease-independent activation of a neuronal TGase.	UNIV LONDON IMPERIAL COLL SCI & TECHNOL,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND; CNRS,NEUROBIOL CELLULAIRE & MOLEC LAB,F-91198 GIF SUR YVETTE,FRANCE; UNIV MAINZ,INST MED MIKROBIOL,W-6500 MAINZ,GERMANY	Imperial College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf			Dolly, Oliver/G-1532-2012; Dolly, Oliver/ABH-6677-2020	Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320; Doussau, Frederic/0000-0002-3769-1402				ASHTON AC, 1993, BOTULINUM AND TETANUS NEUROTOXINS, P191; BUNGAY PJ, 1984, BIOCHEM J, V219, P819, DOI 10.1042/bj2190819; COFFIELD JA, 1994, J BIOL CHEM, V269, P24454; DEPAIVA A, 1993, J NEUROCHEM, V61, P2338, DOI 10.1111/j.1471-4159.1993.tb07482.x; DOLLY JO, 1994, SEMIN NEUROSCI, V6, P149; EISEL U, 1993, EMBO J, V12, P3365, DOI 10.1002/j.1460-2075.1993.tb06010.x; FACCHIANO F, 1992, J BIOL CHEM, V267, P13267; FACCHIANO F, 1993, J BIOL CHEM, V268, P4588; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FORAN P, 1994, BIOCHEMISTRY-US, V33, P15365, DOI 10.1021/bi00255a017; LI Y, 1994, BIOCHEMISTRY-US, V33, P7014, DOI 10.1021/bi00188a034; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NIEMANN H, 1993, BOTULINUM AND TETANUS NEUROTOXINS, P361; PASTUSZKO A, 1986, J NEUROCHEM, V46, P499, DOI 10.1111/j.1471-4159.1986.tb12996.x; POULAIN B, 1988, P NATL ACAD SCI USA, V85, P4090, DOI 10.1073/pnas.85.11.4090; POULAIN B, 1993, J NEUROCHEM, V61, P1175, DOI 10.1111/j.1471-4159.1993.tb03640.x; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, EMBO J, V11, P3577, DOI 10.1002/j.1460-2075.1992.tb05441.x; YAMASAKI S, 1994, P NATL ACAD SCI USA, V91, P4688, DOI 10.1073/pnas.91.11.4688; [No title captured]	20	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31386	31390		10.1074/jbc.270.52.31386	http://dx.doi.org/10.1074/jbc.270.52.31386			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537412	hybrid			2022-12-25	WOS:A1995TN44400079
J	Lee, JS; Shoelson, SE; Pilch, PF				Lee, JS; Shoelson, SE; Pilch, PF			Intermolecular phosphorylation between insulin holoreceptors does not stimulate substrate kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; RECEPTOR AUTOPHOSPHORYLATION; BETA-SUBUNIT; CONFORMATIONAL-CHANGES; HUMAN-PLACENTA; ACTIVATION; BINDING; DOMAIN; TRANSPHOSPHORYLATION; ANTIBODIES	We photocoupled benzoylphenylalanine(B25), B29(epsilon)-biotin insulin (BBpa-insulin) to native insulin receptors to obtain a uniform receptor population with covalently bound, non-dissociable ligand. We employed BBpa-insulin-bound and autophosphorylated (activated) receptor to phosphorylate substrate insulin receptor under conditions where the substrate receptor never interacts with insulin. The substrate receptor becomes phosphorylated in this inter-receptor fashion and reaches a phosphorylation state 50% of the maximal obtainable by autophosphorylation. However, this phosphorylation does not activate the substrate receptor to any measurable degree. We conclude that intermolecular phosphorylation of the insulin holoreceptors is unlikely to be of physiological significance.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Boston University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Lee, Jongsoon/AAG-1674-2020	Pilch, Paul/0000-0003-1997-0499; Lee, Jongsoon/0000-0002-0891-5059	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036424, R01DK043123] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36424, DK43123] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1991, J BIOL CHEM, V266, P434; ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BARON V, 1992, J BIOL CHEM, V267, P23290; BARON V, 1990, BIOCHEMISTRY-US, V29, P4634, DOI 10.1021/bi00471a019; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; JORGENSEN KH, 1980, DIABETOLOGIA, V19, P546; KASUGA M, 1983, J BIOL CHEM, V258, P973; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LEE JS, 1993, J BIOL CHEM, V268, P4092; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; MADDUX BA, 1991, J BIOL CHEM, V266, P6731; MURAKAMI MS, 1991, J BIOL CHEM, V266, P22653; NEMENOFF RA, 1984, J BIOL CHEM, V259, P5058; OHARE T, 1989, J BIOL CHEM, V264, P602; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; QUON MJ, 1992, BIOCHEMISTRY-US, V31, P9947, DOI 10.1021/bi00156a013; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; SCHENKER E, 1988, BIOCHEM BIOPH RES CO, V157, P140, DOI 10.1016/S0006-291X(88)80024-X; SHIA MA, 1983, BIOCHEMISTRY-US, V22, P717, DOI 10.1021/bi00273a001; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; TAOUIS M, 1994, J BIOL CHEM, V269, P27762; TARTARE S, 1991, FEBS LETT, V295, P219, DOI 10.1016/0014-5793(91)81422-5; TAVARE JM, 1988, BIOCHEM J, V252, P607, DOI 10.1042/bj2520607; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANOBBERGHEN E, 1983, P NATL ACAD SCI-BIOL, V80, P945; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P2722, DOI 10.1021/bi00432a053; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WILDEN PA, 1992, J BIOL CHEM, V267, P13719; YU KT, 1984, J BIOL CHEM, V259, P5277; ZICK Y, 1983, J BIOL CHEM, V258, P3431	37	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31136	31140		10.1074/jbc.270.52.31136	http://dx.doi.org/10.1074/jbc.270.52.31136			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537376	hybrid, Green Published			2022-12-25	WOS:A1995TN44400044
J	Fronticelli, C; Sanna, MT; PerezAlvarado, GC; Karavitis, M; Lu, AL; Brinigar, WS				Fronticelli, C; Sanna, MT; PerezAlvarado, GC; Karavitis, M; Lu, AL; Brinigar, WS			Allosteric modulation by tertiary structure in mammalian hemoglobins - Introduction of the functional characteristics of bovine hemoglobin into human hemoglobin by five amino acid substitutions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-AFFINITY; SENSITIVITY; GLOBIN	Bovine erythrocytes do not contain 2,3-diphosphoglycerate, the principal allosteric effector of human hemoglobin. Bovine hemoglobin has a lower oxygen affinity than human hemoglobin and is regulated by physiological concentrations of chloride (Fronticelli, C., Bucci, E., and Razynska, A. (1988) J. Mol. Biol. 202, 343-348). It has been proposed that the chloride regulation in bovine hemoglobin is introduced by particular amino acid residues located in the amino-terminal region of the A helix and in the E helix of the beta subunits (Fronticelli, C. (1990) Biophys. Chem. 37, 141-146). In accordance with this proposal we have constructed two mutant human hemoglobins, beta(V1M+H2deleted+T4I+P5A) and beta(V1M+H2deleted+T4I+P5A+A76K). These are the residues present at the proposed locations in bovine hemoglobin except for isoleucine at position 4. Oxygen binding studies demonstrate that these mutations have introduced into human hemoglobin the low oxygen affinity and chloride sensitivity of bovine hemoglobin and reveal the presence of a previously unrecognized allosteric mechanism of oxygen affinity regulation where all the interactions responsible for the lowered affinity and chloride binding appear to be confined to individual beta subunits.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201; TEMPLE UNIV,DEPT CHEM,PHILADELPHIA,PA 19122	University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NHLBI NIH HHS [P01-HL48517] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048517] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adair GS, 1925, J BIOL CHEM, V63, P529; ANTONINI E, 1970, HEMOGLOBIN MYOGLOBIN; BENESCH R, 1968, P NATL ACAD SCI USA, V59, P526, DOI 10.1073/pnas.59.2.526; BUCCI E, 1988, BIOMATER ARTIF CELL, V16, P197, DOI 10.3109/10731198809132569; BUCCI E, 1993, BIOCHEMISTRY-US, V32, P3519, DOI 10.1021/bi00065a001; BUCCI E, 1965, J BIOL CHEM, V240, P551; CONDO SG, 1992, EUR J BIOCHEM, V209, P773, DOI 10.1111/j.1432-1033.1992.tb17347.x; DOLMAN D, 1978, ANAL BIOCHEM, V87, P127, DOI 10.1016/0003-2697(78)90576-6; FRONTICELLI C, 1994, J BIOL CHEM, V269, P23965; FRONTICELLI C, 1984, J BIOL CHEM, V259, P841; FRONTICELLI C, 1990, BIOPHYS CHEM, V37, P141, DOI 10.1016/0301-4622(90)88014-J; FRONTICELLI C, 1990, EUR J BIOCHEM, V193, P331, DOI 10.1111/j.1432-1033.1990.tb19342.x; FRONTICELLI C, 1991, J PROTEIN CHEM, V10, P495, DOI 10.1007/BF01025477; FRONTICELLI C, 1988, J MOL BIOL, V202, P343, DOI 10.1016/0022-2836(88)90463-9; Fronticelli C, 1992, TECH PROTEIN CHEM, V3, P399; KATZ DS, 1994, J MOL BIOL, V244, P541, DOI 10.1006/jmbi.1994.1751; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; SHELTON JB, 1984, J LIQ CHROMATOGR, V7, P1969, DOI 10.1080/01483918408068849; Vandegriff K D, 1992, Biotechnol Genet Eng Rev, V10, P403; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	22	40	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30588	30592		10.1074/jbc.270.51.30588	http://dx.doi.org/10.1074/jbc.270.51.30588			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530494	hybrid			2022-12-25	WOS:A1995TL67500059
J	Graham, JD; Roman, SD; McGowan, E; Sutherland, RL; Clarke, CL				Graham, JD; Roman, SD; McGowan, E; Sutherland, RL; Clarke, CL			Preferential stimulation of human progesterone receptor B expression by estrogen in T-47D human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; STEROID-HORMONE RECEPTORS; MENSTRUAL-CYCLE; GENE-EXPRESSION; RETINOIC ACID; MONOCLONAL-ANTIBODIES; NUCLEAR-BINDING; MCF-7 CELLS; LINE T-47D; A-FORM	Human progesterone receptor (PR) expression is controlled by two promoter regions giving rise to transcripts encoding PR A and B proteins. It is unknown whether estrogen and progesterone, the major physiological modulators of PR expression, exert their effects equally on the PR promoters. The aim of this study was to analyze estrogen and progestin effects on PR promoters, PR-encoding transcripts, and PR A and B proteins in T-47D human breast cancer cells. The progestin ORG 2058 caused a prolonged decrease in transcription of the PR gene and also abrogated estrogen stimulation of PR transcription. Estradiol (E2) treatment increased the activity of the B but not the A promoter transfected into T-47D cells. ORG 2058 had no effect on the basal or E2-stimulated activity of either promoter. E2 caused a preferential increase in transcripts derived from promoter B, whereas progestins decreased the levels of all PR transcripts. E2 preferentially increased the concentration of the PR B protein and caused a decrease in the PR A/B ratio. This demonstration that estrogen and progestin independently control the synthesis of transcripts arising from the PR promoters and that estrogen alters the cellular PR A/B ratio provides possible mechanisms underlying the cell and tissue specificity of PR regulation.	UNIV SYDNEY, WESTMEAD HOSP, DEPT MED ONCOL, DIV MED, WESTMEAD, NSW 2145, AUSTRALIA; ST VINCENTS HOSP, GARVAN INST MED RES, DIV CANC BIOL, DARLINGHURST, NSW 2010, AUSTRALIA	University of Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney			Roman, Shaun/AFR-5087-2022; Sutherland, Robert L/A-8378-2008; ROMAN, SHAUN/G-7047-2013	ROMAN, SHAUN/0000-0002-7758-7757; McGowan, Eileen/0000-0001-6371-3751; Clarke, Christine/0000-0001-7568-111X				ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; BATTERSBY S, 1992, BRIT J CANCER, V65, P601, DOI 10.1038/bjc.1992.122; BOYD PA, 1979, BIOCHEMISTRY-US, V18, P3685, DOI 10.1021/bi00584a008; BOYDLEINEN P, 1984, J BIOL CHEM, V259, P2411; CHALBOS D, 1994, J BIOL CHEM, V269, P23007; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; CLARKE CL, 1991, J BIOL CHEM, V266, P18969; CLARKE CL, 1987, ENDOCRINOLOGY, V121, P1123, DOI 10.1210/endo-121-3-1123; CLARKE CL, 1990, J BIOL CHEM, V265, P12694; CLARKE CL, 1987, ENDOCRINOLOGY, V121, P1642, DOI 10.1210/endo-121-5-1642; CLARKE CL, 1993, MOL ASPECTS PLACENTA, P27; CONNEELY OM, 1986, SCIENCE, V233, P767, DOI 10.1126/science.2426779; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; DALY RJ, 1990, CANCER RES, V50, P5868; FISCHER L, 1993, P NATL ACAD SCI USA, V90, P8254, DOI 10.1073/pnas.90.17.8254; GARCIA E, 1988, J CLIN ENDOCR METAB, V67, P80, DOI 10.1210/jcem-67-1-80; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRAHAM JD, 1995, IN PRESS CANCER RES, P55; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; HORWITZ KB, 1978, ENDOCRINOLOGY, V103, P1742, DOI 10.1210/endo-103-5-1742; HORWITZ KB, 1983, J BIOL CHEM, V258, P7603; ILENCHUK TT, 1987, ENDOCRINOLOGY, V120, P1449, DOI 10.1210/endo-120-4-1449; JELTSCH JM, 1986, P NATL ACAD SCI USA, V83, P5424, DOI 10.1073/pnas.83.15.5424; KASTNER P, 1990, J BIOL CHEM, V265, P12163; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; KATZENELLENBOGEN BS, 1980, ANNU REV PHYSIOL, V42, P17, DOI 10.1146/annurev.ph.42.030180.000313; KEYDAR I, 1979, EUR J CANCER, V15, P659, DOI 10.1016/0014-2964(79)90139-7; KRAUS WL, 1994, MOL ENDOCRINOL, V8, P952, DOI 10.1210/me.8.8.952; KRAUS WL, 1993, ENDOCRINOLOGY, V132, P2371, DOI 10.1210/en.132.6.2371; KRAUS WL, 1993, MOL ENDOCRINOL, V7, P1603, DOI 10.1210/me.7.12.1603; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; LESSEY BA, 1988, J CLIN ENDOCR METAB, V67, P334, DOI 10.1210/jcem-67-2-334; LOOSFELT H, 1986, P NATL ACAD SCI USA, V83, P9045, DOI 10.1073/pnas.83.23.9045; MARKOPOULOS C, 1988, BRIT MED J, V296, P1349, DOI 10.1136/bmj.296.6633.1349; MAY FEB, 1989, J STEROID BIOCHEM, V33, P1035, DOI 10.1016/0022-4731(89)90406-8; MCDONNELL DP, 1994, J BIOL CHEM, V269, P11945; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P935, DOI 10.1210/endo-122-3-935; NARDULLI AM, 1988, ENDOCRINOLOGY, V122, P1532, DOI 10.1210/endo-122-4-1532; ORMANDY CJ, 1992, DNA CELL BIOL, V11, P721, DOI 10.1089/dna.1992.11.721; PRESS MF, 1988, AM J PATHOL, V131, P112; READ LD, 1988, MOL ENDOCRINOL, V2, P263, DOI 10.1210/mend-2-3-263; REDDEL RR, 1985, CANCER RES, V45, P1525; RICKETTS D, 1991, CANCER RES, V51, P1817; ROMAN SD, 1993, CANCER RES, V53, P5940; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; SAVOURET JF, 1990, INT J BIOCHEM, V22, P579, DOI 10.1016/0020-711X(90)90033-Y; SAVOURET JF, 1994, J BIOL CHEM, V269, P28955; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; SCHNEIDER W, 1991, J STEROID BIOCHEM, V38, P285, DOI 10.1016/0960-0760(91)90099-Q; SNIJDERS MPML, 1992, J REPROD FERTIL, V94, P363; SUTHERLAND RL, 1983, CANCER RES, V43, P3998; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; TILLEY WD, 1990, CANCER RES, V50, P5382; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEI LL, 1988, MOL ENDOCRINOL, V2, P62, DOI 10.1210/mend-2-1-62; WEI LL, 1990, MOL ENDOCRINOL, V4, P1833, DOI 10.1210/mend-4-12-1833; WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356; WILLIAMS G, 1991, INT J CANCER, V48, P206, DOI 10.1002/ijc.2910480209	66	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30693	30700		10.1074/jbc.270.51.30693	http://dx.doi.org/10.1074/jbc.270.51.30693			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530508	hybrid			2022-12-25	WOS:A1995TL67500073
J	Verdoliva, A; Ruvo, M; Cassani, G; Fassina, G				Verdoliva, A; Ruvo, M; Cassani, G; Fassina, G			Topological mimicry of cross-reacting enantiomeric peptide antigens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; COMPLEX; IMMUNOGENICITY; RECOGNITION; ANTIBODY	Rabbit polyclonal antibodies against multimeric peptide antigens were found to cross-react to a significant extent with topologically related variants of the parent antigen, where the chirality of each amino acid residue (inverse derivatives), or the peptide sequence orientation (retro derivatives), was inverted or where both modifications were simultaneously introduced (retro-inverso derivatives), AU peptide variants displayed similar recognition properties for antibodies and similar dose-dependent inhibitory effects on the interaction between immobilized parent antigen and corresponding antibodies, Importance of peptide side chain topology on antigenicity was evaluated analyzing the recognition properties of two sequence-simplified parent peptide variants, one lacking of the side chains in the sequence odd position and the other in even position. These two variants, prepared introducing glycine residues alternatively in the parent peptide sequence, were found to cross-react to a significant extent with the original antibody raised against the parent peptide, Analysis of molecular models of peptide enantiomeric variants in the elongated all-trans configuration suggested that the topological equivalence of alternating side chains could lead to the formation of similar recognition surfaces, thus mimicking the parent peptide antigenic structure.	TECNOGEN SCPA,PROT ENGN,I-81015 PIANA MONTE VERNA,ITALY				Fassina, Giorgio/I-7127-2012	Fassina, Giorgio/0000-0003-1845-2657				BATTISTUTTA R, 1994, BIOPOLYMERS, V34, P1535, DOI 10.1002/bip.360341111; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BENKIRANE N, 1995, J BIOL CHEM, V270, P11921, DOI 10.1074/jbc.270.20.11921; BOREK F, 1965, BIOCHEM J, V96, P577, DOI 10.1042/bj0960577; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; DINTZIS HM, 1993, PROTEINS, V16, P306, DOI 10.1002/prot.340160309; FASSINA G, 1995, ARCH BIOCHEM BIOPHYS, V318, P37, DOI 10.1006/abbi.1995.1201; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; FULLER WD, 1985, J AM CHEM SOC, V109, P4712; GICHARD G, 1994, PEPT RES, V7, P308; GILL TJ, 1963, NATURE, V197, P746, DOI 10.1038/197746a0; GOODMAN M, 1979, ACCOUNTS CHEM RES, V12, P1, DOI 10.1021/ar50133a001; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; GUPTASARMA P, 1992, FEBS LETT, V310, P205, DOI 10.1016/0014-5793(92)81333-H; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; KING TP, 1994, J IMMUNOL, V153, P1124; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MAURER PH, 1965, J EXP MED, V121, P339, DOI 10.1084/jem.121.3.339; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; MULLER S, 1995, PEPTIDE RES, V8, P138; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; RUVO M, 1995, INT J PEPT PROT RES, V45, P356; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; VERDINI AS, 1985, J CHEM SOC PERK T 1, P697, DOI 10.1039/p19850000697; VERDINI AS, 1991, J MED CHEM, V34, P3372, DOI 10.1021/jm00116a005; VERDOLIVA A, 1995, J CHROMATOGR B, V664, P175, DOI 10.1016/0378-4347(94)00407-V; WEINER HL, 1994, P NATL ACAD SCI USA, V91, P10762, DOI 10.1073/pnas.91.23.10762; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	31	32	34	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30422	30427		10.1074/jbc.270.51.30422	http://dx.doi.org/10.1074/jbc.270.51.30422			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530469	hybrid			2022-12-25	WOS:A1995TL67500034
J	Dhordain, P; Albagli, O; Ansieau, S; Koken, MHM; Deweindt, C; Quief, S; Lantoine, D; Leutz, A; Kerckaert, JP; Leprince, D				Dhordain, P; Albagli, O; Ansieau, S; Koken, MHM; Deweindt, C; Quief, S; Lantoine, D; Leutz, A; Kerckaert, JP; Leprince, D			The BTB/POZ domain targets the LAZ3/BCL6 oncoprotein to nuclear dots and mediates homomerisation in vivo	ONCOGENE			English	Article						LAZ3/BCL6; lymphoma; BTB/POZ domain; Kruppel-like Zinc finger; nuclear dots; two-hybrid system	POSITION-EFFECT VARIEGATION; FINGER ENCODING GENE; CONSERVED DOMAIN; PROTEIN; EXPRESSION; DROSOPHILA; TRANSLOCATIONS; SEGMENTATION; LOCALIZATION; ENHANCER	The LAZ3/BCL6 gene was identified by its disruption in 3q27 translocations associated with diffuse large cell lymphomas, It is predicted to be a transcription factor as it contains six Kruppel-like Zinc finger motifs and a N-terminal BTB/POZ domain, a protein/protein interaction interface that is widely conserved in Metazoans, Using two antisera raised against non overlapping regions of the predicted ORF, we demonstrate that the LAZ3/BCL6 protein appears as a close ca, 79 kDa doublet in B lymphoid cell lines with either a rearranged or a non rearranged LAZ3/BCL6 locus, By immunofluorescence experiments on transiently transfected COS-1 or NTH3T3 cells, we show that the LAZ3/BCL6 protein displays a punctuated nuclear localisation. This appears to rely on LAZ3/BCL6 proper folding and/or activities as it is impaired in a hormone reversible-fashion through fusion of LAZ3/BCL6 to the ligand-binding domain of the oestrogen receptor, Moreover, deletion of its BTB/POZ domain leads to the disappearance of the nuclear dots although the protein remains nuclear, In addition, by using the yeast two-hybrid system, we show that the LAZ3/BCL6 BTB/POZ domain homomerises in vivo, Thus, the LAZ3/BCL6 BTB/POZ domain has the capability to self-interact and target the protein to discrete nuclear substructures.	IRCL,U124 INSERM,F-59045 LILLE,FRANCE; MAX DELBRUCK CENTRUM MOLEK MED,D-13122 BERLIN,GERMANY; HOP ST LOUIS,CTR HAYEM,U43 CNRS,F-75475 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			koken, marcel/N-1349-2019; koken, marcel/J-8154-2012; Ansieau, Stephane/I-6195-2016; Leutz, Achim/K-9643-2013	koken, marcel/0000-0002-0839-0125; Leutz, Achim/0000-0001-8259-927X; Leprince, Dominique/0000-0002-1999-0775; ANSIEAU, Stephane/0000-0003-0989-2108				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; BROWN JL, 1993, DEVELOPMENT, V117, P45; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; DANIEL MT, 1993, BLOOD, V82, P1858; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GODT D, 1993, DEVELOPMENT, V119, P799; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; JONGENS TA, 1994, GENE DEV, V8, P2123, DOI 10.1101/gad.8.18.2123; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; KOBAYASHI H, 1993, BLOOD, V81, P3027; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; MIKI T, 1994, BLOOD, V83, P26; Miller J.H., 1972, EXPT MOL GENETICS; NACHEVA E, 1993, BLOOD, V82, P231, DOI 10.1182/blood.V82.1.231.bloodjournal821231; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Picard Didier, 1994, Current Opinion in Biotechnology, V5, P511, DOI 10.1016/0958-1669(94)90066-3; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SUGAWARA M, 1994, MOL CELL BIOL, V14, P8438, DOI 10.1128/MCB.14.12.8438; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VONKALM L, 1994, EMBO J, V13, P3505, DOI 10.1002/j.1460-2075.1994.tb06657.x; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; ZOLLMAN S, 1994, P NATL ACAD SCI USA, V91, P10717, DOI 10.1073/pnas.91.22.10717	44	115	119	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2689	2697						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545127				2022-12-25	WOS:A1995TP18800026
J	PFISTERER, P; ZWILLING, S; HESS, J; WIRTH, T				PFISTERER, P; ZWILLING, S; HESS, J; WIRTH, T			FUNCTIONAL-CHARACTERIZATION OF THE MURINE HOMOLOG OF THE B-CELL-SPECIFIC COACTIVATOR BOB.1/OBF.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN TRANSCRIPTION FACTORS; OCTAMER DNA MOTIF; POU-DOMAIN; IMMUNOGLOBULIN GENES; CONSERVED SEQUENCE; PROTEIN-BINDING; REMOTE ENHANCER; NUCLEAR FACTOR; ACTIVATION; PROMOTER	B cell-specific transcriptional promoter activity mediated by the octamer motif requires the Oct1 or Oct2 protein and additional B cell-restricted cofactors. One such cofactor, BOB.1/OBF.1, was recently isolated from human B cells. Here, we describe the isolation and detailed characterization of the murine homolog. Full-length cDNAs and genomic clones were isolated, and the gene structure was determined. Comparison of the deduced amino acids shows 88% sequence identity between mouse and human BOB.1/OBF.1. The NH2-terminal 126 amino acids of BOB.1/OBF.1 are both essential and sufficient for interaction with the POU domains of either Oct1 or Oct2. This protein-protein interaction does not require the simultaneous binding of Oct proteins to DNA, and high resolution footprinting of the Oct-DNA interaction reveals that binding of BOB.1/ OBF.1 to Oct1 or Oct2 does not alter the interaction with DNA. BOB.1/OBF.1 can efficiently activate octamer-dependent promoters in fibroblasts; however, it fails to stimulate octamer-dependent enhancer activity. Fusion of subdomains of BOB.1/OBF.1 with the GAL4 DNA binding domain reveals that both NH2- and COOH-terminal domains of BOB.1/OBF.1 contribute to full transactivation function, the COOH-terminal domain is more efficient in this transactivation assay. Consistent with the failure of full-length BOB.1/OBF.1 to stimulate octamer-dependent enhancer elements in non E cells, the GAIA fusions likewise only stimulate from a promoter-proximal position.	ZENTRUM MOLEK BIOL HEIDELBERG, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg			Wirth, Thomas/X-7172-2019; Hess, Jochen/ABE-1144-2021	Hess, Jochen/0000-0003-3493-1711				ANNWEILER A, 1993, J BIOL CHEM, V268, P2525; ANNWEILER A, 1994, NUCLEIC ACIDS RES, V22, P4250, DOI 10.1093/nar/22.20.4250; ANNWEILER A, 1992, MOL CELL BIOL, V12, P3107, DOI 10.1128/MCB.12.7.3107; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; CORCORAN LM, 1994, IMMUNITY, V1, P635, DOI 10.1016/1074-7613(94)90035-3; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; GERSTER T, 1987, EMBO J, V6, P1323, DOI 10.1002/j.1460-2075.1987.tb02371.x; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HERMANSON GG, 1989, P NATL ACAD SCI USA, V86, P7341, DOI 10.1073/pnas.86.19.7341; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; KATAN M, 1990, NUCLEIC ACIDS RES, V18, P6871, DOI 10.1093/nar/18.23.6871; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KRISTIE TM, 1990, GENE DEV, V4, P2383, DOI 10.1101/gad.4.12b.2383; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; THEVENIN C, 1993, J BIOL CHEM, V268, P5949; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WALKER S, 1994, CELL, V79, P841, DOI 10.1016/0092-8674(94)90073-6; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; WIRTH T, 1991, NUCLEIC ACIDS RES, V19, P43, DOI 10.1093/nar/19.1.43; WIRTH T, 1995, IMMUNOBIOLOGY, V193, P161, DOI 10.1016/S0171-2985(11)80540-1; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIAO P, 1990, MOL CELL BIOL, V10, P4974, DOI 10.1128/MCB.10.9.4974; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZELEZNIKLE NJ, 1992, J BIOL CHEM, V267, P7677; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	59	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29870	29880						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530384	hybrid			2022-12-25	WOS:A1995TK38000044
J	YAMASHITA, H; NAKATSUKA, T; HIROSE, M				YAMASHITA, H; NAKATSUKA, T; HIROSE, M			STRUCTURAL AND FUNCTIONAL-CHARACTERISTICS OF PARTIALLY DISULFIDE-REDUCED INTERMEDIATES OVOTRANSFERRIN N-LOBE - CYSTINE LOCALIZATION BY INDIRECT END-LABELING APPROACH AND IMPLICATIONS FOR THE REDUCTION PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; BOVINE ALPHA-LACTALBUMIN; TERMINAL HALF-MOLECULE; GEL-ELECTROPHORESIS; CYSTEINE RESIDUES; FOLDING PATHWAY; RIBONUCLEASE-A; KINETIC ROLE; REGENERATION; BONDS	Ovotransferrin N lobe contains six intrachain disulfides (SS-I/Cys(10)-Cys(45); SS-II/Cys(20)-Cys(36); SS-III/Cys(115)-Cys(197); SS-IV/CyS(160)-Cys(174); SS-V/Cys(171)-Cys(182); SS-VI/Cys(228-)Cys(242)) in a single polypeptide chain of 332 amino acid residues, Upon the protein disulfide reduction with dithiothreitol under nondenaturing conditions, the intermediate species with four, three, and two disulfides were generated, The partially disulfide-reduced intermediates were isolated, and the localization of intact disulfides in the intermediates was determined by an indirect end-labeling method. This method included the S-cyanocysteine-specific protein fragmentation, followed by gel electrophoresis and the immunochemical visualization of the C terminus-intact fragments using antiserum raised against a non cysteine C-terminal fragment (Se(280-)Arg(332)). Results clearly showed that first SS-IV and SS-V, second SS-III, and then SS-VI are cleaved, No reduction was observed for SS-I and SS-II under the employed reducing conditions, The conclusion was confirmed by peptide mapping analyses for the same disulfide intermediates using reverse phase high performance liquid chromatography. Transverse urea gradient gel electrophoresis and visible absorption spectra revealed that the four-disulfide intermediate, but not the three- or two-disulfide intermediate, retains essentially the same iron-binding function as the native protein. By far-UV CD analyses, the residual native conformation of the partially disulfide-reduced intermediates was found to decrease with increased number of the reduced disulfides. Implications of the partially disulfide-reduced intermediates for the disulfide reductive unfolding pathway in ovotransferrin N lobe are discussed.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN	Kyoto University				Hirose, Masaaki/0000-0003-2672-4384				ACHARYA AS, 1980, J BIOL CHEM, V255, P1905; AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; DARBY NJ, 1992, J MOL BIOL, V224, P905, DOI 10.1016/0022-2836(92)90458-V; DEWAN JC, 1993, BIOCHEMISTRY-US, V32, P11963, DOI 10.1021/bi00096a004; EVANS RW, 1980, BIOCHEM J, V189, P541, DOI 10.1042/bj1890541; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3677, DOI 10.1021/bi00065a022; GOLDENBERG DP, 1984, ANAL BIOCHEM, V138, P1, DOI 10.1016/0003-2697(84)90761-9; HIROSE M, 1991, J BIOL CHEM, V266, P1463; HIROSE M, 1989, J BIOL CHEM, V264, P16867; HIROSE M, 1988, ANAL BIOCHEM, V168, P193, DOI 10.1016/0003-2697(88)90028-0; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P7643, DOI 10.1093/nar/15.18.7643; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROKAWA H, 1994, J BIOL CHEM, V269, P6671; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1985, P NATL ACAD SCI USA, V82, P6788, DOI 10.1073/pnas.82.20.6788; MENDOZA JA, 1994, BIOCHEMISTRY-US, V33, P1143, DOI 10.1021/bi00171a013; MIKAMI B, 1983, J BIOCHEM, V93, P777, DOI 10.1093/jb/93.3.777; NEFSKY B, 1989, P NATL ACAD SCI USA, V86, P3549, DOI 10.1073/pnas.86.10.3549; OE H, 1988, J BIOCHEM-TOKYO, V103, P1066, DOI 10.1093/oxfordjournals.jbchem.a122381; PACE CN, 1986, J MOL BIOL, V188, P477, DOI 10.1016/0022-2836(86)90169-5; PACE CN, 1988, J BIOL CHEM, V263, P11820; RADFORD SE, 1991, BIOCHEM J, V272, P211; ROTHWARF DM, 1991, J AM CHEM SOC, V113, P6293, DOI 10.1021/ja00016a068; ROTHWARF DM, 1993, BIOCHEMISTRY-US, V32, P2671, DOI 10.1021/bi00061a027; Sambrook J, 1989, MOL CLONING LABORATO; STALEY JP, 1992, P NATL ACAD SCI USA, V89, P1519, DOI 10.1073/pnas.89.5.1519; SUBRAMANIAN AR, 1980, J BIOL CHEM, V255, P3227; TALLURI S, 1994, BIOCHEMISTRY-US, V33, P10437, DOI 10.1021/bi00200a027; VANMIERLO CPM, 1994, J MOL BIOL, V235, P1044, DOI 10.1006/jmbi.1994.1056; WALSER JT, 1981, BIOCHEMISTRY-US, V20, P1169, DOI 10.1021/bi00508a019; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WILLIAMS J, 1982, TRENDS BIOCHEM SCI, V7, P394, DOI 10.1016/0968-0004(82)90183-9; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YAMASHITA H, 1993, J BIOL CHEM, V268, P19062	41	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29806	29812						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530374				2022-12-25	WOS:A1995TK38000034
J	SETH, A; ROBINSON, L; THOMPSON, DM; WATSON, DK; PAPAS, TS				SETH, A; ROBINSON, L; THOMPSON, DM; WATSON, DK; PAPAS, TS			TRANSACTIVATION OF GATA-1 PROMOTER WITH ETS1, ETS2 AND ERGB/HU-FLI-1 PROTEINS - STABILIZATION OF THE ETS1 PROTEIN-BINDING ON GATA-1 PROMOTER SEQUENCES BY MONOCLONAL-ANTIBODY	ONCOGENE			English	Article							ERYTHROID TRANSCRIPTION FACTOR; LONG TERMINAL REPEAT; C-ETS-1 PROTOONCOGENE; GENE; EXPRESSION; INDUCTION; COOPERATE; ONCOGENE; LINEAGES; VIRUS	Ets family proteins activate transcription via binding to the GGAA core sequence located in the promoter/ enhancer elements of many cellular and viral genes. GATA-1 is an erythroid-specific transcription factor. The promoter of the chicken GATA-1 gene contains multiple ets binding sites (EBS), two of them are present in palindromic form. The GATA-1 promoter has been shown to be activated by the E26 virus. In this study, we have analysed whether the palidromic EBS of the chicken GATA-1 promoter is a target for binding and activation by members of the cellular ets gene family products. The results herein indicate that both EBS in the palindrome are required for DNA-binding because mutations in either site reduces the activity by at least 95%. Moreover, DNA binding of ETS1 to the EBS palindrome is dramatically stabilized in the presence of a specific monoclonal antibody whose epitope maps between amino acid positions 240-260. Although each of the single sites bind, the efficiency of binding is extremely low. Furthermore, for efficient binding the two sites must be in an inverted configuration because of the fact that the oligonucleotide containing the left and right EBS in the same orientation binds 10-fold less than the oligonucleotide containing the EBS palindrome. Additionally, we show that the transcription of a reporter gene (CAT) either linked to the GATA-1 EBS palindrome or GATA-1 promoter can be activated by cotransfection with ETS1, alternatively-spliced ETS1, ETS2 or ERGB/Hu-FLI-1 expression vectors.	PROGRAM RESOURCES INC,DYNCORP,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	SETH, A (corresponding author), NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702, USA.							ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ASCIONE R, 1992, INT J ONCOL, V1, P631; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HODGE DR, IN PRESS ADV GENE TE; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOIZUMI S, 1990, ONCOGENE, V5, P675; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; NERLOV C, 1991, ONCOGENE, V6, P1583; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OKA T, 1991, ONCOGENE, V6, P2077; PANAYIOTAKIS A, IN PRESS J VIRAL DIS; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SETH A, 1989, ONCOGENE RES, V5, P61; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WERNERT N, 1992, AM J PATHOL, V140, P119; YUAN CC, 1989, J VIROL, V61, P205	38	95	96	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1783	1790						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510925				2022-12-25	WOS:A1993LG68200009
J	DIVITA, G; GOODY, RS; GAUTHERON, DC; DIPIETRO, A				DIVITA, G; GOODY, RS; GAUTHERON, DC; DIPIETRO, A			STRUCTURAL MAPPING OF CATALYTIC SITE WITH RESPECT TO ALPHA-SUBUNIT AND NONCATALYTIC SITE IN YEAST MITOCHONDRIAL F1-ATPASE USING FLUORESCENCE RESONANCE ENERGY-TRANSFER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-SITES; CHLOROPLAST COUPLING FACTOR; APPARENT NEGATIVE COOPERATIVITY; ESCHERICHIA-COLI F1-ATPASE; ISOLATED BETA-SUBUNIT; ATP SYNTHASE; ADENOSINE 5'-TRIPHOSPHATE; RAT-LIVER; FACTOR-I; SCHIZOSACCHAROMYCES-POMBE	The intrinsic tryptophan fluorescence of Schizosaccharomyces pombe mitochondrial F1 is a very sensitive probe to differentiate nucleotide binding to catalytic and noncatalytic sites (Divita, G., Di Pietro, A., Roux, B., and Gautheron, D. C. (1992) Biochemistry 31, 5791-5798), the catalytic site saturation producing quenching of Trp-257 fluorescence (Divita, G., Jault, J.-M., Gautheron, D. C., and Di Pietro, A. (1993) Biochemistry 32, 1017-1024). The present results indicate that two types of fluorescent nucleotide analogues, bearing either 2'(3')N-methylanthraniloyl (mant) or 2',3'-O-(2,4,6-trinitrophenyl) (TNP) group, exhibit high-affinity binding and behave similarly to the corresponding unmodified nucleotides. Selective binding of mant GDP to the catalytic site produces a marked quenching of intrinsic fluorescence which is due to resonance energy transfer between Trp-257 and the mant group. The high efficiency of the transfer allows the determination of a short distance, 10.5 angstrom, indicating the close proximity of catalytic site and alpha-subunit Trp-257. Selective saturation of the noncatalytic site by TNP-ADP produces a marked quenching of the extrinsic fluorescence of mant GDP bound to the catalytic site, which is correlated to an important resonance energy transfer between the two fluorescent groups. A rather short distance of 17.5 angstrom is calculated, indicating vicinity of catalytic and noncatalytic sites.	UNIV CLAUDE BERNARD LYON 1, INST BIOL CHIM PROT,CNRS,UPR 412, 7 PASSAGE VERCORS, F-69367 LYON 07, FRANCE; MAX PLANCK INST MED RES, BIOPHYS ABT, W-6900 HEIDELBERG 1, GERMANY; UNIV LYON 1, BIOL & TECHNOL MEMBRANES & SYST INTEGRES LAB, F-69622 VILLEURBANNE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Max Planck Society; UDICE-French Research Universities; Universite Claude Bernard Lyon 1			Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444				BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERMAN MC, 1986, J BIOL CHEM, V261, P6494; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BULLOUGH DA, 1988, J BIOL CHEM, V263, P14053; CARLIER MF, 1979, BIOCHEMISTRY-US, V18, P3452, DOI 10.1021/bi00583a003; CERIONE RA, 1982, BIOCHEMISTRY-US, V21, P745, DOI 10.1021/bi00533a026; CHEN R F, 1967, Analytical Letters, V1, P35; COLVERT KK, 1992, BIOCHEMISTRY-US, V31, P3930, DOI 10.1021/bi00131a006; CREMO CR, 1990, BIOCHEMISTRY-US, V29, P3309, DOI 10.1021/bi00465a023; DIPIETRO A, 1980, BIOCHEMISTRY-US, V19, P5671, DOI 10.1021/bi00566a002; DIPIETRO A, 1981, BIOCHEMISTRY-US, V20, P6312, DOI 10.1021/bi00525a005; DIPIETRO A, 1988, BIOCHEM BIOPH RES CO, V152, P1319, DOI 10.1016/S0006-291X(88)80429-7; DIVITA G, 1991, BIOCHEMISTRY-US, V30, P3256, DOI 10.1021/bi00227a013; DIVITA G, 1992, BIOCHEMISTRY-US, V31, P5791, DOI 10.1021/bi00140a015; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P1017, DOI 10.1021/bi00055a004; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; Fairclough R H, 1978, Methods Enzymol, V48, P347; FALLER LD, 1990, BIOCHEMISTRY-US, V29, P3179, DOI 10.1021/bi00465a004; FALSON P, 1989, BIOCHIM BIOPHYS ACTA, V975, P119, DOI 10.1016/S0005-2728(89)80209-9; FALSON P, 1991, J BIOL CHEM, V266, P287; FALSON P, 1986, J BIOL CHEM, V261, P7151; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GARBOCZI DN, 1988, J BIOL CHEM, V263, P15694; GOODY RS, 1992, PHILOS T ROY SOC B, V336, P3, DOI 10.1098/rstb.1992.0037; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HISABORI T, 1992, J BIOL CHEM, V267, P4551; JACOBSON MA, 1983, BIOCHEMISTRY-US, V22, P4247, DOI 10.1021/bi00287a014; JAULT JM, 1991, J BIOL CHEM, V266, P8073; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KORMER ZS, 1982, EUR J BIOCHEM, V121, P451, DOI 10.1111/j.1432-1033.1982.tb05808.x; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEE JH, 1990, J BIOL CHEM, V265, P4664; MCCARTY RE, 1987, TRENDS BIOCHEM SCI, V12, P234, DOI 10.1016/0968-0004(87)90116-2; MILLS DA, 1991, J BIOL CHEM, V266, P7440; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2346; MORADIAMELI M, 1989, J BIOL CHEM, V264, P1361; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PENIN F, 1988, BIOCHEMISTRY-US, V27, P8969, DOI 10.1021/bi00425a014; RAO R, 1988, J BIOL CHEM, V263, P5569; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SCHAFER HJ, 1984, J BIOL CHEM, V259, P5301; SCHUSTER SM, 1975, J BIOL CHEM, V250, P7848; SCOTT TG, 1970, J AM CHEM SOC, V92, P687, DOI 10.1021/ja00706a043; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHAPIRO AB, 1991, J BIOL CHEM, V266, P17276; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TAGAYA M, 1988, FEBS LETT, V233, P347, DOI 10.1016/0014-5793(88)80457-5; VASAK M, 1979, BIOCHEMISTRY-US, V18, P5050, DOI 10.1021/bi00590a004; VOGEL PD, 1992, J BIOL CHEM, V267, P11982; VOGEL PD, 1991, J BIOL CHEM, V266, P6101; WEBER J, 1992, BIOCHEMISTRY-US, V31, P5112, DOI 10.1021/bi00137a004; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; WU JC, 1986, BIOCHEMISTRY-US, V25, P7991, DOI 10.1021/bi00372a030; ZHUO SQ, 1992, J BIOL CHEM, V267, P12916	63	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13178	13186						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514756				2022-12-25	WOS:A1993LH55300027
J	MARIANI, M; MARETZKI, D; LUTZ, HU				MARIANI, M; MARETZKI, D; LUTZ, HU			A TIGHTLY MEMBRANE-ASSOCIATED SUBPOPULATION OF SPECTRIN IS H-3 PALMITOYLATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURALLY-OCCURRING AUTOANTIBODIES; RED-BLOOD-CELLS; ERYTHROCYTE-MEMBRANE; SKELETAL PROTEINS; PHOSPHORYLATION; ANKYRIN; ACYLATION; VESICLES; BINDING; IDENTIFICATION	A tightly membrane-associated form of spectrin (TMA-spectrin) was labeled when human red blood cells were incubated with [H-3]palmitic acid. About 90% of spectrin was not fatty acid-acylated and was extracted from membranes by low salt buffers. The H-3-palmitoylated TMA-spectrin, however, resisted low and even high salt extraction and remained associated with inside-out vesicles that were generated in the process of spectrin-actin extraction from membranes. TMA-spectrin was preferentially extracted from KCl-stripped vesicles by 5 M urea at low ionic strength. TMA-spectrin was purified by gel filtration and by ion exchange chromatography in the presence of urea and a non-ionic detergent. Purified TMA-spectrin was H-3-palmitoylated exclusively in the beta subunit to 0.28 mol/mol after a 12-h incubation of red cells. The labeled palmitate may be bound as an ester or thioester, since hydroxylamine (1 M, pH 7.5) released the label completely. Peptide maps of H-3-palmitoylated TMA-spectrin showed three or two labeled peptides from the beta subunit, when generated by V8 protease and trypsin, respectively. Two types of antibodies to spectrin reacted with purified TMA-spectrin, and TMA-spectrin contained the same antigenic peptides as low salt-extractable spectrin. Rabbit anti-ankyrin antibodies did not bind to TMA-spectrin. The substoichiometric incorporation of [H-3]palmitic acid into TMA-spectrin could result from the slow turnover of endogenously bound fatty acids. Generation of the tightly membrane-associated and H-3-palmitoylated subpopulation of spectrin cannot be due to entrapment of an unmodified residual fraction of spectrin in right-side-out vesicles. Instead, the data suggest the existence of a subpopulation of spectrin molecules that undergo a covalent fatty acid modification and thereby alter their binding properties. This may offer a new, metabolically dependent mechanism for dynamic interactions between spectrin and the membrane lipid bilayer.	SWISS FED INST TECHNOL, BIOCHEM LAB, CH-8092 ZURICH, SWITZERLAND; HUMBOLDT UNIV BERLIN, BEREICH MED CHARITE, INST MED PHYS & BIOPHYS, O-1040 BERLIN, GERMANY	ETH Zurich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								ALLAN D, 1976, NATURE, V261, P58, DOI 10.1038/261058a0; ANDERSON JM, 1980, J BIOL CHEM, V255, P1259; BENNETT V, 1980, J BIOL CHEM, V255, P2540; BENNETT V, 1991, J CLIN INVEST, V87, P1483, DOI 10.1172/JCI115157; BENNETT V, 1977, J BIOL CHEM, V252, P2753; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; BOIVIN P, 1988, BIOCHEM J, V256, P689, DOI 10.1042/bj2560689; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BUTLER AJ, 1991, J BIOL CHEM, V266, P18250; CIANCI CD, 1988, J CELL BIOCHEM, V37, P301, DOI 10.1002/jcb.240370305; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FAIRBANKS G, 1981, SCAND J CLIN LAB INV, V41, P139, DOI 10.3109/00365518109097446; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; HAEST CWM, 1982, BIOCHIM BIOPHYS ACTA, V694, P331, DOI 10.1016/0304-4157(82)90001-6; HANSPAL M, 1987, J CELL BIOL, V105, P1417, DOI 10.1083/jcb.105.3.1417; HARGREAVES WR, 1980, J BIOL CHEM, V255, P1965; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAMOUN PP, 1988, TRENDS BIOCHEM SCI, V13, P424, DOI 10.1016/0968-0004(88)90211-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LU PW, 1985, J BIOL CHEM, V260, P4958; LUTZ HU, 1986, J CARDIOVASC PHARM, V8, pS76, DOI 10.1097/00005344-198600088-00016; LUTZ HU, 1992, BIOCHIM BIOPHYS ACTA, V1116, P1, DOI 10.1016/0304-4165(92)90120-J; LUTZ HU, 1977, J CELL BIOL, V73, P548, DOI 10.1083/jcb.73.3.548; LUTZ HU, 1984, J IMMUNOL, V133, P2610; LUTZ HU, 1982, J IMMUNOL, V128, P1695; LUTZ HU, 1984, FEBS LETT, V169, P323, DOI 10.1016/0014-5793(84)80343-9; LUZ HU, 1989, SPRINGER SERIES BIOP, V3, P328; MARCHESI VT, 1983, BLOOD, V61, P1; MARETZKI D, 1986, ARCH BIOCHEM BIOPHYS, V246, P469, DOI 10.1016/0003-9861(86)90493-5; MARETZKI D, 1990, FEBS LETT, V259, P305, DOI 10.1016/0014-5793(90)80033-F; MOMBERS C, 1980, BIOCHIM BIOPHYS ACTA, V603, P52, DOI 10.1016/0005-2736(80)90390-9; MUNDY DI, 1992, J CELL BIOL, V116, P135, DOI 10.1083/jcb.116.1.135; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; OKUBO K, 1991, J BIOL CHEM, V266, P16420; PALEK J, 1992, BLOOD, V80, P308; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; RYBICKI AC, 1988, J CLIN INVEST, V81, P255, DOI 10.1172/JCI113303; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SPEICHER DW, 1980, P NATL ACAD SCI-BIOL, V77, P5673, DOI 10.1073/pnas.77.10.5673; STAUFENBIEL M, 1986, P NATL ACAD SCI USA, V83, P318, DOI 10.1073/pnas.83.2.318; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; ZIPARO E, 1978, J CELL SCI, V34, P91	44	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12996	13001						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509431				2022-12-25	WOS:A1993LG65800111
J	Aruga, J; Nagai, T; Tokuyama, T; Hayashizaki, Y; Okazaki, Y; Chapman, VM; Mikoshiba, K				Aruga, J; Nagai, T; Tokuyama, T; Hayashizaki, Y; Okazaki, Y; Chapman, VM; Mikoshiba, K			The mouse Zic gene family - Homologues of the Drosophila pair-rule gene odd-paired	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEINS; KRUPPEL FAMILY; GLI	The mouse Zic gene, which encodes a zinc finger protein, is expressed in the developing or matured central nervous system in a highly restricted manner. We identified two novel Zic-related genes (Zic2, Zic3) through genomic and cDNA cloning. Both genes are highly similar to Zic(1), especially in their zinc finger motif. A comparison of genomic organization among the three Zic genes showed that they share common exon intron boundaries and belong to the same gene family. Zic1, Zic2, and Zic3 were determined to mouse chromosome 9, 14, and X using an interspecific backcross panel. Northern blotting and ribonuclease protection showed that Zic2 and Zic3 are expressed in a restricted manner in the cerebellum at the adult stage. However, the temporal profile of the mRNA expression in the developing cerebella differ in the three Zic genes. Furthermore, we found that the Drosophila pair-rule gene, odd-paired is highly homologous to the Zic gene family. The similarity was not only the zinc finger motif, but also the exon-intron boundary was the same as those of mouse Zic gene family. These findings suggest that the Zic gene family and Drosophila odd-paired are derived from a common ancestral gene.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,GENOME SCI LAB,TSUKUBA,IBARAKI 305,JAPAN; ROSWELL PK CANC INST,DEPT MOLEC & CELL BIOL,BUFFALO,NY 14263; UNIV TOKYO,INST MED SCI,DEPT MOLEC NEUROBIOL,MINATO KU,TOKYO 108,JAPAN	RIKEN; Roswell Park Cancer Institute; University of Tokyo	Aruga, J (corresponding author), INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC NEUROBIOL LAB,3-1-1 KOYADAI,TSUKUBA,IBARAKI 305,JAPAN.		Hayashizaki, Yoshihide/N-6590-2015; Mikoshiba, Katsuhiko/N-7943-2015; Aruga, Jun/H-5837-2011	Aruga, Jun/0000-0001-7936-1375; Nagai, Takeharu/0000-0003-2650-9895	NIGMS NIH HHS [GM33160] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033160] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUGA J, 1994, J NEUROCHEM, V63, P1880; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; CIMBORA DM, 1995, DEV BIOL, V169, P5580; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HAYASHIZAKI Y, 1994, GENETICS, V138, P1207; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; MANLY KF, 1991, MAMM GENOME, V1, P123, DOI 10.1007/BF02443789; MASHIYAMA S, 1990, Technique (Philadelphia), V2, P304; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; Sambrook J, 1989, MOL CLONING LABORATO; SNELL GEORGE D., 1955, JOUR HEREDITY, V46, P27; TAYLOR BA, 1978, MOUSE NEWS LETT, V59, P25; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	18	173	176	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1043	1047		10.1074/jbc.271.2.1043	http://dx.doi.org/10.1074/jbc.271.2.1043			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557628	hybrid			2022-12-25	WOS:A1996TP88900065
J	Baltensperger, K; Karoor, V; Paul, H; Ruoho, A; Czech, MP; Malbon, CC				Baltensperger, K; Karoor, V; Paul, H; Ruoho, A; Czech, MP; Malbon, CC			The beta-adrenergic receptor is a substrate for the insulin receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; PHOSPHORYLATION; SIGNAL	G-protein-linked receptors and intrinsic tyrosine kinase growth receptors represent two prominent modalities in cell signaling, Cross-regulation among members of both receptor superfamilies has been reported, including the counter-regulatory effects of insulin on beta-adrenergic catecholamine action, Cells stimulated by insulin show loss of function and increased phosphotyrosine content of beta(2)-adrenergic receptors. Phosphorylation of tyrosyl residues 350/354 of beta(2)-adrenergic receptors is obligatory for counter-regulation by insulin (Karoor, V., Baltensperger, K., Paul, H., Czech, M., and Malbon, C. C. (1995) J. Biol. Chem. 270, 25305-25308), suggesting the hypothesis that G-protein-linked receptors themselves may act as substrates for the insulin receptor and other growth factor receptors. This hypothesis was evaluated directly using recombinant human insulin receptor, hamster beta(2)-adrenergic receptor, and an in vitro reconstitution and phosphorylation assay. Insulin is shown to stimulate insulin receptor-catalyzed phosphorylation of the beta(2)-adrenergic receptor. Phosphoamino acid analysis establishes that insulin receptor-catalyzed phosphorylation of the beta(2)-adrenergic receptor in vitro is confined to phosphotyrosine. High pressure liquid chromatography and two-dimensional mapping reveal insulin receptor-catalyzed phosphorylation of the beta(2)-adrenergic receptor at residues Tyr(132)/Tyr(141), Tyr(350)/Tyr(354), and Tyr(364), known sites of phosphorylation in response to insulin in vivo. Insulin-like growth factor-I receptor as well as the insulin receptor displays the capacity to phosphorylate the beta 2-adrenergic receptor in vitro, establishing a new paradigm, i.e. G-protein-linked receptors acting as substrates for intrinsic tyrosine kinase growth factor receptors.	SUNY STONY BROOK, DEPT MOLEC PHARMACOL, DIABET & METAB DIS RES PROGRAM, STONY BROOK, NY 11794 USA; UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA; UNIV WISCONSIN, SCH MED, DEPT PHARMACOL, MADISON, WI 53706 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Wisconsin System; University of Wisconsin Madison			malbon, craig/ABF-3604-2020					BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GEAHLEN RL, 1989, PEPTIDES PROTEIN PHO; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HADCOCK JR, 1992, J BIOL CHEM, V267, P26017; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; JONG YJI, 1993, P NATL ACAD SCI USA, V90, P10994, DOI 10.1073/pnas.90.23.10994; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; PAXTON WG, 1994, BIOCHEM BIOPH RES CO, V200, P260, DOI 10.1006/bbrc.1994.1443; PORT JD, 1992, J BIOL CHEM, V267, P8468; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUMMERS MD, 1987, TEXAS AGR EXP STN B, V1555, P16; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	19	88	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1061	1064		10.1074/jbc.271.2.1061	http://dx.doi.org/10.1074/jbc.271.2.1061			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557631	hybrid			2022-12-25	WOS:A1996TP88900068
J	Coburn, GA; Mackie, GA				Coburn, GA; Mackie, GA			Overexpression, purification, and properties of Escherichia coli ribonuclease II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; POLYNUCLEOTIDE PHOSPHORYLASE; DECAY; EXPRESSION; TURNOVER; INVITRO; K-12; END	Ribonuclease II (RNase II) is a major exonuclease in Escherichia coli that hydrolyzes single-stranded polyri-bonucleotides processively in the 3' to 5' direction. To understand the role of RNase II in the decay of messenger RNA, a strain overexpressing the mb gene was con structed. Induction resulted in a 300-fold increase in RNase II activity in crude extracts prepared from the overexpressing strain compared to that of a non-overexpressing strain. The recombinant polypeptide (Rnb) was purified to apparent homogeneity in a rapid, simple procedure using conventional chromatographic techniques and/or fast protein liquid chromatography to a final specific activity of 4,100 units/mg. Additionally, a truncated Rnb polypeptide was purified, solubilized, and successfully renatured from inclusion bodies. The recombinant Rnb polypeptide was active against both [H-3]poly(A) as well as a novel (synthetic partial duplex) RNA substrate. The data show that the Rnb polypeptide can disengage from its substrate upon stalling at a region of secondary structure and reassociate with a new free 3'-end. The stalled substrate formed by the dissociation event cannot compete for the Rnb polypeptide, demonstrating that duplexed RNAs lacking 10 protruding unpaired nucleotides are not substrates for RNase II. In addition, RNA that has been previously trimmed back to a region of secondary structure with purified Rnb polypeptide is not a substrate for polynucleotide phosphorylase-like activity in crude extracts. The implications for mRNA degradation and the proposed role for RNase II as a repressor of degradation are discussed.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER,BC V6T 1Z3,CANADA	University of British Columbia								BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; CANNISTRARO VJ, 1994, J MOL BIOL, V243, P930, DOI 10.1006/jmbi.1994.1693; CAUSTON H, 1994, MOL MICROBIOL, V14, P731, DOI 10.1111/j.1365-2958.1994.tb01310.x; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; CUDNY H, 1980, P NATL ACAD SCI-BIOL, V77, P837, DOI 10.1073/pnas.77.2.837; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P3277, DOI 10.1073/pnas.88.8.3277; DONOVAN WP, 1983, NUCLEIC ACIDS RES, V11, P265, DOI 10.1093/nar/11.2.265; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; GHOSH RK, 1978, NUCLEIC ACIDS RES, V10, P3831; GUARNEROS G, 1990, BIOCHIMIE, V72, P771, DOI 10.1016/0300-9084(90)90186-K; GUPTA RS, 1977, J BIOL CHEM, V252, P8945; HAJNSDORF E, 1994, EMBO J, V13, P3368, DOI 10.1002/j.1460-2075.1994.tb06639.x; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; Higgins CF, 1992, CURR OPIN GENET DEV, V2, P739, DOI 10.1016/S0959-437X(05)80134-0; HO DT, 1994, ANAL BIOCHEM, V218, P1; LI ZW, 1994, J BIOL CHEM, V269, P6064; LITTAUER UZ, 1982, ENZYMES, V15, P517; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; MOTT JE, 1985, EMBO J, V4, P1887, DOI 10.1002/j.1460-2075.1985.tb03865.x; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PEPE CM, 1994, MOL MICROBIOL, V13, P1133, DOI 10.1111/j.1365-2958.1994.tb00504.x; PORTIER C, 1987, EMBO J, V6, P2165, DOI 10.1002/j.1460-2075.1987.tb02484.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; REGNIER P, 1990, BIOCHIMIE, V72, P825, DOI 10.1016/0300-9084(90)90192-J; SHEN V, 1982, ENZYMES, P501; SINGER MF, 1965, BIOCHEMISTRY-US, V4, P1319, DOI 10.1021/bi00883a016; SPAHR PF, 1964, J BIOL CHEM, V239, P3716; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; ZILHAO R, 1993, MOL MICROBIOL, V8, P43, DOI 10.1111/j.1365-2958.1993.tb01201.x	35	59	62	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1048	1053		10.1074/jbc.271.2.1048	http://dx.doi.org/10.1074/jbc.271.2.1048			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557629	hybrid			2022-12-25	WOS:A1996TP88900066
J	Nair, SK; Elbaum, D; Christianson, DW				Nair, SK; Elbaum, D; Christianson, DW			Unexpected binding mode of the sulfonamide fluorophore 5-dimethylamino-1-naphthalene sulfonamide to human carbonic anhydrase II - Implications for the development of a zinc biosensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; REFINED STRUCTURE; ENZYME; SITE; INHIBITORS; COMPLEXES; ISOENZYME; GLAUCOMA; GRAPHICS; DISPLAY	The three-dimensional structure of human carbonic anhydrase II (CAII) complexed with the sulfonamide fluorophore 5-dimethylamino-1-naphthalene sulfonamide (dansylamide) has been determined to 2.1-Angstrom resolution by x-ray crystallographic methods. Unlike other arylsulfonamide inhibitors of CAII, the naphthyl ring of dansylamide binds in a hydrophobic pocket in the active site, making van der Waals contacts with Val-121, Phe-131, Val-143, Leu-198, and Trp-209. Interestingly, a conformational change of Leu-198 is required to accommodate dansylamide binding, which rationalizes the enhanced dansylamide affinity measured for certain Leu-198 variants (Nair, S. K., Krebs, J. F., Christianson, D. W., and Fierke, C. A. (1995) Biochemistry 34, 3981-3989). Modeling studies indicate that a second binding mode, in which the fused aromatic ring is rotated out of the hydrophobic pocket, is sterically feasible. Both experimentally observed and modeled binding modes have implications for new leads in the design of avid CAII inhibitors. Finally, the structure of the CAII-dansylamide complex has implications for its exploitation in zinc biosensor applications, and possible routes toward the optimization of fluorophore design are considered on the basis on this structure.	UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104	University of Pennsylvania			Nair, Satish/AAY-2510-2021		NCI NIH HHS [F32 CA62613] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA062613] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ANTOLINI L, 1986, J CHEM SOC DALTON, P1367, DOI 10.1039/dt9860001367; BALDWIN JJ, 1989, J MED CHEM, V32, P2510, DOI 10.1021/jm00132a003; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BORIACK PA, 1995, J MED CHEM, V38, P2286, DOI 10.1021/jm00013a004; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1985, P NATL ACAD SCI USA, V82, P8458, DOI 10.1073/pnas.82.24.8458; BUNN AMC, 1994, J AM CHEM SOC, V116, P5063, DOI 10.1021/ja00091a006; BURBAUM JJ, 1995, P NATL ACAD SCI USA, V92, P6027, DOI 10.1073/pnas.92.13.6027; CHEN RF, 1967, J BIOL CHEM, V242, P5813; COLEMAN JE, 1967, J BIOL CHEM, V242, P5212; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; ERIKSSON AE, 1988, PROTEINS, V4, P283, DOI 10.1002/prot.340040407; Eriksson E. A., 1986, ZINC ENZYMES, P317; FOITZIK JK, 1991, ACTA CRYSTALLOGR C, V47, P164; HAKANSSON K, 1992, J MOL BIOL, V227, P1192, DOI 10.1016/0022-2836(92)90531-N; HANSCH C, 1985, MOL PHARMACOL, V27, P493; HENDERSON LE, 1976, J BIOL CHEM, V251, P5457; IPPOLITO JA, 1994, BIOCHEMISTRY-US, V33, P15241, DOI 10.1021/bi00255a004; IPPOLITO JA, 1995, P NATL ACAD SCI USA, V92, P5017, DOI 10.1073/pnas.92.11.5017; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KIEFER LL, 1995, J AM CHEM SOC, V117, P6831, DOI 10.1021/ja00131a004; KIEFER LL, 1994, BIOCHEMISTRY-US, V33, P15233, DOI 10.1021/bi00255a003; KREBS JF, 1993, J BIOL CHEM, V268, P948; KREBS JF, 1993, BIOCHEMISTRY-US, V32, P4496, DOI 10.1021/bi00068a004; LESBURG CA, 1995, J AM CHEM SOC, V117, P6838, DOI 10.1021/ja00131a005; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MAREN TH, 1987, DRUG DEVELOP RES, V10, P255, DOI 10.1002/ddr.430100407; MENZIANI MC, 1989, J MED CHEM, V32, P951, DOI 10.1021/jm00125a005; NAIR SK, 1995, BIOCHEMISTRY-US, V34, P3981, DOI 10.1021/bi00012a016; NAIR SK, 1994, J AM CHEM SOC, V116, P3659, DOI 10.1021/ja00087a086; NAIR SK, 1991, J AM CHEM SOC, V113, P9455, DOI 10.1021/ja00025a005; Nyborg J., 1977, ROTATION METHOD CRYS, P139; PESANDO JM, 1975, BIOCHEMISTRY-US, V14, P689, DOI 10.1021/bi00675a007; PESANDO JM, 1975, BIOCHEMISTRY-US, V14, P681, DOI 10.1021/bi00675a006; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SMITH GM, 1994, PROTEIN SCI, V3, P118, DOI 10.1002/pro.5560030115; SRINIVASAN R, 1966, ACTA CRYSTALLOGR, V20, P143, DOI 10.1107/S0365110X66000288; STAAB HA, 1991, ANGEW CHEM INT EDIT, V30, P1030, DOI 10.1002/anie.199110301; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; STURA E A, 1990, Methods (Orlando), V1, P38, DOI 10.1016/S1046-2023(05)80145-8; THOMPSON RB, 1993, ANAL CHEM, V65, P730, DOI 10.1021/ac00054a013; TILANDER B, 1965, J MOL BIOL, V12, P740, DOI 10.1016/S0022-2836(65)80324-2; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; VEDANI A, 1984, J PHARM SCI, V73, P352, DOI 10.1002/jps.2600730316; VIDGREN J, 1990, INT J BIOL MACROMOL, V12, P342, DOI 10.1016/0141-8130(90)90040-H	50	33	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1003	1007		10.1074/jbc.271.2.1003	http://dx.doi.org/10.1074/jbc.271.2.1003			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557623	hybrid			2022-12-25	WOS:A1996TP88900060
J	WatermanStorer, CM; Holzbaur, ELF				WatermanStorer, CM; Holzbaur, ELF			The product of the Drosophila gene, Glued, is the functional homologue of the p150(Glued) component of the vertebrate dynactin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; RETROGRADE AXONAL-TRANSPORT; NERVE GROWTH-FACTOR; CYTOPLASMIC DYNEIN; VESICLE MOTILITY; MELANOGASTER; LOCUS; POLYPEPTIDE; MUTATIONS; ACTIN	p150(Glued) is the largest polypeptide in the dynactin complex, a protein heteromultimer that binds to and may mediate the microtubule-based motor cytoplasmic dynein. Cloning of a cDNA encoding p150(Glued) from rat revealed 31% amino acid sequence identity with the product of the Drosophila gene, Glued. A dominant Glued mutation results in neuronal disruption; null mutations are lethal. However, the Glued gene product has not been characterized. To determine whether the Glued polypeptide is functionally similar to vertebrate p150(Glued), we characterized the Glued protein in the Drosophila S-2 cell line. Antibodies raised against Glued were used to demonstrate that this protein sediments exclusively at 20 S, and associates with microtubules in a salt- and ATP-dependent manner. Immunoprecipitations from S-2 cytosol with the anti-Glued antibody resulted in the co-precipitation of subunits of both cytoplasmic dynein and the dynactin complex. An affinity column with covalently bound Glued protein retained cytoplasmic dynein from S-2 cytosol. Based on these observations, we conclude that Glued is a component of a dynactin complex in Drosophila and binds to cytoplasmic dynein, and therefore the mutant Glued phenotypes can be interpreted as resulting from a disruption in the function of the dynactin complex.	UNIV PENN,SCH VET MED,DEPT ANIM BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania				Waterman, Clare/0000-0001-6142-6775	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007584] Funding Source: NIH RePORTER; NIAMS NIH HHS [T32-AR07584-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLAN V, 1994, CURR BIOL, V4, P1; BERLIN V, 1990, J CELL BIOL, V111, P2573, DOI 10.1083/jcb.111.6.2573; CAMPENOT RB, 1977, P NATL ACAD SCI USA, V74, P4516, DOI 10.1073/pnas.74.10.4516; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; CLARK SW, 1994, J CELL BIOL, V127, P129, DOI 10.1083/jcb.127.1.129; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FYRBERG C, 1994, J MOL BIOL, V241, P498, DOI 10.1006/jmbi.1994.1526; GAREN A, 1984, GENETICS, V107, P645; GILBERT SP, 1989, J CELL BIOL, V109, P2379, DOI 10.1083/jcb.109.5.2379; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; HARTE PJ, 1982, GENETICS, V101, P477; HARTE PJ, 1983, DEV BIOL, V99, P88, DOI 10.1016/0012-1606(83)90256-7; HAYS TS, 1994, J CELL SCI, V107, P1557; HENDRY IA, 1974, BRAIN RES, V68, P103, DOI 10.1016/0006-8993(74)90536-8; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; MCGRAIL M, 1994, MOL BIOL CELL, V5, P760; MELLONI RH, 1995, J COMP NEUROL, V357, P15, DOI 10.1002/cne.903570103; MUHUA L, 1994, CELL, V78, P669, DOI 10.1016/0092-8674(94)90531-2; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; Plough HH, 1935, GENETICS, V20, P0042; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHROER TA, 1994, J CELL BIOL, V127, P1777, DOI 10.1083/jcb.127.6.1777; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SWAROOP A, 1985, P NATL ACAD SCI USA, V82, P1751, DOI 10.1073/pnas.82.6.1751; SWAROOP A, 1987, P NATL ACAD SCI USA, V84, P6501, DOI 10.1073/pnas.84.18.6501; SWAROOP A, 1986, MOL CELL BIOL, V6, P833, DOI 10.1128/MCB.6.3.833; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	44	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1153	1159		10.1074/jbc.271.2.1153	http://dx.doi.org/10.1074/jbc.271.2.1153			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557644	hybrid			2022-12-25	WOS:A1996TP88900081
J	Miles, AM; Bohle, DS; Glassbrenner, PA; Hansert, B; Wink, DA; Grisham, MB				Miles, AM; Bohle, DS; Glassbrenner, PA; Hansert, B; Wink, DA; Grisham, MB			Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADICAL PRODUCTION; PEROXYNITRITE; NO; INHIBITORS; ARTHRITIS; SYNTHASE; RELEASE; INJURY; DAMAGE; AGENTS	The rapid and spontaneous interaction between superoxide (O-2(radical anion)) and nitric oxide (NO) to yield the potent oxidants peroxynitrite (ONOO-) and peroxynitrous acid (ONOOH), has been suggested to represent an important pathway by which tissue may be injured during inflammation. Although several groups of investigators have demonstrated substantial oxidizing and cytotoxic activities of chemically synthesized ONOO-, there has been little information available quantifying the interaction between O-2(radical anion) and NO in the absence or the presence of redox-active iron. Using the hypoxanthine (HX)/xanthine oxidase system to generate various fluxes of O-2(radical anion) and H2O2 and the spontaneous decomposition of the spermine/NO adduct to produce various fluxes of NO, we found that in the absence of redox-active iron, the simultaneous production of equimolar fluxes of O-2(radical anion) and NO increased the oxidation of dihydrorhodamine (DHR) from normally undetectable levels to approximately 15 mu M, suggesting the formation of a potent oxidant. Superoxide dismutase, but not catalase, inhibited this oxidative reaction, suggesting that O-2(radical anion) and not hydrogen peroxide (H2O2) interacts with NO to generate a potent oxidizing agent. Excess production of either radical virtually eliminated the oxidation of DHR. In the presence of 5 mu M Fe+3-EDTA to insure optimum O-2(radical anion)-driven Fenton chemistry, NO enhanced modestly HX/xanthine oxidase-induced oxidation of DHR. As expected, both superoxide dismutase and catalase inhibited this Fe-catalyzed oxidation reaction. Excess NO production with respect to O-2(radical anion) flux produced only modest inhibition (33%) of DHR oxidation. In a separate series of studies, we found that equimolar fluxes of O-2(radical anion) and NO in the absence of iron only modestly enhanced hydroxylation of benzoic acid from undetectable levels to 0.6 mu M S-hydroxybenzoate. In the presence of 5 mu M Fe+8-EDTA, HX/xanthine oxidase-mediated hydroxylation of benzoic acid increased dramatically from undetectable levels to 4.5 mu M of the hydroxylated product. Superoxide dismutase and catalase were both effective at inhibiting this classic O-2(radical anion)-driven Fenton reaction, Interestingly, NO inhibited this iron-catalyzed hydroxylation reaction in a concentration-dependent manner such that fluxes of NO approximating those of O-2(radical anion) and H2O2 virtually abolished the hydroxylation of benzoic acid. We conclude that in the absence of iron, equimolar fluxes of NO and O-2(radical anion) interact to yield potent oxidants such as ONOO-/ONOOH, which oxidize organic compounds. Excess production of either radical remarkably inhibits these oxidative reactions. In the presence of low molecular weight redox-active iron complexes, NO may enhance or inhibit O-2(radical anion)-dependent oxidation and hydroxylation reactions depending upon their relative fluxes.	LOUISIANA STATE UNIV,MED CTR,DEPT PHYSIOL & BIOPHYS,SHREVEPORT,LA 71130; UNIV WYOMING,DEPT CHEM,LARAMIE,WY 82071; NCI,RADIAT BIOL BRANCH,BETHESDA,MD 20892	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Wyoming; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Azad, Mahan/0000-0002-8633-3513; Wink, David/0000-0002-5652-7480	NATIONAL CANCER INSTITUTE [R01CA063641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK043785] Funding Source: NIH RePORTER; NCI NIH HHS [CA63641] Funding Source: Medline; NIDDK NIH HHS [DK43785] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOKI N, 1990, AM J PHYSIOL, V258, pG275, DOI 10.1152/ajpgi.1990.258.2.G275; ASSREUY J, 1994, EUR J IMMUNOL, V24, P672, DOI 10.1002/eji.1830240328; BAADER SL, 1994, J CANCER RES CLIN, V120, P415, DOI 10.1007/BF01240141; BAKER MS, 1984, ARCH BIOCHEM BIOPHYS, V234, P258, DOI 10.1016/0003-9861(84)90348-5; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BOHLE DS, 1994, J AM CHEM SOC, V116, P7423, DOI 10.1021/ja00095a062; CLARK DA, 1988, AM J PATHOL, V130, P537; DEIGHTON N, 1989, BIOCHEM SOC T, V17, P490, DOI 10.1042/bst0170490; FLORQUIN S, 1994, J EXP MED, V180, P1153, DOI 10.1084/jem.180.3.1153; FRIDOVICH I, 1986, HDB METHODS OXYGEN R, P221; FUKAHORI M, 1994, FREE RADICAL RES, V21, P203, DOI 10.3109/10715769409056572; GRISHAM MB, 1994, J PHARMACOL EXP THER, V271, P1114; HARBRECHT BG, 1992, CRIT CARE MED, V20, P1568, DOI 10.1097/00003246-199211000-00015; HARRIS LR, 1994, BIOCHEM J, V301, P385, DOI 10.1042/bj3010385; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; JOHNSON KJ, 1981, J IMMUNOL, V126, P2365; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; KING PA, 1993, NUCLEIC ACIDS RES, V21, P2473, DOI 10.1093/nar/21.10.2473; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; KUROSE I, 1994, CIRC RES, V74, P376, DOI 10.1161/01.RES.74.3.376; KUROSE I, 1993, CIRC RES, V73, P164, DOI 10.1161/01.RES.73.1.164; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; MARLETTA MA, 1988, CHEM RES TOXICOL, V1, P249, DOI 10.1021/tx00005a001; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MILES AM, 1995, FREE RADICAL RES, V23, P379, DOI 10.3109/10715769509065259; MILES AM, 1995, FASEB J, V9, P853; MULLIGAN MS, 1992, BRIT J PHARMACOL, V107, P1159, DOI 10.1111/j.1476-5381.1992.tb13423.x; MURPHY ME, 1994, METHOD ENZYMOL, V233, P240; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; RUBBO H, 1994, J BIOL CHEM, V269, P26066; RUBBO H, 1991, BIOCHIM BIOPHYS ACTA, V1074, P386, DOI 10.1016/0304-4165(91)90089-Y; SKALERIC U, 1991, J IMMUNOL, V147, P2559; THOMAS EL, 1981, BIOCHEMISTRY-US, V20, P3273, DOI 10.1021/bi00514a045; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	43	311	319	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					40	47		10.1074/jbc.271.1.40	http://dx.doi.org/10.1074/jbc.271.1.40			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550595	hybrid			2022-12-25	WOS:A1996TP36100008
J	Narasimhan, J; Potter, JL; Haas, AL				Narasimhan, J; Potter, JL; Haas, AL			Conjugation of the 15-kDa interferon-induced ubiquitin homolog is distinct from that of ubiquitin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE Y-CHROMOSOME; ATP-DEPENDENT PROTEOLYSIS; ACTIVATING ENZYME-E1; PROTEIN; GENE; DEGRADATION; RESOLUTION; MECHANISM; SEQUENCE; CHAINS	The biological effect of type 1 interferons is proposed to arise in part from the conjugation of ubiquitin crossreactive protein (UCRP), the ISG15 gene product, to intracellular target proteins in a process analogous to that of its sequence homolog ubiquitin, a highly conserved 8.6-kDa polypeptide whose ligation marks proteins for degradation via the 26 S proteasome, Inclusion of CoCl2 during the purification of recombinant UCRP blocks the proteolytic inactivation of the polypeptide occurring by cleavage of the carboxyl-terminal glycine dipeptide required for activation and subsequent ligation, Intact UCRP supports a low rate of ubiquitin-activating enzyme (E1)-dependent ATP:PPi exchange but fails to form a stoichiometric E1-UCRP thiol ester or undergo transfer to ubiquitin carrier protein (E2). The binding affinity of E1 for UCRP is significantly diminished relative to that of ubiquitin. These results suggest that UCRP conjugation proceeds through an enzyme pathway distinct from that of ubiquitin, at least with respect to the step of activation. This was confirmed for an in vitro conjugation assay in which I-125-UCRP could be ligated in an ATP-dependent reaction to proteins present within an A549 human lung carcinoma cell extract and could be competitively inhibited by excess unlabeled UCRP but not ubiquitin. Other results demonstrate that I-125-UCRP conjugation is significantly increased in cell extracts after 24 h of incubation in the presence of interferon-beta, consistent with the late induction of UCRP conjugating activity. Thus, interferon-responsive cells contain a pathway for UCRP ligation that is parallel but distinct from that of ubiquitin.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin					NIGMS NIH HHS [GM47426, GM15977] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047426, F32GM015977] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOMSTROM DC, 1986, J BIOL CHEM, V261, P8811; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1985, J BIOL CHEM, V260, P4694; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1985, PREP BIOCHEM, V15, P49; HAAS AL, 1987, J BIOL CHEM, V262, P11315; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HAAS AL, 1988, UBIQUITIN, P173; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KAY GF, 1991, NATURE, V354, P486, DOI 10.1038/354486a0; KNIGHT E, 1988, J BIOL CHEM, V263, P4520; LOEB KR, 1992, J BIOL CHEM, V267, P7806; LOEB KR, 1994, MOL CELL BIOL, V14, P8408, DOI 10.1128/MCB.14.12.8408; LOEB KR, 1993, FUNCTIONAL CHARACTER; MITCHELL MJ, 1991, NATURE, V354, P483, DOI 10.1038/354483a0; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PICKART CM, 1985, J BIOL CHEM, V260, P7903; PICKART CM, 1988, UBIQUITIN, P77; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; SEN GC, 1992, J BIOL CHEM, V267, P5017; TUCKER PK, 1992, MAMM GENOME, V3, P28, DOI 10.1007/BF00355838; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235	31	121	130	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					324	330		10.1074/jbc.271.1.324	http://dx.doi.org/10.1074/jbc.271.1.324			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550581	hybrid			2022-12-25	WOS:A1996TP36100050
J	Kim, J; Fuller, JH; Kuusk, V; Cunane, L; Chen, ZW; Mathews, FS; McIntire, WS				Kim, J; Fuller, JH; Kuusk, V; Cunane, L; Chen, ZW; Mathews, FS; McIntire, WS			The cytochrome subunit is necessary for covalent FAD attachment to the flavoprotein subunit of p-cresol methylhydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIMETHYLAMINE DEHYDROGENASE; 6-HYDROXY-D-NICOTINE OXIDASE; 3-DIMENSIONAL STRUCTURE; PSEUDOMONAS-PUTIDA; BOUND FLAVIN; COFACTOR; CARBOXYLASE; SYNTHETASE; RESOLUTION; SEQUENCE	When p-cresol methylhydroxylase (PCMH) is expressed in its natural host Pseudomonas putida, or when the genes of the alpha and beta subunits of the enzyme are expressed together in the heterologous host Escherichia coli, flavin-adenine dinucleotide (FAD) is covalently attached to Tyr(384) of the alpha subunit and the correct alpha(2) beta(2) form of the enzyme is assembled. The apoflavoprotein has been expressed in E. coli in the absence of the beta cytochrome c subunit and purified, While noncovalent FAD binding to apoflavoprotein in the absence of the cytochrome subunit could not be directly demonstrated, circumstantial evidence suggests that this indeed occurs. Covalent flavinylation requires one molecule each of FAD and cytochrome for each flavoprotein subunit. The flavinylation process leads to the 2-electron-reduced form of covalently bound FAD, and the resulting alpha(2) beta(2) enzyme is identical to wild-type PCMH. This work presents clear evidence that covalent flavinylation occurs by a self-catalytic mechanism; an external enzyme or chaperon is not required, nor is prior chemical activation of FAD or of the protein, This work is the first to define the basic chemistry of covalent flavinylation of an enzyme to produce the normal, active species, and confirms a long standing, postulated chemical mechanism of this process, It also demonstrates, for the first time, the absolute requirement for a partner subunit in the post-translational modification of a protein, It is proposed that the covalent FAD bond to Tyr(384) and the phenolic portion of this Tyr are part of the essential electron transfer path from FAD to heme.	DEPT VET AFFAIRS MED CTR,DIV MOLEC BIOL 151S,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Washington University (WUSTL)					NHLBI NIH HHS [HL-16251] Funding Source: Medline; NIGMS NIH HHS [GM20530] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; [Anonymous], [No title captured]; BARBER MJ, 1987, BIOCHEM J, V242, P89, DOI 10.1042/bj2420089; BASSINDALE A, 1984, 3RD DIMENSION ORGANI, P159; BHATTACHARYYA A, 1985, BIOCHEM J, V228, P337, DOI 10.1042/bj2280337; BRADFORD AP, 1987, FEBS LETT, V222, P211, DOI 10.1016/0014-5793(87)80221-1; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; BRANDSCH R, 1991, J BIOL CHEM, V266, P19056; BRANDSCH R, 1993, J BIOL CHEM, V268, P12724; BRANDSCH R, 1989, EUR J BIOCHEM, V182, P125, DOI 10.1111/j.1432-1033.1989.tb14808.x; CHEN ZW, 1994, SCIENCE, V266, P430, DOI 10.1126/science.7939681; CHUMSKY LJ, 1993, BIOCHEMISTRY-US, V32, P11132; DECKER K, 1991, BIOFACTORS, V3, P69; DECKER KF, 1993, ANNU REV NUTR, V13, P17, DOI 10.1146/annurev.nu.13.070193.000313; EDMONDSON DE, 1992, CHEM BIOCH FLAVOENZY, V1, P73; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FROST JW, 1980, J AM CHEM SOC, V102, P7157, DOI 10.1021/ja00543a069; GABRIEL O, 1971, METHOD ENZYMOL, V40, P578; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HEGEMAN GD, 1966, J BACTERIOL, V91, P1140, DOI 10.1128/JB.91.3.1140-1154.1966; HOPPER DJ, 1985, FEBS LETT, V182, P485, DOI 10.1016/0014-5793(85)80359-8; KENNEY WC, 1974, EUR J BIOCHEM, V48, P449, DOI 10.1111/j.1432-1033.1974.tb03785.x; KIM JH, 1994, J BACTERIOL, V176, P6349, DOI 10.1128/jb.176.20.6349-6361.1994; KOERBER SC, 1985, BIOCHEM J, V231, P383, DOI 10.1042/bj2310383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM LW, 1986, J BIOL CHEM, V261, P5140; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHEWS FS, 1991, BIOCHEMISTRY-US, V30, P238, DOI 10.1021/bi00215a034; MCINTIRE W, 1981, BIOCHEMISTRY-US, V20, P3068, DOI 10.1021/bi00514a013; MCINTIRE WS, 1987, BIOCHEMISTRY-US, V26, P4107, DOI 10.1021/bi00387a055; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; REGAN JJ, 1994, GREENPATH SOFTWARE V; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2812; SWEETMAN L, 1985, ANN NY ACAD SCI, V447, P288, DOI 10.1111/j.1749-6632.1985.tb18446.x; TAKAI T, 1987, FEBS LETT, V212, P98, DOI 10.1016/0014-5793(87)81564-8; TANIUCHI H, 1983, J BIOL CHEM, V258, P963; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHAARLEM LJM, 1987, BIOCHEM J, V245, P251, DOI 10.1042/bj2450251; WALSH C, 1980, ACCOUNTS CHEM RES, V13, P148, DOI 10.1021/ar50149a004; WALSH C, 1982, FLAVINS FLAVOPROTEIN, P121; WUTTKE DS, 1992, SCIENCE, V256, P1007, DOI 10.1126/science.256.5059.1007	42	69	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31202	31209		10.1074/jbc.270.52.31202	http://dx.doi.org/10.1074/jbc.270.52.31202			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537385	hybrid			2022-12-25	WOS:A1995TN44400053
J	Mariniello, L; Qin, Q; Jessen, BA; Rice, RH				Mariniello, L; Qin, Q; Jessen, BA; Rice, RH			Keratinocyte transglutaminase promoter analysis - Identification of a functional response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; RETINOIC ACID; INTRINSIC DIFFERENCES; SQUAMOUS CARCINOMA; EPITHELIAL-CELLS; GENE; DIFFERENTIATION; PROTEINS; EXPRESSION; CULTURE	Keratinocyte transglutaminase catalyzes isopeptide bond formation to yield the highly insoluble crosslinked envelope during terminal differentiation of epidermal cells, Transcriptional response elements were identified in the 5'-flanking DNA of the gene for this enzyme by a combination of transient transfection and electrophoretic mobility shift analyses, Since human keratinocytes transcribed ineffectively transfected transglutaminase flanking DNA, a key feature of these experiments was the use of rat bladder epithelial cells as recipients, Serial deletion experiments identified by transient transfection an important response region containing three putative AP2-like response elements approximately 0.5 kilobases from the transcription initiation site, Oligonucleotides, each containing a single one of the elements, formed specific complexes with keratinocyte nuclear proteins, Two of the response elements were found to be functional by transfection in site-specific deletion experiments, Of these one formed specific DNA-protein complexes with nuclear proteins only from cells exhibiting keratinocyte differentiation. UV cross-linking experiments estimated the protein component of the complex to be approximate to 85 kDa, This response element alone increased substantially the transcription of a minimal transglutaminase promoter in transient transfections. Further characterization of the putative transcription factor binding to this response element may provide insight into the regulation of keratinocyte transglutaminase.	UNIV CALIF DAVIS,DEPT ENVIRONM TOXICOL,DAVIS,CA 95616	University of California System; University of California Davis			qin, qin x/GXG-6164-2022; Rice, Robert/AAP-7813-2021; Mariniello, Loredana/K-6264-2013	Mariniello, Loredana/0000-0002-6800-5890	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004699] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR27130] Funding Source: Medline; NIEHS NIH HHS [ES05707, P42 ES04699] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUETTNER R, 1994, VERH DEUT G, V78, P38; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CHODOSH LA, 1993, CURRENT PROTOCOLS MO; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; HEIMANN R, 1983, J CELL PHYSIOL, V117, P362, DOI 10.1002/jcp.1041170311; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; JIANG CK, 1991, J INVEST DERMATOL, V97, P969, DOI 10.1111/1523-1747.ep12491889; KACHINSKAS DJ, 1994, CELL GROWTH DIFFER, V5, P1235; KIM IG, 1992, J BIOL CHEM, V267, P7710; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEASK A, 1990, GENE DEV, V4, P1985, DOI 10.1101/gad.4.11.1985; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; Maniatis T., 1982, MOL CLONING; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; PHILLIPS MA, 1983, J CELL BIOL, V97, P686, DOI 10.1083/jcb.97.3.686; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; REICHERT U, 1992, MOL BIOL SKIN, V1, P107; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Rice R.H., 1994, KERATINOCYTE HDB, P259; RICE RH, 1993, MOL BIOL CELL, V4, P185, DOI 10.1091/mbc.4.2.185; RICE RH, 1988, CARCINOGENESIS, V9, P1885, DOI 10.1093/carcin/9.10.1885; ROSENTHAL DS, 1992, J INVEST DERMATOL, V98, P343, DOI 10.1111/1523-1747.ep12499802; RUBIN AL, 1989, J CELL PHYSIOL, V138, P208, DOI 10.1002/jcp.1041380128; RUBIN AL, 1986, CANCER RES, V46, P2356; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SAUNDERS NA, 1993, MOL ENDOCRINOL, V7, P387, DOI 10.1210/me.7.3.387; TAMAI K, 1994, J BIOL CHEM, V269, P493; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YU LJ, 1993, J BIOL CHEM, V268, P7520	41	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31358	31363		10.1074/jbc.270.52.31358	http://dx.doi.org/10.1074/jbc.270.52.31358			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537408	hybrid			2022-12-25	WOS:A1995TN44400075
J	Namiki, A; Brogi, E; Kearney, M; Kim, EA; Wu, TG; Couffinhal, T; Varticovski, L; Isner, JM				Namiki, A; Brogi, E; Kearney, M; Kim, EA; Wu, TG; Couffinhal, T; Varticovski, L; Isner, JM			Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTING PHORBOL ESTERS; PERMEABILITY FACTOR; ERYTHROPOIETIN GENE; PROTEIN-SYNTHESIS; TYROSINE KINASE; EXPRESSION; TUMOR; ANGIOGENESIS; MITOGEN; IDENTIFICATION	Smooth muscle cells, macrophages, glial cells, keratinocytes, and transformed cells have been established as synthesis sites for vascular endothelial growth factor (VEGF). The modulating effects of VEGF are essentially limited to endothelial cells (ECs), the only cell type consistently shown to express VEGF receptors. VEGF has thus been considered to act exclusively via a paracrine pathway. We sought to determine whether the role of human ECs might, under selected conditions, extend beyond that of a target to involve contingency synthesis of VEGF. In both unstimulated human umbilical vein ECs (HUVECs) and human derma-derived microvascular ECs (HUVECs), Northern analysis detected no VEGF transcripts. Phorbol-12-myristate 13 acetate (10(-7) M) treatment, however, induced VEGF mRNA expression in both HUVECs and HMECs, peaking at 3 and 6 h, respectively, and returning to undetectable levels by 12 h. In vitro exposure of HUVECs to a hypoxic environment (pO(2) = 35 mm of mercury) for 12, 24, and 48 h and exposure of HMECs for 6, 12, 24, and 48 h induced VEGF mRNA in a time-dependent fashion. Re-exposure to normoxia (pO(2) = 150 mm of mercury) for 24 h after 24 h of hypoxia returned VEGF mRNA transcripts to undetectable levels in HUVECs. Cobalt chloride and nickel chloride treatment each induced VEGF mRNA in ECs. Cyclo-heximide treatment further augmented expression of VEGF mRNA induced by cobalt chloride, nickel chlo ride, and hypoxia in HUVECs. VEGF protein production in hypoxic HUVECs was demonstrated immunohistochemically. Conditioned media from hypoxic HUVECs caused a 2-fold increase in the incorporation of tritiated thymidine. Finally, immune precipitates of anti-KDR probed with anti-Tyr(P) antibodies demonstrated evidence of receptor autophosphorylation in hypoxic but not normoxic HUVECs. These findings thus establish the potential for an autocrine pathway that may augment and/or amplify the paracrine effects of VEGF in stimulating angiogenesis.	TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, DEPT MED CARDIOL, BOSTON, MA 02135 USA; TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, DEPT HEMATOL, BOSTON, MA 02135 USA; TUFTS UNIV, ST ELIZABETHS MED CTR, SCH MED, DEPT BIOMED RES, BOSTON, MA 02135 USA	St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University; St. Elizabeth's Medical Center; Tufts University			Couffinhal, Thierry/M-6857-2014	Couffinhal, Thierry/0000-0002-9217-2533; Varticovski, Lyuba/0000-0002-5105-9008	NATIONAL CANCER INSTITUTE [R29CA053094, R01CA053094] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040518] Funding Source: NIH RePORTER; NCI NIH HHS [NCA CA53094] Funding Source: Medline; NHLBI NIH HHS [HL-02824, HL-40518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BANAI S, 1994, CIRCULATION, V89, P2183, DOI 10.1161/01.CIR.89.5.2183; BAUTERS C, 1995, J VASC SURG, V21, P314, DOI 10.1016/S0741-5214(95)70272-5; BAUTERS C, 1994, AM J PHYSIOL-HEART C, V267, pH1263, DOI 10.1152/ajpheart.1994.267.4.H1263; BENSAID M, 1989, EXP EYE RES, V48, P801, DOI 10.1016/0014-4835(89)90065-1; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1993, AM J PATHOL, V143, P1255; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; BROWN LF, 1993, CANCER RES, V53, P4727; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1991, METHOD ENZYMOL, V198, P391; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FUKS Z, 1994, CANCER RES, V54, P2582; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; IIZUKA M, 1994, BIOCHEM BIOPH RES CO, V205, P1474, DOI 10.1006/bbrc.1994.2831; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KOUREMBANAS S, 1991, J CLIN INVEST, V88, P1054, DOI 10.1172/JCI115367; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V194, P799, DOI 10.1006/bbrc.1993.1892; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P1333; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MINCHENKO A, 1994, LAB INVEST, V71, P374; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MYOKEN Y, 1994, IN VITRO CELL DEV-AN, V30A, P790; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PICKERING JG, 1992, J AM COLL CARDIOL, V20, P1430, DOI 10.1016/0735-1097(92)90259-P; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHIFREN JL, 1994, J CLIN ENDOCR METAB, V79, P316, DOI 10.1210/jc.79.1.316; SHIMA DT, 1995, MOL MED, V1, P64; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIMORREPINATEL V, 1994, INVEST OPHTH VIS SCI, V35, P3393; SPORN MB, 1992, ANN INTERN MED, V117, P408, DOI 10.7326/0003-4819-117-5-408; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; UCHIDA K, 1994, AM J PHYSIOL, V266, pF81, DOI 10.1152/ajprenal.1994.266.1.F81; VILLASCHI S, 1993, AM J PATHOL, V143, P181; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4	66	406	426	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31189	31195		10.1074/jbc.270.52.31189	http://dx.doi.org/10.1074/jbc.270.52.31189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537383	hybrid			2022-12-25	WOS:A1995TN44400051
J	Toshima, J; Ohashi, K; Okano, I; Nunoue, K; Kishioka, M; Kuma, K; Miyata, T; Hirai, M; Baba, T; Mizuno, K				Toshima, J; Ohashi, K; Okano, I; Nunoue, K; Kishioka, M; Kuma, K; Miyata, T; Hirai, M; Baba, T; Mizuno, K			Identification and characterization of a novel protein kinase, TESK1, specifically expressed in testicular germ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERMATOGENIC CELLS; CONSERVED FEATURES; MESSENGER-RNA; TESTIS; MOUSE; ACID; SEQUENCES; FAMILY; MAK	We have isolated cDNA clones encoding the rat and human forms of a novel protein kinase, termed TESK1 (testis-specific protein kinase 1), Sequence analysis indicates that rat TESK1 contains 628 amino acid residues, composed of an N-terminal protein kinase consensus sequence followed by a C-terminal proline-rich region, Human TESK1 contains 626 amino acids, sharing 92% amino acid identity with its rat counterpart, The protein kinase domain of TESK1 is structurally similar to those of LIMK (LIM motif-containing protein kinase)-1 and LIMK2, with 49-50% sequence identity, Phylogenetic analysis of the protein kinase domains revealed that TESK1 is most closely related to a LIMK subfamily, Chromosomal localization of human TESK1 gene was assigned to 9q13, Anti-TESK1 antibody raised against the C-terminal peptide of TESK1 recognized two polypeptides of 68 and 80 kDa in cell lysates of COS cells transfected with human TESK1 cDNA expression plasmid, TESK1 protein expressed in COS cells exhibited serine/threonine kinase activity, when myelin basic protein was used as a substrate, Northern blot analysis revealed that TESK1 mRNA was specifically expressed in rat and mouse testicular germ cells, The TESK1 mRNA in the testis was detectable only after the 18th day of postnatal development of mice and was mainly expressed in the round spermatids. These observations suggest that TESK1 has a specific function in spermatogenesis.	KYUSHU UNIV, FAC SCI, DEPT BIOL, FUKUOKA 812, JAPAN; KYOTO UNIV, FAC SCI, DEPT BIOPHYS, KYOTO 60601, JAPAN; UNIV TOKYO, GRAD SCH SCI, DEPT BIOL SCI, TOKYO 113, JAPAN; UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN; RES DEV CORP JAPAN, PRESTO, INHERITANC & VARIAT GRP, KYOTO 61902, JAPAN	Kyushu University; Kyoto University; University of Tokyo; University of Tsukuba; Japan Science & Technology Agency (JST)			Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X				BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BELLVE AR, 1977, J HISTOCHEM CYTOCHEM, V25, P480, DOI 10.1177/25.7.893996; BIELKE W, 1994, GENE, V139, P235, DOI 10.1016/0378-1119(94)90762-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ITO A, 1990, BIOCHEM INT, V22, P235; JINNO A, 1993, MOL CELL BIOL, V13, P4146, DOI 10.1128/MCB.13.7.4146; KASHIWABARA S, 1990, BIOCHEM BIOPH RES CO, V173, P240, DOI 10.1016/S0006-291X(05)81047-2; KATOH M, 1995, ONCOGENE, V10, P1447; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MEIJER D, 1987, EMBO J, V6, P4041, DOI 10.1002/j.1460-2075.1987.tb02749.x; MIZUNO K, 1994, ONCOGENE, V9, P1605; OHASHI K, 1994, J BIOCHEM, V116, P636, DOI 10.1093/oxfordjournals.jbchem.a124573; OHASHI K, 1994, ONCOGENE, V9, P699; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERN L, 1983, BIOL REPROD, V28, P483, DOI 10.1095/biolreprod28.2.483; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; WALDEN PD, 1993, MOL CELL BIOL, V13, P7625, DOI 10.1128/MCB.13.12.7625; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	38	63	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31331	31337		10.1074/jbc.270.52.31331	http://dx.doi.org/10.1074/jbc.270.52.31331			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537404	hybrid			2022-12-25	WOS:A1995TN44400071
J	Stanners, J; Kabouridis, PS; McGuire, KL; Tsoukas, CD				Stanners, J; Kabouridis, PS; McGuire, KL; Tsoukas, CD			Interaction between G proteins and tyrosine kinases upon T cell receptor CD3-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; EPIDERMAL GROWTH-FACTOR; SWISS 3T3 CELLS; ANTIGEN RECEPTOR; PHOSPHOLIPASE-C; CHOLERA-TOXIN; MEDIATED ACTIVATION; BETA-1 ISOZYME; ALPHA-SUBUNITS; ZETA-CHAIN	Engagement of the T cell receptor (TCR)-CD3 complex results in the induction of multiple intracellular events, with protein tyrosine kinases playing a pivotal role in their initiation. Biochemical studies also exist suggesting the involvement of heterotrimeric GTP-binding proteins (G proteins); however, the functional consequence of this participation in TCR-CD3-mediated signaling is unresolved. Here, we report TCR-CD3-mediated guanine nucleotide exchange among the 42-kDa G protein alpha subunits of the G alpha q/11 family, their physical association with CD3 epsilon, and the G alpha 11-dependent activation of phospholipase C beta. Protein tyrosine kinase inhibitors, however, abrogate TCR-CD3-mediated G protein activation. Quite interesting is the observation that cells transfected with a function-deficient mutant of G alpha 11 display diminished tyrosine phosphorylation of TCR-CD3 zeta and epsilon chains, as well as ZAP-70, upon anti-CD3 antibody triggering. These data indicate the involvement of the G alpha q/11 family in TCR-CD3 signaling at a step proximal to the receptor and suggest a reciprocal regulation between tyrosine kinases and G proteins in T cells.	SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	California State University System; San Diego State University; California State University System; San Diego State University; Scripps Research Institute					NATIONAL CANCER INSTITUTE [R29CA053382] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039518] Funding Source: NIH RePORTER; NCI NIH HHS [CA53382] Funding Source: Medline; NCRR NIH HHS [RR00833] Funding Source: Medline; NIGMS NIH HHS [GM39518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDROPOULOS K, 1991, J BIOL CHEM, V266, P15583; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ANDERSON DL, 1989, J IMMUNOL, V143, P3647; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLANK JL, 1991, J BIOL CHEM, V266, P18206; CENCIARELLI C, 1992, J BIOL CHEM, V267, P14527; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GRAVES JD, 1991, J IMMUNOL, V146, P2102; HARNETT M, 1992, IMMUNOL TODAY, V13, P482, DOI 10.1016/0167-5699(92)90022-Y; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HSI ED, 1989, J BIOL CHEM, V264, P10836; IMBODEN JB, 1986, P NATL ACAD SCI USA, V83, P5673, DOI 10.1073/pnas.83.15.5673; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KABOURIDIS PS, 1995, MOL CELL BIOCHEM, V144, P45, DOI 10.1007/BF00926739; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE E, 1992, J BIOL CHEM, V267, P1212; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MADRENAS J, 1995, NATURE, V267, P515; MEUER SC, 1984, ANNU REV IMMUNOL, V2, P23, DOI 10.1146/annurev.immunol.2.1.23; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OFFERMANNS S, 1991, J BIOL CHEM, V266, P3365; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; OKAMOTO T, 1991, P NATL ACAD SCI USA, V88, P8020, DOI 10.1073/pnas.88.18.8020; OSHEA JJ, 1987, J IMMUNOL, V139, P3463; PRPIC V, 1984, J BIOL CHEM, V259, P1382; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SOMMERMEYER H, 1990, EUR J IMMUNOL, V20, P1881, DOI 10.1002/eji.1830200902; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; TSOUKAS CD, 1985, J IMMUNOL, V135, P1719; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; YANG LJ, 1991, J BIOL CHEM, V266, P22451; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZUMGBIHL R, 1995, J IMMUNOL, V155, P181	51	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30635	30642		10.1074/jbc.270.51.30635	http://dx.doi.org/10.1074/jbc.270.51.30635			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530500	hybrid			2022-12-25	WOS:A1995TL67500065
J	Allemand, I; Grimber, G; Kornprobst, M; Bennoun, M; Molina, T; Briand, P; Joulin, V				Allemand, I; Grimber, G; Kornprobst, M; Bennoun, M; Molina, T; Briand, P; Joulin, V			Compensatory apoptosis in response to SV40 large T antigen expression in the liver	ONCOGENE			English	Article						transgenic mice; SV40 T antigen; hepatocarcinogenesis; apoptosis	TRANSGENIC MICE; CELL-DEATH; RAT-LIVER; P53 GENE; DNA; PROTEIN; GROWTH; TUMORIGENESIS; FRAGMENTATION; DISEASE	Transgenesis allows the in vivo determination of the effects of oncogene expression in normal tissues, In an attempt to understand the mechanism underlying liver transformation, we had previously created transgenic mice carrying the SV40 early gene sequences, which developed hepatocarcinoma in a reproducible way, In the present study, we show that constant expression of the transgene was directly correlated to an abnormally increased hepatocyte proliferation, even at the adult stage, We further demonstrate in this model that the preneoplastic stage of hepatocarcinoma is characterized by marked ploidy alterations as early as 1 month, including the emergence of aneuploid and hyperpolyploid cells, and the persistence of an important diploid cell population, We show that this elevated proliferation is early and transiently counterbalanced by a mechanism of apoptosis, which maintains liver homeostasis. The disappearance of this programmed cell death response effective during preneoplasia might signal the commitment of the liver to neoplasia.	INST COCHIN GENET MOLEC, INSERM U380, F-75014 PARIS, FRANCE; UNIV PARIS 06, FAC MED ST ANTOINE, INSERM U402, F-75571 PARIS 12, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite			Molina, Thierry/ABA-5214-2020	Molina, Thierry/0000-0002-3929-9754; allemand, isabelle/0000-0002-8861-7632; JOULIN, Virginie/0000-0003-1091-7819				BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; BURSCH W, 1984, CARCINOGENESIS, V5, P453, DOI 10.1093/carcin/5.4.453; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; CHEN JD, 1992, ONCOGENE, V7, P1167; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLUMBANO A, 1985, LAB INVEST, V52, P670; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FAUSTO N, 1989, LAB INVEST, V60, P4; Fausto Nelson, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P117; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HIRAMATSU N, 1994, HEPATOLOGY, V19, P1354, DOI 10.1002/hep.1840190606; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; LEDDACOLUMBANO GM, 1991, AM J PATHOL, V139, P1099; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAGAUD JP, 1989, J HISTOCHEM CYTOCHEM, V37, P1517, DOI 10.1177/37.10.2476478; MITA E, 1994, BIOCHEM BIOPH RES CO, V204, P468, DOI 10.1006/bbrc.1994.2483; MOORE M, 1992, J VIROL, V66, P641, DOI 10.1128/JVI.66.2.641-649.1992; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOSSIN L, 1994, EXP CELL RES, V214, P551, DOI 10.1006/excr.1994.1293; NEVINS JR, 1992, SCIENCE, V258, P424; OBERHAMMER F, 1993, J CELL SCI, V104, P317; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; ROUQUET N, 1995, ONCOGENE, V11, P1061; SANDGREN EP, 1989, ONCOGENE, V4, P715; SCHULTEHERMANN R, 1990, CANCER RES, V50, P5127; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; WEBBER EM, 1994, AM J PATHOL, V145, P398; WESSEL R, 1992, VIROLOGY, V189, P293, DOI 10.1016/0042-6822(92)90705-T; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	50	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2583	2590						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545115				2022-12-25	WOS:A1995TP18800014
J	Bannister, AJ; Oehler, T; Wilhelm, D; Angel, P; Kouzarides, T				Bannister, AJ; Oehler, T; Wilhelm, D; Angel, P; Kouzarides, T			Stimulation of c-Jun activity by CBP: c-Jun residues Ser63/73 are required for CBP induced stimulation in vivo and CBP binding in vitro	ONCOGENE			English	Article						c-Jun; c-Fos; AP-1; CBP; transcription; activation	DNA-BINDING; ACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; PROTO-ONCOGENE; LEUCINE ZIPPER; V-JUN; FOS; PHOSPHORYLATION; INVITRO; KINASE	The CBP protein mediates PKA induced transcription by binding to the PKA phosphorylated activation domain of CREB. Here we show that CBP also stimulates the activity of both c-Jun and v-Jun in vivo. The CREB binding domain of CBP is sufficient to contact to c-Jun in vitro. When this domain of CBP is linked to the activation domain of VP16 and expressed in vivo it stimulates c-Jun dependent transcription. Deletion analysis of c-Jun indicate that the CBP binding site is within the N-terminal activation domain. Loss of binding to CBP in vitro correlates with severely reduced transactivation capacity in vivo. Mutation of Ser63/73 in c-Jun, or the corresponding position in v-Jun (Ser36/46) leads to reduced binding to CBP in vitro and abolishes augmentation of transcription in vivo. These data are consistent with a mechanism by which CBP acts as a co-activator protein for Jun dependent transcription by interacting with the Jun IV-terminal activation domain.	UNIV CAMBRIDGE, WELLCOME CRC INST, CAMBRIDGE CB2 1QR, ENGLAND; UNIV CAMBRIDGE, DEPT PATHOL, CAMBRIDGE CB2 1QR, ENGLAND; FORSCHUNGSZENTRUM KARLSRUHE, INST GENET, D-76021 KARLSRUHE, GERMANY	University of Cambridge; University of Cambridge; Helmholtz Association; Karlsruhe Institute of Technology			Wilhelm, Dagmar/B-6915-2009; Piris, Miguel A/AAP-1445-2020	Wilhelm, Dagmar/0000-0002-7757-4075; Piris, Miguel A/0000-0001-5839-3634; Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANNWEILER A, 1991, NUCLEIC ACIDS RES, V19, P3750, DOI 10.1093/nar/19.13.3750; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BANNISTER AJ, 1994, NUCLEIC ACIDS RES, V22, P5173, DOI 10.1093/nar/22.24.5173; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BLACK EJ, 1994, ONCOGENE, V9, P2363; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAI TN, 1995, ONCOGENE, V10, P849; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OEHLER T, 1993, ONCOGENE, V8, P1141; OEHLER T, 1992, MOL CELL BIOL, V12, P5508, DOI 10.1128/MCB.12.12.5508; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810	36	298	300	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2509	2514						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545107				2022-12-25	WOS:A1995TP18800006
J	Esteve, P; delPeso, L; Lacal, JC				Esteve, P; delPeso, L; Lacal, JC			Induction of apoptosis by rho in NIH 3T3 cells requires two complementary signals. Ceramides function as a progression factor for apoptosis	ONCOGENE			English	Article						rho; apoptosis; ceramides	GTP-BINDING PROTEIN; ADP-RIBOSYLTRANSFERASE; GROWTH-FACTORS; GENE-PRODUCT; VERO CELLS; DEATH; PROLIFERATION; FIBROBLASTS; INVOLVEMENT; EXPRESSION	We have previously reported that Pho genes, members of the ras superfamily, are tumorigenic when overexpressed in NIH 3T3 cells. As other known oncogenes, they also induce apoptosis after serum deprivation but not in the presence of growth factors. In the present study, we provide evidence that overexpression of the Aplysia Rho protein in NIH 3T3 cells induces the generation of phosphatidylcholine (PC)-derived second messengers as a result of activation of a PC-specific phospholipase D (PC-PLD) as previously reported for ras-transformed cells. In contrast, removal of serum in the Rho transfectants, but not in normal NTH 3T3 cells or cells transformed by the was oncogene, induced the production of ceramides as a result of activation of an sphingomyelinase (SMase). Furthermore, the rho-expressing cells underwent apoptosis in the presence of serum when exogenous ceramides were added, and this process was accelerated if cells were treated with exogenous SMase. Thus, Rho proteins act as an initiation signal that is necessary but not sufficient for the induction of apoptosis in NIH 3T3 cells. We propose here that induction of apoptosis in NM 3T3 cells requires two complementary signals: an initiation signal generated even in the presence of serum which 'primes' the cells, making them sensitive to a progression signal, triggered by serum removal, which we have identified as generation of ceramides.	CSIC, INST INVEST BIOMED, MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			del Peso, Luis/K-9391-2014; Lacal, Juan Carlos/AAL-2235-2020; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; Lacal, Juan Carlos/0000-0002-1908-2777				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ARENDS MJ, 1994, MOL BIOL HISTOPATHOL, P151; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BALLESTERO RP, 1991, SUPERFAMILY RAS RELA, P237; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; CARNERO A, 1994, ONCOGENE, V9, P1387; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; JIMENEZ B, 1995, ONCOGENE, V10, P811; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK R, 1994, MOL CHEM NEUROPATHOL, V21, P287, DOI 10.1007/BF02815356; LACAL JC, 1994, ONCOL REP, V1, P677; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LANG P, 1992, J BIOL CHEM, V267, P11677; LINETTE GP, 1994, CURR OPIN CELL BIOL, V6, P809, DOI 10.1016/0955-0674(94)90049-3; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MORII N, 1992, J BIOL CHEM, V267, P20921; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PERONA R, 1993, ONCOGENE, V8, P1285; RIBEIRO JM, 1993, BIOCHEMISTRY-US, V32, P9129, DOI 10.1021/bi00086a018; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SELF AJ, 1993, ONCOGENE, V8, P655; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SUGAI M, 1992, P NATL ACAD SCI USA, V89, P8903, DOI 10.1073/pnas.89.19.8903; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8	58	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2657	2665						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545123				2022-12-25	WOS:A1995TP18800022
J	ABRAMSON, JJ; ZABLE, AC; FAVERO, TG; SALAMA, G				ABRAMSON, JJ; ZABLE, AC; FAVERO, TG; SALAMA, G			THIMEROSAL INTERACTS WITH THE CA2+ RELEASE CHANNEL RYANODINE RECEPTOR FROM SKELETAL-MUSCLE SARCOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CALCIUM RELEASE; OSCILLATIONS; HEPATOCYTES; STORES; EGGS	The thiol-oxidizing reagent, thimerosal, has been shown to increase the intracellular Ca2+ concentration, to induce Ca2+ spikes in several cell types, and to increase the sensitivity of intracellular Ca2+ stores to inositol 1,4,5-trisphosphate. Ryanodine-sensitive stores have also been implicated in the generation of Ca2+ oscillations induced by the addition of thimerosal, Here we report that micromolar concentrations of thimerosal stimulate Ca2+ release from skeletal muscle sarcoplasmic reticulum vesicles, inhibit high affinity [H-3]ryanodine binding, and modify the channel activity of the reconstituted Ca2+ release protein. Thimerosal inhibits ryanodine binding by decreasing the binding capacity (B-max) but does not affect the binding affinity or the dissociation rate of bound ryanodine. Single channel reconstitution experiments show that thimerosal (100-200 mu M) stimulates single channel activity without modifying channel conductance. The thimerosal-stimulated channel is not inhibited by heparin. Furthermore, a Ca2+-stimulated channel is first activated and then inhibited in a time dependent fashion by high concentrations of thimerosal (1 mM). Once inactivated, the channel cannot be reactivated by addition of either Ca2+ or ATP.	UNIV PORTLAND,DEPT BIOL,PORTLAND,OR 97203; UNIV PITTSBURGH,DEPT PHYSIOL,PITTSBURGH,PA 15261	University of Portland; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	ABRAMSON, JJ (corresponding author), PORTLAND STATE UNIV,DEPT PHYS,POB 751,PORTLAND,OR 97207, USA.							ABRAMSON JJ, 1988, J BIOL CHEM, V263, P18750; ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BUCK E, 1992, J BIOL CHEM, V267, P23560; HILLY M, 1993, J BIOL CHEM, V268, P16488; KALCKAR HM, 1947, J BIOL CHEM, V196, P461; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; LIU GH, 1994, J BIOL CHEM, V269, P33028; LIU GH, 1994, MOL PHARMACOL, V45, P189; MACLENNA.DH, 1970, J BIOL CHEM, V245, P4508; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; RENARDROONEY DC, 1995, BIOCHEM J, V310, P185, DOI 10.1042/bj3100185; SAYERS LG, 1993, BIOCHEM J, V289, P883, DOI 10.1042/bj2890883; SWANN K, 1992, BIOCHEM J, V287, P79, DOI 10.1042/bj2870079; TANAKA Y, 1994, J BIOL CHEM, V269, P11247; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725	22	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29644	29647						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530347				2022-12-25	WOS:A1995TK38000007
J	DEVERAUX, Q; VANNOCKER, S; MAHAFFEY, D; VIERSTRA, R; RECHSTEINER, M				DEVERAUX, Q; VANNOCKER, S; MAHAFFEY, D; VIERSTRA, R; RECHSTEINER, M			INHIBITION OF UBIQUITIN-MEDIATED PROTEOLYSIS BY THE ARABIDOPSIS 26-S PROTEASE SUBUNIT S5A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RABBIT RETICULOCYTE LYSATE; DEPENDENT PROTEOLYSIS; ANTIGEN PRESENTATION; ACTIVATING ENZYME; CYCLIN SYNTHESIS; HIGHER-PLANT; CELL CYCLE; DEGRADATION; PATHWAY; YEAST	A variety of protease inhibitors have been used to study ubiquitin-dependent proteolysis by the 26 S protease. However, these inhibitors lack complete specificity and thus affect ubiquitin-independent pathways as well, We recently identified an Arabidopsis protein, MBP1, that is homologous to subunit 5a (S5a) of the human 26 S protease complex, MBP1 and S5a bind multiubiquitin chains with high affinity and presumably facilitate the recognition of ubiquitin conjugates by the 26 S protease, We show here that free MBP1 can be a potent inhibitor of ubiquitin-dependent proteolysis in several cell-free systems, When added to reticulocyte lysates or to Xenopus egg extracts, the plant protein effectively blocked the degradation of multiubiquitinated lysozyme and cyclin B, respectively. MBP1 did not enhance the removal of ubiquitin from lysozyme or affect the ability of the 26 S complex to hydrolyze fluorogenic peptides, These data suggest that the plant protein specifically interferes with the recognition of ubiquitin conjugates by the 26 S protease, Thus MBP1, human S5a, and their homologs should prove to be valuable reagents for investigating cellular events mediated by ubiquitin-dependent proteolysis.	UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132; UNIV WISCONSIN,DEPT HORT,MADISON,WI 53706	Utah System of Higher Education; University of Utah; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM37009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHMAIR A, 1990, EMBO J, V9, P4543, DOI 10.1002/j.1460-2075.1990.tb07906.x; CARLSON N, 1987, J CELL BIOL, V104, P537, DOI 10.1083/jcb.104.3.537; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COX JH, 1995, J IMMUNOL, V154, P511; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; DEVERAUX Q, 1990, J BIOL CHEM, V265, P6323; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUFOUR E, 1995, BIOCHEMISTRY-US, V34, P9136, DOI 10.1021/bi00028a024; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Knop M, 1993, CURR OPIN CELL BIOL, V5, P990, DOI 10.1016/0955-0674(93)90082-2; KORNITZER D, 1994, EMBO J, V24, P6021; MAHAFFEY DT, 1995, FEBS LETT, V370, P109, DOI 10.1016/0014-5793(95)00799-F; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1990, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; TANAKA K, 1992, NEW BIOL, V4, P173; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VIERSTRA RD, 1988, BIOCHEMISTRY-US, V27, P3290, DOI 10.1021/bi00409a025; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YOO Y, 1990, ANAL BIOCHEM, V191, P35, DOI 10.1016/0003-2697(90)90383-K	49	65	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29660	29663						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530351				2022-12-25	WOS:A1995TK38000011
J	GAUDET, F; GINSBURG, GS				GAUDET, F; GINSBURG, GS			TRANSCRIPTIONAL REGULATION OF THE CHOLESTERYL ESTER TRANSFER PROTEIN GENE BY THE ORPHAN NUCLEAR HORMONE-RECEPTOR APOLIPOPROTEIN AI REGULATORY PROTEIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LIPID TRANSFER PROTEIN; I GENE; CONTROL EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; RETINOIC ACID; GROWTH-FACTOR; DNA-BINDING; FACTOR AP-2	We have defined a 105-base pair tissue-restricted promoter for the cholesteryl ester transfer protein (CETP) gene that contains a nuclear hormone receptor response element essential for transcriptional activity, DNaseI protection and electrophoretic mobility shift assays showed specific binding of nuclear extracts from HepG2 (hepatic) and Caco-2 (intestinal) cells (expressing cell types) to 3 sites (designated A (-26 to -57), B (-59 to -87), and C (-93 to -118)) within the 105-base pair minimal promoter element between -138 and -33. Mutagenesis studies indicated that the function of the promoter was dependent upon synergistic interactions between transcription factors bound to these sites. Mutation of site C reduced transcription by 50 and 80%, respectively, in HepGa and Caco-2 cells, and electrophoretic mobility shift assays showed that nuclear hormone receptors, including ARP-1 and its homologue Ear-3/COUP-TF, were occupants of site C in both of these cell types. Overexpression of ARP-1 or Ear-3/COUP-TF with CETP promoter/chloramphenicol acetyltransferase gene reporter plasmids repressed transcriptional activity of the CETP promoter containing sequences up to -300, but activated transcription in the contest of larger constructs containing sequences up to -636. Thus ARP-1 may assume a dichotomous role as both a transcriptional repressor and a transcriptional activator dependent on the promoter context. In addition, the architecture of the CETP gene promoter suggests that its expression is under the control of multiple transcriptional signaling pathways mediated by inducible transcription factors as well as nuclear hormone receptors.	BETH ISRAEL HOSP, DIV CARDIOVASC, BOSTON, MA 02215 USA; CHILDRENS HOSP, DEPT CARDIOL, MOLEC & CELLULAR CARDIOL LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School								ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; AGELLON LB, 1990, BIOCHEMISTRY-US, V29, P1372, DOI 10.1021/bi00458a004; AGELLON LB, 1992, J BIOL CHEM, V267, P22336; AGELLON LB, 1991, J BIOL CHEM, V266, P10796; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAYNA D, 1987, NATURE, V327, P632, DOI 10.1038/327632a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GE RW, 1994, J BIOL CHEM, V269, P13185; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; GLOMSET JA, 1968, J LIPID RES, V9, P155; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; JIANG XC, 1992, J CLIN INVEST, V90, P1290, DOI 10.1172/JCI115993; JIANG XC, 1991, J BIOL CHEM, V266, P4631; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU XP, 1994, MOL ENDOCRINOL, V8, P1774, DOI 10.1210/me.8.12.1774; Maniatis T, 1989, MOL CLONING; MCPHERSON R, 1991, ARTERIOSCLER THROMB, V11, P476, DOI 10.1161/01.ATV.11.3.476; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NAKANISHI T, 1990, METABOLISM, V39, P225, DOI 10.1016/0026-0495(90)90040-J; QUINET E, 1991, J CLIN INVEST, V87, P1559, DOI 10.1172/JCI115169; QUINET EM, 1990, J CLIN INVEST, V85, P357, DOI 10.1172/JCI114446; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SILLIMAN K, 1993, METABOLISM, V42, P1592, DOI 10.1016/0026-0495(93)90156-I; TALL AR, 1986, J LIPID RES, V27, P361; TALL AR, 1993, J LIPID RES, V34, P1255; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670	45	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29916	29922						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530390				2022-12-25	WOS:A1995TK38000050
J	WU, XR; MEDINA, JJ; SUN, TT				WU, XR; MEDINA, JJ; SUN, TT			SELECTIVE INTERACTIONS OF UPIA AND UPIB, 2 MEMBERS OF THE TRANSMEMBRANE-4 SUPERFAMILY, WITH DISTINCT SINGLE TRANSMEMBRANE-DOMAINED PROTEINS IN DIFFERENTIATED UROTHELIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHTHERIA-TOXIN RECEPTOR; TRANSITIONAL EPITHELIAL-CELLS; URINARY-BLADDER; MOLECULAR-CLONING; CD9 ANTIGEN; ANTIPROLIFERATIVE ANTIBODY; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODY; SCHISTOSOMA-MANSONI; MEMBRANE-PROTEIN	The transmembrane 4 (TM4) superfamily contains many important leukocyte differentiation-related surface proteins including CD9, CD37, CD53, and CD81; tumor-associated antigens including CD63/ME491, CO029, and SAS; and a newly identified metastasis suppressor gene R2. Relatively little is known, however, about the structure and aggregation state of these four transmembrane-domained proteins. The asymmetrical unit membrane (AUM), believed to play a major role in stabilizing the apical surface of mammalian urothelium thus preventing it from rupturing during bladder distention, contains two TM4 members, the uroplakins (UPs) Ia and Ib. In association with two other (single transmembrane-domained) membrane proteins, UPII and UPIII, UPIa and UPIb form 16-nm particles that naturally form two-dimensional crystalline arrays, thus providing unique opportunities for studying membrane structure and function. To better understand how these proteins interact to form the 16-nm particles, we analyzed their nearest neighbor relationship by chemical cross-linking. We show here that UPIa and UPIb, which share 39% of their amino acid sequence, are cross-linked to UPII and UPIII, respectively. We also show that UPIa has a propensity to oligomerize, forming complexes that are stable in SDS, and that UPII can be readily crosslinked to form homodimers. The formation of UPII homodimers is sensitive, however, to octyl glucoside that can solubilize the AUMs. These data suggest that there exist two types of 16-nm AUM particles that contain UPIa/UPII or UPIb/UPIII, and support a model in which the UPIa and UPII occupy the inner and outer domains, respectively, of the UPIa/UPII particle. This model can account for the apparent ''redundancy'' of the uroplakins, as the structurally related UPIa and UPlb, by interacting with different partners, may play different roles in AUM formation. The model also suggests that AUM plaques with different uroplakin compositions may differ in their assembly, and in their abilities to interact with an underlying cytoskeleton. Our data indicate that two closely related TM4 proteins, UPIa and UPIb, can be present in the same cell, interacting with distinct partners. AUM thus provides an excellent model system for studying the targeting, processing, and assembly of TM4 proteins.	NYU,SCH MED,KAPLAN CANC CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,RONALD PERELMAN DEPT DERMATOL,EPITHELIAL BIOL UNIT,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,DEPT PHARMACOL,NEW YORK,NY 10016; VET ADM MED CTR,NEW YORK,NY 10016	New York University; New York University; New York University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	WU, XR (corresponding author), NYU,SCH MED,DEPT UROL,KAPLAN CANC CTR,550 1ST AVE,NEW YORK,NY 10016, USA.		Sun, Tung-Tien/J-4425-2015	Sun, Tung-Tien/0000-0002-6841-1063; Wu, Xue-Ru/0000-0001-6058-6291	NIDDK NIH HHS [DK39753, DK47529, DK49469] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039753, R01DK049469, R01DK047529] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELLA PM, 1979, BIOCHEM BIOPH RES CO, V87, P734, DOI 10.1016/0006-291X(79)92020-5; AMIOT M, 1990, J IMMUNOL, V145, P4322; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BRISSON A, 1983, J MOL BIOL, V166, P21, DOI 10.1016/S0022-2836(83)80048-5; BROWN JG, 1993, P NATL ACAD SCI USA, V90, P8184, DOI 10.1073/pnas.90.17.8184; CHLAPOWSKI FJ, 1972, J CELL BIOL, V53, P92, DOI 10.1083/jcb.53.1.92; CLASSON BJ, 1990, J EXP MED, V172, P1007, DOI 10.1084/jem.172.3.1007; DAVERN KM, 1991, MOL BIOCHEM PARASIT, V48, P67, DOI 10.1016/0166-6851(91)90165-3; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; ENGEL P, 1994, LEUKOCYTE LYMPHOMA, V1, P61; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; HICKS RM, 1970, J CELL BIOL, V45, P542, DOI 10.1083/jcb.45.3.542; HICKS RM, 1969, NATURE, V224, P1304, DOI 10.1038/2241304a0; HICKS RM, 1965, J CELL BIOL, V26, P25, DOI 10.1083/jcb.26.1.25; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; HOTTA H, 1988, CANCER RES, V48, P2955; IMAI T, 1993, J IMMUNOL, V151, P6470; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; KALLIN B, 1991, MOL CELL BIOL, V11, P5338, DOI 10.1128/MCB.11.10.5338; KORINEK V, 1993, IMMUNOGENETICS, V38, P272, DOI 10.1007/BF00188803; KOSS LG, 1969, LAB INVEST, V21, P154; LANZA F, 1991, J BIOL CHEM, V266, P10638; LEBEL BS, 1994, CELL IMMUNOL, V154, P468; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LIN JH, 1994, J BIOL CHEM, V269, P1775; LIN JH, 1995, P NATL ACAD SCI USA, V92, P679, DOI 10.1073/pnas.92.3.679; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MINSKY BD, 1978, J CELL BIOL, V77, P685, DOI 10.1083/jcb.77.3.685; MITAMURA T, 1992, J CELL BIOL, V118, P1389, DOI 10.1083/jcb.118.6.1389; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NAGIRA M, 1994, CELL IMMUNOL, V157, P144, DOI 10.1006/cimm.1994.1212; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; PORTER KR, 1963, INTRO FINE STRUCTURE; PORTER KR, 1967, PROTOPLASMA, V63, P263; REYNOLDS SR, 1992, J IMMUNOL, V149, P3995; ROBERTSON JD, 1980, J CELL BIOL, V86, P514, DOI 10.1083/jcb.86.2.514; SARIKAS SN, 1986, CELL TISSUE RES, V246, P109; SCHICK MR, 1993, J IMMUNOL, V151, P4090; STAEHELIN LA, 1972, J CELL BIOL, V53, P73, DOI 10.1083/jcb.53.1.73; SURYA B, 1990, J CELL SCI, V97, P419; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; TAYLOR KA, 1984, J ULTRA MOL STRUCT R, V87, P23, DOI 10.1016/S0022-5320(84)90113-8; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; VERGARA J, 1969, J MOL BIOL, V46, P593, DOI 10.1016/0022-2836(69)90200-9; WALZ T, 1995, J MOL BIOL, V248, P887, DOI 10.1006/jmbi.1995.0269; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; WRIGHT MD, 1993, INT IMMUNOL, V5, P209, DOI 10.1093/intimm/5.2.209; WU XR, 1993, J CELL SCI, V106, P31; WU XR, 1994, J BIOL CHEM, V269, P13716; WU XR, 1990, J BIOL CHEM, V265, P19170; YU J, 1990, J CELL BIOL, V111, P1207, DOI 10.1083/jcb.111.3.1207; YU J, 1994, J CELL BIOL, V125, P171, DOI 10.1083/jcb.125.1.171	59	118	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29752	29759						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530366				2022-12-25	WOS:A1995TK38000026
J	LI, PM; FUKAZAWA, H; YAMAMOTO, C; MIZUNO, S; TANAKA, K; HORI, M; YAGINUMA, S; SAITO, T; UEHARA, Y				LI, PM; FUKAZAWA, H; YAMAMOTO, C; MIZUNO, S; TANAKA, K; HORI, M; YAGINUMA, S; SAITO, T; UEHARA, Y			METHOD OF IDENTIFYING INHIBITORS OF ONCOGENIC TRANSFORMATION - SELECTIVE-INHIBITION OF CELL-GROWTH IN SERUM-FREE MEDIUM	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; PROTEIN-TYROSINE KINASES; RAT-KIDNEY CELLS; HERBIMYCIN-A; TYRPHOSTINS; ERBSTATIN; INVITRO	We developed a new method for evaluating inhibitors of onocogenic signal transduction pathways based on different growth abilities between normal and transformed cells in a defined serum-free medium. The growth rates of src, abl or ras oncogene-transformed cells, activated raf proto-oncogene transformed cells, and normal NIH3T3 cells were 60-90%, 20-30% and 10% in a serum-free medium, respectively, compared to the growth rates in a serum-containing medium. An addition of a growth factor (PDGF, FGF or TGF-beta) stimulated the growth of normal NIH3T3 cells by 40-80% in a serum-free medium. Herbimycin A, a specific cytoplasmic protein tyrosine kinase inhibitor, selectively inhibited the growth of src or abl transformed cells in the serum-free medium resulting in about 10-fold or fivefold lower IC50 than those in the serum-containing medium. The antibiotic did not show such an effect on ras transformed cells, and the treatment of src transformed cells with other protein kinase inhibitors or cytotoxic drugs showed tittle IC50 shifts between the two media. Thus, this method of comparing growth inhibition in the serum-free and the serum-containing media may be useful in evaluating specific inhibitors of signaling pathways mediated by growth factors and certain oncogene products.	NATL INST HLTH, DEPT BIOACT MOLEC, 1-23-1 TOYAMA, SHINJUKU KU, TOKYO 162, JAPAN; SHOWA COLL PHARMACEUT SCI, TOKYO 194, JAPAN; ASAHI CHEM IND CO LTD, SHIZUOKA 41023, JAPAN	Showa Pharmaceutical University								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARMAND JP, 1990, EUR J CANCER, V26, P417, DOI 10.1016/0277-5379(90)90005-E; BROWDER TM, 1989, CANCER CELL-MON REV, V1, P9; CUADRADO A, 1990, BIOCHEM BIOPH RES CO, V170, P526, DOI 10.1016/0006-291X(90)92123-H; FUKAZAWA H, 1990, BIOCHEM BIOPH RES CO, V173, P276, DOI 10.1016/S0006-291X(05)81053-8; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; HONMA Y, 1992, ANTICANCER RES, V12, P189; HONMA Y, 1989, CANCER RES, V49, P331; IMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P208, DOI 10.1016/S0006-291X(05)81042-3; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; LEVITZKI A, 1991, TRENDS PHARMACOL SCI, V12, P171, DOI 10.1016/0165-6147(91)90538-4; LYALL RM, 1989, J BIOL CHEM, V264, P14503; OKABE M, 1992, BLOOD, V80, P1330; PIRONIN M, 1992, INT J CANCER, V51, P980, DOI 10.1002/ijc.2910510624; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TRITTON TR, 1990, CANCER CELL-MON REV, V2, P95; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	26	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1731	1735						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510919				2022-12-25	WOS:A1993LG68200003
J	SAJJADI, FG; PASQUALE, EB				SAJJADI, FG; PASQUALE, EB			5 NOVEL AVIAN EPH-RELATED TYROSINE KINASES ARE DIFFERENTIALLY EXPRESSED	ONCOGENE			English	Article							GROWTH-FACTOR; PROTEIN-KINASES; RECEPTOR; GENE; FAMILY; IDENTIFICATION; ENCODES; OVEREXPRESSION; PP60C-SRC; ONCOGENE	We have identified cDNA clones that encode five new avian receptor-like tyrosine kinases of the Eph subclass, by screening two chicken embryonic cDNA libraries with DNA probes. We have designated them Cek6 to Cek10. The identification of these kinases indicates that the Eph subclass comprises at least 10 members and, therefore, represents a very large family of receptor-like tyrosine kinases. Variants of Cek10 and of Cek5 (a previously identified Eph-related kinase) containing amino acid insertion sequences in the juxtamembrane domain were also isolated. The Cek5 variant is expressed in the brain, but not in other tissues of the 10-day chick embryo. Analysis of 10-day chick embryo mRNAs shows the newly identified tyrosine kinases to be all expressed in both the embryonic brain and body tissues. In adult tissues, they display distinct patterns of expression. Cek6, Cek7, Cek8, Cek9 and Cek10 are likely to play significant roles in embryonic signal transduction pathways, including those involved in neural development. Their distinct tissue distributions in the adult suggest that the different members of the Eph family may each serve specific functions.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA56721] Funding Source: Medline; NICHD NIH HHS [HD26351] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026351, R29HD026351] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA056721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHAN J, 1991, ONCOGENE, V6, P1057; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J, 1989, MOL CLONING LABORATO; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	133	153	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1807	1813						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510926				2022-12-25	WOS:A1993LG68200012
J	DEPRE, C; RIDER, MH; VEITCH, K; HUE, L				DEPRE, C; RIDER, MH; VEITCH, K; HUE, L			ROLE OF FRUCTOSE 2,6-BISPHOSPHATE IN THE CONTROL OF HEART GLYCOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PERFUSED RAT-HEART; MYOCARDIAL FRUCTOSE-6-PHOSPHATE,2-KINASE; FRUCTOSE-2,6-BISPHOSPHATE CONTENT; GLUCOSE; INSULIN; PURIFICATION; HEPATOCYTES; MUSCLE; WORK	The aim of this work was to study whether changes in fructose 2,6-bisphosphate concentration are correlated with variations of the glycolytic flux in the isolated working rat heart. Glycolysis was stimulated to different extents by increasing the concentration of glucose, increasing the workload, or by the addition of insulin. The glycolytic flux was measured by the rate of detritiation of [2-H-3]- and [3-H-3]glucose. Under all the conditions tested, an increase in fructose 2,6-bisphosphate content was observed. The glucose- or insulin-induced increase in fructose 2,6-bisphosphate content was related to an increase in the concentration of fructose 6-phosphate, the substrate of 6-phosphofructo-2-kinase. An increase in the workload correlated with a 50% decrease in the K(m) of 6-phosphofructo-2-kinase for fructose 6-phosphate. Similar changes in K(m) have been observed when purified heart 6-phosphofructo-2-kinase was phosphorylated in vitro by the cyclic AMP-dependent protein kinase or by the calcium/calmodulin-dependent protein kinase. Since the concentration of cyclic AMP was not affected by increasing the workload, it is possible that the change in K(m) of 6-phosphofructo-2-kinase, which was found in hearts submitted to a high load, resulted from phosphorylation by calcium/calmodulin protein kinase; other possibilities are not excluded. Anoxia decreased the external work developed by the heart, stimulated glycolysis and glycogenolysis, but did not increase fructose 2,6-bisphosphate.	UNIV CATHOLIQUE LOUVAIN, SCH MED, INT INST CELLULAR & MOLEC PATHOL, HORMONE & METAB RES UNIT, B-1200 BRUSSELS, BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel								BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRGMEYER HU, 1984, METHODS ENZYMATIC AN, V6; CREPIN KM, 1992, J BIOL CHEM, V267, P21698; DENTON RM, 1986, ADV CYCLIC NUCL PROT, V20, P293; HUE L, 1982, BIOCHEM J, V206, P359, DOI 10.1042/bj2060359; HUE L, 1982, J BIOL CHEM, V257, P4308; HUE L, 1987, BIOCHEM J, V245, P313, DOI 10.1042/bj2450313; HUE L, 1974, BIOCHEM BIOPH RES CO, V58, P532, DOI 10.1016/S0006-291X(74)80453-5; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; HUE L, 1988, BIOCHEM J, V251, P541, DOI 10.1042/bj2510541; JOOST HG, 1989, DIABETOLOGIA, V32, P831, DOI 10.1007/BF00297447; JUNCO M, 1990, FEBS LETT, V263, P169, DOI 10.1016/0014-5793(90)80731-W; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KITAMURA K, 1988, J BIOL CHEM, V263, P9027; KITAMURA K, 1988, J BIOL CHEM, V263, P16796; KURET J, 1984, BIOCHEMISTRY-US, V23, P5495, DOI 10.1021/bi00318a018; LAWSON JWR, 1987, J BIOL CHEM, V262, P3165; MARBAN E, 1980, NATURE, V286, P845, DOI 10.1038/286845a0; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MINATOGAWA Y, 1984, BIOCHEM J, V223, P73, DOI 10.1042/bj2230073; MORGAN HE, 1959, BIOCHEM J, V73, P573, DOI 10.1042/bj0730573; NARABAYASHI H, 1985, J BIOL CHEM, V260, P9750; NEELY JR, 1967, AM J PHYSIOL, V212, P815; NEELY JR, 1972, BIOCHEM J, V128, P147, DOI 10.1042/bj1280147; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; OPIE LH, 1971, BIOCHEM J, V124, P475, DOI 10.1042/bj1240475; PARKER PJ, 1984, EMBO J, V3, P953, DOI 10.1002/j.1460-2075.1984.tb01913.x; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; RIDER MH, 1984, FEBS LETT, V176, P484, DOI 10.1016/0014-5793(84)81223-5; RIDER MH, 1992, FEBS LETT, V310, P139, DOI 10.1016/0014-5793(92)81315-D; RIDER MH, 1992, BIOCHEM J, V285, P405, DOI 10.1042/bj2850405; RIDER MH, 1986, BIOCHEM SOC T, V14, P321, DOI 10.1042/bst0140321; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROVETTO MJ, 1973, CIRC RES, V32, P699, DOI 10.1161/01.RES.32.6.699; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P3483; WATSON PA, 1989, J BIOL CHEM, V264, P14735	38	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13274	13279						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514765				2022-12-25	WOS:A1993LH55300040
J	PITTERLE, DM; RAJAGOPALAN, KV				PITTERLE, DM; RAJAGOPALAN, KV			THE BIOSYNTHESIS OF MOLYBDOPTERIN IN ESCHERICHIA-COLI - PURIFICATION AND CHARACTERIZATION OF THE CONVERTING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR; NITRATE REDUCTASE; XANTHINE-OXIDASE; SULFITE OXIDASE; PROTEINS; SEQUENCE; QUANTITIES; COMPONENT; MUTANTS; CLONING	Molybdopterin, the universal component of the pterin molybdenum cofactors, contains a dithiolene group serving to bind Mo. Addition of the dithiolene sulfurs to a molybdopterin precursor requires the activity of the converting factor. Active converting factor has been purified from Escherichia coli chlA1 cells and found to have two subunits of mass 10 and 16 kDa. Electrophoresis of the purified converting factor on denaturing polyacrylamide gels revealed the presence of a 27-kDa protein as well. Partial NH2-terminal amino acid sequencing showed that the 27-kDa protein is a covalent complex of the 10- and 16-kDa proteins. The inactive converting factor purified from E. coli chlN contains both subunits, as established by amino acid sequencing of the purified material, but the 10-kDa subunit is inactive. Absence of the 27-kDa complex in chlN preparations showed that the inactive covalent complex is only formed from the active converting factor. Evidence that activation of the small subunit requires the acquisition of sulfur was obtained from the difference in the molecular masses of the 10-kDa proteins isolated from chlA1 and chlN cells and from the differential sensitivities of the chlA1 and chlN converting factors to iodoacetamide.			PITTERLE, DM (corresponding author), DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044283] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44283, GM00091] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMY NK, 1979, J BACTERIOL, V140, P114, DOI 10.1128/JB.140.1.114-124.1979; GLASER JH, 1971, J BACTERIOL, V108, P854, DOI 10.1128/JB.108.2.854-860.1971; GRUBER S, 1990, J AM CHEM SOC, V112, P8179, DOI 10.1021/ja00178a059; HAWKES TR, 1984, BIOCHEM J, V219, P481, DOI 10.1042/bj2190481; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JOHANN S, 1987, J BACTERIOL, V169, P1911, DOI 10.1128/jb.169.5.1911-1916.1987; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLER JB, 1983, J BACTERIOL, V155, P793, DOI 10.1128/JB.155.2.793-801.1983; NOHNO T, 1988, J BACTERIOL, V170, P4097, DOI 10.1128/jb.170.9.4097-4102.1988; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; PITTERLE DM, 1991, THESIS DUKE U DURHAM; POULTER L, 1990, BIOLOGICAL MASS SPECTROMETRY /, P119; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; REISS J, 1987, MOL GEN GENET, V206, P352, DOI 10.1007/BF00333594; RIVERS SL, 1991, THESIS U DUNDEE; VENEBLES WA, 1972, MOL GEN GENET, V114, P223; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493	26	89	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13499	13505						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514782				2022-12-25	WOS:A1993LH55300069
J	PITTERLE, DM; JOHNSON, JL; RAJAGOPALAN, KV				PITTERLE, DM; JOHNSON, JL; RAJAGOPALAN, KV			INVITRO SYNTHESIS OF MOLYBDOPTERIN FROM PRECURSOR-Z USING PURIFIED CONVERTING FACTOR - ROLE OF PROTEIN-BOUND SULFUR IN FORMATION OF THE DITHIOLENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR; GUANINE DINUCLEOTIDE; FORMYLMETHANOFURAN DEHYDROGENASE; XANTHINE-OXIDASE; SULFITE OXIDASE; IDENTIFICATION; BIOSYNTHESIS; REDUCTASE; COMPONENT; FORM	The pterin component of the molybdenum cofactor, termed molybdopterin, is synthesized in Escherichia coli by enzymes encoded at the chl loci. A late step in the biosynthetic pathway, the conversion of a molybdopterin intermediate, precursor Z, to molybdopterin, requires the activity of a two-subunit protein, the converting factor. Precursor Z has many of the features of molybdopterin but lacks the dithiolene function essential for molybdenum ligation. Conversion of precursor Z to molybdopterin is accomplished by transfer of sulfur to produce the dithiolene. The present study describes an in vitro system for molybdopterin biosynthesis comprised of purified precursor Z and purified converting factor. It is established that these components are sufficient to yield molybdopterin, identified by conversion to its characteristic products, Form A, Form B, and dicarboxamidomethylmolybdopterin. Under conditions of precursor excess, the formation of molybdopterin was stoichiometric with converting factor, as would be expected in the absence of a sulfur-regenerating system. The labile product of the reaction, molybdopterin, remained associated with the converting factor large subunit. These results establish that the source of sulfur for molybdopterin biosynthesis is the converting factor and suggest that in vivo a novel sulfur cycle must function to resupply sulfur to the converting factor.			PITTERLE, DM (corresponding author), DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA.				NIGMS NIH HHS [GM00091, GM44283] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044283] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORNER G, 1991, FEBS LETT, V290, P31, DOI 10.1016/0014-5793(91)81218-W; HETTRICH D, 1991, BIOL CHEM H-S, V372, P513, DOI 10.1515/bchm3.1991.372.2.513; JOHNSON JL, 1980, J BIOL CHEM, V255, P1783; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON JL, 1991, FEMS MICROBIOL LETT, V77, P213; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; KARRASCH M, 1990, FEBS LETT, V274, P48, DOI 10.1016/0014-5793(90)81326-J; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; TAYLOR EC, 1989, J AM CHEM SOC, V111, P7664, DOI 10.1021/ja00201a084; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; ZURICK TR, 1991, FASEB J, V5, pA470	18	105	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13506	13509						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514783				2022-12-25	WOS:A1993LH55300070
J	ROSENTHAL, W; ANTARAMIAN, A; GILBERT, S; BIRNBAUMER, M				ROSENTHAL, W; ANTARAMIAN, A; GILBERT, S; BIRNBAUMER, M			NEPHROGENIC DIABETES-INSIPIDUS - A V2 VASOPRESSIN RECEPTOR UNABLE TO STIMULATE ADENYLYL CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DOMINANT RETINITIS-PIGMENTOSA; DIRECTED MUTAGENESIS; DNA; RHODOPSIN; GENE	The coding region of the human vasopressin type 2 receptor gene bears mutations in the individuals affected with congenital nephrogenic diabetes insipidus, a disease characterized by the inability of the kidney to concentrate urine in response to vasopressin. Although it is assumed that the mutations result in loss of receptor function, proof of this hypothesis is lacking. We introduced one of these naturally occurring point mutations leading to a single amino acid change (Arg137 --> His) into wild type cDNA. The mutant protein was expressed, and the functional properties of the receptor were examined. The mutant receptor exhibited an unaltered binding affinity for vasopressin compared to the wild type but failed to stimulate the G(s)/adenylyl cyclase system. These data provide biochemical proof that the mutant receptor is the cause of the disease.	BAYLOR COLL MED, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA	Baylor College of Medicine					NIDDK NIH HHS [DK 21-244] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BICHET DG, 1992, AM J HUM GENET, V51, P1089; BICHET DG, 1993, IN PRESS J CLIN INVE; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BIRNBAUMER M, 1992, NATURE, V357, P333, DOI 10.1038/357333a0; BIRNBAUMER M, 1990, MOL ENDOCRINOL, V4, P245, DOI 10.1210/mend-4-2-245; BIRNBAUMER M, 1992, J BIOL CHEM, V267, P11783; CULPEPPER RM, 1989, METABOLIC BASES INHE, P1867; DAVIES K, 1992, NAT GENET, V2, P103; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FRASER CM, 1988, P NATL ACAD SCI USA, V85, P5478, DOI 10.1073/pnas.85.15.5478; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; KAMBOURIS M, 1988, AM J MED GENET, V29, P239, DOI 10.1002/ajmg.1320290138; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KNOERS N, 1988, NEPHRON, V50, P187, DOI 10.1159/000185155; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; ORLOFF J, 1967, AM J MED, V42, P757, DOI 10.1016/0002-9343(67)90093-9; PAN Y, 1992, NAT GENET, V2, P103, DOI 10.1038/ng1092-103; ROSENTHAL W, 1992, NATURE, V359, P233, DOI 10.1038/359233a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SEIBOLD A, 1992, AM J HUM GENET, V51, P1078; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; VANDENOUWELAND AMW, 1992, NAT GENET, V2, P99, DOI 10.1038/ng1092-99	31	137	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13030	13033						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514744				2022-12-25	WOS:A1993LH55300006
J	XIE, HY; CLARKE, S				XIE, HY; CLARKE, S			METHYL ESTERIFICATION OF C-TERMINAL LEUCINE RESIDUES IN CYTOSOLIC 36-KDA POLYPEPTIDES OF BOVINE BRAIN - A NOVEL EUKARYOTIC PROTEIN CARBOXYL METHYLATION REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ISOASPARTYL PEPTIDES; CHEB METHYLESTERASE; MEMBRANE-PROTEINS; EUKARYOTIC CELLS; ESCHERICHIA-COLI; RAS2 PROTEIN; METHYLTRANSFERASE; REPAIR; ASPARTYL	Incubation of cytosolic extracts of bovine brain with S-adenosyl[methyl-H-3]methionine results in the predominant [H-3]methyl esterification of a 36-kDa polypeptide. This reaction appears to be distinct from any of the three known types of protein carboxyl methylation reactions previously established. We show here that the methylated 36-kDa polypeptide is a component of a cytosolic protein with a native molecular mass estimated at 178 kDa by gel filtration chromatography. The methyl group is not stable on the protein and is lost as [H-3]methanol with a half-life of about 180 min at pH 7.0, 37-degrees-C. The methyltransferase responsible for this reaction is a cytosolic protein with a native molecular mass of about 40 kDa that is readily separated from the well described protein-L-isoaspartate (D-aspartate) O-methyltransferase (EC 2.1.1.77). The methyl ester linkage is cleaved by carboxypeptidase Y, suggesting that the 36-kDa polypeptide is methylated on its C-terminal carboxyl group. Extensive digestion of gel-purified H-3-methylated 36-kDa polypeptide with trypsin and leucine aminopeptidase results in a radioactive product that co-chromatographs with authentic L-leucine methyl ester in reverse phase high performance liquid chromatography (HPLC), thin layer chromatography, thin layer electrophoresis, and high resolution-sulfonated polystyrene cation-exchange chromatography. Additionally, the o-phthalaldehyde/beta-mercaptoethanol-derived isoindole derivative of the H-3 digestion product co-migrates on HPLC with the corresponding isoindole for L-leucine methyl ester. We demonstrate that a similar methylation system is present in yeast Saccharomyces cerevisiae but not in the bacterium Escherichia coli. These results provide evidence for a new type of reversible posttranslational modification reaction that may function to modulate the activities of its methyl-accepting substrates.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	XIE, HY (corresponding author), UNIV CALIF LOS ANGELES, DEPT CHEM & BIOCHEM, LOS ANGELES, CA 90024 USA.				NIGMS NIH HHS [GM 26020] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHSTETTER T, 1984, J BIOL CHEM, V259, P3334; ASWAD DW, 1987, TRENDS BIOCHEM SCI, V12, P155, DOI 10.1016/0968-0004(87)90073-9; ASWAD DW, 1983, J NEUROCHEM, V40, P1718, DOI 10.1111/j.1471-4159.1983.tb08147.x; BACKLUND PS, 1992, J BIOL CHEM, V267, P18432; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BARTEN DM, 1990, LIFE SCI, V47, P181, DOI 10.1016/0024-3205(90)90319-M; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; CHELSKY D, 1985, BIOCHEMISTRY-US, V24, P6651, DOI 10.1021/bi00344a053; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; GALLETTI P, 1981, FEBS LETT, V126, P236, DOI 10.1016/0014-5793(81)80250-5; GALLETTI P, 1988, BIOCHEMISTRY-US, V27, P1752, DOI 10.1021/bi00405a055; GOTTSCHLING H, 1962, NATURE, V196, P829, DOI 10.1038/196829a0; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HAZELBAUER GL, 1989, P NATL ACAD SCI USA, V86, P1448, DOI 10.1073/pnas.86.5.1448; HRYCYNA CA, 1992, J BIOL CHEM, V267, P10457; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; JOHNSON BA, 1987, J BIOL CHEM, V262, P12283; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; KLEENE SJ, 1977, J BIOL CHEM, V252, P3214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW RE, 1992, MOL CELL BIOL, V12, P103, DOI 10.1128/MCB.12.1.103; LI C, 1992, P NATL ACAD SCI USA, V89, P9885, DOI 10.1073/pnas.89.20.9885; LOWENSON JD, 1991, GERONTOLOGY, V37, P128; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; LOWENSON JD, 1992, J BIOL CHEM, V267, P5985; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; NAJBAUER J, 1991, ANAL BIOCHEM, V197, P412, DOI 10.1016/0003-2697(91)90413-N; OCONNOR CM, 1984, J BIOL CHEM, V259, P2570; OTA IM, 1990, PROTEIN METHYLATION, P179; PEREZSALA D, 1992, BIOCHEM J, V284, P835, DOI 10.1042/bj2840835; SAMBROOK J, 1989, MOL CLONING LABORATO, pE37; SIEGEL FL, 1985, ARCH BIOCHEM BIOPHYS, V237, P347, DOI 10.1016/0003-9861(85)90286-3; SIMMS SA, 1985, J BIOL CHEM, V260, P161; SIMMS SA, 1987, J BIOL CHEM, V262, P8537; STEPHENSON RC, 1992, J BIOL CHEM, V267, P13314; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STIMMEL JB, 1990, BIOCHEMISTRY-US, V29, P9651, DOI 10.1021/bi00493a021; STOCK JB, 1992, J BIOL CHEM, V267, P19753; TAN EW, 1991, J BIOL CHEM, V266, P10719; TAN EW, 1992, BIOCHEMISTRY-US, V31, P5572, DOI 10.1021/bi00139a021; VOLKER C, 1991, FEBS LETT, V295, P189, DOI 10.1016/0014-5793(91)81415-5; VOLKER C, 1991, J BIOL CHEM, V266, P21515; WORTHINGTON CC, 1988, WORTHINGTON MANUAL E; XIE H, 1990, Methods (Orlando), V1, P276, DOI 10.1016/S1046-2023(05)80328-7	50	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13364	13371						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514774				2022-12-25	WOS:A1993LH55300052
J	STAMELLOS, KD; SHACKELFORD, JE; SHECHTER, I; JIANG, GJ; CONRAD, D; KELLER, GA; KRISANS, SK				STAMELLOS, KD; SHACKELFORD, JE; SHECHTER, I; JIANG, GJ; CONRAD, D; KELLER, GA; KRISANS, SK			SUBCELLULAR-LOCALIZATION OF SQUALENE SYNTHASE IN RAT HEPATIC CELLS - BIOCHEMICAL AND IMMUNOCHEMICAL EVIDENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; LIVER PEROXISOMES; CHOLESTEROL-SYNTHESIS; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; ACETOACETYL-COA; ACETYL-COA; MICROSOMES; SYNTHETASE; HEPATOCYTES; SECTIONS	In the present study we investigated the subcellular localization of squalene synthase (farnesyl-diphosphate: farnesyl-diphosphate farnesyltransferase, EC 2.5.1.21). Squalene synthase catalyzes the formation of squalene from trans-farnesyl diphosphate in two distinct steps and is the first committed enzyme for the biosynthesis of cholesterol. Recently, a truncated form of the enzyme from rat hepatocytes was purified, and monospecific antibodies for squalene synthase were produced. This enabled the subcellular localization of squalene synthase by three different methods: (i) analytical subcellular fractionation and measurements of enzyme activities; (ii) immunodeterminations of squalene synthase in the isolated subcellular fractions with a monospecific antibody; and (iii) immunoelectron microscopy. All three methods gave consistent results. The data clearly illustrate that squalene synthase enzymatic activity and squalene synthase are exclusively localized in the endoplasmic reticulum. In rat hepatic peroxisomes we were not able to detect any squalene synthase. In addition, we also demonstrated that squalene synthase in the microsomal fraction is dramatically regulated by a number of hypolipidemic drugs and dietary treatments.	SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; ELEANOR ROOSEVELT INST, DENVER, CO 80206 USA; GENENTECH INC, DEPT PRECLIN PHARMACOL, S SAN FRANCISCO, CA 94080 USA	California State University System; San Diego State University; Roche Holding; Genentech					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044350] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44350] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGNEW WS, 1978, J BIOL CHEM, V253, P4574; APPELKVIST EL, 1990, ARCH BIOCHEM BIOPHYS, V282, P318, DOI 10.1016/0003-9861(90)90123-G; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, V1; COHEN LH, 1992, BIOCHIM BIOPHYS ACTA, V1126, P114, DOI 10.1016/0005-2760(92)90224-J; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; ERICSSON J, 1992, J BIOL CHEM, V267, P18708; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HODGE VJ, 1991, BIOCHEM BIOPH RES CO, V181, P537, DOI 10.1016/0006-291X(91)91222-X; HOVIK R, 1991, J LIPID RES, V32, P993; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1984, P NATL ACAD SCI-BIOL, V81, P5744, DOI 10.1073/pnas.81.18.5744; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KRISANS SK, 1992, AM J RESP CELL MOL, V7, P358, DOI 10.1165/ajrcmb/7.4.358; KRISANS SK, 1980, J BIOL CHEM, V255, P9599; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; NOLTMANN EA, 1966, METHOD ENZYMOL, V9, P557; PARKER RA, 1989, J BIOL CHEM, V264, P4877; POPJAK G, 1979, MOL CELL BIOCHEM, V27, P97; SCHMIDT E, 1974, METHOD ENZYMAT AN, V2, P650; SHECHTER I, 1992, J BIOL CHEM, V267, P8628; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; SUZUKI Y, 1990, CELL STRUCT FUNCT, V15, P301, DOI 10.1247/csf.15.301; THOMPSON SL, 1987, J BIOL CHEM, V262, P17420; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105	33	56	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12825	12836						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509416				2022-12-25	WOS:A1993LG65800088
J	Tagaya, M; Furuno, A; Mizushima, S				Tagaya, M; Furuno, A; Mizushima, S			SNAP prevents Mg2+-ATP-induced release of N-ethylmaleimide-sensitive factor from the Golgi apparatus in digitonin-permeabilized PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; VESICULAR TRANSPORT; FUSION PROTEIN; SYNAPTIC VESICLES; IN-VITRO; PURIFICATION; REQUIRES; STACK; NSF; RECEPTOR	The N-ethylmaleimide-sensitive factor (NSF), which is involved in the multisteps of protein transport, is released from Golgi membranes on in vitro incubation with Mg2+-ATP. However, several lines of evidence suggest that NSF is associated with membranes in spite of the presence of Mg2+ and ATP in vivo. We have used digitonin-permeabilized PC12 cells to investigate the mechanism underlying the association of NSF with membranes. In PC12 cells, immunoreactivity for NSF was observed in the nuclear membranes, the Golgi apparatus, and neuronal growth cones, where synaptic vesicles are concentrated, NSF associated with the Golgi apparatus was released on incubation with Mg2+-ATP, whereas NSF in the nuclear membranes and neuronal growth cones was not released on the same treatment. The addition of cytosol blocked the Mg2+-ATP-induced release of NSF from the Golgi apparatus. Chromatographic analyses revealed that the factor(s) that prevents NSF release from the Golgi apparatus was eluted at the same position as the soluble NSF attachment proteins (SNAPs). Purified His(6)-tagged alpha-SNAP exhibited such activity. His(6)-tagged alpha-SNAP also prevented the Mg2+-ATP-induced release of NSF from isolated Golgi membranes.	TOKYO UNIV PHARM & LIFE SCI, SCH LIFE SCI, HACHIOJI, TOKYO 19203, JAPAN	Tokyo University of Pharmacy & Life Sciences								ADAM SA, 1991, METHOD CELL BIOL, V35, P469; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DIAZ R, 1989, METHOD CELL BIOL, V31, P25; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARAFIAN T, 1987, J BIOL CHEM, V262, P16671; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; TAGAYA M, 1995, J BIOL CHEM, V270, P15930, DOI 10.1074/jbc.270.27.15930; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	38	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					466	470		10.1074/jbc.271.1.466	http://dx.doi.org/10.1074/jbc.271.1.466			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550603	hybrid			2022-12-25	WOS:A1996TP36100071
J	Geoffroy, V; Ducy, P; Karsenty, G				Geoffroy, V; Ducy, P; Karsenty, G			A PEBP2 alpha/AML-1-related factor increases osteocalcin promoter activity through its binding to an osteoblast-specific cis-acting element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; DNA-BINDING; PROTEIN; CELLS; LEUKEMIA; PURIFICATION; POLYOMAVIRUS; EXPRESSION; ENHANCER	To identify osteoblast-specific cis acting elements and trans-acting factors, we initiated an analysis of the promoter of a mouse osteocalcin gene, an osteoblast-specific gene, In this promoter, we identified two osteoblast-specific cis-acting elements (Ducy, P. and Karsenty, G. (1995) Mol. Cell. Biol. 15, 1858-1869). The sequence of one of these elements, OSE2, is identical to the DNA-binding site of the PEBP2 alpha/AML-1 transcription factors, the mammalian homologues of the Drosophila Runt protein, Here we show, using nuclear extracts, recombinant protein, and a specific antiserum against AML-1 proteins in DNA-binding assays, that one member of this family, AML-1B, binds specifically to OSE2 and is immunologically related to OSF2, the factor present in osteoblast nuclear extracts that binds to OSE2. By DNA cotransfection experiments, we also demonstrate that AML-1B can increase the activity of a short osteocalcin promoter through its binding to OSE2. Lastly, the different mobilities of osteoblast nuclear extract-DNA complexes compared with T-cell nuclear extract-DNA complexes, along with the inability of OSF2 to be upregulated by retinoic acid, unlike the other PEBP2 alpha factors, suggest that OSF2 is a new member of this family of transcription factors. Thus, this study demonstrates that AML-1B can increase gene expression of an osteoblast-specific gene through its binding to an osteoblast-specific cis-acting element and presents evidence that OSF2 is a member of the PEBP2 alpha/AML-1 family of transcription factors.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Geoffroy, Valerie/P-1521-2014	Geoffroy, Valerie/0000-0003-3920-7482	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-41059] Funding Source: Medline; NIDCR NIH HHS [DE/AR-11290] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KARNIA MA, 1990, GENE DEV, V4, P1701; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	28	151	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30973	30979		10.1074/jbc.270.52.30973	http://dx.doi.org/10.1074/jbc.270.52.30973			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537354	hybrid			2022-12-25	WOS:A1995TN44400022
J	Iwasaki, T; Matsuura, K; Oshima, T				Iwasaki, T; Matsuura, K; Oshima, T			Resolution of the aerobic respiratory system of the thermoacidophilic archaeon, Sulfolobus sp strain 7 .1. The archaeal, terminal oxidase supercomplex is a functional fusion of respiratory complexes III and IV with no c-type cytochromes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPHILIC BACTERIUM PS3; SITE-DIRECTED MUTANTS; PROTONMOTIVE Q-CYCLE; HALOBACTERIUM-HALOBIUM; ESCHERICHIA-COLI; FERREDOXIN OXIDOREDUCTASE; PARACOCCUS-DENITRIFICANS; BRADYRHIZOBIUM-JAPONICUM; THERMUS-THERMOPHILUS; ENERGY TRANSDUCTION	The aerobic respiratory system of the thermoacidophilic archaeon, Sulfolobus sp. strain 7, is unusual in that it consists of only a- and b-type cytochromes but no c-type cytochromes. In previous studies, a novel cytochrome oxidase a(583)-aa(3) subcomplex has been purified, which showed a ferrocytochrome c oxidase but no caldariellaquinol oxidase activity (Wakagi, T., Yamauchi, T., Oshima, T., Muller, M., Azzi, A., and Sone, N. (1989) Biochem. Biophys. Res. Commun, 165, 1110-1114), We show here that the cytochrome subcomplex could be copurified with a non CO-reactive cytochrome b(562) as a novel terminal oxidase ''supercomplex,'' which also contained a Rieske-type FeS cluster at g(y) = 1.89. It contained one copper and all four heme centers detectable in the archaeal membranes by the low temperature spectrophotometry and the potentiometric titration: cytochromes b(562) (+146 mV), a(583) (+270 mV), and aa(3) (+117 and +325 mV). The presence of one copper atom indicates that it contains the conventional heme a(3)-Cu-B binuclear center for reducing molecular oxygen. In conjunction with the presence of a Rieske-type FeS center, inhibitor studies suggest that the terminal oxidase segment of the respiratory chain of Sulfolobus sp, strain 7 is a functional fusion of respiratory complexes III and IV, where cytochrome b(562) and the Rieske-type FeS center probably play a central role in the oxidation of caldariellaquinol. This archaeal terminal oxidase supercomplex reconstitutes the in vitro succinate oxidase respiratory chain for the first time together with caldariellaquinone and the purified cognate succinate:caldariellaquinone oxidoreductase complex. The reconstitution system requires caldariellaquinone for the activity, and is highly sensitive to cyanide and 2-heptyl-4-hydroxy-quinoline-N-oxide, These results are also discussed in terms of the evolutionary considerations.	TOKYO INST TECHNOL, DEPT LIFE SCI, YOKOHAMA, KANAGAWA 226, JAPAN; TOKYO METROPOLITAN UNIV, DEPT BIOL, HACHIOJI, TOKYO 19203, JAPAN	Tokyo Institute of Technology; Tokyo Metropolitan University				Iwasaki, Toshio/0000-0001-9562-4649				Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; ANEMULLER S, 1990, EUR J BIOCHEM, V191, P297, DOI 10.1111/j.1432-1033.1990.tb19123.x; ANEMULLER S, 1989, FEBS LETT, V244, P451, DOI 10.1016/0014-5793(89)80581-2; ANEMULLER S, 1985, FEBS LETT, V193, P83, DOI 10.1016/0014-5793(85)80084-3; ANEMULLER S, 1992, EUR J BIOCHEM, V210, P133, DOI 10.1111/j.1432-1033.1992.tb17400.x; ANEMULLER S, 1993, FEBS LETT, V318, P61, DOI 10.1016/0014-5793(93)81328-W; ANEMULLER T, 1994, J BIOCHEM-TOKYO, V117, P275; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; ANRAKU Y, 1988, ANNU REV BIOCHEM, V57, P101, DOI 10.1146/annurev.bi.57.070188.000533; BECKER M, 1991, FEBS LETT, V291, P331, DOI 10.1016/0014-5793(91)81314-X; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BERRY EA, 1985, J BIOL CHEM, V260, P2458; BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; BLAMEY JM, 1993, BIOCHIM BIOPHYS ACTA, V1161, P19, DOI 10.1016/0167-4838(93)90190-3; BLAMEY JM, 1994, BIOCHEMISTRY-US, V33, P1000, DOI 10.1021/bi00170a019; CALHOUN MW, 1993, BIOCHEMISTRY-US, V32, P11524, DOI 10.1021/bi00094a008; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; DANSON MJ, 1989, CAN J MICROBIOL, V35, P58, DOI 10.1139/m89-009; DENDA K, 1991, BIOCHEM BIOPH RES CO, V181, P316, DOI 10.1016/S0006-291X(05)81420-2; DEROSA M, 1977, J CHEM SOC PERK T 1, P653, DOI 10.1039/p19770000653; Dutton P L, 1978, Methods Enzymol, V54, P411; FUJIWARA T, 1993, J BIOCHEM-TOKYO, V113, P48, DOI 10.1093/oxfordjournals.jbchem.a124002; FUJIWARA T, 1987, PLANT CELL PHYSIOL, V28, P29; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P3120, DOI 10.1021/bi00176a047; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; HONNAMI K, 1984, BIOCHEMISTRY-US, V23, P454, DOI 10.1021/bi00298a009; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; HUBER R, 1992, SYST APPL MICROBIOL, V15, P340, DOI 10.1016/S0723-2020(11)80206-7; IWASAKI T, 1995, J BACTERIOL, V177, P2576, DOI 10.1128/jb.177.9.2576-2582.1995; Iwasaki T, 1995, J BIOL CHEM, V270, P30893, DOI 10.1074/jbc.270.52.30893; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; IWASAKI T, 1995, J BIOL CHEM, V270, P17878, DOI 10.1074/jbc.270.30.17878; Iwasaki T, 1995, J BIOL CHEM, V270, P30902, DOI 10.1074/jbc.270.52.30902; KEEFE RG, 1993, BIOCHIM BIOPHYS ACTA, V1183, P91, DOI 10.1016/0005-2728(93)90008-4; KERSCHER L, 1982, TRENDS BIOCHEM SCI, V7, P371, DOI 10.1016/0968-0004(82)90118-9; KERSCHER L, 1981, EUR J BIOCHEM, V116, P587, DOI 10.1111/j.1432-1033.1981.tb05376.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; LUBBEN M, 1992, EMBO J, V11, P805, DOI 10.1002/j.1460-2075.1992.tb05117.x; LUBBEN M, 1994, MOL MICROBIOL, V13, P327, DOI 10.1111/j.1365-2958.1994.tb00426.x; LUBBEN M, 1994, J BIOL CHEM, V269, P21473; LUBBEN M, 1994, EUR J BIOCHEM, V224, P151, DOI 10.1111/j.1432-1033.1994.tb20006.x; LUDWIG B, 1987, FEMS MICROBIOL LETT, V46, P41, DOI 10.1111/j.1574-6968.1987.tb02451.x; MATSUSHITA K, 1992, J BIOL CHEM, V267, P24748; MIKI T, 1994, J BIOL CHEM, V269, P1827; MOGI T, 1994, J BIOCHEM-TOKYO, V116, P471, DOI 10.1093/oxfordjournals.jbchem.a124548; MULLER M, 1988, ANNU REV MICROBIOL, V42, P465, DOI 10.1146/annurev.mi.42.100188.002341; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; Poole RK., 1988, BACTERIAL ENERGY TRA, P231; PREISIG O, 1993, P NATL ACAD SCI USA, V90, P3309, DOI 10.1073/pnas.90.8.3309; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SARASTE M, 1991, BIOCHEM SOC T, V19, P608, DOI 10.1042/bst0190608; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; SCHAFER G, 1994, SYST APPL MICROBIOL, V16, P544; SCHAFER G, 1990, FEMS MICROBIOL LETT, V75, P335, DOI 10.1016/0378-1097(90)90543-Y; SCHMIDT CL, 1995, FEBS LETT, V359, P239, DOI 10.1016/0014-5793(94)00052-W; SONE N, 1987, J BIOL CHEM, V262, P15386; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; SONE N, 1990, BACTERIA, V12, P1; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; VOLKL P, 1993, APPL ENVIRON MICROB, V59, P2918; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; WAKAGI T, 1986, SYST APPL MICROBIOL, V7, P342; WAKAGI T, 1989, BIOCHEM BIOPH RES CO, V165, P1110, DOI 10.1016/0006-291X(89)92717-4; WAKAO H, 1987, J BIOCHEM, V102, P255, DOI 10.1093/oxfordjournals.jbchem.a122049; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1141, P1, DOI 10.1016/0005-2728(93)90182-F; Yamanaka T., 1992, BIOCH BACTERIAL CYTO, P91; YAMANAKA T, 1992, BIOCH BACTERIAL CYTO, p67N; YANG XH, 1986, J BIOL CHEM, V261, P2282; YANG XH, 1988, J BIOL CHEM, V263, P11962; ZIMMERMANN BH, 1988, P NATL ACAD SCI USA, V85, P5779, DOI 10.1073/pnas.85.16.5779	80	71	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30881	30892		10.1074/jbc.270.52.30881	http://dx.doi.org/10.1074/jbc.270.52.30881			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537342	hybrid			2022-12-25	WOS:A1995TN44400010
J	Karunaratne, SHPP; Hemingway, J; Jayawardena, KGI; Dassanayaka, V; Vaughan, A				Karunaratne, SHPP; Hemingway, J; Jayawardena, KGI; Dassanayaka, V; Vaughan, A			Kinetic and molecular differences in the amplified and non-amplified esterases from insecticide-resistant and susceptible Culex quinquefasciatus mosquitoes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMATE RESISTANCE; SRI-LANKA; CULICIDAE; DIPTERA; ORGANOPHOSPHATE; AMPLIFICATION; MECHANISMS; CALIFORNIA; STRAIN; GENE	Two non-amplified esterases were purified from the insecticide-susceptible Pel SS strain of Culex quinquefasciatus, These were the two major esterase activity peaks in this strain. The two corresponding amplified carboxylesterases, Est alpha 2 and Est beta(2) involved in organophosphate sequestration were purified from two resistant C. quinquefasciatus strains. The Pel SS esterases were significantly less reactive with the organophosphates than those from the resistant strains. One of the Pel SS esterases was electrophoretically identical to amplified Culex Est beta 1. However, it differed kinetically, and in its nucleotide and predicted amino acid sequences from the two characterized amplified Est beta 1s, it is classified as Est beta 1(3). Restriction fragment analysis suggested Pel SS has only one Est alpha and one Est beta gene, while the resistant Pel RR has both amplified and non-amplified forms of Est alpha and Est beta. The EcoRI fragments for both Pel SS esterases were distinct from those of the amplified Est alpha 2(1), Est beta 2(1), or Est beta(1&2). An esterase with the same size EcoRI fragment as Est beta 1(3) was also present in Pel RR. This and restriction enzyme fragment analysis of C. quinquefasciatus field populations suggest that variability of the susceptible alleles may be lower than previously suggested. A non-amplified Est alpha with a unique EcoRI band was present in Pel RR. The previous esterase purification procedures may not have separated these amplified and non-amplified alleles. Hence, the small differences between the purified esterases from resistant strains may reflect mixtures of identical amplified alleles with different non-amplified alleles, which have significantly different k(a) values.	UNIV WALES COLL CARDIFF,DEPT PURE & APPL BIOL,CARDIFF CF1 3TL,S GLAM,WALES; OPEN UNIV SRI LANKA,DEPT ZOOL,NUGEGODA,SRI LANKA	Cardiff University; Open University Sri Lanka				Hemingway, Janet/0000-0002-3200-7173				Aldridge W. N., 1972, ENZYME INHIBITORS SU; BISSET JA, 1990, B ENTOMOL RES, V80, P245, DOI 10.1017/S0007485300050434; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEVONSHIRE AL, 1991, ANNU REV ENTOMOL, V36, P1, DOI 10.1146/annurev.en.36.010191.000245; GEORGHIOU GP, 1978, J ECON ENTOMOL, V71, P201, DOI 10.1093/jee/71.2.201; HEMINGWAY J, 1990, MED VET ENTOMOL, V4, P275, DOI 10.1111/j.1365-2915.1990.tb00440.x; JAYAWARDENA KGI, 1994, B ENTOMOL RES, V84, P39, DOI 10.1017/S000748530003220X; KARUNARATNE SHPP, 1993, BIOCHEM J, V294, P575, DOI 10.1042/bj2940575; KETTERMAN AJ, 1992, BIOCHEM J, V287, P355, DOI 10.1042/bj2870355; KETTERMAN AJ, 1993, PESTIC BIOCHEM PHYS, V47, P142, DOI 10.1006/pest.1993.1072; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAIN AR, 1963, NATURE, V198, P551, DOI 10.1038/198551a0; MOUCHES C, 1986, SCIENCE, V233, P778, DOI 10.1126/science.3755546; PEIRIS HTR, 1990, B ENTOMOL RES, V80, P49, DOI 10.1017/S0007485300045910; PEIRIS HTR, 1990, B ENTOMOL RES, V80, P453, DOI 10.1017/S0007485300050719; RAYMOND M, 1987, J MED ENTOMOL, V24, P24, DOI 10.1093/jmedent/24.1.24; RAYMOND M, 1989, BIOCHEM GENET, V27, P417, DOI 10.1007/BF02399670; RAYMOND M, 1991, NATURE, V350, P151, DOI 10.1038/350151a0; VAUGHAN A, 1995, J BIOL CHEM, V270, P17044, DOI 10.1074/jbc.270.28.17044; VAUGHAN A, 1995, BIOCHEM J, V305, P651, DOI 10.1042/bj3050651	21	46	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31124	31128		10.1074/jbc.270.52.31124	http://dx.doi.org/10.1074/jbc.270.52.31124			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537374	hybrid			2022-12-25	WOS:A1995TN44400042
J	Kim, JS; Soucek, J; Matousek, J; Raines, RT				Kim, JS; Soucek, J; Matousek, J; Raines, RT			Mechanism of ribonuclease cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE SEMINAL RIBONUCLEASE; AMINO-ACID-SEQUENCE; PROTEIN; ANGIOGENIN; INVITRO; GROWTH; RNASE; MUTAGENESIS; INHIBITOR; OOCYTES	Bovine seminal ribonuclease (BS-RNase), a dimeric homolog of bovine pancreatic ribonuclease A (RNase A), is toxic to mammalian cells. In contrast to dimeric BS-RNase, monomeric BS-RNase and RNase A are not cytotoxic and are bound tightly by cytosolic ribonuclease inhibitor. To elucidate the mechanism of ribonuclease cytotoxicity, we constructed a series of hybrid and semisynthetic enzymes and examined their properties. In five hybrid enzymes, divergent residues in BS-RNase were replaced with the analogous residues of RNase A so as to diminish an interaction with a putative cellular receptor, In a semisynthetic enzyme, the disulfide bonds that cross-link the monomeric subunits of dimeric BS-RNase were replaced with thioether bonds, which can withstand the reducing environment of the cytosol. Each hybrid and semisynthetic enzyme had ribonucleolytic and cytotoxic activities comparable with those of wild-type BS-RNase. These results suggest that dimeric BS-RNase (pI = 10.3) enters cells by adsorptive rather than receptor-mediated endocytosis and then evades cytosolic ribonuclease inhibitor so as to degrade cellular RNA. This mechanism accounts for the need for a cyto solic ribonuclease inhibitor and for the cytotoxicity of other homologs of RNase A.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; INST HEMATOL & BLOOD TRANSFUS,DEPT CELL PHYSIOL,CR-12820 PRAGUE 2,CZECH REPUBLIC; INST PHYSIOL & GENET,CR-27721 LIBECHOV,CZECH REPUBLIC	University of Wisconsin System; University of Wisconsin Madison; Institute of Hematology Prague			KIM, Jin-Soo/M-6918-2013; Raines, Ronald T./A-5009-2013	KIM, Jin-Soo/0000-0003-4847-1306; Raines, Ronald T./0000-0001-7164-1719	NIGMS NIH HHS [GM-44783] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044783] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALLEMANN RK, 1991, PROTEIN ENG, V4, P831, DOI 10.1093/protein/4.7.831; ARDELT W, 1991, J BIOL CHEM, V266, P245; BARTHOLEYNS J, 1976, P NATL ACAD SCI USA, V73, P573, DOI 10.1073/pnas.73.2.573; BARTHOLEYNS J, 1979, EUR J CANCER, V15, P85, DOI 10.1016/0014-2964(79)90209-3; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; Blackburn P, 1982, ENZYMES, VXV, P317; CAFARO V, 1995, FEBS LETT, V359, P31, DOI 10.1016/0014-5793(94)01450-F; CAPASSO S, 1983, BIOPOLYMERS, V22, P327, DOI 10.1002/bip.360220142; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DALESSIO G, 1972, EUR J BIOCHEM, V26, P153, DOI 10.1111/j.1432-1033.1972.tb01751.x; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P106; DENIGRIS M, 1993, BIOCHEM BIOPH RES CO, V193, P155, DOI 10.1006/bbrc.1993.1603; DEONARAIN MP, 1994, BRIT J CANCER, V70, P786, DOI 10.1038/bjc.1994.400; DIDONATO A, 1994, J BIOL CHEM, V269, P17394; DOSTAL J, 1973, J REPROD FERTIL, V33, P263, DOI 10.1530/jrf.0.0330263; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HARPER JW, 1989, BIOCHEMISTRY-US, V28, P1875, DOI 10.1021/bi00430a067; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOFSTEENGE J, 1994, CURR OPIN STRUC BIOL, V4, P807, DOI 10.1016/0959-440X(94)90260-7; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAMES K, 1984, IMMUNOL TODAY, V5, P357, DOI 10.1016/0167-5699(84)90079-3; KIM JS, 1995, J BIOL CHEM, V270, P10525, DOI 10.1074/jbc.270.18.10525; KIM JS, 1995, BIOCHEM J, V308, P547, DOI 10.1042/bj3080547; KIM JS, 1993, J BIOL CHEM, V268, P17392; KIM JS, 1994, EUR J BIOCHEM, V224, P109, DOI 10.1111/j.1432-1033.1994.tb20001.x; KIM JS, 1995, ANAL BIOCHEM, V225, P174, DOI 10.1006/abio.1995.1131; KIM JS, 1994, THESIS U WISCONSIN M; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P76; KUNITZ M, 1946, J BIOL CHEM, V164, P563; LACCETTI P, 1992, CANCER RES, V52, P4582; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; LEES WJ, 1993, J ORG CHEM, V58, P642, DOI 10.1021/jo00055a016; MANCHENO JM, 1994, BIOCHEM BIOPH RES CO, V199, P119, DOI 10.1006/bbrc.1994.1202; MATOUSEK J, 1995, COMP BIOCHEM PHYS B, V112, P235, DOI 10.1016/0305-0491(95)00075-5; MATOUSEK J, 1991, ANIM SCI PAPERS REP, V7, P5; MAZZARELLA L, 1987, GAZZ CHIM ITAL, V117, P91; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; MIKULSKI SM, 1995, INT J ONCOL, V6, P889; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; MURTHY BS, 1992, BIOCHEM J, V281, P343, DOI 10.1042/bj2810343; PARENTE A, 1985, BIOCHEMISTRY-US, V24, P1098, DOI 10.1021/bi00326a005; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; PICCOLI R, 1988, BIOCHEM J, V253, P329, DOI 10.1042/bj2530329; PICCOLI R, 1993, 3RD INT M NAPL; RAINES RT, 1995, J BIOL CHEM, V270, P17180, DOI 10.1074/jbc.270.29.17180; ROTH JS, 1967, METHOD CANCER RES, V3, P153; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; SHORTMAN K, 1961, BIOCHIM BIOPHYS ACTA, V51, P37, DOI 10.1016/0006-3002(61)91014-9; SOUCEK J, 1986, NAT IMMUN CELL GROW, V5, P250; SUZUKI H, 1987, BIOL CHEM H-S, V368, P1305, DOI 10.1515/bchm3.1987.368.2.1305; TAMBURRINI M, 1990, EUR J BIOCHEM, V190, P145, DOI 10.1111/j.1432-1033.1990.tb15557.x; TAYLOR CB, 1993, P NATL ACAD SCI USA, V90, P5118, DOI 10.1073/pnas.90.11.5118; UI N, 1971, BIOCHIM BIOPHYS ACTA, V229, P567; VESCIA S, 1980, CANCER RES, V40, P3740; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; YOULE RJ, 1993, CRIT REV THER DRUG, V10, P1	62	101	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31097	31102		10.1074/jbc.270.52.31097	http://dx.doi.org/10.1074/jbc.270.52.31097			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537370	Green Published, hybrid			2022-12-25	WOS:A1995TN44400038
J	Osada, S; Takano, K; Nishihara, T; Suzuki, T; Muramatsu, M; Imagawa, M				Osada, S; Takano, K; Nishihara, T; Suzuki, T; Muramatsu, M; Imagawa, M			CCAAT/enhancer-binding proteins alpha and beta interact with the silencer element in the promoter of glutathione S-Transferase P gene during hepatocarcinogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SYNERGISTICALLY ACTIVATE TRANSCRIPTION; ALPHA-1-ACID GLYCOPROTEIN GENE; NUCLEAR-PROTEIN; C/EBP FAMILY; CHEMICAL HEPATOCARCINOGENESIS; GLUCOCORTICOID RECEPTOR; RESPONSIVE ELEMENT; EXPRESSION NF-IL6; MOLECULAR-CLONING	We have previously identified a silencer in the glutathione S-transferase P (GST-P) gene which is strongly and specifically expressed during chemical hepatocarcinogenesis. At least three trans-acting factors bind to multiple cis-elements in the silencer. One of them, Silencer Factor-B (SF-B), is identical with CCAAT/enhancer-binding protein beta (C/EBP beta) and binds to GST-P Silencer 1 (GPS1). Many C/EBP beta binding sites are recognized by each of the C/EBP isoforms. Western blot analyses of C/EBP isoforms during chemical hepatocarcinogenesis revealed a decrease of C/EBP alpha expression. However, there was no change in C/EBP beta level. In the nuclear extracts from normal liver, C/EBP alpha was the dominant form that bound to GPS1, whereas both C/EBP alpha and C/EBP beta bound to GPS1 in the nuclear extracts from carcinogenic liver. Furthermore, transfection assays showed that C/EBP alpha not only repressed the GST-P promoter activity but also attenuated the transcriptional stimulation by C/EBP beta. These observations strongly suggest that the ratio of C/EBP alpha to C/EBP beta is one of the important factors for the GST-P silencer activity, and the decrease of this ratio during hepatocarcinogenesis reduces the silencer activity and, consequently, increases the GST-P expression.	OSAKA UNIV, FAC PHARMACEUT SCI, DEPT ENVIRONM BIOCHEM, SUITA, OSAKA 565, JAPAN; SAITAMA MED SCH, DEPT BIOCHEM, MOROYAMA, SAITAMA 35004, JAPAN	Osaka University; Saitama Medical University								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1993, J BIOL CHEM, V268, P15681; BETTS JC, 1993, J BIOL CHEM, V268, P25624; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN HM, 1993, MOL CELL BIOL, V13, P6766, DOI 10.1128/MCB.13.11.6766; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; IMAGAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P293, DOI 10.1016/0006-291X(91)91368-M; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAGEYAMA R, 1991, J BIOL CHEM, V266, P15525; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MORIMURA S, 1993, P NATL ACAD SCI USA, V90, P2065, DOI 10.1073/pnas.90.5.2065; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; NISHIZAWA M, 1991, FEBS LETT, V282, P95, DOI 10.1016/0014-5793(91)80452-9; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; OKUDA A, 1987, J BIOL CHEM, V262, P3858; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PEI DQ, 1990, J VIROL, V64, P1517, DOI 10.1128/JVI.64.4.1517-1522.1990; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Sambrook J, 1989, MOL CLONING LABORATO; SATO K, 1989, ADV CANCER RES, V52, P205; SOLT D, 1976, NATURE, V263, P701, DOI 10.1038/263701a0; SUGIOKA Y, 1985, CANCER RES, V45, P365; SUGUOKA Y, 1985, NUCLEIC ACIDS RES, V13, P6049, DOI 10.1093/nar/13.17.6049; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	41	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31288	31293		10.1074/jbc.270.52.31288	http://dx.doi.org/10.1074/jbc.270.52.31288			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537397	hybrid			2022-12-25	WOS:A1995TN44400064
J	Aarhus, R; Graeff, RM; Dickey, DM; Walseth, TF; Lee, HC				Aarhus, R; Graeff, RM; Dickey, DM; Walseth, TF; Lee, HC			ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP(+)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL TRISPHOSPHATE; CYCLIC METABOLITE; CA2+ RELEASE; ANTIGEN CD38; NAD+; HYDROLYSIS; ENZYME	ADP-ribosyl cyclase catalyzes the cyclization of NAD(+) to produce cyclic ADP-ribose (cADPR), which is emerging as an endogenous regulator of the Ca2+-induced Ca2+ release mechanism in cells, CD38 is a lymphocyte differentiation antigen which has recently been shown to be a bifunctional enzyme that can synthesize cADPR from NAD(+) as well as hydrolyze cADPR to ADP-ribose, In this study, we show that both the cyclase and CD38 can also catalyze the exchange of the nicotinamide group of NADP(+) with nicotinic acid (NA). The product is nicotinic acid adenine dinucleotide phosphate (NAADP(+)), a metabolite we have previously shown to be potent in Ca2+ mobilization (Lee, H. C., and Aarhus, R. (1995) J. Biol. Chem. 270, 2152-2157). The switch of the catalysis to the exchange reaction requires acidic pH and NA. The half-maximal effective concentration of NA is about 5 mM for both the cyclase and CD38. In the absence of NA or at neutral pH, the cyclase converts NADP(+) to another metabolite, which is identified as cyclic ADP-ribose 2'-phosphate, Under the same conditions, CD38 converts NADP(+) to ADP-ribose 2'-phosphate instead, which is the hydrolysis product of cyclic ADP-ribose 2'-phosphate. That two different products of ADP-ribosyl cyclase and CD38, cADPR and NAADP(+), are both involved in Ca2+ mobilization suggests a crucial role of these enzymes in Ca2+ signaling.	UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Lee, Hon Cheung/C-4329-2009; Walseth, Timothy F/F-9518-2010; Graeff, Richard Milton/B-3425-2011	Walseth, Timothy F/0000-0003-2558-7859; 	NICHD NIH HHS [HD17484] Funding Source: Medline; NIDA NIH HHS [DA08131] Funding Source: Medline; NIGMS NIH HHS [T32GM07994] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA008131] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; Bernofsky C, 1980, Methods Enzymol, V66, P105; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; FRYXELL KB, 1995, PROTEIN EXPRES PURIF, V6, P329, DOI 10.1006/prep.1995.1043; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HELLMICH MR, 1991, CELL REGUL, V2, P1193; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; LEE HC, 1993, J BIOL CHEM, V268, P293; Price S.R., 1987, PYRIDINE NUCLEOTIDE, V2B, P513; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TOHGO A, 1994, J BIOL CHEM, V269, P28555; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y	27	329	347	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30327	30333		10.1074/jbc.270.51.30327	http://dx.doi.org/10.1074/jbc.270.51.30327			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530456	hybrid			2022-12-25	WOS:A1995TL67500021
J	Chatani, Y; Tanimura, S; Miyoshi, N; Hattori, A; Sato, M; Kohno, M				Chatani, Y; Tanimura, S; Miyoshi, N; Hattori, A; Sato, M; Kohno, M			Cell type-specific modulation of cell growth by transforming growth factor beta 1 does not correlate with mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; MAP KINASE; SIGNAL-TRANSDUCTION; II RECEPTOR; MAMMALIAN-CELLS; C-MYC; PHOSPHORYLATION; INHIBITION; PROLIFERATION; EXPRESSION	Transforming growth factor beta 1 (TGF-beta 1) is a multifunctional cytokine that positively or negatively regulates the proliferation of various types of cells. In this study we have examined whether or not the activation of the mitogen-activated protein (MAP) kinases is involved in the transduction of cell growth modulation signals of TGF-beta 1, as MAP kinase activity is known to be closely associated with cell cycle progression. Although TGF-beta 1 stimulated the growth of quiescent Balb 3T3 and Swiss 3T3 cells, it failed to detectably stimulate the tyrosine phosphorylation and activation of the 41- and 43-kDa MAP kinases at any time point up to the reinitiation of DNA replication. TGF-beta 1 also failed to stimulate the expression of the c-fos gene. Furthermore, TGF-beta 1 synergistically enhanced the mitogenic action of epidermal growth factor (EGF) without affecting EGF-induced MAP kinase activation in these fibroblasts, and it inhibited the EGF-stimulated proliferation of mouse keratinocytes (PAM212) without inhibiting EGF-induced MAP kinase activation. Thus, the ability of TGF-beta 1 to modulate cell proliferation is apparently not associated with the activation of MAP kinases. In this respect, TGF-beta 1 is clearly distinct from the majority, if not all, of peptide growth factors, such as platelet-derived growth factor and EGF, whose ability to modulate cell proliferation is closely associated with the activation of MAP kinases. These results also suggest that the activation of MAP kinases is not an absolute requirement for growth factor-stimulated mitogenesis.	GIFU PHARMACEUT UNIV,DEPT BIOL,GIFU 502,JAPAN	Gifu Pharmaceutical University								AHN NG, 1991, J BIOL CHEM, V266, P4220; ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EBLEN ST, 1994, CELL GROWTH DIFFER, V5, P109; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOHNO M, 1992, BIOCHEM J, V287, P917, DOI 10.1042/bj2870917; KOHNO M, 1985, J BIOL CHEM, V260, P1771; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAMY F, 1993, J BIOL CHEM, V268, P8398; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MULDER KM, 1988, BIOCHEM BIOPH RES CO, V150, P711, DOI 10.1016/0006-291X(88)90449-4; NAKASHIMA S, 1994, BIOCHEM BIOPH RES CO, V198, P497, DOI 10.1006/bbrc.1994.1073; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZAWA N, 1992, CELL REGUL, V1, P747; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; SAUNIER B, 1995, J BIOL CHEM, V270, P3693, DOI 10.1074/jbc.270.8.3693; SEIFERT RA, 1994, J BIOL CHEM, V269, P13951; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	64	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30686	30692		10.1074/jbc.270.51.30686	http://dx.doi.org/10.1074/jbc.270.51.30686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530507	hybrid			2022-12-25	WOS:A1995TL67500072
J	Gaskins, HR; Baldeon, ME; Selassie, L; Beverly, JL				Gaskins, HR; Baldeon, ME; Selassie, L; Beverly, JL			Glucose modulates gamma-aminobutyric acid release from the pancreatic beta TC6 cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOCRINE PANCREAS; INSULIN RELEASE; MOUSE; GABA; GLUCAGON; ISLETS; DECARBOXYLASE; MICRODIALYSIS; SOMATOSTATIN; SECRETION	To determine if endogenous gamma-aminobutyric acid (GABA) is secreted by a pancreatic beta-cell-derived cell line and to determine the effects of glucose on GABA release, beta TC6 cultures were incubated in the presence of 1 or 10 mmol/l glucose for 12 h and then subjected to a 2-h secretion test in Krebs-Ringer buffer containing 1 or 10 mmol/l glucose. beta TC6-conditioned medium was collected at 15, 30, 60, and 120 min after glucose stimulation for GABA analysis by high pressure liquid chromatography-electrochemical detection. After 30 min, medium GABA concentrations were significantly higher (p < 0.05) in cultures that were exposed to high glucose during both the 12-h incubation period and the 2-h secretion test than in the remaining three glucose combinations. To address possible roles of beta-cell-derived GABA, the effect of GABA on glucagon secretion from pancreatic alpha TC6 cells was tested at concentrations released from beta TC6 cells. Inhibition of glucagon secretion by alpha TC6 cells was observed in the presence of GABA at concentrations equivalent to concentrations secreted by beta TC6 cells, The inhibitory effects of GABA on glucagon secretion by alpha TC6 cells were blocked by the GABA(A) receptor antagonist bicuculline and were dissociated from the inhibitory effects of glucose, Together, these results provide the first documentation that endogenous GABA is released from a highly differentiated beta-cell line and that glucose and GABA independently attenuate glucagon secretion by a pancreatic alpha-cell line.	UNIV ILLINOIS,DEPT ANIM SCI,URBANA,IL 61801; TEXAS TECH UNIV,DEPT NUTR,LUBBOCK,TX 79409	University of Illinois System; University of Illinois Urbana-Champaign; Texas Tech University System; Texas Tech University	Gaskins, HR (corresponding author), UNIV ILLINOIS,DIV NUTR SCI,1207 W GREGORY DR,URBANA,IL 61801, USA.			Gaskins, H. Rex/0000-0002-1249-535X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK049192] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-49192] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEVERLY JL, 1995, AM J PHYSIOL, V38, pR1174; BOST E, 1993, DIABETES REV, V11, P204; BRIEL G, 1972, ACTA PHYSIOL SCAND, V84, P247, DOI 10.1111/j.1748-1716.1972.tb05175.x; EFRAT S, 1993, DIABETES, V42, P901, DOI 10.2337/diabetes.42.6.901; ENSINCK JW, 1983, GLUCAGON HDB EXPT PH, V66, P203; ERDO SL, 1990, J NEUROCHEM, V54, P363, DOI 10.1111/j.1471-4159.1990.tb01882.x; GERBER JC, 1979, DIABETES, V28, P1073, DOI 10.2337/diabetes.28.12.1073; GILON P, 1991, ENDOCRINOLOGY, V129, P2521, DOI 10.1210/endo-129-5-2521; GYLFE E, 1974, ENDOCRINOLOGY, V94, P1150, DOI 10.1210/endo-94-4-1150; HAMAGUCHI K, 1990, DIABETES, V39, P415, DOI 10.2337/diabetes.39.4.415; HAMAGUCHI K, 1991, DIABETES, V40, P842, DOI 10.2337/diabetes.40.7.842; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KAWAI K, 1983, ENDOCRINOLOGY, V113, P111, DOI 10.1210/endo-113-1-111; KEHR J, 1988, J NEUROCHEM, V51, P1308, DOI 10.1111/j.1471-4159.1988.tb03101.x; KNAACK D, 1994, DIABETES, V43, P1413, DOI 10.2337/diabetes.43.12.1413; MALAISSE WJ, 1979, METABOLISM, V28, P373, DOI 10.1016/0026-0495(79)90111-2; MICHALIK M, 1992, BIOCHEM PHARMACOL, V44, P1, DOI 10.1016/0006-2952(92)90030-M; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; OKADA Y, 1976, SCIENCE, V194, P620, DOI 10.1126/science.185693; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PATZELT C, 1978, P NATL ACAD SCI USA, V75, P1260, DOI 10.1073/pnas.75.3.1260; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P817, DOI 10.1210/endo-117-3-817; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; REEZT A, 1991, EMBO J, V10, P1275; ROBBINS MS, 1981, DIABETES, V30, P168, DOI 10.2337/diabetes.30.2.168; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; SORENSON RL, 1991, DIABETES, V40, P1365, DOI 10.2337/diabetes.40.11.1365; TANIGUCHI H, 1979, DIABETES, V28, P629, DOI 10.2337/diabetes.28.7.629; THOMASREETZ A, 1993, P NATL ACAD SCI USA, V90, P5317, DOI 10.1073/pnas.90.11.5317; THOMASREETZ AC, 1994, FASEB J, V8, P209, DOI 10.1096/fasebj.8.2.7907072; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; WESTERINK BHC, 1989, N-S ARCH PHARMACOL, V339, P603, DOI 10.1007/BF00168650	33	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30286	30289		10.1074/jbc.270.51.30286	http://dx.doi.org/10.1074/jbc.270.51.30286			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530449	hybrid			2022-12-25	WOS:A1995TL67500014
J	Terauchi, Y; Sakura, H; Yasuda, K; Iwamoto, K; Takahashi, N; Ito, K; Kasai, H; Suzuki, H; Ueda, O; Kamada, N; Jishage, K; Komeda, K; Noda, M; Kanazawa, Y; Taniguchi, S; Miwa, I; Akanuma, Y; Kodama, T; Yazaki, Y; Kadowaki, T				Terauchi, Y; Sakura, H; Yasuda, K; Iwamoto, K; Takahashi, N; Ito, K; Kasai, H; Suzuki, H; Ueda, O; Kamada, N; Jishage, K; Komeda, K; Noda, M; Kanazawa, Y; Taniguchi, S; Miwa, I; Akanuma, Y; Kodama, T; Yazaki, Y; Kadowaki, T			Pancreatic beta-cell-specific targeted disruption of glucokinase gene - Diabetes mellitus due to defective insulin secretion to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							NONSENSE MUTATION; SENSOR	Mice carrying a null mutation in the glucokinase (GK) gene in pancreatic beta-cells, but not in the liver, were generated by disrupting the beta-cell-specific exon. Heterozygous mutant mice showed early-onset mild diabetes due to impaired insulin secretory response to glucose. Homozygotes showed severe diabetes shortly after birth and died within a week, GK-deficient islets isolated from homozygotes showed defective insulin secretion in response to glucose, while they responded to other secretagogues: almost normally to arginine and to some extent to sulfonylureas. These data provide the first direct proof that GK serves as a glucose sensor molecule for insulin secretion and plays a pivotal role in glucose homeostasis, GK-deficient mice serve as an animal model of the insulin secretory defect in human noninsulin-dependent diabetes mellitus.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT PHYSIOL 1,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED COLL,ANIM RES CTR,SHINJUKU KU,TOKYO 160,JAPAN; CSK RES PK INC,MOLEC GENET & EMBRYOL LAB,GOTEMBA 412,JAPAN; JICHI MED SCH,OMIYA MED CTR,OMIYA,SAITAMA 330,JAPAN; MEIJO UNIV,FAC PHARM,DEPT PATHOBIOCHEM,TEMPAKU KU,NAGOYA,AICHI 468,JAPAN; ASAHI LIFE FDN,INST DIABET CARE & RES,CHIYODA KU,TOKYO 100,JAPAN	University of Tokyo; University of Tokyo; Tokyo Medical University; Jichi Medical University; Meijo University; Asahi Life Foundation			Terauchi, Yasuo/AAO-4347-2020	NODA, Mitsuhiko/0000-0003-0413-4631; Kasai, Haruo/0000-0003-2327-9027				AZUMA S, 1991, Japanese Journal of Animal Reproduction, V37, P37; BYRNE MM, 1994, J CLIN INVEST, V93, P1120, DOI 10.1172/JCI117064; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; JETTON TL, 1994, J BIOL CHEM, V269, P3641; KATAGIRI H, 1992, LANCET, V340, P1316, DOI 10.1016/0140-6736(92)92494-Z; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MAGNUSON MA, 1990, DIABETES, V39, P523, DOI 10.2337/diabetes.39.5.523; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MIWA I, 1995, IN PRESS ENZYME PROT; PILKIS SJ, 1994, J BIOL CHEM, V269, P21925; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; SAKURA H, 1992, J CLIN ENDOCR METAB, V75, P1571, DOI 10.1210/jc.75.6.1571; Sambrook J, 1989, MOL CLONING LABORATO; Suzuki Hiroshi, 1994, Journal of Reproduction and Development, V40, P361, DOI 10.1262/jrd.40.361; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WEINHAUS AJ, 1995, DIABETES, V44, P118, DOI 10.2337/diabetes.44.1.118; WOOD SA, 1993, P NATL ACAD SCI USA, V90, P4582, DOI 10.1073/pnas.90.10.4582; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0	23	190	193	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30253	30256		10.1074/jbc.270.51.30253	http://dx.doi.org/10.1074/jbc.270.51.30253			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530440	hybrid			2022-12-25	WOS:A1995TL67500005
J	Wiedlocha, A; Falnes, PO; Rapak, A; Klingenberg, O; Munoz, R; Olsnes, S				Wiedlocha, A; Falnes, PO; Rapak, A; Klingenberg, O; Munoz, R; Olsnes, S			Translocation to cytosol of exogenous, CAAX-tagged acidic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR TRANSLOCATION; DIPHTHERIA-TOXIN; PROTEIN TRANSFERASE; FACTOR-I; CELLS; RECEPTOR; BINDING; FAMILY; P21RAS; IDENTIFICATION	Acidic fibroblast growth factor (aFGF) added externally to cells has been proposed to enter the nucleus and stimulate DNA synthesis, but it has remained controversial whether or not exogenous aFGF has the capability of crossing cellular membranes. To test this, a novel principle to study translocation of proteins to the cytosol was developed by fusing a C-terminal farnesylation signal, a CAAX tag (C = Cys, A = an aliphatic amino acid, and X = any amino acid), onto aFGF. Farnesylation is only known to occur in the cytosol and possibly in the nucleus. When incubated with NIH3T3 cells overnight, about one-third of the cell-associated, CAAX-tagged growth factor was farnesylated, indicating that efficient translocation had taken place. Binding to specific FGF receptors was required for translocation to occur. Part of the farnesylated growth factor was found in the nuclear fraction. The data indicate that CAAX-tagged aFGF added externally to cells is able to cross cellular membranes and enter the cytosol and the nucleus.			Wiedlocha, A (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,MONTEBELLO,N-0310 OSLO,NORWAY.		Rapak, Andrzej/ABE-6262-2021; Falnes, Pål Ø./AAA-4581-2020	Rapak, Andrzej/0000-0003-4897-0287; Falnes, Pal/0000-0001-8114-6025; Munoz, Raquel/0000-0001-9861-0349				BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO Y, 1993, J CELL SCI, V104, P77; CAO YH, 1993, GROWTH FACTORS, V8, P277, DOI 10.3109/08977199308991573; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FALNES PO, 1995, BIOCHEMISTRY-US, V34, P11152, DOI 10.1021/bi00035a021; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1992, J BIOL CHEM, V267, P5676; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; MADSHUS IH, 1984, EMBO J, V3, P1945, DOI 10.1002/j.1460-2075.1984.tb02074.x; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; OLSNES S, 1974, NATURE, V249, P627, DOI 10.1038/249627a0; Olsnes S., 1988, IMMUNOTOXINS, P39; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7270; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SINENSKY M, 1994, J CELL SCI, V107, P61; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N	48	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30680	30685		10.1074/jbc.270.51.30680	http://dx.doi.org/10.1074/jbc.270.51.30680			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530506	hybrid			2022-12-25	WOS:A1995TL67500071
J	Yamamoto, T; Matsui, T; Nakafuku, M; Iwamatsu, A; Kaibuchi, K				Yamamoto, T; Matsui, T; Nakafuku, M; Iwamatsu, A; Kaibuchi, K			A novel GTPase-activating protein for R-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; EXCHANGE PROTEIN; DOMAIN; GENE; BINDING; P21; IDENTIFICATION; KINASE; CDNA	R-Ras, belonging to the Pas small GTP-binding protein superfamily, has been implicated in regulation of various cell functions such as gene expression, cell proliferation, and apoptotic cell death. In the present study, we purified an R-Ras-interacting protein with molecular mass of about 98 kDa (p98) from bovine brain cytosol by glutathione S-transferase (GST)-R-Ras affinity column chromatography. This protein bound to GTP gamma S (guanosine 5'-(3-O-thio)triphosphate, a nonhydrolyzable GTP analog). R-Ras but not to GDP . R-Ras, GTP gamma S . R-Ras with a mutation in the effector domain (R-Ras(A64)), GTP gamma S . Ha-Ras, or GTP gamma S . RalA. We obtained a cDNA encoding p98 on the basis of its partial amino acid sequences, The predicted protein consists of 834 amino acids whose calculated mass, 95,384 Da, is close to the apparent molecular mass of p98. The amino acid sequence shows a high degree of sequence similarity to the entire sequence of Gap1(m), one of the GTPase-activating proteins (GAP) for Ha-Ras. A recombinant protein consisting of the GAP-related domain of p98 fused to maltose-binding protein stimulated GTPase activity of R-Ras, and showed a weak effect on that of Ha-Ras but not that of Rap1 or Rho. These results clearly indicate that p98 is a novel GAP for R-Ras. Thus, we designated this protein as R-Ras GAP.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA,NARA 63001,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN	Nara Institute of Science & Technology; Kirin Brewery Company Limited			Nakafuku, Masato/J-3068-2013	Nakafuku, Masato/0000-0001-7783-9005				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COX AD, 1994, ONCOGENE, V9, P3281; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PERIN MS, 1991, J BIOL CHEM, V266, P623; REY I, 1994, ONCOGENE, V9, P685; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Shuldiner A R, 1993, Methods Mol Biol, V15, P169, DOI 10.1385/0-89603-244-2:169; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J	36	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30557	30561		10.1074/jbc.270.51.30557	http://dx.doi.org/10.1074/jbc.270.51.30557			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530488	hybrid			2022-12-25	WOS:A1995TL67500053
J	GRACEFFA, P				GRACEFFA, P			CROSS-LINKING AND FLUORESCENCE STUDY OF THE COOH-TERMINAL AND NH2-TERMINAL DOMAINS OF INTACT CALDESMON BOUND TO ACTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; CHICKEN GIZZARD CALDESMON; LIGHT-CHAIN KINASE; THIN-FILAMENTS; BINDING FRAGMENT; TROPONIN-T; F-ACTIN; MOLECULAR-WEIGHT; ATPASE ACTIVITY; C-TERMINUS	The NH2- and COOH-terminal domains of muscle caldesmon are separated by a long alpha-helical stretch, Cys-580, in the COOH-terminal domain, can be rapidly and efficiently disulfide-cross-linked to Cys-374 of actin by incubation with actin modified with 5,5'-dithiobis(2-nitrobenzoic acid) (Graceffa, P., and Jancso, A (1991) J. Biol. Chem. 266, 20305-20310). Upon further incubation (+/-tropomyosin), a second cross-link was slowly formed between Cys-153 in the NH2-terminal domain and Cys-374 of another actin monomer. The yield of the second cross-link was relatively insensitive to increasing ionic strength, whereas the caldesmon-actin binding strength decreased considerably, suggesting that the NH2-terminal domain is largely dissociated hom actin and becomes slowly cross-linked to it during collisions with the actin filament. In support of these conclusions, the yield of photocross-linking actin to caldesmon specifically labeled with benzophenonemaleimide at Cys-580 was high, but close to zero for caldesmon labeled at Cys-153, and the fluorescence intensity and polarization of tetramethylrhodamine iodoacetamide attached to Cys-580 showed large changes, while there were no changes for the probe at Cys-153 upon binding caldesmon to actin (+/-tropomyosin). These findings are consistent with the knowledge that COOH-terminal fragments of caldesmon bind to actin, whereas NH2-terminal fragments do not. Since the NH2-terminal domain of caldesmon binds to myosin, a dissociated NH2-terminal domain may account for caldesmon's ability to link myosin and actin filaments.			GRACEFFA, P (corresponding author), BOSTON BIOMED RES INST,MUSCLE RES GRP,20 STANIFORD ST,BOSTON,MA 02114, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030917, P01AR041637] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-30917, AR-41637] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALL EH, 1988, BIOCHEMISTRY-US, V27, P6093, DOI 10.1021/bi00416a039; BIRUKOV KG, 1990, FEBS LETT, V262, P263, DOI 10.1016/0014-5793(90)80206-X; BOGATCHEVA NV, 1993, BIOCHEM J, V290, P437, DOI 10.1042/bj2900437; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CZURYLO EA, 1991, BIOPHYS CHEM, V40, P181, DOI 10.1016/0301-4622(91)87007-R; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; FUJII T, 1987, J BIOL CHEM, V262, P2757; FUJII T, 1988, J BIOCHEM-TOKYO, V104, P734, DOI 10.1093/oxfordjournals.jbchem.a122542; GERTHOFFER WT, 1991, AM J PHYSIOL, V261, pL15, DOI 10.1152/ajplung.1991.261.2.L15; GOODY RS, 1983, BIOCHIM BIOPHYS ACTA, V726, P13, DOI 10.1016/0304-4173(83)90009-5; GRACEFFA P, 1993, ARCH BIOCHEM BIOPHYS, V307, P21, DOI 10.1006/abbi.1993.1554; GRACEFFA P, 1988, J BIOL CHEM, V263, P14196; GRACEFFA P, 1991, J BIOL CHEM, V266, P20305; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; GRACEFFA P, 1993, BIOCHEM J, V294, P63, DOI 10.1042/bj2940063; GRACEFFA P, 1993, BIOPHYS J, V64, P29; GUSEV NB, 1991, BIOCHEMISTRY-MOSCOW+, V56, P939; HAEBERLE JR, 1992, J BIOL CHEM, V267, P23001; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; HEMRIC ME, 1994, J BIOL CHEM, V269, P4125; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; HEMRIC ME, 1988, J BIOL CHEM, V262, P1878; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; IKEBE M, 1988, J BIOL CHEM, V263, P3055; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KATAYAMA E, 1995, J BIOL CHEM, V270, P3919, DOI 10.1074/jbc.270.8.3919; KATAYAMA E, 1989, BIOCHEM BIOPH RES CO, V160, P1316, DOI 10.1016/S0006-291X(89)80147-0; KATSUYAMA H, 1992, J BIOL CHEM, V267, P14555; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P1371, DOI 10.1016/S0006-291X(89)80155-X; LESZYK J, 1989, BIOCHEM BIOPH RES CO, V160, P210, DOI 10.1016/0006-291X(89)91642-2; LYNCH WP, 1987, J BIOL CHEM, V262, P7429; MABUCHI K, 1993, J MUSCLE RES CELL M, V14, P54, DOI 10.1007/BF00132180; MARSTON S, 1992, J MUSCLE RES CELL M, V13, P206, DOI 10.1007/BF01874158; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1989, J MUSCLE RES CELL M, V10, P97, DOI 10.1007/BF01739965; MIYANISHI T, 1989, BIOCHEMISTRY-US, V28, P1287, DOI 10.1021/bi00429a051; MOODY C, 1990, J MUSCLE RES CELL M, V11, P176, DOI 10.1007/BF01766496; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; NAGY B, 1965, J AM CHEM SOC, V87, P2480; NGAI PK, 1984, BIOCHEM J, V218, P863, DOI 10.1042/bj2180863; PFITZER G, 1993, P NATL ACAD SCI USA, V90, P5904, DOI 10.1073/pnas.90.13.5904; POPP D, 1992, J MOL BIOL, V224, P65, DOI 10.1016/0022-2836(92)90576-6; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; STRZELECKAGOLAS.H, 1980, EUR J BIOCHEM, V104, P41; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; SZPACENKO A, 1985, FEBS LETT, V192, P9, DOI 10.1016/0014-5793(85)80032-6; TANSEY MG, 1990, FEBS LETT, V270, P219, DOI 10.1016/0014-5793(90)81272-P; TAYLOR DL, 1981, J CELL BIOL, V89, P362, DOI 10.1083/jcb.89.2.362; VELAZ L, 1993, BIOPHYS J, V65, P892, DOI 10.1016/S0006-3495(93)81113-5; WANG CLA, 1991, J BIOL CHEM, V266, P13958; WANG CLA, 1988, BIOCHEM BIOPH RES CO, V156, P1033, DOI 10.1016/S0006-291X(88)80948-3; WATSON MH, 1990, J BIOL CHEM, V265, P18860; WATSON MH, 1990, BIOCHIM BIOPHYS ACTA, V1054, P103, DOI 10.1016/0167-4889(90)90211-U	65	14	14	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30187	30193						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530428				2022-12-25	WOS:A1995TK38000088
J	SPICER, AP; ROWSE, GJ; LIDNER, TK; GENDLER, SJ				SPICER, AP; ROWSE, GJ; LIDNER, TK; GENDLER, SJ			DELAYED MAMMARY-TUMOR PROGRESSION IN MUC-1 NULL MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; RAT INTESTINAL MUCIN; MOUSE PGK-1 GENE; MOLECULAR-CLONING; BREAST-CANCER; METASTATIC DISEASE; MESSENGER-RNA; CELL-LINES; EXPRESSION; CDNA	The mucin gene, Muc-1, encodes a high molecular weight integral membrane glycoprotein that is present on the apical surface of most simple secretory epithelial cells. Muc-1 is highly expressed and aberrantly glycosylated by most carcinomas and metastatic lesions. Numerous functions have been proposed for this molecule, including protection of the epithelial cell surface, an involvement in epithelial organogenesis, and a role in tumor progression. Mice deficient in Muc-1 were generated using homologous recombination in embryonic stem cells. These mice appeared to develop normally and were healthy and fertile. However, the growth rate of primary breast tumors induced by polyoma middle T antigen was found to be significantly slower in Muc-1 deficient mice. This suggests that Muc-1 plays an important role in the progression of mammary carcinoma.	MAYO CLIN SCOTTSDALE, SCOTTSDALE, AZ 85259 USA; MAYO CLIN SCOTTSDALE, DEPT PATHOL, SCOTTSDALE, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix					NATIONAL CANCER INSTITUTE [R01CA064389] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ARUFFO A, 1992, P NATL ACAD SCI USA, V89, P2292, DOI 10.1073/pnas.89.6.2292; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; BOSHELL M, 1992, BIOCHEM BIOPH RES CO, V185, P1, DOI 10.1016/S0006-291X(05)80946-5; BRAGA VMM, 1992, DEVELOPMENT, V115, P427; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; BURCHELL J, 1984, INT J CANCER, V34, P763, DOI 10.1002/ijc.2910340605; CERIANI RL, 1977, P NATL ACAD SCI USA, V74, P582, DOI 10.1073/pnas.74.2.582; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUNG PYS, 1991, CANCER RES, V51, P1170; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GUM JR, 1991, J BIOL CHEM, V266, P22733; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HANSKI C, 1993, CANCER RES, V53, P4082; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; HAYES DF, 1985, J CLIN INVEST, V75, P1671, DOI 10.1172/JCI111875; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; HILKENS J, 1986, CANCER RES, V46, P2582; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KHATRI IA, 1993, BIOCHEM J, V294, P391, DOI 10.1042/bj2940391; KINGSMORE SF, 1995, MAMM GENOME, V6, P378, DOI 10.1007/BF00364808; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAN MS, 1990, J BIOL CHEM, V265, P15294; LANCASTER CA, 1990, BIOCHEM BIOPH RES CO, V173, P1019, DOI 10.1016/S0006-291X(05)80888-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIGTENBERG MJL, 1992, J BIOL CHEM, V267, P6171; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; MAJURI ML, 1992, BIOCHEM BIOPH RES CO, V182, P1376, DOI 10.1016/0006-291X(92)91885-T; MATSUI Y, 1989, GENE, V77, P325, DOI 10.1016/0378-1119(89)90080-2; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; METZGAR RS, 1984, P NATL ACAD SCI-BIOL, V81, P5242, DOI 10.1073/pnas.81.16.5242; MIDDLETONPRICE H, 1988, ANN HUM GENET, V52, P273, DOI 10.1111/j.1469-1809.1988.tb01107.x; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NAKAMORI S, 1994, GASTROENTEROLOGY, V106, P353, DOI 10.1016/0016-5085(94)90592-4; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; OHMORI H, 1994, J BIOL CHEM, V269, P17833; PARRY G, 1990, EXP CELL RES, V188, P302, DOI 10.1016/0014-4827(90)90174-9; PEMBERTON L, 1992, BIOCHEM BIOPH RES CO, V185, P167, DOI 10.1016/S0006-291X(05)80971-4; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1986, CANCER RES, V46, P4543; SIMPSONHERREN L, 1970, CANCER CHEMOTH REP 1, V54, P143; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SPICER AP, 1993, THESIS U COLLEGE LON; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; VOS HL, 1991, BIOCHEM BIOPH RES CO, V181, P121, DOI 10.1016/S0006-291X(05)81390-7; VOS HL, 1992, J BIOL CHEM, V267, P12192; VOS HL, 1995, IN PRESS MAMM GENOME; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; WILKINSON M, 1991, NUCLEIC ACIDS RES, V19, P679, DOI 10.1093/nar/19.3.679; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; XU GQ, 1992, J BIOL CHEM, V267, P5401; XU GQ, 1992, BIOCHEM J, V286, P335, DOI 10.1042/bj2860335; YOSHIMURA H, 1991, NUCLEIC ACIDS RES, V19, P3633, DOI 10.1093/nar/19.13.3633; ZARETSKY JZ, 1990, FEBS LETT, V265, P46, DOI 10.1016/0014-5793(90)80880-R; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	76	219	223	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30093	30101						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530414				2022-12-25	WOS:A1995TK38000074
J	DRYDEN, DTF; COOPER, LP; MURRAY, NE				DRYDEN, DTF; COOPER, LP; MURRAY, NE			PURIFICATION AND CHARACTERIZATION OF THE METHYLTRANSFERASE FROM THE TYPE-1 RESTRICTION AND MODIFICATION SYSTEM OF ESCHERICHIA-COLI K12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA RECOGNITION DOMAINS; DEOXYRIBONUCLEIC ACID MODIFICATION; I RESTRICTION; CATALYTIC PROPERTIES; SPECIFICITY POLYPEPTIDES; MODIFICATION ENZYMES; SUBUNIT STRUCTURE; SEQUENCE; ENDONUCLEASE; ORGANIZATION	The DNA methyltransferase component of the type I restriction and modification enzyme of Escherichia coli K12 has been purified. The active component, a trimer of molecular mass 170 kDa consisting of one DNA recognition subunit (S) and two modification subunits (M), showed the expected preference for modifying a hemimethylated substrate rather than an unmethylated one. Small amounts of the dimers M2 and M1S1 were also isolated. Subunit rearrangements of the three protein species occurred on ion exchange and heparin-agarose chromatography. Denaturation of the trimer gave folding intermediates, and these and the dimer forms isolated during purification may reflect the assembly of the protein in vivo. Enzyme activity was recovered on refolding the denatured protein by dilution of the denaturant. A comparison of the predicted isoelectric points of all known S subunits of type I restriction and modification enzymes revealed values that correlated with the arrangement of type I systems in several families. Electrostatic interactions may explain the different subunit stoichiometries observed during purification of type I enzymes and the differing preferences for hemimethylated DNA displayed by the three type I families.			DRYDEN, DTF (corresponding author), UNIV EDINBURGH, INST CELL & MOLEC BIOL, EDINBURGH EH9 3JR, MIDLOTHIAN, SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BICKLE TA, 1978, P NATL ACAD SCI USA, V75, P3099, DOI 10.1073/pnas.75.7.3099; BICKLE TA, 1987, ESCHERICHIA COLI SAL, P692; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BURCKHARDT J, 1981, J MOL BIOL, V153, P425, DOI 10.1016/0022-2836(81)90287-4; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; Chandrasegaran S, 1988, STRUCTURE EXPRESSION, V1, P149; COWAN GM, 1989, CELL, V56, P103, DOI 10.1016/0092-8674(89)90988-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESKIN B, 1972, J BIOL CHEM, V247, P6183; FULLERPACE FV, 1986, P NATL ACAD SCI USA, V83, P9368, DOI 10.1073/pnas.83.24.9368; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GANN AAF, 1987, MOL MICROBIOL, V1, P13, DOI 10.1111/j.1365-2958.1987.tb00521.x; GIANAZZA E, 1980, J CHROMATOGR, V193, P1, DOI 10.1016/S0021-9673(00)81438-7; GORBALENYA AE, 1991, FEBS LETT, V291, P277, DOI 10.1016/0014-5793(91)81301-N; GOUGH JA, 1983, J MOL BIOL, V166, P1, DOI 10.1016/S0022-2836(83)80047-3; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; Jaenicke R, 1989, PROTEIN STRUCTURE PR, P191; KANNAN P, 1989, J MOL BIOL, V209, P335, DOI 10.1016/0022-2836(89)90001-6; KARLIN S, 1990, METHOD ENZYMOL, V183, P388; KELLEHER JE, 1991, J MOL BIOL, V221, P431, DOI 10.1016/0022-2836(91)80064-2; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; KUSIAK M, 1992, MOL MICROBIOL, V6, P3251, DOI 10.1111/j.1365-2958.1992.tb01779.x; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAUTENBERGER JA, 1972, J BIOL CHEM, V247, P6176; LEATHERBARROW RJ, 1990, GRAFT VERSION 2 0; LOENEN WAM, 1987, J MOL BIOL, V198, P159, DOI 10.1016/0022-2836(87)90303-2; MATHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MURRAY NE, 1982, EMBO J, V1, P535, DOI 10.1002/j.1460-2075.1982.tb01205.x; Pace C N, 1986, Methods Enzymol, V131, P266; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PATEL J, 1992, GENE, V112, P21, DOI 10.1016/0378-1119(92)90298-4; PRICE C, 1989, J MOL BIOL, V205, P115, DOI 10.1016/0022-2836(89)90369-0; PRICE C, 1987, EUR J BIOCHEM, V167, P111, DOI 10.1111/j.1432-1033.1987.tb13310.x; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; SAIN B, 1980, MOL GEN GENET, V180, P35, DOI 10.1007/BF00267350; Sambrook J, 1989, MOL CLONING LABORATO; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SHARP PM, 1992, P NATL ACAD SCI USA, V89, P9836, DOI 10.1073/pnas.89.20.9836; SOBER HA, 1970, HDB BIOCH, pB75; SURI B, 1984, EMBO J, V3, P575, DOI 10.1002/j.1460-2075.1984.tb01850.x; SURI B, 1985, J MOL BIOL, V186, P77, DOI 10.1016/0022-2836(85)90258-X; TAYLOR I, 1992, NUCLEIC ACIDS RES, V20, P179, DOI 10.1093/nar/20.2.179; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; YUAN R, 1981, ANNU REV BIOCHEM, V50, P285, DOI 10.1146/annurev.bi.50.070181.001441	47	87	87	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13228	13236						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514761				2022-12-25	WOS:A1993LH55300033
J	SASAKI, K; CHIBA, S; HANAZONO, Y; MANO, H; YAZAKI, Y; HIRAI, H				SASAKI, K; CHIBA, S; HANAZONO, Y; MANO, H; YAZAKI, Y; HIRAI, H			COORDINATE EXPRESSION OF THE ALPHA-CHAIN AND BETA-CHAIN OF HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR CONFERS LIGAND-INDUCED MORPHOLOGICAL TRANSFORMATION IN MOUSE FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; ERYTHROPOIETIN RECEPTOR; RAPID PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INTERLEUKIN-3; PROTEINS; CLONING; SUBUNIT; RECONSTITUTION; ACTIVATION	Two distinct components, alpha and beta chains, which compose the high affinity receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF) do not contain any catalytic domains of known enzymes. However, in mouse lymphoid cell lines transfected with cDNAs of the both chains, GM-CSF triggers tyrosine phosphorylation of several cellular proteins and allows continuous proliferation. To elucidate whether the high affinity receptor functions in nonhematopoietic cells, we have reconstituted human GM-CSF receptor in mouse NIH3T3 fibroblasts. In NIH3T3 clones, in which the high affinity receptor is reconstituted, human GM-CSF has triggered rapid tyrosine phosphorylation of cellular proteins, transfected beta chain, and another protein of 40-45 kDa. Moreover, human GM-CSF stimulated DNA synthesis and induced morphological transformation. These observations indicate that coordinately expressed alpha and beta chains of human GM-CSF receptor activates intrinsic protein-tyrosine kinases by the stimulation with human GM-CSF and that the activated protein-tyrosine kinases phosphorylate tyrosine residues of an intrinsic 40-45-kDa protein and the transfected beta chain in NIH3T3 cells. Activation of the protein-tyrosine kinases is likely to have biological functions to induce DNA synthesis and morphological transformation of mouse fibroblasts.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; CHIBA S, 1990, LEUKEMIA, V4, P29; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; JONES SS, 1990, BLOOD, V76, P31; KANAKURA Y, 1991, BLOOD, V77, P243; KANAKURA Y, 1990, BLOOD, V76, P706; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1992, BLOOD, V80, P84; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; METCALF D, 1990, P NATL ACAD SCI USA, V87, P4670, DOI 10.1073/pnas.87.12.4670; MIYAGAWA K, 1990, J CELL PHYSIOL, V143, P483, DOI 10.1002/jcp.1041430312; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; OKUDA K, 1992, BLOOD, V79, P2880; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHERR CJ, 1988, LEUKEMIA, V2, P132; TAKAGAKI Y, 1989, NATURE, V339, P712, DOI 10.1038/339712a0; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6	30	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13697	13702						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514801				2022-12-25	WOS:A1993LH55300095
J	WULFF, BS; JOHANSEN, TE; DALBOGE, H; OHARE, MMT; SCHWARTZ, TW				WULFF, BS; JOHANSEN, TE; DALBOGE, H; OHARE, MMT; SCHWARTZ, TW			PROCESSING OF 2 HOMOLOGOUS PRECURSORS, PRO-NEUROPEPTIDE-Y AND PRO-PANCREATIC POLYPEPTIDE, IN TRANSFECTED CELL-LINES EXPRESSING DIFFERENT PRECURSOR CONVERTASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA; COMMON PRECURSOR; MAMMALIAN-CELLS; CHO CELLS; CDNA; IDENTIFICATION; PHEOCHROMOCYTOMA; SECRETION; HORMONE; PEPTIDE	The processing of two homologous precursors, pro-neuropeptide Y (pro-NPY) and pro-pancreatic polypeptide (pro-PP), was studied in four neuroendocrine cell lines after transfection: CA-77 medullary thyroid carcinoma cells, AtT-20 corticotrope pituitary cells, RIN2A- 19 pancreatic endocrine cells, and NB1 neuroblastoma cells. Northern blot analysis indicated that the AtT-20 cells only expressed precursor convertase 3; in contrast, NB1 cells only expressed precursor convertase 2, whereas the RIN2A-19 and CA-77 cells expressed both enzymes. Despite these differences in expression pattern of precursor convertases the four cell lines were, surprisingly, indistinguishable in respect to their processing of pro-PP and pro-NPY. In all four cell lines, pro-NPY was almost completely converted to NPY, and, in all four cell lines, only around 50% of the PP precursor was converted to PP. The relatively poor processing efficiency of pro-PP was rather similar to the processing efficiency of the endogenously produced precursors in the respective cell lines, pro-calcitonin (CA-77), proopiomelanocortin (AtT-20), proinsulin (RIN2A-19), and pro-vasoactive intestinal polypeptide (NB1). At least in the CA-77 cells, NPY and PP were apparently sorted to the regulated secretory pathway, as upon stimulation with secretagogue the release of the transfected peptides increased in parallel with the endogenously expressed peptide, calcitonin gene-related peptide. Mutagenesis studies showed that on the N-terminal side of the dibasic processing site, the otherwise important difference in structure between PP and NPY, a proline for glutamine in position 34, was not responsible for the difference in processing efficiency. On the C-terminal side of the processing site, the efficient processing of pro-NPY could not be transferred to pro-PP by exchanging the whole C-terminal domains of the precursors. It is concluded that pro-NPY is processed more efficiently than pro-PP in all neuroendocrine cell lines tested independent on their expression of the two main precursor convertases and that mutagenesis data indicate that the structural element responsible for the efficient processing of pro-NPY is not located on the N-terminal side of the dibasic processing site.	UNIV COPENHAGEN, RIGSHOSP 6321, DEPT CLIN CHEM, MOLEC ENDOCRINOL LAB, DK-2100 COPENHAGEN, DENMARK; NOVO NORD AS, DK-2880 BAGSVAERD, DENMARK	Rigshospitalet; University of Copenhagen; Novo Nordisk				Schwartz, Thue W./0000-0002-0261-6904				BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BIRNBAUM RS, 1984, J BIOL CHEM, V259, P2870; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOEL E, 1984, EMBO J, V3, P909, DOI 10.1002/j.1460-2075.1984.tb01904.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DICKERSON IM, 1987, J BIOL CHEM, V262, P13646; DIKCERSON IM, 1990, J BIOL CHEM, V265, P242; FECHHEIMER M, 1987, P NATL ACAD SCI USA, V84, P8463, DOI 10.1073/pnas.84.23.8463; FUHLENDORFF J, 1990, J BIOL CHEM, V265, P11706; GLOVER I, 1983, BIOPOLYMERS, V22, P293, DOI 10.1002/bip.360220138; GLOVER ID, 1984, EUR J BIOCHEM, V142, P379, DOI 10.1111/j.1432-1033.1984.tb08298.x; HOSHINO M, 1984, PEPTIDES, V5, P155, DOI 10.1016/0196-9781(84)90199-2; JOHANSEN TE, 1990, BIOCHEM BIOPH RES CO, V172, P1384, DOI 10.1016/0006-291X(90)91603-P; JOHANSEN TE, 1991, MOL CELL ENDOCRINOL, V82, P51, DOI 10.1016/0303-7207(91)90008-G; LAPPS W, 1988, J BIOL CHEM, V263, P13456; LI X, 1992, BIOCHEMISTRY-US, V31, P1245, DOI 10.1021/bi00119a038; MAINS RE, 1976, J BIOL CHEM, V251, P4115; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; OHARE MMT, 1985, CANCER, V55, P1895, DOI 10.1002/1097-0142(19850501)55:9<1895::AID-CNCR2820550910>3.0.CO;2-S; OHARE MMT, 1989, CANCER RES, V49, P7015; OHARE MMT, 1989, CANCER RES, V49, P7010; SCHWARTZ TW, 1987, J BIOL CHEM, V262, P5093; SCHWARTZ TW, 1978, J CLIN INVEST, V61, P781, DOI 10.1172/JCI108992; SCHWARTZ TW, 1987, FEBS LETT, V225, P209, DOI 10.1016/0014-5793(87)81159-6; SCHWARTZ TW, 1981, NATURE, V294, P589, DOI 10.1038/294589a0; SCHWARTZ TW, 1980, J BIOL CHEM, V255, P1494; SCHWARTZ TW, 1989, NEUROPEPTIDE Y, P143; SCHWARTZ TW, 1990, ANN NY ACAD SCI, V611, P35; Schwartz TW, 1990, MOL BIOL ISLETS LANG, P153; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SEVARINO KA, 1989, CELL, V57, P11, DOI 10.1016/0092-8674(89)90167-0; SHEIKH SP, 1989, J BIOL CHEM, V264, P6648; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; Steiner D. F., 1991, PEPTIDE BIOSYNTHESIS, P1; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKEUCHI T, 1991, J BIOL CHEM, V266, P17409; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; WATANABE T, 1992, J BIOL CHEM, V267, P8270; WIBORG O, 1985, EMBO J, V4, P755, DOI 10.1002/j.1460-2075.1985.tb03693.x; WULFF BS, 1990, FEBS LETT, V261, P101, DOI 10.1016/0014-5793(90)80646-Z	41	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13327	13335						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514771				2022-12-25	WOS:A1993LH55300047
J	ZELICOF, A; GATICA, J; GERST, JE				ZELICOF, A; GATICA, J; GERST, JE			MOLECULAR-CLONING AND CHARACTERIZATION OF A RAT HOMOLOG OF CAP, THE ADENYLYL CYCLASE-ASSOCIATED PROTEIN FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-ANALYSIS; YEAST; PHOSPHODIESTERASE; ACTIVATION; PROFILIN	We have isolated a rat cDNA whose expression suppresses the physiological consequences of the chromosomal disruption of CAP, the gene encoding the adenylyl cyclase-associated protein of Saccharomyces cerevisiae. Yeast CAP is a bifunctional protein: the NH2 terminus is necessary and sufficient for cellular responsiveness to activated RAS proteins, while the COOH terminus is required for normal cellular morphology and growth control. The rat MCH1 cDNA encodes a protein of 474 amino acids that is 36% identical to S. cerevisiae CAP and is capable of suppressing the loss of the COOH-terminal functions of CAP when expressed in yeast. The MCH1 protein therefore appears to be a structural and functional homolog of the yeast cyclase-associated proteins. Northern analysis of MCH1 gene expression shows it to be constitutively expressed in all cell and tissue types examined. The cloning of a rat homolog of CAP, in addition to the cloning of a human CAP homolog by Matviw et al. (Matviw, H., Yu, G., and Young, D. (1992) Mol. Cell. Biol. 12, 5033-5040), demonstrates that both cyclase-associated proteins and their functions may have evolved with mammalian cells.	CUNY MT SINAI SCH MED, DEPT CELL BIOL & ANAT, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; COLICELLI J, 1991, P NATL ACAD SCI USA, V59, P681; DEFEOJONES D, 1983, NATURE, V306, P707, DOI 10.1038/306707a0; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FUKUI Y, 1985, EMBO J, V4, P687, DOI 10.1002/j.1460-2075.1985.tb03684.x; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; GIESELMANN R, 1992, FEBS LETT, V298, P149, DOI 10.1016/0014-5793(92)80043-G; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KAWAMUKAI M, 1992, MOL BIOL CELL, V3, P167, DOI 10.1091/mbc.3.2.167; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SHILO BZ, 1981, P NATL ACAD SCI-BIOL, V78, P6789, DOI 10.1073/pnas.78.11.6789; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074	29	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13448	13453						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514780				2022-12-25	WOS:A1993LH55300062
J	Liu, NS; Fukami, K; Yu, HY; Takenawa, T				Liu, NS; Fukami, K; Yu, HY; Takenawa, T			A new phospholipase C delta 4 is induced at S-phase of the cell cycle and appears in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-LIVER NUCLEI; SWISS 3T3 CELLS; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; BETA-GAMMA; RECEPTOR; PURIFICATION; STIMULATION	To discover a new phospholipase C (PLC) related to cell growth, we screened a cDNA library prepared from regenerating rat liver. A novel PLC (PLC delta 4) encoding a polypeptide of 770 amino acids with structural similarity to PLC delta-type isozymes was isolated. PLC delta 4 mRNA is expressed more remarkably in regenerating liver than in normal resting liver. It is also distributed abundantly in tumor cells such as hepatoma and src-transformed cells. Furthermore, its expression can be induced markedly by serum treatment and reaches a maximum at 8 h. Western blot analysis and immunocytochemical staining showed that PLC delta 4 is dominantly present in nucleus. Nuclear PLC delta 4 dramatically increases at the transition from G(1)- to S-phase, and the high content continues to the end of M-phase. PLC delta 4 almost disappears when cells re-enter the next G(1) phase. On the other hand, the contents of PLC beta 1, PLC gamma 1, and PLC delta 1 do not change significantly during the cell cycle. These results suggest that PLC delta 4 is expressed in nucleus in response to mitogenic stimulation and plays important roles in cell growth as one of the early genes expressed during the transition from G(1)- to S phase in the cell cycle.	UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								ASANO M, 1994, J BIOL CHEM, V269, P12360; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAPITANI S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P193, DOI 10.1016/0005-2760(90)90303-F; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; COCCO L, 1980, BIOCHEM BIOPH RES CO, V96, P890, DOI 10.1016/0006-291X(80)91439-4; COCCO L, 1989, BIOCHEM BIOPH RES CO, V159, P1720; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; FIELDS AP, 1990, J CELL SCI, V96, P107; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATO H, 1992, J BIOL CHEM, V267, P6483; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KRITZ R, 1991, CIBA F S, V150, P112; KURIKI H, 1992, J BIOCHEM-TOKYO, V111, P283, DOI 10.1093/oxfordjournals.jbchem.a123750; LEE CW, 1993, J BIOL CHEM, V268, P21318; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MELDRUM E, 1989, EUR J BIOCHEM, V182, P673, DOI 10.1111/j.1432-1033.1989.tb14878.x; MELDRUM E, 1991, EUR J BIOCHEM, V196, P159, DOI 10.1111/j.1432-1033.1991.tb15799.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; SCHACHT J, 1978, J LIPID RES, V19, P1063; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SYLVIA V, 1988, CELL, V54, P651, DOI 10.1016/S0092-8674(88)80009-6; TAYLON SJ, 1991, NATURE, V350, P510; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; YORK JD, 1994, J BIOL CHEM, V269, P7847	37	99	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					355	360		10.1074/jbc.271.1.355	http://dx.doi.org/10.1074/jbc.271.1.355			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550586	hybrid			2022-12-25	WOS:A1996TP36100055
J	Torres, M; Bogenmann, E				Torres, M; Bogenmann, E			Nerve growth factor induces a multimeric TrkA receptor complex in neuronal cells that includes Crk, SHC and PLC-gamma 1 but excludes P130(CAS)	ONCOGENE			English	Article						c-Crk; TrkA; NGF; signal transduction	GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOTYROSINE-CONTAINING PROTEINS; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; TRANSFORMING PROTEIN; RAS; PROTOONCOGENE; BINDING; PRODUCT; ASSOCIATION	Binding of nerve growth factor (NGF) to the TrkA receptor results in homodimerization, and activation of the intrinsic tyrosine kinase activity of the receptor, leading to multiple phosphorylations. We investigated the in vivo formation and composition of the receptor complex induced by NGF in a central nervous system-derived cell line (B104-neo), transfected with the human cDNA for TrkA. Using receptor-activated immunoprecipitation followed by analysis of the immune complexes by SDS-PAGE and immunoblotting, we show that NGF induces the association of TrkA with c-Crk-II in a multimeric complex that also includes SHC and PLC-gamma 1. While the tyrosine phosphorylation of TrkA, SHC and PLC-gamma gamma 1 increased with time in the presence of NGF and was inhibited by the tyrosine kinase inhibitor K252a, the state of tyrosine phosphorylation of c-Crk-II did not appear to change with NGF treatment. Immunodepletion studies demonstrated that the interaction of c-Crk-II with TrkA not only occurs indirectly through the SHC proteins, but may also involve another mode of binding. Furthermore, we show that c-Crk-II is associated with tyrosine phosphorylated p130(CAS) is unstimulated cells and that NGF treatment results in the de-association of p130(CAS)/c-Crk-II complex in the absence of an apparent change in the tyrosine phosphorylation of p130(CAS). These results clearly implicate c-Crk-II in the NGF signaling pathway and support the concept that more than one signaling molecule known to participate in the activation of Ras associates with TrkA upon NGF treatment.	UNIV SO CALIF, SCH MED, DEPT PEDIAT, PASADENA, CA 91125 USA; UNIV SO CALIF, SCH PHARM, DEPT MOLEC PHARMACOL & TOXICOL, PASADENA, CA 91125 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of Southern California; University of Southern California; California Institute of Technology	Torres, M (corresponding author), CHILDRENS HOSP LOS ANGELES, RES INST, 4650 SUNSET BLVD MS57, LOS ANGELES, CA 90027 USA.				NINDS NIH HHS [NS25795] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025795] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altin JG, 1991, GROWTH FACTORS, V4, P145, DOI 10.3109/08977199109000265; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERG MM, 1992, J BIOL CHEM, V267, P13; BOGENMANN E, 1995, ONCOGENE, V10, P1915; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARONEY AC, 1995, J NEUROCHEM, V64, P540; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MUROYA K, 1992, BIOCHIM BIOPHYS ACTA, V1135, P353, DOI 10.1016/0167-4889(92)90243-5; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OGAWA S, 1994, ONCOGENE, V9, P1669; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1991, BIOCHEM BIOPH RES CO, V179, P217, DOI 10.1016/0006-291X(91)91357-I; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAFFIONI S, 1993, ANNU REV BIOCHEM, V62, P823; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TORRES M, 1993, J IMMUNOL, V150, P1563; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VETTER ML, 1991, P NATL ACAD SCI USA, V88, P5650, DOI 10.1073/pnas.88.13.5650; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	29	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					77	86						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552402				2022-12-25	WOS:A1996TQ01400010
J	Haber, M; Burkhart, CA; Regl, DL; Madafiglio, J; Norris, MD; Horwitz, SB				Haber, M; Burkhart, CA; Regl, DL; Madafiglio, J; Norris, MD; Horwitz, SB			Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; DIHYDROFOLATE-REDUCTASE GENES; POLYMERASE CHAIN-REACTION; BOVINE BRAIN; CONFERS RESISTANCE; ANTITUMOR AGENTS; MICROTUBULES; METHOTREXATE; AMPLIFICATION; INVIVO	A series of taxol- and taxotere-resistant J774.2 cell lines has been characterized with respect to altered expression of beta-tubulin, the cellular target for these drugs, Vertebrates have six classes of beta-tubulin isotypes, each displaying a distinct pattern of expression. Although the functional significance of multiple beta-tubulins has not been fully defined, there is evidence that the individual isotypes contribute to differences in microtubule dynamics and drug binding. To determine if alterations in the expression of beta-tubulin isotypes play a role in taxol resistance, a PCR-based methodology was developed that permits highly specific amplification of each of the six known murine beta-tubulin isotypes. Two isotypes, M beta 5 and M beta 3, were expressed abundantly in the drug-sensitive parental J774.2 cells. Although expressed at an extremely low level in the parental cells, expression of the M beta 2 isotype was increased 21-fold (<0.005) in the cell line most resistant to taxol, These findings suggest that a cell can alter its relative tubulin isotype composition in response to an external stress and specifically imply that altered expression of M beta 2, the class II beta-tubulin isotype, may contribute to the development of high resistance to taxol.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; PRINCE WALES CHILDRENS HOSP,CHILDRENS LEUKAEMIA & CANC RES CTR,SYDNEY,NSW 2031,AUSTRALIA	Yeshiva University; Albert Einstein College of Medicine				Haber, Michelle/0000-0003-2036-8817; Norris, Murray/0000-0002-0632-4589	NATIONAL CANCER INSTITUTE [R35CA039821, P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [CA39821, CA66183, CA13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASAI DJ, 1989, DEV BIOL, V132, P398, DOI 10.1016/0012-1606(89)90236-4; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; BANERJEE A, 1992, J BIOL CHEM, V267, P13335; BHALLA K, 1994, LEUKEMIA, V8, P465; BJOURSON AJ, 1992, NUCLEIC ACIDS RES, V20, P4675, DOI 10.1093/nar/20.17.4675; BOGGS B, 1987, MOL CELL BIOL, V7, P2700, DOI 10.1128/MCB.7.8.2700; BOND JF, 1986, CELL, V44, P461, DOI 10.1016/0092-8674(86)90467-8; BORDOW SB, 1994, CANCER RES, V54, P5036; BURGOYNE RD, 1988, EMBO J, V7, P2311, DOI 10.1002/j.1460-2075.1988.tb03074.x; CABRAL F, 1981, P NATL ACAD SCI-BIOL, V78, P4388, DOI 10.1073/pnas.78.7.4388; CABRAL FR, 1986, ANN NY ACAD SCI, V466, P745, DOI 10.1111/j.1749-6632.1986.tb38456.x; CHOMCZYNSKI P, 1993, TRI REAGENT RNA DNA; Cleveland Don W., 1994, V13, P47; CLEVELAND DW, 1987, J CELL BIOL, V104, P381, DOI 10.1083/jcb.104.3.381; CLEVELAND DW, 1981, CELL, V25, P537, DOI 10.1016/0092-8674(81)90072-6; COWAN NJ, 1983, INT REV CYTOL, V85, P147, DOI 10.1016/S0074-7696(08)62372-4; COWAN NJ, 1987, CYTOSKELETON CELL DI, P157; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; DICKER AP, 1990, J BIOL CHEM, V265, P8317; FALCONER MM, 1992, CELL MOTIL CYTOSKEL, V21, P313, DOI 10.1002/cm.970210407; FUJIMURA M, 1992, CURR GENET, V21, P399, DOI 10.1007/BF00351701; GILBERT J, 1993, MOL CELL PROBE, V7, P227, DOI 10.1006/mcpr.1993.1033; GOLDMAN GH, 1993, MOL GEN GENET, V240, P73, DOI 10.1007/BF00276886; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GREENBERGER LM, 1988, P NATL ACAD SCI USA, V85, P3762, DOI 10.1073/pnas.85.11.3762; GREENBERGER LM, 1994, ANTICANCER DRUG RESI, P69; HAMLIN JL, 1992, MUTAT RES, V276, P179, DOI 10.1016/0165-1110(92)90007-V; HOFFMAN PN, 1988, P NATL ACAD SCI USA, V85, P4530, DOI 10.1073/pnas.85.12.4530; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; JAMES SW, 1993, J CELL SCI, V106, P209; KAUFMAN RJ, 1979, P NATL ACAD SCI USA, V76, P5669, DOI 10.1073/pnas.76.11.5669; Lewis S.A., 1990, MICROTUBULE PROTEINS, P37; LEWIS SA, 1987, CELL, V49, P539, DOI 10.1016/0092-8674(87)90456-9; LEWIS SA, 1985, J CELL BIOL, V101, P852, DOI 10.1083/jcb.101.3.852; LEWIS SA, 1985, J MOL BIOL, V182, P11, DOI 10.1016/0022-2836(85)90023-3; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; MCIVOR RS, 1990, NUCLEIC ACIDS RES, V18, P7025, DOI 10.1093/nar/18.23.7025; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; OHTA S, 1994, JPN J CANCER RES, V85, P290, DOI 10.1111/j.1349-7006.1994.tb02096.x; PAIN J, 1988, J CELL PHYSIOL, V136, P341, DOI 10.1002/jcp.1041360218; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; PIECHACZYK M, 1984, NATURE, V312, P469, DOI 10.1038/312469a0; Raff Elizabeth C., 1994, V13, P85; RAO S, 1994, J BIOL CHEM, V269, P3132; ROWINSKY EK, 1992, SEMIN ONCOL, V19, P646; ROY SN, 1985, CANCER RES, V45, P3856; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAWADA T, 1989, J BIOL CHEM, V264, P3013; SCHIBLER MJ, 1986, J CELL BIOL, V102, P1522, DOI 10.1083/jcb.102.4.1522; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SRIMATKANDADA S, 1983, BIOCHEMISTRY-US, V22, P5774, DOI 10.1021/bi00294a015; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; WANG D, 1986, J CELL BIOL, V103, P1903, DOI 10.1083/jcb.103.5.1903; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WHITFIELD C, 1986, MOL CELL BIOL, V6, P1422, DOI 10.1128/MCB.6.5.1422	59	133	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31269	31275		10.1074/jbc.270.52.31269	http://dx.doi.org/10.1074/jbc.270.52.31269			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537394	hybrid			2022-12-25	WOS:A1995TN44400061
J	Skokotas, A; Hiasa, H; Marians, KJ; ODonnell, L; Hill, TM				Skokotas, A; Hiasa, H; Marians, KJ; ODonnell, L; Hill, TM			Mutations in the Escherichia coli Tus protein define a domain positioned close to the DNA in the Tus-Ter complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINUS REGION; REPLICATION; CHROMOSOME; TERMINATION; INHIBITION; PLASMID; R6K; HELICASES; SEQUENCE; ARREST	A new genetic screen for mutations in the tus gene of Escherichia coli has been devised that selects for Tus proteins with altered ability to arrest DNA replication. We report here the characterization of three such mutants: TusP42S, TusE49K, and TusH50Y, TusP42S and TusE49K arrest DNA replication in vivo at 36% of the efficiency of wild-type Tus, whereas TusH50Y functions at 78% efficiency. The loss of replication arrest activity did not correlate with changes in the stability of the Tus-TerB complexes formed by the mutant proteins, TusE49K formed a more stable protein-DNA complex than wild-type Tus (t(1/2) of 178 versus 149 min, respectively) and TusP42 had a 9-min half-life, yet these two mutants showed identical efficiencies for replication arrest. When tested in vitro using a helicase assay or an oriC replication system, we observed a general, but imperfect, correlation between the in vivo and in vitro assays. Finally, the half-lives of the mutant protein-DNA complexes suggested that the domain of Tus where these mutations are located is positioned close to the DNA in the Tus-Ter complex.	DREXEL UNIV, DEPT BIOSCI & BIOTECHNOL, PHILADELPHIA, PA 19104 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA; UNIV N DAKOTA, SCH MED, DEPT MICROBIOL & IMMUNOL, GRAND FORKS, ND 58202 USA	Drexel University; Memorial Sloan Kettering Cancer Center; University of North Dakota Grand Forks					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043193, R01GM034557, R01GM043193, R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557, GM43193] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABARZUA P, 1984, J BIOL CHEM, V259, P4286; BAKER TA, 1995, CELL, V80, P521, DOI 10.1016/0092-8674(95)90504-9; BIERNE H, 1994, J BACTERIOL, V176, P4165, DOI 10.1128/JB.176.13.4165-4167.1994; BIERNE H, 1991, EMBO J, V10, P2699, DOI 10.1002/j.1460-2075.1991.tb07814.x; COSKUNARI FF, 1994, J BIOL CHEM, V269, P4027; DEMASSY B, 1987, P NATL ACAD SCI USA, V84, P1759; GOTTLIEB PA, 1992, J BIOL CHEM, V267, P7434; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1992, J BIOL CHEM, V267, P11379; HIDAKA M, 1988, CELL, V55, P467, DOI 10.1016/0092-8674(88)90033-5; HILL TM, 1987, P NATL ACAD SCI USA, V84, P1754, DOI 10.1073/pnas.84.7.1754; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1990, P NATL ACAD SCI USA, V87, P2481, DOI 10.1073/pnas.87.7.2481; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; HORIUCHI T, 1987, MOL GEN GENET, V210, P394, DOI 10.1007/BF00327188; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; ROECKLEIN B, 1991, RES MICROBIOL, V142, P169, DOI 10.1016/0923-2508(91)90026-7; Sambrook J, 1989, MOL CLONING LABORATO; SHARMA B, 1995, MOL MICROBIOL, V18, P45, DOI 10.1111/j.1365-2958.1995.mmi_18010045.x; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SKOKOTAS A, 1994, J BIOL CHEM, V269, P20446; Yoshiakwa H., 1993, P507	24	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30941	30948		10.1074/jbc.270.52.30941	http://dx.doi.org/10.1074/jbc.270.52.30941			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537350	hybrid			2022-12-25	WOS:A1995TN44400018
J	Sudo, T; Nishikawa, S; Ogawa, M; Kataoka, H; Ohno, N; Izawa, A; Hayashi, SI; Nishikawa, SI				Sudo, T; Nishikawa, S; Ogawa, M; Kataoka, H; Ohno, N; Izawa, A; Hayashi, SI; Nishikawa, SI			Functional hierarchy of c-kit and c-fms in intramarrow production of CFU-M	ONCOGENE			English	Article						c-kit; c-fms; hematopoiesis M-CSF; mAb	COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PROGENITOR CELLS; FACTOR CSF-1; EXPRESSION; RECEPTOR; DIFFERENTIATION; MOUSE; HEMATOPOIESIS	Whereas the molecular natures of M-CSF/CSF-1 and its receptor c-fms are well characterized, its actual role in the intramarrow hematopoiesis remains obscure, This is because disruption of this signaling pathway results in the osteopetrosis mouse that lacks the bone cavity for hematopoiesis. To elucidate the role of c-fms in intramarrow hematopoiesis, we produced an antagonistic monoclonal antibody to murine c-fms and investigated its expression and function in the normal bone marrow, c-fms(+) cells were detected both in mature and immature hematopoietic cells, Morphologically, c-kit(+)c-fms(-), c-kit(+)c-fms(+) and c-kit(-)c-fms(+) cells were medium sized blasts, large promyelocytes with azurophilic granules and mature monocytes respectively, CFU-M was 10-fold more enriched in the c-kit(+)c-fms(-) than c-kit(+)c-fms(+) fraction, Moreover, injection of the anti c-fms antibody had no effect on the production of CFU-M in the bone marrow, while anti-c-kit mAb could deplete them, hs ckit(+)c-fms(+) cells were readily generated in the culture of c-kit(+)c-fms(-) cells, most of the CFU-M in the bone marrow are, in fact, c-fms(-) cells that differentiate into c-fms(+) upon culture, These observations indicate a clear functional hierarchy of c-kit and c-fms in the bone marrow, Namely, c-kit plays the primary role in the production and maintenance of CFU-M, while c-fms, though it co-expressed with c-kit and functions as the growth receptor for M-CSF in the culture, has only a minimum role in the proliferation of c-fms(+) cells in the bone marrow.	KYOTO UNIV,FAC MED,DEPT MOLEC GENET,SAKYO KU,KYOTO 60601,JAPAN; TORAY INDUSTRIES LTD,BASIC RES LABS,KAMAKURA,KANAGAWA 248,JAPAN	Kyoto University; Toray Industries, Inc.								ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BERNSTEIN A, 1991, SEMIN HEMATOL, V28, P138; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BICKNELL DC, 1988, EXP HEMATOL, V16, P88; BOEGEL F, 1985, EXP HEMATOL, V13, P912; BYRNE PV, 1981, J CELL BIOL, V91, P848, DOI 10.1083/jcb.91.3.848; COFFMAN RL, 1986, IMMUNOL REV, V69, P5; ERA T, 1994, IMMUNOL REV, V137, P35, DOI 10.1111/j.1600-065X.1994.tb00658.x; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GREENBERGER J, 1992, EXP HEMATOL, V20, P92; GUILBERT LJ, 1980, J CELL BIOL, V85, P153, DOI 10.1083/jcb.85.1.153; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; LANIER LL, 1982, HYBRIDOMA, V1, P125, DOI 10.1089/hyb.1.1982.1.125; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; NAITO M, 1991, AM J PATHOL, V139, P657; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NISHIKAWA S, 1994, IMMUNOL LETT, V40, P163, DOI 10.1016/0165-2478(94)90188-0; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PANTERNE B, 1993, J CELL PHYSIOL, V155, P282, DOI 10.1002/jcp.1041550209; RALPH P, 1977, CANCER RES, V37, P546; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SHADDUCK RK, 1993, EXP HEMATOL, V21, P515; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPANGRUDE GJ, 1991, CURR OPIN IMMUNOL, V3, P171, DOI 10.1016/0952-7915(91)90046-4; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; YASUNAGA Y, 1995, J EXP MED, V182, P315; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	37	151	159	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2469	2476						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545103				2022-12-25	WOS:A1995TP18800002
J	STEHNOBITTEL, L; KRAPIVINSKY, G; KRAPIVINSKY, L; PEREZTERZIC, C; CLAPHAM, DE				STEHNOBITTEL, L; KRAPIVINSKY, G; KRAPIVINSKY, L; PEREZTERZIC, C; CLAPHAM, DE			THE G-PROTEIN BETA-GAMMA SUBUNIT TRANSDUCES THE MUSCARINIC RECEPTOR SIGNAL FOR CA2+ RELEASE IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; BINDING REGULATORY PROTEINS; PHOSPHOLIPASE-C ISOZYMES; ALPHA-SUBUNITS; ADENYLYL CYCLASE; ACETYLCHOLINE-RECEPTOR; SEQUENCE DETERMINATION; MOLECULAR-CLONING; PITUITARY-CELLS; LAEVIS OOCYTES	At least 30 G protein-linked receptors stimulate phosphatidylinositol 4,5-bisphosphate phosphodiesterase (phospholipase CP, PLCP) through G protein subunits to release intracelylular calcium from the endoplasmic reticulum (Clapham, D. E. (1995) Cell 80, 259-268). Although both G alpha and G beta gamma G protein subunits have been shown to activate purified PLC beta in vitro, G alpha q has been presumed to mediate the pertussis toxin-insensitive response in vivo. In this study, we show that G beta gamma plays a dominant role in muscarinic-mediated activation of PLC beta by employing the Xenopus oocyte expression system. Antisense nucleotides and antibodies to G alpha q/11 blocked the ms-mediated signal transduction by inhibiting interaction of the muscarinic receptor with the G protein. Agents that specifically bound free G beta gamma subunits (G alpha-GDP and a beta-adrenergic receptor kinase fragment) inhibited acetylcholine-induced signal transduction to PLC beta, and injection of G beta gamma subunits into oocytes directly induced release of intracellular Ca2+. We conclude that receptor coupling specificity of the G alpha q/G beta gamma heterotrimer is determined by G alpha q; G beta gamma is the predominant signaling molecule activating oocyte PLC beta.	MAYO CLIN & MAYO FDN,MAYO MED SCH,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019	Stehno-Bittel, Lisa/0000-0002-8879-6124; Clapham, David/0000-0002-4459-9428	NHLBI NIH HHS [HL07094, HL08848, HL41303] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008848, R01HL041303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BLITON C, 1993, J MICROSC-OXFORD, V169, P15, DOI 10.1111/j.1365-2818.1993.tb03274.x; BLITZER RD, 1993, J BIOL CHEM, V268, P7532; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1994, J BIOL CHEM, V269, P2814; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cochran W.G, 1957, STAT METHODS, V6th ed; DAGLE JM, 1990, NUCLEIC ACIDS RES, V18, P4751, DOI 10.1093/nar/18.16.4751; DELAPENA P, 1995, J BIOL CHEM, V270, P3554, DOI 10.1074/jbc.270.8.3554; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; GIRARD S, 1994, METHOD CELL BIOL, V40, P263; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HADCOCK JR, 1990, J BIOL CHEM, V265, P14784; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HILDEBRANDT JP, 1993, J MEMBRANE BIOL, V133, P183; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KANEKO S, 1992, FEBS LETT, V299, P179, DOI 10.1016/0014-5793(92)80242-9; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KWON G, 1993, BIOCHEMISTRY-US, V32, P2401, DOI 10.1021/bi00060a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE SB, 1993, J BIOL CHEM, V268, P25952; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MA HW, 1993, J BIOL CHEM, V268, P19915; MAURICE DH, 1993, BIOCHEM J, V290, P765, DOI 10.1042/bj2900765; MITCHELL FM, 1991, FEBS LETT, V287, P171, DOI 10.1016/0014-5793(91)80043-3; MIYAMAE T, 1993, FEBS LETT, V333, P311, DOI 10.1016/0014-5793(93)80677-M; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; OLATE J, 1990, FEBS LETT, V268, P27, DOI 10.1016/0014-5793(90)80964-K; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1994, METHOD ENZYMOL, V237, P164; PARK DG, 1993, J BIOL CHEM, V268, P4573; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SAWAKI K, 1993, ARCH BIOCHEM BIOPHYS, V305, P546, DOI 10.1006/abbi.1993.1459; SCHIMERLIK MI, 1989, ANNU REV PHYSIOL, V51, P217, DOI 10.1146/annurev.ph.51.030189.001245; SHAPIRA H, 1994, FEBS LETT, V348, P89, DOI 10.1016/0014-5793(94)00570-2; SILBERT S, 1990, J BIOL CHEM, V265, P3102; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STEHNOBITTEL L, 1994, METHOD ENZYMOL, V238, P263; STERNWEIS PC, 1992, RECEPTOR EFFECTOR CO, P1; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	63	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30068	30074						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530411				2022-12-25	WOS:A1995TK38000071
J	YASUDA, K; NAKAI, A; HATAYAMA, T; NAGATA, K				YASUDA, K; NAKAI, A; HATAYAMA, T; NAGATA, K			CLONING AND EXPRESSION OF MURINE HIGH-MOLECULAR-MASS HEAT-SHOCK PROTEINS, HSP105	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS PROTEINS; MESSENGER-RNAS; BINDING DOMAIN; HUMAN HSP70; ACTIN; SIMILARITY; SEQUENCE; COMMON; CELLS; ACID	We have shown that the 105-kDa heat shock protein (HSP105) and the 42 degrees C-specific heat shock protein (42 degrees C-HSP) constitute high molecular mass heat-shock proteins. To elucidate the structure of these heat shock proteins, are have screened a cDNA library constructed with poly(A)(+) RNA derived from mouse FM3A cells preheated at 32 degrees C for 2 h using an antibody against murine HSP105. Two full-length cDNA clones were obtained: the pB105-1 insert encoded an 858-amino acid protein, and the pB105-2 insert encoded an 814-amino acid protein and lacked 44 amino acids found in pB105-1. The two clones contained the amino acid sequence found in the 17-kDa polypeptide fragments from HSP105 and 42 degrees C-HSP by lysylendopeptidase digestion. In vitro translation products of the RNA transcripts from pB105-1 and pB105-2 migrated to the same positions of HSP105 and 42 degrees C-HSP, respectively, on SDS-polyacrylamide gel electrophoresis. Northern blot analysis showed that the transcript was similar to 4 kilobases in murine FM3A cells and was strongly induced by heat shock and by treatment with arsenite or an amino acid analog. By reverse transcription-polymerase chain reaction analysis using primers by which deletion of 132 nucleotides in pB105-2 could be detected, the polymerase chain reaction product corresponding to pB105-2 was increased only after heat shock at 42 degrees C, whereas the product corresponding to pB105-1 was induced by heat shock at-either 42 or 45 degrees C and also by other stresses. Thus, the cDNA clones pB105-1 and pB105-2 encode HSP105 and 42 degrees C-HSP, respectively, and HSP105 and 42 degrees C-HSP (a short form of HSP105) are suggested to be produced by alternative splicing, Here, HSP105 and 42 degrees C-HSP are renamed HSP105 alpha and HSP105 beta, respectively, A protein sequence homology search revealed that HSP105 shares 54, 34, and 25% amino acid identity with human HSP70RY, the sea urchin egg receptor for sperm, and murine inducible HSP70, respectively. Furthermore, by Northern blot analysis, HSP105 mRNA was revealed to be present in most murine tissues and to be highly expressed in the brain.	KYOTO UNIV, CHEST DIS RES INST, DEPT CELL BIOL, SAKYO KU, KYOTO 60601, JAPAN; KYOTO PHARMACEUT UNIV, DEPT BIOCHEM, YAMASHIMA KU, KYOTO 607, JAPAN	Kyoto University; Kyoto Pharmaceutical University								BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; FATHALLAH DM, 1993, J IMMUNOL, V151, P810; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARRISON GS, 1987, SOMAT CELL MOLEC GEN, V13, P119, DOI 10.1007/BF01534692; HATAYAMA T, 1986, BIOCHEM BIOPH RES CO, V137, P957, DOI 10.1016/0006-291X(86)90318-9; HATAYAMA T, 1994, BIOCHEM BIOPH RES CO, V204, P357, DOI 10.1006/bbrc.1994.2467; HATAYAMA T, 1994, BIOCHEM BIOPH RES CO, V200, P1367, DOI 10.1006/bbrc.1994.1602; HATAYAMA T, 1992, J BIOCHEM-TOKYO, V111, P484, DOI 10.1093/oxfordjournals.jbchem.a123784; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HONDA K, 1988, J BIOCHEM-TOKYO, V103, P81, DOI 10.1093/oxfordjournals.jbchem.a122244; HONDA K, 1989, BIOCHEM BIOPH RES CO, V160, P60, DOI 10.1016/0006-291X(89)91620-3; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; LEEYOON D, 1995, J BIOL CHEM, V270, P15725, DOI 10.1074/jbc.270.26.15725; LOWE DG, 1986, J BIOL CHEM, V261, P2102; MATSUMOTO M, 1990, BIOCHEM BIOPH RES CO, V166, P43, DOI 10.1016/0006-291X(90)91909-C; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKANO N, 1966, TOHOKU J EXP MED, V88, P69, DOI 10.1620/tjem.88.69; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SHYY TT, 1986, CANCER RES, V46, P4738; SUBJECK JR, 1983, J CELL BIOL, V97, P1389, DOI 10.1083/jcb.97.5.1389; TAKECHI H, 1994, MOL CELL BIOL, V14, P567, DOI 10.1128/MCB.14.1.567; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218	35	125	128	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29718	29723						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530361	hybrid			2022-12-25	WOS:A1995TK38000021
J	NAGASE, T; NOMURA, N; ISHII, S				NAGASE, T; NOMURA, N; ISHII, S			COMPLEX-FORMATION BETWEEN PROTEINS ENCODED BY THE SKI GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK FACTOR; DNA-BINDING; TRANSCRIPTION FACTOR; ONCOGENE; MYC; EXPRESSION; SEQUENCE; CLONING; VECTORS; MUSCLE	The c-ski proto-oncogene product (c-Ski) is localized in the nuclei, but its function and biochemical properties are unclear. C-Ski can bind to DNA only in association with uncharacterized protein(s). A lambdagt11 cDNA library was screened with the biotinylated Ski to isolate genes encoding proteins capable of forming complexes with Ski. Two clones encoding Ski itself or the ski-related gene product SnoN were isolated in this manner, suggesting that Ski can form a complex with Ski itself or with SnoN. Trimerization of Ski with itself and SnoN was also confirmed by protein cross-linking and protein blot analysis. The carboxyl-terminal 1/5 regions of Ski and SnoN are required for complex formation. This region has a homology between two proteins and two putative leucine zipper-like structures, suggesting that these leucine zipper-like structures mediate trimerization by making side-to-side interactions between the conserved leucines. Thus, Ski and SnoN have the capacity to associate with other proteins, and a complex formation of c-Ski with itself, SnoN, and uncharacterized proteins might play a key role in the function of Ski.	INST PHYS & CHEM RES, TSUKUBA LIFE SCI CTR, MOLEC GENET LAB, 3-1-1 KOYADAI, TSUKUBA, IBARAKI 305, JAPAN; NIPPON MED COLL, INST GERONTOL, MOLEC BIOL LAB, NAKAHARA KU, KANAGAWA 211, JAPAN	RIKEN; Nippon Medical School			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MONTESANO L, 1982, BIOCHEM BIOPH RES CO, V109, P7, DOI 10.1016/0006-291X(82)91558-3; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SADLER JE, 1985, P NATL ACAD SCI USA, V82, P6394, DOI 10.1073/pnas.82.19.6394; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TREACY MN, 1992, CELL, V68, P491, DOI 10.1016/0092-8674(92)90186-G; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X	26	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13710	13716						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514802				2022-12-25	WOS:A1993LH55300097
J	WEBBER, AN; GIBBS, PB; WARD, JB; BINGHAM, SE				WEBBER, AN; GIBBS, PB; WARD, JB; BINGHAM, SE			SITE-DIRECTED MUTAGENESIS OF THE PHOTOSYSTEM-I REACTION-CENTER IN CHLOROPLASTS - THE PROLINE-CYSTEINE MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENES; CHLAMYDOMONAS-REINHARDTII; TRANSFORMATION; MUTATIONS; POLYPEPTIDES; PROTEINS; LOCI	Site-directed mutagenesis has been used to introduce specific amino acid changes into the photosystem I reaction center in the green alga Chlamydomonas reinhardtii. Plasmids containing mutated copies of the chloroplast psaB gene, encoding a polypeptide of the photosystem I reaction center heterodimer, were introduced into the chloroplast genome by particle bombardment. Successful transformants were selected by two procedures. The first involved complementation of a nonphotosynthetic mutant of Chlamydomonas, CC-2341 (ac-u-g-2.3), which has a frameshift mutation in the psaB gene, and selection of photosynthetic transformants on minimal medium. The second procedure utilized a co-transformation procedure with a plasmid containing a rRNA gene that confers spectinomycin resistance. Homologous replacement of the psaB gene was confirmed by screening for a unique restriction enzyme site within the transforming psaB sequences. These procedures have been used to specifically mutate a highly conserved proline-cysteine motif suggested to be important in coordinating the [4Fe-4S] iron-sulfur center F(x). Our results show that the cysteine is essential for assembly of the photosystem I reaction center although the adjacent proline fulfills no identifiable function. The approach described in this paper will be of value to future studies of the structure, function, and assembly of photosystem I.	ARIZONA STATE UNIV, CTR STUDY EARLY EVENTS PHOTOSYNTH, TEMPE, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	WEBBER, AN (corresponding author), ARIZONA STATE UNIV, DEPT BOT, TEMPE, AZ 85287 USA.							ARMSTRONG FA, 1989, BIOCHEM J, V264, P265, DOI 10.1042/bj2640265; ARMSTRONG FA, 1989, BIOCHH J, V264, P275; BINGHAM SE, 1991, FEBS LETT, V292, P17; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; CANOVER RC, 1990, J BIOL CHEM, V265, P8533; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; DUNN PPJ, 1988, PLANT MOL BIOL, V11, P311, DOI 10.1007/BF00027388; FISH LE, 1985, MOL BIOL PHOTOSYNTHE, P111; FUJII T, 1990, BIOCHIM BIOPHYS ACTA, V1015, P41, DOI 10.1016/0005-2728(90)90213-N; GIRARDBASCOU J, 1987, CURR GENET, V12, P489, DOI 10.1007/BF00419557; GIRARDBASCOU J, 1987, CURR GENET, V12, P483, DOI 10.1007/BF00419556; GOLBECK JH, 1992, ANNU REV PLANT PHYS, V43, P293, DOI 10.1146/annurev.pp.43.060192.001453; GOLBECK JH, 1991, CURR TOP BIOENERG, V16, P83; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HARRIS EH, 1989, GENETICS, V123, P281; HIYAMA T, 1972, BIOCHIM BIOPHYS ACTA, V267, P160, DOI 10.1016/0005-2728(72)90147-8; IKEUCHI M, 1988, PLANT CELL PHYSIOL, V29, P1233; KOSSEL H, 1990, PLANT MOL BIOL, V15, P497, DOI 10.1007/BF00019166; LEIBEL U, 1992, CURRENT RES PHOTOSYN, V2, P595; LIN S, 1991, PHOTOSYNTH RES, V27, P157, DOI 10.1007/BF00035837; NEWMAN SM, 1990, GENETICS, V126, P875; SAKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHELLER HV, 1990, PHYSIOL PLANTARUM, V78, P484, DOI 10.1034/j.1399-3054.1990.780326.x; SHEPHERD HS, 1979, P NATL ACAD SCI USA, V76, P1353, DOI 10.1073/pnas.76.3.1353; SUEOKA N, 1960, P NATL ACAD SCI USA, V46, P83, DOI 10.1073/pnas.46.1.83; TAKAHASHI Y, 1991, EMBO J, V10, P2033, DOI 10.1002/j.1460-2075.1991.tb07733.x; TROST JT, 1992, PHOTOSYNTH RES, V32, P11, DOI 10.1007/BF00028794; WEBBER AN, 1990, FEBS LETT, V264, P1, DOI 10.1016/0014-5793(90)80749-9; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001	29	45	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12990	12995						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509430				2022-12-25	WOS:A1993LG65800110
J	Baldi, L; Brown, K; Franzoso, G; Siebenlist, U				Baldi, L; Brown, K; Franzoso, G; Siebenlist, U			Critical role for lysines 21 and 22 in signal-induced, ubiquitin-mediated proteolysis of I kappa B-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOPROTEIN BCL-3; DNA-BINDING; INDUCIBLE EXPRESSION; ACTIVATION; CELLS; GENE; TRANSACTIVATION; INHIBITION; I-KAPPA-B/MAD-3; PHOSPHORYLATION	The NF-kappa B transcription factor induces rapid transcription of many genes in response to a variety of extracellular signals, NF-kappa B is readily activated from normally inhibited cytoplasmic stores by induced proteolytic degradation of I kappa B-alpha, a principal inhibitor of this transcription factor, Following the inhibitor's degradation, NF-kappa B is free to translocate to the nucleus and induce gene transcription. The I kappa B-alpha inhibitor is targeted for degradation by signal-induced phosphorylation of two closely spaced serines in its NH2 terminus (Ser(32) and Ser(36)). Proteolytic degradation appears to be carried out by proteasomes which can recognize ubiquitinated intermediates of the I kappa B-alpha inhibitor, We provide evidence which supports a ubiquitin-mediated mechanism, Amino acid substitutions of two adjacent potential ubiquitination sites in the NH2 terminus of I kappa B-alpha (Lys(21) and Lys(22)) almost completely block the rapid, signal-induced degradation of the mutant protein, while they do not interfere with induced phosphorylation, The mutant I kappa B-alpha also does not permit signal-induced activation of NF-kappa B bound to it, The data suggest that ubiquitination at either of the two adjacent lysines (21 and 22) is required for degradation following induced phosphorylation at nearby serines 32 and 36, Such dependence on ubiquitination of specific sites for protein degradation is unusual, This mechanism of degradation may also apply to I kappa B-beta, an inhibitor related to and functionally overlapping with I kappa B-alpha, as well as to cactus, an I kappa B homolog of Drosophila.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Baldi, Lucia/D-9491-2011; Franzoso, Guido/GRR-8628-2022	Baldi, Lucia/0000-0001-5550-9435; Franzoso, Guido/0000-0002-0778-988X				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEBENLIST U, 1995, INDUCIBLE GENE EXPRE, V1, P93; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	49	130	138	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					376	379		10.1074/jbc.271.1.376	http://dx.doi.org/10.1074/jbc.271.1.376			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550590	hybrid			2022-12-25	WOS:A1996TP36100059
J	Gonen, H; Stancovski, I; Shkedy, D; Hadari, T; Bercovich, B; Bengal, E; Mesilati, S; AbuHatoum, O; Schwartz, AL; Ciechanover, A				Gonen, H; Stancovski, I; Shkedy, D; Hadari, T; Bercovich, B; Bengal, E; Mesilati, S; AbuHatoum, O; Schwartz, AL; Ciechanover, A			Isolation, characterization, and partial purification of a novel ubiquitin-protein ligase, E3 - Targeting of protein substrates via multiple and distinct recognition signals and conjugating enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; BINDING-SITES; AFFINITY PURIFICATION; E6 ONCOPROTEIN; DEGRADATION; SYSTEM; P53; REPRESSOR; PATHWAY; E6-AP	Degradation of a protein via the ubiquitin system involves two discrete steps, conjugation of ubiquitin to the substrate and degradation of the adduct, Conjugation follows a three-step mechanism. First, ubiquitin is activated by the ubiquitin-activating enzyme, E1, Following activation, one of several E2 enzymes (ubiquitin-carrier proteins or ubiquitin-conjugating enzymes, UBCs) transfers ubiquitin from E1 to the protein substrate that is bound to one of several ubiquitin-protein ligases, E3s. These enzymes catalyze the last step in the process, covalent attachment of ubiquitin to the protein substrate. The binding of the substrate to E3 is specific and implies that E3s play a major role in recognition and selection of proteins for conjugation and subsequent degradation, So far, only a few ligases have been identified, and it is clear that many more have not been discovered yet, Here, we describe a novel Ligase that is involved in the conjugation and degradation of non ''N-end rule'' protein substrates such as actin, troponin T, and MyoD. This substrate specificity suggests that the enzyme may be involved in degradation of muscle proteins, The ligase acts in concert with E2-F1, a previously described non N-end rule UBC, Interestingly, it is also involved in targeting lysozyme, a bona fide N-end rule substrate that is recognized by E3 alpha and E2-14 kDa. The novel ligase recognizes lysozyme via a signal(s) that is distinct from the N-terminal residue of the protein, Thus, it appears that certain proteins can be targeted via multiple recognition motifs and distinct pairs of conjugating enzymes, We have purified the ligase similar to 200-fold and demonstrated that it is different from other known E3s, including E3 alpha/UBR1, E3 beta, and EG-AP. The native enzyme has an apparent molecular mass of similar to 550 kDa and appears to be a homodimer. Because of its unusual size, we designated this novel ligase E3L (large).	TECHNION ISRAEL INST TECHNOL,FAC MED,CARMEL MED CTR,DEPT BIOCHEM,IL-31096 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC MED,CARMEL MED CTR,DEPT SURG B,IL-31096 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,FAC MED,CARMEL MED CTR,RAPPAPORT FAMILY INST RES MED SCI,IL-31096 HAIFA,ISRAEL	Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine			Ciechanover, Aaron J/C-9166-2017					BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; GIROD PA, 1993, J BIOL CHEM, V268, P955; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; MADURA K, 1993, J BIOL CHEM, V268, P12046; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; MEDINA R, 1991, BIOMED BIOCHIM ACTA, V50, P347; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PICKART CM, 1985, J BIOL CHEM, V260, P1573; REISS Y, 1989, J BIOL CHEM, V264, P10378; REISS Y, 1988, J BIOL CHEM, V263, P2693; REISS Y, 1990, J BIOL CHEM, V265, P3685; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3	38	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					302	310		10.1074/jbc.271.1.302	http://dx.doi.org/10.1074/jbc.271.1.302			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550577	hybrid			2022-12-25	WOS:A1996TP36100047
J	Rossetti, L; Barzilai, N; Chen, W; Harris, T; Yang, D; Rogler, CE				Rossetti, L; Barzilai, N; Chen, W; Harris, T; Yang, D; Rogler, CE			Hepatic overexpression of insulin-like growth factor-II in adulthood increases basal and insulin-stimulated glucose disposal in conscious mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETIC RATS; GLYCOGEN REPLETION; TISSUE; HYPERGLYCEMIA; ACID; HYPOGLYCEMIA; METABOLISM; PHLORIZIN; BINDING; HORMONE	The physiological role of circulating insulin-like growth factor-II (IGF-II) in adult humans is poorly understood, We recently generated an IGF-II transgenic murine model of persistent IGF-II production (plasma IGF-II similar to 30-fold increased above normal) through overexpression of the transgene driven by the major urinary protein promoter (Rinderknecht, E., and Humbel, R. E. (1978) J. Biol. Chem. 269, 13779-13784), To determine whether in vivo insulin action is improved in these transgenic mice, we performed euglycemic insulin (18 milliunits/kg . min) clamp studies in conscious IGF II transgenic and in age- and weight-matched control mice, Plasma glucose and insulin concentrations were significantly lower in the IGF-II transgenic compared with both control groups, Despite decreased plasma glucose concentration, basal hepatic glucose production (HGP) and glucose clearance were increased. During the insulin clamp studies in IGF-II transgenic mice compared with control mice (a) the rates of glucose infusion and glucose uptake were increased by similar to 65 and similar to 55%, respectively; (b) glycolysis was increased by similar to 12% while glycogen synthesis was similar to 2-fold higher; (c) while the suppression of plasma free fatty acid was similar, the increment in plasma lactate concentration was significantly higher; (d) although HGP was similarly inhibited by insulin, phosphoenolpyruvate gluconeogenesis was enhanced and accounted for a larger portion of HGP (64% versus similar to 40% in control mice). Our data suggest that the persistence of circulating IGF-II in adult mice to levels commonly observed in adult humans (50-70 nM) causes a marked improvement in peripheral (skeletal muscle) insulin action, which is not due to changes in body composition, These results suggest that circulating IGF-II may exert a regulatory role on insulin sensitivity and body composition in humans.	ALBERT EINSTEIN COLL MED,LIVER RES CTR,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine	Rossetti, L (corresponding author), ALBERT EINSTEIN COLL MED,DEPT MED,DIV ENDOCRINOL,DIABET RES & TRAINING CTR,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NATIONAL CANCER INSTITUTE [R01CA056076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045024, R29DK045024, R01DK048321] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 56076] Funding Source: Medline; NIDDK NIH HHS [R01-DK 48321, R029-DK 45024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS SO, 1983, NATURE, V302, P150, DOI 10.1038/302150a0; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BENNETT AE, 1984, J CLIN ENDOCR METAB, V59, P701, DOI 10.1210/jcem-59-4-701; BURGUERA B, 1994, BIOCHEM J, V300, P781, DOI 10.1042/bj3000781; CARO JF, 1988, J CLIN INVEST, V81, P976, DOI 10.1172/JCI113451; COHEN P, 1992, PSYCHONEUROENDOCRINO, V17, P335, DOI 10.1016/0306-4530(92)90039-A; CRYER PE, 1993, AM J PHYSIOL, V264, pE149, DOI 10.1152/ajpendo.1993.264.2.E149; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; FROESCH ER, 1985, DIABETOLOGIA, V28, P485, DOI 10.1007/BF00281982; GIACCARI A, 1989, J CHROMATOGR-BIOMED, V497, P69, DOI 10.1016/0378-4347(89)80006-4; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; GORDEN P, 1981, NEW ENGL J MED, V305, P1452, DOI 10.1056/NEJM198112103052405; GULVE EA, 1994, J BIOL CHEM, V269, P18366; JACOB R, 1989, J CLIN INVEST, V83, P1717, DOI 10.1172/JCI114072; JENNSEN T, 1990, J CLIN INVEST, V86, P489; KUPFER SR, 1993, J CLIN INVEST, V91, P391, DOI 10.1172/JCI116212; LEROITH D, 1994, HORM RES, V41, P74, DOI 10.1159/000183964; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROSSETTI L, 1991, DIABETES, V40, P444, DOI 10.2337/diabetes.40.4.444; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; ROSSETTI L, 1989, J CLIN INVEST, V84, P892, DOI 10.1172/JCI114250; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; STUMPEL F, 1992, DIABETOLOGIA, V35, P932, DOI 10.1007/BF00401421; STYLIANOPOULOU F, 1988, DEVELOPMENT, V103, P497; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; YU KT, 1984, J BIOL CHEM, V259, P3090; ZAPF J, 1978, EUR J BIOCHEM, V87, P285, DOI 10.1111/j.1432-1033.1978.tb12377.x	34	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					203	208		10.1074/jbc.271.1.203	http://dx.doi.org/10.1074/jbc.271.1.203			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550560	hybrid			2022-12-25	WOS:A1996TP36100032
J	Samaha, FF; Ip, HS; Morrisey, EE; Seltzer, J; Tang, ZH; Solway, J; Parmacek, MS				Samaha, FF; Ip, HS; Morrisey, EE; Seltzer, J; Tang, ZH; Solway, J; Parmacek, MS			Developmental pattern of expression and genomic organization of the calponin-h1 gene - A contractile smooth muscle cell marker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-C GENE; ALPHA-ACTIN PROMOTER; CALMODULIN-BINDING; CHICKEN GIZZARD; BLOOD-VESSELS; F-ACTIN; PROTEIN; IDENTIFICATION; CALDESMON; AORTA	Calponin-h1 is a 34-kDa myofibrillar thin filament, actin-binding protein that is expressed exclusively in smooth muscle cells (SMCs) in adult animals, To examine the molecular mechanisms that regulate SMC specific gene expression, we have examined the temporal, spatial, and cell cycle-regulated patterns of expression of calponin-h1 gene expression and isolated and structurally characterized the murine calponin-h1 gene. Calponin-h1 mRNA is expressed exclusively in SMC-containing tissues in adult animals, During murine embryonic development, calponin-h1 gene expression is (i) detectable in E9.5 embryos in the dorsal aorta, cardiac outflow tract, and tubular heart, (ii) sequentially up-regulated in SMC containing tissues, and (iii) downregulated to non-detectable levels in the heart during late fetal development, In addition, the gene is expressed in resting rat aortic SMCs, but its expression is rapidly down-regulated when growth-arrested cells reenter phase G(1) of the cell cycle and proliferate, Calponin-h1 is encoded by a 10.7-kilobase single copy gene composed of seven exons, which is part of a multigene family, Transient transfection analyses demonstrated that 1.5 kilobases of calponin-h1 5'-flanking sequence is sufficient to program high level transcription of a luciferase reporter gene in cultured primary rat aortic SMCs and the smooth muscle cell line, A7r5. Taken together, these data suggest that the calponin-h1 gene will serve as an excellent model system with which to examine the molecular mechanisms that regulate SMC lineage specification, differentiation, and phenotypic modulation.	UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA	University of Chicago			Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530; Ip, Hon/0000-0003-4844-7533	NHLBI NIH HHS [HL48257] Funding Source: Medline; NIAID NIH HHS [AI34566] Funding Source: Medline; PHS HHS [1R0-1H51145] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034566] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APPLEGATE D, 1994, J BIOL CHEM, V269, P10683; AYMESOUTHGATE A, 1989, J CELL BIOL, V108, P521, DOI 10.1083/jcb.108.2.521; BEALL AC, 1990, ANAT RECORD, V226, P360, DOI 10.1002/ar.1092260313; BELKIN AM, 1988, J BIOL CHEM, V263, P6631; BIRUKOV KG, 1991, CELL TISSUE RES, V266, P579, DOI 10.1007/BF00318599; BLANK RS, 1992, J BIOL CHEM, V267, P984; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAMPBELL GR, 1988, ARCH PATHOL LAB MED, V112, P977; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHAPONNIER C, 1990, EUR J BIOCHEM, V190, P559, DOI 10.1111/j.1432-1033.1990.tb15610.x; Cunha G R, 1992, Epithelial Cell Biol, V1, P76; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; FRID MG, 1992, DEV BIOL, V153, P185, DOI 10.1016/0012-1606(92)90104-O; GIMONA M, 1992, EUR J BIOCHEM, V205, P1067, DOI 10.1111/j.1432-1033.1992.tb16875.x; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GLUKHOVA MA, 1988, P NATL ACAD SCI USA, V85, P9542, DOI 10.1073/pnas.85.24.9542; GOETINCK S, 1994, J CELL BIOL, V127, P79, DOI 10.1083/jcb.127.1.79; GONZALEZCRUSSI F, 1971, AM J ANAT, V130, P441, DOI 10.1002/aja.1001300406; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GUSTAFSON TA, 1988, MOL CELL BIOL, V8, P4110, DOI 10.1128/MCB.8.10.4110; HAEBERLE JR, 1994, J BIOL CHEM, V269, P12424; HIRAKOW R, 1981, ANAT EMBRYOL, V163, P299, DOI 10.1007/BF00315706; HOOD LC, 1992, ANAT RECORD, V234, P291, DOI 10.1002/ar.1092340215; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; KATOH Y, 1994, J BIOL CHEM, V269, P30538; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; KURATANI S, 1994, DEV BIOL, V161, P357, DOI 10.1006/dbio.1994.1037; Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MORGAN IM, 1992, CELL PROLIFERAT, V25, P205, DOI 10.1111/j.1365-2184.1992.tb01395.x; MOSSE PRL, 1986, ARTERIOSCLEROSIS, V6, P664, DOI 10.1161/01.ATV.6.6.664; MURPHY ME, 1978, AM J ANAT, V151, P345, DOI 10.1002/aja.1001510304; NAKAMURA F, 1993, J BIOL CHEM, V268, P6194; NGAI PK, 1984, J BIOL CHEM, V259, P3656; NISHIDA W, 1993, GENE, V130, P297, DOI 10.1016/0378-1119(93)90435-6; NODA S, 1992, BIOCHEM BIOPH RES CO, V185, P481, DOI 10.1016/S0006-291X(05)81010-1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; ORKIN SH, 1992, BLOOD, V80, P575; OWENS GK, 1986, J BIOL CHEM, V261, P3373; OWENS GK, 1995, PHYSIOL REV, V75, P487; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; PARDANAUD L, 1989, DEVELOPMENT, V105, P473; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; PARMACEK MS, 1990, J BIOL CHEM, V265, P15970; PARMACEK MS, 1989, J BIOL CHEM, V264, P13217; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; POOLE TJ, 1989, J EXP ZOOL, V251, P224, DOI 10.1002/jez.1402510210; REN WZ, 1994, MOL BRAIN RES, V22, P173, DOI 10.1016/0169-328X(94)90045-0; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, AM J PATHOL, V143, P987; ROVNER AS, 1986, AM J PHYSIOL, V250, pC861, DOI 10.1152/ajpcell.1986.250.6.C861; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SAWTELL NM, 1989, J CELL BIOL, V109, P2929, DOI 10.1083/jcb.109.6.2929; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; STRASSER P, 1993, FEBS LETT, V330, P13, DOI 10.1016/0014-5793(93)80909-E; TAKAHASHI K, 1986, BIOCHEM BIOPH RES CO, V141, P20, DOI 10.1016/S0006-291X(86)80328-X; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAUBMAN MB, 1987, J CELL BIOL, V104, P1505, DOI 10.1083/jcb.104.6.1505; UEKI N, 1987, P NATL ACAD SCI USA, V84, P9049, DOI 10.1073/pnas.84.24.9049; WILLS FL, 1994, BIOCHEMISTRY-US, V33, P5562, DOI 10.1021/bi00184a027; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WISSLER RW, 1968, J ATHEROSCLER RES, V8, P201, DOI 10.1016/S0368-1319(68)80056-0; ZANELLATO AMC, 1990, ARTERIOSCLEROSIS, V10, P996, DOI 10.1161/01.ATV.10.6.996	75	90	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					395	403		10.1074/jbc.271.1.395	http://dx.doi.org/10.1074/jbc.271.1.395			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550594	hybrid			2022-12-25	WOS:A1996TP36100063
J	Steinmeyer, K; Schwappach, B; Bens, M; Vandewalle, A; Jentsch, TJ				Steinmeyer, K; Schwappach, B; Bens, M; Vandewalle, A; Jentsch, TJ			Cloning and functional expression of rat CLC-5, a chloride channel related to kidney disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THICK ASCENDING LIMB; MEMBRANE; PROTEIN; CELLS	We have cloned a novel member of the CLC chloride channel family from rat brain, rCLC-5. The cDNA predicts a 83-kDa protein belonging to the branch including CLC-3 and CLC-4, with which it shares similar to 80% identity. Expression of rCLC-5 in Xenopus oocytes elicits novel anion currents. They are strongly outwardly rectifying and have a conductivity sequence of NO3- > Cl- > Br- > I- >> glutamate(-). Although CLC-5 has consensus sites for phosphorylation by protein kinase A, raising the intracellular cAMP concentration had no effect on these currents. Currents were also unchanged when rCLC-5 was coexpressed with rCLC-3 and rCLC-4, either singly or in combination, rCLC-5 is expressed predominantly in kidney and also in brain, lung, and liver. Along the nephron, rCLC-5 message is detectable in all tubule segments investigated, but expression in the glomerulus and the S2 segment of the proximal tubule is low.	UNIV HAMBURG,CTR MOLEC NEUROBIOL,D-20246 HAMBURG,GERMANY; UNIV PARIS 07,FAC MED XAVIER BICHAT,INST FEDERATIF RECH,INSERM,U246,F-75870 PARIS 18,FRANCE	University of Hamburg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite				Schwappach, Blanche/0000-0003-0225-6432; Jentsch, Thomas/0000-0002-3509-2553				BORSANI G, 1995, GENOMICS, V27, P131, DOI 10.1006/geno.1995.1015; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; FISHER SE, 1994, HUM MOL GENET, V3, P2053; FUJITA N, 1994, NUCLEIC ACIDS RES, V22, P1637, DOI 10.1093/nar/22.9.1637; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; GREGER R, 1990, RENAL PHYSIOL BIOCH, V13, P37; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HIGGINS JT, 1977, PFLUG ARCH EUR J PHY, V371, P87, DOI 10.1007/BF00580776; JENTSCH TJ, 1994, CURR OPIN CELL BIOL, V6, P600, DOI 10.1016/0955-0674(94)90082-5; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KORBMACHER C, 1993, J GEN PHYSIOL, V102, P761, DOI 10.1085/jgp.102.4.761; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; MAACK T, 1990, METHOD ENZYMOL, V191, P340; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; PAULAIS M, 1990, J MEMBRANE BIOL, V113, P253, DOI 10.1007/BF01870076; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; PUSCH M, 1995, IN PRESS NEURON; REINHART SC, 1995, J AM SOC NEPHROL, V5, P1451; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1994, EMBO J, V13, P7327; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; VALLET V, 1995, EXP CELL RES, V216, P363, DOI 10.1006/excr.1995.1046; VANDEWALLE A, 1981, AM J PHYSIOL, V240, pF492, DOI 10.1152/ajprenal.1981.240.6.F492; VANSLEGTENHORST MA, 1994, HUM MOL GENET, V3, P547; WINTERS CJ, 1991, J MEMBRANE BIOL, V122, P89, DOI 10.1007/BF01872742; WU MS, 1994, J MEMBRANE BIOL, V142, P323	35	237	248	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31172	31177		10.1074/jbc.270.52.31172	http://dx.doi.org/10.1074/jbc.270.52.31172			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537381	hybrid			2022-12-25	WOS:A1995TN44400049
J	Yamamoto, K; Arakawa, T; Ueda, N; Yamamoto, S				Yamamoto, K; Arakawa, T; Ueda, N; Yamamoto, S			Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID CYCLOOXYGENASE; ENDOPEROXIDE SYNTHASE-2 GENE; OSTEOBLASTIC CELLS; FACTORS INTERACT; GRANULOSA-CELLS; GROWTH-FACTOR; PROTEIN; NF-IL6; LINE; IL-6	When a mouse osteoblastic cell line MC3T3-E1 was cultured in the presence of tumor necrosis factor Lu (TNF alpha), the release of prostaglandin E(2) and the cyclooxygenase activity increased in a dose- and time-dependent manner. The increase of the enzyme activity was attributed mostly to the induction of cyclooxygenase-2 rather than cyclooxygenase-1 as judged by the inhibitory effect of NS398, Western blotting, and Northern blotting, In this system we attempted to elucidate the transcriptional regulation of the cyclooxygenase-2 gene. As examined by the luciferase assay, two positive regulatory regions (-186 to -131 and -512 to -385 base pairs) were found in the 5'-flanking promoter region of the mouse cyclooxygenase-a gene in the TNF alpha-stimulated cells. The former included putative NF-IL6 (C/EBP beta) and AP2 elements, and the latter contained the NF kappa B motif. A DNA probe including the NF-IL6 and AP2 sites gave positive bands upon electrophoretic mobility shift assay using the nuclear extracts of MC3T3-E1 cells, The bands were supershifted by the addition of anti-NF-IL6 antibody but not by anti-AP2 antibody. A probe including the NF kappa B site also gave positive bands, which were supershifted by anti-NF kappa B p50 and p65 antibodies. Furthermore, when the motif of NF-IL6 or NF kappa B or both was subjected to point mutation, the luciferase activity was markedly reduced. These data suggested a potential role of both NF-IL6 and NF kappa B in the induction of cyclooxygenase-2 by TNF alpha.	UNIV TOKUSHIMA,SCH MED,DEPT BIOCHEM,KURAMOTO,TOKUSHIMA 770,JAPAN	Tokushima University								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ARAKAWA T, 1992, J BIOL CHEM, V267, P12188; ARAKAWA T, 1995, FEBS LETT, V363, P105, DOI 10.1016/0014-5793(95)00293-I; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BERGER SL, 1987, METHOD ENZYMOL, V152, P432; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; ENDO T, 1995, AM J RESP CELL MOL, V12, P358, DOI 10.1165/ajrcmb.12.3.7873203; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; Kodama HA., 1981, JPN J ORAL BIOL, V23, P899, DOI DOI 10.2330/JORALBIOSCI1965.23.899; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KUSAKA M, 1988, BIOCHIM BIOPHYS ACTA, V972, P339, DOI 10.1016/0167-4889(88)90210-8; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; OSHIMA T, 1991, J BIOL CHEM, V266, P13621; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; RAPUANO BE, 1991, BIOCHIM BIOPHYS ACTA, V1091, P374, DOI 10.1016/0167-4889(91)90203-A; SATO K, 1987, BIOCHEM BIOPH RES CO, V145, P323, DOI 10.1016/0006-291X(87)91324-6; Schmitz M L, 1991, Trends Cell Biol, V1, P130, DOI 10.1016/0962-8924(91)90118-S; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; SMITH WL, 1994, CURR OPIN INVEST DR, V3, P1; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUMITANI K, 1989, ARCH BIOCHEM BIOPHYS, V270, P588, DOI 10.1016/0003-9861(89)90541-9; TAKAHASHI Y, 1994, BBA-LIPID LIPID MET, V1212, P217, DOI 10.1016/0005-2760(94)90256-9; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; YANAGA F, 1992, J BIOL CHEM, V267, P5114; YOKOTA K, 1986, J BIOL CHEM, V261, P5410	38	594	610	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31315	31320		10.1074/jbc.270.52.31315	http://dx.doi.org/10.1074/jbc.270.52.31315			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537402	hybrid			2022-12-25	WOS:A1995TN44400069
J	Kharbanda, S; Pandey, P; Ren, R; Mayer, B; Zon, L; Kufe, D				Kharbanda, S; Pandey, P; Ren, R; Mayer, B; Zon, L; Kufe, D			c-Abl activation regulates induction of the SEK1 stress-activated protein kinase pathway in the cellular response to 1-beta-D-arabinofuranosylcytosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MYELOID-LEUKEMIA CELLS; TYROSINE KINASE; DNA-SYNTHESIS; CYCLE; ARABINOFURANOSYLCYTOSINE; PHOSPHORYLATION; SEQUENCES; BINDING; ELONGATION; LETHALITY	Previous work has shown that treatment(1) of cells with the antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C) is associated with induction of the c-jun gene. The present studies demonstrate that ara-C activates the c-Abl non-receptor tyrosine kinase. We also demonstrate that activity of the stress activated protein kinase (SAP kinase/JNK) is increased in ara-C-treated cells. Using cells deficient in c-Abl (Abl(-/-)) and after introduction of the c-abl gene, we show that ara-C-induced c-Abl activity is necessary for the stimulation of SAP kinase, Other studies using cells transfected with a SEK1 dominant negative demonstrate that ara C-induced SAP kinase activity is SEK1-dependent. Furthermore, we show that overexpression of truncated c-Abl results in activation of the SEK1/SAP kinase cascade.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,DEPT BIOL,WALTHAM,MA 02254; HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Brandeis University; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Kharbanda, S (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER; NCI NIH HHS [CA29431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BRACH MA, 1992, BLOOD, V79, P728; BURHANS WC, 1986, BIOCHEMISTRY-US, V25, P441, DOI 10.1021/bi00350a025; COZZARELLI NR, 1977, ANNU REV BIOCHEM, V46, P641, DOI 10.1146/annurev.bi.46.070177.003233; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FREI E, 1969, CANCER RES, V29, P1325; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KHARBANDA S, 1993, BIOCHEMISTRY-US, V32, P9137, DOI 10.1021/bi00086a019; KHARBANDA SM, 1990, J CLIN INVEST, V86, P1517, DOI 10.1172/JCI114870; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; OHNO Y, 1988, CANCER RES, V48, P1494; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SALEEM A, 1995, J IMMUNOL, V154, P4150; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YAN MH, 1994, NATURE, V372, P798	35	124	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30278	30281		10.1074/jbc.270.51.30278	http://dx.doi.org/10.1074/jbc.270.51.30278			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530447	Green Published, hybrid			2022-12-25	WOS:A1995TL67500012
J	Xie, YM; Pendergast, AM; Hung, MC				Xie, YM; Pendergast, AM; Hung, MC			Dominant-negative mutants of Grb2 induced reversal of the transformed phenotypes caused by the point mutation-activated rat HER-2/Neu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; GUANINE-NUCLEOTIDE EXCHANGE; NEU ONCOGENE; TYROSINE KINASE; EGF RECEPTOR; SIGNAL TRANSDUCTION; OVARIAN-CANCER; C-ERBB-2 GENE; NIH-3T3 CELLS; SH3 DOMAINS	To clarify the role of the Shc-Grb2-Sos trimer in the oncogenic signaling of the point mutation-activated HER-2/neu receptor tyrosine kinase (named p185), we interfered with the protein-protein interactions in the Shc . Grb2 . Sos complex by introducing Grb2 mutants with deletions in either amino- (Delta N-Grba) or carboxyl(Delta C-Grb2) terminal SH3 domains into B104-1-1 cells derived from NIH3T3 cells expressing the point mutation-activated HER-2/neu. We found that the transformed phenotypes of the B104-1-1 cells were largely reversed by the Delta N-Grba. The effect of the Delta C-Grba was much weaker. Biochemical analysis showed that the Delta N-Grba was able to associate She but not p185 or Sos, while the Delta C-Grba bound to Shc, p185, and Sos. The p185-mediated Ras activation was severely inhibited by the Delta N-Grb2 but not the Delta C-Grb2. Taken together, these data demonstrate that interruption of the interaction between She and the endogenous Grb2 by the Delta N-Grb2 impairs the oncogenic signaling of the activated p185, indicating that (i) the Delta N-Grb2 functions as a strong dominant-negative mutant, and (ii) Shc/Grb2/Sos pathway plays a major role in mediating the oncogenic signal of the activated p185. Unlike the Delta N-Grb2, Delta C-Grb2 appears to be a relatively weak dominant-negative mutant, probably due to its ability to largely fulfill the biological functions of the wild-type Grb2.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710	University of Texas System; UTMD Anderson Cancer Center; Duke University			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Pendergast, Ann Marie/0000-0002-1250-6880	NATIONAL CANCER INSTITUTE [R01CA058880, R01CA060856, R01CA061033] Funding Source: NIH RePORTER; NCI NIH HHS [CA60856, CA61033, CA58880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BENJAMIN CW, 1994, J BIOL CHEM, V269, P30911; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GISHIZKY ML, 1995, IN PRESS P NATL ACAD; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOU L, 1992, CANCER LETT, V65, P215, DOI 10.1016/0304-3835(92)90234-M; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MATIN A, 1995, INT J ONCOL, V6, P1087; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; REARDON DB, 1994, ONCOL REP, V1, P37; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; XIE YM, 1995, ONCOGENE, V10, P2409; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1991, ONCOGENE, V6, P1991; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	63	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30717	30724		10.1074/jbc.270.51.30717	http://dx.doi.org/10.1074/jbc.270.51.30717			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530511	hybrid			2022-12-25	WOS:A1995TL67500076
J	VENTURA, C; PINTUS, G; VAONA, I; BENNARDINI, F; PINNA, G; TADOLINI, B				VENTURA, C; PINTUS, G; VAONA, I; BENNARDINI, F; PINNA, G; TADOLINI, B			PHORBOL ESTER REGULATION OF OPIOID PEPTIDE GENE-EXPRESSION IN MYOCARDIAL-CELLS - ROLE OF NUCLEAR-PROTEIN KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; ENKEPHALIN IMMUNOREACTIVITY; SUBSTRATE; RECEPTOR; PHOSPHORYLATION; STIMULATION; DYNORPHIN; INVITRO; BRAIN; CA2+	Opioid peptide gene expression was characterized in adult rat ventricular cardiac myocytes that had been cultured in the absence or the presence of phorbol 12-myristate 13-acetate. The phorbol ester induced a concentration- and time-dependent increase of prodynorphin mRNA, the maximal effect being reached after 4 h of treatment, The increase in mRNA expression was suppressed by incubation of cardiomyocytes with staurosporine, a putative protein kinase C inhibitor, and was not observed when the cells were cultured in the presence of the inactive phorbol ester 4 alpha-phorbol 12,13-didecanoate, Incubation of cardiac myocytes with phorbol 12-myristate 13-acetate also elicited a specific and staurosporine-sensitive increase in immunoreactive dynorphin B, a biologically active end product of the precursor, both in the myocardial cells and in the culture medium, In vitro run-off transcription assays indicated that transcription of the prodynorphin gene was increased both in nuclei isolated hom phorbol ester-treated myocytes and in nuclei isolated from control cells and then exposed to phorbol 12-myristate 13-acetate, No transcriptional effect was observed when cardiac myocytes or isolated nuclei where exposed to 4 alpha-phorbol 12,13-didecanoate. The phorbol ester-induced increase in prodynorphin gene transcription was prevented by pretreatment of myocytes or isolated nuclei with staurosporine, suggesting that myocardial opioid gene expression may be regulated by nuclear protein kinase C, In this regard, cardiac myocytes expressed protein kinase C-alpha, -delta, -epsilon, and -zeta, as shown by immuno-blotting, Only protein kinase C-delta and protein kinase C-epsilon were expressed in nuclei that have been isolated from control myocytes, suggesting that these two isotypes of the enzyme may be part of the signal transduction pathway involved in the effect elicited by the phorbol ester on opioid gene transcription in isolated nuclei, The incubation of myocardial nuclei isolated from control cells in the presence of a protein kinase C activator induced the phosphorylation of the myristoylated alanine-rich protein kinase C substrate peptide, a specific fluorescent substrate of the enzyme, The possibility that prodynorphin gene expression may control the heart function through autocrine or paracrine mechanisms is discussed.	UNIV SASSARI, SCH PHARM, INST BIOL CHEM, I-07100 SASSARI, ITALY; UNIV BOLOGNA, DEPT BIOCHEM, I-40126 BOLOGNA, ITALY	University of Sassari; University of Bologna	VENTURA, C (corresponding author), UNIV SASSARI, SCH MED, INST BIOL CHEM A BONSIGNORE, VIALE SAN PIETRO 43-B, I-07100 SASSARI, ITALY.		Pintus, Gianfranco/C-2975-2009	Pintus, Gianfranco/0000-0002-3031-7733	Telethon [593] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALLO SN, 1991, J BIOL CHEM, V266, P22003; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLUM M, 1989, METHOD ENZYMOL, V168, P618; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; CAPOGROSSI MC, 1986, J GEN PHYSIOL, V88, P589, DOI 10.1085/jgp.88.5.589; CHAVKIN C, 1982, SCIENCE, V215, P413, DOI 10.1126/science.6120570; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCCO L, 1987, BIOCHEM J, V248, P765, DOI 10.1042/bj2480765; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; CONE RI, 1983, J NEUROSCI, V3, P2146; COOPER DR, 1987, J BIOL CHEM, V262, P3633; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; EDWARDS MJ, 1970, MOL PHARMACOL, V6, P641; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; HOLADAY JW, 1983, ANNU REV PHARMACOL, V23, P541, DOI 10.1146/annurev.pa.23.040183.002545; HUGHES J, 1981, TRENDS PHARMACOL SCI, V2, P21, DOI 10.1016/0165-6147(81)90249-2; JACKOWSKI G, 1980, BIOCHEM J, V188, P363, DOI 10.1042/bj1880363; JAMIESON JD, 1964, J CELL BIOL, V23, P151, DOI 10.1083/jcb.23.1.151; KOHOUT TA, 1993, AM J PHYSIOL, V264, pC1350, DOI 10.1152/ajpcell.1993.264.5.C1350; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KOSAKA Y, 1988, BIOCHEM BIOPH RES CO, V151, P973, DOI 10.1016/S0006-291X(88)80461-3; KRAUSE JE, 1989, METHOD ENZYMOL, V168, P634; LAMERS JMJ, 1981, BIOCHIM BIOPHYS ACTA, V640, P521, DOI 10.1016/0005-2736(81)90476-4; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; MCILROY BK, 1991, ANAL BIOCHEM, V195, P148, DOI 10.1016/0003-2697(91)90310-P; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; PATEL J, 1987, J BIOL CHEM, V262, P16686; PIPER HM, 1982, J MOL CELL CARDIOL, V14, P397, DOI 10.1016/0022-2828(82)90171-7; SMITH CD, 1983, J BIOL CHEM, V258, P9368; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; SPAMPINATO S, 1992, BRAIN RES, V580, P225, DOI 10.1016/0006-8993(92)90948-9; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENTURA C, 1991, BIOCHEM BIOPH RES CO, V179, P972, DOI 10.1016/0006-291X(91)91913-W; VENTURA C, 1991, AM J PHYSIOL, V261, pH1671, DOI 10.1152/ajpheart.1991.261.5.H1671; VENTURA C, 1992, CIRC RES, V70, P66, DOI 10.1161/01.RES.70.1.66; VENTURA C, 1989, BIOCHIM BIOPHYS ACTA, V987, P69, DOI 10.1016/0005-2736(89)90456-2; VENTURA C, 1994, J BIOL CHEM, V269, P5384; XIE GX, 1987, J NEUROSCI, V7, P3049; ZAGON IS, 1985, SCIENCE, V227, P1049, DOI 10.1126/science.3883485; ZAGON IS, 1986, CELL TISSUE RES, V246, P561, DOI 10.1007/BF00215197; ZAHRADKA W, 1987, EUR J BIOCHEM, V171, P37	51	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30115	30120						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530417				2022-12-25	WOS:A1995TK38000077
J	WHITLEY, P; GAFVELIN, G; VONHEIJNE, G				WHITLEY, P; GAFVELIN, G; VONHEIJNE, G			SECA-INDEPENDENT TRANSLOCATION OF THE PERIPLASMIC N-TERMINAL TAIL OF AN ESCHERICHIA-COLI INNER MEMBRANE-PROTEIN - POSITION-SPECIFIC EFFECTS ON TRANSLOCATION OF POSITIVELY CHARGED RESIDUES AND CONSTRUCTION OF A PROTEIN WITH A C-TERMINAL TRANSLOCATION SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTAGENESIS; DOMAIN	me have shown previously that the 100-residue-long periplasmic N-terminal tail of the Escherichia coli inner membrane protein ProW can be translocated across the inner membrane in a sec-independent manner and that: its translocation is blocked by the introduction of three positively charged residues near its C-terminal end (WhitIey, P,, Zander, T,, Ehrmann, M,, Haardt, M,, Bremer, E,, and von Heijne, G, (1994) EMBO J, 13, 4653-4661), We have now further analyzed the requirements for translocation of the N-terminal tail and found that the introduction of even a single arginine can block translocation. Position-specific differences in the effects on translocation of arginine insertions suggest that the C-terminal end of the N-terminal tail is more critical for translocation than the central and N-terminal regions, We also show that the N-terminal tail is translocated in a truncation mutant where a stop codon is placed immediately after the first transmembrane segment, provided that the transmembrane segment is flanked on its C-terminal end by positively charged residues, Thus, sec-independent translocation of a relatively large domain can be induced by a translocation signal located at the extreme C terminus of a protein.	UNIV STOCKHOLM,ARRHENIUS LAB,DEPT BIOCHEM,S-10691 STOCKHOLM,SWEDEN	Stockholm University			von Heijne, Gunnar/F-5576-2011; von Heijne, Gunnar/AAH-9389-2019	von Heijne, Gunnar/0000-0002-4490-8569; Gafvelin, Guro/0000-0003-1618-4011				ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; DALBEY RE, 1987, SCIENCE, V235, P783, DOI 10.1126/science.3544218; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KUHN A, 1990, J STRUCT BIOL, V104, P38, DOI 10.1016/1047-8477(90)90055-H; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; SAAF A, 1995, MOL MEMBR BIOL, V12, P209, DOI 10.3109/09687689509027509; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; VONHEIJNE G, 1994, FEBS LETT, V246, P69; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x	16	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29831	29835						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530378				2022-12-25	WOS:A1995TK38000038
J	NICKLIN, MJH; ZECHNER, D; KISLYAKOVA, T				NICKLIN, MJH; ZECHNER, D; KISLYAKOVA, T			ACCUMULATED HELIX-DESTABILIZING MUTATIONS IN THE LEUCINE-ZIPPER OF C-FOS LEADS TO ATTENUATION AND TEMPERATURE SENSITIVITY OF FUNCTION	ONCOGENE			English	Article							DNA-BINDING DOMAIN; CELLULAR-TRANSFORMATION; GROWTH-FACTOR; JUN; PROTEIN; GENE; EXPRESSION; THERMOSTABILITY; TRANSCRIPTION; FIBROBLASTS	Fos protein heterodimerizes through one surface of an alpha-helical domain called the leucine zipper. We have investigated the effect of destabilizing this domain by multiply substituting small residues of its non-interacting surface with glycine. Ternary complex formation between mutated Fos, Jun and DNA was determined in vitro in the presence of denaturant. We also tested the ability of constitutively expressed, mutated Fos proteins to support anchorage independent growth of the cell line Rat1A. Combinations of two substitutions are tolerated in both assays of Fos function, while four substitutions resulted in attenuation in both functions. Rat1A expressing one of the quadruple mutants also showed temperature sensitivity in anchorage independent growth. In dense monolayers of these cells, stromelysin (a Fos-responsive gene product) decreased in abundance as a function of temperature and was less abundant even at 34-degrees-C than in cells that overexpressed the wild-type c-fos mRNA. However the mutant transgene itself appeared to show temperature sensitive expression. We suggest that creating a range of glycine substitutions for small residues in the non-interacting face of a leucine zipper might be of general use as a strategy to produce attenuated mutants of other transcription factors.	FORSCH INST MOLEK PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Nicklin, Martin/0000-0002-0127-1131				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BOHMANN D, 1989, SCIENCE, V246, P911; BUSSLINGER M, 1981, CELL, V27, P289, DOI 10.1016/0092-8674(81)90412-8; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HARAI SI, 1989, NEW BIOL, V1, P181; HECHT M H, 1986, Proteins Structure Function and Genetics, V1, P43, DOI 10.1002/prot.340010108; IMANAKA T, 1986, NATURE, V324, P695, DOI 10.1038/324695a0; JOOSS K, 1992, ONCOGENE, V7, P1933; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LOVELLBADGE RH, 1987, TERATOCARCINOMAS EMB, P132; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MILLER AD, 1984, CELL, V36, P51; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEMETHY G, 1966, J PHYS CHEM-US, V70, P998, DOI 10.1021/j100876a008; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NICKLIN MJH, 1991, ONCOGENE, V6, P173; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PREVELIGE P, 1988, PREDICTION PROTEIN S, P391; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SHORTLE D, 1985, GENETICS, V110, P539; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	47	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1737	1749						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510920				2022-12-25	WOS:A1993LG68200004
J	SLEEMAN, JP				SLEEMAN, JP			XENOPUS A-MYB IS EXPRESSED DURING EARLY SPERMATOGENESIS	ONCOGENE			English	Article							HUMAN LYMPHOCYTES-T; C-MYB; V-MYB; ERYTHROID-DIFFERENTIATION; NUCLEOTIDE-SEQUENCE; MYELOID-LEUKEMIA; CDNA CLONES; CELL-LINES; GENE; ONCOGENE	c-myb has been studied intensely, but other members of the myb gene family have been largely overlooked. This paper describes the isolation and characterization of a Xenopus cDNA sequence, XAMyb, closely related to human A-myb. Xenopus provides a valuable experimental model for investigating the involvement of genes in cell proliferation, differentiation and development. Although no expression of XAMyb was detected in oocytes or eggs or during early embryogenesis, there is a low level of expression within ovarian tissue, which is down-regulated in response to hormones that stimulate oocyte maturation. However, in adult male Xenopus, virtually all A-myb expression is in the testis, particularly within the nuclei of spermatogonial cells, the mitotically proliferating early progenitors of spermatozoa. Expression falls dramatically during meiosis and is virtually undetectable during subsequent spermiogenesis. This pattern of expression of Xenopus A-myb during the preterminal differentiation/ proliferation phase of germ cell development resembles the expression of c-myb in similar phases during haematopoiesis. These results suggest related roles for myb variants during the development of different stem cell-derived populations.	WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND				Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687				ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGER SL, 1987, METHODS ENZYMOL, V152; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CLURMAN B, 1988, IMMUNOL SER, V41, P55; CRAIG RW, 1984, CANCER RES, V44, P442; DESBIENS X, 1991, DEVELOPMENT, V111, P699; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRIFFIN CA, 1985, CANCER RES, V45, P272; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HARLOW E, 1988, ANTIBODIES LABORATOR; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; JACKSON R, 1987, METHOD ENZYMOL, V96, P50; KALT MR, 1976, J EXP ZOOL, V195, P393, DOI 10.1002/jez.1401950306; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KREIG PA, 1989, DEV BIOL, V133, P93; KREIG PA, 1987, METHOD ENZYMOL, V155, P397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOFTS B, 1974, PHYSL AMPHIBIA; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEINESS D, 1984, MOL CELL BIOL, V9, P5456; SHENONG G, 1991, BIOCHIM BIOPHYS ACTA, V1032, P39; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P431; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; TORELLI G, 1987, CANCER RES, V47, P5266; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESTON K, 1989, CELL, V58, P83	53	91	94	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1931	1941						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510936				2022-12-25	WOS:A1993LG68200026
J	CHIORINI, JA; BOAL, TR; MIYAMOTO, S; SAFER, B				CHIORINI, JA; BOAL, TR; MIYAMOTO, S; SAFER, B			A DIFFERENCE IN THE RATE OF RIBOSOMAL ELONGATION BALANCES THE SYNTHESIS OF EUKARYOTIC TRANSLATION INITIATION-FACTOR (EIF)-2 ALPHA AND EIF-2-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS-INITIATION; MESSENGER-RNA; HEMOGLOBIN SYNTHESIS; FACTOR-II; PHOSPHORYLATION; SEQUENCE; SUBUNIT; PURIFICATION; RECOGNITION; MUTATIONS	Eukaryotic translation initiation factor 2 (eIF-2) is a heterotrimer composed of three subunits designated alpha, beta, and gamma. These proteins exist in equimolar amounts in the cell and have not been detected as isolated subunits. Our research examines the basis of their balanced synthesis. Northern analysis of K562 cell mRNA revealed that eIF-2beta was five times more abundant than eIF-2alpha. However, immunoprecipitation of pulse-labeled K562 cells showed an equimolar rate of synthesis of eIF-2alpha and -beta despite the 5-fold difference in the size of their mRNA pools. Addition of equal amounts of synthetic capped mRNA for eIF-2alpha and eIF-2beta to an in vitro translation reaction produced five times more eIF-2alpha protein than eIF-2beta. Determination of the polysome profile for alpha and beta mRNA in K562 cells indicated eIF-2alpha was translated more efficiently than eIF-2beta. Substitution of either the initiation codon context or the leader of the beta mRNA for that of alpha had only a minor effect on the translational efficiency of beta. Comparison of the rate of ribosomal elongation for the two mRNAs indicated that ribosomes associated with the beta mRNA elongate at a rate 4-fold less than that of eIF-2alpha. Thus, the balanced translation of alpha and beta mRNA is primarily the result of a 4-fold difference in the rate of ribosomal elongation.	NHLBI, MOLEC HEMATOL BRANCH, RNA & PROT BIOSYNTH SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BOAL TR, 1993, J BIOL CHEM, V258, P7228; BRENDLER T, 1981, J BIOL CHEM, V256, P1755; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CHOI SY, 1992, J BIOL CHEM, V267, P286; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIGAN AM, 1989, P NATL ACAD SCI USA, V86, P2784, DOI 10.1073/pnas.86.8.2784; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; CURCIO MJ, 1986, J BIOL CHEM, V261, P6126; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DONAHUE TF, 1988, MOL CELL BIOL, V8, P2955, DOI 10.1128/MCB.8.7.2955; DUNCAN R, 1985, J BIOL CHEM, V260, P5486; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; ERNST H, 1987, J BIOL CHEM, V262, P1206; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HILL WE, 1990, RIBOSOME; HUANG S, 1989, MOL CELL BIOL, V9, P3679, DOI 10.1128/MCB.9.9.3679; HUMBELIN M, 1989, GENE, V81, P315, DOI 10.1016/0378-1119(89)90192-3; INNIS MA, 1990, PCR PROTOCOLS; KATZE MG, 1988, J VIROL, V62, P3710, DOI 10.1128/JVI.62.10.3710-3717.1988; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KITAJEWSKI J, 1986, MOL CELL BIOL, V6, P4493, DOI 10.1128/MCB.6.12.4493; KLAUSNER R D, 1989, New Biologist, V1, P3; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; LODISH HF, 1972, J BIOL CHEM, V247, P3622; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PALMITER RD, 1972, J BIOL CHEM, V247, P6770; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; PROUD CG, 1982, FEBS LETT, V143, P55, DOI 10.1016/0014-5793(82)80273-1; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; WU RS, 1971, J CELL BIOL, V51, P643, DOI 10.1083/jcb.51.3.643; YARUS M, 1985, J MOL BIOL, V182, P529, DOI 10.1016/0022-2836(85)90239-6; 1991, PC GENE 6 5	39	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13748	13755						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514807				2022-12-25	WOS:A1993LH55300102
J	DEICHAITE, I; BERTHIAUME, L; PESECKIS, SM; PATTON, WF; RESH, MD				DEICHAITE, I; BERTHIAUME, L; PESECKIS, SM; PATTON, WF; RESH, MD			NOVEL USE OF AN IODO-MYRISTYL-COA ANALOG IDENTIFIES A SEMIALDEHYDE DEHYDROGENASE IN BOVINE LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; ALDEHYDE DEHYDROGENASE; PROTEIN; SEQUENCE; MYRISTOYLATION; CLONING; GENE; DNA; TRANSFORMATION; PURIFICATION	We describe here the identification, purification, and characterization of a semialdehyde dehydrogenase with a novel fatty acid binding function. The coenzyme A derivative of an I-125-labeled long chain saturated fatty acid (13-iodo-tridecanoate) was used to tag proteins which bind myristoyl-CoA. A prominent 57 kDa band was identified, which was isolated from bovine liver by a high salt extraction followed by ammonium sulfate precipitation. Sequential chromatographic separation using phenyl-Sepharose, hydroxyapatite, DEAE-Sepharose, Mono Q, and Fast Flow S resins resulted in a purified protein that migrated as a single band of 57 kDa on denaturing gels. Sephacryl-200 gel filtration provided a native molecular mass estimation of 118 kDa suggesting that this protein exists as a dimer. Two-dimensional gel analysis resolved three isoform variants with pl values of 7.4, 7.7, and 7.9, respectively, and established that the pI = 7.9 form has the highest propensity for fatty acid binding. We proceeded to generate tryptic peptides from the purified protein and subjected several peptides to microchemical sequencing. Degenerate oligonucleotide probes were designed and polymerase chain reaction was used to generate a unique nucleotide sequence. Subsequent screening of a bovine liver cDNA library yielded a 1.7-kilobase clone which encodes a protein of 537 amino acids (58 kDa) with 95% identity to mammalian methylmalonate semialdehyde dehydrogenase (MMSDH). In vitro assays confirmed that the purified 57-kDa protein exhibited MMSDH activity, and that preincubation of the enzyme with fatty acyl-CoA inhibited its dehydrogenase activity. The myristyl-CoA analog therefore serves as an affinity label for MMSDH. We propose that fatty acyl CoAs may have the potential to function as enzyme regulators in vivo.	MEM SLOAN KETTERING CANC CTR, DEPT CELL BIOL & GENET, 1275 YORK AVE, BOX 143, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MOLEC BIOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				Resh, Marilyn/0000-0001-6118-9466; Berthiaume, Luc/0000-0003-0926-059X; Deichaite, Ida/0000-0001-8839-0573	NATIONAL CANCER INSTITUTE [R01CA052405] Funding Source: NIH RePORTER; NCI NIH HHS [CA52405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERENT S L, 1985, Biotechniques, V3, P208; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1988, FEBS LETT, V233, P440, DOI 10.1016/0014-5793(88)80480-0; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; Deschenes RJ, 1990, CURR OPIN CELL BIOL, V2, P1108, DOI 10.1016/0955-0674(90)90164-A; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOODWIN GW, 1989, J BIOL CHEM, V264, P14965; GORDON JI, 1991, J BIOL CHEM, V266, P8647; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GUAN K, 1990, ARCH BIOCHEM BIOPHYS, V277, P351, DOI 10.1016/0003-9861(90)90590-U; HSU LC, 1989, GENOMICS, V5, P857, DOI 10.1016/0888-7543(89)90127-4; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KASINATHAN C, 1990, J BIOL CHEM, V265, P5139; KEDISHVILI NY, 1992, J BIOL CHEM, V267, P19724; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUPIECKI FP, 1960, BIOCH PREP, V7, P69; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PATTON WF, 1992, BIOTECHNIQUES, V12, P580; PATTON WF, 1990, BIOTECHNIQUES, V8, P518; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PESECKIS SM, 1993, J BIOL CHEM, V268, P5107; POPOV KM, 1992, BIOCHIM BIOPHYS ACTA, V1119, P69, DOI 10.1016/0167-4838(92)90236-7; REIN A, 1986, P NATL ACAD SCI USA, V83, P7246, DOI 10.1073/pnas.83.19.7246; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SHIVELY JE, 1989, TRENDS BIOCHEM SCI, V14, P246, DOI 10.1016/0968-0004(89)90056-X; SIMON SM, 1992, J BIOL CHEM, V267, P3922; STEELE MI, 1992, J BIOL CHEM, V267, P13585; TAKEDA A, 1990, SCIENCE, V250, P676, DOI 10.1126/science.2146743; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VONBAHRLINDSTRO.H, 1985, BIOCHEMISTRY-US, V24, P6838; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WERETILNYK EA, 1990, P NATL ACAD SCI USA, V87, P2745, DOI 10.1073/pnas.87.7.2745	47	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13738	13747						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514806				2022-12-25	WOS:A1993LH55300101
J	JI, H; BALDWIN, GS; BURGESS, AW; MORITZ, RL; WARD, LD; SIMPSON, RJ				JI, H; BALDWIN, GS; BURGESS, AW; MORITZ, RL; WARD, LD; SIMPSON, RJ			EPIDERMAL GROWTH-FACTOR INDUCES SERINE PHOSPHORYLATION OF STATHMIN IN A HUMAN COLON-CARCINOMA CELL-LINE (LIM-1215)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-ENRICHED PHOSPHOPROTEIN; RECEPTOR TYROSINE KINASES; PROTEIN-KINASE; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; EGF RECEPTOR; FACTOR-ALPHA; A431 CELLS; IDENTIFICATION; ACTIVATION	Changes in protein phosphorylation in the human colon carcinoma cell line LIM 1215 after stimulation with epidermal growth factor (EGF) have been analyzed by two-dimensional gel electrophoresis and phosphoamino acid analysis. In addition to a number of tyrosine-phosphorylated proteins, a family of small proteins (M(r) 19,000-20,000) is maximally phosphorylated on serine within 5 min of EGF stimulation. One member of the family has been purified by a combination of two-dimensional electrophoresis and reversed-phase high performance liquid chromatography and identified by amino acid sequence analysis as stathmin. Although phosphorylation of stathmin has been reported previously in leukemia cells and following stimulation of hemopoietic or lymphoid cells with several mitogenic agents, this is the first report of stathmin phosphorylation in response to EGF.	LUDWIG INST CANC RES, JOINT PROT STRUCT LAB, PO ROYAL MELBOURNE HOSP, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; Walter & Eliza Hall Institute			Moritz, Robert L/B-9222-2011	Simpson, Richard/0000-0002-9834-0796; Baldwin, Graham/0000-0002-0944-8747				ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BALDWIN GS, 1992, CANCER RES, V52, P2261; BARNES D, 1987, METHOD ENZYMOL, V146, P88; BEGG GS, 1989, TECHNIQUES PROTEIN C, P79; BERETTA L, 1989, J BIOL CHEM, V264, P9932; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRAVERMAN R, 1986, J BIOL CHEM, V261, P14342; BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; BUSS JE, 1982, P NATL ACAD SCI-BIOL, V79, P2574, DOI 10.1073/pnas.79.8.2574; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CELIS JE, 1990, ELECTROPHORESIS, V11, P989, DOI 10.1002/elps.1150111202; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COOPER HL, 1990, J IMMUNOL, V145, P1205; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GIUGNI TD, 1988, J BIOL CHEM, V263, P18988; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; GREENE LA, 1982, ADV CELL NEUROBIOL, V3, P374; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HAILAT N, 1990, ONCOGENE, V5, P1615; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LAYTON JE, 1991, J BIOL CHEM, V266, P23815; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PASMANTIER R, 1986, ENDOCRINOLOGY, V119, P1229, DOI 10.1210/endo-119-3-1229; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEYRON JF, 1989, BIOCHEM J, V258, P505, DOI 10.1042/bj2580505; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SEGER R, 1992, J BIOL CHEM, V267, P14373; SIMPSON RJ, 1989, ANAL BIOCHEM, V177, P221, DOI 10.1016/0003-2697(89)90044-4; SIMPSON RJ, 1987, FEBS LETT, V224, P128, DOI 10.1016/0014-5793(87)80435-0; SIMPSON RJ, 1988, EUR J BIOCHEM, V176, P187, DOI 10.1111/j.1432-1033.1988.tb14267.x; SIZELAND AM, 1991, MOL CELL BIOL, V11, P4005, DOI 10.1128/MCB.11.8.4005; Sizeland A, 1991, GROWTH FACTORS, V4, P129, DOI 10.3109/08977199109000264; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WARD L D, 1991, Peptide Research, V4, P187; WARD LD, 1990, ELECTROPHORESIS, V11, P883, DOI 10.1002/elps.1150111019; WHITEHEAD RH, 1990, INT J CANCER, V46, P858, DOI 10.1002/ijc.2910460518; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHU XX, 1989, J BIOL CHEM, V264, P14556	66	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13396	13405						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514777				2022-12-25	WOS:A1993LH55300056
J	MARSHALL, ICB; TAYLOR, CW				MARSHALL, ICB; TAYLOR, CW			BIPHASIC EFFECTS OF CYTOSOLIC CA2+ ON INS(1,4,5)P3-STIMULATED CA2+ MOBILIZATION IN HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INDUCED CALCIUM RELEASE; PIG TAENIA CECI; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; XENOPUS OOCYTES; CA-2+; OSCILLATIONS; CELLS; TRISPHOSPHATE	The increase in cytosolic free Ca2+ concentration that follows mobilization of intracellular Ca2+ stores by inositol 1,4,5-trisphosphate Ins(1,4,5)P3 has been reported to modulate the sensitivity of Ins(1,4,5)P3 receptors. We have examined the effects of cytosolic Ca2+ on Ins(1,4,5)P3-Stimulated Ca2+ mobilization in permeabilized hepatocytes. Increasing the free Ca2+ concentration in the medium ([Ca2+]m) caused a concentration-dependent increase in the sensitivity of the stores to Ins(1,4,5)P3; the concentration of Ins(1,4,5)P3 that caused half-maximal Ca2+ mobilization (EC50) decreased from 261 +/- 11 nM (n = 3) to 50 +/- 4 nM (n = 8) as [Ca2+]m was increased from approximately 7 nM to 1.6 muM. The EC50 for this effect of Ca2+ was -250 nm. In addition, higher [Ca2+]m (>600 nM) reduced the extent of Ca2+ release induced by a maximal concentration of Ins(1,4,5)P3; elevating [Ca2+]m to 2.6 muM reduced the proportion of Ca2+ releasable by Ins(1,4,5)P3 by 94 +/- 8% (n = 3). Both effects of Ca2+ were independent of Ca2+-stimulated Ins(1,4,5)P3 formation. When elevated [Ca2+]m was returned to control levels, the sensitization of Ins()1,4,5)P3-mediated Ca2+ mobilization reversed completely, whereas the reduction in the size of the Ins(1,4,5)P3-sensitive Ca2+ pool was reversed by only 59 +/- 12% (n = 5) after 20 s and was not further reversed after 100 s. The two distinct effects of Ca2+ on Ins(1,4,5)P3-mediated Ca2+ release combined to control the amount of Ca2+ released by a submaximal concentration of Ins(1,4,5)P3 in a biphasic manner.	DEPT PHARMACOL, TENNIS COURT RD, CAMBRIDGE CB2 1QJ, ENGLAND				Taylor, Colin/G-2447-2010	Taylor, Colin/0000-0001-7771-1044	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BURGESS GM, 1984, BIOCHEM J, V224, P741, DOI 10.1042/bj2240741; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GIRARD S, 1992, BIOPHYS J, V61, P509, DOI 10.1016/S0006-3495(92)81855-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; IINO M, 1987, BIOCHEM BIOPH RES CO, V142, P47, DOI 10.1016/0006-291X(87)90449-9; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MERRITT JE, 1990, BIOCHEM J, V269, P513, DOI 10.1042/bj2690513; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NUNN DL, 1990, BIOCHEM J, V270, P227, DOI 10.1042/bj2700227; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1992, J BIOL CHEM, V267, P16312; ORON Y, 1985, NATURE, V313, P141, DOI 10.1038/313141a0; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; PIETRI F, 1990, J BIOL CHEM, V265, P17478; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SANDERSON MJ, 1990, CELL REGUL, V1, P585, DOI 10.1091/mbc.1.8.585; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAYLOR CW, 1986, BIOCHEM J, V238, P765, DOI 10.1042/bj2380765; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0	40	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13214	13220						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514760				2022-12-25	WOS:A1993LH55300031
J	NORDSTROM, LA; DEAN, DM; SANDERS, MM				NORDSTROM, LA; DEAN, DM; SANDERS, MM			A COMPLEX ARRAY OF DOUBLE-STRANDED AND SINGLE-STRANDED DNA-BINDING PROTEINS MEDIATES INDUCTION OF THE OVALBUMIN GENE BY STEROID-HORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RESPONSE ELEMENTS; DEPENDENT REGULATORY ELEMENT; EGG-WHITE GENES; NF-KAPPA-B; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL REGULATION; CHICK OVIDUCT; TATA BOX; C-MYC; PROMOTER	The transcriptional induction of the chicken ovalbumin gene by steroid hormones is abolished by inhibitors of protein synthesis such as cycloheximide, suggesting that a labile protein mediates this process. A steroid-dependent regulatory element (SDRE) has been identified in the 5'-flanking region of the gene between -900 and -780 that is required for induction by steroids. Additional transfection experiments limit the 5'-border of the SDRE to the region between -892 and -864. To investigate whether any of the proteins binding to the SDRE are affected by estrogen or cycloheximide, protein binding was investigated using DNase I and exonuclease III footprinting and gel mobility shift assays. These experiments demonstrate that labile proteins bind to the sequences between -900 and -860 and between -810 and -820. Four oviduct nuclear proteins, including one of the labile proteins, binding to the SDRE prefer single-stranded DNA (ssDNA) in a sequence-specific manner. The binding activity of three of these ssDNA-binding proteins is increased in oviduct nuclear protein extracts from estrogen-treated chicks. These data suggest that induction of the ovalbumin gene is mediated by a complex collection of ssDNA- and double-stranded DNA-binding proteins whose activities are in turn regulated by their short half-lives or by estrogen.			NORDSTROM, LA (corresponding author), UNIV MINNESOTA, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040082] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29DK40082] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCHER T, 1992, SCIENCE, V255, P573; ASHBURNER M, 1972, CHROMOSOMA, V38, P255, DOI 10.1007/BF00290925; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; CHAN GCK, 1991, J BIOL CHEM, V266, P22634; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; COMPERE SJ, 1981, J BIOL CHEM, V256, P6341; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS MI, 1984, ENDOCRINOLOGY, V115, P368, DOI 10.1210/endo-115-1-368; FAN WM, 1992, P NATL ACAD SCI USA, V89, P6104, DOI 10.1073/pnas.89.13.6104; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HESS P, 1990, P NATL ACAD SCI USA, V87, P2564, DOI 10.1073/pnas.87.7.2564; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HUMPHRIES P, 1977, NUCLEIC ACIDS RES, V4, P2389, DOI 10.1093/nar/4.7.2389; ISOMAA VV, 1983, J BIOL CHEM, V258, P6735; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JUMP DB, 1987, J BIOL CHEM, V262, P778; KAYE JS, 1984, EMBO J, V3, P1137, DOI 10.1002/j.1460-2075.1984.tb01942.x; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; LANDERS J P, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P19; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT G, 1976, PROGR DIFFERENTIATIO, P437; MCKNIGHT GS, 1980, CELL, V22, P469; MCKNIGHT GS, 1978, CELL, V14, P403; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; NELMS K, 1990, NUCLEIC ACIDS RES, V18, P1037; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PAN WT, 1990, J BIOL CHEM, V265, P7022; PARKER MG, 1991, NUCLEAR HORMONE RECE; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; RORIES C, 1989, ANNU REV PHYSIOL, V51, P653, DOI 10.1146/annurev.physiol.51.1.653; SANDERS MM, 1988, BIOCHEMISTRY-US, V27, P6550, DOI 10.1021/bi00417a053; SANDERS MM, 1985, ENDOCRINOLOGY, V116, P398, DOI 10.1210/endo-116-1-398; SANDERS MM, 1986, MOL GENETICS MAMMALI, P183; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHWEERS LA, 1990, J BIOL CHEM, V265, P7590; SCHWEERS LA, 1991, J BIOL CHEM, V266, P10490; SHUPNIK MA, 1989, J BIOL CHEM, V264, P80; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; WILKISON WO, 1990, J BIOL CHEM, V265, P477; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0	51	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13193	13202						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514758				2022-12-25	WOS:A1993LH55300029
J	VEKLICH, YI; GORKUN, OV; MEDVED, LV; NIEUWENHUIZEN, W; WEISEL, JW				VEKLICH, YI; GORKUN, OV; MEDVED, LV; NIEUWENHUIZEN, W; WEISEL, JW			CARBOXYL-TERMINAL PORTIONS OF THE ALPHA-CHAINS OF FIBRINOGEN AND FIBRIN - LOCALIZATION BY ELECTRON-MICROSCOPY AND THE EFFECTS OF ISOLATED ALPHA-C FRAGMENTS ON POLYMERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY CRYSTALLOGRAPHY; AMINO-ACID SEQUENCE; BOVINE FIBRINOGEN; DOMAINS; PROTOFIBRILS; CONFORMATION; BINDING; MODEL	The locations of the carboxyl-terminal two thirds of the Aalpha chains, or the alphaC domains, were determined for fibrinogen and some of its derivatives by electron microscopy of rotary-shadowed preparations. A monoclonal antibody, G8, to the carboxyl-terminal 150 amino acids of the Aalpha chain, binds near the central region of fibrinogen, indicating that the alphaC domains of most molecules are not normally visible because they are on or near the amino-terminal disulfide knot. At pH 3.5, fibrinogen and fibrin monomers appear to be similar, with a projection terminating in a small globular domain from each end of most molecules. In contrast, fragment X monomers, produced by cleavage of the alphaC domains from fibrinogen with plasmin, show no such projections. When fibrin monomer is brought to neutral pH under conditions where polymerization is delayed, individual molecules are still visible showing the alphaC domains as a single additional nodule near the central region. Moreover, analysis of clusters of molecules reveals some intermolecular associations via the alphaC domains. A 40-kDa fragment comprising the alphaC domain has been isolated from a plasmin digest of fibrinogen and characterized by SDS-polyacrylamide gel electrophoresis and determination of amino-terminal amino acid sequences. Electron microscopy of alphaC fragments reveals individual globular structures, as well as oligomeric aggregates. The addition of alphaC fragments to fibrin monomer followed by dilution to neutral pH to initiate polymerization results in lower turbidity, longer lag period, and slower maximum rate of turbidity increase. Also, electron microscopy reveals complexes of alphaC fragments with fibrin monomer at neutral pH. It appears that the free alphaC fragments can bind to the alphaC domains of fibrin, competing with the normal alphaC domain interactions involved in polymerization.	UNIV PENN, SCH MED, DEPT CELL & DEV BIOL, PHILADELPHIA, PA 19104 USA; UKRAINIAN ACAD SCI, INST BIOCHEM, KIEV 252030, UKRAINE; TNO, INST AGEING & VASC RES, 2300 AK LEIDEN, NETHERLANDS	University of Pennsylvania; National Academy of Sciences Ukraine; Palladin Institute of Biochemistry of NASU; Netherlands Organization Applied Science Research				Medved, Leonid/0000-0002-3665-9849	NHLBI NIH HHS [HL30954] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APAPBOLOGNA A, 1989, BIOCHIM BIOPHYS ACTA, V995, P70, DOI 10.1016/0167-4838(89)90235-5; BARSIGIAN C, 1987, J BIOL CHEM, V262, P3674; BELITSER VA, 1968, BIOCHIM BIOPHYS ACTA, V154, P367, DOI 10.1016/0005-2795(68)90051-2; CHUNG DW, 1982, PROTEINS BIOL MED, P309; CIERNIEWSKI CS, 1992, BIOCHEMISTRY-US, V31, P4248, DOI 10.1021/bi00132a014; COHEN C, 1983, ANN NY ACAD SCI, V408, P194, DOI 10.1111/j.1749-6632.1983.tb23245.x; COTTRELL BA, 1976, BIOCHEM BIOPH RES CO, V71, P754, DOI 10.1016/0006-291X(76)90895-0; DONOVAN JW, 1974, P NATL ACAD SCI USA, V71, P4125, DOI 10.1073/pnas.71.10.4125; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; Gargan P E, 1990, Blood Coagul Fibrinolysis, V1, P457, DOI 10.1097/00001721-199010000-00016; HASEGAWA N, 1990, THROMB RES, V57, P183, DOI 10.1016/0049-3848(90)90318-7; HENSCHEN A, 1979, H-S Z PHYSIOL CHEM, V360, P1951; HENSCHEN A, 1980, HAEMATOLOGICA, V65, P535; Henschen A., 1986, BLOOD COAGULATION, V171, P241; HOEGEEDENOBEL E, 1988, THROMB HAEMOSTASIS, V60, P415; LORAND L, 1983, ANN NY ACAD SCI, V408, P226, DOI 10.1111/j.1749-6632.1983.tb23247.x; MARX J, 1979, BIOCHIM BIOPHYS ACTA, V578, P107, DOI 10.1016/0005-2795(79)90118-1; MEDVED L, 1990, J MOL BIOL, V216, P503, DOI 10.1016/0022-2836(90)90376-W; MEDVED LV, 1985, FEBS LETT, V181, P109, DOI 10.1016/0014-5793(85)81123-6; MEDVED LV, 1983, FEBS LETT, V160, P291, DOI 10.1016/0014-5793(83)80985-5; MEDVED LV, 1990, FEBS LETT, V1, P439; MOSESSON MW, 1974, J BIOL CHEM, V249, P4656; MOSESSON MW, 1981, J MOL BIOL, V153, P695, DOI 10.1016/0022-2836(81)90414-9; MURTHY SNP, 1991, P NATL ACAD SCI USA, V88, P10601, DOI 10.1073/pnas.88.23.10601; PRIVALOV PL, 1982, J MOL BIOL, V159, P665, DOI 10.1016/0022-2836(82)90107-3; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; RUDEE ML, 1981, ULTRAMICROSCOPY, V7, P193, DOI 10.1016/0304-3991(81)90010-3; SEMERARO N, 1977, BIOCHIM BIOPHYS ACTA, V492, P204, DOI 10.1016/0005-2795(77)90227-6; SLAYTER HS, 1983, ANN NY ACAD SCI, V408, P131, DOI 10.1111/j.1749-6632.1983.tb23241.x; SUTTNAR J, 1991, THROMB HAEMOSTASIS, V65, P897; Varetskaya TV, 1960, UKR BIOKHIM ZH+, V32, P13; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P5410, DOI 10.1021/bi00591a024; WEISEL JW, 1981, NATURE, V289, P263, DOI 10.1038/289263a0; WEISEL JW, 1991, THROMB HAEMOSTASIS, V65, P676; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058; WILLIAMS RC, 1983, ANN NY ACAD SCI, V408, P180, DOI 10.1111/j.1749-6632.1983.tb23244.x	36	242	245	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13577	13585						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514790				2022-12-25	WOS:A1993LH55300080
J	Boeck, R; Tarun, S; Rieger, M; Deardorff, JA; MullerAuer, S; Sachs, AB				Boeck, R; Tarun, S; Rieger, M; Deardorff, JA; MullerAuer, S; Sachs, AB			The yeast Pan2 protein is required for poly(A)-binding protein-stimulated poly(A)-nuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN MESSENGER-RNA; TRANSLATION INITIATION; ESCHERICHIA-COLI; GENE; TRANSFORMATION; DEADENYLATION; EXONUCLEASE; EUKARYOTES; CELLS; DNA	The removal of the mRNA poly(A) tail in the yeast Saccharomyces cerevisiae is stimulated by the poly(A)binding protein (Pab1p), A large scale purification of the Pab1p-stimulated poly(A) ribonuclease (PAN) identifies a 76-kDa and two 135-Da polypeptides as candidate enzyme subunits, Antibodies against the Pan1p protein, which is the minor 135-kDa protein in the preparation, can immunodeplete Pan1p but not PAN activity, The protein sequence of the major 135-kDa protein, Pan2p, reveals a novel protein that was also found in the previously reported PAN purification (Sachs, A. B., and Deardorff, J. A, (1992) Cell 70, 961-973). Deletion of the non-essential PAN2 gene results in an increase of the average length of mRNA poly(A) tails in vivo, and a loss of Pab1p-stimulated PAN activity in crude extracts, These data confirm that Pan2p and not Pan1p is required for PAN activity, and they suggest that ribonucleases other than the Pab1p-stimulated PAN are capable of shortening poly(A) tails in vivo.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; GENOTYPE MOLEK BIOL & BIOTECHNOL FORSCH GMBH,D-69269 WILHELMSFELD,GERMANY	University of California System; University of California Berkeley					NIGMS NIH HHS [R01 GM-50308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; SACHS A, 1993, J BIOL CHEM, V268, P22955; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926	17	141	145	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					432	438		10.1074/jbc.271.1.432	http://dx.doi.org/10.1074/jbc.271.1.432			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550599	hybrid			2022-12-25	WOS:A1996TP36100067
J	Fatatis, A; Miller, RJ				Fatatis, A; Miller, RJ			Sphingosine and sphingosine 1-phosphate differentially modulate platelet-derived growth factor-BB-induced Ca2+ signaling in transformed oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; CALCIUM-ENTRY; PDGF; PROLIFERATION; SPHINGOSINE-1-PHOSPHATE; FIBROBLASTS; EXPRESSION; INCREASES; RECEPTOR; PATHWAYS	The roles of sphingosine and sphingosine 1-phosphate in Ca2+ signaling following platelet-derived growth factor (PDGF) receptor stimulation were investigated in the oligodendrocyte cell line CEINGE cl3, using single-cell fura-a microfluorimetry and videoimaging. Two different Ca2+ responses were observed, which differed in their delays and kinetics, The first response, which occurred after a shorter delay, exhibited a single Ca2+ peak. often followed by a plateau, while the second type of response was characterized by a longer delay and by Ca2+ spikes with different frequencies and amplitudes, The latter phenomenon was never observed after stimulation of G protein coupled receptors for ATP, ET-1, and BK, The incubation with the inhibitor of sphingosine kinase, DL-threo-dihydrosphingosine, significantly increased the percentage of cells responding to PDGF-BB exposure with Ca2+ spikes (87 versus 47%), while it did not modify the Ca2+ response elicited by exposure to ATP, ET-1, or BK. Exposure to exogenous 10 mu M sphingosine or 1 mu M sphingosine 1-phosphate produced oscillatory and non-oscillatory Ca2+ responses, respectively, similar to those elicited by PDGF-BB. A second application of PDGF-BB, 30 min after the first, was normally ineffective in producing a Ca2+ response, However, if the second exposure was preceded by the inhibition of sphingosine 1-phosphate formation, an oscillatory Ca2+ response occurred in all cells, We conclude that intracellular levels of sphingosine and sphingosine 1-phosphate may differentially modulate Ca2+ signaling triggered by PDGF receptor stimulation in CEINGE cl3-transformed oligodendrocytes.			Fatatis, A (corresponding author), UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,MC 0926,CHICAGO,IL 60637, USA.							ARMSTRONG RC, 1990, J NEUROSCI RES, V27, P400, DOI 10.1002/jnr.490270319; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOCHKOV V, 1992, BIOCHEM BIOPH RES CO, V188, P1295, DOI 10.1016/0006-291X(92)91372-W; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; CHAO CP, 1994, J BIOL CHEM, V269, P5849; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DILIBERTO PA, 1991, J BIOL CHEM, V266, P12612; DILIBERTO PA, 1992, J BIOL CHEM, V267, P11888; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FATATIS A, 1994, J BIOL CHEM, V269, P18021; FATATIS A, 1993, 23RD ANN M SOC NEUR; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HART IK, 1992, GLIA, V6, P310, DOI 10.1002/glia.440060409; JACOBS LS, 1993, AM J PHYSIOL, V265, pC740, DOI 10.1152/ajpcell.1993.265.3.C740; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; KONDO T, 1993, J BIOL CHEM, V268, P4458; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MOGAMI H, 1993, BIOCHEM BIOPH RES CO, V196, P650, DOI 10.1006/bbrc.1993.2299; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RENARD DC, 1992, BIOCHEM J, V281, P775, DOI 10.1042/bj2810775; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; RUSSO T, 1993, NEUROSCI LETT, V159, P159, DOI 10.1016/0304-3940(93)90823-4; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WANG Z, 1993, AM J PHYSIOL, V265, pC1239, DOI 10.1152/ajpcell.1993.265.5.C1239; WESTERMARK B, 1976, EXP CELL RES, V98, P170, DOI 10.1016/0014-4827(76)90476-6; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	36	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					295	301		10.1074/jbc.271.1.295	http://dx.doi.org/10.1074/jbc.271.1.295			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550576	hybrid			2022-12-25	WOS:A1996TP36100046
J	Humbert, JP; Matter, N; Artault, JC; Koppler, P; Malviya, AN				Humbert, JP; Matter, N; Artault, JC; Koppler, P; Malviya, AN			Inositol 1,4,5-trisphosphate receptor is located to the inner nuclear membrane vindicating regulation of nuclear calcium signaling by inositol 1,4,5-trisphosphate - Discrete distribution of inositol phosphate receptors to inner and outer nuclear membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; SMOOTH-MUSCLE CELLS; INTRANUCLEAR CALCIUM; ENVELOPE BREAKDOWN; CA2+ RELEASE; BINDING; PROTEIN; PURIFICATION; PHOSPHORYLATION; MOBILIZATION	Transient rise in nuclear calcium concentration is implicated in the regulation of events controlling gene expression, Mechanism by which calcium is transported to the nucleus is vehemently debated, Inositol 1,4,5-trisphosphate (InsP(3)) and inositol-1,3,4,5-tetrakisphosphate (InsP(4)) receptors have been located to the nucleus and their role in nuclear calcium signaling has been proposed, Outer nuclear membrane was separated from the inner membrane. The two membrane preparations were, as best as possible, devoid of cross contamination as attested by marker enzyme activity, Western blotting with antilamin antibody, and electron microscopy, InsP(4) receptor and Ca2+-ATPase were located to the outer nuclear membrane. InsP(3) receptor was located to the inner nuclear membrane. ATP or InsP(4) induced nuclear calcium uptake, External free calcium concentration, in the medium bathing the nuclei, determined the choice for ATP or InsP(4)-mediated calcium transport. We present a mechanistic model for nuclear calcium transport. According to this model, calcium can reach the nucleus envelope either by the action of ATP or InsP(4). However, the calcium release from the nucleus envelope to the nucleoplasm is mediated by InsP(3) through the activation of InsP(3) receptor, which is located to the inner nuclear membrane. The action of InsP(3) in this process was instantaneous and transient and was sensitive to heparin.	CTR NEUROCHIM, CNRS, LAB NEUROBIOL MOLEC INTERACT CELLULAIRES, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; ALMOHANNA FA, 1994, NATURE, V367, P745, DOI 10.1038/367745a0; BADMINTON MN, 1995, EXP CELL RES, V216, P236, DOI 10.1006/excr.1995.1030; BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRANE FL, 1976, FEBS LETT, V68, P153, DOI 10.1016/0014-5793(76)80425-5; CULLEN PJ, 1995, BIOCHEM J, V305, P139, DOI 10.1042/bj3050139; DALE B, 1994, P ROY SOC B-BIOL SCI, V255, P119, DOI 10.1098/rspb.1994.0017; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; DONIE F, 1991, BIOCHEM J, V275, P453, DOI 10.1042/bj2750453; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FADOOL DA, 1994, P NATL ACAD SCI USA, V91, P9471, DOI 10.1073/pnas.91.20.9471; FERRO AM, 1975, BIOCHIM BIOPHYS ACTA, V410, P285, DOI 10.1016/0005-2744(75)90231-4; Gerace Larry, 1994, Trends in Cell Biology, V4, P127, DOI 10.1016/0962-8924(94)90067-1; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GILCHRIST JSC, 1993, J BIOL CHEM, V268, P4291; GURR MI, 1963, BIOCHIM BIOPHYS ACTA, V70, P400; HENNAGER DJ, 1995, J BIOL CHEM, V270, P4959, DOI 10.1074/jbc.270.10.4959; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HOEK JB, 1994, CELL CALCIUM, V16, P237, DOI 10.1016/0143-4160(94)90086-8; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KOPPLER P, 1993, J BIOL CHEM, V268, P26248; KOPPLER P, 1994, BIOCHEMISTRY-US, V33, P14707; KORNBERG A, 1955, METHOD ENZYMOL, V2, P670, DOI 10.1016/S0076-6879(55)02280-5; LANINI L, 1992, J BIOL CHEM, V267, P11548; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MALVIYA AN, 1994, CELL CALCIUM, V16, P301, DOI 10.1016/0143-4160(94)90094-9; MALVIYA AN, 1990, P NATL ACAD SCI USA, V87, P9270, DOI 10.1073/pnas.87.23.9270; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; MATTER N, 1993, J BIOL CHEM, V268, P732; NAKATO K, 1992, EUR J BIOCHEM, V209, P745, DOI 10.1111/j.1432-1033.1992.tb17343.x; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NICOTERA P, 1994, MOL CELL BIOCHEM, V135, P89, DOI 10.1007/BF00925964; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; OISHI K, 1993, MOL CELL BIOCHEM, V121, P127, DOI 10.1007/BF00925971; PARYS JB, 1993, PFLUG ARCH EUR J PHY, V424, P516, DOI 10.1007/BF00374916; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PRZYWARA DA, 1991, FASEB J, V5, P217, DOI 10.1096/fasebj.5.2.2004666; SHANKAR G, 1993, J CELL SCI, V105, P61; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; SULLIVAN KMC, 1995, P NATL ACAD SCI USA, V92, P8611, DOI 10.1073/pnas.92.19.8611; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; THEIBERT AB, 1992, J BIOL CHEM, V267, P9071; TOMBES RM, 1992, J CELL BIOL, V117, P799, DOI 10.1083/jcb.117.4.799; WAYBILL MM, 1991, AM J PHYSIOL, V261, pE49, DOI 10.1152/ajpendo.1991.261.1.E49; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS DA, 1987, SCIENCE, V235, P1644, DOI 10.1126/science.3103219; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	52	245	257	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					478	485		10.1074/jbc.271.1.478	http://dx.doi.org/10.1074/jbc.271.1.478			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550605	hybrid			2022-12-25	WOS:A1996TP36100073
J	Li, SW; Song, KS; Lisanti, MP				Li, SW; Song, KS; Lisanti, MP			Expression and characterization of recombinant caveolin - Purification by polyhistidine tagging and cholesterol-dependent incorporation into defined lipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI-NETWORK; ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; PROTEIN-COMPONENT; MDCK CELLS; VESICLES; PERMEABILITY; MOLECULES; CHANNELS; SEQUENCE	Caveolin, a 22-24-kDa integral membrane protein, is a principal component of caveolar membranes in vivo. Caveolin has been proposed to function as a scaffolding protein to organize and concentrate signaling molecules within caveolae. Because of its unusual membrane topology, both the N- and C-terminal domains of caveolin remain entirely cytoplasmic and are not subject to luminal modifications that are accessible to other integral membrane proteins. Under certain conditions, caveolin also exists in a soluble form as a cytosolic protein in vivo. These properties make caveolin an attractive candidate for recombinant expression in Escherichia coli, Here, we successfully expressed recombinant full-length caveolin in E. coli. A polyhistidine tag was placed at its extreme C terminus for purification by Ni2+-nitrilotriacetic acid affinity chromatography. Specific antibody probes demonstrated that recombinant caveolin contained a complete N and C terminus. Recombinant caveolin remained soluble in solutions containing the detergent octyl glucoside and formed high molecular mass oligomers like endogenous caveolin. By electron microscopy, recombinant caveolin homo-oligomers appeared as individual spherical particles that were indistinguishable from endogenous caveolin homo-oligomers visualized by the same technique. As recombinant caveolin behaved as expected for endogenous caveolin, this provides an indication that recombinant caveolin can be used to dissect the structural and functional interaction of caveolin with other protein and lipid molecules in vitro. Recombinant caveolin was efficiently incorporated into lipid membranes as assessed by floatation in sucrose density gradients. This allowed us to use defined lipid components to assess the possible requirements for insertion of caveolin into membranes. Using a purified synthetic form of phosphatidylcholine (1,2-dioleoylphosphorylcholine), we observed that incorporation of caveolin into membranes was cholesterol-dependent; the addition of cholesterol dramatically increased the incorporation of caveolin into these phosphatidylcholine-based membranes by similar to 20-30-fold. This fits well with in vivo studies demonstrating that cholesterol plays an essential role in maintaining the structure and function of caveolae. Further functional analysis of these reconstituted caveolin-containing membranes showed that they were capable of recruiting a soluble recombinant form of G(i2 alpha). This is in accordance with previous studies demonstrating that caveolin specifically interacts directly with multiple G protein alpha-subunits. Thus, recombinant caveolin incorporated into defined lipid membranes provides an experimental system in which the structure, function, and biogenesis of caveolin-rich membrane domains can be dissected in vitro.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute			Li, Shengwen Calvin/H-1725-2012; Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018	Li, Shengwen Calvin/0000-0002-9699-9204; Lisanti, Michael/0000-0003-2034-1382	NCI NIH HHS [F32 CA071326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BAYLEY H, 1994, J CELL BIOCHEM, V56, P177, DOI 10.1002/jcb.240560210; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CORLEYMASTICK C, 1995, J CELL BIOL, V129, P1523; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FAN JY, 1983, J CELL SCI, V61, P219; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LISANTI MP, 1995, CURRENT PROTOCOLS IM; LODISH HF, 1991, J BIOL CHEM, V266, P14835; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SEVERS NJ, 1988, J CELL SCI, V90, P341; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; TRAVIS J, 1993, SCIENCE, V262, P1208, DOI 10.1126/science.8235646; WANTANBE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257	45	202	202	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					568	573		10.1074/jbc.271.1.568	http://dx.doi.org/10.1074/jbc.271.1.568			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550621	hybrid			2022-12-25	WOS:A1996TP36100086
J	Nakamura, K; Yamaki, M; Sarada, M; Nakayama, S; Vibat, CRT; Gennis, RB; Nakayashiki, T; Inokuchi, H; Kojima, S; Kita, K				Nakamura, K; Yamaki, M; Sarada, M; Nakayama, S; Vibat, CRT; Gennis, RB; Nakayashiki, T; Inokuchi, H; Kojima, S; Kita, K			Two hydrophobic subunits are essential for the heme b ligation and functional assembly of complex II (succinate-ubiquinone oxidoreductase) from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS SUCCINATE; AEROBIC RESPIRATORY-CHAIN; ELECTRON-TRANSFER COMPLEXES; FUMARATE REDUCTASE-ACTIVITY; SUUM MUSCLE MITOCHONDRIA; SULFUR PROTEIN SUBUNIT; NUCLEOTIDE-SEQUENCE; TERMINAL OXIDASES; DEHYDROGENASE; PURIFICATION	Complex II (succinate-ubiquinone oxidoreductase) from Escherichia coli is composed of four nonidentical subunits encoded by the sdhCDAB operon, Gene products of sdhC and sdhD are small hydrophobic subunits that anchor the hydrophilic catalytic subunits (flavoprotein and iron-sulfur protein) to the cytoplasmic membrane and are believed to be the components of cytochrome b(556) in E. coli complex II, In the present study, to elucidate the role of two hydrophobic subunits in the heme b ligation and functional assembly of complex II, plasmids carrying portions of the sdh gene were constructed and introduced into E. coli MK3, which lacks succinate dehydrogenase and fumarate reductase activities, The expression of polypeptides with molecular masses of about 19 and 17 kDa was observed when sdhC and sdhD were introduced into MK3, respectively, indicating that sdhC encodes the large subunit (cybL) and sdhD the small subunit (cybS) of cytochrome b(556). An increase in cytochrome b content was found in the membrane when sdhD was introduced, while the cytochrome b content did not change when sdhC was introduced, However, the cytochrome b expressed by the plasmid carrying sdhD differed from cytochrome b(556) in its CO reactivity and red shift of the alpha absorption peak to 557.5 nm at 77 K, Neither hydrophobic subunit was able to bind the catalytic portion to the membrane, and only succinate dehydrogenase activity, not succinate-ubiquinone oxidoreductase activity, was found in the cytoplasmic fractions of the cells, In contrast, significantly higher amounts of cytochrome b(556) were expressed in the membrane when sdhC and sdhD genes were both present, and the catalytic portion was found to be localized in the membrane with succinate-ubiquinone oxidoreductase and succinate oxidase activities, These results strongly suggest that both hydrophobic subunits are required for heme insertion into cytochrome b(556) and are essential for the functional assembly of E. coli complex II in the membrane, Accumulation of the catalytic portion in the cytoplasm was found when sdhCDAB was introduced into a heme synthesis mutant, suggesting the importance of heme in the assembly of E. coli complex II.	UNIV TOKYO,INST MED SCI,DEPT PARASITOL,MINATO KU,TOKYO 108,JAPAN; UNIV ILLINOIS,DEPT BIOCHEM & CHEM,URBANA,IL 61801; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN	University of Tokyo; University of Illinois System; University of Illinois Urbana-Champaign; Kyoto University				Kita, Kiyoshi/0000-0002-0426-4308				ABRAHAM PR, 1994, MOL GEN GENET, V242, P708, DOI 10.1007/BF00283426; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; CECCHINI G, 1986, J BIOL CHEM, V261, P1808; COCHRAN B, 1994, BBA-BIOENERGETICS, V1188, P162, DOI 10.1016/0005-2728(94)90035-3; COLE ST, 1982, EUR J BIOCHEM, V122, P479; COLE ST, 1982, EUR J BIOCHEM, V126, P211, DOI 10.1111/j.1432-1033.1982.tb06768.x; CONDON C, 1988, MOL MICROBIOL, V2, P43, DOI 10.1111/j.1365-2958.1988.tb00005.x; CONDON C, 1985, J BIOL CHEM, V260, P9427; COTTER PA, 1992, FEMS MICROBIOL LETT, V91, P31; DAIGNANFORNIER B, 1994, J BIOL CHEM, V269, P15469; DARLISON MG, 1984, BIOCHEM J, V223, P507, DOI 10.1042/bj2230507; FRIDEN H, 1990, BIOCHIM BIOPHYS ACTA, V1041, P207, DOI 10.1016/0167-4838(90)90067-P; FRIDEN H, 1990, MOL MICROBIOL, V4, P1045, DOI 10.1111/j.1365-2958.1990.tb00677.x; FRIDEN H, 1987, CYTOCHROME SYSTEMS M, P641; GRUNDSTROM T, 1982, P NATL ACAD SCI-BIOL, V79, P1111, DOI 10.1073/pnas.79.4.1111; HAGERHALL C, 1992, BIOCHEMISTRY-US, V31, P7411, DOI 10.1021/bi00147a028; HEDERSTEDT L, 1980, J BACTERIOL, V144, P933, DOI 10.1128/JB.144.3.933-940.1980; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; HIRAWAKE H, 1994, J BIOCHEM-TOKYO, V116, P221, DOI 10.1093/oxfordjournals.jbchem.a124497; HOLMGREN E, 1979, J BACTERIOL, V138, P377, DOI 10.1128/JB.138.2.377-382.1979; KITA K, 1988, BIOCHIM BIOPHYS ACTA, V935, P130, DOI 10.1016/0005-2728(88)90210-1; KITA K, 1989, J BIOL CHEM, V264, P2672; KITA K, 1985, BIOCHEM INT, V10, P319; KITA K, 1978, J BIOL CHEM, V253, P8910; KITA K, 1984, J BIOL CHEM, V259, P3368; KITA K, 1984, J BIOL CHEM, V259, P3375; KITA K, 1990, BIOCHEM BIOPH RES CO, V166, P101, DOI 10.1016/0006-291X(90)91916-G; KURAMOCHI T, 1994, MOL BIOCHEM PARASIT, V68, P177, DOI 10.1016/0166-6851(94)90163-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGNUSSON K, 1986, J BACTERIOL, V166, P1067, DOI 10.1128/jb.166.3.1067-1071.1986; MURAKAMI H, 1986, J BIOL CHEM, V261, P548; MURAKAMI H, 1985, FEMS MICROBIOL LETT, V30, P307; PETERSON J, 1994, FEBS LETT, V355, P155, DOI 10.1016/0014-5793(94)01189-3; SARUTA F, 1995, J BIOL CHEM, V270, P928, DOI 10.1074/jbc.270.2.928; SCHILLING RJ, 1982, FED PROC, V41, P896; TAKAMIYA S, 1990, BIOCHEM INT, V21, P1073; TAKAMIYA S, 1986, BIOCHIM BIOPHYS ACTA, V848, P99, DOI 10.1016/0005-2728(86)90165-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; YU L, 1987, J BIOL CHEM, V262, P1137; YU L, 1992, J BIOL CHEM, V267, P24508	45	79	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					521	527		10.1074/jbc.271.1.521	http://dx.doi.org/10.1074/jbc.271.1.521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550613	hybrid			2022-12-25	WOS:A1996TP36100079
J	Platanias, LC; Uddin, S; Yetter, A; Sun, XJ; White, MF				Platanias, LC; Uddin, S; Yetter, A; Sun, XJ; White, MF			The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; TRANSCRIPTION FACTOR; PROTEIN; IRS-1; ALPHA/BETA; KINASE; CELLS; DOMAINS; PATHWAY	Binding of interferon alpha (IFN alpha) to its receptor induces activation of the Tyk-2 and Jak-1 tyrosine kinases and tyrosine phosphorylation of multiple downstream signaling elements, including the Stat components of the interferon-stimulated gene factor 3 (ISGF-3). IFN alpha also induces tyrosine phosphorylation of IRS-1, the principle substrate of the insulin receptor. In this study we demonstrate that various Type I IFNs rapidly stimulate tyrosine phosphorylation of IRS-2. This is significant since IRS-2 is the major IRS protein found in hematopoietic cells. The IFN alpha-induced phosphorylated form of IRS-2 associates with the p85 regulatory subunit of the phosphatidylinositol 3'-kinase, suggesting that this kinase participates in an IFN alpha-signaling cascade downstream of IRS-2. We also provide evidence for an interaction of IRS-2 with Tyk-2, suggesting that Tyk-2 is the kinase that phosphorylates this protein during IFN alpha stimulation. A conserved region in the pleckstrin homology domain of IRS-2 may be required for the interaction of IRS-2 with Tyk-2, as shown by the selective binding of glutathione S-transferase (GST) fusion proteins containing the IRS-2-IH1(PH) or IRS-1-IH1(PH) domains to Tyk-2 but not other Janus kinases in vitro.	EDWARD HINES VET ADM MED CTR,HINES,IL 60141; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Platanias, LC (corresponding author), LOYOLA UNIV,DEPT MED,DIV HEMATOL ONCOL,BLDG 112,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.			Uddin, Shahab/0000-0003-1886-6710	NIDDK NIH HHS [DK43808, DK38712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038712, R55DK038712, R01DK043808, R29DK038712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V270, P11715; COLAMONICI OR, 1992, BLOOD, V80, P744; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; ISAKOFF SJ, 1995, DIABETES, V44, pA18; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PETSKA S, 1987, ANNU REV BIOCHEM, V56, P727; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; Platanias Leonidas C., 1995, Current Opinion in Oncology, V7, P560, DOI 10.1097/00001622-199511000-00015; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UDDIN S, 1995, J BIOL CHEM, V270, P7712, DOI 10.1074/jbc.270.13.7712; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WANG LM, 1995, BLOOD, V86, P4218, DOI 10.1182/blood.V86.11.4218.bloodjournal86114218; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; YENUSH L, 1994, J BIOL CHEM, V269, P100; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	51	115	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					278	282		10.1074/jbc.271.1.278	http://dx.doi.org/10.1074/jbc.271.1.278			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550573	hybrid			2022-12-25	WOS:A1996TP36100043
J	SetoYoung, D; Hall, MJ; Na, SQ; Haber, JE; Perlin, DS				SetoYoung, D; Hall, MJ; Na, SQ; Haber, JE; Perlin, DS			Genetic probing of the first and second transmembrane helices of the plasma membrane H+-ATPase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COMPETITIVE PHOTOAFFINITY INHIBITOR; RESISTANT PMA1 MUTANTS; AMINO-ACID-SEQUENCE; P-TYPE ATPASE; NEUROSPORA-CRASSA; SALMONELLA-TYPHIMURIUM; SARCOPLASMIC-RETICULUM; OUABAIN SENSITIVITY; COMPLEMENTARY-DNA	Structural features of the putative helical hairpin region comprising transmembrane segments 1 (TM1) and 2 (TM2) of the yeast plasma membrane H+-ATPase were probed by site-directed mutagenesis, The importance of phenylalanine residues Phe 116, Phe-119, Phe-120, Phe-126, Phe-144, Phe-159, and Phe-163 was explored by alanine replacement mutagenesis. It was found that substitutions at all positions, except Phe-120 and Phe-144, produced viable enzymes, although a range of cellular growth phenotypes were observed like hygromycin B resistance and low pH sensitivity, which are linked to in vivo action of the H+-ATPase. Lethal positions Phe-120 and Phe 144, could be replaced with tryptophan to produce viable enzyme, although the F144W mutant was highly perturbed. ATP hydrolysis measurements showed that K-m was not significantly altered for most mutant enzymes, whereas V-max was moderately reduced with two mutants, F144W and F163A, showing less than 50% of the normal activity. Double Phe --> Ala mutations in TM1 and TM2 were constructed to examine whether such substitutions would result in a higher degree of enzyme destabilization. Mutant F116A/F119A was viable and gave a normal phenotype, while F159A/F163A was not viable. Other double mutants, F116A/F159A and F119AF/159A, which are predicted to lie juxtaposed on TM1 and TM2, produced non-functional enzymes. However, a viable F119V/F159A mutant was isolated and showed hygromycin B resistance. These results suggest that double mutations eliminating 2 phenylalanine residues strongly destabilize the enzyme. A putative proline kink at Gly-122/Pro-123 in TM1 is not essential for enzyme action since these residues could be variously substituted (G122A or G122N; P123A, P123G, or P123F) producing viable enzymes with moderate effects on in vitro ATP hydrolysis or proton transport. However, several substitutions produced prominent growth phenotypes, suggesting that local perturbations were occurring. The location of Pro-123 is important because Gly 122 and Pro-123 could not be exchanged. In addition, a double Pro-Pro created by a G122P mutation was lethal, suggesting that maintenance of an alpha-helical structure is important. Other mutations in the hairpin, including modification of a buried charged residue, E129A, were not critical for enzyme action. These data are consistent with the view that the helical hairpin comprising TM1 and TM2 has important structural determinants that contribute to its overall stability and flexibility.	PUBL HLTH RES INST,NEW YORK,NY 10016; BRANDEIS UNIV,DEPT BIOL,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University				Haber, James/0000-0002-1878-0610	NIGMS NIH HHS [GM 39739, GM 38225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038225, R01GM039739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; DEBER CM, 1986, ARCH BIOCHEM BIOPHYS, V251, P68, DOI 10.1016/0003-9861(86)90052-4; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; HOFNUNG M, 1995, SCIENCE, V267, P473, DOI 10.1126/science.7824946; HUNTER CA, 1991, J MOL BIOL, V216, P1; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; LUTHY R, 1991, PROTEINS, V10, P229, DOI 10.1002/prot.340100307; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MANDALA SM, 1989, J BIOL CHEM, V264, P16276; MARTONOSI AN, 1990, FEBS LETT, V268, P365, DOI 10.1016/0014-5793(90)81287-X; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; MONK BC, 1995, BBA-BIOMEMBRANES, V1239, P81, DOI 10.1016/0005-2736(95)00133-N; MONK BC, 1994, J BIOENERG BIOMEMBR, V26, P101, DOI 10.1007/BF00763222; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; MUNSON KB, 1988, BIOCHEMISTRY-US, V27, P3932, DOI 10.1021/bi00411a007; NA SQ, 1993, J BIOL CHEM, V268, P11792; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; PERLIN DS, 1987, J BIOL CHEM, V262, P6788; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PERLIN DS, 1995, IN PRESS ADV MOL CEL; PIELA L, 1987, BIOPOLYMERS, V26, P1587, DOI 10.1002/bip.360260910; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1990, J BIOL CHEM, V265, P6638; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SERRANO R, 1989, ANNU REV PLANT PHYS, V40, P61; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SETOYOUNG D, 1992, BIOCHIM BIOPHYS ACTA, V1102, P213, DOI 10.1016/0167-4838(92)90512-C; SETOYOUNG D, 1994, J BIOL CHEM, V269, P23988; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SMITH DL, 1993, J BIOL CHEM, V268, P22469; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; SUSSMAN MR, 1987, J BIOL CHEM, V262, P4569; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOOLFSON DN, 1990, FEBS LETT, V277, P185, DOI 10.1016/0014-5793(90)80839-B	50	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					581	587		10.1074/jbc.271.1.581	http://dx.doi.org/10.1074/jbc.271.1.581			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550623	hybrid			2022-12-25	WOS:A1996TP36100088
J	Patel, AM; Incognito, LS; Schechter, GL; Wasilenko, WJ; Somers, KD				Patel, AM; Incognito, LS; Schechter, GL; Wasilenko, WJ; Somers, KD			Amplification and expression of EMS-1 (cortactin) in head and neck squamous cell carcinoma cell lines	ONCOGENE			English	Article						cortactin; amplification; head and neck cancer	BREAST-CANCER; CYCLIN D1; GENES; SUBSTRATE; ONCOGENE; IDENTIFICATION; INT-2; ABNORMALITIES; CLONING; REGION	Amplification of chromosome 11q13 DNA sequences is detected in approximately 30% of primary head and neck squamous cell carcinomas (HNSCC). The amplified region includes genes for cyclin D1, hst-1, int-2, and more recently, ems-1, Ems-1 encodes an 80/85kd cytoskeletal associated protein termed cortactin, which has been shown to bind F-actin and is a pp60src substrate. We investigated 16 HNSCC cell Lines for ems-1 DNA amplification and gene expression by western blotting and immunofluorescence using mAb 4F11. Amplification of ems-1 DNA was detected in 8/16 (50%) cell lines and was related directly to overexpression of cortactin by western blotting and immunofluorescence, Western blotting detected both forms of cortactin, p80 and p85, at equal intensity. Immunofluorescent staining revealed low levels of cortactin localized to the cytoplasm and surface membrane in normal bronchial epithelial cells and tumor cell cultures with single copy ems-1 DNA. In contrast, tumor cell cultures with ems-1 DNA amplification demonstrated intense, homogeneous cortactin cytoplasmic staining. These results suggest that overexpression of p80/85 may be a useful marker to identify 11q13 amplification, a molecular alteration correlated with the presence of lymph node metastasis in head and neck cancer.	EASTERN VIRGINIA MED SCH,DEPT MICROBIOL & IMMUNOL,NORFOLK,VA 23501; EASTERN VIRGINIA MED SCH,DEPT OTOLARYNGOL HEAD & NECK SURG,NORFOLK,VA 23501; EASTERN VIRGINIA MED SCH,HEAD & NECK TUMOR BIOL PROGRAM,NORFOLK,VA 23501	Eastern Virginia Medical School; Eastern Virginia Medical School; Eastern Virginia Medical School								ADELAIDE J, 1988, ONCOGENE, V2, P413; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; Field J K, 1992, Eur J Cancer B Oral Oncol, V28B, P67, DOI 10.1016/0964-1955(92)90016-T; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P430; LOVEC H, 1994, ONCOGENE, V9, P323; MAA MC, 1992, ONCOGENE, V7, P2429; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER D, 1994, ORAL ONCOL, V30B, P113; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; SOMERS KD, 1992, CANCER RES, V52, P5997; SOOD AK, 1981, P NATL ACAD SCI-BIOL, V78, P616, DOI 10.1073/pnas.78.1.616; TSUDA T, 1989, CANCER RES, V49, P5505; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; ZHAN X, 1993, J BIOL CHEM, V268, P24427	33	53	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					31	35						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552396				2022-12-25	WOS:A1996TQ01400004
J	Wieland, I; Bohm, M; Arden, KC; Ammermuller, T; Bogatz, S; Viars, CS; Rajewsky, MF				Wieland, I; Bohm, M; Arden, KC; Ammermuller, T; Bogatz, S; Viars, CS; Rajewsky, MF			Allelic deletion mapping on chromosome 5 in human lung carcinomas	ONCOGENE			English	Article						microdissection; PCR-SSCP; microsatellite markers; APC; del-27; tumor suppressor gene	POLYMERASE CHAIN-REACTION; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; DIFFERENCE CLONING; HUMAN DNA; CANCER; HYBRIDIZATION; P53; HETEROZYGOSITY; ADENOCARCINOMA	We analysed allelic deletions on chromosome 5 in microdissected human non-small cell lung cancers. Thirty-four primary squamous cell carcinomas, 15 primary adenocarcinomas and five regional lymph node metastases were investigated for loss of heterozygosity (LOH) in chromosomal region 5p15-q21. The sites analysed included the APC tumor suppressor gene at 5q21, five polymorphic microsatellite markers and the putative tumor suppressor locus del-27, that was assigned to chromosomal region 5p13-12 by fluorescence in situ hybridization (FISH) analysis. Allelic deletions encompassed larger genomic regions more often in squamous cell carcinomas than in adenocarcinomas. The del-27 amd APC regions were identified as two distinct regions with the highest LOH frequencies within 5p15-q21. In squamous cell carcinomas LOH frequencies were 73% at the del-27 and 70% at the APC locus. In adenocarcinomas LOH at the del-27 and APC loci occurred in 38% of the informative cases. Allelic deletion of the APC gene and at the del-27 locus was also detected in the metastases. The results suggest involvement of at least two tumor suppressor genes on chromosome 5 in lung tumorigenesis.	UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,D-45122 ESSEN,GERMANY; UNIV CALIF SAN DIEGO,DEPT MED,LUDWIG INST CANC RES,LA JOLLA,CA 92093	University of Duisburg Essen; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Wieland, I (corresponding author), UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,VIRCHOWSTR 173,D-45122 ESSEN,GERMANY.			Wieland, Ilse/0000-0002-8017-3029				AHSEE KW, 1994, CANCER RES, V54, P1617; ALLAN GJ, 1994, HUM MUTAT, V3, P283, DOI 10.1002/humu.1380030317; ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; BOHM M, 1994, CLIN EXP METASTAS, V12, P55, DOI 10.1007/BF01784334; BOHM M, 1993, CANCER GENET CYTOGEN, V65, P83, DOI 10.1016/0165-4608(93)90211-4; BOS JL, 1989, CANCER RES, V49, P4682; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; DALY MC, 1993, ONCOGENE, V8, P1721; DAMICO D, 1992, CANCER RES, V52, P1996; FONG KM, 1995, CANCER RES, V55, P220; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HENSEL CH, 1990, CANCER RES, V50, P3067; HORII A, 1992, CANCER RES, V52, P6696; HOSOE S, 1994, CANCER RES, V54, P1787; JACKY PB, 1991, ACT CYTOGENETICS LAB, P89; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; KOK K, 1994, CANCER RES, V54, P4183; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; LOEB LA, 1994, CANCER RES, V54, P5059; MERLO A, 1994, CANCER RES, V54, P640; MIURA I, 1992, CANCER RES, V52, P1322; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; RIED T, 1994, CANCER RES, V54, P1801; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; Sambrook J, 1989, MOL CLONING LABORATO; SATO S, 1994, CANCER RES, V54, P5652; SHAPIRO GI, 1995, CANCER RES, V55, P505; SHISEKI M, 1994, CANCER RES, V54, P5643; SPEICHER MR, 1995, CANCER RES, V55, P1010; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TESTA JR, 1993, CANCER DETECT PREV, V17, P267; TSUCHIYA E, 1992, CANCER RES, V52, P2478; WASHIMI O, 1995, CANCER RES, V55, P514; WEBER JL, 1989, AM J HUM GENET, V44, P388; WHANGPENG J, 1991, GENE CHROMOSOME CANC, V3, P168, DOI 10.1002/gcc.2870030303; White B. A., 1993, PCR PROTOCOLS CURREN; WIELAND I, 1990, P NATL ACAD SCI USA, V87, P2720, DOI 10.1073/pnas.87.7.2720; WIELAND I, 1994, CANCER RES, V54, P1772; WIELAND I, 1992, P NATL ACAD SCI USA, V89, P9705, DOI 10.1073/pnas.89.20.9705; WLODARSKA I, 1994, CYTOGENET CELL GENET, V65, P179, DOI 10.1159/000133627; YOKOYAMA S, 1992, CANCER RES, V52, P873	47	47	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					97	102						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552404				2022-12-25	WOS:A1996TQ01400012
J	Brown, RT; Ades, IZ; Nordan, RP				Brown, RT; Ades, IZ; Nordan, RP			An acute phase response factor NF-kappa B site downstream of the junB gene that mediates responsiveness to interleukin-6 in a murine plasmacytoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; TRANSCRIPTIONAL ACTIVATION; REGULATORY ELEMENTS; GROWTH-FACTORS; CELLS; IDENTIFICATION; EXPRESSION; INDUCTION; COOPERATE; PROMOTER	The immediate early gene, junB, is induced by interleukin-6 (IL-6) in plasmacytomas. In order to identify enhancers that mediate this effect, we cloned upstream and downstream sequences flanking the gene into a luciferase reporter gene vector containing the junB promoter and evaluated the IL-6 inducibility of these se quences by transient expression in an IL-6 dependent plasmacytoma cell line, Although a 6.5 kilobase fragment of upstream flanking sequence did not increase the IL-6 inducibility of the junB promoter, a 222-base pair fragment was identified in 2.1 kilobases of down stream flanking sequence that both up regulates the promoter and confers inducibility by IL-6. Point mutation of an acute phase response factor (APRF) site within this region significantly reduced up-regulation of the promoter in cells grown continuously in IL-6, as well as inducibility upon restimulation of cells with IL-6 after withdrawal from the growth factor. Point mutation of an NF-kappa B site sharing five nucleotides with the APRF site reduced up-regulation of the promoter but not inducibility by IL-6, whereas mutation of two other NF-kappa B sites in the 222-base pair fragment had no effect on expression. Western blotting of nuclear proteins purified by DNA affinity chromatography revealed inducible binding of Stat3 and constitutive binding of NF-kappa B p65 to the APRF/NF-kappa B site.	CTR BIOL EVALUAT & RES,DIV MONOCLONAL ANTIBODIES,BETHESDA,MD 20892; UNIV MARYLAND,DEPT ZOOL,COLLEGE PK,MD 20742	US Food & Drug Administration (FDA); University System of Maryland; University of Maryland College Park								ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; APEL I, 1992, MOL CELL BIOL, V12, P3356, DOI 10.1128/MCB.12.8.3356; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOTCHAN P, 1973, P NATL ACAD SCI USA, V70, P3077, DOI 10.1073/pnas.70.11.3077; COFFER P, 1995, ONCOGENE, V10, P985; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; HAYASHI Y, 1971, BIOCHEMISTRY-US, V10, P4212, DOI 10.1021/bi00799a009; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KITABAYASHI I, 1993, J BIOL CHEM, V268, P14482; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; NECKERS LM, 1988, J CELL PHYSIOL, V135, P495, DOI 10.1002/jcp.1041350318; NORDAN RP, 1986, SCIENCE, V233, P566, DOI 10.1126/science.3726549; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sambrook J, 1989, MOL CLONING LABORATO; SIMPSON RJ, 1988, BIOCHEM BIOPH RES CO, V157, P364, DOI 10.1016/S0006-291X(88)80056-1; SOLLAZZO M, 1988, FOCUS, V10, P64; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; YOSHIZAKI K, 1989, BLOOD, V74, P1360; ZHANG XG, 1989, BLOOD, V74, P11; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	41	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31129	31135		10.1074/jbc.270.52.31129	http://dx.doi.org/10.1074/jbc.270.52.31129			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537375	hybrid			2022-12-25	WOS:A1995TN44400043
J	Theil, T; Rodel, B; Spiegelhalter, F; Moroy, T				Theil, T; Rodel, B; Spiegelhalter, F; Moroy, T			Short isoform of POU factor Brn-3b can form a heterodimer with Brn-3a that is inactive for octamer motif binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; DOMAIN; PROTEIN; CELLS; DISTINCT; EXPRESSION	The POU proteins Brn-3a and Brn-3b belong to a family of DNA binding transcription factors that share stretches of extensive homology. Both Brn-3a and Brn-3b are expressed as shorter and longer isoforms. The long form of Brn-3a is able to oncogenically transform primary fibroblasts. By contrast, the short form of Brn-3b (Brn-3b(s)) cannot transform fibroblasts but is able to specifically inhibit the transforming activity of Brn-3a(l). Moreover, Brn-3a(l) can act as a transcriptional transactivator, while Brn-3b(s) is not only unable to do so but in addition specifically inhibits the transactivating activity of Brn-3a(l). Here, we show that the opposite and antagonistic activities of Brn-3a(l) and Brn-3b(s) proteins are due to their different DNA binding properties; Brn-3a(l) but not Brn-3b(s) can form stable complexes with several octamer-related target DNA sequences. The presence of Brn-3b(s) completely inhibits the binding of Brn-3a(l) to DNA by preventing the formation of Brn-3a(l)-DNA complexes as well as by disrupting preformed complexes. Experiments with GST fusion proteins and in vitro binding studies suggest that the inhibition of Brn-3a(l) activity by Brn-3b(s) occurs via direct interaction of the two transcription factors in solution. Therefore, we hypothesize that Brn-3b(s) can act as a direct antagonist of Brn-3a(l) by inhibiting its DNA binding through the formation of an inactive hetero-oligomeric complex.	UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Philipps University Marburg			Moroy, Tarik/D-9923-2011	Theil, Thomas/0000-0001-6590-8309				ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; AURORA R, 1992, MOL CELL BIOL, V12, P455, DOI 10.1128/MCB.12.2.455; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COLLUM RG, 1992, NUCLEIC ACIDS RES, V20, P4919, DOI 10.1093/nar/20.18.4919; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; KRISTIE TM, 1989, EMBO J, V8, P4229, DOI 10.1002/j.1460-2075.1989.tb08608.x; KUHN R, 1991, MOL CELL BIOL, V11, P4642, DOI 10.1128/MCB.11.9.4642; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; RING CJA, 1993, NUCLEIC ACIDS RES, V21, P2946, DOI 10.1093/nar/21.12.2946; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIANG MQ, 1993, NEURON, V11, P689, DOI 10.1016/0896-6273(93)90079-7; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	26	17	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30958	30964		10.1074/jbc.270.52.30958	http://dx.doi.org/10.1074/jbc.270.52.30958			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537352	hybrid			2022-12-25	WOS:A1995TN44400020
J	Bishop, WR; Bond, R; Petrin, J; Wang, L; Patton, R; Doll, R; Njoroge, G; Catino, J; Schwartz, J; Windsor, W; Syto, R; Schwartz, J; Carr, D; James, L; Kirschmeier, P				Bishop, WR; Bond, R; Petrin, J; Wang, L; Patton, R; Doll, R; Njoroge, G; Catino, J; Schwartz, J; Windsor, W; Syto, R; Schwartz, J; Carr, D; James, L; Kirschmeier, P			Novel tricyclic inhibitors of farnesyl protein transferase - Biochemical characterization and inhibition of Ras modification in transfected Cos cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; POSTTRANSLATIONAL MODIFICATION; GERANYLGERANYL TRANSFERASE; CDNA CLONING; BETA-SUBUNIT; FARNESYLTRANSFERASE; EXPRESSION; P21RAS; PRENYLATION; BINDING	Ras protooncogenes encode 21-kDa membrane-associated guanine nucleotide-binding proteins, which play a critical role in control of cellular proliferation and differentiation. Oncogenic, activated forms of Ras proteins are associated with a broad range of human cancers. The elucidation of the post-translational modifications that occur at the carboxyl terminus of Ras and the demonstration that farnesylation of Ras by farnesyl protein transferase is essential for Ras-induced cellular transformation has opened up a new and promising approach to the development of anti aas therapeutics. We report here a novel series of potent farnesyl protein transferase (FPT) inhibitors, represented by SCH 44342. This compound inhibits both rat brain and recombinant human FPT with an IC50 of approximately 250 nM, while it is only weakly active against rat brain geranylgeranyl protein transferase-1 (IC50 > 114 mu M). FPT inhibition has been observed using both Ha-Ras protein and Ki-Ras-derived peptide substrates in two different assay formats. SCH 44342 and its analogs also inhibit farnesylation of Ras in Cos cells transiently expressing [Val(12)]Ha-Ras with IC50 values in the low micromolar range. At these concentrations they do not inhibit sterol biosynthesis or geranylgeranylation of protein. In addition, we observed that Cos cells undergo pronounced morphological changes upon overexpression of [Val(12)]activated forms of Ha-Ras containing COOH-terminal sequences allowing farnesylation (CVLS) or geranylgeranylation (CVLL) but not upon overexpression of activated Ras lacking the isoprenylated Cys (SVLS). Ras-induced morphological changes can be partially reverted with lovastatin. Importantly, SCH 44342 can block morphological changes induced by [Val(12)]Ha-Ras CVLS but not [Val(12)]Ha-Ras-CVLL. Recently, a number of other FPT inhibitors have been reported. Most of the compounds reported to have cell-based activity are peptidomimetic analogs of the CAAX substrate. Our FPT inhibitors are novel in that although they compete with Ras protein in kinetic experiments they are entirely nonpeptidic in nature, they do not have oxidizable sulfhydryl functions, and they are active in cells at low micromolar concentrations.	SCHERING PLOUGH CORP,RES INST,DEPT STRUCT CHEM,KENILWORTH,NJ 07033; SCHERING PLOUGH CORP,RES INST,DEPT FERMENTAT,KENILWORTH,NJ 07033; SCHERING PLOUGH CORP,RES INST,DEPT SYNTHET CHEM,KENILWORTH,NJ 07033; SCHERING PLOUGH CORP,RES INST,DEPT TUMOR BIOL,KENILWORTH,NJ 07033	Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation	Bishop, WR (corresponding author), SCHERING PLOUGH CORP,RES INST,DEPT MOLEC PHARMACOL,2015 GALLOPING HILL RD,KENILWORTH,NJ 07033, USA.							ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BILLAH MM, 1990, J PHARMACOL EXP THER, V252, P1090; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; COX AD, 1994, J BIOL CHEM, V269, P19203; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KATES M, 1972, LABORATORY TECHNIQUE, P558; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LUTZ RJ, 1992, P NATL ACAD SCI USA, V89, P3000, DOI 10.1073/pnas.89.7.3000; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; OVERMEYER JH, 1992, J BIOL CHEM, V267, P22686; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REPKO EM, 1989, J BIOL CHEM, V264, P9945; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; ZHANG FL, 1994, J BIOL CHEM, V269, P3175	44	162	178	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30611	30618		10.1074/jbc.270.51.30611	http://dx.doi.org/10.1074/jbc.270.51.30611			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530497	hybrid			2022-12-25	WOS:A1995TL67500062
J	deBoer, HC; Preissner, KT; Bouma, BN; deGroot, PG				deBoer, HC; Preissner, KT; Bouma, BN; deGroot, PG			Internalization of vitronectin-thrombin-antithrombin complex by endothelial cells leads to deposition of the complex into the subendothelial matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN VITRONECTIN; MULTIMERIC VITRONECTIN; EXTRACELLULAR-MATRIX; LIPOPROTEIN-LIPASE; HUMAN-PLASMA; III COMPLEX; RECEPTOR; BINDING; IDENTIFICATION; ASSOCIATION	Internalization of the ternary vitronectin-thrombin-antithrombin (VN-TAT) complex by human umbilical vein endothelial cells was investigated. Radiolabeled VN-TAT was bound to the cell surface at 4 degrees C, and internalization was initiated by increasing the temperature to 37 degrees C. After 30 min about half of the VN-TAT complex disappeared from the cell surface and accumulated in the subendothelial matrix. Translocation of VN-TAT complex from the luminal to the basolateral side was confirmed by electron microscopic evaluation of cross-sections of endothelial cells incubated with gold-conjugated VN-TAT complex. Furthermore, cells cultured in VN-TAT deficient serum, incubated with purified VN-TAT, and subsequently assayed for fluorescent staining using a monoclonal antibody directed against thrombin-modified antithrombin and a polyclonal antibody against vitronectin showed co-localization of both antibodies in punctates. Punctates were randomly distributed in both the xy and xz plane of endothelial cells as evidenced by confocal laser scanning microscopy. Trichloroacetic acid precipitation and SDS-polyacrylamide gel electrophoresis showed that VN-TAT was not degraded during translocation and inhibition of the microfilament system reduced release of VN TAT to the matrix, indicating that transcytosis was responsible for translocation. These findings emphasize that VN-TAT complex is taken up by endothelial cells, not only leading to the removal of inactivated thrombin from the circulation but also to deposition of VN into the subendothelial matrix.	MAX PLANCK INST, HAEMOSTASIS RES UNIT, D-61231 BAD NAUHEIM, GERMANY	Max Planck Society	deBoer, HC (corresponding author), UNIV UTRECHT HOSP, DEPT HAEMATOL G03647, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							CHAPPELL DA, 1992, J BIOL CHEM, V267, P25764; DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DEBOER HC, 1993, J BIOL CHEM, V268, P1279; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; GEBB C, 1986, J BIOL CHEM, V261, P6698; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; HARFORD J, 1983, J CELL BIOL, V96, P1824, DOI 10.1083/jcb.96.6.1824; HESS S, 1993, INT CONGR SER, V1042, P21; ILL CR, 1985, J BIOL CHEM, V260, P5610; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; KING GL, 1985, SCIENCE, V227, P1583, DOI 10.1126/science.3883490; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PODACK ER, 1986, J BIOL CHEM, V261, P7387; PREISSNER KT, 1987, BIOCHEM J, V243, P105, DOI 10.1042/bj2430105; SACKETT DL, 1993, BIOCHEMISTRY-US, V32, P13560, DOI 10.1021/bi00212a023; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; SAXENA U, 1990, J BIOL CHEM, V265, P12880; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SIXMA JJ, 1987, ANN NY ACAD SCI, V516, P39, DOI 10.1111/j.1749-6632.1987.tb33028.x; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; TOMASINI BR, 1988, BLOOD, V72, P903; TSCHOPP J, 1988, BIOCHEMISTRY-US, V27, P4103, DOI 10.1021/bi00411a029; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VOLKER W, 1993, J HISTOCHEM CYTOCHEM, V41, P1823, DOI 10.1177/41.12.7504009; VOLKER W, 1991, J HISTOCHEM CYTOCHEM, V39, P1385, DOI 10.1177/39.10.1940309; WALTZ DA, 1994, J BIOL CHEM, V269, P14746; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2	32	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30733	30740		10.1074/jbc.270.51.30733	http://dx.doi.org/10.1074/jbc.270.51.30733			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530513	hybrid			2022-12-25	WOS:A1995TL67500078
J	Duh, JL; Zhu, HA; Shertzer, HG; Nebert, DW; Puga, A				Duh, JL; Zhu, HA; Shertzer, HG; Nebert, DW; Puga, A			The Y-box motif mediates redox-dependent transcriptional activation in mouse cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; DNA-BINDING PROTEINS; COLD-SHOCK PROTEIN; FACTOR KAPPA-B; OXIDATIVE STRESS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; HYDROGEN-PEROXIDE; MOLECULAR-CLONING; BACILLUS-SUBTILIS	We show here that the OxyR response element (ORE) in the bacterial oxyR promoter can also function as a redox-dependent enhancer in mammalian cells. Fusion of ORE to an SV40 basal promoter driving chloramphenicol acetyltransferase (CAT) expression confers H2O2 inducibility to expression of the cat gene in mouse Hepa-1 hepatoma cells. Nuclear extracts from these cells contain DNA-binding proteins that specifically interact with ORE DNA, cannot be competed by cognate oligonucleotides to AP-1 or NF kappa B, and are constitutively expressed, since treatment with H2O2 causes no detectable changes in binding activity or DNA-protein interaction, Recombinant cDNA clones that express ORE-binding proteins were isolated from a mouse hepatoma expression library and found to be representatives of two different members of the murine Y-box family of transcription factors, Canonical Y-box and ORE oligonucleotides compete with each other for binding to Y-box proteins in gel shift assays and antibodies to FRGY2, a Xenopus Y-box protein, supershift both Y-box and ORE DNA-protein complexes, In addition, antisense oligonucleotides to mouse YB-1 mRNA abolish induction of ORE-mediated cat expression by H2O2, and luciferase reporter constructs containing ORE, or the Y-box from the human MHC class II HLA DQ gene, exhibit identical dose-dependent H2O2 inducibilities, which can be abolished by addition of 2-mercaptoethanol to the culture medium, These results suggest that the Y-box proteins may be an integral component of a eukaryotic redox signaling pathway.	UNIV CINCINNATI, MED CTR, DEPT ENVIRONM HLTH, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, MED CTR, CTR ENVIRONM GENET, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati			Puga, Alvaro/B-7676-2008		NIA NIH HHS [AG09325] Funding Source: Medline; NIEHS NIH HHS [ES06273, ES06096] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, R56ES006273, R01ES006273] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; BECKER J, 1991, FREE RADICAL RES COM, V12-3, P455, DOI 10.3109/10715769109145817; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CERUTTI P, 1990, UCLA SYM BI, V114, P69; CHANG CY, 1993, PHARMACOGENETICS, V3, P312, DOI 10.1097/00008571-199312000-00005; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; COWAN DB, 1993, J BIOL CHEM, V268, P26904; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DENAMUR E, 1994, HUM MOL GENET, V3, P1089, DOI 10.1093/hmg/3.7.1089; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAMILARI M, 1994, GENE, V141, P255, DOI 10.1016/0378-1119(94)90581-9; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FLOYD RA, 1991, SCIENCE, V254, P1597, DOI 10.1126/science.1684251; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GALANG CK, 1993, MOL CELL BIOL, V13, P4609, DOI 10.1128/MCB.13.8.4609; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; GREENBERG JT, 1991, J BACTERIOL, V173, P4433, DOI 10.1128/JB.173.14.4433-4439.1991; KESTON AS, 1965, ANAL BIOCHEM, V11, P1, DOI 10.1016/0003-2697(65)90034-5; KULLIK I, 1994, REDOX REP, V1, P23, DOI 10.1080/13510002.1994.11746951; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; LEBEL CP, 1990, NEUROCHEM INT, V17, P435, DOI 10.1016/0197-0186(90)90025-O; MARESCA M, 1992, CELL BIOCHEM FUNCT, V10, P79, DOI 10.1002/cbf.290100203; MCKNIGHT SL, 1981, CELL, V25, P385, DOI 10.1016/0092-8674(81)90057-X; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; OKUNO H, 1993, ONCOGENE, V8, P695; OMAHONEY JV, 1994, DNA CELL BIOL, V13, P1227, DOI 10.1089/dna.1994.13.1227; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; PILON AL, 1993, MAMM GENOME, V4, P612, DOI 10.1007/BF00361395; PUGA A, 1990, DNA CELL BIOL, V9, P425, DOI 10.1089/dna.1990.9.425; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; SAHU S C, 1990, Biomedical and Environmental Sciences, V3, P183; SAKURA H, 1988, GENE, V73, P499; SARAN M, 1989, FREE RADICAL RES COM, V7, P213, DOI 10.3109/10715768909087944; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCOTT JA, 1988, FREE RADICAL BIO MED, V4, P79, DOI 10.1016/0891-5849(88)90067-6; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SKEHEL PA, 1994, GENE, V145, P231, DOI 10.1016/0378-1119(94)90011-6; SOHAL RS, 1990, EXP GERONTOL, V25, P499, DOI 10.1016/0531-5565(90)90017-V; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPITKOVSKY DD, 1992, NUCLEIC ACIDS RES, V20, P797, DOI 10.1093/nar/20.4.797; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STORZ G, 1992, J NUTR, V122, P627, DOI 10.1093/jn/122.suppl_3.627; TAFURI SR, 1993, J BIOL CHEM, V268, P12213; TAFURI SR, 1993, J BIOL CHEM, V268, P24255; TAO K, 1989, MOL GEN GENET, V218, P371, DOI 10.1007/BF00332397; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P2038; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TROLL W, 1991, FREE RADICAL RES COM, V12-3, P751; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; WU J, 1991, J BACTERIOL, V173, P2864, DOI 10.1128/JB.173.9.2864-2871.1991; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XI H, 1993, TOXICOL APPL PHARM, V120, P29, DOI 10.1006/taap.1993.1083; ZHU H, 1994, ARCH TOXICOL, V68, P582, DOI 10.1007/s002040050118	71	35	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30499	30507		10.1074/jbc.270.51.30499	http://dx.doi.org/10.1074/jbc.270.51.30499			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530481	hybrid			2022-12-25	WOS:A1995TL67500046
J	ARNOLD, SF; VOROJEIKINA, DP; NOTIDES, AC				ARNOLD, SF; VOROJEIKINA, DP; NOTIDES, AC			PHOSPHORYLATION OF TYROSINE-537 ON THE HUMAN ESTROGEN-RECEPTOR IS REQUIRED FOR BINDING TO AN ESTROGEN RESPONSE ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; THYROID-HORMONE; ESTRADIOL; DOMAIN; KINASE; UTERUS; CELLS	We report here that the phosphorylation of tyrosine 537 on the human estrogen receptor (hER) controls the receptor's dimerization and DNA binding ability. The DNA-binding form of both the hER from human MCF-7 mammary carcinoma cells and the hER overexpressed in Sf9 insect cells was isolated using estrogen response element (ERE) affinity chromatography. Western blot analyses demonstrated that the DNA-binding form of the hER from MCF-7 or Sf9 cells was (i) phosphorylated at tyrosine 537, (ii) localized in the nucleus of estradiol-treated MCF-7 cells with an apparent molecular mass of 67 kDa, and (iii) hyperphosphorylated at serine residue(s). The non-DNA-binding form of the hER was (i) devoid of phosphorylation at tyrosine 537, (ii) cytosolic with an apparent molecular mass of 66 kDa, and (iii) hypophosphorylated at serine residue(s). The dephosphorylation of the purified hER at phosphotyrosine 537 with a tyrosine phosphatase eliminated binding to an ERE in a gel mobility shift assay. The binding of the tyrosine-dephosphorylated hER to an ERE was restored by the rephosphorylation of tyrosine 537 with Src family tyrosine kinases, p60(c-src) or p56(lck), Mutation of tyrosine 537 to phenylalanine confirmed that the phosphorylation of tyrosine 537 is necessary for the hER to bind an ERE. An anti-hER antibody restored the binding of the tyrosine-dephosphorylated hER to an ERE, indicating that the bivalent anti-hER antibody brought together the two inactive hER monomers. A far-Western blot confirmed that phosphotyrosine 537 is required for hER homodimerization. These experiments establish that dimerization of the hER and DNA binding are regulated by phosphorylation at tyrosine 537. This is the first demonstration of the regulation of dimerization of a steroid hormone receptor by phosphorylation. These results are significant since p60(c-src) is overexpressed in estrogen-dependent breast cancers and may act to enhance the activity of the hER.	UNIV ROCHESTER,SCH MED & DENT,DEPT ENVIRONM MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOPHYS,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NICHD NIH HHS [HD 06707] Funding Source: Medline; NIEHS NIH HHS [T32ES 07026, ES 01247] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD006707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007026, P30ES001247] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; ARNOLD SF, 1995, P NATL ACAD SCI USA, V92, P7475, DOI 10.1073/pnas.92.16.7475; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; ARNOLD SF, 1995, IN PRESS J STEROID B; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; DENNER LA, 1989, ENDOCRINOLOGY, V125, P3051, DOI 10.1210/endo-125-6-3051; DENTON RR, 1992, J BIOL CHEM, V267, P7263; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GOLDING TS, 1988, P NATL ACAD SCI USA, V85, P69, DOI 10.1073/pnas.85.1.69; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; JACOBS C, 1983, CANCER RES, V43, P1696; KATZ D, 1995, MOL CELL BIOL, V15, P2341; KATZENELLENBOGE.BS, 1987, CANCER RES, V47, P4355; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KLIEWER SA, 1992, NATURE, V35, P445; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; NEFF S, 1994, MOL ENDOCRINOL, V8, P1215, DOI 10.1210/me.8.9.1215; OBOURN JD, 1993, BIOCHEMISTRY-US, V32, P6229, DOI 10.1021/bi00075a016; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SKAFAR DF, 1985, J BIOL CHEM, V260, P2208	29	111	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30205	30212						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530431				2022-12-25	WOS:A1995TK38000091
J	DUDLEY, MA; HACHEY, DL; QUARONI, A; HUTCHENS, TW; NICHOLS, BL; ROSENBERGER, J; PERKINSON, JS; COOK, G; REEDS, PJ				DUDLEY, MA; HACHEY, DL; QUARONI, A; HUTCHENS, TW; NICHOLS, BL; ROSENBERGER, J; PERKINSON, JS; COOK, G; REEDS, PJ			INVIVO SUCRASE-ISOMALTASE AND LACTASE-PHLORHIZIN HYDROLASE TURNOVER IN THE FED ADULT-RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; PROTEIN-SYNTHESIS; INTRACELLULAR-TRANSPORT; MONOCLONAL-ANTIBODIES; MICROVILLUS MEMBRANE; PLASMA-MEMBRANE; BIOSYNTHESIS; EXPRESSION; BIOGENESIS; PRECURSOR	We estimated in vivo turnover rates of sucrase-isomaltase and lactase-phlorizin hydrolase in adult rats. Fed animals received a primed continuous infusion of phenylalanine (300 muCi, 150 mumol Phe/100 g of body weight for 30 s, then 7.5 muCi, 3.75 mumol Phe/min for 10 to 140 min). Sucrase-isomaltase and lactase-phlorizin hydrolase were immunoprecipitated from jejunal mucosal membranes; isoforms were separated by SDS-polyacrylamide gel electrophoresis. Endoglycosidase H digestions and (for lactase-phlorizin hydrolase) N-terminal amino acid sequencing were performed on all isoforms. Specific radioactivity of prosucrase-isomaltase and prolactase-phlorizin hydrolase isoforms reached isotopic equilibrium by 60 and 90 min, respectively. Specific radioactivity of brush border sucrase and lactase did not reach steady state. The isotope kinetic, N-terminal amino acid sequencing, and endoglycosidase H digestion data suggested that one of the high molecular weight lactase isoforms is a dimer of mature lactase. Compartmental modeling of specific radioactivity demonstrated that mean intracellular residence time is 59 min for prosucrase-isomaltase isoforms and 68 min for prolactase-phlorizin hydrolase isoforms. Mean residence time in the brush border was 5.8 h for sucrase and 7.8 h for lactase. Fractional synthesis rates were 414%/day for sucrase and 307%/day for lactase. Thus, in vivo brush border sucrase and lactase turn over at similar rates in the adult rat.	TEXAS CHILDRENS HOSP, HOUSTON, TX 77030 USA; CORNELL UNIV, DEPT PHYSIOL, ITHACA, NY 14853 USA	Baylor College of Medicine; Cornell University	DUDLEY, MA (corresponding author), BAYLOR COLL MED, DEPT PEDIAT, CHILDRENS NUTR RES CTR, USDA ARS, 1100 BATES ST, HOUSTON, TX 77030 USA.							ALPERS DH, 1972, J CLIN INVEST, V51, P167, DOI 10.1172/JCI106788; ALPERS DH, 1975, BIOCHIM BIOPHYS ACTA, V401, P28, DOI 10.1016/0005-2736(75)90338-7; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BOSTON RC, 1981, COMPUT PROG BIOMED, V13, P111, DOI 10.1016/0010-468X(81)90089-1; BULLER HA, 1987, J BIOL CHEM, V262, P17206; BULLER HA, 1990, J BIOL CHEM, V265, P6978; DANIELSEN EM, 1987, MAMMALIAN ECTOENZYME, P47; DAVIS TA, 1989, AM J PHYSIOL, V257, pR1141, DOI 10.1152/ajpregu.1989.257.5.R1141; DUDLEY MA, 1992, J PEDIATR GASTR NUTR, V15, P260, DOI 10.1097/00005176-199210000-00006; DUDLEY MA, 1992, J NUTR, V122, P528, DOI 10.1093/jn/122.3.528; FOSTER DM, 1983, COMPARTMENTAL DISTRI, P73; FRANSEN JAM, 1991, J CELL BIOL, V115, P45, DOI 10.1083/jcb.115.1.45; GARLICK PJ, 1980, BIOCHEM J, V192, P719, DOI 10.1042/bj1920719; GOLDSPINK DF, 1984, BIOCHEM J, V217, P527, DOI 10.1042/bj2170527; GRAND RJ, 1985, GASTROENTEROLOGY, V88, P531, DOI 10.1016/0016-5085(85)90517-7; HAURI HP, 1979, P NATL ACAD SCI USA, V76, P5183, DOI 10.1073/pnas.76.10.5183; HAURI HP, 1985, P NATL ACAD SCI USA, V82, P4423, DOI 10.1073/pnas.82.13.4423; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HAURI HP, 1980, P NATL ACAD SCI-BIOL, V77, P6629, DOI 10.1073/pnas.77.11.6629; HAURI HP, 1982, J BIOL CHEM, V257, P4522; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MCNURLAN MA, 1982, BIOCHEM J, V204, P831, DOI 10.1042/bj2040831; NAIM HY, 1988, J CLIN INVEST, V82, P667, DOI 10.1172/JCI113646; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; NAIM HY, 1991, J BIOL CHEM, V266, P12313; OLSEN WA, 1986, AM J PHYSIOL, V250, pG788, DOI 10.1152/ajpgi.1986.250.6.G788; QUARONI A, 1985, DEV BIOL, V111, P267, DOI 10.1016/0012-1606(85)90482-8; SEMENZA G, 1989, BIOCHEM INT, V18, P15; SKOVBJERG H, 1984, BIOCHIM BIOPHYS ACTA, V798, P247, DOI 10.1016/0304-4165(84)90312-X; STERCHI EE, 1990, J CLIN INVEST, V86, P1329, DOI 10.1172/JCI114842; WITTE J, 1989, GASTROENTEROLOGY, V96, P549	32	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13609	13616						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514793				2022-12-25	WOS:A1993LH55300084
J	MARTIN, DW; MUNOZ, RM; SUBLER, MA; DEB, S				MARTIN, DW; MUNOZ, RM; SUBLER, MA; DEB, S			P53 BINDS TO THE TATA-BINDING PROTEIN-TATA COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; POLYMERASE-II TRANSCRIPTION; CELLULAR TUMOR-ANTIGEN; LARGE T-ANTIGEN; WILD-TYPE P53; HUMAN U6 GENE; MAMMALIAN-CELLS; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; ACTIVATION DOMAIN	Earlier reports show that p53, both wild type and mutants, may affect transcription. Wild-type p53 activates promoters with p53-binding sites while inhibiting promoters without binding sites. Mutant p53, on the other hand, has been shown to activate transcription from specific promoters. These observations suggest that both wild-type and mutant p53 may interact with a general transcription factor(s). In this report, we have shown that the cloned TATA-binding protein (TBP) from human and yeast interacts with human p53. TBP coimmunoprecipitates with wild-type or mutant human p53 when incubated with the p53-specific monoclonal antibody and Protein A-agarose. Wild-type murine p53 has also been found to interact with human TBP. Protein blot assays have demonstrated that the interaction between p53 and human TBP is direct. By gel retention analysis, we have shown that the complex of TBP and p53 (both wild type and mutant) can bind to the TATA box. The similar qualitative binding capability of wild-type and mutant p53 with human TBP and the similarity of the two complexes in binding to the TATA box suggest that the functional discrimination between wild-type and mutant p53 may not lie in their ability to bind TBP. The nature of the p53.TBP or p53.TBP.TATA complex may determine the success of transcription.	UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007271] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07271-08] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREEN MR, 1992, NATURE, V357, P364, DOI 10.1038/357364d0; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HOFFMANN A, 1990, NATURE, V341, P299; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; INOSTROZA JA, 1992, CELL, V70, P477; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERCER WE, 1990, ONCOGENE, V5, P973; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1954; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7305; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG WD, 1991, MOL CELL BIOL, V11, P4561, DOI 10.1128/MCB.11.9.4561; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	84	119	121	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13062	13067						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514746				2022-12-25	WOS:A1993LH55300011
J	Crowley, MT; Harmer, SL; DeFranco, AL				Crowley, MT; Harmer, SL; DeFranco, AL			Activation-induced association of a 145-kDa tyrosine-phosphorylated protein with Shc and Syk in B lymphocytes and macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; GRB2; INTERACTS; 3-KINASE; BINDING; CD14	Engagement of many cell surface receptors results in tyrosine phosphorylation of an overlapping set of protein substrates. Some proteins, such as the adaptor protein Shc and a frequently observed Shc-associated protein, p145, are common substrates in a variety of receptor signaling pathways and are thus of special interest. Tyrosine-phosphorylated Shc and p145 coprecipitated with anti-Shc antibodies following B cell antigen receptor (BCR) cross-linking or interleukin-4 (IL-4) receptor activation in B cells, and after lipopolysaccharide (LPS) treatment or IgG Fe receptor (Fc gamma R) crosslinking in macrophages. In the case of BCR stimulation, we have shown that this represented the formation of an inducible complex. Furthermore, in response to LPS activation or Fc gamma R cross-linking of macrophages and BCR cross-linking (but not IL-4 treatment) of B cells, we observed a similar tyrosine-phosphorylated p145 protein associated with the tyrosine kinase Syk. We did not detect any Shc-associated with Syk, indicating that a trimolecular complex of Shc, Syk, and p145 was not formed in significant amounts. By several criteria, the Syk-associated p145 was very likely the same protein as the previously identified Shc-associated p145. The Syk-associated p145 and the Shc-associated p145 exhibited identical mobility by SDS-polyacrylamide gel electrophoresis and identical patterns of induced tyrosine phosphorylation. The p145 protein that coprecipitated with either Shc or Syk bound to a GST-Shc fusion protein. In addition, a monoclonal antibody developed against Shc-associated p145 also immunoblotted the Syk-associated p145. The observations that p145 associated with both Shc and Syk proteins, in response to stimulation of a variety of receptors, suggest that it plays an important role in coordinating early signaling events.	UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Harmer, Sarah/G-5572-2016	Harmer, Sarah/0000-0002-5627-5500; Harmer, Stacey/0000-0001-6813-6682	NIAID NIH HHS [T32AI07334, AI33442, AI20038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033442, R37AI020038, T32AI007334, R01AI020038, R56AI020038] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ASHWELL JD, 1984, J EXP MED, V159, P881, DOI 10.1084/jem.159.3.881; BASU T, 1994, ONCOGENE, V9, P3483; BEATY CD, 1994, EUR J IMMUNOL, V24, P1278, DOI 10.1002/eji.1830240606; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BURG DL, 1994, J BIOL CHEM, V269, P28136; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DEFRANCO AL, 1994, CURR OPIN IMMUNOL, V6, P364, DOI 10.1016/0952-7915(94)90114-7; EVANS GA, 1994, J BIOL CHEM, V269, P23407; GENG Y, 1994, P NATL ACAD SCI USA, V91, P8602, DOI 10.1073/pnas.91.18.8602; GOLD MR, 1993, J IMMUNOL, V150, P377; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; PARK JG, 1995, P NATL ACAD SCI USA, V92, P7381, DOI 10.1073/pnas.92.16.7381; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P98; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAXTON TM, 1994, J IMMUNOL, V153, P623; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YIN TG, 1994, J BIOL CHEM, V269, P26614; ZENG YX, 1994, FEBS LETT, V353, P289, DOI 10.1016/0014-5793(94)01065-X; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	56	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1145	1152		10.1074/jbc.271.2.1145	http://dx.doi.org/10.1074/jbc.271.2.1145			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557643	hybrid			2022-12-25	WOS:A1996TP88900080
J	Ahuja, SK; Lee, JC; Murphy, PM				Ahuja, SK; Lee, JC; Murphy, PM			CXC chemokines bind to unique sets of selectivity determinants that can function independently and are broadly distributed on multiple domains of human interleukin-8 receptor B - Determinants of high affinity binding and receptor activitation are distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO TERMINUS; LIGAND; EXPRESSION	Human interleukin-8 receptors A (IL-8RA) and B (IL-8RB) are seven-transmembrane domain (TMD) neutrophil chemokine receptors with similar sequences (77% amino acid identity) and similar G protein selectivity, but markedly different selectivity for CXC chemokines, IL-8RB is selective for IL-8, growth-related oncogene alpha (GRO alpha) and neutrophil activating peptide-2 (NAP-2), whereas IL-8RA is selective only for IL-8. To identify selectivity determinants, we made eight chimeric receptors exchanging: 1) the three main regions of sequence divergence between IL-8RA and IL-8RB (the N-terminal segment before TMD1, the region from TMD4 to the end of the second extracellular (e2) loop, and the C-terminal tail), and 2) the N-terminal segment of CC chemokine receptor 1, which does not bind CXC chemokines. Chimeras were tested by direct I-125-IL-8, I-125-GRO alpha, and I-125-NAP-2 binding, heterologous competition binding, and calcium flux assays using human embryonic kidney 293 cells stably transfected with receptor DNAs. The following results were obtained: 1) chimeric receptors had binding sites for IL-8, GRO alpha and NAP-2 distinct from those on IL-8RA and IL-8RB; 2) IL-8, GRO alpha and NAP-2 bound to overlapping but distinct sites that mapped differentially to multiple domains on IL-8RB; 3) high affinity radioligand binding and high agonist potency were separable functions for IL-8, GRO alpha and NAP-2, suggesting that the determinants of high affinity binding may not be critical for receptor activation; and 4) determinants of GRO alpha and NAP-2 selectivity were found in both the N-terminal segment before TMD1 and the region from TMD4 to the end of the e2 loop of IL-8RB, and functioned independently of each other, Stated reciprocally, the N-terminal segment of IL-8RA was not a dominant selectivity determinant. These data suggest that both narrow and broad spectrum chemokine antagonists can be developed to block functions mediated by IL-8RB.			Ahuja, SK (corresponding author), NIAID,HOST DEF LAB,BLDG 10,RM 11N113,BETHESDA,MD 20892, USA.							AHUJA SK, 1994, J BIOL CHEM, V269, P26381; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BOZIC CR, 1994, J BIOL CHEM, V269, P29355; BROADDUS VC, 1994, J IMMUNOL, V152, P2960; CERRETTI DP, 1993, GENOMICS, V18, P410, DOI 10.1006/geno.1993.1486; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; COMBADIERE C, IN PRESS J BIOL CHEM, V270; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONG SR, 1994, J BIOL CHEM, V269, P19343; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PRADO GN, 1994, J BIOL CHEM, V269, P12391; SCHONBECK U, 1995, J IMMUNOL, V154, P2375; SCHRAUFSTATTER IU, 1993, J IMMUNOL, V151, P6418; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUZUKI H, 1994, J BIOL CHEM, V269, P18263; THOMAS KM, 1994, J IMMUNOL, V152, P2496	28	130	131	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					225	232		10.1074/jbc.271.1.225	http://dx.doi.org/10.1074/jbc.271.1.225			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550564	hybrid			2022-12-25	WOS:A1996TP36100035
J	Hennig, G; Lowrick, O; Birchmeier, W; Behrens, J				Hennig, G; Lowrick, O; Birchmeier, W; Behrens, J			Mechanisms identified in the transcriptional control of epithelial gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; HUMAN PAPILLOMAVIRUS TYPE-18; TISSUE-SPECIFIC EXPRESSION; SIGNAL-TRANSDUCTION; FUNCTIONAL-ANALYSIS; BINDING PROTEINS; CARCINOMA-CELLS; FACTOR AP-2; FACTOR-I; PROMOTER	Epithelium specific gene expression is fundamental in both embryogenesis and the maintenance of adult tissues, and impairment of epithelial characteristics contributes to diseases such as cancer. We have here analyzed the 5'-region of the epithelial (E-) cadherin gene in order to understand mechanisms of epithelium-specific transcription and loss of expression during epithelial mesenchymal transitions. The regulatory region of the mouse epithelial cadherin gene is composed of a promoter (from position -94 to the transcription start site) and a 150-base pair enhancer located in the first intron. The 5'-promoter consists of positive regulatory elements (a CCAAT-box and two AP-2 binding sites in a GC-rich region) and the palindromic element E-Pal that activates and represses transcription in epithelial and mesenchymal cells, respectively. The enhancer of the first intron stimulates the activity of heterologous promoters exclusively in epithelial cells. This epithelium-specific enhancer consists of three elements (E I to E III; E II and E III bind AP-2) that are necessary and sufficient for activity, We thus propose two regulatory mech anisms by which epithelial specificity of epithelial cadherin expression is determined: suppression of promoter activity in mesenchymal cells by E-Pal and enhancement of activity in epithelial cells by both E-Pal and the epithelium specific enhancer.	MAX DELBRUCK CTR MOLEC MED, D-13125 BERLIN, GERMANY; UNIV ESSEN GESAMTHSCH, SCH MED, INST CELL BIOL CANC RES, D-45147 ESSEN, GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Duisburg Essen								APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BERNARD HU, 1994, ARCH DERMATOL, V130, P210, DOI 10.1001/archderm.130.2.210; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BOUKAMP P, 1992, J CELL BIOL, V116, P1257, DOI 10.1083/jcb.116.5.1257; BOYER B, 1993, APMIS, V101, P257, DOI 10.1111/j.1699-0463.1993.tb00109.x; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; Buxton R S, 1992, Semin Cell Biol, V3, P157; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; CRIPE T P, 1990, New Biologist, V2, P450; Cunningham B, 1990, MORPHOREGULATORY MOL, P9; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; FLEMING TP, 1993, J CELL SCI, P119; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUSENIG NE, 1994, J DERMATOL SCI, V7, P142; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HATTA M, 1994, DEV GROWTH DIFFER, V36, P509; HENNIG G, 1995, ONCOGENE, V11, P475; HOPPESEYLER F, 1994, MOL CARCINOGEN, V10, P134, DOI 10.1002/mc.2940100304; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMHOF BA, 1983, CELL, V35, P667, DOI 10.1016/0092-8674(83)90099-5; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KATZ S, 1993, EMBO J, V12, P1321, DOI 10.1002/j.1460-2075.1993.tb05777.x; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; LAKE RA, 1990, EMBO J, V9, P3129, DOI 10.1002/j.1460-2075.1990.tb07510.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACK DH, 1991, P NATL ACAD SCI USA, V88, P9102, DOI 10.1073/pnas.88.20.9102; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; REICHMANN E, 1994, SEMIN CANCER BIOL, V5, P157; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; Saxen L., 1987, ORGANOGENESIS KIDNEY; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SNAPE AM, 1991, DEVELOPMENT, V113, P283; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; SORKIN BC, 1993, P NATL ACAD SCI USA, V90, P11356, DOI 10.1073/pnas.90.23.11356; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLES AM, 1991, CANCER CELLS, V59, P17; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122	71	125	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					595	602		10.1074/jbc.271.1.595	http://dx.doi.org/10.1074/jbc.271.1.595			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550625				2022-12-25	WOS:A1996TP36100090
J	Wang, Y; Yeung, YG; Langdon, WY; Stanley, ER				Wang, Y; Yeung, YG; Langdon, WY; Stanley, ER			c-Cbl is transiently tyrosine-phosphorylated, ubiquitinated, and membrane-targeted following CSF-1 stimulation of macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-CBL; FACTOR-I; PROTEIN; ONCOGENE; IDENTIFICATION; TRUNCATION	Early colony stimulating factor-1 (CSF-1) induced changes in the behavior of p120(c-cbl) in mouse BAC1.2F5 macrophages were investigated. p120(c-cbl) is associated with Grb2 in the cytoplasm of unstimulated cells. Following a 1-min stimulation with CSF-1, p120(c-cbl) be comes tyrosine-phosphorylated and associates with tyrosine-phosphorylated She and an unknown phosphotyrosyl protein (pp80). Simultaneously, it is ubiquitinated and translocated to the membrane. By 10 min of stimulation, this c-Cbl exhibits substantially decreased tyrosine phosphorylation and is de-ubiquitinated and relocated in the cytosol. However, the association of p120(c-cbl) with She persists for at least 60 min. These data indicate that signaling via the CSF-1R involves the transient modification of p120(c-cbl) and its recruitment as a complex to membrane.	ALBERT EINSTEIN COLL MED,DEPT DEV & MOLEC BIOL,BRONX,NY 10461; UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT PATHOL,NEDLANDS,WA 6009,AUSTRALIA	Yeshiva University; Albert Einstein College of Medicine; University of Western Australia			Stanley, Evan R/J-9154-2013	Stanley, Evan R/0000-0002-2910-2065	NCI NIH HHS [CA26504, P30-CA 1330] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026504, R37CA026504, K04CA001330] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; HAAS AL, 1985, J BIOL CHEM, V260, P2464; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAMPS MP, 1988, ONCOGENE, V2, P305; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LI W, 1991, EMBO J, V10, P277, DOI 10.1002/j.1460-2075.1991.tb07948.x; LI W, 1991, J BIOL CHEM, V266, P6808; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; STANLEY ER, 1994, CYTOKINE HDB, P387; TANAKA S, 1995, J BIOL CHEM, V270, P1; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WU RS, 1981, J BIOL CHEM, V256, P5916; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YEUNG YG, 1990, RECEPTOR PURIFICATIO, P315; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHAUNG ZP, 1989, J BIOL CHEM, V264, P14594	27	136	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					17	20		10.1074/jbc.271.1.17	http://dx.doi.org/10.1074/jbc.271.1.17			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550554				2022-12-25	WOS:A1996TP36100004
J	Boucher, I; Fukamizo, T; Honda, Y; Willick, GE; Neugebauer, WA; Brzezinski, R				Boucher, I; Fukamizo, T; Honda, Y; Willick, GE; Neugebauer, WA; Brzezinski, R			Site-directed mutagenesis of evolutionary conserved carboxylic amino acids in the chitosanase from Streptomyces sp N174 reveals two residues essential for catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLATED CHITOSAN; BACILLUS-CIRCULANS MH-K1; ACTION PATTERN; PURIFICATION; CHITINASE; ENZYME	The comparison of four sequences of prokaryotic chitosanases, belonging to the family 46 of glycosyl hydrolases, revealed a conserved N-terminal module of 50 residues, including five invariant carboxylic residues. To verify if some of these residues are important for catalytic activity in the chitosanase from Streptomyces sp. N174, these 5 residues were replaced by site-directed mutagenesis. Substitutions of Glu-22 or Asp-40 with sterically conservative (E22Q, D40N) or functionally conservative (E22D, D40E) residues reduced drastically specific activity and k(cat), while K-m was only slightly changed. The other residues examined, Asp-6, Glu-SG, and Asp-37, retained significant activity after mutation. Circular dichroism studies of the mutant chitosanases confirmed that the observed effects are not due to changes in secondary structure. These results suggested that Glu-22 and Asp-40 are directly involved in the catalytic center of the chitosanase and the other residues are not essential for catalytic activity.	UNIV SHERBROOKE,FAC SCI,DEPT BIOL,GRP RECH BIO ACTINOMYCETES,SHERBROOKE,PQ J1K 2R1,CANADA; KINKI UNIV,FAC AGR,BIOPHYS CHEM LAB,NARA 631,JAPAN; NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA,ON K1A 0R6,CANADA	University of Sherbrooke; Kindai University (Kinki University); National Research Council Canada			Brzezinski, Ryszard/A-3192-2008; Fukamizo, Tamo/AAY-7251-2020	Brzezinski, Ryszard/0000-0002-9090-5051				ANDO A, 1992, J GEN APPL MICROBIOL, V38, P135, DOI 10.2323/jgam.38.135; ANDO A, 1993, CHITIN ENZYMOLOGY, P283; BOUCHER I, 1992, APPL MICROBIOL BIOT, V38, P188, DOI 10.1007/BF00174466; DAVIS LL, 1984, BIOCHEMISTRY-US, V23, P1065, DOI 10.1021/bi00301a005; DENIS F, 1992, GENE, V111, P115, DOI 10.1016/0378-1119(92)90611-R; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; ELOUAKFAOUI S, 1992, PHYTOCHEMISTRY, V31, P1513, DOI 10.1016/0031-9422(92)83097-I; FINK D, 1991, BIOTECHNOL LETT, V13, P845, DOI 10.1007/BF01022084; FUKAMIZO T, 1995, BIOCHEM J, V311, P377, DOI 10.1042/bj3110377; FUKAMIZO T, 1994, BBA-PROTEIN STRUCT M, V1205, P183, DOI 10.1016/0167-4838(94)90232-1; FUKAMIZO T, 1989, AGR BIOL CHEM TOKYO, V53, P2641, DOI 10.1080/00021369.1989.10869717; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hopwood D. A., 1985, GENETIC MANIPULATION; IZUME M, 1992, BIOSCI BIOTECH BIOCH, V56, P448, DOI 10.1271/bbb.56.448; LEVER M, 1972, ANAL BIOCHEM, V47, P273, DOI 10.1016/0003-2697(72)90301-6; MARCOTTE E, 1993, J MOL BIOL, V232, P995, DOI 10.1006/jmbi.1993.1447; MASSON JY, 1994, GENE, V140, P103, DOI 10.1016/0378-1119(94)90738-2; MASSON JY, 1995, MICROBIOL-SGM, V141, P2629, DOI 10.1099/13500872-141-10-2629; MASSON JY, 1993, CHITIN ENZYMOLOGY, P423; MITSUTOMI M, 1990, AGR BIOL CHEM TOKYO, V54, P871, DOI 10.1080/00021369.1990.10870047; MONAGHAN RL, 1973, NATURE-NEW BIOL, V245, P78, DOI 10.1038/newbio245078a0; OHTAKARA A, 1990, AGR BIOL CHEM TOKYO, V54, P3191, DOI 10.1080/00021369.1990.10870469; PERRAKIS A, 1993, CHITIN ENZYMOLOGY, P217; SAKAI K, 1991, BIOCHIM BIOPHYS ACTA, V1079, P65, DOI 10.1016/0167-4838(91)90025-U; Sambrook J, 1989, MOL CLONING LABORATO; Sandford PA, 1989, CHITIN CHITOSAN, P51; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; YABUKI M, 1988, J GEN APPL MICROBIOL, V34, P255, DOI 10.2323/jgam.34.255	31	66	69	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31077	31082		10.1074/jbc.270.52.31077	http://dx.doi.org/10.1074/jbc.270.52.31077			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537367	hybrid			2022-12-25	WOS:A1995TN44400035
J	Cunningham, SA; Awayda, MS; Bubien, JK; Ismailov, II; Arrate, MP; Berdiev, BK; Benos, DJ; Fuller, CM				Cunningham, SA; Awayda, MS; Bubien, JK; Ismailov, II; Arrate, MP; Berdiev, BK; Benos, DJ; Fuller, CM			Cloning of an epithelial chloride channel from bovine trachea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTES; FUNCTIONAL RECONSTITUTION; EXPRESSION CLONING; MOLECULAR-CLONING; PROTEIN; SEQUENCE; CLEAVAGE; GENE; CFTR	We have isolated and cloned a novel epithelial Cl- channel protein from a bovine tracheal cDNA expres sion library using an antibody probe. The antibody (alpha p38) was raised against a 38-kDa component of a homopolymeric protein that behaves as a Ca2+/calmodulin kinase II-, DIDS, and dithiothreitol (DTT)-sensitive, anion-selective channel when incorporated into planar lipid bilayers. The full-length cDNA is 3001 base pairs long and codes for a 903-amino acid protein. The clone does not show any significant homology to any other previously reported Cl- channel sequence. Northern analysis of bovine tracheal mRNA with a cDNA probe corresponding to the cloned sequence revealed a band at 3.1 kilobases, suggesting that close to the full-length sequence has been cloned. The full-length open reading frame (2712 base pairs) has been expressed in Xenopus oocytes and in mammalian COS-7 cells. In oocytes, expression of the clone was associated with the appear ance of a novel DIDS-, and DTT-sensitive, anion-selective conductance that was outwardly rectified and exhibited a reversal potential close to 0 mV. Whole-cell patch clamp studies in COS-7 cells transfected with the clone identified an ionomycin-, and DTT sensitive chloride conductance that was not apparent in nock-transfected or control cells. In vitro translation studies have shown that the primary transcript codes for a protein migrating at 140 kDa under reduced conditions, significantly larger than the polypeptide recognized by alpha p38. We therefore suggest that either the 140 kDa translated product is a prepro form of the 38-kDa subunit of the previously identified bovine tracheal anion channel and that the primary transcript is post-translationally cleaved to yield the final product, or that the cloned channel and the previously identified bovine tracheal anion channel protein share an epitope that is recognized by the alpha p38 antibody.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Fuller, Cathy/B-4046-2011		NIDDK NIH HHS [DK 42017, DK 48764] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK042017, R01DK048764] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; ARUFFO A, 1992, CURRENT PROTOCOLS MO; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P479, DOI 10.1073/pnas.91.2.479; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; FRIZZELL RA, 1994, CURR TOP MEMBR, V42, P173, DOI 10.1016/S0070-2161(08)60823-0; FULLER CM, 1992, AM J PHYSIOL, V262, pC396, DOI 10.1152/ajpcell.1992.262.2.C396; FULLER CM, 1995, AM J PHYSIOL-CELL PH, V269, pC641, DOI 10.1152/ajpcell.1995.269.3.C641; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; FULLER CM, 1994, J BIOL CHEM, V269, P26642; FULLER CM, 1992, J BIOL CHEM, V263, pC396; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; JOHNSON LG, 1995, J CLIN INVEST, V95, P1377, DOI 10.1172/JCI117789; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY D, 1993, J BIOL CHEM, V268, P14948; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; PATIENT RK, 1983, J BIOL CHEM, V258, P8521; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; RAN S, 1992, J BIOL CHEM, V267, P20630; RAN S, 1992, J BIOL CHEM, V267, P3618; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSEN OM, 1989, DIABETES, V38, P1508, DOI 10.2337/diabetes.38.12.1508; Sambrook J, 1989, MOL CLONING LABORATO; SPAETE RR, 1990, J VIROL, V64, P2922, DOI 10.1128/JVI.64.6.2922-2931.1990; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; WHITE MM, 1990, MOL PHARMACOL, V37, P720; 1991, PROGRAM MANUAL GENET	34	185	196	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31016	31026		10.1074/jbc.270.52.31016	http://dx.doi.org/10.1074/jbc.270.52.31016			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537359	hybrid			2022-12-25	WOS:A1995TN44400027
J	Iwasaki, T; Wakagi, T; Isogai, Y; Iizuka, T; Oshima, T				Iwasaki, T; Wakagi, T; Isogai, Y; Iizuka, T; Oshima, T			Resolution of the aerobic respiratory system of the thermoacidophilic archaeon, Sulfolobus sp, strain 7 .2. Characterization of the archaeal terminal oxidase subcomplexes and implication for the intramolecular electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; THERMOPHILIC BACTERIUM PS3; PROTONMOTIVE Q-CYCLE; BRADYRHIZOBIUM-JAPONICUM; ESCHERICHIA-COLI; PARACOCCUS-DENITRIFICANS; ENERGY TRANSDUCTION; UBIQUINOL OXIDASE; ACTIVE-SITE; ACIDOCALDARIUS	The terminal segment of the aerobic respiratory chain of the thermoacidophilic archaeon Sulfolobus sp. strain 7 is an unusual caldariellaquinol oxidase supercomplex, which contains at least one b-type and three spectroscopically distinguishable a-type cytochromes, one copper, and a Rieske-type FeS center. In this paper, we report the purification and characterization of two different forms of the archaeal a-type cytochromes, namely, a three-subunit cytochrome a(583)-aa(3) subcomplex and a single-subunit cytochrome aa(3) derived from the cytochrome subcomplex, in order to facilitate fur ther studies on the terminal oxidase segment of Sulfolobus. The optical and EPR spectroscopic analyses suggest the presence of two different low-spin heme centers and one high-spin heme center in the purified cytochrome a(583)-aa(3) subcomplex, and one low-spin and one high-spin hemes in cytochrome aa(3), respectively. The Rieske-type FeS center detected in the purified cytochrome supercomplex was absent in two forms of the a-type cytochrome oxidase, indicating its association with cytochrome b(562). The crystal field parameters of the low-spin heme a(583) center indicate that its axial ligands may be similar to those of cytochromes c, rather than conventional bis-histidine ligation, In spite of the absence of any c-type cytochrome, a ferrocytochrome c oxidase activity was detected in the archaeal purified cytochrome a(583)-aa(3) subcomplex with no quinol oxidase activity, but not in the purified cytochrome oxidase supercomplex, which has been tentatively interpreted as a representative of electron transfer from the Rieske FeS center to cytochrome a(583) in vivo. Thus, our results indicate the following scheme for the intramolecular electron transfer of the terminal oxidase supercomplex from Sulfolobus sp. strain 7: [caldariellaquinol -->] b(562) --> Rieske FeS center --> a(583) aa(3) --> molecular oxygen.	TOKYO INST TECHNOL, DEPT LIFE SCI, YOKOHAMA, KANAGAWA 226, JAPAN; INST PHYS & CHEM RES, BIOPHYS CHEM LAB, WAKO, SAITAMA 30501, JAPAN	Tokyo Institute of Technology; RIKEN			Wakagi, Takayoshi/AAJ-4145-2021	Iwasaki, Toshio/0000-0001-9562-4649; Isogai, Yasuhiro/0000-0001-6905-4208				ANEMULLER S, 1990, EUR J BIOCHEM, V191, P297, DOI 10.1111/j.1432-1033.1990.tb19123.x; ANEMULLER S, 1994, FEMS MICROBIOL LETT, V117, P275, DOI 10.1016/0378-1097(94)90571-1; ANEMULLER S, 1989, FEBS LETT, V244, P451, DOI 10.1016/0014-5793(89)80581-2; ANEMULLER S, 1985, FEBS LETT, V193, P83, DOI 10.1016/0014-5793(85)80084-3; ANEMULLER S, 1992, EUR J BIOCHEM, V210, P133, DOI 10.1111/j.1432-1033.1992.tb17400.x; ANEMULLER S, 1993, FEBS LETT, V318, P61, DOI 10.1016/0014-5793(93)81328-W; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BERRY EA, 1985, J BIOL CHEM, V260, P2458; BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; BOTT M, 1991, J BACTERIOL, V173, P6766, DOI 10.1128/jb.173.21.6766-6772.1991; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; DEROSA M, 1977, J CHEM SOC PERK T 1, P653, DOI 10.1039/p19770000653; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; FUJIWARA T, 1987, PLANT CELL PHYSIOL, V28, P29; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P3120, DOI 10.1021/bi00176a047; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; HONNAMI K, 1984, BIOCHEMISTRY-US, V23, P454, DOI 10.1021/bi00298a009; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; IKEDA M, 1974, BIOCHIM BIOPHYS ACTA, V336, P15, DOI 10.1016/0005-2795(74)90378-X; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; Iwasaki T, 1995, J BIOL CHEM, V270, P30902, DOI 10.1074/jbc.270.52.30902; KEEFE RG, 1993, BIOCHIM BIOPHYS ACTA, V1183, P91, DOI 10.1016/0005-2728(93)90008-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; LUBBEN M, 1992, EMBO J, V11, P805, DOI 10.1002/j.1460-2075.1992.tb05117.x; LUBBEN M, 1994, MOL MICROBIOL, V13, P327, DOI 10.1111/j.1365-2958.1994.tb00426.x; LUBBEN M, 1994, J BIOL CHEM, V269, P21473; LUBBEN M, 1994, EUR J BIOCHEM, V224, P151, DOI 10.1111/j.1432-1033.1994.tb20006.x; MIKI T, 1994, J BIOL CHEM, V269, P1827; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MOGI T, 1994, J BIOCHEM-TOKYO, V116, P471, DOI 10.1093/oxfordjournals.jbchem.a124548; Palmer G., 1979, PORPHYRINS, P313; PEISACH J, 1969, P NATL ACAD SCI USA, V63, P934, DOI 10.1073/pnas.63.3.934; PREISIG O, 1993, P NATL ACAD SCI USA, V90, P3309, DOI 10.1073/pnas.90.8.3309; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; RAGAN CI, 1987, CURR TOP BIOENERG, V15, P1; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SARASTE M, 1991, BIOCHEM SOC T, V19, P608, DOI 10.1042/bst0190608; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; SCHAFER G, 1990, FEMS MICROBIOL LETT, V75, P335, DOI 10.1016/0378-1097(90)90543-Y; SONE N, 1984, J BIOL CHEM, V259, P1405; SONE N, 1987, J BIOL CHEM, V262, P15386; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; SONE N, 1990, BACTERIA, V11, P1; TAYLOR CPS, 1977, BIOCHIM BIOPHYS ACTA, V491, P137, DOI 10.1016/0005-2795(77)90049-6; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; TURBA A, 1995, EUR J BIOCHEM, V231, P259, DOI 10.1111/j.1432-1033.1995.0259f.x; VANDEROOST J, 1992, EMBO J, V11, P3209, DOI 10.1002/j.1460-2075.1992.tb05398.x; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; WAKAGI T, 1986, SYST APPL MICROBIOL, V7, P342; WAKAGI T, 1989, BIOCHEM BIOPH RES CO, V165, P1110, DOI 10.1016/0006-291X(89)92717-4; WAKAO H, 1987, J BIOCHEM, V102, P255, DOI 10.1093/oxfordjournals.jbchem.a122049; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Yamanaka T., 1992, BIOCH BACTERIAL CYTO, P91; YANG XH, 1986, J BIOL CHEM, V261, P2282; YANG XH, 1988, J BIOL CHEM, V263, P11962	64	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30893	30901		10.1074/jbc.270.52.30893	http://dx.doi.org/10.1074/jbc.270.52.30893			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537343	hybrid			2022-12-25	WOS:A1995TN44400011
J	Meisels, E; Gileadi, O; Corden, JL				Meisels, E; Gileadi, O; Corden, JL			Partial truncation of the yeast RNA polymerase II carboxyl-terminal domain preferentially reduces expression of glycolytic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPSTREAM ACTIVATING SEQUENCES; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; LARGEST-SUBUNIT; TRANSCRIPTIONAL ACTIVATORS; HEPTAPEPTIDE REPEAT; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; ENOLASE GENES; RAP1	The largest subunit of RNA polymerase II contains an essential carboxyl-terminal domain (CTD) that consists of highly conserved heptapeptide repeats with the consensus sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser. Yeast cells with a partially truncated CTD grow slowly, are temperature- and cold-sensitive, and are unable to fully activate transcription of some genes. Screening a yeast wild-type cDNA library by means of comparative hybridization we find that CTD truncation preferentially reduces transcription of genes encoding glycolytic enzymes, Using a newly developed dual reporter assay we demonstrate that sensitivity to CTD truncation is conferred by the glycolytic gene promoters. Expression driven by glycolytic gene promoters is reduced, on average, about 3-fold in strains with the shortest CTD growing on either fermentable or nonfermentable carbon sources. Sensitivity to CTD truncation is particularly acute for the constitutively expressed ENO1 gene, which is reduced 10-fold in a strain with only eight CTD repeats. The sensitivity of constitutive ENO1 expression argues that CTD truncation can cause defects in uninduced as well as induced transcription.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; WEIZMANN INST SCI,DEPT MOLEC GENET,IL-76100 REHOVOT,ISRAEL	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Weizmann Institute of Science			Gileadi, Opher/F-1105-2013	Gileadi, Opher/0000-0001-6886-898X	NCI NIH HHS [5 PO1 CA 16519] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; BAKER HV, 1986, MOL CELL BIOL, V6, P3774, DOI 10.1128/MCB.6.11.3774; BARRONCASELLA E, 1992, J MOL EVOL, V35, P405, DOI 10.1007/BF00171818; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRINDLE PK, 1990, MOL CELL BIOL, V10, P4872, DOI 10.1128/MCB.10.9.4872; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BUERMEYER AB, 1995, J BIOL CHEM, V270, P6798, DOI 10.1074/jbc.270.12.6798; CHAMBERS A, 1990, NUCLEIC ACIDS RES, V18, P5393, DOI 10.1093/nar/18.18.5393; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CLIFTON D, 1981, J BIOL CHEM, V256, P3074; CLIFTON D, 1978, GENETICS, V88, P1; COHEN R, 1987, MOL CELL BIOL, V7, P2753, DOI 10.1128/MCB.7.8.2753; COHEN R, 1986, MOL CELL BIOL, V6, P2287, DOI 10.1128/MCB.6.7.2287; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; COTTRELLE P, 1985, J BIOL CHEM, V260, P3090; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; HOLLAND JP, 1979, J BIOL CHEM, V254, P9839; HOLLAND MJ, 1981, J BIOL CHEM, V256, P1385; HUET J, 1987, P NATL ACAD SCI USA, V84, P3648, DOI 10.1073/pnas.84.11.3648; HUIE MA, 1992, MOL CELL BIOL, V12, P2690, DOI 10.1128/MCB.12.6.2690; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V83, P8447, DOI 10.1073/pnas.83.22.8447; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KANG ME, 1993, J BIOL CHEM, V268, P25033; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MILLER JH, 1972, EXPT MOL GENETICS, P401; MORROW BE, 1989, J BIOL CHEM, V264, P9061; NISHIZAWA M, 1990, P NATL ACAD SCI USA, V87, P5373, DOI 10.1073/pnas.87.14.5373; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; Sambrook J, 1989, MOL CLONING LABORATO; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; SCHMITT HD, 1983, MOL GEN GENET, V192, P247, DOI 10.1007/BF00327674; SCOTT EW, 1990, NUCLEIC ACIDS RES, V18, P7099, DOI 10.1093/nar/18.23.7099; SCOTT EW, 1993, MOL CELL BIOL, V13, P543, DOI 10.1128/MCB.13.1.543; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SORE D, 1994, TRENDS GENET, V10, P408; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TORNOW J, 1993, EMBO J, V12, P2431, DOI 10.1002/j.1460-2075.1993.tb05897.x; UEMURA H, 1992, J BACTERIOL, V174, P5526, DOI 10.1128/JB.174.17.5526-5532.1992; UEMURA H, 1990, MOL CELL BIOL, V10, P6389, DOI 10.1128/MCB.10.12.6389; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WALI M, 1995, GENETICS, V140, P79; WEST ML, 1995, GENETICS, V140, P1223; WHITE MF, 1988, FEBS LETT, V229, P383, DOI 10.1016/0014-5793(88)81161-X; [No title captured]	67	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31255	31261		10.1074/jbc.270.52.31255	http://dx.doi.org/10.1074/jbc.270.52.31255			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537392	hybrid			2022-12-25	WOS:A1995TN44400059
J	Ojamaa, K; Samarel, AM; Klein, I				Ojamaa, K; Samarel, AM; Klein, I			Identification of a contractile-responsive element in the cardiac alpha-myosin heavy chain gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-HEART-CELLS; HORMONE REGULATES EXPRESSION; BINDING FACTOR MEF-2; THYROID-HORMONE; ENHANCER-BINDING; DNA-BINDING; MESSENGER-RNA; FUSION GENE; MYOD; TRANSCRIPTION	The mechanisms by which the cardiac-specific alpha-myosin heavy chain (alpha-MHC) gene responds to contractile activity was studied in cultured cardiomyocytes and in vivo. Deletion analysis of the alpha-MHC promoter transiently transfected into neonatal rat cardiomyocytes localized the contractile-responsive element within -80 to -40 base pairs of the transcriptional start site. Mutational analysis of an E-box motif at position -47 showed that it was necessary for the contractile response both in cultured cardiomyocytes and in the intact heart. Competition gel mobility shift experiments indicated that the protein-DNA complex formed within the -39 to -59 base pair region could be competed by the E-box element at -309 of the alpha-MHC gene and that base substitutions within an E-box motif at -47 eliminated the protein-DNA complex. To identify the contractile-responsive nuclear protein, antibodies specific for E12/E47, an E-box binding basic-helix-loop-helix (bHLH) protein, and antibodies recognizing upstream stimulatory factor (USF), a widely expressed bHLH-leucine zipper transcription factor, were studied for their ability to inhibit cardiomyocyte nuclear protein binding to the E-box motif at -47. Anti-USF antibody abolished formation of the protein-DNA complex, thus identifying the protein as antigenically related to USF and demonstrating that bHLH-leucine zipper proteins are involved in the contractile-induced expression of the cardiac alpha-MHC gene.	LOYOLA UNIV,MED CTR,DEPT MED,MAYWOOD,IL 60153	Loyola University Chicago	Ojamaa, K (corresponding author), N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT MED,DIV ENDOCRINOL,300 COMMUNITY DR,MANHASSET,NY 11030, USA.		Samarel, Allen/Q-9810-2019		NHLBI NIH HHS [HL-34328, HL-41304] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041304, R01HL034328] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADOLPH EA, 1993, J BIOL CHEM, V268, P5349; BACKX PH, 1994, J PHYSIOL-LONDON, V476, P487, DOI 10.1113/jphysiol.1994.sp020149; BARRY WH, 1995, J MOL CELL CARDIOL, V27, P551, DOI 10.1016/S0022-2828(08)80050-8; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAUNWALD E, 1982, NEW ENGL J MED, V307, P1618; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; COOPER G, 1985, J CLIN INVEST, V75, P1403, DOI 10.1172/JCI111842; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; GUPTA MP, 1994, J BIOL CHEM, V269, P29677; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; IMAMURA SI, 1991, AM J PHYSIOL, V260, pH73, DOI 10.1152/ajpheart.1991.260.1.H73; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; JACKSON SM, 1995, MOL ENDOCRINOL, V9, P278, DOI 10.1210/me.9.3.278; KENT RL, 1989, CIRC RES, V64, P74, DOI 10.1161/01.RES.64.1.74; KLEIN I, 1992, J CLIN INVEST, V89, P68, DOI 10.1172/JCI115587; KLEIN I, 1985, J CELL PHYSIOL, V124, P49, DOI 10.1002/jcp.1041240109; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOZLOWSKI MT, 1991, DEV BIOL, V148, P625, DOI 10.1016/0012-1606(91)90280-G; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MCDERMOTT P, 1985, AM J PHYSIOL, V249, pH763, DOI 10.1152/ajpheart.1985.249.4.H763; MITSUI K, 1993, J BIOL CHEM, V268, P24415; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P2602; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; OJAMAA K, 1994, P NATL ACAD SCI USA, V91, P3468, DOI 10.1073/pnas.91.8.3468; OJAMAA K, 1993, ENDOCRINOLOGY, V132, P2001; QI M, 1994, AM J PHYSIOL, V267, pC520, DOI 10.1152/ajpcell.1994.267.2.C520; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, P NATL ACAD SCI USA, V89, P9905, DOI 10.1073/pnas.89.20.9905; SAMAREL AM, 1992, AM J PHYSIOL, V263, pC642, DOI 10.1152/ajpcell.1992.263.3.C642; SAMAREL AM, 1991, AM J PHYSIOL, V261, pH1067, DOI 10.1152/ajpheart.1991.261.4.H1067; SHARP WW, 1993, CIRC RES, V73, P172, DOI 10.1161/01.RES.73.1.172; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SIERRA F, 1993, GENE TRANSCRIPTION P, P131; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	44	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31276	31281		10.1074/jbc.270.52.31276	http://dx.doi.org/10.1074/jbc.270.52.31276			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537395	hybrid			2022-12-25	WOS:A1995TN44400062
J	Okino, N; Kawabata, S; Saito, T; Hirata, M; Takagi, T; Iwanaga, S				Okino, N; Kawabata, S; Saito, T; Hirata, M; Takagi, T; Iwanaga, S			Purification, characterization, and cDNA cloning of a 27-kDa lectin (L10) from horseshoe crab hemocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE ZYMOGEN; TACHYPLEUS-TRIDENTATUS HEMOCYTES; CARCINOSCORPIUS-ROTUNDA-CAUDA; ACID-BINDING LECTIN; LIMULUS-POLYPHEMUS; FACTOR-C; ANTIMICROBIAL PEPTIDE; FACTOR-B; LOCALIZATION; HEMAGGLUTININ	We separated granular components of horseshoe crab hemocytes by a combination of centrifugation on sucrose density gradient and high performance liquid chromatography, and a 27-kDa protein termed L10 was found to be a major component in the large granules (Shigenaga, T., Takayenoki, Y., Kawasaki, S., Seki, N., Muta, T., Toh, Y., Ito, G., and Iwanaga, S. (1993) J. Biochem. (Tokyo) 114, 307-316). In the present work, lectin activity of this protein and its unique primary structure were elucidated. L10 was purified by four steps of chromatography, including dextran sulfate-Sepharose CL-6B, CM-Sepharose CL-6B, Sephacryl S-200, and Mono S. At least three 27-kDa isoproteins, named L10a, L10b, and L10c, were isolated. Their amino acid compositions were almost indistinguishable, and there were no amino sugars. All the isoforms had hemagglutinating activity against human A-type erythrocytes, in a Ca2+-independent manner with L10b showing the highest activity. The L10b-mediated hemagglutination was inhibited in the presence of N-acetylglucosamine or N-acetylallolactosamine, and the association constant (K-alpha) between L10b and N-acetylglucosamine was 1.95 x 10(4) M(-1). Furthermore, L10b specifically agglutinated Staphylococcus saprophyticus KD. Ultracentrifugation analysis revealed that L10b is present in monomer form in solution. A cDNA coding for an isoform of L10 was isolated from a hemocyte cDNA library. The open reading frame of the 768-base pair cDNA coded for the signal sequence of 19 residues. The mature protein had 236 residues with the calculated molecular weight of 26,757. Amino acid sequences of the peptides derived from L10c exactly corresponded to the predicted sequence of the cDNA, whereas amino acid replacements of Ile-129 to Val and His-213 to Tyr existed both in L10a and L10b, suggesting that the cDNA codes for L10c. Cysteine was absent and there were five tandem repeats with 47 amino acids in each segment with internal sequence identities of 49-68%. The entire amino acid sequences had no significant sequence similarity with other known proteins.	KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 81281,JAPAN; KYUSHU UNIV 33,GRAD SCH MED SCI,DEPT BIOL MOLEC,FUKUOKA 81281,JAPAN; IWATE MED UNIV,SCH MED,DEPT BACTERIOL,MORIOKA,IWATE 020,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Kyushu University; Kyushu University; Iwate Medical University; Osaka University			Okino, Nozomu/AAY-2635-2021	Saito, Tetsu/0000-0002-9045-6743				AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; BISHAYEE S, 1980, BIOCHIM BIOPHYS ACTA, V623, P89, DOI 10.1016/0005-2795(80)90011-2; DORAI DT, 1981, ARCH BIOCHEM BIOPHYS, V209, P325, DOI 10.1016/0003-9861(81)90288-5; FUJII N, 1992, J BIOL CHEM, V267, P22452; HARLOW E, 1989, ANTIBODIES LABORATOR, P471; IWANAGA S, 1994, ANN NY ACAD SCI, V712, P102, DOI 10.1111/j.1749-6632.1994.tb33566.x; JIMBO A, 1984, J BIOCHEM-TOKYO, V95, P267, DOI 10.1093/oxfordjournals.jbchem.a134593; KAWANO K, 1990, J BIOL CHEM, V265, P15365; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LIU T, 1991, J BIOL CHEM, V266, P14813; MATSUMOTO I, 1982, 2ND P INT C CHIT CHI, P165; MEGA T, 1991, J BIOCHEM-TOKYO, V109, P600, DOI 10.1093/oxfordjournals.jbchem.a123426; MIURA Y, 1995, J BIOL CHEM, V270, P558, DOI 10.1074/jbc.270.2.558; MIURA Y, 1992, J BIOCHEM-TOKYO, V112, P476, DOI 10.1093/oxfordjournals.jbchem.a123924; MIURA Y, 1994, J BIOL CHEM, V269, P542; MIYATA T, 1989, J BIOCHEM, V106, P663, DOI 10.1093/oxfordjournals.jbchem.a122913; MIYATA T, 1984, J BIOL CHEM, V259, P8924; MORITA T, 1985, J BIOCHEM, V97, P1611, DOI 10.1093/oxfordjournals.jbchem.a135218; MUTA T, 1991, J BIOL CHEM, V266, P6554; MUTA T, 1993, J BIOL CHEM, V268, P21384; MUTA T, 1990, J BIOL CHEM, V265, P22426; MUTA T, 1990, J BIOCHEM-TOKYO, V108, P261, DOI 10.1093/oxfordjournals.jbchem.a123191; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1986, J BIOCHEM, V99, P847, DOI 10.1093/oxfordjournals.jbchem.a135545; NOWAK TP, 1975, BIOCHIM BIOPHYS ACTA, V393, P115, DOI 10.1016/0005-2795(75)90221-4; Ornberg R.L., 1979, Progress in Clinical and Biological Research, V29, P125; PRIVAT JP, 1974, EUR J BIOCHEM, V47, P5, DOI 10.1111/j.1432-1033.1974.tb03661.x; SAITO T, 1995, J BIOCHEM-TOKYO, V117, P1131, DOI 10.1093/oxfordjournals.jbchem.a124818; Sambrook J, 1989, MOL CLONING LABORATO; SEKI N, 1994, J BIOL CHEM, V269, P1370; SHIGENAGA T, 1990, J BIOL CHEM, V265, P21350; SHIGENAGA T, 1993, J BIOCHEM-TOKYO, V114, P307, DOI 10.1093/oxfordjournals.jbchem.a124173; SHIMIZU S, 1977, BIOCHIM BIOPHYS ACTA, V500, P71, DOI 10.1016/0304-4165(77)90047-2; SPINK WW, 1952, J LAB CLIN MED, V40, P593; SRIMAL S, 1985, BIOCHEM J, V230, P321, DOI 10.1042/bj2300321; Takagi T., 1979, Progress in Clinical and Biological Research, V29, P169; TOH Y, 1991, CELL TISSUE RES, V266, P137, DOI 10.1007/BF00678720; TSUBOI I, 1993, BIOCHIM BIOPHYS ACTA, V1156, P255, DOI 10.1016/0304-4165(93)90039-B	41	63	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31008	31015		10.1074/jbc.270.52.31008	http://dx.doi.org/10.1074/jbc.270.52.31008			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537358	hybrid			2022-12-25	WOS:A1995TN44400026
J	Eggert, M; Mows, CC; Tripier, D; Arnold, R; Michel, J; Nickel, J; Schmidt, S; Beato, M; Renkawitz, R				Eggert, M; Mows, CC; Tripier, D; Arnold, R; Michel, J; Nickel, J; Schmidt, S; Beato, M; Renkawitz, R			A fraction enriched in a novel glucocorticoid receptor-interacting protein stimulates receptor-dependent transcription in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE RECEPTORS; THYROID-HORMONE; DNA-BINDING; COOPERATIVE BINDING; STEROID-RECEPTORS; ACTIVATION; PROMOTER; DOMAIN; IDENTIFICATION; SUPERFAMILY	Glucocorticoids influence numerous cell functions by regulating gene activity. The glucocorticoid receptor (GR) is a ligand-activated transcription factor and, like any other transcription factor, does not modulate gene activity just by binding to DNA. Interaction with other proteins is probably required to enhance the establishment of a functional transcription initiation complex. To identify such proteins, we analyzed the in vitro interaction of the glucocorticoid receptor bound to a double glucocorticoid response element with nuclear proteins and describe here three interacting proteins with different molecular weights. One of them, which we named GRIP 170 (GR-interacting protein), was purified and microsequenced, and it turned out to be an unknown protein. When tested in a cell-free transcription assay, the fraction highly enriched for GRIP 170 does not influence basal promoter activity but does enhance GR induction.	UNIV GIESSEN,INST GENET,D-35392 GIESSEN,GERMANY; UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY; HOECHST AG,D-65926 FRANKFURT,GERMANY	Justus Liebig University Giessen; Philipps University Marburg; Sanofi-Aventis			Beato, Miguel/B-5564-2015	Beato, Miguel/0000-0002-2878-2222				BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BANIAHMAD C, 1991, J MOL BIOL, V222, P155, DOI 10.1016/0022-2836(91)90202-H; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVANAUGH AH, 1994, J STEROID BIOCH MOL, V48, P438; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EGGERT M, 1993, EUR J BIOCHEM, V213, P659, DOI 10.1111/j.1432-1033.1993.tb17806.x; EGGERT M, 1994, INDUCIBLE GENE EXPRE, P131; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; GEHRING U, 1993, J STEROID BIOCHEM, V45, P183, DOI 10.1016/0960-0760(93)90140-R; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEL CC, 1994, MOL ENDOCRINOL, V8, P1407, DOI 10.1210/me.8.10.1407; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MOWS CC, 1994, J STEROID BIOCHEM, V51, P21, DOI 10.1016/0960-0760(94)90111-2; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; REXIN M, 1988, BIOCHEMISTRY-US, V27, P5593, DOI 10.1021/bi00415a030; SCHEIDEREIT C, 1983, NATURE, V304, P749, DOI 10.1038/304749a0; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHMITT J, 1993, NUCLEIC ACIDS RES, V21, P2673, DOI 10.1093/nar/21.11.2673; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SIVARAMAN L, 1986, P NATL ACAD SCI USA, V83, P5914, DOI 10.1073/pnas.83.16.5914; SRINIVASAN G, 1990, MOL ENDOCRINOL, V4, P209, DOI 10.1210/mend-4-2-209; TSAI SY, 1990, J BIOL CHEM, V265, P17055; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	40	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30755	30759		10.1074/jbc.270.51.30755	http://dx.doi.org/10.1074/jbc.270.51.30755			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530516	hybrid			2022-12-25	WOS:A1995TL67500081
J	Gotoh, N; Muroya, K; Hattori, S; Nakamura, S; Chida, K; Shibuya, M				Gotoh, N; Muroya, K; Hattori, S; Nakamura, S; Chida, K; Shibuya, M			The SH2 domain of Shc suppresses EGF-induced mitogenesis in a dominant negative manner	ONCOGENE			English	Article						EGF receptor; Shc; SH2 domain; mitogenesis; Ras	EPIDERMAL GROWTH-FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE KINASE-ACTIVITY; TRANSFORMING ACTIVITY; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; RAS; GRB2; PROTEIN; BINDING	Recently, we have shown that an EGF-R-mutant lacking the autophosphorylation sites phosphorylates She and retains mitogenic activity, In this report, we have shown that in these cells, in response to EGF, Ras is fully activated with formation of the tyrosine-phosphorylated Shc-Grb2-mSOS complex without the receptor. This pointed out the importance of She in EGF-induced Ras activation, To investigate the mechanism of tyrosine phosphorylation of She by EGF-R, we carried out in vitro kinase assays using immunoprecipitated EGF-R and bacterially-expressed She proteins as substrates, The EGF-R phosphorylated She, but not the She SH2 mutant, lacking binding ability for phosphotyrosine, This suggests that intact She SH2 is essential for the full-length She to become phosphorylated, probably by inducing a conformational change in She. Thus a She SH2 peptide may inhibit competitively She phosphorylation. We microinjected the She SH2 domain into NIH3T3 cells overexpressing the EGF-R. Microinjected She SH2 greatly suppressed EGF-induced DNA synthesis. But microinjection of neither the She SH2 mutant nor PLC-gamma 1 SH2 had any effect, This suppressing effect was rescued by comicroinjection of the full-length She, suggesting She SH2 specifically suppressed the She pathway. Thus we concluded She phosphorylation is crucial, whereas receptor autophosphorylation is dispensable, in EGF-induced mitogenesis.	UNIV TOKYO, INST MED SCI, DEPT GENET, MINATO KU, TOKYO 108, JAPAN; UNIV TOKYO, INST MED SCI, DEPT CANC CELL RES, MINATO KU, TOKYO 108, JAPAN; NATL INST NEUROSCI, DIV BIOCHEM & CELLULAR BIOL, KODAIRA, TOKYO 187, JAPAN	University of Tokyo; University of Tokyo; National Center for Neurology & Psychiatry - Japan								BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	40	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2525	2533						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545109				2022-12-25	WOS:A1995TP18800008
J	BALBOA, MA; INSEL, PA				BALBOA, MA; INSEL, PA			NUCLEAR PHOSPHOLIPASE-D IN MADIN-DARBY CANINE KIDNEY-CELLS - GUANOSINE 5'-O-(THIOTRIPHOSPHATE)-STIMULATED ACTIVATION IS MEDIATED BY RHOA AND IS DOWNSTREAM OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-NEUTROPHILS; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; FREE SYSTEM; HYDROLYSIS; PHOSPHOGLYCERIDES; DIGLYCERIDES; INVOLVEMENT; RECEPTOR; RAS	We have recently demonstrated the existence of an ATP-activated phospholipase D (PLD) in the nuclei of MDCK-D1 cells (Balboa, RI, A, Balsinde, J,, Dennis, E, A., and Insel, P. A. (1995) J, Biol, Chem, 270, 11738-11740), We have now found that nuclear PLD is synergistically activated by guanosine 5'-O-(thiotriphosphate) (GTP gamma S) and ATP in a time- and concentration-dependent manner, but these compounds do not alter the sensitivity of the enzyme to activation by Ca2+, The synergistic stimulation of PLD activity could be blocked by addition of the protein kinase C inhibitors chelerythrine and calphostin C. Stimulation by GTP gamma S was abolished by guanosine 5'-O-(2-thiodiphosphate). Incubation of isolated nuclei with Clostridium botulinum C3 exoenzyme inhibited the potentiating effect of GTP gamma S on ATP-dependent nuclear PLD activity, Moreover, use of the Rho GDP dissociation inhibitor to extract Rho family G proteins from cell nuclei also inhibits PLD activity, Western blot analyses of isolated nuclei revealed the presence of the small G protein RhoA, but not of RhoB or the ADP-ribosylation factor. GTP gamma S-stimulated ATP-dependent PLD activity could be reconstituted in Rho GDP dissociation inhibitor-washed nuclei by addition of recombinant prenylated RhoA, but not by addition of non-prenylated RhoA Taken together, these results indicate that nuclear PLD activity is modulated via a RhoA-dependent activation that occurs downstream of protein kinase C, Nuclear PLD, which appears to be a previously unrecognized effector regulated by protein kinase C and G proteins, may be involved in the regulation of nuclear function or structure.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego			Balboa, María A./V-9493-2018	Balboa, María A./0000-0002-2130-5298	NHLBI NIH HHS [HL 35018] Funding Source: Medline; NIGMS NIH HHS [GM 31487] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL035018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGWU DE, 1991, J IMMUNOL, V146, P3895; AGWU DE, 1989, J BIOL CHEM, V264, P1405; ANDO S, 1992, J BIOL CHEM, V267, P25709; ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BALBOA MA, 1995, J BIOL CHEM, V270, P11738, DOI 10.1074/jbc.270.20.11738; BALBOA MA, 1992, J EXP MED, V176, P9, DOI 10.1084/jem.176.1.9; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOWMAN EP, 1993, J BIOL CHEM, V4268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GSCHWENDT M, 1993, BIOCHEM BIOPH RES CO, V194, P571, DOI 10.1006/bbrc.1993.1858; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HOCEVAR BA, 1993, J BIOL CHEM, V266, P28; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; HUANG CF, 1992, J BIOL CHEM, V267, P16859; JARPE MB, 1994, BIOCHEMISTRY-US, V33, P526, DOI 10.1021/bi00168a018; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KANAHO Y, 1992, J BIOL CHEM, V267, P23554; KANAHO Y, 1991, J IMMUNOL, V146, P3536; KUSNER DJ, 1993, J BIOL CHEM, V268, P19973; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLSON SC, 1991, J BIOL CHEM, V266, P17236; RIDLEY AL, 1993, CELL, V70, P389; SAFFITZ JE, 1994, FASEB J, V8, P252, DOI 10.1096/fasebj.8.2.8119495; WEISS BA, 1991, J BIOL CHEM, V266, P2126; ZHOU GS, 1994, EXP CELL RES, V214, P1, DOI 10.1006/excr.1994.1227	39	83	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29843	29847						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530380				2022-12-25	WOS:A1995TK38000040
J	MOROOKA, H; BONVENTRE, JV; POMBO, CM; KYRIAKIS, JM; FORCE, T				MOROOKA, H; BONVENTRE, JV; POMBO, CM; KYRIAKIS, JM; FORCE, T			ISCHEMIA AND REPERFUSION ENHANCE ATF-2 AND C-JUN BINDING TO CAMP RESPONSE ELEMENTS AND TO AN AP-1 BINDING-SITE FROM THE C-JUN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSCRIPTION FACTORS; HETERODIMER FORMATION; COMPLEX-FORMATION; GENE-EXPRESSION; RENAL ISCHEMIA; MAP KINASES; PHOSPHORYLATION; PROTEIN; ACTIVATION	The transcription factors controlling the complex genetic response to ischemia and their modes of regulation are poorly understood. We found that ATF-2 and c-Jun DNA binding activity is markedly enhanced in post-ischemic kidney or in LLC-PK1 renal tubular epithelial cells exposed to reversible ATP depletion, After 40 min of renal ischemia followed by reperfusion for as little as 5 min, binding of ATF-2 and c-Jun, but not ATF-3 or CREB (cAMP response element binding protein), to oligonucleotides containing either an ATF/cAMP response element (ATF/CRE) or the jun2TRE from the c-jun promoter, was significantly increased, Binding to jun2TRE and ATF/CRE oligonucleotides occurred with an identical time course, In contrast, nuclear protein binding to an oligonucleotide containing a canonical AP-1 element was not detected until 40 min of reperfusion, and although c-Jun was present in the complex, ATF-2 was not. Incubating nuclear extracts from reperfused kidney with protein phosphatase 2A markedly reduced binding to both the ATF/CRE and jun2TRE oligonucleotides, compatible with regulation by an ATF-S kinase, An ATF-S kinase, which phosphorylated both the transactivation and DNA binding domains of ATF-S, was activated by reversible ATP depletion, This kinase co-eluted on Mono Q column chromatography with a c-Jun amino-terminal kinase and with the peak of stress-activated protein kinase, but not p38, immunoreactivity, In conclusion, DNA binding activity of ATF-S directed at both ATF/CRE and jun2TRE motifs is modulated in response to the extreme cellular stress of ischemia and reperfusion or reversible ATP depletion, Phosphorylation-dependent activation of the DNA binding activity of ATF-S, which appears to be regulated by the stress-activated protein kinases, may play an important role in the earliest stages of the genetic response to ischemia/reperfusion by targeting ATF-S and c-Jun to specific promoters, including the c-jun promoter and those containing ATF/CREs.	MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Pombo, Celia M/L-4479-2014	Force, Thomas/0000-0002-0450-8659; Pombo, Celia M/0000-0003-2541-9468	NIDDK NIH HHS [DK41513, DK01986] Funding Source: Medline; NIGMS NIH HHS [GM46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041513, K08DK001986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046577, R01GM046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BONVENTRE JV, 1993, KIDNEY INT, V43, P1160, DOI 10.1038/ki.1993.163; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLINT KJ, 1991, ONCOGENE, V6, P2019; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812; KIM SJ, 1991, NATURE, V326, P2019; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; OREILLY MA, 1992, J BIOL CHEM, V267, P19938; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; PARK K, 1994, J BIOL CHEM, V269, P6083; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSENBERG ME, 1991, KIDNEY INT, V39, P1156, DOI 10.1038/ki.1991.146; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; SAFIRSTEIN R, 1990, KIDNEY INT, V37, P1515, DOI 10.1038/ki.1990.143; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214	50	101	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30084	30092						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530413				2022-12-25	WOS:A1995TK38000073
J	SCHUBERT, LA; KING, G; CRON, RQ; LEWIS, DB; ARUFFO, A; HOLLENBAUGH, D				SCHUBERT, LA; KING, G; CRON, RQ; LEWIS, DB; ARUFFO, A; HOLLENBAUGH, D			THE HUMAN GP39 PROMOTER - 2 DISTINCT NUCLEAR FACTORS OF ACTIVATED T-CELL PROTEIN-BINDING ELEMENTS CONTRIBUTE INDEPENDENTLY TO TRANSCRIPTIONAL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							REGULATORY ELEMENTS; CYCLOSPORINE-A; EXPRESSION; GENE; LIGAND; CD40; IDENTIFICATION; FOS; JUN	gp39, a cytokine expressed on the surface of activated T cells, is essential for T cell-dependent antibody responses in vivo. We cloned and sequenced 1.2 kilobases of the 5' flank region of the human gp39 gene promoter and determined its transcription start site. When used in reporter gene assays, this DNA segment conferred promoter activity in response to T cell activation. gp39 promoter function in transfectants was inhibited by cyclosporin A, as is expression of the endogenous gp39 gene in T-lineage cells. At least 0.5 kilobase of the 5' flank region was required for promoter activity. Two putative binding sites for the NF-AT family of transcriptional activator proteins were identified at -259 to -265 and -62 to -69 with respect to the transcription start site. Both sites contributed significantly and independently to promoter activity in response to T cell activation. Additionally, when incubated in vitro with nuclear protein purified hom activated human CD4 T cells, both of these sites preferentially bound the NP-AT family member, NF-ATp. These results suggest that NF-ATp, via binding to at least two cia-elements, is essential for the induction of gp39 gene expression in response to T cell activation.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Bristol-Myers Squibb				Cron, Randy/0000-0003-2661-3086	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026940, R01AI026940] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-26940-07] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FULEIHAN R, 1994, J CLIN INVEST, V93, P1315, DOI 10.1172/JCI117089; GAUCHAT JF, 1983, FEBS LETT, V315, P259; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; HO AM, 1994, J BIOL CHEM, V269, P28181; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MASUDA ES, 1995, MOL CELL BIOL, V15, P2679; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MELVIN AJ, 1995, EUR J IMMUNOL, V25, P426, DOI 10.1002/eji.1830250218; NONOYAMA S, 1995, J CLIN INVEST, V95, P66, DOI 10.1172/JCI117677; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAO A, 1995, J LEUKOCYTE BIOL, V57, P536, DOI 10.1002/jlb.57.4.536; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; RYSECK RP, 1991, ONCOGENE, V6, P533; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; WISKOCIL R, 1985, J IMMUNOL, V134, P1599; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	33	80	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29624	29627						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530342				2022-12-25	WOS:A1995TK38000002
J	MILNER, J; CHAN, YS; MEDCALF, EA; WANG, Y; ECKHART, W				MILNER, J; CHAN, YS; MEDCALF, EA; WANG, Y; ECKHART, W			PARTIALLY TRANSFORMED T3T3 CELLS EXPRESS HIGH-LEVELS OF MUTANT-P53 IN THE WILD-TYPE IMMUNOREACTIVE FORM WITH DEFECTIVE OLIGOMERIZATION	ONCOGENE			English	Article							TUMOR SUPPRESSOR PROTEIN; LARGE T-ANTIGEN; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODIES; P53 PROTEIN; CONFORMATION; GENE; PHOSPHORYLATION; LOCALIZATION; REPLICATION	High levels of wild-type p53 suppress transformed growth of many cell lines and yet murine T3T3 cells shown partially transformed growth despite high endogenous levels of phenotypically 'wild-type' p53. On sequencing T3T3 p53 was found to encode missense mutations at codons 230 and 287 and, although endogenous T3T3 p53 is 'wild type', the protein adopted the mutant phenotype when expressed in vitro. Size fractionation of T3T3 cell lysate indicated monomeric p53 possibly in complex with a low molecular weight protein. When expressed in vitro T3T3 p53 formed dimers and higher order structures. Thus T3T3 cells appear (i) to drive endogenous mutant p53 to adopt conformational epitopes characteristic of the 'wild-type' protein, and (ii) to interfer with normal assembly of p53 quaternary structure. Phosphopeptide mapping of p53 from 3T3x cells, T3T3 cells and SV3T3 cells indicated reduced amino terminal phosphorylation of the mutant p53 phenotype. Alternative splicing of p53 was also detected in 3T3x cells; similar splicing occurs in wild-type p53 (Han & Kulesz-Martin, 1992; Nucl. Acids Res., 20, 1979-1981) and a possible regulatory function is discussed.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; SALK INST BIOL STUDIES,SAN DIEGO,CA 92138	University of Cambridge; Salk Institute					NATIONAL CANCER INSTITUTE [R01CA013884, P30CA014195, R37CA013884] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14195, CA 13884] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADDISON C, 1990, ONCOGENE, V5, P423; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CATHALA G, 1983, DNA CELL BIOL, V2, P339; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; GANNON JV, 1990, EMBO J, V9, P1591; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEDCALF EA, 1992, ONCOGENE, V7, P71; MEEK DW, 1990, J VIROL, V64, P1734, DOI 10.1128/JVI.64.4.1734-1744.1990; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MILNER J, 1986, VIROLOGY, V153, P21; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZERRAHN J, 1992, ONCOGENE, V7, P1371	46	22	24	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					2001	2008						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510941				2022-12-25	WOS:A1993LG68200033
J	KOYAMA, N; HARADA, K; YAMAMOTO, A; MORISAKI, N; SAITO, Y; YOSHIDA, S				KOYAMA, N; HARADA, K; YAMAMOTO, A; MORISAKI, N; SAITO, Y; YOSHIDA, S			PURIFICATION AND CHARACTERIZATION OF AN AUTOCRINE MIGRATION FACTOR FOR VASCULAR SMOOTH-MUSCLE CELLS (SMC), SMC-DERIVED MIGRATION FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; CANCER-PATIENT FIBROBLASTS; STIMULATING FACTOR; MOTILITY FACTOR; SCATTER FACTOR; FACTOR-BETA; INHIBITION; ATHEROSCLEROSIS; FACTOR-BETA-1; PATHOGENESIS	Migration of medial smooth muscle cells (SMC) into the intima is a key step in intimal thickening of atherosclerotic tissues. We previously reported that cultured SMC secrete a potent migration factor for SMC, named SMC-derived migration factor (SDMF). We purified this factor to homogeneity from 20 liters of serum-free conditioned medium of cultured rat aortic SMC by sequential heparin-Sepharose column, red-Sepharose column, TSK-heparin high performance liquid chromatography (HPLC) column, and Superose 6 HPLC column chromatographies. SDMF was found to be a 58-kDa polypeptide by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Reduction by mercaptoethanol caused only a slight decrease in its molecular mass to 53 kDa. Preparative isoelectric focusing revealed that SDMF is a basic protein with a pI of approximately 10. Purified SDMF enhanced the migration of rat SMC dose dependently, its maximal activity being 4 times that of platelet-derived growth factor-BB. In contrast, SDMF did not enhance the migration of endothelial cells from either human umbilical cord vein or rabbit retinal tissue. SDMF had no effect on the proliferation of SMC. These findings suggest that SDMF enhances SMC migration in vascular walls and that the autocrine system of SMC migration contributes to the formation of intimal thickening in atheroma formation.	CHIBA UNIV, SCH MED,DEPT INTERNAL MED 2,1-8-1 INOHANA,CHUO KU, CHIBA 260, JAPAN; TERUMO CO LTD, CTR RED & DEV, NAKAI, KANAGAWA 25901, JAPAN	Chiba University; Terumo Corporation				Koyama, Noriyuki/0000-0002-7509-6583				AUTIO I, 1990, FEBS LETT, V277, P247, DOI 10.1016/0014-5793(90)80857-F; BOWENPOPE DF, 1984, BLOOD, V64, P458; CHAMLEYCAMPBELL JH, 1981, J CELL BIOL, V89, P378; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FISCHERDZOGA K, 1973, EXP MOL PATHOL, V18, P162; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; GROTENDORST GR, 1981, P NATL ACAD SCI-BIOL, V78, P3669, DOI 10.1073/pnas.78.6.3669; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KOYAMA N, 1991, ATHEROSCLEROSIS, V86, P219, DOI 10.1016/0021-9150(91)90218-R; KOYAMA N, 1990, BIOCHEM BIOPH RES CO, V169, P725, DOI 10.1016/0006-291X(90)90391-Y; KOYAMA N, 1992, J BIOL CHEM, V267, P22806; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LIBBY P, 1988, NEW ENGL J MED, V318, P1493, DOI 10.1056/NEJM198806093182303; LINDNER V, 1990, J CLIN INVEST, V85, P2004, DOI 10.1172/JCI114665; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MAJESKY MW, 1992, CIRC RES, V71, P759, DOI 10.1161/01.RES.71.4.759; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; NAITO M, 1991, EXP CELL RES, V194, P154, DOI 10.1016/0014-4827(91)90145-K; NAITO M, 1989, FEBS LETT, V247, P358, DOI 10.1016/0014-5793(89)81370-5; NOMOTO A, 1988, ATHEROSCLEROSIS, V72, P213, DOI 10.1016/0021-9150(88)90083-4; OOYAMA T, 1987, ARTERIOSCLEROSIS, V7, P593, DOI 10.1161/01.ATV.7.6.593; OWENS GK, 1988, J CELL BIOL, V107, P771, DOI 10.1083/jcb.107.2.771; RAINES EW, 1985, METHOD ENZYMOL, V109, P749; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P1079; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SCHOR SL, 1988, J CELL SCI, V90, P391; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; WATANABE H, 1991, J BIOL CHEM, V266, P13442; WATANABE S, 1992, PREVENTION TREATMENT, P361	42	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13301	13308						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514768				2022-12-25	WOS:A1993LH55300044
J	WUEBBENS, MM; RAJAGOPALAN, KV				WUEBBENS, MM; RAJAGOPALAN, KV			STRUCTURAL CHARACTERIZATION OF A MOLYBDOPTERIN PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM COFACTOR BIOSYNTHESIS; ESCHERICHIA-COLI; SULFITE OXIDASE; DIHYDROPTERIDINE REDUCTASE; PHENYLALANINE-HYDROXYLASE; XANTHINE-OXIDASE; DINUCLEOTIDE; OXIDATION; CHLA	Purification and structural characterization of a novel pterin that is the immediate biosynthetic precursor for molybdopterin formation in Escherichia coli has been accomplished. The precursor is purified from acid extracts of cells of the Escherichia coli molybdopterin-deficient mutant chlN by reverse phase and ion exchange high performance liquid chromatography. Under a variety of conditions, this precursor oxidizes directly to the previously characterized pterin, compound Z (Johnson, J. L., Wuebbens, M. M., and Rajagopalan, K. V. (1989) J. Biol. Chem. 264, 13440-13447). Like, molybdopterin, the precursor is an oxygen-sensitive, 6-alkyl pterin with a 4-carbon phosphorylated side chain. Analysis by P-31 NMR indicates that the precursor phosphate is bound in diester linkage to C-2' and C-4' of the side chain to form a 6-membered ring. The precursor does not contain either of the sulfurs present in molybdopterin, and reduction with sodium borohydride yields a C-1' hydroxyl function. Two-electron oxidation of the precursor results in stoichiometric production of the fully oxidized compound Z. Liquid chromatography-mass spectroscopy of the precursor yields an MH+ ion with a mass of 346, corresponding to a structure for the precursor which is a dihydro form of compound Z.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM00091, GM44283] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044283] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ARCHER MC, 1972, CAN J BIOCHEM CELL B, V50, P1174, DOI 10.1139/o72-160; BAILEY SW, 1983, BIOCHEMISTRY-US, V22, P1790, DOI 10.1021/bi00277a008; BLACKBURN BJ, 1973, J AM CHEM SOC, V95, P2873, DOI 10.1021/ja00790a023; BOHME M, 1980, ANGEW CHEM INT EDIT, V19, P473, DOI 10.1002/anie.198004731; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; COZZONE PJ, 1976, BIOCHEMISTRY-US, V15, P4860, DOI 10.1021/bi00667a017; DAWSON RMC, 1986, DATA BIOCH RES, P125; GARDLIK S, 1991, J BIOL CHEM, V266, P4889; GARDLIK S, 1990, J BIOL CHEM, V265, P13047; HAAVIK J, 1986, EUR J BIOCHEM, V160, P1, DOI 10.1111/j.1432-1033.1986.tb09932.x; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1989, J CLIN INVEST, V83, P897, DOI 10.1172/JCI113974; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON JL, 1989, J BIOL CHEM, V264, P13440; JOHNSON JL, 1993, IN PRESS METABOLIC B; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; KAUFMAN S, 1959, J BIOL CHEM, V234, P2677; KING TE, 1967, METHOD ENZYMOL, V10, P634; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P9, DOI 10.1021/bi00594a002; PFLEIDERER W, 1985, FOLATES PTERINS, V2, P43; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1989, J BACTERIOL, V171, P3373, DOI 10.1128/jb.171.6.3373-3378.1989; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; PLOWMAN J, 1974, J BIOL CHEM, V249, P5559; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; RANDLES D, 1985, EUR J BIOCHEM, V146, P467, DOI 10.1111/j.1432-1033.1985.tb08674.x; SHIMAN R, 1985, FOLATES PTERINS, V2, P179; SIEGEL LM, 1973, J BIOL CHEM, V248, P251; SMITH GK, 1986, J BIOL CHEM, V261, P2725; SUZUKI A, 1973, BIOCHIM BIOPHYS ACTA, V304, P222, DOI 10.1016/0304-4165(73)90132-3; URUSHIBARA T, 1971, BIOCHEM J, V125, P141, DOI 10.1042/bj1250141	36	96	98	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13493	13498						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514781				2022-12-25	WOS:A1993LH55300068
J	IZBAN, MG; LUSE, DS				IZBAN, MG; LUSE, DS			SII-FACILITATED TRANSCRIPT CLEAVAGE IN RNA POLYMERASE-II COMPLEXES STALLED EARLY AFTER INITIATION OCCURS IN PRIMARILY DINUCLEOTIDE INCREMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-SII; S-II; GENE; SEQUENCE; TERMINATION; TFIIS; STIMULATION; EXPRESSION; INVITRO	RNA polymerase II ternary complex cleaves its nascent transcript in a 3' --> 5' direction in the presence of elongation factor SII (Izban, M. G., and Luse, D. S. (1992) Genes & Dev. 6, 1342-1356; Reines, D. (1992) J. Biol. Chem. 267, 3795-3800). We have characterized the cleavage products generated during the truncation process with a variety of stalled RNA polymerase II ternary complexes containing uniformly labeled transcripts. These complexes, which remain elongation competent, had stopped transcription because one nucleoside triphosphate was missing from the reaction mixture. Using a novel assay system, we demonstrate that cleavage occurs in predominantly dinucleotide increments, liberating 5'-phosphodinucleotides (pNpNs). In one instance with a particular C20 complex, the first cleavage event was equally partitioned between either a di- or trinucleotide increment with all subsequent truncations occurring by the preferred dinucleotide step. Our data indicate that both the kinetics and the exact increment of SII-facilitated transcript cleavage are influenced by transcript sequence.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NIGMS NIH HHS [GM14111, GM-29487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014111, R01GM029487] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; HUBERT JC, 1983, EMBO J, V2, P2071, DOI 10.1002/j.1460-2075.1983.tb01702.x; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KANAI A, 1991, J BIOCHEM-TOKYO, V109, P674, DOI 10.1093/oxfordjournals.jbchem.a123439; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; MAITRA U, 1967, J BIOL CHEM, V242, P4897; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL TK, 1990, NUCLEIC ACIDS RES, V18, P6293, DOI 10.1093/nar/18.21.6293; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1992, J BIOL CHEM, V267, P3795; REINES D, 1989, J BIOL CHEM, V264, P10799; RUSHIZKY GW, 1963, BIOCHEMISTRY-US, V2, P787, DOI 10.1021/bi00904a028; SHIRAI T, 1991, P NATL ACAD SCI USA, V88, P9056, DOI 10.1073/pnas.88.20.9056; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SOPTA M, 1985, J BIOL CHEM, V260, P353; SPARKOWSKI J, 1990, NUCLEIC ACIDS RES, V18, P6443, DOI 10.1093/nar/18.21.6443; SPARKOWSKI J, 1992, GENETICS, V130, P411; SPENCER CA, 1990, ONCOGENE, V5, P777; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WIEST DK, 1992, J BIOL CHEM, V267, P7733; YOO OJ, 1991, NUCLEIC ACIDS RES, V19, P1073, DOI 10.1093/nar/19.5.1073	33	84	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12864	12873						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509420				2022-12-25	WOS:A1993LG65800093
J	Retzer, MD; Kabani, A; Button, LL; Yu, RH; Schryvers, AB				Retzer, MD; Kabani, A; Button, LL; Yu, RH; Schryvers, AB			Production and characterization of chimeric transferrins for the determination of the binding domains for bacterial transferrin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SERUM TRANSFERRIN; HUMAN LACTOFERRIN; NEISSERIA-MENINGITIDIS; EXPRESSION SYSTEM; ESCHERICHIA-COLI; TERMINAL HALF; GENES; PROTEIN; CELLS; CDNA	Pathogenic bacteria in the Neisseriaceae and Pasteurellaceae possess outer membrane proteins that specifically bind transferrin from the host as the first step in the iron acquisition process. As a logical progression from prior studies of the ligand-receptor interaction using biochemical approaches, we have initiated an approach involving the production of recombinant chimeric transferrins to further identify the regions of transferrin involved in receptor binding. In order to prepare bovine/human hybrids, the bovine transferrin gene was cloned, sequenced, and compared with the existing human transferrin gene sequence. After identification of potential splice sites, hybrid transferrin genes were constructed using the polymerase chain reaction-based approach of splicing by overlap extension. Five hybrid genes containing sequences from both bovine and human transferrin were constructed. Recombinant transferrins were produced in a baculovirus expression vector system and affinity-purified using concanavalin A-Sepharose. The recombinant proteins were analyzed for reactivity against polyclonal and monoclonal antibodies and assessed for binding to Neisseria meningitidis transferrin receptor proteins in solid-phase binding assays and affinity isolation experiments. These experiments enabled us to localize the regions of human transferrin predominantly involved in binding to the N. meningitidis receptor to amino acid residues 346-588. The construction of these chimeras provides unique tools for the investigation of transferrin binding to receptors from both human and bovine bacterial pathogens.			Retzer, MD (corresponding author), UNIV CALGARY, DEPT MICROBIOL & INFECT DIS, CALGARY, AB T2N 4N1, CANADA.		Schryvers, Anthony B./AAF-3417-2020					ALCANTARA J, 1993, MOL MICROBIOL, V8, P1135, DOI 10.1111/j.1365-2958.1993.tb01658.x; ANDERSON JE, 1994, J BACTERIOL, V176, P3162, DOI 10.1128/jb.176.11.3162-3170.1994; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAKER EN, 1992, J INORG BIOCHEM, V47, P147, DOI 10.1016/0162-0134(92)84061-Q; BAKER EN, 1987, TRENDS BIOCHEM SCI, V12, P350, DOI 10.1016/0968-0004(87)90163-0; BALDWIN GS, 1993, COMP BIOCHEM PHYS B, V106, P203, DOI 10.1016/0305-0491(93)90028-4; CORNELISSEN CN, 1992, J BACTERIOL, V174, P5788, DOI 10.1128/jb.174.18.5788-5797.1992; CORNELISSEN CN, 1994, MOL MICROBIOL, V14, P843, DOI 10.1111/j.1365-2958.1994.tb01320.x; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P5584, DOI 10.1021/bi00475a024; DAY CL, 1992, J BIOL CHEM, V267, P13857; FINKELSTEIN RA, 1983, REV INFECT DIS, V5, pS759; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P1654, DOI 10.1021/bi00458a043; GERLACH GF, 1992, INFECT IMMUN, V60, P3253, DOI 10.1128/IAI.60.8.3253-3261.1992; GRAYOWEN SD, 1995, INFECT IMMUN, V63, P1201, DOI 10.1128/IAI.63.4.1201-1210.1995; GRAYOWEN SD, 1993, MICROB PATHOGENESIS, V14, P389, DOI 10.1006/mpat.1993.1038; HERSHBERGER CL, 1991, ANN NY ACAD SCI, V646, P140; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUTCHENS TW, 1991, P NATL ACAD SCI USA, V88, P2994, DOI 10.1073/pnas.88.8.2994; IKEDA RA, 1992, GENE, V117, P265, DOI 10.1016/0378-1119(92)90737-A; IRWIN SW, 1993, MOL MICROBIOL, V8, P1125, DOI 10.1111/j.1365-2958.1993.tb01657.x; KIRBY SD, 1995, HAEMOPHILUS, ACTINOBACILLUS, AND PASTEURELLA, P115; LEGRAIN M, 1993, GENE, V130, P73, DOI 10.1016/0378-1119(93)90348-7; METZBOUTIGUE MH, 1984, EUR J BIOCHEM, V145, P659, DOI 10.1111/j.1432-1033.1984.tb08607.x; PADDA JS, 1990, INFECT IMMUN, V58, P2972, DOI 10.1128/IAI.58.9.2972-2976.1990; SCHRYVERS AB, 1990, CAN J MICROBIOL, V36, P145, DOI 10.1139/m90-026; SCHRYVERS AB, 1988, MOL MICROBIOL, V2, P281, DOI 10.1111/j.1365-2958.1988.tb00029.x; SHARMA ND, 1994, BBA-PROTEIN STRUCT M, V1206, P286, DOI 10.1016/0167-4838(94)90220-8; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STOWELL KM, 1991, BIOCHEM J, V276, P349, DOI 10.1042/bj2760349; WARD PP, 1992, GENE, V122, P219, DOI 10.1016/0378-1119(92)90054-S; WEINBERG ED, 1995, CURR OPIN INFECT DIS, V8, P164, DOI 10.1097/00001432-199506000-00004; WILLIAMS PH, 1980, INFECT IMMUN, V29, P411; YEH JC, 1993, BIOCHEMISTRY-US, V32, P11087, DOI 10.1021/bi00092a019; YU RH, 1994, CAN J MICROBIOL, V40, P532, DOI 10.1139/m94-086	35	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1166	1173		10.1074/jbc.271.2.1166	http://dx.doi.org/10.1074/jbc.271.2.1166			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557646	hybrid			2022-12-25	WOS:A1996TP88900083
J	Llorca, O; Carrascosa, JL; Valpuesta, JM				Llorca, O; Carrascosa, JL; Valpuesta, JM			Biochemical characterization of symmetric GroEL-GroES complexes - Evidence for a role in protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CENTRAL CAVITY; CHAPERONIN	When chaperonins GroEL and GroES are incubated under functional conditions in the presence of ATP (5 mM) and K+ (150 mM), GroEL-GroES complexes appear in the incubation mixture, that are either asymmetric (1:1 GroEL:GroES oligomer ratio) or symmetric (1:2 GroEL:GroES oligomer ratio). The percentage of symmetric complexes present is directly related to the [ATP]/[ADP] ratio and to the K+ concentration. Kinetic analysis shows that there is a cycle of formation and disappearance of symmetric complexes. A correlation between the presence of symmetric complexes in the incubation mixture and its rhodanese folding activity suggests some active role of these complexes in the protein folding process. Accordingly, under functional conditions, symmetric complexes are found to contain denatured rhodanese. These data suggest that binding of substrate inside the GroEL cavity takes place before the symmetric complex is formed.	UNIV AUTONOMA MADRID,CSIC,CTR NACL BIOTECNOL,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Valpuesta, Jose M/AAA-6002-2019; Llorca, Oscar/P-2784-2019; Valpuesta, José M/T-1977-2017; Llorca, Oscar/K-1144-2014	Llorca, Oscar/0000-0001-5705-0699; Valpuesta, José M/0000-0001-7468-8053; Llorca, Oscar/0000-0001-5705-0699				AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ENGEL A, 1995, SCIENCE, V269, P832, DOI 10.1126/science.7638600; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GUPTA RS, 1995, MOL MICROBIOL, V15, P1, DOI 10.1111/j.1365-2958.1995.tb02216.x; HARRIS JR, 1994, J STRUCT BIOL, V112, P216, DOI 10.1006/jsbi.1994.1022; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HUNTER WM, 1978, HDB EXPT IMMUNOLOGY, P608; INGRAHAM JL, 1987, ESCHERICHIA COLI SAL, V2, P1548; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P372; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; SCHMIDT M, 1994, SCIENCE, V265, P656, DOI 10.1126/science.7913554; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9	24	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					68	76		10.1074/jbc.271.1.68	http://dx.doi.org/10.1074/jbc.271.1.68			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550627	hybrid			2022-12-25	WOS:A1996TP36100012
J	Lu, XJ; Rahman, S; Kakkar, VV; Authi, KS				Lu, XJ; Rahman, S; Kakkar, VV; Authi, KS			Substitutions of proline 42 to alanine and methionine 46 to asparagine around the RGD domain of the neurotoxin dendroaspin alter its preferential antagonism to that resembling the disintegrin elegantin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; PLATELET-AGGREGATION INHIBITOR; SECONDARY STRUCTURE; VIPER VENOMS; GPIIB-IIIA; ECHISTATIN; FIBRONECTIN; ADHESION; BINDING; KISTRIN	Previous studies have shown that the neurotoxin dendroaspin and the disintegrin kistrin, which show little overall sequence homology but similar residues around RGD (PRGDMP), preferentially inhibited platelet adhesion to fibrinogen, In contrast, the elegantin which has different amino acids around RGD (ARGDNP) preferentially inhibited platelet adhesion to fibronectin, To investigate further the role of amino acids around RGD in disintegrins, we have constructed the genes of a wild-type and of two mutant dendroaspins with substitutions around the RGD, namely [Asn(46)]- and [Ala(42),Asn(46)]dendroaspins. Proteins were expressed in Escherichia coli as glutathione S-transferase fusion recombinants and purified to homogeneity by affinity chromatography and reversed phase high performance liquid chromatography, Platelet aggregation studies revealed that wild-type dendroaspin showed an IC50 value similar to that of native dendroaspin, with [Ala(42),Asn(46)]dendroaspin showing an IC50 value similar to that of elegantin, Interestingly, in platelet adhesion assays, the mutants showed a progressive shift in inhibitory preference, in particular, [Ala(42),Asn(46)]dendroaspin showed nearly identical behavior as elegantin when fibronectin was the immobilized ligand (IC50 = 0.33 mu M and 0.6 mu M, respectively, compared with 20 mu M for native dendroaspin), Native and recombinant wild-type dendroaspin bound to a single class of binding site exhibiting a K-d = 67 nM; [Asn(46)]- and [Ala(42),Asn(46)]dendroaspins, however, both produced biphasic isotherms with K-d values = 87 nM and 361 nM for [Asn(46)]dendroaspin and 33 nM and 371 nM for [Ala(42),Asn(46)]dendroaspin, which are close to those of elegantin (K-d values = 18 nM and 179 nM). These studies prove that the amino acids flanking RGD provide an extended locus that regulate the affinity and selectivity of RGD protein dendroaspin.			Lu, XJ (corresponding author), THROMBOSIS RES INST,PLATELET SECT,MANRESA RD,LONDON SW3 6LR,ENGLAND.							ADLER M, 1993, BIOCHEMISTRY-US, V32, P282, DOI 10.1021/bi00052a036; ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ADLER M, 1992, BIOCHEMISTRY-US, V31, P1031, DOI 10.1021/bi00119a011; COOKE RM, 1992, PROTEIN ENG, V5, P473, DOI 10.1093/protein/5.6.473; COOKE RM, 1991, EUR J BIOCHEM, V202, P323, DOI 10.1111/j.1432-1033.1991.tb16379.x; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GROSJEAN H, 1982, GENE, V18, P199, DOI 10.1016/0378-1119(82)90157-3; HORNBY EJ, 1991, BRIT J HAEMATOL, V79, P277, DOI 10.1111/j.1365-2141.1991.tb04533.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JASEJA M, 1994, EUR J BIOCHEM, V226, P861, DOI 10.1111/j.1432-1033.1994.00861.x; JASEJA M, 1993, EUR J BIOCHEM, V218, P853, DOI 10.1111/j.1432-1033.1993.tb18441.x; KARCZEWSKI J, 1989, J BIOL CHEM, V264, P21322; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; KNAPP A, 1992, J BIOL CHEM, V267, P24230; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; LU XJ, 1994, BIOCHEM J, V304, P929, DOI 10.1042/bj3040929; LU XJ, 1993, BIOCHEM J, V296, P21, DOI 10.1042/bj2960021; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; NACHMAN RL, 1982, J CLIN INVEST, V69, P263, DOI 10.1172/JCI110448; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1987, BLOOD, V70, P110; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SAUDEK V, 1991, EUR J BIOCHEM, V202, P329, DOI 10.1111/j.1432-1033.1991.tb16380.x; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMYTH SS, 1993, BLOOD, V81, P2827; SUTCLIFFE MJ, 1994, NAT STRUCT BIOL, V1, P802, DOI 10.1038/nsb1194-802; UGAROVA T, 1995, THROMB HAEMOSTASIS, V74, P253; WILLIAMS JA, 1992, BIOCHEM SOC T, V21, pS73; WRIGHT PS, 1993, BIOCHEM J, V293, P263, DOI 10.1042/bj2930263	40	41	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					289	294		10.1074/jbc.271.1.289	http://dx.doi.org/10.1074/jbc.271.1.289			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550575	hybrid			2022-12-25	WOS:A1996TP36100045
J	Mangel, WF; Toledo, DL; Brown, MT; Martin, JH; McGrath, WJ				Mangel, WF; Toledo, DL; Brown, MT; Martin, JH; McGrath, WJ			Characterization of three components of human adenovirus proteinase activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASES; TYPE-2 PROTEINASE; SERINE PROTEASES; SUBSTRATE; PEPTIDE; EXPRESSION; PURIFICATION; POLYPEPTIDE; SPECIFICITY; ACTIVATION	Human adenovirus contains a virion-associated proteinase activity essential for the development of infectious virus. Maximal proteinase activity in vitro had been shown to require three viral components: the L3 23-kDa protein, an 11-amino acid cofactor (pVIc), and the viral DNA. Here, we present a quantitative purification procedure for a recombinant L3 23-kDa protein (recombinant endoproteinase (rEP)) expressed in Escherichia coli and the procedure that led to the purification and identification of pVIc as a cofactor, The cofactors stimulate proteinase activity not by decreasing K-m, which changes by no more than 2-fold, but by increasing k(cat). rEP alone had a small amount of activity, the k(cat) of which increased 355-fold with pVIc and 6072-fold with adenovirus serotype 2 (Ad2) DNA as well, Curves of V-max of rEP . pVIc complexes with the substrate (Leu-Arg-Gly-Gly-NH)(2)-rhodamine as a function of pH in the absence and presence of Ad2 DNA indicate that the pK(alpha) values of amino acids that affect catalysis are quite different from those that affect catalysis by the cysteine proteinase papain, The pK(alpha), values in the absence of Ad2 DNA are 5.2, 6.4, 6.9, 7.5, and 9.4, and those in its presence are 5.2, 6.5, 7.4, and 8.8.			Mangel, WF (corresponding author), BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA.			McGrath, William/0000-0002-9375-624X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI026049] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26049] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON CW, 1993, PROTEIN EXPRES PURIF, V4, P8, DOI 10.1006/prep.1993.1002; ANDERSON CW, 1990, VIROLOGY, V177, P259, DOI 10.1016/0042-6822(90)90479-B; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BHATTI AR, 1979, J BIOL CHEM, V254, P2265; BHATTI AR, 1979, VIROLOGY, V96, P478; BRAUNBRETON C, 1988, NATURE, V332, P457, DOI 10.1038/332457a0; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; GRIERSON AW, 1994, J GEN VIROL, V75, P2761, DOI 10.1099/0022-1317-75-10-2761; HANNAN C, 1983, INTERVIROLOGY, V19, P213, DOI 10.1159/000149363; HANSEN J, 1988, EMBO J, V7, P1785, DOI 10.1002/j.1460-2075.1988.tb03009.x; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; KOTLER M, 1989, J BIOL CHEM, V264, P3428; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LIANG YK, 1983, J MOL BIOL, V167, P217, DOI 10.1016/S0022-2836(83)80044-8; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; MANGEL WF, 1993, NATURE, V361, P274, DOI 10.1038/361274a0; MANGEL WF, 1974, ARCH BIOCHEM BIOPHYS, V163, P172, DOI 10.1016/0003-9861(74)90466-4; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MIRZA A, 1980, INTERVIROLOGY, V13, P307, DOI 10.1159/000149139; PELTZ SW, 1982, BIOCHEMISTRY-US, V21, P2798, DOI 10.1021/bi00540a035; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; RANCOURT C, 1994, P NATL ACAD SCI USA, V91, P844, DOI 10.1073/pnas.91.3.844; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Roberts R., 1686, ADENOVIRUS DNA VIRAL, P1; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIHANYI K, 1993, J BIOL CHEM, V268, P1780; TREMBLAY ML, 1983, BIOCHIM BIOPHYS ACTA, V743, P239, DOI 10.1016/0167-4838(83)90220-0; WEBER IT, 1989, SCIENCE, V243, P928, DOI 10.1126/science.2537531; WEBER J, 1976, J VIROL, V17, P462, DOI 10.1128/JVI.17.2.462-471.1976; WEBSTER A, 1989, J GEN VIROL, V70, P3225, DOI 10.1099/0022-1317-70-12-3225; WEBSTER A, 1994, J VIROL, V68, P7292, DOI 10.1128/JVI.68.11.7292-7300.1994; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WEBSTER A, 1989, J GEN VIROL, V70, P3215, DOI 10.1099/0022-1317-70-12-3215; WOO KM, 1989, J BIOL CHEM, V264, P2088; [No title captured]	37	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					536	543		10.1074/jbc.271.1.536	http://dx.doi.org/10.1074/jbc.271.1.536			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550615	hybrid			2022-12-25	WOS:A1996TP36100081
J	Nguyen, T; Erb, L; Weisman, GA; Marchese, A; Heng, HHQ; Garrad, RC; George, SR; Turner, JT; ODowd, BF				Nguyen, T; Erb, L; Weisman, GA; Marchese, A; Heng, HHQ; Garrad, RC; George, SR; Turner, JT; ODowd, BF			Cloning, expression, and chromosomal localization of the human uridine nucleotide receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSITU HYBRIDIZATION; CELL-LINE	Extracellular ATP and ADP mediate diverse physiological responses in mammalian cells, in part through the activation of G protein-coupled P-2 purinoceptors. The cloning and expression of cDNAs encoding several P-2 purinoceptor subtypes have enabled rapid advances in our understanding of the structural and functional properties of these receptors. The current report de scribes the isolation of a gene from a human genomic library that encodes a protein with the greatest similarity to the human P-2U purinoceptor, a subtype that is distinguished by its ability to be activated by uridine nucleotides as well as adenine nucleotides. When expressed in a mammalian cell line, this novel receptor is activated specifically by UTP and UDP but not by ATP and ADP. Activation of this uridine nucleotide receptor resulted in increased inositol phosphate formation and calcium mobilization. Fluorescence in situ hybridization revealed that the gene encoding the uridine nucleotide receptor is located in region q13 of the X chromosome. Dendrogram analysis of the G protein-coupled P-2 purinoceptors and the uridine nucleotide receptor indicates that these receptors belong to a family that may be more aptly named nucleotide receptors.	UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON M5S 1A8,CANADA; ADDICT RES FDN,TORONTO,ON M5S 2S1,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A8,CANADA; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212; UNIV MISSOURI,DEPT PHARMACOL,COLUMBIA,MO 65212; SEEDNA BIOTECH INC,DOWNSVIEW,ON M3J 1P3,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia			George, Susan/W-7494-2019; George, Susan R/P-9669-2018	Erb, Laurie/0000-0001-6372-3378	NIDA NIH HHS [DA07223] Funding Source: Medline; NIDCR NIH HHS [DE07389] Funding Source: Medline; NIGMS NIH HHS [GM36887] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE007389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R23DE007389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007223] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BOARDER MR, 1995, TRENDS PHARMACOL SCI, V16, P133, DOI 10.1016/S0165-6147(00)89001-X; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GACHET C, 1991, NOUV REV FR HEMATOL, V33, P347; GONNET GH, 1994, COMPUTATIONAL METHODS IN GENOME RESEARCH, P153; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, METHODS MOL BIOL IN; LAZAROWSKI ER, 1994, J BIOL CHEM, V269, P11830; MARCHESE A, 1994, GENOMICS, V23, P609, DOI 10.1006/geno.1994.1549; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; ODOWD BF, 1995, GENOMICS, V28, P84, DOI 10.1006/geno.1995.1109; TURNER JT, 1986, PEPTIDES, V7, P849, DOI 10.1016/0196-9781(86)90105-1; YU HX, 1991, J PHARMACOL EXP THER, V259, P1344	14	164	166	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30845	30848		10.1074/jbc.270.52.30845	http://dx.doi.org/10.1074/jbc.270.52.30845			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537335	hybrid			2022-12-25	WOS:A1995TN44400003
J	Olofsson, A; Ichijo, H; Moren, A; tenDijke, P; Miyazono, K; Heldin, CH				Olofsson, A; Ichijo, H; Moren, A; tenDijke, P; Miyazono, K; Heldin, CH			Efficient association of an amino-terminally extended form of human latent transforming growth factor-beta binding protein with the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; HUMAN-PLATELETS; MARFAN-SYNDROME; CELL-LINE; EXPRESSION; FACTOR-BETA-1; PURIFICATION; SECRETION; SEQUENCE; CLONING	Latent transforming growth factor-beta (TGF-beta) binding protein-1 (LTBP-1) is a component of the high molecular weight latent TGF-beta complex found in various cells, including human platelets, LTBP-1 is observed as different molecular sizes in different cell types, probably due to proteolytic processing and alternative splicing. We here report a novel form of human LTBP-1, which is longer in its NH2-terminal part (LTBP-1L), Northern hybridization analysis revealed that the LTBP-1L is derived from a 7.0 kilobase mRNA, whereas the originally reported shorter form (LTBP-1S) is derived from a 5.2-kilobase mRNA, Transfection of cDNA for LTBP-1L and -1S in COS cells revealed that LTBP-1L bound more efficiently to the extracellular matrix than did LTBP-1S. These results suggest that the different splice forms of LTBP-1 mediate different localization patterns of the latent TGF-beta complexes in vivo.	BIOMED CTR,LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research			Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Ichijo, Hidenori/0000-0002-5005-6438				BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; DALLAS SL, 1994, J BIOL CHEM, V269, P6815; DAVIS C G, 1990, New Biologist, V2, P410; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V4, P11; KANAZAKI T, 1990, CELL, V61, P1051; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MIYAZONO K, 1993, GROWTH FACTORS, V8, P11, DOI 10.3109/08977199309029130; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOREN A, 1994, J BIOL CHEM, V269, P32469; OKADA F, 1989, J BIOCHEM-TOKYO, V106, P304, DOI 10.1093/oxfordjournals.jbchem.a122849; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; PONCZ M, 1987, BLOOD, V69, P219; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TRUETT MA, 1985, DNA-J MOLEC CELL BIO, V4, P333, DOI 10.1089/dna.1985.4.333; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	26	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31294	31297		10.1074/jbc.270.52.31294	http://dx.doi.org/10.1074/jbc.270.52.31294			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537398	hybrid			2022-12-25	WOS:A1995TN44400065
J	WolffLong, VL; Tao, T; Lowey, S				WolffLong, VL; Tao, T; Lowey, S			Proximity relationships between engineered cysteine residues in chicken skeletal myosin regulatory light chain - A resonance energy transfer study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; 3-DIMENSIONAL STRUCTURE; PEPTIDE COMPLEX; CALMODULIN; ACTIN; SUBFRAGMENT-1; MUTANTS; DISTANCES; PROBES; SITES	Resonance energy transfer was used to measure the distances between pairs of cysteines, Cys(2) and Cys(155) and Cys(73) and Cys(155), in recombinant chicken skeletal myosin regulatory light chains in the free and bound states. The fluorescent and nonfluorescent probes N-iodoacetyl-N'-(5-sulfo-1-naphthyl)ethylene and N-(4-dimethylamino-3,5-dinitrophenyl)maleimide were used as the donor and the acceptor, respectively. The distance between Cys(2) and Cys(155) was measured to be 35 and 30 Angstrom in the absence and presence of myosin heavy chain, respectively, suggesting a slightly more compact structure for the light chain in the bound state. The distance between Cys(73) and Cys(155) measured in a similar manner was 31 and 30 Angstrom in the free and bound states, respectively; this latter value is in good agreement with that derived from crystallographic structures. For heavy chain-bound light chains, no measurable distance changes were detected with the binding of ATP or actin. These results show that no gross structural changes oc cur within the regulatory light chain during the con traction cycle, but that resonance energy transfer between other sites could be used to monitor potential changes in the myosin head upon the binding of nucleotides and actin.	BOSTON BIOMED RES INST,MUSCLE RES GRP,BOSTON,MA 02114; BRANDEIS UNIV,DEPT BIOCHEM,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115	Boston Biomedical Research Institute; Brandeis University; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR017350, R37AR017350, R01AR021673, R37AR021673] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR17350, AR21673] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXIS MN, 1978, BIOCHEMISTRY-US, V17, P2319, DOI 10.1021/bi00605a010; ALLEN TS, 1994, BIOPHYS J, V66, pA234; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BOEY W, 1994, EUR J BIOCHEM, V219, P603, DOI 10.1111/j.1432-1033.1994.tb19976.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANTLER PD, 1986, J MOL BIOL, V192, P87, DOI 10.1016/0022-2836(86)90466-3; DALBEY RE, 1983, BIOCHEMISTRY-US, V22, P4696, DOI 10.1021/bi00289a014; DOSREMEDIOS CG, 1987, J MUSCLE RES CELL M, V8, P97, DOI 10.1007/BF01753986; GOLD AH, 1964, BIOCHEMISTRY-US, V3, P778, DOI 10.1021/bi00894a008; HAMBLY B, 1991, BIOPHYS J, V59, P127, DOI 10.1016/S0006-3495(91)82205-6; HUBER PAJ, 1989, BIOCHEMISTRY-US, V28, P9116, DOI 10.1021/bi00449a024; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ISENBERG I, 1969, BIOPHYS J, V9, P1337, DOI 10.1016/S0006-3495(69)86456-8; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KRETSINGER RH, 1986, J INORG BIOCHEM, V28, P289, DOI 10.1016/0162-0134(86)80093-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSH DJ, 1980, BIOCHEMISTRY-US, V19, P774, DOI 10.1021/bi00545a025; MARSH DJ, 1982, BIOCHEMISTRY-US, V21, P1925, DOI 10.1021/bi00537a035; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MIKI M, 1992, J MUSCLE RES CELL M, V13, P132, DOI 10.1007/BF01874150; MORITA JI, 1991, BIOCHEMISTRY-US, V30, P9539, DOI 10.1021/bi00103a022; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROOT DD, 1992, BIOPHYS J, V63, P730, DOI 10.1016/S0006-3495(92)81646-6; SARASWAT LD, 1992, J BIOL CHEM, V267, P21112; SARASWAT LD, 1991, J BIOL CHEM, V266, P19777; STAFFORD WF, 1978, BIOCHEMISTRY-US, V17, P607, DOI 10.1021/bi00597a008; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TAO T, 1978, FEBS LETT, V93, P146, DOI 10.1016/0014-5793(78)80824-2; TAO T, 1979, BIOCHEMISTRY-US, V18, P2759, DOI 10.1021/bi00580a011; TORGERSON PM, 1984, P NATL ACAD SCI-BIOL, V81, P3723, DOI 10.1073/pnas.81.12.3723; WARSHAW DM, 1990, J CELL BIOL, V111, P453, DOI 10.1083/jcb.111.2.453; WOLFFLONG VL, 1993, J BIOL CHEM, V268, P23162; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	41	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31111	31118		10.1074/jbc.270.52.31111	http://dx.doi.org/10.1074/jbc.270.52.31111			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537372	hybrid			2022-12-25	WOS:A1995TN44400040
J	Woscholski, R; Waterfield, MD; Parker, PJ				Woscholski, R; Waterfield, MD; Parker, PJ			Purification and biochemical characterization of a mammalian phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOINOSITIDE 3-KINASE; SIGNAL TRANSDUCTION; HUMAN NEUTROPHIL; PHOSPHOLIPASE-C; ACTIVATION; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; EFFECTOR; BRAIN; BIND	Characterization of the enzymes involved in metabolism of 3-phosphorylated inositol lipids and their subcellular localization revealed that in vitro a 5-phosphatase activity was responsible for the degradation of phosphatidylinositol 3,4,5-trisphosphate, whereas a 3-phosphatase activity hydrolyzed phosphatidylinositol 3-phosphate and/or phosphatidylinositol 3,4-bisphosphate. All these activities were localized in the cytosol. No phospholipase activities were detected. The cytosolic phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase activity was purified to near homogeneity using ion exchange, affinity, and size exclusion chromatography. Characterization of the purified phosphatase revealed that it is a magnesium-dependent 5-phosphatase that is able to hydrolyze phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate. The enzyme is only partially inhibited by neomycin and vanadate but is strongly inhibited by phosphatidylinositol 4,5-bisphosphate and to a slightly lesser extent by phosphatidylinositol 4-phosphate.	IMPERIAL CANC RES FUND,PROT PHOSPHORYLAT LAB,LONDON WC2A 3PX,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; University College London			Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933				BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237, DOI 10.1111/j.1476-5381.1991.tb12330.x; CALDWELL KK, 1991, J BIOL CHEM, V266, P18378; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLAGUE MJ, 1995, FEBS LETT, V367, P272, DOI 10.1016/0014-5793(95)00576-U; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HOPE HMR, 1994, J BIOL CHEM, V269, P23648; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KODAKI T, 1994, EUR J BIOCHEM, V219, P775, DOI 10.1111/j.1432-1033.1994.tb18557.x; KODAKI T, 1994, CURR BIOL, V4, P789; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; KOZIKOWSKI AP, 1993, J MED CHEM, V36, P3035, DOI 10.1021/jm00072a027; LIPS DL, 1989, J BIOL CHEM, V264, P8759; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; PALMER FBS, 1994, J BIOL CHEM, V269, P3403; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PANAYOTOU G, 1992, EMBO J, V11, P4261, DOI 10.1002/j.1460-2075.1992.tb05524.x; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; SINGH SS, 1993, BIOCHEM BIOPH RES CO, V195, P104, DOI 10.1006/bbrc.1993.2016; SPATH M, 1991, CELL SIGNAL, V3, P305, DOI 10.1016/0898-6568(91)90059-4; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; WOSCHOLSKI R, 1994, J BIOL CHEM, V269, P25067	43	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31001	31007		10.1074/jbc.270.52.31001	http://dx.doi.org/10.1074/jbc.270.52.31001			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537357	hybrid			2022-12-25	WOS:A1995TN44400025
J	Apfel, CM; Kamber, M; Klaus, M; Mohr, P; Keidel, S; LeMotte, PK				Apfel, CM; Kamber, M; Klaus, M; Mohr, P; Keidel, S; LeMotte, PK			Enhancement of HL-60 differentiation by a new class of retinoids with selective activity on retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID RECEPTOR; THYROID-HORMONE; SIGNALING PATHWAYS; NUCLEAR RECEPTORS; MESSENGER-RNA; VITAMIN-D; RXR-BETA; ALPHA; IDENTIFICATION; EXPRESSION	Cellular responsiveness to retinoic acid and its metabolites is conferred through two distinct families of receptors: the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). Herein, we report on the identification and characterization of several conformationally restricted retinoids, which selectively bind and activate RX receptors. Under the influence of retinoids, HL-60 myelocytic leukemia cells differentiate into granulocytes. This effect is mediated by RAR alpha, as has been demonstrated through the use of a selective RAR alpha antagonist (Apfel, C., Bauer, F., Crettaz, M., Forni, L., Kamber, M., Kaufmann, F., LeMotte, P., Pirson, W., and Klaus, M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7129-7133). Here, we show that conformationally restricted RXR-specific retinoids, at doses that are per se inactive, are able to potentiate by up to one order of magnitude the pro-differentiating effects of all-trans retinoic acid and an RAR alpha-selective synthetic retinoid. We also present evidence that these RXR-selective ligands are able to bind to a DNA RXR . RAR heterodimer complex. This finding demonstrates that agonists for RARs and RXRs can synergistically promote HL-60 differentiation, which could be mediated through a heterodimer of these receptors.			Apfel, CM (corresponding author), F HOFFMANN LA ROCHE & CO LTD,DEPT DERMATOL,PRPD 60-409,CH-4002 BASEL,SWITZERLAND.							APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; APFEL C, 1992, RETINOIDS NORMAL DEV, P65; BEARD RL, 1994, BIOORG MED CHEM LETT, V4, P1447, DOI 10.1016/S0960-894X(01)80511-4; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V343, P111; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LARGMAN C, 1989, BLOOD, V74, P99; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1995, CANCER RES, V55, P232; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PICK E, 1981, J RETICULOENDOTH SOC, V30, P581; Sambrook J, 1989, MOL CLONING LABORATO; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	41	84	88	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30765	30772		10.1074/jbc.270.51.30765	http://dx.doi.org/10.1074/jbc.270.51.30765			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530518	hybrid			2022-12-25	WOS:A1995TL67500083
J	Prasad, K; Barouch, W; Martin, BM; Greene, LE; Eisenberg, E				Prasad, K; Barouch, W; Martin, BM; Greene, LE; Eisenberg, E			Purification of a new clathrin assembly protein from bovine brain coated vesicles and its identification as myelin basic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGODENDROGLIAL MEMBRANE SHEETS; UNCOATING ATPASE; ORGANIZATION; POLYPEPTIDES; CYTOSKELETON	The multimeric clathrin assembly proteins AP-1 and AP-2 with molecular masses of similar to 270 kDa and the monomeric clathrin assembly proteins AP(180) and auxilin with molecular masses of similar to 90 kDa catalyze the assembly of clathrin into artificial clathrin baskets under physiological conditions. We have now identified a much smaller similar to 20-kDa clathrin assembly protein in 0.5 M Tris, pH 7.0, extracts of bovine brain coated vesicles and purified it to near homogeneity. A polyclonal antibody against this protein did not cross-react with any of the other assembly proteins, and sequencing data suggest that this new protein is similar or identical to myelin basic protein (MBP). At a molar ratio of 3 molecules per clathrin triskelion, MBP catalyzes polymerization of clathrin into artificial baskets that appear structurally similar to the baskets assembled by the other assembly proteins. In addition, like the other baskets, the clathrin-MBP baskets are uncoated by hsp70. MBP represents a significant fraction of the total assembly protein activity present ent in 0.5 M Tris, pH 7.0, extracts of coated vesicles. It is not clear if it acts as an assembly protein in vivo, but because it is well characterized and easily available, MBP will be a useful protein to investigate the mechanism of clathrin assembly and disassembly in vitro.	NHLBI,CELL BIOL LAB,BETHESDA,MD 20892; NIMH,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BAROUCH W, 1994, J BIOL CHEM, V269, P28563; BEARD JL, 1993, NUTR REV, V51, P157, DOI 10.1111/j.1753-4887.1993.tb03096.x; BROSTOFF SW, 1974, J BIOL CHEM, V2, P559; CHAPPELL TG, 1986, CELL, V45, P3, DOI 10.1016/0092-8674(86)90532-5; DYER CA, 1989, J NEUROSCI RES, V24, P212, DOI 10.1002/jnr.490240212; DYER CA, 1989, J NEUROSCI RES, V24, P201, DOI 10.1002/jnr.490240211; EYLAR EH, 1971, J BIOL CHEM, V246, P5770; GREENE LE, 1990, J BIOL CHEM, V265, P6682; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1987, J CELL BIOL, V104, P887; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; LINDNER R, 1992, J BIOL CHEM, V267, P16567; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MARTENSON RE, 1992, MYELIN BIOL CHEM; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCKHANN GM, 1982, ANNU REV NEUROSCI, V5, P219, DOI 10.1146/annurev.ne.05.030182.001251; MURPHY JE, 1991, J BIOL CHEM, V266, P4401; NANDI PK, 1981, BIOCHEMISTRY-US, V20, P6706, DOI 10.1021/bi00526a028; PEARSE BMF, 1987, EMBO J, V6, P2507, DOI 10.1002/j.1460-2075.1987.tb02536.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; PIROLLET F, 1992, BIOCHEMISTRY-US, V31, P8849, DOI 10.1021/bi00152a022; PRASAD K, 1993, J BIOL CHEM, V268, P23758; PRASAD K, 1991, BIOCHEMISTRY-US, V30, P5590, DOI 10.1021/bi00236a036; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SIMS TJ, 1988, DEV BRAIN RES, V40, P223, DOI 10.1016/0165-3806(88)90134-4; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; UNGEWICKELL E, 1995, IN PRESS NATURE; UNGEWICKELL E, 1981, NATURE, V351, P411; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	36	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30551	30556		10.1074/jbc.270.51.30551	http://dx.doi.org/10.1074/jbc.270.51.30551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530487	hybrid			2022-12-25	WOS:A1995TL67500052
J	Wang, JH; Campos, B; Jamieson, GA; Kaetzel, MA; Dedman, JR				Wang, JH; Campos, B; Jamieson, GA; Kaetzel, MA; Dedman, JR			Functional elimination of calmodulin within the nucleus by targeted expression of an inhibitor peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIGHT CHAIN KINASE; PROTEIN-KINASE; BINDING DOMAIN; IDENTIFICATION; MUTATIONS; CELLS; GENE	Genetic manipulation has proven valuable in identifying the role of specific genes in cellular function. Genomic disruption of genes that are expressed during embryonic development or in multiple tissue types, however, complicates phenotypic analysis. We demonstrate that targeted expression of an inhibitor peptide derived from myosin light chain kinase can neutralize the function of calmodulin. We have shown that elimination of the nuclear function of Ca2+-calmodulin causes disruption of the nuclear structure. Targeted expression of this calmodulin inhibitor gene in the lung epithelium of transgenic mice leads to cellular death and dysfunctional lung development. This approach is a strategy to modify the activity of a targeted protein within a specific organelle in order to evaluate its role in cellular and tissue function.	UNIV CINCINNATI,DEPT CELLULAR & MOLEC PHYSIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041740, R01DK046433] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41740, DK46433] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; DEDMAN JR, 1993, J BIOL CHEM, V268, P23025; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JANIN J, 1990, J BIOL CHEM, V265, P16027; KAETZEL MA, 1982, J CELL BIOL, V95, pA24; KAETZEL MA, 1987, J BIOL CHEM, V262, P1818; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LU KP, 1993, J CELL BIOL, V121, P621, DOI 10.1083/jcb.121.3.621; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Nghlem Paul, 1994, Nature (London), V371, P347; OHTA Y, 1990, P NATL ACAD SCI USA, V87, P5341, DOI 10.1073/pnas.87.14.5341; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SUN GH, 1992, J CELL BIOL, V119, P1625, DOI 10.1083/jcb.119.6.1625	31	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30245	30248		10.1074/jbc.270.51.30245	http://dx.doi.org/10.1074/jbc.270.51.30245			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530438	hybrid			2022-12-25	WOS:A1995TL67500003
J	RiveroLezcano, OM; Marcilla, A; Robbins, KC				RiveroLezcano, OM; Marcilla, A; Robbins, KC			Mutations in the non-catalytic domains of Fyn and Fgr tyrosine kinases reveal differences in mechanisms of their regulation	ONCOGENE			English	Article						Fyn; Fgr; tyrosine kinase; mutation; SH2 and SH3 domains	PROTEIN-KINASES; SH2 DOMAIN; C-SRC; GENE; PROTOONCOGENE; ACTIVATION; P60C-SRC; BINDING	Non-catalytic domains of tyrosine kinases from the Src family are believed to be regulated intra- and intermolecularly through protein-protein interactions. We have deleted the SH2 and SH3 domains from Fyn and Fgr and have generated two point mutations in residues completely conserved in all members of the Src family. The dramatically different biological effects of these mutations suggest that non-catalytic domains regulate Src family kinase activities through distinctly different mechanisms.	NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			marcilla, antonio/F-9996-2010; Rivero-Lezcano, Octavio Miguel/J-9089-2015	marcilla, antonio/0000-0003-0004-0531; Rivero-Lezcano, Octavio Miguel/0000-0002-8793-0731				ABRAMS CS, 1995, J BIOL CHEM, V270, P333, DOI 10.1074/jbc.270.1.333; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BOEUF H, 1995, ONCOGENE, V10, P433; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHANG CM, 1995, P NATL ACAD SCI USA, V92, P3928, DOI 10.1073/pnas.92.9.3928; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1984, J BIOL CHEM, V259, P7835; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; RIVEROLEZCANO OM, 1994, FEBS LETT, V338, P183, DOI 10.1016/0014-5793(94)80361-7; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; SARTOR O, 1992, J BIOL CHEM, V267, P3460; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; VEILLETTE A, 1992, ONCOGENE, V7, P971; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	20	5	5	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2675	2679						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545125				2022-12-25	WOS:A1995TP18800024
J	Stadler, M; ChelbiAlix, MK; Koken, MHM; Venturini, L; Lee, C; Saib, A; Quignon, F; Pelicano, L; Guillemin, MC; Schindler, C; deThe, H				Stadler, M; ChelbiAlix, MK; Koken, MHM; Venturini, L; Lee, C; Saib, A; Quignon, F; Pelicano, L; Guillemin, MC; Schindler, C; deThe, H			Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element	ONCOGENE			English	Article						leukaemia; growth suppressor; promoter; STAT; cytokines	ACUTE PROMYELOCYTIC LEUKEMIA; PRIMARY BILIARY-CIRRHOSIS; DEPENDENT PROTEIN-KINASE; ZINC-FINGER; RAR-ALPHA; T(15-17) TRANSLOCATION; STIMULATED GENES; NUCLEAR-BODIES; EXPRESSION; CELLS	PML is a nuclear matrix protein with growth suppressing properties, whose expression is deregulated during oncogenesis. Moreover, in the t(15;17) translocation of acute promyelocytic leukaemia (APL), PML fusion to the retinoic acid receptor alpha (RAR alpha) is the likely molecular basis of leukaemogenesis. Here we show that interferons (IFNs) alpha, beta, and gamma upregulate PML mRNA expression. Analysis of 5' genomic sequences of the PML gene revealed an IFN-alpha/-beta stimulated response element (ISRE) and an IFN-gamma activation site (GAS) in the untranslated first exon. Binding of TFN signal transducers and activators of transcription (STATs) was demonstrated to be weak for the PML GAS, but strong for the PML ISRE which also seemed to contribute substantially to the IFN-gamma response. Thus, PML is a primary target gene of IFNs and would appear as a suitable candidate for mediating some of their antiproliferative effects. Abnormalities of PML structure, localisation or expression in human malignancy, constitute examples of how an IFN target gene may be altered in oncogenesis.	HOP ST LOUIS, CNRS, UPR A0043, F-75010 PARIS, FRANCE; COLUMBIA UNIV COLL PHYS & SURG, DIV MOLEC MED, NEW YORK, NY 10032 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Columbia University			koken, marcel/J-8154-2012; Quignon, Frédérique/P-4249-2017; koken, marcel/N-1349-2019	koken, marcel/0000-0002-0839-0125; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21006-19] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHELBIALIX MK, 1995, IN PRESS LEUKEMIA; DANIEL MT, 1993, BLOOD, V82, P1858; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GULDNER HH, 1992, J IMMUNOL, V149, P4067; HANASH SM, 1993, GENE CHROMOSOME CANC, V8, P34, DOI 10.1002/gcc.2870080107; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NIKOVITS W, 1990, MOL CELL BIOL, V10, P3468, DOI 10.1128/MCB.10.7.3468; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1988, NUCLEIC ACIDS RES, V16, P1371, DOI 10.1093/nar/16.4.1371; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; ROTHMAN P, 1994, IMMUNITY, V1, P457, DOI 10.1016/1074-7613(94)90088-4; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; STREHLOW I, 1993, J BIOL CHEM, V268, P16590; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TERRIS B, 1995, CANCER RES, V55, P1590; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WERNERT N, 1992, AM J PATHOL, V140, P119; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601	63	271	277	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2565	2573						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545113				2022-12-25	WOS:A1995TP18800012
J	FaberElman, A; Lavie, V; Schvartz, I; Shaltiel, S; Schwartz, M				FaberElman, A; Lavie, V; Schvartz, I; Shaltiel, S; Schwartz, M			Vitronectin overrides a negative effect of TNF-alpha on astrocyte migration	FASEB JOURNAL			English	Article						turner necrosis factor-alpha; nerve injury; wound healing	PLASMINOGEN-ACTIVATOR INHIBITOR-1; PROTEIN KINASE-A; EXTRACELLULAR-MATRIX; NEURITE OUTGROWTH; ENDOTHELIAL-CELLS; OPTIC NERVES; S-PROTEIN; REGENERATION; PLASMA; PHOSPHORYLATION	Morphogenesis and tissue repair require appropriate cross-talk between the cells and their surrounding milieu, which includes extracellular components and soluble factors, e.g., cytokines and growth factors. The present work deals with this communication needed for recovery after axotomy in the central nervous system (CNS). The failure of CNS axons to regenerate after axonal injury Iras been attributed, in part, to astrocyte failure to repopulate the injury site. The goal of this work was to provide an in vitro model to mimic the in vivo response of astrocytes to nerve injury and to find ways to modulate this response and create a milieu that favors astrocyte migration and repopulation of the injury site. In an astrocyte scratch wound model, we blocked astrocyte migration by tumor necrosis factor alpha (TNF-alpha). This effect could not be reversed by astrocyte migration-inducing factors such as transforming growth factor beta(1) (TGF-beta(1)) or by any of the tested extracellular matrix (ECM) components (laminin and fibronectin) except for vitronectin (Vn). Vn, added together with TNF-alpha, counteracted the TNF-alpha blockage and allowed a massive migration of astrocytes (not due to cell proliferation) beyond that allowed by Vn only. Heparan sulfate proteoglycans (HSPG) were shown to be involved in the migration. The results may be relevant to regeneration of CNS axons, and may also provide an example that an extracellular component (Vn) can overcome and neutralize a negative effect of a growth factor/cytokine (TNF-alpha) and can act in synergy with other features of this cytokine to promote a necessary function (e.g., cell migration) that is otherwise inhibited.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT REGULAT BIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								AKIYAMA H, 1991, J NEUROIMMUNOL, V32, P19, DOI 10.1016/0165-5728(91)90067-H; ALOISI F, 1992, J NEUROSCI RES, V32, P494, DOI 10.1002/jnr.490320405; BLAUGRUND E, 1993, J COMP NEUROL, V330, P105, DOI 10.1002/cne.903300109; BLAUGRUND E, 1992, EXP NEUROL, V118, P105, DOI 10.1016/0014-4886(92)90027-N; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CHAIN D, 1990, FEBS LETT, V269, P221, DOI 10.1016/0014-5793(90)81159-L; CHAIN D, 1991, BIOCHEM J, V274, P387, DOI 10.1042/bj2740387; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; COHEN I, 1993, J COMP NEUROL, V334, P431, DOI 10.1002/cne.903340308; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; FABERELMAN A, 1995, IN PRESS J NEUROCHEM; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GRABHAM PW, 1992, EXP CELL RES, V202, P337, DOI 10.1016/0014-4827(92)90083-K; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HOLMES R, 1967, J CELL BIOL, V32, P297, DOI 10.1083/jcb.32.2.297; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KORCGRODZICKI B, 1988, BIOCHEM BIOPH RES CO, V157, P1131; KORCGRODZICKI B, 1988, P NATL ACAD SCI USA, V85, P7541, DOI 10.1073/pnas.85.20.7541; KORCGRODZICKI B, 1990, ANAL BIOCHEM, V188, P288, DOI 10.1016/0003-2697(90)90608-C; KOST C, 1992, J BIOL CHEM, V267, P12098; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MIMURO J, 1989, J BIOL CHEM, V264, P936; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117; PEPPER MS, 1987, J CELL BIOL, V105, P2535, DOI 10.1083/jcb.105.6.2535; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1990, CELL DIFFER DEV, V32, P287, DOI 10.1016/0922-3371(90)90041-T; SELDEN SC, 1981, J CELL PHYSIOL, V108, P195, DOI 10.1002/jcp.1041080210; SHALTIEL S, 1993, MOL CELL BIOCHEM, V128, P283, DOI 10.1007/BF01076778; SHALTIEL S, 1993, INT CONGR SER, V1042, P311; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; SKERRETT PJ, 1991, SCIENCE, V252, P1064, DOI 10.1126/science.252.5009.1064; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; WIMAN B, 1988, FEBS LETT, V242, P125, DOI 10.1016/0014-5793(88)80999-2	45	30	30	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1995	9	15					1605	1613		10.1096/fasebj.9.15.8529840	http://dx.doi.org/10.1096/fasebj.9.15.8529840			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TM761	8529840				2022-12-25	WOS:A1995TM76100014
J	FOOS, G; NATOUR, S; KLEMPNAUER, KH				FOOS, G; NATOUR, S; KLEMPNAUER, KH			TATA-BOX DEPENDENT TRANSACTIVATION OF THE HUMAN HSP70 PROMOTER BY MYB PROTEINS	ONCOGENE			English	Article							ONCOGENE C-MYB; GENE V-MYB; NUCLEOTIDE-SEQUENCE; CELLULAR PROGENITOR; PROTO-ONCOGENE; EXPRESSION; DIFFERENTIATION; DNA; CELLS; CDNA	The oncogene v-myb and its cellular progenitor c-myb encode nuclear, DNA-binding phosphoproteins that function as transcriptional regulators. Previous studies have demonstrated the existence of two distinct transactivation mechanisms for Myb-inducible promoters. One of these mechanisms, exemplified by the chicken mim-1 promoter, involves specific binding of Myb protein to Myb binding sites located upstream of the transcriptional start site. A second mechanism, exemplified by the human HSP70 promoter, does not require the presence of specific Myb binding sites. Here, we have more closely investigated transactivation of the human HSP70 promoter by Myb proteins. Mutational analysis of the human HSP70 promoter failed to show a correlation between Myb-inducibility and the presence of a particular upstream transcription factor binding site, but instead showed that Myb-inducibility was dependent on the presence of a particular type of TATA-box. This suggests that the TATA-box is involved in transactivation by v-Myb and that only a subset of TATA-boxes confers Myb-inducibility. Activation of the HSP70 promoter is dependent on the presence of most of the carboxy terminal amino acid sequences of v-Myb, including the previously identified acidic transactivation domain and a putative leucine-zipper region. Finally, we show that the HSP70 promoter is activated in a Myb binding site independent fashion not only by v-Myb, but also by chicken c-Myb and chicken B-Myb. These observations raise the possibility that the ability to transactivate in a Myb binding-site independent manner is a common property among Myb proteins. Since chicken B-Myb has been shown previously to be unable to transactivate a Myb binding-site containing promoter, such as the mim-1 promoter (Foos et al., 1992), our results also show that both modes of transactivation are independent of each other.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,STUBEWEG 51,W-7800 FREIBURG,GERMANY	Max Planck Society								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENE JM, 1987, MOL CELL BIOL, V7, P3646, DOI 10.1128/MCB.7.10.3646; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAM EWF, 1992, ONCOGENE, V7, P1185; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; MCMAHON J, 1988, ONCOGENE, V3, P717; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKANO T, 1992, ONCOGENE, V7, P527; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; THEISEN M, 1986, EMBO J, V5, P719, DOI 10.1002/j.1460-2075.1986.tb04273.x; TOKODORO K, 1988, P NATL ACAD SCI USA, V85, P8900; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	47	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1775	1782						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510924				2022-12-25	WOS:A1993LG68200008
J	PASH, JM; ALFONSO, PJ; BUSTIN, M				PASH, JM; ALFONSO, PJ; BUSTIN, M			ABERRANT EXPRESSION OF HIGH-MOBILITY GROUP CHROMOSOMAL PROTEIN-14 AFFECTS CELLULAR-DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CDNA SEQUENCE; MULTIGENE FAMILY; TRANSCRIBED GENES; HMG-14; CHROMATIN; MYOD1; NUCLEOSOMES; INHIBITION; MYOGENESIS; MYOBLASTS	High mobility group (HMG) 14 is a ubiquitous chromosomal protein that binds specifically to nucleosomal DNA and may be involved in a process that confers distinct properties to the chromatin structure of transcriptionally active genes. To explore the involvement of this protein in regulation of gene expression, we studied the effect of aberrant expression of HMG-14 protein on cellular differentiation. We produced stably transfected C2C12 mouse myoblasts expressing the human HMG-14 protein under the control of the mouse mammary tumor virus promoter. Transformed colonies retained their potential do differentiate into myotubes. Induction of human HMG-14 expression by dexamethasone inhibited the myogenic process. Revertant colonies, which lost the ability to express human HMG-14, regained the ability to differentiate into myotubes. Inhibition of myoblast differentiation by aberrantly expressed HMG-14 correlated with down-regulation of myogenic determination factors. The results suggest that proper cellular differentiation requires regulated expression of HMG-14 protein and are consistent with the possibility that this protein may be involved in gene regulation.	NCI, MOLEC CARCINOGENESIS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bustin, Michael/G-6155-2015	Bustin, Michael/0000-0002-5147-7242				ALBRIGHT SC, 1980, J BIOL CHEM, V255, P3673; BALL EH, 1980, J CELL PHYSIOL, V102, P27, DOI 10.1002/jcp.1041020105; BEGUM N, 1990, J BIOL CHEM, V265, P11936; BROTHERTON TW, 1986, BIOCHEMISTRY-US, V25, P3447, DOI 10.1021/bi00359a053; BUSTIN M, 1990, J BIOL CHEM, V265, P20077; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUSTIN M, 1987, NUCLEIC ACIDS RES, V15, P3549, DOI 10.1093/nar/15.8.3549; BUSTIN M, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P137; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CRIPPA MP, 1991, J BIOL CHEM, V266, P2712; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; DORBIC T, 1987, EMBO J, V6, P2393, DOI 10.1002/j.1460-2075.1987.tb02517.x; DORBIC T, 1986, NUCLEIC ACIDS RES, V14, P3363, DOI 10.1093/nar/14.8.3363; DRUCKMANN S, 1986, EXP CELL RES, V166, P486, DOI 10.1016/0014-4827(86)90493-3; EINCK L, 1983, P NATL ACAD SCI-BIOL, V80, P6735, DOI 10.1073/pnas.80.22.6735; Emerson CP, 1990, CURR OPIN CELL BIOL, V2, P1065, DOI 10.1016/0955-0674(90)90157-A; GIRI C, 1987, J BIOL CHEM, V262, P9839; GOODWIN GH, 1982, HMG PROTEINS; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; KONIECZNY SF, 1989, ONCOGENE, V4, P473; LANDSMAN D, 1986, J BIOL CHEM, V261, P6082; LANDSMAN D, 1986, J BIOL CHEM, V261, P7479; LANDSMAN D, 1989, J BIOL CHEM, V264, P3421; LANDSMAN D, 1986, EXP CELL RES, V163, P95, DOI 10.1016/0014-4827(86)90561-6; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; MALIK N, 1984, J BIOL CHEM, V259, P699; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; PASH J, 1990, P NATL ACAD SCI USA, V87, P3836, DOI 10.1073/pnas.87.10.3836; PASH J, 1991, EXP CELL RES, V193, P232, DOI 10.1016/0014-4827(91)90562-9; PASH JM, 1990, J BIOL CHEM, V265, P4197; REISS K, 1990, EUR J CELL BIOL, V53, P42; Sambrook J, 1989, MOL CLONING LABORATO; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WEISBROD S, 1980, CELL, V19, P289, DOI 10.1016/0092-8674(80)90410-9; WESTERMANN R, 1984, CHROMOSOMA, V90, P355, DOI 10.1007/BF00294162	39	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13632	13638						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514795				2022-12-25	WOS:A1993LH55300087
J	Graves, LM; Bornfeldt, KE; Sidhu, JS; Argast, GM; Raines, EW; Ross, R; Leslie, CC; Krebs, EG				Graves, LM; Bornfeldt, KE; Sidhu, JS; Argast, GM; Raines, EW; Ross, R; Leslie, CC; Krebs, EG			Platelet-derived growth factor stimulates protein kinase A through a mitogen-activated protein kinase-dependent pathway in human arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC ADENYLATE-CYCLASE; CYCLIC-AMP ACCUMULATION; SWISS 3T3 CELLS; ARACHIDONIC-ACID; MAP KINASE; PHOSPHOLIPASE-A2; INHIBITION; CAMP; PHOSPHORYLATION; BINDING	The abilities of platelet-derived growth factor (PDGF) and insulin-like growth factor (IGF-I) to regulate cAMP metabolism and mitogen-activated protein kinase (MAP kinase) activity were compared in human arterial smooth muscle cells (hSMC), PDGF-BB stimulated cAMP accumulation up to 150-fold in a concentration depend ent manner (EC(50) approximate to 0.7 nM). The peak of cAMP formation and cAMP-dependent protein kinase (PKA) activity occurred approximately 5 min after the addition of PDGF and rapidly declined thereafter. Incubating cells with PDGF and 3-isobutyl-1-methylxanthine (IBMX, a phosphodiesterase inhibitor) enhanced the accumulation of cAMP and PKA activity by an additional 2.5-3-fold, whereas IBMX alone was essentially without effect, The PDGF-stimulated increase in cAMP was prevented by addition of the cyclooxygenase inhibitor indomethacin, consistent with release of prostaglandins stimulating cAMP. PDGF, but not IGF-I, stimulated MAPK activity, cytosolic phospholipase A(2) (cPLA(2)) phosphorylation, and cAMP synthesis which indicated a key role for MAP kinase in the activation of cPLA(2), Further, PDGF stimulated the rapid release of arachidonic acid and synthesis of prostaglandin E(2) (PGE(2)) which could be inhibited by a cPLA, inhibitor (AACOCF(3)), Calcium mobilization was required for PDGF induced arachidonic acid release and PGE(2) synthesis but not for MAPK activation, whereas PKC was required for PGE(2)-mediated activation of PKA. In summary, these results demonstrate that PDGF increases cAMP formation and PKA activity through a MAP kinase-mediated activation of cPLA(2), arachidonic acid release, and PGE(2) synthesis in human arterial smooth muscle cells.	UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT ENVIRONM HLTH, SEATTLE, WA 98195 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DENVER, CO 80206 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Jewish Health			Bornfeldt, Karin/AAI-2241-2019; Graves, Lee/AAG-5470-2021	Bornfeldt, Karin/0000-0001-9208-6523; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042528] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-18645, HL-03174] Funding Source: Medline; NIDDK NIH HHS [DK 42528] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALL RL, 1990, J BIOL CHEM, V265, P12836; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BUDNIK LT, 1991, J BIOL CHEM, V266, P13908; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CORBIN JD, 1983, METHOD ENZYMOL, V99, P227; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DOMIN J, 1993, J BIOL CHEM, V268, P8927; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; GELB MH, 1994, FASEB J, V8, P916, DOI 10.1096/fasebj.8.12.8088457; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HART MJ, 1990, J BIOL CHEM, V265, P5990; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KRAMER RM, 1995, SIGNAL ACTIVATED PHO, P13; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LOESBERG C, 1985, EXP CELL RES, V160, P117, DOI 10.1016/0014-4827(85)90241-1; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIYAKE R, 1992, BIOCHIM BIOPHYS ACTA, V1165, P167, DOI 10.1016/0005-2760(92)90183-V; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NAIR BG, 1989, BIOCHEM J, V264, P563, DOI 10.1042/bj2640563; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; PYNE NJ, 1994, BIOCHEM J, V304, P611, DOI 10.1042/bj3040611; QUI ZH, 1994, J BIOL CHEM, V269, P19480; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROZENGURT E, 1983, CELL, V34, P265, DOI 10.1016/0092-8674(83)90157-5; ROZENGURT E, 1981, ADV CYCL NUCL RES<D>, V14, P429; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SCHROR K, 1993, EUR HEART J, V14, P34; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VEGESNA RVK, 1986, EUR J PHARMACOL, V128, P25, DOI 10.1016/0014-2999(86)90553-4; WALSH DA, 1991, METHOD ENZYMOL, V201, P304; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	52	99	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					505	511		10.1074/jbc.271.1.505	http://dx.doi.org/10.1074/jbc.271.1.505			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550611	hybrid			2022-12-25	WOS:A1996TP36100077
J	Heasley, LE; Zamarripa, J; Storey, B; Helfrich, B; Mitchell, FM; Bunn, PA; Johnson, GL				Heasley, LE; Zamarripa, J; Storey, B; Helfrich, B; Mitchell, FM; Bunn, PA; Johnson, GL			Discordant signal transduction and growth inhibition of small cell lung carcinomas induced by expression of GTPase-deficient G alpha(16)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; GASTRIN RECEPTOR; ALPHA SUBUNIT; 3T3 CELLS; CANCER; CHOLECYSTOKININ; ACTIVATION; TRANSFORMATION; STIMULATION; VASOPRESSIN	Small cell lung carcinoma (SCLC) accounts for 20-25% of primary lung cancers and is rapidly growing, widely metastatic, and rarely curable, Autocrine stimulation of multiple G protein-coupled neuropeptide receptor systems contributes to the transformed growth of SCLC, The ability of neuropeptide receptors to stimulate phospholipase C and mobilize intracellular Ca2+ indicates that G(q) family members of heterotrimeric G proteins are a convergence point mediating autocrine signaling by multiple neuropeptides in SCLC, Expression of a GTPase-deficient, constitutive active form of an alpha(q) family member, alpha(16)Q212L, in SCLC markedly inhibited growth of the cells in soft agar and tumor formation in nude mice, SCLC lines expressing alpha(16)Q212L exhibited 2-4-fold elevated basal phospholipase C activity, but neuropeptide and hormone-regulated intracellular Ca2+ mobilization was nearly abolished, The data suggest that Ca2+ mobilization is an obligatory signal in neuropeptide-stimulated growth of SCLC, In addition, the proline-directed c-Jun NH2-terminal kinases/stress-activated protein kinases, which are members of the mitogen-activated protein kinase family, were stimulated similar to-2-fold in parental SCLC in response to exogenous neuropeptides and muscarinic agonists and were constitutively activated to the same degree in alpha(16)Q212L-expressing SCLC, Thus, alpha(16)Q212L expression induced desensitization of neuropeptide stimulated Ca2+ signaling and persistent activation of the c-Jun NH2-terminal kinase/stress-activated protein kinase pathway, We propose that the induction of discordant signaling by selective perturbation of receptor-regulated effector systems leads to the inhibition of SCLC cell growth.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DIV RENAL DIS & HYPERTENS,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DIV MED ONCOL,DENVER,CO 80262; NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health					NCI NIH HHS [CA 58157, CA 46934] Funding Source: Medline; NIDDK NIH HHS [DK 19928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BUNN PA, 1994, CANCER RES, V54, P3602; BUNN PA, 1992, CANCER RES, V52, P24; BUNN PA, 1990, P NATL ACAD SCI USA, V87, P2162, DOI 10.1073/pnas.87.6.2162; CERNY T, 1986, BRIT J CANCER, V54, P265, DOI 10.1038/bjc.1986.172; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JIANG HP, 1994, J BIOL CHEM, V269, P7593; JOHNSON BE, 1989, J NATL CANCER I, V81, P1223, DOI 10.1093/jnci/81.16.1223; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEE YM, 1993, J BIOL CHEM, V268, P8164; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MOREL A, 1992, NATURE, V356, P523, DOI 10.1038/356523a0; QIAN NX, 1994, J BIOL CHEM, V269, P17417; SORENSON GD, 1981, CANCER, V47, P1289, DOI 10.1002/1097-0142(19810315)47:6<1289::AID-CNCR2820470610>3.0.CO;2-B; TREPEL JB, 1988, BIOCHEM J, V255, P403, DOI 10.1042/bj2550403; VIALLET J, 1990, J CLIN INVEST, V86, P1904, DOI 10.1172/JCI114923; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOLL PJ, 1989, BIOCHEM BIOPH RES CO, V164, P66, DOI 10.1016/0006-291X(89)91683-5	32	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					349	354		10.1074/jbc.271.1.349	http://dx.doi.org/10.1074/jbc.271.1.349			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550585	hybrid			2022-12-25	WOS:A1996TP36100054
J	Hirsch, RE; Lin, MJ; Vidugirus, GVA; Huang, SC; Friedman, JM; Nagel, RL				Hirsch, RE; Lin, MJ; Vidugirus, GVA; Huang, SC; Friedman, JM; Nagel, RL			Conformational changes in oxyhemoglobin c (Glu(beta 6)->lys) detected by spectroscopic probing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UV RESONANCE RAMAN; HEMOGLOBIN; FLUORESCENCE; TRANSITION; DYNAMICS	Hemoglobin C (Glu(beta 6) --> Lys) shares with hemoglobin S (Glu(beta 6) --> Val) the site of mutation, but with different consequences: deoxyHbS forms polymers, whereas oxyHbC readily forms crystals. The molecular mechanism for this property of oxyHbC is unknown, Since no detailed oxyHbC crystal structural information exists, spectroscopic probing is used in this study to investigate possible solution-phase conformational changes in HbC compared with HbA. Intrinsic fluorescence combined with UV resonance Raman data demonstrate a weakening of the Trp(beta 15)-Ser(beta 72) hydrogen bond that most likely leads to a displacement of the A helix away from the E helix.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT ANAT & STRUCT BIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Hirsch, RE (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DIV HEMATOL,DEPT MED,MONTEFIORE MED CTR,U-921,BRONX,NY 10461, USA.				NHLBI NIH HHS [HL-38655, P01-HL-51084] Funding Source: Medline; NIDDK NIH HHS [DK-41253] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051084, P60HL038655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041253] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHER SA, 1988, ANNU REV PHYS CHEM, V39, P537; Bunn HF, 1986, HEMOGLOBIN MOL GENET; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; EISINGER J, 1969, BIOCHEMISTRY-US, V8, P3902, DOI 10.1021/bi00838a004; ELBAUM D, 1981, MOL BASIS MUTANT HEM, P253; FRIEDMAN JM, 1994, METHOD ENZYMOL, V232, P205; FRIEDMAN JM, 1985, SCIENCE, V229, P187, DOI 10.1126/science.4012316; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P3424, DOI 10.1021/bi00686a021; GRYCZYNSKI Z, 1992, BIOPHYS J, V63, P648, DOI 10.1016/S0006-3495(92)81657-0; HIRSCH RE, 1994, METHOD ENZYMOL, V232, P231; HIRSCH RE, 1981, J BIOL CHEM, V256, P1080; HIRSCH RE, 1985, BLOOD, V66, P775; ITOH M, 1981, BIOCHEM BIOPH RES CO, V100, P1259, DOI 10.1016/0006-291X(81)91959-8; KITAGAWA T, 1992, PROG BIOPHYS MOL BIO, V58, P1, DOI 10.1016/0079-6107(92)90009-U; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; RODGERS KR, 1994, SCIENCE, V265, P1697, DOI 10.1126/science.8085153; ROUSSEAU DL, 1983, ANNU REV BIOPHYS BIO, V12, P357, DOI 10.1146/annurev.bb.12.060183.002041; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; RUSSU IM, 1982, BIOCHEMISTRY-US, V21, P5044, DOI 10.1021/bi00263a030; SCHROEDER WA, 1980, CHROMATOGRAPHY HEMOG, P61; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SHAPIRO DB, 1994, BIOCHEM BIOPH RES CO, V205, P154, DOI 10.1006/bbrc.1994.2643; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; UEDA Y, 1978, BIOCHEM BIOPH RES CO, V85, P526, DOI 10.1016/0006-291X(78)91195-6	24	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					372	375		10.1074/jbc.271.1.372	http://dx.doi.org/10.1074/jbc.271.1.372			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550589	hybrid			2022-12-25	WOS:A1996TP36100058
J	Ridderstrom, M; Saccucci, F; Hellmann, U; Bergman, T; Principato, G; Mannervik, B				Ridderstrom, M; Saccucci, F; Hellmann, U; Bergman, T; Principato, G; Mannervik, B			Molecular cloning, heterologous expression, and characterization of human glyoxalase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE TRANSFERASES; POLYACRYLAMIDE GELS; PROTEINS; PURIFICATION; INHIBITORS; DNA	A clone encoding glyoxalase II has been isolated from a human adult liver cDNA library, The sequence of 1011 base pairs consists of a full-length coding region of 780 base pairs, corresponding to a protein with a calculated molecular mass of 28,861 daltons. Identities (50-60%) were found to partial 5' and 3' cDNA sequences from Arabidopsis thaliana as well as within a limited region of glutathione transferase I cDNA from corn, A vector was constructed for heterologous expression of glyoxalase II in Escherichia coli. For optimal yield of enzyme, silent random mutations were introduced in the 5' coding region of the cDNA. A yield of 25 mg of glyoxalase II per liter of culture medium was obtained after affinity purification with immobilized glutathione. The recombinant enzyme had full catalytic activity and kinetic parameters indistinguishable from those of the native enzyme purified from human erythrocytes.	UNIV UPPSALA,CTR BIOMED,DEPT BIOCHEM,S-75123 UPPSALA,SWEDEN; UNIV ANCONA,FAC MED & CHIRURG,IST BIOL & GENET,I-60100 ANCONA,ITALY; BIOMED CTR,LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN; KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN	Uppsala University; Marche Polytechnic University; Ludwig Institute for Cancer Research; Karolinska Institutet				PRINCIPATO, Giovanni/0000-0001-8800-0301; Saccucci, Franca/0000-0002-8407-2516				ALLEN RE, 1993, EUR J BIOCHEM, V213, P1261, DOI 10.1111/j.1432-1033.1993.tb17877.x; ANDERSSON SGE, 1990, MICROBIOL REV, V54, P198, DOI 10.1128/MMBR.54.2.198-210.1990; BERGMAN T, 1987, EUR J BIOCHEM, V169, P9, DOI 10.1111/j.1432-1033.1987.tb13573.x; BJORNESTEDT R, 1992, BIOCHEM J, V282, P505; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOARD PG, 1980, AM J HUM GENET, V32, P690; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSH PE, 1985, J MED CHEM, V28, P828, DOI 10.1021/jm00383a025; DALBOGE H, 1990, FEBS LETT, V266, P1, DOI 10.1016/0014-5793(90)90001-B; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; KIM NS, 1993, J BIOL CHEM, V268, P11217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANNERVIK B, 1989, COENZYMES COFACTORS, V3, P475; Mannervik B., 1980, ENZYMATIC BASIS DETO, VVolume 2, P263; MURTHY NSRK, 1994, J MED CHEM, V37, P2161, DOI 10.1021/jm00040a007; NORTON SJ, 1989, ENZYME, V42, P189, DOI 10.1159/000469032; PRINCIPATO GB, 1985, IRCS MED SCI-BIOCHEM, V13, P952; RACKER E, 1951, J BIOL CHEM, V190, P685; RANGANATHAN S, 1993, J BIOL CHEM, V268, P5661; RHEE HI, 1988, AGR BIOL CHEM TOKYO, V52, P2243; RICHARD JP, 1993, BIOCHEM SOC T, V21, P549, DOI 10.1042/bst0210549; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAH DM, 1986, PLANT MOL BIOL, V6, P203, DOI 10.1007/BF00015226; STANLEY KK, 1983, NUCLEIC ACIDS RES, V11, P4077, DOI 10.1093/nar/11.12.4077; SUGITA H, 1983, JPN J HUM GENET, V28, P201, DOI 10.1007/BF01876599; TALESA V, 1989, BIOCHIM BIOPHYS ACTA, V993, P7, DOI 10.1016/0304-4165(89)90135-9; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; THORNALLEY PJ, 1994, AMINO ACIDS, V6, P15, DOI 10.1007/BF00808119; UOTILA L, 1973, BIOCHEMISTRY-US, V12, P3944, DOI 10.1021/bi00744a025; Uotila L., 1981, METH ENZYMOL, V77, P424, DOI [10.1016/S0076-6879(81)77058-7, DOI 10.1016/S0076-6879(81)77058-7]; Vander Jagt D.L., 1989, GLUTATHIONE CHEM, P597	33	66	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					319	323		10.1074/jbc.271.1.319	http://dx.doi.org/10.1074/jbc.271.1.319			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550579	hybrid			2022-12-25	WOS:A1996TP36100049
J	Tumminia, SJ; Jonak, GJ; Focht, RJ; Cheng, YSE; Russell, P				Tumminia, SJ; Jonak, GJ; Focht, RJ; Cheng, YSE; Russell, P			Cataractogenesis in transgenic mice containing the HIV-1 protease linked to the lens alpha A-crystallin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS PROTEASE; CALPAIN-II; VIRAL INFECTIVITY; BETA-CRYSTALLIN; PROTEOLYSIS; CATARACTS; CALCIUM; MOUSE; HUMOR	Several lines of transgenic mice were generated with either active or inactive forms of the human immunodeficiency virus type 1 (HIV-1) protease gene under the control of the mouse lens alpha A-crystallin promoter, Mice bearing the inactive protease coding sequence displayed no gross abnormalities in the lens, while mice with the active protease developed time-dependent bilateral cataracts, One line, TG(61), developed cataracts in utero while the second line, TG(72), developed cataracts postnatally. TG(61) mice, homozygous for the transgene, developed severe microphthalmia and were significantly smaller than the control mice at postnatal day 30. two-dimensional-polyacrylamide gel electrophoresis analysis of the protein profiles of TG(72) and TG(61) lenses revealed extensive modifications in the lens crystallins. Proteolysis in the homozygous TG(72) mouse lenses began at postnatal day 20 with the disappearance or partial loss of beta B1-, beta B3-, and beta A3-crystallins and the appearance of crystallin fragments, Protein leakage and the gradual breakdown of cytoskeletal elements also occurred, In contrast, the opacification of the homozygous TG(61) lenses appeared to have been influenced by differentiation and developmental processes. It apppears that HIV-1 protease expression activates other proteases, and these enzymes, in concert with the HIV-1 protease, are responsible for the protein modifications that eventually result in the opacification of the lens.	DUPONT MERCK PHARMACEUT CO,WILMINGTON,DE 19880; FUJI IMMUNOPHARMACEUT,LEXINGTON,MA 02173	DuPont	Tumminia, SJ (corresponding author), NEI,LAB MECHANISMS OCULAR DIS,BLDG 6,RM 228,6 CTR DR,MSC 2735,BETHESDA,MD 20892, USA.							ADAMS LD, 1992, AIDS RES HUM RETROV, V8, P291, DOI 10.1089/aid.1992.8.291; AZUMA M, 1992, OPHTHALMIC RES, V24, P8, DOI 10.1159/000267138; CHAMBERS C, 1991, J BIOL CHEM, V266, P6742; CHENG YSE, 1990, GENE, V87, P243, DOI 10.1016/0378-1119(90)90308-E; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; CHEPELINSKY AB, 1985, P NATL ACAD SCI USA, V82, P2334, DOI 10.1073/pnas.82.8.2334; DAVID LL, 1986, EXP EYE RES, V42, P227, DOI 10.1016/0014-4835(86)90057-6; DAVID LL, 1993, J BIOL CHEM, V268, P1937; DAVID LL, 1984, INVEST OPHTH VIS SCI, V25, P1275; DAVID LL, 1994, EXP EYE RES, V59, P501, DOI 10.1006/exer.1994.1136; DAVID LL, 1992, BIOCHIM BIOPHYS ACTA, V1139, P210, DOI 10.1016/0925-4439(92)90136-B; FITZGERALD PMD, 1991, ANNU REV BIOPHYS BIO, V20, P299, DOI 10.1146/annurev.biophys.20.1.299; Harding JJ, 1984, EYE B, V1b, P207; HOGAN B, 1986, MANIPULATING MOUSE E; HONER B, 1991, J CELL SCI, V100, P799; HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001; IWAKURA Y, 1992, AIDS, V6, P1069, DOI 10.1097/00002030-199210000-00002; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LINKLATER HA, 1986, EXP EYE RES, V43, P305, DOI 10.1016/S0014-4835(86)80068-9; MURACHI T, 1981, ADV ENZYME REGUL, V19, P407; Murachi T. M., 1983, CALCIUM CELL FUNCTIO, V4, P377; PENG C, 1989, J VIROL, V63, P2550, DOI 10.1128/JVI.63.6.2550-2556.1989; PIATIGORSKY J, 1980, EXP EYE RES, V30, P69, DOI 10.1016/0014-4835(80)90125-6; PIATIGORSKY J, 1978, NATURE, V274, P558, DOI 10.1038/274558a0; RUSSELL P, 1990, BIOTECHNIQUES, V9, P422; Sambrook J, 1989, MOL CLONING LABORATO; SANDBERG HO, 1976, EXP EYE RES, V22, P75, DOI 10.1016/0014-4835(76)90034-8; SANDBERG HO, 1979, EXP EYE RES, V28, P601, DOI 10.1016/0014-4835(79)90047-2; Schnaudigel O.-E., 1994, Ophthalmologe, V91, P668; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; TUMMINIA SJ, 1994, EXP EYE RES, V58, P367, DOI 10.1006/exer.1994.1027; WATANABE H, 1989, CURR EYE RES, V8, P479, DOI 10.3109/02713688909000028; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052; YOSHIDA H, 1984, BIOCHIM BIOPHYS ACTA, V798, P252, DOI 10.1016/0304-4165(84)90313-1; YOSHIDA H, 1985, CURR EYE RES, V4, P983, DOI 10.3109/02713689509000005	36	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					425	431		10.1074/jbc.271.1.425	http://dx.doi.org/10.1074/jbc.271.1.425			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550598	hybrid			2022-12-25	WOS:A1996TP36100066
J	Hallahan, DE; Dunphy, E; Virudachalam, S; Sukhatme, VP; Kufe, DW; Weichselbaum, RR				Hallahan, DE; Dunphy, E; Virudachalam, S; Sukhatme, VP; Kufe, DW; Weichselbaum, RR			c-jun and Egr-1 participate in DNA synthesis and cell survival in response to ionizing radiation exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ATAXIA-TELANGIECTASIA; TRANSCRIPTIONAL ACTIVATION; CYCLE PROGRESSION; GENE; GROWTH; RADIOTHERAPY; FIBROBLASTS; INDUCTION; P53	Exposure of mammalian cells to ionizing radiation results in the induction of the immediate early genes, c-jun and Egr-1, which encode transcription factors implicated in cell growth as well as the cellular response to oxidative stress, We studied the role of these immediate early genes in cell cycle kinetics and cell survival following x-irradiation of clones containing inducible dominant negatives to c-jun and Egr-1, The dominant negative constructs to c-jun (Delta 9) and Egr-1 (WT/Egr) prevented x-ray induction of transcription through the AP-1 and Egr binding sites, respectively. Twenty percent of confluent, serum-deprived SQ20B human tumor cells, normal fibroblasts, and fibroblasts from patients with ataxia telangiectasia entered S phase within 5 h of irradiation, Clones containing inducible Delta 9 and WT/Egr dominant negative constructs demonstrated attenuation of the percentage of cells exiting G(1) phase and reduced survival following irradiation, These data indicate that the dominant negatives to the stress-inducible immediate early genes Egr-1 and c-jun prevent the onset of S phase and reduce the survival of human cells exposed to ionizing radiation.	UNIV CHICAGO, DEPT RADIAT & CELLULAR ONCOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, PRITZKER SCH MED, CHICAGO, IL 60637 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, BOSTON, MA 02115 USA	University of Chicago; University of Chicago; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Sukhatme, Vikas/W-2776-2019		NCI NIH HHS [CA41068, CA37435, CA 58508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041068, R01CA058508, R29CA058508, R01CA037435] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARTER R, 1991, ONCOGENE, V6, P229; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; FUKS Z, 1994, CANCER RES, V54, P2582; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HALLAHAN DE, 1994, RADIAT RES, V138, P392, DOI 10.2307/3578688; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1990, INT J RADIAT ONCOL, V19, P69, DOI 10.1016/0360-3016(90)90136-8; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HARTWELL L, 1994, NATURE, V371, P286, DOI 10.1038/371286a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERMENS AF, 1969, EUR J CANCER, V5, P173, DOI 10.1016/0014-2964(69)90065-6; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JIRTLE RL, 1991, DIGEST DIS SCI, V36, P659, DOI 10.1007/BF01297035; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MADDEN SL, 1993, ANN NY ACAD SCI, V684, P75, DOI 10.1111/j.1749-6632.1993.tb32272.x; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MARTIN M, 1993, CANCER RES, V53, P3246; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MORGAN IM, 1993, ONCOGENE, V8, P1135; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NETA R, 1991, CANCER CELL-MON REV, V3, P391; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TUBIANA M, 1988, ACTA ONCOL, V27, P83, DOI 10.3109/02841868809090328; WEICHSELBAUM RR, 1990, INT J RADIAT ONCOL, V19, P313, DOI 10.1016/0360-3016(90)90539-V; WITHERS HR, 1988, ACTA ONCOL, V27, P131, DOI 10.3109/02841868809090333; YAN MH, 1994, NATURE, V372, P798; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	52	101	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30303	30309		10.1074/jbc.270.51.30303	http://dx.doi.org/10.1074/jbc.270.51.30303			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530452	hybrid			2022-12-25	WOS:A1995TL67500017
J	Yeung, T; Barlowe, C; Schekman, R				Yeung, T; Barlowe, C; Schekman, R			Uncoupled packaging of targeting and cargo molecules during transport vesicle budding from the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PATHWAY; YEAST; PROTEINS; ER; TRANSLOCATION; CELL	Formation of vesicular intermediates in protein transport between the endoplasmic reticulum and the Gels apparatus involves a mechanism that sorts and packages two classes of molecules into transport vesicles: targeting molecules, which are required for targeting and consumption of vesicular intermediates, and cargo proteins. In order to examine the importance of cargo in this packaging reaction, we developed an in vitro assay that quantifies vesicle formation based on segregation of targeting molecules. Here we document that endoplasmic reticulum devoid of cargo proteins is competent in the formation and release of targeting molecule-containing vesicles in a fashion indistinguishable from its normal counterpart. This observation implies that packaging of cargo proteins may be uncoupled from the recruitment of targeting molecules during vesicle budding from the endoplasmic reticulum. Using the same assay, we demonstrate that the packaging of targeting molecules into vesicles is not dependent on the lumenal chaperone, BiP (Kar2p).	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Dartmouth College								ANDERSON RGW, 1978, CELL, V15, P919, DOI 10.1016/0092-8674(78)90276-3; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1983, J CELL BIOL, V96, P541, DOI 10.1083/jcb.96.2.541; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; ZILBERSTEIN A, 1981, COLD SPRING HARB SYM, V46, P785	18	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30567	30570		10.1074/jbc.270.51.30567	http://dx.doi.org/10.1074/jbc.270.51.30567			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530490	hybrid			2022-12-25	WOS:A1995TL67500055
J	Givol, I; Givol, D; Rulong, S; Resau, J; Tsarfaty, I; Hughes, SH				Givol, I; Givol, D; Rulong, S; Resau, J; Tsarfaty, I; Hughes, SH			Overexpression of human p21(waf1/cip1) arrests the growth of chicken embryo fibroblasts transformed by individual oncogenes	ONCOGENE			English	Article						retrovirus; growth suppressor; cell cycle; waf1/cip1; p53	CYCLIN-DEPENDENT KINASES; SARCOMA VIRUS; P53; DNA; VECTORS; CELLS; EXPRESSION; INHIBITOR; PROTEIN; P21	In normal cells, cell growth and division is controlled by the interplay between proto-oncogenes and tumor genes, Cancer cells usually have both suppressor activated an suppressor gene, High level expression of a tumor suppressor, p53, can block the growth of cancer cells, waf1/cip1 is transactivated by the tumor suppressor p53 and the p21(waf1/cip1)protein is itself a suppressor of cell growth, To test the effect of growth suppression genes on the growth of cells transformed by individual oncogenes, we have used replication-competent retroviral vectors to induce high level expression of p53 and p21(waf1/cip1). Overexpression of p21(waf1/cip1) arrests chicken embryo fibroblasts (CEF) transformed by v-Src, tf-Ras, c-Mos and c-Myc. These data suggest that p21(waf1/cip1) might be a useful tool in gene therapy for human cancer.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; WEIZMANN INST SCI,DEPT MOLEC CELL BIOL,IL-76100 REHOVOT,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine				Tsarfaty, Ilan/0000-0002-5230-7093				CHEDID M, 1994, ONCOGENE, V9, P3021; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIVOL I, 1992, ONCOGENE, V7, P141; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4923; LI R, 1994, NATURE, V371, P535; LI Y, 1994, ONCOGENE, V9, P2261; LOWE SW, 1993, CELL, V74, P954; LOWE SW, 1994, SCIENCE, V266, P804; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MICHIELI P, 1994, CANCER RES, V54, P3391; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; THORNTHWAITE JT, 1980, CYTOMETRY, V1, P229, DOI 10.1002/cyto.990010309; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	41	30	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2609	2618						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545118				2022-12-25	WOS:A1995TP18800017
J	CHIEN, AJ; ZHAO, XL; SHIROKOV, RE; PURI, TS; CHANG, CF; SUN, D; RIOS, E; HOSEY, MM				CHIEN, AJ; ZHAO, XL; SHIROKOV, RE; PURI, TS; CHANG, CF; SUN, D; RIOS, E; HOSEY, MM			ROLES OF A MEMBRANE-LOCALIZED BETA-SUBUNIT IN THE FORMATION AND TARGETING OF FUNCTIONAL L-TYPE CA2+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; 2 SIZE FORMS; SKELETAL-MUSCLE; ALPHA-1 SUBUNIT; DIHYDROPYRIDINE RECEPTOR; CHANNEL-ALPHA-1 SUBUNIT; BINDING DOMAINS; EXPRESSION; IDENTIFICATION; CLONING	We report several unexpected findings that provide novel insights into the properties and interactions of the alpha(1) and beta subunits of dihydropyridine-sensitive L-type channels, First, the beta(2a) subunit was expressed as multiple species of 68-72 kDa; the 70-72-kDa species arose from post-translational modification, Second, cell fractionation and immunocytochemical studies indicated that the hydrophilic beta(2a) subunit, when expressed alone, was membrane-localized, Third, the beta(2a) subunit increased the membrane localization of the alpha(1) subunit and the number of cells expressing L-type Ca2+ currents, without affecting the total amount of the expressed alpha(1C) subunit. Expression of maximal currents in alpha(1C)/beta(2a) co-transfected cells paralleled the time course of expression of the beta subunit. Taken together, these results suggest that the beta subunit plays multiple roles in the formation, stabilization, targeting, and modulation of L-type channels.	NORTHWESTERN UNIV,SCH MED,DEPT MOLEC PHARMACOL & BIOL CHEM,CHICAGO,IL 60611; AA BOGOMOLETS PHYSIOL INST,KIEV 252024,UKRAINE; RUSH UNIV,DEPT PHYSIOL,CHICAGO,IL 60612	Northwestern University; National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology; Rush University					NHLBI NIH HHS [HL23306] Funding Source: Medline; NIAMS NIH HHS [AR43113] Funding Source: Medline; NIEHS NIH HHS [5 T32 ES07124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023306, R37HL023306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007124] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARTHUR H, 1984, J VIROL, V52, P483; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BRAWLEY RM, 1992, J BIOL CHEM, V267, P18218; BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CHANG FC, 1988, J BIOL CHEM, V263, P18929; DEFELICE LJ, 1993, J MEMBRANE BIOL, V133, P191; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; GALLI A, 1994, BIOPHYS J, V67, P2296, DOI 10.1016/S0006-3495(94)80715-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HELL JW, 1993, J BIOL CHEM, V268, P19451; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; KALASZ H, 1993, FEBS LETT, V331, P177, DOI 10.1016/0014-5793(93)80321-K; KINGSTON RE, 1995, CURRENT PROTOCOLS MO; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LEUNG AT, 1988, J BIOL CHEM, V263, P994; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MITTERDORFER J, 1994, FEBS LETT, V352, P141, DOI 10.1016/0014-5793(94)00938-4; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; PEREZGARCIA MT, 1995, J GENERAL PHYSL, V105, P1; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RAMPE D, 1990, BIOCHEM BIOPH RES CO, V169, P825, DOI 10.1016/0006-291X(90)91967-W; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SHISTIK E, 1995, IN PRESS J PHYSL; SIEBER M, 1987, EUR J BIOCHEM, V167, P117, DOI 10.1111/j.1432-1033.1987.tb13311.x; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; UKOMADU C, 1992, NEURON, V8, P663, DOI 10.1016/0896-6273(92)90088-U; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WEI XY, 1991, J BIOL CHEM, V266, P21943; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501	40	224	229	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30036	30044						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530407				2022-12-25	WOS:A1995TK38000067
J	KIMS, KI; BAEK, SH; HONG, YM; KANG, MS; HA, DB; GOLDBERG, AL; CHUNG, CH				KIMS, KI; BAEK, SH; HONG, YM; KANG, MS; HA, DB; GOLDBERG, AL; CHUNG, CH			PURIFICATION AND CHARACTERIZATION OF PROTEASE-CI, A CYTOPLASMIC METALLOENDOPROTEASE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; DEPENDENT PROTEASES; SENSITIVE METHOD; PROTEINS; BACTERIAL	Protease Ci, a cytoplasmic metalloprotease in Escherichia coli, has been purified to apparent homogeneity by conventional chromatographic procedures using I-125-labeled oxidized insulin B-chain as a substrate, The purified enzyme behaves as a 54-kDa protein under both denaturing and nondenaturing conditions, suggesting that it consists of a single polypeptide chain, It is inhibited by metal-chelating agents, including o-phenanthroline and NaCN, but not by inhibitors of serine proteases or thiol-blocking agents. Furthermore, protease Ci was found to contain 1.1 mol of zinc per mol of the enzyme upon analysis by HR ICP mass spectroscopy. Thus, protease Ci must be a zinc metalloprotease. Among the polypeptides tested as substrates, oxidized insulin B-chain and glucagon are most rapidly hydrolyzed. Intact insulin is a much poorer substrate than oxidized insulin B-chain, even though the affinity of the enzyme to intact insulin is approximately 100-fold greater than that to the B-chain, Since unlabeled oxidized insulin A-chain is capable of inhibiting the hydrolysis of I-125-labeled insulin B-chain, it also appears to be a substrate, Protease Ci also degrades lysozyme and lactalbumin, although to a much lesser extent than oxidized insulin B-chain. However, it shows little or no activity against proteins larger than 15 kDa (e.g. ovalbumin and denatured bovine serum albumin). Hydrolysis of oxidized insulin B-chain followed by amino acid composition analyses of the cleavage products reveals that as many as 10 of its 29 peptide bonds are hydrolyzed by protease Ci. This ability to hydrolyze relatively small polypeptides suggests that protease Ci may catalyze the later steps in the pathway for intracellular protein breakdown.	SEOUL NATL UNIV, COLL NAT SCI, DEPT MOLEC BIOL, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, COLL NAT SCI, CELL DIFFERENTIAT RES CTR, SEOUL 151742, SOUTH KOREA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Seoul National University (SNU); Seoul National University (SNU); Harvard University; Harvard Medical School			KIM, KEUN IL/D-2959-2011					AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; ANASTASI A, 1993, BIOCHEM J, V290, P601, DOI 10.1042/bj2900601; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; CHENG YSE, 1979, J BACTERIOL, V140, P125, DOI 10.1128/JB.140.1.125-130.1979; CHENG YSE, 1979, J BIOL CHEM, V254, P4698; CHUNG CH, 1993, SCIENCE, V262, P372, DOI 10.1126/science.8211156; COLEMAN JE, 1960, J BIOL CHEM, V235, P390; CZEKAY G, 1993, BIOCHEM J, V290, P921, DOI 10.1042/bj2900921; DUCKWORTH WC, 1989, BIOCHEMISTRY-US, V28, P2471, DOI 10.1021/bi00432a018; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P7695, DOI 10.1093/nar/14.19.7695; FOLK JE, 1960, J BIOL CHEM, V235, P60; GARCIA JV, 1988, BIOCHEMISTRY-US, V27, P4237, DOI 10.1021/bi00412a006; GOLDBERG AL, 1981, METHOD ENZYMOL, V80, P680; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; JOHNSTONE A, 1982, IMMUNOCHEMISTRY PRAC, P43; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LI D, 1992, J BIOL CHEM, V267, P2414; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; SWAMY KHS, 1982, J BACTERIOL, V149, P1027, DOI 10.1128/JB.149.3.1027-1033.1982; SWAMY KHS, 1981, NATURE, V292, P652, DOI 10.1038/292652a0; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1960, J BIOL CHEM, V235, P64; WOO KM, 1992, J BIOL CHEM, V267, P20429	29	11	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29799	29805						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530373				2022-12-25	WOS:A1995TK38000033
J	MALKOV, VV; CAMERINIOTERO, RD				MALKOV, VV; CAMERINIOTERO, RD			PHOTOCROSS-LINKS BETWEEN SINGLE-STRANDED-DNA AND ESCHERICHIA-COLI RECA PROTEIN MAP TO LOOPS L1 (AMINO-ACID-RESIDUES 157-164) AND L2 (AMINO-ACID-RESIDUES 195-209)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; RECOMBINATION; COMPLEXES; ATP	To function as a repair and recombination protein, RecA has to be assembled as an active filament on single-stranded DNA in the presence of ATP or its analogs. We have identified amino acids in the primary DNA binding site of RecA that interact with single-stranded DNA by photocross-linking. A nucleoprotein complex consisting of RecA protein bound to a monosubstituted oligonucleotide bearing a 5-iododeoxyuracil cross-linking moiety was irradiated with long wavelength ultraviolet radiation to effect cross-linking with RecA protein. Subsequent trypsin digestion, followed by purification and peptide sequencing, revealed the cross-linking of two independent peptides, amino acid residues 153-169 and 199-216. Met(164) from loop L1 and Phe(203) from loop L2 were determined to be the exact points of cross-linking, Thus, our data confirm and extend predictions about the DNA binding domain of RecA protein based on the molecular structure of RecA (Story, R. M., Weber, I. T., and Steitz, T.A. (1992) Nature 355, 318-325).	NIDDK,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; CAZAUX C, 1991, BIOCHIMIE, V73, P281, DOI 10.1016/0300-9084(91)90214-L; CAZAUX C, 1994, J BIOL CHEM, V269, P8246; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; EGELMAN EH, 1993, CURR OPIN STRUC BIOL, V3, P189, DOI 10.1016/S0959-440X(05)80151-4; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; HICKE BJ, 1994, BIOCHEMISTRY-US, V33, P3364, DOI 10.1021/bi00177a030; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; KOLLER T, 1983, MECHANISMS DNA REPLI, P723; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE PARIS, V78, P289; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P538; KURUMIZAKA H, 1994, J BIOL CHEM, V269, P3068; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MORIMATSU K, 1995, EUR J BIOCHEM, V228, P772, DOI 10.1111/j.1432-1033.1995.0772m.x; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WILLIS MC, 1994, NUCLEIC ACIDS RES, V22, P4947, DOI 10.1093/nar/22.23.4947; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; YANCEYWRONA JE, 1995, CURR BIOL, V5, P1149, DOI 10.1016/S0960-9822(95)00231-4	24	61	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30230	30233						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530434				2022-12-25	WOS:A1995TK38000094
J	BONHAM, K; FUJITA, DJ				BONHAM, K; FUJITA, DJ			ORGANIZATION AND ANALYSIS OF THE PROMOTER REGION AND 5' NONCODING EXONS OF THE HUMAN C-SRC PROTOONCOGENE	ONCOGENE			English	Article							EXPRESS HIGH-LEVELS; GENE-PRODUCT; MAMMALIAN-CELLS; KINASE-ACTIVITY; NEURONAL CELLS; PLASMID DNA; V-SRC; PP60C-SRC; SEQUENCE; FORM	In order to help clarify the cellular mechanisms that regulate expression of the human c-src proto-oncogene, we have isolated a series of overlapping genomic clones that contain the c-src promoter region, as well as three previously uncharacterized exons. These exons encode the 350-bp 5' untranslated region of the c-src mRNA and span 35 kb of genomic DNA, extending the human c-src locus to approximately 60 kb. Subcloning and sequence analysis of the 5' flanking region of the gene revealed a high GC content and several consensus Sp1 and AP2 binding sites. However, TATA or CAAT boxes were not present, a characteristic shared by other GC-rich promoters. Promoter-CAT constructs demonstrated that the promoter was functional in transfection assays and that its activity was dependent on correct orientation. CAT-promoter deletion constructs were used to define the 5' boundary for maximal promoter activity and to reveal the presence of both positive and negative regulatory elements. S1 analyses of human c-src mRNA from cell lines indicated that multiple transcription start sites were utilized.	UNIV CALGARY,MED CTR,CELL REGULAT GRP,CALGARY T2N 4N1,AB,CANADA; UNIV CALGARY,DEPT MED BIOCHEM,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,AB,CANADA	University of Calgary; University of Calgary								ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; DORAI T, 1990, MOL CELL BIOL, V10, P4068, DOI 10.1128/MCB.10.8.4068; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; EVANS T, 1988, J MOL BIOL, V199, P61, DOI 10.1016/0022-2836(88)90379-8; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FULTS DW, 1985, MOL CELL BIOL, V5, P327; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GHOSN CR, 1992, ONCOGENE, V7, P2345; GIBBS CP, 1985, J VIROL, V53, P19, DOI 10.1128/JVI.53.1.19-24.1985; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTKIND JS, 1991, MOL CELL BIOL, V11, P1500, DOI 10.1128/MCB.11.3.1500; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HOFFMANFALK H, 1983, CELL, V32, P589, DOI 10.1016/0092-8674(83)90478-6; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JORCYK CL, 1990, ONCOGENE, V6, P323; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15505; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KREIG P, 1983, ANAL BIOCHEM, V134, P288; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LICHTENBERG U, 1992, ONCOGENE, V7, P849; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; PATEL M, 1990, ONCOGENE, V5, P201; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROSEN N, 1986, J BIOL CHEM, V261, P13745; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SUDOL M, 1988, ONCOGENE RES, V2, P345; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TANAKA A, 1990, ONCOGENE RES, V5, P305; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TANAKA A, 1986, MOL CELL BIOL, V6, P3900, DOI 10.1128/MCB.6.11.3900; ZAFARULLAH M, 1988, MOL CELL BIOL, V8, P4469, DOI 10.1128/MCB.8.10.4469; ZIEGLER SF, 1991, ONCOGENE, V6, P283	53	41	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1973	1981						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510939				2022-12-25	WOS:A1993LG68200030
J	MILLER, CW; CHUMAKOV, A; SAID, J; CHEN, DL; ASLO, A; KOEFFLER, HP				MILLER, CW; CHUMAKOV, A; SAID, J; CHEN, DL; ASLO, A; KOEFFLER, HP			MUTANT-P53 PROTEINS HAVE DIVERSE INTRACELLULAR ABILITIES TO OLIGOMERIZE AND ACTIVATE TRANSCRIPTION	ONCOGENE			English	Article							WILD-TYPE P53; MAMMALIAN-CELLS; GENE; EXPRESSION; MUTATIONS; SEQUENCE; DOMAIN; TRANSFORMATION; ELEMENT; JUN	Accumulating evidence supports the hypothesis that tumor-suppressor p53 can act as a transcriptional activator. Insertion of high-affinity p53 DNA binding sites up-stream of a promoter yields a p53-responsive vector. Chimeric proteins fusing p53 and the GAL4 DNA-binding domain demonstrate the presence of a transcriptional activating domain in the N-terminus of p53. GAL4-p53 chimeras constructed using naturally occurring p53 mutations at either codon 141 (Tyr-141) or 175 (His-175) of p53 had little ability to activate the reporter gene; in contrast, mutations at either codon 248 (Trp-248) or 273 (His-273) produced greater transcriptional activities than did wild-type p53. GAL4 chimeras can be used to analyse interactions between different domains of p53 and between different p53 alleles; a DNA binding site is defined, and a simple measurement can be made of function. We had expected that coexpression of GAL4 chimeras and p53 alleles would squelch transcriptional activation downstream of GAL binding sites. Surprisingly, coexpression of either p53 (Trp-248) or (His-273) with the GALA-p53 (wild-type, His-273, Trp-248, His-175, Tyr-141) effectors conferred an increase in transcriptional activation as compared with the effector alone. Oligomerization of p53 alleles with GAL4-p53 chimeras could underlie this effect, leading to an increase in transcription-activating motifs near the promoter. To test this possibility, we constructed a GAL4- p53 C-terminal chimera with p53 residues 160-393, lacking the transcriptional activating domain but retaining regions believed to be important in p53 oligomerization. Neither GAL4-p53 (C-terminus) nor p53 expression vectors were able to transactivate G5E1B-CAT alone. Both p53 (His-273) and (Trp-248) co-expressed with GAL4-p53 (C-terminus) were able to transactivate the G5E1B-CAT reporter gene; in contrast, p53 (Tyr-141) was not able to activate transcription. p53 (Tyr-141/His-273) behaved as a dominant negative mutant and inhibited the ability of the combination of p53 (His-273) and GAL4-p53 (C-terminus) to stimulate the reporter gene. Double immunoprecipitation by sequentially using GAL4 and p53 antibodies showed that p53 (His-273) and (Tyr-141/ His-273), but not p53 (Tyr-141), can efficiently oligomerize in vivo to the C-terminal region of p53. Transcriptional activating function of p53 may be modulated by oligomerization; some mutations, such as His-273 and Trp-248, participate in these functions. The p53 proteins with mutations at Tyr-141 and His-175 have lost their abilities to transactivate and oligomerize efficiently in vivo, perhaps resulting in loss of their tumor-suppressor activities. In contrast, mutations in the region of codons 248 and 273 result in p53 proteins with potent abilities to transactivate and oligomerize in vivo, suggesting that these proteins in conjunction with loss of the normal allele of p53 may be able to behave in a similar way to recessive oncogenes.	UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,DEPT PATHOL,LOS ANGELES,CA 90048	Cedars Sinai Medical Center; University of California System; University of California Los Angeles	MILLER, CW (corresponding author), UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,DEPT MED,DIV HEMATOL ONCOL,5019 DAVIS BLDG,LOS ANGELES,CA 90048, USA.		Chumakov, Alexey/N-1541-2014	Chumakov, Alexey/0000-0003-2733-3166	NATIONAL CANCER INSTITUTE [P30CA042710, P01CA042710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA42710] Funding Source: Medline; NIDDK NIH HHS [DK42792] Funding Source: Medline; PHS HHS [IRT370] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BUSCH SJ, 1990, ONCOGENE, V63, P729; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FIELDS S, 1989, NATURE, V340, P240; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GLASS CK, 1990, CELL, V5, P1549; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, ONCOGENE HDB; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1992, BIOCHIM BIOPHYS ACTA, V1119, P11, DOI 10.1016/0167-4838(92)90227-5; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MALKIN D, 1990, SCIENCE, V250, P1236; MEDCALF EA, 1992, ONCOGENE, V7, P71; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1988, NATURE, V335, P653; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SOUSSI T, 1990, ONCOGENE, V5, P945; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570	47	48	50	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1815	1824						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510927				2022-12-25	WOS:A1993LG68200013
J	TSUTSUI, K; TSUTSUI, K; OKADA, S; WATARAI, S; SEKI, S; YASUDA, T; SHOHMORI, T				TSUTSUI, K; TSUTSUI, K; OKADA, S; WATARAI, S; SEKI, S; YASUDA, T; SHOHMORI, T			IDENTIFICATION AND CHARACTERIZATION OF A NUCLEAR SCAFFOLD PROTEIN THAT BINDS THE MATRIX ATTACHMENT REGION DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-II; MOLECULAR-CLONING; SUPERCOILED DNA; SITES; ENHANCER; CELLS; GENES; PURIFICATION; COMPONENT; ELEMENTS	The association of nuclear DNA with the nuclear matrix (scaffold) is mediated by defined segments of DNA called matrix association region (MAR). By using a plasmid harboring a portion of the Igkappa gene within which MAR had been located, we searched for proteins recognizing MAR in the nuclear scaffold components electrophoretically separated and blotted onto a membrane. In the presence of nonspecific competitor DNA, the labeled plasmid selectively bound to a protein with apparent molecular weight of 120,000 (designated SP120). The protein was purified directly from SDS-polyacrylamide gels and renatured by a guanidine hydrochloride procedure. The DNA region in the plasmid responsible for the binding to the solubilized SP120 coincided with the 365-base pair HindIII-HinfI fragment that had been identified as MAR. In solution, SP120 exhibited a cooperative mode of interaction with the end-labeled MAR fragment. Measurement of relative affinities of MAR subfragments to SP120 showed that the whole region is required for efficient binding. This is consistent with the minimal length for MAR estimated thus far by in situ mapping experiments. The MAR derived from another gene, fushitarazu, also bound specifically to SP120. Immunostaining of whole cells and isolated nuclei with a monoclonal antibody raised against SP120 indicated that the protein is localized in a nuclear skeletal structure. These results suggest the involvement of SP120 in the MAR-mediated anchorage of nuclear DNA to the nuclear scaffold.	OKAYAMA UNIV, SCH MED, INST CELLULAR & MOLEC BIOL, DEPT CELL CHEM, OKAYAMA 700, JAPAN; OKAYAMA UNIV, SCH MED, DEPT NEUROL, OKAYAMA 700, JAPAN	Okayama University; Okayama University	TSUTSUI, K (corresponding author), OKAYAMA UNIV, SCH MED, INST CELLULAR & MOLEC BIOL, DEPT MOLEC BIOL, 2-5-1 SHIKATA CHO, OKAYAMA 700, JAPAN.		Tsutsui, Ken/B-1863-2011; TSUTSUI, Kimiko M/B-1955-2011					ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADAMS LD, 1992, CURRENT PROTOCOLS MO; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; BELGRADER P, 1991, J BIOL CHEM, V266, P9893; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BLASQUEZ VC, 1989, J BIOL CHEM, V264, P21183; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DIJKWEL PA, 1988, MOL CELL BIOL, V8, P5398, DOI 10.1128/MCB.8.12.5398; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; GASSER SM, 1989, INT REV CYTOL, V119, P57; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; HAKES DJ, 1991, P NATL ACAD SCI USA, V88, P6186, DOI 10.1073/pnas.88.14.6186; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; IDE T, 1975, NATURE, V258, P445, DOI 10.1038/258445a0; ISHII K, 1983, J BIOL CHEM, V258, P2728; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; Kennett R H, 1979, Methods Enzymol, V58, P345; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; MIZUTANI M, 1991, NUCLEIC ACIDS RES, V19, P2907, DOI 10.1093/nar/19.11.2907; Reid L C, 1979, Methods Enzymol, V58, P152; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TSUTSUI K, 1989, J BIOL CHEM, V264, P7644; TSUTSUI K, 1988, J BIOL CHEM, V263, P7235; VERHEIJEN R, 1988, J CELL SCI, V90, P11; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J	29	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1993	268	17					12886	12894						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LG658	8509422				2022-12-25	WOS:A1993LG65800095
J	Spizz, G; Blackshear, PJ				Spizz, G; Blackshear, PJ			Protein kinase C-mediated phosphorylation of the myristoylated alanine-rich C-kinase substrate protects it from specific proteolytic cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MARCKS PROTEIN; TRANSCRIPTION FACTOR; MAJOR SUBSTRATE; CALMODULIN-BINDING; CELLULAR SUBSTRATE; NEUTRAL PROTEASE; DOWN-REGULATION; CALPAIN; EXPRESSION	The myristoylated alanine-rich C kinase substrate (MARCKS) is a major cellular substrate of protein kinase C, Its concentration in cells is important for the normal development of the central nervous system, and perhaps other physiological processes, We found that MARCKS concentrations in cells were regulated in part by a specific proteolytic cleavage; this resulted in two fragments, each representing about half of the intact protein, that co-existed with MARCKS in cells and tissues. These fragments were present in significant concentrations in quiescent fibroblasts; they disappeared, and the amount of intact MARCKS increased, within 15 s of activation of protein kinase C by serum, In vitro experiments demonstrated that phosphorylated MARCKS was a poor substrate for a protease activity present in cell extracts, whereas dephosphorylated MARCKS was a good substrate. Both the protease activity and the specific MARCKS cleavage products were essentially absent in brain, but present in many other cells and tissues, The protease activity, which had the characteristics of a cysteine protease, cleaved MARCKS between Asn(147) and Glu(148) of the bovine sequence, three amino acids to the amino-terminal side of the MARCKS phosphorylation site domain, These studies demonstrate that MARCKS is subjected to specific cleavage by a cellular protease, in a manner dependent on the phosphorylation state of the substrate, This represents a novel means of regulating cellular MARCKS concentrations; these data also raise the interesting possibility that MARCKS is involved in regulating the activity of this novel cellular protease.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV METAB ENDOCRINOL & NUTR,SECT DIABET & METAB,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,SARAH W STEDMAN CTR NUTR STUDIES,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BROOKS SF, 1992, J BIOL CHEM, V267, P14212; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BYERS DM, 1993, J NEUROCHEM, V60, P1414, DOI 10.1111/j.1471-4159.1993.tb03303.x; CHEN M, 1989, J BIOL CHEM, V264, P14282; COGGINS PJ, 1994, J NEUROCHEM, V63, P1491; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; ELVIRA M, 1993, J BIOL CHEM, V268, P14294; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HONG DH, 1995, BBA-MOL CELL RES, V1267, P45, DOI 10.1016/0167-4889(95)00024-M; JOHNSON GVW, 1993, J NEUROSCI RES, V34, P642, DOI 10.1002/jnr.490340607; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LINDNER D, 1992, J BIOL CHEM, V267, P24; LITERSKY JM, 1992, J BIOL CHEM, V267, P1563; LOBAUGH LA, 1990, J BIOL CHEM, V265, P18393; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MURAMATSU M, 1993, EUR J BIOCHEM, V215, P123, DOI 10.1111/j.1432-1033.1993.tb18014.x; OTSUKA M, 1991, BIOCHEM BIOPH RES CO, V178, P494, DOI 10.1016/0006-291X(91)90134-S; REED JC, 1991, CELL SIGNAL, V3, P569, DOI 10.1016/0898-6568(91)90033-Q; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L; WARRENER P, 1991, BIOCHEM BIOPH RES CO, V180, P716, DOI 10.1016/S0006-291X(05)81124-6; WOJTASZEK PA, 1993, ONCOGENE, V8, P755; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; ZWIERS H, 1990, PEPTIDES, V11, P951, DOI 10.1016/0196-9781(90)90015-W	54	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					553	562		10.1074/jbc.271.1.553	http://dx.doi.org/10.1074/jbc.271.1.553			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550618				2022-12-25	WOS:A1996TP36100084
J	Riedel, A; Fetzner, S; Rampp, M; Lingens, F; Liebl, U; Zimmermann, JL; Nitschke, W				Riedel, A; Fetzner, S; Rampp, M; Lingens, F; Liebl, U; Zimmermann, JL; Nitschke, W			EPR, electron spin echo envelope modulation, and electron nuclear double resonance studies of the 2Fe2S centers of the 2-halobenzoate 1,2-dioxygenase from Burkholderia (Pseudomonas) cepacia 2CBS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS RIESKE PROTEIN; MAIN CHAIN FOLD; PHTHALATE DIOXYGENASE; 2FE-2S CLUSTER; CYTOCHROME-B6F COMPLEX; 2.5-A RESOLUTION; N-COORDINATION; 2 HISTIDINES; FES CENTER; SPECTROSCOPY	The 2-halobenzoate 1,2-dioxygenase from Burkholderia (Pseudomonas) cepacia 2CBS (Fetzner, S., Muller, R., and Lingens, F. (1992) J. Bacteriol. 174, 279-290) contains both a ferredoxin-type and a Rieske-type 2Fe2S center, These two significantly different 2Fe2S clusters were characterized with respect to their EPR spectra, electrochemical properties (Rieske-type cluster with g(z) = 2.025, g(y) = 1.91, g(x) = 1.79, g(av) = 1.91, E(m) = -125 +/- 10 mV; ferredoxin-type center with g(z) = 2.05, g(y) = 1.96, g(x) = 1.89, g(av) = 1.97, E(m) = -200 +/- 10 mV) and pH dependence thereof, X band electron spin echo envelope modulation and electron nuclear double resonance spectroscopy was applied to study the interaction of the Rieske-type center of the 2-halobenzoate 1,2-dioxygenase with N-14 and H-1 nuclei in the vicinity of the 2Fe2S cluster. The results are compared to those obtained on the Rieske protein of the cytochrome b(6)f complex (E(m) = +320 mV) and the water-soluble ferredoxin (E(m) = -430 mV) of spinach chloroplasts, as typical representatives of the g(av) = 1.91 and g(av) = 1.96 class of 2Fe2S centers, Properties common to all Rieske-type clusters and those restricted to the respective centers in bacterial oxygenases are discussed.	UNIV HOHENHEIM, INST MIKROBIOL 250, D-70593 STUTTGART, GERMANY; UNIV PENN, DEPT BIOL, INST PLANT SCI, PHILADELPHIA, PA 19104 USA; CE SACLAY, DEPT BIOL CELLULAIRE & MOL, SECT BIOENERGET, F-91191 GIF SUR YVETTE, FRANCE; UNIV FREIBURG, INST BIOL 2, D-79104 FREIBURG, GERMANY	University Hohenheim; University of Pennsylvania; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Freiburg	Riedel, A (corresponding author), UNIV REGENSBURG, INST BIOPHYS & PHYS BIOCHEM, UNIV STR 31, D-93040 REGENSBURG, GERMANY.		Nitschke, Wolfgang/C-4812-2012	Nitschke, Wolfgang/0000-0003-2084-3032; Fetzner, Susanne/0000-0002-7228-1871; LIEBL, Ursula/0000-0003-0869-4388				ANEMULLER S, 1994, BIOCHEM BIOPH RES CO, V202, P252, DOI 10.1006/bbrc.1994.1920; ANEMULLER S, 1993, FEBS LETT, V318, P61, DOI 10.1016/0014-5793(93)81328-W; BACKES G, 1991, J AM CHEM SOC, V113, P2055, DOI 10.1021/ja00006a027; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; CAMMACK R, 1977, BIOCHEM J, V166, P347, DOI 10.1042/bj1660347; CLINE JF, 1985, J BIOL CHEM, V260, P3251; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; FETZNER S, 1989, BIOCHEM BIOPH RES CO, V161, P700, DOI 10.1016/0006-291X(89)92656-9; FETZNER S, 1992, J BACTERIOL, V174, P279, DOI 10.1128/jb.174.1.279-290.1992; GEARY PJ, 1984, BIOCHEM J, V217, P667, DOI 10.1042/bj2170667; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; GURBIEL RJ, 1991, BIOCHEMISTRY-US, V30, P11579, DOI 10.1021/bi00113a013; HAAK B, 1995, J BACTERIOL, V177, P667, DOI 10.1128/jb.177.3.667-675.1995; HAUSKA G, 1986, METHOD ENZYMOL, V126, P271; HAUSKA G, 1988, J BIOENERG BIOMEMBR, V20, P211, DOI 10.1007/BF00768395; INGLEDEW WJ, 1980, BIOCHEM J, V186, P111, DOI 10.1042/bj1860111; JACOBSON BL, 1993, BIOCHEMISTRY-US, V32, P6788, DOI 10.1021/bi00077a033; KUILA D, 1986, J BIOL CHEM, V261, P2768; LIEBL U, 1992, J BIOL CHEM, V267, P14068; LINK TA, 1994, BBA-BIOENERGETICS, V1185, P81, DOI 10.1016/0005-2728(94)90196-1; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MIMS WB, 1984, J MAGN RESON, V59, P291, DOI 10.1016/0022-2364(84)90174-4; NITSCHKE W, 1992, BIOCHIM BIOPHYS ACTA, V1102, P266, DOI 10.1016/0167-4838(92)90519-J; POWERS L, 1989, BIOCHIM BIOPHYS ACTA, V975, P293, DOI 10.1016/S0005-2728(89)80261-0; PRINCE RC, 1976, FEBS LETT, V65, P117, DOI 10.1016/0014-5793(76)80634-5; RICH PR, 1987, BIOCHIM BIOPHYS ACTA, V892, P138, DOI 10.1016/0005-2728(87)90256-8; RIEDEL A, 1993, BIOCHIM BIOPHYS ACTA, V1183, P268; RIESKE JS, 1964, BIOCHEM BIOPH RES CO, V15, P338, DOI 10.1016/0006-291X(64)90171-8; ROSCHE B, 1995, BBA-PROTEIN STRUCT M, V1252, P177, DOI 10.1016/0167-4838(95)00151-J; ROSCHE B, 1995, J BIOL CHEM, V270, P17836, DOI 10.1074/jbc.270.30.17836; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; SCHUTZ M, 1994, PHOTOSYNTH RES, V39, P163, DOI 10.1007/BF00029383; SHERGILL JK, 1994, BBA-BIOENERGETICS, V1185, P43, DOI 10.1016/0005-2728(94)90191-0; SHERGILL JK, 1994, BBA-BIOENERGETICS, V1185, P35, DOI 10.1016/0005-2728(94)90190-2; Sussman J L, 1989, Prog Clin Biol Res, V289, P171; TELSER J, 1987, FEBS LETT, V214, P117, DOI 10.1016/0014-5793(87)80024-8; TSANG HT, 1989, BIOCHEMISTRY-US, V28, P7233, DOI 10.1021/bi00444a015; TSUKIHARA T, 1981, J BIOCHEM-TOKYO, V90, P1763, DOI 10.1093/oxfordjournals.jbchem.a133654; TSUTSUI T, 1983, J BIOCHEM-TOKYO, V94, P299, DOI 10.1093/oxfordjournals.jbchem.a134343; WILSON GS, 1973, J BIOL CHEM, V248, P6059	44	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30869	30873		10.1074/jbc.270.52.30869	http://dx.doi.org/10.1074/jbc.270.52.30869			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537340	hybrid			2022-12-25	WOS:A1995TN44400008
J	Schodin, DJ; Zhuang, Y; Shapiro, DJ; Katzenellenbogen, BS				Schodin, DJ; Zhuang, Y; Shapiro, DJ; Katzenellenbogen, BS			Analysis of mechanisms that determine dominant negative estrogen receptor effectiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAIN; DEPENDENT TRANSCRIPTIONAL ACTIVATION; MUTATIONS; REGION; CELLS; IDENTIFICATION; DIMERIZATION; MUTAGENESIS; INHIBITION; RESISTANCE	To analyze the mechanisms by which estrogen receptor (ER) activity is suppressed by dominant negative mutants, we examined the role of specific ER functions and domains in transcriptional repression. We previously described three transcriptionally inactive human ER mutants (the frameshift mutant S554fs, the point mutant L540Q, and the truncated receptor ER1-530), which act as effective dominant negative mutants, inhibiting the activity of wild type ER when they are coexpressed in mammalian cells. After additional mutational modifications, the ability of the ER mutants to suppress the activity of wild type ER was analyzed in cotransfection assays of the dominant negative mutants and wild type ER and an estrogen-responsive reporter gene (SERE-TATA-CAT or 2ERE-pS2-CAT). Eliminating the ability of the three dominant negative mutants to bind to estrogen response element (ERE) DNA (by introducing three point mutations in their DNA binding domains) dramatically reduced, but did not completely abolish, the dominant negative activity of the ER mutants. The mutation G521R, which rendered the three mutants incapable of binding estradiol, also reduced, but did not abolish, their dominant negative activity. Immunoprecipitation with monoclonal or flag antibodies followed by Western blotting demonstrated that each of the original dominant negative ER mutants formed heterodimers with wild type ER. Rendering the dominant negative mutants dimerization deficient by the mutation L507R strongly reduced, but did not eliminate, their dominant negative activity. Deletion of the N-terminal A/B domain resulted in the nearly complete loss of inhibitory activity of the three dominant negative mutants. However, these double mutants retained their ability to heterodimerize with wild type ER, suggesting that dominant negative interference also occurs at an additional step beyond dimerization. Our data indicate that competition for ERE binding, formation of inactive heterodimers, and specific transcriptional silencing can all contribute to the dominant negative phenotype and that these receptors suppress the activity of wild type ER by acting at multiple steps in the ER-response pathway.	UNIV ILLINOIS,DEPT MOLEC & INTEGRAT PHYSIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL CANCER INSTITUTE [R01CA060514] Funding Source: NIH RePORTER; NCI NIH HHS [CA60514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ARONICA SM, 1995, P NATL ACAD SCI USA, V915, P8517; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHANG TC, 1992, MOL ENDOCRINOL, V6, P346, DOI 10.1210/me.6.3.346; CHO H, 1993, MOL ENDOCRINOL, V7, P441, DOI 10.1210/me.7.3.441; CLARET FX, 1994, J BIOL CHEM, V269, P14047; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FUQUA SAW, 1992, CANCER RES, V52, P483; GREEN S, 1991, NUCLEAR HORMONE RECE, P15; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; INCE BA, 1995, ENDOCRINOLOGY, V136, P3194, DOI 10.1210/en.136.8.3194; INCE BA, 1993, J BIOL CHEM, V268, P14026; KATZ D, 1993, J BIOL CHEM, V268, P20904; KATZENELLENBOGEN BS, 1993, J STEROID BIOCHEM, V47, P39, DOI 10.1016/0960-0760(93)90055-2; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JA, 1989, NUCLEIC ACIDS RES, V17, P5477; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P1571, DOI 10.1210/mend-5-11-1571; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; NAGAYA T, 1993, J CLIN ENDOCR METAB, V77, P982, DOI 10.1210/jc.77.4.982; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NIELSEN DA, 1989, ANAL BIOCHEM, V179, P19, DOI 10.1016/0003-2697(89)90193-0; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; REESE JC, 1991, NUCLEIC ACIDS RES, V19, P6595, DOI 10.1093/nar/19.23.6595; REESE JC, 1992, J BIOL CHEM, V267, P9868; REESE JC, 1991, J BIOL CHEM, V266, P10880; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WANG Y, 1991, MOL ENDOCRINOL, V11, P1707; WRENN CK, 1993, J BIOL CHEM, V268, P24089; YEN PM, 1994, J BIOL CHEM, V269, P903; ZHUANG Y, 1995, MOL ENDOCRINOL, V9, P457, DOI 10.1210/me.9.4.457; ZHUANG Y, 1995, THESIS U ILLINOIS UR	45	61	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31163	31171		10.1074/jbc.270.52.31163	http://dx.doi.org/10.1074/jbc.270.52.31163			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537380	hybrid			2022-12-25	WOS:A1995TN44400048
J	Atkinson, SJ; Crabbe, T; Cowell, S; Ward, RV; Butler, MJ; Sato, H; Seiki, M; Reynolds, JJ; Murphy, G				Atkinson, SJ; Crabbe, T; Cowell, S; Ward, RV; Butler, MJ; Sato, H; Seiki, M; Reynolds, JJ; Murphy, G			Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; TISSUE INHIBITOR; GELATINASE-A; METALLOPROTEINASES; MATRIX; STROMELYSIN; MECHANISMS; PRECURSOR	Membrane-type matrix metalloproteinase (MT-MMP) messenger RNA and protein expression were shown to be elevated in human fibroblasts following treatment with concanavalin A, coincident with the induction of the ability to process progelatinase A. CHO cells transfected with the cDNA for MT-MMP were able to process both wild type progelatinase A and a catalytically inactive mutant, E375A progelatinase A. Both proenzymes were converted to a 68-kDa intermediate (reducing gels) form, but only the wild type enzyme was processed further to a 66-kDa end product. In contrast, both forms of progelatinase were processed via the 68-kDa intermediate to 66 kDa by concanavalin A-stimulated fibroblasts. Further study of the processing of E375A progelatinase A by plasma membrane preparations from concanavalin A-stimulated fibroblasts showed that addition of active gelatinase A enhanced processing to the mature form. It was concluded that cell membrane-mediated activation of progelatinase A could be via a cascade involving both MT-MMP and intermolecular autolytic cleavage.	CELLTECH RES,SLOUGH SL1 4EN,BERKS,ENGLAND; KANAZAWA UNIV,CANC RES INST,DEPT MOLEC VIROL & ONCOL,KANAZAWA,ISHIKAWA 920,JAPAN	Celltech Group Ltd; Kanazawa University	Atkinson, SJ (corresponding author), STRANGEWAYS RES LAB,DEPT CELL & MOLEC BIOL,CAMBRIDGE CB1 4RN,ENGLAND.		Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015					BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; CRABBE T, 1994, FEBS LETT, V345, P14, DOI 10.1016/0014-5793(94)00412-9; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P14419, DOI 10.1021/bi00252a007; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; HEATH JK, 1982, J PERIODONTAL RES, V17, P183, DOI 10.1111/j.1600-0765.1982.tb01143.x; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; Sambrook J, 1989, MOL CLONING LABORATO; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P11403; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; TSUCHIYA Y, 1994, INT J CANCER, V56, P46; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023	26	217	220	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30479	30485		10.1074/jbc.270.51.30479	http://dx.doi.org/10.1074/jbc.270.51.30479			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530478	hybrid			2022-12-25	WOS:A1995TL67500043
J	Park, IK; Soderling, TR				Park, IK; Soderling, TR			Activation of Ca2+/calmodulin-dependent protein kinase (CaM-kinase) IV by CaM-kinase kinase in Jurkat T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; MOLECULAR-CLONING; ANTIGEN RECEPTOR; BINDING PROTEIN; CALMODULIN; AUTOPHOSPHORYLATION; EXPRESSION; GR; GENE; IDENTIFICATION	Ca2+/calmodulin-dependent protein kinase IV (CaM-kinase IV), a member of the CaM-kinase family involved in transcriptional regulation, is stimulated by Ca2+/CaM but also requires phosphorylation by a CaM-kinase kinase for full activation. In this study we investigated the physioloscal role of a CaM-kinase cascade in Jurkat T human lymphocytes through antigen receptor (CD3) signaling. Total and Ca2+-independent CaM-kinase IV activities were increased 8-14-fold by anti-CD3 antibody. This CD3-mediated activation involved phosphorylation since the immunoprecipitated CaM-kinase IV from stimulated Jurkat cells could be subsequently inactivated in vitro by protein phosphatase 2A. CaM-kinase IV immunoprecipitated from unstimulated Jurkat cells or CD3-negative mutant Jurkat cells could be activated in vitro 10-40-fold by CaM-kinase kinase purified from rat brain or thymus, whereas CaM-kinase IV from CD3 stimulated wild-type Jurkat cells was only activated to 2-3-fold by exogenous CaM-kinase kinase. CaM-kinase IV activation was triggered by Ca2+ acting through calmodulin since activation could also be elicited by ionomycin treatment, and CD3-mediated activation was blocked by the calmodulin antagonist calmidazolium. These data are consistent with a CaM-kinase cascade in which CaM-kinase TV is activated by a CaM-kinase kinase cascade triggered by elevated intracellular calcium in Jurkat cells.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044239] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44239] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; CARDENAS ME, 1995, ADV SEC MESS PHOSPH, V30, P281; CHO FS, 1994, BBA-MOL CELL RES, V1224, P156, DOI 10.1016/0167-4889(94)90123-6; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; ENSLEN E, 1995, BIOCHEM BIOPH RES CO, V207, P1038; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; KITANI T, 1994, J BIOCHEM-TOKYO, V115, P637, DOI 10.1093/oxfordjournals.jbchem.a124387; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LIN CR, 1987, P NATL ACAD SCI USA, V84, P5962, DOI 10.1073/pnas.84.16.5962; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MISRA RP, 1994, J BIOL CHEM, V269, P25483; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; ROOS G, 1993, LEUKEMIA, V7, P1538; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SAKAGAMI H, 1993, MOL BRAIN RES, V19, P215, DOI 10.1016/0169-328X(93)90029-O; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284	45	102	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30464	30469		10.1074/jbc.270.51.30464	http://dx.doi.org/10.1074/jbc.270.51.30464			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530476	hybrid			2022-12-25	WOS:A1995TL67500041
J	VONAHSEN, O; VOOS, W; HENNINGER, H; PFANNER, N				VONAHSEN, O; VOOS, W; HENNINGER, H; PFANNER, N			THE MITOCHONDRIAL PROTEIN IMPORT MACHINERY - ROLE OF ATP IN DISSOCIATION OF THE HSP70-CENTER-DOT-MIM44 COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-70; BINDING DOMAIN; TRANSLOCATION; MATRIX; PREPROTEINS; HYDROLYSIS; MEMBRANE; HSP70	Interaction of preproteins with the heat shock protein Hsp70 in the mitochondrial matrix is required for driving protein transport across the mitochondrial inner membrane. Binding of mt-Hsp70 to the protein Mim44 of the inner membrane import site seems to be an essential part of an ATP-dependent reaction cycle. However, the available results on the role played by ATP are controversial. Here we demonstrate that the mt-Hsp70 . Mim44 complex contains ADP and that a nonhydrolyzable analog of ATP dissociates the mt-Hsp70 . Mim44 complex in the presence of potassium ions. The previously reported requirement of ATP hydrolysis for complex dissociation was due to the use of a nonphysiological concentration of sodium ions. In the presence of potassium ions, mt-Hsp70 undergoes a conformational change that is not observed with a mutant Hsp70 defective in binding to Mim44. The mutant Hsp70 is able to bind substrate proteins, differentiating binding to Mim44 from binding to substrate proteins. We conclude that binding of ATP, not hydrolysis, is required to dissociate the mt-Hsp70 . Mim44 complex and that the reaction cycle includes an ATP-induced conformational change of mt-Hsp70.	UNIV FREIBURG,INST BIOCHEM,D-79104 FREIBURG,GERMANY	University of Freiburg			Pfanner, Nikolaus/AAV-7878-2021					Alberts B, 1994, MOL BIOL CELL, P508; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; NICHOLLS D, 1982, BIOENERGETICS; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1995, CURR BIOL, V5, P132; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; SCARPA A, 1979, MEMBRANE TRANSPORT B, V2, P263; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; TYLER DD, 1992, MITOCHONDRION HLTH D, P182; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VOOS W, 1994, MOL CELL BIOL, V14, P6627, DOI 10.1128/MCB.14.10.6627; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; WANG TF, 1993, J BIOL CHEM, V268, P26049; WILBANKS SM, 1995, J BIOL CHEM, V270, P2251, DOI 10.1074/jbc.270.5.2251	36	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29848	29853						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530381				2022-12-25	WOS:A1995TK38000041
J	JACKSON, PK; PASKIND, M; BALTIMORE, D				JACKSON, PK; PASKIND, M; BALTIMORE, D			MUTATION OF A PHENYLALANINE CONSERVED IN SH3-CONTAINING TYROSINE KINASES ACTIVATES THE TRANSFORMING ABILITY OF C-ABL	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; NORMAL CELLULAR HOMOLOG; FUJINAMI SARCOMA-VIRUS; STRUCTURAL SIMILARITY; SIGNAL TRANSDUCTION; NUCLEOTIDE-SEQUENCE; CATALYTIC DOMAINS; PHOSPHOLIPASE-C; LYMPHOID-CELLS; GENE-PRODUCTS	c-abl is the normal cellular homolog of the v-abl transforming gene of Abelson murine leukemia virus. By constructing recombinants between c- and v-abl retroviruses, we show that a point mutation in c-Abl is sufficient to change the myristoylated form of c-Abl into a protein able to transform fibroblasts, but not capable of transforming bone marrow or inducing Abelson disease. This activating mutation, which changes the phenylalanine at amino acid 420 to valine (F420V) found in the homologous position of v-Abl, is positioned outside of the SH3 domain, a region typically modified in transforming alleles of abl. Phenylalanine 420 is perfectly conserved among tyrosine kinases with N-terminal SH3 domains (the Src and Abl families). The equivalent position in other protein tyrosine kinases is a conserved hydrophobic residue that predicts the specific family to which that kinase belongs. Mutation of phenylalanine 420 to other hydrophobic residues activates c-Abl. Unlike other transforming variants of Abl, the F420V mutant protein is not highly phosphorylated on tyrosine. Mutation of the nearby proposed autophosphorylation site, tyrosine 412, shows that this tyrosine is not strictly required for fibroblast transformation in either F420V or SH3-deleted variants of c-Abl (IV).	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; ROCKEFELLER UNIV,NEW YORK,NY 10021	Massachusetts Institute of Technology (MIT); Whitehead Institute; Rockefeller University				Jackson, Peter/0000-0002-1742-2539	NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NCI NIH HHS [NCI CA51462-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LATT SA, 1983, J VIROL, V45, P1195, DOI 10.1128/JVI.45.3.1195-1199.1983; LEE R, 1985, RNA TUMOR VIRUSES, P861; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MELO JV, 1992, LEUKEMIA, V6, P786; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PIWINICAWORMS H, 1987, CELL, V49, P75; PONTICELLI AS, 1982, CELL, V29, P953, DOI 10.1016/0092-8674(82)90458-5; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REYNOLDS FH, 1980, J VIROL, V36, P374, DOI 10.1128/JVI.36.2.374-386.1980; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; ROSENBERG NE, 1980, J VIROL, V36, P563; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKEMORI T, 1987, EMBO J, V6, P951, DOI 10.1002/j.1460-2075.1987.tb04844.x; WANG JYJ, 1988, ONCOGENE RES, V3, P293; WANG JYJ, 1984, CELL, V36, P349; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEINMASTER GA, 1988, J VIROL, V62, P2016, DOI 10.1128/JVI.62.6.2016-2025.1988; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; WITTE ON, 1979, NATURE, V5730, P396; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	57	34	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1943	1956						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510937				2022-12-25	WOS:A1993LG68200027
J	NEUMANN, D; WIKSTROM, L; WATOWICH, SS; LODISH, HF				NEUMANN, D; WIKSTROM, L; WATOWICH, SS; LODISH, HF			INTERMEDIATES IN DEGRADATION OF THE ERYTHROPOIETIN RECEPTOR ACCUMULATE AND ARE DEGRADED IN LYSOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-GOLGI DEGRADATION; CELL ANTIGEN RECEPTOR; SEMLIKI FOREST VIRUS; ENDOPLASMIC-RETICULUM; ASIALOGLYCOPROTEIN RECEPTOR; PROTEIN-DEGRADATION; MEDIATED ENDOCYTOSIS; BINDING-PROPERTIES; MOLECULAR-CLONING; DOWN-REGULATION	The erythropoietin receptor (EPO-R) is synthesized in transfected Ba/F3 cells as a major 64-kDa endoglycosidase H (Endo H)-sensitive species, with a single N-linked oligosaccharide, and a minor 62-kDa unglycosylated form. Approximately half of the newly made EPO-R is processed to a mature 66-kDa form with a Golgi-processed Endo H-resistant oligosaccharide, of which only a minor fraction is expressed at the cell surface. Both the Endo H-sensitive and the Endo H-resistant forms of the receptor have a half-life of 45-60 min (Yoshimura, A., D'Andrea, A. D., and Lodish, H. F. (1 990) Proc. Natl. Acad. Sci. U. S. A. 87, 4139-4143). The mature, Endo H-resistant form of the EPO-R appears to be degraded in lysosomes or in other acidic organelles, since receptor degradation is blocked by treatment with NH4Cl, Chloroquine, or leupeptin. A fraction of the Endo H-resistant EPO-R molecules is cleaved, generating two fragments of 46 and 39 kDa. The sizes of these fragments and their reactivities with carboxyl-terminal-specific antibodies indicate that the receptor is cleaved at two sites in the exoplasmic domain, 7 kDa apart, and carboxyl-terminal to the N-glycosylation site. Both fragments are membrane anchored and are probably formed in a late or post-Golgi compartment, since their formation is blocked by incubation of cells at 20-degrees-C or by incubation with brefeldin A. These membrane-anchored COOH-terminal fragments are probably degraded in lysosomes or in other acidic vesicles as cell fractionation demonstrates that they colocalize with lysosomes, and similar to the intact EPO-R, their degradation is inhibited by NH4Cl. Finally, double labeling immunofluorescence experiments demonstrate that in NH4Cl-treated cells both intact mature EPO-R and the 46- and 39-kDa fragments accumulate in lysosomes and presumably are normally degraded there. The sensitivity of the EPO-R to endoproteolytic cleavages in its exoplasmic domain may relate to its low surface expression and to its extreme metabolic instability.	WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA; LUDWIG INST CANC RES, S-10401 STOCKHOLM, SWEDEN; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Ludwig Institute for Cancer Research; Massachusetts Institute of Technology (MIT)				Neumann, Drorit/0000-0002-4805-7511; Watowich, Stephanie/0000-0003-1969-659X	NHLBI NIH HHS [HL 32262] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUET M, 1981, VIROLOGY, V115, P249, DOI 10.1016/0042-6822(81)90108-2; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ASCOLI M, 1979, BIOCHIM BIOPHYS ACTA, V586, P608, DOI 10.1016/0304-4165(79)90051-5; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CASCIOLA LAF, 1988, J LIPID RES, V29, P1481; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DUNN WA, 1980, J BIOL CHEM, V255, P5971; DUPREZ V, 1986, J BIOL CHEM, V261, P5450; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GORDON PB, 1988, BIOCHEM BIOPH RES CO, V151, P40, DOI 10.1016/0006-291X(88)90556-6; GRANGER BL, 1990, J BIOL CHEM, V265, P12036; HARE JF, 1988, J BIOL CHEM, V263, P8759; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNUDSON VP, 1991, FASEB J, V5, P2130; KURAMOCHI S, 1990, J MOL BIOL, V216, P567, DOI 10.1016/0022-2836(90)90384-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPSON KE, 1988, J BIOL CHEM, V263, P10495; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; MORTIMORE GE, 1984, FED PROC, V43, P1289; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; QUELLE DE, 1991, P NATL ACAD SCI USA, V688, P4810; RABINOWITZ S, 1992, J CELL BIOL, V116, P95, DOI 10.1083/jcb.116.1.95; ROBB RJ, 1987, J IMMUNOL, V139, P855; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHWARTZ AL, 1982, J BIOL CHEM, V257, P4230; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; TODOKORO K, 1991, GENE, V106, P283; VONZASTROW M, 1989, J BIOL CHEM, V264, P6566; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1990, INT IMMUNOL, V2, P743, DOI 10.1093/intimm/2.8.743; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; ZUPAN AA, 1991, J BIOL CHEM, V266, P15384	50	71	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13639	13649						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514796				2022-12-25	WOS:A1993LH55300088
J	SPILLMANN, D; HARD, K; THOMASOATES, J; VLIEGENTHART, JFG; MISEVIC, G; BURGER, MM; FINNE, J				SPILLMANN, D; HARD, K; THOMASOATES, J; VLIEGENTHART, JFG; MISEVIC, G; BURGER, MM; FINNE, J			CHARACTERIZATION OF A NOVEL PYRUVYLATED CARBOHYDRATE UNIT IMPLICATED IN THE CELL-AGGREGATION OF THE MARINE SPONGE MICROCIONA-PROLIFERA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAS-LIQUID-CHROMATOGRAPHY; CHONDROITIN SULFATE; MASS SPECTROMETRY; PROTEIN LINKAGE; HIGH-RESOLUTION; CAPILLARY GLC; SEA-CUCUMBER; HUMAN-URINE; BODY WALL; BINDING	The species-specific Ca2+-dependent reaggregation of dissociated cells of the marine sponge Microciona prolifera is mediated by a large extracellular adhesion proteoglycan. The glycans of this molecule are involved in the interactions of the proteoglycan with itself and with the sponge cells. Monoclonal antibodies against the glycans block the aggregation of sponge cells (Misevic, G. N., Finne, J., and Burger, M. M. (1987) J. Biol. Chem. 262, 5870-5877). Proteoglycan oligosaccharides were prepared by partial acid hydrolysis of the isolated glycans, and their reactivity with the monoclonal antibodies was monitored after linkage to phospholipid and immunostaining of thin layer chromatograms. One major antibody-reactive oligosaccharide was detected and purified by ion-exchange chromatography and high performance liquid chromatography. H-1 NMR spectroscopy, fast atom bombardment-mass spectrometry, methylation analysis, and sequential chemical and enzymatic degradation studies indicated the structure [GRAPHICS] for the oligosaCcharide. The depyruvylated derivative of the oligosaccharide did not react with the aggregation-blocking antibody, which indicates that the pyruvate acetal is an essential part of the epitope.	FRIEDRICH MIESCHER INST, CH-4058 BASEL, SWITZERLAND; UNIV UTRECHT, BIJVOET CTR BIOMOLEC RES, DEPT BIOORGAN CHEM, 3508 TB UTRECHT, NETHERLANDS; UNIV UTRECHT, BIJVOET CTR BIOMOLEC RES, DEPT MASS SPECTROMETRY, 3508 TB UTRECHT, NETHERLANDS; UNIV HOSP BASEL, DEPT RES, CH-4031 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; Utrecht University; Utrecht University; University of Basel	SPILLMANN, D (corresponding author), UNIV TURKU, DEPT MED BIOCHEM, SF-20520 TURKU 52, FINLAND.		Misevic, Gradimir/D-8294-2016; Finne, Jukka/B-6881-2008	Misevic, Gradimir/0000-0001-5047-2936; Finne, Jukka/0000-0002-8076-3344				ARAKI S, 1989, J BIOL CHEM, V264, P19922; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BJOERN S, 1991, J BIOL CHEM, V266, P11051; CHAPLIN MF, 1982, ANAL BIOCHEM, V123, P336, DOI 10.1016/0003-2697(82)90455-9; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; DELL A, 1987, ADV CARBOHYD CHEM BI, V45, P19, DOI 10.1016/S0065-2318(08)60136-5; DUDMAN WF, 1986, CARBOHYD RES, V145, P175, DOI 10.1016/S0008-6215(00)90428-2; EGGENS I, 1989, J BIOL CHEM, V264, P9476; EGGENS I, 1989, BIOCHEM BIOPH RES CO, V158, P913, DOI 10.1016/0006-291X(89)92809-X; FONTANA JD, 1982, CARBOHYD RES, V108, P221, DOI 10.1016/S0008-6215(00)81792-9; FRANSSON LA, 1983, J BIOL CHEM, V258, P4342; FUKUDA M, 1984, J BIOL CHEM, V259, P8260; Galtsoff PS, 1929, BIOL BULL-US, V57, P250, DOI 10.2307/1536826; GAREGG PJ, 1980, CARBOHYD RES, V78, P127, DOI 10.1016/S0008-6215(00)83666-6; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; GILSERRANO A, 1990, CARBOHYD RES, V204, P103, DOI 10.1016/0008-6215(90)84025-P; HALLGREN P, 1975, J BIOL CHEM, V250, P5312; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HEDBYS L, 1989, GLYCOCONJUGATE J, V6, P161, DOI 10.1007/BF01050645; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JUMBLATT JE, 1980, BIOCHEMISTRY-US, V19, P1038, DOI 10.1021/bi00546a032; KARIYA Y, 1990, J BIOL CHEM, V265, P5081; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; KLINGER MM, 1981, J BIOL CHEM, V256, P7932; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; KOJIMA N, 1988, EUR J BIOCHEM, V174, P255, DOI 10.1111/j.1432-1033.1988.tb14091.x; LAMPIO A, 1991, ANAL BIOCHEM, V197, P132, DOI 10.1016/0003-2697(91)90368-4; LARRIBA G, 1978, FEBS LETT, V95, P190, DOI 10.1016/0014-5793(78)80081-7; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; MAGNANI JL, 1985, ANAL BIOCHEM, V150, P13, DOI 10.1016/0003-2697(85)90435-X; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NIKKILA EA, 1960, SCAND J CLIN LAB INV, V12, P209, DOI 10.3109/00365516009062424; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; PARKKINEN J, 1987, METHOD ENZYMOL, V138, P289, DOI 10.1016/0076-6879(87)38024-3; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; STRECKER G, 1992, EUR J BIOCHEM, V207, P995, DOI 10.1111/j.1432-1033.1992.tb17135.x; VARNER JA, 1988, J BIOL CHEM, V263, P8498; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WATANABE Y, 1989, J BIOCHEM-TOKYO, V106, P972, DOI 10.1093/oxfordjournals.jbchem.a122984; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	51	72	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13378	13387						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514776				2022-12-25	WOS:A1993LH55300054
J	Rogi, T; Tsujimoto, M; Nakazato, H; Mizutani, S; Tomoda, Y				Rogi, T; Tsujimoto, M; Nakazato, H; Mizutani, S; Tomoda, Y			Human placental leucine aminopeptidase oxytocinase - A new member of type II membrane-spanning zinc metallopeptidase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MATERNAL SERUM; 3 AMINOPEPTIDASES; MOLECULAR-CLONING; CONVERTING ENZYME; PROTEINS; SIGNAL; IDENTIFICATION; PURIFICATION; LOCALIZATION	The serum level of placental leucine aminopeptidase (P-LAP) increases during pregnancy. P-LAP degrades several peptide hormones such as oxytocin and vasopresin, suggesting a role in maintaining homeostasis during pregnancy. In the study reported here, we have isolated a cDNA clone with 4084 base pairs encoding P-LAP from a human placental cDNA library. The amino acid sequence deduced from the cDNA contained all of the sequences of the peptide fragments obtained by digestion of the purified protein with trypsin. The predicted P-LAP contains the HEXXH consensus sequence of zinc metallopeptidases, indicating that the enzyme belongs to this family, which includes aminopeptidase N and aminopeptidase A. The deduced sequence also contains a hydrophobic region near the N terminus, suggesting that the enzyme is a type II integral membrane protein. Northern blot analysis revealed that P-LAP was expressed in several tissues, some of which expressed two forms of mRNAs. These results suggest that the enzyme is synthesized as an integral membrane protein and is released into blood under some physiological conditions.	NAGOYA UNIV,SCH MED,DEPT OBSTET & GYNECOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; SUNTORY INST BIOMED RES,SHIMAMOTO,OSAKA 618,JAPAN	Nagoya University; Suntory Holdings Ltd								AKOWITZ A, 1989, GENE, V81, P295, DOI 10.1016/0378-1119(89)90190-X; BELDENT V, 1993, J BIOL CHEM, V268, P26428; BOS TJ, 1984, P NATL ACAD SCI-BIOL, V81, P2327, DOI 10.1073/pnas.81.8.2327; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; GOPALASWAMY G, 1984, CLIN CHIM ACTA, V144, P39, DOI 10.1016/0009-8981(84)90258-4; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; HUBERT C, 1991, J BIOL CHEM, V266, P15377; HUNZIKER W, 1986, CELL, V46, P227, DOI 10.1016/0092-8674(86)90739-7; INO K, 1994, JPN J CANCER RES, V85, P927, DOI 10.1111/j.1349-7006.1994.tb02970.x; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LALU K, 1986, BIOCHIM BIOPHYS ACTA, V873, P190, DOI 10.1016/0167-4838(86)90045-2; LALU K, 1985, INT J BIOCHEM, V17, P1227, DOI 10.1016/0020-711X(85)90013-8; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; MIZUTANI S, 1992, SEMIN REPROD ENDOCR, V10, P146, DOI 10.1055/s-2007-1018870; MIZUTANI S, 1976, CLIN BIOCHEM, V9, P16, DOI 10.1016/S0009-9120(76)80004-5; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; SAMBROOK J, 1982, MOL CLONING LABORATO, P108; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUDER B, 1994, P NATL ACAD SCI USA, V91, P9534, DOI 10.1073/pnas.91.20.9534; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; SPIESS M, 1985, J BIOL CHEM, V260, P1979; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; TSUJIMOTO M, 1992, ARCH BIOCHEM BIOPHYS, V292, P388, DOI 10.1016/0003-9861(92)90007-J; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WANG JY, 1993, P NATL ACAD SCI USA, V90, P1222, DOI 10.1073/pnas.90.4.1222; WATANABE Y, 1989, BIOCHEM MED METAB B, V41, P139, DOI 10.1016/0885-4505(89)90019-4; WELCH PA, 1995, INT IMMUNOL, V7, P737, DOI 10.1093/intimm/7.5.737; WU Q, 1990, P NATL ACAD SCI USA, V87, P993, DOI 10.1073/pnas.87.3.993	38	179	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					56	61		10.1074/jbc.271.1.56	http://dx.doi.org/10.1074/jbc.271.1.56			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550619	hybrid			2022-12-25	WOS:A1996TP36100010
J	Yamashiro, DJ; Nakagawara, A; Ikegaki, N; Liu, XG; Brodeur, GM				Yamashiro, DJ; Nakagawara, A; Ikegaki, N; Liu, XG; Brodeur, GM			Expression of TrkC in favorable human neuroblastomas	ONCOGENE			English	Article						neuroblastoma; TrkA; TrkB; TrkC; NT-3	NERVE GROWTH-FACTOR; N-MYC AMPLIFICATION; RAT TRKC; FACTOR RECEPTOR; CELL LINES; PROTOONCOGENE; ENCODES; NEUROTROPHIN-3; CULTURE; FAMILY	Human neuroblastomas have been found to express the neurotrophin receptors TrkA and TrkB. Expression of TrkA correlates with favorable outcome, while expression of full-length TrkB is associated with unfavorable, more aggressive, N-myc amplified tumors. In this study we have determined the expression of TrkC in neuroblastoma primary tumors and cell lines. Using probes for the extracellular domain and the tyrosine kinase domain of human TrkC, we found by Northern analysis that TrkC mRNA is expressed in 14 of 55 (25%) tumors from a representative panel of neuroblastomas, A 14 kb transcript was detected by both probes, indicating that it would encode the full-length TrkC protein. A significant association was found between TrkC mRNA expression detected by Northern analysis and lower stage tumors [stage 1, 2, 4S, 11 of 30 (37%); vs stage 3, 4, 3 of 25 (12%), chi(2) = 4.4, P< 0.04]. Only one of eight primary tumors with N-myc amplification had detectable TrkC mRNA expression and none of the eight neuroblastoma cell lines expressed TrkC by Northern analysis. Our results suggest that TrkC is involved in the biology of favorable neuroblastomas.	CHILDRENS HOSP,DIV ONCOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia					NCI NIH HHS [CA 09615] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009615] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; BIEDLER JL, 1978, CANCER RES, V38, P3751; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BORRELLO MG, 1993, INT J CANCER, V54, P540, DOI 10.1002/ijc.2910540404; BRODEUR GM, 1994, SEMIN DIAGN PATHOL, V11, P118; BRODEUR GM, 1993, J NATL CANCER I, V85, P344, DOI 10.1093/jnci/85.5.344; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1455; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHN SL, 1990, ONCOGENE, V5, P1821; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; KAPLAN DR, 1991, SCIENCE, V252, P158; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; KOGNER P, 1993, CANCER RES, V53, P2044; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; MANESS LM, 1994, NEUROSCI BIOBEHAV R, V18, P143, DOI 10.1016/0149-7634(94)90043-4; MCGREGOR LM, 1994, GENOMICS, V22, P267, DOI 10.1006/geno.1994.1383; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; NAKAGAWARA A, 1995, GENOMICS, V25, P538, DOI 10.1016/0888-7543(95)80055-Q; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SAMBROOK J, 1990, MOL CLONING LABORATO; SEGAL RA, 1994, P NATL ACAD SCI USA, V91, P12867, DOI 10.1073/pnas.91.26.12867; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; TISCHLER AS, 1984, CANCER, V54, P1344, DOI 10.1002/1097-0142(19841001)54:7<1344::AID-CNCR2820540718>3.0.CO;2-J; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; WARIS T, 1973, EXPERIENTIA, V29, P1128, DOI 10.1007/BF01946760; [No title captured]	35	73	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					37	41						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552397				2022-12-25	WOS:A1996TQ01400005
J	Danielson, KG; Pillarisetti, J; Cohen, IR; Sholehvar, B; Huebner, K; Ng, LJ; Nicholls, JM; Cheah, KSE; Iozzo, RV				Danielson, KG; Pillarisetti, J; Cohen, IR; Sholehvar, B; Huebner, K; Ng, LJ; Nicholls, JM; Cheah, KSE; Iozzo, RV			Characterization of the complete genomic structure of the human WNT-5A gene, functional analysis of its promoter, chromosomal mapping, and expression in early human embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANHYDRASE-LIKE DOMAIN; CELL CARCINOMA; DEVELOPMENTAL REGULATORS; MOUSE DEVELOPMENT; MAMMARY ONCOGENE; XENOPUS-LAEVIS; TRANSLOCATION; FAMILY; REGION; TRANSFORMATION	We report the complete genomic organization of the human WNT-5A gene, which encodes a cysteine-rich growth factor involved in cell-cell signaling during growth and differentiation. The gene comprises five exons with the terminal exon coding for a large 3'-untranslated region of approximate to 6.5 kilobase pairs and utilizes multiple polyadenylation signals to generate at least four discrete transcripts, We discovered a new leader exon interrupted by a 411-base pair intron that was retained in our original cDNA cloning, The promoter region was located in a GpC-rich island and harbored numerous cis-acting elements including several GC boxes and Sp1, AP1, and AP2 binding motifs, It lacked TATA or CAAT boxes typical of housekeeping and growth factor genes, In support of this, primer extension revealed two transcription start sites, Transient cell transfection assays showed functional promoter activity for the 3,g-kilobase pair 5'-flanking region, Interestingly, internal and 5' deletions revealed that the distal promoter was not required for full transcriptional activity and that the first 631 base pairs of WNT-5A harbored the strongest promoter activity. Using a panel of rodent-human hybrid DNAs carrying portions of chromosome 3p, we mapped the gene to 3p14.2-p21.1, between a constitutional and a familial renal cell carcinoma-associated translocation, In situ hybridization analyses of early human embryos at 28-42 days of gestation revealed that WNT-5A transcripts were not restricted to the developing brain and limbs but were also observed in the mesenchyme bordering the pharyngeal clefts and pouches and in the developing gonads and kidneys. The relatively high expression in the celomic epithelium and in the precursors of follicles and seminiferous tubules suggest a novel role for WNT-5A in germ-cell differentiation. This study provides the molecular basis for discerning the regulation of the WNT-5A gene and offers the opportunity to investigate genetic disorders linked to this important gene.	THOMAS JEFFERSON UNIV,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; UNIV HONG KONG,DEPT BIOCHEM,HONG KONG,HONG KONG; UNIV HONG KONG,DEPT PATHOL,HONG KONG,HONG KONG	Jefferson University; Jefferson University; University of Hong Kong; University of Hong Kong			Iozzo, Renato/AAS-1980-2020; Cheah, Kathryn/C-4222-2009; Nicholls, John Malcolm/C-4375-2009	Nicholls, John Malcolm/0000-0001-7217-7444; Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282, R01 CA51083] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOGAN JS, 1994, CELL, V76, P603, DOI 10.1016/0092-8674(94)90501-0; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; BULLRICH F, 1995, CYTOGENET CELL GENET, V70, P250, DOI 10.1159/000134045; BUSSE U, 1992, MECH DEVELOP, V40, P63; CHEAH KSE, 1991, DEVELOPMENT, V111, P945; CHIN H, 1991, GENOMICS, V11, P914, DOI 10.1016/0888-7543(91)90014-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DANIELSON KG, 1993, GENOMICS, V15, P146, DOI 10.1006/geno.1993.1022; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DRABKIN H, 1990, GENOMICS, V8, P435, DOI 10.1016/0888-7543(90)90029-T; DRABKIN HA, 1985, P NATL ACAD SCI USA, V82, P6980, DOI 10.1073/pnas.82.20.6980; DRUCKER BJ, 1989, NEW ENGL J MED, V321, P1383; EISENBERG LM, 1992, DEV BIOL, V154, P73, DOI 10.1016/0012-1606(92)90049-M; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; HUGUET EL, 1995, J BIOL CHEM, V270, P12851, DOI 10.1074/jbc.270.21.12851; IOZZO RV, 1995, CANCER RES, V55, P3495; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KRAUSS S, 1992, DEVELOPMENT, V116, P249; LAFORGIA S, 1993, CANCER RES, V53, P3118; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1992, ADV DEV BIOL, V1, P31; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; MOON RT, 1993, DEVELOPMENT, V119, P97; NASO MF, 1994, J BIOL CHEM, V269, P32999; NG LJ, 1993, DEV BIOL, V159, P403, DOI 10.1006/dbio.1993.1251; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PARR BA, 1993, DEVELOPMENT, V119, P247; PATHAK S, 1991, CANCER GENET CYTOGEN, V56, P209, DOI 10.1016/0165-4608(91)90173-R; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; RUSSELL J, 1992, DEVELOPMENT, V115, P475; SANTRA M, 1994, J BIOL CHEM, V269, P579; SIRACUSA LD, 1987, GENETICS, V117, P85; SLEGFRIED E, 1994, NATURE, V367, P76; SMOLICH BD, 1994, DEV BIOL, V166, P300, DOI 10.1006/dbio.1994.1316; STARNAUD R, 1993, MOL CELL BIOL, V13, P1590, DOI 10.1128/MCB.13.3.1590; TAM PPL, 1994, DEVELOPMENT, V120, P2925; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WARY KK, 1993, CANCER RES, V53, P1498; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	61	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31225	31234		10.1074/jbc.270.52.31225	http://dx.doi.org/10.1074/jbc.270.52.31225			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537388	hybrid			2022-12-25	WOS:A1995TN44400056
J	Iwasaki, T; Wakagi, T; Oshima, T				Iwasaki, T; Wakagi, T; Oshima, T			Resolution of the aerobic respiratory system of the thermoacidophilic archaeon, Sulfolobus sp strain 7 .3. The archaeal novel respiratory complex II (succinate: caldariellaquinone oxidoreductase complex) inherently lacks heme group	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; FUMARATE REDUCTASE; UBIQUINONE OXIDOREDUCTASE; DEHYDROGENASE COMPLEX; ELECTRON-TRANSPORT; THERMOPLASMA-ACIDOPHILUM; OXIDASE ACTIVITY; ACIDOCALDARIUS; ARCHAEBACTERIUM	An active respiratory complex II (succinate:quinone oxidoreductase) has been purified from tetraether lipid membranes of the thermoacidophilic archaeon, Sulfolobus sp. strain 7, It consists of four different subunits with apparent molecular masses of 66, 37, 33, and 12 kDa on sodium dodecyl sulfate polyacrylamide gel electrophoresis. The 66-kDa subunit contains a covalently bound flavin, the 37-kDa subunit is a possible iron-sulfur protein carrying three distinct types of EPR-visible FeS cluster, and the 33- and 12-kDa subunits are putative membrane-anchor subunits, respectively. While no heme group is detected in the purified complex II, it catalyzes succinate dependent reduction of ubiquinone-1 and 2,6-dichlorophenolindophenol in the absence of phenazine methosulfate. The respiratory complex II of Sulfolobus sp, strain 7 appears to be novel in that it functions as a true succinate:caldariellaquinone oxidoreductase, although inherently lacking any heme group. This further indicates that the heme group of several respiratory complexes II may not be involved in the redox intermediates of the electron transfer from succinate to quinone.	TOKUSHIMA RES INST, DEPT LIFE SCI, YOKOHAMA, KANAGAWA 226, JAPAN				Wakagi, Takayoshi/AAJ-4145-2021	Iwasaki, Toshio/0000-0001-9562-4649				Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ANEMULLER S, 1989, FEBS LETT, V244, P451, DOI 10.1016/0014-5793(89)80581-2; BACH M, 1993, BIOCHIM BIOPHYS ACTA, V1174, P103, DOI 10.1016/0167-4781(93)90101-I; BARASSI CA, 1985, J BACTERIOL, V163, P778, DOI 10.1128/JB.163.2.778-782.1985; BECKER M, 1991, FEBS LETT, V291, P331, DOI 10.1016/0014-5793(91)81314-X; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BROCK TD, 1972, ARCH MIKROBIOL, V84, P54, DOI 10.1007/BF00408082; CAMMACK R, 1987, BIOCHEM SOC T, V619, P1207; CECCHINI G, 1986, P NATL ACAD SCI USA, V83, P8898, DOI 10.1073/pnas.83.23.8898; COLE ST, 1982, EUR J BIOCHEM, V122, P479; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; CONDON C, 1985, J BIOL CHEM, V260, P9427; DANSON MJ, 1989, CAN J MICROBIOL, V35, P58, DOI 10.1139/m89-009; DARLISON MG, 1984, BIOCHEM J, V223, P507, DOI 10.1042/bj2230507; DAVIS KA, 1977, ARCH BIOCHEM BIOPHYS, V180, P459, DOI 10.1016/0003-9861(77)90060-1; DEROSA M, 1977, J CHEM SOC PERK T 1, P653, DOI 10.1039/p19770000653; EDMONDSON DE, 1976, FEBS LETT, V64, P255, DOI 10.1016/0014-5793(76)80305-5; GARTNER P, 1991, EUR J BIOCHEM, V200, P215, DOI 10.1111/j.1432-1033.1991.tb21070.x; GRADIN CH, 1985, ARCH BIOCHEM BIOPHYS, V239, P200, DOI 10.1016/0003-9861(85)90827-6; HAGERHALL C, 1992, BIOCHEMISTRY-US, V31, P7411, DOI 10.1021/bi00147a028; HATEFI Y, 1980, J BIOL CHEM, V255, P5530; HE SH, 1986, BIOCHEM BIOPH RES CO, V135, P1000, DOI 10.1016/0006-291X(86)91027-2; HENDERSTEDT L, 1981, MICROBIOL REV, V45, P542; HENDERSTEDT L, 1986, METHOD ENZYMOL, V126, P399; HENDERSTEDT L, 1980, J BACTERIOL, V144, P933; Iwasaki T, 1995, J BIOL CHEM, V270, P30893, DOI 10.1074/jbc.270.52.30893; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; KENNEY WC, 1977, FEBS LETT, V73, P239, DOI 10.1016/0014-5793(77)80989-7; KERSCHER L, 1982, EUR J BIOCHEM, V128, P223; KERSCHER L, 1982, TRENDS BIOCHEM SCI, V7, P371, DOI 10.1016/0968-0004(82)90118-9; KITA K, 1989, J BIOL CHEM, V264, P2672; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; KROGER A, 1992, ARCH MICROBIOL, V158, P311, DOI 10.1007/BF00245358; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNUSSON K, 1986, J BACTERIOL, V166, P1067, DOI 10.1128/jb.166.3.1067-1071.1986; MOLL R, 1991, EUR J BIOCHEM, V201, P593, DOI 10.1111/j.1432-1033.1991.tb16319.x; MOLL R, 1989, BIOL CHEM H-S, V370, P936; OHNISHI T, 1987, CURR TOP BIOENERG, V15, P37; PENNOYER JD, 1988, BIOCHIM BIOPHYS ACTA, V935, P195, DOI 10.1016/0005-2728(88)90216-2; PHILLIPS MK, 1987, J BACTERIOL, V169, P864, DOI 10.1128/jb.169.2.864-873.1987; SALERNO JC, 1991, BIOCHEM SOC T, V19, P599, DOI 10.1042/bst0190599; SCHAFER G, 1990, FEMS MICROBIOL LETT, V75, P335, DOI 10.1016/0378-1097(90)90543-Y; Singer TP, 1971, METHODS ENZYMOL    B, V18, P416; SUCHETA A, 1992, NATURE, V356, P361, DOI 10.1038/356361a0; TUSHURASHVILI PR, 1985, BIOCHIM BIOPHYS ACTA, V809, P145, DOI 10.1016/0005-2728(85)90057-X; WAKAGI T, 1986, SYST APPL MICROBIOL, V7, P342; WAKAGI T, 1989, BIOCHEM BIOPH RES CO, V165, P1110, DOI 10.1016/0006-291X(89)92717-4; WAKAO H, 1987, J BIOCHEM, V102, P255, DOI 10.1093/oxfordjournals.jbchem.a122049; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOOD D, 1984, BIOCHEM J, V222, P519, DOI 10.1042/bj2220519; YU L, 1982, J BIOL CHEM, V257, P2016; YU L, 1987, J BIOL CHEM, V262, P1137; YU L, 1992, J BIOL CHEM, V267, P24508	55	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30902	30908		10.1074/jbc.270.52.30902	http://dx.doi.org/10.1074/jbc.270.52.30902			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537344	hybrid			2022-12-25	WOS:A1995TN44400012
J	Rahman, A; Esmaili, A; Saatcioglu, F				Rahman, A; Esmaili, A; Saatcioglu, F			A unique thyroid hormone response element in the human immunodeficiency virus type 1 long terminal repeat that overlaps the spl binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID; DNA-BINDING; RXR-BETA; INDEPENDENT ACTIVATION; SYNDROME AIDS; RECEPTORS; GENE; PROTEIN; TRANSCRIPTION; HETERODIMERIZATION	Long terminal repeat (LTR) of human immunodeficiency virus (HN) type 1 is activated by thyroid hormone (T3) receptor alpha (T3R alpha) in the absence of ligand. Addition of T3 reverses this effect. This activity is mediated by a high affinity T3 response element (TSRE) within the HIV-1 LTR, termed the HIV-T3RE (bases -74 to -50), which coincides with the Spl element as demonstrated by mobility shift, DNaseI footprinting, and methylation interference analyses. HIV-T3RE mediates ligand-independent activation of transcription by T3R alpha when linked to a heterologous promoter. In addition, the viral transactivator Tat synergizes with T3R alpha to activate the HIV-1 LTR in the absence of T3, which is relieved in its presence. These findings have implications for the possible control of HIV-1 LTR activity by T3.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego								BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERNAL J, 1984, ACTA ENDOCRINOL-COP, V105, P429, DOI 10.1530/acta.0.1050429; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURMAN KD, 1980, J CLIN ENDOCR METAB, V51, P106, DOI 10.1210/jcem-51-1-106; CROXSON TS, 1986, 1986 P INT C AIDS PA, P37; DESAIYAJNIK V, 1993, MOL CELL BIOL, V13, P5057, DOI 10.1128/MCB.13.8.5057; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOBS AS, 1988, AM J MED, V84, P611, DOI 10.1016/0002-9343(88)90144-1; DURAND B, 1992, CELL, V71, P732; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GREENE LW, 1984, ANN INTERN MED, V101, P497, DOI 10.7326/0003-4819-101-4-497; GUENTHNER EE, 1984, ANN INTERN MED, V100, P847, DOI 10.7326/0003-4819-100-6-847; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; JEANG KT, 1988, J VIROL, V2, P3874; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE MO, 1995, MOL CELL BIOL, V15, P4194; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEONARD J, 1989, J VIROL, V63, P219; LOPRESTI JS, 1989, ANN INTERN MED, V110, P970, DOI 10.7326/0003-4819-110-12-970; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MILLIGAN SA, 1984, AM J MED, V77, P760, DOI 10.1016/0002-9343(84)90381-4; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; TANG WW, 1989, WESTERN J MED, V151, P627; TOMICCANIC M, 1992, J INVEST DERMATOL, V99, P842, DOI 10.1111/1523-1747.ep12614806; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	39	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31059	31064		10.1074/jbc.270.52.31059	http://dx.doi.org/10.1074/jbc.270.52.31059			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537364	hybrid			2022-12-25	WOS:A1995TN44400032
J	Hu, CD; Kariya, K; Tamada, M; Akasaka, K; Shirouzu, M; Yokoyama, S; Kataoka, T				Hu, CD; Kariya, K; Tamada, M; Akasaka, K; Shirouzu, M; Yokoyama, S; Kataoka, T			Cysteine-rich region of Raf-1 interacts with activator domain of post-translationally modified Ha-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							AMINO-ACID-RESIDUES; SIGNAL TRANSDUCTION; MOLECULAR SWITCH; IDENTIFICATION; PROTEINS; MUTAGENESIS; P21(RAS); RAS-P21; CYCLASE; KINASE	The interaction between ''switch I/effector domain'' of Ha-Ras and the Ras-binding domain (RBD, amino acid 51-131) of Raf-1 is essential for signal transduction, However, the importance of the ''activator domain'' (approximately corresponding to amino acids 26-28 and 40-49) of Ha-Ras and of the ''cysteine-rich region'' (CRR, amino acids 152-184) of Raf-1 have also been proposed. Here, we found that Raf-1 CRR interacts directly with Ha-Ras independently of RBD and that participation of CRR is necessary for efficient Ras-Raf binding. Furthermore, Ha-Ras carrying mutations (N26G and V45E) in the activator domain failed to bind CRR, whereas they bound RBD normally. On the contrary, Ha-Ras carrying mutations in the switch I/effector domain exhibited severely reduced ability to bind RBD, whereas their ability to bind CRR was unaffected, Mutants that bound to either RBD or CRR alone failed to activate Raf-1. Ha-Ras without post-translational modifications, which lacks the ability to activate Raf-1, selectively lost the ability to bind CRR. These results suggest that the activator domain of Ha-Ras participates in activation of Raf-1 through interaction with CRR and that post-translational modifications of Ha-Ras are required for this interaction.	KOBE UNIV,SCH MED,DEPT PHYSIOL 2,CHUO KU,KOBE 650,JAPAN; UNIV TOKYO,SCH SCI,DEPT BIOCHEM & BIOPHYS,BUNKYO KU,TOKYO 113,JAPAN; INST PHYS & CHEM RES,CELLULAR SIGNALING LAB,WAKO,SAITAMA 35101,JAPAN	Kobe University; University of Tokyo; RIKEN			Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; 				Barnard D, 1995, ONCOGENE, V10, P1283; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; FUJITAYOSHIGAKI J, 1991, FEBS LETT, V294, P187, DOI 10.1016/0014-5793(91)80665-P; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINATO T, 1994, J BIOL CHEM, V269, P20845; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	32	128	131	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30274	30277		10.1074/jbc.270.51.30274	http://dx.doi.org/10.1074/jbc.270.51.30274			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530446	hybrid			2022-12-25	WOS:A1995TL67500011
J	Hurlin, PJ; Foley, KP; Ayer, DE; Eisenman, RN; Hanahan, D; Arbeit, JM				Hurlin, PJ; Foley, KP; Ayer, DE; Eisenman, RN; Hanahan, D; Arbeit, JM			Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis	ONCOGENE			English	Article						Myc-Mad network; epithelial differentiation; HPV; neoplastic progression; keratinocytes	C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; CELL-DIFFERENTIATION; HUMAN KERATINOCYTES; NEOPLASTIC-CELLS; GENE-EXPRESSION; PROTEIN; PROLIFERATION; DISTINCT	c-Myc and Mad each form heterodimers with Max that bind the same E-box related DNA sequences, Whereas Myc:Max complexes activate transcription and promote cell proliferation and transformation, Mad:Max complexes repress transcription and block c-Myc-mediated cell transformation. Here we examine these antagonistic transcription factors during epithelial differentiation and neoplastic progression, During differentiation of primary human keratinocytes, Mad is rapidly induced and c-Myc is downregulated, resulting in a switch from c-Myc:Max to Mad:Max heterodimers, In normal epidermis and colonic mucosa c-myc expression is proliferating cell layers, while mad restricted to differentiating cell layers, Using HPV18 transformed keratinocytes that vary in their ability to differentiate in organotypic cultures, we find that Mad induction occurs only in those cells that retain a differentiation response, In the epidermis of transgenic mice in which expression of the HPV16 E6 and E7 oncogenes are targeted to basal keratinocytes, neoplastic progression occurs and is marked by an expansion of c-myc expressing basal-like cells. Expression of mad is found only in growth-arrested differentiating cells on the outer edges of preneoplastic lesions, The squamous cell carcinomas that arise evidence a variable number of sites within the tumor masses where mad expression and morphological differentiation coincide; increasing malignancy correlates with loss of both mad and capability to differentiate, These results indicate that c-Myc and Mad expression are tightly coupled to the transition from proliferation to differentiation of epithelial cells and that restriction of Mad expression may be associated with loss of normal differentiation capability and with tumorigenesis.	FRED HUTCHINSON CANC RES CTR, DIV BASIC SCI, SEATTLE, WA 98104 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT SURG, SAN FRANCISCO, CA 94143 USA	Fred Hutchinson Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Arbeit, Jeffrey/K-6920-2019; Foley, Kevin/ABC-1041-2020	Ayer, Donald/0000-0002-5595-3269	NATIONAL CANCER INSTITUTE [R01CA057138, R01CA047632] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA47632-07A1, R01CA57138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; Angerer L.M., 1992, IN SITU HYBRIDIZATIO, P15; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ASSELINEAU D, 1986, J INVEST DERMATOL, V86, P181, DOI 10.1111/1523-1747.ep12284237; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; AYER DE, 1995, GENE DEV, V80, P767; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Broders AC, 1932, NYJ MED, V32, P667; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DOTTO GP, 1986, EMBO J, V5, P2853, DOI 10.1002/j.1460-2075.1986.tb04579.x; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; Farthing Alan J., 1994, Trends in Microbiology, V2, P170, DOI 10.1016/0966-842X(94)90667-X; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUCHS E, 1993, J CELL SCI, P197; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; HURLING PJ, 1995, IN PRESS EMBO J; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; Maniatis T., 1982, MOL CLONING; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MERRICK DT, 1992, AM J PATHOL, V140, P167; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; OKUN MR, 1988, GROSS MICROSCOPIC PA, V2, P806; PIENTENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POTTEN CS, 1992, GUT, V33, P71, DOI 10.1136/gut.33.1.71; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHWEIZER J, 1984, CELL, V37, P159, DOI 10.1016/0092-8674(84)90311-8; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TAKASAKI Y, 1981, J EXP MED, V154, P1899, DOI 10.1084/jem.154.6.1899; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; WILLE JJ, 1985, CARCINOGENESIS, V6, P1181, DOI 10.1093/carcin/6.8.1181; YAAR M, 1993, EXP CELL RES, V206, P235, DOI 10.1006/excr.1993.1143; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZURHAUSEN H, 1990, VIROLOGY, V184, P9	63	149	150	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 21	1995	11	12					2487	2501						15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545105				2022-12-25	WOS:A1995TP18800004
J	REALINI, C; RECHSTEINER, M				REALINI, C; RECHSTEINER, M			A PROTEASOME ACTIVATOR SUBUNIT BINDS CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RABBIT RETICULOCYTE LYSATE; MULTICATALYTIC PROTEINASE; CA-2+-BINDING PROTEINS; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; PURIFICATION; MEMBRANE; IDENTIFICATION; CALSEQUESTRIN; GLYCOPROTEIN	We recently cloned a cDNA encoding the 29-kDa subunit of human red blood cell regulator (REG), a potent activator of the multicatalytic protease (Realini, C., Dubiel, W., Pratt, G., Ferrell, K., and Rechsteiner, M. (1994) J. Biol. Chem. 269, 20727-20732). The sequence of this subunit contains 28 ''alternating'' lysine and glutamic acid residues (a KERE motif), Similar regions are present in a number of Ca2+-binding proteins, and using standard filter assays, the recombinant protein is shown to bind Ca-45(2+) and ruthenium red, Ca-45(2+) is also bound to a ubiquitin extension protein containing the 28-residue KEKE region from the 29-bDa REG subunit, Thus, the 29-kDa REG subunit is a Ca2+-binding protein, and its KEKE region is able to bind divalent cations, Ca2+ reversibly inhibits the enhanced peptidase activity of complexes between the multicatalytic protease and recombinant REG, This raises the possibility that multicatalytic protease activity is regulated by calcium in vivo.			REALINI, C (corresponding author), UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132, USA.				NIGMS NIH HHS [GM37009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKSH S, 1991, J BIOL CHEM, V266, P21458; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; KOPP F, 1995, J MOL BIOL, V248, P264; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, J BIOL CHEM, V267, P10515; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; UDVARDY A, 1994, J BIOL CHEM, V268, P9055; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WADA I, 1991, J BIOL CHEM, V266, P19599; YOO Y, 1990, ANAL BIOCHEM, V191, P35, DOI 10.1016/0003-2697(90)90383-K; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	37	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29664	29667						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530352				2022-12-25	WOS:A1995TK38000012
J	HADMAN, M; LOO, M; BOS, TJ				HADMAN, M; LOO, M; BOS, TJ			INVIVO VIRAL AND CELLULAR JUN COMPLEXES EXHIBIT DIFFERENTIAL INTERACTION WITH A NUMBER OF INVITRO GENERATED AP-1-LIKE AND CREB-LIKE TARGET SEQUENCES	ONCOGENE			English	Article							C-JUN; LEUCINE ZIPPER; FOS PROTEIN; EMBRYO FIBROBLASTS; V-JUN; DNA; AP-1; TRANSCRIPTION; DOMAIN; ONCOGENE	A direct comparison of the relative DNA-binding capabilities of in vivo Jun-containing complexes derived from overexpression of the highly transforming viral Jun (VJ-1 CEF), the weakly transforming chicken cellular Jun (CJ-3 CEF) or background endogenous Jun (RCAS CEF) was assessed by gel mobility-shift assays using a synthetic oligonucleotide containing the consensus sequence TGACTCA (consensus AP-1). Chicken embryo fibroblasts (CEFs) expressing background c-Jun levels (RCAS CEF) contain almost undetectable levels of c-Jun but retain significant DNA-binding activity with two distinct complexes capable of binding specifically to the consensus AP-1 site. CEFs overexpressing either v-Jun or c-Jun contain these same two complexes and, while showing marked increases in Jun protein levels, do not exhibit any increase in DNA binding or transcriptional activation activity, suggesting that much of the overexpressed protein is inactive. Gel-shift assays performed in the presence of a Jun-specific antibody revealed a reduction in binding by both complexes, suggesting that each contains Jun or a Jun cross-reactive protein. Antibodies specific for Jun B, c-Fos, Fos B and CREB failed to interact with either complex. However, antibody specific for Fra-2 caused a slight supershift, suggesting that one or both complexes may contain Fra-2. Gel-shift competition assays with 16 'AP-1- and CREB-like' target sequences revealed that, within each cell type, the two protein complexes varied in their ability to recognize the mutant target sequences. These results clearly indicate differences in potential target recognition by each specific in vivo complex, and suggest that each may preferentially bind its own subset of target DNAs. In addition, a comparison of binding by individual complexes derived from CEFs overexpressing v-Jun and c-Jun also revealed differences in target recognition. Thus, in vivo complexes formed by overexpression of v-Jun and c-Jun vary in their ability to recognize and bind to a number of 'AP-1- and CREB-like' target sequences. This has important implications with regard to the mechanisms involved in cell transformation by v-Jun.	EASTERN VIRGINIA MED SCH, DEPT MICROBIOL & IMMUNOL, POB 1980, NORFOLK, VA 23501 USA	Eastern Virginia Medical School					NCI NIH HHS [NCI R29 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1989, ONCOGENE, V4, P123; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1990, ONCOGENE, V5, P929; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GROSSI M, 1991, ONCOGENE, V6, P1767; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HUGHES M, 1992, CELL GROWTH DIFFER, V3, P889; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; RANSONE LJ, 1990, MOL CELL BIOL, V10, P4565, DOI 10.1128/MCB.10.9.4565; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYSECK RP, 1991, ONCOGENE, V6, P533; RYSECK RP, 1990, ONCOGENE, V5, P1091; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SHARMA A, 1989, P NATL ACAD SCI USA, V86, P491, DOI 10.1073/pnas.86.2.491; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SU HY, 1991, ONCOGENE, V6, P1759; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1990, CANCER BIOL, V1, P27	37	41	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1895	1903						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510933				2022-12-25	WOS:A1993LG68200022
J	CHEN, WN; LIM, HH; LIM, L				CHEN, WN; LIM, HH; LIM, L			THE CDC42 HOMOLOG FROM CAENORHABDITIS-ELEGANS - COMPLEMENTATION OF YEAST MUTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE GENE; ACTIVATING PROTEIN; MOLECULAR-CLONING; CELL POLARITY; RAS PROTEIN; IDENTIFICATION; ENCODES; G25K; PRODUCT	A Caenorhabditis elegans cDNA encoding a homologue of the p21 ras-related CDC42, designated as CDC42Ce, was isolated from a nematode mixed stage cDNA library. The encoded protein of 188 amino acid residues has 85% identity to both human G25K and CDC42Hs and 79 and 76% identity to the yeast CDC42Sp and CDC42Sc proteins, respectively. The CDC42Ce cDNA maps to a position on C. elegans chromosome II in close proximity to lin-26, a cell lineage gene. The CDC42Ce cDNA hybridizes to 2- and 1.5-kilobase mRNAs. Their expression is developmentally regulated with highest levels at the embryonic stage, decreasing progressively during development except for an increase of the more abundant 1.5-kilobase mRNA at the L3 stage. The glutathione S-transferase/CDC42Ce fusion protein expressed in Escherichia coli displays both GTP binding and intrinsic GTPase activities. The GTPase activity of CDC42Ce is moderately stimulated by human n-chimaerin, a GTPase-activating protein for the related p21 rac1. The CDC42Ce protein complements the temperature-sensitive lethal mutation cdc42-1 in yeast Saccharomyces cerevisiae. These data suggest that CDC42Ce is the C. elegans homologue of the yeast CDC42. The developmental expression pattern of mRNA and is biochemical properties of its encoded protein which are closely related to CErac1 suggest that the two p21s might be involved in related biological processes.	INST NEUROL, LONDON WC1N 1PJ, ENGLAND	University of London; University College London	CHEN, WN (corresponding author), NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE.			Lim, Hong Hwa/0000-0002-0951-7220; , Yang/0000-0002-6620-8897				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHEN WI, 1993, J BIOL CHEM, V268, P320; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FAWELL E, 1992, GENE, V114, P153, DOI 10.1016/0378-1119(92)90724-4; GOLDEN A, 1992, BIOESSAYS, V14, P481, DOI 10.1002/bies.950140710; HALL C, 1990, J MOL BIOL, V211, P11, DOI 10.1016/0022-2836(90)90006-8; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HART MJ, 1991, J BIOL CHEM, V266, P20840; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; MANSER E, 1992, J BIOL CHEM, V267, P16025; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MENARD L, 1992, EUR J BIOCHEM, V206, P537, DOI 10.1111/j.1432-1033.1992.tb16957.x; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; POLAKIS PG, 1989, BIOCHEM BIOPH RES CO, V160, P25, DOI 10.1016/0006-291X(89)91615-X; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J, 1989, MOL CLONING LABORATO; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WOOD WB, 1988, NEMATODE CAENORHABDI, P602; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	31	52	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13280	13285						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514766				2022-12-25	WOS:A1993LH55300041
J	RATAJCZAK, T; CARRELLO, A; MARK, PJ; WARNER, BJ; SIMPSON, RJ; MORITZ, RL; HOUSE, AK				RATAJCZAK, T; CARRELLO, A; MARK, PJ; WARNER, BJ; SIMPSON, RJ; MORITZ, RL; HOUSE, AK			THE CYCLOPHILIN COMPONENT OF THE UNACTIVATED ESTROGEN-RECEPTOR CONTAINS A TETRATRICOPEPTIDE REPEAT DOMAIN AND SHARES IDENTITY WITH P59 (FKBP59)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; CELL GLUCOCORTICOID RECEPTOR; AMINO-ACID SEQUENCE; NON-DNA-BINDING; SACCHAROMYCES-CEREVISIAE; PROGESTERONE-RECEPTOR; 59-KILODALTON PROTEIN; STEROID-RECEPTORS; GENE; COMPLEXES	Using a rapid single-step affinity chromatography procedure we have isolated the unactivated estrogen receptor from bovine uterus. Results of sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western analyses for protein extracts recovered from affinity chromatography of receptor cytosols, either preincubated or untreated with estradiol, suggest a component structure for the intact oligomeric receptor which includes hsp90, hsp70, p59, a 40-kDa cyclophilin-related protein, and an uncharacterized 22-kDa protein species. We have chemically determined the amino acid sequences of eight peptides derived from the 40-kDa component and now report the cloning and primary sequence of a cDNA encoding this protein, which is designated estrogen receptor-binding cyclophilin (ERBC). Homology analyses confirm that ERBC is a new member of the cyclophilin family and contains a C-terminal domain with significant sequence homology to an internal region of p59, a binding protein for the immunosuppressant FK506 (FKBP59). This conserved region includes a 3-unit tetratricopeptide repeat domain bounded at the C terminus by a putative calmodulin binding site. We propose that the tetratricopeptide repeat domain mediates the protein interaction properties of ERBC and p59. Both immunophilins may have important roles in receptor assembly and may represent a new category of ligand- and calcium-dependent modulators of protein function.	SIR CHARLES GAIRDNER HOSP, QUEEN ELIZABETH II MED CTR, DEPT SURG, NEDLANDS, WA 6009, AUSTRALIA; LUDWIG INST CANC RES, JOINT PROT STRUCT LAB, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	University of Western Australia; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute	RATAJCZAK, T (corresponding author), SIR CHARLES GAIRDNER HOSP, QUEEN ELIZABETH II MED CTR, DEPT ENDOCRINOL & DIABET, NEDLANDS, WA 6009, AUSTRALIA.		Mark, Peter/H-5365-2014; Moritz, Robert L/B-9222-2011	Simpson, Richard/0000-0002-9834-0796				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ATRACHE V, 1985, J BIOL CHEM, V260, P5936; BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HARDING MW, 1986, J BIOL CHEM, V261, P8547; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HOHMAN R J, 1990, New Biologist, V2, P663; HONORE B, 1992, J BIOL CHEM, V267, P8485; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBAU MC, 1992, J BIOL CHEM, V267, P4281; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1988, J BIOL CHEM, V263, P267; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; RATAJCZAK T, 1989, J BIOL CHEM, V264, P13453; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RHEE SK, 1989, YEAST, V5, P149, DOI 10.1002/yea.320050304; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; RXIN M, 1991, J BIOL CHEM, V266, P24601; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SHREIBER SL, 1991, SCIENCE, V251, P283; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SPIK G, 1991, J BIOL CHEM, V266, P10735; STEARNE PA, 1985, J IMMUNOL, V134, P443; STEGER HF, 1990, J CELL BIOL, V111, P2353, DOI 10.1083/jcb.111.6.2353; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; YEM AW, 1992, J BIOL CHEM, V267, P2868	51	169	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13187	13192						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514757				2022-12-25	WOS:A1993LH55300028
J	Blomquist, P; Li, Q; Wrange, O				Blomquist, P; Li, Q; Wrange, O			The affinity of nuclear factor 1 for its DNA site is drastically reduced by nucleosome organization irrespective of its rotational or translational position	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; FACTOR-I; GLUCOCORTICOID RECEPTOR; TRANSCRIPTION FACTORS; ADENOVIRUS DNA; BINDING; PROMOTER; REPLICATION; ENHANCER; PROTEIN	A DNA-bending sequence has been used for in vitro reconstitution of nucleosomes in order to direct a nuclear factor 1 (NF-1) binding site into different nucleosome positions. By this strategy nucleosomes were obtained that had one of two rotational positions of the NF-1 binding site, one oriented toward the periphery and the other toward the histone octamer, translationally positioned 50 and 45 base pairs, respectively, from the nucleosome dyad. The affinity of partially purified NF-1 for these nucleosomal targets was compared with its affinity for free DNA by dimethylsulfate methylation protection and DNase I footprinting assays. The binding affinity of NF-1 to all nucleosomal targets was reduced 100-300-fold compared with its affinity for free DNA, The two rotational settings of the NF-1 site showed the same binding affinity for NF-1 as did other nucleosome constructs in which the NF-1 binding site was translationally positioned from 10 to 40 base pairs from the nucleosome dyad. We conclude that the nucleosomal inhibition of NF-1 binding is an inherent characteristic of NF-1 since another transcription factor, the glucocorticoid receptor, is able to bind to its DNA site in a nucleosome.	KAROLINSKA INST, MED NOBEL INST, DEPT CELL & MOLEC BIOL, GENET MOLEC LAB, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet				Li, Qiao/0000-0002-5941-1985				ADAMS AD, 1995, J BIOL CHEM, V270, P6975, DOI 10.1074/jbc.270.12.6975; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; BUETTI E, 1986, J MOL BIOL, V190, P379, DOI 10.1016/0022-2836(86)90009-4; CHU HM, 1991, NUCLEIC ACIDS RES, V19, P2721, DOI 10.1093/nar/19.10.2721; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; CORTHESY B, 1989, MOL CELL BIOL, V9, P5548, DOI 10.1128/MCB.9.12.5548; DEVRIES E, 1987, EMBO J, V6, P161, DOI 10.1002/j.1460-2075.1987.tb04734.x; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; ERIKSSON P, 1993, EUR J BIOCHEM, V215, P505, DOI 10.1111/j.1432-1033.1993.tb18060.x; ERLMANN T, 1990, J BIOL CHEM, V265, P17222; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KRUSE U, 1991, NUCLEIC ACIDS RES, V19, P6641, DOI 10.1093/nar/19.23.6641; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LI Q, 1995, MOL CELL BIOL, V15, P4375; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUTTER LC, 1978, J MOL BIOL, V124, P391, DOI 10.1016/0022-2836(78)90306-6; MCPHERSON CE, 1993, CELL, V75, P387, DOI 10.1016/0092-8674(93)80079-T; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; MYMRYK JS, 1995, GENE DEV, V9, P1366, DOI 10.1101/gad.9.11.1366; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NOLL M, 1974, NUCLEIC ACIDS RES, V1, P1573, DOI 10.1093/nar/1.11.1573; NOVAK A, 1992, J BIOL CHEM, V267, P12986; NOWOCK J, 1985, NUCLEIC ACIDS RES, V13, P2045, DOI 10.1093/nar/13.6.2045; PERLMANN T, 1991, MOL CELL BIOL, V11, P5259, DOI 10.1128/MCB.11.10.5259; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RAWLINS DR, 1984, CELL, V37, P309, DOI 10.1016/0092-8674(84)90327-1; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RILEY D, 1978, CELL, V13, P281, DOI 10.1016/0092-8674(78)90197-6; RINGOLD GM, 1977, CELL, V10, P11, DOI 10.1016/0092-8674(77)90134-9; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; TRUSS M, 1993, J STEROID BIOCHEM, V47, P1, DOI 10.1016/0960-0760(93)90051-W; WU L, 1992, P NATL ACAD SCI USA, V89, P4811, DOI 10.1073/pnas.89.11.4811; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; ZORBAS H, 1989, NUCLEIC ACIDS RES, V17, P7735, DOI 10.1093/nar/17.19.7735	53	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					153	159		10.1074/jbc.271.1.153	http://dx.doi.org/10.1074/jbc.271.1.153			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550551	hybrid			2022-12-25	WOS:A1996TP36100024
J	Bosserhoff, AK; Hein, R; Bogdahn, U; Buettner, R				Bosserhoff, AK; Hein, R; Bogdahn, U; Buettner, R			Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PATHWAYS; MESSENGER-RNA; GROWTH; EXPRESSION; ENHANCER; DNA	We have recently described the isolation of a novel protein, MIA, which is secreted from malignant melanoma cells and elicits growth inhibition on melanoma cells in vitro (Blesch, A., Bosserhoff, A. K., Apfel, R., Behl, C., Hessdorfer, B., Schmitt, A., Jachimczak, P., Lottspeich, F., Schlingensiepen, H., Buettner, R., and Bogdahn, U. (1994) Cancer Res, 54, 5695-5701). Here, we report the structure of the human MIA gene locus, describe its expression pattern in melanocytic tumors in vivo, and provide an initial characterization of the MIA promoter, The MIA gene is encoded by four exons, and the mRNA initiation site was identified 70 base pairs upstream from the translation start codon. MIA mRNA expression in vivo correlated with progressive malignancy of melanocytic lesions and was inducible in other cells by phorbol esters, To investigate mechanisms mediating this melanoma-associated expression pattern, me analyzed the promoter activity of the 1,3-kilobase genomic sequences located 5'-upstream of the MIA gene, The MIA promoter conferred high levels of gene activation specifically in human and murine melanoma cells, and its activity was further enhanced by treatment with phorbol esters, Site-directed mutation of an NF-kB site within the MIA promoter did reduce the basal promoter activity in melanoma cells but did not change significantly enhancement by phorbol esters.	UNIV REGENSBURG,SCH MED,DEPT PATHOL,D-93042 REGENSBURG,GERMANY; UNIV REGENSBURG,SCH MED,DEPT DERMATOL,D-93042 REGENSBURG,GERMANY; UNIV WURZBURG,DEPT NEUROL,D-97080 WURZBURG,GERMANY	University of Regensburg; University of Regensburg; University of Wurzburg			Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				APFEL R, 1992, MELANOMA RES, V2, P327, DOI 10.1097/00008390-199212000-00006; BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BLESCH A, 1994, CANCER RES, V54, P5695; BOCKER EB, 1988, INT J CANCER, V41, P562; BOGDAHN U, 1989, CANCER RES, V49, P5358; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUCHANGE N, 1992, NUCLEIC ACIDS RES, V20, P2853, DOI 10.1093/nar/20.11.2853; FROHMAN MA, 1989, MOL ENDOCRINOL, V3, P1529, DOI 10.1210/mend-3-10-1529; FUJIWARA J, 1994, J BIOL CHEM, V269, P18558; GANSS R, 1994, J BIOL CHEM, V269, P29808; HALABAN R, 1992, J IMMUNOTHER, V12, P154, DOI 10.1097/00002371-199210000-00002; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERLYN M, 1991, LAB INVEST, V65, P262; JACOB K, 1995, INT J CANCER, V60, P668, DOI 10.1002/ijc.2910600517; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LUKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490; OROSZ P, 1995, INT J CANCER, V60, P867, DOI 10.1002/ijc.2910600624; RODECK U, 1991, J INVEST DERMATOL, V97, P20, DOI 10.1111/1523-1747.ep12477822; RODECK U, 1993, CANCER METAST REV, V12, P219, DOI 10.1007/BF00665954; Sambrook J, 1989, MOL CLONING LABORATO; SHIH IM, 1993, J INVEST DERMATOL, V100, P196; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x	26	86	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					490	495		10.1074/jbc.271.1.490	http://dx.doi.org/10.1074/jbc.271.1.490			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550608	hybrid			2022-12-25	WOS:A1996TP36100075
J	He, YP; Shelver, D; Kerby, RL; Roberts, GP				He, YP; Shelver, D; Kerby, RL; Roberts, GP			Characterization of a CO-responsive transcriptional activator from Rhodospirillum rubrum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; IRON-SULFUR PROTEIN; DEPENDENT PROMOTERS; NICKEL; INVIVO; SYSTEM; COMPLEX; GENE; HYDROGENASE; MUTAGENESIS	In Rhodospirillum rubrum, CO induces the expression of at least two transcripts that encode an enzyme system for CO oxidation. This regulon is positively regulated by CooA, which is a member of the cAMP receptor protein family of transcriptional regulators. The transcriptional start site of one of the transcripts (cooFSCTJ) has been identified by primer extension, The ability of CooA to bind to this promoter in vitro was characterized with DNase I footprinting experiments using extracts of a CooA-overproducing strain. CooA- and CO-dependent protection was observed for a region with a-fold symmetry (5'-TGTCA-N-6-CGACA) that is highly similar to the consensus core motifs recognized by cAMP receptor protein/FNR family. In vivo analysis in a heterologous background indicates that CooA is sufficient for CO-dependent expression, implicating it as the likely CO sensor.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM53228] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053228] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONAM D, 1988, P NATL ACAD SCI USA, V85, P31, DOI 10.1073/pnas.85.1.31; BONAM D, 1987, J BIOL CHEM, V262, P2980; BONAM D, 1989, J BACTERIOL, V171, P3102, DOI 10.1128/jb.171.6.3102-3107.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COPPOC LJ, 1991, THESIS U WISCONSIN M; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; EIGLMEIER K, 1989, MOL MICROBIOL, V3, P869, DOI 10.1111/j.1365-2958.1989.tb00236.x; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4973, DOI 10.1021/bi00438a011; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4968, DOI 10.1021/bi00438a010; ENSIGN SA, 1991, J BIOL CHEM, V266, P18395; FILUTOWICZ M, 1985, J MOL BIOL, V187, P225; GRUNWALD SK, 1995, J BACTERIOL, V177, P628, DOI 10.1128/jb.177.3.628-635.1995; JOSAITIS CA, 1995, P NATL ACAD SCI USA, V92, P1117, DOI 10.1073/pnas.92.4.1117; KANEMOTO RH, 1984, J BACTERIOL, V158, P713, DOI 10.1128/JB.158.2.713-720.1984; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LEHMAN LJ, 1991, J BACTERIOL, V173, P5705, DOI 10.1128/jb.173.18.5705-5711.1991; LEHMAN LJ, 1990, GENE, V95, P143, DOI 10.1016/0378-1119(90)90426-R; MACKENZIE C, 1995, J BACTERIOL, V177, P3027, DOI 10.1128/jb.177.11.3027-3035.1995; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; Sambrook J, 1989, MOL CLONING LABORATO; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHWEIZER HP, 1993, BIOTECHNIQUES, V15, P831; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WIN PD, 1992, ANAL BIOCHEM, V200, P81	29	91	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					120	123		10.1074/jbc.271.1.120	http://dx.doi.org/10.1074/jbc.271.1.120			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550545	hybrid			2022-12-25	WOS:A1996TP36100019
J	LopezBayghen, E; Vega, A; Cadena, A; Granados, SE; Jave, LF; Gariglio, P; AlvarezSalas, LM				LopezBayghen, E; Vega, A; Cadena, A; Granados, SE; Jave, LF; Gariglio, P; AlvarezSalas, LM			Transcriptional analysis of the 5'-noncoding region of the human involucrin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-EPIDERMIS; SERUM RESPONSE FACTOR; KERATINOCYTE TRANSGLUTAMINASE; TRANSGENIC MICE; C-MYC; PROMOTER; DIFFERENTIATION; PROTEIN; YY1; IDENTIFICATION	Human involucrin whose gene transcription is directed by a 2456-nucleotide (nt) 5'-noncoding region is a structural component of the epithelial cornified layer, Transient transfection assays demonstrated that this region is transcriptionally active in multiplying keratinocytes and is enhanced by 2 mM CaCl2 treatment, Calcium-independent transcriptional activity and the interaction with the AP-1 transcriptional factor was located on the proximal part (nt -159 to -1) of the 5'-noncoding region. However, CaCl2 responsiveness was mapped to a distal 1185-nt fragment (nt -2456 to -1272), Moreover, this fragment potentiated the Herpes simplex thymidine kinase promoter in normal keratinocytes and is responsive to calcium treatment in a cell type-specific manner, Interestingly, the absence of a 491-nt fragment located between the two enhancer domains (nt -651 to -160) resulted in transcriptional activation in multiplying keratinocytes. This fragment interacts with AP-1 and the YY1 transcriptional silencer, It is concluded that human involucrin 5'-noncoding region contains at least three regulatory domains, a distal CaCl2-responsive enhancer, a putative transcriptional silencer (that interacts with AP-1 and YY1), and a proximal enhancer/promoter (that interacts with AP-1), Thus, this study demonstrates the presence of particular transcriptional factors can potentially regulate the human involucrin expression.	NCI,BIOL LAB,BETHESDA,MD 20892; INST POLITECN NACL,CTR INVEST & ESTUDIOS AVANZADOS,DEPT GENET & BIOL MOLEC,MEXICO CITY 07000,DF,MEXICO	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico			Lopez-Bayghen, Esther/A-8006-2008; Jave-Suarez, Luis Felipe/T-7036-2018	Lopez-Bayghen, Esther/0000-0002-2849-7587; Jave-Suarez, Luis Felipe/0000-0001-6209-5031				ALVAREZSALAS LM, 1995, CANCER LETT, V91, P85, DOI 10.1016/0304-3835(95)03721-8; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BASU A, 1993, J BIOL CHEM, V268, P4188; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUXMAN MM, 1976, BIOCHIM BIOPHYS ACTA, V452, P356, DOI 10.1016/0005-2744(76)90185-6; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CARROLL JM, 1992, J CELL SCI, V103, P925; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ECKERT RL, 1989, PHYSIOL REV, V69, P316; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HAWLEYNELSON P, 1982, EXP CELL RES, V137, P155, DOI 10.1016/0014-4827(82)90017-9; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOHL D, 1991, J INVEST DERMATOL, V96, P414, DOI 10.1111/1523-1747.ep12469779; HOHL D, 1991, J BIOL CHEM, V266, P6626; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LIU R, 1994, NUCLEIC ACIDS RES, V22, P2453, DOI 10.1093/nar/22.13.2453; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCKINLEYGRANT LJ, 1989, P NATL ACAD SCI USA, V86, P4848, DOI 10.1073/pnas.86.13.4848; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; MILLS LK, 1994, J VIROL, V68, P1234, DOI 10.1128/JVI.68.2.1234-1238.1994; MOMOEDA M, 1994, J VIROL, V68, P7159, DOI 10.1128/JVI.68.11.7159-7168.1994; MUFSON RA, 1982, CANCER RES, V42, P4600; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; OGAWA H, 1976, J BIOL CHEM, V251, P7281; PARENTEAU NL, 1987, P NATL ACAD SCI USA, V84, P7571, DOI 10.1073/pnas.84.21.7571; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; SCHEIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; TAKAHASHI H, 1993, J INVEST DERMATOL, V100, P10, DOI 10.1111/1523-1747.ep12349867; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THIERRY F, 1992, J VIROL, V66, P3740, DOI 10.1128/JVI.66.6.3740-3748.1992; THIERRY F, 1990, MOL CELL BIOL, V10, P4431, DOI 10.1128/MCB.10.8.4431; VOLZ A, 1993, GENOMICS, V18, P92, DOI 10.1006/geno.1993.1430; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WATT FM, 1981, J CELL BIOL, V90, P738, DOI 10.1083/jcb.90.3.738; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WATT FM, 1983, DERMATOLOGY, V81, pS100; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WOODWORTH CD, 1993, CELL GROWTH DIFFER, V4, P367; YOUNUS J, 1992, J CELL PHYSIOL, V152, P232, DOI 10.1002/jcp.1041520203	54	71	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					512	520		10.1074/jbc.271.1.512	http://dx.doi.org/10.1074/jbc.271.1.512			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550612	hybrid			2022-12-25	WOS:A1996TP36100078
J	Mahanty, SK; Scarborough, GA				Mahanty, SK; Scarborough, GA			Site-directed mutagenesis of the cysteine residues in the Neurospora crassa plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ETHYLMALEIMIDE; <H+>-ATPASE; PURIFICATION; INHIBITION; PROTEINS	A high-yield yeast expression system for site directed mutagenesis of the Neurospora crassa plasma membrane H+-ATPase has recently been reported (Mahanty, S. K., Rao, U. S., Nicholas, R. A., and Scarborough, G. A, (1994) J. Biol. Chem, 269, 17705-17712), Using this system, each of the eight cysteine residues in the ATPase was changed to a serine or an alanine residue, producing strains C148S and C148A, C376S and C376A, C409S and C409A, C472S and C472A, C532S and C532A, C545S and C545A, C840S and C840A, and C869S and C869A, respectively. With the exception of C376S and C532S, all of the mutant ATPases are able to support the growth of yeast cells to different extents, indicating that they are functional, The C376S and C532S enzymes appear to be non-functional, After solubilization of the functional mutant ATPase molecules from isolated membranes with lysolecithin, all behaved similar to the native enzyme when subjected to glycerol density gradient centrifugation, indicating that they fold in a natural manner, The kinetic properties of these mutant enzymes were also similar to the native ATPase with the exception of C409A, which has a substantially higher K-m. These results clearly indicate that none of the eight cysteine residues in the H+-ATPase molecule are essential for ATPase activity, but that Cys(376), Cys(409), and Cys(532) may be in or near important sites, They also demonstrate that the previously described disulfide bridge between Cys(148) and Cys(840) or Cys(869) plays no obvious role in the structure or function of this membrane transport enzyme.	UNIV N CAROLINA, DEPT PHARMACOL, SCH MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM024784, R01GM024784] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24784] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1981, J BIOL CHEM, V256, P3165; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BROOKER RJ, 1983, J BIOL CHEM, V258, P222; BROOKER RJ, 1982, J BIOL CHEM, V257, P2051; BROOKER RJ, 1983, J BIOL CHEM, V258, P8827; CHADWICK CC, 1987, ARCH BIOCHEM BIOPHYS, V252, P348, DOI 10.1016/0003-9861(87)90041-5; CHANG A, 1990, J BIOL CHEM, V265, P15531; DAME JB, 1981, J BIOL CHEM, V256, P724; DAVENPORT JW, 1988, J BIOL CHEM, V263, P16007; GOFFEAU A, 1981, BIOCHIM BIOPHYS ACTA, V639, P197, DOI 10.1016/0304-4173(81)90010-0; GOFFEAU A, 1990, MONOVALENT CATIONS B, P155; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHANTY SK, 1994, J BIOL CHEM, V269, P17705; PARDO JP, 1989, J BIOL CHEM, V264, P9373; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; RAO R, 1989, ION TRANSPORT, P35; RAO US, 1990, J BIOL CHEM, V265, P7227; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH GA, 1976, P NATL ACAD SCI USA, V73, P1485, DOI 10.1073/pnas.73.5.1485; SCARBOROUGH GA, 1980, BIOCHEMISTRY-US, V19, P2925, DOI 10.1021/bi00554a017; SCARBOROUGH GA, 1977, ARCH BIOCHEM BIOPHYS, V180, P384, DOI 10.1016/0003-9861(77)90052-2; SCARBOROUGH GA, 1992, MOL ASPECTS MEMBRANE, P117; SCARBOROUGH GA, 1988, METHOD ENZYMOL, V157, P574; Serrano R., 1990, The plant plasma membrane., P127; SMITH R, 1984, ANAL BIOCHEM, V138, P156, DOI 10.1016/0003-2697(84)90784-X; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341	29	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					367	371		10.1074/jbc.271.1.367	http://dx.doi.org/10.1074/jbc.271.1.367			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550588	Green Published			2022-12-25	WOS:A1996TP36100057
J	Sachsenmeier, KF; Sheibani, N; Schlosser, SJ; AllenHoffmann, BL				Sachsenmeier, KF; Sheibani, N; Schlosser, SJ; AllenHoffmann, BL			Transforming growth factor-beta 1 inhibits nucleosomal fragmentation in human keratinocytes following loss of adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; FACTOR-BETA; CELL-DEATH; APOPTOSIS; PROLIFERATION; EXPRESSION; HEPATOCYTES; INDUCTION; CLONING	We have investigated the role of transforming growth factor-beta 1 (TGF-beta 1) in suspension-induced programmed cell death of cultured human keratinocytes. Suspension of keratinocytes in semisolid medium induces TGF-beta 1 mRNA levels and synthesis of bioactive TGF-beta 1 protein. Concomitant with the suspension-induced increase in secreted TGF-beta 1 levels, steady state mRNA levels for c-myc are decreased. Both exogenously added and endogenously produced TGF-beta 1 attenuate suspension-induced nucleosomal fragmentation in keratinocytes. We propose that TGF-beta 1 may function to protect keratinocytes from DNA fragmentation following loss of cell-substratum and/or cell-cell contact. Taken together, our findings suggest that loss of cell-substratum and/or cell-cell adhesion is an important component of an apoptotic signal transduction cascade regulated by TGF-beta 1 in normal human stratified squamous epithelia.	UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53706; UNIV WISCONSIN,CTR ENVIRONM TOXICOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Sheibani, Nader/AAG-2379-2020	Sheibani, Nader/0000-0003-2723-9217	NIAMS NIH HHS [AR40284, F31 AR08366] Funding Source: Medline; NIEHS NIH HHS [T32 ES07015] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR040284, F31AR008366, R01AR040284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007015] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLENHOFFMANN BL, 1984, P NATL ACAD SCI-BIOL, V81, P7802, DOI 10.1073/pnas.81.24.7802; BURSCH W, 1993, BRIT J CANCER, V67, P531, DOI 10.1038/bjc.1993.98; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; LOTEM J, 1992, BLOOD, V80, P1750; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; MUNGER K, 1992, CELL GROWTH DIFFER, V3, P291; OBERHAMMER F, 1991, CANCER RES, V51, P2478; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SADEK CM, 1994, J BIOL CHEM, V269, P16067; SHARPLES K, 1987, DNA-J MOLEC CELL BIO, V6, P239, DOI 10.1089/dna.1987.6.239; SHIPLEY GD, 1986, CANCER RES, V46, P2068; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310	17	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					5	8		10.1074/jbc.271.1.5	http://dx.doi.org/10.1074/jbc.271.1.5			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550610	hybrid			2022-12-25	WOS:A1996TP36100001
J	Rochefort, P; Caillou, B; Michiels, FM; Ledent, C; Talbot, M; Schlumberger, M; Lavelle, F; Monier, R; Feunteun, J				Rochefort, P; Caillou, B; Michiels, FM; Ledent, C; Talbot, M; Schlumberger, M; Lavelle, F; Monier, R; Feunteun, J			Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter	ONCOGENE			English	Article						transgenic mice; activated ras; papillary thyroid carcinoma; thyroid dysgenesis	TISSUE-SPECIFIC EXPRESSION; ONCOGENE ACTIVATION; INTESTINAL NEOPLASIA; HIGH-FREQUENCY; TRANSFORMATION; MUTATIONS; TUMORS; CARCINOMA; CELLS; INHIBITION	Four transgenic mice carrying the human activated c-Ha-Ras gene, the expression of which was driven into the thyroid gland by a bovine thyroglobulin promoter, have been produced. The M1 and M2 mice developed papillary thyroid carcinomas and the M2 mouse also developed a lung carcinoma, however none of them transmitted the transgene. Both the M3 and the M4 mice gave rise to transgenic lines. M3 progeny mice develop a goitre with morphological aspects of hyperplasia as well as a thymus hyperplasia, M4 developed a papillary thyroid carcinoma and a lung carcinoma. Lung tumors but not thyroid tumors were observed in M4 adult transgenic progeny. In this M4 line, thyroid dysgenesis leading to growth retardation and premature death was observed upon serial backcross that enhanced the DBA/2J genetic background. The development of thyroid tumors in M1, M2, M4 transgenic mice demonstrates the oncogenic potential of activated Ras gene in the thyroid gland. The M4 line raises interesting questions relative to the interference between the Ras-mediated signal transduction pathway and thyroid morphogenesis.	INST GUSTAVE ROUSSY,CNRS,URA 1967,LAB GENET ONCOL,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,SERV HISTOPATHOL A,VILLEJUIF,FRANCE; FREE UNIV BRUSSELS,INST RECH INTERDISCIPLINAIRE,BRUSSELS,BELGIUM; INST GUSTAVE ROUSSY,NUCL MED SERV,VILLEJUIF,FRANCE; RHONE POULENC RORER,VITRY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Universite Libre de Bruxelles; Vrije Universiteit Brussel; UNICANCER; Gustave Roussy; Sanofi-Aventis			Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ANDRES AC, 1991, ONCOGENE, V6, P771; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BIANCIFIORI C, 1979, PATHOLOGY TUMORS ANI, P451; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BOS JL, 1989, CANCER RES, V49, P4682; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHRISTOPHE D, 1994, MOL CELL ENDOCRINOL, V64, P5; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; FOWLIS DJ, 1993, EUR J CANCER, V29A, P638, DOI 10.1016/S0959-8049(05)80170-4; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GUAZZI S, 1994, EMBO J, V13, P3339, DOI 10.1002/j.1460-2075.1994.tb06636.x; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HOGAN B, 1986, MANIPULATING MOUSE E; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; LEMOINE NR, 1988, ONCOGENE, V3, P541; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; NAMBA H, 1990, J CLIN ENDOCR METAB, V71, P223, DOI 10.1210/jcem-71-1-223; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SANTELLI G, 1993, CANCER RES, V53, P5523; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SCHLUMBERGER M, 1986, J CLIN ENDOCR METAB, V63, P960; SHI YF, 1991, CANCER RES, V51, P2690; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; Whitten WK, 1971, ADV BIOSCI, V6, P129, DOI DOI 10.1016/B978-0-08-017571-3.50013-9; WRIGHT PA, 1991, ONCOGENE, V6, P471; YUKAWA K, 1989, J EXP MED, V170, P711, DOI 10.1084/jem.170.3.711	40	58	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					111	118						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552381				2022-12-25	WOS:A1996TQ01400014
J	Baldassarre, F; Mallardo, M; Mezza, E; Scala, G; Quinto, I				Baldassarre, F; Mallardo, M; Mezza, E; Scala, G; Quinto, I			Regulation of NF-kappa B through the nuclear processing of p105 (NF-kappa B1) in Epstein-Barr virus-immortalized B cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; DNA-BINDING SUBUNIT; REL ONCOGENE; P50; PRECURSOR; ALPHA; ACTIVATION; PHOSPHORYLATION; CLONING; PROTEIN	Transcription factors of the NF-kappa-B/Rel family are retained in the cytoplasm as inactive complexes through association with I-kappa-B inhibitory proteins. Several NF-kappa-B activators induce the proteolysis of I-kappa-B proteins, which results in the nuclear translocation and DNA binding of NF-kappa-B complexes. Here, we report a novel mechanism of NF-kappa-B regulation mediated by p105 (NF-kappa-B1) precursor of p50 directly at the nuclear level. In Epstein-Barr virus immortalized B cells, p105 was found in the nucleus, where it was complexed with p65. In concomitance with NF-kappa-B activation, mitomycin C induced the processing of p105 to p50 in the nucleus, while it did not affect the steady-state protein levels of I-kappa-B-alpha and p105 in the cytoplasm. Differently, phorbol 12-myristate 13-acetate induced a significant proteolysis of both I-kappa-B-alpha and p105 in the cytoplasm, while it did not affect the protein level of p105 in the nucleus. These results suggest that in Epstein-Barr virus-positive B cell lines the nuclear processing of p105 can contribute to NF-kappa-B activation in response to specific signaling molecules, such as DNA-damaging agents.	UNIV FEDERICO II,DIPARTIMENTO BIOCHEM & BIOTECNOL MED,I-80131 NAPLES,ITALY; UNIV FEDERICO II,IST PATOL,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	University of Naples Federico II; University of Naples Federico II; Universita Mediterranea di Reggio Calabria			SCALA, GIUSEPPE/A-3280-2009	MALLARDO, Massimo/0000-0002-4001-3856; QUINTO, Ileana/0000-0001-8212-8515				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRUMONT RJ, 1994, MOL CELL BIOL, V14, P8460, DOI 10.1128/MCB.14.12.8460; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; MASON DY, 1990, AM J PATHOL, V136, P1215; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; QUINTO I, 1993, J BIOL CHEM, V268, P26719; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; SCALA G, 1993, J VIROL, V67, P2853, DOI 10.1128/JVI.67.5.2853-2861.1993; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	31	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31244	31248		10.1074/jbc.270.52.31244	http://dx.doi.org/10.1074/jbc.270.52.31244			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537390	hybrid			2022-12-25	WOS:A1995TN44400089
J	Smith, JW; Tachias, K; Madison, EL				Smith, JW; Tachias, K; Madison, EL			Protein loop grafting to construct a variant of tissue-type plasminogen activator that binds platelet integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; VITRONECTIN RECEPTOR; STRUCTURAL DOMAINS; FIBRIN AFFINITY; FINGER-DOMAIN; CLEARANCE; ALPHA-V-BETA-3; FIBRONECTIN; EXPRESSION; SELECTION	Protein-protein interactions can be guided by contacts between surface loops within proteins. We therefore investigated the hypothesis that novel protein-protein interactions could be created using a strategy of ''loop grafting'' in which the amino acid sequence of a biologically active, flexible loop on one protein is used to replace a surface loop present on an unrelated protein. To test this hypothesis we replaced a surface loop within an epidermal growth factor module with the complementarity-determining region of a monoclonal antibody. Specifically, the HCDR3 from Fab-9, an antibody selected to bind the beta(3)-integrins with nanomolar affinity (Smith, J. W., Hu, D., Satterthwait, A., Pinz-Sweeney, S., and Barbas, C. F., III (1994) J. Biol. Chem. 269, 32788-32795), was grafted into the epidermal growth factor-like module of human tissue-type plasminogen activator (t-PA). The resulting variant of t-PA bound to the platelet integrin alpha(IIb)beta(3) with nanomolar affinity, retained full enzymatic activity, and was stimulated normally by the physiological co-factor fibrin. Binding of the novel variant of t-PA to integrin alpha IIb beta(3) was dependent on the presence of divalent cations and was inhibited by an RGD-containing peptide, demonstrating that, like the donor antibody, the novel BPA binds specifically to the ligand-binding site of the integrin. These findings suggest that surface loops within protein modules can, at least in some cases, be interchangeable and that phage display can be combined with loop grafting to direct proteins, at high affinity, to selected targets. In principle, these targets could include not only other proteins but also peptides, nucleic acids, carbohydrates, lipids, or even uncharacterized markers of specific cell types, tissues, or viruses.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; LA JOLLA CANC RES FDN, PROGRAM CELL ADHES & EXTRACELLULAR MATRIX, LA JOLLA, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA056483] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL052475] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA56483] Funding Source: Medline; NHLBI NIH HHS [R01 HL52475, P01 HL31950] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barbas Carlos F. Iii, 1993, Current Opinion in Biotechnology, V4, P526, DOI 10.1016/0958-1669(93)90072-5; BARBAS CF, 1993, P NATL ACAD SCI USA, V90, P10003, DOI 10.1073/pnas.90.21.10003; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BASSELDUBY R, 1992, J BIOL CHEM, V267, P9668; BODE C, 1991, CIRCULATION, V84, P805, DOI 10.1161/01.CIR.84.2.805; BROWNE MJ, 1988, J BIOL CHEM, V263, P1599; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; HABER E, 1989, SCIENCE, V243, P51, DOI 10.1126/science.2492113; HASHINO K, 1992, J BIOCHEM, V112, P547, DOI 10.1093/oxfordjournals.jbchem.a123936; JANIN J, 1990, J BIOL CHEM, V265, P16027; JOHANNESSEN M, 1990, THROMB HAEMOSTASIS, V63, P54; KAGITANI H, 1985, FEBS LETT, V189, P145, DOI 10.1016/0014-5793(85)80860-7; KALYAN NK, 1988, J BIOL CHEM, V263, P3971; KOHDA D, 1988, J BIOCHEM-TOKYO, V103, P741, DOI 10.1093/oxfordjournals.jbchem.a122338; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSEN GR, 1988, J BIOL CHEM, V263, P1023; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1993, METHOD ENZYMOL, V223, P249; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1992, FIBRINOLYSIS, V6, P105; MAEDA T, 1989, J BIOL CHEM, V264, P15165; PAONI NF, 1993, PROTEIN ENG, V6, P529, DOI 10.1093/protein/6.5.529; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; SCHNEE JM, 1987, P NATL ACAD SCI USA, V84, P6904, DOI 10.1073/pnas.84.19.6904; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH JW, 1994, J BIOL CHEM, V269, P32788; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1994, J BIOL CHEM, V269, P960; THOMAS JW, 1995, P NATL ACAD SCI USA, V92, P3779, DOI 10.1073/pnas.92.9.3779; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; YAMADA T, 1995, J BIOL CHEM, V270, P5687, DOI 10.1074/jbc.270.11.5687; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	38	44	62	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30486	30490		10.1074/jbc.270.51.30486	http://dx.doi.org/10.1074/jbc.270.51.30486			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530479	hybrid			2022-12-25	WOS:A1995TL67500044
J	Vaccaro, AM; Ciaffoni, F; Tatti, M; Salvioli, R; Barca, A; Tognozzi, D; Scerch, C				Vaccaro, AM; Ciaffoni, F; Tatti, M; Salvioli, R; Barca, A; Tognozzi, D; Scerch, C			pH-dependent conformational properties of saposins and their interactions with phospholipid membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR PROTEIN-DEFICIENCY; GAUCHERS-DISEASE; GLUCOCEREBROSIDASE; GLUCOSYLCERAMIDASE; LIPOSOMES; BINDING; PROSAPOSIN; SEPARATION; VESICLES; PATIENT	Saposins A, B, C, and D are small lysosomal glycoproteins released by proteolysis from a single precursor polypeptide, prosaposin. We have presently investigated the conformational states of saposins and their interaction with membranes at acidic pH values similar to those present in lysosomes. With the use of phase partitioning in Triton X-114, experimental evidence was provided that, upon acidification, saposins (Sap) A, C, and D acquire hydrophobic properties, while the hydrophilicity of Sap B is apparently unchanged. The pH-dependent exposure of hydrophobic domains of Sap C and D paralleled their pH-dependent binding to large unilamellar vesicles composed of phosphatidyl-choline, phosphatidylserine, and cholesterol. In contrast, the binding of Sap A to the vesicles was very restricted, in spite of its increased hydrophobicity at low pH. A low affinity for the vesicles was also shown by Sap B, a finding consistent with its apparent hydrophilicity both at neutral and acidic pH. At the acidic pH values needed for binding, Sap C and D powerfully destabilized the phospholipid membranes, while Sap A and B minimally affected the bilayer integrity. In the absence of the acidic phospholipid phosphatidylserine, the induced destabilization markedly decreased. Of the four saposins, only Sap C was able to promote the binding of glucosylceramidase to phosphatidylserine containing membranes. This result is consistent with the notion that Sap C is specifically required by glucosylceramidase to exert its activity. Our finding that an acidic environment induces an increased hydrophobicity in Sap A, C, and D, making the last two saposins able to interact and perturb phospholipid membranes, suggests that this mechanism might be relevant to the mode of action of saposins in lysosomes.			Vaccaro, AM (corresponding author), IST SUPER SANITA,DEPT METAB & PATHOL BIOCHEM,VIALE REGINA ELENA 299,I-00161 ROME,ITALY.		tatti, Massimo/N-1382-2017					AZUMA N, 1994, ARCH BIOCHEM BIOPHYS, V311, P354, DOI 10.1006/abbi.1994.1248; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BOHLEY P, 1992, EXPERIENTIA, V48, P151, DOI 10.1007/BF01923508; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRADOVA V, 1993, HUM GENET, V92, P143, DOI 10.1007/BF00219682; CHIAO YB, 1978, ARCH BIOCHEM BIOPHYS, V186, P42, DOI 10.1016/0003-9861(78)90461-7; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; DOMS RW, 1985, J BIOL CHEM, V260, P2973; ESCUYER V, 1986, J BIOL CHEM, V261, P891; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P15389; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GLEW RH, 1988, LAB INVEST, V58, P5; HARZER K, 1989, EUR J PEDIATR, V149, P31, DOI 10.1007/BF02024331; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; Holtzman E, 1989, LYSOSOMES; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1140; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIMOTO S, 1989, P NATL ACAD SCI USA, V86, P3389, DOI 10.1073/pnas.86.9.3389; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; MURRAY GJ, 1985, ANAL BIOCHEM, V147, P301, DOI 10.1016/0003-2697(85)90276-3; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V401, P317, DOI 10.1016/0005-2736(75)90233-3; PATON BC, 1989, EUR J CELL BIOL, V51, P157; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; SANDHOFF K, 1995, METABOLIC MOL BASES, P2427; SANO A, 1988, J BIOL CHEM, V263, P19597; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLOTE W, 1991, EUR J PEDIATR, V150, P584, DOI 10.1007/BF02072213; SCHNABEL D, 1992, J BIOL CHEM, V267, P3312; STRAUBINGER RM, 1983, CELL, V32, P1069, DOI 10.1016/0092-8674(83)90291-X; TAMARU T, 1985, HISTOCHEMISTRY, V86, P195; VACCARO AM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P55, DOI 10.1016/0005-2736(93)90024-T; VACCARO AM, 1994, FEBS LETT, V349, P181, DOI 10.1016/0014-5793(94)00659-8; VACCARO AM, 1990, BIOCHIM BIOPHYS ACTA, V1033, P73, DOI 10.1016/0304-4165(90)90196-4; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; VACCARO AM, 1991, BIOCHIM BIOPHYS ACTA, V1119, P239; VACCARO AM, 1993, FEBS LETT, V1, P159; WENGER DA, 1989, AM J MED GENET, V33, P255, DOI 10.1002/ajmg.1320330223; YOSHIMURA T, 1987, J BIOCHEM-TOKYO, V101, P1265, DOI 10.1093/oxfordjournals.jbchem.a121990	43	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 22	1995	270	51					30576	30580		10.1074/jbc.270.51.30576	http://dx.doi.org/10.1074/jbc.270.51.30576			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TL675	8530492	hybrid			2022-12-25	WOS:A1995TL67500057
J	AVIDORREISS, T; BAYEWITCH, M; LEVY, R; MATUSLEIBOVITCH, N; NEVO, I; VOGEL, Z				AVIDORREISS, T; BAYEWITCH, M; LEVY, R; MATUSLEIBOVITCH, N; NEVO, I; VOGEL, Z			ADENYLYLCYCLASE SUPERSENSITIZATION IN MU-OPIOID RECEPTOR-TRANSFECTED CHINESE-HAMSTER OVARY CELLS FOLLOWING CHRONIC OPIOID TREATMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLIOMA HYBRID-CELLS; ADENYLATE-CYCLASE ACTIVITY; NEUROBLASTOMA SH-SY5Y CELLS; NUCLEOTIDE-BINDING-PROTEINS; PHARMACOLOGICAL PROPERTIES; SENSORY NEURONS; CYCLIC-AMP; TOLERANCE; EXPRESSION; INHIBITION	Using CRO cells stably transfected with rat mu-opioid receptor cDNA, we show that the mu-agonists morphine and [D-Ala(2),N-methyl-Phe(4),Gly-ol(5)]enkephalin are negatively coupled to adenylylcyclase and inhibit forskolin-stimulated cAMP accumulation. Chronic exposure of cells to morphine leads to the rapid development of tolerance. Withdrawal of morphine or [D-Ala(2),N-methyl-Phe(4),Gly-ol(5)]enkephalin following chronic treatment (by wash or addition of the antagonist naloxone) leads to an immediate increase in cyclase activity (supersensitization or overshoot), which is gradually reversed upon further incubation with naloxone. Phosphodiesterase inhibitors do not affect the overshoot, indicating that it results from cyclase stimulation rather than phosphodiesterase regulation, Morphine's potency to inhibit cAMP accumulation is the same before and after chronic treatment, suggesting that the apparent tolerance results from cyclase activation, rather than from receptor desensitization. The similar kinetics of induction of tolerance and overshoot support this idea. Both the overshoot and acute opioid-induced cyclase inhibition are blocked by naloxone and are pertussis toxin-sensitive, indicating that both phenomena are mediated by the mu-receptor and G(i)/G(o) proteins. The supersensitization is cycloheximide-insensitive, indicating that it does not require newly synthesized proteins. This is supported by the rapid development of supersensitization. Taken together, these results show that mu-transfected cells can serve as a model for investigating molecular and cellular mechanisms underlying opiate drug addiction.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science			Avidor-Reiss, Tomer/AAK-6153-2020	Avidor-Reiss, Tomer/0000-0003-0918-526X	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006265] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-06265] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AMMER H, 1993, BIOCHEM J, V295, P263, DOI 10.1042/bj2950263; AMMER H, 1993, MOL PHARMACOL, V43, P556; AVIDORREISS T, 1995, FEBS LETT, V361, P70, DOI 10.1016/0014-5793(95)00154-2; BHARGAVA HN, 1994, PHARMACOL REV, V46, P293; CARTER BD, 1993, MOL PHARMACOL, V43, P465; CHAKRABARTI S, 1995, J NEUROCHEM, V64, P2534; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CRAIN SM, 1990, TRENDS PHARMACOL SCI, V11, P77, DOI 10.1016/0165-6147(90)90322-Y; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FREY EA, 1984, ENDOCRINOLOGY, V115, P1797, DOI 10.1210/endo-115-5-1797; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GRIFFIN MT, 1985, J NEUROCHEM, V45, P1585, DOI 10.1111/j.1471-4159.1985.tb07230.x; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HERZ A, 1993, OPIOIDS 1; KAZMI SMI, 1987, MOL PHARMACOL, V32, P109; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1686; LAW PY, 1993, MOL PHARMACOL, V43, P684; LOH HH, 1988, SYNAPSE, V2, P457, DOI 10.1002/syn.890020414; MATSUOKA I, 1994, EUR J PHARM-MOLEC PH, V268, P215, DOI 10.1016/0922-4106(94)90191-0; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; PAROLARO D, 1990, PHARMACOL BIOCHEM BE, V35, P137, DOI 10.1016/0091-3057(90)90218-7; PUTTFARCKEN PS, 1989, LIFE SCI, V45, P1937, DOI 10.1016/0024-3205(89)90548-1; PUTTFARCKEN PS, 1988, MOL PHARMACOL, V33, P520; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; ROERIG SC, 1992, MOL PHARMACOL, V41, P822; SABOL SL, 1979, J BIOL CHEM, V254, P1921; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; SHEN KF, 1992, BRAIN RES, V597, P74, DOI 10.1016/0006-8993(92)91507-B; THOMAS JM, 1990, J NEUROCHEM, V54, P402, DOI 10.1111/j.1471-4159.1990.tb01887.x; THOMAS JM, 1987, TRENDS PHARMACOL SCI, V8, P308, DOI 10.1016/0165-6147(87)90124-6; THOMAS JM, 1988, MOL PHARMACOL, V34, P116; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; TRABER J, 1975, LIFE SCI, V16, P1863, DOI 10.1016/0024-3205(75)90292-1; UHL GR, 1994, TRENDS NEUROSCI, V17, P89, DOI 10.1016/0166-2236(94)90110-4; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; WANG L, 1994, J NEUROCHEM, V63, P1726; WANG Z, 1994, LIFE SCI, V54, P339; WAY EL, 1993, OPIOIDS, V2, P573; YU VC, 1988, J PHARMACOL EXP THER, V245, P350; YU VC, 1990, J NEUROCHEM, V55, P1390, DOI 10.1111/j.1471-4159.1990.tb03151.x; ZIMPRICH A, 1995, FEBS LETT, V359, P142, DOI 10.1016/0014-5793(95)00028-8	47	150	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29732	29738						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530363				2022-12-25	WOS:A1995TK38000023
J	GAUGER, AK; GOLDSTEIN, LSB				GAUGER, AK; GOLDSTEIN, LSB			THE DROSOPHILA KINESIN LIGHT-CHAIN - PRIMARY STRUCTURE AND INTERACTION WITH KINESIN HEAVY-CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BRAIN KINESIN; ELECTRON-MICROSCOPY; MONOCLONAL-ANTIBODY; IDENTIFICATION; SEQUENCE; PROTEIN; MOTILITY; GENE; MICROTUBULES; GENERATION	Kinesin light chain (KLC) complexes with the kinesin heavy chain (KHC) to form native kinesin. Proposed functions of KLC include coupling of cargo to KHC or modulation of KHC ATPase activity. In this paper we use the KHC tail, which binds specifically to KLC in blot overlays, as a probe to clone a cDNA encoding KLC from a Drosophila expression library. The identified clone encodes a protein with 70% amino acid identity to rat KLC. Drosophila KLC is predicted to form an alpha-helical coiled-coil between residues 34 and 129, followed by five imperfect tandem repeats of unknown function and a sixth shorter motif. These repeats are highly conserved across species. The Drosophila KLC gene is located at 69D on the third chromosome and is widely expressed, with 1.8-kb transcripts in most tissues, and slightly smaller transcripts in gonads. Finally, we present evidence that the heptad repeats of KLC are required for interaction with the KHC tail. Since the KHC tail used in our assay includes about 20 heptad repeats, this result suggests that KHC and KLC interact via coiled-coils. Such an interaction could provide stability to the KHC-KLC complex in vivo.	HARVARD UNIV, DEPT CELL & DEV BIOL, CAMBRIDGE, MA 02138 USA	Harvard University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035252] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35252] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOS LA, 1987, J CELL SCI, V87, P105; BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1991, J CELL SCI, P103; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVUEVAS M, 1992, J CELL BIOL, V116, P957; ENGELS WR, 1986, FOCUS, V8, P6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GHO M, 1992, SCIENCE, V258, P313, DOI 10.1126/science.1384131; Goldstein L S, 1991, Trends Cell Biol, V1, P93, DOI 10.1016/0962-8924(91)90036-9; HACKNEY DD, 1992, J BIOL CHEM, V267, P8696; HACKNEY DD, 1991, BIOCHEM BIOPH RES CO, V174, P810, DOI 10.1016/0006-291X(91)91490-4; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENSON JH, 1992, J CELL SCI, V103, P309; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HISANAGA S, 1989, CELL MOTIL CYTOSKEL, V12, P264, DOI 10.1002/cm.970120407; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; ITOH N, 1986, P NATL ACAD SCI USA, V83, P4081, DOI 10.1073/pnas.83.11.4081; JOHNSON CS, 1990, CELL MOTIL CYTOSKEL, V16, P204, DOI 10.1002/cm.970160307; KOSIK KS, 1990, J BIOL CHEM, V265, P3278; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Maniatis T, 1989, MOL CLONING; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; OCONNELL MJ, 1993, J CELL BIOL, V120, P153, DOI 10.1083/jcb.120.1.153; PEREIRA A, 1992, J CELL BIOL, V116, P377, DOI 10.1083/jcb.116.2.377; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; ROOF DM, 1992, J CELL BIOL, V118, P95, DOI 10.1083/jcb.118.1.95; SAUNDERS WS, 1992, CELL, V70, P451, DOI 10.1016/0092-8674(92)90169-D; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SAXTON WM, 1988, P NATL ACAD SCI USA, V85, P1109, DOI 10.1073/pnas.85.4.1109; SCHNAPP BJ, 1992, J CELL BIOL, V119, P389, DOI 10.1083/jcb.119.2.389; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEWART RJ, 1991, P NATL ACAD SCI USA, V88, P8470, DOI 10.1073/pnas.88.19.8470; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VASLET CA, 1980, NATURE, V285, P674, DOI 10.1038/285674a0; WRIGHT BD, 1991, J CELL BIOL, V113, P817, DOI 10.1083/jcb.113.4.817; YANG JT, 1988, P NATL ACAD SCI USA, V85, P1864, DOI 10.1073/pnas.85.6.1864; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	54	91	95	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13657	13666						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514798				2022-12-25	WOS:A1993LH55300090
J	HUBBS, AE; ROY, H				HUBBS, AE; ROY, H			ASSEMBLY OF INVITRO SYNTHESIZED LARGE SUBUNITS INTO RIBULOSE-BISPHOSPHATE CARBOXYLASE OXYGENASE - FORMATION AND DISCHARGE OF AN L(8)-LIKE SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; 1,5-BISPHOSPHATE CARBOXYLASE; PEA-CHLOROPLASTS; BINDING-PROTEIN; PLANT; CYANOBACTERIAL; ATP; RECONSTITUTION; CHAPERONIN-60	Ribulose-bisphosphate carboxylase/oxygenase (Rubisco) from higher plants consists of eight approximately 53-kDa large subunits and eight approximately 14-kDa small subunits. Cytosolic ribosomes synthesize the small subunits as precursors, which enter the chloroplast, undergo proteolytic processing, and assemble with large subunits. Large subunits, synthesized in the chloroplast, first form a complex with the chloroplast chaperonin 60 (Cpn60(14)). In the presence of ATP, large subunits dissociate from Cpn60(14) and assemble into Rubisco. We now describe partial characterization of a new species, Z, containing radiotracer-labeled, newly synthesized pea Rubisco large subunits. Rubisco assembly occurs in low salt in the presence of small subunits and ATP. As with Rubisco assembly, the formation of Z is ATP-dependent and is inhibited by high chloride. Once formed, Z is stable except in high chloride. Z does not appear to interact directly with small subunits. However, after Z formation, Rubisco assembly occurs in an ATP-independent reaction that requires KCl and small subunits. These results are consistent with the hypothesis that Z is a large subunit containing structure that can contribute large subunits to Rubisco under appropriate conditions. Z shares some physical characteristics with reported cyanobacterial L8 core particles. However, formation of Rubisco from Z in the absence of ATP and the presence of small subunits appears to require conditions that otherwise destabilize Z.	RENSSELAER POLYTECH INST, CTR BIOPHYS, TROY, NY 12180 USA	Rensselaer Polytechnic Institute	HUBBS, AE (corresponding author), RENSSELAER POLYTECH INST, DEPT BIOL, PLANT SCI GRP, TROY, NY 12180 USA.							ANDREWS TJ, 1983, J BIOL CHEM, V258, P7514; ANDREWS TJ, 1985, J BIOL CHEM, V260, P4632; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BLAIR GE, 1973, BIOCHIM BIOPHYS ACTA, V319, P223, DOI 10.1016/0005-2787(73)90013-0; BLOOM MV, 1983, P NATL ACAD SCI-BIOL, V80, P1013, DOI 10.1073/pnas.80.4.1013; BRADLEY D, 1986, PHILOS T ROY SOC B, V313, P447, DOI 10.1098/rstb.1986.0051; CANNON S, 1986, J CELL BIOL, V103, P1327, DOI 10.1083/jcb.103.4.1327; CHAUDHARI P, 1989, PLANT PHYSIOL, V89, P1366, DOI 10.1104/pp.89.4.1366; CHUA NH, 1978, P NATL ACAD SCI USA, V75, P6110, DOI 10.1073/pnas.75.12.6110; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; GATENBY AA, 1992, PLANT MOL BIOL, V19, P677, DOI 10.1007/BF00026793; GATENBY AA, 1988, PHOTOSYNTH RES, V17, P145, DOI 10.1007/BF00047686; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HALL DO, 1976, INTACT CHLOROPLAST, P156; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HUBBS A, 1992, PLANT PHYSIOL, V100, P272, DOI 10.1104/pp.100.1.272; HUBBS AE, 1993, PLANT PHYSIOL, V101, P521; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1990, BIOCHEMISTRY-US, V29, P9352, DOI 10.1021/bi00492a007; LORIMER GH, 1981, ANNU REV PLANT PHYS, V32, P349, DOI 10.1146/annurev.pp.32.060181.002025; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MILOS P, 1984, J CELL BIOCHEM, V24, P153, DOI 10.1002/jcb.240240206; MILOS P, 1985, PLANT MOL BIOL REP, V3, P33; ROY H, 1988, PLANT PHYSIOL, V86, P44, DOI 10.1104/pp.86.1.44; ROY H, 1982, J CELL BIOL, V94, P20, DOI 10.1083/jcb.94.1.20; ROY H, 1978, BIOCHEMISTRY-US, V17, P665, DOI 10.1021/bi00597a016; VANDERVIES SM, 1986, EMBO J, V5, P2439, DOI 10.1002/j.1460-2075.1986.tb04519.x; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	32	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1993	268	18					13519	13525						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	LH553	8514785				2022-12-25	WOS:A1993LH55300072
J	Bolger, GB; McPhee, I; Houslay, MD				Bolger, GB; McPhee, I; Houslay, MD			Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts - Characterization of a novel tissue-specific isoform, RNPDE4A8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; DROSOPHILA-MELANOGASTER; GENE; EXPRESSION; RECEPTOR; FAMILY; DUNCE; CELLS; HOMOLOGS; CLONING	In order to characterize the structure and regulation of members of the cAMP-specific phosphodiesterase (PDE) family (Type IV PDEs; PDE4 family), we have cloned from the rat a cDNA, pRPDE39, encoding a novel member of this family, which we call RNPDE4A8. Sequencing of the pRPDE39 cDNA shows it to be encoded by the rat PDE4A gene, but to differ from two other PDE4A transcripts, RD1 (pRPDE8; RNPDE4A1) and pRPDE6 (RNPDE4A5), by the presence of a unique region at its 5' end, consistent with alternative mRNA splicing. The pRPDE39 cDNA encodes a predicted protein of 763 amino acids, of which all but 21, located at the extreme amino terminus, are found in the pRPDE6 protein. Expression of pRPDE39 in COS cells produced a protein of 98 +/- 1.4 kDa, as determined by immunoblotting with an antiserum specific to the carboxyl-terminal regions of all PDE4A proteins, compared to a predicted value of 87.5 Ma. RNase protection analysis detected pRPDE39 mRNA only in testis. Immunoblotting of testis extracts demonstrated two bands of 97 +/- 2 and 87 +/- 3 kDa, the larger of which co-migrated with the band seen in COS cells expressing pRPDE39, COS cell expressed pRPDE39 partitioned between a high speed pellet (particulate) fraction (15% of protein; 8% of activity) and a cytosolic fraction. The particulate fraction had a K-m for cAMP of 3.3 +/- 0.6 mu M, and the cytosolic fraction a K-m of 5.4 +/- 2.8 mu M. The V-max values for the pRPDE39 protein, relative to the RD1 protein, were 0.16 +/- 0.06 and 0.29 +/- 0.05 for the particulate and cytosolic forms, respectively. The pRPDE39-encoded PDE activity could not be removed from the particulate fraction by high salt concentrations, or by nonionic detergents. The pRPDE39-encoded enzyme was inhibited by rolipram at an IC50 of 0.5 +/- 0.2 mu M for the particulate form and 1.0 +/- 0.2 mu M for the cytosolic form, which are values typical of PDE4 family members. The highly tissue-specific distribution of the pRPDE39 mRNA suggests that the pRPDE39 protein functions to modulate a cAMP signaling pathway that is present largely, if not exclusively, in the testis.	UNIV UTAH,HLTH SCI CTR,HUNTSMAN CANC INST,DEPT ONCOL SCI,SALT LAKE CITY,UT 84148; UNIV UTAH,HLTH SCI CTR,DEPT MED HEMATOL ONCOL,SALT LAKE CITY,UT 84148; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV BIOCHEM & MOLEC BIOL,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,LANARK,SCOTLAND	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Glasgow	Bolger, GB (corresponding author), UNIV UTAH,HLTH SCI CTR,VET AFFAIRS MED CTR,151M,SALT LAKE CITY,UT 84148, USA.		Houslay, Miles/AAM-5281-2020; Houslay, Miles D/A-6825-2011	Houslay, Miles/0000-0002-3826-8091	NCI NIH HHS [5-PO-CA42014] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; BOLGER GB, 1994, GENE, V149, P237, DOI 10.1016/0378-1119(94)90155-4; BOLGER GB, 1994, CELL SIGNAL, V8, P851; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1995, BIOCHEMISTRY-US, V34, P7979, DOI 10.1021/bi00025a003; CONTI M, 1991, ENDOCR REV, V12, P218, DOI 10.1210/edrv-12-3-218; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; GIORGI M, 1992, BIOCHIM BIOPHYS ACTA, V1121, P178, DOI 10.1016/0167-4838(92)90352-E; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LOBBAN M, 1994, BIOCHEM J, V304, P399, DOI 10.1042/bj3040399; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; QIU YH, 1991, J MOL BIOL, V222, P553, DOI 10.1016/0022-2836(91)90496-S; RUTTEN WJ, 1973, BIOCHIM BIOPHYS ACTA, V315, P378, DOI 10.1016/0005-2744(73)90267-2; Sambrook J, 1989, MOL CLONING LABORATO; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TIGGES JH, 1990, MOL PHARMACOL, V37, P7; TILLY JL, 1992, ENDOCRINOLOGY, V131, P799, DOI 10.1210/en.131.2.799; WELCH JE, 1992, BIOL REPROD, V46, P1027, DOI 10.1095/biolreprod46.6.1027	33	81	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1065	1071		10.1074/jbc.271.2.1065	http://dx.doi.org/10.1074/jbc.271.2.1065			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557632	hybrid			2022-12-25	WOS:A1996TP88900069
J	Cal, S; Connolly, BA				Cal, S; Connolly, BA			The EcoRV modification methylase causes considerable bending of DNA upon binding to its recognition sequence GATATC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSOR-OPERATOR COMPLEX; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; RESTRICTION ENDONUCLEASE; GEL-ELECTROPHORESIS; ACTIVATOR PROTEIN; LAC-REPRESSOR; CURVED DNA; B-DNA; RESOLUTION	The EcoRV methyltransferase modifies DNA by the introduction of a methyl group at the 6-NH2 position of the first deoxyadenosine in GATATC sequences. The enzyme forms a stable and specific complex with GATATC sequences in the presence of a nonreactive analogue, such as sinefungin, of its natural cofactor S-adenosyl-L-methionine. Using circular permutation band mobility shift analysis (in which the distance between the GATATC sequence and the end of the DNA is varied) of protein-DNA-cofactor complexes we have shown the methylase induces a bend of just over 60 degrees in the bound DNA. This was confirmed by phasing analysis, in which the spacing between the GATATC site and a poly(dA) tract is varied through a helical turn, which showed that the orientation of the induced curve was toward the major groove. There was no significant difference in the bend angle measured using unmethylated GATATC sequences and hemimethylated sequences which contain G(6-Me)ATATC in one strand only. These are the natural substrates for the enzyme. The EcoRV endonuclease, a very well characterized protein, served as a positive control. DNA bending by this protein has been previously determined both by crystallographic and solution methods. The two proteins bend DNA toward the major groove but the bend angle produced by the methylase, slightly greater than 60 degrees, is a little larger than that observed with the endonuclease, which is approximately 44 degrees.	UNIV NEWCASTLE,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK								AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; AIKEN CR, 1991, J BIOL CHEM, V266, P19063; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; CONNOLLY BA, 1992, METHOD ENZYMOL, V211, P36; CONNOLLY BA, 1991, OLIGONUCLEOTIDES ANA, P155; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DICKERSON RE, 1983, J MOL BIOL, V166, P419, DOI 10.1016/S0022-2836(83)80093-X; DOHERTY AJ, 1993, GENE, V136, P337, DOI 10.1016/0378-1119(93)90491-K; DOUCRASY S, 1989, NUCLEIC ACIDS RES, V17, P5173, DOI 10.1093/nar/17.13.5173; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; DRYDEN DTF, 1995, NAT STRUCT BIOL, V2, P632, DOI 10.1038/nsb0895-632; FEUERSTEIN BG, 1990, NUCLEIC ACIDS RES, V18, P1271, DOI 10.1093/nar/18.5.1271; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; HAGERMAN PJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P125, DOI 10.1016/0167-4781(92)90066-9; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HEITMAN J, 1992, BIOESSAYS, V14, P445, DOI 10.1002/bies.950140704; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KERRPOLA T, 1991, CELL, V66, P317; KERRPOLA T, 1991, SCIENCE, V254, P1210; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM Y, 1990, SCIENCE, V249, P1037; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KLUG A, 1979, J MOL BIOL, V131, P669, DOI 10.1016/0022-2836(79)90196-7; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; Luke P A, 1987, Gene Amplif Anal, V5, P185; MATTHEWS BW, 1988, NATURE, V335, P294, DOI 10.1038/335294a0; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9891, DOI 10.1021/bi00494a020; NWOSU VU, 1988, NUCLEIC ACIDS RES, V16, P3705, DOI 10.1093/nar/16.9.3705; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PEREZMARTIN J, 1991, EMBO J, V10, P1375, DOI 10.1002/j.1460-2075.1991.tb07657.x; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROSENBERG JM, 1991, CURR OPIN STRUCT BIO, V1, P114; Sambrook J, 1989, MOL CLONING LABORATO; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHAKKED Z, 1994, NATURE, V368, P469, DOI 10.1038/368469a0; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; STOVER T, 1993, J BIOL CHEM, V268, P8645; SUCK D, 1988, NATURE, V332, P465; SUZUKI M, 1995, NUCLEIC ACIDS RES, V23, P2083, DOI 10.1093/nar/23.12.2083; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10734, DOI 10.1021/bi00034a005; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10724, DOI 10.1021/bi00034a004; THOMAS GA, 1989, BIOCHEMISTRY-US, V28, P2001, DOI 10.1021/bi00431a007; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1989, ANNU REV BIOCHEM, V58, P427, DOI 10.1146/annurev.biochem.58.1.427; TRIFONOV EN, 1991, TRENDS BIOCHEM SCI, V16, P467; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P697, DOI 10.1021/bi00002a037; WATERS TR, 1994, BIOCHEMISTRY-US, V33, P1812, DOI 10.1021/bi00173a026; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; WINKLER FK, 1993, EMBO J, V13, P3927; WITHERS BE, 1993, NUCLEIC ACIDS RES, V21, P2571, DOI 10.1093/nar/21.11.2571; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WORRALL AF, 1990, J BIOL CHEM, V265, P21889; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106; Zwieb C, 1994, Methods Mol Biol, V30, P281	69	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1008	1015		10.1074/jbc.271.2.1008	http://dx.doi.org/10.1074/jbc.271.2.1008			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557624	hybrid			2022-12-25	WOS:A1996TP88900061
J	Jiang, YX; Chan, JLK; Zong, CS; Wang, LH				Jiang, YX; Chan, JLK; Zong, CS; Wang, LH			Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANNEXIN-II; AUTOPHOSPHORYLATION SITES; SIGNAL TRANSDUCTION; CALPACTIN-I; PHOSPHORYLATION; SEQUENCE; AGGREGATION; REPLACEMENT; PROTEINS; CANCER	The tyrosines in the cytoplasmic domain of an oncogenic human insulin-like growth factor I receptor (gag-IGFR) were systematically mutated to phenylalanines to investigate the role of those tyrosines in the enzymatic and biological function of the gag-IGFR. Our results indicate that tyrosines 1131, 1135, 1136, and 1221 are important for the receptor protein-tyrosine kinase (PTK) activity. However, mutation of Tyr-1136 only slightly affects the kinase activity but dramatically reduces the transforming ability and overall substrate phosphorylation, in particular, annexin II, which is strongly phosphorylated by the gag-IGFR but not by the Phe-1136 mutant. Single mutation of either Tyr-943 or Tyr-950 resulted in significantly reduced phosphorylation of the receptor but not on its PTR activity or transforming ability. Tyr-950 together with its surrounding sequence is involved in mediating the interaction between the gag-IGFR and insulin receptor substrate 1. Our data also suggest that Tyr-1316 is involved in phosphorylation of phospholipase C-gamma, which is, however, not important for cell transforming activity. Overall, our study has identified several tyrosine residues of IGFR important for its PTK activity and substrate interaction. The transforming potential of the gag-IGFR correlates well with its ability to phosphorylate overall cellular substrates and to activate phosphatidylinositol 3-kinase via insulin receptor substrate 1.	MT SINAI SCH MED, DEPT MICROBIOL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA55054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACKER JM, 1992, J BIOL CHEM, V267, P1367; BRAMBILLA R, 1991, BIOCHEM J, V278, P447, DOI 10.1042/bj2780447; BRASELMANN S, 1992, J CELL SCI, P97; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COLE SPC, 1992, BRIT J CANCER, V65, P498, DOI 10.1038/bjc.1992.103; COOPER JA, 1981, MOL CELL BIOL, V1, P394, DOI 10.1128/MCB.1.5.394; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DRUST DS, 1991, J NEUROCHEM, V56, P469, DOI 10.1111/j.1471-4159.1991.tb08174.x; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5766, DOI 10.1021/bi00073a007; KOHANSKI RA, 1993, BIOCHEMISTRY-US, V32, P5773, DOI 10.1021/bi00073a008; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; MA ASP, 1994, IN VITRO CELL DEV-AN, V30A, P329; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEKONEN F, 1988, CANCER RES, V48, P1343; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RANDAZZO PA, 1990, EXP CELL RES, V190, P25, DOI 10.1016/0014-4827(90)90139-2; RESNICOFF M, 1994, CANCER RES, V54, P4848; SMITH JE, 1994, DNA CELL BIOL, V13, P593, DOI 10.1089/dna.1994.13.593; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WEI L, 1995, J BIOL CHEM, V270, P8122, DOI 10.1074/jbc.270.14.8122; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZHANG B, 1991, J BIOL CHEM, V266, P990	43	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					160	167		10.1074/jbc.271.1.160	http://dx.doi.org/10.1074/jbc.271.1.160			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550552	hybrid			2022-12-25	WOS:A1996TP36100025
J	Uchiyama, H; Hirano, K; KashiwasakeJibu, M; Taira, K				Uchiyama, H; Hirano, K; KashiwasakeJibu, M; Taira, K			Detection of undegraded oligonucleotides in vivo by fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTISENSE OLIGONUCLEOTIDES; RIBOZYME; EXPRESSION; TYPE-1; CELLS; RNA; VECTORS; DNA	A method was investigated for monitoring the integrity of oligonucleotides in solution and in cells using fluorescence resonance energy transfer between two different fluorochromes attached to a single oligonucleotide, Ten-mer oligodeoxyribonucleotides labeled with fluorescein at one end and with rhodamine X at the other end were used, The oligomer had a specific absorption spectrum with peaks at 497 and 586 nn, which corresponded to fluorescein and rhodamine X, respectively, When excited at 494 nm, the oligomer had a specific fluorescence spectrum with peaks at 523 and 610 ma, The fluorescence intensity at 610 nm was 6-8 times higher than that at 523 nm, After digestion of the oligomer with an endonuclease, the fluorescence at 523 nm increased more than 12-15-fold but its fluorescence peak at 610 nm almost completely disappeared, To examine effects in vivo, sea urchin eggs were injected with a solution of the oligomer and excited with blue light at 470-490 nm, Two fluorescent images, a green image at 520-560 nm and a red image at above 580 nm, were obtained when a single egg was viewed under a fluorescence microscope, The ratio of the intensities of red to green fluorescence decreased in dependence on time after injection of the oligomer, These changes were not observed in eggs that had been injected with a solution of similarly double-labeled, phosphorothioate oligomer. These results indicated that unfertilized sea urchin eggs had nucleolytic activity, Analysis in vitro on supernatant of the egg homogenate indeed demonstrated the existence of nucleases, All together, our results indicate that the integrity of oligonucleotides can be estimated in living cells by monitoring the fluorescence resonance energy transfer of the double-labeled oligonucleotide.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; HAMAMATSU PHOTON KK,TSUKUBA RES LAB,TSUKUBA,IBARAKI 30026,JAPAN; MINIST INT TRADE & IND,AGCY IND SCI & TECHNOL,NATL INST BIOSCI & HUMAN TECHNOL,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; Hamamatsu Photonics; National Institute of Advanced Industrial Science & Technology (AIST)								ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALTMAN S, 1993, P NATL ACAD SCI USA, V90, P10898, DOI 10.1073/pnas.90.23.10898; CANTOR GH, 1993, P NATL ACAD SCI USA, V90, P10932, DOI 10.1073/pnas.90.23.10932; DROPULIC B, 1992, J VIROL, V66, P1432; ERICKSON RP, 1992, GENE REGULATION BIOL; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERMAN B, 1989, FLUORESCENCE MICROSC, P220; HIRAMOTO Y, 1974, EXP CELL RES, V89, P320, DOI 10.1016/0014-4827(74)90796-4; HIRANO KI, 1982, DEV GROWTH DIFFER, V24, P273; KATO Y, 1988, J CHROMATOGR, V447, P212, DOI 10.1016/S0021-9673(01)91474-8; KOIDE SS, 1975, EXPERIENTIA, V31, P646, DOI 10.1007/BF01944606; LEONETTI JP, 1991, P NATL ACAD SCI USA, V88, P2702, DOI 10.1073/pnas.88.7.2702; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; MERGNY JL, 1994, NUCLEIC ACIDS RES, V22, P920, DOI 10.1093/nar/22.6.920; MURRAY JAH, 1992, ANTISENSE RNA DNA; OHKAWA J, 1993, P NATL ACAD SCI USA, V90, P11302, DOI 10.1073/pnas.90.23.11302; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P285, DOI 10.1021/bi00001a035; PARKHURST KM, 1995, BIOCHEMISTRY-US, V34, P293, DOI 10.1021/bi00001a036; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SHIMAYAMA T, 1993, NUCLEIC ACIDS RES, V21, P2605, DOI 10.1093/nar/21.11.2605; SIXOU S, 1994, NUCLEIC ACIDS RES, V22, P662, DOI 10.1093/nar/22.4.662; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TAKAHASHI M, 1991, ANAL BIOCHEM, V198, P246, DOI 10.1016/0003-2697(91)90420-X; TRAINOR GL, 1988, NUCLEIC ACIDS RES, V16, P11846, DOI 10.1093/nar/16.24.11846; TUSCHL T, 1994, SCIENCE, V266, P785, DOI 10.1126/science.7973630; USTER PS, 1986, J CELL BIOL, V103, P1221, DOI 10.1083/jcb.103.4.1221; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEERASINGHE M, 1991, J VIROL, V65, P5531, DOI 10.1128/JVI.65.10.5531-5534.1991; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340	34	51	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					380	384		10.1074/jbc.271.1.380	http://dx.doi.org/10.1074/jbc.271.1.380			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550591	hybrid			2022-12-25	WOS:A1996TP36100060
J	Walter, J; Schnolzer, M; Pyerin, W; Kinzel, V; Kubler, D				Walter, J; Schnolzer, M; Pyerin, W; Kinzel, V; Kubler, D			Induced release of cell surface protein kinase yields CK1-and CK2-like enzymes in tandem	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HEAT-SHOCK PROTEIN; II-ALPHA-SUBUNIT; ECTOPROTEIN KINASE; MOLECULAR-CLONING; CASEIN KINASE-1; GLYCOSYL-PHOSPHATIDYLINOSITOL; SECRETORY PATHWAY; SIGNAL SEQUENCE; INTACT-CELLS	Several types of cell exhibit cell surface protein kinase (ecto-PK) activities with Ser/Thr-specificity. Ecto-PK sharing certain characteristics of protein kinase CK2 can be detached from intact cells by interaction with exogenous substrates (Kubler, D., Pyerin, W., Burow, E., and Kinzel, V. (1983) Proc. Natl. Acad. Sci. U.S.A. 80, 4021-4025). However, a detailed molecular analysis of this ecto-PK was hampered by the vanishingly small amounts of labile enzyme protein obtained by substrate-inducible enzyme release, We now describe the stabilization and enrichment of released ecto-PK by precipitation with polyethylene glycol followed by affinity chromatography on heparin-agarose. Ecto-PK is shown to consist of two separate forms released in tandem, ecto-PK I and ecto-PK II. Comparison with cell homogenates as well as cell surface biotinylation experiments excluded contamination with intracellular PK. Purified ecto-PK I and ecto-PK II exhibit respectively selective phosphorylation of CK1- and CK2-specific peptide substrates, a complementary sensitivity to inhibitory agents and a differential use of the cosubstrates ATP and GTP. Ecto PK I consists of a 40-kDa moiety; the ecto-PK II is an ensemble of three components of 43- and 40-kDa (catalytic subunits) and a noncatalytic 28-kDa subunit. In addition, components of the ecto-PK II react with CK2-specific antibodies. Further, comparative peptide mapping and the results of mass spectrometry in combination with assignment of amino acid sequences confirmed that ecto-PK II is closely related if not identical to the protein kinase CK2. Assays with intact cells that result in the phosphorylation of a variety of endogenous membrane proteins showed that both ecto-PKs participate, and further, certain ecto-PK substrates be come preferentially labeled by one or another of the enzymes, whereas others are phosphorylated by both ecto-PK activities.	GERMAN CANC RES CTR, DEPT PATHOCHEM 0210, D-69120 HEIDELBERG, GERMANY; GERMAN CANC RES CTR, DEPT CELL BIOL, D-69120 HEIDELBERG, GERMANY; GERMAN CANC RES CTR, DEPT BIOCHEM CELL PHYSIOL, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)			Walter, Jochen/B-3677-2014; Wang, Caihong/T-5837-2019	Wang, Caihong/0000-0002-6808-3709; Walter, Jochen/0000-0002-4678-2912				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ANGIOLILLO A, 1993, MOL CELL BIOCHEM, V125, P65, DOI 10.1007/BF00926836; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; BORDIN L, 1994, BBA-GEN SUBJECTS, V1199, P266, DOI 10.1016/0304-4165(94)90005-1; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; CHEN XY, 1991, BIOCHEM J, V279, P475, DOI 10.1042/bj2790475; CLARI G, 1994, BIOCHEM BIOPH RES CO, V205, P389, DOI 10.1006/bbrc.1994.2677; COLE SR, 1987, MOL IMMUNOL, V24, P699, DOI 10.1016/0161-5890(87)90051-4; DEVILAT I, 1993, FEBS LETT, V316, P114, DOI 10.1016/0014-5793(93)81197-8; DEY CS, 1987, BIOCHEM BIOPH RES CO, V146, P422, DOI 10.1016/0006-291X(87)90546-8; EHRLICH YH, 1986, NATURE, V320, P67, DOI 10.1038/320067a0; ELIZAROV SM, 1993, MOL BRAIN RES, V19, P310, DOI 10.1016/0169-328X(93)90130-H; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; FANTINI J, 1987, EUR J CELL BIOL, V43, P342; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FILHOL O, 1990, BIOCHEM BIOPH RES CO, V173, P862, DOI 10.1016/S0006-291X(05)80866-6; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; FRIEDBERG I, 1995, J BIOL CHEM, V270, P20560, DOI 10.1074/jbc.270.35.20560; GEAHLEN RL, 1986, ANAL BIOCHEM, V153, P151, DOI 10.1016/0003-2697(86)90074-6; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HARTMANN M, 1992, BIOCHIM BIOPHYS ACTA, V1136, P189, DOI 10.1016/0167-4889(92)90256-B; HERMOSO T, 1991, EMBO J, V10, P4061, DOI 10.1002/j.1460-2075.1991.tb04982.x; HEUFELDER AE, 1992, J CLIN ENDOCR METAB, V74, P732, DOI 10.1210/jc.74.4.732; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; JORDAN P, 1994, BIOCHEMISTRY-US, V33, P14696, DOI 10.1021/bi00253a007; JORDAN P, 1992, BIOCHEM INT, V26, P97; KUBLER D, 1983, P NATL ACAD SCI-BIOL, V80, P4021, DOI 10.1073/pnas.80.13.4021; KUBLER D, 1992, EUR J BIOCHEM, V206, P179, DOI 10.1111/j.1432-1033.1992.tb16915.x; KUBLER D, 1989, J BIOL CHEM, V264, P14549; KUBLER D, 1982, EUR J CELL BIOL, V26, P306; KUBLER D, 1982, J BIOL CHEM, V257, P322; KUBLER D, 1986, CELLULAR BIOL ECTOEN, P191; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; KUNZEL V, 1986, CELLULAR BIOL ECTOEN, P179; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MITEV V, 1994, J NEUROCHEM, V63, P717; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MOLINA E, 1991, BIOCHEM J, V277, P811, DOI 10.1042/bj2770811; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MYERS LK, 1990, EXP CELL RES, V187, P270, DOI 10.1016/0014-4827(90)90091-N; NAGASHIMA K, 1991, FEBS LETT, V293, P119, DOI 10.1016/0014-5793(91)81165-5; NAIK UP, 1991, BIOCHIM BIOPHYS ACTA, V1092, P256, DOI 10.1016/0167-4889(91)90165-T; PAAS Y, 1995, ARCH BIOCHEM BIOPHYS, V316, P780, DOI 10.1006/abbi.1995.1104; PYERIN W, 1987, BIOL CHEM H-S, V368, P215, DOI 10.1515/bchm3.1987.368.1.215; ROWLES J, 1991, P NATL ACAD SCI USA, V88, P9548, DOI 10.1073/pnas.88.21.9548; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SCHMIDTSPANIOL I, 1994, CELL MOL BIOL RES, V39, P761; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SINGH TJ, 1985, FEBS LETT, V190, P84, DOI 10.1016/0014-5793(85)80433-6; SKUBITZ KM, 1991, BIOCHEM BIOPH RES CO, V174, P49, DOI 10.1016/0006-291X(91)90483-N; SKUBITZ KM, 1991, J IMMUNOL, V147, P638; SONKA J, 1989, BIOCHIM BIOPHYS ACTA, V997, P268, DOI 10.1016/0167-4838(89)90197-0; STIGARE J, 1993, FEBS LETT, V314, P327; TAPIA C, 1994, FEBS LETT, V349, P307, DOI 10.1016/0014-5793(94)00679-2; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; URIARTE M, 1993, BIOCHEM J, V293, P93, DOI 10.1042/bj2930093; VANCURA A, 1994, J BIOL CHEM, V269, P19271; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WINFIELD J, 1992, CHEM IMMUNOL, V53, P47; WIRKNER U, 1992, BIOCHIM BIOPHYS ACTA, V1131, P220, DOI 10.1016/0167-4781(92)90083-C; WIRKNER U, 1994, GENOMICS, V19, P257, DOI 10.1006/geno.1994.1056; YANGFENG TL, 1991, NUCLEIC ACIDS RES, V19, P7125, DOI 10.1093/nar/19.25.7125; ZHAI LM, 1992, BIOCHEM BIOPH RES CO, V189, P944, DOI 10.1016/0006-291X(92)92295-9	75	58	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					111	119		10.1074/jbc.271.1.111	http://dx.doi.org/10.1074/jbc.271.1.111			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550544	hybrid			2022-12-25	WOS:A1996TP36100018
J	Woo, PL; Cha, HH; Singer, KL; Firestone, GL				Woo, PL; Cha, HH; Singer, KL; Firestone, GL			Antagonistic regulation of tight junction dynamics by glucocorticoids and transforming growth factor-beta in mouse mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; EXTRACELLULAR-MATRIX; TGF-BETA; GENE-EXPRESSION; MESSENGER-RNA; PROTEIN; GLAND; ZO-1; FACTOR-BETA-1; STIMULATION	The synthetic glucocorticoid, dexamethasone, stimulated the transepithelial electrical resistance and suppressed the DNA synthesis of 31EG4 nontransformed mouse mammary epithelial cells, The addition of transforming growth factor-beta 1 (TGF-beta) to mammary cells simultaneously with or up to 24 h after dexamethasone treatment prevented the steroid induction of transepithelial electrical resistance and stimulated the incorporation of [H-3]thymidine. However, the TGF-beta inhibition of tight junction formation did not require de novo DNA synthesis. Confocal microscopy revealed that the organized immunostaining pattern of the tight junction protein, ZO-1, and F-actin at the cell periphery was disrupted by TGF-beta, resulting in disorganized and diffuse staining patterns throughout the cell. Western blot analysis demonstrated that TGF-beta did not alter the protein levels of ZO-1, In contrast to cells not treated or pretreated with steroid for up to 24 h, TGF-beta had no effect on cells pretreated with dexamethasone for 48 h, Transfection of chimeric reporter genes containing promoters responsive to either glucocorticoid or TGF-beta demonstrated that the mutual antagonism of tight junction dynamics by dexamethasone and TGF-beta occurs in the presence of intact signaling pathways. Taken together, our results establish for the first time that glucocorticoids and TGF-beta can antagonistically regulate tight junction formation in a nontransformed mammary cell line.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, CANC RES LAB, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NCI NIH HHS [CA-05388] Funding Source: Medline; NIDDK NIH HHS [DK-42799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK042799, R01DK042799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BARRETTLEE P, 1990, BRIT J CANCER, V61, P612, DOI 10.1038/bjc.1990.136; BUSE P, 1995, J BIOL CHEM, V270, P6505, DOI 10.1074/jbc.270.12.6505; CHIQUETEHRISMANN R, 1988, CELL, V53, P383, DOI 10.1016/0092-8674(88)90158-4; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; CLAUDE P, 1973, J CELL BIOL, V58, P390, DOI 10.1083/jcb.58.2.390; CROXTALL JD, 1992, INT J CANCER, V50, P822, DOI 10.1002/ijc.2910500527; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DANIEL CW, 1992, MOL REPROD DEV, V32, P145, DOI 10.1002/mrd.1080320210; DRENCKHAHN D, 1988, J CELL BIOL, V107, P1037, DOI 10.1083/jcb.107.3.1037; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; Haslam S. Z., 1987, The mammary gland. Development, regulation, and function., P499; HIROKAWA N, 1982, J CELL BIOL, V95, P249, DOI 10.1083/jcb.95.1.249; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; IMAGAWA W, 1990, ENDOCR REV, V11, P494, DOI 10.1210/edrv-11-4-494; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Jasani B, 1990, GROWTH FACTORS, V2, P149, DOI 10.3109/08977199009071501; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KURIHARA H, 1995, AM J PHYSIOL-RENAL, V268, pF514, DOI 10.1152/ajprenal.1995.268.3.F514; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LINZELL JL, 1974, J PHYSIOL-LONDON, V243, P129, DOI 10.1113/jphysiol.1974.sp010746; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; MADARA JL, 1988, CELL, V53, P497, DOI 10.1016/0092-8674(88)90562-4; MADARA JL, 1987, AM J PHYSIOL, V253, pC171, DOI 10.1152/ajpcell.1987.253.1.C171; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NEVILLE MC, 1981, J PHYSIOL-LONDON, V313, P561, DOI 10.1113/jphysiol.1981.sp013682; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; OKA T, 1974, J BIOL CHEM, V249, P3586; Pitelka D. R., 1978, Anderson, R. R. : Lactation. A comprehensive treatise. Vol. IV., P41; PITELKA DR, 1973, J CELL BIOL, V56, P797, DOI 10.1083/jcb.56.3.797; RABITO CA, 1992, TIGHT JUNCTIONS, P203; RAVITZ MJ, 1995, CANCER RES, V55, P1413; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBINSON SD, 1991, DEVELOPMENT, V113, P867; ROBINSON SD, 1993, J CELL BIOL, V120, P245, DOI 10.1083/jcb.120.1.245; SILBERSTEIN GB, 1992, DEV BIOL, V152, P354, DOI 10.1016/0012-1606(92)90142-4; SINGER KL, 1994, J BIOL CHEM, V269, P16108; STEINER MS, 1992, MOL ENDOCRINOL, V6, P15, DOI 10.1210/me.6.1.15; STELWAGEN K, 1994, J DAIRY SCI, V77, P426, DOI 10.3168/jds.S0022-0302(94)76969-1; STEVENSON BR, 1988, MOL CELL BIOCHEM, V83, P129; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STEVENSON BR, 1994, J CELL SCI, V107, P367; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; TALTS JF, 1995, J CELL SCI, V108, P2153; TOMITA K, 1979, CANCER RES, V39, P4407; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VALVERIUS EM, 1989, CANCER RES, V49, P6269; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WALKER RA, 1992, EUR J CANCER, V28A, P641, DOI 10.1016/S0959-8049(05)80116-9; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAN ZF, 1994, J BIOL CHEM, V269, P13231; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	69	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1996	271	1					404	412		10.1074/jbc.271.1.404	http://dx.doi.org/10.1074/jbc.271.1.404			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP361	8550596	hybrid			2022-12-25	WOS:A1996TP36100064
J	Brezden, CB; Rauth, AM				Brezden, CB; Rauth, AM			Differential cell death in immortalized and non-immortalized cells at confluency	ONCOGENE			English	Article						apoptosis; necrosis; confluency; immortalized; non-immortalized; p53-independence	P53; APOPTOSIS	Rat embryo fibroblast cells that have been immortalized by viral transfection have an altered cell cycle control. These cells have been observed to die via an apoptotic death when grown to confluency which, in at least one of the cell line pairs studied, was independent of the presence of wildtype or mutant p53. This confluency-dependent apoptotic cell death was observed in thirteen of fourteen rodent and human cell lines tested. In contrast, primary rodent and human cell strains (fibroblasts) entered a quiescent G(1)/G(0) state at confluency. Two weeks later, these non-immortalized cells underwent necrosis, not apoptosis. As the medium was not replenished during this two week period, cell necrosis was probably due to deprivation of nutrients and growth factors. These results indicate that mechanisms of cell death may differ between transformed and non-transformed cells under physiological stressed situations, such as high cell density. It may be possible to exploit these differences to increase the efficacy of chemotherapeutic compounds towards neoplastic cells.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON,CANADA; ONTARIO CANC INST,DIV EXPTL THERAPEUT,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto								BOWEN ID, 1993, CELL BIOL INT, V17, P365, DOI 10.1006/cbir.1993.1075; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GANNOUNZAKI L, 1994, EXP CELL RES, V213, P375, DOI 10.1006/excr.1994.1212; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KARNOVSKY MJ, 1964, J CELL BIOL, V23, P217, DOI 10.1083/jcb.23.2.217; KASTAN MB, 1991, CANCER RES, V51, P6304; LING V, 1974, J CELL PHYSIOL, V83, P103, DOI 10.1002/jcp.1040830114; LOCK RB, 1994, CANCER RES, V54, P4933; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MIRZAYANS R, 1994, BRIT J CANCER, V68, P838; MYMRYK JS, 1994, ONCOGENE, V9, P1187; PEACOCK JW, 1994, EMBO J, V13, P1084, DOI 10.1002/j.1460-2075.1994.tb06357.x; PRICE TNC, 1994, ONCOGENE, V9, P2897; SMETS LA, 1994, ANTI-CANCER DRUG, V5, P3, DOI 10.1097/00001813-199402000-00001; TOMEI LD, 1993, P NATL ACAD SCI USA, V90, P853, DOI 10.1073/pnas.90.3.853; WYLLIE AH, 1973, J PATHOL, V111, P2552; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	24	23	23	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					201	206						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552393				2022-12-25	WOS:A1996TQ01400025
J	Lenz, R; Zenk, MH				Lenz, R; Zenk, MH			Acetyl coenzyme A:salutaridinol-7-O-acetyltransferase from Papaver somniferum plant cell cultures - The enzyme catalyzing the formation of thebaine in morphine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; SALUTARIDINE; ALKALOIDS; REVISION; PROTEINS	Acetyl coenzyme A:salutaridinol-7-O-acetyltransferase, a highly substrate-specific enzyme, has been purified nearly 3,000-fold to homogeneity from Papaver somniferum plant cell suspension cultures. Purification was achieved by fractionated ammonium sulfate precipitation, dye-ligand affinity chromatography on matrex red A, gel filtration, ion exchange chromatography on Mono Q and a second dye-ligand affinity chromatography on fractogel TSK AF Blue. The purified enzyme was a single polypeptide with an M(r) = 50,000 displaying an isoelectric point of 4.8, a pH optimum between pH 6 and 9 and a temperature optimum at 47 degrees C. The K-m values for the substrate salutaridinol and the co-substrate acetyl coenzyme A were 7 and 46 mu M, respectively. Salutaridinol-7-O-acetyltransferase catalyzes the stoichiometric transfer of the acetyl group from acetyl coenzyme A to the 7-OH group of salutaridinol yielding salutaridinol-7-O-acetate, which is a new intermediate in morphine biosynthesis. Salutaridinol-7-O-acetate undergoes a subsequent spontaneous allylic elimination at pH 8-9, leading to the formation of thebaine (1), the first morphinan alkaloid with the complete pentacyclic ring system, or at pH 7 leading to dibenz[d,f]azonine alkaloids that contain a nine-membered ring. Acetylation and subsequent allylic elimination is a new enzymic mechanism in alkaloid biosynthesis, which in the poppy plant can transform one precursor into alkaloids possessing markedly different ring systems, depending on the reaction pH.	UNIV MUNICH,LEHRSTUHL PHARMAZEUT BIOL,D-80333 MUNICH,GERMANY	University of Munich								AMANN M, 1988, EUR J BIOCHEM, V175, P17, DOI 10.1111/j.1432-1033.1988.tb14160.x; Barton D. H. R., 1957, FESTSCHRIFT A STOLL, P117; BARTON DHR, 1967, J CHEM SOC C, P128, DOI 10.1039/j39670000128; BARTON DHR, 1965, J CHEM SOC, P2423, DOI 10.1039/jr9650002423; BATTERSBY AR, 1963, P CHEM SOC LONDON, P189; BENTLEY KW, 1967, J AM CHEM SOC, V89, P2464, DOI 10.1021/ja00986a039; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DKNOGGE W, 1981, Z NATURFORSCH C, V36, P197; FRENZEL T, 1990, PHYTOCHEMISTRY, V29, P3491, DOI 10.1016/0031-9422(90)85263-F; GERARDY R, 1993, PHYTOCHEMISTRY, V34, P125, DOI 10.1016/S0031-9422(00)90793-3; GERARDY R, 1993, PHYTOCHEMISTRY, V32, P79, DOI 10.1016/0031-9422(92)80111-Q; HORN JS, 1978, J AM CHEM SOC, V100, P1895, DOI 10.1021/ja00474a041; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENZ R, 1994, TETRAHEDRON LETT, V35, P3897, DOI 10.1016/S0040-4039(00)76696-2; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; LOTTER H, 1992, TETRAHEDRON LETT, V33, P2443, DOI 10.1016/S0040-4039(00)92210-X; MAGID RM, 1980, TETRAHEDRON, V36, P1901, DOI 10.1016/0040-4020(80)80203-1; STADLER R, 1990, LIEBIGS ANN CHEM, P555; STORK G, 1956, J AM CHEM SOC, V78, P4609, DOI 10.1021/ja01599a025; THEUNS HG, 1984, PHYTOCHEMISTRY, V23, P1157, DOI 10.1016/S0031-9422(00)82630-8; WIECZOREK U, 1986, PHYTOCHEMISTRY, V25, P2639, DOI 10.1016/S0031-9422(00)84526-4; Zenk M.H., 1995, ORGANIC REACTIVITY P, P89; ZENK MH, 1989, J CHEM SOC CHEM COMM, P1725, DOI 10.1039/c39890001725	24	60	71	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					31091	31096		10.1074/jbc.270.52.31091	http://dx.doi.org/10.1074/jbc.270.52.31091			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537369	hybrid			2022-12-25	WOS:A1995TN44400037
J	Motokura, T; Endo, K; Kumaki, K; Ogata, E; Ikeda, K				Motokura, T; Endo, K; Kumaki, K; Ogata, E; Ikeda, K			Neoplastic transformation of normal rat embryo fibroblasts by a mutated p53 and an activated ras oncogene induces parathyroid hormone-related peptide gene expression and causes hypercalcemia in nude mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; HUMORAL HYPERCALCEMIA; MAMMALIAN-CELLS; PROTEIN; CANCER; MALIGNANCY; IDENTIFICATION; TRANSCRIPTION; PROMOTER; CALCIUM	Parathyroid hormone-related peptide (PTHRP) is a 141-amino acid protein identified in various carcinomas associated with humoral hypercalcemia of malignancy (HHM). Although the causal role of PTHRP in HHM syndrome has been established, the molecular and cellular mechanism by which PTHRP gene is overexpressed in certain malignancies remains unknown, We have demonstrated in the present study that PTHRP secretion was markedly induced concomitantly with the formation of transformed foci after normal rat embryo fibroblasts (REFs) were co-transfected with an activated ras (ras) and a mutated form of p53 (p53-mt) genes. In either ras- or p53-mt-transfected (nontransformed) cells, only modest or barely detectable secretion of PTHRP was observed, respectively. Northern blot analysis revealed that PTHRP mRNA was markedly induced in fully transformed cells 11 days after transfection with both ras and p53-mt genes, Inhibition of RNA synthesis with actinomycin D resulted in almost complete disappearance of PTHRP mRNA at 2-3 h, suggesting a transcriptional mechanism, Transient transfection experiments revealed that PTHRP promoter activity was induced in ras + p53-mt transfectants. REFs transformed by ras and p53-mt genes and thereby induced to secrete PTHRP in vitro produced aggressively growing tumors associated with HHM syndrome when injected into nude mice, These results suggest that activation of PTHRP gene is closely related to malignant transformation of normal mammalian cells and that ras and p53 may be important regulators of PTHRP gene transcription, The transfection-focus formation system of REFs should provide an excellent model to study the molecular and cellular mechanism underlying concomitant overexpression of PTHRP gene with carcinogenesis.	CHUGAI PHARMACEUT CO LTD,LAB BONE DIS,SHIZUOKA 412,JAPAN; JAPANESE FDN CANC RES,CANC INST HOSP,TOKYO 170,JAPAN	Chugai Pharmaceutical Co., Ltd.; Roche Holding; Japanese Foundation for Cancer Research	Motokura, T (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,BUNKYO KU,3-28-6 MEJIRODAI,TOKYO 112,JAPAN.		Motokura, Toru/X-3682-2019					BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOS JL, 1989, CANCER RES, V49, P4682; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEMETRI GD, 1990, J CLIN INVEST, V86, P1261, DOI 10.1172/JCI114833; DEPAPP AE, 1993, TRENDS ENDOCRIN MET, V4, P181, DOI 10.1016/1043-2760(93)90114-T; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; ENDO K, 1994, J BIOL CHEM, V269, P32693; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAICH G, 1990, ENDOCRINOLOGY, V127, P1444, DOI 10.1210/endo-127-3-1444; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HENDERSON J, 1991, CANCER RES, V51, P6521; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; IKEDA K, 1993, J BIOL CHEM, V268, P1174; IKEDA K, 1994, J CLIN ENDOCR METAB, V79, P1322, DOI 10.1210/jc.79.5.1322; IKEDA K, 1990, J BIOL CHEM, V265, P5398; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KUKREJA SC, 1988, J CLIN INVEST, V82, P1798, DOI 10.1172/JCI113794; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI X, 1994, J BIOL CHEM, V269, P6263; MANGIN M, 1988, MOL ENDOCRINOL, V2, P1049, DOI 10.1210/mend-2-11-1049; MANGIN M, 1990, MOL ENDOCRINOL, V4, P851, DOI 10.1210/mend-4-6-851; MANGIN M, 1989, P NATL ACAD SCI USA, V86, P2408, DOI 10.1073/pnas.86.7.2408; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POLLACK R, 1974, P NATL ACAD SCI USA, V71, P4792, DOI 10.1073/pnas.71.12.4792; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STREWLER GJ, 1990, ANNU REV MED, V41, P35; THIEDE MA, 1988, SCIENCE, V242, P278, DOI 10.1126/science.3175653; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERG RA, 1989, CANCER RES, V49, P3713	38	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	1995	270	52					30857	30861		10.1074/jbc.270.52.30857	http://dx.doi.org/10.1074/jbc.270.52.30857			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TN444	8537338	hybrid			2022-12-25	WOS:A1995TN44400006
J	LEE, HJ; LEE, YF; BURBACH, JPH; CHANG, CS				LEE, HJ; LEE, YF; BURBACH, JPH; CHANG, CS			SUPPRESSION OF GENE-EXPRESSION ON THE SIMIAN-VIRUS-40 MAJOR LATE PROMOTER BY HUMAN TR4 ORPHAN RECEPTOR - A MEMBER OF THE STEROID-RECEPTOR SUPERFAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; RETINOIC ACID RECEPTORS; LONG TERMINAL REPEAT; THYROID-HORMONE	The key expression of the simian virus 40 (SV40) major late promoter could be repressed by the human TRA orphan receptor via the +55 region of the SV40 major late promoter (nucleotide numbers 368-389, 5'-GTTA-AGGTTCGTAGGTCATGGA-3'). Using the coupled in vitro transcribed and translated TR4 orphan receptor with a molecular mass of 67.3 kilodaltons, electrophoretic mobility shift assay showed specific binding with a dissociation constant of 1.09 nm between the TR4 orphan receptor and the SV40 +55 oligonucleotides. in addition, chloramphenicol acetyltransferase assay demonstrated that this SV40 +55 region can function as a repressor via the TR4 orphan receptor, suppressing the transcriptional activities of both SV40 early and late promoters. Together, our data suggest that the TR4 orphan receptor may play an important role for the suppression of the SV40 gene expression.	UNIV WISCONSIN,CTR COMPREHENS CANC,ENDOCRINOL REPROD PHYSIOL PROGRAM,MADISON,WI 53792; UNIV UTRECHT,RUDOLF MAGNUS INST NEUROSCI,DEPT MED PHARMACOL,3584 CG UTRECHT,NETHERLANDS	University of Wisconsin System; University of Wisconsin Madison; Utrecht University; Utrecht University Medical Center					NATIONAL CANCER INSTITUTE [R01CA055639, R29CA055639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55639] Funding Source: Medline; NIDDK NIH HHS [DK47258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; Chang C, 1993, ENDOCR J, V1, P541; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; COONEY AJ, 1991, J VIROL, V65, P2853, DOI 10.1128/JVI.65.6.2853-2860.1991; DASILVA SL, 1995, ENDOCRINOLOGY, V136, P2276; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GARCIA AD, 1993, J VIROL, V67, P3940, DOI 10.1128/JVI.67.7.3940-3950.1993; GETZENBERG RH, 1991, CANCER RES, V51, P6514; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEE HJ, 1993, BIOCHEM BIOPH RES CO, V194, P97, DOI 10.1006/bbrc.1993.1790; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; LEE HJ, 1993, ENDOCR J, V1, P203; MERTZ J, 1994, J CELL BIOCH S55, V18, P369; MOWSZOWICZ I, 1993, MOL ENDOCRINOL, V7, P861, DOI 10.1210/me.7.7.861; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; QI JS, 1995, MOL CELL BIOL, V15, P1817; SALZMAN NP, 1986, PAPOVAVIRIDAE, V1, P382; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; ZUO F, 1995, THESIS U WISCONSIN M; ZUO FR, 1995, P NATL ACAD SCI USA, V92, P8586, DOI 10.1073/pnas.92.19.8586	27	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					30129	30133						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530419				2022-12-25	WOS:A1995TK38000079
J	MALLET, B; LEJEUNE, PJ; BAUDRY, N; NICCOLI, P; CARAYON, P; FRANC, JL				MALLET, B; LEJEUNE, PJ; BAUDRY, N; NICCOLI, P; CARAYON, P; FRANC, JL			N-GLYCANS MODULATE IN-VIVO AND IN-VITRO THYROID-HORMONE SYNTHESIS - STUDY AT THE N-TERMINAL DOMAIN OF THYROGLOBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; PROTEIN GLYCOSYLATION; HORMONOGENIC DOMAIN; CARBOHYDRATE MOIETY; CELLS; THYROTROPIN; IODINATION; SECRETION; BINDING; UNITS	Thyroglobulin (Tg) is the substrate for thyroid hormone biosynthesis, which requires tyrosine iodination and iodotyrosine coupling and occurs at the apical membrane of the thyrocytes. Tg glycoconjugates have been shown to play a major role in Tg routing through cellular compartments and recycling after endocytosis. Here we show that glycoconjugates also play a direct role in hormonosynthesis. The N-terminal domain (NTD; Asn(1)-Met(171)) of human Tg, which bears the preferential hormonogenic site, brings two N-glycans (Asn(57) and Asn(91)). NTD preparations were purified from Tg with low and mild iodine content in vivo and from poorly iodinated Tg after in vitro iodination and coupling. NTD separated from poorly iodinated Tg was also submitted to iodination and coupling after desialylation and deglycosylation. The various NTD isoforms were analyzed for their N-glycan structures and hormone contents, Our results show that 1) in vivo as well as in vitro unglycosylated isoforms did not synthesize hormones, whereas fully or partially (at Asn(91)) glycosylated isoforms did; 2) high mannose type structures enhanced the hormone content; and 3) desialylation did not affect in vitro hormone synthesis. Evidence of a direct involvement in hormone-synthesis adds to the role of N-glycans in Tg function and opens the way to new mechanisms for regulation (e.g. TSH modulation of N-glycan) or alteration (e.g. Asn(91) mutation) of thyroid hormone synthesis.			MALLET, B (corresponding author), FAC MED MARSEILLE, INSERM, U38, 27 BD JEAN MOULIN, F-13385 MARSEILLE 05, FRANCE.		Franc, Jean-Louis/C-8861-2009	Franc, Jean-Louis/0000-0002-2900-5468				ARIMA T, 1972, J BIOL CHEM, V247, P1825; BJORKMAN U, 1982, EUR J BIOCHEM, V125, P585, DOI 10.1111/j.1432-1033.1982.tb06723.x; CRESTFIELD AM, 1963, J BIOL CHEM, V83, P143; DESRUISSEAU S, 1994, ENDOCRINOLOGY, V134, P1676, DOI 10.1210/en.134.4.1676; DIJESO B, 1992, J BIOL CHEM, V267, P1938; DIJESO B, 1992, BIOCHEM BIOPH RES CO, V189, P1624, DOI 10.1016/0006-291X(92)90263-K; EGGO MC, 1982, ENDOCRINOLOGY, V111, P1663, DOI 10.1210/endo-111-5-1663; EKHOLM R, 1990, THYROID GLAND, P37; FENOUILLET E, 1986, J BIOL CHEM, V261, P5153; FRANC JL, 1990, BIOCHEM BIOPH RES CO, V166, P937, DOI 10.1016/0006-291X(90)90901-X; FRANC JL, 1984, BIOCHEM BIOPH RES CO, V118, P910, DOI 10.1016/0006-291X(84)91481-5; FRANC JL, 1990, ENDOCRINOLOGY, V126, P1464, DOI 10.1210/endo-126-3-1464; GARDAS A, 1991, AUTOIMMUNITY, V9, P331, DOI 10.3109/08916939108997135; GROLLMAN EF, 1992, J CLIN ENDOCR METAB, V74, P43, DOI 10.1210/jc.74.1.43; GROLLMAN EF, 1993, J BIOL CHEM, V268, P3604; HIRANI S, 1987, ANAL BIOCHEM, V162, P485, DOI 10.1016/0003-2697(87)90424-6; IEIRI T, 1991, J CLIN INVEST, V88, P1901, DOI 10.1172/JCI115513; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KULIAWAT R, 1994, J BIOL CHEM, V269, P4922; LAMAS L, 1989, J BIOL CHEM, V264, P13541; LI E, 1980, ARCH BIOCHEM BIOPHYS, V199, P393, DOI 10.1016/0003-9861(80)90295-7; LIS H, 1993, EUR J BIOCHEM, V218, P1, DOI 10.1111/j.1432-1033.1993.tb18347.x; LISSITZKY S, 1989, ENDOCRINOLOGY, V1, P512; MALLET B, 1992, MOL CELL ENDOCRINOL, V88, P89, DOI 10.1016/0303-7207(92)90012-U; MARRIQ C, 1977, EUR J BIOCHEM, V79, P143, DOI 10.1111/j.1432-1033.1977.tb11792.x; MARRIQ C, 1991, MOL CELL ENDOCRINOL, V81, P155, DOI 10.1016/0303-7207(91)90214-D; MARRIQ C, 1986, FEBS LETT, V207, P302, DOI 10.1016/0014-5793(86)81509-5; MIQUELIS R, 1993, J CELL BIOL, V123, P1695, DOI 10.1083/jcb.123.6.1695; MIQUELIS R, 1987, J BIOL CHEM, V262, P15291; OPDENAKKER G, 1993, FASEB J, V7, P1330, DOI 10.1096/fasebj.7.14.8224606; RAWITCH AB, 1993, ARCH BIOCHEM BIOPHYS, V300, P271, DOI 10.1006/abbi.1993.1038; ROLLAND M, 1970, ANAL BIOCHEM, V33, P307, DOI 10.1016/0003-2697(70)90301-5; RONIN C, 1986, J BIOL CHEM, V261, P7287; SHIFRIN S, 1983, J BIOL CHEM, V258, P3780; SPIRO MJ, 1979, J BIOL CHEM, V254, P7668; TAKASAKI S, 1982, ANAL BIOCHEM, V162, P485; WARREN L, 1982, J CELL PHYSIOL, V113, P17, DOI 10.1002/jcp.1041130105; WINZLER R J, 1955, Methods Biochem Anal, V2, P279, DOI 10.1002/9780470110188.ch10	38	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29881	29888						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530385				2022-12-25	WOS:A1995TK38000045
J	VANDIJKEN, P; DEHAAS, JR; CRAXTON, A; ERNEUX, C; SHEARS, SB; VANHAASTERT, PJM				VANDIJKEN, P; DEHAAS, JR; CRAXTON, A; ERNEUX, C; SHEARS, SB; VANHAASTERT, PJM			A NOVEL, PHOSPHOLIPASE C-INDEPENDENT PATHWAY OF INOSITOL 1,4,5-TRISPHOSPHATE FORMATION IN DICTYOSTELIUM AND RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; DISCOIDEUM; CELLS; 1,3,4,5-TETRAKISPHOSPHATE; HEXAKISPHOSPHATE; 3,4,5,6-TETRAKISPHOSPHATE; PHOSPHORYLATION; 3-PHOSPHATASE; DEGRADATION; PHOSPHATES	In an earlier study a mutant Dictyostelium cell-line (plc(-)) was constructed in which all phospholipase C activity was disrupted and nonfunctional, yet these cells had nearly normal Ins(1,4,5)P-3 levels (Drayer, A. L., Van Der Kaay, J., Mayr, G. W, Van Haastert, P. J. M. (1990) EMBO J. 13, 1601-1609). We have now investigated if these cells have a phospholipase C-independent de novo pathway of Ins(1,4,5)P-3 synthesis. We found that homogenates of plc(-) cells produce Ins(1,4,5)P-3 from endogenous precursors. The enzyme activities that performed these reactions were located in the particulate cell fraction, whereas the endogenous substrate was soluble and could be degraded by phytase. We tested various potential inositol polyphosphate precursors and found that the most efficient were Ins(1,3,4,5,6)P-3, Ins(1,3,4,5)P-4, and Ins(1,4,5,6)P-4. The utilization of Ins(1,3,4,5,6)P-5, which can be formed independently of phospholipase C by direct phosphorylation of inositol (Stephens, L. R. and Irvine, R. F. (1990) Nature 346, 580-582), provides Dictyostelium with an alternative and novel pathway of de novo Ins(1,4,5)P-3 synthesis. We further discovered that Ins(1,3,4,5,6)P-5 was converted to Ins(1,4,5)P-3 via both Ins(1,3,4,5)P-4 and Ins(1,4,5,6)P-4. In the absence of calcium no Ins(1,4,5)P-3 formation could be observed; half-maximal activity was observed at low micromolar calcium concentrations. These reaction steps could also be performed by a single enzyme purified from rat liver, namely, the multiple inositol polyphosphate phosphatase. These data indicate that organisms as diverse as rat and Dictyostelium possess enzyme activities capable of synthesizing the second messengers Ins(1,4,5)P-3 and Ins(1,3,4,5)P-4 via a novel phospholipase C-independent pathway.	UNIV GRONINGEN,DEPT BIOCHEM,9747 AG GRONINGEN,NETHERLANDS; NIEHS,CELLULAR & MOLEC PHARMACOL LAB,INOSITOL LIPID SECT,RES TRIANGLE PK,NC 27709; FREE UNIV BRUSSELS,INST RECH INTERDISCIPLINAIRE,B-1070 BRUSSELS,BELGIUM	University of Groningen; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Universite Libre de Bruxelles; Vrije Universiteit Brussel			Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916				ALI N, 1993, J BIOL CHEM, V268, P6161; BALLA T, 1994, MOL BIOL CELL, V5, P17, DOI 10.1091/mbc.5.1.17; Bartfai T, 1979, Adv Cyclic Nucleotide Res, V10, P219; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOMINAAR AA, 1994, BIOCHEM J, V297, P189, DOI 10.1042/bj2970189; CAMPAGNE MMV, 1988, BIOCHEM J, V254, P343; CRAXTON A, 1995, BIOCHEM J, V305, P491, DOI 10.1042/bj3050491; CRAXTON A, 1994, J BIOL CHEM, V269, P4337; CUNHAMELO JR, 1988, J BIOL CHEM, V263, P14245; DAS OP, 1983, BIOCHIM BIOPHYS ACTA, V736, P45; DOUGHNEY C, 1988, BIOCHEM J, V251, P927, DOI 10.1042/bj2510927; DOWNES CP, 1990, EUR J BIOCHEM, V195, P1; DRAYER AL, 1992, J BIOL CHEM, V267, P18387; DRAYER AL, 1994, EMBO J, V13, P1601, DOI 10.1002/j.1460-2075.1994.tb06423.x; EUROPEFINNER GN, 1986, BIOCHIM BIOPHYS ACTA, V887, P335, DOI 10.1016/0167-4889(86)90163-1; FLAADT H, 1993, J CELL SCI, V105, P255; FREUND WD, 1992, EUR J BIOCHEM, V207, P359, DOI 10.1111/j.1432-1033.1992.tb17058.x; HOER D, 1988, BIOCHEM BIOPH RES CO, V154, P668, DOI 10.1016/0006-291X(88)90191-X; Irvine Robin F., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P161; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; NOGIMORI K, 1991, J BIOL CHEM, V266, P16499; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; STEPHENS LR, 1990, NATURE, V346, P580, DOI 10.1038/346580a0; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; TAKAZAWA K, 1991, BIOCHEM J, V280, P125, DOI 10.1042/bj2800125; TAKAZAWA K, 1990, BIOCHEM J, V22, P107; VANDERKAAY J, 1995, ANAL BIOCHEM, V225, P183, DOI 10.1006/abio.1995.1135; VANDIJKEN P, 1994, EUR J BIOCHEM, V226, P561; VANDIJKEN P, 1995, BIOCHEM J, V308, P127, DOI 10.1042/bj3080127; VANHAASTERT PJM, 1989, ANAL BIOCHEM, V177, P115, DOI 10.1016/0003-2697(89)90024-9; VERJANS B, 1994, MOL CELL ENDOCRINOL, V98, P167, DOI 10.1016/0303-7207(94)90135-X; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	34	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1995	270	50					29724	29731						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TK380	8530362				2022-12-25	WOS:A1995TK38000022
J	DUTERQUECOQUILLAUD, M; NIEL, C; PLAZA, S; STEHELIN, D				DUTERQUECOQUILLAUD, M; NIEL, C; PLAZA, S; STEHELIN, D			NEW HUMAN ERG ISOFORMS GENERATED BY ALTERNATIVE SPLICING ARE TRANSCRIPTIONAL ACTIVATORS	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; MURINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; ETS PROTO-ONCOGENE; DNA-BINDING; C-ETS; V-ETS; CHROMOSOMAL LOCALIZATION; GENE FAMILY; PROTEINS	The erg gene is a member of the ets gene family. ETS proteins have been shown to bind specifically the (GGAA/T) motif and to transactivate via this consensus sequence. The human erg products exhibit almost-equal-to 70% homology with ETS proteins in their DNA-binding domain. We have isolated three erg cDNAs from a human fetal liver library. Two of them are different from the previously described erg-1 and erg-2 cDNAs (Rao et al., Science, 1987, 237, 635-639), in the middle of their coding sequence and in their 5' part where a novel initiation codon is introduced. These isoforms are generated by alternative RNA splicing from a single gene that leads to the inclusion or exclusion of different exon sequences. The three cDNAs expressed by an in vitro transcription-translation system direct the synthesis of proteins of almost-equal-to 38, 49 and 55 kDa. These in vitro erg products were tested for their DNA-binding activity by gel mobility-shift assays with different probes containing the ETS-specific binding site. The results indicated that all these erg isoforms are able to bind the ETS binding site in a specific manner. Our data using transient transfection assays indicate that erg protein isoforms function as transcriptional activators.			DUTERQUECOQUILLAUD, M (corresponding author), INST PASTEUR,CNRS,URA 1160,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		plaza, serge/F-5290-2015; Niel, Christian/G-3712-2013	Duterque-Coquillaud, Martine/0000-0003-3943-5629				ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1988, ONCOGENE RES, V2, P371; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JORCYK CL, 1991, ONCOGENE, V6, P523; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MESSING J, 1983, METHOD ENZYMOL, V101, P20; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRASAD DDK, 1992, CANCER RES, V52, P5833; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SACCHI N, 1988, Genomics, V3, P110, DOI 10.1016/0888-7543(88)90140-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SPEGELAERE P, 1991, J VIROL, V65, P4919, DOI 10.1128/JVI.65.9.4919-4928.1991; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	62	45	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1865	1873						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510931				2022-12-25	WOS:A1993LG68200019
